From cfbbfb4fa5c807539f7a3e0ce13f9a87ad605de2 Mon Sep 17 00:00:00 2001 From: Matthijs Berends Date: Tue, 6 Jan 2026 23:08:50 +0100 Subject: [PATCH] (v3.0.1.9007) fix #246 --- DESCRIPTION | 4 +- NAMESPACE | 2 + NEWS.md | 13 +- R/ab_property.R | 23 +- R/amr_selectors.R | 32 +- R/antibiogram.R | 2 +- R/data.R | 4 +- R/sysdata.rda | Bin 117984 -> 118616 bytes R/translate.R | 35 +- data-raw/_pre_commit_checks.R | 112 +++- data-raw/ab.md5 | 2 +- data-raw/datasets/antimicrobials.dta | Bin 10373 -> 10432 bytes data-raw/datasets/antimicrobials.feather | Bin 141570 -> 145346 bytes data-raw/datasets/antimicrobials.parquet | Bin 112713 -> 113323 bytes data-raw/datasets/antimicrobials.rds | Bin 46540 -> 46780 bytes data-raw/datasets/antimicrobials.sav | Bin 371976 -> 380992 bytes data-raw/datasets/antimicrobials.txt | 780 +++++++++++------------ data-raw/datasets/antimicrobials.xlsx | Bin 79638 -> 79882 bytes data-raw/translations.tsv | 4 +- data/antibiotics.rda | Bin 46584 -> 46832 bytes data/antimicrobials.rda | Bin 46612 -> 46804 bytes index.md | 8 +- man/ab_property.Rd | 2 +- man/antimicrobial_selectors.Rd | 16 +- man/antimicrobials.Rd | 2 +- man/custom_eucast_rules.Rd | 13 +- man/custom_mdro_guideline.Rd | 12 +- man/esbl_isolates.Rd | 2 +- tests/testthat/test-amr_selectors.R | 2 + vignettes/AMR.Rmd | 2 +- 30 files changed, 628 insertions(+), 444 deletions(-) diff --git a/DESCRIPTION b/DESCRIPTION index bd3548c91..78686eac2 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -1,6 +1,6 @@ Package: AMR -Version: 3.0.1.9006 -Date: 2025-12-21 +Version: 3.0.1.9007 +Date: 2026-01-06 Title: Antimicrobial Resistance Data Analysis Description: Functions to simplify and standardise antimicrobial resistance (AMR) data analysis and to work with microbial and antimicrobial properties by diff --git a/NAMESPACE b/NAMESPACE index 0f5029cd6..54f6c9563 100644 --- a/NAMESPACE +++ b/NAMESPACE @@ -321,6 +321,7 @@ export(oxazolidinones) export(pca) export(penicillins) export(phenicols) +export(phosphonics) export(polymyxins) export(proportion_I) export(proportion_IR) @@ -360,6 +361,7 @@ export(sir_df) export(sir_interpretation_history) export(sir_predict) export(skewness) +export(spiropyrimidinetriones) export(step_mic_log2) export(step_sir_numeric) export(streptogramins) diff --git a/NEWS.md b/NEWS.md index 4bdca2899..60e0cb992 100644 --- a/NEWS.md +++ b/NEWS.md @@ -1,10 +1,15 @@ -# AMR 3.0.1.9006 +# AMR 3.0.1.9007 ### New * Integration with the **tidymodels** framework to allow seamless use of SIR, MIC and disk data in modelling pipelines via `recipes` - `step_mic_log2()` to transform `` columns with log2, and `step_sir_numeric()` to convert `` columns to numeric - - New `tidyselect` helpers: `all_sir()`, `all_sir_predictors()`, `all_mic()`, `all_mic_predictors()`, `all_disk()`, `all_disk_predictors()` + - New `tidyselect` helpers: + - `all_sir()`, `all_sir_predictors()` + - `all_mic()`, `all_mic_predictors()` + - `all_disk()`, `all_disk_predictors()` * Data set `esbl_isolates` to practise with AMR modelling +* AMR selectors `phosphonics()` and `spiropyrimidinetriones()` +* `ab_group()` gained an argument `all_groups` to return all groups the antimicrobial drug is in (#246) ### Changed * Fixed a bug in `antibiogram()` for when no antimicrobials are set @@ -16,7 +21,9 @@ * Interpretation of capped MIC values now consistently returns `"NI"` (non-interpretable) when the true MIC could be at either side of a breakpoint, depending on the selected handling mode * This results in more reliable behaviour compared to previous versions for capped MIC values * Removed the `"inverse"` option, which has now become redundant - +* Fixed some foreign translations of antimicrobial drugs +* `antimicrobials$group` is now a `list` instead of a `character`, to contain any group the drug is in (#246) +* `ab_group()` now returns values consist with the AMR selectors (#246) # AMR 3.0.1 diff --git a/R/ab_property.R b/R/ab_property.R index 8966b2a01..75de8cbf1 100755 --- a/R/ab_property.R +++ b/R/ab_property.R @@ -164,10 +164,29 @@ ab_tradenames <- function(x, ...) { #' @rdname ab_property #' @export -ab_group <- function(x, language = get_AMR_locale(), ...) { +ab_group <- function(x, language = get_AMR_locale(), all_groups = FALSE, ...) { meet_criteria(x, allow_NA = TRUE) language <- validate_language(language) - translate_into_language(ab_validate(x = x, property = "group", ...), language = language, only_affect_ab_names = TRUE) + meet_criteria(all_groups, allow_class = "logical", has_length = 1) + + grps <- ab_validate(x = x, property = "group", ...) + for (i in seq_along(grps)) { + # take the first match based on ABX_PRIORITY_LIST + if (all_groups == FALSE) { + grps[[i]] <- grps[[i]][1] + } else if (length(grps[[i]]) > 1) { + grps[[i]] <- grps[[i]][grps[[i]] != "Beta-lactamase inhibitors"] # leave these out if there are other groups + } + if (language != "en") { + grps[[i]] <- translate_into_language(grps[[i]], language = language, only_affect_ab_names = TRUE) + } + } + names(grps) <- x + if (length(grps) == 1 || all_groups == FALSE) { + unname(unlist(grps)) + } else { + grps + } } #' @rdname ab_property diff --git a/R/amr_selectors.R b/R/amr_selectors.R index b0a53d5bf..7636c51ba 100755 --- a/R/amr_selectors.R +++ b/R/amr_selectors.R @@ -425,6 +425,14 @@ phenicols <- function(only_sir_columns = FALSE, return_all = TRUE, ...) { amr_select_exec("phenicols", only_sir_columns = only_sir_columns, return_all = return_all) } +#' @rdname antimicrobial_selectors +#' @export +phosphonics <- function(only_sir_columns = FALSE, return_all = TRUE, ...) { + meet_criteria(only_sir_columns, allow_class = "logical", has_length = 1) + meet_criteria(return_all, allow_class = "logical", has_length = 1) + amr_select_exec("phosphonics", only_sir_columns = only_sir_columns, return_all = return_all) +} + #' @rdname antimicrobial_selectors #' @export polymyxins <- function(only_sir_columns = FALSE, only_treatable = TRUE, return_all = TRUE, ...) { @@ -450,6 +458,14 @@ rifamycins <- function(only_sir_columns = FALSE, return_all = TRUE, ...) { amr_select_exec("rifamycins", only_sir_columns = only_sir_columns, return_all = return_all) } +#' @rdname antimicrobial_selectors +#' @export +spiropyrimidinetriones <- function(only_sir_columns = FALSE, return_all = TRUE, ...) { + meet_criteria(only_sir_columns, allow_class = "logical", has_length = 1) + meet_criteria(return_all, allow_class = "logical", has_length = 1) + amr_select_exec("spiropyrimidinetriones", only_sir_columns = only_sir_columns, return_all = return_all) +} + #' @rdname antimicrobial_selectors #' @export streptogramins <- function(only_sir_columns = FALSE, return_all = TRUE, ...) { @@ -685,7 +701,7 @@ amr_select_exec <- function(function_name, } # untreatable drugs - untreatable <- AMR_env$AB_lookup$ab[which(AMR_env$AB_lookup$name %like% "(-high|EDTA|polysorbate|macromethod|screening|nacubactam)")] + untreatable <- AMR_env$AB_lookup$ab[which(AMR_env$AB_lookup$name %like% "(-high|EDTA|polysorbate|macromethod|screening|nacubactam|inducible)")] if (!is.null(vars_df) && only_treatable == TRUE) { if (any(untreatable %in% names(ab_in_data))) { if (message_not_thrown_before(function_name, "amr_class", "untreatable")) { @@ -713,9 +729,9 @@ amr_select_exec <- function(function_name, if (is.null(amr_class_args) || isTRUE(function_name %in% c("antifungals", "antimycobacterials"))) { ab_group <- NULL if (isTRUE(function_name == "antifungals")) { - abx <- AMR_env$AB_lookup$ab[which(AMR_env$AB_lookup$group == "Antifungals")] + abx <- AMR_env$AB_lookup$ab[which(vapply(FUN.VALUE = logical(1), AMR_env$AB_lookup$group, function(x) "Antifungals" %in% x))] } else if (isTRUE(function_name == "antimycobacterials")) { - abx <- AMR_env$AB_lookup$ab[which(AMR_env$AB_lookup$group == "Antimycobacterials")] + abx <- AMR_env$AB_lookup$ab[which(vapply(FUN.VALUE = logical(1), AMR_env$AB_lookup$group, function(x) "Antimycobacterials" %in% x))] } else { # their upper case equivalent are vectors with class 'ab', created in data-raw/_pre_commit_checks.R # carbapenems() gets its codes from AMR:::AB_CARBAPENEMS @@ -723,7 +739,11 @@ amr_select_exec <- function(function_name, # manually added codes from add_custom_antimicrobials() must also be supported if (length(AMR_env$custom_ab_codes) > 0) { custom_ab <- AMR_env$AB_lookup[which(AMR_env$AB_lookup$ab %in% AMR_env$custom_ab_codes), ] - check_string <- paste0(custom_ab$group, custom_ab$atc_group1, custom_ab$atc_group2) + check_string <- paste0( + vapply(FUN.VALUE = character(1), custom_ab$group, function(x) paste(x, collapse = " ")), + custom_ab$atc_group1, + custom_ab$atc_group2 + ) if (function_name == "betalactams") { find_group <- "beta[-]?lactams" } else if (function_name %like% "cephalosporins_") { @@ -1001,11 +1021,11 @@ find_ab_names <- function(ab_group, n = 3) { # try popular first, they have DDDs drugs <- AMR_env$AB_lookup[which((!is.na(AMR_env$AB_lookup$iv_ddd) | !is.na(AMR_env$AB_lookup$oral_ddd)) & AMR_env$AB_lookup$name %unlike% " " & - AMR_env$AB_lookup$group %like% ab_group & + vapply(FUN.VALUE = character(1), AMR_env$AB_lookup$group, function(x) paste(x, collapse = " ")) %like% ab_group & AMR_env$AB_lookup$ab %unlike% "[0-9]$"), ]$name if (length(drugs) < n) { # now try it all - drugs <- AMR_env$AB_lookup[which((AMR_env$AB_lookup$group %like% ab_group | + drugs <- AMR_env$AB_lookup[which((vapply(FUN.VALUE = character(1), AMR_env$AB_lookup$group, function(x) paste(x, collapse = " ")) %like% ab_group | AMR_env$AB_lookup$atc_group1 %like% ab_group | AMR_env$AB_lookup$atc_group2 %like% ab_group) & AMR_env$AB_lookup$ab %unlike% "[0-9]$"), ]$name diff --git a/R/antibiogram.R b/R/antibiogram.R index f0a8a2163..b7199e13b 100755 --- a/R/antibiogram.R +++ b/R/antibiogram.R @@ -584,7 +584,7 @@ antibiogram.default <- function(x, if (length(existing_ab_combined_cols) > 0 && !is.null(ab_transform)) { ab_transform <- NULL warning_( - "Detected column name(s) containing the '+' character, which conflicts with the expected syntax in `antibiogram()`: the '+' is used to combine separate antimicrobial agent columns (e.g., \"AMP+GEN\").\n\n", + "Detected column name(s) containing the '+' character, which conflicts with the expected syntax in `antibiogram()`: the '+' is used to combine separate antimicrobial drug columns (e.g., \"AMP+GEN\").\n\n", "To avoid incorrectly guessing which antimicrobials this represents, `ab_transform` was automatically set to `NULL`.\n\n", "If this is unintended, please rename the column(s) to avoid using '+' in the name, or set `ab_transform = NULL` explicitly to suppress this message." ) diff --git a/R/data.R b/R/data.R index 841e2fece..c387b4668 100755 --- a/R/data.R +++ b/R/data.R @@ -38,7 +38,7 @@ #' - `ab`\cr antimicrobial ID as used in this package (such as `AMC`), using the official EARS-Net (European Antimicrobial Resistance Surveillance Network) codes where available. ***This is a unique identifier.*** #' - `cid`\cr Compound ID as found in PubChem. ***This is a unique identifier.*** #' - `name`\cr Official name as used by WHONET/EARS-Net or the WHO. ***This is a unique identifier.*** -#' - `group`\cr A short and concise group name, based on WHONET and WHOCC definitions +#' - `group`\cr One or more short and concise group names, based on WHONET and WHOCC definitions #' - `atc`\cr ATC codes (Anatomical Therapeutic Chemical) as defined by the WHOCC, like `J01CR02` (last updated `r documentation_date(TAXONOMY_VERSION$ATC_DDD$accessed_date)`): #' - `atc_group1`\cr Official pharmacological subgroup (3rd level ATC code) as defined by the WHOCC, like `"Macrolides, lincosamides and streptogramins"` #' - `atc_group2`\cr Official chemical subgroup (4th level ATC code) as defined by the WHOCC, like `"Macrolides"` @@ -368,7 +368,7 @@ #' @format A [tibble][tibble::tibble] with `r format(nrow(esbl_isolates), big.mark = " ")` observations and `r ncol(esbl_isolates)` variables: #' - `esbl`\cr Logical indicator if the isolate is ESBL-producing #' - `genus`\cr Genus of the microorganism -#' - `AMC:COL`\cr MIC values for 17 antimicrobial agents, transformed to class [`mic`] (see [as.mic()]) +#' - `AMC:COL`\cr MIC values for 17 antimicrobial drugs, transformed to class [`mic`] (see [as.mic()]) #' @details See our [tidymodels integration][amr-tidymodels] for an example using this data set. #' @examples #' esbl_isolates diff --git a/R/sysdata.rda b/R/sysdata.rda index 3ebfc35266f3fe5a65a3a0c76c80eab2b30b1a1b..bd53f6b029c53cdcb3e8f9a75f38e641e23dbe9b 100755 GIT binary patch delta 110593 zcmV(xKZN$y8O1NaGxGZ04K2<`GK5sD!+$?HjS?2*0{c6jE(XgSauv-c zfl)^!0KNzn6Nt(g6unt-didWwMe^5$? zj7X$AnTvh4DoK;Xbb*D))Ld=7+SgR8l`5AL;0e%@X>AnfGUK?uVHEn zqmO9H494*lGmQG~at)OeSp%tQU34$w1^DV`VROMAT;wE2nP##I*~~M)(95B*2+?) zi`%~Rzoi^vf;{%#GGHH03f^lNHycpoMKsy44~tK*%PVQ0L@so^N3M^lg3C(V0<(`F zX%95Rvd`Dea9X}C6uBB6Vj}vFtk}!%vtqKDyB$Z_Zah25)EDGVp)H&kf1&C$01DU? z;bw`kp9D8<77dB>g{;C~{LuY6OEyu*K$8TKmDrf_C&eHQ0`GAZ4#Lb!zG1(PB(Lo` zEXvJq^*&jmZ%izN%F5M;*^HP~yUJszh@x_Oi3_%$eaO(Qa^3-=rlXjFL$4&CeFnSG zm5?wKF>}S2C5Ou7`w-L->QcY>PMJ zy7(7-QnTyxa1$dvO9Hdt<3)&fw77i3~zu|#V?TViL-pZo`!hV;Z?x-CU6&&tWxyCq(?3CpPkHTfTy;shbrktc~IOGDo@X?m_Rhjnn~f$tqpI=huw6 zTQRSg940OCsf7u(7tj8*9N9%MJc`IG6mK260OXjV2OoC#I}r#kz* zc_F3hxjEGPDM<(~z?^cVplPOy8|uZ~eM{3YU&oYK)(^Iye;5= zy(yY$&AZXtf2>RuOm`C5#Ova_Mgyu5RrDC;p?-^Kow&;ptl3QU1H;HPI*WiSo?Q}J zI+hN^8g+8x7LPcamz^rRSmtG7sZ^0y*lB$yQt^!?_9xi$I>0@nqQsT(`J(a|xqS%? zjf=`&C~tGMP_{b*jjU0q|0_t$*2MnU7BV>IcYL4of1{tbflB^`ga*hE|2sSy5&&hL zPcz$tncADAD?PB07ze-6py=&5QTox`BISTdRrq1acIzo!-cIWG2_yHVKAh6Qi75nf znZv-RyA{}05c#pVb}o7|V$mL+SC*^*aK8w0Z!0T61`s&ihkA27a1Fyf?kxh;qwQ7a z8REQbf9l2o^P)I1L@SbxyKu9RE!k?p08&W@v{*d%xzI;JuR4cZ{RVkE7XmDIA>^gc zH+}oIFv_qV%>tA!mPG&}On3;QG^XbuuIy3vqP5wy=27$-#6o13uFlH2TmWaC7t^cO z8$1&6tZ$4<opZ^ctt!zy9$fJ|hNMGE$_!U`M4SZ$n ze}RCX3M6&$c$v(eqrGw01c`zJ4=Vq=qupbIhb=?Hk8`2lsnL={#1`4NJn zy>!?Y>%o6sHo6XM=N3x$WTygN#A0V3C&Y(FkKVF+CRAf~hx(!Br z{dc5AagDEgfe}fIXucT%(2EDif20ujet274du1zuvVMIXgU473p1#0j^kdSrFbO1a|Kk?W z{-k8IW*aqh4Ej398U?Ab0)Gc{LdM}R$_#M(UmmHy>h%pM2t`YNQ1>E+^yDB6iWu zqKEA%x(px$evwl4yK4&2dH-e-4+H0a+L^6NJF3YQV~k`Le;k|64(P$N+>Q}-Gsp%0 zCUye%WnGJKn8DYi=};R@Sy=!zaRzO7;nANkSBJ7#u;0DzG!9W78xT`l?Z1Rdu+ zGcnoPc1l?eTvmEWOHPiQ%AC#*N}_RJZV>cTe=_QEJ>c8>0GPj!6=Lzqc5pH*ADL=9 zm*Gj(RVh=D4Jy%?6SjC4`Sg!H%et+EA~)jJSA10LF=VjVv$`VQDIAqpbEv}k9vC*; zfyfTD6ItGoExPl@szm!OH)^|D^`8&AGE=>9v5b)O`-lzLd3}T~EQU7dme@>1(I?Nd ze~ZhE3rz}};KGwn#8>w8ws~i_SGA;b*XC~kAtiB11Vh8I$~GoF&9LqNAzdp;pSR*U zjy3qVlnZ!B4ObxUb@DJ&K--V;7}lJ67Ot$VJ*hcwz%*Q!$#*l&)6jDoIFy7f+4MkV z9dQ{Xg1b}#fzE}mz9%f}r9$>9bVT%1f7-O~$piY0!8Ba11r{-L3dd+pX8xlXn>#;r zRs)!S5P1?1u=ksxY!c;*WcT(cTrcI$rxBQK0UNwMW}xOBtqKk?e_V|ezoiEPbp8BMk*VW1 zSb(nftKru{7hPRM&rcJSlX9$KV>Hs2)Z4zH8#n{T&6p?jmiY$dkQtVP6B#$;YnqxxYK!~aN5uE+|%HI1UQ1e7+&}B zu&+8j7uO##AI?S_9{k0z#zSdh5nc1bJ~E#t^>0T?=n5#%o&}xe0rl#7e+~{)18aqE zH4Phg`K3{4#te~Ev~#E`(HOO4-TGfX>xY}ryb*5bfO4#c8F-{XaN+0W_4y;HKX1sH zPe%X@vcq-erZ5;~L>xhU_4X+5Ud`4mJQ-jjdA+oyJ8#9aBT7u10a#n=&~Sza#Ba1i zd6X`b#*wF<2V^-6t|pm)f7cC=*L8@~-9r0ufoQEP(JOq$H0jT}?;@uNf2r{rXGN&1 z*4jXng$l~*9DX-Tz!A~z* zqp=g6B&eTtW(`HRf7wM7i3IZ_L-{B(&q!~=oV1|f&l$h423M}rTxH2M39B!{-&hpAEl=f zy+;QW5B+?AAs?PJc`8r^`bblH%PY*e)g99oc1boE_>`mwe<^e&N1472>+HnvbN&2S z?na-7F$0Yz`dd%$I+E?ZQ*N$vo}PtW2-gjoN*@67P@9G6CU}oPE=(S4F${r5%#KrnoaL>p%geHeq_mPW4E~|ELw8(9nqKQr#c%gk z!}JnLlIdzlf7`tN&bQ5%=7f`X(RldcQ}G)KMyTJP30KML{X(K9tG+X;%&Oa(D)`Cc z{=X4Om7+V-U-^$IBYuq>+Be&A9O1 z+GLpoD*Mkg=K9CAJ20VVzXO!64ow?%>UJ+t?|P+Be=YQF@hC3Z9rX`0n#LLpAd%%U z#?|uKK46*5cgUNi0+yx8FL=^mt^NrjB$n;qr`Hw-(^RUZKULp&PZ-1yg;y_Au1oCq zc2gs9`i&15 zKnicye~{FH$APlrwx$s9x)^!(+wv2$roi4qf;G6CyF`D?evc)lO!qYMsIN2%_UhyM4AxcC5X0<(k6BRorN@pg8 z&YbhJZDr;Cm$9QtT3Z!}uLaMZm@KUotmDK9ZfvBsO=!(5+->3#kStL8^+dZl&SF3&U^ws^7KiEFWZJKhr1Y~;~)KF?YRh$kF~mcQ7OVDv&TWKm9g(G(wv))enV> zZ6PzVWJnjNC5$771&z8I&|yUCN55f^b0(f`;EVzrWYUq-7na2c6(w)y3J`KajknwQc5r@y)hU$ka4=eB>z>W*bU2sC>b5Ol z0b!@MVSS2{!nO+>;lR3jT)V{Rxr_^0LEvP{AS>{>!%Z%d-NaXGlZfpnJ`$P4RyPnz7BAp(8Puh4YNYnc8b|N^!pPf1f@e zZkI;NFiV0|e}0o6*FV`&K|<*CCF=yGXK)2yc+;k)2AATdax!;OX+5;<>)}kuhAB~R zQ)tyxfymSUXPK}IV-NH#Rk^GNJqq#7^gpn6S`Sisp$!u?quxrRPHjkWUzOXOzPgpK z0lfcqn;>3e#hj$!)bX_!HHj&4e`@xv1iyeMB|!V^MLk=FGRf}3}fD#588^W=?gYus^ zr9Y)>{J*&8{7}$BsM0DWN}OYH2|Uxm4Fo-BCJ@wvrO~S*hch-h#ns)Qf4ijVos;W= z!#im}(!E}hJn-RFZxn6tfO`LFN_S5YQLH*@B&A#bpdUOV zHH}z=hdhf~IMg_>M=(#Ce@EV)y1MH{J6-3!=zzoSD3s~cK=?O9yLLFdVk%bSkwu57 zE|_oM)W3KBt(ZD$!cXDG=V$4e>R^8tPry|wS_^BosYh82XW=O8gl?aM5`pp&cZP1g z_Uf3?HwBo+E0zX$57G+{wIHYNayC zIkYhk6dm}tFCz?tZkk_2joXvuiboA9onT8pO)76v_6 z1=f!wAixxF+}h7oL#O(*9BkjEdOvbq?brf?j~SDk1sp2ye;I&1fyEKU-@2$7lj}mC zp^=p3%!nKJAeM9!AgI%Fdw~@`r@^nxr-eo%)PoCN55HLBlC6MUOx0*fS8&cyZO@;Iseje*SmZ3wNMYvbF&yUTa@;w z>P~s`4ceQaET?p^<#B^TJLT3^1@in@?0x9F`&U$LNkO&o)=(a>7ylaABxfA9cWC~?ZvaDb9 zPqYC)e^*xTjlkD$gm@{jtevoAy+v7Ee2GFtKrwG^W5 zk6|>ru6&m#@?}JZhHYs(!X(F1D_Ws+0}GVaanvuP8mLu$;=A=o`Jhz`z<1(329r|Z zf8&FP?2T1@c%qsMffG3CwumPn7QRJ@;{w7i?-(FK0?$Ia-eno)#B#sU`hBH!SD!*u zl0<%O^kW)l)ojJ~>rCWGS<>u$)M@4Hbd8)k0zzAC$`o3yx+-m@L761OD>;!VAdRTV z6FWdwg-T%{LiNq^`)xjbnpZV&dvTbCe^gK4e8#xRahz=s&WQbol~5}%$1SoY4<*@J zPbyBvi3@@Z5#%zwB&uGWy-}laK;`^_1^0(FCO-cZV7J}J=+mrgE)0?<4j^f5UGiyf zm6>E7>fmy#Lj=0Jp-m7s$<3C~4)Tdxu(4U`UTzy6cVOrYX^xtyLfkAUgKo2ffe&mw%AshP^G8mvl*nH zeC)+PV{oT+KygdE^F%JZ8#?a`f0bT1djtchn}QKbuTF1u-4!dm9EI=xk$LlAX6p!} z-ASJJ7Y28lgJ;TIPm^YH)rd0VGhNS3EU{(l8h9r=F~4`in!c=OiU^6IGpG;=~)_cognBdeBGPTPiG8zRV{pl z4&$I?njHT|nZ1HXy&h982!uK>5qUZcrlddUn-cHxh@|{#lazvtIDUvWJ!4{?q;<#l zzYS};Jl7)&L&7a6XIX6ve}`WxPV9oW;uGAicAr0s1ygK!xyBuG$0l%v)L_1~EO9Q= z6y5YmYJcY}v$EK8s8UuAW9TWTu5*iAGR9Bm+;wVvZFESy-C8Q)4ziU92iIx_4CZWu{F{U_5nPMN(J+q>e+vvhap-3+PKd8Q zBD6a1B}jIU%`ix2&+MD%t=DJfb8-}x{%s?EpV1dly(*Euo|)T6A4qvfVuSkV3_2`N zBLe~dkYiqnapVU8X~z%l`qY38)h7rOuU8~%Q*^5mtjZWrH7ubsLYc=!SP}Ec7?w)T z?ctdQx3~wdSx|r0e-RlmZN#BhUpJo)$_{15E7+Z}Fc82AgS{_{A6W@Z*Nf9+9uH=v0p)8r|3zR zy2@7x%-)cmH&Og+*EptvB^gmt2+p#%U@^kZ12y#=V=%d;ra!kPK^oDv67&Oc;L;wP z_665O9sR28w+&7a+`PH-WZtv@QYXrN8>T=CLnJt&f46KLKi@`m>T+K_?qnbS+^gX= zfxi6#@ud2;wrq5-wGB#A`q!D8I_qj%pgkM%#5E6x6tQazbLBLe%P&A7ovzjCOJ6T? zK@iDed?v_!5k6b!>}d>mw|PE|BjEn7w*2`8dL1H=shmWSE_V<;h@aSM2_{F%hOGPb zs@xjGf8zFe!64;eGjSiMhmmkgC9qBqYx6*iH^|DB)Qm5ePGEaS+&I7(I9cV~d_-=|f1_<3<&#~vxXY1S=ShxxA%2>hMMN;& zZ-p`=MBmM8F)eKB=t&Q}@hlc4vdP(q6n_7@zgfNmA8B5zs(CvTVkt>Vk8?trugvIe ze;5%O>l55-Wzv0J_e(YZ7Gp}TP4Alu{Taa9g{4h!_fJtwqy6t>SV1HJG>_w-9x(Wm z#F~a`LOYhVv~2m%pkg<}STb^_hZgEY_tX8;EW8gHoBN0pxo z_m;@NL%8(ai8jo!rz+zuF;*D+_tMs?e=2#0aw;{`gaqB(5xg53mPqlw{;)!$DGqY* zkW;wb08@!Ie5g)Yhpeeh{Z_Gep1;Gs2)!(0jj47wm1oNow^f4i2ur1Pl2D~;!O%7b z;0Z56G6W93ih*TrUD_=Uz?5jP*QwT(${bi| zflh>!T&re9bCm~vZVe(t-V%P$>avmx8zsi%7RtY#f`-Dx)5!n{<1X)D21b&D$fGut zYyXhewmHe&+T=I;?4~G}JLYGF1I@nX=apQ4A z<|3T}V2R`3Kdx0p5AsU}5RMc)b=9I$ zzQEqk2%w=hY1FtKYTadXfTB(WYMlv-Qse`qYNEhIZyw)re`qmfx7V1pA3O=- zqcFk@ZWJr{73n>pY53V|M3q-3iH}kBRdp31vA%xb*gHMs$e?eA)5x*-Es_*dUR#GT z)|F!U`{Axk_s8-#+zyrF%G!j0)p|qoJwQv*r!pEvhlq>|*|823^=-^gPJZ@ zlhQW$cCjK8RLP~b?Y0CTSGY0j7W!ADYM=abFm*8nB7>kye~0SGa*}hM^<1 zZO}dud^D1(XMC>6iEc;#JBtb_zma&c7`q>F0VYTXqtQ^;{*O0(REy6noC3SAC>uyx z;jsq=`P(|`f5!{J9+lHBOa(To(`S1iCo9Zb!7m6}pF9Pl!5C<2CPTi3U=P9c9*Iw- z=zyj*&gX;PE|YOP@|F=*w_!$DWznsnshB^ghHP$c%C~I_;K7&P3b_${Ie35SrGq|8O}^tduy~gOowI^%O#gfz;1WZHVmPRBg(*9oWa+ znOTyIe_Pee?e{P#8+GoU5=}lLqp5IG!=MI-y-2UvZ>rbLT@-WRL8Pw5G0VS?62J&e zmQGFKDF(cu*%}D@V#)TZg$?&+$me~%t9?0NRuGiSE9o_1FSjXskE&X`K^wR%6M~$+ zTJz)di7?41&DIWE=4;fse4M-W_R)-!l*ta!ek7BV27oyo6u4<@?yjaupj0IdywiGwo;zx%M1`)|(NFh^v|qC~lZdQGmd0FiVV6O$ zu=85O6^6bu`R6YX^58>er(DM9v>2K~T~3o%sC=nvkCgjFDTQKLd4XuDYZw)2Dnpkx zf0QCmR;OLt)Vh_?NS}h(h=DEM2q*OrP1BkthB3{=>Nsoh(34EpCUbu%3nV9|wX{!q z$r&s;f#8!W9G@0+oa{)T5Jd5YVDc{k#y!I`R)eHnClaQL+a zC`?=)Cs9}xPZjB){u3i3Hg~%Nvv)VZ=|~{nMb)+`Ls$*M`UV>wxI9KaR#*5Ce>#ZS zMOH5Cqk=jh_Rl{bA}bYF47!iQA*Hl9FWnchZe5lUBE>2OkE3PMnQ@am4wP4v+@jLPr9gVqA5vp{v^*bB zHCr@`F{$jI=YWk8U67tBMkj4=rmKA@+9On9UZeXpLJSrzk)j zo_3VA!NaBiRsouT*UY;oBB7!Gqkhg}s%_|JG%=!Zh>rpbVtR zEZs*KTvb~t?hPW+x>OfVfAWdz$3fH!x$12ci)h>M8_;{A4AjRI9bA(RXLU?J-Msta z=C>B%Y-}l+WsEcYl1Y7Z72ppivk=oHJG7Mc4MWqg?^PY)v4J9w2)utneTQ!%cR#nm zQF301xp z+&{9zI74ErH=nD>2k&wu0ADpNMh=;;=af>^OE_lm6wzNn9TR#0mxeho$5TmSfT#C) zlaB&@+b_`C_XIuXe<>ck&p{cQO2cI@&5l(Q^wT5&1Mnn+=YAO~V&{qd5r=ENoGyj1 z8HyZBD|})*d??a{h@kV4Tpby&;QeSY2sAHJ9gY@&6*Zhx?B^^6SrVn87@tm?k7zjy z-{C^*!_V#q3yhX}6!2BdjBpL8A@2|^22oB{0 zo_Ar7anqJrdlTjHiT*M(s%swph|&n6iXFBhLxE#ZfWpHQknf%c4hK$e+L!6K&J5|> zV<^AE=#>6U#3#~Qy^`LYt9Q1f5&GDLzw-r@b1fmyULL+%DL8d&wRcO1WE7NAcWaJ? zqwsTHcp`a2e>M!f2JHaiDy>`KvrY>C9ge$~EEvnkEj|%SZ!YwOj%KSq`PwXEWz?g6 z90sZy>xrJv)Qo>nHqP#=FXxJopdu!a+C3v}{&0E_8*X++vK1X{Zn6l2gM89;GyKGf zIWxyo{RH->(DWe`nRTv|3}=2}CnZGXE^N~F6foD+e`%U1BNV8ZE@L5G_l;}bA#T_YL^$rzP4lJJeDM`Y~dRD?6bMT#^$L8ybdpQ`qJ#}1#L&+Pm z7Dg$@e`erWWlE2l1g@QE&H`FCD*IYTcN}Gb6t0(0eXxh?u}*j=tnKL63mm~kg8@3l zD@`R?NwN2?P4cLu;*5h2-;VfZ8jTLf7nq_4=x0yWYh%h+z)VWiTU^@{+}CgT*4*3K zA@qn5hZZBGk?L3R1qg?}&DF-y?nTFN7I|2Of70)fbpLwL@?ZY2_peyq=ukGCD9b2( z8wFdk;w(5X(%tLWKN*I7)IFUW+lO3y!)@r{QYFtJJy%yO^HT(5^7B8?;7OMj46Q#r zhSA{}>?`fi2%FVF8p-=u-|j4+tvxCA5zAn&svF{R3bZEr1qi}x(t|brdMEPKUNfu* ze{a7#shsfl-gzI_Q>YFkmON0FA)cYe#oM0YlizV*CUtaUES%aib|{!862vH3PWgW0 zP7X^N@DNmn7(rY0}gBo!C!n zXkw>v3_r5cg%V2xN{aT!d<)ueDAznZ@}4yP=D9xCD>$Ou=r{XEIs^Xa8#g_Ue}exN zXTuJ>PSBHw*oDwCy;REJ#H#LB#-8U)TWeDaA*y0YU67ojoVoy69&{*rGjpKaMT@3Z zgB2ox%VJJxGEevqBxb)*7K|T;+5Zx(OMoZbGP{P#tupwos)1?>w5XIw+esg;5y0QM zkMN|Vz?#}`vufL-Z9aTN3vu~Pe<1K8SVcxxy<_me7u|TP3Qr~8#yZaZ%xhm*w!qKA z#3ufqT%$*`zXZ|e)ABoM7uR_d;JxC}5Q>3$eHI{MtwbHlcp^xgq4ki>-Eud2kAVA^ zO;zys?$}&|fVL3tgPg05#6R+cxupDAx`_aiGS58DZ8203TJ12}DA>cCe}{;Q!2pw2 z)a8ul^ooK)*^*oytLzQ#+IFKy05rkf|Ll3!JJ1ei)b|Ml#X zFq9&4&U)qcPI!C7p?Sn{Quh-(9+^9?Qy5>+#sHI96YtU-^A1K&f5r;b@>@_bI<2BN zk>Hfz&8yYyE_LoSqgMiK#Z(l`!2msBUhj{B`2&WpD3bh@MvmX7x@<-yqP^)}Zx0@~f3`-vZ5asL5JW;_rsMD!$Znpb5gY#08!waDo#kq>thkzDnc81WnGGve=jgscxe2a!`fC9>aU0n zeS)Cf`$)QeD&f#91QiIr%lqBN)BU5iM=4pyZK;3(7~jePKKq4F^8V95?YCG)T=3GO zc=Lb5pT_f)lr_le7Nkj!Hrw(g6!Jl#$a11bxqF}-f>@9N7{@_yv{rXfd1jOq9po|Q z&PN4%;Ggeae`xw;^I$suERQcnj(1bUtuK_p3T7x9 zga)pd68OzHu+}y?udOI>RAA7piVt~*-vjG~4uE-l9&pk%(y*3hB9GKgzZ7_?g=lv1 zS1-#q4x;NBebz&&V35bXdjT#H?$8#KiaAd3xy;^`jz0)pk@fLd^sDX&wD0bo`^rf@e<&XIq z5b2|fEF7{=G@E5G$cV7Q=U-@LH3U$uiw4d!e^V_WN>Z*iy}vUfbeAKy9?nkf^sCrE zAxCRxpeFF1a9e>5SanV|2!|3l$i@e&m=77d)inliDu>XIg-y~$y!6Shge6!%1KOWj{)ek1r1)N&PHZojWv<*>9aH&WK({)>To&gf#XczUMNpZ4Zdy zCedW}b8)~>U^vjuM{joLolUebiFrzge{ook{XEw$Ou46et^S?hjOzGtKug0&L9p%z zUaFb`1}ZEk&1!P829h}sEhol@z#dnUG?}z2k5S#5pA|YW`_<&LXHz|twXHdc=KFxI z_|nVeJa#S_>C0vPELx|qU+rF9jHIc0!CSo>O*4DsVnIawOIek?QmM2yu$-~;uIEuyP+vKq_{pU(EqQ^4Q|G;l44M+hP4BZ z2L&?GvA%e{Lv#4Eyh}|AsOy>f$m?InK^;5w`?QeNJ*+88XT3ONd{-V4O42Wk`Z9Xx zwASs|X#Dz`{Ece7sA}wrssI;2e|@gr=b?k;08h1{*U(x~-p{Ox-(0#|%vTu(+JDxm z;s<>QnzzRJIeQWChE^^!k2hQL9$mz;fv6_r_IJNRV{hQ!*hnJQm^_f6!7UtK>kt z2e;iuKR)_a?|c}RX4gCgYDv#r@gX?nwgx2G%C5i16J{CH-uZ#k+nZ@zr~{rpG05ERY~+KX*pu?w{_DKvU%AQ z`59DA180@TNPWTz9aZeOWe^}4wmNpCof#0C%g^~3iiLA(ia(&{^5OJKT-pL@Aec_w@-Xn4rt z58n4J`?7hE%VN2&(xfuU#Pt5)XCI%Gja|-*la1#ZrA`!ae?*Y{!)MXYE#+8P?!?mr zhhk}1?*(seU!v9_-}@-gfJ#1GtHSKB;X!Sd z%Wk(i4XNBF>AXMnZ>w)X^~juU^w9%fHo@{(HDuj5JFEHcqi>1fW}w^*KvDXkuF(8-ThQo+X@AwKR_}6X`F3|k zm?$L4j#RcTr2hGfh{i1Mxi`>e{%sdtt*pUcWQGije`iR7APhGPc%3$OFtCJ3RG3W% zD!xsHCg{iCKq_07?UL1Ju*I{l>{Gy4(KW+r?-N`$N*kL1Y4sdAg|$;PQO{Qcmc0oj zm1>dvxTj}(^8G!0Gd@+Xb_kKHense9@D`keK#%$vV1N1_cj}lD-8=_9xfGVfXSNKN~>S;cpj3iAiKL6`uoU_R+gqj6!w znSpeU^1@|XXiGS?_^wm+h!!^R`M6%+?V$Rve{&HkX0MErA3bFCoWK4VTMQEuUF#tM&FIV%4zsEuDH%<14>LLukfa-aJfJG=63kdC(nMVv~V4QDhLsJ_Pz9kQRTrrJ`?7s9&jc$@%KBU`2Bf{h|JfJ*b`=~ zc!4Dq+Jd;X0id&rU-7_Qd`QT6ySgx$e>4@Y`0wg4_(0P3VQ{?H;X&(rE=5CX$-{7> zN&N{sCXY4!K324Fu+D4FZpKLpDk{Zs@aCu$Fk9Eg!`vmP*KvxbBSyy}pS#X5(V?#k zj!2#Tv&thy-Hlvi#?`&YUUf&to7r6rw5DXz8~wuBu%zpOM$q#8j|{#3pO$&!e^;oo z_?JTGvV_g9IW}mR;M@YzTN!~Od@Yst>A9tA`(V|5y?ItDbuh3Dow|nuSAnjA5%cOeK3Aajo#voYK>h0JK^l1 z9W!_jw>^O94dgwVWSf;Ls|jYIf5`JKbb#HqPPyK9WOT!r*qt=jZ?6x{!sYt&CL+s{ zoW%G+bJW;d+;{&10Mykga%>mTvMBy{7kZL<7rKs8h>+lR+5U@)|0;z&SkM{ z8rM~~*s#Tv`J2(ds0sWu$=A2|WGJf0Rg~d0;;v z(XDDMs0MR}I{?salc3;WTpLX|W5EEKjihpO`mQCbEq#W;yp|Pv4DqG zxe!5-*xe*a*4ddU5=+xJ%F*sc_Ms?}Pso$+&M-Fk6Me&iwXef{tq{mL8QiK! zQ$NZ`3&tsKvTn=#Hh<({=c_tu9%FJQoc~VKj;T==dJf29jSK+Be=|(?N@+sWh|5HL ziy#^l>WWbJmOy-2ncJc#)`n+X6e+=omz8d& znfBI^R_$*)h(Yz`roQY;_GM~IegN_$C%XOo*v^zmc+8S6eb=pgh|X6n2y=0NFidSzR^;abNzz0_Pm5WOv9wCt59gx~WA%Rv zo}18b59vIFe;oOJLB6cJQREy{*Tmh`-FDiR|0<-Jn>{>=F`EYsK+z zDPI7y+N_x=>Rfe+BzjB{8DW9evdE+NSc1HDl6^ zq50oq@H_L*q21E2MAj2B`f!EFX|%vZmX4bn&`OTr8Ug(fo63ucr?NF8JnK(%6itG1 zcxr^?NbJP8WIPFEKdSmve{h~9po>g+QXei*XtZsKcs{Mrjaji1if*5U&&U zeOJ5afBu_@l-ZY1OX4|vyYJ!Q^F(^)dEj2h*_CRpKwc$Qdn>Okzb;Xz z@}h=ygRhTsf7$BVuXuf~22M98(vg2D{UGKYf8Fy@_g(-WK;Xa2dnW2Q#14#ikn!6B z{xX~(=dPf0x>?4u%=euQaM0zZe3Ua01j^hT{y(OFj;pClD?I6t<6P*aA?${pnE<G~PU6*EE?ABmrYy%M0&VO4L#4&;JcBpb1*cY&6 z*4y}Xg@0zt)-De^>$;^IDk#W!IryJLaRwPCh27w*OCy_jEkEmq=06_0)4#Fb>2sJb zH=|y9{z2I%XMee06?V{qhs;>7tZqOzLYG8*!;Pl`61L)AfEnOT+_J9Zz0qf7_~IOOmv+IWe4ecaMgTmp{p9MerXf zv_NK@q{CPvyc+AA%CWh)SfY1~0K$o2@2I7`1F>Tz_7$ zMOyrVd}Ex;FjPEU(?Ut^xnfrM*`n^d(hg8}Ma#l%gOC)OUlfFiGhwkhCj8&5KMxW@ zf4{Q}Mjq3>w2**n6n4lqv#na-(Sdx=kfyDABvO&_FSt!ew+No7KDhopqD;YqzI)5q zJUP{0EEj+q2il~3JC&*lenn!L2!FeibxLTgYpMkR1DhSf0lgTlC``Hq+CMg0OK*M}KM?J3&;% z-ZQOaI&D|$6?ut1SG$un4Oz6{a0MC%63+^y)Z(EONvu0#8xG|JqO)UJ4iMn52;yJK z@R82jO-^@7^HAKa)4_3(IaOn{+SNHQy(UBhSERS7b@T0}E$u;VkUnB+Vd<8aWY(H~ z+)D4yETf_Y2`|3=9~RTkgMZjo;ClF?wR{6LdUQGFlkQkwYzKKU0gxkp1`a_G3w?rj zdz@ywO)ktf9}*=Nfqoo4F`J(QYZotRnWjmlN~(J~Wnuhy?@y3vV_5Q)_F zY-z_T@j&MAi6FZvBb|NwsDD+(y#iEzC#pys19NAuH=O5T!Abp8j(?mya|;v&g1c5M z0Sl{!+=LI^5-w}_XIg1StW6W*R`Z@!REZ^N>&qNo^P+-czUo&=rCSA536>e7O)i^T7axoy=?F!V0ZvREfE*`6FK7+ev0}y{o>#E-waGs1wDYsox41$q?lBK`gxEqZJI^ zFNf_Pts!SHqiUC?98}0Y)G@V7l@@OxnsNW($mpDt{r!#37_+v%!hf9C3G8e;E_y z5I^jfs;bpAZX+#O2kxSlAufKu>TrZ0EG!xkE-$mpr_Pfe{FB7R(TD&+s}!h`8jkcY zWB-WnMXeC$G<+UES7j`oU&OiO_e`6)N%s9L1EL^1lS5n)-re@K0)h)}#+ZT{p-n1L zBD!}IIDgbl+>0~Ce8&p|5XFk(6}htJl!NNOm}aUy@k>AM6kg-Yy8V0;EMk}eN_#n5 zk1stNMNvt3mj`z!rJ|YFB|uslj(M8Ck6J~!Cko(yTA`MCy5MaD=vK4f&$q9;*ACXvjCx;?TnNb6 zXA)s>1vjeu2o%I;l?`ns0YT-fO{RqsP5nr=mFMrECbOM|mxqQ9ej&&K)*Ea)5~Zwu zOMlytRa?~>qysDXOYX32T9tcx*qVL?R0;xJ$Kfr}lJ%(7=7*?>OZJ8Gw;Oy`(%6UdZIBGHpU88GDnRup%l< zQl9owesch0!q;pJ#i3#Y0HSr%R(T~{7=N^4jG`L{q6x^qj(6}=5zL0kY$=!**{MtF znoY*5dBGqoD*!_<^qk7mkWf$ShBacU!Yfo>b>?LMN z5)K33rsODE2?qRWdmtfUqayH&Y=5YD@?1nW$4qs^&58L!A>Msddb$Byih@!J^_B_-aP}#|5s`}AyIk<;x(Yrl z1XPz!1rH-^iN_+vi4PrNWzG9IkeGx+aRBl8asdTYM55mS2|&!fil2{vBzAQ9f&f^l8$K~}3lD`&M*s@_qG68@*MRK(g z7!{mocrr$e?~z!Uo5f0>rZhV>$;*QDQE6$8zxwVXha`d3cgG@*`9MCtb#-2ptSxG! zn(xhmG~XtDeUeUR&m?lC`+qj5UYc{eY+0?45mnN%44|Rwf{MBBxxJ~=KrX0W`~t~y z`UcIhhS^6k{3?n#w6M?YwPB0|*u%PBJe}DKZV7oDta}v;f$ja;?;rY?wHl-|9js*u zrdYn-)-6Vdj!@;Y0ARkE2RO(rv2F-mDvt0!Yrd8g+)$NvyK^N!gMS+ibZ_gl5q9ZK z))$aYYdxRjTTtgx*xjQ1(X$LteHuW6{k2+)_K~TC_Bp{Bk;R@;Z~6NzLh87?QH*v+ zvHyBh_wo7n|2V3SDSe!5>QEz~yzU-T53;jFgYfIDj)lmRX7w(W73D~9sX_jJbBsKVW`?gIf3-S|%dt@y=yJSy?(S4M- za~?F!QmUr#)@@znEb5QK#XHvoDvP5Giq zW$SmR;0G>G@(oSx%eBIgYGfMds1j$u#vKT8wO?k^fmRXL<{C1602Y{{bQ7OpeSoh! z{ROZYZLRwdu7BnF0wx=u(Uc0#R)A9k%R-K7TzKKzd*{)mj2A(|xOiqvW;U}xcnEE| zoHb3q;1FIO^5AYI$PhG+Rl4dQYE89|LqLPEKIB%=hy#l}pw!lb+qByss?g49fX{i{3aZ}XG8H#YIe}x-B&<#er#T!>MG#XdJ znv6NVs(|u(S}mL_k+{-^A5|3owjpi|lGvbl>dL%}?{xT| z;-uPb5r1gOv_f?}_c1|(wAjys2v%id7<(NI@%s})# z<-?Jk`@_wczQThA)tz&K`$Yf{t&qmF!qv^>c0R9}{zhj{mmFf&Ru|(RqaI`o1&gPe z&W{^=>tpy;w(_0psQYI&IBcLP+@VvAeHy9a?0-o??aRAGl3LH-C5lEIRCTQv3$)HC z`^p2XMqDV}xp{hqn@9SCXco@_rt8=Ir`@3rRw(qR6!T_l`zQiaqcBBygEGzaZ6fHj z*A3*=P&dn=|8UhH;7-dy{feIYrd4Z$+1r+MoO)toCTYZz8V<4d3Tnh?#xinpaCY#P zh<_STY(883oO*IT*yv$w4r6Q%l9V?hh>+q7uF1Z3_Mu3MCAAO~152o;V@Ze}YD$%)zhm zWeVy}4c3}JCd{lS32(eNExX9Lqsilwe1G0qEDrGPN*#_OLOYf#p62ZRciW|CUf*BG zviX(xy z|17;#zwcN>Ej1`)=}wa2`t!z4`&T(ZPPJj7yDs~9PM`8f1#32dTTD*t)Ag`iY3#3e zpUar%k;=Y@sJti5J;+x~hs5Z}s*2e2D+^bZOVU>u4IZEXzp%nU$H0z&R&AM;!y>b@?%N?VwQ={PiGOyN%AKvwy^C z%d>LgfOsVZw0hhLs8AI`NvC==zQcH|mTrIJ@`on=piYB9C^)5_bUqZ#?7X$)pmz!ti_DTCnj46)E@Kj$_EOCj?n(gQ9H8oh?XG)@KF9@}ZYy zwN}L1zz{@3)$1}2GvpVB{fBLB7IRxUPN)}P4|v$M8fSP(HZAg4{D0)(ywV48pPHe^ zU{Ivv(6OWyZLOwSFfG6Y3(+1&B>e1?yZRmnX&p2G#wxXX0jYRq;ngeUlx1>Pf{+Bc z7tL3inTik9hEpk8>&5VXS3lJttWP^NxBuvpFil3)x6B!p#~$W*?IWFLPWlTb-nm)Z&BHh)9q^$$9 zJS>M5Bx_{}l!P>k)~`Z|3aVWxJ4K6QG9?+)VzmMF7j5Xi%+Hl?+7g%cH&KKr0WSp z4vA-f+_G1~6*H~h(>ihikQAbQmUiRf;rnoxco3@Bn2Sf`zewKzD7^TSs6G^VBUW_r zT12(0pVASe&wqHB!9ufhGrNvfnGr(ckVercc&QNSWu#Z-?^g&7(O&iR`@83k_r zpFOtW1YnX3FbhrI(mdSgajfJde4Wc>=a)!?_@_c7hA7!L zD=TC-E}B&Z`;ob=Q#!BkvGVWG>NYJ41QV05uHkP|9Sgo~AF_HjgJ`pHCXJRjCDxht zZ$up7En4BXYJZ<^B!ijD!(!$B8j=Do(-l^O%9bL~Q@0YiXcPo@1lbMx8I} zitLjI1VH^+EY92b*T6uSIuuja?`{Ck%)dAMbP5mKOcg=E?}>lS^Hwo;G+_4LBhqv0 zVMy=Ja;KWNDpmfjtsZMOX5%LmWg?^)s^63*4uAb~)whE3`QcM9x@Z6*a3d}s?=YjY zIX|Pjujbjl2na`YHnNvnV3uTy$Ep!tivHZCU!~I=d(Wf-=sa9xm$--&!|rd7Qv+yo^1>d=psj={NOU}s zJAZXz1mk17W|wiPw0hXdEbLd^*n_~tY(gz;E91bP#5X9UmYNl8eF}{?clKS1nQ=SS z&PFQbYXaERDfEOQVBkzrs4G3qZ#&OuB6F!Ea$o!^C%VwMS_YT!dEz}n` z>+}^}hS^m9#0)`Tq>M@nG2di!A&3K&SIgbdTmge_21no|Aw`bl4h z2#N38V8?|>Y*j;JG#?1I)nFdGr)~qp)p#AqfQ*6=l_QA+4?1+Kwb2dgH?`275Os{C z?&=%gNKpxEB~g}@SY{bPBiK<@o+(j=OWw@{&o57rLjmOyt{$D~kw&F#AzBA%cz-nu zAb+>qXHsyFe$$%E6*Vs6W_~Gq0{DVh48X~t9WM(u1B%)lKdM@eepx&0J|IfJbQYnj7Jl)3TPGTnj)c0^#1 zT7ikY;v33neZ}U?*DTG7rdOz9L4Q7}bF>4vG~b`+e6lq+?Fg2GJE*F`rLLdGN?QDE z%vZ}f=Zh=w{={!51l?=(fK!k*Mm{oE+N@Z!VKEBJwB*{83F!71jv{=B9t{Uk-%Y^6x2`<}UH&)C9p_=6|QlW?UTx z6}&LOu|clUBMJ|}jenDL#!p*ENHdBjrUy*+ed z5rFU5*6{bn=$dB-9=p4r534}+{J#hopgA$kuDtYm<)@D~mgm=>e?Vxtk`*SM%bsFQ zDi|jwpR=Ol!wpBF@%v27`hSpQHp9cy;^|V}@4MY`lDdd!BPCPgGPJKp%glXEs3!)D z=r7`BN!#;g!yn(S|JeXxctJDnbpTI_ju1@VK7aKo4BRdW5I84Vap!nOBqS^q6}PPX z=kDidQpLwK^X*7O2mpa>u9lm)3uRF@X-Bs$&F8Hx7ulRrX}hoY9Djp(rm8A2KF54U zQd~uOwfkl;2(q?lph6!Z-xOr?l3yk?qY{`lU5mGcRLB9C!C~9JTcm|}s4X5F_`5nq z=Fm%y02eYm`aDsL^oSrcz1Do$I4K#u$o4DB$Z<0}wAI8%bA44dS4Rc$!(K^ie#fk) zRvAET(9JsQScu33kbgDISZb!78gXOIH3boQp~)l&j=%uo=(Y5M;RH(Tm7{hV$Q3c> z2Jmk_-yyz&JcYufo6qAkA|fDsicWhJe9{Q5mFgsdotoT_t_?^B1^7mq|8DOr3x;OY zAePC+qC$Sn<6z*Gd`v3|iD{5(W3T3Cq1AE5egvN;tT_H2CVx7kyM!{QYtBYEQ{<%; zf}S;nZ2zidwc#`00CUUDEwe>0IT)`YHS7#u6{-_-$~PHRCs0{2UR87wY1_bGpsNjS z7*o(qhUBC^bV$%j!|0{F{;gm3nKpc4u|~O%y)YbjX`bJ?+JKSxTnV(oP&8MbeSi@o zP=f(nC^#wf9Dj9Vm~k@Ujn)E90p?&!ILt9h>vpBWYt(u8s&rY8B-DfjmZB#|DqE*I z<0PEQJMwsUBF*D$JtzZ|%?vw1iP$aF)mw4+>TncF(RfhAj(;Vsl6@>}}OYR&{0qm*;H>iuytzgWD&i zKH7TldfRZUV>~I2MJ8q-pKsj^M7-BX&^?(Y;eRK^+%p_#MaPwC{lkCxR>%yxS!rda zG4eFh6~>wfuv<`K;e*j?$BbEyzevyOLF%P+d1d$7+{zJn{nNOui!Wt=%Y5S9dRZCm zO}igFi+H6v^BS{;k~c_%sTd_RYvG}SAPH*ILGRCS}S@=j+9ql^6P>#_b_H=4)>49 znk%&{d-tT-+LU1AV)Jczru}Z(Z=+O4$bT%arPjaAKrACea3UEezI6s@5;`^Ij8#}+ z;`|-U43bA1vF6Ri*yS3?GbO_Al{=FMu`p%VP4xv<#i=2F-0HGzw>kEp7S)5fz(#R| zgjtW}E5mV#xKl0#P&8-HWY(W|A2m>K;s`-(2n^V#eJ7u{S(kX(ZYIi)iQ zAO#1fSmi?TsHZ&a;G9UX&EKf-{=rBuNuM1 z+Nfn!{dhl2yjjB2Bq)=4g4#ans;Xjd&I4@VS!qY4jHJZYje$ zgjm86!_42d92$5ueV8%BwNM1wmNpB(+}Y558PIqOpg>oG`t=0oV|PoBlLSBr=wbb- zWs=$g)GL}7GqrZ&Ch2zkJb!JT39I(uR`28AvA$!VOGbQS3xYaN;jcg z>b`RIIYd+eWPWG{814&l7*RUv-JmA%X#lMZbs9MpYAj%Mx)C8pp*vK#t(TLr9DKYvB_$OTwMi5yeS zfEU;VPyEihFZaT(hJ$0EzOF@bGIMHY664NtGFe|yD}z|+L0z7CJ~@Z){SMSSB`??{ z%he_|iH8Rg=2}alED%cbM$1JVNLPV-nT@k`@35JR$Zz`0fgX+m*liKceuV_D&xFQ) zf$;B>BG@^E#U-f2)qjqccspCuu1`^bUCn;GddrHB>Y1uJa!Ym?eelqeTj!kRXlKr@ z;WC{!fcUsiGgTb}a1K^)Uw*AcYW(?>wng0Z5g*KAqzDxg78Ced^PHuFhF~5ll2>4| zvBTlmEm-P2-@dC4-s`tR9`A6nH&!lXP@D+1&@+Z3koj)+RDVDkBbK6A6#F<^!zZ|y z@#kwoLp-drOm~h-`}q~iVuh?cExWqjskAvREP62`(r7gkCk?A!H?I+d#w|X;TWfLf zPV!$ouGZGeyQ6ZXRb|PgEc%Tmxh~^gTSv-Z_EGSkJ_4x53S4eBh$2?RY&M6vm7ako zkHKW}!maN-`G3#(UVbe|1l87a9K-2DVu<^Bi%o*PqjF=#vCn2}5R?i%;}=nM@m^#4(7;|bQ>Nfh^)8Gr9Y2bJnC>O?c*rAeFk=BTp%BGOw?s1)D{e=S|Q zUe+FNzkW}mZ*@nN6q5>T#lf%qZw>7mUrh0OV4Zd@XFeA)mKNJ{!C_v%Rb`qL8G?(e zx<))D4}W;B4AA~|S-ec%*zNt+PrCr8d1#o$lt_6Q{wsU?ET5Kf{`ix%jS!}xdCbhZ z9gjaXI6SI5iVtStQTa!{y$V>n{yn!RCBO$>7x%=IpFc&-WjVTA*W!dxcir1y`B`|k z^&Z3Bt^ShfLM50B>n?gaHF~VMWiKl246lB(>VIr_@C}Y|?@#OR6E@7B*Zn!XwdHqe zl%=igg$HvBzY(*p$h$6}KW9=w7|`6Ti%T@hN8rpkxw!SVJqt=m6O`aWe!^Z``r*@6 zpQhD5WYc_joy*Q3)Vg#vXGPEI#wqK`3KL19SW2FqAg@)O=D&^s56%&;fj;gL_JMz2 zc7I(=y9u{l5wu~({zm;ahn@znb6df`Z?{j35_@2dHNX6;{;NgYuMYGnvEYSH@#&5E zAv{2z5{9GBs?=+H&Km7?!XY(*LZa9&dKDOpOLd7P7n|h3?aa5?7l2BX2$%DsV9>}U z!5Jr|M)Z9+PyOyhOyDd*skV!mZ+V@0zklkc!d(|Zne9(jtl2HZrSR>%?B67DNP-UK zOx3t?i}zJ z0@2Pj0gM8HkQ1~=P8*zngO)h`LnJyRSJ~lQDRc^Ck^13`Pune=;(PRzYz0uc0)OZ{ ze0D4Qab8$Pi*oRl%8e4ua9HIfMitNOQe06=?vMW}xLD)(6OOZptw8)mpWMhcnL8}S zeypjkqk^^9pplZh(62#CA9K)La5-a=F3<}v&jJW`VavfVzPsw{=f|X_qJF0l)QsEJ z!F=CL?#l@wb=QJ6V;v}`ARrKkFz9fum2BXMe2(K^K|JDyp+uYkj1J=dI zr9ukCV>ijE&MEg=jo(VF8}rM+R!Zpv>=*=MSBu284VS~El2IS<{n}RiPJcw;cvp2P zZP4@z%j3bxJ2qTf12X=6NM?A8E1F9>?lXx~eYi`b>q8>-nAGynk{3cDcEuet0F0jR z#PVAxI&cN*kQ%RE9R)nmU0X%Zr#&+~_@?zEH#w2V@UQ|6Sn?fcJK&h>RW)nU;a{Co zU8{qiEXUNr8=`HK*Z0&_f`7U#dKj@O^l9d#<-_#k3w+LC=n2qNbvz%SNpqs(qEV)% z_1{af zgQ?cvmjScBuu<+2&=>Ik`i%IEOmb2Rj89x4y!AuGbgH?}4T9x9WrwiCiS3bzR~b4e z@dr;f@y1-lz8#u&S#RxsuH@3jZ?F=7Ul)7|n6{k^SNZRXhky8`)H5a-R2?F!d%bx7 z0%9g1H~?(j{KD|O)HS(;B@)e)r1I1Ga@9TB_H3oyWbwuQ+~=A!brfB zDt(OyUNWLa@P8v(mbp^JQZEVfG=h`&HOtIIob((KCdX=?5l0?EG@sSo) zG^&Z0oJgoqDHfCESX>5cE@vwENX?QkKi85PS>7;*k~}loM_)#atnTaKdrIP>FSaVD z(wv%ebpFjjtI7;!lsN0mM0Hb{csI>Bbl`A| zwA>5kGkyB;MtmC?_{X)u!4ofOO z(KhxJqVvR^B$dR2KRAj0R8K{_Dmd|#by4`jM1HL0qJQD_1eDubPa-tbVLTA8e41)FIfQM!yfb z^&h%w9!nsQ|A5%igey8I^p{VWVPz29JVui?jZQD%(gC;uh3VHF*(ekeT)Goiq@9SC zcJ7uM+q9zGEJNGVQfW+2Fa~2vw7-vaXX@&)RG2wZ7z+Y3B7qW3s_TgD*R4#$BY$j| z#RXGfxPM|LYhYGR|MG)P4=-jJm0$BH+LuZ}|A+Z@aR!G^Y1m=9$$O&?X=1MT94nii z49TXK--cf9h=04a*dqWe4q_Rp9Uk3!clbQfyfRLL3ao6KfyuCvvj=~ikt?a#hFR$0 zeJN(S+c2tdM9c5Fj?j)egi%zw=I{dL)A<(5WJjmdmmzRKY)=gKL2^pd*kC7Aj+ z+IU6DqnDM+MR#jxx`=Fz0gOiN5Qtn-^JGD=VoJVZLRUtknd;$>qVSf6;qwRzt0|zh zb1=+1GBPbn$xD91H>2k7kpZH^5cgAq-`vZMJ08{O-u3t?Uu}VVIQbw95`X5#mpy$z zX^gvuQZ#)B(qj3HX&L1p#YWnTar7i={$T3GRTvm$yb5QalOU$ylh0nVqZZgviMs#^Rz7(|^=BXg~NM^aWL2 z6U2*t0#GOx4(PhkwzFewTbQ74*QK&U9E(w7v6p(FrS+d83~(xEf)C7W zpZ3(&&#m!_qqxdF6My8Pg_uy?JBP&GK4BTVOs{MqhNW^@tLQTNZ>$X^AbnM)vQ#I4 z3ZU4T`|4e;A591}Ri$g?mk+T<0}R)2Q(@0b`U&!InmT>s1&z&H{SFDL0_*rM1F(N> z#TpW+P?7yM8R6to8YJVM6Y2r_zGI{x#rq)J&QL}}WSt6mPJdq6AcS$e<%CN#+YLIB z@vLwIvsUPbn2u&lBWpKyP<|Oy0P@=&uVVRYd%*DFb(_1IlJ1gX%sPU1Bu!?{xv{&< zO6p1Y;A~Mr9e*&N8fMGgq8-+m#KGU_=q?M1-$VZauP&{IAA^=**&a}ZC;uiWi{o&? z>h@w&WB|^!gAx2qfS4A1c83h_QS#sSwQgr<1vNT--r^@Onf@9=2H@#Ki=E^MHE3zI z6$j$yT)&X9utK~q@f5uLZ#DzZYo~NGvR;XsFt4Otynn<*V@iZF7Q`w98%j+=g5S$! zW6%aw79h|wyZHYCdnc6va;1gST}nf{WSHJ^!e4F{yRJw%Ih|@KgyR*sMf3nf7MrmL z(ZZSN#^~?ItZ3Aypn8lG&JJ5YKKxpFc}a;nPeLnGqoCgZMsZ@o5xw&adP?)#ojbp^ zV^tNwUVr`~0@@S*@s>?#Iw!)c0%;@z9DwmJis}Wkz5B{>~&={V*QIo{&u+iqVg1248BKcn3!P>QL-AF zcz@2Qo&=@xcDsTOsedAffzxCSdGm=+a!y}_Lmk2KM-C9G-4cvm;or1;^|Q)h=Eq`1 zDFO}Ur+lV0BHN1Va}|X?2s=G|gJFr=VrU|OSoD?XjC$f$H?02X!>0m7+*0wdy(wH% zcIHx4CM~s19hdu5e$;0I2?QHS*IIAT?|+l(o!mQ-MO-^VLkS-PE|1++PWUKTTe!&; z!`hMS9I4F=uxR$U!UkW|fL(3yHl_~ljJRWpHFZTIcXl$9Z6UTCVv5}T1pi!lCFKH( zBFPrZ;i$-sHjBN%YzcnB%+bfvs$lnFBHKHu8!0k34xvDAbAvGQboi#Ny3Za+z<;dN zAilGw+s7%S-CB8<^mVVj2G(Yn9ZAL`W!i`g0D?oXle-vLmj&a`D>3O#u;B3gL&nRU8i7+ z!Jk-uT<{AJ5f;=236eo`4WyPJvVTIc=t9I+*4&LJg<9{eY2x*&B1P+(mJsJX5MgYB za>h18&ETkjRY81W)SvY%A=w}~&Wpo289vR}W<3CEzoW@k2?m7ttNbksUR7DP82u6? z#s~~L;8)s1&=t(&k*AacC_wd`p4uPGvJ&3L)ZW~q{URw=Usd?U{*;pi;eSdWTuKgc z+7Z5g{_1Yy%^%o`8=3uKfPbF7RjXxd*Q^C1zDpk{(+nTWDBdwK29wZjGzaO1MF(Zc zL}IuX_ajmWUAEnV_FzgfQMp4Xl62thiAQL$&g^NW0IoCM?oKG1+#VfGPRovqJuxLP_~y zfGW7Z`>rBA?)O$DHGeLxy-J!TyU3S!(_8?(XWk{PJVqCix_JE}dT?w}O8F0|6{v!G z)pml746a`pb9a1EnS;M5u4G3rkVbiU*nStGH7wklBcq}05z(b|_&=^hf_@pH;d?N_ z+9|k#`^JNkQLVfqb0vI>a0;_0I4mbm?J4v#MhE(ivb~WnrhhEu7b3J6)hBzXv;U4vf4*F5JtcJCu(jNslp@u*C05&-%o8RuVJA9WVcrd*0H zUT;bc6~aQVB-AC3@+G9ZpT_S3dKfmSw&q(Z>{|Ob=);^4*;-Zxiw#Z6`w}fecm&C@ zA7L2N{nASw=6^F8g$&-U75TdxOW5df5b&L6l4b#sUoSn{f7wD=$gB2bJ}d7Y`>UuU zc~xu+aXmq_hd6m)kZ?*m8{c=kCaG(Jv0u5>(wCGb&06DDNW1El$$^y3Yo3ej;K!WB zm>X$gALaT-CViWyw3pw*bMh`WB@HzIypr-Jf)BjGsxY$<~+;K4Wc@F4%n&w7=uR`Iik2x#7=|O(x&{ ze#n7g$bU9zZJkmAE`*Vt>n%RWmO%g7?B6It66AMa#^t@nKFzrWE26mN5CCh9c>Pxf z_diOii!tT^v0vSG{xzrYrdSTeiISuQMSodqH}dTa!-KE zT*SW6s+xr1#P55*7o1*inj48bi~! zTr|iQzJpU2E_uFBGlExc0bF>{SJC?3wXDg@7+ZYMN~-W$ItRJErt9SD*`BGfSq85a zvXEf7a0}+|0pQIWfgfm1JkBdDUsvvF{lIUI;7Eb3fj3eHFLDl`!Fj6{9Fh6d16)d6 zD}Twr!~4I?mMUzvPQ96>*EOCljZL-4?sDq^sEjh4=fl%cLZVEDbWWHdbt#`&6z!M> zha&cPtfX&X{lE)`EQy>JV@!FX7HqO#S-zY~7F9Vz4yRmm2vK=zb8cvSfc*qkKKVx- zNm8z?VA3P(<7;kAQlpPdSS=K4Jzz~3>VLB@#ABnMI#-#z^Ubw``CwSyRR@O}_YrkL znfch>$w_p?SI1(?T{B`==G%KZq*Ap(U)-BWC3g_Hv6Y&TvP`0Rqq0Ug;4p_2)0p+D zSl7n42xD5l12R{84ycdzNtF#OJooCs%e)|}f$f(aU#yR#LX(NjXR1obM26znWA2ufuwAD9OnO1u6hVwKn0BAQN^{4FKBKjdof z=yF%T&BI;tB&3$9^TH&AveTX>Fn^||Dl`@w@$EQG9)cDxcA&wmu&N2zvqST>2%S}Z z31h(xaTZ4*DLJ?T?SGG7 ztI8A;4O{iTek{uHtQ3+$77QC+n0VBI+=pDF9{7#FVB7*b?q=)lAqsQnlYiTk@y)!^ z?2v-3ZSz?gZn!H!77%s9ZG4m@lgTU_8VRrHL=_XL63$?|69kbq7KJ|O+nDH>n*Njm z8n>n17Cp%n91h9B__&F2x)Ne}z>xWC``Bix=UKiz`q@vg((B3bXmfu+#`979dc|+R zZsMphpVsb46P(rcS&0@;7JqFd$1JwjUBIUAi#lo7SU!+ZYQDpar72Y-oGPmwUUTT8 zQZ3)D_z?!3nK#W6YMw=ykv%u=o81xwG0*!{NiPEwWvRbKRqxtS!ibuVfbdEquq_h< zgkWy116WaMh95)|Alk^4TOKTBJ6E6+eYOZDT5gqh3iW0zA*NTc0Ds+kEh1wdby8y~ z+pkYb?~}E_xs*;jK&tJ=@lcG#Ua##*>K%O#X$M0|^ zgL`Awo?PosO9VgD6O4>kY4qF?!H`6hylc!&S>OkVn&;5gzJqIBGYG2=tb)|#c?WVq zI)K-Y7%qJiKdp4JSa)cOPwYd>uVGyUk5{m9<1ZpuD146GrGL+5CX&RID}?HO9lv)O z8pHl~nWAX4gQ|-z0eO0>6;RTOebIjhfX?w&6BCqi#Oz7gp&*e$*kAnr4)*08R{Z_B z!j0%T0xY}*)bfqWBJZZ)^wt>UzPB?*7aiU+)uQ;kAw7v0UF)~><%Z}216BXPf z8R_Obj7L<-Tou!1*55o%^6@zcCrbNO z^~~8g9g?7qYiR7-6U1+hquHXf$a6R%ZDiWdAu*L-UF!&Yc!zO@+*;qOcmo+gDkT@* zVPw$9Sl@#1_jST__w#jKYbTScDi%R41y$AFcbIlDEq|h6M<2{I$VN5MC0cgC&)_<~ zK+MZq`0pI|6iO(*##$Wx?X;4%pf{>{mTLTM_shqQcLaSyB;aos5xw>xGK_5K271L) zNe4f6C?ueAqC%6X@@3X9i$39{rzFZgIa`O177mkXFLCT0;d*?}R{!NLt1!c6T$u+S z-m^v*#edBW(G>w9Iz?(;EsuOw*d8M*UW0@@;mw?=SA19ceLe4SwSER}GFh-SyuAhX zp86^X6Lh+;Wd_F@jdRvuUH0B;MZHD#@)+#_0Pj(6TF1o1Io2m49uwTMXy-Se?tu&8i^w+r^0#!q8um zDC#!R&q>#Xbpo@4Thf)+%=+)e% zu?%vz^x5Mr?c~8p^T_l4m~$lvA;QFeBaA4XRw?^HUDX!sB{dd!(ZbT+n{L+3tyn!f z=YQ|wnUT6H%@Rlwu9In<6X>X1!)`Pei=6=xQp0-{@b&Oj-IK`zYHrJ$_Kq1cmn8jm zb9f6tf#L({#9*5o;?Zcyu6$bULiBu_9@)etQGs**yW5&CXWW*6vN&A1T!UHox-He& zc~D#luE%6+cTzK)yPVKiETi7Eg;W*pH-9-8kmMFEvl#`t<9d^!EK7D3UT7Jxaa2xn zA$dweLDjb5CRq2Mltgbbgod%9>5V}NR#)*5YFTK0gjBxXq7Iy7MFW+60Zi!vhIkw! zhFxjrl(PFRc?5TEcL9tY9@mD3!l}InlYgbHTTQ@3fmw1Y(nI%BhOhWu$EUq?iGK^M z@Vzx8K4sd*k;jG)n7u41cxEK-?Dg(~xLyRb2t;j`qG?;7)C62*Ipz;ePxGkG>P-W>r8XR0ibx=l*)m7`-I&KnF^?#Ff?y5%7 z$CqOIYBSJJfn{a)QV59eaax_Q*pCA{sk;hm)4vyv`02SyWLnGU8p@7@aXo5U71K1| ztJaVoXL?%x>2z0$>KVndOu~1QwVuwfr3v5kLiQPjL9c3%9yWxoWg!zufRlY4N9Xvl zPZ4M^%}s;rN)%;~1JouFa(@#m2f;h^S}QgN_>zngGpy)TJ2p@o{20YK!yp{BA?g>Lvb%5gFXLTBp9K|q(6Jq>5l{&hqdZG zq5U0Ynf(2ah7!v42Y*?JAiTfg*T625-xh043$f9^4V>(TfuinQd1&84CG+S$q@ONV zolT=;we%584@GFOmZUc?1a(u!GhTi3T7m`D!2QdwrA0=W4~24r5@%zyV+EcI@!(6J z-np@o6S=bcFLNo@G?VWkj83~4upI(erfRSY8Q+`D`HU*pn}4N?VJtt}V-On76AR!V zy8gil_HaVEE`g*#m`UEfAAM3G#c}{cK)k;n$cN{z<3rMJ{lfw+N5~rbFJ>X|dSnoc z|Mz-ILJV?~;uK&$SF9`?FM=?P4QEVx`>TDu0AnnBR-uRN+dm!^-@4i-8%8hhcTeAB zA&)zj+~8lD?2IfjpksexPH{$WDbHwIh~T9P|ABHggJ^X=foo4hJIH+=bD-M{;9?%u z?&jW|3TSKx@Jd*M+5HJ%0)W`aF&)b3S~ALm#GRUgFzbLxJifVpv-6NJoovlt)OgN_1UvE^qtz5Fp9y~!=O>vXh3IjVqJ4}@ zzbdpHb+X?gBYi#W8w%jtDE-pF7b6&{(Ls70O6c147$#$8SkWJKD6u=ogY0M~uvgtX zQJDwA%@Id*@|0MW8hue3+#qCMQ+M-d)B|_@^Jmrpi*l`Y@AF2o&BbIWK=oD(oehq>YlnD9O%WrE;lr?Aico6m=o`rI0zYg2oU0ics?x4%U~= z*?r3Y(5GMJV&}Ub#{pA+`*oY4zvv>h(;`F1DQ~NfsYM6#buKP3$*bDHhyCcpjYuAK zK|*$?q&On$Nwk&o`?utDO)NRhHYCRk?L|$fp7)Zm<-;<_^yQM~jdB7{W%=&%26>yG zLrizW1{Qw<)=?p+X8U6AyRMmYrWfm=QBPr+9(MSn z2>)LvFW=@6bRnn%_vAUApc%3T13B32KBWBgx;1|$F*5q)_r3d$D<|Wzi*jJqjuwIB zLD!REe>t(s8Yv385F2g8;BlMA=E;9C$n$NAHoS#Wqg8k8wi5p*Q9i$i@rs820re(y z7v{Y8G@y2lF;fH;=|*8&9M4q*$FidJ@I2ZZn@#YUE15tm(jL-1n^B8$ApmFG4l;2u zF@1m1=?v}Ix&nP&6ih(6?RiV;8=_LA1u;m8VjLsg&l zL-W`0<9iFcMPd${OW_&sia$-q0kInP4^h}1sG%U?$e2vLs}-`7!J9_j2Z_f39*t&Y zBGU_*2hv}+1+r%QQQ0}#a&SU^zGbU&0djxpHAOB3`;$M@mNuYX_V^RZ2r@EiW7LAM z!zQ`-h0;Moh4mSx$9O8=?7%$NP>gDAl2uGy?2ZuSO#FWExmXiq@xoz@InAvf7ImN& zd?>v#VRrc|2^HDxE3G!O+UV?v#qPGsXawOypxkXx7cA^CN{ousFt`Nh%9-7ZE?|FJ zFPH(9=*vQcXsoI*73k@^=`J+ z7jLE2W6!C2<#SzDeXAV&hYlEikCBUoooIyaAT#AbvKVuJ_!vTUomib0)UrpgWHt7@ z6{!Fnh4;)pcSh%h_Nyg@D~!Nd6JdYb+hs2=4tx&uXQcZyAC$QGt0vT_9+)q3&n-;1 z+_?lQwTwY3Ajb@}&T-u}2IKFUic)@WSo(M@SpMuSQ}YZ*Ei3?@5E#$mDcx~PF!QZF zkT5pL-;&z!HO~kz=)?5;ovU^DvUBx(W)#6id3#vItQ&6E;0I~Q`-WTbh*y7$WKCYj z)jffct??@_+SYZ6`&)tJt1H*T%e^{H5VWR&x*p)Ppd-gV9%Rc#(K3MURuG9q4ytO; zbh3JSNe=E5803*?dPglhU${$YPg8cMYszz1+%(>^Jz4cjlWC=mN>GSv`vjx z_>f1W+WY z?tjv+vjSSdr_#vwp$mLGG9k?RW2_8rMgJNS(%4g2iVcuIi7;tv{F=vAFaeMC#DP^- zw?Bi(^6k3eUHwE{F=>H3UR%zzrU4|G81D#G#)v6ywBF~9d4s-5Nch_Fk^T%(Pe-M1 zXJ0yl&Q?|MDC&$97*&6Ora<<$Pv40*=A<2MXmqL*HY@gQ$u~Q^>f}vHpO4{U2QW%U zcJgo`it%Y|x3dBmr?(BUdO!_S?`chI?==j9&on?}hP4M*!$tlxDiO`f-+hdb(WIJK zSstcW*qffKd{le$6(Kpx5c(p3OGNe&OqXU0%jWClRYGNv($vn_q zE50#o-dkC-2+M1mE)BRcC7m6(FQJ=Q$iS=f3-sN>6f&dQKPU^4q!*-xiVwiNE3&J{ z0*5i>zsMX@#wdtGUZrkFjw|V>^dmlcOWlgUz`1) zoaj)5@iY>j-TX*D8lvtmEC%sP*Hl`t->Z+jheF;J-1aD`MD4;W_|=8FxjaQ|iJ zFxAeUY(Z>;m;;Nmn#xmmuVL7SH71$okK=Hg@yOjw<_&)g`RI!dLoT#1h!sFxN@Pj4 zbWcTxIjgF(_yhrtjqd_`rb3CuL=>?Do-9e*^$Tp2hkC;=!i)OLa_kv&Q0a^kr}yJd!?Brs~z z6Gh1+t4L590ULVVHMR54^Y$7u$(t=IDW;f|2(AcqlR&rs_zXp$6k$;np#5`Me3WCA zY}kKh<#Rls-(70Y4TtZ=a;Wl85*pEP=`%nZ2&aq1$ZTofFz|lRB>@1AUKrGXWuE@Q zO?$ugaaDuVb5S=%UOhD3+I@S9FHx>&pTAAxH8fYcJ^0`_;MG7&3f&=TaUYic3K2(y zf6t1YpH0S*EdV-^V7T_&*At`Sj46)rSVDirK_p<@SVukVliLA(S#Q>Fs(1OSw=JYl z-dCin7kXK=nA*8+y=<92Gtylq)zKS~n^qKquqPWIPNP%wvJ*Oz2Qy*KRlvH0>d6CzuKbrhfx)-1CBsH?U>Z70u)|xeb*$NyaR|J>WntLK=BN=~j z9Mka-WEuOoq+d-&QRQ>wC4ZsM4k-eilYo)%)F0PH$v1e8=lzeQwzEVnJe!F-V^%na9PWoUq2EDO665R8AO%H z1BPoqJ=VNxRTV^ zqYr&D!#5}Uj05qInIKpAMtbU@aY@uKHu@w&zb$!>e*8y09dKk`%n{ALh?al;uck~E z)$@Dwb(Sbj` ztOMD_ryuufG5v$MdK`by)DwRvNK#dnHVzb~E*LEWYx&(8$)rcUQ1P(NF0zJWyVd`C zziIlG$OjN&46>|p^H^_F%a68eIaM$U6Pau+ELkDL>|-gMl0{Nj{}a4>*Jt0U5;q7H z`C|uPm9h#L(_l>qk!+OK1j=b!TaAYI3Lg67NGC9%&W_aT3iEQ`BsjGEky2;nSd4C1Y+vwbRc1BoAYpm-^Ise4^3Gl zJ#xKkt8T3j=NpOt-rujykdGK=*;-^aYzYa-WC;a0kpvQgArN7qpVo%ZR_1gT81=p0 znE3)k#SPEz@@{`yWbk`&7SZ&ud1L6{Y^wt_oXOT=a*@wuG96Uy4Pzp>WJBma6l~h* zCbVn|G6BuJO?-@a;Z_G@KT4Ntw>mAxTgUieIENR;AQiz5gZV5z76x6A zoGpB?3ov_0Rx$ua<8Tl=&RzfUaHWpFD(g>GsQhf4^B{ltYi%`N&xt>P;RUBWnQzAE z%8Wg5@7-m|229`&DadR!SyK=JMYDfU?4oYjMVUq3An`gO&k@~WRzaBwr5CHZJoitF z?lHkD&N_!4!u2kBnTmEFqx5M-_5*SpU{(J6gc)lLNMary_&qmls8d! zB(bTw9zv7?(j6PUnZ|9yKpk>k)kNYeEMyHyL*ILNp49@NCV{Evk422l)j7ndw?lAj)A|T5W$Zwxk^cjSaEp@irs)X(YEr8XRv^GQZQ! z@$%zG*#G(ET%`13r9&oeo>r48PP%B0K*O4Bxp-KK6ORozZdqhuAtdb6EdXEXzvc~y zIdMUUor|q`YLHz$!CKxOR3gnGCLr&Lvk(N2pIUD9^_Nd$b!W32BEK5ua0}kz*gAha zT(_iAqzLw&28^GDWQ6h4gVlHO>rymLCH$8}!3U9E0XMQ2WyLg8HU+D}#W_(O4?7yb zo3W8VYAb9vK69hR%PoO*d3kfdu4ekPZzIP(p0E?QkDR%X;V|=~Gb493@y-4$ePn#q z%0=qXbWK?XGLpM!zlsSDi{WeWrK^8g*HWzfgEOn^sW0v9KUTf1)Z}wjKN4$lcYQL^ zi3Vvq%pJ{8*c+|MuDx#2dv7XhjhmWdeYrir)X2aQp%+Uk0%@*fS?`AQuJGAh6FsG& zbk$7+%lw7XgXn+(%8*ItBTh^Yrkud8SG#)Jr#}l8nQvPCY33s?ohFRNfEs_B0co6h zSv26@V23hTPXLmw=nSpNG965O`*^{?UrATz{tHR$ggjNVsyXUIMfMc?`_jFf-Lu+jbI5S1aIfCa@kQ5dlM1?7WGu<@63^_KrSm52C_ z`W_W}ybS?95Bxo-DppI`AmyZ*F`{{reLw@b6#qREql904Et!Kul>evE%=9OyV3Sra~> z%HMf8wRN8KAa&k`9stjKcA>kmOw7g$jwK1uB96wnbfP*0W6`fvSRz{HVkcIUTuFO< z5WQlTxIgL+g1Y(dUW8fF5ukS|XnlFIo3|{^NSGPwES5>*33p>BV(^uxi@%pfcg`Fn zdFkFaChINi|AE@*I%a?FaU(IsF;Dx2w}_04)<+cOVB5do?!41=cj0`kg?Ne;Pvr>E z5b#3D=ezKENehkGVEpG<>xf<%X}QqjDxJqXeccV4SN??bOR%(5T1aYtm0=ZDbaOss zRJ=k8RW%zm(;I=JbzQI zZrU&lx{@wdOo+hy*a-*VS)(CDYF~Iy1p1L2g{J9kjPE3Tj2w8gl68E4vP@2mDApLj z+N<2*10ku21%ZD(kLH|lVeYIEb+#$ST929u90Hn9apoXM0F|xt2$q|VW)Q>ZgKpcI z(ik%&7OPxK!2&tP(lY1nBC7JvLs(NMQp#Kz&PhVyGQq_VFC$ENgn(7?$9eh)Do4Po zpQ#V3-x+faLtZHXcPWxZ>VVA7O=T2c-n{ttC--)V{8xWc*Y`_ktk_mxu7>Hs>odqQ zmtA<#eNbR+CueDQj?oCTIKTsR!YQzsXF@NzGTv$1aexhTkkVb#9C0 z{BPym!~K&>Red=-TEkJFvAb0nmK2mGBr0H9t2KeZ6D?=egbKXbwi67c5wqty7TY|uR8p#qy*8062h#Pf)rHp`^8J|Lc6Ywu$4?-!GarA&V-EBGXY zLY^}{ob%Q##-CcfIZKx*&n0oO+M;2l){?#?9$|lx<&W%!yr`Q3pMTck{-S$G*d`o7 zF0^=aw4Fh(M^5*ziYU!x3Z$0~D(HnQK&b3r7;fPvAqIzI*54{sU^HFi9#UMGb%X{N zlGX7=6S}65uusrBwpK_&7r+8&>)kOg8p6k(Eywh%GgFCBcoILT0`% zVlArGOoTNW=}srZv@KcDG%n-&`5>=D)G=r&r;BqZw6PU+mJsEwgn8U)_35W=G)4Gm zmwHG}?yP-CABnpJO^fP3KR2m!s;}eqJk5XgRa=jvi!D}VhU~s0TRQ2cjnps|zKrMV z5|)udKW6$j1_`kqcgs45jev{!DnJ5T^RkX1npZn7TKgq8+}H>8*2r1pi9nciToMvi z{1Tgrwld#X0_pHOJ-qB4*{8qhA@qE-#FPL{m^ZBl=R z*JJ^?a!aJO8O)iCHYhyPW&r&*r)HEdAAFc7B<;}33O0o^MoQwAsz}XE^kki4bVoc< zTo|Tv`uguXU~@#nL)hr~>|YUMmY^KgOk<)LMJiw`W_ZkrayV(0Sdn5*L;)mM->v&2 zTh~4&IZ?1_hu)}jid7F@gI)M zh0$b-#3W5C&$0em+FasYWf4}{2 z6CSj1xmUbGr)tsT(8msVJrSi=Xf9bYuzF#H4gjs1bd}k zO4nI1HSE5RktbaB4t09e!Mh@cp8`%32RV(|V(OFT0_O`6tMZgWI~f&35nV&nOaYSb zK9W)B`R3Mgm2VPM=?TkmnFJkzBfr`*5`;HX4&*)vrfmBvPW$5TuOEL@So|AHW^lMC zWT(;2W2XOOi3-<3SeBmiVZzrN2^@Cd)g#=YF8yV?z0pWp3-sAZh%Et2H(Zk3;T8ZBy}9%PEMs`$4yi04@nHrW@C9quzL-6It@& z9ZjB>J{ywgIc}4<->6oHFjmxyIwTA!Fpd=LuqDLK{yMCKj&6MSCL(kJ3^Rd!#%3^_ zzm^f$gpo3>&jNoswJe^ktDut62cKdJ@WoaWMg71ZVA3qQ!Bgl)W?%cR+i~bp5qGQxm9`(pKFY*$cMr z`Z4KA7z&5FWyrMa?sv$f=G*^ELz{EpAGkm2vgdw;zKclt@ zDqwhoT7wMyf{#Sve*kN6&ZECT_u(MFoK1@0EYKr_V`xnnW07val}_yC=T|YZ{A^ z4h#i9cO|HpWmV?wNDlU;O1Qf=RS-`v`ySml*XrJvti6&veM*P2H{iggYIU=C5w_ad zQj|kSQWuKdQubki4;ygf!ASzU|Bjq;6;!SJj{(A;RjFeEORTE4!{r zI0b*y%gTylfB>e?9FMZyb^HE4)J{|hm8XPp=6TFWO<>0}rIr_now>T>0;Z22cNCO@ zOXl|=fU2$ERi?GeW4xsx114$HA$)TctqjL3V0pIES8t{Q*ah|=vY*I8kfXU52%43K zfE`A9)OZ0qAllARpsjofR#%N6i&5(35{rM@|LC6>u0(<-=4R&0_Adl|3SN{ke1z#V z$rn{d=3bAgdA(mIK@H;wh6<*I3$9JK{?RaPoqcXk5*k#a;O8<%Pzhaja0~D_y~>D4 z(~`#>PUc=bXU^bgVmBn)ek0!WLp6|0!<-;|)q;uL)u=g2otE}XUX@$Au{$@E>*jwO zn2+bPp*1h65*Nvt#3(-pGyg;nZw*vmSVlF}6GpEBGSs2L1RumJY?v6IaFJM^sAo2T zQr1fHkI-R&{-n|`lzpG5q<5@YH{>QuIw7e$v~!vIqEvqCF{x6czQkDKtN z*5s&O^=o>S!rRO3#vi0#gnS`Dbp(GIE26~rJT}{*73RS$G;!jrp>{B?2XSW(m6_;* zEM`<-u3e9+uoLq4OWTu?N!gVux@)(Mvg`cus{BV@PWoeu15-3^5N2E(BGsBf03aK1 zUl=7r`fgBCIAqJ?r@Ocked9L_eXj7_PmmUa&3f4}Dk%yh%A;aqVf>o+NZ5Y_esYs1 zH(q!MD%vMr`kU&@ZQilCYA$JDG;WlcRJ@}CuABl9`NcM!4eS9A6gC!d7bOF4A&KF} zz5qt=gi+5tL`lI8tXK*u|6?56-q^NB4SY6j)$WWG&}=Mp_-w`paMdvgZlMUZIRPu! z;^ct0dev%n{G8bnpL5}QYp8#{e=HjRMX*PqMoXur;1Dk9JVs*Gr|&)_?v`g>q`qV^ z#&V|72^Bs_T;bf4nk}EUw*c*CGG_-V@pW*0SZ~tvI7%kdmh5TX5HX;a&gW|^oh{Vp zVL>rkcByc77R9@!8O5=$D&xN;84=Zw_V0F-#B~%ZS?iS+jpsC6|H6OwC2|apE0}Eg z)~yN*re!Oz&L1N94AL@XMxZr8l`Phh%7u@Fz4sUwbZYRw#M^dS_cvmvxyz8?6Xfn~ z<^$5ZHv;N0dMXBCCJ1{LW{@SmO}v1^TMTrDv+-v_pRu)6HZJ}k3DpOA4@~!2*adVq zG*kcPn)Rxn?iF(9;SqlY#8)iwgpoJ`MLvKA=XTtJvTz$DW*y+9OQDCZXsM7i1i1TE zTXVFd`^jbZB4ikA^dp=73Ls3m0^Qq)Dy3!10Rv<(-~gyC->+a?{&?Q{LU3mObJu^Z zlt6u?Jlw_|FAMG(^8sWxg83v~P|r~$9sFrHbH0k>`b%Qg?96+wl9Op%KW zjL4j12!Y4&sHJ04N|jGuwCUN~nyK98GHL)f zbrv$2L=fVv*GhkW_mnFVk$9BkDC|?>ovfoF-!8NLMX_e~#C-H?fLe~tFOQh0{>8Pc5eByA*wpus~|j-bhBp&)PbXy|dE0!ie{6+|2F^ zn}$oSQsJZI^M;Y)oqAhlzfHxz+HZMC^5KFJaBg}23Fv>evQA@UY2IX&cYqm44M#8k zVDlLa4n8n8z5tbAWOuHf<;pX-ImTjM z_R`}N8c1mmb`uwFDS=afniTVa=k0!==ic^#go_gge`eVvBxde_nmpxhhuaYceJPB4 z^vTr{aovA~$}X@3xnr=d8DVI$hpk3l2;bP9-YoZ46@j~PE4cgNH-RVE)NX3ZXTz58 zpX6uTUs-lgk4H4Mlo+|SEql7kM5k0SU7rGEZs{VvO~QkV-U|> zKZWOL=m0h7!lH8fM34Wb$e9=c?xoIR`}`v4^{m5U%pzSLQlk)1-v8F-%mG3ytZN36 zw)lASK_$M{rn0RX;gaLA=}b`vG?fG{q2qpJAhCWvY}H=>wV&R4-Wp_O{4K5`ze7)f zI&^=wBF{cv?oE=K&r2yz=qY0?WM=rOxiTI10f3;cpgo1T)kEZC#&eyedW7Qwe^eo@4oH9AS<3pY2BI*_SEzI+A703fYgjku`(Bp{Sl+)UKQ~hKS)#_#ncaG%#2nmKaIHLJ3_$A&`HG zO$BFxWG9H$1*Q>U+w0U?)M8WtN3ol+0TdfOVMiI7I|ndygdiS_wl_dv`)562o1htu><`h07F$K(xNPI;21YM6F*DjHBE z6B>jW5Mvhlwh{zs!`{ej=sN-h!R&u9J`~oXT2y@U=pr9-&B1U3!qq~0y%xHKgHg1W zewCdDPGD{fF%FR*s6{2fXY4Btr?sa86E}nZSeyG+dv%LPBzp zE6%01wXb8Vq|Vp^Q6j({sD^TKWBkkj1hExC2Cq3^&YDW9R657nk}4*Q!-+z*LsF45 z=Z&C)$%S2|-npZjR|jSep$314fy(-ogNXrMRU2uuQ$p>E%r^%On`3auPD{O)$V!m9 zug0Hic+-Q`LhcVe+=R}oXKl(YBvMt2Q28-eZyIY_u!F`QHOqqu7y7Oe|bUdO>Hmg*sk>xO+PEvm=jd2=z96AGC zmYe6h(1>P8i=(lr8eZX^rn*hk=c@5nfPPdrV8t!*d=;tcOvGBNE>1^BXkyjRiEr78 zR-jq_p>2ulb}x~QKEXERd6<@-`wL-44P?hu?3v}z08@?y#Ka3A;}jCa5vZlzGgK$5 zt~0cXY4m%v+c?eS759Gw7%!TT+Atns4NUVeCjkb*dl2t(S>K>!DD;M%XGM>8(+~Y) zQo24UzU6=6TC>IEk!OPdoFY@V_%8G{i0mrW+-Hskk545lkDjP@?XaEOYVJjrV~QR8__u3!?$C?Vf)WavLZSxs>yZ=^80d zkWqjn`RmK3hW7OkwH@!Nh6N}`v*?E5Z+f6vaAtnlJoNu5FO?W^#VqJ@`k4B=e$%ts zr1<0_HZAQbWEp_{1yzw~DpN}|&#^8@Fg5Rcpv;1i&;+1(s?VnRJv7U@Y3_?6L-L~; zfU(SlOK-XOO-O$kLxxj_<>`L?HUD5KN*!VpRBwfX42{*!>D<}QJ=z{gz3PIiol%J9 z;?vLkN}K?V8Q0iycDZV~1wW_s3<=Kw+Tui4@HdseVQAFF%eJ6b9NGBKe*jP2SP=vU z)6$NN9<(K27XVO|q96Oa`XA=%BVSEAT#hz{VKkH$%^`oMfG8xRT#W-omD*7mi zf&+MMHH#|!hn+Edi(a|@<*$rR-h&o zu~yMagy?_A1NuQk?3+#0JAV?Z;)vH|)UNeWd21c{{;he51s{iZC5A|8Jn#7o{0!nP-|%?;k;B&2|A-&Jiy zud_^u4eo^GV=`UYlLG?Mf$ZV1>4f* zv??_(+4=+rez@=#uX;mP$QvaLA6{3%r8KCTC+TG#mn7S0WU@&L@rFw>d=ypHI6$2a z{I!2dP}Z^gB;Mo`5{d_th2c41zAkt*L|62VJhj1D*`${lWFjpsmMClm_@uZ1Uhil; zXZ^17*yOA8NC0NscAil!xGQ$7K#T~52H?_MslmeEcG;(MzWIL2k1Nb3{085JrCCi>#*{}OD*9L0-wSbyk!YAa4+NaWRN!pHtzanj_1y{YdYiECCHe7;+y*>$T16p^8K z)zt9YgU>8Ue>x5zcOWPexr-8Jc1F3%V^7ZQ-+ztKuU37nZvsd@ny3!<{%+}-lP-o- zdMn&nRz}i11PEZ?E{2W~hS$DB1{rrXF2>+ij`uj}rDaWA$8;SB@68PAi&H8ybQq4R z$m|^94BIMlfUFK`Eb{S=?@CNAT}*$!URP%X4te;agbQXQ&9w9Mz(2C{IfFb%)omd# zdsXZ8_({WjQn*Uj*W;~+@Gpc?>;J6(NKnJF4aG-%TeWc&CA>52Xtn)ccS5FKn>!K! zo?nJ?>7g1uOy+V-JW&XFOC{_+uUxKVfojo*b4GIP5lOCj6hmX!!IqcyBV&J?sw`U| z%xd4Q7Rh_p!L^KY#JYxy)1O7#Xk`)RO-5l z{NK0EX?g`OJj?6c(A!U&S<_~sF_Q;SSWvziuRWL(oFc(9ll_-33pQRc;GO-xQq<{h zGX^yx3Q8i#velxP8c2T%gW#(sS*l#o)+O%ut+yeoka&sfhMGbJL0tH>PA#gDV$8;3 zIEe)X+VuCWV;N8l3jWQGJ99;@3}?T-_8*@>?s3k=xfq2;gqwnOD!i=B^jU7EV}<_# z$dFKmp!ay)wj1wU+hn@x(3VAo#bAJHwDw&d8(^z*KRh%IOG$s5vp6S-za5g(Ro-*G z-*?7VjqTd_O!l|Z{YvMQheOc#DwuljHA#vxso`>*tkypEk%O9Wc_C!3?hdlsjB5im z;e0{C&^Lz3s_1gWdLxbmC0$zmd~k$Uy-&Diq2Ldp8!>EIRTM*>UlW)00_=DuqR*b@ z7HTIGsBi8lsRVx=$ zr0s5afF;3w#G+V{7oX>}9`=Ck_m@JbEi}fXk5>prF-qK6xL;AXB{VOY$SwHSNy5p= z3YPX$yQ=2o^?sJAhXWs(c}dNwRQD@}W3d0+Mw}NeHN$_opS4KaQei3Ygd2goNaH>R zYI|&%(*s)W#ef~})K0KmwV#NGAzi2d>37Y(eF0>kZ2q5p8YCBl`Wsnb*~oTie5w=W zU3V%^sFgsYPwpf@K08|kEI?Vz*uy-{xi!J|C5w?pQQ9i$4_GyuLslB4Zqh58-m7qL z&*e!G5dD8vWpMULLBR-IKc*Byy5VFgS00KQJrwp4FdCvCj-KfBFed=IE=+z`Yx0#H z5~98N0t$b^bl+RN=$@*HOu*lED&K8R2*_ht9yh_1oer26TUXu0|@4>l>$1sO28jyT)GNkL^{ehsS1B`J|PwFAdP0 zFhU(b!kTX7{XwYtwkoa=pC11PJ<5NsQLP<4_7X={4Tmf>`!f|GJoJnLy8-zP)Q+or zWR=3nCE0tvF1v&g^mSC9RjBPrLlS`-6hLoM&Jg8V92u$d`%8y}E%rE873FV)wH-+t z@$;D*`br4_yoU)LNJERo_tBh6}_vJ1Y$m4-~cnhnE;>u98Z|4t1vc09GlRBah^V=6Wz>r zLg)Fu(rEK~%*TlRFc!f}wy1w!V?Fp>yj84e7-howP$;(Y-J8=GUk1QWA%60{wxHz4 zm>xM)Bznuea&_K1f*`oiB_kKWp6nbvNs~_PmulwzR*udIIkaGx z=R9~{1EeZ!el;9{^xyi0+ZXWZPkVh^w6OUFYXll!d?s=?AfG#CnuvdH$7vn2h%cZy zJD^o8h_)X$`dI+H&1~!p`R9mxHap5@wJ{~{ggm)u1j?Q7wC*tNd>-C?uWtMK}&rQVt^Q2$HrwNFRF&%T08%=P4;ZjV0FUl1QxT3`}@uLm&eT7{T>^0)S zPZQFg|Ivg}aAQ>&7Y%=%x~16K>>>B|^_jox<}F%Heltu7*sVHxyaqtEXrW(#y*;&Y z5I;1vaC6ac^ZrT#u;4hWK*F3;#rsp2a?ycP@4W2BM?Ptn-8W-^iZsGMd>_(?g2TB4 ziNbKz^FCkynkAb;N*?w=1#Ty;*u{79(%ZQDzEtKxPUaUoNXt3;2pR$$@aY`u#>w; zL=86e=g_EF=Xq)%O7qOC9v2<&@`gt6Y07cu9fQRW{nLL%gHD+-UkMv9Vm3%~i|WV+ zMB8psP%?9*TB%6wa+&qwU?BxjWAcZ7+qea^E1r-ai5JDHfJb*{q9=Wub0TXTq2W=^ z)N=i7N$wKa)0Ab|sCbq|i9Y$@zq&5we*d<}Mr7RAwzpy)PsaoC672`XRZtOWcwdGH zcSdGtu3mpha7fR0z|IZK%0;KrPs5+Mo};i(65ml5-8Z`dyXVt3f^8AWBV;ZY(#fRz zN3q+-=J2)VPrXpVFvR097!GPFpDgT}v)f6Y-#PICUT0IMj5mV51YXg?7_b8DN?}(O zZEU;PU(8Nt^tFLr zJp<|jN-r=|4}AOvzLKk?ArS!yYj!D(N0bQ=qXp`CHwgBRzi&m_Z4vS!*M#x&!SLqX zODWrCt0b^cWNvCwcKvdR1adaaSF(ggq|Zaj?s5e$x*!Szw%#OLvs+M8SpPZtrR&Qc zp?H5JEjIW`4kz}AD0%2q=YLCK>W!rK4`RIfl#3Ue{LkmR-bY%ZqzwziN^M^bAq*a~ zR@`vE%V+iWCDC+W#|e3y{Jz_9t9?6Ru?wqxzw{_TkE>Fy6oG1yP2D zBx}OT`Tkx}uCxmEimT&u?y%9KpUFvG;5C1?F0F3sL2eUM?r)%Sjv+4Exp6RSw#CW# zDNEzT=b(WOuWTW%QAx%#iK9Zsd|K#?fKFUCfbuXh)H*57vKW%Q6{3~z&+zQW>eU6| zo64)sq*p>OY5|aou6Xr9Vo4f?EZ%*J(DC8X-dF~EeK#%d%uaY3F!W}Bb=2NP`?`Nv z(k8heV2I|w$?~l3YZ^5J*mfAQW!WbqfzJdeJlN2FB-7RU7&eB+ZB2Lr8}`jR#JFGg zz+O_cTnKb2&`%=Jx0GF*n|4_5>pel zx1}6C0Ui5al`bNs396(Zplix0zkgOWUM>%9Q@_AM4M^AZo1>@)Rt0LO?_jORz|LUT zahYU;r*3$sR7qm~3{(V%0ZWxPRQp+~d@bIrKFcc8z`^1Q(7DC8hr9-OhB<$;%8!0! zcGi&DJ0kClzJrA_1JaDQ6z4ZGKp{0_Gt?^|!(X|u;3?1Cg zfi1N>!Nj`iDzF8taqyqnY`X#5ZB4mbajlxM};wM`#W;h0?1Yv4=T zCo`jbl5gu`#C~LrwI6@{(Yo@oChNr}XKS-a?9~@{Abs*zMI1&39T;(IkBkDZ+=nT{ z^~j$OrzFvP_DV<5=MPqpKhcnLr!o>)XLXe9p%^!BOqlMZ>02^AY()!8#Y2+ruRz7(9rgvh^|CV{A1zP#K|5(trMxgT4$L7-R7{TbmC}u6}mnp&buzmarH`U1jjO!roZ^= z;g~|8-t$=plw7@dS=Cz*8ruDqT&9RM*+(jCfbj73rm^o zFyK&$$#dNXw_bnB$!CD2#^VyExvo)|<*uJnyJXPn{ha7Wv zyH#FK9>}Cr+IF6wYx+KnKu^3XTdZ|%79YmMPp9BYn!mD3f7ZS)yt^{jGN2P=4{x3_ z-t-zY=X-2`+E@=wJo1%Tcct#Ys}?bSJhJKP01mPMvLAmbV}feS6WvEx@yKFSR~Cfj zM(=NZj^B(N86mDL*w&VC7ysh5{^`ZA#bBLX&GI>U#gh&uKr*)%1u+1QgDjiFGDCR) zlF?X=vKcPT`GIH-OJwDM|7aXyh(zeIY`qd*v+94vJ}*11WIxDRgbonRjDdgvG>xld zPJ+vo)<=I4X-2^V;3u?2M~SvD^L|x)rlAD4FNzPNz(&&c%i3TSH~L^XdSz;Iz1@V~ zlX^wonk#i3>S1)Ga7Wabi6H(!QXjQ*AwUukHA^)OddOVb;=gx;xx;q zJqM0whpglXIcl=#yKA#0q~(xtuU-v##Tx{J!+3w>!ZXb(q!uLs!{fn_48Mt4HxzJ2ug#sPM;o1s?Fqg1-_UUW$gDy z=skbRr%_2oO$g;YYZvCl|GjW;$bmUV`iR1;ZB?hpH;9YS-;M|~23az$)1pP!VhHrTJkTYohIAMCZ+FQyI3ns#*R70Og-uReTP_ zp`0RH1w$m4pRz26hnS0xks-PHDH;1ZGBfz;o&aHM2t%Is2d# zL$=x;WePPmXS;-Ma(Zc$qkC-|_z$=LL&7>r8~AZHP<6^Q&oj-?#J6(VEgQjp0Y+0bV?e~T4M2QdQZR?ac5iv1Ta`5>n zzPp1}VUUhSRK^oE!ze|Z{4chC$tOqp{kevs7(*#Lyl(~Y*C4`f!4YXH=5)KCR?P-Q zG}~4c!ryPl<;4k&g2~jDaxc+fuK|K9yPm8FeYgIV5z@Zx7G4vc=|HMT9im^1T+8(anJ?n? zUR8F-{=*uXbAo%n2Fj^N4K!qw(&w=s5b^x^u6zRMrhR%l?_0w*OmhUTAaRSpQMxrP zzXI2kU7{}rBfL`-ms4>~IAUIg%-h?-SjS}YY(Lr?e3X@meRTG8JTTi{ngfu3pLXTK z`@hM-JEj#MLZ?xqmE5)rH%|H&=bkPau|o_aCt@ZHS+5%xBmnPU&g6T6Nscy$HE9gN zVGhy92;DG76Qxmc@ znNxMtP6^8dHg$_+1#Y*ndb)joz0RWf9b_MS0NQuJ{yQcPX@aLoZDY5bFT<3BK4%%C z?^V!1i)mZj(D~6mRr!6cV<&L@$gQX7ko1)-3AlLweNF11^Fcgi>#@}>#w=HrRq2yc zfV!m9*3#{9GBh%=r*C9U8`OXC@Sb4OhfYg>rxcl1iul|sm3*E&aAmfC4h4F-sYR|; zb~827&~~_tR)V|IbqWX}6vChyfly?9sj&`@0L_b8uJ=^NlkPkS!_(Cz6M46o`q+-c zL^W(ll{Nkd_@x||&)4cpzqNQ4DVx)w?xqv9FX-QHsWJ5H+7O?K<-DayZ#PXh;P;vJ ztGiu6@-oa_h-!c;@V|6_h|%c_3V`24lu_+Zl+e9_LXHFJREauvHcqAG_kz!tt{mti zd^E|4CA&Y$(q0b+(g`AD6TCU_q#1n?ejWyGsBtJ_AyuY4tbw_dy#`iu=^_TEbgG&} zuy05G+Y_->GOKlg&MSMDPT-xd2}E&X!wp&@YY6utdX{jjG(*zZrC)M zMUxr%>x${x!?)f<1<3E^-#QVM#VHf^jmt9`)AQ@E5LWrlGO*+hYpL_Z^=Fb5PMceP zrP&e3@K8j7*ODPrz89#`lHe=Z2e`1s9~6OcL^CJ4(&3n_f%kV3=vE;H;WVG7GSstT zDH%sCEJ_tJvgojX7>E)5exQLUvH%luwGY;1ELrQ%-JH+1q7a(3760P0!|{qx@*Udz zsDeo%Bw1h5mr z5;a5*l;oF0sE13P<70G20vo}l9=`!L+%LB_8#?S#CFlHSGm+1OL?A7lLgbWIzE=S&l9dQ*qqX z=UXQQuuz93y;S1A2{UC3UrfS63=qKIGXb1oy-3|CYNM%f1Szl2`H}M9%l(=x66A67 zCdi^HtXQEbD?Qr1pDj)0`6Xr|zd0?9p9;o~KnK--Q~o;#Dmu)K_0*w^N|Xf20gzBn zk0rCc;j6PAZMTLFst@kfq77q&oALb%1MWVC3Dz1iZ$`mGIbf(xeJ|oX=w0QVV0Ia= zKO@`wGiiy15r}je|zS;OzT!>S`?#r}U z%B1q0ak6Qa73sOGhRrWX0wXq|3W4=r!G5)3wqA)cHmFLsEM7Gi<$f`q-^s%LP)$K` zMvTQiC~i-xHXA%iFH>wjYqf*$EM;o8?N-!(0eW@CZJKXBPW+$Gaa7T4!(J*VaJ4F; z`9XVZYqGeAM8hX5jEGJFPuS~& zFAlpnGG8<;;NJbnQm(JL@;;gqVpeN80qMo2VOxzTA7T_omLrrC%@I+*mi!GTL>}qb3mYCc613%O6nA{=tcG}N;5=jr9OQdb;wIPL&t5yNq3OW`r&db z6dUb`3lhqkSRe%pEktm?NtHjoH--RxqgK!?Uln;k1cOw>1Ybo^77-`>#V2DcpI1}( zV+6j&#KiDHh(-FdA5RAcUe-*QAk>(DQzPs%l9O_h`@LTT7;}yCJ7+!S`)mkeU|3%# ze~1oVdxy~OOTRJM09RLnUnv(To*x_RfwdT-U1{$B2d`wZpDd90zRQrJuB?K@+%Ok2 znqMr}#`PkB-j9AhWeOsM(ai8t9LNd99)Nb5dz(V2F~RakAC?uj_Mv+yVc) zrELpO455~sw&-rnk`pXdzbQa_p{}8SQF^b#?wCcJ!nV_9_pC_;GTJIe$y9aiXfvED9J-OV+wI+bTpD zuGXV8k3kb*eCMtE4h3rVqAh%X7_3tmHtqO01FaECqogh0>Q}Fxr3CeUVQQqfpE7(g z|C{$VUbTE)%yCNSm2l$x5y8$^PpqU((nj0=LL{Vox1(%0lPM!xVT8{5k$At(?PWKZ zc5l4VZff}M;m0L1>V;`{s<)Dd`BHjD8?W|wl;${nw2=Pp-k`9>LD2AjTt@|DqSChg;icX31d(J{jOkf-n8yYd(Jt z6K+_~vgFt}@2D@%R01=9!-HF8Jhnk6Ol-ZP7!E!vmm;U0F??zMw;$a>I3rco07GE< zyuT0U#VamhIiH;0#=l2oJ|oD;-Xn*WIFkQoFIjdx_0Xo$r_ivE!0ryvFczto(qw^+ zJQj>7{dK6cbiueAuUl0roo2me3{|*#U)>8Y4z+HtXrPi;tO;Cy|9TICOgV!wf)mjI zTS;hV*}rh$ux??|aCZbL8sO%_Ve_T0^%U>xatb<3 z+prsAVeGW~eW@*SFAYmae|Q(#lGa*g4xSHK&}p++F4XgX^dFAB=aQl3u7*|=Fl6=P zcVD-V_>QChd6vO4Ib%;y`s$*Ny6_8LF)Fl+6J1-DUrj^5Ji${=x!N==1Huwq;W&*D z37dg4i}n-yfm}sTV+Mg5l6z{{jM`NV=FZGK!5^NvdfWj9EZ3wZMMb49b^drV?@8fG zb8dO(#1VXd7BugG&7FsFQI&Z>4%ytILe)5C4EMxdA%NN^fF#Aa>Kr`M*{tc9WlJf$ zNv=!74{pryF62SuSH#sQyor@B{hbYxhAN>@g%eyYs1O2CWt>5A3XVPyEklMUl410C zj&RnX%X-YM#-|W^ZKzPGw|^E?1W?6stgOtwxnfO!i{}dkZbwy132!~s+S%Fyb{o|3 zl*-!ltN}PU_p;NDNYP%I|A?zQpl{}ND{^OA(h zfj%nlFBo;r-$GwF@VQ87Gs*&(WDRkMj|9`yhqyau?}~|A=XML}z+f~J@itOrlcLjz zXLPBN2P=9yOZ!jVKG9_IX5>NWdx|xXps1LCi*le9WP>b`nF?Q4mWEJePrPe?yd9Ts z_(u$qi~soX4Hq15dzIKpd&^HT!%C?}er7Z#1NF)M4}t?tp+yc>ivgTmTSHG{g8k?M z#zN|0HlK(!^LCm7Vx$|n2R(;S-^d{SlHwmg&&&F+-eGA>Y-N=TK*cqK;-@D&_e?l{ zdYlyb96#d(A%1D`24F_sZk}Vmkf$KQO_f($JE?l)+KbyA7QJS8x@~21SmmC7-#aiK zRSW@th7p3K<9}PMNYY>VPumX%$(MGGeSN;JuPQ8f811JlOxKBzD(E~i;7v~x;iSbd z7O3YEyPxWcfahR6-eahkB0$}T+S`PGLrL${wZKbO$&JnD<3ZRmyx}hH45i`9aODfA zecZolmrQcLzphFXnHnpb?Zn`F+%TF;KFe%O<0%1Vcs z)C`4LpVN1X>bpNC{s$Jn7ODhU7p%U`9`t$(R%`5>MlxiMjW-4u4$1>jG}p0z?I!s9 z%~HiS&DrM@edTe(h#SC-c{#I-`R;kJIz@J{&u|~U4|@%%4)|Nb8=t5=d5aTkgetF^ z0n`qCo!4U9mu>Z1373y8D=gpZM~6#T07#z7kLkfnO>D@hExI895oD%j7x`5A_x|T9 zeMufw3Lum1h$3{SaP%P&}5+=c7mKLxI`yYy$Fl>)5px{k#!|yg~6^X0i|k57y>a z1ivcCL;8m&T*=oZAFLjbZ<%3UI8}8awQYuI9~wm9aV{Y!_JO}s`r<$Y*@2D(!qlz( zGMb)bj%&Bf1&1FEKdv{Qdi;U`#lNOzA-rw1B0qM@77mOHS zKD9BLKMmVfrd*nhXDSI_^3Yvf;CNZ;QF7)1!MECx6H@5;it4yi@uL20AjP~F75&`` z?BD+r?YfufJm=meJl%#c=?{rR~UE2IK6vSe@_Kq!|bqU+-@Ys=Hv zE$No=6^tJzIj~qCScTm1dRNgDwk7E@*p()ZI0oMY}GNq6vu>Zc&lE)Vj)gcE}cmkyDu% zZ2`BcH`~;-kf+rGa8EAovMItXgRq3Auq6Y$3X|=B52R9rJTg^BURWXvK)*a@M|ki1 zSY|sm7pOyE2H{Hu$D3ytBNv<*t6=8`Vo-8UdIn!%C|(f`+vcD7VwuyFtxd-E!^%{2 z@Z;ODUr8GZ5$RrR89T6z^<2Ak8!<=e?4Ucd+9UW;HJDWCj;FWGvIhqCKY|l;@xY0z zr3>?aH=$Ilii2l1ON8%yM}R!$R7JN<7Z#(@xoDnyRjS=b#0e-0=lr%(qal%c(b&Du z+PnR(aw~Kop<&arKG59A`=WmP!(vn`!kOLG6T(VZ{9E>~9&e>M|3cLZhLSgUn{uHl zy@c})pK`|>pc+5C>|rH>O)mL(Q}N*!F?KC~R5O9oJqLSKKHZfI*9_9;v3kSn<}QZg z-nc;vhI0B@@ebP&q&!x;&b&aO8_8DcrO;oQsFpmFD6hFy;o4q-dCm9ZAS@H>;s=T% zBwrRGE;!+SxFoo&zxHsdi&LkD=}P4MhYIZ9V&cj0m94f_?g060nexf(j3CP7*wU_l zT8j^<%|qE`F9KQB_{TNPZvzCd>4{KNzcOgDa~07^QHZz|-MU(VXWi?|ixtED{*&s(Ux{lDg@s7e(X|3! zFW||3X5o}O_@ssNHcHqRF>P2>?8=+^OLYw{=>eCP;ss)L0OZdNC{vRffwg{U5Kf&k zpN!4lLa`^EB@6vL0xv?E2ApSLIN_Y54{pHRB5l~zfAn`AU1qwzAH(CdL?u&y;xZ>? zOj{+}&(6onK#uGOIv#%FVd?y`C6+R*`L^~H>MXO{Xb!D&-DIMcxJPKT|8lZ{s&C1v zMh+~0dCgN~C5{OM%1zDOzOA+?$*_869QV4ORK@ogje~5vo-u~-lW8xLi%1Fett2!$a}1fsLe!R0B3M zm|-JfK%fzH<1Z@J-8^Ctp6?7hSc*^3WUX)=-Pq44+AgZi#JVDJif^gEmk!2vqF`(} zt*i}A2@&}d$vX8@$o_*gCQ})Q5?7KUCl=RFlxF6$p?yrxr=603I9QWGMRI6VT0v?nRA&Ow4^mtF+7?A<{Y6i8aCsUHwNR0woZ=Mt&RQCkc|7J5F{8TliY8wpg$S86NgFc$1C2G zgZkuz6tS=}svDR8vaT@fw~(gZEOF373sBc-i&NSiEf6i+)X=dJdiJK-Yx0LK20*_3o(7`%Id=_^jbIY zLZYnpLC^i0KJp)hH=GJeT-(9*yGG(iF_EyL8r;G?Q+|c3A6uF1Tul8`FB%UU2ZH5s@8Re(l}e%M><>5C5VOrXer{eUB2&4;SOjW&>Y93aI> zDTq2L*&rXcuLsG{OM>7DxKhOK^)=K5^G8wpC+8omaxeZJ7hm1{f(QJohth+aKzW7%5BHVVkCE>fh4nSl2eC#qOV&#j`q%TZw!OswpVM{bR^AAiam7wG}-)Ozl>Yx{+ zhM0#@Iyd_?E6s@;Y`siq2F%k2e!&vrbMr6Rq4R z`sevr7&x~k2C(B^&dE^(FgwGi=B``?=aFeutb-@CspucMw`qM%9D!zJJWN79K>wgX zM?*b-1rvvP#3Al6d1v|o=^&CopR&>ITR&SB^TzZ6QX_u{Wm-Y~n#OlEMp%87{6}Q+ z8qaXn?B}ur zchpwWJjoCV>xLJ>ac0?*|PwRCdzwxCZcu$2BipnmTqn&ovGk z>5uwy4GN^PecrD(m~e0h1odA|ZLPoGd5I2LX{aL*jW-zMLq<}Sxx71!V_CkaXcant ztW51Q=i6Kp)ulC2i~}_FmX>cm{fWrR*seJ{aZ`4ODrI;p9zU8_C;3P2dILYH5BWlm z!#9&ezc}s|xoW2FypC{CIDwND-D}q^0oC)kC5cROo4gidEkCtC_#_qHxdQw6HN8GM zBL+@nnz0@2a)th?0eLX2@TUhm$x7jW(?~-LMZIiH_n-C%VQGp%fXM`8u{tRjyazYt z^X-9we|Si&0pw@2K-EeKvbJ(596FPH`!23BPVBiN|E9^FB8O(nF()vTFbO~c2C%%6 z1IFObP2wD@iQ{vyBiB0|K^@X^2@l&k%vDVR_U|8CNXkOU!Y(-HOXd;-3wTa{RwA6P z-xNP<%2S_XXq(h3Q=u4vZB%S;w49i6b!t>>yFtk5PqPgdlGyQ4XFlyp##~ zWs>BfzNlcF2I?zs#-+Um935ovWdoO@mnhb{L5na012}Q>r8};KEFWaTo!uw8w2ToA z1?vO!3Gg>8r+ZCuf_H~|lpf?c#~#{tcvV0ewVuWh`~E5D*zh)gE@E}bs%q~^lv4Kr zKX8&a314GjGYv9@NB0$wbnSbir?xOxx)5k9D$UXN@WXi>OQZJ>#3HCO*6Zyl`cQgC zfQ>9skf{=lWRzC1A$!;-?(<%Xd>;_Gpm!TT@+f5P_K)l12mST#t%6XOOr^$@dk+W$ zRC(UHp)wy{RCQl}@A)L)MwhS|8dxnbc32gw2_vh_p8es{Az68XIv}|_yf!P* zob|t#qD0efw>+ln=qYZOq&iWQnJpcSD^v2ZxJB51NC2jM8%IPA*b2X#7LJ(E=cSwV zx>hX4YfkbrDPlrlx*n96kzv3x?WH2I1uy$rTf^C*&eAL^i>3HIFb_47S$M@yKx7Nf z9~%aG4xpN8S#=`*kdBxYmIUAvGwv`dzQhvukErAfz$(4}2F3xa=pl{^K8A8vF{-@R zvlo|t8;xR}l{?+!3PG$)M7?wO@`h!PEBRb+%Z#u2wRI6VeV(w3^N|Kqdeu>fNwYfiSXlhzE-2y4)!pVY+yli%@t3~@=g69I01-i6RD2ROg$vO&u z_2go>J9U}^U@8{v%2oqc8u|paLkle&WL?5kQH97pF5LK4(E_(#mO}cX;=}`LeVD~EL%x7tegYv(K*~7&uRt#sS15-=e=rTZmh(viE z-YMVk$6QLb7fOCaq^U`E2LN|2VwNUBV{!SznC*K}3=J|5CA7@m+#;LescBatz?vKi*`F_wxP@nkSkcmq9hid4Yt;}U39U2$aM)#Ec z{H_$@kN=WpYMdR#4@(AIw>ENrvv(eyfI;!SjHqV|8hKVF@NO+%eG6v-J16iEngF5X z5&XSgIn(x6pY2IAnK@vHkP5$iU(o~ta~QW)a+7l3S16+5gxGsYFgm_i zq#Bl-7L*@+@sC&B|LB^WjpZS@o*|+{J6#5)`1h2U_Sdc!J0xhUu9gdb$w{r3H`oA! z{Rt)o6Aw~pZNf!u zC+&tuU^(lGwjgKA-t8ZNQ)K<+P_G8Wxt;>*Pb+ehvPquwk_xM>$l$@u`WI`Y5b!hN zH1K_!{f-shWbP5s3tAh0^Sz-;|8gKKnbUPiQJHG-o*v)JQD`komA#r295`BG47eG1 zJ6MjAJ85TJ$eTWp6%RIWV!Jif+%v-#H*SE}gS|DvYlIH6f4E)x*YmE>g^gPF#R9E~ zaFo$7ei2UMP74stMN8=r(cHg$LfbC`IHzRhL+U6@4)5h3+i)d+++1nwaMckC9T3qg zM!BgRk}n$OGRW0gyo$5o=!5!fR~ygNic^lpks`v@&7zF zV!izh&Shpy-rfnPm}wck3)Q42p_My8Vh|BsQ*xlyZzV{7{13+q(wSehnnG242c9H` zou+0USFD$ay@=fCoj2;IS@}JI;i|yx7`x~msUtzzUr3W%5scv~ENiaZ*B{^xSH6?i zr1f{G$|?YC)%R_?UDwQn$&PYg_=lMc7pVL3l`rhLDlSt?wi;$-Rjewl( zet^t~AGVveXqx{LeZZMjKBu2@0WZp2f*BWgscDyg6JvPhtY>icAKI5qSBX<$MTX4w zMOgawrYVEy$8!w-AGCYr&|Nz`(VV=70bYy=zkqK4Opnpa`JcU3irO|UU}&v0M`*TV z!xFj=upi|Ad^hQV(-NWgi?4$rCA2yDna8y;aFSvkd1144`j^<;lIn9b&2evP9psAt zSX63%EK9iQ$S*gB4%Cx>)f}ABeCn;8DR>x`h`?_5g)-)1V(imSY<{MMh1f{sgD`nB zP`~#BSjS>%qG2$?2IF{2Uin24kj#w>W=(QPMrY@>($g@xm!P^fFqB_rFgBjsXD>&T z-43D&$U3wvT7ue2hj@^Qe0q@rPyV|fo|TP%t5*bke^nf3i+h&)e;}isG;o~=o23&? zZD1>)0vC6;S!s!me5V~BRu`*l;LWjyMpa6}&6eT)^fg9~nRg%MF#{u5_ab$$Q|J#r zqqkA`1*#rH2{AwO)nzDx4G05UP7$gaS>%2{02WObWyNC|A&b z(N#@sA^_qg1Oe5y#x`8=Blu&3(7r8^t75{temxp7zf}T&gx+OXADv#f#9C=GZ@Y#L zm*mn<>~?_HtnI9@>o?Qlqs^FLCXcY7Bmqq5rWf$fkNk(LlGCNdb~nrGE+`;{Mu<(& zu~0~akI&83^bxLhi=5I_DKT8|Ke4TUy4NqHOJ-pnfxYj%uZ}%G!2U*iMBVM2X+?T= z6LXEyN2pJs_Tv%T7RT~sbM};?8%yIB{bXH;+o2wL0lO7Y^9$Vkfm6)@bF$?mSxK|IlEN4oEkD_~Bps zp!Y7C?sOJhz7pQ#Nf(<;hNo>UjFD_=lF%)m31mI#!iF0xkvi$QA|0D zxzcr|F^Wrcu43I_!R=;h%KV;x4*+ZQm|H2FNJlbl9rC*bM_rQixt^@cR{N5~(&i>yepzt6)Bzz3LRQ)vlBEMEkzwpZ?C4gka%{*0O_ipjLCZw9G+-)pnT`tbP zBJ(KMSBA?rol6UH>}lgmtB*_kutW8n!Xf6GiWEAF)eDw}tP zObg(0U~E27j$2W?)diifUfphFzSz22vZiBg|x$ww;*WEkspL3P=7C=1c zGAKpAm+(Cd5DKo--_3*`{Hy}Uk|XR`Fiv50gCC@gs0*P8lB5p9+|kRMh6jhP_Ym=w zsnM_l@c>7lyux|)64+)emGvOp@mmB?D?jp^UQc86zOzbkK{W@Z3+|=3_5Eu;EDk4D z2NLv%zGDG#BUpQX9I{^3tEOg#_WhY|I5Z;2EbCw5{D7F5nq57#T73$hhs-8@Y1Q|E zNuyvQ?ai@5h}baM4D3xDI~#QIjz1M;cbuI++Acw@h~>6eEk1aoTu3RUaR40iz3(Bx z~?~(-y8awiZ)p@D}0Cs2s|v38)ET|Q*QoX%UUI|3-m zfH?lQYEe`IQ)DO}jXF*yA8k##%VL1GMkosC)F@apfJoiA{cgWR2MaEmqA6)t< z&O5*O`G5n~QnMG+k9vq1$=0+w2+NrDMdWS+v*Hwn$@n;)?!Zd^Z#{0eGJ%9WArng# z(<{&wT=fG6f^IFc>K1ZUcjtO#x(cYT#(mlz(#`a`7K@Pd_K5cP)Guz9BT_VglB|}0 zf4u&r!NUmeU-xPIss|?n%*R8}s3m4;4gyo@0YaZ{A%VMW7#OqA?l#_qu>o=yhzvSR zBLZil!lp2@&?Ds2kwmXGD4N(?cz-e!IV)YM!a0y@oPy{PWMrK_5;3)i#1ri$BjnR( z&>+-jeF#3;HR&`R*fCV&r~ecy-E1m<`@Br;CvM!+1h4bJ0V^A#<2IGpc)QwxKkod6 zzt1UIeoukRgf_0IdAU~(U zPVj$IiE6O!-XX%T7a{{zF|2fVPm>iCncF6PY@hiwng~ zp<;w?6Ik6f3K*(KFSH+n0M6OMf?34Jholq0Q<^{rp6*LhKY%qHwyt|xT#xd4?R5ub zAo4XWHQu!-N>uU_mbsi3I!7>nxDBBQ3a~qxN?{yUm!F8;{ z@VAeQZ1*BOMQFu%B7%<&o)`5?iAUD|K}mlQHqEO`p`q7e|4e#P{!v^W8YPONNXyPWtX5@S2Q+2 zjXdZ}7B|~_-CkzF0MeNd zJ@f_){^}{2ri|stbpBZHa)*>Z#|0^mK(^mc-$0vwtw{QGoDMX=J@|rRa3!6qr|aDR zP4$(y`CVUkt~0@ZE3lNK85INN%eaP!aPK2lFri)zmNHc-^Yk=01Ydn09fKGCV8Lk5BT!Rt(&N~v8K5DbB}z6i2J zbYVNiE!PRBTX6rkj!_89VE^pL0&}hB%GmCp8K!;^Czt4djayQ5aYk7&qJ~D_19^~V z`;dm}g5jQdXARx@HvPX|UL%x=YV5T>ZWcV>AzJZPlgbG8PJ1AEDyXS+nE&uo!-oO3 ziNA*dxY(M}0bi(##{WmJNORM@{Un?e(dC6!Up8i)5s{a<-TwHtZHV3Z?!d00$V1P=!QY#C8uR$no6I(ZWJrqLs0xi2a07PRAcIZjZ6T+DbSEDY+ZNS)VovdZNxzx3t z$vUytoiWH&6j6W*BY&e!Zp#MJJ^=`==4K#1sJ<_ua$Q2?<lir zhJ?#7S?@hwUVt|S1UM{y$R{WHZyKRCQRyAna=#ET&*){_Gmr`@ZrlkNg0~ZwE2op0 zzxd{VIg{}LA2Obss9OwkZ30e(lrbxHr9UYc1fv!uISC!8smR#gfb zS)mtVLzcr8&%1FcC@|5~8xwl$Aiy`?BcS`+DFY>(A^stPobfU7WxhkP98wjnezxa- zTu`|T>fZ&E0Y-beFD9 z2^U2*5{yL)vCa;h<81vM*ip>1GovnB7`IGUyC(IEb^pPrMsi5J0TT%vg%R5>F+hSO zXbo(|AU27Srx7FAg;in9g7rxIWOgWjk|a+!RNGm--Z z6xaSKK|^5sWMSZtLp<(j&-8zJJxc65qcogOqkYC>^!`<*37NE-J?$}1`RLav3iT+3 zk7b;^4VO-Y^Fg!cK+H%@0l52@j#vYsPX*RSPfa2Cv5jnt9}3dauyKw-+Ie){JpM2E zUZ`pN9r@$AC~x zm#4V4l~lNJ09ls552XNyeObB3^@FVeux+2prBeqaRztlf^qf@x-B_b%+d2pyCSQYT zL?z*q?F(5_0~>2P47!_t$gp*P`x;nVwP8l2VG8o^teq=$%?hECcP`#`ZJ2iQro*R) zZ#W9Dgrk$3?gWdT!7bkcdtq>}z*T5LL8+(gTP6;-@+w2xc3q*UvNjq5Jd*F(QY){| zTlk`8ZJ4nCN^Qn#od?SzFeh5c%@;9Tdahp0ci8}Wz3kqq${nJAwm7rpy*LD~n{kio zNRC;+XDpsr7)<1I?JpdPSK|7j2NWgM+9J`dHodpHr9@o6m*+&7>in?g8jQQ*-f&j5H=z+c} z=NZ|BLA@}-bbA}!`K{8c#ziy9&pu;(M_uNgIQHnJ-K@6*kJU*NSbr2S5lRU6olws|FW14hVM;39@CEGo zpBp@RF7;}EUJ(3JNtf{9Ea>UtFSGY61VB^cIWhf?e#A=UA{h7hfHNfG@S8PwUNix) z;u>u+>0MqNtW%5Sqb#t1Ik?45lZF*rRaHh0nZT?f-5EU+QrHP|fNV3-edZ23WnxrR z8@PafnG=#&bYE6wVcMiu>n4A`tJx|dI|_sBQNYoE@d)JYnSPojUp)F-)&xgVvr}AP z4R2$Rjy(#DKs^_a3FeaY#@<}y?&KOreSL*&`YS2$Ai}x?qGHyyHH3Fo?Q&kP1Bday z${zt`C{zQI>jU(LwsBubacugeFftZ*?taEDL17_RBYTF`_JDe{M>=1UGY>#t{F?J( znyp%YVdKiS51n1U5c$qjl9`0TbY`x}ox9*Xk^q3+YNK74NG{0nU(e8@;6I_`NK(!l zQs#0BGJsHLhdt%q{4)r6RUdn(cUgV<>clEhs{x=F*aa0*#}l!x%&e-OV=^i)1N!db zZIb+DS}yBcvmAe$l|iJlhiL3L?3bkAnGLLe^hFz}Nv^rgEBu@1Ti8YlNuqGoNoK*u ze0D$8c#|EQZpEAeYqw@N=K%Z_&ZET+Y5^hs4wQe;L1avBewT4SKrzkWm&9_)wdS4N z{mh;*T3tncgT;yOGcKJ}WAd~nh4B3;*n<{h{zN!Uwho6`U#aR%alX)f4{imy>Q#Gx z7W|5SNA7d5lWB~G!E1y~^&sKTO9kv3JcYYyS8BlvATew-0dLpdz}xmk6K1G>J$r-; zFf2fZgwat>;C$X%&S_=;Ty_mK3xUoto?Xwum;8~eH~G#G=Zqn7M&aZ;nq!&ydSaNDZNnXo|o*SAe;1zh{TyX@q}~QWE9}+ z$rO~w42Kr-|MIfIl%Bq^L%92EN5y|nAAQXps>1V(iJB}k7b9os%-m7|<;TN+l{rYR zQOY2K-x0k9bbmvXa-Az=fZ_(1skK1fAO0>0@N-qq1cpX!$2saWhlY1NExz5)^LUdl zKsOV)Jzf+0aE4LYa9%$ra~0?eQlZb0ej3PrMK@xgL&sCh=xFqm4^?d)3XFV7IQWfa z<@Q=Y!uYmZ?_a%Pba2T*96o4&w`I|M*6wDxjAgFaXMEbesJ-+GUgTpY9t%T!Q6zm= zgwjl$eEUT^f5r#9oNqKUo;s};w=o2Rn05csrnK2{3SO`2#o2JJjY<@SlKEoD2u?EubH6YQE^_P5!xfJH zk+XgSxP5rZWjgT(kbE;ijbV?4UQ0Yh5f8YX>680Ns>kwZf`R$%mFjfqcnftf!+gy_AvA#RMre3D*ox5m{WWOwvz5WRA!ucEyq>k6#)Fz5&LLG+Ou9 zTae(dQ+L0Mm|-q|%a*+~4E4Z+WG0sf47^|Z=`S)@LzIi7a#xKWSgot*$(7q~tHeF@iPvX zaYeCspMhpk+bZ^nF?X1{Ipt9CGjq85nNuulk0DB zBSOv1JAiZpWcT#qit2L&&0{a;?-t;bZAMzlR~9oRKInw1`SX@ytTGo>({&vC9j$$H zrMV=6qi9Eeoj8A;^--|bDSN@pu&6&YN&`RrDVy!=BUWeEZSpC({8K0MZgpji6}ZKb}N zK-}KG#`06b319z%Q_6UVRv1zsOcS)f4H}>i;f}yu2U0k5!CZBrV} zx`=qK)6Yi;gsK5D5aDvJBZ-Xy)I5_aBA0{Mie}dBgdruv##(A&NzG!eR6ZUzjOKy=} zzL?ze!&Wi5KR~}54+iJYqV(Xee-bd12e6S=iC*|*K(kIsA1TiU`d3tSc@|c-@~v$j z1z}%|Cs&P|+l7b0 ze=3gZj~FF{6L`1}9w*R^e?ev^1%fg;rd!8c9Lv25I-5~(A8qqXl*&}1s6MjEvqx@i zb;_>4+CGl5-p(vIA!_B{JaW?Tp(jkw)?CI&W{jYh#34ofzx-JU^FP}1%q-BvPK@vy#=o;%0v&SRqB21 z=Yul`MJ#c!b+RE&an>6mrdm_#f9-6UsIm*-L@2AV3f!wX^DDKYZ-^Z?+6FKf40a(O z|CsElKy(~uK7P&l6?4Q`*OVewoQUW6I~@<8gU!)trjW?Zb4JA=Fb7=J6@QKAf4VZ* zeXvY+Yul*f`Bt|?b>llXdsx1D^VRz}e}wWuoE|>=s5cJ5nXyAEC($Ysz%2rsWod`4J{%%gB!NRC5P;v=IC0fczg;k z!D6>I)8&9ulCi_kUrmrIZTC1*&0JT~_}n4scO%QUs_e^9QZMMpW=%lc1R)ab9+p8_A&3LqfnLTU)jy9jhQIO;Y@1we+-7OQKl_{ z9_hJH@={7#q2I>9_vv?%T3+Ev>8-o1QVx221@F(YBv&HZ2$HJ3Pyqm2dV9Aa;`dPR zzt-!?DBy#aA@>T+|Jq1r`D^;Qz-|h4FR(6s$3+2#<2|3Z`XrpJ5>knI`$I(=>{?Ci zG&V`CMEp7O=pzKyD7D9Ge~Zs@MmPxfs}FvILZH@akqz1^((KD$t0t(urQyIK>pipu zN&NyRywTBgXLFF}MGPezhWs+%n51+A`0mw5P?atIUmFX-u{?mQ+)Lo}{xiGaFw2BO zIH~dbdMz{AN>@_jlAL{@gv*bxVhfy*q`ek*2W;v-@SShtBU3qaf4JN;kLLB}4N|`k zX$*306aaKuKD1@qRNiC`7zdnbj;Q1t{)szG4e-tG4x^pI>C`<&DaSZY&0LMqA6 z4a}B;m$!3sf5kpCeyKaNdraMe^eQon_Y>g&}G<9-5wQKM^va8=*wu%A|oM^TWS+ax(as7uEHeq zVHE?b20~N%jB(KM6qGcvs?>@^h+ovSPX!@S$h5v{W@atQ9-*Kj+bu%h2lTbpM3S=X z12aP5z)3Y2xsSHvb9)xzZp*rxXJl1Q*xm`>0ya3KhZ@N1f6uXX4XihkzLS|g0>3EA zmdVv4Yp0am4KwfL5JJy)HZ*uF-IE)#xdNerF+;l{b}51qPiXt;?BoAtXJm5eU0vDZ zz2K9Pl=?f^hcunRPMA$KG~S^HIVm&DvBk=RqSvNhDCFc zy+ZKo?Ii1ve*hXH`9bN|aen6mwed21Sw(WLjLCy=ob6;Fk7u)SCfi}_5I-a@=Hiz3 z@ciQzs`>UTWzr9}!td;91RoER0djuBSVn?4MRGcOd4nK~Q|rZyVX4Nb9k8Yzf}CWu zqxkzd|L1tejLX%wB%axmeg`8u{M53PYq$`exdj*OfA3buIqoHpm=NRZmn!9ywKIvC zuHw{ryuem7?5o7f9;;6ucEnl(QlTl+st8rnv6bgBA~QMfE31|OD-kccPX{!6P6Z_1 zsKXbT>_CjS??Kn`?ucuf+N2@SrpwSXCa-ix!z+8>gZ9KptwGTEdQ3mJX>9c5ct=qT6%q zxolNZ!6&5~Jpb^8>u(aV$GaC#ADgQSEQQ~He{me@PEiU{fd`4otm`*ET1)gVxQ(4f z>A)(T1e;Q-3Dvy4{9H*y3gq&hP=JH1{;P5+i>Nmpr*bFNh0c*hydXS{3zG~tyv&w{ zMKYO$QtVbuZ$N#PhRE_uOEe-7AAwam0kkVHe)>I!A#cBB=7ON!pA#DKb(xpg!mUpq ze^#{>SaTVuJT`&KbwaW4_lvP@_r++f|H1f%$-K!EHIrC*Dx+}2kU-5>*lyt`sol9O z(>~r-6Row5r@m<-rbwo{mnPBn0g@tM4~aOe79oBET6&3ewm8KqG|lvH(lb-@<%sHs zTOIo-n?B~b$L$!N;a#0}h&jN?D0-b87^bQ(Xq>KtlnAR`WRmTt;8xI#Vpq4>4M`7q0!9KdFfGm%T4Lwr8>|!MM!tPz z_ojTR+o?;j+?Xt~lr#aYBB4%`;M0U7_l9jc?{$oF1uXLc_dSd{ygW{-;f!U+t zq}a9S60gu1@qHA}YAbn4mT1c*lAGulx8ouQupBk9m5@7L{%DpaA6Ay5f1@f!AX#X- zOOWx)g(*OU7os{L^2VMsJZP3N4#QXK;bPX?3fV!kUrN6 zTSulaU)w=UC$Nz2Z!!&Gkk|OP0M7UI{3YIEKQ058#x@aHqK%yqfAzn)KSV4S*h|u- zIFI#)n|frzzl#Cpck4Y*${grz|Du+C&I#g7c~N)fL-nFf^1pm#;bBcee01g~nJNEc zppw%7Hz10iVj+r@%5~{Y0xmhfi2>!yNKokx$Cxm@SQRQ~3qvC7yleDKJc}O9Ee$Y_A0-0Mk zV@FmXZbWO%My*52=rNRuHmhdjGUrR?%I1|teSS{M2&_I_e_8(4zh~@PLvu4qEbn(< zJr*7ZF8YPU1c$(3Ua2ri^ealEn#UM7Y|V?wuFstbgmAUBnq032e{BWqGlcSyE{E+On_Nad7 zBTa;eb(N_hf8CMlkWjZ~@7+>-ozdR; z4t#WLW@IR292x7Yb0`bbJM0MlXPw(G9u#p!_P|=V%#+R&S3X2@`J0%2Z^;RnygQ&Q zUcmkCa#tgCsuVkvj|eD$g{W7Pc{f#G8?~ZuPgK}If5bxS9Uj;!0S*h{5S3Wm^C>Jm z^s=V5PaYOy<2=82BSk@VD&?lm^#9pbzwYJ=zA+dq%}B-iyrlmx{-FUOfLoO_`QoUK zx%7!EUouQ}axw`GXwNC2eB1>eO)F|#e$djW&Pum<42*77n(+xTxwcHTe5ILEsy5jD zZ=CNFf0L0#9jz%V&ZRH6dTy zv(jazkGpv&$%jw#90rCzw$QmJl@2^V^F!K9|rhM6h0QOzf7O~Xo(&N?u z^IpNn^D+v2u(F>ME7bW2mN$eT&(pX#BWFlNk~e=1N~IQE`Mv$W-Wx2~O9X(M+n5QOy+=k5q^`%Z{Pn zv{MaY(pA*SETvKNf$EE*l?ETp_u_{t1Y+Br{uU~WTrY~+P7jcvHHXD5LV${p@LgY(NE*?i?+VCLIMgXS!>VoM0?1BX z$*FbD*FAYr#WT;J^n98x-k`V8e_YExVAT^+{yo}X9}@e9O{B)b{JD6=gQn!{!1PP` zB8V6dd*qqnbu<91fAjcm)6jwEC3BuZkGURX>0JuV@(tjK1(`9MQTs_lMG0f_Wt^r#}}O(k}oOITjZ9`QGeymygn&afArpT|5SQD zcdr%b{RH=;PjccMVPvZ$A8 zcR*_KH^vl6AF=71@NYni@XujDD&&RA^wq92Yu^-g2gd65QLQVi|3UY zr^Qd&BVs*sYh5Dy=c9<@f5Y6M{1+3rRsE9uRL4P?sS@>){g;wMD_d$1eu{E`)?wr{ zP#k1TM#A}^a+O!jyKi7}SIExIYp^k%>xDS7vuT!zNijO|!+a+4*?HkRjcTN+2{1{0 z>uh!{RScWxM*NG<9H~4o&M!f$BcGu1kU2pjXB3DrNizdV$^c$Cf7eP7rJ19f6^n@T z>H1ox@XLr-ZJvo4emahr-_n6MU#jecBpzE-2>T|Ht4TpWgGAz&+!r5 zvB)W_^gWbW+0C&(FypjHi~3l$zzuSJ`Ia^?0#hDwL+p@Z_zRct&s3vK>1bMhxhYKq z8|FE|0e7&f*5@{Ie~%+cM#f-pfsSDiK?wj;=SLE;w+3`hr1{S^Dh2+*kZ&tT=!Eyd&9mXH&I8Sn46|B|Uy@D4-;{jl72e>U87kNTd=3doHUu!)H? zxPIE56rix}5R9zpQp31QKlKtVi_02JqcNboWMg4ZmT#wCub}h@4AyvXA99p1k=@EZ(5SWgzfG7U@jIT4~f>hAu4}uCc)ixCuG!_x z4NwS{T)RRax^5F_tmOWQ7y_|^1BcYVhy5~&KzV7@nOV( zTD9egzavWoczOFa40eQ)D~{T5S%eVO zXtwc(&GmC7&f@`D&I$H<$yhK-c=X98*cbT`d3jyM+Po55nv{*0#g6I<&7cB0gH#Sh zKcfueEUCL|<#FH{-A7h&sE%>TzLo=`a?2Yh&Y;nn{?gNGn{K?1=(D+*U87~G&{6G#y!zc0)75-o3W@#e@bqhgo6V1F?S$I)mM ztPh#?l4lzekC$I>auK-&w=K2vit@vDJu{SKOrrm1YtY8Y1q2JKrQ7% z{b%pYXWsl=i-P6b9YqCZYVvwP+y+~@@^Jl3bO!l~<~y$9Lko+13aFED>L zEjh4QMWw~V)Z25r_@V)AmE|o$U*|5B(Bwz%BiE$6?0@hSh9v8!HoI$F{oao2?+}9= zP7ry&4`N!bN`J0%C>Q%(m(iZ;f1syUjM5Wsd!b2dzqYjqD?OLy-X7lO38d4afAGk&ftjCO%?^WA%o+YC)&eY0HiKRGw- zncevnV%SGKA)3NZGFqP8wFbO$qc+iGa9)c~3H!49{wzBf70j(UKQ7MHf7~?U)~Tgb z`~@z(u~^5m-X1{8!R{(`iwhwfwL7~#Q53ORDi@fly=oS}f#-`5nI>{Z49ry6N+g9Bb@T~rDuObE!^ z%+BtP_d>IOq>2^LjsXm9_LTCs1r~4pAf4of8=*fu+OF@_H`32-e?OulG-Q%1UimJj z;i5b;Fz3Ip;==gUV4NmtWooYx3HQ5P)VS8y*%v- zE57ym9t5Ne*s6p%a=}`VpU*3Mo4v6nqS7)hC!Xl{w#`z+g(xUC^s5+K+vy=t2x@qO z5|omqVS_DXJowghxJnL=xz>!o*={yr)%)UB8`UR9!7@ozz#1HZnlXNCbVt zM~Um>B@9U2co)@L6>bds6grx{jp+_UCYA3_!%uGXp~+lBGlH6Jsg>KVJOYoLj4+qt zpCi)J<%r7#e_+L$A8m4Oo}BaVK?ig*r~oEToE;0yxE9qKcG(|~`y$=;<7O*i2HuQJ zt=%~ACuBDc5}wtM(m$%-&F%c3;H^jMp}7Ot*;)yakbQzRM#_Caa9FiyF7IuAAlN$! zf_l+`)|w`KyU$wXAccIh9en5P0(W`aU1W<@+;+rde;^IXnb!UWvHaQ&nr82q*exM? zIft)2^bz_A{?844U@UU<__F)o$RzWX0hevYv}d%K(eM?Za3GaF26-ssN|*`ljtet7 zXQm^b<}yAKV3@dQds*)MED*RleNN#z=2M*|hbP8qa18|O>WRpDg0&3aaD6?T30+&8 zGRVr@f3eP*zn6}k;=8#VmQ{a`S#e(?g4!9jUcZ@%wY2E>$yC@V>}rvt^)W|ZNTN+y z+QS*2bzj*j6V;gt=o4#BT1(ynC$~sNcl2W)F>r^<)V!ptss>iu@{!DN|HG9&t12-^ z{ol?joZ-C~=86{(psrpdzx8{4o?);g|S)d^Cjja@}NLiHoqM#b;Nc5 z%&KQ{R7T}i2Xg;;uP8nHy=)^G@(MFGjHe+*7Tt*03Xt{b6-~bI!}-3DPg$8=Rk)BG ze>jR|7w6omS+ivYoNlcua`{Xj4is`oauWS=aHdPbjSldjeqtt3g+HrcNP@WovW@>` z`5aZG1kJs{7(&&kag;OO6yNuKj}a;ce`&p?(GLlkJiSV0a=#u$gld-gc{n<~)t%wE z)ic5T5C9%`Z4jd&-Ms%9TW0%cx`W1K>{B`B$n3UQSf2mak&vE)8j<=@Zw+{!X>9ss zRE!%Sd0hY6U9tNBE^V$#qT9}qa14o4T0k#ZCN`nH1!Li70Wj#HGRr{qBC|`Ne{Fq> z7(+sV=4kM8p2_MQRlW;Z4vH~pRpSbIU>47|Yu16l?1^v)Fkx_e<^>~44(Fr1>{se z2ex=$ik-6%PrLV8Dppdh}L+^ z+k=jb`?1QoYpFXv5!wWdR#iM}Zr(2VE9a7%r|`_zs){9}Xa8Kl4pd!|fAeOmg&))S zcRglVThKwiAIbdFG3-IRYahpZc@ZOw&QeMf?jH~_caF=6Uq^pHD5gS>Htz6R44w&y zJE*IM$B`f;_Xha?w3fmwsZ!0(=BNpnNiH^ze&moNi$;T?{0t%=3%5!@H=|&$hr@u; ze5rlmW%g)Lx8H|y_R}lae>1BGDb9xDebT730uh_CtioDO0Yo7MrLG9L-Qq{*cNP<} zrGjjbQ*tXXBm8DgYyrp5?-^_p3Ex5ama6#)l$lRHlIaM88H?LEZJ*T$W2chpJ~Isb zkE7T(<#6;%uMo7m`tVueS6XGg3^JyOY~Fq?R@4yV5bqRXWHXD5f6|`8VAm!C9*V7w*=oiYL7BAVMG;gp}*ANL^rRQo0vjTwWC_-!=gbi-3||rI9&+;9Gl; zD~c_evde&c#I7tz(v^|pS3B=!cdU@*R==ZnuEcYnC>u2ve;;LKZSI;`TAE~iL+zwy zv<=eNPwU@43W<8)lW=lxk|Vq}0mG;!#ccs^0oLE380VT5_HV^hQXei8=|2Y`uwSO* zfP^jw*-f*u5rQmez%C`a$Aw-|l(^ zf-mc>jIa6t>Qli$0iM=A$7FyrI4&X%k%P`>vVw;y)gx!DF6C%Xd< z_(G#nm5BY{ZCorT!~T*h7`$5-iJ_xo6??v>p^B%C97j*w``xf{I0-K07Uam=w!EUB zMvP=ne^osgk_$zrM#`OSNMsd7&z^O!R6*1KaRp+ex_6ODiVCFkcA2BG;Q7%v_`S`D&+i$nVnv zb?#q(~iCU5Rw=M1VY)rb7qb3 ze?1$;@yhj#JgR*lgW$PJMM=d=-jiGi-(ZCKJ6W6ld>G|8sh930TqEBn{7B#*Dfvq!U$OIeBO0 zABt#4@yXF))3mJqyC;LT|BiwobfY^4LjlhaLXtvCBZjwTCmz4Gn_7LCsZ$$#MHx1c z;7f$KNUxsTm;^3pMrO>Eo*A>+hM$E2?y=ccURfj}z9B0vazZXZ&xAlS$nV-dLWL)_?`4dYbKG9$!nou(-d$>_YB$V{8~(*Q^oobXml>h z7q}~Cy^e71U)HbU@(NDa9#ji(f9S>YWgaG_mipOvEhq*X0rshH>^0~$GE!w}aK39s zF8c9AQb*VxESykeEE^J2w$B^oO-G=ignlLd^!tELu>OY_IDfz!g0%K}xbKaxi!_00 z5!=HX`N20(^d0!@-UQjxT@wDl%*v?~Z^qO&4r<4x^r>7Sk4&y_a>B)7e}2wB*l1#g ze=NPkL|B3E;fu0|yYA}z$?9|6O?{)(isodj@fXp!KLho*i53Mx>uQ+A_qWEAChC1O z4XZu;(df0(s{RFxWBnFR%qPMd|3Xg1@tiyV>8HAd57a zHhMU;g@Wo~G@AB+!k1|5e>(+&SF@24T~kTJUFRb=aqFY;?HYO#Ow8Pw2a>o0$wd0l z=Td9A90*cm_pubXhs#$ty!@L_W{-#Mj)|;M<{pLp6iT3>II}e6#MN;!jVR(Jj}I`% zwh$@GMXVt{=y+h<{77{L#hKLwOuBS6WM!NYKy_1w92(SjyNv1je^~$4IaDMZ!Yu3f zSj&H^S)K}#1IcHPx_o!#VDwwVWBT26Y4{TR<%i6a_=K{F+|VSXrQrmHW3k0omlQn# zeE6?}ZU|E7P7W)0hRs7HpAkh)-cU5<^f||$54`{y9&pNYP6hlB>0#s4b$qrZhgXWs zFjD8_{R4JqLK542e_$$p0;2hMqG}}qscia4D`nY)T8&o6qtmeMLs#Ujev;~oP;6mp z&7Pv?*&HR$@d-b6kIk~2?;bb4LsA3#AUZ%xOF2Cl0My4j1xCHy4*}c<-vyJC-h4i* zyrZ}lh~CL+HsvAnD~N?fdjkWSu+GsS64l_%B;#f+mNBqte?U(tg$DH`UMgZ0TpTd< z0#iKbF83WPR_cLui$`F!XNooJOWq8OymCZ?=Hr)i(`TEH8rAw>7x_hV3Bp?$gUck( zMajrL^Zu59qgH*>4&8zHuWIVN+G_MJIu+scDfYhLZqoYu%OavrE&_!EwFjvqje!j| zv+z5vHDj8#f0rV#n#>-#TZ$T4LbH`mXHnC-3AcB$69#s&;qyj|F&I+Pd_0s>J`}JX zrqc|<>T89~05ybBAIsvxRo87>w86&f5q6>BEGs+-urb@edzFo{o?qqz}9e;CaWS4(Pk`WR=!>E0po!JK>0 z!aIco3pz;v8ZzK-Tv;nB&zc#zIul=Oqv!s4Gn#*z=JMHgiiQE!&TQbXHQS*UL&1Po z(&dB?F?4S9>l`K9CvjJOE6L;FT!LFacaokHbUadin(93;!jv4;QLxP}%^N&e_e5FE zeZO(Re<9eB9SWZ{-Q%;GR%bq*ta#rfLA$5iX@=j;vjI!TGw#Z5d^)fH+CdkFWLQk3 z%XSt0S&P@?xZ@&fiR##WNSzTnfZ!pib~@j7aTt`xpf0vCr61x=$PHI&wuLqe)V3d~rN~)#j z!+%^082T%Xq_8kC9Co4ccD_2rdRijJtA$ydb!!aC#B`%E1bmR30N%RPY_1;$P6f}H z-y5Bm!3t=fYwZdgqSJYXz?o9^{lx#Mk64rjy;IF))j70FY=ikb#qmD&!L(AP*RXAC zf7w?>5+xp%X8H(9e_T;1Pi8DJ;g8x*eIGq8td*!awd@b02_Up|3C@=^MpvuGbq6UT z)x4?(QrboopBIe?kC$W(h{j)qd#ST~8sd3!7*F}WGK6#%@GP_tE)FgBO=RlSy{(`W ze}^Xl?ce@FK4TgM{`fC#uM5;2`m{3_!bSN2_fUndt^ zUy5-J9~q@tGdNOjQr;9bZW08Po)0_~KN28|OJetXE$A;_F|2Y6Kvjb_K-s{QEGz5CF6#H7!Q-%$=zZg*85JL1P~_WiF$ z*{dw%$D3BMqO3#Qt&(fpzP>96e>|*8V;6V5i+s;uDDm?T^@OCGoFR~Cwlj1~u|qX<73dgL#4 ztS}>7@W*ElilpLF$wX{r`f=ic9c;eJbZ6PQioPxPL>gbx3!4CCV=;z#e`-y8_;cbK zV~*+bi`6+e{n?X)zNQjvYPN}Jvwepdug&et-kHO(9Ed}L@f8dyjXg!LHINN9%M+P~X3qA#1dLQ7|p~+o08IQ?Qg@8&c zj$KA>?U052F*1zgt6WNg$i1htJBcL|@0ksNbHcA)>eq=T=yK>bf_`7#_oAl4ngd|I z3J^p_h#$cy<(FUi5HpG;lmUaJPF=@7rOIV5np`MNyoIh9d|Rjje>r5$=QhXBpCL&L z%Z8N?SRf$N;@t(M-heixN=bs>Xmd1AfhcG2hI$U6k>iFqv#*_c(LUY`U>uGF!F=;+ zIOi-+9nZHKPxFu5Cj1sLGA;MH=5lI5pE@wOx`d~8 zLUqO8XP_m>;Av^$e~c33MZ|jGfKQOl00mct$%L{C9=tm_=T`2z2E!sXzq$IrVrN+v zAri-LrZ}$|&>W^*py-Sj03)+CY(bNl=ME`398;yHHn#`#qx=5Ozjf5Ox~{J@Fx(J# z??k#0r{3t7h!>*v-(M2f9y=HKusopLj$Z3vCBjw|TkO(|f5=Z8JfT5wRe2$DZLmjM z28X<%bXCtbL>c0~noJ;Z6x)2jmf8iZM7LUaJgRoyC-D0pyYF6#gI1D+2~gos3;v56#&n@`&qq<`)07z$BbF#$khAA zvs;fWtlI4~f5_u=^`ZVDd-L7AQ%Pq93l5tz!`gs$khR==ZzR;JXHrOYmo8`>qgzQb z<@#GGC)QHqge{>q1e#fIOv0F-ZqEHhrdSj+YWf-vpZ4M=6_^_n2sISMZSy}L87W*C41 zK4OOfe?ZL4Zp4(Xv~5rOIfA`dBx=YI1xd~)V(8fbq?7%h&7m}y0I|I^oq)r*Ck|*9 z&yMz+oP-kQi{QVRKIo|rKs^&LH;1V|id(~P6+y)nTD^H{70VSrjz*&YGCj_d9Xfax zwtIER@}hTw|EFn#dzyzTmtFhe(Iiy}Gsycfe~v2%8Lvkv{brQKy9cm+bKNB{3mS3I zh6}kgXx_(Ib6@e7lKw1NeT#V867LIW>B|ACutI1h7Mq1n7%5)ts|4nlFCMrKVqhI{ zfEj0$e@f%EUl@I@%LqI)k0)VD@!Ca6(|r1x^%i{Z&rO{6;5z;epXL-F_=7cEZ$Z&% zfB4w)w^#VKyLkg`sYfAUoeI%(LmN*}Y8g?X)oR9g>hHdnKkwB&u`5`=r?Kw!+gTqa z;JCIi;d0p?25Al=L1s%%&K7es-LUsUaDh`_Wx5$S!2VCT^2Fk<#toZwX*R?eySn)i z9zOMujT1c8NW+Q+93@OY4E$ zDe6i}GK7g~OE>#|t6&_2+(o5O_rnoIB2E$k34@Na<@{do5qJ#RNllbZPX3o%f7}(% zsGZF$5Z>7aBg=OBxYGV2#9T{SKQD9xH1D?+CQuDXXf@hos@Owy5Aul|ZHU!qT!U1^!}#DQM+&1*&xW z=`Q_;r#EQ~@)4ge`Pc-=LfGQ!UaeC~f~ndKdrK^@5^!JrGWjdwYm+3nEoeX3xIK@w z*XeF`RcS^Hbt`KdkFF}luk&VPe;tZecFrEjsMG7@GGrdiQ`9Mx zH5FlJYDpl;ECeFL-%8c0wH6tK{tn%KLTcjn6fl zeFDeD+Bf)i?F7RoM<7qMc7_mhrNtaa(hL%fQ>x^Gns$eG9R4$N6Bi&6h)|)A`f`v* z@@fO;y?&~+OeXxqqm60}!YZy}?npN29XH88ueGOJ1xZUHe*?{X{JmaXB%*QB8>IVa zwGk&^j$ut6@dD!h_LsCuMy@F%aHz>#Hu~RXs?39cWw#9v(N@YUB-ZD|lPJ%qwtQw~ z^)PY`hZI2lcRHt)CcuDQ4hN`qCB}R9!f#m#r>r$*i(#<+qt)`A{pS8Mj^_-$(Z7Ua zvl#;Pp64Ssf6nj%Na&5@owME3#;0rBh6z$duSfxDSh&bX?ufX_dj1`QRr9308k9ft z7e%SPWM+F3MLZ>HFNhZ~k(qj5U+GaKt^~XwhK^?Uy2t%OG})l*z-eb5u98mabdXGX zLia!j+hcl%+6i|KRZU#i=c!Z#3Ywrb}E`M-^ zO&)z8s|k}AB3y#L)`Mkcwx7P9U6qOazk%|U5RrRt!iiK)IzTLji*-rtE}*+i=iC-D zjiM@!e_HxMCn>-;8$!!tF6HfV;VLA9mCzn}3~NjRP7CKHaG^PSHmk=@YV=Rkg|F{& ztK1uGF)B6OXHc%M<`*SBfSf45DhmE*-_t=MzgqN$EiNk}6bhuA@_4#mpMhJ?2>c_c zmD|DD=2{hjhU(4k5(U8jG;w-Qw4F^jJv{1*f7Vd>&4@YnS@)(_p=gaAwUcJ64WeQahyr`pX?4(y% z-Flvze~Ba$a`?nu>d9Wu2^%kJ--@!HrJ(jueAOPd2lkDneF=EEq81!0>w)5$U@8Bf*0c8l4SDb1r`JMhM9Yi>7VUV?=p{x_-5U#$saDn&JP{CG1yTdmJ4Qg` z>avJ=2#G)DD$kN7C#4{rE~>F+S#I3Mxa{rYkLFDgi~&Qpnaw|PQ^~XpWp3_gDNE1j zkQg=nhzH@D@)IH+`QeyM0>pLje``Z^X$D7H#Al7EzpC%g>a9EjBs?|1_7&Lc-@Y8V zj2jkpq>;k#&d;9w(N%HE?z1y_QP?Uo307lrC{i>1LWN5Ke;AL8b4e27{5c8wA9 z3)kUe461hdBNBLDtc;_nN*;;ijzp9)M#DsjIrOVS46o?qr$#KsaYQPL_$ z)-Ab|etJNTM?hu*-)Gm$4b=UUhFQfUaN$7^aIJ&%+W$}v6}UcSt(s=UnlfMD0}k;Z z;y~b%5Q6#&s@B^)bza1*f48@~=$AiAq9AF4w#6j5@k6~uG=$tJt`3BEE=Rz1cqOSM zlr8=>R!TnEhTaIB@ofs)?3SKnwu>3_R%lnFRqX7!#yD`q5q)juTkHS@QG=?Wi>w?t zFo2`pQ&ehw4ZC{gTu%o-d;1AzUJSaFpNAy$g1VK%*k!xU~*b9tub-0%-k7jIDP!(}^kDXR= z1AF?1G|l26K-!9AFNlYQpyNUf^qa3<3U$UW>~S6D)wNYj5;v&L1)8>Huv2C>PuylnX9+896qMnr}He7vJyfX$d-{sLe}v!oke^VQ_3)qZPfrg z1qzbqhs&Tx;5O_hlKHl=4i+%YlvmAQ6Y@9S_CJIpK`wD`I1BFcXcP$FvIVJ|vzcoC*#N;L#gPA|?_vv*nZF-|(mV z2Ul2JA=s+7e;Nd-*hY9(Op6onx^c7W-=0f_-d(hg^- z-RXCwNYn8*3w8&`noL~SD;QCq`L4+l$?n0VCFiSXf2Yd{=SATfglAa-{#XSC;5R6f z5h2iBi=^;36DjRi*hh-M+dmyyV%7t~ z7H(oD2E7xt9X^}eWapb!ssH0nLyuUIu8}IW^+E8fA0%zQcnRFCUOwI#i@^dk^srfi z5M0-Glw@VBsL-E_vSoYX!~!0;N8>~)>yqOFf4r|Vy{MKSB%ckDrAfq#RbXzY9eZH1 zxLsP}CibQb~orIUz2SfYh6&!Pd`l1<@ z-s}6s1%$sGr-7I?heejI8{d=U#PmE6ttouLAcl3jdA~h;ODyeK0^U2TN*#`|sRz8F zf5a<`3l%fmAVCPHH-#pZ6$KoH1~PjfU)pVrpV5WOjYCF_%Q`o+oyS0{o<UfzFEa~0n7_FF{*wwjzroGGL>=}P5Y+u^!LELt z4}H7B!7H{5?kmKmPnaHqP1A*oXqBF>M9$ep`ynWoB}B4* zV-I;D>#q$|#3JGBy67pmle>CFZrWJ3J{t`LRkQvySWx+}Ly!4s47!3F4)_AdnVGSbC z$H+U+PD1vX%~1~1Xp@Q{8$!*xVZ51po_C8Iq(#cdBUA@)uTKuLZD)6DYnY!1Jd@xT zvWjTdr&-zXJG}=U%_f$S7Zw8Tjs`fG8T>yOxa<1GM)O`12D9aGe^lS_9KdI#GQqwv z8q-!5ixa{Q7vY-b(0DD@TjgFT@#e07+CYon(V|E+rL3}`Xu7}}cF@AXnLE|-uVESi=6ypX%8n?n&i5o&p4jk7=^a)^}^qrwbQiY>6+#^f+mX+ z3tH@2hfY5RwExLBe_oooez0H_dh?SmO$?3_WNz|#-aB}Q`70!0B0COekUjQu-OLs* zeiZuOsmLJ!m~OdgzQwI5v?N}$2rAzRaHdZLC>O0CdKZMj1LA!D>7WMVtk#1(9U!V# zAwc;B*=aJe=Nh&4$+CttrCm-X&vnNOD#1~?A+I0`flJQP8h0x`5D|?hq z=>E_Gc+a<#+jZmJ_Ma|yzJxEyPwW~-ATRQT+b~xY2>=5TNIrkNp-!PJTb~nX2lN0$ zK)b)`y^yIWN4y&f|9{=OYi?Sn%A8dwq2U%GQzZW$N~wP=P2C=mHC>qZENh`Ul^36` zjWN1Rb}SmT@Gb1jmsKNo7s-}&Jw%quBHAW(x^WPDfn_rpNX%+@dc)~hoyP>+T~X!< z8a**X;;&%tb%?De0C4Jve}ubX1?Q(G8pyNviZ>&p@|nhm+J8`Fap%YBkV3z&qI9QP zbx=BUMUW)0;RQyPaO-Nm{t&SCi#yj%XoT*tA+gxM&bVGh-2m517Vs$~19+oKec)Qt zoVKfrIZUQ>b<`0v2DrsX$arB3kE&>RghIHu%Y=_igM_=IN{c>^uZWfPu)f%(L$vkq zue9>(`&7_gV1M^o;TNNG<|Yq_HXM=wlg3~7sp*@JW7Ioz1Q?CPcB(REgSGoAiWiDG zZNoiFx8RjQQs3@_{jWu~;oZL<)||Oy%9khbt~3Xt#lPh(_j25cbLBeExQF`O&(hz@ z=3-g0;%}RAq8IN6DZPF3OdP3i*R38x6|i=NCMj`onSbVSb$AkI{xShI!?ltLUS7(r z?T%K0G4HOUtO5>~-|{aW;dce7RR~Fxdz4bH12x~fu6?n1sUUVF5fj1w3(F{7^^!R2 z<_*ZazgT8zp64O(Sz0GQ^kDP6uA2GD-gZBoFcsZ`7l&AgEH#D?Uwz~zcQsfI!v}HB zhE~3=(SLTsn4*0RAk1*S6bhXs-6L{n0u4t2AW-75v)v=n{nRT3U4+?`94sDf!x4_@ zMWRb|(0SXp*ZW%V@M5>pYe9>Di3(+9vfMaHSx!FYwu}UT*BWC`6e*?qL8hJA;)Xw~ zUm>lxv*hr2w>*VhDFms)25BH|RQ`gDQShUG=YI~mWrC$xn~mUvB8=_Uh;N=ZX!9;}|A%^#vG)4s3!1b=b<} z_nI4}uy}#jvSP(wj#a`t&-T(C~KpwsX0+w~3+sEdqQZ^VAJAba) zYE+`>b-LY40?)M&<>eUyY?ApE@wPZ~*`qU&Z^O^WKo@33cN$lidqi=ws1ya5$IQgF z;m$)hQAo5KWGz^9`)}mV-ethR#n{UNM?LjL!!M5xo}A2SmN(e49nuhm;eypk%hT?K z4@z0#TGk3~V!$-fJ;u1J%{ZPPnt!F8NtibLlNok)k4(wXQR+HFSE4e3%O9{GX36;v zpoLjP7E1pLAT|k;oq9tQBrd-q6^pcCqu~D(;9oU4jnE6y zkSqhL-e^u*O*|oJB-K3NJK301_JKr199TUfEPrR(shu(?tOT#?lotdDo_=Cl(p;IoVpuV>;x0>jVo2lb zd99VKF5;B0|CLmJ61VJtp=Weg$P3EzOIyeYd&2$wYIyKk0FBqugO;?dpSdkr9y9ZV zYglVG%E33JIOz`QQ+aVRui2P?J&^xoV~;$uw0wds9h4+mLm`pF}VSS&b<`5Tvi?tSZh@=cD=`h&!lUc8o7O;cPYgzSq#UeMt!d z??=PmOHL_iRba00vPBkme-w=U$nB@WVa1V?1GtAca zNBfw)+f3xkag*wALmosVTcZ5Dvo6sw!>P<V z&^F5d76t17{(l#dl&gsELH2}b{6mYce}Ew@^rfv|WCvO9up0cEOJaEf zKG(9#wmihxhNl7eMU!g|2>UX%qR#V7yNatEv9I$rCV%pecx%jEs+zzX)4~Vtnt7$* zT}CYWnVUH|s1K=8uqU7enQT`Q!O}2H{owCE>_n0pf+(rnkQYx|72TJC$9@0yn+JvW zSrVKkU-|ApyjQjI>-fTs+`gaWj=xBaFzpGl9A2rcqFx-hL0(!SLx7jf?7i|Y^5;&J zo^Zlz^nVbeXo%%M>=ILeuV z6Z3j_(_Knvs!_V;IH*C$1qzje`1s@Uam}FKXE&kL{Q>eRkgk;$!}VKuK*x=CfF{p4vlu#G%*qFTQvrhfp65IHxada5YMq^Jw9d`~9M-OSP& zch2QL>tRWzv+{x^fd19yp7su01>_R#-Kp0>MOE%NTx9EEM!U~2B3{2>=Jc$`%Q5}M z130_i1JWILNtHd9bI$N;9 zxTa!;88D5(WlE&!93gs_58+b$|9GK(*nbx=d(+sAMyIMFEmy7VPT!zuhYss=VDHAbWaSBFE4>Kc;OhXr!~PCR|pZ2Th|8^kI z^Kqy=k#n4tL*c?+bFHkRp@}Y}qkoS^LB|!Zo_b+NsEf_O)088UC?+74$Uf$mQcupH z$w-1k8Q|Je&ogMru={p$fN3N@A7|rdRaXx^>x6oYOM50L91uu)E+#z+mX+1=-E%B1 zwx*G75(Z_CIp{li(~rxAHpCef=%xkmVL>uzi6AlI6t9)H5X|Sj_OAwEA8A}oG*a*&wMb~7fhWSlSB z7n9z*@b+H47lAi;qnthp?}%&{#=hU4(jQ!v$=IZMSSQ_ERpw{CHQzzPq+Ew&{Stw4 zEPt}B)TMl)yl3br%;og%Ie(>CX}mQ{Lvbq<>^Xpxsfpe#h2xwTU&>*Mza1mL;5x0> zx=Y#H*C7>FgvM8a;sIT}uP4o`0OF_)oE5F$ob3q0tAb2K&LbIZZ<;9!S%;VSg;Yc7WBdK2S>r z^WNILzs+iI&OnY7S3b!-;)cMH%HU%GjUhL9LT@oG>-LBB+;8lUCXWjHshA#b3v23m zJYhrFsdEBxN~JWmD?E*1YSabT1J6O*omA5ll+>g&N|Gzp6+y?O<>rkm-}DrxQ4+ z!PYVM2PUh$KPl(t>VLR8wD?Fg_$3olk;YI2RWte8{&_Eltb!fSW+PK(V?iU%NSj%F z`LY^pW$o2?>geTP%XJ+tUj*luTu2Ks1I=2`?UD>k>e-tmsQ33V$v8R*+$FjC#r5x7^); z;A*PL9&|Hr<`E}1Fg;}yNsQH$t$2)>hKCKjKqUo5v}I;4Jokb2OB<|$dnt;CXk$zh z)p35cC%@ZBx&P@k+$pCpsfRljm?I>aUEkE{Y1i#fH(YGR|E!gsI&Oe#s3NSNiGQ9w z?^M`D8xqDf(SJ1Go`ukOKnYe@T@6f@d(ivaHRopp8^%kR9>0^U({5d)5~@{&bg(d4 zF@pRbYN!Bt5z>AMxjy22{rP)(o)QHR?y2>e3AjbZnDIy)qqp?D@%(Lo+(+shwvjc! z>L|o}lgwFDB(?Tddc(_Ctummn&&E3X^U9s=EadSdY6CDRu z=H9<(7Gy0o5-WYk+Pibou}>G1OWAiNc|0ufevZ+~TfKj)UO%AYOG2f}g4l|v;D#3_ zR)!QtK2G%j^qEkucd|IW*pRqZlKo#0O$fh23dq9yihATYAGqcQv$TrWf=AYnMt)A6 zH-Gjd9sjO^Az{T>e(}lM4!s&`HPJ$(=vZru_)!wx|F371+`%-fSI&89p!@grzfb;) zg!Rn5NS~s4l5?K_)MCNZUOSz$I3STJg_Pp(9fMa@0sF30Y0LKA2o`5T9l@0}bYfrEJ z8mB?J;IS$XO>M8qFY1`V!!^i;ly%|1>?CRj ztz>yO8j-%*Ch;n}H#J!POFAT|8--4!oTi->ZqMZ8rdbqm{zQhNr&coo?9oYIfPVvL z(aK6Fz0OvewhaC55r+8U#BLg3sUkH*`bt%1GsQ#=@KoqPY3QR?q??5MyG6(JY-(~s z{qKIOa(2V8wwa(&+?x~7*`es!eLQr0Aa4xKuo+7xnJ8l!lHW|#@yEb>B&;+Vu*NkR zQ``nd#W7&oy!p$_xXz3xgY|7GM1L;xgu{K_XAj!Z+qT4$HYU7LnWvI;45!V~xl1(P zJiL!dmMrC8BV2!*klwRhMZ{2#nO>76PKhKxXzKzVN)!4dX+`4|fT6TU{&CCTe}8ce z)<^`w`<+UH*aitQd|fh7w0&0Uq#2q!92|^*t|M=Um~@VM!9+U~WeA)Y{%42 z`dX~Z-aQ<8yejtA-|jiR4S(BLlk}e^#$SP6TXbsF(9*sfuKAwqjGS9;I5Ok7Hxbhp zAHaD1dT_53SNivnJCed4T4*8P@Zr-(AhgQC&pUa1>3waAC12ML+KCZf4KM`y_yw31 zF=|AuUFd|vZ7vZ8(5Lj*EIP);d)Dju z)$@KPsfE@+@7LIP8-K0D)T-afg1x}V(X^#Y6vIciXkTKo99KH;^WH{jF-m0uJeFRM ziKeQX%|=?D=^V&fYXGEt9EuQu>LH&8FCO9i4%&L-r`@zj3qH`Pw-!be!f&HeO-Crj zTXQu2FLD+`8{ATh#+-QV=>QMu@(Aq1dVLHZ9V&P%s8)cRXuJfW`U5l_0&4MTT}H@B02z6NR)nx`b2IaVjqtd zK(9dj(-qPu2c|^r3dzg?NmUTG;VO+%R!oNDS-58*ZIQ43$R$G(DQJ5?^l=6o3_JHy zovV}%n=%{uy?<#4v8Di6WQbzpR7e#5E48N^pbZ!@4dU%CZDWr(m??8tG?9L2Kw7)~ zYc8dI0XbG47{+E8-XvA4 zNLJbq6MtNQT;q;j>8Tu7-{a8>MbRs5J;3W8>I8R^qD3#nqyB-P8n@$@HgE4{+e}43 zOV`zy_A*&Vf|Je#c_D{VAr7tp0hPYqP@flI220r~7l8g}MwGgDv+W(oWsWicEcevH zN7rBuLs;j0tu}kGXg*0n!S7JTqFXI8QBIaWynh51?@$46z4;$-{|<#y6D-kYU5bn? zHj3K%+by2nRd_UZv-QgAe1NYgo7jB1p5c}FP-=3U9JL#&VL;h){F}!jm;t4~d4sDr z2>(pG%W802hM$1Jr2)YM+)HgTvLk!I5*otTPM9R7;@67@T~4ONP0I6c3Zgv(E5g{A zzkeb!!0Cq&&vw7;ho@x1lb0H}#A7S`MrjREQLIngBP8lw_Y8pv7PzFE)Ai?@p-Qc3 z=hr@rM@LaGez$3*^v3O<8beM=%u{ppOot|hT9}9NC1>q;$bJxeH9yeX5xWBD=DTFTkNlKC1Rg zO)4T${??6g5^jeV4LCZs>DXER<_2X$B2&H+=?=C@1i5>OhKy$b!EZ9VasgZOtkSIz z)}Ye`9oCb~-4rybT45@C^OgZgKnu2|S|>4fdQ;zX1v#hdEs~01%Iz? z?vBF!N%*62#LUC4WdMyJ9`EGAGP*w@dIn7CZYk+DpI@DPq1QV+8g}ryd)J*4KyxW@ zRwlSx{W5}Vub^(hVygT+5=N*OdW+s=12>Hc$%mX!YO3TFSdH21gg@xSE<)kBQXH* z;bMI90wrGUL>qk05pXbyW^IC-Zort`Xfi63hH?>zsdD2X1g$ZH$+wk@0e|}djMBe% zH}k@C9f&yW*U8=QPLda5Mkbz+0=1Z~G!sW0{QXCJxAm8oe>`0;5Um}07YU%XZ1JBf ze3LifRbhQ7HWta~k1e$Q-*>!(!)L6?sUgtvDdV}_qXs9tzgvHX)?8HDi^oBhr&kjr z{ctBM6ZorKt)VLjQOx#u(tpMmK_=B4`u!hBU`b>sW3$38fSfqanPnLWgH>@P)#er~ z%RDRc1394sere%CQAp=-?sBl3P_|G?yJd2a$;K@wwb0T)h`{&aZy}A~5f+kQA}8Tf zo3f~8(bT^7CJg11oRe;(Le0akZBbos-^I1+_;#5y{z&)Kb=LTcF@FvACwF;D+t3?_ zK6`iEo*}AZ|D4WS+b}soMf8h*@J;9TrxHdidvbU*AZWJwikHN{n;#K)Fxy)`LCVBJ zM@2iiL2eP-5(zWfQJMy6U-gkd5<=_@VR1#WVYUFw7w3R-XyDfr)+{Hsj^S9;zrG&( zw>4WFP3_{5v3x#&R(}O`9f}mU{lGFJQ3#3lWQW3oG_x(&>mypyob$Mnl`R2XQHa<` zerl2tx&{gr+0b{;Lu-rgEC;DTrcY&zi|b9I%UP*2TJFxhG@_dkJ&)ZPm`vqNI19XP z^pE$9DPz&bg()UdQ8?^ZQFkd1E>SpUONZ^tZ8E~^S4ms+&VPr~cAL~ME~oB8=5pM^ zoA2nu>+^6sFCL|>H+8*`artY13=#fYZR_F1HZ{3;EbTJ1Jhoj{=n|0O>2jpRn zDsVD2w?HlYKIOjcJF`@Q^hN2X?Uniis$R7>gZ!x|(UE(9$6Ea0Kb)%76}Z3?QbanG zvbB?I@}-2fOMgk@_E}#^KrrV6ave|+DN_OX3o*~g%Nz}Yd#>Zx68TEw`GTuA<@G() z-ZB*~Q$(& z0Y<-8$FwAHV5jp5dT5HmP@*3`xO!EI*z$0%jg;DaaerChP=n`$d%?vC-Fu`(Bx9;* zb_UAP2qvk|ma8g8i)if%b2rSxw}8pgQzA#ZfoM^9LV%yGtQ#InuvDf?aB2TRbv)k3T%TinqOBDQF(iY+P?^Git2wsE!QT#{u~nS{9)^{ zwQq42a20{oRZb2jLn6Q9Z5088-U}PFT5jepmw)K)!GUE*xYQteo)))#t2td*-!ZPC z`X;F!s)aYvO}EG{BK3O1VM_aFKklh^$Nx1YXsUug*sE_Ts~5SZMH;A$!gD@)fgZcK zxyn`t<~f+)n2+`ARekLU?d<19K*3JjZ8xE~Fs<^E5GZ#T?u(LlX3ZlpO>ZaIqln@L z0)GXs@mORc@3PQYxKXYlXWY=@e1P4I*Y( zRh~h%WCO6i>30IZt@qj^rv#TM%5!AHcC-;V2#}(A?w?C9%C8lk5OwGJ^}L{_;jMvw ziQm4s*0j+gco!o~IX?+Ca}9H!kJoA#a)0jHaGZA?G0cZ<1QEJj%hvMgA+Z_=zX4^0PRTeQQ8ume)+K$&{6`trhj>5 z-Sr6c-jf!YNj!dquZj3wHDmF7Tb4;Y3f7AO8ef*9X<46@s$iaB$OaP(;^x+uRmxxD z7eZ)~cY^_~BtrPe6Sp}v2~{=}{M3$Q&UO^8x;kUt8q|@hY+Y4!iA?90-Z;M!*#%-h zqGF>BTOC{(;2JFvCToZkX7&VXTYt6`*s&QewQAT_t`8s>nI8_M%{I}8=H=26*B5nN zYgEwh^_s~pHp8s!(uMe|F*&VITu@eNmEpBJ%eR0%E^y3Ui;U?~G(>ujB#0i28Rhhe z6%4UG@&J&-o-iix+|7t8tM!dvKgayCfvSJQ)e7kgPq}FY*M=qK&O^1(pMS&Jcn!~Y z4#^$$)5lApxVV3zf)JO!p!VwhNv*xb6#dvZJ% zp}fw*!^Y18oZhGI*5Ccd$6UObvb5%uqlLUT_e%Y{Iu<;MoTC88{*w}0`$TJxTWSs7 z&cElz!wLnEm-vBK-f1H!#D9(@nky1X^&hS+i802X>jyvqzW8XmhDqX)ZwWRtH`c4Y zc8k~f9*ZK zW4B(7Y0`jM_b>iC*w`NxT!e_Yb~|E*4efZkkFVEey98aVEd|dFbY%^=GhiSs{=c5I zZGcot#n-5Oj>@lU~u3O$!x{|%?F350+Y+aw@ zTZ}93@YouOYO-95{TXJ`y*5?XCY>rmHa{1GfZ}WU2q{KM)`oe zaoj=%R|db2${biR%LzadHm@vZqXTFKs&bQ)qs{C0HsQY@Kq>SKn7;pjQuJQMA`?cg z6fokXzHoFk*9X%~8|jbi?#Qu(%2xT$=&I;spJwo!zN$oi7Ju9&3WJKfeDtj=+}FH) zH8j;9XcdAEu@koHa&td7W6LyH^Xc0c^L>%TM>r*Igc=E_v{Z zyl&U$E5@v!wx8Uncq4RN;j8Be2FDIQbE)xTw*{)76rwa4#YWJ3=f+bHb*wZ5T}8Q< z&NLPYRu3`i6n`v|A-GG>pUR96H-RX8ZthG;9!) z(36!<&Bpi?l5PNrv1bf{s=e=>!>$!NP<6y%kF>mj(>7`GM^qzbQQc;HIuEMQ>TUah zH`N0UVD#e4W?di!6cLKbGe2{|BY%L^gjDFfXC8w}CVyFQTb{2}!X0=M1qQBoXicfg z_n%cn1sa&tiAo}XyGDym6qgP-cO-({7#|%IO(SQe?sJ@doI^HL=X@)s9FF7ldc*kF zZH(A|Y;B8zU$l9)ue#QMeXsf3mcfJLCm(k$CF3p5#z>kGY%7Cl7HB3m+HFrnO=JBb>=-Ec3WVX6&2``C@cI#r zkAHl~oHci96Lh-C=s3{{pNE1cmh4uv4TD0C}G39@8~s-k^S#BDNqpnlMw@vM(ZK^1T*5?BUt?-Pai*|NDmUaeYHo1$4<4e%J{D46sHP z>a!_w9vNcpZ-$)VAIH9Dq1D&b24}1{&hI<+3qqz)PLqb(#VdCNHknzR;*v@%m?Is;GlGq08J)Id}dF? z{)oG`)GvJUtEUgg9N;rB0wO#(=)hOKX80-cF@G76ju1p(1aHazBNR|A#dG09u2>E% z=(gJG;y%&m%E0|`WZRb)qWK!j)!37z;m8glj2{ubp=hE492ze}qGj%b+ka-v2|KFF z5y?v%(-`2QR`k7y*ft1_G%Coj7?l=>u`-Y`{*uQF4k|^S(GmRt``g^uxP{kn~3VjhsUaD`eAoU8L*%p>ymS7zES9Xe;FE&r1VQml{L`&p0)PL8S%}MbOs3Si# z#=RcL&PH8h?N7xxoH3Br02})S5*h*b8qRaGD2w|9p0HJ}8ckxPWVD(h(-BS3Bwn9~ zLeoU{82-Vt)hb4hR{8~nm5#jA3A+98$PRGKSoi1vazrJUz+G{Z#RYTKrI1@y5Aw)e z*c#YtTLC(Da(#Wzynn0mNFhluj3#q!=qU9xHR@5D|G09Xxf!>$&AW9xsJK=-=e)A8 zlmalgF=+3olodwe`?CkyklTWHTShXt?EZFk9aEc&KMB??B>l#`wDWzdBPfgcS}tPd zAx;0b>bwzo9B_8E#ckOgW9>`?4VR<8!R$pNLO5c1-v=PMgnvsoO8x7JT+b{PONwI- zhR#fx+C>t0s?>cSeOVuT983-S`qP7N__Tv;JAgCk16mZTQHl}N;e7=!as$4Tl=m&_ zkkq4kTA0FqCEKS6mZ9lEUywjYC^O}w1psaB^I^3IPongF{s{gF;9P3mxs+6I*BC3P zV7S%yK4fvBAb;WUCu+tVp4#h;mnrB4Co8cY69tXtawDhpt~~5yb4ZMXIyM|5vu134 zV1E)G5$V*;+S(N4!fMMHqgrd(~{Y7tk@Uv1!Upm=wie z&-iz@Ci2O&xmX*=XgQJnxuGdByz4k z>Iqci3tl9E>r0_f*>D`x*z~lN;5(Z};jko9h zl;`#Qeu)p!Z&{_5t|*9=oEY85vE}q(8Xmj zCxeqiAv&6jxWj!C^p2WH4{h@_K!3h>-n?>&W?{5f@pDEpF}dZQK%y&atg$Edxy@I~ zB!Lr`lc=rBVx8R{bLY>w;#qn4L#OO)M-f}xhp4}A_g_yp8wCwNCsj_q&jjrMi?GgT z(vETkWk>-*ByP#1rWg%XA^a|~qFMtxD`1by9(>viYj+qbmV|dR5=zL_oqy3a68X(@ zyF!Q7bpVy7xWt!^j_1?~Spa{>+|MOLu7>ljbdW6!kVyESXBXz{f<2S%B-aqb{+w)K zL*CfnS&eWhOyQh_ASc^7+GR(%-hxUCxed7daqWE(NR7g+3T*C+6dXoLK7 zB1|(`RV}11_oH@(M(yDcT}Rm9@yqar2aqzY;6eQ3$NuQE zZ{mdi3S`Hm|USDEub5?9>WqgatYm7A(E8)9; zO{2XHq$4n8`a5w`_Qvx0LnZc8$uMNuhr_Y+KA#KBDe`~xMmTR_@;oI!4xZC76<;&K zc4;7lQh**4JpxnQ|4bzBGWRj4fwQ}i=XkaAK%hvZb=+-e8GqS0h*LVI@i3Ep8%olC@$rp$k(YWe2B?8 z7p&!%op40|$x~fMqfT?g0@cxkmpf-u^tQB0YO@b@y$}kzss4}M&dzn6yG!#=%-)w! z(+A$k>en){1%Em0vK!>*Uf2ChG%}O7wJr<+=%a{0oOLW7xby_9Ph-ZmpoDK*x!IZ5 zcLOts7hLqsaF+KBP$3amh2=_IX2$d#BnD_f!+FsL`(ugn;pq0*w@k|bO> zx*Fx+&8h^6O_hsYzL!E(k(}{QzSp_`X)8RcNH3U%NMYA-iWuD;W4<$?xr!V0brAZI3v2+c>iS(5|~6jfu1d5w8r8t`a{gQ9(zT@c?B`L9Uo zRH0#gVI7Hv3A479NIp#iYRf^AuX)qXEt)@ zK`bZ&LVp=&X3u!mro#pGb7$8hX{=qZIvu>s)@;X?kdXPh7uZ&W%%9PvCsQt75Eae$rnw6`cU}y@s$&ajChw5ji;i2R^HO zM&w^yCao(l;D~QNwo$oF(G_fE!8Ql+F@Lj{#QA0>6@X+_{paafXY^xk)RL*ARAON7 z(;RCV?`#a?cs9>sm_g&_`grlU$yWtWv|T(#?*xsB+09r(baZXHUWTAk!n#qSj|Kg3 zS#LU@{?84Dg`XaChp^f$udoI|J_1eq=yh|d*0z@ z9ixy^Ma)I4X4EWXGr8J6MvO8AV6h?ru&U#O|O&tofH0 zzpjezZ>&#*j+k%io-p9Z#?5)^ z){WFXp<^b+x&Fax^EcgD=QL2GYqI%5k1QF3AuIyij{Ee!#HSqa0Wg~KKMzg5zs}c7 z06!tumvYb)0yKWyozV`0rGMc>7)fTy?M>BxZ6R$qHFMx*AjsN+Zp}}rU2@oiB$wE- zWlfWd22H;Zpj5O~F-~quV$O_oB$cz6t~YL33fVX9w4Dm-CLIGSJop(wJ`c{^bJuo& zbX_fDe4yzcl*(N-8btMsq4JhSka40klJMvQ+b+Ih9*^6Bz&Kg_ zfbG#rb}sc1R5PA2=6juvOD@h6B+F%{x zT*G8zuqd^lO7T;_ii}EpCKJ4qs8h)icjN^MMka`p(C!nYyYiY#-N$ zS;-sIz7|o3N%8N+UidLdpuC#3r;kS-i8b3M!v%#f3>|;-+<$`C`=%6AyEN4|J&{ttSwdNT? zm)H;%gYG-&v5@G?v#&Q9@zitF89mI9P)5_iu$7}jbI+~q);qn;Gb#=`VqlbrUjtm9B5gwttng8U*s*?&}J>Ri9JN=^}MgheV%$590=}#kuJJ5|E0fEeDxUqP9Uw z1(qMWF!x_5qB5m=BJ;~#lfIb(4_6#m933|rH&8WbWi})jRS4-U$Xwn;$Q#5cYcu4S z^4hxngmc5!jZPTtyObhM`4t)7bYSE9^Wt7_X88G@HQQPOSp2cs&G1@)g!>BpQr)&F@9C{;+Z~&AKaxUZtl-=JyXhK4 zJ^L*SOzH_i zy5cb@I+r3Db~uPDG2Qo>rxqC5D)~g$+uHN6kVK&@s_1RUkhKVubreAmK=%eMTv_wnc6lBjH4X@4VuCjO*<^wJz+PzMppHL-6#>QR9wsv^X) za{*L<^>+C0wuhvK&!mkclw?_}tL@WuQY9jdK1@e&s5PsLgPPY#*3NaKjUID+xpMmP zX)(xmg><;zHkRh*{AE4_7bhF0J^^a{>~HYlvWJ|H%CQ5}H|nUPCO@XrL6s(2Cx0$E zL3iU2;!Z?c|Kwh|XaLj>0zS%kf2U;M zj2_7)-(Y1qwc-OUB}NX-B)%$uZn)Z(aj*(|qVe4@WDJQX3JPn0WlR*I z4g9K}Ky>+6+G+Wve<5l{A?>>wUS!ynsU%rMyuLqp$ptQ%zAdgg-2#M%(HBssFP^F% z74lNch4L@!~w+Y{bQ(MS#dXLk(J?8AR^?K;mBLs zE@)@az9djhY23crI1BK@D1RJvTA|J0B>Ig%Zis=g-gABo0NVm1|1EISilD-;V3A{G z*vL9_%%ED)%T~}pXSqQ4pOOgV=Q?H@hl(^rC&YcDdKUrj2kBG>isRF7B$AD!G3PCf zi*b8_9Nbz4t);2N7w}`&z#&Jfd*Xx0gc@)8^6(>A#At?;E~a(a^zrTmaVE-#m)#9+!v$U?Vj4QI~3GfivUx~}C8ilqG+bPjP+ zBlujC6cSmVv$MjPR-ZWV_RY)LL?#Y0-JBBQEddyB%F>*h(ueUcd&_hi;f@>pMywuQ zNwLrMcgCx&SRyR)TFJ!6iz)ZrRtuH2hY&a({FAr9>wh~!Y#iRT-_ExLMvSA8(r}?x zseEUv)X;X01uTFSsquv2W2;iZF}S?TGLKP1?GG=4wz= zvdqFsmVY%4B67m#!l{FRHPpiUM1KeV&&tqWkvq4uA-DyCqkqB8z|Pb(1w-w4LKl0Cx_G!d@*=L!!Fblhpq6+J zgv0G0;q{t?9RtiCMF87DQ~-tB)h#m76^NN{G=EMAu{i+uc2i*i&W1a$`iO7@wjb(` zYOM2c*BrO0D<{Ww@(p$XfWY(XIb7#>+!Oql(Pxh*ubF+&GE!!U+e;}{la*gJUf)i^ zA?B5%Zlw*Kv&e4|)1&7niS*B3p46=iQsbgiNUh5gGU>EV&2F=q*A^lMu@vKddlV3u zrGL>Ta-TRiDl2i!Upw>1{=h|={>|9-vDW5z4qfpy5;}gtxwkrIx9S+^O9X&JF%oEjR zqHHulK)Pk3LKI>qi)vz3DP}9+kX94Ya(|1t0;2K;uOiV914z7iyJE%bM1W_4chzz^ z-cUbZpXT>jYS8x$Mj7)B1-{X2WPGV8VYjdSoc zJXv6OuH%*#4jJ=ys!{}F?##`N%mTadCQR2XvbB z0D(5Y&-g@APBdj$;g(-iTM@WA&P#6uFCgx>0e_6I$;o%LAb&O{-A$+9@4ODf@iC9( z1By>XP<@w%4E_{TR!uLKUiKh$fYc$t2JVy!x(`YU03PN82+*50LHB#ijDMvPB_g%u zt)N&c@gJJ(w@iy5JKpY+mt%C#v`r-Ez2tsuZ@Mge624dTE1>TmZfA)D5;Cj-wk}E0Z%0oSlI}>aFtWnTdGVf}Z+B2ZDK-|w zgoW@GUvq%;Ml^2*p5ba)^4K=Bu_&!AbDBFXJPEs`dxw{fb8#ya$2&DKJz;+c?Uu;u zl0vg6Js!U%nzS+y!Rk{qXMYpr;um;v*OYy$g(0AD2qlH_ghmK3@pzz*>9!$KupoR0 z5O3B((*fKKcg5m%|1$?BIs=x@Jx}Jym^>3@q-Ieo<1Q#6%ZWS$4x{b&iC#SKFboVK zrGw{@b?+uuiuwVpSD1kt98!PQ-HV1PM@X)DUy94M%TEjvdhHS%U?Sa!saP6+ktK<6 z4bQ!49oY|brnI@C1$hKJEM8Pn6wy{5QY1T|#DwyKn9$xhZcv+Kda8*dU zkE@oOGTED7w_XU~F{S&q>}~xgr65SA@m5{N548cw$BSgebo>DtFvioqi&DmzE(-5^ zUvA*^Z=QI;-1@wV*Mxs$(zFNy|IYP_q0ZANP^`b9`=o&ZF@jmWt?~9}pWYVy(@8HS z@@Z#3`2Q$u!x%HpIVM^JodPK>$cSH=1pW^$Bpit^#}A$vr30_-28K?ITt-Ii7S(#Q z%U3==+GY7C9nIaAVuTPC6W5{YG2n5tenG{DpaikjlWHndhlhV~lvY@*IM4o=A{uE6TRDb?)OG>_&=a#_J`ntL|nw%o-miu5d4~k_FR~`12r&g~% z*Lr9#6WdAF-rO=TtczPeG?t@nYd)Y|7H`EdFy`T}$_XDhzpqF=OkSw)>4o z1D2jQY@nRHMo)joJJN9dH#5JxB(qf%bK&hu=Z}lTpgK_&OcDM`G4HpW{XZFMjHOA$ z0MzcABk`VVHP2ACz}qEasgyQN?VR33_U}^Y!7u{;oZs-p>M#x6o{Tt1zT_RSEi|U+ z%lQk+Uo|jM_B$7tx8(*qR8(;u)+1LBspMV~$l|KpP%3|>E*BiDL`#;Q=YGPS`G9Di zD!oiSK(}6dEXch3O~xjE6}6f3nXf>AHaIHf`7hU)uWTj16iI!-i5v;g*$>FU$*Gu1XW{2O2?owqFR)GIDu}<3I2X zy0d?bo^iuI#VDWOh9@PI(wR(hR}}4!xK3aI^nVOD*=~eS^-K4a0H+`VzPHy}xtt&& zp!E@QtJ!FE*}Gd`iD0^*HgIRme#3bEntsX~+kA}IN8MPIUOeP!gwPcMJ4eXi?WzX& z2rPDS<95+Euvfd3pL@3<5j>U?Ur#VT>O_A?T$v#X3WjB%AaHdZEpdSJY7XEueXtXi zk>6kxlhR3T<=vo_=ac}&VZnE(gf{O`>4^+@tIr^|lTme+ZwPlKz&BP#$3=dU_KeEsP8(Jk$tA_S~Y+7 zbRH_=0;O~DCh&nrfp84ZJ7?c#K$8*d@QS)K{~1?n7LF+at!_2H!V$vcj!DRs3Hp=*mZ)YqC25K?%g5fgfK|*X+T)5zC8dwzlXGS&jrd+Lgh|zx-uS#EliUaSz z+-6Uav7~+VB4$6K+hb!-wxY52T|Hk|*bwvxnFbX?O1rAuwWTFD5BvYH8w|^_lT7>E zB^HeT0_ghAQfR^vy|8@=n2`5+b6HV!dn1=E+QDPSSo%93V!eV%$!kMlzjM}SX^ScY za60-d`n!|xFJA^gysCfUg_4Vn{3c4wtciOV_d?!HMO0` zatdK-AD@R^^I*$&zO(ZDX@M$XsWtheXU;m2wLq&UON|LCs`99<9KkTD_%K%*T~)d>k-v1Uf?8D>IuC)AY1 ziO`eNS=Yk1;oPlDZ}TCJpo^`=;XEsiy#a0Wkl|!;i#B*;cN~o9YRB^}$RNe}%+KWw z_+;zox~@?ggaLnG+C>IMSQ7^T9KZ1Kuy54G>QG3NWq!}|!5H?=q9 zVkZBHR%@`Eh(dRk*>}lRu!$f!5L&T#T4IJu9Dm~pmz;n0R$R7G6{c6lHx5 z$!wXJQ4qj--lM`DxVSOq;KF@3z|}>Vp?vaw!)0Rqif@C@?IR+rlfk)zB~YWIkm4 zEuw3fN|`y?$j5Y5-i7jU_A-p+XNhd3*ENF_--CY*oKc?Eu_1Ex6W9lkZoci+SDCrq zUZngI*B3bvu@s9Kqy|BP&i4HSp1{2H_@bWXxR(RMHb6)@k=>B}y!g}w5Q>1&psGy+ zd^>kH0D zoH-4<9VvZZxVwg!lP4_^-rL|8Ohxe{j&`@VKElsdfRo?6?w?G&Vtf_&fBerJ3=09*#eo^ z(nM9Kc_vOI+#U0vXj{a)GWkZ@um0N$J4CRkBD}Si@x~`a8j`%xP&J&%KvmV54*!3q z1RY1rk9suW&u%lYBV-;eczFs{-i%l~!Xa-7jc=^VTJmT2I6FEKG_!~(H-9#}HNa3p zW-@_*StQ({htENu!OVAs22l@|H7F_slej~XB?Nwl^@=+qIZ%9oD{!r9)6lbGI9ETv z8XKQlOZ_*&6Bd6)kV)U(`oZYASvy-lLp}a5R}3Ab{9%quVT3DL zm4V21=BHp^TR~u6!}I(>=2yFPU*X>t%Z#h=^m$7<%|Wmu1ZqzNf<`si5FV`!GdR4x z@(HqG8Rr2XNViS{K!`(`eVuTVd(Y3=2G3rLa#e6jPVGFT#XRL_` z%lK)+3xMe7u@}!)F?d$5G#_L0ScM8G-DJ}EW(N)(lij4F3Z^?l6N?qs4%>gomjZXl?A5ZM^d{r`)$CMNz+w&}Zi0{c`1%q%{*Y$F zaYa%CuWFTKLY!5Pj`dmKV#Ro3>{PJWhZX^Y0;6oElJ5XWN(Q7~cK8invM(kFMhuA` zYMac-38oZUQlh@3+W;`nl4xteE zmI|eET36!Y$NrZr3&R0V8^SZ%L2+x=j-a%;&QdH}p`D;#?WlOndl|EjGi@onQ>X(! zoaS)P9k~kp4@cV0|3#FXi(;u^8njgoRtId~$jI)mhaEHJ1U<(t<}UF$DieJ0-Y^QodI%j0)fLunVo3bOceCuKDuFl;V5Fax)XO z2G((TS3&|x6NKc9VfgPL-jYwom}XG{W23E!&zAnK^5w3 z3+}MhN9xID$8d!|xV75oJ~ivTFct8>_I*98x()7i^7HPBc#6^hUs(Mv#EmOV*Vpi( z^F@C(DpjbvrzBkW_Ji;)oxX3vTY51uR^xnTMq~Hbk7{l$zOp^chRSD}5L>7=3!`be zEs?vJiiv;W1M1{hPSmJL8%dpsn+{=&;^@YvV)mz_3-xq>V)ZrKIgPfQN#?^UI!s)R zOTea_?l1MAk!K7FW;ph96mM>x%}Uj==l6emRBh0SvkLEmqz&hYmcQT6+dL*Qc&?Q7 zZApk!D3YQAPMcpa3jV3?qF;@qQuN|GXuVwnnW))r_%VyGm%%NK&H9`rNp1hc>kMOu zu`WFBKUx=HJLVFx$*y;k&{uv@6v*?WZ*|mUwVsEku}|xyPlmb2W+obeh8N#9K?h!_5nGSF-=k!F&H?;7{JjU3~X+De`vcevWsg>gO*%fz-H zO3SzM#L(ixk8t2`-mNRx=T-dyvMEuVpf3@IPN0e*Q)P0_C+$d#!sZt}8PI35blrz;*5lHte2wK_9fuuA z?yk*}ci0WUxLp}lSYjP@k1eSoSyF-J1>EB#Z(&-^4V2hGR=}i2&!FcJb@=-!t?U|Z z+%r_u|563W^v^iyiS;gzyODo9`c}qEV7}+`nAKWb^Ud!>quY(PM22i`9Y*9DyZpT!Z&Q&X!@W|zRQH*enAji=|9XcBLxmlWXhpaahiDT4-tbro)4 zo-wNF5#w80Vs%OZN5BH^BxH8Xx;XHSya8`84%$;uU12fdyiQ?YY9D`W{&TXPs9!tC z&ZRrl_d3p$hY*ySols3jmfx!?HOSd_?pvbuI>??*xW^Mzw1X>&X=Wd}56iq&B=Svw z`srB}h@s0K?UFhDPi$!r=?9)a#RC zO6vRb!2cPCd1;E?w^kuB6O{e8XgaWxo)M7?G+5a9*P^{E$9*j(#f3hz0!ndxCsi8p z!%t;opvJ=^f6#LDv$YkQzHLasLhEKhAS8M5@xnBRzcu$@Y8%p*QSE9s%zJEo50aS?lh zUUTj`&J1I&iR#oZX3D&Nl{ro@_NmlAqNsgAXe3ceh0&Il8QK?7cN!2F#|J}mD~@W= zZfJw9x^90p%MZ6}cx%x$y&}8Nx@kMs>3Z)%WA2)NgW+fg-hMmBp*r27Zt2^Y2 ztGgv!b(>SHLvHKN@fPs}KVI>?flbjrf1Ucf#g>2Mdy||b46%{jW#AWnQiAf1zf?sG zpks04r8Oyk))f>{n$7(XiLuZK7xl1jPuP(p=((@ev)tp4hNcz;fp|A{i7w6loqR2fGNXj?ekF$A3Dz@H zcH@7J0%Dm$i}4r5Ull>-nckOCz-=xskoFp)0T99L|+$NO4XuZ#xlX$Y6qdk zJ*4cx{%vQPT=VFW%Se9{u2-KxlMP`wd0{K%#UWj-2%kW6XS98D zVx&!Dy<=v@6HXZv&|>!5t0H>$V-T>OIo9;FCD4RcQPF$YCSxrUj{kGv7|GFIWYv*U z>an=2a2RzUS}&S;!9tM|_8Rg~nuvT`-im*s-dfSPs>l0Z1!jv^hQSx=(QLTj1y6sn z`LP{}ZX8&FQHB>TAm4R-fRM_P1AVzx^ZxP-E1cmJ&Tm1=qg_Pm@gX%)5PJ!#qtTaB zjY=a4_0QuHFe$R0F8;x0`oYvl_jy+@&GZ1>myGbE9|sDwR~I=Mb5d2mhD|!ZkE*RJ zMXAlTv8RNqRqk?AbDB)Dwih-&S~uh{@G#Q zhFC+SXKw_a64;(k!$)Kd;h9)wV#(82C-s48I9sM8sm!ff21^RO1)GGw-EOpcM{`h4 z(fC@KrLL8C*V97U7Ua)H5s&ctdXh0=;E|}Lex2@CINI6C8oJY*Nl<@ESWkg7 zjHeeUoFvK3h8YEKO(u1fi*`U}+C$%sH<5ty4X6wruMZ3A>0C!~sv+VGSnbxL z9?5NDSYLs3KTtw;4hiaIUX_21NrkIMEZ{!RDQG4Gw1xqb;3Yba(7Jf*)uxR5P;Nt2 zqN0O+Z>`eG%45WBe>FUSoXj0+8nI<@Smxt0lxFlKws3IL^GQsNu0|;R}xj&8Qw0<2#CZjT~%_jtA$66PIFG zK|n-Ua9Xn~WhS_)9;LsH4@# zEQ|NLWzo)ZLn_%%n9e$}3x(%Aj9*nmB_vri((w^S0&tL@_oVV*BP&)Mqz+hxtz&nk z_%`D^x}FWsPrYK9mbE*D{CZKt$T*dQPPL>n5vE@p)9sSHO3;7!iRM-SG?XTruf982 z)`yJ%Jy$6JZ6-*46ckhws(msM`!6~;A))fUxQ6`ZOX5 z{4!C9K1H&>v9W(azMq4ATOhQzd&MhrDvW<(x-hkXBKJG8*@#2h>ekig1IDh+xR}GI zABF*A-gR^bY3hqtnD^XJ3&{$6!CwT*$FbbfxD4o2yM0hp1!E1`5}OlWm?V*Fs39e2 zx53EO3lEgqkd(2_8~&>0LjtcKha#nVJns+?=7!v0Wr2SkNCg`~oBR#>iX3W!e36H| zrg+egpWD^a8A*G{YQLIvqgFhVg$J?F$uM{wX|B3*ddIE=pcHfp{-8@~!@eBM;6Qxx z=~%3My{*8I09#Sh+gM~=TSHQ2g{1>E=4(o<`_GsnLvVtV*Zb&3$Fl4a^XHp^)h027 zQ0Vo2tZ;wXhI!8Nw6lIelqHpVb)M!nKmN_EhDtTt$cKsTBp<%&%a{TK0#7t#|Cx@# zk~&H*8$$ffsHk@LP&=lxo7`I_K&yMnkFdO;_6_mLU5*tib!U;&7X!r6uyYqXk5U!# z|G%w;wZ49tE^DutV5$|06gX?UQ2NNl-xn9}&g)Rcy-5*VxNWYgm_pUkflAuNl% zYrcPstxKG#i_zokPcJHV^S%&e>q^>GYh#(%SB6NQsL0DO-jQXm>7Oszf zd(YhU6&JL;%lG?1@nUhs_M15Oaq z5ze**GK=W8ANW`y1v8(&A+GVW&mhKO9GK)bvUm$V0P$Ig|8U(JRb#&ydf}hyd&W8~ zXz$uoY3s}R%jO8z22~LIYgnE#v>ja$=Ka_fykD3Q0_lTfmk|Zv=;|fkR)0 z#9__BRZ0zTA+r*LP)!4Ix5KazD6M}V6?mg4!o7VUD*wHriD3yB^u$!KlA%J|0t3+T z7ahq^3PLW$lc5xKYB#J>@+C|?JBlig^#>NICd1`uE2J-4X75j6zEesF9*&n9I<;7( zCl+?LpKiFQr90qDzs>i*$C*t7AsEtIJ5tz{U)$6a33-u^m}uItn=&fFC|-YQZ`Y?< zjLjE!1Y0pq6sF|~ypU_@&f;pM2OL8jb(6Gzz6h5L!Rd}9icD3qVSaut=U0x}TsmZm za`9XygB9vM6cDj1L{( z+E*-%vUQ{L&N9qh@%*fB{(*l6`|250krm3jNsucy`Uvd3d*7EKybD?xuT{^;BC5B} z&k%C?!VsU0GA2Sa9u1+hjyfYV#9#5i9mhkq4G~LGVX2K8L{uHA87D2 zD#SHuJRI{uIRt>$t|AN|F9%18uNE<}{G6qn?a~W0mM)tL))F9rhva`z7BHN~NEuki zS_K_BfRl;>CfIG7&ri2Lu{cS43Y zg_Rn_o5`dmF}w&inM?MiAeeuMybc>GG?9q3O8rLuN^r64n^luMR?yLa#?E=;Sc(cltSXpY z|AyAhKydaEiSkh(1&VhqxT>P6oj0^n;XRbaO9mxq>AEF)Mzk>6n$0p2L^Sv?3(@*M z=j}iA1CdhDlDi9b;e)LZ5MU|;CWYQX#4WMf*X`k>bOF`q&7XeONKW{(l-K% zb@}{sA6{)y{LX)kc$wRtce-gZ>QeHDnD$D}uR`i#UghOfQ3g-zLNGOgl`El+97QPj zr`T)HLd*hD5TcK}Se3bP4%bV!+bs^=rr~c=f}3G<7SzJ5sp92uc0l`0SN$!4F7kk} zICD!6a~$0qZ#=UGWQSUqVTa`ePGs_`41x(4Dg|D;#Xo;4R5dMS^OUk)EsaW_XAuG# zss9SLN7_O6G8$-Yqg`xJ0mUw-KZFo{f@wn)JRqY+7?~N5MmV z)^>1pTSE9!S!~ha5&Vu8CcRTw_-&MYXTm?gyf%*0E?fMx$lcb`k6>_xeQwkxfYPJ; zfDsMuQ`LWKR*xiEHC$)h5;5vyIokXq?zi6cpN^=)xHUhXXHU<;{GJa9eOt;EMi&ba zC5`L|qKv)Q3#hy!;5LlUt77Z3`Q{Hr2I$5{=Bwb;fpX2)k$hS7yqYvd!_qtX+|+k$ zA30vnIKbsoBUZ08TfqPJRjXAPh`>*TA=54k$Ftb|yUuyhIxtN8$M`V?f8F7Qopz+CTATMcN0t^p~ zlj=pWYPrzrwPP=#;UT{6jm_UEp27r!a|=O}nSoW4jN6L>^W-@mtcPCOLZofBk+q+rmgfL*yA{rcGDQ$youn;O(0W`e>L-5) z%5?OwX7K@RbX(d0Dfz1q<}yd?$Y<23O>8%?op9w^c!1L7M7H9XJY@8wAx7FP5R?wb z^5x^M=lOGi5r*-lwaW1YGa`(|#=V`>idJlvb*Kd#FC#YDVT^R#L(Oz>NaJ2;7qr;k z#NpVm(Q7%okEdp6sgxv0l4@rYY&C!VVozP7+mjLwZ>lycC=a zeMg*!k7l@rM!+inPEMe~#kZQaBDF&3*G$c#&#^uQ|5T{Rt#z?RIa?oSiSsZlw+`%~ z142U2+qAKDe#kf^ANVZUR?^h-0XV)(5nM%+5_uIg(EcCzAqN7%_%9SUAfbO8AgLZT zTNxg)T7)%$i1?@L_0zRO)JEPm7Oe-H!H_sJ(-5`J4_mcjrC`zXD69Gl7>jPC;6ES4 z%Oz1L?`$#a;8J>rbzY+L7ydaZog`Le+`lN9$B^+(NB*J)Gj1l@*|hPDuM+Xu0Vf&WOoQI)qM{`B$1vjB}=83-(iB~y#8?3pgjG0a9e}? z)8L=nra$~|618q<-Z2G}B>Jpt+zvW-{D>z)P}b4jLG(bJd+D(dJKf8(X#-Y4h)&Rc zqc&pP$#25{q3HMY*E7AgETjKXY-^ESh=i4RFS=qa%^ElR2t2gXM}B|z0_!G7uMVrC zmsq%Ur~11myf*FRQcqCn>TU-- zc`lz*5L;rt7S+p3Gb7)My=i$W`T_|Dl$L6n{zlH{{lgl&>8l&GCF>IB1r+`eJ}YWO ztH7Yu(F*pK+sm!6xgmd+>pH&1%U`J&pm)UP6;+re>g<2Xr))T?lNTn%>Mi9gftKU! zA3J1%cD(w*CC%11R!6P0d$1j6N;xNuV<~26N%!LS!9urq5XZ}vGaZUo1r$m@ zC1}c%iN89sX;lweG1`HsTIQ)o`W%;jy~`EyJgnlVrn)ZWGYWrI$lYNIx7WZNBL*ua zatP(bgq0aFXfKuSB`6Wz*nH|983(7Pll1`ntU=OPLMNi zRn`n2z~%KyZ(vm8;xu{ZRPa`=qSY<0D6lO`YcA!YB>k0i4@`gL8r%t-ZP;Wq0qR2L z0FEbv^XH#76|#S5IRtf+s_7B^%;|U;eKE-9hNAwwq}oL#ZCfK_%9-d5;_BgsIDF8n(OJv9*znKmRaE+ItjIhU)P!3Y*2%DGs3woe;w#ANVoAarI?uOnz-A zOpLX?Fov4(P|($ox{d2^^Ib?|esb5}4sJsV)`UoNm#*qoa-XPGHcYgG?5!MOxf`S1 z4sc~3W7B_1=NWtSY+oO+yT=-OJnh`KA8?idhk8j5(izfbB(Novj#xAeO81eZmz5lze`{;e z2Ege?y}?#lpeT5^G(j>kqA<8BW#zkNZT9g3?=gS*8}SqdC0XMV@{`W=KV^KE61Jp}!ZwJNQ`X%>oOEs8}Lqc7m~46SG_5x^WL$6;9%D zSa4C6agc!;v7GrAxz~I(d`(PaSiRm)J(Pb`#SsU?1lxICCW<58RXJQ&w4%kuJ&SJh ze>hq1!A6%rsm^JQwz9%pLF}i?!t3*pPoj zXvYGq?s{PC=jOC{WrAX}pmo}r1!jvS$?(cVdF3N8L|qZ?JpivpVALk%(Vdc#Ty&)A zyWd@&GcmQ@<8$~IY4C01?Nr8UxS~0T(ZfpOkEEw1i-z0n-H_rx4u{QvP-=H6<2krJ zzvXOD=TFVWR~4XcaNxu8`4uE>RRn(-Dj16w>#T!(eRq&kYB6@*-RLMt60i>B$cFxM zB`l`>wb#24;e3)3B)CcqfDFMShlbE5W?ZG^Tpu-}$d$ZavVSgafhnT7kpE_ociF4^4qEjhdbsdwwr+H|G9GMVqrD# z#K(aGZ{R|Fuu`0Tn!|v>hE8wH@jWIED5%gc2Uy z_&8it5i66#Ze0u^VF<+ak6^~ea+esn+3<|4p(vOd5%dMU^8 zv6r9H&1uk;;1|(y#Q`eQr6$`IW{TOwPZ17QmjoPSK}HOcYQXTWH9 z_0vfN+Qt|+9xZfIH!iYPC72Vubj8Z zHE5m%JP#8m(a&j(7~k;O^};laQ0Im7!~=p8*;mU}^^P0-TFw#3I3mMGbfa7_c7>*F zrtA@~v~J$!h-1$Pun@sJD-ET2cxH_8l?6C41)887HZYp^Doa%?e^X5BU-PN|VD`5W z*WzXD*W&ca^2@ip606)lI!7qm);^2XS@$o(>>jBwaq0r3Hbem(Z1k88{eNnA;)MQC z6F}VDoZ?~tv_#(}A!}D-p35nEf%&GM1(r#j3+7#*-$4?SIChKUmiAhgm204|uBndf z1O(k5Q`F=y65IXDe~!o=QY4U80i6r}jA+bi{oC%acOgTk0a`^gd zH?%I%(Z$vvST|E>W8B>+H7&7#pHXcHnno|ee!eA@OL3W>afLCG8RqhXxUNd+WYCF< zIGm-dDrr-t6GGspfAnHvPN+S5_jXpaHxv%GfVZDIdZ;1pZWLS<+38 zAu5dh1()*u1pHiWo(gWqcKJy)MD#&1ZZqZVdxBVNZcgzvwLQNTK_06Ul2)RsI5f~H z7hTq}AAHQ;_xYFY*Ej=+1ztOOeYUXiu#(U8AS4;GP^CuX%39pirI^!%mJtU%%d3<0 zG2mJ2Wo4kef6lu!_~>lxSn%h6$7gRH2}}3lC135f+U}z(|4P139|gd02vWMcVZBOm zm2p4JJveM3PS3vyjQBdPf7ck8rLK~}xDe&hBMQBt6meW_!8w|MKdrbX*1T^KO;a#W zB?Ks(i&>AeHmi3_v@m+@YlkwtR%;w?72$Tt#g(V^f8xjE^Q;s zXd)1J?x~>2<9c#8NemgbTj41rE*1%l-5sXvf9&DwcBY75K^@fy4GeXIO7u#4P62vN zu^#jQ33nIh0`zHG%>vDkUG1*W&$27b`^VvsLgAfHTE&8k1zDFUO^`kF{PF3g-`ORJ zxndW~LGZAi&%;UHk_LzL8F1X^4J99?RO294&{;q4Y1L_kw9v$)($?JF%GydQ407Z1 ze-Ds*6d9f=2A>+SmF@a7@)m)*Vxte-xpiz_%+YImHv)X6wi%CMfGI`l=X~$yifFT5 zKwk9_5Bu4^mH6)N+ke`drpJudl*u{;keC(*6Y1Sx=(emUdtWOXIM+V#{F#KnmIT7P zPvZ8}U?zny$RBRH&MY)%4*{p6@2wd`fBrzfFO8OuTY(Z?va=9XdU~ld2FLeZV5X*; z8rS4EDQ>%|zZ`IF1g0_m7h-#F;Ey2ZsvQi-f(tc9o_4;8M*l%J4|Rqb1}cY>c=~Zv z7F65DmQO`&Jg`SMnq8hq)88ghRm8H3!v!*&{_r3^kpeOdv4m#lC({pt990sUCR^;&w}3cU}Mu^;6@oRj%D$dkeEHI~Pr z87Bc3f>B|t711mh`P5mbl7EzWX*i}W=$w7f5m~=k>Uz$?*N8*w@7z|I+@SakoJQ3JkO#L&!Q|q zWG3sM5Q|X?z)SCoN)mY+>R!XX^P+TZlG;xpD7B#XPbx8L+v~wRj9X^e9h-W~&_O(4 ze4@UCyydiy+IM&hii%0GnM_ReM?e-N;VyU!I8 z44;+7R;v%RNuc&+wED=;I(l6th7K_U)Wqljkb1T=@l)_- zo9(ZaLW}QIZNO?TgHKlIh)%yZHG9Tj0Y01>IwrCQzZxob`B&7?$dyUXqtkOOITQUJ ziB!9RO_u9~Ob)9G5PZ3?f9m_d6?3dY_onN@gMSf>EWcPsAI)#H%T6{@$)Ru*p%!#| zx3#ayJ`zASS%1XTe(E++R0Clk&G<7t$MgND zz}}{mLIrtv=bCcG?h+ooNQQOc%aAA&;VNEvtz`nHk!U<>5Av&mf8jFM^m!>WF=S`> zn>Do6kM@k7shTipO*UpfN*PHup+kPuRY=+RC4ktrzN3TBFh+}rx>uC_-CZz|7d`6+~7fw$7_q*_O zMmQ3xpXgjDKqCvsf3GN?cEPr(es%)6$Ad60Uoo;{!Gw?aEi&5+kw>m#R1^;aTp>s! z$srZq+(Nc>*vys06~He2&~h{80B77M=BqW+6D!*3mZptll*mOFm*T6lRpMl{b}n2s z80aE`f_#@JHV491@z7|*7ye>24oXOoL^CD??Xq_R;| znz3bg^DF{`AK(-$t?QV&$WsS-v-o-tZA4RTl`LFFe%5)+H=e$jvJxVfWxTPG>xVj3~h}Trtfj5d!dGffMR{aR9?YXx-4aN4b%V0 zdg$QraJ$t;e=2D|_q49){~@JES&_W%Af@s1RAjGpP*3$kapl)Ybj|4G=3+sZ)`!)M zDQvR8<&_eU$sA7Op7T)rx<^JZjh>xH&)PuLhhF@`=b-vy(urp5pPLU*gxD9T>uF|= zgg~kg_G*nX|Jpt~3q=*m#$LcOZ#j_G73-^hg&tZWX5;`EOY&u$vZhO71ubytijk*S&5Bmrd@yRGE;-HA^@!%x zYO~bbe>DF6O(0HNmZKQULvOU<)HlhA!d`)+$C4mKKoJI<{%=URA2-RgtQ}m+i2ovZ8YQHM_epJK$nb|hzke^BE@9tD?eUmHmHwN%j*0Y$}H+s^$u-%9v@v7;jZPsRW}%(6Oq(}jAj{PAE8YY8J27w7VHB# zv*OsjV+ui)hxy-npc^mj_thJRiYQ{0>{WXIAjsh3TW-F^giQl)ujH<_&2P~Vt1?mM ze|bP1bdv(SQRXGdYOJ?O%@N;oRRXmm7P{xesH1L4O1&e5#I$tA3uG*U#)C;Cle%kW z_+S&WH`WSvUQi^9LON|&G*)lA%D*OAjq9d(19j3|yQil8T?TginUGi?kOcF2e_AgiBS3`o7F?^+YrSnJ)~921H&2)K;y3Rf zy3$XYa(8>UR(2M!oyMH?is$leS>hO?hnSMK6p_Afu9m?OD#M<9kSu8w?0*^13O2PV z_^-XD^Ro;p{GJjv=^fNgTe2%G^(lY;g8v{Cm}%>o@can3Eix+Dqp&pxuBh;Vf90S0 zc~!@DCbmH!vORDV7xQ=0++Q#wA=k1DN=g5^M}S_3fD1mOQp?`6J9cc1WL|igy<>MQ z$_@W)EOzaf!pXU7uI&d}=-p2Ea2yUXar8sSyYlRq)XkJ6BbrQ3_y^~Hh;wU_5ku-| z15d+xhiVXp2;2xr1MT7^jU8^ee??mUmtRhy%c4@4rv0>!t7p4Qb#@ap@b*0TSDxs) zp^Y^~k&xZjr*_@169Sr-2HMJEVMZ|PMx&p;WTp%UN2^KJam=@~Z@lviZLAe*kjt&|V4! zTh&DgT!E#(DjAQsG>_B~|%2+Y`6mqs+8zETr)(#{TKQZ-DIv6Pq zWj>?1$}2Q=r$KIyL^}wGe~0uCsQIIUHc2fXFHrNtbeXxbTzbQc&>ey??om#80#_4}*Qi4R{}v9aDwQ|dOOq^^DQ z$D?I)8;vyUCH6{D;7)B&?5U%wXLvW~S9RDds3*|dVVFuw;R7b-f2qJ8AdA*tK^{5X z#)t8JF`YgY^iwMEa!`rQ53Xa^;!&4(CX?~~rp&>5Ie9hK{d0|8y{AIgANe{6$WPTw z=Vn>2$>ZbJ!V2TrdCb6TM8gROIPg`pK$*J~1WO^*b{vd@`fLe^q0B6L^=Rv+}onRxSK?z^Z)~3hM@9xJmX0W3DJOC zDcZAf7N;0+El!f2GBcQWTMUI2j#C@{tWf>)N?cI1Vdx87f9i=1K@?rfzIYXSzj5Y= zR;r%fDcl2e+{>4H_LwriPa*7G65I=OXAG-!H)e`2S6+x1H1{Fsw@Oj*J+p}`Obcz= zWGkxCBJ`8g9jK)iBf53_%-UseESnZZoI8Xi}w#7bnPJ{3Rf*$zONd5nEiHV5FJ35X6QH_a< zP5{FaHequ&Lef1*+nA7^RA)gvIf2n5_a1EOLk|tVV*Zr~Pw^Ijf?lLPfgL)jNB)j9 zukN4n4YdW-_O(AwQ>8EK`&?)g_sosXgnG3yiHG$8e;4N}+h|1|2$-~^iDH(;nOLfW zSVkovDeAR20dO9OTd$P1y=4HIP{b6{^9IKrKHpIZ(xfvw%xkF`F;91H)VG8EdLtOv z1tmBo_kT}5(rZW}J<>(%_;|(nn#K))WyrVEB1@&5LpkSV@bt48|3CESF6E#FJiBpq zEmzo5f9?NGF*Kc%-RbSpDFRQ*0eYj2LI(Y)KOc%wjq7)IlWj-^U^DUca^-fG!B8Wc z`PWn!X)xDJwhX((5z{YPG9e#F!85Y?quc=foXg4j^KnpCFg^bq3kvI#8G-NOm$f;l z3iTEc_>VS2^CKt}E>^_hqkxh{%J6I)DQk4RNonmBfxVeM3x<=iptx}&+ zUgR55u=q#{I>OK;swS4O@Yp|SDd<+;{}v|elV(p9Iwg@Z>;}4SoUfMYHI|!|eYk<) ze>L>2jeyaR%c)=~s6WE^?A!)hOLPLg8ZVT{?`2L34%NcgVO)-%#N%H&HG1!7{DIH6 z<5e2ms|V@6;ve$c5m9^}HY|x!E-9M1ejFMnT>s`Cm+NUQW=1MJ*{N*GoVK-r+g35f zIb^m3c8qo+p+-VrL|2N#eE`KqT;hf@f0E;P3nHg~DTU>*M;q#L6x66YiwFF!s(!SG)sV%`{@ znVcF1wT|L*BNveAv*+GIH0tVlBdqx;79XHY4Dy_;xNXP;zolvoIpZ)@bp+*Se`)4| zV=l=E;1=J&v7L`#UmCgwf~pQYS%USiBn2y2rgp>2g@Xf2o@A5aetDc+q*{8(X+qr-Y_>#r?e{>@jUIp~oIGZsrZoa{hgi$69IWTXyuekB|1>IlL z)u?)6iw(o~u8rSGzI4L zt{$z3so`YaQdLRpunTneWT%0Y?PCZWo0H7p7V_Tf-yQ$G2Ad%OfAm26urgO1 z0`d{q{-Nwg>mB9A{cW^Wv1~RbnQVR+SsKb|LA}S_6$HwQ28E;Ssy-GV`Z9Y{_Ldwh z!3fl{69q)#IIhx>j+G^;VEbut_rH9g*U(%oma=MFNzUGD{so#A@@y$#oC2omFL}%2 zp9kzp4Xgf`{qJ#=6~^6Pf9{}^A)Gv)9!D=ZH(UWT3_ohFXJuu?X}3y7&L1{6yQch4-Wu(5f&|d8xJQJLGW)yqi=gbzo45zv@1K?Ggf;KoHCdLM1T(Fya ze%c%~^ScCT&!pgmO#n26+JXT;f$3GFG5bG#4FY*H*SIs(NyLc79TwE==_)wbbP8LY z{P$^`gy8t5X37oXX3)b(2#z%1OKV}Xc6LZL+u@14l!RZv6+43GWErYyW&Fk#uEIAl>MN-gZrL*@E-I+?ebLEi)92 zv{so4=($`AENcwi6Wp>WY&Bh9zb$w6XWj__G#QnlimK120roG~@uP@D^}bXe3s{;G z9Kf*V$CU5rf33*RTVFFfbYv>Ynj=E6I6m!tT`N)^*+y{`!a|>JUMO2i$Wf-o z#GWDhL%P1~(1?`1G7G)a#b4&7 zLY!&-lbRpTor75k3sbyQzW%B8jig(16lhK*^C5q5?Hi#|eyd@>*-;hyCBa#j13Y1c zyP@%Ge@xygN2iGyR}NP)a2yyOz4>d>pnc>>QyrLtZMZ*aMP`U_l*REZoBBl*{_X|A z7p^)ml2xZ}Q!PfNeAXt~fa|86ioI-)ro#3*FlPIUyYwD|c-;b3Yi+IITiJ$)8RDP7 znvejv>;fiFhvU)2TaYjTOLnsFmGMx9*Q*gAf1Mn|#q?p7PdlA*&k@f^O)iv+dlq_N z+zxJ7@iHoL4o9XH0M5DGkG2MiI^qPl6`eOxI_DFe>Q@_Dfj%0=n-wC)zRdlUf)s;3 z2^OCbBjM|>(zn2xe)(y_GFZY*0q`6;S^=y)qq0$YdB|DNCnBRCkN+mHObOvy#Ep4l ze+AU1yNaVzYSEnnIe0oX!Ht}KCzUTRh{#$|G~r%w2tab@4&%-|^;Vb6r}DG0l?6u7 zhXV;oBc%(YCi-aV7?SK@Q7vhLN6eT1oKzCAoNtu zGcXhurJg*sDvqeVx|%VW*ma?sGhSg3u~$SLC#8_O%>vzj^)GL}HxJsnG7+ zP>6mm**g{-Y908%`QX!kdkm@CoD$O zbDh<5xvwP+5bDMc7G$LNj%Cb2L&_ykL2$qVCyk51mQuitbYV~b3(x`Fe`G5y4~(m@`ur5@Ye`%{fBtL?D_fN!j3aLn9zK&v=%vT#~kDQ zRf<>&P%_d_BCtykM?*e>zsn49H)}%O&Dzl*oyYF6R*Iq43J@^I`b6S^P*8GsTnb!< zarcBH{et8cg8P8syf8$WfBsd3idoxU9ziJL8ANYH-PFUk*AdOGqb5CIBPrDQKt1#$ z^5xb3PwBRZ)N^0%PNZZ-IktoUvqF@B#shp{+$W+LFe}z;6<|f3TR6x4mRJyG$B~ zuqJ+A|6lYe9vShLFht9jg=L)eL7~&YQw}@jgCB+8%gC)=dm^2z@#N-d&Ne3pThK8k zOJ7c4PRo6kUPMCZ#jd8aXFqs^RE;^8ffw`i$kq|jMwRteTT%%l4^D6HdCyWx2 zvbM9T2Jszj^%5orpw5zu>XK5Sw=7enF%VJ%+eEt(2uHpqNP!rs`3$Doja9XCA;ir6 zUg{NBlI`fNc|Df&a3z|>cJ-aoP#R}cc=y|B^feZ0>p+jUztZJ%shBmgvJLY5I`utX zgi=m^DlkMbeJqp8Wfk6X9PRU*w6LLGhkZ0aLEAUR5NP1)-o!1*-aYO zg0aA_T{+g&1C*P-s8atLdunIjFrwvRF0LgfsFkHca`{EiVpbJ+GIwIqirF00NGD5w z_`!dv?m6kty80@FPNUTJ^;Y7M)SW(WyPg{+{_Yx=(cdR_>*RrJ& ze^r__C4(R?$sYsaRY%|iA{+>YBkHLx)WmM=V1Kvh5W@X>PbP&1{H+8EuK@VxfQTa2 zQYYgfd@hzXc8l+j<6mhd0+mX9_4GlhXL(PBn!YuvoE`;Yj;7lAU@we(G}QsB6$TWq zTvWXVZ6de?t%0k#Wy@=?*5&{4Q@Eblf3)|1)ZRFG)(YS&@*!r`yRtXepc%JPwEEf8 zJ%1ARW%+aCq`%A_9|@9;Y{^xfl}vtDCNsW=I6p=|`Y zaL=4B%y@;J0Z`pv?oNw#jsc`dtNRC7rS1+!WU>y73z&%$xtW%XpV!BQ-{kW7E9x7rRu-R{?R#$WCCV`aun|Gepb_uBMbuI=Kf& zs%XFt_AndI0%8MlHq;7htExR3X@^(t`6gOj3r!s;v9_(<2X|47CY=r~)h`i7FEvx! zBep1X-hlC|JWgeM>7l1~RzIf$_~ndRhvE$!;*d6WK4I6Fdp!(AoOmYAbz`(BDDoTblE#z07f>jNJb{L!A_zS?#81a&J6LkG* zh{RRbX$-s0W9pc%&fT~Le>qixBq8X`T6K2O1#d~ zVfTs)R3?rj)+`zH^2#eq=7TZb^Ft9bldkK~LWlLA*x{95UgfGWe=e(`S9>h97-N4c z03on#9O&e>LNS_U$;0HK=}E40hBTquUPW}?-7M+5J^HcwM>44;uZrEM(;%bZp~LFJ zn>In8nBzMmGT*=g%8M-{6gw&!H0k$=tR4Z}2fb&c0bG{DObGocXOqin#p3%qU`=Je6)nW)_u7IYHnb=6&u5uaHTl~HY zBtDkw`3#}sj*Gypf9pK(QAR1e1xzMF+_?RauO8I>-ZKm(e^$_mdwB&yi>%ty2;Oqy zH!yTy&K^u(lqSX+(i?Sqg?E5_D4i;IyGVM`3?DW3>*pw%Fr%s@)}$pUV`wJlG>{PX zJP?G$S3|42N3Rv14YT8?LGR>Z3EEq?UPeQGm;iY70mckiC^8<0MqJ%f0P^^Fl=?d(paD2N7ImiE{d}C z(Z{8Jw>cxRXwI<;3P@^_@<0uB&#ms_da(3zNRF0hjqB@xj%)02l=omasl|wN-{J+* zZ03|S>#AN`d%=)?4FR6#t#=7$hjGdYQ9q4#HT#k=-C``LvIfB|q;)=OP@LUY3+LT;qcas!t1s%wm&i~%N9+arGs`BT{@K_5o^5a#7alaV zVy&^L&uz{q7r}w0N2+RicqQ#WcRQe{7e?!($aYI0v5!Z{Sy<`_rf7^6VBe zi7?sf^DRa9%XQhB!Gq10Js2SCq0q!$ey1^Yecdr!j7}dEHmUXv(eKeo0>@mDd&3KF z^UU0a{dH}2r}epsI4T9(003?SL!`Yabf(YZ$4Kl?|6QH+;OrYCtr`?UukH)~@;@F8 ze^cU4rR$+Y`5nj$UY4zH&0SRJrcJ6^NNJ`MT5vMs!k%@qQmzlF@HlvnJE>$+M$Ir9 zzDfdD4uDYXdrQ4QAl6I-G zV`A!Ba@qJZGoG6i;{A~Og^jb@NWcZ|f0kwUKontNuJu1U&V%bb3@d??GnFy)1qciAPD9;_@3>DT{lY(e+mjQyC3zX17MZMTUg5s0PRb+{!)6#`mR43-w@+; z5?Li2Y-5SEEG;HVG%NxLOGPHg0{83Va+a9YX8J|kt+h+m1s}$5Pf`K;yNlF-s^(<( zCLh(BNiEHp5M?)JR;n(y1F4ve%GWN{2kt4l*?zEE0lBizM>ynw;-;SYe-phDTbKM^ zAa?w;rA)RRGc8SnUUxy-FZ;}&OxtPbTlgJw4i6m9J`CRSYcV=@q5N(r-L3%ROWa)} zJvD)DDd8gP3H9Iv5||E~eh-VL^~2`$?DP3w&i*@pLoW;!;CvqbC_B{42BgkVEA&e? zTnS*e19>TC)S%%H9r2SWe>Q@fdS|oqG2#|rBIK+c4-`%o{dkPPYfAy|vU-n{8^R@C z-vu{MhFE9gNY{yeUp|&y+5}VMGA@TvA$-u?T|fKr!@47~M%sa-Kfa=d9Y9Nc?jgR@ z2|`H#`ILnF%F~G%;DEXLJv9TsAuLK*H~qZ|M7w~T^MMiDdsPW&e^b#Tll?QTG+j$Q zKa|#~vCt}QzQKNE_W>WtwpZ-Esa4vTqI1X39AZxD_I6m`U|q*3x!0R(cKC2>aPHF= z`%$@oB(68cVT4n2YL+Nm_4&kI!WFHvBe&K%7R|vy5WHFW{-X8{MD~_-7&XbIucUl8 z2EA;6?*vDlpmZxXf1GGn2=avXONFBz*5_VS_R@92!MY79%|vO6(EM6z7p~r7XS3~s9qoxik{vB zlpL6j_u4*6d-=Q;(4}CSo~ep>{qEIOEUKO<>a1)i`oG=hf1#i<0mTCMw{NCZMrTWU zEir3EsuXR8zKPfGsCtdg{CIx)S01w06kJj$UW#+Kwtp>sZzipsGFJv6755Ol%>I{d zRlcSovf-6&KgU;5Ccc%n2J4Qj7%2N?&7`dRmp z!28{#w&0A7%j8r0xBn#j?q8r~TRi&qnX>^&bz~#@)&M}DKl{JjBdpAgk_hT#zi-pX_g5rK!A-i zta73U3lSN~*(gv`bE}XY&qvD8@gmaF;u5qFF3(sS(Y$>B@V?NuISA}Cj zh47~la@BrKBuap$<_fKtt#mhrr%gWW(L%m}cjzBIN5W)8YfT|f!KMBw?+TQyQ3py5Mi*nhfl~YV<90)XPykL&C+81 zf1QHrvrjK!(Ncc6?C79lp179YbjI*fGZ?$&3cX;{N9L%7qIT8`2U(8;wRWqmg z<0E#UIek*_|6)e3z#XHcZ-d_Z^%yMG#3{<1|N2rX=_~zD-=%`?fR;#nzrpj{Ku@|$ z;cmuVgq(4Nbuk`xTKh_6)eZ|x<)ZiRe_xK`MDuJ#T}98x4TS&<)e9pS`r&#E14cB> zW*q3djLZBceXXZ6Kbcl_)4M*8hJL$SesDSvLmXR|;^(Y;>S{QHh(jW9d{!>O27dqI zv>kWIG?sY^3ClD)=z5Bx_!?;$d$_>Zr2BI=CVTxpwqBD3f^RridsjWr~v2=1_? zC5Ho@x?vbC21Hhfn3PHs(I5N1td7DrXDEx1J5@etF;~QumLS%>80)wQkUhEwGgD_B zoaU9bc>@j#dlZ|f^>cko$U_=Xe?_```4uSssWN2k*S>#Qzg>?@E9Si3kNfSzj=E5d z-^EoK&|@)E+HSMc4xWinq3j53D|vS(l%!9F6jpiJC%NX~Ltm*2Fs)op{(+BxH4`qq zLkXau<}dP%mqVMpUu?tgkUloavp52??K(?|;YH5h22D-hu^pI`V>U^Ie^*LU)X}Ug zHkP^d#5$V5)EIdagH!2tOFvunQaSM zGHRH*3Ox|^941-r@-{skCObX}a~O06Sg{TKq_)F)ls2Ow&_Sd}f79}8HEe*VT#~97 z^G0&2e(wKESLs6-ElQRh*?j!dw2_Z;7Jt^`G4KT5JNOeMO|SzF8cKUkkyt#c;M+ot zEm0$Z%#FwwSR7>tlqyc%_kqQRv(GUFVyCDKF(;@BPjfnj%O3DEdOsJ0dK2Q%dndT% z-yA5*+x|wa;cBKNe+WG($YvJ8TMTT}DwCv`v~MRt_)_fT>z#A1HGmuiDWvw}mG5Lq z)X0939{-~5r-wU++7SfaR|`MekA+$-hsSBXzCC|DOo;NxrNmq=e+?>jI?Q4EZ&6J` z8$6@waHyF*RyRe*-{|fb3l+@%5NPiK{Q+eNbSqE5p3`?Rf7Ajt8lfI;XGYTIFnMJs z9Nc*Td5@X*mt#|islh&%t=!D}oG}a}-ujjQ;x_#*of&j_^3s_}F-U#z6tFUN-V%ST z9FhQRm7|9>0(X5*T)!)>PQ1I*kI$o9J*)A1pa$c?S)h)TrnXzl&aDIbWBu#p0)xnP zR!e3dP2YXefAVQO!Pg?SWh7aC&4fRb4xN0Or@x@m`-P%PKzyA;jg6@XCe72or@@Y# zpCe-7Kv4!+m-B+1bZMc6Nx!R@c~e7OM~rRY(4L&yD(YAg7}q>11!=`D6go zo1WSh)OE}{#iarmR@#J0EZap&4VlgSU{(}RGI?j>e=zHkiX+Te=#*j)J5K?V&x8&U zLj1W~X{M#@VWrt%dUM{BQ`9PSYah3%4eB>`<={|JrJoYB+xr_of=_|f4F#4zvkZP( zLmIojbp0fz2~n#=KC)e+aX=x%3!XSF%VP;f#sNeo`BFZ6j-%aAsi0oenApzfloN#sDx z@V4MYI?_+eWkVua;?7#I6#B@d%?W5=%_KyPY>PYaom_9imN5S6RnZV017;d57Q(4o zS=uKtju`2~b~XG`-hDE6*v%sQ6VSIQZGk<01d^u}#g`u|XH}_R4O3M?qgJq&e}Kkc z+SoG75a0!WqE}oF>G}$d_a~akgWGXuPKnfn{X;EJ}mWIJjMeKJl@136J8s@;QkUdq?;ydv`L^i zj45iIdMNFlmJ+?kH=VhST6vG~e=Es33)LwMB|4Fx$KpenwLSn#lk#DQqp-ECXF(qj z4@P{5hqPPJHVEvc7To5#n7jtcI}Ps6KsLInsocQ?xD=*FBhXd(HZZ?+6ns(qJGD$L zS?Q$05KV%9la8*rKi03Kn_@c*s=n_Gy+9ng_P@epqr@zWKB=5AoJ6iFe=Sb!UxRIN z_5y$a3gv5=TJ`w_yOi*SK;8{Y67VsVInf`fPH#qSI47@%+Ady6#LyD(Px6spJ*s_| zn=Ysp8yg)M2Bu2Z){Yha5Xh(K3Wl*psAg^w$CuZhVcpbO>#H5|u?dcw4j&4spw-TIt@97Bo($amf zJ-jws7HmXE+VV|z=gP>5qG{mDHwS7}!%KEbkNss=d6b~o@FFihpQGCwMlMeDL3hq) zHxFd+2wB8tq*p2}e=4VTV6`wrEaf0QJwxkcn6`=pdm5RHjuGgnGO)(>mf3H<8Z&~ct<_PaW>&#Y?_e+G6s{$UM2vX4e|t4in*nE_!?z&U~4>P##579h8#nAX5Ytf zKak=(bJbT-D!w(amdq%Cx<*juC4yHybNWR$zBa+ctU)M$=`>WQnIS;5yv>d}jb8K( z$N`~ZmOy6MPPCZTvr>vc#e!TlJn_AEHb+)*+nx;de=43g;5G8klxXv;nkVzg9#6{(c2^488s56 zEEX7k8CZG{2I*48fcl26g+f@OsKpL$I5a~mv@XQfor+uww+={OU&KEK*>iCV*9Mx3 z1}dwef1dpym*8Cd#K)E5%K@0>Lx1&kcs0r__Do{IKTqJAED3sh+FRKL;B|c#F^uIf zhz+HsXSEce~RQ$ybRN#k8+isnWNXALkd?#Tii7H zT79+qr*Q#0nS)fcNcnEK^!JU)=0?z)=L{!_z%l-(a@er9FjM~8TJ5uLp)+n*+AA&dhK>< zEQ`bg59KHaRqjmRDnhgYlvqa~OeI6QX(;3TAT`}7At+UT0g+I^Y~-n^awdV~oum!x z6BSHkCz<)Rw%dxU$2#W+j+3G!h$H`Ye_)pjpM5noOx%M&=tdy1{(Pm{}#Y+o1MULUPr8NgMMv z;$gK-yFY3mZ6?cDErLk+D! z12{8!!p>0BzH|pD@Yd?@xUg*aD>AH3qb`~>@&sTi7JVzr+8NeMu?`{itVf5NU%~#5 zyiq-MQJkXfmtn%V2RNLesns5-VC))iFY8-zXMAXfCv{!9XXzPh1GFL(f2lc*KcbUC z#0Sqbh?1uLaeJqJ9Au8CjGM_1nnG!J@;z6vNNseLO6*VF(WH@FI(Ld>+aC>1lqyG2 z^o6h%e7PV%kSZXPWKp#)lzC)DXl=wv?2x0w#k|j31Ody4HN1875eud%OQQ1)6%rx% z%vjt~;+v>-7e6tcx4j^&f13!f9L^wis@=Wc*a_oIWPzG3!t8;XBigJ)eL>ku?0*D9 zu8~GpFYU@e{706?NMv{x9R2&@BD8Qb8I4ieBXj!t4$u zblLLR2G7DMzp89vy31;rwT0wiAFd?tau7%D$SRkmQrx7$GQfv*KD)DmFEk-mtuf&A zFZ~SNN?S}k>}ewc^Sab@3uZFR)aizW%RCCY1v>pE>ll+?e}qV{FWdm7Uf3F7bFP|Z z#$)`jK>%xK%aG%aS{5J*%8YcS3iha1<^9WV65xu0DRt)428Fw7KKjps&N@X~sp-x~ z)#C>s5OA^#wbQ3As@(!uO$gQFp&uZ*7TUF_rhc9lZ8w}wCZfNiwFTRBFE^#VdpV9 zHeNHGk&q~yiWi|JsQ4p4rF2<02n~O`PsW1>LABetk*Li@{cC@2e9Q#G@{UoCgY_6C zKRwtdulJa8JRQ&a1)NEtC8I%@=Sfy zq?IDmg>8ns0h#M&SM&+!myx>XD*N;UWj9CU0b2A^{W^r@u_4b`uzcow_=n z3QNdAg9L(BlFSyXLgAM$hmq^rmLf__n+m85qV_ogPn zm%yR@6V~jBsh+CIeQLNl;35Bb8Kwls5u#ijdOZxr$62lJ>!wvJ8d2*2q*Wk*dTyB# z^42uY&4#0Jr6CW8Ej)F0IVXy-jjMU!g_}*b1O-!^p@%m;y>;2|p*qT- z?ukd?^g|Jp?g?>?3%<_Qew2#;@f#jp8Wkn@x)!JVZSs?d1&KzR_h+H;p-!iZTtFaw zqz|j7_OGzsfxP?q@5+^eUOOK5mo`R6?K#k0^tATs*!2&rIH;mLr?)%Stm%>Y39g_9 z<9~4K*%z*YC(5giccU*7j!B*-`@&Gt?n;InLEU7IIS;kyabSaBzOM~t{r|H4qb!92 z^`lcL@osjT`9=SvpmQ)r+Zwj?L7P}rpnJoA1OrmW+*`WSP}|!zx6Gj|x=VSG;E5F# z^I?-{y|G;JjIjG(l;$l#c}dQ4Mnxd7!hZ@;$UX|*qp_AQ$b51Ik94Hh2g$f9{+g8H zGItK|{A@0*I=vDis3;VYGQp)j^Y59qW^G<~y;W@ftoaE=%ez*81L(Vrri|__QQ8#J zUOIZr*iLl&PQY~#BWWr4h&~>xWL^Jg_k;cqkf>M8|B)X$bU@k zY;Vd)WeSlG`J5S(-`LcJW)dA?bNCP3{YBb;r&;eP4HvBQFT4i5V4B~?=<7$wN@Dj4 z_RU@QT{(s8Qy!050g}%LA(G4F!V8FCrjLh8*2znWBB;4@YcQMs z5J}BwbEO3XrmhOJTelXhUm9%hAb-3hK1AtT_V%Y_Hr4=&GJ05qrn8LML?svM{b+~% z3!W1BdwyV0nENPx=`NvN%9*Kb?FHaOcQ(%P*T;#0d?J$#MJ1LxGeMJ;g`-{><_nYL zL0kKMY6tHBWR(Y1%!hPDu@s56ri6;snR9o0a5R2!p_MB&$1?wa3l(Skvwv&+X|iNo z)|8Vn+3P3rW7Wi&{X4}uP4`mZp}3BJwSvHB_H=bCV(8pT-->CiCkRpB3)`P3hJW59 z<^m>5`A^=31=0GZPB{?EV!87e&hNCwEAVjfjE z`d6+GFbjqBh@)+wKB<>RS%0F}#q!^vYp_8ehLy|(#qF^@cc~-i|KX(z|HfWgJESB5 zkf*QIrNL@Us0HQQx8)~3e&cetQETif=3xd>Y>Xn?ojAQKoGdtHYyt$?Rk8GtrFDz%eBi!i6)0K28VakuGSLXW z(y7ncMNw(-4a7i1JFGSp^+d8wLPyYoFiHp(R%TlD1+myd-o!LmCr5o>sfZ%2sm$%s9LBzu$Fg@fEJ zEtcHot$TqFg+mzvwTieMiCgcY}dN; zJooTh2^fR^Er0iWTF~Ij)#uPREHycy;tODEm=+C%P^#dR;rtKTgfcd?_+2y-a;g!%KW}#y$xkQ+CaOM|o@+HH$~GgU!nP zZBjA6TbAeuXok;47_wTLK_9C-u@TKr|AhBJ-<--ev`uzzOd`M9 z5Boq);`dPE5d(}af9WT;cw4^}rQh<#F7Qy#Ux!J4iQGRmT17^!*jbC=Fl39eV%J#Z z!*!%rU4OC73^S6}uaJh*Fg~_F+t=Q}x_8HP@-#X-{_B({mHplkdz?$E#iy znZHYPa3@YC9Pv>0rIpBo+0obf7cOm+-RDkn?D~GWi#1r2j%2*&~j{^>xXGGoiE)@_w$u z7k_^J6n7pbV#)VuWtMG{P9`dIZ!QW)TfOICM__kWHf!S27b%Vc>S{$VuwVuF5-!y5 zA1`Yp0Jh3&fsi%KgA-cLWKbL69|p}CiUxn7nMs1Ng+;5^%Ouzl#^dX8m(p(i(txHj zIW;lgXUUcLqZxWtYR+S(&PjYCmdg==ZhuVo)P*<$oEP%VG0zF&PyKozV;mtRj8i1> zV|efE)PmfT2#Pu+-A%oJ_vn99Vs~X&kD+s~T9o*X=qoGrzZGva=@2<{*+1Q$~M^nV84 zGcg4?Iwp3}0q9R5v#MJb?Wt{-g_yP^pvpZ6T=8BmIWx;oO+c)3OIh#lFzIyZ3FCCi zCwxj+gRgl;97Y4tu3&n@rIunkWP2`$Q^qwGQ+p9XVuRRj0q>bma1`ApZH0#YO^&z< zpNI|kH;42H8HEFT&jABBNJ2?e!hhBt{E!U`$unqHn;+Fz{gP4YF;K0q3x3=d{W`QT z`cBVqsDybEPeeSX{#jPbc25yBfqi}m(WC#C+P0Oj941zdoz%bmW}M-4i5#%*xo9l+ zlI=ik_HefXG^NufATvB~W$%xHqnx=#)k`eClpTwdJw%%3Zp9B>o3O+SwtoPeb#4HC zak8M(jvba-K|?&Iiz;zn7f6RUySuda96AG`*@L*{br0`UKfj0(Z|F8*RuQIf~ zlvHbz<9;Z9l2f*L0}yjrwW9@m7DFf|u^~{>Tg|K&lQxPk9njrhZB)5<;LoIK`5*qo zWLz(W>=dI_1>DPN)va9(EC5x8Y;}OSp}z8PEvkU(-u}q@HRU*&2!HjwS~g*-z8o+%(y9c z^BiNY2F11fLPGzeC)5V7xMP`I<`!*hTDfY4dDVK$oQuyw8QM@sdDqNb}`-3#Mm z3ivDjfcN!F+P8+{B!8tW2AD?{!9`JcScnBF(>A@Kj_vD&EwIO)+xsz@Bapgkf-h#h zrr?GeoT=z?&LpPLs!Z!*@22bZF|Flx2jOF+tCfscI#38ds|Y}$7juIcos0%l<}suv z1-UH|oSGV6KUipH)4~*a;odSF!(qlJ;BJ7+F9=B4?6qaQppCznMW+Ud^&xi=PnS2fJ8nI&(7Gd6oOhP$1K%KWmJ0 zMh1X*9jDTPuQ@`&SP4E_m%_szB%?FmRP?IJY;_ZJ=-wfsOZsE!B!9wN7!|qS1ch8= zBP*aClhk3*@PE370QA65moP>SW#%j+D76Ale*2Dbu@b<-A+_U9*WZ< zE&8y>Cc`L+lbT>}PPv%2@OI~^;baK!{T_~JSLZtgP}QIEXC&9n#d;8lELcLdQ}U-G zkH(mSh+g+X-C-$DbgF%WYMbQRd|SGgZwh%S5QLh35`UNwcCha60|dftpJUHiVsEQI zNk77u#2Ea>EJjm1EYV zM^K++vbfUd?bPFNrT17bm;w2D#mk^g%eaf2hD{din50k=389N3fW2>HPL|K}(#S(> zN(uYzFn`g(P_u&_#!5)60NN@f9$y)F)c(?@wOq1iUJ$kTjN~g{?=Xh*{k5f06HvJ7 z8M*#i-*h{tpo(DD(XaD_D_JY8huT@fbB zvW{SkLC==z=frgyxQPqCf#$XBs%u4bBKS=d%R_wXifxmY3yy6^@wHOu)Kfl&EeT8q z`1L<;Y4;^9PeaB}W=6Dq&JcwY9FNux*wILbuB`o-Ij7RQ9TMEhc^P7$JTL2q<98N#MgLvF~0q74V!p*CTM46i|aIFLNUw1VIeG9dO3ue0A&8N0uwR# zF`P=3;igEvfHI;dpTgp?|Uv!$F@P$MRCDL%Tm1l6#WeNI7f#42sy%PPiJE zd^V;fV@|$D|HfH6f--NVPB~GqD5RHGtxaLq7A=fjh}r}(xeYHyrT3&KxrP?AdueN!m*fw z9PI_uW2kQe2)o2C^{&9d&&iq4FvenVCimJJJk8(@*a*}F_}=DKZ=%pA?3q9;2Cgr< zmHR4YJnSP!jsx~o${B+x_>#)iMHKYKLvS1r}Def2?@)j5H^P4Z#m<@*pTy) zdVrvLWlHS*yzz$nVYpr+lOLOV(!G1Ej?<$rQ8_Yj_y1GkPfH=vzJIw|)q?M?{c!>@ z+kwtI)16vnwQYl-jFJTggb>u`TcWPpf_cY3i{XW-g&8x(y0p!~pt^idt5xVKsKr@skuHIw9Tci9z{Y)SOzfkv_4rS04@7k>?Rv3kcx} zV&5q+F%v=xX#9?j34iM_6K`TwJP^0xXA`?#+>QIO!mmEk(!SMsU8|BrJDDlJ@>7gH zzzLMEnSUf=35L6griiix+{8HRmL#N#f+;Q&$5sVMWugYiiSIox5*2@dqVPnhDkeHe z+R&;HildS@@3g9y z?i@wn6IgDR(j9I*n0|bz_*8az0Q#O9f2vzr-q%v$vxTn`f687Z2Kp!41RDaUP|Lutd_QV(;nWGF=jg2qf?Yr|^UDFBe)GQgJOKA!LC!T6?IvA=Z z3OjZR$VgKxu*FOIX)0g;&A2x~C);WZ)gpjgpJ3oYhq0F#GvF#DS#e`uV(oIHW=0apw*iMsv%)V5mTS4l_S0yy-LlyXLLRqToeH2OvYsHfLqz4OtxRFIKn_5?PN&2<5a3 zemhJ|^bf;dL12&}a#&e~_iEjSDo85}nthOkzv98z! z`_mGhJL(VJqHryQDbt_v)`1uyhd{V@;)OLUzFJqXNvm=4D;N)iR*363f?8hqWCbW- zw|}CbsI+rL`61Kip~4Pu!X5kualgx)U*r6lBU>VHgv$EOM_Rl$8)E12_-P&KkaRh; zfrF32XuRPccQ!&s;1%aAaKRZS?<>MK2p_FxPfnw2KnOIs;F36t4ckU>LJ3=Q& zL9wLVWQX@m*fZ97s|TdKou1jo=q+HnmDVy6MD=eq)wKAQv&-^7+GIzjp`9RL^?k)r zYF<;N3!LHkuG-do-Gst+Ch^7fL4OIA3jj`GE5<#fxTC1&;k(o-B;wtWR#c0I$qt^>ENJBdsr_3sY{+txrB*Ev7P| zpR(U|@iOO?Hv5}>_x@KG9FZai)oftGf^PyM!@dPNnji`v<&d#x&3|+J4GoAYX=wNX zd+!XV8xd$u6k|!2_<$e^&Vl*@NVVikZmA}+}1uANzWMuEc zw(|8}vNz@#i!v7Hm&_eftFJWStF^pAQK43{Dq-_}?Uwdgl~>L0+6CChusy;5h=*PS zT4zG!thqFn=H<&J#eWytX#)6&MJYLxGCH7zxavf&C`H%L984MG=fLzYZ^Vl-Uy&@Z zgAZp6MN?Tm>CzYtqj_Pb*~kxkaUv_Iqoz8mN%h-|qkibi1@u)3G{apCRae@)AuCN8 zrPg~vLrOo}m~|{ARi0-`-73*^l4FXk|0~XP$mLLBJ$*55k-`*6sGyeca{4h(Cj8G1o?e9TIx zSwia6_YJBR%p2jbOR#bTUhju6aLd=b9{lf}feKJND!dfUh&w$bsPgwF@sj-H;-mgb z7;RvN^U8+zmQi z<(?tXYB>?i=&` zUerer;Ns{x69*fs`bbUzip0m2q&8`vh@-wZxbM*k}Z0szKZmWKuaZ!J7Szi4uwb7}V zDP})EerH-5_@rfv1B8;yVr2j`^kMrO!l1T`&w6ALJwz}(Z7j)(ryGMvarJ=BSZ07|NCdrCnwdrI6y8ED-bU>HkSdS5vNz-x z^*BeEDNVKRPeU^g(L;bMEvb1|^|odTZHg9>{66T#_rPVNlRfwbDt&qJvQwmXHWP)Q ze2QtZ@^IDPUQpihs6MIGDR7u#q0#bX3x6gF;KTDyehm(~+dRTjwlz35zxAkx3T^9W zEJ&IxFNQ|sJlI;KnH0uzzwsZ>?)?!*(H!{)f!*Jcyb{~bTZ4ioY=_u^&%%`GV@%*F zgfhTA=G5#G;uDZj){&uV=qyP$ItJIB^^fw-7_8L|pMhSXAmf_*o^SY)c{~vNDt{9s zF<3RGA$KZdvzmtqK(z3djm?cbpji-gHkG#loqxZIeg{j51XX59C2SLwwfZhXJ&uz0 zDG&D33@zwI6e^qq(s{iR{jeHxM9qLM;*{TiFuz7!AWL=PwK3H4%f4s?oE(5n&F+~A zKoRw8&H~=GFOgWiinbjzg;x^!$A6)jPu*-{kDc<}VJvpnO7auFL@Opv$LY)U#LJ01 zUD4ts0?t^!hUclMY4_=2=|>`z7rlXpnW zNs3Ho?oji-VOu#2l)4qcJp0?k)aZUkg+kbTIX3!XS zn4W=W3)a&VEy+X{x-*I2_5&$kF;>P&Od&e`*xzd%bvz3TN9U z9#@$9m3@lP4kVba#ki~I8X~~aTlhdl;1rPhL&vMd;tnE{69g&1+VC-QwpceJ{5>R3 zg_6E3DSZ1FP9G@amW|QlaOa1=%31 zo-T95T-opDW+%jJ{7@FqaduVDE{bQj?)fVO(#?4RvZk z7=fInt56ieEPpLNGdcipD6x*4K^tXs5hf=C*Mef+9Z4|@%*Dq)KRD>{DpCHW(uNML z#WPiu>tddOLCcr+?qIlzaQeU2n;J(!bU}YeIp_ke*m07=b}6(2ExuYRFR|(HOg6gF z9#idWDJX)dOT)b%97C9KcT3?v& zB?!$GwgLmXc^lk<5XCC@vk_9JSnyztnXd%5^rRmv&!7rRv7#JSWiP-q?uPCvJLE6D zI>p~z&jZsDXv0;4JA66J4J>(W8E+BOx;HaBTz^Rg_;?S+6PF($$d~L)EN+_*$(0=> z@y@X}BfcOzXY#mBsK3@d0k<1~m~eJ{LHA#Z_m#ixGXNmQ^JSDmRe}&RBn1l(ygHbn zIe1i^*&?YfGYmkB@McK`>Z`}8wAq=O;}jd`C1v>J=#+Q2VyJ8&qqMwK01CbmtVp7V z`+xKWtv-L{7nH`Wsh%*3n%U;SM;w~RCaVQ5ep>084IKQnLm`m3h)kqea+)!dCm95O zt6)jb9y%1u{!_9Oi5K)Mf+(?=R6nOWWs^439k+iZ%KiYFyB<^TC0|6VO~Fv0DK_nrwiGk<@( zW|{o#6-P6PhaWCZQz&k#qi!ax?65LDiOxsn#U4+_N7L0Hak&V9cN1>G@JQ^=2M#8I z`%(5MPFQ7mf^7VC9VOZDQcpv@!WP;Qo7cNmZ0)?rxxw=y-}&}?Z;$%tr$WLR%W3?_ zF*n<&nNC?zLJpp@v(nmJ0~Ob4l7Fa7o-5=GMm9;vPSrm6`vpO)Q>?AzWDCj>=$yxr zqEch26hwRE0(hs>LOx2RXRyTXD2B&}Wp|h+xBGQPT>NaLnJ%8R8f;?~a zw3u6Mw`?pzR~0qno>=D1@aC`yIbCJg-q?oed2s>3+u-96=Z_fevMKsw<>F);cAA>t zW<MLLOhVu!5IL_zwMg>w>|0Ha<< z=}IBRtHw@Hm&utk9vpdMt?c|R!nknXAt&$M&iF(jqEcJ<`=y9UlK-BfeJJZv3)C+ zwVfsxpKmjfVol8pmVZRm$H%l5f2v$k<0Fd8<5&8^TNR=!-J5Ye-%8&pqciRh7TyMY z!+H3l6YWIKJcU1(W(*HxGwrVfKY^lVFxxQ*Y&PkZPK8d`d)JT2CtbU(4s!O|rHkag zh8S{u5vmAlbiy7(r`@9q!cS+^c)d;5uAwCU7j#gq;(Jn`4XA-X5Yz>5vPY=>zubHd8& z+6eD#nnz~)P=6>5m!EopR^iQeZ^0@WJgzbe5_I_j(^0rK^>t!{m#Pms^mM{~{#1W@ zXh4OMCf<^q_rym-=YAaZnDpj9qrn3oE+2rjp%DXPj~FcETig&Z>x0by$_l;C%>g@d z<+-sikEYpHNpJ}!eQoP*JSxS0C3Uxt8PcMIiG$RnZGU@CS@akX=Z*Tl;{86>=V*|@ zdyH@ewC~Nf^QHHM(`BskDn`cavk_Pn> zZH)dq5JVpB195iX#~&ndSHSU%pDpdRgdPhUIVk92J&> zfb$*zWDCT2Q|b}aLFDSoEt0T13STrZv>?LYLVvF8BMSDcZPS*PKj*pSw4MOUBr;dK z_21qgRbi~eC=K!%3EYvDrh>b{v!jQ z&hKL_sm#ZfjHw#~d~J-p<_3yk4SvsK&boODOz~mDA9*hyHw|{f@piUR6!iSljMtEG z>3{i?Dd-J|Z{<@}XS zx>r3LQUKl}sssO5dEhH$-rRwy7p&k`8Go*79z*NC#%v+@P>Bv=C}7-px5}FbHzabz z77#~%=G%y1=H`&C>o=@&4zhRJmO14x)kIhrU6Y0+rrQuwOHP3zYhJ_H80zoNb(V5%iF=jvb0&2GFLm+YN`Eu! z4lK(G&xC^reb5IryJ)ao#5D*A?NjrC;3Wb&NI37d6X+{;_yQ zhnPj#B?q$psZ8AFAdDCl6xU0w7YS{9eUPAHE_m*eW}b=Ss(rDi-tN&)LguI54_d&E zyJdrjaMY##9NPKE_PNg9RaYU(M}Mqa-r@9+_TAM!_da_nt{@kBLqw_Q2Vawfd;)qy z>FT1oI~m<5Go^}OC-)5_pb=O4XVXNu)ejz- z3X{Wzi`_pVownA%O0Y1m?yv1=>p9k}J1w7Yp<;HurEOnK%lsW?o)^38>wghEb_4nq z8W0#@7^BImt&|Nmdi_SI%%I z@cFkycvg~p|6MS08ayDRcFONb$V72(r%DDcjk>LO1F|bDZU2<~d-A`$xd&*8B8J1_ z09XZe7rWB7$O2Et_IiqkOn?3k1ls&Fr(tA>fb53KyGjK?Jxp)k(6kl*@F(fBp9Y1? z@#PR3&3n8FD6?(%h9^#1LRNSw1&Kw!;5$0`c?y<|wZo56F)O9SzP|jr_9=2p8-juN zRPYrB+Bz@N}R&^J%$bXC((}$*5ebYlo^=V0MDN+L_aHZ7AoK&74tOW?$65}3du;} zr;%HrKZhf#(dHm-FqYC;p8ILJzI(0-s2wJ88*hj%S<~|Y{bHEhTFsd{igfkaMT3Qj zUu;wMnM5A|H3G2G>wku0-_;qteG_g$J+TjiGc-o%x1zcV?#c92+UD~4FhEaSAObV2 zf+tA07Gs&ARU$vv4YTnHJe8@)qjP#~C(X!GxW#}tUT8ykU%gppPKoo1Q4g9Szeo$h zT=kBK%(2v|*ZO$hQWLRp%H%&yyyy-9G23XKeJ%R=9|c}gbbo$!Hv_Ba`PRW(Pu?fLWk-&qSZ^~^sh$zvvM@l z6A(Ux!BThMb8trf=n+-SI^y~DmY8}E? zME`Kvl=tAtEAK{L7k>%!=7}RJUhT!ib??9e2iemv?55vZ`gpPZsAUm-Wxs!|1S zbgttYAaX?H?gvblCYj47r)1ax|E$sy)mBWnyMJZD(*N%n`n}T%s$SK2&sJbgdN!tU zxKVhx8gn84WxW-W@0+E?-z>>fy7%@L4^R1Wm;jL54bLM)>yMgd-)7dry(c#5;I8z) zNmes(vy}}}Vf+aDS)^ZBWvdxyGL&W_Q!gS2+i2s{aQ>c95xGAq)`>EFh0o~*=~GrD za(`%&|JZ*Jciz;Rhzahg0sHSL2o-T4q&hTG+y1-pqAq`R@%Us^o;`T&55uJ#jY-?M7g;QT<6Aj}gov-W$GF&ww4YzvR_w)jjWt8lq z#T+lPO#8%u#M`-#Nb@!|Tz@W7e?BA8*HSi@;g+^#B2m}3?3AO-+7;gag=Q#aRq^98 z2~lJ`z*7EP+gd93R|^+>{;pLt;gjkQpBpm&(W@ap*F-n=ay!9}o%F{9uHTrR6VnYS z6#s7`c7aQEwzKQ!zB|vF5-E7doO#@`huw2SWd9P1{S8(RK()H6Lw}5-n5Zq0&di3I zQ}Fwh2`|1W9RtY=M|i+5@)a%#aM_jV-+6yu{*zGDM}nQTexC%=*R^N!sAJ14mSaL_ z(Xm~T>&=}O$a^iH7a|x>R((P3Q|bS@Lu^s-)y4}EpWe@<8WzEou&L@ES&hQ~O{SDQ zUZ0=yBzaoOkm61fu3TvCQQ<5%xbo!C z8i9AyCYp``DE5aRQ##U?>HmAF;BLiJO8^dqbj1gr+*cqSOXk_O21%-O`qWjlGz0KS z>4efaIa?kBF>|jpZ%!%hG>#MbXNp4dS(vk*d9~L?7ZR%AV&3&anJe*IfK-!h#6JY@IR+fJ7MrJE3K#C? zxbYR}lI-*G5*!U*^34Ys&s=nll|{>Q>~r?~PIMrjQ|PWKRB+hlv|&K+?Rf>m*K({{ zb8M_M=aCHn7OvtQ6-B&!FriIB}6eEWOdS zm-?{rpJ2QJ)VqC@5Ial(ONpz?+7X48673S0z#XlQryc(0O#m(_MGXYBZFMwQgtP3z|D1_$^N!wDjN)~J@GQ@_jJ@;XrO5`IcDCrHpMtDe zld?0J*tuY(Jx$F^=h!Q+X;nY}w8&iR6i_Xo<>3@lKU^)s0U>_Ajb9iu95iql|%(w8y zO}JK^lKByr{{P+MXFt}uEu_3fCu249c5Zn97mRHw(&&m|Y3E#p8DplP2$*DLYhl~+ z#G%o_*p4<67{n-Nu`xjzw95ap`JDfz z9e?QV0HB6VYo|@m^UKh2OPIF@lyR#`PFAcKfJ<)HrD*Vp&%6HMwzUy?y+XGvEi?R} z13Go`6nneA>t~(-Dyp#&v9C~{mb<({O6AaB&cCnIIS4JGZh}y$Q&HGk5Y-!Nl^Ua; zOqF(Ot!%%+@yV!;nb2HpQp!*d;)s8DaDQR14*(L&8!H;^6XTxU0-X|zN%~s>*D+Q# zdp@@zZUg%G>TXIcuGLvuymeO3*y3#E5g2otPez6{?`NLyH7IMy5p4t6;?C-{Sx9|2 zMh4(SLe~z>yvk!fu}iy@l(mrb)3OW*YEF!;US%gQRj?#8JeyBhqnXd-wG+|)l{y?&fV_18IoU^pMOWNP-xs4A!++_ohg#;1@(*x6)pA%EWM=$8C7^*ca5&qGni~J6 zTE_4c6N`3On3SiY`yG1hbVWbCv4R0bAvV_D>7_YmJ-G0TEvg&5m)Bn}6+0k68wW zLf4kWy={0!RTQvP^VbFwgD}{5(9PcCGkJ-U+TgMO4HCEVqT~X{Y&)g&L+MGN8sZbq zOOuhLFgJULx&@}YfIbH1uGNh_UNz?03gf_M>Li~rD2xQBLO&5z#vN9EB%P1nrzWnF zG@jZ;!R-@`wZ9c)TbU#1ReuCZ;7c@==-~Wms$AdAB`7YfxSlpCR7$+vH)hqMs!k{e zf+7A5#UOfuYjw$GkT~ri>bOYZRLG9b4`h;+!ty6Rubzq9!jh8rq3WH4tOABFXPE8k z7Gl*zK;O>0Yi~~)wBSE)l_%P8%lOSeem~p^0ET1d(o%iS_xRwGCx7<6W$%&3W-mV& zrQQ$RyjAV0ut?%#Wq$`G4sYYu4C1jj4Ubj^)&u&0Y?i zQl=E-;iS}rqSPrJsKs=?(;rj{)n#A&+#!{Fgr4WIJ9+>j-?X>Xq*54^j?g8hY9s&V z9O-HhKD%mhSn+0jJ%5H8)OSz63r1E;!)@kHnYiF~3$}}X=^Xg62FQdG3B@kdXhn@n zKo|9eHcsh-+OBTA)=fU1+?Lm4e#ft9BcnG$=oOdz@K0_qa(Mybo7zJ-=={e#M+O?> zMYUR%SH1-YGR#%q4^jjm>AOdYx5l^F4o}$AjMEX)!%s*k;(ubCMobS~c0P3u&^7rQ zWNUR>#tGJsCwthmv1y#ux-S*Fcb>&9U`W_tVp>eGHQZ8Zcd?M>4c=cEvK-Bgab@#l z$+^xv@iW%DX4~=R^g**@XAQ0Q4AGkJIj=hdjF;%n{z4x8KoyB-bZLP4N(0Vb)ku*% zoBVrYg7GvrRDZ!~gnV8M=H2>fZy48BI~M&FhUHx z{#hW9qIKAnaNj?zr4|nO0p9brdRZWQYqO#PgvXzeh$8V(z zVsTtpPwt~y6w^nl3u4!hJ2yu30#3sOvzJ+@gf}I_X@8M7`nNYlpooV#uj|%RqaP?p zk?&*cXa{h-v`hrg)V+d=2V-KKVbtuldrfE%oexA#Lc9w(1j;>Lob9VkHIPNa+Yjf0f)Av522i3{0xa*F|{VE|M$-Q z;dF5cYkwVg@h3Gp|ZBZorD0hc;I^Qw~m@=(^G=$axg%)8fSr zJsGrE;T1q;#}nt$k{O1^$3+(kM$}dv(g08?^}SPAC{!(SdF+_f+N!Vh?79`{!O%Xd z!GC7%p6qI5YS3~E!xP^=xX0S%7b8`;Yc?rNi=+q-&0qibUyET70kTSu;Xo!WZ9Fp-uR5) zHcL${XO^s2AVNVAnf`P$84^n2|7Nk|6i5x!3a5wt_W+f}>X6Va>>NnGb{UJlvrj&- zP=8a_IQ(R1$xl-7(R=1EeVbgGIX620{A}GAwck{ZXgcJ^5DgWz*Gk>~)!@gTCwMkp zV13W{%fc~D^}Vr}APR`rrCrHlQ>V8dSAw7Xi(k5q9blrf52oGy2< zA<3&6leSbnsKQyqB5YO_4GmkVRq<$Cqkqbd42n?d0vR|Gb;UACTtr^zfq*e)sbNu~ zrCbAxFboWIEQIdARUbC10ePHY4dAo=cRq5v)OmGm`OyI-xAI;&oPi`M~G#K#e9y6 zjk~0Xb3?azek*iAKYJaA@q@RpmWCG^#<<3A_q| zjt0d-%bmYxacV7MoOi+7?(s*qJAy74f@`w_R(Ep!rtMBc8-_bj;5dfal)p`CTrh3g z1R%tFFO&P_Et_l~yxPS(Z6Yd<{(2MKzBda-CQ{wRYz=hly0#)&tlaVMHhWaVI54zoLPcG{D|JimC@ zP+sqQPDj5|A!}HP$pj!M(qmFV_su7&ba|<#V~ZbsU1=#OuSH5M!>@55SRJU#ZGXMa zG!O7q;b50`~6GUG>fRDZBJ!)f%n3BF51b+QJfm~4&~>`3L>B=yvb{}4r0dVl=& zsf0niB4ZF>E5VR$Uw2TxiWQ&MIgsGqRAR16m5x!l_c9aY?RqBzpuZ5#fol#XP$X4W$tx<5Zk*FKB29ggnx@j2%da*xXohV zNjM>)vJ6#uG_Pqxr?G-PnPnJ8S}K^OEb!0%2vkG(APlj?HTuw~Fmu^P#j{(X)O^Vv zQ&~XAly{x@uS4eG$pS&D<`WYBTl@Hy?L+I|)~7Fa(PouYjAM3-=E&Iy_V$!46JN9F zLLXl;aeDCgSSPAwhfTshHj)kSK>JFRUjd?TuA7(0E@yUj0~@dzaz{O@5y8)S;lCn`Yp2UuE3tU{moA_1A4nl4WGGv)Y6n#Yj$IJ~CzH?NGMY9AQ z`yNHexUq#>2Q$BqcgpP1pm6M4uq9S{Q=B{#b_l{)%7ti_4J2XD|}{ zku(0sG6q3e%Q(HA8;LuuKYX$D9F0Dd!H$~)aVwL+k0*aW^nNH~4Wz~0>7uU{d1TSJ z|M86fOuT+&0q_J@g=A&s=K~-#xs>rOlDqu8i$dGNGUK{Nmv-7Fw|1@DIAPUKHs`ev zcnC-GH*<_pst<@!hSJbq)1oM7)!BmIS%brwgplE2K=L(nGFK!@K$o&AVm{t7@c9N!%Yf_n#8{CLN3TFmNJNyt(1<}SUstJLsSF?$ z`0gO(8hSWXC3n7ueHYf;S;pgrAcl?bkqR>QS6+Wpl~vHgw;@tR3X7I^#)^OY;DV1& z&^5J$*U)x~5?4V50D8H$u}oeZyFuwp70?Cbsj8#?gE9<}>e4r~pFGcxV)ow4$JPA2c0u!h)|pbDQNAV6zyGq*g2oTIeUX<3Z%oa>oJ z?0k%f+GHcix>3_kqfM**4QEv9Wu|yBekoRBPIO%AqdF&Ju93!4h(2+ zKdVu5Ud~@q{~^=nn4?Vw!NP*XJho)i;)#FGk*deU(_|`iqJ_!uc8C`?0(DbWoL7ZhWqx3%zRIg2_{OKydX8(bfJ=yQwXMB$!d zdgoL~2}8K2d|S_yyKb=$gI}gEXe%k)!B(mFdXk{9ZviBupATxC@3Fin@#PDGx>kQ| z_?&&{EE;KFm+??TqF8rTC5rGtcd^Qz>EsT2MZO7pZ^q>`Jbzclk;)OZpJalW zEm^qbvh2!jP`)HK+!vojPdfI6ft!EV%vD;-+i|QL3&O*rQyN{(VX|+E?@*8P1+AN9pCp&>%GEjFLwQd5cH~77e%j$thU|9J?i@N2S4q<}H32l)ZD$-{;DuZhG~UHoEKPiDLlWvf(kXoo$0O8@eekLsOe24PbIH}iP{CLEECkX5hVy)|aTqtt zu}U$62VkAo9OuGT5S5bfQ8( z;fBm-^zvG1#RT%kXfDW_IX5I542M>gzVsA(i+9sT@0~jpmRE-7afab2FLpr&U23*Q zj?I6yB30-n)7}J>;6K(O@P6QH|D$(~5`agn`H2<-TsXClSZv3X{Hn34rQmhmL*wtV zx+f1K9tFCLsS#k2fmX;mu134o4dofMpD;en~5!4rG6vT*N6pVj*X`&^u`mxEU3?+v^iqRm z)`J5XZHKBy<2T}-;rPCfAijX4L`ncF15=8;nP9aWVQ-NAV9e1f5|l9j%b|ZZT-CXa zg&Jx3kDHg<&Jdq)Dd%N{==Md-?PX&8lfra*(f|rOTX^ju zDpl?=#SeXEBKgCAqbt<&bTogg)VknSHAHRYkgbi|TzfkVG;q!)M?Ujt;6fZ-T4`{A z`H(t>e$Y67`%-vCNuUZv1?n!(MSo+>ba|D5qXny6vCr@v)(87=nl|tzKssIv%|(rT(l=*Jj(uupB4K}zcp*et>IIJw zuT?eTYW(?R!0GEy{_qb<}cChXj{y`zpiS7K$$H}9_b*=GMUs$z22C9eB%mMiPU_9BYr*VmUWN<4L8{w;U7J_RFfjraJ4Bjm$%VZb9%J!c_` zH?kw69B>nVlW|u5j9VL^Pev5?ua4RNYCG|~i)Ju5m2#7P-k~P5-9rYP1@<-+#l?{F#-ZP0^(1SS7;)P~yYk zSMg+q&`TJrvN;_l_-*Jx?(lf` z3mm5fu+i^k?K0i&2c{$&srzSkhGHOSJ%2E$>dul+V{M;K{ zA~KkiYziXkv7_>8oF2c&vKpYxmX#5ooy@uf^TB`DN7#_|cL@~C5dSn9?Jo@x>nXIK zNyNQ$6V~*Gk*_oYcgT-NaAEK~=THq{S3pkwXlthS@D#%Uos~TVN7ln3dEuJ|YlgfW z$58az(KsijQ_%u`Y?MDps(1-O^S8NOxWuS*?tV<9K=o!>%1s^dM;EV^gx6U~uHo(u z*42MMq4b-;kwh85yy8MX=cELX9qQ;gV&?BVtwbLy@W1$q8PaKE!C*(yAD3y`D;wt2%KFKX(oey8B6<&r+ns5xa*LiRt7Mc5dIB*4Gh9a+ z731BP{0`~_XfIinGUcemHq%lVUoL1)CRRX4aRdtb;AhsRN1S?7!K)JHxA z*pnXid)(9Y*UKh32w32Dc4k`u=Qc_-ogYIS7 zBY*<;Std1h*&TvjL6`Z9_dB93YGJHHIL|=38La#@;Az^`KXEm~^X%}VSoDA5IjEE| zea)W{&ioK8x2&SzHDLP}>(LLeJF%x@XIVBI%_SDng~OtyaaOBx+#089qdfms+1U>i z@YY#~+H+kn15sD^Nm%NRnAGivUdM1nDaFFD>>a_k(klmK#5FUho9rf6qVu(AL599g z{w9s_sIc^8VYgSl#4lYm06%||s#~fL658-?JJv=BUAPsGgN4OobD7;oVt7NP`SUq7 z$qEN4zY#eVn5>uey-8+9uUfX>S(SgL1y}*NzP0<+C}p*UCb}t!IWSw`i&R9Al>FLte@n5v-+ z^sK1l^Qk=*JFn+l@M3IPj`D9bl~;X|1j8pg4~1hSHL`kYExX@XKgR!J1Vak2{x;v8 z^epT=^H24w9`az_4otJWyv_&;vANtQzo6*KFF3KB<*FX*MdLs(KqpAOLOmYHN}kcv z*h-B3_}g=?5J>T+Q}%y))Wp!iNy@>ww`EnfBi1xzl{kE8L;0S3z|o7R0!Sl zZg#-D&Pyw>m){1mLE=7vbNkP*Uq#4rhOJx^Ee+1@WV}yy)8u)5rfgcI5W}^3cL86L zy2%rw`QS`x4q3Z8NOVe3>dcOE9#-F%qjkN4oP)gXwS;#agb__i5z$YpfA3&9x9YcK@!WZ08eTEpd4s!rGVknh|qqtRcTg_AY?u1S% z6mF$2mj^1<{61ciE)lC}ojGm-C8gjI^&liHNM=oa~peOB)Uu-D1-nj!5WJ)>f$9SfH!hrZ^9Vv?hL<9^EZ*FV0k5> zA?O2x(s6%kfvdY0B|0%v?3{Tl_&Cz2k%2+jLbZG@7J_%@nBh-U2~R%DZm-V+WP}^v zBiHg2xpwd@B+DIJj)l?ZAyOuD@)@;s%+ZjCt8-5PfyN3{*^xb25E`BOhM^+cOGzmN zHhnaa*nA|l$swR@Jb{T!n@=;69dn9}G!WAkA02-&U`H%Md?bXzoCAfR(Y%l<@Dap( z`7bq3bQld&asXluq2;Sw*Tsk_>Y?%@$)eMmd^Pt&;dCl#&jNyscMx&#I9R)EcCmdG zMW=8mjhKDhuaWT;PYV+mZ*6N4nxoMY%C~Hli(1FD%!1fbDeZU$(j;HVR>Q=E~4Yx-?mmJkBS2v z8M^B?0%(yW#5>Dw6&=9wdacce*c%)-?+6yH$rZWHSdspv0Bg5F;AM4Xx3`I@o?2<* z7a*KU%yTB$l0#*Zq0EoL4XVjwr+)qs9bJFa3+`Z~9}~L;`g4Jlm2dZ*)~;-_gvbjCP$)}Ol|g^k%-r z>eDxi-{s1LKAp#+4&pK^(wUAdUv}6G99*_y@S@0!+v*Buj+K#i;DhyyIYGoBlW&8| zC!~1lC17973|j+IGADz$$UotR{HXe{QzWjCYrM8Ft?~u&Ur-1s7aKL@`3-+0gej5I zT#DbNC0pj{h62YLw4lVDz7x%2@G95Mrqk7!x7k{_K?p3vGkRAh)>$bgysN5xM?5ty zM%vMYQOW8XI26dT<&ZQ}tjBdM3qu73vqn*&#ez4EA8Ub?2{)9|tD$u6&F<6NnD;fBA^W27yW*U_VriL`-11aSIhj z`u75tPD>J9TK(~c!Et|Sf6%7X2B6I1SdJ{EuGV|(`;j2Z{F+|E92z)*+5GcWwpl&= z!9!S64?lV_faaEk_J-iByL8mExU?eV0L10Sxv5Kyr`5-!s>VGLEAmtxKeQ9mxnwva zAYpIT$^$x;Oi8Z6o@cxfW0IKfHUOA?P1uZPZP>eN(|AK0`D7 zL`dFIrJeOUJ4e({aHOA5c7oLRF!K9Ux*l+{ViO?t|J&XuUE-o|w?9VJc~pD5g~3+j zVy?XZjH)V6`R0F`8HBpHi2&+-5R0&QfmG)md@21Ey&S#t#o1iV^jd_KEBooSS-??D zHUJxl^IU^LRRd>(Gy22787TBCsTDUT-E|1%|s>;8O)gu%KEIc9)tjui* zDo`<;?lz$sZ#N!y>=WhBW-^A|L$2pK-_pf}n}=FP^|*ib`mJ;xBP+dETh+%QengwZ zj$wvisDNYbD|e4ZF&TtRL%+hYDqbG z3L@N@QEuVt+#RH3pQQDuzP`>|x=|C`U5HWbXh`XQn@S!*%q78!4-VQ5|9Q4iqaS}l z#hwENe}aFGU4NZ1u0ClU&;hu3ue&gs>yoNbW`hn?8Wn+1%MDMS)AbzyPtkT1d~`zO zrl{*Av!hbnJAto+liQMsfy8Zqq7R_G!D1w~p=@4vW5DYG{Keb^-*J1S{7Y+!5t_Fb|_R%T?*80W9<$gy<&C4f8J=2IST(to}(QxXKKVk=3> zA%8C)0eT$N9hm46%{%gSmsr?vNrpbQNO!}(lb1$%qNPECNtvkpRJE zD^A1~=nlMhgsT=*zLSX};GE~DjV)1brIHicw54ik9$mJfM&&BAMgTzvAwRg)pd)`5 z!4PJ2$aa9cP;C>1=!U~iL_G4CLAWT?Kf7pKq~SA|uh2ylX;S2uKL^naS$2>Qf(;en z0}p^akkdiR=P~Zj%8T7@<0lCz4E zL;tmB8PP`1CddN)!vI91%!SMyQaob4%uNLX&wB7fMhI1(VDbi z<@h*sy&&IqP4jr}ITqmE;|iWiCV|v!z?oyU;pBXW_B|6%+7{bIRu=}=YB7I;yaXD9 zE&x8@E@3~odqx?(H53KQd%dr0yG2CzXVcB8c|7PgxeF*F;Rt(0k;!UOhi;eV9=z5Y z@}35A#NV#smfFudZV6Q3`ggVO^z^v{>NFs-2nvH^*K0!DG6KV0h5^f7k~SF_`|{hCY{IuxOC2|8OyGLDra{X8ylL+Ryu9?2nbj&t`a?hqQf-J6=Z>LV0| zs{#EN8bf+J%HWSDF(?qtQLQ7xQ3&lLRW3N zAp1Ob+hY>=VTX(`RI%cz_u9kFo?pImaD@HRY>o`Y$hWfgC;EZj$&BkHfrO$E-%e=w#I+v(o82{A&0JOJt6xCYCX27F<(9znqKp^%mrdu+K~fCITcw- zkxP5AsdN^wrlf@a9i+E_GVRXxcfEVGP2uTF89Ktt=#ur$nMfBGe##ht^0qP!7a;D9 z6ugrBU6^P%`6*G3m^f-X|0m$tQ$vRHS)i3@}iyTZVjU%05My_My92 z&cA3NEypX2$tD(DK=sk?=gdZ%iT!^aE481R3VK}({K?QUxf_Tj>J%8zl1T$)!9-~R z7O85>^-=@j@eY5`ImWGdb*IE+mU9-<$td zr?R#d*onlK>~M`8t?)(>vBFdCjv;HIT>f2g!-_XFeRO}^&x!I(tcq5IS+bMVZ>xXs z@acQ%t_hJLb_+f8r25eP%<4FAzvlV*W%ce(}PBD2@siVNN4l!tJ4#g@ui4wEb(uoRiNdY_&oPJ|$QH3(zSa zsh6UC*Sde`c2(E=SF^2cZK93CZWtc1?7)GgP`m&#b$Y+f*^w z41V4%mbL7Jg_};&yi|o4ws6%2Pc{G)-q>eC!gqful!;>gKVcxInWjtY8%OY`s9fpI z#$UksHlutPrl7a&#)+Op(+FE|N5qs*Mr4F@)w%3X=`BhdsD1{C00*X6LKb5S*AInp zu7bLw2csc2uElIlN`dq)u@_kjyZxg?T%L322pkx@V4NA$s@DV%HPqr=pzHYatO02VT8sI!*eiW)fOEI>y;q6p z)#F^Nn*MS_0atrRx|-H=E;r?CQ^)vfvzmWSuA{12A6A_-CG=>4W)6-!(s^cYw6&UU&mO)vC4vS?Nfe-WoUkF=wO3`=hBCE{pAg;pn79Bifj>m{_p zzWFSnSKMC7;H$fF{-9isxi3`oK&9T$*UR4(U59kXYV8ouyp}+;&z!-_~W;)!1Pp16i?N z5v=(D{=_tqgL9;OQm$hmv8*9W%wvCR>HbcuC8(#gUV*B!*sznPaKL`PJ@vqzWbvK= zA3l69>siC`8dM%uc4_EXeGtnet#FaE-uwM;enfz)%d{lpW=yQ_jxF|{?G01`#okeFh%L$Fn0!4KTQ_F6oGVo<8%|TK5xp56gf)wkf zRj%%YcFY9x*qiEIf-gY&LJ_vw>Y%a{GRSj#0N9Ez;o-qs7w;TZ{+Xsa_rb5?lWiG# z?Rh7WynAqo@hqRwBH{{h9W#Gw2P4G9r$<0*4-Wwy<_Z)Y+r$?XNGa*V%y45}DmBYF zVytUz=H+)LQmYhj_7vM{e)?ISL>MC51VHYwcwR`*E{IlIgWK6>q~*bk`$vo9F=xno zvFw1)ft;y8tj-)jY7yo^_9!swf0H7;jCn*5%^ytJaWaJv`A}ZJb8CNR_?C3q1$egn z_wN*iGnVM0jrh@it!|uAkQs&yRVhsH8-V*}guWX^`Zl{3DNMEgv&3IESF zex9rEhVy0O`Ff)F@{?P=uhZ8q8=0uQDByT~syFItidh?Yo1_)`>~^-^a`iFdV9=n- zpZK3~9lwJ!#I*}QuRecKR+)#wow`W+7gZfZLsGd+6%9VCLTSpZT)DoSD9GttSEy$rTymi4?^8~E;P;8WrlKuwq zEN^w9B#lylGdDgOeL4a9-t#?%_^>TEgp4e1QOT4rBV{0TkC=Zv9a0K+Vu^GcCLO%M zV9PZW`47$6KJQm)1ZWQ2&LDos_B|L-7AtkdjaJ6tmilP{ki!0EIGZW31_(F!BlX&l zj&WvP$D1OA1OH+mnQTkId2F5@@J7ah&V^2(rBJYxBQ+NOL7p z@_|Wh1QG5B4r;r-z8=;)n_?a97Io7DldiZRCvAkPmjQp(f_IL)z!OM6+Qb9dD_*?e zqzCrc{2cAQJ2KF&Z?(M<@!lGwL1N$2eI=1}X?gPa91WoG^Qu1T#6aFdDk?av>i!_Mf@uCouGSGr zL|S@Jbo!_==L8s!dj;2|W1V?YXn=f=+(tI-Ez##Ql;n)U4ev*GQSNn?$>pqMU=2|B z{43~1LvOasUnORZdpzX6FnI`N$?GeAc24?(<1T-j3CoymA}?!zBHuipV82Nt2TT=$ z;o&hiSJyDC;)X7H!qQ&Bw9h9xO#25uK*@ijr|KK_p~ZWA;9)n^8WR-+l&hQSI(XB2 zNbB$O+9Vs&AZ@GGsdsQ~%Q9^7vd`A>#2MQV&AC;h*>i5sNW}^DwL&sZkw#!I=I52D z_JDu$5Y0DllB+M~GVduLZp73|raTRx!VMF0u4nkykEwmCyU)z>S7~{0# z#>k?e7+v2DZ=T&{Xt}qGFQS{bgSNda|9YDq=4WJ_(}Ds;(sN=XLLt9?aKz;2(FN~Z z)YQJejkNV>E2WPd3XKO75o0DE4X12Sb@0{m_b6=#ADwHe?$ z54l>D0c4k&{rx&%3o$RIGyQBo42XZTZGQh-q6-jf-H1a;l)XADg%Jd5X>f zS3M?mBSRy+j1mG7W}X*iOiC4~Cnw@`>`WiG5AOY`HYMPwsNpOLA)D}i?Vo>_I;KhE z08;u3YOgqZ)en)9Ef9(vqkelt=f4SH${+h&Cg3Qqb1Ox9@(VJ-V0lfqB^u+?j^oQx zSk}RfAvF(cS-x1(S5aGHpM$!|D((>?NGeQ7mJDxM=J32#Pn_rHxaEaRn~xZxHHrdinux-p_1=h>>ONs_l% z^rQ(rCC_iT-6+#kzzdpyb~ivMC=8$3`6izK8I9R8g#cioNpG1Go--zhco@>(> z@7zlDXWrM{|8IzOTi$J2HHO9hGR*nGj7^oUgoLt=&SKpBcI(JHy4-Q!kiY<)qruuT^grx=NCxwdX>P%f4((G(UVlXbcrVe+z>}_bW3)KT!M2{p ziB_>zU`T2S*!U89H-jh=G@BTR^pOlR~?R<>>`&L*DXcY+fAoh}dI zK2&3B``Kj89lytdeo)a=OHQDf5{#aEb`Ln}6=V#w%2R;Bx=smPY8ElpwD_gX5MA6tGaxJ)T?7oS z$FmKpbI#$%ozZ{k8$&}W;m*iUJ)|)qR$B{Bq6z>I8*GI$cr6t8&5&r+m71@*qWhRO zBDBq_<5o}9Tv-WhomChw;dn16;RhTh3hM~E8A&Pk7y&AyG35+ay_?Qe(*n}0k#_wR z7g1(#()d%r4(>O7K&__I0KHDrVf7mzbrq!*V0L?KBUyiU_T3fv-LteSE>q~XN6HIs zKYhh5E6P=kKnZy4Sv7o0WY+U7197BwdKGS53s5-Kbhl8Jw+PY0xb_;odY_6NP`Cc) zI||27Yt9N^eptw-@n&ljxK`=x#V|Uld2gqvZcV!p&($(`GHGm>RoK+gIX9qkz6$#I zEm^LScA9^Vh$DTmYE)XYF0P~5<@;ef8xBF8tekWqRdakNelU! zksD$q+2ZPUEzQFH+uqzgB63Ag$RnmwHM#L4b-|J%ShskTsJ}u>@W8N{QTo&yL>P28 zar5&YJ&4c3Ck2!qsl%Q^KK$IwK>Ii*M^!;mFbseF1HGBjCU5@9bG7A{zx>k{x9=}W zHT}cEWpLTAWr$^d5|l=x_(T+Y{(m5e|F-$LYI{dZ)oMNc{2YHZ`c($OUCIYVFx*HrjXNOe3d#5Owk-lwmScEim=L9V4h#{4m5f zv(Gju!MEXzdNyhGhXeew@G9I`WG_<9ON!ruyo zo&@XbF#egmTN7BMi01ofw_*`6#2WM1pG`F3n7DLq-I%0eQkdi{UKs;t`ZZV{-y&K+2{#aJl_yZ@5_#-Q*|E~;!7a{MSa zMtB#`Z=PF?TWBvI9%u`$L$ z_i~b^MirdY7`RIVzlz~4>m!C=bG8g^dpd?b?XegUYW`Rm*!F2^(P6oTomQ%vYj+Pv z$sQSa+JE=nO28s{f5Gk^de2{&IluB@(%WgEFNPHHc=DL*a9fXxvmrd(!u>mOR@thT zS!e4=^<$5nkaFubOJjfN0)hfYx47)q{IlL0=T1s$r&>2dF{_sxhC+usOEe%z;AvO* zAkA}0Jfdj!D(BPk9=M+LIF&j%H;A;essQ;vtjNyhLu! z1Xqu{O6rUZ{nEOyWp=mZF?1AY@2SKen*hMQtq}6K6Zg}y54l7_f+O&JG=+;13s9+> z%S}kHM;Eh<&2Mb1vSXxXyrKRck&MQNv<};ZP$H^e1iNVjD9*o`oH>V1Eh3PY+X#vJ zY8l$GrIlg2PiTMk5z14S%G^8KEe^+{tx<2nwnq7qai71+9e$1wG?hWUyQ%l)mPOCb z@+dlLPNgnl?<(egbL7^>`|dw8-p24jM{`^dH&%O?*>s+ikn-){Qv2QvZQ{7}yfo6G zvVb(-;_Owi>{kPrl4$gH7u)y@6aqOyP~xB%y!!Fq0o8xffZb$1bF;*Dw&h@W>{frJ zL3bSkbEC)6-Mm=bJ4s~en);W)a2%~GWkR)f3#2(S%69|9HlQ_8>}TA>>mr7HNjCO1 zJo&NH<~z#m-WrSf(ViEqLurs9Um2Tm-uvzX@XkJHV6H*2M!wR_Y=N@YF|L|$gai3= zLKwf$SOrf>yX4GB+ z3R*>vGJg{U9|fqvDSp=KzJnL!P-PhMOZP+8%)oyH4WJ0%i!yh)3AP1fj@tEr-D|0& ziwIS*fdMUg<0uXRgE82D(R*pU-~0#RgoJc2H)}jQr|9WFPo$O8=Al{P9cWF3CnY#P z{PuYji*rYM=Edj1z4OX%gQ_g$B(!*y5)i!5$~az+u~u6_wW}V6=*mgOJK9l9EHLFkWwu?!zOQdwh93?WszGoEUO(X5)c^VSJ)?Yc=Ue zLc(Vh1JORT}y^cdQExQ)@mk0X$RQY^z7En<{oUft*Ph>P`{n4TgWU z-diiw(cAz6gPBo}a@wZP275lbc#v0^beqr~HiF;zm$0qSgrCiNZ<`K7kV{p4#QN@g zAx+mq_)MkO4Nf7EduM4{ildzax1`>%js>v-HpetfuT(6w64`#F{2TT(rA-kqG|*=J z5=fkk$s5bZ5k5VixwQQ5_{T{nu1xp^>hJ3B5oWxO?sI4?N?qWYcqb8eH$f;S&8K{d{M zS_KKRu5V}2dhaGCaBWlyrYk#bsLTe9_r?+;y=>rx=Ee02IANl~gGfwStFwQ~f$8xI ze~3h-!5IfT&4%khigO^!%su6vUuit!sK;M~Yz@KUW)=8%CBGEzhKIZ(>QE;3Lxy29 z#}Zt?sHmb{%MV0mn?eR>5LB>CY?;dC?Llb-p;lShPMVaW=AsEUnXkP`isFuJEFPw@ zaXC5I>;|v?2iPLYl8vNysDpo+IsC!Z8o~EV`82TuciH{J$t5d1`em#{8KpqC!*)Kb=SwLis+c2 z>U#>wjE$|ff@~56EUJIhkj-g%n*$9?2+bKvf!1P>=g3sqTSANrGhh|ew4d9zRec{sC=SQ;$EW+zDV7ing`K%X<)#{ntT-HcpEQC#Yc^~J{uTJSq2@ZI9 zFxs`p#QOz+uNwFuv`gd-lq@S?7qNARylt)we-ICci`QWD76lRPxkuP+F#uN+Nf;g@ zq?%PS+D?B`F{L-a9LxGR}`UX0Sh z`L7%`9gh95AgXwUtQiiftTVY8bRkl+>Ms@JB6(8d9R%i|(yOqSzE5y`=Ni!lc!`*C zknXd5Y%00CVYj@S9P;}vCBaU+B%d}zgF%CW+uzf9$Z_TL=W9|+&$%c-YZX~SiVtt5 zyhMLedwI_|{eP$WnJOQf4QESLb_cBq)H!3tx5`%9IuOg7 zn4@V7l?@(oK5Dwx$U%UU@=sF0=1abJ7y^F_Lxry?9i2IdXruAZ@DhzjY~yP6;Qk|d zGkep&$!K4nA(f5~e;1SNUFCQUM4@t6vJlKs@-CfrAD4@Pq*Vt`mh8RvL?OzZ2*{x7 z9YMH%Let0fptVmN{(2a<2HL_W2pG5^&0`?=PSVvB$n}hx=Ys*6Mc}Q{#7r+$0#kqO z2aA9HKPkMXm>`;HA$1rqEQ)TO$1KmkeQQ|BhrR|@e9eMcgg$4EJymivtH01H!3w4) zp2~aa;mhZe>kA&;)^76jct=J15zdfI$9F!bpg_0Q5n72+bka@kMEOj~%GfLht|y3I z3_`i;mh9bJ$e=%$8ARptCGB1vcWZwPdc*$Q{1*#t+1^}blvqKpv4*33RK;pGotvaU z|Eg^j?+O;G?|2|A!~vB2YbnBH83j?XZp5wv)F(_d8Bfv|;t{{3uo zHfDotj$g;XM`-8E1821rAUPy7HPSo~r6=sgDtrQ(8co^o{tp&?5p~x{$AN!452m1J zET_QX@S5tt?Hw`=WJso*DG5w0UGL5Y)RoT+AeqpRjasbeDKS58CIe0{faT~FN zWBHJ=*r_+-(qkeTn34Z^~^022y_53K+eB^ES&{)ra4cqg?tf$f~$JPP5V$D}hEEv$ZKHDR*^8&xl^8P;7qtIq{?RVLDHP=PuU}gM&VEuI&>{Bj0 z97+DX$J#9-Rz;kF)cSeySv!=6Ts2DFtq$lFd z9zJgv?7fd(M`k2}>HzhBjRD#rLrfSlvYMDLQsfY}_!nV??s*j1Us4<(;+5v&dUpeI z)RTU>^LdLgQdStps@r1KBQ%sALQ+nJ!g&KU#h@`K*A?{rUH_38kC(o3Wlb)a1}zF6 z0FCyw@z9G@g^$xn(-%@w2Uq7X1IrDHonBhtG>Pciz1Hko?nBvsJ2uw=7vIvMk01&S z4)wvIjts`pM7C=~s88<5EjPS0ltmX-ybTpt&#Mg^JOM~8#nfYfMO|fgsm$=c&E`=a zy0-jZ$SKuh71fuT)#Xvxnjyh0sbJAnlh7X117GcQ5+~G7GnJpUtJRDXVY;D;J01&fZ_*&m`5ip(ky zo$bW-lR}`Q;=NpIQ!v6)W~MY}0*O&MjdcwLy6q75p9A}|Hp`IGrC8;*(5`o36(Jl( z74P(DPbnxKBdA7Gyt03SsbN2L3kBb+1X!1nkuD|4gbKuezp@eicW54}S@)_JU>Q5I z71eUe3_bYio9ScVCw=NNg3G1~|Jg5Nrt9S>Y)d*uf><#iUEhqx0Rmdysk{nG@>ZEr zDy#2RtUrE0=;B_C>#w(#ugZrga@)2(C-PO>$I2QdUKG>x98maL*5DQ^Sf}~29e6ws zzFVY`+xTjKHsy`neHAOm-<&;`5Mcc6D5QL3?#j4;?e9{H-9+VGtrW*1%lBtSqVL1} z)U1d4e!ruZ;W*^T^eU!j%=;plPNd`iS7c|fA*vPluWvE^yjN$CJSHl~c04013q6sI z*>DI2XU(3S$huNCeNf>sk6%?Sc52YuqlyNBL431+^oJ%%R&JO#;OCWG?boHFVBd;4 z>rV|RHkC~?3^r~7!qPF%du zsTdM}RT4Tsux+e2xhfrB2Xb4z&)b+yiQR!0)LNg;;3r}lfyd5#Z9;NOUWK+1VhNG`u zW*b`_EN=dXD|wWQ?N{?QcO;1oaM|0lPB^xIUdS;;ICR>gUJf>NT}zAz!6ZpNP(oyi zy4n)oNdQLzy>U! zz@9s`c`ce(3B%<>rbV=L4ICSG&pnh1Cy^k4O)jJ@Nj_>(C6BKuGn<=DEYhL)C4CSo2F!Y54>jTRtDr)X zc6M-H|4-EPo~(On^qjAViZs;`W=$%8Ay}sl=sMlY6aFDdwFmUH0%9Yd49E z^)Q7IFM`_f=_z+A@@`c!6x$DXoNA%DZ_immFDS3YHp2@%jW7DeQNPdWiPEukx+LLC z)l9w%Lw>eHgeW^tO|{L7xdO(PD_%~$qUV4eeEPFvSR}%kbAQgi53x;uF0jO-6}{4E zzhu~=jc1obl1la=v{2)Q^IRon`uRsZ_h}zbdY_W0n=-b9%JJ9w;OVMnFF-2`CdfiFm zG6MFOFNj?qT|wY7TE9Yn^v1<})b34ti%H&x(+78pY0QBXqEL*K5WT|bAK493f&vHo z7UV6xAdr)fnsY%~v*$?i%!bC-xoo`hYhy?2XjE*t!SCKG<~$F(voB{^6(^qst;)pP zL;otyDZa2?MI^G{sld^L&f>~wUX7(#_$VpMN+?(NuO5Ue`oK%LX&jMY43bC#2 zyx&W$SaH3*m=KzSM_rcm($36f_^ueTLqtvAf%oTxt_8caB~T{%#D^{;)GSf_oO3p44T#F|!~jq?qM#b4W(0nw8k-Ba4y9EF!d*9 z3^3TXksZRC$4&Y)x1XUUSGA5Zf=B|jjPzV|V}8I1dWV*BvRT|?gVxs1Q@}5B)I^3> zZk>E01QTX&fH-%*Kc9RYux155xlKYRrU8}F^dm>I1KKNp4qWQP8`50JLldlYNF2N= zdOX3NKwSdg_P-!)VTdn*J%7ZV?+}jd8)ArUKyEnm6?Pz+Dor~zFl|FCVZF^6FunJZ zHY?fwbo#hBMHGJ+!7O^yc#(mc(wqrC5p8b)KZxF_qE^@NLP3lt(@R-n&a6h{2(NN* zjZ+4>&jk{H_8^Jef?a*~F%FiZv~lG0m20GQnMrgRJze3*Q?Ve+H>0Ia^oc-! z``?*jX5M&*=PR2$kP}LPCZw2s=vnyz@_ai_++YiWC+L|os;II#c3_eDe5LFUN`c{;B6lqjnG`Z8_p-GPHJ6>{Q;TW2g=neLgu0 z4)ghcnzbIZ=443V|3;W4yt;t$_V$J0dFCezQB$^D;)^`#IbmoKXUaCVigeX7rk-3mk;24WIBF!_O}C2*R(XWGOIG44=rYdeoy>^_X7?_vnbka)l{V{Z&Wf|Si+e!bGa@y;*oLJ?nEo!2zB8SXD2ScY%wsK2)h&j+7DjuMWZirhBAdnT57on)Siz${ti*~e4c?*|dWLejL;DkN3 zxr@~4g;Zc0_!LBUR%X=BYj;>B?_^qvATC0CPLPInYjV+|sE|7khz?deP<=M*Gbnnx z>>R*_I&5IDpBcm71WqU|JomKUIfSyd9C5lcF6R;N5jH;~Uurfom)UQ3>lj}m+NrBRci%TVNgoa>4{prF= zXS0w|NN6b{b28?yfdvcZ2Vz+`mLhl7QTl89#HMa!9fFmZii2eU!yfr&>t=VK;q$TGHs9ibO!{jo%*pvPr)f7dD@+w z5DS>nnZGWuQ@#Q$0~~3tLO@9<A6v@6wKURMcii)5bBgf0)~^1;TZf{z!muE0gg?wtRBR+^$qJ}LWHode?H z)K5@GO-=MGD%ekNTK@M5x2Y zI!!xdZ`ttJo00x-KTta5*!DczCE&f$n%^3x+O#pVDE=-7Ga9LR9T59$qX|l!HTaWl z9yaqy)XZ@?17aV4Kx^fpj~n63KEj4q18Xz}U1Z{PUQ%8W2p3?Y%BoD?Tdr4AR1w?_ z4qOx2+}|~<^fv4b)gM>(=4vm*wxv$+OthMB&7=WgJQ4fa5zK}Mo($(5ht3NS+&x;% z(nzAv%TyJ$;w?z_)41{ zenuB~KPJrm*{~^l07srMA18tpreh!(1A-tv&3=Ia5e6244(4>vt9&I=k6l!tbljkg zm6A!l1VK-I=~$d)FbPmAE0Lt(-RfiCiJ6ZA!T5}S?U(n095<&5JX>%g7tZNT+QwJy zI@T8P8@(&Gu5*SiceWUpC_Ye6M*#IsIpS{=No~9Qj1jWX!_#ZJu~}Tbq7Ab(Bfex@ zDap{ZFEYJ>myjd<8s9hTSRZJbK)QO+gC=89YRS0M7fttSNPK<@(M%1S)2csepBM8X zxcjkx&i4}NadivCUuG$}TX>;gj&=PMr9h0JQtgOr0|i0m#1E8Dsat&lIj7RkEHCZ< z@TtL6kPq&4Q;y6Jh@4bsJs)YP%E?k13@Q@-K+&uO;#Zj+RO38du!51e8^M5|^fM)wsE7!@*VsaTf6P#tM32ve>}?ZBHNMvOsyEIDaHVyr zlMK|^%Y&pni;Y)3MOZ#FNc%WOKY61LYzaG@@LbQCk;>2S8ENmf)S0JDY1RTKzPP_M zR=VEYf^TIXVQkO_;F!g|8^Rh+?e@YZGmJyY6zp0~+DKdPBq6yU-V$(-(TtrNex(3^ z3}`K;c&qkWiQUlE-LThPUFa2Z0N+humj}p2S$`&JXL$n27zVKh`A@|$)+iwyH|zxr z5GnCFf`aFX6`~emEvlRMk9+!w76}Wv@eERmC(u&B0gVv^tCw`P1xP!veoNnZ3Ny^` zz@Wyc?}MlBv>87}LK66y0MvX7WDE~~R|M<6zh5o5dS!XC$`c;Wl<9fPN*eVep=cr8 zTG^u2m&DO&egrW#Qxa_Nh7U5WC=J!SJxOQzh-&)jg>&!TD{&TOE-I~NSGNOy%2Jat zWq)-xVF1{0zqWNEmJ~(Caue}Z=}-*X3{sps(iy0w&Add-Y3*8Qm{}k) zEre?8vD(+y(`rND&+FG_G%s#%}0CC^vFKdrM+H*pX|{# zllV;E*+jr4ZD!_K(|HaWv{4)fLL zOhUj@yzM#X7M7^6p%k2dZZ;JoRDqp7^{lK9npzaKfQh2^Dorr)Olb=O8`daWTvciz zk_T>v)~Mp+MbHMp6yHGcxI1Su1yWD|a4?qvkPT){i4iLzf%$qWbNaO3Y8EqA+#XtNgp`P!bfwuEe}*JP56zww|=@rXZ8 zRS56+#-{-^%5+jMG70^0Kq168_e25%t$@!YqUeY{xbeD2`9>n?#(qks**14u*X(iV zhngvUkq$N~y)uY@ZjeoA%M4x8Fhi&#kRN7fid#&Zem$_j3 zDs=kUjpU8UA623xc)@jfgt>6V^$R>lX%M=~5GdMebZT=n^KU$Me$iHdbL%G1w9we;rEjGr_kHak#gX9}QiK5{J9{IS@v%{bZ;6tqV9oVKxlxjaOej({-4LfKn!2gat; zXP5{WhujD~KChI!kw;dAVO3|)$HJ^IoigmS(t1J+Hs-x&D|OrLj*57`4Z=rE8DTe+ zuKnFNSM3v%J$x1-^mx~um}U3mwGBb6D)%4Gd@c;y-_r%E@T2RUi79z*iijgyt!Wgvix=;efTd zEYB6bqroqD+I1BAgnrADD83 z*Zl}4aY7H+56p3EM0+FaLq*Qx$YvIIeDy^#3U$dbIpJ9&`1siUwG57l?QZO?DdKaT ztw6wQ5Ys?7P!-+Wf2DzQ#0`7?z>D1RFKV2dUxq>Z=-EFp>^99OEcR6KrG~GBCYKgN z8oybGYp_U)Vm#*%u zq=-gq+|7wZRBbbc2gP>(RamLG=W?iJ>}+gdIF)r?-E-#CPqO8PrNvlLf5CxudKx?d zdiY6EGu+V|?4V@GscY=NPeblUo7_Nn?e@ZdjB5At!&g;2Mku0Y=`@BtV)8orY3J-( z%k~cOY`9|~bNiA!_61Y?*AbZBUdi*AO0#C%PH1;1zf)pfJmR}k__?UKo*Ijdh&)fn zl}dZCjV~W4^k|w`lkbMJCY>J!mUCh8%OP#R(B!BHlt5+^u+ zc5wrHEyOY7>E(2b_SDMV7LB;kLG?#T^p)WIygqE%LD_NhCs;d}@7C42v*rB2$yJUF zBZc$k1*l6Fm6gfjBDmq^`3?997n}hrSd~oSq0i&^BG@R#5qH0Kv94xhHJDjR-sxln zg2I)ydqZL{{q<`hrRPq?cc;WDJ;?`uXv7s{YKy}923Ro};b3JAZpO!gQl}ulyFL`G z{mr2vF4Y|+PJj!qf*+R9?2v|emmebD3_vl0n#1Ok8W33cl4f+e>B7t8MU-5nv5+Ih zzMQw|$t>mgr#>6DZ^rRvEVCW;=Sc2iMEzow_XizEJ`}u7GA38M+h?)Zcg?PU66<~W zAievru$PW~>8KodaQ*b7BN@`N#kF2Ho#HHRlIWNJm&{sr{VFwI@T@OHYI2F&6WB9HUNW{gx}-@%cDS20)nklnlYynuud-{= zQ$c)R*;4@@06aP<3cdJ;!^6`!h&7RGp-LWe0j9OQSTi2exp{7b@ZxPs$U1(M%;+=z0ljrC6nU<_Ry22#yw{Aw2 zZ$Gi47k3Y0hi}~Y+bluA5@;uHp{;JU+%g7B zopo?kr&*h(v>$?Tj5FW^!pnxT4_z^$=ktoABP~)KcLif@Gahv1C=StG5T3KSPzOX! zUjn@BXp>7zz>oHSHPmwVc{MxjLo<9ynE@}NWL^^Y3JBC}K7^!y|1b!SKAIUd`RgUv z6Tg4664H3J-!3;fak69TuqY$CF3nJp04xV?Rkyb8oMd0u{YttQW&$7(+;~#!D>}E} z`XtLv69lRACYpf9ed{!#mz~4{?vu4_CaBS=a3e4)Ps;|H+13mbHU{66dK6oRoL;W+ zJR8G=y2&`r7rfbj=sk42J9R@|hSS>u2Nw2EVKT$T3t;nKFQ?}85@O?VY4^(wuX3^S zEE1TLqHUHkUV>7K)*DmF(<&IUjb1rU^%ZZ!hxDDxL-ho3wwna9fGIj(_ki`Z5wFG0 zw7f$2^u$>;5IUENPJ3cr!}HIWi{8fI0;S1j2(rD)2(b!(M!0;-#d2X(DoX3^3MwR6 z!#1671^hNH4Z;qAc4m@{i(Kv{T4jP?0Oifz3CAk6^K5m?g*Hv>wq=>i{m$an%JD;` z7oaO_Z^Fyx+^rZHW*XipMLg;aA+QtUAb!2NCkei)`vPrJ?bEu`8>>PWss2$NmPziV zO3_Ns4@xqB$7DqG3x~$A5hZKX06Z~ml6}VRupcf9Af&g0yC^BL`N%#$H}Zpn8{l4@ zQ0a0ex27z1S?4MMcHL1ubUc$!DdR<}QP)mYdmr@AsnMLQ<%zI&#G^Tf3!8N})FIWb zQTT8EP86HTE;S1{B)lYIW?nvd0tMtLvQ8^{hdmvC0Edy7?z#zH*G2F45yLFin#V8? z41oFa$ZGmBZqAuxl;FLpoeAr|N2v|S43=^kqPSb-)Y(KLr@{Ay zC#fiZ%gm|XTjBiym*V)RLNbMC&k#H~C~S*U^UrQY)y5M!;F8#kH$P3vFsM7)lo%2R zEK|v`k7nC~?GX(MlM^a}hK(T9({|el?Jkb6fk<~nz(iG+`#D}@6|Y@@xs)KZQ5q^E z!ff@Y4N<%*B_maD9*}Tf;#cRP9(x$%_i!bD#Gz_vs+cEK6!|2qsOa6czFAQO--JP9 zxi@I=%!zOtYLHv%-TB8rYb%dkmqM~tuxevAm(}P5SMARvkocF@`EJfBuv9a;n_(~6 zu1`MqEXm7~ys?c$qe_+MP6a}eBwSEB!yknO%2X4coUg}8F>eW-q8MFQF=3Ub4R5c1 zR9@m2NFYs=mQ+&)Opzu^Ew&U)*7GEL-DE{A3;N8cb2wz_go}I<4v4#p!+{nF`AefB zrC#&LO;%R@*(s*hQmD7QeBEQvk%hVcWZeefZ92?Z*DY4B(Iwb-%|84Ceu)|?YeVw& z=Q)jP_df%HLi_8-11k`D(o+W>OyXL95nQ!G0<>+{N#liRPShah?P16BXN=w@Ir!GQaB00% zpdB^07|2bHC(-mI*jP5i9&nq$z^H#1$WtwUk@m`o zYB~q7k`-&**(lb&D88EHIby|hrzQP+7ymDu#EAd#+T^|10{|ote>@?diC!g>!HkD} zNR4s1d&#C&oj{TO_1QM_-&p*;INv;|h0oQtozKyN4sF`ZcA1Ui4v zne?enJ#<`LLHvWCJfmdj>_f(g7@K1uD!`=PRR>Gi2@}D-x2h>HX8cHC_;(!$$ceXK z4Nw+!`gMM&caqIl>B;O8w0c(OLkx+V8HZ1!=bpL zSPM5BF;%s(&~mD9T;f@OzDruJm+ZbKr8KW)6k%Yu(`Iz?V8U?vGG0KcQu$qBS&ZQ~ zV~3(2H`>7*fJC9@h7Dwem|36x@`aUk-x-x!xpb(<$9kQ#rUYa5_~*|moEhU%WR5)8 zb#hC48C}5-tp7wi^*cQ><|O>qbNpD$x0D@~VfBNo7Ki9R$DcZXLexjsO<{Fw@NY6<5YQG_|`A5FU#l9cQ7>piA z`D9k%JMGn1@QU+)-BA6>o?-Fajaqe~wFb`GAGz}iMd#_tEjM>aZpvxw+=_khdga=L zY6o6wN*k?FAsZV|q4U?*Zy+>g-&6R^e;o@pBsUH0!$~fZ3WUD;e zbWustO6gL6Du!x3*MQ_1R?=Lu*E4;VZxJo-;wq9MOX*TPqUjY}l-avPCkrqm;gFN1 zPn;r4Xc5r^=mR|0b?-3jHczR=?Xz(W56`Q9m8w=zKoVy2&Z^m^*#feK_%}^X0s&S0 ziG&qeLN5&IT5q7%{v=GrWM{)P8#HMySh;X6z9lh#g~w|~!F8xetZ=KjEnI!45`Oaj zdS(WGghrxJ{JgMWVqkiSqS`(znJvYi_t3huc*BI{P7uhY2tkEm!Z_+r(K2eQ#D(boV9V%QECR>^;;a>0@GJ5@DqC# z&Bug)6np^;?kWM6A!yIPEb$wA!{y@ zkQE5V95IuQBmcwqReR%l^2aFs>tYfBP<*?@{O003cC-rtlfgx1KXj(7$@LkjNb?ZP z6Y2@q4nRkK@XqGK4`Fmz-ChgpbVkZuHmOB_3`M?Jo3T|UDD(ci_7wg+fA&Sb*2m{t4pF-+Ku(l6}65Cb!@~1FZ zBjyjU_1z38aA<2_c-h%Q=UnWa&Jl%ETq56mnxVZT5PTWN6%dVcd-L-_OuV+uxBDteEpHW0EF&UZu^ zosF}bD>Tg@WYouWxyJ4{IoeO4Y#kkc;cZ~B3-dFQgX1~cB0@l>J6KEACq777dayPw5;I2K0l&qRznz`A8rTkrx@-cD<{A8gJrI z;ErKmEK3dov#J8k#%qN-E%y2^7{@7@wM2N@+NaC3-*qlxH@RVi4vaWk=(8uD$JrLF zp&t6%`Mx@QVeq;7Bg3E662DiO#P2eMtgU-{RRW={{RGs=djRXA*ONa5w@%<%cA* zk;gqaW=fNW5ISILM~7>Tjz*5*-ldg8nX%A>ng>T=&q{VBF|Tf(`Vx0%G8D+E?<|WX zf;Lu~?#Qdltos|Gha&hWC1^ieC7s!8TS`99HlTB8DDYHfr$~QATV>@n<*FqkQ-Pb0Dnio3WpG8 z$#Fs0pA}a$m^V~&NGM*ry>Bp*9vPsRfVzWjivQmgh<|8G`qA-;^BO--I)Cr2wTvMj zo-f=PI&?J^iKAhAe2yE3fH)*Gq%sXxmob<>A;P zo#eE0W~L$pioTaS`NsHHN97qiy`O^|Z@DHiQU&}``}fRwc?r&`+kW3ahURSzkd?yn zZW%pTNF$gOo0nYjG1Ij`cxi3QlfBoyu?HkdJ77%M=z2{tjfq0Ha$M1Wo*Qn16xZLb z?q-*_TcmIHNO^sK>(4*-hN<>W#GotLsXNz=LsLpx@WL1;jj!;@lQEg2xh#<*SXx$%_js%UwCwQNsmk?!XrQvr?vMWg2> z{Lz>gEHXF9z|b4!e_K*WI>ABEdfw=L4Y2n9sLD)~s*Rj*j4R6PkA)trk8 zSLIJ~OEKAhUfBs~vML&JQ;oC0yktKuh1>Jq=N&%er)}D=^6vp()y)d+bOxDsgK+&K z#8?Ifmg*2({6`(3pdiK_!S))bY$NWvO!Y0=1=zL!RS99(0is>)kc7{vEXQZP9epf8ljFEPApZYyiFAOia6x)Y$$d_ar`jCrfL&cl67Y8vEbZ{nh?IfMU z1DW%Wr9Zeh^oCayld3fDW4K$CDyO@akw=7sp8sdm6_TDDZ*cfokG7ufOjZ>ZSsKv5 zrGburoNF+HUS zW{pSSUK!`qPbC}cTfk1cajd>QtCo0Q(t9~OQ5cc6K#1fk+6g6&P{QYgKtZ`0OAsN% zvN*+Lvu`T5o?g;5HgOF1X+2doqNPyv3N2^&EsKSb_~7U4y$v!BZVXG%?RXoz#Hu%c zC3R{Zskx!#X!=(kGNS5D5rGQRXON|VRi!o}9N-%`&c5c1jq{T6$qj-4XPUWM$#>~; zga(CZX$8i$UNGb?1!-bl4Mn8~6aqd28Oa*YloAU29I>eGsE*~;(q-{(dM3JK7 zdj3$TNF!+zTm?FX_EU2H!^f3?R?Y!`bK?`iQmwWj<;mC%nQ57Zz5MGg)v}Rca5Dw~ zLMHt*dg#-3|1)O9bx9D5W_H;#7PH-iukoHP0w4Q#K(BCO=UnzjUGH^e&2%--?P0Id zkl(d>=~?xw`A(Mz6Ihp6IYRZn4~%U;ecE?X!EcQt#3?!t8?wv z?Q!e_J$WK`ju*V0dXXa`C&Lth@Q$e#mQ;iuJQ0<`o+qKQ$b~qnqQNWxuw90JXEZy? zOmVdgADd)h<(;7p4Y3@$7%3wj3GEgOQ|b^`9ff1Lukl)1l*ap^c@8kFlj6a_Sk;tb zVIM*^0rW|JUB|;(G(Iw8(qoN(j&~t}$f~j1HqF|Ib*u8JG?Vs;X=>U?W_i|w0k6$< zKx=)=8G@xNMfgX9*lDh-d!#gh?rjs7nYx%GErIFiRL=e(&3kgC4^n`oPrVO+%Q*DK zP?4T61L|}e&&+%^wts;VRJi9LWTX$%Xx)sMn!TkIh1Mg#5@&!|d#v(*KL;4V%57n| zp77|jgG^kWNNH-pG%7p1asT2R0~S*m2Hggq5&DXAZr68@+t2W5#&u6 zv$=f7k^AtNG}5O_qE=XcHv1S;YrEQ%Qe^Rv0hisJ?T$?FNWRHZ_4+FKZbk9Mg&exl zlM3K@o5c@FfS3Y*t;WxvG{K-Yho@+wF!K=ZLLFNq4kHnD?iY9}8)>>!_q`j!r9kKv z{zuUszXVR1O(qMzUyG9sUn}v>6plvih5N@13)ENnC@h+XFDCbYgynj;J-E+G*UHPs zqO_Bct}*2kRIkr5;c)_S6Ted1TY0{Q-TQP}Tv(;e;|y`D1$PfdeLMBMwJ&kbvzOf8 z6eQZ6X!u}AvfsQMHc>NUMN^O49F5b38jFVZ@tKpCgGo*SZQv!G_NN57BE;sS*Py!P z4hbB=)kR?wX(8i(m{e=6@sA95{%S{()H@+PnRo}?zyB+|s(7?VD%jT)qGF1_p0u}l zH8yv*y;T77#gF!Kn@qe=0C(LG(e_}#bJ)E#>3cHWNUs-kb&RS;U*Nxcl)0|eA8hxj zPfA6gd_Qqq%pDM0&rVIASv7#mUAhE?H#(rFMO3ld0G=FwZez>k+AY9$wBt{h%+Gyy zo%0Y(AWJRlakqMpDX?>`7%aGCF*Ut+&~H%|_{^T*SJQ|Nc5j(#bk7ObGCXre#s!;t zj5225$==Hm0bPd)*8fu)aZ^W>%Vi3dm4Q} zohmw~xl;Fkm2M!!DJ0rX`HhtgUPRAm0B=(b$uT5B3_a~<7N4m~PB|(%FG?3S9XeVV z8+(2HzO*USh7OyB2e{JI;n4axQR<2%-G_!tQCMU_c)eqU^Q9X`tk0XORzR)O|$T`92nMuu0Y_f&O)W*w%r}5EtkRfbP8E4cT3QX~el! zm>jlD1?gqIoq5DbatwfnN`F+L)(DM3ec}+`sceW^P1??3IU8nETnki-Y*o)&1A1l!hv8|91EIyp2jFN5tt4o{7b7UZ9t^qDUnTc7?LiRvz zFzAk4hS{d=;c<0%HiIbIjPPsAgs7D35;RW3{3qOfib?z!uLgU-YCBfp|mMk0fi9^$WIYH@6FZn zi~lQe-6TU9K<`u@kKlTt{V!lmEZJ22>Z6aTP9^73+ia4L=u%Mhjh*YB`AF><*|83P zaH3u!Qnu3I*-PcutiHoclv0Hnuk~{NsSYo5S6`KzmlV@^sf8;f5B!LgUv7!gE8K4G zBhi!*@eUL-SDHqn=0r`+(I+^*k*G<^M=WO9kk~VAaWbnwjEzzy{f$)f2K#BJ6V%sM zCBa0QBzwEJ<)>hhn;hXdG{~--%8RjoZak;1Zu(&6KE<5a{e+2p=c);vtpJn^dy#nf zPY3{g=pB~u>z*93H_fTx#lkB7i9u(7sMTl;R1VU_7htsX@cxxRzHJP}0kI2t3&VUx6NsmOvjstY z>J+{8ImUn~e=SCtE)G(qzml^{p_qh5*g8k5DAz#cjoLsHDclzr$lVdYKJ%|}5xzBm zbwQh&#OOCfWG>GbMWI$dt^f|;tAcfjl~2fBHpAy_v>A9zRSkWp;8b!#9ee;YoicH| zLmnM0>4N97#5}?Or7XV>6}Xsx9iNDi0e+tE@l#slC5SzEy861=9niz@k%&`8uzI6q zLV^14h(s`XA4*dxc!F!+zIUzROpyUGhP%pc3-s8$%r1e;1NEjMr8o5@r{%B^;e)+E zP|6@Y8C%31e1+T40SMR>6hDkba&|8aw>EiysEYkd$u~d(NeU?$yx9k(+QO>EoYX$& zS+(Cr9L*#rP~@|Ve4zU36z7Oo?8>Rq^%{mWXIq=dd?cx`Mq5J!(9aO>Op(lkaf}?- zxKDc#UH1`6kwXZZUwD~+TgCn)l0{b}`YY~VJ~V(I4?`hoP&`%xwU0#huR{q@2F>yA zzU&(VV$!oosoZ1tdaoL-?!}NrS!bEFwyq}`DkT{st_%`9E(f)fEtLRs7^vo4(mbb% zf3lqZ&@HE15oX@`iLp+XIYN0X+hLv^+kSI%FAA&O}CQ z-*ajb29;l}=()?VWh4}y`D!UnlVf%WoPq1TKWTzk>KNDuB!Z&+;vwJ@m&Tu5n+Xft=xSJ!sY%nupXYt+2UtyXPueeKuO}8 zD!8ev{BMu*-14`7oa}vXjx6iyOQhpqtq*+SS{C{4evjw_Ah}PZKlY^YCat@4F?ApC;BYsaPRi)` zP2+9@$D~)-QJt|EYBoxwo_WvMBXCG`GC`Nv)AOyK=Xu6|=OL4?S^>+Kh~HA9&taFr z;W5*j$=NC7$s0N@K?Dl6_+#*TPP=$cRaT_=$?j7T2YcmUjccOLj>!(ZEGi5R>K@AN zwGFtJ<%U^HjDU;YgHzJ%ovlsXYdSR`ZwrPCjlkn}#q-7a`gpz_d`M2LS+UgMn9$?1 zG#m43F(TK0b?W3KMt=Gi_nMQj=nA79;`~(FFwpR(7d54HyRrc z0)la<{fUL2nFklX_5aOdk3n9WU4o{Zet%UeIA(f(J6ffukov8OkY_$ugMt3rLI~L? zqH4NXg{W2`gSS?)dZ4|G;TSH4N2!z^$o={NsSQ{Ed!t{*hl55PvI;gZ{#62l|MUm@ zQK0FJzgh$W-s=2{F*#|}Kp1ck$}|%^V>v|Y|98{no%dvzjH?DAxitdHiR3DU@CRTA z8eG%}17c zC_Mw%(`1Tu#%osB{e=`#3?HsfR8~?NkW7<-*_m+-hD;M& z8YA&+Vw2mL`w>X1_hm9h8%qjphoyXf7k~PH+4~QUT>@{`%SaYS55nFgedww+*5AA7r)=>Ug5cTFWU@ok$xlYIAAWOU21(&+2W%UIzbB*a z`^+5%;KLp;X@B^1z_xv~X)o`_w>Y9Z2{K{1Lh~zRKSs$r0RfKys^VB?#v`y+=fC7q!C^iS_sMo3E_!<*Z3QMAKaRfX&TU>+EHC&i|&{2%jeFt%}zJ; znk00Nl5MJy1dggXQ2i~(kAtWjv0veKuj9&N&$hIOAev;E*ePUIK5XWMewFI z0MF4}St$=-3hkss;Dp)Abwmr#y>)4TJ3S-d6;j=&B^N<1oG)1->kO!(93(>>U58Lgm)87Z>~R%zFyd zsPWI6g9AnFPzt~L!C%FEvi;v@-i?X3cT@)qk+p(vhMtuyQp%ZFz<=#pwE79aO`OBG z1N;|h$5V&E44(PYw+7X#|KKQp!2Dv_0O=hC_(;3J*_^Wnc?-S+Do_+jhI0*VYXOI+ zl)3zt(1%?*1`nM*7?2R$Qn<20suxn%Qu)PCcA6&hC+5mgFfY#T5le0owg?O=vbl*gbBeEHXZbYHum`$*o| z*O(5R+SPq|f}YuJ>XB!kmjL_q5|a3hnwnclO;|8>(9+(NRPwRbE1+;ba?Ud!AMt!a z^%U&_7ezaH3Y8Ss!YFSS#N!iWdm9v*ILkpjW~9|rnI(ivcr(UeNffCN*@ON=>-zvy zH^1QgP7_@CS=bSYtQ9JMB-zcecv03BwAN+A10L~`Ke!>*OWw}OTJHwuZ6+&r+TX+t z+`oM)gGt$^;LLzB8QrHlt(RbTpu`k3BfH+r6WI4kdlC`_yvc;}NG+u*}?I=uaxAFD^!8o(l$3THC(#K1@zHn?4 zxxytn6TuThrkF5MTjr1BCHbG&rRG$&Vr~XJVDxc%(gHg6H)WZclY%zMIVN4+k{a(o0JdCHn* zm&2$cx4j@qp7Nze0%}!}roB(Zy5Or*!y`DW16%5?ab8AE*_!1WGS$ulyU8x?aE;7u^m9pd1Qx5`_GOC2$QsI&U~BnM$IVjVW`g8wxl;x_-n|OI?KSNm zc>bP`nyll0JC~h%-mz-67i?cc&s~Aa><=ADOlCDgo(FbvCF`nCsK*-^c~^~~h!?it zuiMAmn;6F!)|wCE8YTK`!3E$Lh3qZZ*(&$6E5bE4f`~**Iw`Y0u;~q^qnXzSYGhX|DbM4_aZ$ov^)dXpCr7{LPIpb`( zS-L(CcTgJu+;$T?#E&$~WSZsn<9D|j++wH?%c|n5K`WGM;TwpnQE3JH$VE7bI9{x# z3HoL$ljkIjSw{Ul)7OoM!vupD(2PZS??Og8>IlFCCG)= zEG~iyG6ijSk}w>!8i3#mTK1V*P;y=;8-vJ5uJfNs8`C{){-rx*xm&OUQ=1GT^P3Z2 z(vs{cf8kg+p|=vL#)lOFC6&g1spvew(4GzB_RBE*O5;e4+Ht|L*o$dv>cDZe`k0~r z=EfIY3-&fLaQ?OuK^yfd(abQ?U9NY242_lk)7@fzJ1vn(-d!p-kgaI(*1sg327Ymx z@k+Y-xCchhM64RP;2JwSvbffV2ejTHT`EG*f8h*X2lw-PbCcjA6@FoRD@{hX*kw-x z!UK0#@${S5f28l?GeA1=6c}J&=kl<-;1H;yd}9>|2&UYidP->y@8gq;qshgE@9D;p zuphHcU^bZKsqa;vccjR^!#yHtU);g?&n#L)mlCRH+)g*G$lFx_A9xxBc8^Frn*szW ze}Qf6pECG`Hq?p-?|w5Vjo2L3gckyu;V~10MCHqLXCS>@aNuSGd|$|6KdD`77F($( zFm({KT4S@+el9zlSITJ^M#o#+T=q@?Fc*F~$Y9y|rLb@*9;f9q8kpqwiVR|++`Tp`w}P3|cxy=F+AVwkyD ziw*6y`cv%d6xnP7*!E&uil-aql(e{*Ov zhfpb)&LLrDL#-qmvc{b1`+6j-0x>RS*ofUYDB7;&XVjlGxFQNTYlIKP9#3r9 zHqn;h^11J*zb6UGui#ECVGQ`@(2acvrf0ajsDZk$1*-jAx#b{T8)9MVe@q@=-M^0R z0NoV=zmlnH$q_-V(s4&x#9d{6mpQX-s8wz!np$*dTIGh17GLqBx+N_UiDa3i34r|OW*b=n$tV2YI9Ju8uhT#r&}D~G zg9aUi_;(P%hf!bmaYc%`%mdmSTVDLk6FL{Ar-e>jf*$nJe;vO0Rt2x-QygC@!5tOl zoa}eg7J3TsU};Urm_@8>ss6)3`OxnkU4ml$rK%iWB<>eQypmRjz#1{2)!FyiM&55(%2?)1{8vL7CQ&Z*rO8tPj)MIygE-f7lT*P!L19HqW=v%JFJ$pO4HyVIDN#PEBrQc)(=iiC1iVg*HMKWHPE& zJx*9R=@|qh$YYkURc5f2o%i5G9t@zB09eq&@e0>$wMpT`F^3?V+JQ1da_VZv+jmq=)RiU2&Y9UpvjcAj_@8`vRO#tr z=cpYQizFo$dOI~GlbP_fcD~E|r*RT>U9r#jT_@A=*jSUZFo6LXikb+C#KXG@Ga>Qw zygYAtew3%?y$`!K6P@NFgqao0Mn9_Am&nKBinhc3dFI$&3- zmIdou`a;kZg1C%}rTU4ju^dM2viGU%jE+qK2@5uiE zdFeuKT~SFSe7OCjwAhNz6!iGZdpfo@-Y=P0xE=>*@ztn(;-=?)J@92`f(DtHSZ?XMT7mT&{ zD{a*;K|xSw;byB$=bXiL6)uX%erOz+difR}A(U5_VL>Of~o~ ze{&vKo|U7pO(v+MCl&(^7_Z{Nqocd)>W!8LAI`wI`ZF~VXqqpbb&G9DecG6wwY@BZ z0f(Zde7ivompST!Q(32?Cq;NT{X2krE*XS~E7TayP^Iqzm*H|6Bj^vuS-*j>8216| z?$hShN<8hpZ_q+7&t{S&##5r+)Pkl7tneOFX&7%RAP!e>*;MKiaFaQK3937USo7%8H$0u{0EC7ChGSi4rpW)# ztJhC=jAUEl+aa%Zp$5t?a(Mm5e_Ds!3dBA{I)#E2u%UyDiHzxZk{iCdxWwMroP96; zrs}f1GQx%nDdXW!qPfl&>exj*3QWxP%aSly4EG1KjB~nVK(lE02#8eeQ(jU2*%H#V zpKu#t<1i#o5olamRm#a=ooWu#fc$lUTybWqYXkDxX3-$0X})ogB0p$re_Hkcb{Z}y zi`~>dqxZy9+rM`*+>mhZUBh_Ok{5hlXO6MeO@GesP4{ zsLAq_fRrt7mgAZxe>(eie-AwjG;N2d+?NYRegvCq7%t^B-50ljBqEmEjBN8s<}b}P3I8AAeuTL`FjSk$CytnK_Sm4SJ@rPI1B;@2lsFQwk{ zO<7!H*qAsOwnP5!ju{v=$yKq3i1cnt8g(4k0=KdqxsN)lBi4kxe|d<&=o*3sj=2IJ zud`vEY?I5sj3l%O7e($l0msR;)kE6}MNTu-lYC?FFc7~jMiwHC#^wexZDiHg;thl3 zWtc~EXQXU&CIz@hu6b#dZyH#u`!tQ=&zuR*F}Qvbu(ow$L1wzLgK7M#={HxQLZx@o z3wBE9w$*{C@os`(f7wrCt5zhpWmpHHc zdZ8Oeo|_CB5@*yvZa_)NB+mEFOq3OScfb%70SgsX)8e4Y0_ZOn{3^Erb)MVB%6%N` zIdz334pRMfaH{RB)s{rM{xz#Fi6a>XXz_}7W8^McB0(m8fACMQXd~%S1dujsphM!F zVJb|{KOCH>?4$LE)Y}OZV=B9zDK3i7F ze8tk4rtv06Wv3<^=~Cwh)H?1yg4jUsi^;qXNaFwsF9dVt$|LVRreeM@d6&RgHpKtvYf;8Aj-xO_X_b76Sdxi}x!mvtb`iz(N1l$-b0+J3 z8+m}`0VE>I41%s{ATN^5N9!iB%1;l6lhti&%1A9YYRPe?8rncg=^|a^zE?#QAQaT~}Z%mU$!y0F&|4 z-B2^)8weY3nYAdZzp-`6P7jZ$Alum;Nb-II$c1|;c~&3;emrSpX6LVSdYDp;C(s1x zkEcL2_nvyU2kg&gi0ew~NPy6#w9Yo3aBfjqT(7S6kf(HgW-}8WXdnsF|0Z zj(1Rf?t$ScZiH)CF=_9D;8Hsu0EMSV)t>)ehh9I;zca~M(8vfx!^*1ZrNF^tW26lu zI2B96%TlJ2$tr;pL;Da<@i3d>(3@D)3a>Z(5O`}naOCl=we47Ac6N+5eoEa4EFW@^cI`2KyS#fe`_wG)r)Iy-gVt={B9@9lrt1w z!43BrDsi6S=SDwMs~?)2yh(CKI(F`;_+(f$L4Rj8-8xm1T(m0-8ca>o2Bn7HYxiV7 zO0w{B3ks7&`7=5Ecs+Nre;gw$x-H_+h@Nx2kGg?8_rI;k6`<2zGyqM+(KFr;a*uqM z68MCYW!vqMgS6qXU-OCpb9i5jcXSoit{ILknp@4a8tQZs$Pdc6=VR_o#>P|>&i|_z zit;#7t-z1}r2u8i8Q5)KXYhHWg|a%QpAtK4T+L{2Ww82a88aM&fBk?*_!57+VCR=7 zI5*V5T`ni_ih54lmTU4_vPijjXkxNau>qyO^gnh_z^z`eLk&4tWS{8Qmng!(Olys= zE>of`u70N3Kh>`Q(W)HoBt$$nU9uQB{mg(0lk0kG#KwNEpCBK0Rg?q~;gq)iEn-1& zpLXc(|CGTrJnD{Cf1x#>htj|O5WM^BEG0^qwC(11aFbUu{XvlT0-iM2seN?DmBBYZ zIDZO8Z@Yj$RaU`dLSn@7P$0~!D1)K zKOw?Nj@qkINi-Dm(xtE*@DjPeOvsx`Go;zEF^Lh3Ylw)qRD4f@HpuFhbJI`IE{>KT zF{y$RWXVY$7*omgfepFDi;qafZJ7(2NQv$HW6Y7c%Fsw38=6~{0{sGPtD%|?R!lM2 zL1$z+<2#G^e`UD02ZnD9i8)b|Jy&hqK9{~K4l?)~n@z}0PLSIT)=r?UKxopumwHiQ+U1F^%EV^mP9A!{ld_Y|XXhZf#xJsARMw^$? z7r|C_x;*pS+Ryyx$Zb85OlPI7gXLBg{=s`CN`5jI9%oB!R$ESXI@(#z?O*}Bif9g( zW0i>6f2;mYtY?7ipOBdg)|I~zaG9q;#~yRXO&+awML$rM3lA<;nI29a5#6q!nXU7F zf4ceQb}u_F+KZ=_Qv}TOE%4#Zq>k4U7;0FkjNXFq54-In9T2T zZm?9R!FGuIjgu4$N^R1;QwPse3Xu&(6a+)_n5*9v2lef?NmU4Hfi=RF+!Q1Jy)Ftu)MLW+v{iuGv(HSd2J>JT>cS?9f64ga`I;5@}Q*jSSUZ3T_;5L2tk9$ZaQIT#* zM=bodaZ8B2pUu1u%CbNsmH@^Ai(n1y!=Q&Y{~6k3_^T4%*A1x3(t~XqgpmAae~QGT zFix@8=Y$j{+pK?oBLGA)X_M5}IGho3zj5rEyWgaxx4nw42~j}Zhy~UB{YeRtZyEhp z|KPQXX}z>u3%#Fy0_#RoTXR$r>>m{&eM&V3{2ZlkbN^gDga;l7%|TIo@=BU|y~|D& z92d3`Y{eiUC)C^`CE+z#oka>me-qUPRn@uZYk%@VjOC4vPvS5Whe#)Q8=@{sa%rRB zFo?C7rK30Z5HUe+rKUgL9b;_ZBMFjxg7Y>hFFYU@+*H)<*@>#Y*wDjd9?R??LBt3m zhfzt)XebIWQ>Bpr3*JW9Q(?lu{F#HPW5K0nUQzgfe<%%mtYVwmhZU0{e^L>}3E69l zjX(2I%!@7S0m>EferU^>8T|l61k_HZ!jm_!f~d&l12^KiBi^NBer~S*NZ}cvBzJHc zA-;qiw+B0^0;`F~qW5wWq`%%Xg@(@}uFuKGqmX^N&5$V*T3jsK^-Qr?NM0k2ri_=H zMJq?FbyI5hxy7<|3iOcje>Dxw0dBoNnQ?x&5LwJ5fvfX=S1zRN8a{A>s&ok34Qex; zK>M@w3f_0ja`hU6BcpT@g^5YOA5NM6Zri}}%?a?)(D1nGYOoDzI2SBE?B9C;01g#7{LQ2pR!NpnXq-sT&oTSz``YKu~izl?v|*Qw;CMK2o6 zXe(A+F+?ao*9{O(SZ+Yn9hj6c-8}q{+7qy9JGcr!E-i_#yWuE*HcrklotF2Ug{}a} zhzY27Jwc>tT2Vame-LNvyo|+Dy@L9)Xsk?EzN$Bnu+A{EzMq$8Lx$MTjb>lpZRlog zzAaFtOw;9aDTGy*oxpZrk};vGo!IV=KznGF@RTG?St0>0DiNloS{p>Cf`$JbM-%1z zFNt23J9@QM>auN@nS3CE2ovrxu^=;c3T@!Ep-%OiViw84f4?Sjld4X@X*nKrAO~0~ zF^o^Qf5~>M^PSqbOa;k!t?W(>zdU@u10B1azC^xRB;sRCOHp)949Y$&r>gQ#=7bK;&GalYiYkZ9nsrNhMr5)DG!;_F?hzZmk;$CPGfR)h zHgZ)ouivq)b+Aj8!A%_plUfv|ma;}r^l zf^Bb(aRO-d7ey|+ge+)pgIovaT@K$0+(v$xy);W|srB|W>eGtj4I{`-k%zWx%7aI; zksTM|*c}0ZTO5ygzTAu(wI>kIoZv1~Cil6Z-1R)C43$?IkNC+}=w<6Tr-yX6FEnvK zyEi`Wf4EizvLpG?be&TfDhN4~AV6&Op$Ye%se>&SfF;^JR-gtqG;$lnm13Hxk2xlsJ z1>(U*LK6K% zb`hNeCU~vBr^T^038}C9b%sBr<}}%*u~PSXDG9x00xtbg=F^IAhKNh!eGF}7aL4KN ze_2~^bsJ3=x}kLEItim)89`%8pq!J_&wU|?Y5L5SN~uF@Q`*06M5FC}xWAb*#}uQj zdikv#MS5Fplh{nr)4rsX6O334czYc8!LK>yVA3>lM@gH)e#GhVryu`$c&z~bc@0^e zb^uQ^0zdN4B|!P|pFn^-JKow=S4FeIf5}^vGL>8VD(rzeo?akN=aKQN-TELG6}0hy zcy(%*S;sgwycZ!|IjTZy>(K&pc2`u1V!^Qy#LeyllV&?Pf7Fly z;R4Nye(SYXrm-j2hi!=EsZhf6XYT;-0n--GlerZb@87Ggm_MF0+q00K{$^G8LpW>v zscl6oi+Kf};x16^!)xlJ7$Fz3`P^J`+GDo-+?EuXEfF0)M#%e79q{5+n!ODJ$35mv zH%6;!)l~4>sOWi7HBIYKjZ<*9f0NTH*Z;kr%~`;{d`BZ+KJq)e$vTjCJ;Xb1)AEE( zl4x4+IyO)^F$im`l`thD>iy<+u}ADA$i)ADq%M-~KI~8i4=E{2&M&L>A>;+Po2=|r zGuw*rEhL7f4tRy{D)STqqAQ$-K>YDV&a_sIc9ZA?3VWoiZhZF|L+R~1e^wQ@D?fPZ z41=BR;{Ap-ga3l*7F}zbve=ALmpDrI$#h85Ii7{!*y`k&I5^AA3g6p>q*ct@h=-1Q zn7Bh0-nP)3X(V?Uk)=UuIQ{s%x^Z0KF}(@!B(xofq*x=)q zAmB5;1zC)Bfc@Y>q6hPKcV%4)AKnEqL?}t*C(SK#jP3?if;U!j4lZy=#3OMe;YK57pcLk24gdjLK zl6VGBrvA=n+#8|7%!#B|Jv&4Ge|GIn9R#!{tPmo&rSZYn6aEqs^ro=4&o}-?kjcT` z%33BF!85o+T^%C!MZUjHE##+h47Zhio6y(cXZdbAd7d1a+?of@-yI`UCy86;B_JBP z&yR4|?Y;LNJ}9{TF<{P;#~*5f+c?c>!$_ zf^+q9ghShU{5vo#Vc$uFm6^K@>ko%B{KL&VK&&xp@~lLO+-VIQd`qDJduu=f3(8^j{;9}pf!skUSgvwQbcZ% z!?dA3AlHlfeNb?D6_2b+?ZTQ)TNhgSFceP*Oi~+i`c6tiqf4IQ)!Dd*Po%^ry{?l! z!7n#H#`I*9*K);oEZz;%7hX24@DUhb@~Y>KR>g$BGljp|gIPCacsKRt2P!5=u;Bri zUYE}8f5gr?AI#1IOSL7@+SVPM+(RFuQz016|HYD3D!Jb(EaEn8dd2JHxzq#I_$G% zx1z$2@`55x?RCYF6FSOXb6ue=@HEplJ(A+;nxF5yDFBtt!VFbPWXPNNRm_vy{*vRI zf0~U4flhi~>a2F2yc3OtrT1S>^ake`d$j4860yhxt1u=YywQD&H0PgBTyY*&j3kb= zj=(-4nBr9UVgdbL(B?gOn+|@N^qqk=(7>73zHhpxSb+d-{>C8yx`oYCfEWy!*Re@c+w6ZUhg-JAax|T%0drNm#tSZ6AI?L>SL8#ompBri>8Z! z1pva&o}YjEvI@R(7IJsWAMXX-_^sJkcH(1knJUPxVXA;#9d<5)&;K5L=swX$k_?D)Kl?%tv_=393r^ zpQZLm&*tF`U*ZemehnU7OLsbs@02n0M*|i1 z1gXsvDBt;M5o=7=ZyqfCexWm=M}=y5e$drRw45DmhyFwi*4Rlpe?1Mpj-O~AxzGqB zOS~xV3F?vlB=5~T{MsSsk)@0a_RE_WfM24_0YVdM#n77G)$4Do=;?^~P^K&FCI=DE z_57R{_mqrfbEWI-J=Y}83Uh>0F=r;x&XQqsdV-JOoZ?@4Uxu*RtX9gsnOyMYD(T+$ ztUHW`@9u^*yFWGhe+|^35_lwpA;Qz{mlamgYkbk;%M{salkF!~YhfU!R=Picdk z#q!X$#6A#_8>Sf8eahOBet$vD7^~052DicXi8fR<*d%eQ+yh@?#A9a;7oN93s0d_Q z1$i~XiLvPjf4%xg1#ukTbme@v!G#c;%#0G27XPMD2}d*PZv}^DMsqqu&l50kPJ>z- z8;c2IVwA^iau-<)GrPX3u;>%0W+kc6fcEd2oUaZ~Qok1H-oyDH5%RV3H%LoWxT{bF zB|c$T{2jlHYHBv6;b`8{TvsOXV?UXp8qHEo&V{DPe`0_Lcmtw$x6Bym=y5qSuMbex z8SAl9rWksOQk814_*CA4Dj{e)ME7~HnHv)rgrN}d(I$Ku;UZe&gE*PwJ#NKZc1kVE zNMj~UHv;WHf?hu{%Z2Q#oPoIXTBT7nTx2`&dzBB2InqLEQ93Y9gSHTRW-dh#n4NGD zobcx5e^}u9!IWBxgTRt59geKFp#FLlT*m7?aP5Q5DADcgd)}pM9Ro33k-&?hk73aU z35$5x%MHIom(MeWvI1PT$#+&n6sXvEGV0O$~9X<7lIYRwrFR;X0>#qu;c-XLc~ctqz-T!y8G* zQJED?^lT%anPq5QDePU?TeZ1keWscK^s=Fx@+;00jGuhFpIuc&L8@f${V?nz@hnxo ze-d}{h!vG5Ws&S?*Reid=V-3iyoX@>kzsMMy>e&1u|6fEZDp-4>rK+9>zQj`}L5rFhgM*g%jB2e#z z=ZbD(k@7rlVQbvQcYRH3+tS=b3Z(eDe_hseNnc;TKvv)$GdFa3L=f~Pm}Li==W^s* z5Q2qD4*jvj-NVC}aUmRJ28(-%JUcc7+}88Q=gtM3S)_544{h5KVUMAJ)YI5Czd8C@ zE)~#R1#Vd$@KEfmrxS4W|33OB##Vco;}PR;gtU$`V3)q)<=jE(32Lpu#jw_se~pa0 zCroU9)f*RbwK@lvUDuYh-}fViT~JEne~ z*yM(&WEg0jOUoL-SGoGSdi@fDf6e(&8VVgw%yLDa{K2ifX$B_Afzv42Y6u#tf3!Sj6HKGP zd%QuwBj~{%|0lzYVJ>QT0n|Usn@bM$?9;niX)|kUhi#2BNe;t&6%!l%^<9)0Y$t$s zZU*l`Edo(Lk~K>hE~O6SJ)W2pGh)7XmY^Zhnnhmu!KR^F$Ye)a6aJvRE25k?XjYG7 zG4K64ovaioGiRyDUlGrUe|oRBSU&VK|I#T{wJF8njttGA%j4*yrEpB>CP~>{wd1ct zZs=sTtC2@w^VEnaIR{OkqKvehpNnUN-bR+&TmZYaE_}pxILf>E-)K?aw`cIbvfV3f z9XUqNO}=3^WOy{>{0Yg#p+AbYt`{D}-1Je%F+iuPFCz3{X{c%je-VBPm5qf4h@unV z?L|*+Ff}5+x#q*hREbP9Y!=xeU2!0&g%yfMk-r$>S2dS9dOAheI|R@`#FNS;f52!_ zre@?=)d?0$q|6Zby0jdEsYOC*Uxxf2}8lD_L8%w+&Pg^p9v$^V|2{2kW(Bz7BM`h{Q{tW11Gy+udUz z8>$yv3{56uH<>teB4DkoE&NB0eiahIHPTFZ8>>cQ9SB|Ve7<)MYjORiIt;|wr~`RT z30X%BRB;JpX&NhRnnd1y02tJ53u7F66~KX@=AJOtYJa(yywlOUvs5q7`)n$7gY)wiu5`<<6# zq&bV^Ju%pVaO}$;Qguvykx>YW3w)7%iQD`BHxd%ffJIh}bqy#MeMUBjgyku?H`oI9 z0#;Chiv}cWe-w`_&hd>A7)F=oRmG0OX=?}U%UdsvpHr7=PsTd5rtOZa7gTLH23^zs z`1It^$!mq?bEcp$C25I)BpSc_+jNL{@!sJuHPPTT%Blq#ItigBCD1$rn6TM!beuE( zKU0AL>xcyo`GhLsa`_aeEm~#p@a{7;IAKUeqZ9DqqGQTI`L|}t%G?v? zpgGWj9|F?BC5Jl;Rx37mCt}fF?5G=&OeQscm_8B1*gHyn6Y&`qT|y9pA?vFTp+~rO zi_RwBf3aw7cFOcq>zp(M)+5Rw<_T?kW7#k)xxvb`kjHjkG`mW77!5vTn;e3dh97Y{ zc3j??5^OSaT8J6ZztGp)z{^bwPN)&^HfHE|m2UR%JEEO4`@>^td?nAQN6-GU9HD7q zGIkNWx%p0E zisyg0-q!x2=~@{CZhL!Qk356 zOlCqN1t|6jLRn(Hxbu~yVLNxKR}VeQ4$j5rHdvI;F@s$932`VhnOu2@6opI3$Q17C z_6H&D>l7jv)^GMRP5?dyUxskXe<6U&8aSnZ!1jAm2~z7)Guy5PA5>~Z;H9d_4}}#+ z*dLimGn*YR*lp|3FzrulgiqGPmns2g?Af8)u;q;5z9{;Yo_|G!*5pzm7G_MyfBp0H z_L8m;n{sn2s?>wkN>Tg$+AVbGa`-NC0nazbx2z+E0acniLG;463Wm-!f6%4|;Le@R zOSozUnZMIS6BY{H&hR#*80@QXJeYNL6Q*ja=lngFL9WDfyi`|N52dI&+bgJ4qoL5t z4%3WyESSc5cRRDN|G;Pr>lbF|MmysMpL*j3U<#Qoa3L}1MNoo$1$@=Tv|E=! z)mA;I3k?7;2+UM1^TyAgfBH#~>DJL1q{mIH5UQ^A;fL~8>JF!VYDTAO@8$NZ@Lg%# z`?0yIAYxAHeA%PbBI=lBWQY=^+}5^Erm0+Z1;q>4@bGN_MdUDT)25Vm)t&?5?@ok@ z?n5X7^?RAqjuJqGKKZ9GWARq_12AWd6b{)-hiW95O?!-%W+{nfRB4&mPB|V!PQZK}AG$|`mg?z-LMIKhwQy9cX zX?Fn>>GxUCpIN!F+}})q=(&4a5NhpSYJ%*3biQT6B-;&nD`T>VWd~rK!CiHEDh!EP zCkVkPVscc)2aqJDf8Gfz=*Y=Thk(?KxUcKl*&?Q&BnncYhm(@6T#S1`Cq_!u2{rU! zQyXpo9JY!wJLd>SsQ~i_(>d_BeV`9Uz<@qYi+6W?ZW1Ggj^3HP+5HeiCq>vf4dGl$2s>vI8;ejd^PY% zz=fHxwoY#31Ifwbh?cT#d7j!HRV*}?B;g+!l!GgxvSrGu6|L< zYR+Oj=g!qf!T+R9IuO>dd@e37=ks3O_r#u0y3Gc`0L&?d&4k``i5iU`4_sixZk4_YN~W;H7(PJ$0q+kgM&08N3!=DSt`I z#p5Y1@4-Vf@5lz&o~95we=_+kfd(#Qkid zDGJ=ZXIa9fRe0YaPFL!Zju+N20S%n5(JzKq!v;EAk#i~Y7=e}IEPk?n*r|!tE~^7`Bt%(|84(cZOWYZCmR22NHzFq z3k&}xjwx}798^T46l1xeVVFKX)$NY6gGGiNw9|_2$x$%$Xc@y$Obq{Cc+#-MO-+5y zeJ?Xsf130Vb7r3mLE)@`cDai0GLz7XrL5|BceA6P10Y%k7cf^bE3T9=xZCage|`Yq2XmGqTbA-Nr4y|Ah?-O&F;ghD z7f+(>Lb;6XsZQ#v4%~-~wOiI&4#;yz&?g2Noo1owA7J}J-|`yk!Z`Kfst7Eb^49a5 zm#xM}c|X-k1qLrxt^tkGmeb7C(+IbO9@PBAlVs~XSRvqjbiA!GGM?dti9OINBEpEl zf9a$lne-Mks9hqPlmnav)%9?>7MHCdC0;wWCS7D`0t@R{x6YR>G zRIt1 zpEa4i8SxoTLr#>FVR|I)2oz)d`z2c-UDl%GEq?}D-%60D<<}-@)%b|sAca|3Z>iKf zujzDWP`V)8oqKyhJ%|mL>b!)bVA~Pu7B)4@5XD1MHlcd77VJCvw>S!q!xqs$f2#|S zJUi2Aa%9}<71tJgPpl3REJyxe;*`eNk6j;dKkZ%Rc=@o<*=tRTpsjtjqoGp{!LMcN zv+V{d`h8-eVQi?=y3Ofzp=(lRJKQ&BHj!VD)HwlUa|2GzQ*hOOue;b-r4x%&3S9MnPiYiPwB;sVrU2MGIdvguhv_DNl zF^h12lcuHEBSe{0zuT?W2m-`WWUxb6%=kcnD}^7-WT5WRl~TV@2eIy3_H|BiOMX?H_De+?gREf~o|4Ple_jsCyc1NPCa(smTK@nB7Q( zBhYByRe;7(es7V$tQ<9hS23=albl(%E|+;?_J1>l?Lo?(o8%EWTipOIKI6ZjA^jb2 zNEam=TJO9_U`l}nji`m4e;={{@tmO0G5@5xeUgd>t3bt!;a?}?-b5Nb!Ax^HOlPyvwLpfT@=M(N_7sMITV2;%_C z^SOMG{q`o%wB@Te8oYK}b=GYWWLVL<&anJXnTJ`#Ad}7Zzl5%X7si9owbg+iKN$7R zRxy1iV=HHQhrcKV3nNY4u}lKU zAPpkA7xjzzZF2VMsv|rXqxR!Y+GRG0@kaPPbtb-v7FhTxwZ^ci(X=CY? zj55y~jgb4Ff04V`3n_RR!k*}AzFXcTk>qVHQsFsaC9x0V?N;#5EFLB;gG;|82SdeC z7$mqAVreZemkg=*Gf_mhdiyfBg5;RZ85BuT)}7_xZr0X!v)j zipbxBm>;y>D{f&G#AzT1>MTiv2tE{J; z)Qz4!e-LhzWrk_hJur$(W_d7_H;P*YYXcMeyBD-{KX#_xpDP@kcixa&42 zZ=p*jv9_uaD8X0?gz%T0N0L0#?hGjx%TdBPJCWocHS!(;r+s0hh`c9)nJq4z1r#<$ zP0j4#>YU8U+0B25rH@8O0HWYu-y3-T%i?laf17;`M2ToFrSk%;)l&B?atSt0q2;jY zI~0Y?PP~(nr%?d)Q70o8_3pXT^!-6RF1Yo&gU0Y4p<@oPSQ!X*3mD?cr7qU`(hP-B z$is(_)Yw`39*Mf+sRT*F0u=NFi7QINxtr`ZXfueb+vgD$!^kIII7I`;Z4nzA&bz>4 zf0C<%hnnGAP;xsIkJy0+GQJ+Iv~zyZP>m?3-rf6f;%QmpWc~ck5#eLW)YuuOu_XQ$ zhJ6O*y?-h`284x1cuA4ENl+r=@0|F)$_uYp+4jImxC~EH0%}iKa<#5Fn+;|ALvj{% zj7OjTX*{=KrTfEFc`qsAm^4M3-2N@>f4y!l(1*uW(nR8u6ND|bMpXWsKNh{#)vBN9 zOBpkji>M^vbUsUPd)>~yw%0wA-{?3-&CsBw85W+6ee0KLa@)=m9j%wK7g1aH*#5E{ zDObbuiF_Pfsd49%{W7|UKVL?IP$m4%6^-Yiiv{$a9J4B_|)F?qt)q%r^v zD4be`2?v|w^lrKJ<%$gsD=37AL{Yh{$tv&E_AsEfG>f3yG8k& z6FFdaAa-*VTrz2421N4{s9D@0XmM0q%@?^6M{wv+{y!pBvga8}z6d__ff?Rs2C8CssY7P(Ciaw| zz@704u93J14wIdUmtS2vyiXY|3YvvRKRwQt&|Q5T>)L?D@T7A|=C_W}DKg$l$=Be_ zS%xov*(^03>oRKPigWoPf2N)Jh9$l>HX@wq9ExOU^xy6nSS+iRku)a44_+&AxP#Rf zi+Ls~v(;)#Lma%s8pi)j0$iVXz7&Eks<2m6jGs9i?*5heG4OE)#D-z|#<}Dd2z(^L z(IJa*3+QUn;aYs=4p*v_yChFn<R_AP1cSCc`74UGMLgM$0_kZJO(EzLn%A0d>nI+Z6W zIuEf0_w|r2o%2v-$oI|RA7f2jCq;E}kz_SkBV>8ik6fOgZ93YUodEY!xwL2z(i zWaHzLTQ*_YZ#V-CfA`C(OxW!^76o(K<{}h~53|I9%I5GG!*$`X%!)99I;Hoe91X51 zed_SNSR*xWt!vTnV^A5}%BRl!lh|nwHCoobwyEwOA27lO&=Y;y+u!Y#abfUgbj8~i zg#E~kYQ^`USxS;N|K(1QqCat9mT!e&W(t=!3*nJ>9 zvWrc>PB-YmdvX&TC_He4c<&3s`y?wpg{k8J3M0DbUDP1hqL<2>mB2REo-Mt+y9Y#x zdgDo(Z5+HbD)mXR-&S{@*GQ;CS@870hUa30aBcID(!xnSg$36<1OobJvDGQs8V*hu zBG=UaG_q88e<>EwAW;{gkNp5!K%~DPyot?CauX58RqyF+NMi3WbsM))v)geyOAf8S zxJQ&}hO(bgxm2V5#|2d3f=MqI$45bkN|-SOgG%zu1S_XtI;Es(E(pSC$j ze2--5ee61`PR#d?PTK5XUMdRSZxY@Nv4vU(lNFY8<1h_M;bz*x8YmA~rXU)OG`sq& z6Ka;*b)~`D={4VD(@d$*p&_1|Vx;cSOZt*p-Yp#>g9u>gePfRbKT8LL;L^3WXL4~{ zl5zKJRP4qdFn>Y3+ftc_I!9Bgvi`N8X!>FU9u@_uEq3bU4o70*_poB!qO;7 zI}GmyF^zUNNYx%;_utNn`%Y2tFhyJLziiE?W#`%Q+ z?a@BybOyXgZ8#z!ys5EWSKT)0=773s1~_HN)uy&~4S!Z4>p82SL_)L*evE>T1l-k& zO}j_P7(BxSt#9wHQ(X3(TIh0n<5Db<;zguj%1LYfOv%bw(pBThQm%yXMCZ%^zn$H3H?-| z4ZR`=h<_k80t%HTcw)&D-oO@T-h}nW7VNhACn0AVws!6gE9=@6LZ2c0zov=1X+O8` zyk`$VN@51En)c8I;Wu~B_d8qgJRCIS@kDl!oPi-JO{F77M*b(0-i z%OG$TG%lChTwv9D4~>w?3ziaM%%u|!{6T08+=j#xlDnyBy8P0v^@mhH3ut>(hG>g% z6D<6XblF}%U*^Oie|ip7GrFFYF9j1a2Y=ncsRvPjWOE3(&pLWLqnzt#Q8DeCCPdmu z=AV6jT2*$}q3kdTLNBT>FfnKI&VeQK1W`?Pt8FEh?Kk;P8WMRomf%+eZ1vBZs`yOM zKJ7_3-ZNEY{0L`d;eqzGGuV-Q=_t%M_EZGRxTX?Nce1USWR``5#h;saq*?$Z z8VAD<*9JV2)7X<0)I;Q;6a`Qvo_{ezg*D-eaUDcD5#=Btt|+P@jxIL`L&?ykE!fQo zyh_4&9Gd1kPaRa_=uf#MTs{!w&QM7XrX&7fV%2c(D0I2Rna=!{c7}%OygAMhZ^S&C z#=_LVr2wd7#=%LIMW*JZU*yY(yCKZe1(st=_Vs}{%Wdc;vi5=6lXu|&b$_fuLQt(Q zyi5NiVr|`m4su@55;?vn_YcY`)4VOBj_ zIO&0X9YfXgA;K&Ncpa^`@&>d6%ks5flGN4&5;3voF1 z*q;Vt?0cqDcchLmh|f#9Uhv?!BRnl2rcVSy@*;Z11l|oUA%Ba@lYLBAa=*9%|ATSX ziPQfgy8f@E?z9>t1Pi$ck@A#}GqdX&+qR|>Ej#~f=Y{%9`-Q=n7G?T5srKi+K*5Rj ziZ;j}?8XccrQ@mcnZ}@v-`KgzYU3KQtOLu8t;sVDFsAufSWZXVWeeCtzRZ=1XWrTv z=SAm}URg6&^M9@h2#g+N^bEh2dDGWpY1}BV65emtFrvJ9y2Rh6rvx!L8Slfejbxr( zk1q!D9{IE#p$%_LY0TgqHvNKZ$=jk3ay5$EA_Pg#>vS6Vrrj3b^>QF1H=YSB=Bd-Y zEkt8M zs6I?Yl3LPjWs!BC%h!@0tO$Q^pM$i|c)1L;%P$BPxa_&4p6Ra+K<2THBQ`rh%=Ww2 z$j6xrm0L}4GXx7i3$I8|{jw)euujW2s#@k1Bd|Z}enFCL%fq-Kx+oJ!{4DYSpdS$>yTH;li+u|r zb3*@iyr`~fE|5%Deo9ya;(K2YVYbeX1BnHO-x>_txM^AH@|z`DPiObPU;hiu{4EEPGgsKI1WJw1X$$DiYOh~`5~ zG=Ht2;mP^w8syTcsE5YK+w@gL#y8Q*D`Q?V4zZR^02G7U>Is-!N`6^5naT&WO z#l_lKy_?>UH86{z0UiaKWZk24fn+3IPr-a*I{oW81JJeZ{iaQbIzQe z4p=_-;|F(t+#3)YQx$;K2^Em-w462(-+wzZ_LfUq%RT@DPO-CP34+LZ-Iv*=BK)pH z4PJmEc*kNN0mGJ;G6wor>y)(t8!Dt+-!XO?pkmfib}V7bP0#I%(LJMAw|mKb4Fq}` zf94yooO=rn<$q4*f>13HggOJA#ReYa3t=xDf$M&8z@wyhkp*gz-(BoI<(N~i!hhzu z>Wd2yaflXJONgUw0%esoSC(MX!r79|1948>yT~bF4}=-uP~4EaiyS|ajBAP+o`t3y zTj;Fom~N7>$fLNYp4S7Q5^2Xbs*e1TJS7!3oCbZG-f|e=61UZ|-#F0l)+cV-I2)mVZkE95m&phP`8IRITyrRNMDPoaDP{>z8emi zy}MzfGWtG*dA97o2y9Dqzy(IMmmTu^0(c%JmNWf6U7>7{8qQ~R< zB}A&Z-hGwnJ=j1NE=jLR>hlMd>;Zu4#!8aNb-vkb6Kw<7GrM`LzDku75UjCZM7rpJ zY$rA{G8;3#jFmx`isbIY7ijm1VTkP~*Du0==g@i0p_g@2T zfSaK#FV_cvIExOLe4r>TA7`R;#W3V;jFcxlYg4{9e=oS@&^2WF{u_$0qAI>}(bb1$ zKmV^1X81W}xe%L~CrM}8e+DO4#ixIR#V(}(UFOV+LH)w>{SAL6U2-k2K++!IThG$nJkh(x?@|*_r&+!5^gi7V{bz0O z(3p$Wdm6yK*CQKK-53({CRWokJwIJj9X`tGoW}c4T=*3tS6Mv!V?MFo{*H5j`VA8cvdqmw=LLtcR`mka#4XdmB@cQu;i-tYKvZpxXyJ(|+j zP&r~w?6yP;imbIzq7-_QbtZDI$ zisRm&V}@v|%jQA34bXlLmU3Uq&JMP37f~kiy2A|`1Aoc*fG^a&OpuiW*r_n6?9E+$ zDgDXl*idp(U7-3bKsKm=U((k`1$BZnRs^O^7VB(j+V$B29G=v*=E?Ixj`%t&Jj(qu z26zTN|CdF&;h#qzH*78VI?i+b^uZs%bAMn{&!$xLAX-k$kdZP0OnDpi^#q{<`X zcm;YZ#dPmZzrNEZnGCn@P!LC1@E?vvzBBpQ`x|PboV7g>Q~7oC$A`x9865XXIw=gf zhOQ98nV=r`#EE}#t_fLLTz)<0TeZDH5=w&2Z+}`t>+3{GuXshrrn{bjhzf!KvOU;* zoj@ZIe{R+pWcUJq>5WpX@8!iAT(mMpv+L4t?4ns$os@oMmE9kJ^7aO)*E0ZwyAQ$6z1Gj_1u(L;$2%YKIekW zhBcvA#t_%@_^Vo&Z-k!%l7*i&bLye_0)H~;wCGg<*nN~74;Y`*35m-kmg42$sFIH+ z5HQtyQe@i<@>_ZgI(|f|Ol6BT z&FSV$w<)rK@El*G`E}T}JQ)KKEA2*9gb0Ev)9DGALSr7DJ50wyvZRMLDB_gBq6e8a zzW%M5yu)&KZqY`_2=7xx*DN{`kbmoY(MFaQXg8}8h%ZaCNMMkS1KGg=ie|A>mDSd9AA;;0aULWN)b#a)z7X*h+CopzCybblL}bG`zB zqHI*G4O;*h%qK@*!CmH5Yj)m$-zh3$zfj@jbiNAfgBPCkZel;;6%4(j4QPA4X2Gl>U$e04KQu52jXbGWW` zlZ}+<-ES0-dDGi=OPVE)d$$lwt;Xx>y;Ha5-)B$<8EMDBgxc)0wcR8>y%5Fmv zlY+XKA<~?@KL-z7RULuzZScXewbQj{OsBT$)kpwz6xY>)2QdM6=z)$vaxovVSg5DsrVldCr@* zt$~_oW7MVmKxS2MAxZOrUxTVGd7~kvjQu$`TtG|wFaErw_aHFjrOP-%%$2Q1r%NAr zT(FY9z+t~*>>IPD^2<8NlvD8ZnI)Av&8~@M!soTNX%qiaNldz1xb>H_zu|W$1-hb)XzZlIlz4M-e#`4>y zk%kVJHNM8K9E2`%d8x|tv(|du4oH%k-3;797{!~?RecsLGWIsuqP(gvuldf~T5x|h zHfMxV##&|#=)4aCJ%jK?4y~xeJh*Doh{w-<_-Kujv$)3adBk2ily`x0v14mqcQptI zb}_$gsz6QPgMZc2fw(Y7Rb0}r*kBNieURpl+vp*2$b(_DtiR4@qo~6|N30no|1X2q zzW%nFw#sgeHZRn_9Y7PHkqkH)j+A5}hF8UjIkqN-pG0U<8caK2l^m+_bFKc~iQdL*9Y7PX)g2D5jYUcGe+J|HbhfT ziy%5-J%92p7!o&`2d~la6#eO`l>{HdUK+g)qZ~u$jQbm<05}zg`%VJGt|F=RH5x2! z4cGcR@nZ9v6`YtJnS1K^<;0f~WgRJZ5Zh@1_*F)zF2Bzy^}yf()^?_lc`_12AOwcL z+My>_R{IDKU`wAmp^*8ExPE}!07IVh)5%b(o_|8}E`xY#u6|DHG&MLF zxd+C~>ZO8IsMcUOj3tA83< zku}gLtM(CqM!P)Psw*v9@^)cI4H=u;&)q1r4kVFh zXsr$LHiA6=GL%aNMaf99eE*@44u4fCGsGq0bmQG`#$^KG@y{#+QcD=Yxn-KY&c0_s zw1=PL0cywgVP}Y{q-Y<}&&N7H=gff9;jo5hM|G~-5DuX%2a!eTXl!tnFu#dQfGV++ zNO%qPlsBs%!>#`G8z_=#R{Q0HifY;W^hhL4F@ZldShU*G^^x<+DCRjcWNFSq9XV&4NSqEheuOyFt^%= zz<5~}25klcqrbb`Fs^gDMN(@OSWXgO7yUD?wy@zv7^)xBpU7mMk8ZbJlE#Z_*uPda|x2=s|0>dw)Fbld!6Sc=O&E zgU=lPq~z}Y^|R*9&7NCQBWp*43S2ZibssSDAgX6Yk-$TC5KN$@yAU1@zSA5dwV9AS zfxPn$rKn-{&s#J@33JuxKwG0;dYt4JkmN=mnSk>f59Hy2tY<_8w`cbup~K40akINN z2p4Ju-TVb$+{2i21%H7+ZzL+CU{yn=yB#>F^@|9|NRqxwx?WmUbQ@Y*N5A);I~q3S zPE{%yR@Kjla_JnTHoBzC&?3-hR=J?Jq=Yw#@=Ns;U&f7#6~3`@0$+Pyc*(K)2eQdp z-rh%Oo|uXF4}iSYR&X6NuMDH8YrcT%==%wD(^sXAl#2eXHh<7+bW|*PD30J->npN4 z1bxUdrqeSYF`zqa@2KSaw$Lj>2ho4?fb=N)aZa6C(71xsH&&@{&fB~ElDKa1+Z8u8si1f1{E4k&{IG>cH%4q$}9}){#!XAULcCae+Q8vWklr}mRfwj zzaO6c<9~_mX*Z6y20Mqb3E&UyKjvHYb-;~mWalCg5!8TB#$Um1O}7WYP_ON z5P&uWg0yJk(vK8-SprMSl9$}OQ}$`9HH6Q{B7cw+!=rT){;}lVp6YgDj^0&oP%jr9 zQmA8Q@xG6Um)Ah%1LcZz?>)*?nTh@YCE^)@-xFh7`ePz3eS4%p?`C?A3yCHqOz=JV zE;Bhoa<@YC!xVFEAUYxK&2Z%vUHKMcNYncF3mMj~=9c|$30~gb(KyFLV3q89_2o^~ zPk%m{KC=({tENSdPa~7LTSnV-eD1*$lxTJ}UR$d1X;u2-Ag|xLxj-POuYSSMOO<3@ z`5i|m)SMedY-uPxiwc0jkN9^;?B@M!rlg)DUDj6>b)F)$XWjo` zqPljH_Au4`I~Oe{yP*Pnu$&B1+iSIW{(sP0j3GB#Mmo9YwzZA|nMHJx${I}gB1P6D zrCG0P++*_b5ETr>@d}9AM&LC^A!HxDL}88*7@OcbAW{mt3yYuf>&el$BAZ5*>*sZEqTmgbwc`KRDx=-em&V?9G#(7 zx5#&_Fb2ua%lb?mU4cpr?3m;h!b0C-7aS;tUYQUimsCl}wGs}yCsxO30 zg=m!V5;vO*Lw#`wcYPl8#^s5Fgn!0P2G+4{fwABqG52x-Aw;#2rv;3WN459$o8Tjn zhFsAs>UIB9y>u-rui#sW5)pD@;=>fiuV}tj%1h3d7anK>HBx0?xZNzCqK-&5KfV82 z@}<#Mm@1^l)*2yx|89{ZLWs4q!l?>GLytVjT*Me7WnS?F9SI|b)hu1F?th&qmm8J~ zzkD$R1U%&m?xEcI0$It~h>k5{F!p3C1cM0`Y&UVrl4=Y=+2~V-wVF11w_WHCMJHJi zK`1hnKeAR@&j)YQh3(4q!AjDe8VDpwc2+<(Tlvi12sXlES~0lk{$^EDU>xQKJHxNr4Nm&f}pzU%;a z2Ab`kh|58jQz0m>rBWz`(gS!%+$c>1HH0>3iZoZ+#_I&!t&kaLlS`=! z8urAQEN+FJji87Ib@u?5p3M4JNvQul3m#OdOvchjD{xoHvB$nJjFL~BP-hOt7kQI_u5GJifB9M5-mL&w8c@_OD* zdjHicxK4Eq2HrUG-fR2>dd7k7g@H2={43_Lz$atBpn^P>Nce@XKo}HG-xYo9jH2YS z2nDZ=q`fe&R+uro&+=NYY`+lqF>_2;sGelcXsH*ekO|1SF)BB3>l?^C8#sc|$xFAK zJTgDGT5wq)Q-9DJjMeea*cJNC`Ri~(Xvep$p^ek1p=?pkJQQ{L+40ons@(71(Ym9{ zC}ODPyc+U-(jwK4jlg`#X%>iNHOaSo&?0^!{q=S&doHO(K)7Qes$h#pbD4$|d6+It zBxtUqk%3!5F)HYt%(3~b%m)SHxlczU|1f<_e#wsdpMQr;OT0Sfv8s@{BkWg;8oS;M z42Q05f?ZHn%INx`0gl{lER1D!`d=h(lA8-6xtE|41FN+JyZ8Vf`i>SuWNcuk%LOMU zoOw$cqTXhU2M29m#bln#C;2}_NTzf5p5&v+wp|%|cth7$j1-*uK;ja@oL=Bo{X%9& zbKG0ck$=Lfti^cnFi-|kRAiajQ%Uh0E<98E{Y({$wy48?<is)62lQ-tMH9WLIvy?1fm;j5UHx zLSQ!OMor7J9IlGBGtjEx`{+@!V%byBr>pg-XsbCMUqB}8cjv5~qK#day&y~@FKA@< zQgWetGLc?&ff1s_C?()Ir&|h+#yaIro_~$A_+{3>N>=3f4KC_Jph$yxNlq;a%?9sm zdWUP&C7bEP#1&=GpK>WoiDxfQJ{8dv4b)m7c^&;Fvw+V#!X!(n&@JHu33~%w+3%>0 zCsl8VJ*r684w`Cy4|YDt;;(qp1Is_IOClY7#y~E_Oj_#qW&)vbBNd*Ly@b7Mvw!%( z@5nT1`m+Uxm8#y_U6qlX6;5u2CoGFWP|z=S69L@Hv{I}f;TT#Xr~)tRy}s>N6ka!b zX#iNO(COzE?Mp(wnSDVthOP>jsIxnscRCQZFDW`xt4Ze?c-Kgt?>0O%Oz&&kg&<~+ zb|7JW;F|ad#?~~wJDLq@94?cbet(Ahf}k^O7qz=u*H5YTQ5rddw4uh=d#HB-(JA@Q zJPcRsH=^LrzR!>zDiUO(TtTM2fHq}L3P*Y(5v7BH+l{ZsgG>=?SeNMN?>UkUR)XDz zE-Ok%Z3BZei!NDl3bxQ5S}js;8@@o;h2cUGS}(&de{|DVgBs(MvRezR>VJF20trDG z75J>Y&Wm*Y+Pf(OJgl#qZL0e`iWG!~rFXLmgB(TSoy-xpu!6JAE++aCc;DT6&UhPi;NeItZ^F#0hPu| zH^M~azO?FlfI(w4VhaWv`=mF8FuR^Hd%^$!?LM*&{&FGZU<4djKYyH^(2^*XGXegJ zQk=H1AsRRHt&>Qt?2c%cCefdyzeYDS^RW=yVN*{scu7){Fj2pN6h9pFny@+TJNCg* zJXy3JYT5}^7q0w`T#*r%#j0n}cyKMWZ=?@1Z7a!bICA;C1E^yUr2MD+Rgv+gao z%q0?rnI%gG&6G1sqJNcziJ`I|bHMDd25vK=2Bk7)W5C>quwO6`Gg&ZL8TX-3X9e+y86+{TjKkET^y$?go#3l?-#QOq^!a18zFT`wf?a0=r~x!* zK^-BSz>5HxN6h9nnjbWe^Yb?SGPyx%6A)s-;`0AMRSc{WD1T9Wd|cWh1qwwEQEDo; z*A}D&K3laI*+at(WtfV=A4zU1mND1K)h?G#o zwkz}J9cOvDmUg}EB#|ArS_ekJ^-iM2jT4P2cLC2>hX;F6`?9f(R5+kO6inYH0mziRxo-Vs~=6KWAG!!gN#gW7Jpo1&6HszQp23dRq}X28uK#V z#9iRN;Dbnx5l{M^eMg(LN9`#C`FrXRAldM!4h2HQP7#!k_HXE;A_`!G{$-duZ+R*l zlEz`(`C4hM;K8g% zC*Z0OKIz+ixI!qrDhZO6g1S=4J~8=VPNycwRCaqwYSug3#KRe>&p_&XD1|XfU`|q% zNS2D22QjjYc#)_7n5f!J)R+*wF$uO=j%>0s|9`Q>s|+9#OAf2D1GdALai*Yx7sc?w z9TE)Af${zF%1SsX|KAl!swCbH4tN(Bg#&XCe$pk*=7_%l!eQhK;gwp++R_&2)PY?B ziDC1O5Y9ISt*OS&xF4wUZz=Ew>5F$_@swU7Ph*<>)1r0`#$}0DzVm9Oj%1O_I=<10?axDu1od%>taCBp~-UseIg>&uv@ z;EJS*H2fg6!UhjY+T7I+f-%}Y5mfEmHV|W~x~&e=vxlbFU<8KD#7CGdr>5H3BY&tD z5wn>9EDB_C2&IY)Hj^cQSHxarSHe^yjAKM3aayJ|Hw*TL{&=6F|GBP?{GKYmKi79n z9fxwhx9xR$umk!dQS$+01&p9TQifR&tNd68P?%m+Xvv#YOZv~8X!VDB1A)ZKBnHWW zuZ1B}eRVSjj^*PsjtiBoZ|GFU5`UV{UzRy!`kNDOdGBPx@K z;4@wvXa1a&iqI-R1@l5X#8)OKjVKsB&2#M$R{suj`s+Q(A^7v|X#&A$K(j`}Qej*?KiJ(bKA^3JugOaa!j+JMXE;YJ?pS^)@!m3dZX zX_D@cn*_s{;p_}UxOqYIgMZ!)iY)QCGX9R82zHm?CVo$bP5B01Jv||Kn#N!uAEfi0bD!F)cLBkNDvcm()2YXl_5mQYMFyff}BVWY*@i9VVEaR^q z`&*`)+E!&M)lsFp)H+^}OQLqa1qdE^PfI5N$kie-Sz}+M7U5v;>=~>^iuk}6R0?Ms zf8zKPYNB7zfyf&9?0-fgy}Dhjwa#}#8+iEg)9`V*(*1`%u^SuoO40aqSfm5YA5^wa zit9z5^|?uy^r|_x3N{xn!4=c-fU4G4G6!M=iitW2nw7Y=4F__?S$Uz*z17$7^~f6u zmR~&OFwz@=r?;I?hW+^%7Q`p>dWoJ=Q&#STV!iLX9XJ?@=YQ|-j^k%NgKoDs-%^w` zw{O4CK(&$2TTneqij>~8<^klF5Z2pb)g)UJCM^XVU<Qn$Zv=(p3?@eEZ!uuF z_wh?f;UNLY{%(N))$!1v5|-|)&uzR{u_-@{(9&}Pu&70l#}k)#7V+595@SV?SbpP& zc<3Npf)tCYqXyd{BS4+d zt2%w4+QEXDJUl3ATZ;cNt3#UpxFwthIg3hbw{1vkIAu^@=y!d3R_aP>v^40fn!R4+ zlOhfWPlpiodz<0dfdr}th<4!?Qzb&>nW1!@=>`>C0e{=ZFUA`Hq2b(!15^b{rcrYu zk5m>~iFTw2N(!1UaU>~mF?7}3K2PYP+$rnQvS%h$OSZi{FnLO{#M4l8qL-}rI}r2N z{LYED|EFaft1eR1Z!m^J!mD7Xre*;41cDG-o`fhFfjM{Tkv>Vq)1KhM5><)>OUo}c zZZlN1et&BYd`$N}tqZJt<8Xv>4GuvC0t3cQpF=${WNSl)C~j8?-37SZR#z{6(HHe` zJ*_k!5WL?{gro!My@yqKP(IV=)hju*Zf;y9#jS=45oHwW?pChi(`_lJ4dh2yUhfILfMsYQ~6Ug=NL~rZ-1*zfC8(AIgG#927CX@!_un&)dP&} z_K8z~o>(An%{Z3YMaoA$h^hRGY!Ad$r|2FSWp3}OlO4`74W9%I?jKEsh(YGw7{a)L zxaJ7cZpf=l0Cb<_FhFqnRJvQxcOD)vai>2Uq8~MQ*0Ih#k>|eHEi(!Cf~;o55xP+v zB!30TN-dLNB$op>ISG-ilW)eG!tg!vl2umE!=8vS2*B71M9ngCnLJw8??C#7T9r>kTBI;*@ErWGcYox?D` z$K~|z%q~Ysd9Sg^>HTnweU>R9hHsyQYPHQhD8#Kjw;e#ogezr?MX_I~K)oJ27k_=a zp7q(9@+`rrdR<{o-9?{T)N6I*k4$7gd!aREp#&XX(-P12y5wfRV5gK&eiX12*ck8Qy;o4IWn{6Uef+0sgR>wk{IR8VWK!;MaM(B}Oza3Zmxt$KZ!%5g{Y{U7*u zjz?h?+W4ilORC<*8j#t-990azQJ$Afv1uMI(FHC|KD&pK+{pT78G=xI#Bi3T^q{|! zwOR(X&=!+XuqioHTd5fz$Vj7DA4vH+gTJXQjSwb}cE2=;ls8~k74G#jx_?ZVQ}WzK zEDmE1f*w)D->h+wR>jft>@)cA8hi2!0!D^_Nt~{~8v~6N4}VQ-2#|nw%!sUeFmd3gFuejU7`zH5 z?Cd9=@@c&R(uRl@d+SvwcN7;p%_{m5?GCFjZA-SoL_cbFeA$#bM%3xvCm7* z1?-P!M}ygqq|uMK!IwkO8&RfZa{L8T!oxwX7Y!)jI!h7Fo~*(M+p%9;a3b(+l|qeY zcZyzXY(gBdzhnrJQh$8P+*(HY7nY%aQr>Qgj$gY+x`FMH2)GR_Dul8MvmxL(uS~3n zR7pgNwu*1{Z_V;`3q&1P`LHN4xJ!V&v$j?W07*czjsm*eqHGW|Ek+k`h1vDl@!f&7 z%DSqmQtiU|ILE2mnnJhW`%B^XY8crOK~l<(y6hEr&rYB8pnqR|hFK9b!n|*}86wHe z7S-Q%dTPtlzWzS^ay72H4TSq;WEVcWsf_zgTVN1*VDm{vWoPKpfQ- zB*vGVv;R-LT7Q7dyosfx@R<2YvXqJO2XpjynzfsoH|D!gvD-4y1n+i@x0h%A(_(9I zL>CO8v^>HUAb#kZnMsXz-k*5L@u=&%`CddBO)m$ zw8>#;51iP!s+{8&{7W$5=c>f(SS|D!ZKa-UOW=Sefo(?%H%Ce1hjVb9v;b-JtCI^d zfFJktiGK*%F@F?SU>9zJfQ;%U+HxY256BUGuSq(DHtKUKL7FYWxWrsiQ+YOWyP;e@eD0xAY*HT%yFhuGBEFlFJ zFX{@+DJhj!)r`&#DHE@KHIRtDPkJZGo@{BCAW7=1%X^nNRL%VL!k>_g(>thjO`&!JP zfb`IEkhmDxlnr9AoeqlyGC)*PY{F!bEp*>P`guoNLZ6wZ74CqxT{vE|lSe#Cn~$_( z-;tm8KPWO2(4wWq$sFrD0G|br6}Xy_M1R7<;Ksm7F;JzGL@U`ivB^i@?e*fg9&7;~ z?zCgW+w>0k=;bBCeQ$QC=Zk$OBtT5PQo`WUSorShQ)|ms&;puQh}Kl#L|!W}Y=6?* zC|t8q_un_TNh?iWvRI>fp5*>s1Xei<9~xk z2Ip20b{&>pQU6^;F{>ikpS}^P&vQLU?CzdNg1P^qDySUrW~9G&CX?N+NR~p^|Jq z-^y2(J7EIAQ}C;Zn0AahtA9hp$IH}rv(GecgmNd@c@W& zSw*Q36dw=E7mprWc?CE}{2Ybe6OY_)`OlH`Sg@_lqgHrZo=*`=H3UbaU)s&x-zLf= zwS~1)q7dm@#TdR;g5mW%57>%4&3Pm&)lSd@GpVp!f8ITKI=8&m)9KK52Y=V`%Uf|K zp?ftZ^yZ$H$CA0P6qk-nwFO^>ClAx>icl3X1&os%W;_DTZcN_61J%~tAZRlfQ%d5F zt1esc<4o0aXotx_NBdpslJF*aDz5)Np!z2xFN|4Tim9+aW?0}b09WfsP&5CHHH!$N z!8NA=lxL)K6OX(RQgoKD+J8u4^OVcZaksT*H!{AR?c%`2o*P!n`Ni5@mHw38besBi z(RRuBJJ1Bn12~peW?AoiDNs@ykLjU!x)p96pY>{q ze!h1xR!O|aRc-Gg9Dlijgjh3Y8O~`5JPr~vh!lTao);`yQf4O<W*gp4 zDXnW105^m*^-N|%b(6pBwJ}7a@U}utRPW3`_%ymZM9+aMZ_2nL{1`Bw$H5fugICAqkl=^_qM`4(7X4{ zs@sU);isZa$n4hNxz=%V4XSUW^6{uFt91S&wxS#LUXmyv_}BII#cY%X@*%eJ#<{ z*4)Ae8;P*&W-V56s39M%rxvX^uIJ6)8^`h*_j;W2HBwNh{;M|xH_id&DySfCBV}dI z5vcVd`hPSagXWz;g)D_>_h1ZDWr$^Y7?FuI&dNDdpgk4*F3tGCJ6_mUaOMoB$wnqu zYQm)T8_bTuU!)Ia5f>|zFAhNi>=7@MT>YfdSA{}&WOL$2v9T~MyzK?46w%S>rt0U_ zfN69Q;0ecTy^AY;`Zr3Aj35Uvh?_lVC+8UVwtstNB5wRz_mjRdl%}mY!G`n>Qf;wp zJg`>r)_;fMXTKS?SP}Vp?+k4^bU&H0~GR387Rj#s`S6c3LCDG8W376 zFn_>bm;4L#6&EA!`H<*y{bX;C()RO90bnNUSyH{ zGTEF=hlOfGybr*G*1}?4I+5^POA;`H5q}GO_KJ^z4hqv9t9@a^x4R5>Pz4>RuJ&l2 z1+PpPa|a^LbZp4&PWe(JV8jaI{K5yR^w%ARi|$h&n#{KpHG=I*%a6ECrq+5YBr<;> zFyxad6l{{{4I}Y;1z2fKnw&|!c{EKlJ+2)oOdg@PVLsIgyp!3;>b*-zOKaNp>VJo> z!MFt8nl+1=Rrd%alM9Ux63a*D8Q5EVo7DQmPfYz{{*VBDH7KzX1-<>`dr$lfJOO5t zjy01*^p~vYeYq1&2{4v-d1G1c&C@6a-_-cACWyp#Owvsp16w^WXS6^2sR$yS<$zun z8pt%1KV_g{YLYjZ5UBlBKpj+wihpfSRHV93At_6;ez|yTmchQ%){)W@Y)*MI zX=9q{U$Op7&)ytD&OK;PR%xTR!Z~MtqzFB$>$vYQh$}gNjkABh8s5o}qjU4W!!PKX z7n$T+S-W8M4c|#F+Gvz^6R>||!Czb~wDj+01~;lbj%%K0E}Dwlq&p+fzkggFH^0|6 z9-iX_v$!3#y;uEyojo(EglX_N2QsQ8u-1FpeZBNV4+P%pNskFz;a#Q_n!|Mdn7pCZ4&H!u#iKM)3q>gkZ| zR%r$DT?HtmEP{aTie#}&^|++FMT-k9%lc&V5!S)RaW6l5!x9lQK@SAzpl}xww4`LP zKk@?TrtBOH;k?XFH{SscEb-I*=(W|DWz9mQi=tS#J#AjoR95!O{Fg6aNz&(d!2R;dIF$I?%lvJ{^ zu@G$%lc!j#8TD+LLAUF)n)+b@j*XkCUiyf6G&dFCMPEcF46>LpkTYM}m%v!$H0BU# zF-1V`@JBxTLp+nJG8160=ahfMib(jqeYZcmne+PcDummi&OK1Px3YZQvV@S}u?Y9T8#XZ3AYD?d-UKY;?j?d1sjMD%LfEVyo={z7JZsIe~i_fdO%bFzP#SnC`U!aD{; zC8q2?s_Q=oHFAJWTSV`o{%2yRK`c^SWNh#P5{n9CZK|ERU65yflw|p0Yu6G(WGe9K z^DJ+jZ*XB!$fv1l#UCXM>(?<=#07WzzmZCAZeK8dHZ&9#>pUpDk49*Dh8-vv$`EdH zyw4|uT1XItG4F|9K~R5r#3BUc$mk^Y#y8x|l;%pYQ-0Qld8b=&&`g*=Q{D_2Pc%yA zOeJX7?d}gf8ps(4w;ncdTRj%1y~Tg(Pn5Fi6#$>HgnM3Ews~gwFnQi6b%CG~BNu-R zBe9u^mPOM)@Uk*o(<2yba|x{fkE@}fweQO4DIZ?CxqDP5vRHp#|3_Xu0QTnKs)w58 zhv*?7pS9Oms-I7Z{*u>--Q5ws+av2oVs?!Zek+)s@ZRbg*fWxFBe5u7bm{QM>M z;|UP{P#YU8<)#l^-xy4!Hy}VD60IOM@4T*g^57OT<-Z8d%g_)#;xigid{8xxaM5_0 z&{_9Q?ZRve0m6T_LO)>QN*l_u(GEEG*TDs;uBGW#emQ; zW?QU~KP1vJm}64sp@KNNc8O>NS;9aMy@TJ}w5HKanA_j2Oc8tUy-lhXCQkWe-?tza zs|vTDP+NKkSiiFAC_*2$K3vy$InTFzC*!n7{YD=~AmM*4*2v_Jb}fLCOl24_SOiSE zV8oG8yze98Q;!si{D$OWE)~>@weR%nuWDrgNzUReinh7kJ-sEuzI$ehMIV9UpE#wO zr2L!9en76)$mVFV7Qr(S^p-J&cnZYwjFxMx#1`X0A$*Wu)$$TJ)r9;TR)Dp>9Xx1GHK{J2ytel?vVUUcgXQ@Yxb9YU#)z(KV z9y7JD6p2qraw=4xP)Au;_ zv`fVqgn3cxK~CB=7)hxFLOQY}BXJMj`=I9RvX{gd37E5xQ@a5-Nb7(NFbG1xUt~!! z9)y2Nyvm5)w@0d>}AsLHEAJGXHHbqr0Vd32wL&qvvxWJA^~6IZx7U5ieAU zuMe=ojw_k{0Hp8GBrM}7C#rWAWw<&+rcfgcMbMdY6K_+QQl~MMt3fm5e2&a$N zi+_lo!2tI~VjWkK*K{Q%i)4#{ueOgpXfv1YBJ~vv*~R4+2_|of;vSuS82|rgJo%vC zqjJIQCSkTt?KdD?c?9%SasWsHUuK!k99F0Qtoc(A?C9@!4YtQa@jV~;U(Vv1$wuN)bp($EGbs~W*{9;N!I%@MM6u`W{dR0k(iewK zsgVP~zZrG~iBr``LKBTZ`U`)XVfj%6at_>XMTO+_VPOj%McwZqkKs$a`3Au_o?JyE z@C6Zi9Q}?853{*k&I|~@47`dFyB>d6>ZFY7%lK)?BnDwHZlx@l7d&O-1P5nuG}xV0 z5I%p$mdEU)ENkBcmA(%<>*XT&qLcI+#7;JN>;u4e{Uy@7wOup1Ie?a!-0bXW#3eI? ze8eoSbg{>Q)0UPw9`b_t&2hb1b`m^Nd!hNByk5+gMFW#+y!2lDeJ(->!PkF6cyDBd zB*fBy^-_fbQ$w(C#jV_qtbf)j7dpc?)DF8<%aTnTNL?izAm9*DQSO#B?A(v2nin6r>gRtCSpHp-vF~!~ z*eq>AaVct~!&Po%T7s7BDxa%`t_cy+Y?r#L6|p68duug)R%V*4mXAC#a*0sJcY(q2 zxuKQ)2fal`PvcC-2bNhBBOLSCF(4079+kr((m#Wc=-VNQ6T(TJl<6YO`>{5HRs$RH z!#4Yzo_%MSPrz-jz;u5r)K=MDnYc?pFfpSN;W!gvE|G~yg#4Viug|GwrPP#43vkhB zdI}<6`PCfuGQro|`ri>!{oD@}dh#S4*z0-|N0F*u-2=^aJv%u!(W`ZRkn=&1I=|9T0df|4zIBK{1SnG?Vl|c$ zW9Vg#ifeG*%XNQQzlTSp^Qz#b@F(3{%vZ7~AV03T1dg3v#!Ot&7_e}%;TCK_(k<%9 z6hVhtW@H-(mwTB6@Qj^DU@f}U#9u4}93e4`br{CTsSY#xl?{VI@)}croHYLDFTj47 zPf*#}M5!djQm4voU4dx(lBES`#u+Y#XlB;>AXNur{#}2BC}=y0w|fuo0?dO!9^FQc zi&Yk|q+Nmu$xC3RieHzpfky$T%fT6ysA+1ddbyC|@kqnK2K3VKeoMj33`Ii5I#YJ5 zO`!M>_@ZHMo$t?LLEN?8;Pd(#QIl?@(E>r3U9jiEfSpjJavdm=lLyEHDv}S|Oei{g znX8>CWMhA0%fPMdT1UWr*v8|Y!QYwtlabwLI(H#YKzm7OkZgEvu*bV;YdcTC;^HNq zD!U<#GBwVWHTo-9DebROg}K-)jsl3_h3Na{3QUP!>+ojjqVQGK@r{cmQ@=;Wf2bpgA`sWLKSDg)9#g!^SG z^y8M9GirtirFn#f)F&e4|JZw#YdC)j#~j8VOmrPR_129OhGx_Uvb#d6eZ|px$IYt? zO(>3oo3mj-BquCT!rFD@U3+&YNc$jpz6>dBvw*z85OM6(*Fa9f05F-5f6Or)r+gd%_N3HJRpyc@?k zn(`r_9(W&bl(6Qz*dp~AHMaT>98>3IS3{KMeec_bKy1G%AGE-mN~U=6j&qgjb6cgI zY5*$#<9DuCgXY?(nBywHdfq|;*~JY%t2c2F=EP(Ki%whT$4PxB(oy{TXlwJ8-|nCT zwZutpo$V1hR#u0D$}yDr{tMyy}1A%9CTa8IsAz0`Pw(^J-8 zWE)%RGMH2WV}ch-tqn`39Ki9^7;?G|O5FiEFr2}hw9;&w&9=4m~ zpc~ATx9Ob4=4p<}*M_D+DEEjr8}h)1k&=bQ9Q^o`p4tS5hjM>!7@z?J94*>`;c0mf z-oBDB4>u3vrD6tJ)!*VQM*$;W_DJq=uyS=~SWa^j&5>uxexj75hh}tvm4MbdmNeN2 zVh0OWWfNBKc^fpkR8ST<-HwgN-xTBF&k?|6t73(>ExIzbl98fl5O?B%y2gaeuMjeQ zlIqGRqU!%7Dq zXO&SWzV80&LkU~F&mn}2Mp#qVY0rk?%~8PIhSTsNb(y?pyIE6Ys zg&6S+;kj1i6eA0B-InCvg0sfYZ8$dxPL9e>bINh#x237fjL=UEcmKB@3Lx$w+0Eq! zf@HGfAAVg&DP5IED$*ry(g&s|2mYk?F@~iFL8`g`a704OV6fV-lvupK%CoU z?t5bfhkWOULm8;#B<}}v5Z+0R9@p{D)Km#Wo|07Obg?1vdmkpxEl@ZJ z!Qi6GfqWHK`IA_Kk^e^WwN1?E_oJQs8GC=+IH?dOshhPA9h`2lhI?I)l%9oGZd?E^ z-@V3;zTrz^LmZm7Cv&gO%KPV%FJ~GHj1dN);IY?G60FURDtZZJABqw*_<$ii@REJ? zu1yco4c6k06G2Sto&3S2wd09B53i{xeZINw*uwr^!^%swt^nlfg!^93DGPGfvSNSM zX{h4u|GnuC4{p!!LAi2ZR8RVdRc?gDLa_g8n=H;tY)k(hfkbzEvPaNmlRqapZ)Z(< zQ*}(_(qIac9O-_qz^c|DGb7YXiko#kf)nUo>YKWd>~?;yRA^JfB4r%u_P!>tjxi2< z^*|#8dAeM5Yv;`RwXm@J1;drai=BTJ)8|WSp0HE3=f&ZVemuYQsllB}Yl-_ zWu8!L;z8;gt{%6CiAOdFn&JHWhY{JO`5KurH^oO zH43q=Li9hD>1z6IOO02b^YO8r=zxoaMb7|8DT^Bk2L(F!c|WM%HY0nU-RpD{u;%KK zOqt`zjh~JG??sCpuuf^c{~Q-<4gFZox`Hr1bZ1i5_9VQujRDV;2?iiOhbu_1)QMHl zhy?LI{oWOi4IG=yJU`%7Wqh@~WD}@{r6R#aTnfnwX^r&3?6Da!akwY(g)ulPalj=Md+w4+!Il?-`3FxP^EmfIl>ytdwo9{W z(2cKT6_%y!+YwhvnhGTcoBWg^) zH}AR28$mvrPI|!}`(4*UDW%>m>5=#j_saqxFAq`6A1|m{@2mQUM2cX2Y53 z*$vcbz{47j488^XB{B~pWothtVMdvD`?-&Bkf=told6APu*?}ctO`*?m(k=9peSGC zkg4haCwO5-){&#(1|-O!IEzcq(NJ@fw5l`p-b}bCEq19RQQh6(**5aCp$Z~r+(oZ? z9t8a)d-iTnz)Kv90wWTdeR~3gjjEENEi(eOXpO=R*81#Vgm?o5Krjdki*NQXrZa}W zbo!@zDnfsC<7wxi)d5S^EXH3av9DzDQd8cC0;KTwCi|h7R5|97Nya4SyMaX~kW?d(g4S(tQHk87AykB`m=08pt z_*+Jzis7kJIb^YjVdGgmV5x1GfZ=Q#rsrPo``Iy{;9{+M%&IA{9`^o06UgKZGqZiW`WWg&9{^ z^U8mUbT?vKN!C`n`7HKFbp|Hs8%iPZC%YnYwY?Ua_+R-{t%C;GEpfzF4wa(Cs8b_< zcF`Kzy0vhB?%c40$*5UT%tFx1spAt;7lI`CMdYBX*74qT!~QIII7_7PHu{GGsp4_y z$Yw7}mWZRf^dho7kN;|H3i2Gqq~|DuF1&v`&aBd;Nyd-OUeh2C&xgWanpW0CPF^-C z5A#%LRz>KpF4d||f3UOk{QB}WjK+hp;GEv8_!T&s&!{I1=O?bQt5~u6VK~uju+dC~ zTRuo2&?*}hPfi|tD;gZ>4{Gn+->!xmU=jvv=5b22+btb@)S(d1G2aMOpP%5pXc~Xm z(t5z+VYgO%)xr(DJvQcDVp?ju2*>&3$x6czG9?do0r^Tw(f&fc{c*DQQ-iv>d4JcK zR5h>>!Ja5NXGho)xaX$7{vBlU`-KhzoMH6#5Juf|iRULVA}eaT3u-S*@hD^TOrWe3 zVZ=0CGNl>FBu-_jUsG>dRq*cWOVEE{*aJwZD)I&5aZB6PmaZMnEB_m5t7!M)mzkZ2 zBlJ$MLj_J#L%zM2ELTrdyu;QG3H+X~s&mT?rda(pw%tYa*XVxFHOp=j+@g`n$?~oD z{<8I~OFOu1zwukWv}=)ymECJ(Y^}|UeL^X<`e#nX9Q3^|y+s@Z5=*1>ZXnB`rMV7HCsZ+`TV}8tNfJd`k=VHxuUa@LNI^OL+%IOE-0yMw5!%i( z3a4)RSpvXyLYo!R%@WBQJWhY!FlGe^d}*;ozIuUmGSpvxuv+j#QBTHkGDdAMfOz8{ zgN-<*+JpEGI5rsKYRVr~#!hUUfo?;s_;Et-m3n~Js?f4tePQ-|O%4073PjQdGgJAt z8Qt@O#OQ5DTC#BkAUjUBTKw-tCq`Z+5tGTOhRc2~Td+aw8P;%g4Yz+Vp^vvEo7opU zO-0|@#E~oYnDZ?_ShY~b=l}RT{ow{&woI~P-4FMq;)}{KHH>69n=f1ylbI6X_;q6j z!a^kdRCG@bc`?vV&pcge_SUloO{1g!w*m-&Z;GBFsux zuO@a1PqI-tj%#FPaL}Y!OvoVf=`isiq?vwHF^&4y3fwn1e&QIcQ4y zL46k*PzD@QM+%fi!e1?B)z*hG^Z9tYbyL^yxizHDcNpV}*<+@ojj8Hr;Me!o=?X%q zORNNL8|HhhHi+v4N#HR*PotPLW%DZPBz|u9cMuu^!@_?Gdw+hNA;~Tre(24iC|JeD z{EM6P8TAuakHjN`x_~bo*Tze1unWIXoos2g=yWO7FkGXpj9Bh0^?4MBaB2J3T{AJ* zHqOk>LS)_sE2ku0TT_O@=wc}r6Fu7!JDY7}e)rV~0vIsjz-?Ku-au7LjAMB=K^qPG zBXtd55$%7lm^qVdflQ^MgTg*SAp$29_@)%h%ZuU~zUmmaK>9N2&D)5r@$w_|Pn}U5 zp*Io4&UN=EU`|Zg9l5f*^06gncGQ&S3&^DBk0gZGVwWW0)Ac$zcTd`hMNXYz_jOmpwo5QusB4ml#P}r z51zxfs3k+>mSqrdc|#>f{&G%gNMQ}lrW$|Ix5UB#D`=dJERaNLLBdhXv!Bu~ClJ@? z(sDj0@M(Xjfx8VP@cie@YSd<|Bb1UV4+2l^UBC_3IzQPVsml|DVY@H`sP4cP==BI*d3!@-2UA z1m1uwyk?INc0DIF7%xn$fO`Uw#mg)!sLh$1pn)jG5LQ_F$T*<6e>;&*54@$C?pY1& z{%pln5@%3rbG^~TM6#|0v-ue)!#Pun{C&?%oI{D>_tKY);=euDjk3ev@Iv57xbwoI zvrPy7!lJ`&AAHPjCMcJC6!(3>uLplj(BGcLB=&E29&NU5>>wi&@`z7Lm@iHF!wE*0 z`m;d~In2L}TUCNpe2aiN)baEDhKK08Qa3+3rPO-c9Sv#GN4hVxxaX>B8PS zot@1$Z~)Tu)5n!L$EPu4*XdQGsv?9qjfERN{+W@8hv9@){`I?f zX&;B7G;p8uJGG2_GQFVajo#jaw4728Qs8cbIM1s9WOUbc)obvaL0r_(P zj8t0ksI(lMR=g4l1qBV9{yMsb!3yZ7-gsY(!Vf&S_h!*4IG!=nnRDaV+aXjed4E)C zRDCju+)W(e!2uB~%FgqiC{vWm2R4hyx1(^yh4C=F)1C^q48M`=g)F@nY5U_o=MH|~-bDr?b!h6!f6r5{lLxUmzIBMm_ciW}0JNthz& zvJnknn= z+~LBBnTS}!md~`u<5~i96KctnF_|n^V^RMXEh9LlRBc!gE{q4T&RzOd(xx~ zjNq@Klg-||%`Oy;KGJl_fbRUaRWgbKH+Da`XySh=0XrO3nhl$F!OGgRxh(@hKjBhv zCfQKAdZ2|^ZSQY`LMYV7wBJn|-T#zsNqjluwR5k|l=Rh`#(}u48L{K}XZ{d8=6ZMz zWtr)WN}!56I2QP~v6h{zNIirjnCEg&K>qX$9{4bS&JC^gmV z;jMopWZ*|oVs2)oM@LbspQh%SHQqSsjPPU44qpJx2&*uC!mY^N{`R2!a*plh@)J0- z+}TNwlqC;;hcGMK0QB>s_@~MRj~_NN2h9-Z2gu*E86}$CQO+DZfN@+m=R`WCoP0}w zmEf+eZK)898w>&kPjdpq@rlBg`k?{^_3nSrPTF?cjY*u-z+>Mj0Y23!BSv%D{u0qz zuvmGuoo}DA90fM*aNg_E+oPNdO*;G6E1hbln5D-BMG@WmP}`+P`Oa1NFW2*)z@_Dz z?4xxs;4uy{5abfN--5VaQa)crz-d2V{$IJGWNM#PD}je`*5MeZ8Y}{fGGb|5u)TkX zu1Zx-OjVU5t|Topov(^+UV|`j;7qmUPb^Qe&g%QHe{&i)VY|-eZ&=m#A?XyRZ~guZ zOKEm=kjBCv>ARb0NNm9AFf8V_q~h2Ug93rLGt2zo-9dc&OPZ|e@{~sa0UBAPEj`YE z4PtD;vqI62;sxmdj`4Br;lpf+Plpo6wZKTRH*V2FhRqFFElPe^iHJ&*gF4WVEU zvzD1y_{u3ZcEE?`z+AVAG@>WW&3&g&cj_idIioumI-VZJc(%BSei_K>;DijKAe%b{Zct{p|Gg%{6#A0m0sCyL(r< zQ6&bPVHF=wi~2b$5FTDY@`gx#{gIP9Y49{v9QrcZij_dkJ#ANzh}FtO{cLt$z00Sl z;HB)%fp0&Mr74PEnv)&?xI2Fk8JD#!Ah1r4lVOugpFM03Rp}uo$kEsq$`qsCa99h3 z_er1|RD+Q$T4%qRPV>)Irduqly@LZtzCjLc`Fgh-h{sZia~!G@BCJw*AA?BzD#kQB zUhocpzYFqB$r(mPlz2Y{?y%piC!RIm*Jv?P4g?M$EDnDX7CP)Hu0vh< zpgPZ-z(qzzHXo90F-FZ^ND(J;B)9UdSl44k`QM+j`{95bcq`s6LUo*X$E#3N0r|Mp zUM>~pio`euDmYmnFk@du!dmR!=J>lnN>L^zEwCXWo6QYEv59+G$yC1yiTXIhf)?D~ zAztxsRCEzXe?YL=ZvubEI+>v+Lg5s#mwnAsPN^?w6H)sWeVT;k0pTL~1?>0Ixm9+% z_;*_clv5?B?4DIvuF{pwHPk31ERFez{th|>tO*!0hjfB@sRXj#k9Sp0zG{A0z9K6l z;48dI8?j6@f#dA!O364ju$SP}f%D`GMZ|@=vQ&*}?loal7&(8|g#Z>jkm=yxdtu?H zZbV^c`@MMb-FERS$OABoU_cQ*Y7&%=om4V41MU-jB{Qp7ugis6y;+`-X_>{{vFSZd z&kg?I`o=H}6Jjnz;9_X9CvW$tEMCUMeB-W%D8)c!qidgeYX*Mn5n?+%QXa#JE>74* z;-NlZBV7k5-57t*OhT5-Zyaj*qRkypbOp+{)Ew&tj80|>&8PxXS^EJnRRBSF)Vdbp z5~yh1?~~`2s|9abP3Z>%=E>a2mr@a$1t(+Ct3;xzLE+R4)s^$S_oF^U)!0JpyI)YH zcDFr1l?$lf$*;^Jyj`t=%DT&hiZ5n@7l1KBqbqDdi?s`Rw4f88{ z!%#oNm@{tS15wLJ`xuSO)GVib-+HBsQS+n*LgV8j&6+jJ)2n+R~!o%Bq*q?xQ@qkL=;?>()Kv@UaZTjq)IwI@FCn@#k=cobe7 zt#2;8xXgb&hyd!;gTqMI?`T}c1;!L@+-YLXM7~@ZTHxU1dXE>ie{5CiXC%xINqd+T zrIRG5_pVdWA|%YaV}xp!@fi@4R*aHl(UAmx)$}6a0D3^ng*R&UZ?ifzqgh8wwRhnj z11Z*KF18OWVxNcAz+*l0pfiF}|MX@yz+9H)iu`}rw@OhYsc(>p?&~IPNT5A%Z`)K& zRo!E%EGdoTkGaMqHN2{4oPbC6|I?GvS+j>(48QH@(4UyPoy%g0cP%n~+cqHc2j_4o z^Z{$la7Ci7guK98(e87Jhsv5T^E;cWi;_!qQBQZt^q-K%v&+MpmvIujKsh~kEB&>T zocVG=B#J2lFBk4WHk@-ng@h$B(TJG$md_9e5yx9T?Edz&-Ea5w-Ve~o@mNv|nlg|r zQS5OeK7Pui;Cx_I__3E0Cl%ET_Qc^s>sSxMGC3@O?W_O*095c8+yDW(nFr*QJoD0Q Qtv)afivj=u00045TB{53wg3PC diff --git a/R/translate.R b/R/translate.R index ab89cc44b..96792049f 100755 --- a/R/translate.R +++ b/R/translate.R @@ -263,20 +263,47 @@ translate_into_language <- function(from, df_trans$pattern[df_trans$regular_expr == TRUE] <- gsub("$$", "$", df_trans$pattern[df_trans$regular_expr == TRUE], fixed = TRUE) } + # regex part lapply( # starting with longest pattern, since more general translations are shorter, such as 'Group' - order(nchar(df_trans$pattern), decreasing = TRUE), + order(nchar(df_trans$pattern), decreasing = TRUE)[df_trans$regular_expr == TRUE], function(i) { from_unique_translated <<- gsub( pattern = df_trans$pattern[i], replacement = df_trans[i, lang, drop = TRUE], x = from_unique_translated, - ignore.case = !df_trans$case_sensitive[i] & df_trans$regular_expr[i], - fixed = !df_trans$regular_expr[i], - perl = df_trans$regular_expr[i] + ignore.case = !df_trans$case_sensitive[i], + fixed = FALSE, + perl = TRUE ) } ) + # non-regex part + from_unique_translated <- vapply( + FUN.VALUE = character(1), + USE.NAMES = FALSE, + from_unique_translated, + function(x) { + words <- strsplit(x, " ", fixed = TRUE)[[1]] + # print(words) + for (i in seq_along(words)) { + word_trans <- df_trans[[lang]][df_trans$regular_expr == FALSE][match(words[i], df_trans$pattern[df_trans$regular_expr == FALSE])] + if (!is.na(word_trans)) { + words[i] <- word_trans + } + } + words <- paste(words, collapse = " ") + words <- strsplit(x, "/", fixed = TRUE)[[1]] + # print(words) + for (i in seq_along(words)) { + word_trans <- df_trans[[lang]][df_trans$regular_expr == FALSE][match(words[i], df_trans$pattern[df_trans$regular_expr == FALSE])] + if (!is.na(word_trans)) { + words[i] <- word_trans + } + } + paste(words, collapse = " ") + } + ) # force UTF-8 for diacritics from_unique_translated <- enc2utf8(from_unique_translated) diff --git a/data-raw/_pre_commit_checks.R b/data-raw/_pre_commit_checks.R index 84e73e9f5..386593b98 100644 --- a/data-raw/_pre_commit_checks.R +++ b/data-raw/_pre_commit_checks.R @@ -368,7 +368,7 @@ pre_commit_lst$MO_RELEVANT_GENERA <- c( pre_commit_lst$AB_AMINOGLYCOSIDES <- antimicrobials %>% filter(group %like% "aminoglycoside") %>% pull(ab) -pre_commit_lst$AB_AMINOPENICILLINS <- as.ab(c("AMP", "AMX")) +pre_commit_lst$AB_AMINOPENICILLINS <- as.ab(c("AMP", "AMX", "AMC")) pre_commit_lst$AB_ANTIFUNGALS <- antimicrobials %>% filter(group %like% "antifungal") %>% pull(ab) @@ -397,10 +397,6 @@ pre_commit_lst$AB_CEPHALOSPORINS_5TH <- antimicrobials %>% filter(group %like% "cephalosporin.*5") %>% pull(ab) pre_commit_lst$AB_CEPHALOSPORINS_EXCEPT_CAZ <- pre_commit_lst$AB_CEPHALOSPORINS[pre_commit_lst$AB_CEPHALOSPORINS != "CAZ"] -pre_commit_lst$AB_FLUOROQUINOLONES <- antimicrobials %>% - # see DOI 10.23937/2378-3656/1410369, more specifically this table: https://www.clinmedjournals.org/articles/cmrcr/cmrcr-8-369-table1.html - filter((group %like% "quinolone" | atc_group1 %like% "quinolone" | atc_group2 %like% "quinolone") & name %unlike% " acid|nalidixic|cinoxacin|flumequine|oxolinic|piromidic|pipemidic|rosoxacin") %>% - pull(ab) pre_commit_lst$AB_GLYCOPEPTIDES <- antimicrobials %>% filter(group %like% "glycopeptide") %>% pull(ab) @@ -410,10 +406,10 @@ pre_commit_lst$AB_ISOXAZOLYLPENICILLINS <- antimicrobials %>% pre_commit_lst$AB_LIPOGLYCOPEPTIDES <- as.ab(c("DAL", "ORI", "TLV")) # dalba/orita/tela pre_commit_lst$AB_GLYCOPEPTIDES_EXCEPT_LIPO <- pre_commit_lst$AB_GLYCOPEPTIDES[!pre_commit_lst$AB_GLYCOPEPTIDES %in% pre_commit_lst$AB_LIPOGLYCOPEPTIDES] pre_commit_lst$AB_LINCOSAMIDES <- antimicrobials %>% - filter(atc_group2 %like% "lincosamide" | (group %like% "lincosamide" & is.na(atc_group2) & name %like% "^(pirlimycin)" & name %unlike% "screening|inducible")) %>% + filter(atc_group2 %like% "lincosamide" | (group %like% "lincosamide" & is.na(atc_group2) & name %like% "^(pirlimycin|clinda)")) %>% pull(ab) pre_commit_lst$AB_MACROLIDES <- antimicrobials %>% - filter(atc_group2 %like% "macrolide" | (group %like% "macrolide" & is.na(atc_group2) & name %like% "^(acetylmidecamycin|acetylspiramycin|gamith?romycin|kitasamycin|meleumycin|nafith?romycin|solith?romycin|tildipirosin|tilmicosin|tulath?romycin|tylosin|tylvalosin)" & name %unlike% "screening|inducible")) %>% + filter(atc_group2 %like% "macrolide" | (group %like% "macrolide" & is.na(atc_group2)) | name %like% "^(acetylmidecamycin|acetylspiramycin|gamith?romycin|kitasamycin|meleumycin|nafith?romycin|primycin|solith?romycin|tildipirosin|tilmicosin|tulath?romycin|tylosin|tylvalosin)") %>% pull(ab) pre_commit_lst$AB_MONOBACTAMS <- antimicrobials %>% filter(group %like% "monobactam") %>% @@ -430,15 +426,25 @@ pre_commit_lst$AB_PENICILLINS <- antimicrobials %>% pre_commit_lst$AB_PHENICOLS <- antimicrobials %>% filter(group %like% "phenicol" | atc_group1 %like% "phenicol" | atc_group2 %like% "phenicol") %>% pull(ab) +pre_commit_lst$AB_PHOSPHONICS <- antimicrobials %>% + filter(group %like% "phosphonic" | name %like% "fosfo") %>% + pull(ab) pre_commit_lst$AB_POLYMYXINS <- antimicrobials %>% filter(group %like% "polymyxin") %>% pull(ab) pre_commit_lst$AB_QUINOLONES <- antimicrobials %>% - filter(group %like% "quinolone" | atc_group1 %like% "quinolone" | atc_group2 %like% "quinolone") %>% + filter(group %like% "quinolone" | atc_group1 %like% "quinolone" | atc_group2 %like% "quinolone" | name %like% "ozenoxacin") %>% + pull(ab) +pre_commit_lst$AB_FLUOROQUINOLONES <- antimicrobials %>% + # see DOI 10.23937/2378-3656/1410369, more specifically this table: https://www.clinmedjournals.org/articles/cmrcr/cmrcr-8-369-table1.html + filter(ab %in% pre_commit_lst$AB_QUINOLONES & name %unlike% " acid|nalidixic|cinoxacin|flumequine|oxolinic|ozenoxacin|piromidic|pipemidic|rosoxacin") %>% pull(ab) pre_commit_lst$AB_RIFAMYCINS <- antimicrobials %>% filter(name %like% "Rifampi|Rifabutin|Rifapentine|rifamy") %>% pull(ab) +pre_commit_lst$AB_SPIROPYRIMIDINETRIONES <- antimicrobials %>% + filter(name %like% "zoliflodacin") %>% + pull(ab) pre_commit_lst$AB_STREPTOGRAMINS <- antimicrobials %>% filter(atc_group2 %like% "streptogramin") %>% pull(ab) @@ -453,13 +459,99 @@ pre_commit_lst$AB_SULFONAMIDES <- antimicrobials %>% filter(group %like% "trimethoprim" & name %unlike% "trimethoprim") %>% pull(ab) pre_commit_lst$AB_UREIDOPENICILLINS <- as.ab(c("PIP", "TZP", "AZL", "MEZ")) -pre_commit_lst$AB_BETALACTAMS <- sort(c(pre_commit_lst$AB_PENICILLINS, pre_commit_lst$AB_CEPHALOSPORINS, pre_commit_lst$AB_CARBAPENEMS, pre_commit_lst$AB_MONOBACTAMS)) +pre_commit_lst$AB_BETALACTAMS <- sort(c( + pre_commit_lst$AB_PENICILLINS, + pre_commit_lst$AB_CEPHALOSPORINS, + pre_commit_lst$AB_CARBAPENEMS, + pre_commit_lst$AB_MONOBACTAMS)) +pre_commit_lst$AB_BETALACTAMASE_INHIBITORS <- antimicrobials %>% + filter(atc_group2 %like% "Beta-lactamase inhibitors" | name %like% "bactam") %>% + pull(ab) +# for EUCAST: pre_commit_lst$AB_BETALACTAMS_WITH_INHIBITOR <- antimicrobials %>% - filter(name %like% "/" & name %unlike% "EDTA" & ab %in% pre_commit_lst$AB_BETALACTAMS) %>% + filter(ab %in% pre_commit_lst$AB_BETALACTAMS & name %like% "/" & name %unlike% "EDTA") %>% pull(ab) # this will be used for documentation: pre_commit_lst$DEFINED_AB_GROUPS <- sort(names(pre_commit_lst)[names(pre_commit_lst) %like% "^AB_" & names(pre_commit_lst) != "AB_LOOKUP"]) +# Update the antimicrobials$group column +usethis::ui_info("Updating 'group' column in antimicrobials data set from AB_* vectors") +prettify_group_name <- function(name) { + raw <- gsub("^AB_", "", name) + pretty <- tools::toTitleCase(gsub("_", " ", tolower(raw))) + pretty[pretty %like% " (except|with) "] <- "" + pretty <- gsub(" (1st|2nd|3rd|4th|5th|6th)", " (\\1 gen.)", pretty) + pretty <- gsub("([Bb])eta[-]?", "\\1eta-", pretty) + pretty <- gsub(" Inhibitor", " inhibitor", pretty) + pretty <- pretty[pretty != ""] + return(pretty) +} +group_map <- vector("list", length = nrow(antimicrobials)) +names(group_map) <- antimicrobials$ab +for (group_name in pre_commit_lst$DEFINED_AB_GROUPS) { + ab_vector <- pre_commit_lst[[group_name]] + pretty_name <- prettify_group_name(group_name) + for (ab in ab_vector) { + ab_chr <- as.character(ab) + group_map[[ab_chr]] <- sort(unique(c(group_map[[ab_chr]], pretty_name))) + } +} +for (i in seq_along(group_map)) { + if (is.null(group_map[[i]])) { + group_map[[i]] <- "Other" + if (antimicrobials$group[i] %unlike% "other") { + print(paste0(i, ": ", antimicrobials$group[i], " (", antimicrobials$ab[i], ", ", antimicrobials$name[i], ")")) + } + } + group_map[[i]] <- group_map[[i]][order(nchar(group_map[[i]]))] +} + +# create priority list for ab_group() +pre_commit_lst$ABX_PRIORITY_LIST <- c("Aminopenicillins", + "Isoxazolylpenicillins", + "Ureidopenicillins", + "Oxazolidinones", + "Carbapenems", + "Cephalosporins (1st gen.)", + "Cephalosporins (2nd gen.)", + "Cephalosporins (3rd gen.)", + "Cephalosporins (4th gen.)", + "Cephalosporins (5th gen.)", + "Cephalosporins", + "Penicillins", + "Monobactams", + "Aminoglycosides", + "Lipoglycopeptides", + "Glycopeptides", + "Lincosamides", + "Streptogramins", + "Macrolides", + "Nitrofurans", + "Phenicols", + "Phosphonics", + "Polymyxins", + "Fluoroquinolones", + "Quinolones", + "Rifamycins", + "Spiropyrimidinetriones", + "Trimethoprims", + "Sulfonamides", + "Tetracyclines", + "Antifungals", + "Antimycobacterials", + "Beta-lactams", + "Beta-lactamase inhibitors", + "Other") +if (!all(unlist(antimicrobials$group) %in% pre_commit_lst$ABX_PRIORITY_LIST)) { + stop("Missing group(s) in priority list: ", paste(setdiff(unlist(antimicrobials$group), pre_commit_lst$ABX_PRIORITY_LIST), collapse = ", ")) +} +for (i in seq_along(group_map)) { + group_map[[i]] <- intersect(pre_commit_lst$ABX_PRIORITY_LIST, group_map[[i]]) +} +antimicrobials$group <- unname(group_map) +usethis::use_data(antimicrobials, overwrite = TRUE, version = 2, compress = "xz") +rm(antimicrobials) + pre_commit_lst$AB_LOOKUP <- create_AB_AV_lookup(antimicrobials) pre_commit_lst$AV_LOOKUP <- create_AB_AV_lookup(antivirals) diff --git a/data-raw/ab.md5 b/data-raw/ab.md5 index 6fb3052ba..ee098f16d 100644 --- a/data-raw/ab.md5 +++ b/data-raw/ab.md5 @@ -1 +1 @@ -a6b3279028d26ee414c47e7a074b420c +9999a0a50e9717a93dd44b9e719a439b diff --git a/data-raw/datasets/antimicrobials.dta b/data-raw/datasets/antimicrobials.dta index 10a5f5b87226575bded09ca248fb24dfc9daa93f..50f2942185a6f9028bd855f88a2ef1fd4c61d607 100644 GIT binary patch delta 74 zcmZn-JPj-ban<1V7|%$rWK&H&eh4hj7p5L Tn++IcRVFtuT5tAMwO|GSvUm|2 delta 70 zcmX>Q*cv#YLeR)W!7sl|!N|bKRKd{D%E)A5XO`4d6?O&?uub9s(@{`5Eom|@qY|Ui OW&=i9mCYTh7R&%x^$z?1 diff --git a/data-raw/datasets/antimicrobials.feather b/data-raw/datasets/antimicrobials.feather index 9fd93c1b249317999b9d3a6e3dfd08e13585408b..40c830f2ce2a29424096fc5df0a1518144a9bc8d 100644 GIT binary patch delta 8399 zcmdtoiCg_3`c>tGzyE@ISAwOV{P+H^O^< zZS7^1-n3i9`FW32PxkIz{@(qVC%pSn-ksQ1o36Ba4`e;%-M6YuFQ4sA*Ij?DHodF% z{DxBR`C#3<|MWR?|G)AJ;XNQk-5qc9crRS)-HHCoyg`YtcmH99cb`?8j@jZ(*KO<4 zb@}=2@}B7?z5A5i?9K1rI@)_c)c2nGY_2zbe5p5GSE3k?H@&X5M90hi&-vxvv@bo? z{3NdMrU!bHVnJ=XF24(;@0Z`dHp5$M{+VG)g*UxPtIgqcZ@O!3vS)3&HYw`TbtR73 z?7iOR-HG;Zd4s_r-k+F#Sb7_~D6%dKAsTwxwCvWPEqRZ;JM=C~OBt~Nl#$r4sBF*fz z=>(IIflN$67F@_i4swx)$54nO6ytGB#|+HGQ+OJ);Km%xMJeWE0TyBrp2rK4Hh7U> z3CuBSj>~0u1?HGE$6+~Mg*oO{Vii`y98zmx4xM#)0~@drn_vzZbC_(w+t`Y2cn90D z13P`#>_(-hdVQGtBcdvNj6?VYhw(2Q#W5Vm34DQ*IEB+VgMZ^JzQkAf8s~8V7jX$c z;3xcy%lHLX@T=JvR|#(5cl?1raTB+32Y;gmnkIw=R_HL`fD`pl9}Un50ceasG(l4| zLoh-Rif}||%mK{_TA-!p!wrG%HbiaF4)N%Kj_8C0bU{~iLwEE*PxL}>^ufdEhyECV zK^TIeNJa`$F$$wG24gW!qdq1OOhg*ek%3H1MK-1(2f4^Y0SZxsVmyJFn1$JxgJ)5S z`B;F3ScK=W7%yT8UecoJlmyH03d*n?uVMvOVii_<_HPX9yOC%!wqPsX!4B-gZd76) z-o<{rhxhRz4&WfFJQrMn?juA;aSX?C0$<=HPT@4p;4HqxS2%}n@GUOl628ZesK#Yn z!Ed;VYq)_w@E3034*p}-`dxy15Iiz8SfRs!9Zr~!#(Joa2JlBC1fU6m&wr_~6g zAs;g_53gV?%m>FIoWObfWj_8SBiR?hh(<>|gn=-pV{;lVf;pXHl+nls!Ed;oJw zGN%%A`Y>k*b2jipQ-q;Cy1^WN!|@1QD8UOFQ*SxJ8!-FfVVFJ3>`i7bGJDEx*r*jh zm)sup3o4j-PQ87M=Px*RQS68OfLk7xFM4FJmqC z;ZvN#ulNrPgYJyBcmSzLM=s`J87i;R}fl{o-9(;@w zxD1P(afT3dMlvSCg*jM(jo5{wIEQLT2kSaCLo5=Igk%TppGELE=3qW5@HY10Brf7t z+<=p(LlC0y5C&rm9)latVI8*Pef%5Oa1Ra^_K}E3cZ|YhH=6=1L>XSketd>AxQe^5 zGYXrd8wOw`^6(TEU@f-dU7W&q_zgyVW+O!40rbZRi9K}yC-xTVjDLSGThF}VcF&pJrj~%GQdpP4}^F6NNF7yDZ4WVd- z1oS{M#=?anJd4Fxh4pv`yKxA|aSqkE0c&IW4;mpHZIFl|aF1a#8F?teGgyi>*owV) z9|v&~=W!K(!^yi*IO5O+{V)vUF$INiV-a4&8f?T~9K`8B+W#wpA8;Li!P11PL{qdt zXY|K7q+v2#$iplwz+$Yzdc1{Q_zb6U5m#^%GKiZ-V?>~35bd8p&=Z4@f^o=3G3Me0 zti}fH!6Ez$U*iW{Lk%3fB?ce@?a>WAF$kkE33-@-Qmn>CH=9Zv#A*D58~7VeUOAg0 z7M<`Al8}mtcpP)F1TUikZ(%<0 zNI(xHV=Shi0411@GOWd$_yEW7CBDZs+<`TWK81#eL>oMaL1Av%oZwMpqXaWiiY2JP zChS8MPT?E;hFkCnXC;I%v_L!bzyORz268bIZoG(cY{DMwHxC}b5nRL-+(NwwR*-0c zw&;ew7>!BDLlK_EVywb??7;yX!C73wRosEzoEt@JbVE zNXKJ%5{t0{71)AGRN*jA;amKM-*Fczie8U6B%mLLAtTC7`w+OX5G(Ko_TT_c;w&!V zD(*mUNe4v;q7jc?7=#o&iflZAId}mcyoT-AkE1w?YB!r3xCt3e<_JIwbVOe~0vAd! z8>Lu^)!2+ZsKN=H$7TElOAI%PV8kK;y)hKyF%|A&HnXu9OR)x_Iz;~6Z*t9TQeQHd&?z=qJpgaJXc212r+3&N#4}-oG5XqAd@4moE%qPQHoQ1&^xm@y-f}o zr{_kC0HdS$HoYh_+?AK*n&c|ZFB~mwsy!?F*M!<4LRFQps$70E(_QLQh3YA+GES;A zX{fH!M^6xHu5d1K_cQOJAhV$O1F7Z-tA0<)JtA#nVWw;H0qGY%BtI`nbNEOVNZ#vN zk+v5h>SMBcS4f+1j+7j*aMEd!k0J z@dXCpDHVO)L=>&5_~ZEa+vNT1k7`qvHApA8HO-OX9nP)!uZq`|JdjQpZ_e;;3= z_hM`}aJ2Q8gQbe_x7wRZ(M?!{f4qA@QT|;2b~AE98mXlz`8hLkXH0kH{pRm@&%eW9 zSHZ}}*78R7dJWaj!jQYnuA*89Lu?a{UxeeBaGYqYPKqE^EDYTx)s2Q$$Fo8YY)s*N zRUt1;KMFZWs1wpE=`wSL+Ca}dEb6BV$W?|W> z8BU>pWO4jt&Su8vO=P)n_G`RhsH?aze@aPVdY)6rRzgn}G_qOl2yC)JN(wo=pON5Xzes7-E$AZ6cS4U+LfHIRmxQ+cxhwT$b| z2;J~VAE$6Mv*=Gr^`MneJTj_?Mpjy?__iulseYV{#Pw{>t)p|>PwT4zKlJ-WL94}O7E@|R$%I;>P z8>@txYzb1WMUWn@*$>dhESZJlxTc0!t#Z3if85V8LREXKSUqad?bn5~Mw6f4?=`vn z-KVXzBx`z-RL8A-sjUE|N!_i^39C<6L%*o$$A#*0e-g4f$5G09l)>mMRkRi%dI-ns zn!a0nkXl^G9G5?}Fg^G6NJH%t4eK)}ZlSBS7LJ8Nj@RrjSk)+g!7)@=MrqWYdfg_9 zhP$SuGntQ&jsU5G`K^7TRB^OpAoZ{NYWC|E{g|dl2z8tmm~Qq(!#+-^p_)}D31>Zv z8cwgTmJTM@^`fy(ixmk;hx1jUUdL$F-5MhH3d>s>e}YiIN9rm_G*m4`L!Ut{>>bSC zIgl_94x=Z;GYAq@ki36^a+irX5-nsGp)(XpELQbCz2gC)66hJh+=A7rhTZ>RT@4Uc z$I|+Cr*7uh+Tql%Skxe^p?(xrW21%NsW_%v?dPnVl`&GY3E4itx-;5##9xdNjv;~> zSoWkoymhRmN!`9WTd3-2tBR3^K3JNaX0=eexL_cE1?VgsYYeB$M&B{)#TK%4mI;+a zFQNQg%C+{%nt3n32`hi!^Eqo%rBbg*EpQd)7tG+{;HS-I;&Pc!5ti8PGWWF0l(#D) r6M5>gn&gLAtl<`GVDq!hJizDH6i(kh}YEQ&=J%zn?DNuTYXu!rY! z-s^eKd2iD@bYf4XOUkP36~sRD^3og1E^$VR93^9PPdYc+pN1kiJXp@R zJw3D2zvHq?iLFRqR~}1WQ(o-YA~LT%v7l{dOZolEA(iPvXZpgxSV{LW;EL2mNq%wI41G_~D7Me%O2NP50J6 zbhTfyFXx6rfmAedOyGS+?(!g z@X!{&WK4Df^0xZvr*HDZ{XKs8`Z7OUvy6(||L-Gk!pq>;obAz?`}}lok56RNE(_E< z&OP9lPx6y;&8mN_zag8>&$idy^^fIwYgOj{vW?a59s3{jD_rI$MIQ3gy~*BmZ;wx` z^ULjQwbPILk!wr*D{6n^r<1Y2w;=gM&t&TpO)niZOqn}h98`7bBb|GdzNjym(HvYrfZyX3f=oyhRTzzNxB;`#g5^l#3GBf;_ylJV zVsc`*0zX14?!^W?hr{>`7Q4R0X1Rg!Jha)(J9NtFdxEwd28OyOAdvFM! z!U&06jIp>839P_I?8UqI9Cnz8L^Y-&73Xv}et}(h3m>Bgg>2NJsKt*l7YW>f2k{i1 z#j7}ikMR{E5gr;Na1CZ*K9=KgY{N_V&j|DXCnDz%$Q3C-4Aq#7nP|c7xDOk#0|)Ug zKEyd(Ktwa2sKR*6L;`opKoU!l#wP5*D|jD&!Flv$+YQASZ~sli3^bw*KSvsyuorLQ7`{TJK%^K$ za5?G_$DLS(E!d00_#@81;1$px!!QO@FbkbXE$8$oHe(mw#Bux;U&HFhI>2`@7Sj;N zomhp9cn-hAr%?SF6;z@c6EG7AEI}8Zz&^aypZWhYk@E-);6hYjG{&P2bFmOBu^!Lh zRUE;`_zHnSdWaaRF$J@bz&%LgSJ;D>@gMjcRuS`GT*M9WeN4`}g|G>C-~p_|Q+OFi z@g>wnJTNLygQ;l3Vywg_?8RZ6gt}NHj2OmX5~im(-HL^{2M=Q_UceFj6@g-reyBt> zeu&xVz!E%w4R{gX>~kN5E@&LJ3OIxrZuxEXC&hAynfljx2z|E~}^j1TZRzDA&ocLB;U8du_a z%tR9w;BKtOI{X^X;s6fePxxhmY_Dg5TkW7=<5XN$=rhc!xFcy29DDcQ^B)I^F-u){c0~qK3q6_358A z_emwIn&YhviDZ3CMDzf$woK`0YHTm7r`A=n{mPbjYhqqA)svTtt7SXca~HJEt8Y$L z)i9RQ<95Uwl2l^$4j6*(K^|vs&5I4mC4>sgMDGC zzIq-u#O4Kw_Qd=JJa2QN^_21S`1UoyNmS2kDG^=-}x5rx=JDL)0gq231 zc1mac?a6YpEZ#bYRb)s%GdRtRJYnjCQWE?ZC9_1And*G{&6eWSxRI@Mip10-C7_F> zM&Btj^f9H}TvauyJy%&|P8&D6qv?KS5?!Z`bMW%$3u$$s;^Wl+p|Fk_9$sZEE%mnE8${YAf$W9v;hcE4%&rX2SXN9QqrCqsqqOwnVQ2^NdIA)z-N zeYH~BQMNN&2_5NnlpZVgzfMgwFKSuT8E<_eWQ39-XJ^PgBl;PC?p#*S4hfx?&>_)h z-2(SU(Q#!39}I`)ihe9&sTalliMV-^`;w?swS-UQ>Ltq7Lq$33B)CiT5wUWYh|ZTj zdQqm)ey*u>4bckeW1lf~sj}s_qTewx%P(-jWLk3cG*Qc@HYJj6O^MdCD*U_(Ps`P( z{RZ@-V!2g{o<_oJC9FlS66MxON>5OBn7(-nb*Bo1o-u>tL_Z`dc+AjYF@v?@IQe>u z^p$ZEnq~1+rtZs)w<*iLUBag`jm@wu{S!tm#>(kd?sY-?4?%`X=`G53e*DOdVs zv7N1XEOq6!hsH*j%LdW&$>lnRsmT3< z=&4eqoA`BFqe3^D`f0-oe`(Mc%iShURO!)N|2B=Tm(Xt0ogw;rT>81#?iHd3)6zz< z0yhK#p;V@QcbzHYgpRPhRm$J*9a17C zN{=v9;98~YSdN$C=Z2-1NM-n(8EA_HLZZLo>XRxWH4>U^=;!^Vs*6=g_zlTTiMvB` z*@!F2zrs+?K2ukiuEfQxF@j-nI;`+M(e3nQjD)5tX7Z;xwV9cA6vg@``gFhy95D27 z*2?qB8+f-uoZA>|I`uz)a~+yK9(8Ke!8z&AvSgzmDP zTP&~aF4Zq|PVClvSt_BQN^ZXB2HN~AGnlrsOM_FiVA4cz3>}7EL-@mFz*Cnz4r++I7ouFU--@X19=8jo0 diff --git a/data-raw/datasets/antimicrobials.parquet b/data-raw/datasets/antimicrobials.parquet index 04f09560403b2d4561c2de76f114afd168c37d8f..f693a7106b11adc9ebb6c0963562eb629cd3d8b4 100644 GIT binary patch delta 2707 zcmZWr3v5&86~2Gs$2GPgA-*OKrn?S~2@T{ru@f8yEZ4CUhrH~>Aqf-}$Iom0;@WwN z$$2!8WQ5Z2xU?HErmBnRhSCrc#5%2{RTcI?j8&bgRNIP~G@+Jd)i$B-dG5^+n|5{m z-~XKNobP=9Irf$Bu1enii)7YSl6!j{F)M8(Y6)y3hFub`ww(2psMG5(3~Tau*?5HU z`IBO>T2diDy8$+Il!?WIkpXW!$zyVGIYaSeA{37?-lSaFq7C%Kf}Th+2W>F(u?ar_ zOeDg@WaXL-)e1)yD_XHcZ+V1+3ioU9`Aq`&gxIf zihiV<6vZRrjH;1|LAzv`d;+x9C*$JZiv}Wle?o62o$<&(bfBM!6%FByOrk!w?7Xf; zpKfMSY&_7zdSXST#t(s^iRzvz5)Wg)r{U3u~(cIX#@mFP-r zWdY@hzDV~Xe03?hxyJq4_*J~2xNzu$0_-qhok2rytt;5S`SnPSjmEE8ug=of3RElS zN36M`Yu8lzTx8qc?mF+@-e`EU0FyTj=ZLUuC^@IhmZYn5@b{}#9}eeBr?rk&*k~Pv zDrvbwTCN{q$>CWoK5BF+;4LRpqW_ zn~r$4$s5DfW1XsQ*SKA$9(zf}x|Z#_O=EiDR!WZZAnU@%oPdwmArHdcYvJ{LAn^@c zPmC$^kql#z4#1aW=@*g72s}0*bmFzT{4sF{Hm%%)r?@M|M+ zfUFt3ppUeFCKBruzuhL9`jutMq)1ycs+wbDjc(8K=pIL_LX4^I7!`KXeA=#C8a6|z z)3f!~j9WD=vuCu29INDp={=4@pR_O`Ed&hOrMH)frp}79puz)-bfe|;earhGZQJpe zGkkt?rr7#R%T%7vn(3b;Ri6$gqz`@TS4k@mY17LvoN46L;b;*i`n=$d{zmrLf|!R6o0iK+Q&9Gx{U~dK6RHqN%N-C8MI6CC4zkQ$**g zXs5_7&c5|C=E#VK zF??#Pq9#-AB+bn^qLJ@mR-L{OzGI`iOBZ*SB5S!mS9n+a*Lx>PWNFlx#_&jbPpqjG zzK@INj-by``tx~2d@6^Zkw$%S0bv@g`of7U;(CGLdDP20#=oCM{4-l{TsR?wEZoW> zo{9v|q!2PRlugVNf@8?S=lt{xPF#Ki37)sENO;%9>oVeFo`yGO=VZiFfWHoPzsll0 ze_fCf7oNfQZp(~A!L!j01VfE%)J~!mG~0@IXA^!3L&!u zCSjOA&;2?C1<#z769)BfrZ_EwiexYl!ym56wE3KeL3!L^2AS~%h$v9cpXOd?KoU&J z@Z=rtLk8`{?*me(9(tAg8-un=U|NQmc}^cj`|&T=a$eC9Cqcfbk&0P&c&Z%=k z&Kd6GFe;P43=Oy5<&;O!9?f+?^y>LDa>9+N-#xui{YYxS)iWpMi`_@j&KG1C4^#YA z667vUpf-`sXbLR;aROP372R|bP1gi%G;K?Ad*{%;EZWO`a}JrM7H2O-8N=MIIaDgO zhAk9T)yI9oBdyLsimDjoif^DQG{AM=KxWzgK?tCXRDip316ff6_wWYVEupCZMRjn6 z^N5l*I878~wsD>FXrHupunOcDxl4fHc0S7F+{Jw~kIJQuHh?Vkobo1=GVw`+Zq9KN zmC9&$35f7g6nAAF?Xb~F3KWK%P`8h!X;)u6th9q)Xcxa&`K6X$Xdbf0ywR#MFK^a{ zfvKc#jcF%N^F-xNiqp@dt?7zTcZWblA9L=asD6Q?o~FBKYaib&nzsL^0Bo%^;BX1F zLP5c#p`nmb9y!WCtwFkuPk|>~^|U<*WOR_XK`t+z2VK0MrqhDiE-0Y*Jp{rfoQU7> z1V9<;;@$kmE)akwn(pVD(f{1G@mY1X18{ItW30Z%7i~6rW5O8(e%FEhZSFE}<-yL7 z@nA>Apr@m%=f#%j^A6O|{E1yOJo&10H@^s4tbUs2{xyM$M5Y#-i!)9lO}eYRKjbwv zH8i=q8k&Off#z_1f3q9xU;^Ymw_99^um@yybu=3fcGfpEh1-oaaFjZp++N$(ezdBy zC3?W@t2@x+EsykehZCuTovopRb+yK>wMGadSnK!Ry;we(@UX|Yr;Df_A8dy|kaTO= FzX5)eG=KmA delta 2176 zcmY*aeM}qY8Nb)Dk28kG4cvhv8X0O_C?RJX2#_vO?#!1Bc8q68VEtpp7~ALbM|=ii z@(08vDIxAUby;3oMKoPPnq(oPEgw;|NKsa$O&4YVOkJc-jCE{_rb*2oU4x>E?zu~* zuCL^~=lT8K=l6V_y- zMO8oz4aY;E#3E~{teuVoG-XMCJec;^ijc=2lh|Z19tlK5P?ripwjH$k0220KGVB+BF}$;A-2DPU+2VskFA(awlmJeBI;`D8R5;T_)o?r@ z`Xwnc6bTA;f@pZ&UT*I21=A^iAQON}gOV1+JmK>8vVlHdLFH(Ntz^xyQ;4{&{oj-R)w}~ZXkHv zS0NRl2^rN^vU*PMoi+w@wrNY{RO)^;pYu97hxQ|C%em9`ccSwRf9j8ZdGqm(Nj*>f z^{C~}OS46PxcSeuqhB>Yo|PW$-B^_tZdU#M=vOztSv~6g?D5&6U%B>->n>B}#p--C zWpjLxHJH>Yskr!$CT+QKdgf(#bZGmIGyHFx_e($=3UrPQWuX<))Tb%@c?1M^Ft z_ebZKKJMqIDyBWH)d^_*Babo{K!D6qzYSNfPSqi;YVOgoLAl_D5 z_=69ERv8$w+DxwItxOG|f1~lmj}ZN_h9L+8^Rr(f!cfNC*+lfU?FzC!A_LdoRnePU z6yVGW<;p)6RP=^gL8g@}3mYnWkye0-COPKG6h+UzgB0ZAyQB<#dQnS%F3ZTy+7&Im z0rV@7_lZhIF8)SKpZOoX`JtBn*VE|h3cGqQpU&1PayM2GL8}elmf&4M)TpBiDpjSL zP%1H;TzNBy&LZu(lRDbStbLb{>q96;-2%6iIX!_dhfsol0A2;NHld>h!c3IW1%?KK z)Ek~D&?;sIXB#(J-nkg<%;;gFHxrV4i@eiTUi9j{YgW z7DhEB%+S1X9seba_UdM*<&0OdI{Fa)Ac9Kpz6dHLVW{S>XK;4}`KViP!^C7?!}AeT zMZ$2+%jfYI5frA@mDubg?i5fH2~#$&F5!~`+D)A}C97UNjz1AlJqhDBufKs&6z!!h z0b^#qIgZ<+sFH-Kn`h4B!%^gg;(RJ%jF_9`o%CJx^|g?_B&LUki6h8*In3c5KL$9YEW z9M{6(&?4HW;vM+?MO2^H;TdDuIv@UW5$(!r^)<08!tL&4zvA_Ad`J%IlRZ1fJ7h73?DM1YP!+u%8HZvNx2;Wnd6e>G z^!tRe0Gz&qGA#diMF48zIG0b}TtGGzpR>qTI1qP^3}zZKUGaWlu){ef^KH272HO6A z%|c>m4vGvtP0+67R{A_7*VNkD=^9OB+=9#E5_&pazG&TnmQcMN?A~5)dzUZN=^hJN z>;eZImvM&@N9=;b<`P=15NEZ=+*02m_n2L1wE^Dg68bVO-*^uIj!tOi86f-7&OTc> z9Ei0EgYCT;;H_>h0e#3-@O+Qx^z@D;#bAe59EiJ<1Gf6z0|$F8eFwea!S<(ndAgwQ pw?UK|lm67<;b6KpkWAM4Q>nzLaU__Muy_MCQUyKmU&(o`{{^#@p0NM` diff --git a/data-raw/datasets/antimicrobials.rds b/data-raw/datasets/antimicrobials.rds index 27f92517acdc25e0a24426d8664eb78a1c587d94..471b749799f7dd56abfc93d9f40e3b82dce9ba80 100644 GIT binary patch delta 41456 zcmV(pK=8lJ>jJ#(0+1O5@;kPFu^j{!f1FHrsaka|$dD)+;7qI{wKsL4kQ0Tj#uR>_>+Xzh=zBs)@iq6cO@dOi$9FYUPM@Xk{uNrIpie*{Sh6oP||aC zk~@6G$L%Sy1rGkVLEK_*3L$WR?+JYc7Zz!qE5A>*)iK5}BfveGCI80_*GXh{f4>Qh znH6$$*O{1M_X}_M;v`LQUvtfT;5x5XbYzzCp-_s!(W9L|aiiunu0^BA5;)U6YGn%I zXCbe~S~;Xn@3rJ+CwKiwedAL8)CzZ9?#H_!IpGX0r)%Y*y(k9kkIG9`p)Y%K-7b5& z8(#Lm*@1Chbe5>xu3;C7k#EtHV-xx#~{ljWQoHgJnTeDsY~Y zq*KX(Jyh#@^KruA6;I_$@%<-i*8Le6HXw&{a9X zrw=wze47^-kH`jDtc&}vfJzHuxjsN2aCdA;B<`fMa{YYpv`f&JwCxn`;wmFuf%2vFlUQc0B}FQE8F7=L|uDf)LFfK08*5 zZWxYWbiipyh{NfHo%jiLfEu`V6mm*xmaIW zlo@pZVfO4LiA~e$agB<2(rTo_WN=9sayGy#Z~?2MlKoEfxNl&Eb-@%_v_NY&MbWN$ z3@NlF^KJ5^aZZar|JZv#;uP(O+B2zJUSNcl4c?5*!dsi%ADMQhe@Z~3-qid-bctVJ zv_Ur$QP+c{@H64Y-X)r;xm-i|5kyV{*|~$#P8~h9LsSafbp#-Y5#eE~Tr^*a$zyrK zC!Sd%;{6i<+emExUw4XDC6<>|)bTU>^^Z9rp7ZeGUU|_Z2S`6uNfVe?q=n|Z>&}nR zjiwi}(6sKh@Hkkue=i2NXte4E%Kl)ePe_3;qgGJ6K>KOPg=tLuga0&G^Z?18>IJ1t6T|ITGVU$$_FwtMOeI@)KEN5(?e8B zx^nqmBqi5v;+U4a0je;v7(zA!Ic;4CTcU?tyH3_rh8uuGe>Qj+tdyUXRN-9d5MyNE zba26upQRkrx>EZ9$YvqB@*G(9lGxUNXdA^ind9fGC>7P6WS^4mEJqznEy?v+1K+CI zWMtDd9f!AAoJ88G2q+DeTNmrZd?!%qmiM`IBY>?>xdjBID?M1k;d(0#B)cngb3g+( zk|^#f+O6ime^)$XiRc9K>{`f4?Ni_4f zYWF6+f9(w;$42l@%U1Ht!>eOn+b|GEoTvl=1<@@Q;SBk1{uS3Z&U`pX>c)ubAN-)3T8W#{H5Ul-(XC0`^Sz@6a@Pg#_zAHjPPBd5VjBqg#{95M7dg% zh-HeiVHuI(oADud#+I|}hBD5K0}br&vFsfxfA~Md5ACR=$&B@D*n_0B6;_3t!~`(c zMc9FGe#qy;4$IE;^rM4(A& zf02&RqWTjQ4bCl$gmenf7rd>FiBzex_+cj_PsD)oS&ro8t3L0ggUf10gQ7QW9Ph}exj(ByA6gQ}IPcDg*j{lD$i zczgOe-^&uVmPmjr&(ai=2oSCwC{*-8jhPI}($-oM=a=tRi0f`xL%@?ijD&zPR^`2| z!K;!3(vutX#nNuSWjG3#NP=Y@2@?MSaMvm(N(3M2t@NAJ63#Q~P=YF?qdy-QfARd9 zO%sPra&!i&I&8KSG1>mN=T_uBKQ!JlQDZ@Y9b=+_puDNbKS~z;8 z&rmGSIFdDI!FGK+;lEAXdilqe*k{mE2nqM zgxCn_{#N}PF@WL50E&HJS*3Sw)b-H~+2vC6rXnb(*8pwzf70J`N z2rZkuIf3(_B-nxeAU|vWfArapbksr7CPCId7YWvyhCwX>YiXl84R@^N{&M6Uc-pie z*?ybx=cQ45nmXEe=s7e&k4j*_kdpw&UdJtD|5N8=%O2p;^hYgo(i1zE04_s;vnq0 z*LEw&UK=HQln{}#+X^4}6JIIT-MBf@CktH$mDp;f(!{8%Ucs?QU;)>WoCu8xfN7MC z&2lX4KF%&gBT_}p4wVX6Jmp4O4B34Nl0*K~q+CUTraGVkf9g}Q9=E^b=(K0&8+k}N zXf(cr!AT$I!nZSVhynlyWCKX0qCksW&oSj_e8{$N@cF)oRdzUs+Uq?yiM{D<55-aL z9Q;kb_BkSJVK#U3vRy3P4RE4+rH>Aw{Fq3eHecelNC)Kgol|9!L0FWD)p*)6iw0{G z7w|f@pA17qtBGBg7D3XjQh}F%3Dt zzg+KKdVrF0R&ls++}O!f{WHSp28(uXIY&#x+McA6fGfe8)n#6`#jePUm5$(;6R10Y zdpH{V%Q6ij$-g!q%3OTg?_AM3m^4412W4?8go<;of1`GLN=cQTo>>w_R8XK^MQ(XhEBHMx{?lcnq^dilSuh#0KG7>OhU>`!{zMCm?(3@8J<$|?u%i3iA z)vg+*TnkUNN_LNczy=J_HxgkHtM+)=j;${e1wFQTZDC&GLA!idTH!k_fK-Avsj8xy zcEJ~6w7GPSS-6|l=pl^sVWc~G3MA@Ge?*a5+Aj=sRG)RL5O{!P8P+6A;9#oqU`&yZ zKridZpC6oFKU4c}!3XV=L#8=3RxMOv9~@ttg+_jUopR&wLoy4SKnYxr6^2kS z(x@y4L0DBdvG2Mr{UZqR0l8Zaf4!QJ<;6d9`c$M6h^o63%)Jq0f&hlDw1N>Z4RY3> zOVr!fL3cxzUspo{Rn`(lfG7S(-kjj07RQ*Sqy{$~qM1QL`=ZIwr-fJMVKVH2R<|PD5k({37$M-3|zBCLLmE9TO0C=$NU>?<;|$i`71!&fA@mu)ohIT zeW;TBjo3&K^z@D{dmqRS!&jo7Hqv(&Q#>%p@bzw5+5&Kzlt*uHkOzH)Z+*eVe*a!P z;EJ`(mUXH+#oU%dk0S#A)mSbUS~@q(cIQ*4#c%3Q|N29|edamYK(qtV6(dVd0^Kt8 zu-!N4tV<%fh7d^8!)5CGf0=vjdnI1-kRKB#y1F{I1%$YMQE{2T%BhoN)BggwgcQlK zpJ>=p=*Yx`biNubM%mors%B4HGc)y zMU*G#0O{N64v13j9RU*g58-z%m53am?BHX2gTq7Z)*We4bQeuVO$BTdX?w`AU86qU zJd|{S%3x{4Ik|`T+A9d(Ok&s$iiGeOYe_~TOJ0x}2gSLx(>r8v! zdUrs8wSy-a0J9(Zb|Hu8j0K<$8&6tykL?UPU}_E^Ep1`ApTVq^K07uERirj! z?~_JY-p59(S$~PMn_YB)31p5R-SuzSAx__?vlhh~f!-4=nd@ZdUJEIIp6^tXOhTgK zR{xVDe@IL#&B=FMzaEG}yoJAoLDgE2vl%Qa44&<<=_bai1EW8^A{-e^1V&}%r=v&a zFVZ53GFp4wgRHXj1y1{!Rb7{6z2SJu9rORcgX}p*;yMED!*FMqeLmqW8BYPK*LgUy zlfcpsyTcNKEz)K$1+*dnEfnsmU_^PZ?7 zK`V8AW@5c<5kl#V>ZQ*+?cic9AIkJvYV)N~wV5@5K`>MB^Q7Fr;GU-phYNBgUV$td zCAqzy#d6;p8pGCn9m| ze`gd7=poOs55-MzrFjL^&SiMjl|7N^U778M{^_hhaM!sY%%ARO>~fWaF%Z4>v_29{ zzs3<5EdTj$CtLo05y!c0a&ehY38K}z_W~|^ax25(HAMZ*>_F}njsh-&q0c*T9v2|> z6f^jbk?41C_L6E(OeQO6yvto}2c5q!f1J&At)qh!e`lo=C*HQBd?D}I72SMpI766C zWtGLceejk*y&&01yij_u;sO8|-8a+9>@R+3v9a^B0?Kmt;_Vo?`NQQ1Sb4dbUh$`I zugImDp!(DLw9!dauDxvIP~smLU@r_?-h&eR*9Us;4n)>#YNwR$R(9 z6(j_3xCSJexUtIrfnWRXMl@SvE+OI-!2#C+YKg{=_lQBI5=I&G!}bQw`z86>x|wNzm{|TOvv&ES>_v~BAU#Q??Cj;pGtY* zhe5$zA?^w#k%E+}SAsLm{RP4f@%}BI{Hg`X8e?tjq>^o5)vnF*e}&h@!bixa)r915 z-hx!{H}8X+HHEbkz~{Je*iKHU(6diSm}vA+Fs~bB0FX){pv=GWxNY~n1w}5d0Iq*9 zB_@7eba`&>@{6e^p*+2-qc);z;a>CEkbK6NVc4H3!5Kd# zGhXfp#cU3c3Wz9Oe|zvZ@g^hJT?2p#Oy*hYA{M4 zJ#pr%-0!C2e?P%$@iKx3zoKAFCEk33av~FLHy7!6>$M=j;y_gUJDy7e}d9V=Uzu3n&Ps&r&^3r3;N2e9Pxavh5?{b3l;1D@XYjWWoJzjgYlWI+90L_sVDYp z3>2lI}hmSbtE2Es;xi)(pw#&g{hyC_sldT9r`2Qj0hwWmfXSxP7Vdt#j z(IV(l*~VO`T~aBVORGRe{#mLnfNamrMrBpIf0LE-2jeKxmG2hb8^p1;g}s@uOyDhz zU|h3I{LgM7Z=LiV%p#xYxa~nc!>7!(wY6a}sKF%R?K~(LGPl&4{Jr=}x36}Ht2XIc z!iJh+LcaTvj&~H&QYIX&03NFx>Hjpbzf9s?`;hOqDIy{{-7jv*C9zccO zV386FJ$2z12l-)683MA6e+%K%rJ;$#cxsuDzr>`yD$=Se3_O>cH6|D-Yj;EfsaWD- zR&#&z0{r_uHOZEo5kdF%St^QA&fi!if9y6Mabo=b<3>W9C`mdom87tWUw0?!uXx7J z_xeh=#@|e5ltyaT9_G9vsu14a-? zrX^@-5`-h4V#(sBgbDTWUrAz;P)VnWIbkBs=`18A^mscag=&;D3GMm%mfFv3?JQ}^ zmeADqp~irJAupV(BS=?a{m!Coe;ZElQ+^qOiG3rkL#0o4>|q+0cn{?4(Xvm~ja*x) zrSy*K3mtQ5E!2*YkR_+exFdhEC(oN5hW^!jAS@-g^?rsM#7cOTNC6%W-L^Qw zGZTB2f$o_7)x?hQlZQ~Uhh5@QK~a@B>;iCey@4482H{$V@^l+&Q2s0+f6owb6Kf>A zNaLATIkVnpyw+Je#auPXOQI^?&2qVUkLXC-`00MF)s^}KK^S3j=%KpC$m82=y2QJr zmb2=o-%}$hdsE=dgl;!c(t70+xhBytG+`lE?=GbOoj+D)K*ZfVErI!;!#R>!w>5n( z_GaYy$VV&%I?6RgC@n*ce`uLel;)%F(sPzZM!g)Kl}H8YrPI>XWdGd@Go&sK810dx z3H}W0TPiZU;}U*{+Lbzn+(RwUz8yN~q&(&~rkd2&AT*X9ZXNdFN*k z=^w3lOtw(H!*6Di^!xX;Nld;&JW_GCc#@KTSMC4@Y^@+%O>FT$Mrb>wJ(D%>d6EtI z@@wlOk~B&;e`jJ55^fY*s`$|;$U$1cIFV8A(8$0Smf+!le<~y#S{0&fe+O@0suLg< zK1a|b@v<&-q|J(KguyIE*#!YY2z5kL-=Mwjw`vcgykcvGD$@Nlbp4nFhO*&fJqqfqe+v_-MM>hws7q zRD^$LFV-v^-(CXre6>hA)cr>yxxfEH|En;bN%jZVNs6l4Cs>R1(=Q_rkMd& z|DdLRC&0AFYO6u7AJXuMoq!w2P~CxyMB;vN=h)6Ae-c&X2duT~^9!Bkpj-*eONa|R zR(!o$hKqVY1QXF=i=T!~M;&^cIlS{AM+b6Tf)u%o2z#V`&P$y=BM0tg`LSMxcX65t&g8ymQJo-r!Hm}-?_-E#i*CKY{`=0 zcet&aR>ZyiKBkZHP1?_TOmcZ*r!C+DKl*!8}*G+L$>e_%YyTf(R*Rcn2fQFqE;$d#a&y!=Eo ziFiDR8MpI`6y`fIRG5oJtM*RjHt+S~}MpP%mG05tMvQ+yjKGQ65Bb{%R&O8k34jKUkGq8=FB?F?|<&mS|qF zf5VIu-@A~1$GqF{&BdkHC5RwW5Qx|EIq_2jK)bipZ`zBwfcJiBh@PCv?eBD-yU`Ye z%eK~wMd~7nY9?!R=sJ~YhGpY@Yq`)7kHqx&-eTX<(hE3}e@yK5yaDq|6!&IC(76*H z+>2NDV>Y&)Zz130-I>FBc6o)ssCmnde|m%OhC{N9b>9UsO(fBxP4kS?c@HF36b7Ma z6yHsYNQC4U!E`+UL7UJT_?l;9{!1Si7F51`2Efa!K1|2(KQ8X5x!WOUKF`fABsW zuLyVal{<7&)=|(3Js}$uSZ`n0!9OR&QLK4NjYO>Kjg`naF}JUA+&n@culDo}?Yi)| zQnqBjS>~{-DE&z9&>Q9G8l!ui7vlGS%~<^_sbkr&Cq+> zDTqcGlr5+XjMsNHuaQm|lgJa$e;LUHlJy01$hY`Ld)wgWVDdN8o819%$0-rZ0nVaz zSV=l$iI~*$o%$0d7jg**^ryoerSOIP#sx-Njt*&8^zQah3g_&oq=j9(6E4c7X)#M_`Co+cHy5SRuxM2hG$z8J+=Gy0rtl6De#G+K%% z*HTf%CSuOl7i%r|d2Q8Kz;WQ1z>9J0o(XQ!O<1i~A#_2j3sQ_Vg`dOlr%r`vXSg$~n(1F`1N z#-%R5HJ}96J9@lku&}#je_-GxnQ58_;D24a+=|5lLnclqyKT6vYY}CYGq#^;5f2IM zHm8Gj;cSreA9$DdUw;u%Dw1?X9&f=e?4-&c^w?0d@1xY1nba}V@s_<}zTb_6Z7&e$ zqK3^NEjFDi88SJr7(Btz!79x|7G5=(G}R#I*T@PjI501LlS9XNzixO?Fu{{#fY0F2ofu6fb4kH$Af7)CSU46{H^Q{S+L{ zmPP!WR13?7#9D-@0)wpbndmc4R=A+9S@-LcK0%1l>`r%MrNmcA2-(}_03ba%Vwd|f z2h1gm7}Ucd9^}CFe=FQ*2l}h1c7X_;4dSLUDL(70S!}%hRdSM%G|cF}&A>zM1wzCO zy|Kn0Hzhko8`_#{<&`?*w3Qe-vIWA&QXUe)BN?u;l{Q zPm%2o$ZusGY$hUAnIF1;gCtBVqf!j50ph32WG>E+&qCrmJ`kTL#Gfq?dsif98 za1wd)zKttC|KoqL_pN=mG--VL7`ZP~rJlhsJ4)lD@T&X!V(gZSnc}wcs#lTLCz7sk zGOt3{d=$4xe`&q90xn%ry>yx3F`tU8FgqB(N4Z&+?LBiPfnQ}{hJf&IYJR2THjsos zQzd@M74~okyBT0%yk!m*77>xpKgf}|lg@*wvO2KeGV8ckk9%Usa$oj-F6hO4mV?Btr+Hc_<#EI9|`0ZazrQA7M zry=f52z+gvex6f_JF9t1%m#pHpVvhY8<)JgfNjvIxI-&>ONMOL^B+Sv zq_K7af#IE%F1b}4*ja@hH$$m}Cf>q~{;pSZe~U?`2o!cjRUZCTQJJF+q6k9zA)s-!0Ym$LtY{osj5J0C86JRJMXTjWd{LpPUe zgwSkAMhoV~-N?K;-90sAA{CaZxQt>-ymb0m1!hFLS27$fYFR+C+UyefDhYI9D+%w# z8G)Y~$bh@t$BE~jLQ(6%^5``Em6M|se}Ss!mv zFF5cf@;2^^V>8hkN9NGA}ua_r4*JRWW0t=RI+*=SPF76BYCXf6bm9 zh!<(vWtkg6CMTB=tW_^f4}qoMTwsV>_+We#VQSU%7H#r(5M#-2twKqWluXGpRrNw( zYH}eV4E$|X-52ZTw;H*{H4Z)Sw7kdpgkmjFy;_K0%=dKaas-AuNFy!nz2l3-^3g0ea2( z!#%ep%c&gXi)U)>n}jh80+ofToo7ig)~0l==!UV*pXIJDbJ-vp=<2NC%$nY-Z~B>l z)!z;=Rgy%>^QWX8@`h#m;TH=+gNqjekw}#7W)PUt&PYRWHT$`3&q?`If8Xp7sJ#?X zZ?;%KFSRNmW%Y()JGjLsH8cS`OJbvpbumWk@c}yi2=wH5*y7)i+|*8@)rp_E5dX5X zGGpAHrfpWM@q~Y`ODL-XvUSjn{x@h{or0u#CjJV~M!WJQ|J}U!D%U2!bVSJ|M#n9x zVl3#|d_6H94m!bzK8HRRf4GGdgH!kaT31#hd#U<7oazl_x0-MQrL;BvvA4nSSk!L9 zHJ$nf+N*Qn)=fYA;B#%4%St(iQL-6Pfj(VCO8&Bf5`Rnb+yx z&+(w+ontc>A3Nw>81wfj5w)t2yHx-=)c;*_1v#NEYgxqgm*scZf6G2(iZG{xOgP?t zJx-ByJn+R;56LN(YBxAHWf$f!`i!2AiI$YS;8<4>4+`*qxyP$Iba0nf0<07!2pG{w zn=}Pa6*V9tK9iZp)@|f&#~(ewv7zS1EW_SK+kA!^oD5J=A6SeU26XNlFK0XF0q8W6 z1zF$lw$&Y94o<~(f0HD>cHfqPg=Dyr9ldInQ_U)itys9H?hXliN&{4Ia3Z!2_4F#q|DS@{Jtaz8kAy**+jxdq!H z7zcbNXf0dPyN4UV7IId_yd3LZw6v7)#+-;|M*njVXdxok&i6sl8Mw6 z?T0&gG#R;MrOS^_9Ij}OZ?4Bu^c1G1x;#{_XH(u=^A5UJmf~+GE_8-3x^KC}k2SHpz4 zVY>`kn>s|9(5&=nEw-t>-|2E;G-{Y*f8m}#8hx5hG$6=jLX{OyeomF1WbObk!UZtS zMgqwRTMAR&0j)u|$3~MLGQY(=&NGJMN@)AzxbUp%M)m`2^8%sH_N=$WGz#P&c!8q6 zGhu8r^!&)nZ3E-!miYU7Kl0~)VN^mZrSj36dvgHl0WKp9#^4?T2S}k59V(T!f7yx1 zDs)HBOHN@O)Q%n*GeMFR=%_ZEZZeRADkOg_q!HloGj=L&okCqg`4Xz00w=th_LMm~ zhwa+Nr_C>i<{+n{_yQR-HtOPN^QA_!x^F_RcdUU_#D~{FcfaXR^k=vs9^-IwJ+R@# z;RMEJXv=v_{#-$T>PHg(7=))hf8=~DHkz@lVXZiWX*6GH%uOfbLNhLY)riE)vb%@E z!S}75O~19s?_)LI`4=#!}7!r9no9ptFuyC!4A^78N8; zOX~LktobVavN-vioLti;u^Z{h8pQW62Cs5}tX=7zTmh^He`&O5A-@Q1 z`w7$Ln%0QL?^A9}?wYNJB2!hth?z?Trse*b@X^k1SC(1@6$GcQhtf(5Jx&BbBvTl3 zc|6*2iiENEe9;AVnQcUPRgjN3RTFlkse11B+l?Xi1U)eU-xJyi+%YFWi=WcUvf5w+ z2-z7m1++fTYTNrv)0syOe^3zJ#WQC`vHtI5lAW6ZsHd)edLwTe&YgQS>jfvqXdH5L zfIzwD(GLXAr?Dwoo^0eWA7LnQwcNpl*c0&HNZ4z*RoGx*Y?fc7?pkzhI$HkPe(AcF z1g*0<2eNl4LQ5EW;kQ7&S7B*@V-YCWe@4c)eSn6n>lLAwxX4vH`U377O!tEo^t8-~{;($75laKiRbz*~ z!6Ixd&%)lC7$Y0U8=)n3_|IQ7<&Q#@5hfL|JXvvf45|0tZ~WIOnF??r7!}5 zPH&2r(X#v!^IuXYJ;A=IT*Nc%8<@1TaK%MD`WO^FNE1)|T>@`4IJw)PNl@;|#PkFDk# zPo0rLzE3&~4s2+uZo&AP(0YD?sHkVPdFzwNtRs1Xf4?OxD-Eh1>hKfYSa6m>VFT1& zmvH%M41)oEX|5qIHfxpbsVcl?JP{5;jB!1@WQ+$#@R@r>yrVQP^*bUg{6WFMmwY}~ zBjO;Fq8Z~-fz4VH>kV0k1c_?8eA09=kQ*?lvci~yo;=(gLWJd`^zsoz=w~tjF7PH% z^^%!Gf7sup#hMt&izc1d8N&Ab?fp4~S5>GqwC0laMjdC-{)!&rR!rGH%9}e+Z4ST% z8??d4E81>nPRkZ73@DomR-M0CF<|^Xcd{P6DcQW}Iovw5#^)RX2d3&0V~WP;1?Rx*ozH;6yq6Dgb75+1aA!rh&Y+%G z&E4E2pV9EOrfy7(#$eLn{Q|s{qj0hvzAAjC#>}2J!pH3DdKOAtv(j<#4*cr_e3(r)CO>J^xpBgCQwnI?*(q+6+=_>8H?zkb_u}I$|JVj1p4IO66Vs5O&V#8&!qEhv7<;$V)n3o=VAJd=eh7%kOZe}a_AT(poH zjbD<>o(6=ygMaN*)GZ44`*+>JU3HN2&6E>fmx3UAPC3LwQn23wiP-KvW;+#S44G4E zrsLcI5Gh@Puvu_^^4)1ManAzI%!ee#N-fEJB}>?vt@MrbcZ)SC>kFq$J66b#E%&5X zero|BuOF=6^N`mP>$l?We+NKha-5a|W#fGLZYDUEMYGU|M*xvyc@dI)a;p?va0xDB zuPUs#j_uP)0Tu!%K{@tE3#NeZEgU6{TA?S{yAUgu1D2r4Dq@!A>@=%-YspHS9 zmRtUvDg^BmD~xf4HHw|5_pWPZ&&s`&uQPo>=nm>5=D#^r7$B{_jzUhnEZD7NzI*5 zV*wGtW^~zj`Tq2kf0Wo*X6&KFLQT~Gwm9wauy~F`OcA!=r?JUJK;9Y=>uq zG>4L7y^|6Y&D6RzN8jdGLYpsOiENuyAqaQT`Q7}bC2jw|e?R73D#bu&uQ@Y#c4M~o znx~$r5+gDdl0x3M#)W{Q1@^8xsONYQ$LP30^qoOmNV`zHI^*Idg9He|;{!mb zqhIbsFG_Lp*=MPI2lU4B^K!{|(*814c$P9}JsVN50}ZPo#7W;aO$`cn6fWo^Qidg9Vt zh-(1keFJFTB5srE+;*8G0^L@$R>1)I!$mIGd+u2d*h_vQi7ZFKM+94*5VV`x_kDv&6C#Ns|-CBJ+G3nO7(u&Eg%8jj-2! z=U@p(1lkV6v^VbBCOdy(B+ZSEe&nULtceS`KHb0B8#+U_A)&Guc((^8KE8q9KQ&&{%}ucoVN=86}PnZT%Fr6y1d4Jep{LSi=mU0vIk z=z)mx0Wzkf8^b1Q$_9PfYZ#HvdyLxH4xxYUf3(LHog4xhaB~9I0COeW=aYD@O*d+1 zHXAJL`z(5yKGxJr9AF4VC`6?NT|gC(88bo2F7k-PZ= zq)*wf0%<8S@$<4S{f2i9ndZxRx+Mzoy{jS ze`fp$oaCm3&V(JRv8<`mLs~fKGI0vxSfpC*PsZ;z7J^$TKLgI2EJtkWTIHPQbC*)M z_RcX(T}kXr70Wm*D zI@qYM!YM|=Xv8pZWTC3?d&3d_B7LHvDnbdcvV}f^pF9~P7|P!8w(9qv`mI8pHfa^U ztnA>NoCNTZvXlt1+G5zbDEKR4zhVDuYU@OTbOlifm36XXLdP=hl@FK)RB-bBeUAV^d@J1d6><&#ppAYU^9GlT3Ms*n~n{1C$Rn6Lz~5iIEz zI7{H&4?c*83%>tV+@J5eNB)>;AxRAFMX@h5Kb3l#0*3C0gpt|mmgrYC`*wInOKEWq z9bw;x8%nFuiiS#Vp6I~>6g4a}e_KDNfQ4of1I#2B0kv0ARvKRSsIPK+d--iA$o~mnL6M9#C2q&6X2 zF{lFUduRBdP}ERE*(}&PoP`s*Ps;S`(hxMfBBf26u4s|NcYhlxun}D7e+lvuFKKmJ znpY67x59^wLt{m|WV8&3mk@*AD781gk#SN$Xye{5Uj~(lt=~DXt6_(X3Ph_5WL0~* zgY$PY%oCci&_PZYu@~`$4Dh7+1KXsk=G7oFn3c+X+y4;CfCt>%7y(x>gmrA22k}NUoxIb2A>BRr1g?)b{#lS10K{Pp<7MuDbCF_8n^gh40xC@Ij%gqQ$`;8% zxqse@*L(MyJ@3L~*c`dPG|xbRC8sy1%`|0y!IRRinJC`TK>=XXXBnR2;B4HwxlKk0 z!O0*Un$Aj^w>K|5e{TgFywgZdDlmq+qT90(76A|DhcEwbABXkWw!U@%?O(Q6xF3b( zp6h0^l@@Ybm)*;f+`n+jpusK>2%gTw>2U9d?Zqw2g<`#)Lizz4XbP?qOx83ZprpCH zdj&*~afsnp{I|HS%dm)!KST1$+KJTr;TQH{&s`@z9L?jbf42?1;bmNuXv~e@m0->7 zBz1w8M0(EG!I91`IW;epku0!Ehb&9PGs5;$R2T1M@gM~cI<(PL|Jy$n=6fb|bymZP z1t)P>8|%Tig@@5hpgmB}nSWQRgRR>dvN%O3vw$+aZ;oz7g94nCtjfcQ2QN>&W&!K6 zCh2{@JWO2Ie+L8m+ZCmvE`Zz`Rv{a&F(R(2e#}E4T=d&0pOT!{>WgD8wA9ChyV@YZ z;XCkN!X1gskT$PBD6rW~$)C0bCe8LC~Rf1^0YH}|OG*olnFmYMZK*%d@X!%e6qZxO4nZI7K;814wbCo=LBj$k+Yy52v zY+raIIkocn=9;IOA=UOvtTuMUdn*4a{y)tO zK)x@W&l5ulF4U5Rxb@Mx#a!F$z~mjHJCOh>K-RzR)_=CLf#3TV5borv4{wqMo89iX zg_cI=Di(;Flsg+fIxGzDbUm7Gyy%St4oRt+A4o#8##va*0^p>jUQ-a(nk7?Fw9<3? z6kc@Yc{TG?q82rArxi%B>&U$=qFzTXXO5Jm<{#nm>x%vAq7-D`x(YT#J;Y28(iwWK zzGAv#5PuV)b@eHI&iDb>UY4U_e6Js^x?hC9hudFIuaMm87n~Ae55ma(aU=ynd-+|@ zz0^fLyegtVMW0gY}VWXLx;4E*+<_L8;g!hsS! zUxV=*S+D&JM3q3&?ancz@+fJwR9c*_)?U-k41e=$Sf{DKSS;!Mtx0lsS@Cbx0S*IihWrI<)Azg(%WUg}X*R)6{6N(_F|V}3NWF= zcPm?ldKq5xP`F#7GHu7;KkMY;3<_OE7e%HW!Y7itR*kU;E!XZ@>TwTCmIb33k@mW1 zK|}J!w2uqFZUq8JGu?Ip4eW~SB(!OOsI7|pIjD;(fFE7#71jI?>#R`8I}smM3PXrK)i zj2bsR3OT0R%lJn^nraMDR8xsy+6D3)U5xC#Vxc?^7zrw#5Xeco6O0d!Dt~xbthyNf zhCHuS>M>NoIoVbyZ43Kq6GI5<)RUbBmk3BR691LrVE`ywfGem}|Btl$SonPzHyicHfECC+E*OMjY~r6B_+qNt{Crzlq{5`KJRkYsO%VCR;t3zi%FTAtXf zxC3SK%h)f_>^R8)6M-*Q$i$pDddZ*6shGUlCF$|MI1lrBryFPSn=Va1r@y z{Yr73Xz&8i5;*ZZK)6H|@X~zm`M6>;(?^yNXobHD%uah)HaHT1fq(6Th&yE+T)E~< zQO0f0Aws9WKS6i#*n>S_A8$JCo6&*hEj5ITWM$Y7;aFRmr>0~lVM+`tX~P{Nk4v(tq?G=o_d{<8liSZII%sFhrK4@tW3+1#S@X-~-(#7|VCvrKz+z z=|P=mN`{`D#|s6UVzFh_a9HbS-?gzIYM`dRDaw?_iPh=xQDq@kn?>>;WUp6lgu^Be zVm`5*pw~FPZ9R6nwqHZAs%<%EL_niHm}6}ZQ>HI~Z}(%xH-D|f&7l}JvOW}+MzXtd zhC8y?r4V}PtRq-Fq|euZh>#kF81rBvy`yGxC<>0hk|MRxIt2V{W>5ZSX1^!_^WsMR z_m2g%CX;E$y~aiP8Oic?$=3KLEdMVJPPDCK!~hx0q~Dex!;H{4)MaX?@h0g55OGTY znC1+)w$QU}k$=mRi8?`_D2aTY=?2Aphd+Kub@xt|-*kFhCy(NQ@UUgPV#!?LE&I3( zT9CkT?fjDa#Wm%9?Y>ZgZ9*seN)N!8#C}N7IG!gyNU<8Y64Z60eH`6C_!f}eog%UT zm9>7yd6&W}#O0Zl***5uJIy7E+_$J7sk!hZz9EHKfqxKHA`|*FqY?I2w+ZGa-F=Rs z0ASgFiEr51QN27rJqllY4T*LTMly*Z8=dsG{?;# zERyXZCs%v=uttgrKO@^|?xRIWouncmO65l8gVD36cS!igScuc*T1mq=DQrfmi&R+t z@%=%bB7Z^bF#(VGy~vq?P2z)RJ%XBZgt4lE`*vied}f($a3%}Zcgm%GcaXmdF!djb z1c~xXvf>G?E4m%|8EJw+5FLM|Io#1|g;hE7F_iLNGn{?jc=mR}z2ZvQ>x%L9EacrT zZ~&>DD{K>8xE!0acV@D`eVViO=(-g%JW>x7y%9Vz1Avard`+89EvsQ2%Rcw!-a7YjMSs;=Qgl_9(sZkRcipH^ z?^tNLPE14wnjF#ZFx6QzaoCxX3&x+FnEKJ-lyvOBlxd_$@m-Gp#d~R&0>4re(8cCc zLw_;*&Hb84V(pQy#227V%txI3siUF{1!#kOae z$9@t~^B$ju!Hh*cIy-dqCF;$cH|C|f>bV1ILC<89XLsizP(hT}S4~3Cvc)fH)q4lv{sp7D?WBZA z){HQenPfdTiasV{zZ<6FBA>yp$A3dtdNWLK#rGRChF>^|=^7g7^9fw_zjyBYfE6V+ zzVrol7?zk{_!w-=bub^=Ge&(?QTK>;O==gko2>0L$AaZeQFR_qNLa$zsR~kS0)Gvw zxlXEX6}&uo)|Na?_W|O=d8S?%3oC%N&wvXB1w`Te?!zc^j_%6b?h$+^DOPE*F~+~S~$fgv$zp^O(p9=A}lij9cy zfTBP!<0e>O|x&P^n)67a83#+h?d~Ksidw!Bu+6p|_^Js{7`;iqa zQ%Cv)XQrXUpLt!Pe8|X1b)5ojUfvRq8ddjArFFjg8iyy4X$U~-G!@Jc7#ZjrC=p!4 zcj49cRUXVdViyOl!c9UoZckG*>RJCP-0YIx&TAKb%^QcmtjOr~(|^-6WUBUh%!*a2 zR=Ku5Km#%FyZOL~usF@QUp2^8c*Y;tDS2fslBiDq~iRCY=DNh>7gt-whGZwz(5u8OeHPcVAKMm() z&vR_pzeiiVVLNZ{Ie$z2kO7V;xtkyz%ET!en3)D)1tYW zpX1{~RP+7mQGbzEr7zLLfJ{+697Ast2f)p(W2(n3)-3!mk3d%Wn5bZ= zTC;4D_`$sPZPHA+nJZ?&-N~w%(jG+y}>Yk63E%JVW3kYkk*O>`@cx5g5P~^Nf*vJ zX&@UCSWh!v5|My4h+|^yJzU-TX3ZWs2NVVk5s4%AJ6r+rVcWSZc!M3_DClV!K53WEmg;J#JHOV>sVZM@)qIVGL70p8K-Z;8(@+R)L(7Zy87##b;J z?=Ug2gTo(f8^pL^G1Q^99u_+p3Ow4v9Xg8B_I(2*-90N_2)ZmB-lTLJT!BoVP49~T z%BQ0F-q5fMw*z=Nb`*vM+b#6hn;n%VN7zzDLVsTD7ZH#kdhB8|rGHS)c%wu`Xh5X2 z42PNBIor)dDs&n{xZ=^mUvI5!g0qN^>bH0^xnC#>kOV{AP0E80_6sz-RSBrw?5_k+ z;;$95rH1JX46+;$nfxsa9TuPA?{Fgwe+Ou)OUneJrTT-T(so((;K5O37(htv)3mCA zD}Q%Gwib)N!d?T$@lcv=zlTIeA}ef!)M&wxGZhaFB3h2z;-FqS$3%f zk$%tj=-|6+oN6Yp@npGQex~~w9pqjkt#_JV5?<$4+VX|ZEWG0 zj{+&*77%!>KhpKXObZURd58q8m3NX=iV*cGK%$ll{ji!%2NqlScLYOa_DNIOP=7!- zY&~t|AkHYvjp#%|WB0exRQuyEB*=!&JJU#&oNY76^Um5)QCp4`4(` z353!IR1)NoP5>(to39uE~kb z2O)n&Xh7Wt-$>MyehclW1Hbza&fwXQGev{;sM&&h<;TLG>2`poj}UfOW!x&p5)k+pjyv@nx*{61=k&ctNsE!sJ5`qqY#f$17~3n1~*KdQRE`t5jzZC z!_?!lAUpwMjz>N?(OBgxsX-|ZKl_J3P_G$^K38JB!FI6HN5WiW&~se$2tXK|f2P1H zz2O)44aCd#Lv?`n2Y)Is^rhE-z&IQ!BPt$k{?=b_+V5W^C}IVhU8;XR4;H-?x1J6h zETb`ttXcYMCnhW6{qMaqjcA+Tj-y;T`wvc!yFRBl=Tz5L(IC62BrrVfbV!$ z4FG}B>LnU&+7_(H)t45@1u0Aaj6MfgFzT@lVG6nvca)pivw!iX;F(1@IJ!aW@zWXE z6OZ)MCvV*PdWOY{CxRmrc~a$ZVHj&PO9K{3fO0Q?wpWjI&$x9z+M6Q;h*qT2BuAsi z$Sx)Y$Jp>BpnnQ7EpV``5z`&2yx9=q;wHGk&Hj~GT98fr z-qKUbBY$V&x#7OijbhpWBNJV|oVqzXE9HQ}KZqJf@f z=p$CEAEU#`-WUi5Xzw#H(v0fplSd||;Ca5-I6)|_!@ozj)I0NZ&++dr4X3!qq(>Um z4hg^2CzC?uxVqK&?ENkK`j;NPx9q?0U(MZ}qfqDyCc^6y9cE9_eM-|(;q~VML11wn!_r%>_raN&VtFEPvz0E{sG^9}do zQ-xrNkF6nBUrUWRWQjG*ojw#MAXik6}3O2RcMniRzGDB~rE7bySx$&+GI8ZBA> zi4AJ>#dkBQBc;Y^(4UGMXMV<*mqAjQ(IW(wVNdHue4_Flht2nen@t(<2vyym)qhZR zofV(^TVy$+Z4Lxp{S1+=%Nj9&>L74MIp(arVt~&(KiM0~PCC4>H7pD+w^pquBO3*&HgGo6yC0y7*k=wAXk>X91y${t3{#`MpU6#-gZWE) zc$;r73<|dO-?#~uSe=iaSyAbnbAR)_CN~C&DxBDTr}Ael^f%XxpVM13(k>XM>BC)J zMzVVGrPaz{;q(*V)uXC#v47?mQKcR50Qhx-c67d1F zBF3`X*gBMy-qiKDHfJu_^UDgNWO81L+ou?>J$#W$%K>;aEgce1NjZI9X&hpl9pBXG zI0X(tLStsos)vAc@6-p&P63J(5BVI8++C);iIhpfo!q6FQbVBGRxnyFrFjg|r4<8- zbE$DgDJ|PYgda8wjSov^a(_?Fmo&ECy3g*cY79(!ALx#zl4sR{3uJY9e!$1xPe?`) zq@cs5o13Q+=o$$TNu{^A%V5p4{IB3(C8Sx@E<5?4g3MvJ$}fw4aOTYQ#O!@((a_vF zBcP0wr~)7AaA>pGD28s0ox!@|us$m) zMEzH>pLI;i_KoOoY!zTh{rf<;N$FvLCYTzyqfQH#R4W_jgV^1Gh5t}h*v;49`4$A3 z(K!y7OtLJi?vznaHh&ESQ=8ZqO7Qm_FQU_23ZM?N=}##PvfWo?lRS_;kt2sur#XW= z%ImF|(}Em&OZ@{8CN!kpX2us>w(Sj2l2 zCia&71^;E{YCz*xxGIG>$U81?CBs>~1uX)>ykrZzW%^z5`}nGcZFE*zEQFwOpbEze zS%GXip$_D_*dFT|vO2|)JzLH(p-NSMQ@X}P&L3<4wCW);=qnSh+3$$lbL7^a9kq)J zbT^1ifSUXfV}JAj_dFrGBvjmA0_!at^00m1jTgK8R96+A3%awG@~RGL-j$4hpEsTO zz_TP!XT=?&y~HH*>a51Ad>T3GCPM;kd3{27)%o$z6no+dmSPTnhDSx~Yl)5C|GXdP>q;fEvV|fU=!GAfF)Ity5Rr2y0gh1{7fBN8_V*n6;NUE49awJXOBCa*h2ls#B^<7^-y*Y^HNi_kI)j4H47)6 zwUat&4-tPM)&aJ0k?>)D0oM0K{q=lxgwW>UhT zlkatu&pHw!g%fj^Y9L@`^)EtxN;}Wz?#Nqbuzz*7GVGS@CCvCFQQ_Xva@pL*?iP*) zOmXk%-{M(^qD+R$K5i1f8pL7I(_fra^CMrN?!5VjcEJ6zAB8+snlFeI15{eqSSU%* zpjy4_0)PPd*BMj;^*lUDAx?myhq4JvD-I^;T8AGpK>4pPcetNnEdL&2<^v!sh?>p~ zlYivBQn0&;y~UyUS{wR8RX@^RlbxN_H}xRKLH-4)FxM~fxIjyAszRn(S4>EV;R3@U z5UP4|kO$y?b=zbOwt_e5{-6@==!M3zR?+ip)6XZU;Cb-_+d=Xgl0}h9e=h+!Ncv%m3Q1xwg3wbta#(MnG&MJK&&-! zCX)n(d)}8%NhJI;m3d@7#vOXXkX*&5o-YjQrOL{bI5JJ+J8L{ zN(K;no4~U+U-F=7yL)C#L3b6-mwTm(r`!X?ec?;|KDLT9TSJ}7Ic=}u&fXaI-7{^i zh?nr3r&XOwDCeK2yFJ=5qNUQb86@0EzX~h9X4-25)FXbESRkj13|&DUn*`*I>5u z;pEHuZ+x1?P#;EN`Ipx1aZ%R;40k!2UDq%v&f?J&dN_W-?mW4OKkIugyci$(EUcvH zRs?dOOqO1kC7?cB%=M}w?Tr+R6RBLCR$PAFrH#IXKz0)4Rit3DkizRE76MZ{3TIeI;PADHuoyZ3vkKCe>!f5PDS^@Jr7rb4owGUe?9;PA^FDYa85Hnv zVf>Vnv3E8U5xc9OFVut?4}Xl^>6jhYlI?==R3ZNo1Oa~44Q`I6hyFl7N3|j^hS-&- ze^#06)Pf4kkvxO;pO8eQGo!1cgl>!T}FU+bhtzJ)=t%8n6$KPXA6KMvtkIYjfB~$Vr@GV?M)+lj;}- z(=ouFMO>m3@3Rq}RwzqZ!+Jd16Dgyy$k{3|6T7$S zI*66rov+hz^=YUZ;eVdgr@a$;Ld-lC-D4_NYRj8dFUdG~_lcMhM0&AzJKs&6D}UG; zi1U_(I=rx@f9n)H@LQqhZcSkX;*r0#4Z^(ospW1q;$qhdN=4QqZ3Moj?^$ zJ*d`D%BU$+DYaVz_0O#HKU5S4#F{t`pb7;-6X@ufmw(DzYeHCax9N&=lP^b$QxyMf zU5+i&%J&5VjcZd8-m_mBV)Kvx=ke2RSNd1&`s&mndk9@5tfR&(hbRT-D$heXTYnHQ zCT@O!l{k`W^vYrR7G>Uv-mY8KjLP*TlT9MUIz^vnOC-lXPbw%#+LYNC+*`QapQ zG`1mF)EL7burruE510Q6IyOL))W$^_H56g}yBxnW#LmKijh`TrD^AR%q^m2o$UbZi zM{%4gxQ7;;k^~6fHeH!MAUF0mn#9Z$Cw3@kxxAt_AdY)Q82b^nP zF12k6DUcrs$TJ}HXn`9ZoI7Ch>VS`P%!LqL#;1XI_inL~FzX#$`!QQMOTRvd z27rQz81CLRXQCu+@390#p_=F&ZbSm7_U)W1ty5orCg7;&c640et8Fv&xdq;D_b)oic7H!ek7Kj;mnVXgI-!`T6{%3hZc|(y(om8j zgKl<|C@qf-X`$7@#5rmVL2Y$5Dsn1^|3lmhiroo)%Zd~a-W#m*QcFoQH}>UM{qYN2 z*OnLZ;85a(cEzF6-3Rm^!k&>8p53si?k}aJ1g5*l>t_&z`I|t;$qf)L@ayK@Gk;cp zNXhcdP^Q$|8VBC#6rwj3SSu(q6C~)MKDRWXN9Vq5TqbvK;lPu7H2zqX$Lw4Uk6H4f zbVp}U!HH_}K<`H7L;sZ4OoCiw_zx*O`72|*tJ%U0S53uGmQ2GPYln|xIq zVUVo%zrNNxvG3H8MAuOE^u%8GgMagiO)Ux%n5q0cRQYLCN>i~)J1y2-R*iG5~GSApfvX%e2Amp%Lmg;YoL@V3$K{_ zmcG|lWAAYgGwV9JOEKLQ)?PM>gfZ8^Weg`1PUwBac{m0AgKnEI2{*2=)Ske@Z;DX=fEfY@ev;NMF+IT)zc*|d~5KQ~nx>J70;VK07!HkO)-?I?+f^q)7-gIYD+!jsL!)n%{ckJ?>4=8^G5(Ch zSY_nzRr9wLI_eq0m^F-i=6@59*5K=?J};XaIU@<8Xi5ohj&Oy*@`^g`lE4Z_3>!K{ zqla%Ibzc@aMu#H7rDH9@2he(#L1&S4>qoc%bcT`*Ji?QAz#l_RV!UGBr;~4@${$k& zXcI}T4FgEXT0Ifmg zuJ-~@Q7g1@RVT%WY+T8_kv2X5&DnUHwgIU^@kCV6WY8eML$n=>SLHhnBj(9@sTkQw zOCkkQA2EbU#pLwM_;N{u@r!L*a7tA2{BSl1WQkT!P`>2q=&5-tT;w>>P7C7+x9!71q+Bq3#cHUG51%pUFp36D^c4sQPtw)|mVf1kqO5zevtG~pAhs}K z{yGt}QcOa_pEfrzOV+f)=AZ;YPb5<8mqjJ8OYji=d+OOXf3O(qadT~cqk6V=Zd-cK zCW479PH@7X;y4kn@C^PWyVfJG3(<3^YS460|Qtm!saV}A8bGQhVrRXfPW87Hu#TKD_BgwF2zi3|ID;KaOHj60+Jfd zQq&)=-odbXE{h%EdeE227YO+P=ej>=QlgV`fF)x z-FgKJE@fjI8A$uD&5CA`_dae#T=-s>mM!Tta^NZH@IgzCn50-ay4iOS^Mpc_Wr$0T zK$d(FD1W^oq;Rr|Xh`NEK*5c8BJZd^=T$g0*B)b8hvYXx`9r|vuL*=i&-JvWCMz9l ze;}BwMmUkS_FTk7Mf9V3B&;GM>a?dnJH??JYechu>$&U!<1@k_K#5I}xl33DCwy;c z58h^BAU!tDZR2V0`hO`>|GLliLa%~N5B}_dFn`d2oI=$LE)qM$lL}k*k}4Nl61Zp( zuG#k@seL^TyEGj1U9gaof?))25ydM~3U6PdNfmwMx^f24w~51TR&U_8%z6Fb!t%6+ z=80VuUF~-k@6=R7{W#>3&t-5@e7*(_cE)vdUZh)h1y3^CKBCM7^m*)hmyg>?)}wu? zl7I436Cnd>o%=0%fT89}!xQ((c^|`hwfZZTZ8a1pQTz;c!&O_1Xs|8m>&7uZvW*w1=jleC9V8}VxTW_x9_e%$s(cJ;NHwg)D4w?Ptxho;RX(}sZdciShQtKv{ zuJ@LFnt$ng%v0AFDg8{K-X4AhKkJ1?7k}R3hpGxo8}LfUaGed&e%+r|d)#^H1h}@+ zQ3~*j+a7~1`9{S(t^$=2U`}cfPOZeiTA5phTI`3aR`NHN?Ha?nwm|9&ajhSYIYlgJWYew!%M#+b8-K9T z4|sTxa?WX|{4L5VQlQdX>gw$xDWIuh?=~k>U!7y&v4=4?8Y!cA>_j@SM04lil*Gz! zn9#>D24dM@SG2evRPfjbP3+Z;cUk5z@BB__{0?@48u3c1^nb&1A#XWNAA5+@ymG|l z_`solX8t&@qZMJbnsf)X<$b`pw9yX`=wP3@Mu^^3W%1jNSz@yP>DoqqpnJ${^i@8M2icVAui+=`y18St} z090tI)0zN5xL0e{ZNM|FayT%zJ7ySxai3Px)$*cQRrd!7NNN|EtN*7diNvWO?o~3= z<#Gv^HVhowT=Bvo8ffX~6z6E=XIteth4ojdA$_z zM|L_tV~Fpdw+3+sabMz0Mt{Sj#y@%ht+9(}R6q3$8u14E<*68cA3lFh+k6#RDn;7% zhWiX*oy4BQ(k>DsK-wRIdpe3)u!izl!&5cPeS3c9w?hEC{z`*9sB`Mfo8BNbybPqh z+3LL;TsG~zD+8#mR>uJ^JqE8Ly&PJRxi!V`HjV2h2b}=r>rt8epMR~9mvLjBj7ab$ zwsb^e)eT=aC?dmk>fkn``1XG!kR7gbkju%m0F+D4`7*H&nm z15L;qeweseI7v9k-+zO~bnNrXYI5aDlN9Hxrtt_4!kNb|D9l!r$g3r~>T?mDb!KYh z08~YdwD;qPpp(sEOqNq}izH}2L4PI%nu92UlIJ5hu;3vz%u-yUBr(+|5o7Y`nn8*)fEODIi+wDXXYsB? z*J!Ap4AoA@2CnPXA29}87zX1yO%&cUvZlPv^cV+uBtRcMWbbxAzw^65DmL{tL#&0WTH5eU!#OG&Cnl0L{8hpkn6DJQ(mp;_A^jiGVzF4p z$uD?U+m8bV=^{gIXD^9FMe!Q?T$>`P0Ki3pYog6{Yg? z>l^kLk;I*KkWTmR)QnIX^;o@)t2{_PI_IY`_c8RcS*g#3_7UCH&eU_WxLmJvbBaCP zj!R>9S%CtKDrKVR@H>3^wuN?A7O400n+5sot3w`{XqkGwoL zeJI1E@u8`srEyu=S@~EqB|Q_~qO@)`NsnQnlJjXGa?TW@3E)3EF+4+jv zqZ)4`(fxe7(^%a<+qnK7ji0^xK~_?X#Nd6@Mwy6(D0RmO-Z^GABUREp!CUawH9RuW zFIw?JCf1Rx)uQrpi+gfGI9MMA2QD3lg?}CB|C*y1e^kKaFUom`NJN5+Wt$WDku>lY z;y;YKdpG$3+Xk>|m7Du>hBAUg%|R;3f1-3^h{jU|pZ}vP=g+&-TW8_3(0Lwd z?)OTV3YC?1+o`tD9{dk;w{h1vYJYKP12f(Gg{f!kf%CR4qJD@E+Ql->Zn z!d5b8oHv`mvjGQK-x+#Ji#U=pVRiZ5vwZ2X-x>yZMb`F2Ni4@oqcOhq zw!imW?Ms|R_~7N^^F&J7l+sLcYbDPobS17uy@VzG&$`bryBg265q~cjy!S-L zfocm3=Ug#fjw)N=HM98*k~%*$= zJ`|)JSClmIzcaH~^Uv-{R=NDKvFh&wwaK*$0h)?D0s|Z?%>v^Yya40rA^>f$RqF;t zH$OlA#P^X;4#C9yYJMj1+JCjiJnQwa*Hh%4NmT^^y5^ws^CIhyRpdP3*f?tK47WVU zrGKc}31rqX=c3@3R~7*uiP^_UYDKX^h`5i^M-i@1f5&;;v6bO2o*I(lkD=^HHWM?D zqHKzq=wm?*&f+*0C=}`^#5Wun%vtHY5ggto^ScJ|dLVV2g@+2c3V((qL2Jr`jrgRP z@`{J*-ac|qgH3;+VdbVmF#NY*oG(+UZC%eO?lIRW>N1%nn+Tc`xKSbboyJgj+%H}T z6`vm=W$HB%dO>|UK%H?RsPL-hQzFss;30n8SwT(qzHR1P*DNnSvk3mHdlRNEu3(qw zIdRN#t1Si0?!U}prrz;nxX#cR>n&TKOea8Ur7i^S4?lOHhU z>c_0IfyX3579OL5>?*{!OTwCM?kMeg`^a$r29NgSXEl5}<9{_?Z7kqj8hU&1F@L9v zi2@wd?<0neqaU-!P#^(35iA|acylL{(?jZAV~b@T^A)_40vO{%Wsm@Fy|1;dr*Vz! zcby7tPS1GqqXrc>2Hl)S8L}Wd-QmrM_K-%>E{2q{Gv2mHMBKoPryeNvbp+urYl~bM z{+m9ST;2C|aA{|W8c!i}RG>?g&`8;=cL7lGX<9|(sTv^4pzB?a39}S!?UkeMH z2z!5AG5b7X^CMdx&{;j0;ie^{B85pwaF2H;DQ9kP7}6Q0oWg~J*cHfzom1V?q{Wca zYrMmbvqNTsm|P$;MH?M?<5~i;z*mUhQQB{Xh2n{wZwxj)p&vWB+b7Ew7XvjmBO7$G z*NXfR4S&O?!mgXESnMO?x3;p!B{*V0#z>Fn$jtiFIh(*8r=UN;zD|}d^AmPk&fSQv z4hy!!!A-1FXqIlwUGQ=kD4JCg;Y&)&q>sTyabk zcj*$RyPy5OPNL-1v-(U1*)djd_8gOOv>$+|ln8Y({?w=xZo=59{GS2l(^pRKETeMX zzkl{Z3;?tGE%C!ko2w_#yBLkDn>!@=akieFs@0~=AZ{+cPcdrg$ksGbbwq;eRNVyE z^y^S9v{4i`o~w5b{CaN>*dwSi;|$@0y$^Y5CNRD8s;3TX=I2xpiKG;TNV^_-bvXnA z9G|%Sy9*rrETus@`{Vk-I!Z;pm`c3ZEq~+}byHjcD-aDrbM*d*`y3MneHiaY#N@q8w3VeNr6n|;( zT+4=*S}|ae>c)hRSVZ)sbUobK)Rv~H>hwHJ?D3LP(>HWs`C!F!r9oiWLFZ%n(PL=X z$TB)OSgt}mj4HKiU^L;Vkd)PV&p?Mxz91-U1!n5xlTboFOj{_`wcm_{M#5H4$(A~p zMnnA2%S#g8gs{&fZE}M7q~k%?k$)@tv>v{GO`IHLF%m6sqJxo2t>U7i3W-y52r%_v zfoQTa0(#u>OezDbNP#47bV29DXcIaU0V5KS^suh`vVILTRj1jjtlE6uTtaV!#y zTsuqbrE(PH78?}LREx-i@gqkdDDKiAVQ@*RXP3`n18R}$ieUq+L^Y-0iejwNsdKT0Y#dw%@KerE3jqL( zOByM|*y!9e zn=BA;JH>)(g?H*3eAgi0obbms;a+4ow#Y+w7Z`U6u++t9IJ^2}`+t7NdV==U!tkxI z@O7k1W6qPyU9e&l!inFz|-ai!6YQjjJjJy0~v=m(0mLX*tUbRt+nb23BK3n-XBV%*mx`x0Jiq_}gX^N>EEFNdwx<4Jq=h%YU&u8;7mGt7whXtgQC~ zhW+C1P5+jH^zM2;XF%oan;qxVNLUw5y@HIiNWLCK7Sr(pAGj7(WzAC*(EwHJzKy2D zce2*?!MRfr@sFTTZ#X!3X&tj#4Rw+Ur4;a)F$+W-eTN@S^SEK56LZt6&56!Tv8R{R22J= zW`U8b>ZEin%Rq4!M>qI@QRGlktO0gduch?4#TkQNe#JZHIAHG%%?frW<-bO&v|^&e zXZVa?QGXDLaJ401LU{;E?rV9BLAN$;t~rE?^_*RWv{#4F3I*@Gv4vuBt$hw5Id?jg z1bM9-wW;d{iS$9eU6)6Q8Va+vA{Jz$%fc;Hf$mZO7@_&v)0ivx~k?)$WM2#u#IwyP(xI(<@ z_aAOdG!V_&jCDB3&@4oNWM$S1_zq+ENg|3KSCV*y|!jA<) zy1deV9mW5THECaaObdrbJ1;y?tlUv3({17)c+c$c&6MUJOlV%H|FUTRvhjkIt1Qy! zhkq+gA|jWvymN#9WCYLpf_b0nSq|aBJpSjvasb7fXyFYB`JI_i{f*WYi_FQZYnIa} zF7=t$I@$%J66Km4=0y<*-|`a41#mu{A{yU6U|UQ)$V^QtmB58FP=+GQDQTPxMNCzh zEixuV(wMyu5B^&5g+zDP!hq62m3SUKJbx)k_GF)}rU04XdnBWCMo_Tz@eVR3&Q-ig zcoei-cLXE+-@Vx)i(_Iw!G^wSZ@Wj{7-9#Tm7gF3OmDe!&~b8=?7IYFZ>cmq^>i@gXhoObN{i61eWTlX=*k1?g{89!*I z&0Q3BY&tB*+z1q-l^J6qL+H{Q<1!M@1i}Xv`BybMTIy`RIPJf8k=Z^H9YQs%vsk=_ zZ*M|PsD)Oy4rMXW8^BB3);l@>lYb6WWRQ#XBz$%~B}qVy@oLc`jRlhZD!ULB*JCBX zJx=ASW}8H|N46XB{pl?ZhDGBj*``pP~8es^y%gC&8n}T#u*$BDK z|2)T`e!TER5usLHI4AkmIo%`BM2tW3U~-FVv~f6$b(tE;A&RxtTn; z9pYW$ykXX)d(^r;Ebfem!Z-`CnqOIL1gmW%8r|9D(~ zlM&AF<$lJnL63|B?th736y>7(y!)x20$2`V!~6h9@HTr0qC)Hu5pEaJc#mYTR|tvK zGDz+Rhn}fQcH0gc;5x$Q)@*{WJ_St|_93GPTrNz7A#*B2D{}DtL13kDjw10yj^6V- zKR^NN5gex)KdQmes{gOI%{!o4d)iVkdK;T4D_7_l6)xrTbbsJ;sl;vIhpX4}pv+^$ zv+iFQ;cK5gpq@U4l!g2p>Pry6w=N@#0k|PY-byh${O$o~Vv=J5bM5V{Vp|n|i6Vsx zr36&o=_4B`+XK6JOjxo(0xyY|xHqt2dgEF3VynaF>;bMB!J#0C#P zg;u69cmL3*^w@3!gkOILBKmZ7#sA7G6onv8_ZLzxzA3e$T%2bq373AmLHp56)HJj- zRk74g6FdS*Hk*fVLg+z}!Z0QU#CDWQ4O2eE(Kdy@}43p#XqL#tJ2 ziH`e4Yjp@ai^2vz8fE#Hc6RtEUX@6Xx2G~tSN6+D*BXMZk6V$N#&a;Z+Tpikqt~2 z+6e|DZc9zwEtr2WQ}0!pwh@BaWHxzi8-;(S){yO1ih2ObNy-IlU4C>04s%AT7Yj)v3 zw$#?Yi1?E`t$ROyYmUfG{p#}u`W9~LW)YDzR@hRo5}M@)7t#Cb(cXf1Eb^(SzJgbU zK2=J}%_y#!H*9xw#8}IUa;d?Cq6khw`a; zN8RjAEs^_f1Rusf84~LoRkc54s}xI9qxMS@D)f5F3grQ9Yv{Cu=@^suQX>=m0d^h=}ag3Kg^15#+V~C%^cCjL0BAREQ0Gr0X83WY1 z3bnU*-Vn9HDqc?=B+zh_`ZT|dbT3rh#KeETtI|hms?wsWBJ#tYRu<@lNIUf}qfbP# zpCUTVhU1Zo6GX?7IPI)gPc*oRE#_UM{NSCnI(si6at&I+M zXhn$IIDa&t*Ui#ENGUI$>ho*|{1#M)xv zm8Gs|g~fpJIi*cj5enT)J{#RW1e4zyE!FtA$h&9+cKZZT#QL0TyT@7fD-LfgdnGjo$4;TJ zhoD8KYC^DTn6A(Sv~i_$^Oq$MAPE%%)dcxHv9CDoqO-x(3JN_Fc*8lZci<0ecqsM|8 zHIr-sC)E^|wX5R4o6M2~gd@`35vJ@oF)LU}BrMb~y0ok%25!sgmx~Ei`FsOlivwxA zGpf?AlYb}{7aD&q!O2waTv}~aJ9b|aosjU`RK+PQ1^_E3!yhqJE$@TnjNO{8vv=lG zE0VZ;@Vtl0rqh@BhQgHjJuot8z8Zrhqz149eqL@CLUR&+9>+&~c?t&u84Zryl41`= z8O0Yh8YWjt?cr;~YJJ{4nU6LZ6EW_4xZhssDI~^eR`!3|6RJKQ9+NTcK(SJc?hNmD6zJw6EEJ!Ltz`j!G zd>J@6QnyyKr13%SXg`lP9 zWk93#FzbILoNDzi+d}(Hfq$BeA#GOh8*YJzFx6x>(a6xm8&V#SvI`(^N_YhYK{K^M zY}o0}yf83l`vSUUdQxMg7jyq5UNH$s5)~1e?i1h3U}QR)`R z8^=Z+^CFLVqHt!rp=E>wo7ewT05~&m)9}PRGCf4j)B;=I)VO{rwrDdyWxswQuqkkO zK66%@<3&iu>lKrbkQIn0R=F2+KwL`bhpMHC;G(|w(Xff(fF$!$Hj!Ov61j&RN!-YK zuyTLRHl)_80Za2bUn>7C%+`d!j+K$!lTKjUgpNa>>W#sh@1cpA9qJeW=vb-t)^a#TsQuZ4(~cWa?wUJ-TH3d z*r-bWf;48p_8J3HzPGj;=A6tN%A)DGFG+tUAh|yWm$knU&jv84N$?!WYzndO+rsv% zDHEg=>Hy(0^3{Q&_3$tn7(Nrtq?=b_a5ZDhGZm%t7gR7y(aeQFpT>IkByT_VVXm() zlm3l&2G+)ho$_y6IYAABxAm!i3cL7`!+)`{@N4m+#8WZhQL*LK&4R+j@ROOF@3DWl zKwBOtdic`1HPHtJW8D67(`6TSW?w8ozsYIcm8ND8;zCJ$Jws;pp&E}$p-bT6<{rR# zpmx0Qc4OQN=mcE8KSVsjN5l3_j+4$rWFL8x(+d8Ucmdg>9+a~V@UCkL-WJ@cL||%+ zVaOUSuii-z%{?$m+FB?h&>KU!WKn+=#9H|}WMqEvBR>jbn~k?i<{S}QIA`lJWeC1w6X7l?#-8O(pWMf1ca zy%0zYZU9YqTHThCo{snQVF}5@+HdCV!HH(j$31iTBFgB}6bs49FYcT$uM!fpqx!Vb zAnFy;@0YI6f^LtF|I7}A)z#{<9f@RaUSdhGZz6ng%2z(3BXfvo%uU@T1#kwpq3>8n zV6^tawk)fkVtpmu@i9!^mZ5)}rXxj1qMWo*TwlsD=Fv@;>T8wRDeF~j)HVg!VwL=b zu&JY_x8PAi92+XO5qWP1?zF~I01}kn`BQ{~{){OgnXtRpSy=~~qf1mGByuF|-1{qO zEH$yd_1PM%x(%xo36-u4hKO%J%rNng2YH6=nK^=D`p{SvueW@c(VmTCdARLjZ|06zbjM-R<<7u-k18j`SATQsS`+Fo0Q z$y+oFV&WwGJOGnP)i!(7zQ4BTu?MWJLfQ`lu-bQNU3)L|VjAcEZ}gr#j0j2zVz9PsF2;a_HO3zfB# zfMAu!lkg~d6qBBb0I4a};Z7RWWq%NM2lhcN1$eS$JeB6;`{951`=?x7sWcHd2}*7s zP^_S4@4%RC8{dgfF2^r;bA@|tGl{nCDjFUoFJU|&ht_3U!I@Wdue51P9=Jmt0J=5y zio9y2pR*RHt|=*v-nNZog?dMdQL6&vHwO& zlbYL3Qenk-(G7p@+AbX(?X453Z8$M?Yd}9DL{h)5bBPmIZuwg>n(oApSzDiL-HgT8 z2dK|Z!a1X7QXnzzLVucBwtQ7ep{l!ww?_S)X=o6Xdlr!{SswOQ}-Vm zhS^_IWz8nb)G4F+=Q4I?gT{VBOVJ$iy-!^Lpf;^KD;5TIX15~{4Ajp{7 z>sQ0`EyaI;OiBb&^GSo9!>eeb@DP1zC9KRAjjs7)l^J%PFiToGb<^CD7uSzZ4y9QZ z!O)joFd zL&Q$gQ%R|gx7ki%9$d&pNw2PLoChf4KaLh*|5yRNfU7Iu znb&_QmAP@O2gZ5cKfcCI0z>@`WC7WF^0n~LY%bCf3l$-EXX0O`S_lpl+~7J6)f`Vf z;R_{iM$rIIY?`)BG3oCX$)oL`=YThpuuYj$83Yy$aMrl;(j;Z;)tOX_ty5xFpJOLq zWM8lVaQ2MFzRABZHgbx2!?TFqzI}U#S)hNGz{3xhY31NBp7Rl-g20nUKE5(`{a1@y zayatKzG92=kYoI-GU@z{TbbyjhrZ@8C|6_DPM}LZ#I>D3{Gw*7N0Fg3p)%K zs7L<`kJI{5e|h4S;IG0T5o zdo*Ugc?>*3+P_bf3C?64a*AuMoHO*sXgw3^n0S5TSn>w++y#A&(n%0}#CD$Ec`P9aJdjPNWc5m?V9Q<1zHYNb1>k7xYlvXVz z734#+1{9|f)W+iKu^_OYCdwW1Y$1QhaO2jVwf^F;wIL%YF@1ciCq}mh%M{(H@o^3J zeQ6m3IORd+Gmu%^4@_xR*A1WFndHDXrYV6qayKjqMIwZ#xoWK7R`^8J zfryc9-C=o#)k1{}#zM*1N-TX5lA!O|36bUIC-}G;2kq^na}(M0!R>*9Z~T!KIjS)x z6GvPdOQjU6#oQ?~5Ms!TpMrnEX_5{VJAP+XL|t6>cu0b(?rBY}8zU5E!wmZ|j-9(5 zwMNDTTli-Ag&M?yJn}K?FP9K+j4(wA2vpOPm9H6sq)3~M@NHg<>2uBcO?=YAGt~dY zz@+J1!+v8G+({Q$=xnnmlRN#0-{12Pb8oDXRP z$EeF$?^XK)Z1*cJ{4G{K z2o}~)*aLU@)<9ppJNhAszMa$kdksVp0KF!YvKh{!x_KqAv!G?JSVoYdV!w|tw-TsZ zk%`$=0A2FkaiN$`G60=kr%^W_7k{G~upO(tb29L{jynoip5TAaJ#0wglZq((87~QV zAIsa~HO1$eUTt1ckZJ0`1xMFtdWK?OvIQTR5V!=UMq?-%D0SyK6ij^nY%^{tz2UVD z2lN0OuCjGh8Da3-7Mj?x_3J59I*vG!0U*dKL{O_$0{LE7-78M&W7Yqs^IPm&tDlC0 zUqVY@os5b&+(duq#t?@f^rciboWlO9cxk6LQLQQL7FOk-O!~fo_ZP56Npc1@vABF~ zT=zIcA5-6d&)D%#)8j4QMsHn}7I|-xd6Av^5lxuXSg-<=J#S{bJf}Wnl*cGX-*k8C z!2T#wVhNB<4*$M<%qbS5cb-A7^BxT@ zKsK(kReN>fVdjvAy;Dg zHjRCQ_YkqyMHvrs+JC}AQMh+3;5B2Aa7lk#)}xhk)v(}T*B!WEjCFyES5CL}Ot<$# zc~C?!(zl;?Eq={mOTFJm+>N#$d1xm9;V{kGS$gL4debpl?(?t$%tg9RO&gvgmqYEo z;}?fLJDr+e9NFPy5Voa>KH@1j{im8RNCQnEb^(& zN{OYQYbqMn-d!Z)e^(vB7zLzeUSBk{O%j~k)L_$%$u31x0EGd{T{`*XLXue-24Eb= zFIjIUZP+QylqDniJkpnvv8zg0h3$d`H;Z>tw}bK;jD1SdM+JKi1JlD9ALTRGa0hP8 zayXsRS>z64u5qsC;THh?c3n8q)h>Sk->Q$gr9i8HNIi|tqlhz6U4Tp zhekkKr@TJ(^{ahLmvDpRgpDW|jLxS6$E z)T7p9#J_|H*DD5H%zzi#RbTaZH6iKCoXL9D~g_59{3 zkR!RLIBw`+8t=plG0%V3ft+}b z1XS7I-2d4Aq+Qy)`CZaly&YtZ_eVlFEq#+n!f{xXEZQ#nX@qs zkPVh?53(@AD_Ox&%1vUzOmvwAT16in$1P3#ndL+@APfYm1cZM!{6{d79tg;6H97Tt z0jK4f$YbYmZqrhD+FcBl+9|@yPR0+PRkN(D9ARz(tB@cNQ}amtz>YNCPPQEQ$Ul~= zWW0s9T=3>MU9{8qe=+JbY_B@zX^#5wXr0@8yW!atosezkZCGc2*-8dG=5IH-`#i;o zXc^s@i?DGaQ7(TYR7jz(WQLFbUWB1ac%ruQOT2Mv~!ZVF3 zBIUgs4HIsOpl}GD(v?h)1yjG3WyIf#XT4qhUKcVa@}((f3(GaU!~u-Qx5_>6;$`S1 zT3kg1bV*3_mInYayaBFTgmLrk{L!eZGP`yAOq~*DRPWLQA6Dhim+FYa75kD70UoSr zVO=HNg1&!k5)djF^mAZt%pm^Pz&c%~H)bgURi&WHd+f45>aI3aZdQK!c>r}{ZjQO1 zy*->E-~5ZRka}#)gpm1>c*G`LS0H3V*pN|+DGz0BN)0g`A10q)J#zO%t#-G4`czuE zTp^bTSVyN_t|%2QU1mvaHjsRLJxxEWAo9F`InIBvCnRJp8yi#9N^*hwdm^s6@4#d~ z^Mv|TFmX3l60xemyx-bhIL$)u7k4RqwIhi34Y{cy6}h}{8kk_`ht+3$p!tX&Zb|KE zTt4aP&R@VaA+>NPo#`v_r75IsOrl@VY;@7SAN8x{#!UdFRWG8lu=#$HPi5-A;E`P2 zVhVq{l_yn-)8k3zKOC151c4doE`M5A{k|ls@>(QIH{Vz0#??|Rx@AsCaYqsAnV~E3 z?}%FkMxFOY9r#cpOxxGEgm&T52NuhJ1ByDvjQzwVPB1Yr){wa6Regnw z(DP-Y{X#Q`q+f5ZPS;iOjRl_J7uX~%*fM`!_C~Vp7~TeK{-5o(ClYP;-siz!@pc=B zh~$P+Y@&Ad`(ar#h!N@aBXZo`iwZc-bKvOi+l1<4MO+R4Hiv33h)r3KE$Eu_CN`J& zGn{UeOmST?y+u>dhO7_BDiQuD)PUG9v0G=q2#OpgAphq=xihLp@+EiOWNvSBcr1UM zKFyf+)?#CgOA6H!X$Rx-c>bJ0!*diQofu+>hd#&g*1~yx#&u3qDmP0ZReOn|Db~FW zPu~ycFpNQ8wiO78gU8BqxsA9HRk(Pr)dnp6?cNCLT;#p$0X{h=Lhng5XTrfJAv}BV zRZUmHHpjby`Kp-^w>iMMf-NBWbwz(f%b6;p@h8uyI8fU&$2LK`<^0y+3cSwvP4Kyr z_iDkOACR(PW>boymXJG6lfRydUJ5=8b?YaGTj4w7vWMC?=$niO`|&Twj1EE2VsH*3kb+|vcsf;gKH5Y$TT5e2cx%?*$5l;j{bsHiNFwKwqzQcxZq}WUq;7z(C z?Cq}q+^oeLYVc~zKSqkC9nd$C>`4FDNcTosaEtVwOm0f{uY^QdC`wsjn*Pj^K=&To z=BDcp5=#vzzmf_%6iue<*(Z5H?%*PjORoR*ZiwB6cmeH}vfv}OT>yVNd&Vm~ocpj< z05Q|GFJN%J$=H6Tp@g2w2?)?lsbrPms>32`?a_tR(m-0m8+0L);vH?^A@73r&&D&H z@)u|w(QXTefjUHY8HIE3h(d~yS$3goOePqVKKx-&oH^bDGs}=X=}%){L^0t5c#`Dx zju~?cllXtMl#vj@9VudQ5{Z~hY?CLr`pCr0nUGm0D%LQe?6PNias2o}0M6;zlln-*x zx%2(7&T$54gD>KS5Y?9Zcyb27;#h8f8DBWjt8bZ1?E=i}0+1O5&n~r%u^j{!f1N$K|Jw{5TZ7sJN->Ck0L-YAx^FvL!gJ1l z5Z5Sai^cC*qk#sGMsFDmd#mL)cTU~~xa5f@F{Rcc0rg_)O?DXWYN|nQUk z97So9Zgl_iV3c~=!+Zm3MaVpye`1($92esfRc(2r+6i>Z-V3D;8B}Pcf9ngey*1wQ z3bnRyT}|u71SQ3(=HNVp2hNbnM?P+Z=gw z9`Ks1!q1ee(S#cutZ@}vA+kf*j-Nx%laR3^4-gdR1(_zwMw78LhewbLr(p z=-;7t`DXJ?+TJ=)%uLG*+&_MF;wn@P)s|KRX4U{UIa{L^uI^OEo{m)fGUQ`f7|&{b zEkmw@w#tHeTOnnGN3M_me^Uwt<2_wRc}pjLc~^`T=$g>w)1&-muNBaC_*04Qk{TNS zL;1X~v+})i+vZk?`%j>7EM`?# z=IWS4MOQKcc7jlVHDYYkjZKiFXZ_{yn>1z3ib5IR4sUL7a^&IRe}&8o=h2$k{cznO zr&JooU0wOLh$DwkNWGU5!j*PZKbZG&r@JMH`yoVGObGU2)Wz$xDfA76Y&;~FC9>;n zg?}k!MafS2rn$~4o`?@7pDe_d?`(+^_Gmentckv$x!1T1$}){$YfFsOt&77loA1$6 zs5O7ezPY_b4+x=Qe<@98qRd9Ogeyq*HMe`rFZ5A}3EuZ#Naw@>DZBplTp(DnnG*^+ zNsvXs^QOb96L^9|k&6NNFno{}A*11h<-oWTZx@vekz|}3`4U(7iMq=H!z?+(j8 z7%)biRpAwjlFMD~=45u)oT^C&hUJR0g|kM4qao}J4V^o_f57LsMTvB20En+B{~HPW zde8=0h7#|OCfajX8%M(MG2(uG&Y#rSVWnaY^;7X4zuGb?fOZb(hRCrOiLvnuh8(*c zSO@D}M@kk}#Zlhg@uXSSTZW2d(pD{*&Y$jDh3(lb&HpD-4l!}>E;Auv%P5G;H@r#W znKyA#3%_OLe{OvosVN}BH$?<7P<(IWwdeY%f4CTF#u?vFcCS!pz=hklLFmKxrwd3Y zit1(rxb_6~K#17~wY!jaLWinq!56zJN35u+3QH_$Zs>;6oIEE=JGDkSnw(~>S9$IGSSNHO(uRAa7YCETTt`) zP#~JDCMn~anB9efj#1GO-k9`jgL`3QA=o!iE{(?R?Nc_Vs0&J(GEnCt z$M4C8lZyzl9aczscR9d8oOYh1jx+t=9crp&c!wPY^yPco2DwGJukZ5`3W!pG1pt}ILy?%U2m+8=6!f3=bmsOd;&&t+Kxf_XS#{I4#wH&PVH z5?DwXri_uiK~#!v1P%;1Er@EePfKGGZ+lZNQFZ5tAk{3ybNx@U8ZiIcEvM$kF-0&m za>Fa8E&)PQtB7&A?>8?GbCo!AWFJqfwHkDOG47)^PJ$@&sfi?=z1Xu5%I=yGwZoR) zfB2CQiC_}|@!8>A<$VXJjeNBSv6`kxy!nKOtc<6qMzAw%+yd6j&c@6jJH=p+(5nxy zX_ElS`_ALPjtoN-FuZ8vb&YX(&s*WDL^?}eGbJWw0wL(+vdbv^D(_0zeWytW$gsB4E2Oe=t3lPG*<; z`%r*<GV1%59VI{~P+^L(clh}^$d(Iq`d0oql0zlR`sz*2W4;}`cUXO{qF zM=X*tYNvUiBGB-I4gE)!;V3;+axosieBY%Ucx%dM%QZ?dy9BV|wE!*5`&nm7j~7nV zz-W%EO-q+!`tZ=eI?KRde~Va-dcrdl;sde$e6To+AOToEi+47W3W7u17q-{|jg!uS zJs(|YV{CG$Bp9n(fND)xZD~gt({|7LJ7Tc`K5v)WeWU5WFizR5HBM9&^easS>$H$- z>=l{x*_1Q{BxtSE07m~kBw&#s;EWDIkLy<40v4~@V({D}j0!qqpxErCN2ki7Fy1e9p$#z}P`_zE9B%-*({t%~LWY8~^j7q^Y z7h4knS^NZxC^Dhb=jLUGWLY9odhZnL${Z%w;rzVEUdvcHu^Em##$i5+jONK?#mEB- zT4f+-g?Gm$Bi#j7f6W%+;ECn8ojdyr{$Aby0?k|l1RLyM#mgQa-ftg~v$7(0c@IP^ z5R?LxFaUYExm(OR_^TL_p-CAE?qpZ~+m6cp2wF`md?q6}=Y|%Q+SOAk-!$&lHkBW` z=Wr$xT3GvO?(R&<{eMnmD4|j~92BM!ius#!9Ng2=9~!Ede{NjiSY3!O#x~f)uLcvl z-9HqkU~AG17Awc0;kMSf^amZfCv&aS9Uy>C3oP@<2Y;@RkT!IXC|e=1dlSWKJh_g+ z`;Ve=?QS>x6dv;V?3`wFA4`%`n=OZwM9dBMe%5Uu#2=3r$-dO$iNpCmtg9UAPAKk1|Fe+Z#SNwU^V>;YB?zw9myR7^KUm3^g zCJh*(aRSzj-48*KVtLNoA?oiZ)|;g!|s3+rXw zlV8<-f0+d6dz1uIWr2@7X~CU5icHG`tO1+He@7^}yqyNK_XR^WfkuunJgiRu0ZM5Bhbe<`3d`~&&1#aFMEV`V&bvUpt$>j}=Zf7(gKg3i!=-kB~1 zyT}Ng5gz-AulD?ptM@yB^QhH9IE^qqj9E4S!oBQK2IRAnaXQe9m?L9f1~}sDUZj- zY{TO@{4pbp`U!^@d$^gg#@_3cg>yA8OIeh%CHeMZN5DUa^%xz$wYchnhS^@W)f++b z+14LN{2xi0GbSWiY~%g25A4}&ru6BYv~J?R7@)4&Ck15W zDURhKC|wES+cfoltfbILfB#H51)L+qib3SX()m&Y|3SPMq(}Gbcb;{cpm=jDW6CEL zK7yG_ku13GeDS6&|qE|3EmWsFX>KLnT` z>^d$|um;L!MGHKsSXUHjE7HM2uOJ;zTM?(gn-FCs0ViGevqv8xW8aUe3C-@e8kd;9D z#s5VfE7VvNCrc?6wiqZehJuXYga&0*gaq0<{r!$+dVx5b`X<2^)C1Lo(N=z4V3G-fle*h< zhDc~rV%!5R(m`Xk4nanm@mEzM)@64oKr5(GO@tm1e_tM$M!q1*Kq1K~7z<&wT1y8I zKw8OJ320#o_vDRPPTaP=?Ob^BrKr}&uSM;4OlHC_Dfx191@ zr(d%rNcTCPu$UQIQFEE?Sf2;bspnu3&AWZEJx&ikd5M`j4jUy}pS@#pqH|%D_=v(j z$aFCb8*9BsjEeVwIApWp{C@vNBw$&M_yCJGJ4a*Cd)fqi8h|5@sB65B&0>~fkg8w4Rx=`Q zZOrK5tg$LauxdYl1kKXq-7*{xi7l%IN)f&Z=w3@PWD<=zV#`@w5Uc zUBgLd0Nwd7-&f*aflOCk4FGdfvo}bvod%dM2Bp2`Dj1-c=YiLmbA;>I%)xzh0Y^5m zJE)q?G*-Qa-D~x*+!`g9yi(haw6IvGF9Mc{u<1P zuXU)fXUkH}+67+nCCO`dg2ULWlW%?r1~DipW!1GcFKpxDH3d>BAfQ#R+-YO#XFr*7 zwLM#}%$cTT+>obdIrm#dbgvAw7m?C``QI zJ*?$$0^%Bg(&}G3eCDKzHgyxK#&3grE7HDLcXmi#rX@<{XQ_Pek%N!bbBRPywly`f z`IZCI=S4CYik5CLf&(}de@7wHpzLi}wNYtb7p@PxN;H5N*_7b73ePq_uKDrB8 zHxnyo#9%N_W;d4Ne`r4iA|r+YV6xj|v*$>(LK2YJ-jn24`rhP;VGOLkICo-^Pi_^} z{+$vvN$a9tf83FrJO3-?Ke?ORuk2K7ifec%w4n_t5 zD}jB1KB+{e0T1p1G26nz(IG#GOX)bL)}>6v!@p2JYH`?Hk;}JmX$qY%mCK+2l96&+ zA?h=syOPs|p4r23K#cdsu&d&M>AHG<@r1HGJ9Wm{;LxiF3>=3s3x!wogdb$DtXZGqDu1c3ISk}u!f(~OxZHZ%0>{`(l)w& z=jH0Press9R&uV|L-ne%ox55(uXvIGQvf)Xe+@^|P$x!t0krP_EBr0{DW?n5xJPtp zGM`(mny6mJvbI6OGiY~y6t#{8(;Y?=RE>IW|Df#bp;pm5efbnE;4px_R@0yG>nHw_ zDvm%iViK`jgaDXA#f7}*3xdhJ;{wn^q-P$xi4fDnrKCK1o+5{PW(%mxK-gtalHwLP ze{K!CEVfn2pDtczEC|9tzW$$+ia{6Wg?;bRe)&!9q+|e+D7Ep7J_o@hB^70Ov}+{2UoYdBdF-a;n#< z${;2~ZfKMF#aQ5>ED33S=JcAcn**FB*t0|DPpJM42@IlF^q43p#QDZnff>|lgR9)+ z3wVPnhTuIGHVLNzx|e=5ORv~^jrhe6;%5nFiewy+3QX!b^NX?uG9oj6?Pch4e>~1& zU0VMqk6)RPKLD>_ZD1KZAd_;gUu6+YcD)RMj$4@MBU2a!98?XVvzz!Lyr*R{eKy>5 z@jb1fQcq&6s3!HfK%unT#%dVb-+rwhcUOYp5iX1(ya-M(BzLri9Rr!@%=T0X5|eDT z12l&VYqXe?R#&V#k-~nx)qkGxfBwQWx}-Q3%cyJ3F1W~_)p7C(HXS+k?`3F;Ar5s{ zvcNtaX``Z&oSp!DdT}_4qlbcL82-j7)t>x!C71w`m%J-^3v(YoY~(%zxpJQWK7@baV8P74%Yf1VqUf^i2c ze_h?QL2gs7#kS|hSb_hd<^E?i9$l+A(Lq)+zy5k*Mj)jitw}>}`@-Nby+-NQpl`hJ z@)Sbb(FGtC%B4$F?!x6M3p-nc$%1Q$}}hOB$incH@ae#bG4G@68Q?_W@YBRIrPMLjJK!V*|= z@KbcqLJzqmWL5-%e=0Y;NI4$XLS3*&iBK?GfX*3r^P_PB-=n9nW=h0wy$HT&QKZ~r zFP$$zLfA@YfbpD3L&t1l^Xi1C0c@(VJz(VMu0@OMe_UqMT?sG#e>D5!s?k=1voB@Y*UO51 zR9O8sist6g`ffGpHIo>UkNTW^v5<&`lD=f?SJZlO7U>`&<&%Vs`XB`gGmEq1a0|t!ikRWy zGBWI1XMKj^i{^r@u!(^k{TTg0>;gwJa7%$`f4v%p;J^rs6dUR46<1V5TL13$>_`ES zhu`^p|0pY_TV?(fG>51mn|`eQhYg~hsc^B&O11qtA$Yb-K@G_!!z-X zpjN*-S)p1&%}FiwBRfYpHr^h=pSS)zVMV9>kM^eM*KW`ZFnv0E{yP7-m977ZNJG^z zf8)Mhw9;rMe z{a- zB5O>an?KZ;dI<#Gw z!E1`EX!77g!PmE)r_r_X#AeXsk|h{gHbJho0he+=796n`*rqkceaElj1zwQ~9f>d<7tZ+u$2H-b9+9p*^8 z8g$ZOql%yTYc@}iq~St*D%ij!vI~MvAO54^Pl}Jm;2D>Z9E6Tb(J(Rx2+iJhS;AHdmhO~d0 zA?_sycEIAF7Pd*%p-aWhsz2^=Z(WAN;=r zy1Vf4?-$|McL(e+MZ!Jj~HIe{ckR5?r!tEiH&}#P~Vj5l)A4f`Y5f zXtiv2SR0A(H#2xw1iXv&sUuii0j~Kil4Ysv)$YveQ<;$Auq-)}6Ib3zy^+E3p8 z$Uu4I3A?-(zGzsWPj zvN5A?gg)VDupB6Rj(s&{1avw-XuZ0{$B@|eDZ(-aVZ+Cj2F6Ghp{K@yONx5kJ&I`* z@{l@8sjfIKe=j3hfBb;s_;ge+K;7bRFt|zK9&`Yd&l{y^Gp-IYDD?NehC{?!w4mNe zNS=4}%Vf}s3*n27y*#v^cHd7X_1Y}GuCEnH1EgIL-oTnWln5$sfC67;wr;bo>20<4 zWo6I~>!*~lRLtaFh0)YBMz+4NGU*p+^&Rs(hYtEbf209iZyr+fN`FT{SkF5<#3J0K z8s5fPE{96uJ=Sb(>r9o3aM+^8P_h&yYk#J2G-C0>~{AUgxAz zpbGJkj=%F&z{k96`tBlI?h6f^7P-;Fu!uR)GgCyQQ4Z0kzo0`sNp5Q#7;vx26~_gJ z3D=^Ff2wd?pdg4HeE#*V(DSgKsLIR3=T>*Hmsc$N2+f{;`z~d7il<24C5e9VjR)#1 zqMIqb4I?C9tq6g$?4wHC0mTd!Ei=ao=zcjptrTTwm-pJ1V0=s(H_vKq1;F3w8JPhq z@tVYtEBMaSkm5WCMvz4Fbs-+xpu!=2EdKqtemmDLl{_k?Nb zk~a5&_C}9NE%=}H`ACI|^5C8kco+W*Rd4o3QDa^1zy1e9;6gB0f)h~uO5UUoJ;#|6{@~~c!%B+!zS^G zsqfZGj~*$+Vne3&AXgXB1=|5bKAAH`@`X{E&%PsEI;uUP2oor{|+V>N=g%d<}(a%>8e-L#1h0_FuPh((Sx9hY97J=9m%R03s{GU?* z@KMcErFLMf-EI%03YgQA>yv>Pb|eKf5z;} z9I@XzFKDJb?_kg-KYIeDkt_;=)L1({6-Z(VSl&YAu0I5DTRIz|dqn+wArw`)fH}`q zVrq}bPd}_sgc`$WHkM`(P~2K_g_9QUHjM??H$#Bnh{T$37*>cR;c>dOY57nf0avqh_2Kz(mn?=)cAFH5}?9FVunlawE5IrRP8Sa zp6LCT@Ca==3TNnMW7IbPRxl~`myt$%q&cuveqZpL`-aeu_g>c;2PSOpjeIYLb8U%? z&@^7iS`Nm(KQB5YRU>ova^Hf8U920F>~QZA-ElxE1?-h0|kTyOC+ia+Mv4`^HC`chDy9VqIB5phHDBa+O87<;06@^@hy-^F~gNzE`5xW-k zt8yyn%%B4%2AbVt_`L5b2k)m^Afu5YdKiI)PiemU5qcZU>GX0g*L|bm9A_(cN!GuU z7NOXby=@LL_OkW}fdg9je{_81J@QP=!2y%z#NS>EcNLV!dYtgWB_kg#we$4RkJw!w zZ$ZJ^0#`ciArCJ-5NSu@obv-cVQFNhWTSpBGtNZ|)HQ{kx5U=gMvG)b&ICLq&EEFB=neDse!Xh|zi?)OPke>deJzr2~Zi^Xx) zBZI*I-_iXR`AnYx`{LR>Ky^%a z?W2?Th~4Ns<)0hx+@Rm_ixNy5$Td7W^GNQr#~)|uIkV`vl=5%$1L_U!$Pwitq&Ww_ zsSiOTqxHwN$8IaQe^Sn6hR0{H`m!6dzi_U$=QSM53JqZ}Dorz@IxnH)e8$f!!XsRS zbfw1{!afrvGqFWU!TvHgp~8am^1utf7~Q>S4cWR9;zJ-#W=|< zJ1c<Telu^3c< z^j~5W$o4AYf8dD*pTNIeM6X4H3NTlMSvdc?|JV3@YHW_3s-Me1O!suve6Epdf`!a&_cNDZe}s@Vye7oy%Q5CECqe-EP`lS_)vaK-HDO~^&cLfBup ztp+GO5i4-C$0ZwoPs|cbx_20^`fUKMd0bE=927F}yH?|M-c#Lkere9pR;Jw!{E?Ak zyajxSSVvm=CUh?@RiB8l|4Kxo7<2Z(rN1)$92niX?(R>);wdR$yQ?t5W@nhq*Eql+ zVwJcwf0FzBaojD?W3`$yKCp{NS3<8VZoW4l@7sY&_kII^%T+lH{xiR?NL%QfHkv7B z=p98vsx*L*h>zt|jg`)P3>ZD>z3|Ai8}gK2v$1XMp!{>|ye0t@PqnfLs5gE*R(}F2 z8kn|DZk_Q}rIKE$yq9>*>asxY-388ILryGFe%!u`Uyhr7e%bSd`C zZdr>cidN&YMi#o9$EvSQ*6RU`gU1N_HmnFc(%$Mvrcl-p(gQ!p|0IxMS14k zu`#5a*TL9(rE_>m3H`saRG%`-NmHs7&$a)!-o-B+VV8pRi{p#Z6tn@m)$mOvF+zjf ze_0NRV{wQ3*rxDf*hQJrD$vEC?pgoZNyBw@yWPNaIYQC*9afBwA?I8lbUDq;voqMj zg7kvJ@nSHZ@L`h}F52^izcE>)K2I>^o18O)mL&O!eG`y{k3`_@K!A4v zYuh&Y4zX##rv3UuhBsFi3RO`@yO-fP z_lnRooeF6c!oC|yh1yEF8JyY()iwWh?8; z3un?DH4&k7f(vOrX6#G+yWmzNBSWTdwLrWDH^B$Lw!8ohk&G=e!zHfQni&p(*5OXfAs&>nv#)pR6ZGG`@r_#`o&m<`mI1Et(N76;~9$?;}q?rt-7S$@0y{c#m+ zd&rKq-91zh2EYjd#z=xUe$1JY(V2o4HHs@Su9*<_e0XPoM4f=$%IhoAX&4kis9V?7 zH~%4$|JwiUl8BhqwpLx=e`3#W;nJTUHkc(Yi_IB%#^#o91W@e^3IYY^Q{fi7Yc0pR zwm?SbAz>l{l$xLAeRd07@a!Q{~pAeBpJRN(m9mf84yijx$pqCnR*JY(mw~C?oM~7 zq$SKP4oYPlNtX`Oe~|QU^vHe4VTuunarJN@LJr-2L(9!5K$@Rn}Ie?;14zs=L?;xe_;IASFlXZPG{Ks11O|Q zKgG-Xqf5h=mi!v!$U#v?Em5nF-c=c7KHom?o*cZ48A1oV|y>n zY+nNriY1oIY!2(2E3Ev+`f5GcW28{8OB)H7BQneyu$M}E5 zprH`87}p! z?{gHBjYNsmffI-rawImjUT>RyLF=_TS_a>YX82VwgrKP8 zgsh7meL$12c*rr^$%)bLu^10y53?qK`6Pp;sB!VqIjBm4t|!%Q=Xv|C&fmtnJ3wk5 zGHYx_TVOP=gASQUOj3N*(g&)UEV;oB5>oRDe|3G1OWx<$_>@gkSv(+&f+xl1RQ71g z1V_@F+THxh?xA^#jvwGu7!j7BiFHwx>Mg92^{uFvCg`XDV417t6&Y=$DX9jMB_l=T_3zJaX`%elS ze_XzhOga5g28+ISPd(llV`u?6rB~17-+X6s#m1`TQV*)Fv1TpThug$Vnf?pg z_9Lw72W7pS)dgB4>*}f(4z*ahX=qBV|V4!f3NvJN-#gqJSse zR4v{OED>EMBsJpbBj?=11p0QwybT08e@CluH=5#yj1{EJ;>G0)1|a9$e?5w|s3-LoyXBkn zu63mG_saGKT}5Q$N`%|g=tD36po7T{1vtV!*V7i*;4ERw2l!@F^2Z9I71Duof90|c z1y`UwMHT-l>9TeQX8|s*L8uo1bm}6)q#RV2OV}igC7mGTsp)8LX#kCBjaB7J6(K{* zFWGLA%>ElTW?_HiRIg7_%LG#g;0bsKM1*ls&)3p?jfKTK;3L6LD4g$kdVbW3NGkI- z;ImqbsXPs%JhH~WKRU~tMG|mDf0^w3D_I8ta+@puWjpA-lN*>hMTRLr<<`3p8NnH` z_zier_h%g|yRh0oas8Ck6p@59zK%G$kZduxrmrLA{xE{<92ZMVjy)em9qvjnJASJg zI6HoEvA^>J!agR`gj>u8LB+Z9lDZ#6!kEi@%AXYE_-2lD;N#&i7#+X9f0X=!S4{)V zxcN-nfNS``$ZOrGInonctclu)1V>%3Lmfx_IGvMCEab?iA$cM@s02Yrd#Fm8@bKOU zJ@JQDh#kk;faTLqnpNLn7Md(>Px*7tVp#1o7yzE^uC$xFurts-4dX(ao!I;)I+A?T zO!`^KFqV7s=%j)L+9asMe}k{|$|uPCR#;RPfu*c!O>k0wv8*T)fX8cB-914OQOQ01 z6tjV&;+Ccs)Zh;&oWN2Ve~(NqOC{kU?%~VD zPoT%}Uf?~5LlC;}^Kg_}aW+Krv~GM!qxXAvqTB$!Ky)2_a0B7=YP}Mr;c;R9n?tcX zeeA#0+65Sx)qfS{Oh2`zDa!0j!&SJ^+IWXHc`APtXJ9e^Eh5=wvgK@(U?AxKvwd zk6jVOXbR3Be}pYfzSg=ATGj?cVBnOx%h$UVx(XehJ+^1da}xE}&Ahj=H7eQkN+UTD z07i`7$I+V`Q?TuC)fioM8(x^%n^H-q@_j)l-8Qyo_;Wjm4)}7!gdTz`@v#UmON}lDvL@yG-A5(Rwpm9 z77NcIL`8hIjW~$16z6#+iPJB%J%wmAIC5w!GT1h z7&dJnPRZ%SuXGpLM@RtF0M1uow2u)zW9cZ;Urfjye?K*S!ntj%=lAF)YKT!`(}Aoa zM6m93UCAnxN@dlrJdx03$+>dBjD;UOGIP9vt!CfkQWtV-T>DxCrVZVDFof3V~S9;H}y;rc<`e&gKkhj$+JnuA#@fkdcQGbqd;BM!h{ae`$sL6%p!E!=?BOW#Dy;WZn)jM9JU4 zWGS<=?z^yc+$>fsEY+~2(1dk;X2G!_XZ@aV5SfSI;Tk_dxq7N4D{}rH#rxOF;R|&& z*G+kl`b!1jOX&W~$P}TCPa^W*oSM(srZ(hqBf-{!eCE|z@#X0Jm>Tx+g09QRK+=u0 zf1ea~@GiShXZ_!i{`~?p+Z zsUtMQMG*k30<2$Mz1gEiOK5hszLfrHrZ|75FVm$-syphBwkAly=#tgw#ZQn0fA0E- z-R*`CVKpY)9H!1vuTd!=xD9m!Mc~KUz+YK78?ELuO1-!>z_jsIRM;@Q$eW`70vG^} zJt#q{2HMmSbu*Ceycd!8^sl$ILUuCE{|evkdVWmP8R6RrTf$O{bXf}QZV*S28@t+7 z9F9P@XnzrUSz?qs*mU54AOHaHe*veOpz`PMO&n{DtZo!|T&^Y&b2D6^N-ykf5h$RR ziV2v=SfNt)OR#AcV~E43T_)$h1LkeFgR~d;i9*WrT;@;Y(h3(}MM~x`(p3L+-M|Oc^`7_*r<|5zLU>z%sqmTCXfXvDKKI01nx2O9{$}Ycxu6DRK@vor+ zRfa^S8h=YD(ZEdtYX2nse?zVMyES^HmXS)-4A^nG-{Iv29L%k?z^mHI1%7b?KeJTS z&7qBJ0%8an?^jVpuvRDm*hhr~C~I86+RXHGGW0pv^SOToQYg^M)&a;?q(rYi72yxO z1-WDas|uM=TfPR7;V#?C!6+7BOl|VF<$`&Hgyo$%XO#1ic>~8;f8uaY{dYR(h?jOr zd}$(T#?hl7`pulOss&Gt4n`eeqV*Qm7M3@p%^s>JqBcv!L;ec7fJUf~dxL0lbD5Qp zw4l~X06I}yvGu4gpm1VR%EtLF!*;Z=dK35@wb^R4Zrcf|(ykc@i?duNjwTogb>HN3 zz*EKJ7W_6&%^b%?e}Xwp%)b^hIL)@`J`?G~Ld{>d#tDn92^{#Y)+3G9Jwnw&OB90s zexReuocaR-`C^DM56j+0 zJljZMI1PfhC!?i$NfNZR%HNq${umBmUj*o;3f)I?_Q^^hN3=E6t(6&|sVa}1jrHckUGO|T#BC}et>%nY4 zsl754%u$0Jz&*u63aaWzboi-u>5BhSDIV;92y2jeKiU`UY0b_aM++hVE=oOV@cRj? zw`62Nfzl;ne?VUMPxy;UyjaZM?AVrSnuN=1%aF+XDUXp_1C?}4Qml@M>D%A()P4eM zEaSf_yZ8i}^aqa|7#^JSTg+`49d<08v96K=l&?RT?nlzs4ol8+!go(kMc~!g$}p6a zOFcJLvR#XUm^HVTP@vN0@iW*xmE?4EFB;X4f6rAVe;7432JjEDVD)kIB2s@?9~BPc z3qXqY#jLGVi7`1^qeAz>6TTzz;<8zs>W3H681F zT&1yi9i(!Fn~5HYNL<9@yAW)#fTeLqNFwRY)t$8^sI30mXnXON;gXVj05IXnHVOD1jLE1=ouaXQRODR3YQ$OSie~G$862ZB z1qg1ysUXpM?C(qMq3h04iC`U~UTEy2ospBOd^4z#_E-4NHcqu8dL=fvU@t(x`icc) z67dfOTYH}aIm3iB0)v6|f)NMd705?F$zkeT308Ct%0L|0TmDRtjGuqnS z8oPJ^(xHQgeSTWZJC)pG&>d^+VW^Np15lp3f?azk{so_G#T=KIwD__sv&V9C2ZJcF zl=dgDI8fs-zv6d^ZO0wSI!Kf6eXzCvyeZv-S-jHn^Uju5qaU%{W(U}WqA6l8Rs15dg)~-Lp@cuedswy`w z&b=~FH>wHo^@_MJ039LBa}Zl~4lC2otW9h$pX=QXH9tyDG73DQLCnV^nD@U-1BY>w zv`SUgxGO|;va1~_Z!w(;n z(wMX8wAPnKOErTx1V!)AMSNZYOK8D9>ZI&$@sd3=V9yZBKirmrSp=00xJ5#z93>)3 z1AYlIUY=0y2%8iW0Tk#h?|0Z#52<)Hv9&|zy2+Q${xZHVClYhPoZ=|yqlo$_BF|Z= zG=KTEru08q@Te0Y?Q~bTAtq^`Y7>^T%AYVAs7P}>Cm>O#y%4h5+&iERk7DnSk0(zt zhp~NB#Ha7jsNJ9gMY1#sw|v|d72;*x3cUY#yc@cs7Tf?*{q<$O$<46Zb@1pd;*Y{& z)TxFvI!w-i2YlZa8sh)ZcYxHdTn**3CVz_E5tUr;Gw(#Ze{*ob*Fhxx(Q!=k;!)TV z8!`X^q1wMwC}K7Y+s5U-s=tw4mIO#>q}_|xa{)ciix>~6c5Y#xc9NluSea&jxFlpF@@rIEA-qRk`fjTxb&5bdCq1dO4TAAgE7 z2Csj0VN4{1(Q`#&d9iQfp>gdc_krm%jrHN1#B{LB`)l6ptVy)NoWE8H>giqkVc7`+kv^KXV1+9k1#iI{me~t7dzfe@RTn-_lFtP8y51{BNy;@=s zIGY?u1+den0OPP>I{QO1C*<()kA?^rk~0A4mvj9aH#w92%%$PZ$k3_=x_@=%rEQTECV?A;BaJD(JU?n@6^Rr8;^C0EBch@ z$H+gER$7gkHvW93AP<*$iE~e4#2%EJE(P&f=*6fc9lusvl}{fwIc9F|Wj>QE{Negy zY*!;laV(AZabcIxfyYa6`J7kmRlOGI@Tdd;Y2^=hsvN7zdIY}#6BwZz#)-X93PMKC*S^h@WUR@sH z=ctBf6=v0biW@?WBoMSe4XCn^n zN9delcaH(WLhy(VL#jc046KHrRCh=Vt7QePPY<4e->$A1q}d?TPc|H_|mr6Rtk z4VT#2|NaN+?**?9>5~#gP<#VfL_X_EnKB||P~3bhdQJ25OzwZdf}_8v^9|BG`S9G` zQ$pdgowz2ZJnuASpST0hpf{ubUeZy>Ep|fhhndzCAOwwRN4V*YaV5R}yn%y1(kj8T z)#`xxbxZ9>yMHgVx@V6RNv?UxFMrv|fp{b>FELij%V8H?JhqpZ zk(|SME>IiZ%g5}!2MpaoSM|Ezbz#>pT8q{T)SYr4h@(6xL6AGvD0zc(1nWD+X>wsV z^x@@NxPQq_Z@5g$aOKS}BOi2s%%HyxBZO)d zc&j_4M9X1eq8J}7x5Q<(RR7hZj&0lJ2f#5G-0nI)FdlW;dfEk28*_Yv_e%>@CsV|i z6;EU=Zc5pTU4^hvbF}PGXxL6p%W_&^HqxGZ6n~C;-`)ZTrkO2;9;s3r*BOmj#|dkn zg$IFIX}DI#Id5k5V)c$H1XhI;`OGpde=$krxd+DJtodoJo9;>-(Mgt#0tv_)7r^71 z-`?WWstf-Sm|c5?Fw?l-9u-6e{NoR--&kbObMwzpJj%zskLie;i^Vy45YfXgvOQuAeMB4+*wTSom^ z+O|mGZjKOGsH@v&vvZ}eIk6edy(VY7`zUmh>pD|PP#%LbVpaqqT1bI6jP?IW^Wx>l zY*$2Q>Z|vBaSPRUK{#B7xYtMzICy;B*{5IQ=tlz$OIX~yR>5#vNy{W!CR`ol#liw7`XwQzLHZgJmF?KBf4@jmS>ag zs$2hAH29ho(mTy=L8U&6&VQ|V@g^#-ycF71|4ac1=FAw?6f^z!h|F&w3ZLQ&-Wv5! z-OO^FhuzS{GKWuX+b#iA2eV~)&^I1VMx#2AKZk_$2F^0$YcMY?L}og4O{E@*AZkoK zR!c6R57C7fN`|>c$$>Z1@Sx-s13NYSpPZeSgMeTNhQlt*zCx5L6B+2}?hxX%u zw!`w$fJQ2H3QK(&g#El7%DX#{Zci!kr#WoizA!ZKp+iGZY&Ko5WIZQJ|9=-~tnI4P zqDYczlj-V;sM{Jkt6N}u1>i5l$TdPsyifWwDmbaAbkIhn4hUZhWEP|L74G=!86LsH zJ*}NBaQ-wNWV?D(%zx^J`l+x+r%2h8rH*Kw`B(TvuK^rQ;Za;%D)*U%*S{XnmYtaG zDa~1fNfg2I#AjxHz|8}b<&0FP>Yp{uuNa*kqbmc72ZhR5& zVp-KsqvnAYoWLQ-NRM#F-#T(|Z1b|;7mXc8t9lx~%PmVMm2p30Yd$rf`uND^b7|aC zY*&{87?8CC-hU({OLxjv6n7FBe9RHX`p8C`(zhtFCB`W1nlIC?(|CuGZ#!qwlL;^N zjJx{{^0iKg-e<`51`cp#%i+A-*_v7+a*o&;cfnt!R3_OrxDq!=NBn)YuV6P|Mc zy_U-EQ0wOdTi0?fz>8)II@L(|oC(RWaoF4>3##g;!=Kz#P!g2Ke$b$w;{6H76ez-n z0$}>b+}XoU;F*`tlqMaaJ-F-+0quT8rlXPiYFm~Pzu}D}zQE?5D}}2Rn!s7Fat$+{mw3jsrhC%Q10CZxhB<$u;ZP##LOC`O-;wO5yn4A!U?X|qFZ^Z z6Surjx=^>aIYgvEK|6l3sC!+`(Z!zZte;5f@)M8{i$H%j8bVSkH5j=D|T-PmoA z?3wHyz?21umIv!dGQBC}r*0}GDsHnqqGQrj39bSFQ#$&=K4ML@%zE6F5N}OA)p$&r z(nR;QlzcDav-Z?R59|2>x#a>VKQa zhb~YF2f#h`|8UkVAa?@9%EsmgLPe_GUegMUmv~86$R*2OiH(L?XyD(-#83ZsZO3cA zEK-WVtqwd5S|Uh|@<;jsv1SQOaNh{a(jLwhg`f&8%foC)8R>4+;isdnX0(;7vJDYV zIcX8b9@0Vd*M})~r|X{Hz_Ty7NPpuBN2J3PV)IQ31WG=qL+jSjBIjGo(*nmNPwqxd zVE;Wi37|!3LTG5qK@$woov&8 zG{618ing9O ziB3rW6V@>$)>e@_Qb3Gx5Kqyd!M-dz<%8YXpN`#W?17^!*61YrWGIxgWpdq3@-fbC zq<)o$3R$$k;+4t**aD5q;DmwDVe6<@N*K1$XovfFh;+%}Yq9R$lPm(1e2u4%F3fWi zy|jAVlpu@jR?-v8Ub_i6(|>H;1MlGi(*>Y_dx`EAW}XM)59Pyhxd>O__+7gI@~`A= z1V#~s=>(W)7s~mXkNk4#c$hP$diCyIC~1Aqm!&auYakCWey8hf(P~LW<#j^LZ+{C1 zC|?Y4j?$i?!%j5s^q{g^G_@6`wr*^ekDAQj`G$>uFYmL9nW%=L%YQ4#PN%1KuQxV5 zJkXJ{Gc_6Bl^S{_k6acqzsjn1|z7JrNGd9?+_ z0+`xxN=}N&t_9zf?Fm0ulzJpErRz@irVA5^O%8}>g*NOR}@ z(QdVkYwUSLEILR~&S{Pr-)60dTFf&Fro`P)r%TTS{$FdQ$%pG?DS>+QWoTx;VYAwv z#vZC(TVF&wM}O~i9)JvtOW!ZH1a~RV;Erj5A_Ozf?-~C za-K^wZAF0%`R(Vl<)T#Yagac`86y|%z#rP~<*zmWo3DE0549oR$#|YYhE@)6qCYo4 ziTA=)|FB{JAsX71PWl->lJqx>>k77SO|}t7Fn{3HaRzgw(cc@Y0-V1I&Hy0B#XHEe z&kV@F-DbD*Z!IdDX9kDL&9_Ss@ao96w>Ny zxPNWz8}Mchv4ZvwO|U8es}eM3B8foompUbb@!NxP^56RoWEe44mnqwho}!XVD^0S7 zO;Tj1Sf6ooj>J>{S?u&@35chhM=sMdE8-z4%b|Q!=IKiDm{Ou2Zkz3IHe~1WfvI<{ z1(&DYS&TbTi$GKuEIz3R)TO*=ijNfAwSR^vx;iwe_!zhx(W2IE%D(e3_&&hMJffCK z72Y&NjGK&xIzIN2cXdrJ9G-Hc!&Cjk(UJRU@CSN^N(sW;zE;g#20Gv5F30pXgor(l zw_$aOwD6{&j_!Yv&JJ}&|gJ+SG!@@K8?s=6kQl#e-&i=bt(RM)PsN4b#X(2^ko)O6dZ1Fd~CT0tFV zEZ7vpGfqzDTYHsg7Bp}5X7bqX$jIOcAzf^%;JcILcuu(ZIu8Wef6*+9cHm(>LRIC~ z=E6PUx@A@mX%Ct$pc_u;3X28}_J0?a6>R}DwuJbKjZ*#SXyFR^e?L3MGb*3X5ln?g zpr;36pjQYY*f4u#v-7v}*Upy%z8Q7^S~dd;v&Ew$+z!%2BiBCU^*HXpQu^sUyf%G} zLd5kOEt|pcdcjEXu)pDT+zz68njeb+3N)PF>Ez>$yD=7@P08}kwORK-1b@|wmu*jE z3rxIByjS`=rzjbFF}?7%if4M8M`Gw^_hDa)WUPLfH#H}w*#3|?q70SOdmj7J;`$qg z3~^Dt-qOa-q-H1fYo*3sA~O7w#yUC7ep|92;I?eeBEBgzM9`ik-x~Kk;~w`nHCM_f z+s*AD*bub`)su|l^Jr4mRe!wJnZ7*H#+K#Yy6HvOp5VHbESB2Ha;gO&3~{*GZjKu4M>D5g?IgVWycA+Q;dTZ!R~Cx4%6@M;C~Z^E=< z4iWpmOn&f)P#wxLS-nc!t^jwdI*SL%(zFYk-%Em+q{&RGp~b(Ex_|ydh4Q~Lhg>0K z-XC>U>eAW_v!h$-PV014H{*>>z}Y#tV_4KwH)*XH9>7C3?*hLy{Ca_~Dg89XW$49L zOMUw5s8qN^$Ohh-P(OW+cx?(^M+MKuQ_3K*@=5F>5?Wrtzoqne3Aba!3ZjTF&q($> zI_$^6<_j{yX)pmTEPod@-8`y*ua_VQPnF`(KIs6cv#cmwSRWOPJ5vPP9G)e4HK`~E zgTuoqkCcDtm0IW3X*eZpI)yz4j)Q8b>um!<0~SU7s+$pW`k1u?p=q=Ut{PWs*jf*e z1E!E?O)HT`TU6;0LybD_CwitU1S3P_I{1pQ2>NGNLPng2MSuOfB^~HFmgnv9vNy5^ zv%x>3vca!6r^#~P+UDF&*T%uAAA2VMeQ;t0$wHPt3*pelzlxd$D;+Jow^qfXdyXfQj1*KjgzT>mRiv-ok`7L^NHhxGObb{TA6#Q|5DK1qjS zE=>r&o{Vitn2+JK*asxZC)kK2O3$cJ_YgA%Wvw2Bs6bsyJsX?rA&KdE7UHhr;C;!E zAk%?&<9}|(L!C{zQ51}hBbvAHu0l}PC?W@ObSIP=1{9Tmz%-g84j>I9wp&I_%9jqu z;(7F~kK5raNH5~%ndVHVO4Mdmpz3rzyEWTASp>LVt$hp``klT%QoG*_hZD5PgIfWgU#=^Oo5j;|kUzkU2%Y>|X6&GBuI zWehh9AUYdV-dWvJ+fhk;+a;7Uy~jnqA%;^2|9?=0j^PjUUJnvdPmiI$j|@e)B7f4< z9(^uqHF>9~Lz-g7ZCZX2XE&n;dz}_GEaHn@6*-+<*;M4{_;G%*Ld&+gMspCAKJh{f zp4LKSkGbW-nC5v@{sjl*uKcguf(ty>X{EAQ)lroLCbm8w(z2z8=O1#A?LGX?s7Wyb z_#d&M>;kwJdln@+@VSKj8-C=hzgko}4y0Q+;Vpyr1`^( zsL@W+7Nf{J#oezCnCB=ACdGB*&_X{hlpf9vo;v0oxV^b?f$vqL5nNgJPsmNw4FXlD zadAGUl*%|ho7um``@uEMH`cBPDG|Nm#XRx!k5$E3Bj6$dy`$X8JX%;P7Jt!6quzFg zbEpL$L)Wp>o%C+%p*8?bv%9)jOi}vq)OhY!`FN~BWptwFe8UhLNTNRE{*2N2%m7{t zB!=LT|C^Y}LH3&Y_3nXFazPkg1#p7@K!j^YC`MCMZr`#;B*>{m-)o+ophTf7s%&xn zQTed9_0FGQ9u_USePbmAo_{^o@qkTB!KYD)cv#wi)Pb5-V2)`}Uea^2gdlT~qC*|7 z*0_6PKlr_b>D|SMA%Qv=>`;j%sxH^I zR2hG#E5FYwv(r-@m48JKxX2+AcAM5K@`$4n`x@iR!+AEAHbx3X+-mnfE#K6XBZ zS?A>+`)w3lE`MN`Ysm_y(Ur+^GV*A@baes+$A03Twpn)4zXn(%y>8hNK@`tgGaXLz?#B!m~BF7A~3+EOiaiH~km zB2r9_1twJw(@#iJI4WLnDeGd)k(ch0@QZDNPSi81tHty{)R0SUqf9ligRQ%;7bH7c zeSf!tLc_Tmj)0kDZeWpuUP;jxbG#W%8t`73UvpHkloVrlrZ*8if9=zpbLH1(XfX3` z^_-K}OOPmK+ctOLEZvEp5x-FaF=Y#UAR4Q3SC$FD$LqG3n^X;DQ`f2h|655hP`!5z zf#9_D#yb|iv%T1| zi~ugtQfmc^8_{xcw}PrJ^;1Qu{jK8s=oS4q;OSGbQ0h|EeW+aLTsJ3gbt~)jVtB*D`gZr!b@VNO^nc=~QlH%Af^@OnL#!br?Fx6Fl`)0_eh;X`EenFv z<0<>_w@tLKl4N9v3&C1F94bd1D44{uZy+I)ZFR;bV1svAh@OjZ8sI!_PBD;1WW919 zQy%g?^|ZX^yUv&Wuk!go8Y%Qk@!DNbv~YQl9>(H`kypOWxCIXhgDE0;t$%QlCg3ld z<}^9@c91TC^TATF8OCZ?4jd!U$7Hl25uMG1>9oDBP?+4VeR%@N{6&gb8d#fO^MwiZ z^WOJt&w#Klrfmxoh*cArG2}AETCuw^|2|RqZtmz5xA05&AG_F*FW|`&5{z2Wu(^Vx zpv16nS4m3;r7r4uGOK`fB7dzHwa5gT0abx_H^@f&SBZB>B!GvuGRt9s)wJ>~r<`Po zB}}aVoy`n15sn>Eq=1)Her15p$G(s)kmWR03*?c;2aW4h0= z?a+B>!Q&(WE}*+dNPl5?%vnXknP{TTZ!V_{2|bHWF=~m|&Jv8Ae1f+T3Sq$GjkUQqK2)$x1Ot?M@HAQYhdff*7jdE|CYSMGe zOIQl^H5?$#SR3UzkihplyOUda%q2=4@?tg+6 zr^~LUuvMdr)kD!S)J_FL6de|kC7(sD2=zU2+{sz(%XZbr)-RXM_kr*&`4epc)r??| z_~!)h)-^E|K7S91oa!p;vP1J}DF3pwv)&CCKyt)UL>4-76U|k)&#^-LET3BVpF z1M8P9c5aYUxPC0pjLZpguP#%yWoF9a7RM2&BSo_{(PAV6lR0HBP39_{+zG)|$~ za1}a2AQmZ5SxUbGf2AfPWEE#>Lb_O@TM;=FZZA;!16<0WPo4%XP~ew;*)EBl+3WP1 zLKn~Eqa3es0@s7}!%-yM%uGufy#t>-2Rl#ycor?|`Kg@o$zjd)DYs-v|F(78pS zqroswNq?((VfjFGc>>7mMfm9$|Gt=uq?TpqKXMK;HmMKqWrtUgKmN}Uv|6(qLOvb3 zIhd>RSV~EOar&t_^wi+Q3gf6n7RX6!Jk8L%kQ+_>bVbD(&j%DdApcAY{Q9vQllfqyr*TMIbr%rUENg}z;`H`jPjUWgOS zCG>REEk*(nV&fTUU*>&y!Y%`aeM!9xbbD)^OOo8b(s^C_FCF9kkqiSMvYIG7DI*LmR8}s2gaX$So zzl6#sb{;Cq2d5QrEJsEzxpQXWF{nV(oi7AxMx3WwmMB_%(0KosqDX#DspzdWFXe9bx{W4nhktbj+`F`u*M`5F^WVVa{U#jddWADYK+f14 zD0BEy2?&Sl@8zW|88Nc$ zI4O~|&a+9RMw15Pfmv(X?r4H54W9g$*&s^M4pkWHObA8X|a0DT`HC> z&$LjAA^-+I;7Bo&ztgH4l(U$DoWP;Y3A2c*@mo00c{B*auOJ};;6CE2O@F?uKB7U1 zUw=dci9}SZZup{5qEZ z223hh#xrOYUz=5-kT@V!Ie*6xdtfU7%J-ur%$12+w_8St7Ne2a?-_8sExS{2?v3MYyPN0`RGLL(3j@1Oa z4zpC=RUX^gfH5RfbAKd`f%pY)4Waka!hUasl{!D@(gM1ME(xJUnV-7LYC?Tu73-4x z;bB(`hLFV-&l=ThjW9>sy4@mx^8K`=jy5?&B-VNCY$X>7GPl{?rv@6gmx6vmnqg1mQn5`0@2oLlifh4{h^Y7`+K* zi)YisdWNNJwXuLEDLZi-7kuK>RSg7e7RUn`y^!chf<^wC^ zRY|e(kcS?aY(!Kw9tn#AIb0d@=>1li++;gK1(B(8{qw$DBrNW~N-Vn&Pc$hLR+ z!*77DTCI>2woKI=@*NzyRwZQ71zJZy5xih;k=(OJh<|o5P_;5O5cEQWKP?61<(@H2 zkk3?(rg>g8ltr106tSh3gV_lu zxo51AlHm(6h-U4;wA%gRVQUBlGATFQn$Q84y!Yp)R-HE$h7>=p%1e;2Y$M`(Od9=d zc#}~}-+w^U#|1?N0Y{jX=C&*to7~TPCIG93Roqay3`A!q9~gPKE-Nt#C>eWXKJy2B z&jboDBA^<{%rui{ujNPo{HT|dIvACB#Ufmb_TPa;>wJ$=$q z#=TM|RzecHgo!lhVFbbztIcZpjCy^7e-b>TnKE6f7$xAq`NZdFi!j4%cxhb_77EqH`NgC;#*V04+#M`4dP)s4k*(l zD{GIIL8;N^(;&`Ycr!Xk3b)utjumo-N8Ok$WV0cVBX8r8v)v?OEzDiz<(quV++5>r~>tv5{rIJs7QtsOp;3*L6_@t7_yfR zQ7SZ^YJ)%=0wO6mTSz*axpUa+gP2zCaC%6^r+nA-f!FF87gMWt}Eyitv;Kl!ozsF)=yEDrn2Xx&*L!mW25|KdCjq4zR-&;Fu%5i`)wn%sba3`Am@OY#jX&6j-MzdO)+(C)K%?AV2SByuYS*!3Z z(J)3QQbn$J=b>n#j|ff0DM#WqFVS6->C_6E8Gn?TB~zoWd2wTwkUq1l=uwdbToqFI{Im}0SbzF-$gF9gni~q$)%1!PS75)(_ z?qQdMY?8yFXC0EJ5v43|-$EOPtc|b9aOMJAkQ`0(Y_X<@CV#J0X1XrJFzl$cU+;oH zJ~FQ2v{YO`+6CAKJRYgNn!?_@SI4m7P-l&Enq^lOOD2I!R@odADX4N&vw3b3mi^W` z>9NP7Nb-w{&7CQl8iSioJ41^S9`8D>5Sv>3#oBkwyah9=X9;*dQuI{)l6)pmFxCpK zL1D?07v4?5Kz~1M*+XA+Rmz~qSzcc&D|-S!L5=HwjxiFa2hc!B6#stp)NXGGv^}j& z{4tEc+gCcpsEnA+X*aR!S$w4R2lp+F2pGd$6u5G{B4lNjK2tGBQmVk)y_fSeL=x>U z#8oY(EZphkxlSpQ>_8y!B1i$k4RBvAtHV_`Yx710|1Q@}#iE2g-u3P+RccbweeP8FD;R zVQyg>coW#=xN*#L1f$#WI^xWnHP}Y!q4`){r42a*GQ3Y<6ME!8y%r5n7A$0RlTgYEoFVQNh>UTj4-2 z@qe(ttW|r7wSJU~|8t+4ej9!~pw5*QGP?HrwMKlG#u5??DD>DE+_+$ahK{$`PN0b2 z|14TW&EnkH)e1Ic!8kXL@JMn2<>CK9gyU{9S2hi^bjFl>7>^vyi|`f2*!$(|JSO0# z^(eEUNv4?-ArLP<+l;o5J>Y6Ldx>()mVdloJz$#QFc*m3FqL2>+jcD(#zki*qS~BzZ&BJ7*tXWmQ{}1&N&)eBr zG0JK7M_9Eoh9auIF@@8Y7^+ZSwvdV61>bRoOD~DM#?g?Y?~bLzbEB#;r!ru&xRLn+ zNUX|GMrpauKz}O-$E=|cYaP`wkAJp7b`+YI9QikaA!ku>yqP)VKzct!yZk|RQ7c@pF{Vqq{AbE`^Yo?~8 zIKZfb8>Y=mkj4U04q9AUh@*j)Hlt>|U@5B*gxi~Zyn$Wenmg7-Pd>`e;(aa$na6DW z+q~^j1jRBDsEh0CSJrTWj(<*mv>Nyl7Vh~mp(NZdHiHQDGvuZJzXYB3BGN|@i)ST) z@)iIBOcGp_8R1nYvgU@`y}a4cVNKESL;CyR+Z8G5G4wh5bab3j%fcvm_tWF?8Jp*5 zXJdC!%I(Nj5lP^{8TH5F;CU*R61FiM(bV#b86~x&17eW#&?F3evVR9KiQZXs7WXPJ zHnu*tALL;bt6&99*>zJBTjV#B2%_uuU&ZN2TnyxzPwoCr)6wM3f0@#E1NB@c6`bB=i~e z9uCCN8>|s{)YD~6l7GxS4GQ8GcxwcTei5wi!r99Q1(Y+SCAhoJnEW=KY}D)4y)aai ziiO9#CE{LTmFzCerS^h9?Dh*~N=Db7pkn2wo^veFJBg}9ceuH!^LEVcr7Q2s?Gm|8 z)NXa)D?=39jw8@_P#3qxcW{nMEedK>SWoy0K;YP!a2JDs&VNvr&u{;jR~q--7c{!- z=Bk0KKp$qsMgz`wED8>T{@(4*dom1(+7)FPvifTg0B^Uj4mHvg$5`j|v0U4Acw%ed zn#aJP75x+^*tygNxW*mW0q7E1?1B4!O7W$PinSspIw-uiGXEBXUGwaMayxKN_h6s& zwptq~zIm2hZhsAMneq=HKRLAIr`7tW2qJ}k-CZ=3=G;N!UWeks)Vmo}3;a)^wyoU?WT;``BJ|v;wjagdvJoks=c4`^;SBC0uLC-em z1%Di3H-EAPj}@a$Kz1(NBo+ghTvz!a(8`+t8cx4mKK=ld!94o6AfVb){`!^}l#7)^ zcwS?EqZt~k$@SK^@d4?{+RQ-wj{rO+KHg5Y)po+Wjt|7tRDDwFy)*F;!J0gIexeXm z`mi^G!|Qq|z;Ta&`F7&w7rx4;e2^8Uiq38>3V-t3>@^ohgeEP!rNJY$WzmPgebk-2 z;p*cJk3uS3aJD?Q4(>~39H(HV@Mv=^u*!R;vPr6NR-3w*{W&n z!f=3z(DJx-rNFDau{JH8Yy{y#smM()|MG!xCwGhfnfJ%wR8rbAd?`Dmcj?gp$vA!K znKj)HqWyi5Y;scthB0w7r4i=Qq9&ADn5uXTX=*0L1qamqg^HgwpWoqgUNZ10ZY4 zAIs%M&IP7%TA%}BkccFDSq{Rb?hI3Wfks2Sw%#bc^j%;%;>h;YsC}?YKJ+TG6MsS_ zyit{N0yF2dk?P~n;%NDI*>LB-ErwX=a2!o!VAS=HFs(QSeZ{m$EA;y|g%hjppCnc>RKTsV0?tjcz3(q_- zN;5cmsA*uI@{I;^^K#l9XIiu?@l`iw%uhcWF2wn~*IX9si~6L6%VUrwMS7`KFZ?vw z4tu0Y=DEtDRwxFv4zEF`OQ`=P^V$z(C4sC=kfWo5=aA)f!g9y~yC8u2a0TQqskNn{ z4CkwLL`S3@-{*qWAMP5X41Yx>W*71smztv*sWW_Xq3_Q#(}eA*@)PXPfapR905tfJ zC>mV@Ma~7J{-~mMM9W@hayko3UTzm&mm)zu+dF=Ls3@YFkb$FN0C^2wW%>WfFKUG9 zltS>t3pkRuWmTk(z3AA0Gtx*hX^oCX!{}XI_0dy40g3zG5Vcywt$(^n;0k^3UR<$d zf>>*dDVWNWu$yp>{?q7x=38;q6+OctdbAT;dVn2G5_U!@&$)CRYBXC1)-F?Z$Eh^X z41Q5$ho!ugzVQ6O9|DZspyB(&eaw!mC^tl8VnOx#@e6-jn9|=}Q;3Gh2BdGu57?V* zpVJ94!Ezwh4o|mH0C~c{ZkF80ow)q=FVO_YM%u}a?A{Sd45&Z% z)1S%<-X4FDsjiMtSUeRV_ZRw8Bkp*PgbIdSWNYu@B~ON6gz$d8VYf~(m)0b{d|egL z+3axnZmHF8D}e{a!=dbVOOlg$%gmLusa;t+$&H7sh{~Ea;eQkphKzT%&u-ekkvc+sn1uBT6}6)48z95r{w}j%L(VN7RAwA^Ijwf%8>uNuyH| z%dm`UO!(e%pm4D}RDyq&b=dkn+g+KXJ%s+&yTOVp`QSy)TA&{m;KZ@;s)M*-QhW!* zZqK9VsDn1qu%?>Te6L>xXWNDhDdm_Tw9D`gP29#_|0-}{`-fwXY%u>xWU96g+!5W%UpjpG~~l?Vz2NFG5AQ4 z_xdQntSIW0*jC&FE!@anW7xO;{%+2==1^-8uNc+5;jjy7QewQZjE-oTrM6N0)HYyB zZ`0xzajFFAfWuA=K{0mGaDs5<&AIW}e!Cw9w&J~?KS0xF-;4EXSLdJT`Fas6i6RJl zn_6&FNRR&8@R0hv5geI#o4G>xcpDc4& zPxepE-aWiP>ZMPzrh-9-SN=IeREVsuJ9`~hB~?mwI(cZcd(U{&Tzl|L0DHJ$UyOdy z5AG3%k9m^G+PNfqq-H1ytA*kIw`9Eg0voXDQkFhH%bC#5C`FyYgkJ}UnSx8#1}kZNU3@NcZ|+oDL2dC;ub z(4=Xm@kYn?5ey#*s&B+=*#rU}H8rY_e}eU<#6N#X`8|-9@PT_hNL87d_TJXIi3Y*o zCUfO>%rqy39wS`(8(<7Vu2@7JfL;Ytn?PGUlvgToql}Cj*Lc9JtMnMcF9|QBs%z zmg9W&1dhrdU1;t5KK^~$Z?XvI9pYtTrv9OK0)11%=YPHt5K>L@0?-s-=Dwbb()Aw1P-13P(oO=3)nj(9w3N@LvnV<{Q3{gE96ZlLb?PKp}o{k(s^HQ3c2i$JNmceV_0H7S89skUiv(Wb1_A}vd- z#%w`I#2MuujDv)h1`JYFwd;0+GVN6QHS}-=s|t(brI3RRj1946#{7#5f(Y~9=PK3` zVHK}CjAi9Ch9141@kW_S1;EL%mb=K-RTKFEunu0CQ-D=1p}@})pz62L2;6@~_0Nah z(y)Y^&X;Bj^kOE%0%E^{*M#adxK1ny{ae>&2Q|KmeS^l=Zy--%roXI9gB6aF4O4MZ zJd|E-O>3i&=BDy5FS3pP6erERA$QS7lC_w`YOD_RXDCkgOpAI>uy?0WOb&$uDrB7# zyezhV0fd-i;-RJ0ZpaB+OR9ga;Ow(~X0o>W%K8<1)mB!yQulbh0RoF^Du@%6t_dL| z?X0P4CwNcZEOnhNK|!6h0-mXI8TkCH zN}`4SI}0WTk3>gMy;v`lSeQO^>T*Pgm8O5>3ACyekH(xzIbetsGo^pSidnK^jJnIl zP!>6h=8`{6jR=NcYa%PXFISIr1U7BY$l3Ho z{3P>ay=}H0re|ECApxntpCdiLy@eV(pgho>4#xzF`3*oBBxIw(5N2vvp!CF(IDg;3 zNb0q@hmg>Y2a-Y7HJ5*Da(iYkOh%W9>wB^Df`+bOtg94Mz^E1fOw1lJ_&(JM(BDeM z3auw(a4ZqYPH3>AS|1Qs=a!kkKGP!IF>e<>OL9mY86NRRlX@bamx3%momq0;6(*AQ z^=>tB=z=;v%|<3l%=9poZV%~-Di{7oUR%cF)lx<(J|7hAn&f{G*96R3B^p%2J?sgj z$K(CywwW@WXNU(0B9EVm4;UUs-`gq8^?D^$5Gt4kMevAO zZH{F^nRzz{S9|l}&(@=PQ^J43P7{~neSTT8+OSc=+&<163u*94MAOvWBd#pxzx!rb zDkC!$Y|m_#@FYQ|_R1JVEUkoq z402`UCGrV)1Q$)BJMgcRJj~h<>|FaCUWUx^8=oNS%}K+#B5J_44^xC$kwpyBKn&xa zlU-g1!$N;u@RHrG10Izz@&v8D*3s6AN399-pZ%(LFw3+$24< z$w<)g5(=vRo!~WfMdU}DsOc`KxCk1T7+2>D=wEiQDd;a^zJ3zou85XQAnn= z;H^;1y}LC;Si|K&*jTU!lyS|vCs(0))^ z>&9Y;KX(#Al@TS985fD>x*x;#J-bzA&duk1K#o^FEfiMR^AQxS88abi19A=VoVZb= z+#Y`jV}ptHZc>JO<0tWF!|y`WThDX*M^(qypEOA5ETZZCS)`k=rbm>~*yGWKWYok} z5UOqkShdVm1ohi}8R|n{xCnuz(qf&`KWi60rn+AnW(@dmcptroG{;;AR5s;hnP^nT zk$zEHg|`0J`aEP4>hD1wQknjOYTz!8-%--QoynHrUbTof@*tf`o`MN&#idT9; zoW9BU*%^gb3qoF_<&L0&GF{oI>YM%|E5g}|9d)86RvP52Fs9ihi!_{&frBAE8R2L8 zsSbhNWi8j^6O$B0%980exAucK7ZBZJwMBmHpGp;-O->9cCz8~+Uy<;8AtHk6wVi(- z#)Is(gr!^`6zFQGLS*C=oSya*JT94TA8|$6PMD)wGIyufj74I<89hS>_S# zYOA04S!X#i3xbI2dN=1EsdLi1{y~4U&foZRcn``_f;9=X@42x>k&tN9>^_x(cs5Cr zbexiq7WxsP0~5?VMsyE>OIJ6fJ}`KlyLP&Mj+cjkXjgy4fnl z;hdzGN?(n)Fe;CQz9zVZ0{~30nN@ukH{HXyB>^4shaDC%ksqQYj8Yxi4>l1{XEkV$ zBudk)10IXv8-O0_R-wD%-wJ);5}C0si?9l=&n9j zzzU%&AzC;l7nIe0+`Ag@f?-k3F{m7>29rgDivF@)u%CVjM9j^>0P251pJZXAzJzxzg}{)0Sehq9P{4qL7og=$T}EK75%n^= zgXDLwKn~&ZF-u$%wY~fy)5TP{b@Y}#11-mHgF5YFUKArVqJ7`hTZf9!Ro3mi%DxW2 zoa%+koWAHLn_k+?FjRjO1MZfFy>W}>@S5WrzqC+9pT57o|1=LD#I!a--<0Poa;9Rs zcb8VUG4gMl7ncv0f0&UPa+;tyuwAgvKXe*sF^;Wi;5m%`q_sl?AWdi}0|Fm0)5_b7 zls?Es9y%Gy$Gi|OZ@m1ok(yU%GAZIAA)&7B&_~qhY^jZ%C(nP!2Y?+2oHIQ*yQ;O! zu0933-Ph9hRR@w_r8ntjim=G#(fevKL2zQo2k@{4O^F+l*_ihgp8Md1U5UX2sS}me z>MMmi^!gg%K=D(Miuxk9X{OK^;uE_Fa^Xuo^S}cC->b&4_d5Uq2T+y`5N#^_-yYB7 z+FzNsd}puqzej&C58VU?ks!I_Y*dsWQax?e4IBg=h_G zY_oLs!Gz=M!$J~r^Ot5>&xmWHR84GxTP=Wbelu(yp<3cXwqH7S+pSHd=e4}*EF)kL z6d0Q=q=P^_*ewtE^g?h&DTPX;Dfz32;^bLJRk$Q?iO2eR}&g zMFWfRQtGH_!*M?eIR-D!M7!l#cu^^%m29fC3I-xn3^-WB)*bSt!2(LLS*?fW^>K-S z!kxx6(BN0XPnR@GLc5AM-B~h)O?`*oGrhuX(-ev>5kkGd{*VTCGe-y&##u4`^B@kZ z|KZmzuup&5QeUKgypEzP0GNEv$dWU=UF=7N6r!Y4DIFgG21WU5!BjqfeldB~{VR>) zcmwqFdXEV~D(=-%VNuI+=ZzqC?78%ipBtoN@uBHG2Ty>Uh^cpONUSA6IV11zcs=mJ zgXv|KXg2%1!)+{fnj#4RUNHP^bx!CRURo^E8sUHHd+V(awyQ2iW`QSS3oekQIV$ID zsM$$kR7R3z7cOC-2haTy{_)!HZi(ux0i>MU5|%#=fK&6VOM8X+{McGIe~M)Uuk5Yy9N$BSTUzJVcXcvHuq|KRVr z{lUZy?ZZgD%c7P&sw6cFI$S+U6}mZ4T*H6CH)`K&i@kLh;e`q0M3@;$Yq0oE-OPhd z_tG7JvaL=K&R9Hi84fU)80hbPx-u-J^r={{*=#9t;Fi=Z5Xf!m59r z+-6M<$GW%yBuIUyk5g=|g4*a|sR7=5b`Ub}1sAhA;E7HTRTRRm_Q0U`QzC=!lH=5> zy-Ul~%tMvhX*i3P3|mFvx!OHhQua^~ILiNXUmvM*7544&Wd?R&FyR*=fi8z)^lKOZ z!;9vd0`^ZtfMRinbcpeSBqiMhjl+MZJZ(JAqjxL~Pp=7LFv(jgRWdZCP>=B2v({}(wX;Thr0*3W zBgbx$i*(sI%rXaYFg-X;>&D0OC7E?5 z=H_MuL7{Q%f{@qxCFTAgE+EeCQqu8k+3qbTAx_tj@>+hVuMCZ&E#=bcMU*}dur-S@ zRNkW3I(loiW?LwoC0-9reFA^;kH_<&p|HgWiFS+ImOhCk|CgChZ4=d; ztLQ6V2+U~1dW$FITkteM^MQCG+3dDuw^s;>RNayq&xpk3pSk)u0(tKJdV4p}P}xn3 z{WW&1whOa_fOvIL`rV@t*Ddl?9e21IH@A+UWpRW z%loFf(_fE1enEfHgqz=5o{liy)2mfz zt9zmputp~a+wC@BJ7^0V15quxO)k~_Lvhwo4h^DAE3udMRuRfh|CL_&M&p^Pd=+ID zrx@rmV>?-k{wWpxw=@M2=*}}w?tOG(;aG6NG^W*vHSz06M@M2Irt>rl2I0>}s7xR! zH>=IDw_Yfu5*L30veM*?R@ualIV0w%{;l9>l8UQOU>|=C#l2RC13snn11AixPyIu? z=7A&%lC-oTOLX5nND465S8WSp0Do@-1SZrf-Izy|Vjf}=qDLEdWq5;(F!-whbh7R% zUeZj$whKhv^j{q=yy&pHpYgLa0kCGTgt|x6qvjfN!ArG@s9@{Uy-IDP(Jzq$RL2(r zpaSB_yA^+-s!-6JHe38Pvo{djHnR0f|gWfo?Zarz~o4=bTe>mKfg=#dnWv&rg4NY0 zP-PnDsb?ET`R9j(R(EYRi84_}ArUsqHrgRa_s7eKYbD7HQdK+sWkLXRdXmb}%+O;q znC-L^3+qd%!a?60$7E_FPf4o6QNoG1`!IjHo~?JIz%J*Oh%leXOV(H+rc{Y#o2!W8 z^@&0zCT{#bJYvL3gE zDgJC>r(pBhCk(nwB8*lpOzEX_P?)WEtBXb6EvW8k^j*gbDb4(yurE&uI%>lAc}zKada~IV;{e8>trZ_u7l%WU$}%Ql)iSriMTq zmi}$>>$7js_nxEO2B_%wegGcws2hLS9mB0natl_M$c;iY&^+${NnoQ^yaj&rouB$(*f_xg`Hr6s-HmN!fwHXBs!Hhq|?pVFHxs)WE;4eFtK%l zu9zamjDY#>5uzsu!T3!_M{$KLxcT04Uw)&^vsPow!Q)kFlD!sw8Mj<~#HZ$=cbvXQ z@!N694a$m!F1rcq;NIC@me1CoCM$Pjd=gJ=#zmCC)rfx-_L+PDA6S1y`^1jkCwB3s zzg`X4%U*sdvqx+Xf8Txsxe@pz2T#qLFd#r}aP58-whQg3XavE<>Q~(eHq{G``jS1! z5;y$q;u6DxCITNQoUw_4+;7Caijgm}>UJrwj3}vKF7?1ulFCs?wV%loWucU7*VKP{ zUK`qFRV=fKJe3VXb>@Gtv2yLx#rkw~NA8bi4USpYN7A;WJ?zC!j7q~(Ax)qmiYap* zTo0z7J0}SIMXSoJFT4$9fZ8BU=rT^?Vq|32%`}y!gsL<8U2^MIfA4!(Pn)q&SW{7Z zI6HGMM?<^i(e{=X%|dCvN{ur<1LsrMT|*e(?H8!e=^(6d>*#-p@w%Uj<1p~uD`1L+ z!kkQPc(keZ)70n|Zv=N^Czle?K@19>=1-QgrUrZIUSyK31vXg0d+DtD;>!#2+Mh>V zS=90EZ|xi}2~xxnE^y0Y`jq(O2m%#MdH>cDjNw38jHp>zYCh8!^&KMqM<>o&(I~UF z8|^rsPyX-UX|8`5{i9#I8U@s%u`Qf%@R&y?Xoer(uYN_{=FmtlCFSOap8=$E;(|i9 z&fH(-jWb2RHuH`Ufu1N`QM+0bK{2I|&vcCG!EAa72n)wi*(hlKg)sW09!|$pYmtn|lfK2cnv{ ztF#VXL1nUAvS=~sHTZ0me3}OZFw7a{Si$s%F$u$NdtFDzZ5Ckw2 zPSLuvi2_!`ZB}_bQ=Cu8a2vG+Wu`0m@}MPhc}F8diA-!)OJb)oByeu5#c}t>d~4VW z*ggl_XT^VY9~X-eC{|<4*fb2Y2@0CSI-V?`*jiXZWG#DHBM4x4XQ=4yJ&yy;!ZcM=f+>6B?YE2o#@Xx zVn(rt_G=#cqfpwzU#oue>ua}ML|`ecTt72ab_wK9$9+A{P#91fIxBJL`bJcJ61x^TBP{=I<&|ocERSpGKekSJJx?-qcl@M?yUbBxi}#8bNlBp zSVH|E#JUh=l9Njxj%&5#hQzgJ@ORo0r6hkAi-vC|$~9?ujIU1u>!Bzm$p8rV9KXWB z_6?wskpO9?YO{@89q7jS8?eyCC3Y)60eXoUt+#5C=%LfKV;fqiI}Tp4;*Tds)6i+V zVI%#&Y;v&z!RVtL{*?WhZrLf*+1L~ePBZZTO|IFyN2p8a!{5-3mZxiOO`HS)jmLjO z^mi8t{=6n!Y#)BJbj`dkKN8=CJp2|hAGp>uT!Klb|Ic_S40{u4m!L)KJ{wOa$o4d> zDNFsJj;IITgF&Va*av{X33A_Nc+-N;`Ruh|cTe;G4tMWMHN(m^m_#JUrs5B>-MiKy zLIa{kXL+sQbtu#6>P}yKCB122--F_HB%_5TcGzXoo7zJj!pSZ5zGr@Usz&O2 zb5r$06$Ar@lZbRx-@lm=FyHa`s~?#C*5DBC%1=?MZ``f*6h>B|B45;R7S%0G1{yyU z6ztTF(RkjA+aJ+x=tH&Z| zQH)pDs6jfe?{axltIxW2I!X2j;Dd)S;ww_>y+?x(GUgO*A1N1ScbtpIyc0J=CypBL zap~=e5eY!K=%jh!aU~fUjM)BvfPh%kSc#X!Rt`?^mta5$M%ST`p!1+zK@}goVqWS} zZkC}(dE=na9W}jT15zx3uV{Z8=8{$}7LKssid8Exh`-ns(lPv=2pBrX!Oh<%DYTho z1)ZbK^4aWTxc{_T42-Q4BNb433Q2v*Ol7#0U+u{jl=Y>TI7Xg05#D8Qb8Bwc^6|yq zEl~VMwlXH)Os@dI3XW?1xm|MIuEM^>MZ7aVeA@l8?0+dnGlUM?uefab7fz^A??))l z$TmW|b1|r;gZ_7bh4AQI78X}LG_Gp1Igol|d2ywS3w%pHV0CzCA~^}LX&&6ty{pv@ y7!kTb`FF^nL*UO~MW#Lg0000V6Z>}n0j28#ubvN`%Fxn2Fb#_W000000a;ozL}my8 diff --git a/data-raw/datasets/antimicrobials.sav b/data-raw/datasets/antimicrobials.sav index bef443d83e78e96fe43d08a39bd599f068b906fc..cbfc6eb65aed4b666e4eba5d5185dd4f28a6859b 100644 GIT binary patch literal 380992 zcmeFadu*gxb{|G57Oa`rhGPhUqL&M8S=fcPcUUYIABs0_HrYMft9kUy^sYyPIND;> zS7Z%~RkiitkVGO)A`1?jSdnDKhy?vH0TRRkoWL-WNOIz692f><#DFX-h+`zdz_PHC zB|)pK5eR|F$?x|&=iKkBBCERC>|Sk?B)Z9a?{}Z)o_p@O=bm%!ci(?y>CPwq)F(@C zJ$&n}($>bKjne%GuiPu$F6|D7y}|dr^wLgixI5bZbiKR((w}P`*ZPfDYxS4j%xaCd zhP7eo8y6N9e(W0-7Vu9$|4#%Ke&EjHO6ha8PHAansq%e`Yu{I`mM-~&7TDf5SyT4= zo6sQsZ``%I`Mvn_joBspL_ho00KpyNB;cl9{vGb{w=Qm z^7C>2`MQVi4gTJ&UteQim-K7e`d_+P|2O>44gYiH_m^qwzjCwwZ`S|K`oFg8fB9zp z->mv;ZrF9y%Q?}5JHzt;ba{>gJs|Nbzh^k2dMKZO6^jQ`()|M5e*huM}b3F-WA zo-8adf8=F3=K1*J-?cv<|LzZ;dYt+GRnL15e_0Rf=MT#<9Cb%}G0)d?cv}CbrB53R zVf05G4u2niH|~C>w*3MuV?I-FHC~_v%x5~a{p(B+OXB_3|hR&U=SF$?;;7GX?I(lI!E@$d}QB-zp2Tk^77Kc3zoC8T3&d8 zIsZ8R69tw4x+8LCZT{Vwi z{nD_X)rR|7XISbsOT*E2)~}D+-9gJL-Z-Z>wN9g?&ZFuEI&pxBILIu2p*1#fQvbv) z4ycB~-1<~W;clyUN=85%ge>?iqs(WIiHQM)JmI8t+D%{T+ z{;d<88FadhR_#{QqmBarwWx1^&-JcK?biDHwLR~M0IZ($v*VTnDvj&3eb5r90Sth; zZxB_a-|`45j!7Eyvih)(j(@U%Cs!rdJNfwZbjOzCwDmV-tOa_o`D&sE|NGCpy|Gcx zhDYuFRwJv|uE-eQZ`Zgq!7Dl%&mP+z{Cj`r&PE%gVbpGRJ6VY&ezb3ZC9lAr*N3}VA4!TB|8RF>u`-Q* z75NA78)x{3cGm0H*h26b6Z}Qnn>~$uYS(@x{7pS3>eSkeT5o{vd&EZ*cvnpB?RqwB zbfB1q$q1t~3tLD9JP2MQ)zhzSd#2;a-e~P-!`)g(O#=CcD%F%__ z2@kaSsSqX;^lxi%W#jGg5@+*si{+Q^F0LSG^L%=G>y5(aH}dbd-gs-Vys@!VX0Zr@ z2u)1hNwkalg#XrlNi?^}lH0lh8jkfc)|v6edu$6?{Ewol7mXqr>_>Y5BI0xLjRaU-P8Z)u;zaiz=|T zwz6nnmli9l6%STcmXm2Kt(i(?Y0*nmmVC&S>dK0LUS2A#EH5cTs%LqvjL!m2b#ZNR z>Gm2s$6)0)3BWBBUs|*3tLqi?Q*c;WtgbBIUh;F%!U8ffscNmStYhG+a}8ryvhl2~ zFRu|uVo^>$Mh}3`8{dCl^lHQD)Jx6oplJ+{(rwkAo?>2+rAQRmw}-pk0e7!fec%g# zYvktVsX*X~`6;%(@#^boAA0|X{yFv`Fv{&_3+z*Jx&)9%Ka>iuZPj)1J^8Pf(-y zh2iLf_7Zg6YXk_lO`g;4*0a8eTNoUg%xJ&WZgiWi!(x9Ri5Wu9$2L_Zj>E<+b{kp8 zI@jHAp|8x*^YPrAFAA9O*kIvY`|8`md-7!;v_9f`IHYI`Fpu@1DGoZOI472Fk$Ka1P36Q8PNHUZhO`$g zOfYGmDi!)xDs-&$9z0T&vO{nu4eZFM8RZ+LkX>n*C5$iFGvi>eZUBf|%+4R6T5bPO zaxQj3a?tt+2ZwZwuC<#iL!?Bo)v(p4%=oq6;u%99_q+9W7QselCHA{}0|%^UN^Bq& z;n;dbD;()zFnHY_1bkiy>(@hv&W3UnIB-R3^oMOF-ZD+ORLb=+ z)D!jEy42Tp8-Bi0y2%*y!OwgIEQchJMmGjRAjZ}A_Ohnt4E4NtD;xDnHvVQi??!|*F6=uQ?pC^oQ4c$?Ln(E`AiWFW zZU^l%eYZspWZ!u7T@13DcMOsv4LRyT_7>$rF^tx6w>`9K_Q1XOyAYT=yxM8x?OK0F zSQzInoIj8Tk(9*J`?X-kT_$vnv^)RYX%kn&^_dd&yu4*he7BOa59fk*Gj|M z4l{N#94fFIbkKm}kX2zGhp{6JqMn{ci4wSE$Or(n!&CY?e_#| z_6kQX@C8DRsOQ#ThaG9z}gf9Ts{2Wkq3^E zl9$h8MmIqR+0A1$W;?Ek;~&f~9Ij4qn*de04Qi-!c zdDXM5;rM`2mT{sg`>AYgE#SD~hX$N%bl$+ZMit^zBaU!sDb83+IBuz;r7F%umRhMq zJ

BB@qa%ASuwKc_J0$3GldR;(8Yt@?>&u^jtSrGiE<72{Lj_YcUl@hY{TB)5L} zKmWwR#s((ZG2|tXyMs|17d`1#67_fopJ2ZS%qClj*pW&%|^hNjo&F=m-MSQ$b=0zx}FA+Q758=kA(64&?)1~d4X&LV<;YPmT zC70XOwbpC<{DXP~a&QIM&TX$BiDVtNeLmC_%jY>1iXEEZC!*o|UZP_V!lcy0L2IuN zJ4&C>?P!q~y}svYs?AEf64W$_$o4t0U2cglbI5%3A} zFKV=a6D#2p_5@WK@{n`nDo}ITxNGObjm1?Q4=Jb%`f=-Jit~A5cY_Cu885Pf`-&rttHU_l>o%W49e!O>utLCoM18ur^RVGDXOC?xvc zWLIkYP2D)vF!JKLmhtY;#ei&ALt;6|NWiPAEP`2tv2poEv)xMjLU-TKW~j`WTU87R zN!N8ktf9;|s~r4lAmFIZP!!|)1LL?LQ{|F(;pF7ZHKReA6&|1yQ4cHi#Jn&L6BgM8 zGw;`K9l#OWu%$<2#QjB6z z1MbE(k~gim1fL8bfSAkqU3TwWW2I897^{lV@@=c<^i)ji^5W{^suf4D>QevZ^|k7{ zrGn+8i2V$IIXNGo10gqm^|NG~N*hA7SpT$;ns6F;QUlLZRKnJF^bRE+#DPK=|G7Af>pNBjVl50sDH2s%3Uub92gxLI> zywJ9R6wc@Wjn7pnPqgp40WRx)D}t(SlFoch97%mmdE>3U)DNg|Nahs%0T?0s zI!Ha>IgcYZ=nd+5L7XR|x&srHv24_ngpZKMj1AGxCddnI)2w4cLB+5gdWG#)(mQb} z>4;Yt4%F@1QPyWp97rK15=6JLX$SQ52{J9VTa;tgF;+WgwT9Rttzcc!UiFaW>PO%f z7=Sp^0BDi?e&0LMfOxf^a=eHF-95GF<7@CrCE-$I1evm;0UyDR0!RW_L)aOi00d7a z;7u`2e!JDo2wi2|uc6_nCxnaOTQcuj2P_O_dVUt|j1B^F-F+ybnxqsrN>9<)OEINt1Xl!LDhPPxVD2e~%8K>$A;5%wb?QJrgCcM6VNlBu?io9USe|b{ZuJbD z2U-7s#eJF~O@z)bq>Sv$V5FvX)JDiUJIoH5J;vpU-Mv;W7liDw)NMm5sv!-5(|H4o z0TZc8qBR-yFx^|j%7A>B%rrY8F(%4;erT9@wow}ykxL*PMLkONn-qvCJTHcrcj2Jb z$oqQhy(6u&U@WzN{K5Qcp1hmugG|UNlRn3)i4&J-FV1~tBX`z$XRj8CM1g3GXvhGTVNZjq0do;_)}X` zrLqnQs2I6j;vGZwD26_#XKRzw2Tb{?bHe-Dh*62A4Ghc=0ud)*M zdxL1KB3~WT@XWzql)JpC3FEo(m%sdbTpzR_2(@6W3oA0I7yQPGNyDbx== zb-3HAd7U62PcV+FQsi>ywbvdb{Q2O~AKKXHv>G4<675g}WafDtlL9=Tck z!qf0~Qr>nlP2QI4Ls2@H=hAvXyW`S1yQe|dg^e15Z}^2tPIy}!q8%KHDRz2MW;9m( z;u=&fhYs6<6;FGpI>4YG!gR_`mDd^{1LPm`r1~>I&7WUL_p`v4YPGU#_n^pW3`2Ew zalLBnM0IT$cdFWTS69p6H&)K!52A_5zXiJZ@Rh*pJ3sx>4{U7o$d-}~RgDL)!?b_C|6lwEF9T0-#y!U_Z$in}_8UwV@W<{Q*3(7y%Xilo)4mQGK|z$#IAt?u zM) zwX7n^PdW_pSaTt`73k2L>0WH%gTMQgI~&l9mC=Tgp?rTGS0XRs7i60+-!=Oe>PaX( zA6+6oslD^@DY{~NV8je#BIf9HYP4q;cUF*3Kq%ngn2pZ?>8t&>u+RNcai6O!!44zV zqbcrGD{DBGYjdkEmtm#hRtIDAGXq)$yn2}H?f&>rfbSpll41{0OHyLgG}r!yP9mRV z=q4kVKF$WhbK;rZ$EXJ)PwI?tq%atQg6%**)4CcoE8;=X7*}Q#_LICJWy;v<7(O<- zN9}B~okEk>D){l~?#ZR>)d{VQw;qWy@gD!b{sivvA;^|!IOm%L)N}X4dBIJ(qXcsw?IP*SRcTr2IIs<>HLN}hZISS`n+Af!uc-8KYbzX zZ>4+x%l5{`K`ZGF73t9VQa5M?3ERf-;G&=g-TuBz4ucMjYOKAvx_SjO1wUM=u2z=?M-0-K6(+gnG=qNGK5`{bN(KNlX)YvSeT*gJ44iXW1(ul{%Y8ym;zwovI$ z$T#0}yEgLB3{T^mFMLllv2PA=8;xt_gJh496x$&%;s6Sh8u(uGAqKmhkJ#v_;>^sl z5|J4}&GP{lZ|G!#to&kdA1vCPq_1-Y3Uu(D{C@L~Jot9v<8T)ockHYoe?Ql+5a!Iz zZTC0Ix|Zd+&B8vN&?j<77`jR}M;Mf-PIU7m>L(uH=QM+P1caqe0g&b4QhGQw!j*p-V#NaN> z&(uFgVA9tQHy^N{9wq$^sGtal`>jK%W2+X}zPSno^g&<-VjCO`KmEL1<^UPTE z2YMRlsgz$3IwqV{FTB6CVNj?Khk~Gu?U;5c2d=$=X^DDl7=pDGQjo5yIE;v>Izp?Z z8Dz-q8(9x=msw$em09d~dFYk$-1Px`qE zI{2m;4ak;U;i>y@=wGl8qK2HhwfV4(&n6NSh(`Q5v58u^}Q1bfDPza+nw?(shS zYd;77iO29BF?o-N`2+rczMp}YgGQLk45jum^KvivB`Yua=c06kP5z1SRQw6P3`L)r zKLX!BeQRq=y&~|gCOD{n?1JsL*s!^J?HeM_-vz|-{SNfgGa*;HXiT8B4Gt@BL=PYm z_CI4Bc^<0&_!M4bi+Xz?s7c?>=q3qkkjTo)niJD?`@6ho#B{lAq<6Wz0s~|5ZOcnB zub|Z;p|b%};2$65{Ntbbjn89!fJX!Ega}1Hh4aj--HzN0(>DjOBrsTdafauHM_312 z_g!y3!c*6Q>1k}!E{JsWG}!=7c;_fIZvEl_9dC_c8#=RQfAC2lId*Pts7sR?MrRn# zQ4&&Ci{rnH7VSGY9D%`N1c-%LFMq%=6uv8SUNLgp5~$apXX5Syk2=&wbuXNz*M!D1 zlXkK!q)hvHYye*Y+uL*QhXlrz{o%dD*t#kDL0h#oLFUB$dT|XodqIxG^++ofcmvZJ zhRbHjS5$e$X7l6(=1}RYyE(%J8+2bq&zIc<3Rd^xZux;$Sbfy3`&F$2?oSF&TbJkb{U&J& z1fGmP341raG6Q?Jpt~AM@rU(WCU?0@@{T*nYJ;aAds zuqwv&>9x6axQ2B=Yrzp?HY`Ak;tPs}bFp5sIg#)sh*bwvgf*fF`?0tcK50@aJrFR4-dDwefYb!cS;7WH)>QCsX(@vtsNJzT4h9pxRz zZ6a;(P*1Gh!bgfXO?(NzmC9uGoSrH(opU19ZD_F~d!<6*ZSfsvmS$*1&)3d<&}W`de6^TW^TJhWzvWpZT#z z8+Wrt4T!}JLh0x0A!r@&DV^_6i_XH+_S4kzP2jN*_*&ax##EFVY zJs5O{XY0%Kk){LL`brs|C?Gz5Y-`F;z=wOeU-`Fx8GIMCYjJ#!>$CawYmG327(>4n zC&2moF_ue1CLN_JZzH3R%IJ!yBWy*`Gv5Ay^!WP0{T%gy^Yj$w2#ogSBLeZe*t!|( z-&KoH@AlOAg#Z=Xq?ccV9C-w!2y9xCYZQkdti$kLXmv<;hN8Fmq@G^ITw| zIlp7)dcz-NMLzQJ_ZEfb;^P^fhF=%v;|r})dTgN_d{e%CNKY!#-$aya| zY@(Wj+>4il808p$ukmGPwAy?SwYEj>$ z-lwZJCZZ@@CHH)tB9;w`FVi$(d*<125VKIg2ah1 z7=#BfYeo)K_~NZWX#{PhJpUk%#_jA7w@-io`@^NgevJBq7%$ux`4G-uZ{w@)`G`H8 z{aAV?qKmib@s#^;ksg)?br=jlt9Pd~#FIrA+kfYUBc=?K?oEjtUI%&JywI7`)|Dadw1@($l7H41wMHbHq@3V5>YsD z!-`Oq*!<$0zxCN9U$pSFbJ+MykUps0G5i%~==`MC`{K*sf_I0s%(wX)dXYnt{K9$n zM^qRweOBc4dm|+Ib9ek2j&Gqb!q@Cb`SWULg$i=W&3CxHl&F{cl|TL!;87j^`ipw} zR?idC58y|=i|06Uxn|xi;tBVsTI+a}6vA`sEr&AA@O2X;kbm&3EITn_pEFM%%g@n|%T*3eZHy(;j-kB|nLq`qmk z-qJhMX8#itA($HeVZXb#k-y)f@HG58iMmkK^zFl@h&CS4Dtc7xglvu)knkMThFUae z9Hwv6?A*5Vp&26PaYIGM4S#`m8m681QE)$iLVVsmB6t|WYf9`N27g6x=`zER-JALI z%Ke;Ntir;6`T68$VqxLaU%qp9gh#vF=7WeC^l!#{5q#p|ep&h!dhUVYY4|s*n?ecF zzY!eSdKX02@-F33;V){Fb&8?S&QYgJg@g<64YRuQ+<&_iz1rMLeAMn=|JEPf*sRI+ zC->*z`{L_|GzsFP@I1QD%db86u>D#L;K}CC^-Qd9ssV>7I!vs5wXCX7m zUpNS^YcQ)aNC+9e);&LBkzqYjU&CK~!M&-4r>*akt^R0-54UhJvpind?Ps+ipSa@l zU&9d`SJm;J)S#v91MgD+bG%>i{uxbN9lcI{+llSwhW>M2&i@%ajeD!jjl`#X^LKsn z1FU;IAz$E#Ij3xXPQ1BWk#II_!L${ zanFwRUS6p#hu!Ikn}tAIXvtKF;H3{5LfY+N7J>&Ar5Mein^Q69d6$=xT?i~c^xiw3 zlZRTGio=tME-0xaT5-Q@E7k~}z!Bb5-E?cE>}YpNC+I3gLsx%uG103tBh2}n&4T~G zg)jW-9SW1ub(8TqLTrrxVM>3joC)umRLGM^pM>G5_#M(JjN@6^DQ?^A!*z^|ed1rd zL+CJ33e2DoWfvr;fFTt`682Dna{D>bO7b4d?zxy>oP7QvE)U02#NCgj7-NQa6Oz7o z0qX2hgYQbjjTz$25v6Kz#kiBjz1mJ+8OQEPcaQK@D;+1`qLz6tJq_DC!hspSVx-s3 zh(Bc5JK~rK8hE?W*%=?v6Lv|V5>DK@cyRDthd*cRDzWIzKQLfr>k$rv!*UDaI@dJC zBUPdSEB?4Dj47optv3qn_GVuCTU@UN{fQ6%U#{0yr{TD9ne}St6zYO)Kt}wvS+BsJ zNjr`LLJ<|Y9~v@4U7Q*MHOb&WZMmc$w_07Cv|f`)k(3dsh&$w!?md)2V%FGlLoxPV7Cr z5CU&gpD05;XD91?`jbS4@sCU~PFK4N%Ih{A_p=xu>DS#{Ki0y&4Y~fJ($3?%P7Gg@ ze}j{xB{1RN;C`z=7~V$r;2)chj+g4zd+X2XX^cY2^)bFA##>LI5Voh7{C>noWk#hf zJOg0a3_=#BA*KP7aVUjBcuj{`H}Y#BB;{J9o4Nl%+zHO0)AQoDR`3*2Qkmbr4o_uK0LeFPj}Rj@oj^yq9emz1{E@u zLkP-Z5%kU>5!#t-elNX`+;k1mHrQafo`q7b0RRU-EK5cI5aNwgCOKS%j3giL2yX#B z*b4`q&46WLzq+6J>4gvWzN~c&-RQ$syTDHab^u!yCC$d6ty$6dIqXI zf1hY)GP%xjxvSO<*IDp?*bn_BN%+{2)dXInG{H;Nz2~gB6KI|<=laRl*DLq(cPu{q z2meIt3)&!IZg1z+XR*F=KRS2Kp2a$D_AFaWJC9C0C4O*Xz2Su?6SFki;gP%m##mpq zM!kmnPDw;@y9WN!)NkOYP%JXnN|JZN>xLE&oOS@5`b3)#-?kM$u5I(y8l@|EqN)RiFk%?tuyo>`>lq=KFM8}T~8Zeo&qJizJo@=(Pz=Ek$Oi!>@ z*h)r!lw|V+!#|k?!2`N?l3DTa^av2KAdf2=ABj91_Xi&-KfhTMFB~^C$#m`lix*`D z*1?T?tuMB%nI%9r19UAI&cuFkqCvE_Q%_qRb*7~BJxD@TUX5TY(ecwP0}yKiyJKAF zxl*hgxkBqW5@VkCvOOGJ4YBsHH=<^a5|1mQnW)Fm6xK#9p9U)4IXu`Eb2+CYV7uGG zV$giUUID#fby3eP@R!ziwV^d?P4Cwl8WYpu2YJxKTv~YFP(_ibr?#JG&eUf?8K?s{ z!PuLv{Z7`!Kv@tW6%fQ=VHNctS)XBZl`8CvFegmy!nv@I5x`0z+J@TqezI?KsPIV_ zBRgsc!;9Gk?Szh&l>Ls1_{bRmr?e%Sgl){7Pk59q?US?w?nA~A9j%B-u z6L|J+y+-e#LOANdQwaQ}_#%=aJSp;{up9 zrQqwaz_j5jGx>?+SsmyI3Mn83K62^{$=*Q97Tb~~9NU6He%7MZ81Q^<`iGPdUBTFl5TKUmg$Gf2)PqssS{k&S)im-B^EA}Yf-TcH z5Mibr?EKa=V^I&*G#m@1hPa17D^&#)?vF)?ek_eoEQ4Uwa|<@Wuo?p#`F(&Yp+%*< z10?!|`T_RI_KqcEJi>tOs&l%5C zdB5=0ja+}@U;g87-`E6>;Y>kJ*6`O6;2e3~<>c@Ay4`#l>-Hk@cMVZEh_Tw={aCkQ zC#^4s~r?wA+A!0f@ybYlm-jnk!j4@~JoXkMZ&BS!v z)!K8-N35f^IZ9z_yZbIqtgMqUft<{9)RU*Cb*nu2&gO+;KSR_RLe`hgd49xG8p6>P ztZ!9k?MEzUu2WmqAM-yVwwq_XTuxuoA<}AvSr@jkQU9v*o0BW+sqAB$kCGkC`~UtB zdR&~uehVk2$L?d7JCBNdIR6P#=*hu({28n_j_=&{h6Mz4jgC5NYo!@jb=IdvMzxJndZ(H22nzdt)h62h6m7U+y z&|?WHk|Z+*mB9Prexfh7X!;Oq6Z7pTlgG3}M3jdY)T1syuIfen5OsadF@-4@3qBpW z#5?KT+=Y++%twaTFob;O{Mjun%PnnfYh$IQU?pI@X09SMUkyM9wO~3k$7E^P9xv@1TX(75ywk@tWUm zl8u5Ol8zA4dcr-4o#Od%KXVzU8pSUrCcOp*^Md0oE0%aY#ke-39*vWAvAczhO%3LJ z8$YM+VBb@AmW_JE!zopTvi7l__bdr=EjqEYt(T8!76cq9!5r=Up12o#Bra2-$>ih0 z^^p3=%&@r61f_oFl@7bmv9kKnA5PyXyW&X<@(v{CP2aEJFVclceT@8^xJ1zL=;%)! z@J%GwyTIvj$u>=d{J}?@BXQ=_<_ZmtC7);M;X#d8hssqt+D4_Q(UheY*I_cF^}SZb zlV;L*oDJu~K6~H%Ce!at@7BkpN89jl2l(5RK?o=% zyzcMi(T?FX^!Uan?s2gKUTr4%`-j!Ptn&}-YN1~JcsWF+|KxhKTjl)x!|+A$5&av- zM~)WPJNwxiu zB2VU*!U^=|R<6hUPipTFAHWy2X6fV4KmVA)n1A2bw%jib@9`L(Hji`j$B%Yf{d3gu zyV`!xzKJCU^g~^jCRDv4VMN_Ed4*({a}8UYTGRF1?S=rKkVX44c0_?D?S_bjoDg67 zfSTXyp^(ItytI?j2a0l21papSq0bK1&X0YQ=Yr=C`!3((!uwYFdli^3cs8gQzlS!A z4`WiiBU@dCR|0Wo6$Gh@`*?YNbT;2lw;m*aOJDrOf3$7*k9$VACDzZ3`|QiDgIpf6 zRelQckPEE?TLDDpxV|ppA<><7u)=qNLWfFdQb2P|=Mn%qAbIl_7y`X<^Z)gK6!&eS zrM=Ha{M8WyNwCV-DTBeX9W)rU)5W}S&G+-I2WdaQbMj;22QjO{-?0t-so*ij5%l~C z=AC#YyLusBs1)sIE!0WU$j1ZQ-6Ob!z#AZbd^qJ>AY9l_(B4%ma;bg(ey+E3=R3YE zzAx*+!{7|OSRU>^vE5zaU5qV;FTKy-?~eMz-TCb9pb*{D#sCV2L26eQ@&T!kV7t7h z+tV2Jo@7}5(ISWVBl&vZEtSNq#(lA(wL?NswW*zb9;&UKlT%Vpel})-A|gVYnR`cl zXrEE~DGKC2Itsif(S4zZe^OL_pueZ`^(N8)xX0y@X3XzBw|7T>Db% zxA30!J%p#O-*|@xU=^o4`5sO9u#0??--FIazJS2Z-!l++Qu?ox-sZz(cm2^{`?KP6 zMgL!_w`&I@7-_h(zh|`{%!yCqg9cI=ABs+LCD$Q9=U_ftN(Zrc|TZpdqfm6sr{k7m0kd?IB+{>As;|tGOGr>LS;h;V^IqFNHA!o_)5eX zg>S*|3#M4m=pt8sbN&KICiQyhKhX4g@iE<0!AVTI3dl`ZmKPx%nqU5x%l|hYJ`ntI zPJ92Sf2WAgW8(j(gVz|x(~qv@NR8Z#%uO% z(k^x#S6Jd72nS;t*4LNT79&_)ELFC4F62=$VDUT9GGu2xF%wv*Q5TSz@8Zx!LrUn zgHf+<9@J=RXSM=(l}}vy{Cs49{Yw3vrjJ9vscvT%?`Pl|8S6eQUv=@@Dw)@Gjiv-ZMKT(q&H8OI_#<>M6IdU$wcgbD;0DKnAD3 zTh+okLUS;U(kCuQ zkJGy=TU+i|K&XN{wYTtoA9f%p@keMmCa^QZYVF4w6 z1N0Hr$#Bm>>*IOhSU88in(X%%7JlTP(JspFlb^L88Y$_RJ=G$7T~C?ex$$?l9~!)4 z<;N#%%@Qsa+6(-(Pc%JrmcjuM*7=Is>PLO)T?2=g@Sa)VXN~2LW%OuH%;uh#La(k~ z@QfZ=849@uPwfAqY25$a(G2!~nD~k6L1|0YPHX<4)|xw@S*HP^sK`7nH2Z}+2AG@4Gx-~Ry&zn2`ndHV(Z>%fb}oY-MA%rn zf#0*bp8!q7yxRT5)1Z$t?$y~_#?3oPNciZOEzA&gQLWFkz&4ixzf4LysHa5&)?G& z{i6`TJ;uRxfZN)V-E{@?^{TIe72_Y)SIvTFJ;?(gE)Z#%4aoxj-%s}33t#*zhW`aO z0kiI9E_MDZ=X}K$!*NdH9spl*OgnEJbMwbD=|7M-=s(UK#CtcxXohjdG4Y%*ByFi% zYES-3ke6wIkvfPhS`s`D@|jt4u%J??)*jwv!1jUkKFSG`29d3k?L?6EvPt!cuCC&I zX>}*pSZWl%*md)GP%Pyh&{HjNm{44>UW6+<>d9N|CbuQct{aWg#XRa_$M%n8gu-C2 zHr!r6@1D;az#r{d;iB^VN=Z z?{E204Crno8C=s=sQCgMZ{cVRA)$nW47!~MgRxVt(C$|kBiaS^thZJQbOPaN<9SMSA?FLRt}yzseR4J^uiw{6JQtD%ej4948%asv z=L1_|zj`fy58#XcmhD%3qpk7y^U0<7wX(@0sr$c)@TKwaBK%svHU=kw*!L|BJ#lD? z86yUtP9($A`Z*uiuU4)}d@Vzs81{JD=gW((8&zI(&8YIC-@}kV#}lhy$7tjy_T=LD z`_?^ReW?U}sgM5HhmyB<2M}uvl!|$FI*Iw6Ja0ThJs8Pr(2sFE z#l=T+x%-w!Ne*}CTYls7)Q@oGMnixZ^M5IRn{TNl`N~tEUl-)BE850EkuX?xB)t!c z1jU>2M_1qOaCxYRXTcwh0ji)Zfj_uoN&fOI1-4=Qc8Kz}JZZ1xcGI~Isd!zl#=3Nv z-hGPeb<3S3K&F3M>qK{Ta*PLLbkSDu^eDj_~RmQx&ufe9h;e1(%8!N9*Ul#98`YUQYMzevb~; zdl@(G!p8EVbJt}^OodwIMR$5zE>j;Cpe5a3VRk3W@EguEx_fhny*Gj?%Agkp2d^S_ zkspcGRrvo~E#fQqB{}Wm90E_gU-3x4`6%i0mEPMle#L0mq~-Rr-Mt}&IEXsx_=y+$k?&~B2t-0 z7EKBHVLW(m!d!%g77`mw@IiVY&Y5-I{0IVP_{uW4HYYoJXSfXiJmwXs?B0Li2gt4| z$v>{zoelX$=ghz%dg8Lza|#B~Z#2mZ`lTj=yw}9!LJ?}oORua$5d>F;qOY^(NOCh} z*?e?A=<&k)f6nA)L%i5A_?d)|jrtgH;+Q#G+3GWAZiI=bx zvSaLVqmSq9O^pxF?Ad&HeasBSX}c>Li|Ck%`k?i6vtAqr@mTH2NkuRd^6s84HfVkLJOZumWT*p0kliN zypCtR*0IEY5NEWG0gm%<=RBO54|4fE#QoR55cKqe7w*})=pdWRFWUTg0}KtkG0mv; z@?8ByInua;33)CN33z0m(A6Zp>UQ{Crd~vvtN!beDewt?QYlBWLAw-XbrmugT3*Zt ziXz@5`R~I2^gG`s`R`#1j+%u{GtWbp+mA&Rk*m-Afj6k5Px-I9F*n}Khh5J}u1Whs%3{qw zG2raXZ@KInf4S_+4dt?{Hk8Y**g&3o&DJ56rpCs`Fv(a#MV~|9UPr)m*!jGQ_4c_=)+~H`zQFu^CRz+Un&`;+ zQNtJXV-jD~kJ`JT0gv67hTi+np+at>1 z^j_r4V|>C!4Lz>)0}=(cP?^C4_@_{<@~C0wAcNf0pWGabXo&k@xD z?~FZ6?`eMM?*(8Ex?zSi3vVyCe@ZpL_s^%GZ+fwJ1A1N48)^1TyZl@{#w+JoZB9}7 z=8q(rf=-Uu!ed|@K$gxp2s1NY$%FkILxd-=m$-XfkaNa3&+OwkW~B3p9V6gc-*rY1 za?KBfT*qT&1y22S+`xfh$!@;jZeJ37%!isT-9n0=KM>;aLzH7izwoKR4?IlzukZi6 z->dgldff(&mCx8-zwjR9){OTcpAtQvw9mj0h33s({3U)9W=5bb*>mB~GIRGRK|mHQ z1?)?t{|2hGOe|^(1U9LFqRkTY>u=~e!ONei{!GfyDH3q;ivTZ!#TELOmv~%OiZ274 z*>P#5G#=3XX$zjZ*DTfRIb{+J7f=|%a5jY7uXqjvORM5WP>X9=d480&u1@=H>xXl@ z`7oEib$@+){q*`>$^4%hUxfC8FPhe~8R>zy+qDi@VE_aOOoWXfyX)azH|7Dpwp{fv zkUd6aS+N2#Wk5wHOT$}Dc=Cu}yI^Wm4?1NRVq7o#xCoKZZP429rAL4ds8tCDeMbMU z`ll!3%V}=|MBH>gX`6{CW#=kXJuCivMQhP+6%d|p9?^5rQPZaaa!{Yj2<26u>`RP~ z^z(G`eYT6$SKR;8dztV5n}1q<)3Ctta=A`(GtYDL%NH@vLAU%ow+WxYpb&O{@HG4f zU+n$>LlpS}TTD6#OU&4(5rxs_*gjwD!x-P3nr!!5gXHcED@~A6Ra}K!hhz$r>Rd7$ z`h=+?((#oI4&cC$kHg>a$wb>pKf~oEY{&*rygLSPm6zOSPkE_os>tP~71xjfAK-e- z*vOgfLVQ+X9o&0E7!Ny|4?p{lwGO^Cg0qk~AkLthPkKIlwNl?oU?IZ z8&k~5t!5RIJ3)W%7UXFRPus8OK7ZY(Q2*?6hW>8xm^^LRI-G{5K6G{;q|##{GgCD1 zwB=UipvF|Ey1~;N!^9uhyXy;gLSHKXJWr^ApZAmA^}-Lm@ZFU6Lf;y?LXW?9n*YAw zEPiek?wuIEG=9#O_fECa}a-xI-Z`69Mb?r^xFB?W*5#$a$P{|8Y$wyvU3pf zJ8FCKxRWYR41D*f(dphG8_{Wk8pSX15tf+R?j4cAFdwZbTrc{)X1i4QLb~(`P=yfT z7If0~Yg|FdFls|DA(O4!JXmtY@|=;^EkRQ-;7#z*dP;6p%21s(b1vNI%QmVEae}Gr zf+1N-3cB#Kq5{=w;130U*d`vcpBC2NTb~cUWZ|Q~r~A6WDBZRMe-6HL^1g)~e%gM{ z0Sx0OfJNv7n*hS8KRMFk15h@`d&57ZRq|x#dta!V`TJ2H{oJ?xN2J5U8sFW0JfBd# z#Jk5279~0pd&=-MI-CZnK*AGrQAmQVJg1wHS4+$Ai9>N$G%z4&BgSHIRs)MxD;b4u z{=zE8>|$0cD~l8Q&rGV~5Cq^Mh(nU3G7P%X6M~R&N~nq;SXRrhT#oe$qf(Nm$J3|q z^YSpge;4@pQthA>ZeC{HtIda(#1c%p^RMGXtp*PR6Ypu>;K!vQa0b6vqv<`5Bb6}8 z3H*Gm7WTD`q=$0nzyA%Ld+-t-UJ-xB_f7?Rwl#yE&3*2<2wz!~!!PWZzH!oZfruaw zTstWsVC2%B8Z?KBd$L6i@yFKZ82yBZ3Mv>@anB2Yc;fvlrZtm1A1Us3tncq)?X(T< z%m=>#h^Pp>P4Zc8row%H(v-E;czTLzLMvw|cb;eI`+O*Ib#k5IAL$#w=J({p{p`zM zfWN-3aK&%9V54s?11c5gF)QxCt6ZVZSJZ>);N6#7=PyCO)qQ_KBh?8z{Q$VR7=x|= z%OLiHsE6~)_u-dv+kRJvrL~M3_ahiL&Mc}ug@fnmfycT#_4W05w1l-7QE(jZ9tSnYOU%>eX0qQ|aK8p5k=)O|ruT4j;@>mb z-;TpC0s@jXW3S?xE`l8TVuJ;~8c!@azdDlRLKCBdTkK=Q!ay z7RsJC`rl(vy_`JiQNo9Xzwt*UmmFs4^~I1&YF&?CO_e@zxqGXezq(7G&SN9WBXjR> z7rD2}j?blA@S#S}abT!L-17HN3?QZqPUPfIo+%`z$`xd;-5vOo6i}T1ga{yeU(8s4cm)buC(alG91xcJM-tT>n$s=0ZBPcc-fS(F| z!~6$*i}OOcpf`o^rSbV9@`&&zK5SX2xjicCAJm6R=GQTOn0nSQmx)66&<;d4LMt|J zAv=C~azb{?73kj7XTxn=SM^&>7_<@5p=N{H5keJ0Wonu4TeI*VI)u)lVg5D3^U0x3 z+xL0W&;1pMUNXs#_YC^+9;bGy(Fl-}m7gEa<#&%BBzuZGkG|XZ%~rQL0&AzAXRuz3 z*@Qj}@WY(?Q(wkAIu{*8X5wsX-2bdl)$buR1jEkk5SH7S?teQqgzW@#K3uM4YRHM< zhGo(08UO|pUIEFVYHgO%2!`MYG9>D6bFSutSdMR-?<76zJ3su}j&H}$-cF&Qp0)Kf z{0?1&J`+`4Abf0^**H%-LF6K++eiE6SpkxOZvn4i-)R-F$~+|anO2xGV|}Pifwf@7 zhPs*L>!Jt8&i!CL=9|YWo$HL;7w@iyA8@l{fXg9KEqZsA;FG>x&9VWq++_>mIYQ8A zrQ+pQyxk_wAm*D^4i!^6s4U059SAs`89jbI73HVNj{JjfF+VdtyIHB$uKAg1Cjb7m zI?r8cq4@(f@4Tx9Q0kEz5BO0`ZS_{S11IkWvi zkuTAwc z0&S?BlashV!My2S-KYC>IjKP5Z7iv3@><%j$9XO7tQoGNanBBiDuVjF`%&S1@@6^@ zzyEDtHu+J%RXfD9S2mB+@ppcH3Uy4-$*sj4KN-F>eqP{wg2Cw&k_&_Stgp@- zl_rcV!zNpzr!sV)?eK&1iyeM&=Bb*B2v0SeW=18s1&_YAM@VSLX<2%opKKQ{di~>-|>LDHudRZO(0q#aM zucNklu0FzWAUwMwi1)9i(!&WfeJ-P5eos#9JoZsKkB#%g)v%{Ni3bI+?V11*p3%*4 z36D&f1}a!$vvR^d?P*Jk%TU_nejf8Ezo=E);;|$99#6TyduU`i2gpGw*TU^1@TIw!>aO672KFtneS~uTLdZP<>zf<=I zj<6*V5g5S*-|qti|G8PTpBt1uF+V*;d%>sAg;D4r^gm%0J9h3+PmB*vZy;kW(@jdO z>co1dcjCC*KxH^0%hlGS=_=5JLSkId4tHCLtPE|5f>LzbKKv6;X~&7zJu^&a^A4V zx&P`C@n|!Me)badNTB;9KdbHR)EQfohdI7svVdoLi?*OYx;aCC`DC-Zzs>1FQJvUY z-OixYZ9=4mD}7)HZis4aJVF}zCck?(P9xu3>*RW7l0Ek%eZLqeayi92ufIn0D51VP zr{?c%gyS(?T> zu5i95qYGM~*#GV&KNAZd{megw-{0OY-l+-m(OKt+`StYx{KxEjbDsld>*Y<@>vJf= z7pM>U-=HrIm*}Bu+LA!$>;WF-gO3Tqpcr=MTAA_7G6cpdcOdK@y&zaohb1E!kQV0j z{(eBR*B|T!M+&3XEP4LliBu>x;XZ{G9AJ<2jg>)s;1I4bUO#SVasLGoPkJZI`~t14 zJMW51Fyme0)l)oL3VE;2rLgoOg+umj7EAX_grr44p*$_|qQdnxyU7|^?pYR;0$PrE%&~-|_9G(1ZuGhTq^3UDb z+--wF-G}tI(*k=;Iw@E_^aRc|f0T%s1AWO`kr9Zr;X}4uC#PL9bNGq$h!@7K#~|vvcJ2V!gtf7s3yexhdUP5J>2bRWtG3~h zXlZSKyW6yj0YaTHXDRu2XMz1eR>zDejfZ?c4b{Fhs_h@;(b0g*(FkhIB36+a#V^Wn zqAxq4i{_Fz= zc^xR$Y*ENm!q~l@=%O$GF|-_w$)CKypyu8e)byaxDh51k#dKk>Ds(vd)9X3f1%E1${Aq8@_+JLI$RqEbrg zV>av@<$c&c^6gb{z{!V1Gu0CS?LwxPgP?mbYG*c%7TxS%#tqJ`Ub~1`>799j-w~Av zi3u|bp?(w-Y#mrin&WiNX2}G9WrEG1UuH21WK|5O02H}oNWoQJ3z>RP#EaL zDCKO9hy@tlsvor-tpYw;ZH;WeWVYGBmXqapP>2dXjqDH$Eul#x@jFN^HUyZ$6rIBt ze+4E9ZV@@nY$Mypi7^%#%^u(jKl-EZ==)f08ScO_F9Qh+vObopb(XIx*>Y7YI}lbx zJqe00-a>M}JJMwDl-hXJ42WQh1NVWc9|#u*5cTZBroJ#G0IP-{y>AV2a?u(TI|Ge& z!ZhlMCf^+$6!B}XwqHBQ1eLuYJsL}j3G91g_{07r-%X{z{*$2rV7gM_?Aa)ga~ zki!x!$37;z6*#$HJAxz5#*RP%i4)#1v<6c`J<%VVSaclKMRSN5^7$fHoPaarM3lF~ z=o=uP`t#x~Gyd!9t*;t66iTP6R!so*-jpkVE zP{_+5-Y*?u=CD7guc@9I#dyjrcM(3kl8S&n#}qOCrO_B__glcMs3%Yl>s>HVBj`mQ z!D|_5!46tt9em+2wZb_)bb{SJdNIc}*6!|I|rh6ewdtng{kBWsxomQbt zfv(YOz)88{*>W4fS{f=bqm%2*3qw^v2yKvC`zyH^kb<_$W0+ zlI|qlDCB%2&k819j$So#GVv)tn0MAg9y+BNhrUG6M6htKJBfYNpvfAjdkPrOoeru>@6ZPmOHdQ1F7MH8y9x>>2 z9%tRkQAmt>T$r=lKN_H4d%^aBFTftq0<>{IPAWwi4GP$Y5{!&8Fwb-PbH)!gUvo+G09fJf)Gux0m5Xw` zZ9y^{SFE^1b!R+lt1FAtZ~|!NgGoW|^{L1-;tA1@GNSuRt?u^|Ag61ZZa)JfO9sHCb!N7EX*|-?&l&UI14lBVG7di2JIK zF-3IP9YCvHYbxro{%CY+mE8jZGu-KJgSvg4*R@i684mrp%VeHG)N|BvD3u2gzP=Vd2wXzC--&@=YtxKfk<6b5ri{7Ltu3kyH>UjlzRaLbOZ zO|zBb&l`Lspbaf=7X%mZ2b|ukcNe8)L#|KZsd|}FkInbVDXj6vZqf}u%rie*E3|`7 znJh?M6qV|j-*sd%Yf#Zsks{zV^F!dGj23kMgda3UkjtQ3B%_{MXas3aGeKOf468%1 zwF7ww!`P-f-Tuw{S2-e|+28pZmBZQYvqGD>Y`V;J_2(MQ+~56`H|k3zv;8^uh2p-R z>^~P4{xjk=OaPmBu*q@TZb`MT-*1n=1m`HnSq(IWthB&yVGzJ8;t%N_$^UQZ+)QqNMz!3<*l083^po`<4C)7H)8AjZ}Wy8=S$eFt_1@@RQKz;Iw<^)c!}*K6ju83TSmVxb>3E)eNaKt+0C=cmJ9&7lWMAXCl0XAi4B*APf z#hExSz&x0Ps7Di-V{&kG%?LGP`Q=B6erm<~xQ+Hp}jzvR?U zpQ1m#!kBFdp{*Bhao_HD--`)D*yl&-X(D?`-owciR~Z=`3N(JP-qSqM;R~h$P_g96 zdGGcI1erdLuz`3m&T;i4^d)AIVK3ik4VpEed5nwYn_0Vc=&oLxcp53@4}aN9tJ&uf zHL1;Jd(^4nd=T}ND2Cr2)is<}hi6g_0-j%bLTR=`))$g(2KO?!1rJ2Wo|ELeu;BR; zGZ@wgvlGs@ISzi@$H6-~Dd{fG;Y{ze4x>NTX&hOhCnxmh>6H`5d{E)`EwT$)tX7qh zabAvUqaIwW0Rn0jUkOL6qQ`mHH1#0M?Y5892+|AbXzRsW2%P_;~iY|$1)5})``z3%2K#k0_jjFgBG8CRuBB(f)l?U;*QqFJ{YArAB-RaAO%r7BRp^) zV;kXO!|zW(jMczs2(QN-fe)%OdedK`Ty=S|x^`PKKxC-8_H%h{+0)jlw*#K8sl8&lF6FgVGjb%q zz_(yAS@bIrVpo_xx{df!wG8&7T%2Dfd0!axhcp@V2Q(?bbq^Jg*}}_(WTKU2^sA!& z0I+Ovd1=M1x}e-$hJOpQyIh1uPIBx!J_q1W;vK^WX792|JmMS@S;kdZ#erXrPkD1A ze}7KlseF0puVQ@S04DWVLw_~$O@0r)CGw4r`zBU^z>}TVLhsrAQH|qG7uQq`nutK} znLkg;*8)eh8hMUW_y%7J6ZZ!cyd=Ju-+^&_!7l%_@WoWG3}0sWuL!zvLtmab7Cjlh zXku`m_)7Ahv+&D5@-Oae;*pxx5clIc8RYVyS9z<}25WS#Jm~($qBd;O5rwDHk*J4M z3qPmX;8P{=y-+R&r_9>nyQBmLip&>9E-jc}@F&Wh(|&!In=|Cs{>RU|wnHJgZ#-$e zZFYVztD89YZf}R$Sj~cdJcRTba4^=;x=a1KPzTtiIt3uYR{4G^^nlW#17iEk4m1?t z+qsmXPSPXtzQWif+GbDf$!UgK+o>3@j{FG>ez22f^oQf_w_I|s@G!tpn8)Z#A<0jY zQ4ee3XwjCR%aGC?;N0syO*o-=zZK`ZBV3(~@#WCH!h~wfIKg2i#mDksX6FPLQQ}Nw zql0+5&AWYLi=l;*^htE(f&^Y=XhQcO1hAtaLJm`fdYRfnSb$>p5RP#HUY_FTx4kYp zATE5rW>d)T5NEVQV_spk37w^=$Ew-SAng!3;ow3Aom|i1ORYv4$N}y^Ouc06%j(D`67f6pl##jUKA*OM;BQk)vVoJ)>I)?6D6 z`Te*Ygj0j{B41y|3%Qc6@g(3ToA5A)dgYe^3_ePvpgUAxDjh1sykb7U{=-mH@@%sI zYgXxUWgUkO)sG-*Qhylqvjh}3;BW!;2*O07wZ$sVG&-EX`yCE55b2GBzaX!CWh4Ah zEmZkFb-M;t%^GeTOT=#IZ&=AOd$#e)=8b8nl<(mn3Gp0z3ItSZXQKg^SYnZLP|Kj= zP%Jy3mP4N4C*G_NC%Rb9-u)?lCg$z>mB@F={W-ty`{=FT!Tt>T9Op;U4^7ww`Tu#r zib<53!nj}Ac}riHe4Jn26I9?ZcE#2Y{MZ>isVqT=VB!SWjl22+P00P7Zx9hZTQKK7 zP^2FZ$QIGwap7CYJa>o6+C8UF~T<2U;5GQT=GyI0#~EMJHN@8paWd z?L!#7)c93|^bi-3kW(5BgK`y0K+V-FqOuhey#FWZ0~AyvkD4fQOlb<7E~fZ|9RmvH zTn~F1MhplJYun;|8t__*hE&rYm?Sc07&7`JID^Mw?IupdAP_6w9~I}~s)sd275#iQ z$tCTb=zp2wm~Uu$F6DZllHDz!LUrMB8Om~@gAA+BM|lp{mbz1qzyjsg0jPP zD+Ym~izb)hr_wzz@m7<*Y*8(P?v05-a|6M8I6?dhR}^Y?rA#TM4pg8Ih%D7wd$T#_2okF?DC;ajYY!2a^_Y#oX@DMaS#%Nd=QI`}js?7LBNcfSsi`T*pGAxCI z9Pf?`L6KzY?I*V*xZrlOjD1KJ1@`IezIat}^Sp5t-f{SaNjhxzDuBC@MxNkS{H%t% zoJGIkL2%UwFi&GEMiLo>!89iXLCqgp$AM9lnq<_UEN9SPpIl!lgSf9urK8dPB7b#1 zozE8jZ(A?0^@63W{hWI~LuY`W;GEum+x0;rJav79ew^?J<;T5@6!qtDS)II(_wkr|6QG3c1*>2c^i5 zeDv)&$T|b)1{^@LW0O3V8B3rr^=v}>KIkpqcJe_Ivw(a^0Uygol%UM`Wm$_~rW9sv zNhF!WFzRs?XchK`li#>vqG5kNVj(-Em_EEyDL-FNdQJVk%e>Pl5N^Jb{HlNJuhA|E zz%M$Ki1X;9g8d35`@$o`AK>)HM%hl85uS?QQI8r2k^)C`H4y0$FW_keg*rwj(M1TD z3+UxtHf*7KP2dMGIqnUjp6mMe>EO$w{N8Ed_qD&moPA$++T39SU&xP!=D5-cb;B1~ zrP+I()LGw@up;P!{88LDZxv?0<}Z8ZSX}2M;rpFzT#@WpF z`EK8sURAT(9k!vGsQVwj*$$~kNv!wI5j50T8Mtm!V_@W6-v0qu8gldphTnx=k{zdW zP1OPzYzLeptS&}`fLef_1*~#%|#BgL^1tQ_$|Oq8^@&d{!7V zmq=D@uMmTx=(Y_JCdRJ)iVLGG+0B@F4eyW!wI+N0;w@ZI?UdewZaJ%iS$L+^zzCT_ zSJdMej(|kyk1$VNM&dzj2ag%Gv$^m$$JwvvP{>uwi*TfA@P}O0Bs54$N@MGbuE$k{ zKkQuAvcd=Fr|lmT<1X_3xnHD(UxA+-Q`I8>Lh|GCcJVt82GHUH%;9SyXQVh?vlu$x zuTGrIlX0^LcUtaPjgS5G3SeJ}KR}#4uuicCBP; z;fmOxiUE~=nJ4OrBR%!%3LCnjjCXdA8sQzo2B6}i7mTNRtl9z(8C5vd-G__Y3kLCZRZ@IG)TOr!$v0+1*-@9 zp0dCpK&>B{A`&ngW;^iK;7_;~@Z+iknbT|yVfeW`FisA_5NSEi~D6^F3u^wxSR7;sQDI{sq~r0Q2(x%D;2h$PE5A@N33DJ;tPIF z$~k8Ar*4ZL0}zSOKuAB-1c`?3OX}t|2R?k&0kwimq+2L~z1lFH5y0V0EUlBgjW`xq z2|s9hB(YH4ZHhB@jgG)zF6v1Q?$tUw*yKm77tUQ$@%)`s(LxA;e!>cgxj)yDu%QJ3X60HF5X6y@Z<-Ne!2v zK`vS05>!ic++12;#!ZhFWvn}0CrM&x?ac?`*;#-rfTp_lNnqSU&nPGuv2o&FBp7LN<(8(oWFA zlYCl?qj*B?B6nUlE`|fXT&f+#;1X!O_NWJE;k+hM$*~lpqqy8IbZj5D@~P^m z=a#3MD>xc4*<-CBjo@hVOL#_trXoi&aAQ4$8N3&5(@T?&{Jq*h_2683?!FcCbrt{W zeunxZ3k$z7em}FinBIBy`)|-wKW{C8uo}@U^MD2T)8&!r;gzdKM4^Qj?-|7Wfwcj( zm1+iq{%ALYt}#d6r)*qP1v+}hE0O!*LuS+NzhheR^V`-&;(I??9ixP1TT#N4TNM9)rF_=*e^&psZKqer0jsNof zN7rM`-+u&L`5c$=^#G1vM+#`@A+^NRdXDMGtr{SW-AHImar%LQ7CWo5_F=q@s=DSXiNV=*U){j~Km zSNE<+rjTpll}7VR$8i}2)~6XcOviq`hNv{>fyn` z40vQv9MdZ{`aylbx5I-oRXj+oV?J-md$WHgd!z4X=yH*-ksN7)ubETd1MeibUPz4ZKGJQi@i4Aio#l*Zb66@CpvZ%-M7IKVLj7aJe!g;pQHjF7KERTB7;s{4v z&z<4L05jr;J5xeHj4HXeR0Y^C+NKi#>_gPU=3$WG^;l;FD+?aAF)+C5bn>Gky*i+}R(b--_huT?GES@eed)Z4k;n8MTche`R-#q?x=4C0Su%LH5- z3fu8_iE;xCG*YUPdofQ}s%7{nR6==LVPRWi&iV+ZLl#8VJTwgX&uM0dnM_Iz5i1`|F-aKA3IvZ$fo#xwmY9b?#A~ge{9PNPs6JsejvN>!_m?v-OT>U9bHr9iAewOS9TQ^*rF(^Dh zlQnRLZsL(x)4mtb_`1$?z z-Z;;z|Mo9_$HrD`JHyjrXZ%ubKu_PKb_0s+jJ_B?0O?-7oAZ+v4*X1SI!k0JHHsxV z?U_J?lc-8-UPI|HtqTwK?8yXLSxuJ9muJ_VI}MxeV(H zkhi)}z_#|iS`YX2x)p>UZLI}sck@ScBiGc|W_*&=< zQOU*7n4oY>E%YO;3saU!&`M>JvJcjXgAea}CEXd4|CCptJ{$MdmCr@gV;5klu3W#S zIB$MZ^Ca6c*&;ke1ihojY#i_&L+=WszB<9F`Y_m6mIKaykF>Iiw+*$(xW%}4w_8+#?t989j7)`|?D?=SQ_qu-)_biB^5&(z8bDon#2TQ5#yL zT1@9xd@WN$t`14Sy8I6l3a0YGB)1A8*eGJ%1DDwpPKX4(oHm zn;X%pnF&7S{zf^;0TiA_H=fvz{`~gIm$1KMtPa%eyzB4iz6V4>RWM|N? z*}-Ge0j4l{E;Kg%K+(~y*ApHu^nM-pjhH4VZD#w1uEwXJQsBjAjnC5Yo94D)DHiWw z04b0U{P)&p^ZRjyr{cBo&)cTwhBY&+-G&_gtd&}!arI2&wDub4GBJ#Qd!hJVfJ4G- ze0SGT4IdFUa2wc<{gR+rYGPG=-` zK42E;>+4DW`mO)tzXmx4{PiXwMS;G~kW<)eRpKK|4#6OhL0zH#Dxba5XO~l)<6q%| zatb@wb)_EPK#vVA*>h_Z=eT^o3B07UIX?x$*GJM?;*+mFV(Yi^!;+|r>odK4XzVSu z!7|-s;C^!K3!b-w%3&NZ;Yk{Gs}lTj))>fy3G zOzu+{#;uy!3?ZCeKqN5Sxw3-(&|o9(Nlx(DyObuHz$+(i5WoP;Z!IXhqg;&3Izu-sV6P%_0JAL%zl&SqyexclW3GHm zZES$G^e&WT#{r>>y^!tTEvy#Z)d)c-WEO5bE&vd-eGuqY|&ro(uiF();QUL{5{y&65s<5YfhzDe>W9SI5Dn~w) zIBJaF%Od673`*9ju7EU1hgDJ>#SlxiGvsV6lA}LNG#D{2Cr)QXM1VW2owZ?>Ef2hB z$K3K8?BJuGel5C#L_Jxm68}GY?;aazmfeRjvXmH`1YX1o!O_Z2p`#e9WL85~@u`2p z>Y47I-s#u$^lo|wk+MayimYM1rpV$nDIl2uc^K;iSuG4p0c>EAf1<>RvJ#R=ae!p< zFk~Z=AwxYIl;V~xyNm~W^e~LQ2m2>f{Yld)x}6yJi}|%s{CgA zx*(oe6}}rxKTt|7Lb$lQ;X-G*P@8hM;Gkp7IRo+gnSaGOapR55PV0|;X8i^t?)lI3sp#SOt`PsB7H8MTkKXt#HIu6q9uymAzQ^3A;c1z8nNvPHy zfT;&eBQmGLNWx5I)1j%wdO_s^mVs^xML$(w0lK-Va5i;wlO6>Y6H;q(F^vbqw13Mc z*b5`<@dR@pM{~_xpUu1;h!Z>h31K9A)IQ-e;;^bpzHcG+2KJhoZFL+jj?r5S;C!tG zo3ov5KQ!!N6i*CXh5N0rrL2Fw%k;Bie~cz<+9WUTy3 z#ARk6na%5EPsY8t3h$I=CxH<=du3_4=3IRmPZr*(5CGLK7Sl}*_T_hM-`u!qe3ct5 zM8+Ur!wI00zS(q@@`iNMY*|HvQFk!5AEvG4s+2pg{e$M`#=S&$&&~blf3kkV!(SP{ zdR9JI+y@aWX_2_VxME08yblIL&G6yVal*!#aOyNr0q`L#D|J5e|4`#U4R6x!(MmQt zP*F1+L9aScKNE?@bl{gZtVNZ%iGa-rBV^PADhM{A<2=MMi9pJD2~=#Tv7m1$=n;9Q z?%^Rml=7@dxOn4;7@ag4jrr;i2AkS{;#d)AyD?M@8D7ohW|>!vs{-uVI5YWqIWEca z>Ow)+NIpWk#$60otM2HxT3vIyu$ueqt0HuXir1E);$bd;9gUqpwTR9EC&96IE2C5H z6?~TU#<#Jritr!8XTHFI<8ctz#(4&xc|Mzm$w|@|YPSR*YMJyz0|dD31}hcYspx65 zOa~M%9Da+8fME-;W}5+AL4>%mwCyj@+aS+%NF!)^2ksVpgTV&_+%(u-;0SS)(uSTq zxJ&;go!_;U1(VZb$RwU&VK5*A+AIVp88ZX&#^79~9!&uv<4C+z`OrVAw0r-J#faA$st|jQ6tC zdS3d^*DJGs?ctnKtY)xZY}@DZfCsqgxt9#$^t0pvZ+QGm(tk=%+W#}_A!MDXd`O8_ z^9jz5EyxpWIT1vJSH9uM1sd5R2maV@&h>f>W#cT=&g#rvgrz z(S)5V@f53X%{$ng01CwEFIROXpDu=v9ws{EqYwVnSL-*1u;O*jG?zN$?2j_8KUrs* zX{;RRS_yv&IXirsOxCxbQQkv-UE@IgD3(?r@Psd*`CMdQ`P3wRyoGs>3&R<5gYVU) zMKFlPD~5tSY`?<*a=KZ}@Wi76Pke3TdjLQ3!E|x?wlRcF)_n#%JqP)A6J6FJq^>Kq zKL|WySVnM0JViM@%bS?K(UAzH-Glx2(JOp320Ns0lm8~n8{(HPhTo1l zze9Tk;E1qmxf7#?mk+uf!l5KKlr1LIn3_4ng@*t?Qt;S7vs7Y^8LV50+P+NGvIphi7? z)EN@cX2D-9?3npJ3&*D7l<7N4huF$_x>@-CQ?0E zQ!fFR<z)d2KX9_d(AP#{mvOdE=1^L1#-3# zO1ru5FpVHNg#$H6@8Elp!+@Q-{E%v@#etUq(La&{)Apw6Bj_O}hmpjiUx?5R)fZf@ z;@)P1{}3*EOwcZ5@ZI^-V%)p9&&2;aPY|>v;LkOi7Z#Qf;K2ONviTcqC^o8Polo42St`^?qUM* zs&Im-w0Edl3sFA=_2JcLsfy@&Y6txASSR=81JV6y_GsBT_vo$SoE!cx>o?#?xVte* zffR_%xx7>I6W?}^&h)Rv^hAC_#1rAT*+yZxc)G=+(QA|J9N|Bo(MnFSb0po>m3tn# zNaken|L(>FI*s>|hLzwP82Z_Q=K@U$KZjof&JX*|Ka+98hrUgkHQ*11JJW<(WnDy^ zOqC5rss!^p1j;d4JRL4%Mc`J9J;~_F@6O%!;(Mj3GW)n9j@0<``2Kc-1#I8Nh8lKH*KgcdO%7>srUGoj9eK$xR4CZR@dnuI+om{*6bs)4m`4AD^uk`~G#hYJvKTafD~w|94YdmBl*K&u#xl zyy}Q^ADDpiLC|{^{&?}=`O>y_NNl>U1qNUZ#2c-tcNDLpKUww2RcrjBqVJ1(du<=P<;znpiZ#+ zUNx?r$v+kdaWyxD)pe2H+idKcFdhmfcmUG2hTxvmHlaSk6Z=CL9>O9z@`inHh|WxT zX#%WgaQ?C-Gkcvef0^@ZW><_kNYp$|Tb-Ps=3&g}j)!Zjalj)^wL22w5nuBH^!H$Y z5bGPUfTKP%R&dlixj_#%9-5M;xs&lsIw7CpQqRLaL;XMqG#%lmp4+h$Io+P=*M9vM zNVh{vJiHha@7gydIScaMd9bulf4r~~HO}zA00>CY+7Wgae{+T^E_KoKoueU-f9&%3 zCrzliF~pbsow|;fdK&+s4eosFh3(HC-mDjTV_*6HPu6cD(vFz>XRRB)1>Hc|#O*}q zSb8FzGbX1%oVe5N@T}Y>xmDnQ!L1*I#x=mtWM}cicp)$ltU&o3{VeTUAvE-huf*-O zGAN!!yofx*ekUj0h$hkUar02Iw2>sOQM?dFV>hn&-=y=2enty>XkGT`XVl{!)6XdF zNzXhN#%H!TCvLu(^oA>Y|NLhCCJ4MI#31xBe8pp7-S{r8B+T z-^}foSHLC|J;cc{Jw?JBnFiRygtsi9$#fHz!Q1WRC%N(?pKbx(dKdT4H(e*jO9}No z0kKREwc{_Z@H5XnoiYs;{)JfoE{X$9<*{wfHlUg)T>W4m@K>!;dW1+3N4L zaQj495aA8T=rZ0P z-dK=Sl5ni_Bsea2M|hLvAkoB(9gwO{VdWqbP0Nfvhw z@I(DM$eC@J?k{Tz93~R>Q_fd@o)-7bZ~ha1L^v7JfiU8a2{D4tu7)1KAw4sLpRG(l zJo-amxn4(bN??R{zOZEJzzcqColPeh{Gi=a;fIbf&?Qz6&ySmdm8i!3q2ZxsEAfrl zMBFaAv=0{7xuE(4T&kfi4O70#pMv%<=IBfzw9 zF`Y2v6`>0Fct8(S4<^Ytxn1weXxIWH7id+N58h7`xbRiCCnHfl}M0| z=`q(#t{Q4wUBLwdxr8af-!p%5I4|rRKK@(34mckbP61);KzS1X0MECdYkXHBb=g74 z(Ln6m;WTQJDvN50bAz2m=tS>#bi%imjS00! zJw*i7^h#OjykP}~O;7-LyRne8Q4huo%80$O!qoGE)kno0mh>&QYR2HA0v3z2pU{&+ zJz8qe{fvK04Gg?EQgzeA^%%6gT#wJyF68DN3k)f`{tKk*NA8QlINfo6Ja-p43@K`QTix=d^Wc^JRHC;5|eaDiE2ydB=bfnZSOe=O2QHRksXqH?RBY(>X~HW zpls|fEnBf6VO6g-^$ArBZRn%jW>Hu2IuiAuFom!2A-jrhw<`Ui_pl}Su=jK~V!HO7 zKBT%V8ueW3j`po9*qR9ZZZ$%k5;N)5V`aTg=uT!S$hSLAN1U9XalF+Gs3%8MKxUUv z2|OKHiXUA5`@N>t?n8yY`|)SMG5r!*ybpZgx|7SR@Yk#>Hsz{|W~N_-)KlBGy0~Wi zM*1m|1wUg7isQ{jxwq&)cFEr1TIE_+tMFY%^-9dW_TR*xjE;EYk?3OKn>&VY4)%RQha3$LKa3klbb}Kbu-I{Ill+w< zim3eQq*Cf8zAKlmP)}v4)iM0DInv(2);y#>h4qiS2?wOVIn3Y|MTEZ^@D{XT`wn3U z`x}NClq_;p7(ecggKu5q0EZGErjUGTLKBAU#Gud0bjCzDMEw{iReD+9E?DJTi zKnX=7sK>^~f?4yvEuR4&69MOCe$hMbJwN-+n?>9cIQrMV={CVX@@4|V0^*CIeH1}TPT?0T8JhFgBfUH8HXmmEA6B5 zj3&5-KT^?FkZzRCijWc3X#v-E>&ae(@S`YNaFp|@ab9%PlfO!vVyt=W2Fsy{B`b8) z-UNMRgTZkGFL-cc>4>^K#4GW{{QwWo{44a+W*d11-#1en<+*SCi=V3BgxD(4=H$=$ z#Ggvv%+_d>4mhNQEHy>cD088fr*O;Q8plVk{)e;`>pt6Gw$At8O?2#QZ+%wlT$ZES z276#KN^nXIuc$q&n4QOn-6%Si=dq>nN=3lmdKbiPJ&a5(`7|AC=Wql3TYQF(VU_|m z6A+OH!jAXj`B^_&0+E)f7};^#w|gZD>4@!1yO!|fk1bb7>hJM3=I1~Thh#GAJeSxu z>4y|gDvY13P!a@NsSIgR^c!+qz;(L^ADJN3F}1;O<~@z zy!tT3+nbyFv5(hpV!y)N8q6huOL2aVMG#Xbuy}yqH|N(p$R3#ip7wP`{3GJpTi4eN z?>>aH;>Yu*dmu}GyB}rQkvq-$TKg^cX375@JC@E}b%pmKcxiLCwW7IJGrJHwZus8XU@Dy`@nECr!CiEkt-Zbmg82~$dF7sqCl8P@4&;~U zIpm1s42Iv&6ZcZSl#D1>O|n>B@;Fr0<#{uZ;BAneKy8CeH!m3-^~EGV|L89-y;r}9 z&`q$GiS3^D`#s*Qpt}q!dLaU}gGF;X>PDfr{g~;A_raitCecepI|#)Z#%O5rlyPZG zaUbvEmen_?V-L4WN#8&!j7snx?zOdNVx$6bNW8G|S<5W*cuKD>PnPaw#;5qTq$fMu z@G>}i_+HQ(AANG~k--_=D}r9+i@28+>;Dv-(V6{Yj~ATMjy9mDAR7J#)Ht+&XZ91Q zhJbPe1=y@yz|#g;&B=-K5Y~4FLeRW8jPzELLp4%a9SMDeZ*Y+f8t52qM~X5RjWr-I zN~ux&pbWAM`KxOv9*03Z7ZrPLc8utC)T34$=Iy)m!1lfQF3pvmG&uR5(?76X5%q9b z<{{;pC9Pyd52+pwHr1d`d7sJG*B`Xgw~RNqjU;?#usyg}flY-UIxRbJu1T52j^yO$Z+`LJz(;d` z>$h(LA0b{Yq}YhkJ=WB#jZ zTs9_+3W8q|I{hPFw7=tLoty6xw9s`?uNenIpIg6MjxOK^$7I(S^0jC$gA)w}<0LbS zNQhm7)ET6zQG-ecdm+YcMI9Gxf}>1d^(Kbn%%)E@%baAZm5*uw^{A^Yt%L7@#xBI> zQ{Z!-q)YlAr`Y+Uf0)i;Sh>P0{WQtWjch~d?{jtxmYC&1t(c@)|4j3l z!BsueFZpBt72pb*8&Dslw3&c)VYrenGKVXq1*8~<`1K3*8+Je7Ny_BY{Q3Y~?JE2< z$4<;~U>5`#TtnAN=O+Jeg~F5G+fTqLV&@H|GRZM>v%s-#5om%L8x3%N?Jvb;@qE}> ziGX;7|0t{vIbJ>$xigA0H@n_(% z+QNLz`8?QvrX-Fm_m+XT@UtcC$)sD=EG{g9(4968MHVmj){S(&e`Tw_QNIOU&gZ%x zlYThxJg~-uMSi9}%jx?L=YjfLf+Ni{=CMVt?SXa!3$+c&q-R4qDvVAUMQOEJLE9_Y zbl}4G6uy`+oJ*apDf@}f{OqmYI{NiQZ=Ry($ddy1G5ldVOkagr?mvdfWs_df>kFO6 z@JN|%=CbqTMnR{{eg9uszlBRQNK`*fbe^cn`dRV_-omucK#ttHE>@-bjUUFdS z#0yJN*qqlQXTPDrDJ6E!HZ~3xfz_xT6bU;_T=WXT2naS?I<&6B_`yjgS%)2UsuSMw zjY(oHBynN!Xs4PWA?jf%Nhpd^#=x;>N+Pn?d@Np5Snl;m-rj-5RgzC2P+EI`56a-Z zwg$TgO(nX-;tVn^bFM3iH{>7x7yrz^{rm6y;@?bo0&qsZp~-0 zHDSiW(gJKn1!)w1tQu2?$u*O0R4r~47H0*nAH_UDcvkq061Y~E!`T!Z?wca@a`>ED zc2Bf8L*e$Zn&>2~8nfK&kV!_2WbV>(d`#5ka+lijvb*(1Y7xx_yzz_WW%rC(TbqZ2 zEb(v_S5T#mZfSlwBC{zRMD^c0}XwEmI7&^6Be`94#f807(+OuacWK@cPG*JGP3Y)3>3_pJ=&~@2y6%jLtepf``Ou6+ z$a6&R>)y?8X*#us>n$sW=*=#&2TEvzW%Xaxr&4wgOtx)Km_m%1EJSVw+PAW zDb9$#Gdm@J&6w$WKNB4naM$RLpgSOd+iG^Y-btZ0gy7n?j;k}|I_h{yJ@Ny8(ygXCVTX^}0Gd=_%Wcq^f+ zmt;EC(1ygwg|r+E1(E4x^oOHFc8Gs9Xf(=J)54{O(n=csXNjoC>-O!NJ`HMJmAN^I z)m#i)&rwg--@Lo{zMqY&|Dh4``1B~C%cd&oIoxX-qX6cwL;n&|Z0G`r2I{nTNA9YY zNrcbP1a{#l!RE;8k$x<^H`rHujKzj_ATL(3n9nDpM(_Q0Z`-k)pTmOKm;Oii#N<}r zD%}_0SiXo4tIIN?X(4uzjus}}7LrMFsfnPcn~mZee5-z)=%K>)f95B?ul^RIYVRiM zC&MRWH|XiwIkl9Q9(V|M-d(DR5U`XMh#;ll*UTKYcLUxU(9&bUjrOkVCPEhxWSYez z+1zP%gR9(XY`{6P-IRA?H1a#Z-t3J!a2Ktr0GRR3pe_At%;2d#z8aYqqNm<^BgF;z z=r8_e3vjf#V?kyFUeljTx-E*wB%YA1KlC_gQd>ua5WoPBC8SmIouVi;ovaKt!q}3H z+wq@Fvg7BuDJ|FBE}~pn!0#piO&m92>m3a^F=g!WF!V_g?_Dq#*}-NpbrvyIjPGI@ zJs8D{+!`N8xhGfS>0)qsqmaA(!JqhS{VjxEv1qOdE=4f`A3dPoAUO{aM=bNa0taZC zYOFlUfu?_>z98lZgTodT#*c$%`o^FUaOkteeMhH84JamPj+g@}c)KjFVTSuHf zaKnxIOZ$*V2=$@t6`UFHXn-!n9#odX-PkKSrhp)>H_vDKQE`qMd}lD8iu{f4=({Ph33e!JTSnb8DXaJ8hr_6EZnDf5~1&YN#7C4Q#T zliDsk*CqBM?*X#|`x(}NjM)u)-k$+l$ z03YyUhB^tpal=H(aXe0sq3zxd7#jO*gLU+WxXhwH)Pu7hxLlCUd#uuv@cMMac~y!t zFpdv}4v07S(ooJgS_rH#1KfChx8MDe-~;!)^)GI{SHHd2ILJL^@(kwR8S)^~^>56F zzM`e4g9B6z8OVX)Q?2NSLnWLt{yHMofuq&Y5j@O#=BM?v<1H$`#3{|&xIW?dGv;*_ zPQk%Pu$i#4XBB@`^_iA`UGNKTzia0W;OC=%>a|;dAIQOH(<21#xOLqX`yxFFeva$T zcfepx9(gXkJ;ELPS%M$UALd7|TzaQ8{Sq4ymSK#TGIsdXQhE5Of@`v;c8&g8DM^5`u8z~xaFa2!M8 zF%JQ)4=@A;h%~d^bTn`h7Omx~uH;kDZ3M4^-)cfrWL2H6N77vfvEZVc_DnZp864hA za<93$p5U+uhV674>*V-axeJX`iuVcSndpXkd+?Z4fYQ1)unspwB$imnDU#8~cpWyWvo6%8yZx=jwBY0`@q?W!+?vH)oW}P>3)&M%vh1;2Ij+#CP=B_)s){wJqS2Fa!ahx&75Tpia5mWy{Lyvs|MT9>&N^EVA^{E1V5$w z8wrw#91TD$)eOD$<0zZe*H^~_K=FaAyCKyvbpoV%^qGl{Mt_KZd!}^6RGUDmap(b+ zc?bC_tJJwA)7ic=M1N`2CRpBgFyNUKQH z!wNXR>AT%nLABV)hFp~C`KCdUsHcZ0E1WMI-M#^-swmA(HZ?R?34*Ji{5~LPw%5Y= z*(i>uPhD$Q6oT8dgix#Hv#qScqeB#q{#35fG9kvobbQop93tS`$Rjj#4>u4aMni)$ zCbntmsHYhLA$m=OF6udE=`~&D2~EW8EV)c0Rc% zK$jB+lYBsn_AqR44XjE#&DcTs=IS3sJr3V+%@4Yrszsl=2EK0EUrYl}>oX+fmN6do zfobx6Is}4&fr~e759tZP18k&Np1u%gEbd-ogqEW}F;dHQxP@+BFD)Wr&Ue4S&%8r0 zNoI7^gK;7Y_NnSSl6^6I_M2o9VGnyYcdsSkZ!`7=AS#`wIPf@L0$KhZY$BgIz5!B* zLeQU#q^isNgM-bt4lHA%S?C2CAPS&yB1OG8rhNE3v7(;rb<^-3DFW;X(giUsOyf*d zM{p`)ypc@jSBRPM9h>y`Fw)g&vwsMcQRX3t1OiPR8WPk4um&+s^yk_EG#t34nfWPb zGr-#xnycVjRNG+aSq+SoF^yr78?!M96|i4i#bvikM{dB=isw=wcj*lVBPK@SPpjKM4|oN}UI&xgs#|rb zQxz%-ORP8Qp*atX6m@l5oUg(5MlCTky_@qOiRcVsi!$jJIg98O<1%q08P+wf0+CS9Hp!DGqeG5Y)XS@icC{VvEkA;i5(zf}QkRnYIK{8`_Rwg2j| zn1S=k&jkm!A0MB{twhC zu~IH~(AEQfK?obf@box4dcX%li;(4S!Qp&~PN7N&YkVU0oOVx@D;$pzX2mmiueGh$ zMzpF?{1nCPUgrgm8rYffA)7KiUB2x!cl`z9{6sw}-02_Tz!YWD?>S1}Yj#0;XaX3% zzJYAfpL*!^)qA8>5BC>5L@3WYX2-&?(r)kr99}kk`TP|Sb~#g;nsNT}_%qKZ#O(>Y z%wxmU3pkZrtjPd85w2$mSl{HL)s=ZjV9i?tPAd8$1GLnt#*YCC2F@3zufboZ%Y7+S z^Mh<<9y~&Q%}_o(b9{N8u|5S~<_m=%^z|S6vybXuU|Nbq7QK@tbwr?;-Y#JXP^cqqwHsbhs zdN~368KWB4%cNg%lk4L{r<#@kflkxFNrS5y&|d=;4aVraGny;l@$Gu%uiLl} zxSa-%As;E(BLk?g59N@-?6xFkndhD|cq6|$drfeKF9z*7^Se-0TK*M~!~n)R{hZ`7 z>gP^Jh}?dRYTr%q5$yuZAa>nDqJ&)nCHbV12I+gfOh9c#4X9B(rcL9K=3)Qh8GSVU1Rv& z?i<`IZ`X~_|8@YNxe-X`$f^65A5QZJWQ}#${nx~Y-)+E+z*s+~spQI(3HgqI6mX(} zClH8*w*{Ya9{pa4n%=HkJmIv?uQL!dh*L0Qgr~f{3$6E+S*mjl^g{Q!w=;X6ANq~Y z*53wmaK`%_t;^o9b5?R+sWt>Yy7tz5^$pja=4J1CW|HO~$t3NjD@0_)aVl4nA6tHx z(GgSM3vV+t0@)j7H}H0zqm#rV7_yF54PB}IP1_})6Li{^&RgiYBA~0?2;u*l3|8H` znol5C&;<(@wHQC0OYZHnQr+JCGc=iQ&8cZ%N_I3olTDWR&$@rHr@lCTaw7vaMEx%Qqjf%%ZtWA!7Tn68JN=0QKJRWBJg*87QY?_IPw)BxbiuZ8%#_7^wN0d$7R zTDB<|R=|oJqEhx~53JT05IDStNC(?>DE>2{J>^l7C*tG@=3pD-x=sAKcEro|k?fg` z&-vRWd*=DIHH!z2DK~=`^9O zmt6!-FZe1KGjO4E;Z8mIHUIdB_a4>nU{yO58Yg~$&2ib!57zU+(!zBh>vODtKos~G zZcaTS^ai2{m^PWE3}vY&2G5`aU0l+M{t1<*rwH8Fs&*vAYJS-jg0F(o`@1Jo#$`xI*r~iU+HM@QRo^5OyoIJ|xs}}yw z`W;wGcl%G8t%OemC|vh9bb&w&K=PUQDxa$jw<_=v_ai?{fGNLZj_LDj@lb^<002w| zKX1Yjr@##Gqx3}hF+7&+uwZxo`Hoo=PzS5fLVL8+9&UXe-2v4@X??}6JN;-sdX4rm zJhqMhL=^J>PDAA|i8NH;A&aC2j`E0a5|hI3TA&*_MMg8xR}4HcC%q3duu2~oIS6+$ z!<~_%Olyzr1QKM9`JUWqM?VmdOWgd~*7Z`A{?5rx5#M{Zk!A3G_ltsLputc7{P#Yo z-)Xks&j|!?f^Vz2d|n2ggD+G-6I?k&vv3|Djhm7JZbhiczDGp$tE!P zBD6OFKhNG6^KA`IM5%N=E&o4*gUrwHxBl@@*6+|3asciumFh`%Xq9vxX09s=JQnyX z>*uV=z$egS@}~V-T4bOvy6Sb3o=X(P8^b004SM@wuh}{1N0y!-LA7_&-4kXV!b@5H zV)XWx3jd1hweJD`I7lx2i9#+)M-})5{?&nNh%5L963l`eh|Y@SQ*eJi`U;H*9}$9_ zDL{q;A7j7q89@+O;DE;O=u*IM1DZq@Q~)~4ForUHNqDkjd@TLb%CAQYqW|58p&9{B^X*u21wPb zn(ONMg;cFZh$=Z4wm+{vKp_5P3= ztKwc>Z2v#3Cws*Or6srs8pX~>~ z^1(<4ds7x@nrGC3^A5a>n>SsImeN5lfS&uplD!vcKDIu`=heG9qdx>85pV(}mmFm6 zqSxwoqhpRDS(XfyEI5WP6Pg7T#t#cIq&O_jK#7Tg@_xIB_RTgGF$2Yv-fj$1ALtM{ z>d}`f(djjNu63{HqGEqE8Zqq$yC6k9DceatdoFc>-kYpDk2z9Q!6XT}}Pkcmx2|EcFW zyRY9%@ucT|=aV1cer!@uS;#qzqPhQsbQle5Angsh2A#J3`1rBOzj|U7zbB8n6(F9 z#5!031NNi#0oahT2RS-KlAkG|&1EU^6_rH6sn_9B?*mPx$#wtl1pnjDfS>AGW``1B z4<*ac1EapM>3!j2*XXLrg|+VkgjTZ8R_7HDjvv${ z70eUjn~UBP3VrXp()|X|tM7@gB&2P8B`VV914H^ke5J0KE}gz`5B?)oOn8vbDY~ZM zOZyS~Z38MfW)auvZ|lM&Jc#n7N<5wLU`&>w+-&xY8I)xhvV>2(#AHI+>p4-L>VQdh zD$q|J)tNG5YH)zaB_a~#`dr<=NpV9+FNA$X#GQqTs(DL+afH(g9_bj|9k-#QPd%!v z&M>bTop3+dJ+1%M&p{soDpK@$7y?Y&N1_MHBFf6=s=f2eFGEF+@=KlrLCs#Sibhc z;CjBI8*Hyn)CYsob?`YO-Yd>_BMs(P+2 zG*6f1K~pxaH#zFe`L(2$m%id`R>#Nf0}*WSrq`}MMj+nAQp{Rp4) zUYV*MI7UaIBfk$T^&CXt<3AaH6Pr9o>p2O`i-g!YrJvi)acNl%Oltq^- z{U?W+R>BCb_8Z*M6VJ7B&o1}VfO=M8XEfVT?Y_ou?%pyvGT;y1&Iau#f=a@l!PBXB z*|RnFs`TkIaG`tJ-Fl)g=f3in|1R*ya3e{%g+I8{X4RuK{p!2*wJG(hq35S|OZSez z2YTg^$E=tO;r&{p4m&?kQ|OCtY{nUN;Q4WXK8xgQP z(i7>t@WM=Z5g+tIaej`E$K(9y{35ru&|xBp)-f!Idq{Dg5y+lWezOmDfGKF~NKu6I zqr#|!N1!U?lo^<(88jG&DB%_%^Yo&Vax;4CMvCL{&6T;I ztl!0Kk4}-Jg}kfe$8l2iukvS^fs37YH`2Xw?q?8}^)8gX6kDU9S46R3U!LW^-S7)G zrQx49VLr&6NkUoaiTKC()rntnp12!bV`Ct4iy;Gr;v_ob9|O8zKzbv|WOt~L8+aA? zh9wYTBtG`g9QGaZoo}Mra4t88LzJB~9xrtz{`(Fr^OIdZ)*bp^)nrHS@)6|GBbF|E zO1pg=?}Bbczqqgn?uodD%XGsf28GUBF3>VOvj~*%&aL&4awC0cf4N2(b%)*XpGh~! zgLm+pLDKX4J?z@W(ZjpV;+@5p{K zPF5=Z6SlJF@%RR4C*m7i3CMY|gFGKTbp5}(H!LnevEB!bjXoKxSjR;FUvRwvl(F7{ zFPAcWiS#7=am1FpUS_Qu95LlM6W!ryQvAWR*Od`r`3U=*P#f71Mw;O;dtFw;rV=c26N8Ix%(*H z``-G(Kl4?rGdvNTho7%gjdT|H`3R&jVd9S;Is09WqYLErQ9cm)@vQGrh#n|64@>u@ zfERdRrM;W%QBW-B!|PF_P+|NypMm}vY@wR1;Jk%$Q|0-ltUgh_?!hgYR1JCeKW+(dfzw~9n=eg~t00(x?fiIEdPfAaO z*PxaNM;GQxU=qgp64|`43HEOTstUaO5JETLcF~iYbfuh>6jc~M*T`pgriQ?<1s}(* zdDv}i!+o_?#2wLfv8>XbAN5!s?b2MbRb-r+6Z<8M*`gkrvzQ~vQU$)9sJq!WgP*>} zBTNrRBHJ7Sc`H#5;|aoLG<cs45{xIpKjX%#e_}2^%fA@*-0`=L+ zW8>co;d5Z$sSTnA0Hr-7n9(b&vld7jBb5PsID&cUSMTBjxESB#vH7RNvVZi`>$iBX zYy<7@8&%46=iiL_73Uk18ZvyWE;zf(`V%XDzN#1LEz0L19-8 z_$b|OH->Ok#nIwcqf0zeDvTcxxd*0wi+D`d$|iy^$*cmNN*StxUn2S+JzA+32n*CR zt{yU@9;k`yCHMgT2`)eJH6;B;ETEF@X7o)Desrd|fhb^oxba||qwV%VG~z0bpn)*g4rKgdC&lfO3MAhq zAmn=tY`5dFzp{kSTNkmxyr1cQMcFYLP=C~z*e0qN17)3-w&5ua7P|GHPcg3OMj)Zo zuS5XhTH{geR14y?TJ2BT8>lYoVS|8?=q8e8Ym3`a4;K{K46?&s0FGthDAWita)^>1 zsZAPN=#6l<+0!Z6AEp@|zzDP8?0{#q-v>z~@WKrXe$D)^+mso?5Mdz@-;(t)32qUS zxL|5Icg%EXPY-+nr$=16^0>J0I{`9!u-m$l{f(hbsy&4}N_*-SaamM5E9wtip<53X zj3-`!L#A=?Tk9B7G!P>5A;yJ1GSjyX)2K1kvD<$?OFNXKP`9}&inv&Jz^uR4)H+8D za11D6hv1OLJdfxBQ8Pmk{X>+2sz3Wf{H0Bb2w<@Yh%5!CouOTo@E41IxBLk=gr4m< z-wXH-@mtm+?#i)Q6H#qIZgd%wW!V+QA??@UP^-G4K@C~~y8f-qBL)k-hfO>FjDL2c zutz@m<39vC<%n)q)5X=Wvhea3hfPd2FHZJeEBv7Rm|YXi!=@GiYlm_2j#^)k0)+0X zOi$#uMMYY7{NUbMDf@(Zt#swg`ce6?y}wg|+omQo$OSd{ew;6k{&btNTgHEm)iCmF zMirkh9$J^D6Z+3C=$_iZ)eOTYgl;qrJ;l%CCW#7EnB_A@cbZWrw$pQQA52+}2I2SG zz_%03cRwk=TY&l>K|j88@_tzl2b;v=M_|59d8StL0ChEN2s5vM1+(oMI9L*|x5iNC zve~0WziZtnz6Qs%xB!pVvW-BvBlxt|{$i4bPuO5*j~n|c^ef&q|BTswVg$U?^eZyZ zC1?fYi|tc>zNkJ8U<%-hZaixoXOHrdza{<8{mxZayhe`qESS(eeyT~y@b2xK{H((B zVDLkKx_%cChZWkb;1{aKQ|%`VA2D1(A-}NnM10D6AWJ5G5=H|ThvCVGm9e;Xg+BiVrqU!`){*O@B#z4rX15FBla(E!+S(M35^au4q_>Yqo z*6PyyBCR*4pU(__-zeyYxgWzlmr-AJqY+q;zo8jF1AcX1ofnp7Y^*nQHRbyA@0vyV zP(SVJD}lO&^w8DU?z{HAf@@g?*Kqemd=RVU_{8;dvnoJ)Ff54G@h;N!1tIxJmf-g} z#r*)@#r$w)GB8vZv0e?B{144tV*@UWg0iLk+YsO{awFZJa4WToDyF;NYTJ!wi&}dw zX;Wp|WZYQT^{Rl)Yk7QLWQUqE?J^ccoCLvRTu`y=bn7wtMHNLoc7w(Bfc+L0u%vDl zxZ@tQbvZm3L6^m7cc3AJ^j1|z?XE!y^sjWT!1l2ORb4Wc|)^KTtIqLVKn4kNu%n>WH5*U=J};WO`yZ z10F+X!|JpC8`x$8G6>&mY~wufif~28!FHJ9@Su7jf^tW%)YHZIptqC1$n_sbe9yap z798JPHysdhKAdVVWAKFgB4T<9*m+-6dJ{OofyEba;%eI5>I7{80C& zIA;N3R~ zT`T!cQB+zVD)ThmG@~B0&hM_V^cCc?+qToy_~e)|e{`VYSe0Xka4({p3qCaj(zTm# z`^QoWNoNQRCMJiDA?43{|<4UOlJhq=GsM5koNT9_MKlIz$31c+)u#7jwuM>xf=?aka%|n9ixV))|uv zE}jRFTU=XNawqFcOAAY04lHr{Sf4~M`0`}<{f)vtbW`+7KPOkxefD&ELHkEEiieeq z^rZHmFTGL*wqpMU#U)55)#70my8vluTM~|A-+)Ys0sAom4{^oL=ytck1NkUxohCejN6_2J}CUiIfSpqE^q@+GG}ZTz}te#@JdJc*0DY1 zyk>BH|DGrmoKy3E_Ui}ryHNY&qCtUlt3B!huC4p$@~2rIdBELfe4|vp z&EaU9jA_CL`J2NELd7@sv8wx(eyg%S+Gq|pM;+iJT6Km0;w}HGD9z9LcluW)xL{N4 zC!(3P7+F@M6v|8)9Jl4DFn)%u?eVhqr30|fRsih~F{-`lQavZx3$-w4gNfQ=lv-7! zN0%=~TCNc_xU2bdF}S{2#69}jU-=&3!zU?*1>uP>N6-O0oGX50VfTf&N1#|#8P*B< z*yfa0!pKNIWnX#`|Fj6VXR!6ehiF;BPP zv@$=7p2_H!FBbaKpT7Rt`rXl>J;bfhxQN`Z1{o##1&v}ppaTi{sN_r3hqQF`2mA3M zZrG2_4`L*r+K*+hvwFLuf%X}C68{e^9w$o221631)ejzxu(2^aFFwHV&}BH1=IAD^ z!uUbuHa^=-@nkzGp6pZ^Aa*Qoo_dFktLR=n9Vf5oAH_Q&98~9Pt3h`k8`#&Dczv|H zC6XR`YZ)Ny{tuX}SpnQ6`Q9hA3=or^3i!QOPxkMh{7e7FPuB01ysG$lgK9FZk4(!0 z-ZOY8;crq)ukvS}feXX8wY3ROtWA{rUd^a742; zQ2N^K1zx~9o~0jV@PS1{Iq;ld?Ucdr+I7L}fKE0jQA(dYV=xv|+Yh3EwulE%X;?t#DGl(b$DU1(@TriVav6M?98e z=jUwhKzq{d_~D2F+FmTl34zUXBvGZXDzm*iiC;R}grb!dZ7OYYwRW!utpGT7Q6=%D zhxeiB3Dp`_zB}5BeccOvF^+3Xx-l$aPmKMWKRC&tm2)GSqMpbtp?vsJ@paBBvaZG( zOdE`lqn;?XKiZ@_25((l27C}R#$IomsvIH|BiGgnY=o%CH6xl}BVZY9*f3Z~-r}LW z-`9ZM$Ms_PJ>s{aRohe#TO8%%}yirha*82 z&MixU>&_s|u;cm^^5KqNV@0ahl%gC{+#p_h!2S?Mt=xz0-af=F-d8?xWrGiFtXSo!l=Z&) zn=}LGJx5gEz06i^MBxn9#*Z_ug@<|>P#tL^e^ixtseo(E}yllz{Hl!`KX53_o~0d)yP|=6>ws^?OZI z5)S&ZP8FTg^_I;JLF-OC1e(HUdJz^5M_goMBI`l~__&2PJf+lc3JcXZ4 zNKhfmrGY?6bnEs%W3yGF$9tGs4xIlVZu*UGY%O0s7BkSMo`2|{#{b~g(C$}uhg@5; zR^&a~y?^7Ly&R^C@B=P$l^TMy3eIX!b8_zWO6WydgS=-iLH081J^NnfziQ|2{Q&SP z{J%-j$LSisX9pY^{FLR9{AqHW{lsTe3*;9j(?kmNJ*$du$hC-iknQc! z{gkE4<@sc~J$fRq(ZR1SG!LDi~Y>^%|_`OxC%$g0xk!w6?UoWYse1 zZvUBdO~sYqE6hXdaqa1S;DgWTp4&-|H22X@{*UYTVB7_7?a(QS{b`?+~_^(P&ycaqB2)#_yfbYl1%SzEs1u7Bn3bWsa+nv(AI~FhCsMCaV7`I~; z7$Ksyd7UYq%6voumkQb4JU#kp&1ai};=MhOO#Xx(5M7O+56F00MN)`M**NWmxT3RH z@PGMX|B281?5*EA`k&MJJKH>D=i8&gp8TWteh2t#AFB*Tv}>GB;`7h}+T(?VaXNCE zZUlURQ`l<@D}jZ31lr1UJ>h(7)N(`R&BV_=9H3u>h^>aZ8{1;kHPeUNfiwVqb@_T1 zu5!SlX0nH&q=Xv9&y)TU$ClpPqaTbKdc5K+M4wod%}UghYVgT&>>9-w#KO8jcVjl4 z%osE_;Wi1(WY)vUQl}MT)lP8es~*64Yh}87#5B|W(v)dZe?PmYF)m{A4`UZG#zk~H zY{o?-0q7Go-6%7-zn%O<&b`0zW#H$)!^B84;Ait^V7MBdY9{pKnST9>_D{jjfEAnv z3ZdS5U4YdxcOLtu*NH|2Yz}h%--2$c0Nr7LBFx25R3J<`p`&w$FR=l4vxi~vpu+fp z`ZqHTE5p+oPb_{Z!I~XldW4iLdpb-9NYq2u=k0wKg_l71y#>92bZZ2&7#k8Q_R#X| z5UQ5|hiQJ0?9J79%C)OrJi41~J&vWd(fK0!18iYqveI}^kxF{BjqHzp8uH0)Dxw}` z^$oEwjVd|B>uc#w?6uQ!Lsx+Rgr%_L@t%lixPJP&2vthdX<8jVMN1pyv9PNAue_HnE z=um~?X08fK6h?DDk*zUhgkNC!s7L+qty+wXg=~7#w3o92!Kd@2DD9XU&I!|0z+S6J z!-0M_PT+FAivGm-sq~!{s~`Y&{tOJS&p3|^oEQ3z$ZxJ zixHjryMsS`f7Bdk9}!FceCt&&z4#6=lp|I%S zQJ>R-_cP(y30UyOWXtaBboR4Urc zKyT*fOQNejI{2kW#rbjsiSx7Q|7qt5O9e2;`jqH+fhO_$=7=6H0T8^|C7u@1zH`3F z&+Va5@g#=HVJCeDhs!dog zBHO@>EQ)ZpL-lNZpnh&0COx#&D$IUUx``Maeg$a(kNPO+qBRw1se{cNUs$J|(dZAA z(6aRB(pz=jUL=2|>EJ-42}`L=f79p7o`%|#N*6JuS_uylW12=fiy#I_D&BD`Y35_S zQYWaK!{uOpH{G{@7}CK=h4fU-9?*jOy2S^3yEfZ=cWJ#X%(VI02N|_7o;`4yrO~BAC0Pu z2rNe0laoB%9|Di{X;BAehleg+7-aA z-C8yl@aoFS8qEf#?RSQ!Gr!>G9@3nL$R`?gw{js{V0%I5xF;?MX!RQbA7h5pBUK*pX z62PbHVFus#6CZMJ?!Sc|C~RxpHO+H?@4NLv@7>Y?2QGJX{-xPn!Y$c2UU{b8==i47 z_|XX98*Z2cnHW+0Pd~smL&`Dk&lAUI_)6bF?hbrs$aMpHLx!kvlWl|cap{T0g+%$t z)ZynvZ2z=Iolt4q#=$f6lLaQ4*lXUiPNJ{k+`-i%ONOjQi&6|iYBg#RHQ92h^Y}sC zW98!hVwjt!SU(NJlTj7w^?FW>5ZG(dtlMl=a1cFdRJ?PDyyt^B^4hN6KF;nHznA!| zfIG@HQ~YpOyN9UJFBs0Asx7a&?!fYzi!fIqgp@Fo#-EFJ{mA5zRONqae~fK+?Ca3C zy#LVjEdxNnw0cU}((V~p@)sn3LdAfRS9+LZt2E*9eDb7N@4GjIukRJ>{kq~bFxUe9 zh3c*Nmb0%nz5rZ2J4W1D{i1^I^H_nJN*+BG# zt)aXvFzKpFN`{_YA-CuwM6S`M;1g{%JBe+XJ%%yrCISJ8T>+w3X%t4+^k;S8gtEaK z%^Xu<_uDixP9DcwRUh?;o{l$0YE#U@W>pKg_4yNc`K;wfe8uT* zm^+xF;L3v2<||dF)>mp)hDy83$eViJbg$Oz-TN}Foh**Tzy8(7^?Q(OLZ_w|_^}Q; zNP!nRPwDlTuDYZTbeW&)y+i+n9`h}W8tzn!S4nx-kNha}tbPOdcuz*x1pn+}2y!wI z5Qw52Ahgwh78uKJwZV7gc=!OAM&xVb5e7WdYZsWY#;wIsz(%4xwxQhC+t=O0T|I%1 zuU@n}ESc)z29r3zN=MqtA~t+*S*`Odt(KxT)T5y=6ADdWX{E7(f&8rdR5lBjC#id@ z>@nv4@L#@b;cyr)WMO`J&HWU?uf6RTWVwbdw@xVA!ZnNEPsw*$12<|CT{kvs1>fm@ z=I?9n@BG~Q{Sw#dqW2W=nv&jyr461ke_!_Af=fsd!gx^1j@+mB&qerAeX*hXE#ul_ zyaaa#&l6;Wy~3P+%i&U8#=0PWB5*!mSxUzdisKq(+59y2O9VL#Mipfqc<&+Q#**SA zd85wsi+a?EbqcMhtLe#(IeYZO7=7=!N**I#9Ozu*;!9F^0RHmO1lC}tX*8Hx{fz<0 zRe01CkNXK5f98I~jw}2l>8zq?W6_wu)f&9_+IdB-`Eb^|vgq8Tl_l4aUyuT&Sn%yJhJr!Qb} z-@Nbq=KF$ofY$4M93BOW;-dFWx98G*6X{8K>D7Jn^o4p6xfi;x+`nUdEuL4u`t#pj zzu##h08hGZru*hysy9(B#>gq7a{;W_M}P&ys4$zrNKb@|sK@uqNptVD3M5`2SfuQ^ z2L={G78*59_CAPl;j#Fx+&<)8>TikeR@LYiK2En6Xp3bk7+uO)?Vb07{vE9e>ntPgBD8cu7|s{5urFDi<8n6O*X8+G=ePo_y0*{Cnv2^I!N)B6AZim@1j(~T zv}h;TbaRl=J$IA6(9Z9F=BxGlUFa=l0Se-N@Ca6FkxvLyJLs&zGh$;Ucvkv6>nltS z>3_NX=>~KaN(nT~U-+*j`Hr2_rMPa?LoVVG3Pz}h>=GX&;p)@1#7cPJj5#dsk@p`I zddMH`|NZs*U<^Rah4(NPV`oQdj-=dHe zzVwhZ5xmxSx{l^>aa-RJF5dg4Uj07f-cxeohQb+K+-VQYBSwf%xGPKYl;B%oa~nPI zIHPZso&>kgv@^-u$%VB79<g7l%A6OcaS(mO+Jx>j?%axdYP_3i&1=M89tw7NWRti}?ZXn4b7 z@9J_x;oh5aQe*T2(o%|Z%kyXsa)7X_ zjQ=s;yyz}y@-aZ5Ai~@K_xo2pF3kA$IHW(xh)XyA^6cjf?>$a>D06d*zqo#%vW#&*-B@3&%k4co?+)R9 z8cOXdC3}#w9C!!4L?Y)K0*KbQfJ0k33~WXW}j@1e|$FC5K<fsFnxWOh<1w;2Sl$?%o{2yk4)8zJl(p;4LcRuH9n$dwaeH(Sr@UvZF<$ zLTSNz!g=7It4UZUO$%}dL&*o9emL$BJvt$!jXq)X)yb;a+CH`q0!zwh+jrbq%NdBsw zA6Vx?QWeo8VZ|WLh1#lnR-fFsem+Pt5F-_k%F1@9*v*2(WN@f4IMc!dA=i zv2iSc(%Vo8(s|O~=*w-NS--&t2~lF39`=-il{tEo(oqjf^F8q6u-BB?%RU^f(^)UG zM;*}RW@pKs+7X5ngdfHXWj$P0Sf8XkTB2C3ql$h0EPRjv<1!>D$2ti-JKKQreevbE zH~uNc$-e*Oa6c0{rG0UR911!%_3Ksb3wmHR*Ql}XuBRrg1rSSktBaGt7dm&nEYC%CZWQIfS_(_4-?QmP%WvS+wPs0pCgUEZQFDw(OKwu z*1Du4oH0ZL^?akZa4nCp>#PgDLp;cLjO!Zwxui+M1N<6Uy(|vvQ72}1LG~W*dM}8L z3`pBaeuP&}ZKhXGWu@5TP>RZdoJ~c4%CCZGEMlSqE(R9EKoBxaW_tb@^$;IBwTfwB zu|qw>A&P+(Ka^5bdd#|anDicty=Z+IG&<-ydki>`#}g)-3@@QfI0e~k40Nplow}ds zS)fW+h5Vqs5hld3i!2!T7 zhRI0qS{&T0V}5A=ukz4+?i59EK#ZXJ9XiWb08n%F=qlD^X+DHnl*^4>e17 zY~}P2t7H%T?!eC97#BK&t+d-vC_|+o7Hsz`oU>2a%P!>x)^8Mbzep;I+^C16f)a_l zVgSjIFWmmHUD|I5wB)NY8t&P?RXsRd)KJQ`IYgXiK#a})Omy#Tht;&Do0I%FuhiDY z>@ayHsT#|jN^=pdW#FTsfhjeMqDpW@#1Ad7eNmF4fP zKLEYaHOfbjafZCjtaaiVM9Uqd{a9ffa$J*cU0-v>!Wrf_;KUG5s3yTf67f(xBF+*R z2T%FAw@g3$w;LPqaFM7gJZ4WjBWR`iZ2;7n8pV%)>KB3ZEzJ(n11MI6{K_9WWh6No ziT*aiHl|Y46+VmSpn>6-EUPA-@OH{|oMBeK`-^Um`9ob=SXpp;0m$n_&=AbsAYcjc zeddj*VbUXtGg+l$iRp%$?}OyOZtlSkd;tDCARB@MU@<0>2sDmjzox+w_+~x7%k5v5r|+CJk1x!ZdT^tNzgzkC@2)>+=1^sH z6xRUf;<)P{Qt$=&tW|OPhxao$4Z~Vr{ukB(W7*t{W6xr=K`lFnIX8J6>mYtRQ0jGxnx853>u#Qa_|5eD= z)S5nb;lF468F0f(qsJEkUbS!|PzH>Mx-bSXVbvOJg_S}?U1Hjt5BZGwwEH2~2=Fg? z)q}L2V*;z3{+x9mJfj!sH97)#dnKPr6LMzaV)u-DceSFpKUS{)`wX6d7bAbP`QCg?t;n3ggE)h$%lVsf*f&=l*BqR&`=?ESzzuHn?~!IffrpKb83 zKcsfjtM#_oxX|xK&!+{hE6%6K|G}U9D$l1jq;(-pNPO!@g}_RzYxUURK;qv8>5r1` zhP@(G+9!-?HhFEi5`sM8ZWF3&O)7iwgxP|i!eu!WXi|QqlShT|qZ25TX#vmJNKDj$ zM;mS-%t~1jgay3DkyGx{m3q1uoZU`z(A+l=M;dSj`MPn52!A+NG?{gBwZ`Mco^P53 z0)Ut92q-87V0s8?BbGWkp~7g#1e)241Se6_sE_k?=~8`lF?cBAPJQ(LW8t0sHvE)Z zbOgeK%~i>+;e6A_r6s+hMO70LS{IMp+vltLQhs%@b-nSJ+nMLdH~!>b>)||k(%yzw zDbkModjadZd5AC<5iOv%-GKUEc)5B-Ut|z^v2}eb*>TK$?|=O1`U3>9fo@>B$j)>x zz=p(r1g(I(tEq}bdeT0;sD6F<9t+$uevfToID*e&!gM5{p9q)&rIrY40X-d)Y=HQn zo~8Nq%jF!6;U>$II$_eaRp3vJszFf=B!1A*@gP!A9}Dq`8pRLn@}cvBh#jm(e#wVpFay7<{7$hBLhTM)T0(rueXh(TVs*l3c?E@ z8|LNe;x7EK;n74%-NqC9BsqaX=pBNz%VLX+Q**?Kjs7UA zQ`!*h#HW~5DK?3U!^oiBEua8T8f~uE1En5%R`m%)43C(hy%8sd1KEShSCK5LLw@w9 zIV`F;?CtM3%gMh^&zdcKh77L|Bs9CEdaxJN9wJ2bQHUQOG%?66O{|vL+21cCALhb( zwj@y=yjAEC%>A!_b)9$-DtWZR&Fzs$-%igrLD7UC&HJO_N63x~^i)bcXZ(1o{ZR`b zLJ%NeRSrBAaKdeaUE=u(ng%^980O=-JyK&3kiFS}s-VLk&2DjY0UtmJ=Y{hC_Hz=3k-on=e;1>tA7u8ee;ay*z<)5A zPYQ*>4=DuR2AG;&tc9HquvJd`9VXF9tjwKISU+NMl{kWvihLHo$B z=O-g40MIXin)b;C1Jaq`d#m3;Kxg(5%G#iSrOm$ENb%lA&?7>8GC^Or*`*^WZ4=lC z=_}~P2WWy8G@Dm+gLB1l12u{t%W|V4FAz3NKC>8vebc7KxxQ`>XqCjI)pK$}A|26H znFTW>u83YE4JG$T9)MzWfWJE6o<=Hp)3_Wxy`3tN=^5RAAixH{U~cZ+|4aKI&UC&o zs1h80ao7ZZ$j@Owg%IuoJC@@y6FOw_1uU-9Q}u;{o??39eu;_*7wiKt?wR)7SwAWt zw)b}`%_o4DEzmER5PT1(l7r^v{&3_9rs&Tg_LPHS$)1}a?D?=>P-;M!v)XK5HhbN) zJFsyI+5?V-@R6R`fBp${E!UE$UqwOy8_$?YYc9(`PplT+OWCtnA#&HVJr~(=%%EV_ zDQ-L1^%#Ko2_ma)kIyv~pIvv2%m4^yt0f-1y9E zKZtulft6n02U>BFbp|gppC1G&!anP0?l(T)krX@wrVwJI|9-wa%=np1KezK`JdRcz zgX|ywa2&n{7~kytNM&PEU%Bsi?!2yR3Gg`P$Mp7zZsd|zMf zAMrrKQmB2MXROdCo|W(k>OM?bHfX89|H>mz>FUx^;~+o2k4oo3aRvn9UtBl~Zx@)? zFz$F`r$1+O*~8?=c<&o-go5 zbj1nJcyt0-k0`9_z?%r_a=15Y2Kt!t{75~zj0wUA?>Y2yDms#bG+GQt&H0GO^?7}~$_(q7_Y>qM);r?G1Z1CZ0S8~K^r;E(#rYFOv9@m%W z@;CqV9}$kjJU|M!=Z52CUk8{*?4AkzdcJTB)ISc#08fnP)N_9m9>RqH zga8_BR};wzo^hr))5<0XklyucN;X?Y7wo}h>=Q70XFA^|%+BS=7QfcwT>SR=?E|n7 zoQ?-~l3nPh|K>aYR{cQ-mploh5*?{oJ5`Spbr_z#b>0130M9Bt2|mwS0rlso+1(np zOYn8pH&@|Z(1G+zEjt0OoM9{arCu})M!(eV4P~u5A6CR`i?A_f@SEu-D#K%UQe1?} z5B&H4Zv8>O1LsPJ9#^sapbJy}(|-8OeqQ=u0E@@h75LKk|8WGvOzL9(UT#@aS}wxe zwAh0DiN*QOyT%X2plUG77wMT5%}TyIZv|rf<9@DBpzsB(6;aD8l{3aO*wFcGbmgGm z(PQ8&`7&NjX9zx9+ViBFVN4vyXr~J+jxAj@n@|2Qf;MH z_)(Vs7|2WDvrI^c$rVF6OfnEB7Jx~Y1+LC7Ei%@GVV>zGJv+A_COwpozV`DQ^#{Yo zRtf|g_h^6^`Z9N^#y~uQ4im!Z9B}>`b2saSoO~y21~M-UDs78t0K+ zN>^7_O;KlmG;1s-X_ z9TmKpZ6*2zt9o)0=T@1D_I1Vz>l|FHzYU&+or9L1cn-cf9BuDaTGH<&uVe^Mwavyp z70D|7R%L$#+ltLm2ad9gU^0I3mVZ^0CeGpC>0g!LP~~3zq!|$Z%=E$jMxwLVYO70# ztojT(IMv|^!IRPt9wz?o$KU*^$ABl3Rs|hZ2&Ejp#;cnCIq(WYPWC~}xGwBg6YiBg zjojqV%qj+OGLr=)gqps&OIz|{^z*~pfj_?0_{|pA8yL-#gn&VP1btuy}y@`65|9&a~Rr!uA;LM&3?*@n9|E9WzUfDr= zxNVy*)q^IAT(zyoUOSuEloQiZWUwB>P)uO)#zyAH;f#3frP||^$K`s6wJJikXnrw_ zf)nD(d}NBah98yv)<8&bj;0&2(F>gM2U#4|xj*p>pfCHIu-t7zd#QI+vYc}K?h6I_ zAQPn#z%o5QsQjuQC@VUG_NCH4qnz2&e$2}sC*nEry_R^a|1--)vR+U@tZZ+J%E#?Z zv-ULA=x?J1b5BPMj0pl+rtfNh;yV?_4+hTM!X~hB08>htBXLsrt>#k?L&QFF(I}s{ znuCNF3jN%z<{tI@qs=WKF}C2FaBBpQ;!rx%_Yif*chMjCdb0f=Bamuvl&W0Yg>e)< zH?-GjBI;W4u8UzuJy|y)spltbu~%toa7yp5z-Fh<_kkf)9aF^yL-66TlM3C(lie z^svz1{Nz9Tf4KiM>AlW-ZPl6gd(tbx-abRGB=#%UnfHcg>Gwx@lsoVK-e?4{7!+!} zzQX~OHhgx6f4=QfemFhL@Wxe5N}g%*`aekbjoBt6ySKib_+MZ7bH7gh7Z!rSEkds1 z>v5_)bGAmKG(nE%lh#&E1zz%&OXx#Re`G4>YI3=Ir&2-;btTR3FzA-DG;?YhUhZbZ&>R1t^RPcZw7yncMM2Kco zqQ3&Zn!EeW4VNM|_nSKbW&5bw28`oSh4DjZOfTX>psDdQGiGV*F)EFEqFAX4IQFsY z2|Cnl^@mak$Ia!S4Qa>|)+jy=e7H=Sze@?oV}lZ2BmZn}?sqSa*B+W5Ki2lme-{3` zhoeqAJPH$Dv|zLH^@Fa4&u$Cl1-e@4N$Yk#Kg;EbVNWFw7>*7s;OGaV_Fm65FF))L zsq9n!pfA-gJljro(x?_C4BMiJPqi0{$MM%jNT@jb!ao@7<5Ynp z7q!`I476o|tvF`*M@!jiWUF0zwpxyl@ppWgN_boPVAs?1H3iVZLCJC<2FD@^b zG^Yv?PSp&5s!J3gONIi4ma2=2k&N|&6_GSw77->zDhG>D0W%%f>XO-;E>@S_c(l4! zql6hN1eOo%Mp199pJgqWxN&KD9^a_dwQ6;d=A>ueiwl0xJ8vd@vi>gkzqB71IRo-_ zXy3QUnI}h>n-YI#^Mg(P3~q3B41vYt@eAPpe(<_5!UwiX5sr`Bk@Lhx5k21Whl>2> z-jwhk7$KY_6j3?LX>UbGU;VH6z`QR3yu+>;d`am^Fl)h$pK;7ifBhk}{(!sbYu4eKfRaM{VTup54N!GMm-Z;=lM7pL?OAU)IeCbey#H$#4Pqf;3{*u_6P2OD0x zC?)C#pO#BkDv-M9yKEkHl%Rj`u!>;2Iw6=GZp+kX*!=(7`}WvKv+OQQK_LtvLP8{7 zii&0xWu;7}%C7Q5Akprg?%CcuhsSOOX+R`|ppaz9{C>Z4&i!tcU3R(bdAZtBSKse` z_dEA>?z!ildmaeFXdUFHWLy>KQqk|a^HCYdsZ36`pFkg-qxIxXi_i6>@eDrV7$;fN zl=yAp!zumcsT}5O@APEzriF=lyOa3U+kfm+Ke+s)iQr=lYOprO{25(%wOqM(Uq&~# z9!L6Ix&U1j-XmW@{~YTV?PLqH(G(u;G`pXJmQ0?X6`9IpcJKA8SC$VySy>fgP}*?& z)_b>!FSr&Db*o~%pB0b6@WpKRQrr*N@tqU*W7**ZzN|BJ>97+*w8;07p;`y#e?fdfmo$u(uUTR5+8Y!MLBNHWkK?4m94^r07H>jL!RsrO2>T)dAHZ02d%s zzul`GLTw58^nmGtj%eHz{(mj;A)h>WIpWd0^Vy$kgN{Mi+N68&sTCoz0pT2l4&PVtHXM`^Xw z;s)3)0Y4?VA^9;lcwm237(dGGHTR1mdJr|Lce@}l{t6@2)<7C1^HELm6Z7hDCcPXr z&o?bUyZ;)r`z)8|lYhk}lMhzrAzU{}cx8SLB6Ab3Be`J5^~w^QGTMo4w#)+3C!9_8 zqx0~qBgyz|wH(Hx5Wd47q7;!KaR+=WfMmtR0kiY9nib&ua{?f2uQ_nqc6l(jrTGf% zGiX(M_9SKJ!3Qa>?%#~{CVwae|E`)QUT?Y^fF32+8`8cFnjWR)X$1_mbNIgQD(jE; zNP+aba)uh~(<fA zb=&wGFhuhEF#z=vbW(4l8*rjw*iEveGZUK#T#>R{8@#TILiW_i^*Y&lUI9iC^+a82 zn>?1iqqbOxTH}$mrS|9pm9l==Gh75Fu-!HlN-5w4z1)NmEdycZGciW57 z*k8ki3ySWVFHhu3UrA16KFg3v(ni6No%L^zygeC%0p7t-ips`wh} zBUBe3xlV?#^5gZWt`Fbm4?kb7OGY<1qEGHU&_0J_z_0(U@34K^kn1Icu&D21t7*4h z!o4*V>M`)S-pCW;AvNkRv2Q;thu%nandx!&?F;R?hW%rPg;(IsMf-j>e*A=Vgq=pL z0mY%=64?#6UrG}TLGiNhrad_szvyvCpWHV*6jF(7Wk^RluUV14(qwp7>|YPDe|;43 zZrbr@xc`&m6L96pBO`1XKAC!pX_TBz+^z%9bT2JF=^{H)BUYegEqwFC$4M>J@oh~{KV zyRf<5Qg-A9oxG;=BISCU7^VUKOikkXu(6AfG!|wCh8`MC9wHE=w0KJ6(C)RfV<)7^ zI4SBxLN0Ld5Jq0Oc*m!{#e>2)_$NB0*paL4VW4<+f!d4})dcX3X-^_WLr#CPUTeL0Zj!NBAxIB!%z1v!;VmaDAV2wiKlYD*>pTBpx_`qs z59rl<9F&Fm`B?@^3A%Q{lFsCK_mkh9+bch6^!^a4--X_*ff~5~z$Bs_Mx`ZoG$PHU zkO4c1`%kQxdxYZst;es_D)5QuY-_FZ^eNTvhv)nF0sLiC{TA>z5+_jopt47EZxd0C zng`+LyL6`fe6aUw650!?TBohP5kp~{f)KKjK|%Tk*OAO@^{xHTH;2ScSuA8WLquec zEyiSWnaBrtfK8GsJnR;6Y!iB`=0vXbR7lF)`ywRdpq}vBxc2FAs`)>~H?Yui_pXHzn`4 z9^5cK;~AJ@^>(4NGe_y6B-0RJ2Fi-mdEY)LMJfdii1rMaZ$ zUINL?VmtgoOg6w;?}A%jAEt|wLA)7XU2R@p`yP_X66DVBZhyz>@{{%sXl-$_;U2@k zhxK(tW^kqDSXZFIm~ZHx+|T0qDLrbxo!H*v?E10Z)!qTVNLv-!CA;o6wC!7sKEjjp z9KgK{PI|0=dQf5f0E~yFG>E#+uw-_+CEy)Ov}wjq=|>HpA1=4lvVG;% zw6A>mli&Iyz|U5**PtJxBPiAFH3C0Zv%I8NpYRimRq{Wh^ho>+IGRu3KI?7+?%?)Zp!fp;*zrUzHyV&foEsgu+k^y|fxr;Zzo)J^_l z6cRc4PJwDT{JQX40){OUPR|<%gB_1_oL!`00e%?m@$zVZGxunJWc;B$D8{5cLV1W7z@s8oPj*1bx;las49FuiVds662a^M=N2ci z2Y!pW1%#1Wadd8!@lAt!H?BHlI-NDRICi&vM?qP{46~8{02od>03C^$$S6 zkMNMqvEl!{?MwB4yivMgrOv}U_*d57iRpAz5#m-N?P}G-YE-LPx_e?55qq+=n8&3lKwXQc$}lZeG$DKb`E|9PH5nOkGl}`=!Diu zeKDGu9zis1lo?l{C}q5d90s_224vDbf}c^}v}I-dZ{dgca)VId-O6%-cc1@@uPm?7 zWoe>%+|Ld2pd1o*_m66oJJ`9$suwUIE&<##&rv+zlc6Q;!kG$>!Q9$MIv)j|NUZ1i z=^iF~ettemGs1H__XT?LEcilkfy{C~kV$fa82rVB+R_~M*YWQGay-i7MRvY&d!=qp z{DU&qJ)`60NoTTT|`xkggd9n6c4n-0Yo7<5Rq{;JhfsA91SB8&8T;q3s2hR1t z$A+I60gZIc2-}(GZqC2tPPo+;Pf5SBO21#{ddf9{LO4RF19`V`M5KDo#|^KPZ2$XW zIxh?tI{!JxlXMUF-mCv}jd-$){m8t%8lDJKFh7sroWt_3S?)}lWAo3dDP-|oPEFx+ zkfL44W2|RZt{^Dq_jfAZUP(^9axdA{&g}p2*KV&g))CVpnWK&5gC2n}+$k?iLeDwv zocGNZ%?5fVAn01X7JVtTVNjl+GFGCwx6$qzc0m4t7neJK+-SVGmiWUf4_35a;QnIf zy`T8C+bdA?6GN)pVjo!^vSiiB+Wg9XHpMwX9L)3Lv<4h}DtqgR>}RcBghCOc!~bE= zc1j+CQo=u6SRfuj$hW{t(_@{Jpy+K~h4CZiCvpw(;>p-3)#eP7Dh{b|v&)eK2n|ij zMO0DUoLuVMd?WEza@{X{`wxEQ@fW_7_BGH4I)Mv&wi7ojtGd}*wYun%URbZ`3ZjZ| zEXjo%g%zjf{hYze_QmYJ{rf)ohnH7yYnMwTCgbOWuX?yVTgZQz9>rG;wiT$;RXYaw zXCV{``HQP@~)k1x&))`HO_0MP>05pJp{#+(^&NJybq@AU4E|Dy$$3U|&@yqbxQ97^9%>2-A++Kla!Ry?YihKNrywe{^k0z3n8(l&86>(AS z6A_Q-LC}$me-ApucrB@q;^^?)mXajj7%&wEkgTY2XIX|ZXwT|fFadUUYs~S#(U`1z zpy9Z7*q`7BV9DxX!Yk>J#=e;OG^?ONN0#UAdO0Rar0Ooj|^iXEre)CJf zYwFt;lK8Xb@WD?(nK#L)lpcwVV^~#rxWK{KAVm}cH!7Fd8%Vc~6kgU>7vEN71mkKw=CPFX61OMxh5UrT$~%ID=$ z4h|FvPHJTuO+_r~ozD033!Bm2LZ~41LU7P|7_v9bmV_^pvKKU)*K~54;`Q|P6GUQ< zecsM1i{=*-NMYVJutL&>eJz}0)ZB-4wKnHxm|B&p^x_;wESRC}eEmGocQ~fMz4vFH zF0W9HJ1+0JPdkF1bAK-0!2P17bl^2(b=P>O?}`OO4Y_8$L#^v>6JF*W)ten#Q_a{X z_=Y2ecBqMrwm~KrvcgM@-%u}Z=Hu2-+&i477sJnb=t;p%i>XJ!Ig2Q1wYK0l{l-{5Y+gpB9Y_b1B*eOG!UeGmT#pj)Ev2m#Y&fLt1J zTqUsO6S)tI&-G~yspgy zCROL=$}7dW+0rBNA>cSZoQ#qudOJihc_O}+5xUtxuEh@?@F4u)&D<{k;_ZAMNXTQ~ zig`Q(A7l?^^ns%0WrbMLd}I9G9;_fAdVh*PJr4L2;fdj;ZpFGin#pOi>cJ&e@{esf zwwv{AGlN>N47)&6;!orz(UKk;4PVGpX5rOP6ZCD`)Xc%Dz97qYTYYoYQ>MhI6&W!u8sc zdt$G-6S(Sp`Nf!L+wBoi#ddo%#q|5;7b@=3t-4rQSg@wdFF_SSU*LRa$})hXNxX#| zKl{;%8zWN)5e8=%d}{Ck9+z$wGB_Js1sqYTtx>OGwOdp;t^UmR>gX;u>NDu^M`n&cjD`&F(~MM7=!e=ih%Ddx_;%6uX~r?(PRjuuui=?| zrtn+;?w=@imx+%_pUU<<;UnhpVm+$@AH(Ym7~i{0UmHGVjVQf^8=q3+5FTMRz~P|h z__tA#w6TLbQ2h}v8#usa<3haTy4h*SxCm-o+--{|6Wseas4#%1xa_ahYYvm1%C#4%BlDmHs6R3 zynNU1ks>|G{17Fi7n+(NZY@2Dv|X;BH@fu1`z4q3%InE*5Im%Qk@F6(BinFM0yl4z z(YavtY&o6jso#5C85M_caNxP0VH&s3)>B_cl!K-_Ji&1vp?-7~!K8ac+2|MXLh)Xn zOZOU^xF+d~)8AtzFD&X2n-hM4_MX8$QW(@`*VwaWC*6~%henYglWdtQWr1Ny1Of6v z2%=R$urEay(Mwiv&_IAsHT#sDVQ?I7=F`M@$l+Ld+4z3y8_xV`(VtBipJwg+bq!d~M=-SBOdh&EhPTr1HY9V6M< zt(UZ(S#6`&Q{S0pkUk>{P&%^FiuU*tZ-N`?^kTs`;e8xR5^O`a3H8nm_id+#XdNFK ziLOLhXu1Rq>9*ki38wsdMH*t$W)xu`-t!O@G69SB06WrX5HH}(W!Hn%>ya>`HGFL_ zRfQe{jxeMkK2{9O7fQZxOOP~n;SS1jIE0=PaJ+21(Nw5#uj2~XtTuH64+uzNU1mDP zmw_HoG%^&h!HaDNdhi{(jt>l~REDh4s*-Wm@ON?oRU)2QY}$Yvv48~tjvg8knf5w; z1XM<$N%#nnfDiFU`W3_e{XoAcN2%I493Q**Z(+7F@0Y>zwEn>`R_Ez9N(si%Q)1pE zd$pwn1s_J91{0l}Un={-WuXjBSPQxcI(2^kjsGLfS}FX2%)I+6$HoWv#Jxmc741V2 zT+&3&-{t7=$q9+@z4H91_8hMW%j)zec`n@@zP}?5lh%5(PR^v)--Yx2dh5GOnet;c zF8UPx0p)1H3Nx1JdfU347R5d?NVoJUMfVtf?FzoqpP#pFP$%XCIJCgSbT9PwPyOZ) z9uDro-04GZyqdjA_js5r%&VcE&iAxuyZ0xt{}0CZs64qx*`VNMh=Jrs0WWcd4Y#aN zza_#UWtwjrP2wK2loAr-2RtbAuq^PJs=0=wTdnq*5nyf&mJ8=iWT9As(de0+O1^b) z#!nQFdpPfc=lmS~GSR3cKK7p{K31$FjQZ(U34fQRp9zm~uI79Rk00}_?c|7YYG|3x zOVBIf@vH50?K2`&Oc6T?(1`q5j>Jipiea$_6@!E3D(X|zc4piVkt5q03hM5%2 zl2a5kK%Pc#parHe*_Kvtiw*qjjM=xOZumiVr-V`Ti zkb%JG5}Jk6KO$CX*-;P>?eQ!$GTM*xY7$nE>4^LwJDgctz4&M?;NUbGjE${wW4d_` zwxcbZj|L1s2YCuOL1m68mdTI1qCP&viMX6D5OC=GKCf%w0FJg4y>QCLjO>$u<3;;< z!!w%dgI!QFWgP7tMco01)3Tj<?3OcPQ1z>DQmD%%o+rU>H`jNGF8Q$4*R0-QuM{hN5fu7Xb{NDNGrT` z6Jxb-KZ=C&f;MeKZ#UVIT~K!DHRvYwZ9rFWj+!NDS;^3^@e+>=m@D!9MtH_PKSf*? zoS#4^N6BM8%=6OFSWNxn#OH91+{&vd-X+5~?niQ~3_AfnvY{6-lwpJC!kIv^P zAm$GxNpvY4=EpqXAnc~yTdl!@?O9zwsoB}?*SAu*?IFZ;6&^B)W9VpK!KgmGp{hBTz*ossHrcvEA&KeKQ zk+J>0|8Dk6S}^RV=FjWT_yCNz-bQ;!u05ElzCbIAVN_15Zfe9VxsNTccw&PCPSkkn zb7T}_LKr^rgpCtm^dsOP4``AGQH9VVRAu8787L9Gj3%p>0Z09hg`m3Z3mce$7PW)S z1VB!1f@2+PAI9tmq4b3p#{zW#r!vswfTMbgqG?8u7444>?r%p<0$AK%4bIN~_Hg4l z+!|AIXFj};ws8aq&EkK6=s-~6C11FOYj6th^c{+HV0ag5);WF3NY#gu+&DyK3FT&X?*Mm=qsHxe_7QYC&T(1)g=*YCFqhEKGqFp0 z5O(RQy#=j&xI7%(*Rv_QQOWCGk2*h4zVr6q{TaK5Y2m)sjt#tb z!QU0+*u{O!c4#GO^eiLn8vjxh}MX4-^=D8Pq=y@G*b+R@Mg z+b!hGkf0u&@g6mw{s`hvmNj)QtKHjkLVlLh>TSZ4T3^b5Kq6oCUc#{HSWkg9*XB=% z09W38O)H4&>YcBABlUqX*z?6+{@*qEAMj?tRtegbs=H9Jr?NP*ps{y z{Z~)NmIKEW+{pihSHy#vng5;S=a=j00RJ>c#1gn)aQ-PaXs*|Z@JjcN2&RX7MVW!| z`ut^uxCb~j^%euB#%sHltRU?DFdmN0XPt|Gs1nEq0(Is&-6h`z$uwzo@x0quOY&_$ zb3*z_>?QT1VC<+xGU=LVmZA54M#^%WejekEXeVAZTPkaEWryf_{yn3|wAWF!Z5*Jn z>0IOOLEr@nJVlLp1!%!JZc)zJ?z*CuZ86#Q(r&q*Of(8-X#1L(d@#zc`!%9N%F&`V z2F__eH=T6!%u za$EUCbiEg7g^i#uW3SKmLH}w*lcqNNYI57x&$ut;V&(dkpF$hgfw%@!JJi?Oan9Q@ zV+p{fdU*f4prV0&yqfm$FQe7@B61zJNLJ7^ostX z#8wMRZ|$CB&isNpa`-^%KAzTAs`RtSKjJsrN$yM0sD11&lB^U?Ospt#tW7B^<)r-| z%6Klw39WiU1%Mrw@IoL?brI$wVvI{$abn%IWb~`cLDP})|0<)0E_lDfxrT?CySY9kf`?z3KRVwo2=P#% zt4T9wqynG4*;EL6;P1fDz> zX5B&h{6bimEWQ|i)#cZ|I=^Jgwz^O@OOx8t5+G=!XL8ov!IWXmVz~>m^9xm$MSC>5 zh@w=kg)jESG7MDArQz8_Z|j?1LeHR<_?>?}u)YhC<<WfyIaf|G z*lA4}?}1u9B03ks`Vkfs6B~70l-ts!#&e-Z+`%2W3Sa?fKfy&*bY3)xm3-ED5m*Yu-H~zY%bl1EDr8Y?-A0 zU3{h__Rr9=rY%}97m7`q6tohY4!u>_mrSy0Xiy0-{SgGfg%$|xVYPK-Wv3HNf`bpb zeaKQ^Xhs-Rb7O0i&MepJY7#$9ZzTy2I0724U|*b#z{Fx`yb$q~oy$kfnCD)j)!>3M25Wc#rs#QM zxry&X3kg5JRO~~zIddT=-%fh|4m_=X7+6IQEpH@&NibbmS8C z#!4#W&|&ZrZ=g;e+k;aOGbPCv4r{h5@^fDSA>NXlXXjCURcsSl&@8H@8~a5%zGfQ= zN)F4$PqmU6T(1GAs29V0#&{^#iAIphX!j{Ntr$u>^QN)%BXAlH=kw`a*(MSDyAueU zEDlLRZV(9*btm=7P)WeUiPJ*cfN-jjiyO+6~5>0HQ>>?@(Q#+hsyYl-zVWz{y|K7W6gfommxb_2IXp5JkeB2ZEzzA_?l0QJyd?P1rI$NdV*biPjsq zLV97(xlA$X1&fB_DcY0EH8LffgXUH{?L=hKQe}vK6!rE&mmSWDA36HzEopB1u;fA& z3LAsiMp_DK*?8XcWaGGT4SJ&CNA}fK$qS4QYaI<(wO~DIJXbSI7wTpz6R#)?xL3Y9 zA9gPNMP=jC-F!dZyZ_et`LH`6K4<}7R?jNahmkyq*mOs#F#xBohCWOt zZo>Oha{sZyG*DnE67&!%%JdYj5|(r} zn+7ex^UHuGF^^`>VvOW^z-hNyJkpCM!Mlrw6@*2prXgED|W1AkVYMql87~wa2U}NVhsT>_293Lr&4+D-D zj^Tsh3eRbKrObyO20YawcLg!OoQZ(5?@e#<8mrtK8Dwk&K3fKKW1Nnq4DYh4s#q1{I;^JYLw9vEMSO}aJ9tl%I5(T zq?K;BAf>+CJ>V5~kMTdf>ONB`JAeP^-+a~hd+7NosL90pOvsC_?k{VSdkQETAm}aU ztln9N@e@%if5QCd^rL=&5XUB{rzK;vy>E978?b8Bw?a^VBJL0tL{4%~6!?fNkZ2VT ztyLDYJbaXA+8IG*L(EgGk5ey&h$$DK>>FjvPSKhUXP<-^?XgzEH4D6u8olE6M5pAg zTXf^G$#10dvCc52y?~8As4fl=+8mF= zuTjY~2y;dKRJ)(QY^)xoYCZzMR7U`y3b@%}t#w@#b9LB@U g#RqI z51&Ix_ke@ycXqgmOX>&U-?XAtF|Xl_7z7-G5o^VIM51-{;0#=31Wuu;8ZLLM?JhUY*w@X5BU{ifVc9B{@R*v$*`zG?IFk=PytxmX4QprNPk{TSJOMjj41Kw*+0Jx>F;_jsc9_0O?I{+TO|m_g z2;VY_1syv%S8MFC0Vg)n9Ef&S%h1A=LSQGZ zMiF4G?W84aeX+yjeG*C7<$*BT6Z~SXQs!R>3~5L}7|>Pl%z#tuLiMca{2HG4GduA% zrqxCrZ2>PBumg@)>iy+gNh3>=I6;}6UPb`bKGd69;C;4|O;v;XQ7(`<({DJxqAN zU~->3<;78Y7#{>*xdsUd&V^d~YjxOo`jsmVi&EXx`U!jl&O?J0OEWW0?b#>@Rk82} zzS9bWJTZnU;N**`yKs=nVe^7({F{~%y#{z6Q5`G8)V7;~A z;fRSU3vNt;*u%57kygvqvLj6y@rW&8Nf~b)&WXgGRREE3N)^^%j$#pBalwNtF4X1` zuVi+-eK^CXS5w@wxBvYAS>yi8dxwUU*{+Aa0Nwz75$d-)h!J*B-~JfR_xsi4z@u7i zc2RaktjGunvX;t5N|>yeO%NCSc#X;Ddo|e){L&xzL!56iBM@ETDqZt!m)Ga}6C8$^6C+dyq5tO)& z#ca5WvxYLfI^5%89D^(JqR26Js=o(EBxYeS-n`xDQrW%JHTdm${Rx)?&k>LQ>B~O^ zyoPzX$0TR|mG;HKX$ZXNS`|RW*e_F+b_P_vgWpc`6Y1L}{|dUbx?IGg-v8X!Zm+`P zc6Wb>ZUOoQbj#=tX3*)VuXZs%KFq?PX|JQ}FzHW;>pU1p0pb*3^WHXR&`mv%ncPWj*x@(-`pDyC3Fh#*njWt_fd=B;a8v(Odi|4ofA=6~kB?>@o4^bC#`eDXQ&B+wYw;A?>ur6IeR?p>xw(UVK_%cI&6d^=cR{h=L*lp~=(|6i-0mIJV7Y;WUmt<{94FZUBG%kGD? z&~s2!*o8N-2iZX3iK64_M7@Dt$N8^XS*Vy_3B2}grm`>_8x4}N)l?QFJs5xdvi;^x zI``kc{rA_FR~u_h(I%h&z+24kd30+OUJi8Z`NLQva5XygW{Q_s`u^Pp=2IaXnj6J@ zsu8bAa!joas7}Xu*VZw3;HOXFyT|!qrAN*0vB{gMzYMVWK0l$e%6LDVuSVdT9@@up z*~kb~uic?@kD}dKfhkX7l#h@9+F#}0&nG{(!_Qc+3v;!_d6wmPnMiSAZoa%|l0zit zByr~G4~+jg!<*5Kdw2C6w!82D^`G4Xo;4Bv6qn4ds0~~YoL5@#lfTcaW>~01J!li! zM?70D_BW*`#~5NMHCCsx-0e$PLt*rk!csw=T8ps+U+4%@0!2Q44+@b(U^XO;ela; zeB5ZfKEIOZZ^s*ftL=ZUz7ce3=E0wP1$3!ZKVV2C3bpY^T;&u3KVNO`x8XsuAWuZg zoQ_a(ttR7(M6Yz8Lpc%X6}<3`=+cGzVqVXM^ve8Ez%dQFavGo2BeW04$_BiVuot*d z*@L+H2;CMXgN~97!Y#wzlM`DNRy}TLO!EZ0%y2bA8&@UrW+$76RPHLnqqA`p3 zn|D>0@rEGVH(xFE^Zw3%y-)mX_O?M@I9GYU~agJaAZv#P#BB3X0yf;a+7$Qbx>;b3NXnE3&H z=X-zS_G)9dzDYk3PAM}wdB4?%F_+xW(ausrs>gk5G3hDWUlV>lTxJYHlcy^^5?($+kV(L>(W?R!wS69UK*`U)(j)OVpr{)BP}+Om zJ$2TI)AvF6e)v8J?ExkR0-|f9@qDkbRbMkR6@G&2oVW{0V`6ru>?;Pq3!zjXypJ5Q zTjMd^KVLuDJ|3{o06t6q71QMB=_*t(OtA}2>J71%<{Yt? zX88T&j=m#)fB7dCfZrWBK!7fJ5#LAg}i3OzZtAdz0gUukY}~dZ5Q%>K=80N6qz8AF34ii*m#7RU3Yy9F#cLSYC~= zA3#-m>zfMD2n<~VLjuc1)0`!9;_3BvimSrG(0km2!Xhh@(9=+I7m;QoBA>!E_Z-(X ziZ%|a7pox#*7t>YbTPGFXCIr(SbfF1d^owTp4GvJ`*i31%es1_liCl6ufW)xuc?$F zyyjrD_qJ@9MI|PT8h49Xoc#S@GTsQ~>m0J z1q&hWTOvIP9TYxc-ElcGQl*SY;2{H!T#j7wluQAWznIiqjs>vF8=sI54Euh&V=v)9 zB$l$Wl7j)oK-3D3mWb4mn;G_j+&t&aZ+`?tluxYk{Ga z_zR96@e0$cJ3rG;BX$j)+p5do1DOFP81e&4kHW9xmplC}Qdq4Q{B%liY*6p*!m_B; z-YoU{a6P&X9nEgj&TA%T-|(-B()d)9d-hiY_z`#u>}wuS#Uz9W-s7N)>c2sSy|uH# zHxh#`*Qu+?t?qtC_(H1r>2LWF&@Zg=^`muiXTl?&$2@;Xp1utFb*Ccyf~nrJg{IM@ z;)l|9WEoeRm1H~`FM8`SsowIE1hJ1_sjdv==&)Do;7Ubh;30)-U~CyHjrQE4ADDHZiY-=1bk?_9 zIIaUo>Qe(-MDeuU#-3y?%;CTwFK-h9;WSW)vLZ1(t>)+Y#VFBFMb=3SMYN~rIbC@b zPmrH)72i|qJ9~-EF&Z0iZtX*>(u!z|JM9CEcl4gFD-JLkF5SdZS+g<2IC3o3TLH(X z$nvc@bW&CiJ}|Aa*lCqfzzsMXaM@hs!juzZ2lK!Z>pQ?`#2E^Y&yIF5YMiuQx4A?2 zZQWki;7|`ae}Mve285VFM2Gcx5M>pff4qO_uQHvZBCa{sU8P*9nS20)XVRx}=M6AGryRV%UXouKx1t+SZsL8GQ?>e9 z(jP9@e&66e`w|Wd5QisOJZIueeM{gP@E5z{li2AZJ(8ab`vjpWen8{9WaR1tHVvgy zb`0^}uX0w}mV5tO$xjrm-$vN_oji+c3o`We> z%IXR@s3h=6?a7{fMKkA_V_FoE&Ax=70SCQ8L7qiumnMf5@D;UQGBY*4v(QpSlZ%YO zexYcWl3Z%1cd||txp^js!I@W9lIDw}<2)|2p-md6Bos>k(i&37F!2#0GWo>{+#y!P z03-R#?>ExWGGQY-IG`~;SP?PKMp5zHgQ!{vZMEa9l-elFDIj(Yf3S|>d)Y2wBzTF1 z0WnMyB6q<-5-MVoE%^`hE7C*qFLSeVi_&*s?Z!;wt^%r6I@H&yv*jvpHX;lb~Q{!V;& z4b$tpSrgzkCmz*=eh2Y{D8!hycnX0z8ZhDOOksyQ{0w}6UjA&MpJ9gi$O@H2BwZ;H zs|k@H?MfpmIsgA`{VW%JsPi3(kWnB==@ns(Eq9LlY|5SCrDsGtJ`B0@h^9hsj>Qy3F*o;Z2-};~X3}7hHs#`QirS?3;_J z#g2_;65vOXYRA$-s@Y4 zC852FyIj9V6_(h#*or~@6>plef7VV3O-Uc0|0O;T8iTR};leUyE9w(6h&VVACaETm zB*di9#+q=ydQjZImwx+yyuHeUMDiwL`xWcQ{+X#jvDVO_qOG9Q7tjEdgG>#&S8-oz z>5=p&poo6p=l#&bvWq0seKkGn9?mO#1xJIZ|-8LT)wcT8# zTyu9!)uknSSu2;Rh(Z|rgWeV#a@k3!JZr0_R-UuZYd9Hc#Xu*Vmk%sFZ z#SO|a=aX5!*qHRi#^jQzzTl!F!ho}d@ES0Rei?sAoLjw{*4w+)zx)(*I<2>t;JEsL z?nxmAz^#&5{@HD(@bSF$H@F@%3uU1>Iu-WkzCNEMeFpmW8Lhv0Y5U}1{$QVHCpf|I zaXlW_pAXmHOSW*=ef_Rud^kT^M7G}S1m9G6n_i0x7%x?z-rr)?dsDsQ20PF7cM|Jw z@YO|6+4<&`0)PMZx8feAxyAct?D2#8T4&y?Ve$<29-YA!V0D` z;YA}m1@ALE!!Hi%6;`Ur&Tz>LCaSY@prm$XjHFX(<~p5ba=|Hotx}`;;U(@%fX6s* zam-gAn%@uNFP!qr*9XsEqPKVte0T`$3v&h0<(vkmlJPrJFnJ$97biXU*gW2O%xNo8 z-t+c1K+mt)g6fVLy)fVQPtE7BNeU-5%vfL@V**q47my!GHL5nr`W1rV2$b5rX#Ra|Yp9~6Es4uASB>_2eKj0hS~sFbBB=3C=%wjG?Ed+#qV%}+2`0{pDM-)S7Q zpU-D8fN@@}l*{Ghw}3`LSYL~abMSp?r&J^hN8`ok=cO{f<3ZB@xcv{lW0mucJFl2^ zt#bjoVBRkw?;!kvb*rr(`vU95@@DrG(Z$pF&s)SJr3wRMz;8sh%RAyR&WMN!1KqJ; zNX{FLDR~$8Ld*!hm~k6;AG8>1Yrj1S=cF|+m4*gtSZglj@K zKR8d1h+4PzXNB7kc|3hN>~q8*-r@#w$MtZtl9Ibw(OZunxvuW%bK`|}=nr58Y|TV4 zN!-&z$3XhF>Ob%fVuz;ozhXcFf9tz+>O%Cz6>WFBDO+CznE?+gp`DV3zsJW%%G$#9 z`<5lQ>#))BG{n=a#~Pyb(86Vwtql6o#4rXNzU@-MrQNfu;BLF~xjwGR1;2Zgy#YwX z3Wwb>K2e&pVQ{dXEYs@rB?O(;Hq40h3Q9EK<`4$ew)1JE(~8{~=RDzcb}t6{RjV$| z7XA=TR8pgVs+9C~1yKj=lAzK^cq}u^JBn$1=5gQxR<}>B$xa9;0cvd3IPR z80&~jE2|+rxH!~b0oL@cqn)e9e;^L6zMSMGrGN65*0~N~gw({5K>GgKdN2$#d!PZn zBSXEhl79Y(dVIZ&_32a;n)Ljk!C8Hp=5yxV-^25!IVG6roH^NW2mQgCmD>mBEA7FQ zo%{`!Z_qJc#?!bT4v+Gr^RJ;?eNfmH_P*u!V?95^z=H=$`o4P5UMuYO-~Ga`-Ck{nm6_8~moF^C{0}x-qyqgx5%mWO%x!7&u7N?>u^`>xT9652I)1kW zo?eCVgChm*L7BS)Umk-fpeefY^3p~QEwuT3bR=J3!i*pcNQni^g- zL+$o63i>4!VLQ4F)0IFv)cwcA)3K2GqgqJ!0AKj_AN!_vFGN zd|&Ep!s}rVTQ@tq07-ycw=?M;b!TS-e->avCOb36b@Es{vk1!S-^^9Y@bfWGjA7Ch z|Cn@tgaK!+HaoXuvMk&|Eam@DX`i#*W*W*AK2|BSbTzVn9Y0ca}(x zM22?v^`9{^jMHw_TBd1;yk&TbuZ^!kGzavWCBVQVjJYS7((VstE7|=+tSJ5h49JGb zEXj&&M08Ljbqq`V2@>?jk>0CP{D3)vlOa^e0!?^ginL}R9>{EnZ-K!UWSa&W(^L=p zfMahhCAbJ_W%g6xpSrl3@K@`Mg^UNm0T3Ki3=q5u>}UOAo%WSAY@>luDQPS=WHezA zHu|vJw@x;?upwe_U`VE-U-Xp_l{NZI3IbvaMA6L#>@l{COGCe-#3r;w(ZqmLy4BoC z)6(4A1XT6N{479wh~aRIzhqdiJrfhRpnz%s3plMh++$iRTJWyW7MegfoCccdC=qGv zE6mmcj#aL{ws+kr&1X`ED}U(pU? z&$bT})8t4A^r(}d^qLLWs4|z80}ElBHiSR^LZhIP@Oo3w6=#8qoVIX7MWQ|Ej<>?T z)T8m>{O-^LIWrABj>f>@n5P2{#s7B3LD3i@fXtwyoBlmg@U~k#V6XyC%EYmOY1kaH zVV0CyNIcQj*XHQ}j(&Y9zU6RE8ZA`emA`Q7t#~YH>JDN17!7*{<4}7zi*DvL^n*^T zE9R%Z@Do1#3_1+I5QRQZM9svduzL%yEG$5GIq~sXa?!5wX3KMMGpPb@r-PcY&)N0y zto+`~J1IR(%o)=STQ~&U6wh2O!vndwmMDXH_Pm%+gm)6ZUaO>pJDEU`9TOtdP?f%i zUXeAUCY4akel7XYNlbfE2jxLUjRvDmt{laY@^Xt{-g$*mLN3_$g*o4r=tnJ^XWO5- zXRSOf?1z5#KYiQsDly*o=a+!5Kv6zs@q-OwUar`$EsplRa%I%{a_s$hSg(^!q1sf8 zuY@4nr@2a^!QWMa$Kuv^$KK678+hWRxY((>hdtN3H9hK=M96v;W(n}pg6;NgS$0LE zdeqs$Vo(zR7fv+&6wegf!P51uw8ZKdy=ZTGy{|nkkzIZXr!HFaOgCG;w=xZPF9gZ_ zfMaIK%t7Fb4QzZ-z^msQ_~9~=r3V=OYVq4cz}b(?ou1Ka?EKFl`-pK4{-V)oaUWJK z45}H`1RQu9+V5FybWhZ=JpytHq^%0_1&P}UCP72B-rP_3wO+REY>y@jO%ic0X3kRE za6zO2vqvFkv}ZU!SP+gsw$lxfczx%CyMbN>P2A}4T&X`dDB0-41rROz8@nNIe0^?wPfX5ebGy%tu0+#Ag$qTp0W0ZUx;p<4Z>KxxK@PBoW`K~mf2b@#@ znVL?P2p|Pj-)^)H$WLi}(dd!gY!{m;z()(gjA#oFII3wMpBvlEVrgJIbzXs~VZ_#sa6l;=9k>KY{8z$MC>^BA zJZ!-S#7hk2nCHuDWl2KLe1i$ z&eZoa|3pfUnup_n6aBkVoPfdZ2_*MbxNvjA4+Z$b8C>Il$5d>GY87z7B5C}rRB z-oxF7p>zJM%>=Oq;AkyyJ)I}pRFeyXD=Zu+D=3s|V0t@21U5ta$Ja^>cJfD2z=&6c zjDBEh?2v+Z2SvSa9pU`%V?y5|M1;X1y3tP!#yJQ*BJ%fGdxbup%dXuNs+QD;;1^g6 z5n^}ny`%7UXyEeo^BToaCF(7```|0Lv3?|42Y;L%V<|2ev=6>2~bP=?F^6K7r+&j`cf` zB}^N=xd`bs)5G!dhMzIskQ7vB9W6W#3$y0za8Km{mq=iLPl3iRs@&dZbn5lA&%g5< z@4~+r3^&J*2bAm(s$vyY9ZO>4m@T1+o+)r{*!ks*zc^EiJKM|7Q}vzOV@=j0eJKJJXTO}u1*$%;f%yj)S*n>AiMFyasDJ!kvPl8mIpPd`om`cB~m9ULDBnY5=eJZM}J*TE~Jj9fbl9 z=sy|zlXZIDW}j0&4;nLy{}>t}n{UE+^yKxJ@0o92J-PilLU~6xu{1yk(URfdM+LVKjVUAdN`&<%}<_(s@o5DOC$CTDf=pKd`N zEl>E2D><%%*q@YzZO6ajeYj+oR@9{gEX+0wFd(E;zLnzR^YfTZ>gF*lgyLKu|6^XL zb7%V##?o}tn6+T{ZwQ8Eo>mY77}r~V{RPGvmt{g8D%vet5_)u+Jp5Grc5ZG78gIVS zEiFLHPT$NSnH1^Z!$?Mc)iRvE>qZT!1jnQb$e~yP_ybkCIo~g#qGxTa!I_^xz;}#a z_sx>3qPW31IiY49!)GH4?7!EzG&@`Ma7IfD^VpFi`ta~N0Nr(eZEq}F{JJ;NIvof% zeExd1d3gSNwGo(<-m2C&9wa%_x4-a-cb4DqxErK8EUy+f6B6<{l8u>Gq!2@Zdrrvz9;{Xz>$7AvnlXd80@>SxyK*8c3|0MJb z=5fVuiUH8aofTmL6*Dye*%6S`D3-AEPh)ku;K$#1knAAetN-#Q@T>zfTS%F;L6ILf zfY14{u?F@sg(jsBnvpkNOY=4}^8;VI{RY;o$99vYPu$~>PK=1(_-RB`x|{rLS$foZ zRGdcO1ogbc`9M$b%s`E+xbWsZUanK2a~($pACtdAQ$;q^WTiUmj%Fu*EGK^#^ymOL zkj79IeJs9LEWWeEJT;^piwsNr&_7N0iJYltCd+WX5yD>bLoBtzVE~)!5nJAO(v*|2Ob#CfIn?nSE8eD zK6qINSjeM(>QDXH=a=7vB9kUY+UAl+X$CUyTABAkcrCQ!?*({z?vw~Vd?FX4 z6iIOD6%4{)=J@;0Bks+cnN?X;J)iPZ$w@S5z8W>|yb(vuC!=Uo z_{O!hwIBV4wKe=FzyHSrYu|sjyk2;%cUUM_OQr8CuYX^$TDas7EwH_B(x&v^Z$g9k zzjjaS=J)LH8^8IR*7$$@;f`eB_i{Ev8RhZ+YqeMJGXuYWgr8^mhVT4_HU7_U{5=of zZ+YkW_ZG&7|6h9J_0K>0I_du}XZ!cd=pX*CJ*_`C@O|F#Of8k;6d6>V;j{mtY zpPj#tFn{>}$@jnZ`fK0+>XV!Kd;a;S=N>;X07ud1k$?TVhra`tf3xeq^n9ETzV6|B zgTFWH*VfqACH-2q{>wM(|Azm$;eW3D{<3WSS8mq-&HBGt|JQc?uivcyoArOQ{;%!& z#|7sN{@>vLmB)V!&{^QG%k%li-9H~Z|7PWX8#n9!hW_2qzbjAwmaYHIoArOQ{%_X* zRbT%Qz(fZp|IqEUl?MgN+SACOO_7pT*m z#>+3bjxTE69mI!8G)j8i;R~)h`kCQzx7R)H3}0|&;xoNL)c%2Hv#BXy05oOXO-92P zlx6r#aws{RL10|J3rYA)yO(qu9NC|+k$oHfh9=9U_43*anzOQ5T6=*x|0Mn=4iLu( zEB@TB=gR~teiQzt(`oJ1n%Hef;wS&k-Syj1C+YTvQ9EfIR=aPZcEG>qmnSmj2)$ z3^bGDNWS+mW+~N-qkc5hFgh9|!VG(yf7Hf^*K=!c5Ov3vVLxss{iLZCBa(@A<4!c} zN$uUFZ}|akugCh^k2>CU1e2jwg#j=Ub=eDv95<2>!BB2}%IneZGL71QW@oh9?6CyD z52I$RHQ|G#O5z~Ojtkiuy}@qMu$;|g+_7LB0s>d$?8Hs`)@5hVi1#NNc6-f)HM5Og zJM#L5NN)5beLos>q66!Q09f)5;*%s(53{1bhl$JufB{es6rvItBo;x%Hc7XJ{kSn2 zpyQv+;>lGB_a`4s_jDO9U4Ki)n$m&#tAP&u?_YYeR%^tg<8~)$#*GN;J?VP=m{8UQ zBSHWjpNDsVQw?A+^A6A3{*rE8@8plBADtHfGLI}&dqOM0LIL#ri+}O&{ix035KBa- zQR(=zoj+HE)mwCbbz0{ z9w&SuzfiJa+{Qxh3Bn4Uh~F8f)um8~Z=oK6F^Ne44he+g`FUsH3go{i-U%P^$`i-C zwYC4~@87MpK@G<3R<9cuNaDvG1+4QCuaEZQ0d{hr%nT<1KH^@jSXoL(IR8^rvV@Ol z$NfRXmh#_ix~Il(gnZd)W8K8#&~u_t)NV%oA%>w5=HV}&hlB0!TQ+QTpoWUk2%|I$ zYe?#8CR)p6!jCa|i$Sz&nNB==GwH;m{irK|#3C3;*>3N!HyT(=LmwAGeZ)jV;Ow}r zOL&5P@K689Z$19`@A}{V{3Z570axwS&!zbM&cC=@>m&ytQ(d4QzE38IcYAwnaKb~` z_kcG$#f{pVr7~yn<)Y2+wDi)w;s%o*XFflExtOLuDVA!ra*267h&jy98S9&GcYXoc zx(dBxZ&^-zStt;{57-tklz+6|=@d~<#yB;DCUga*v=-;92?}tvg4Qfa$Ow%Ne5@tv zs)I$#@8+3p}|Sj)TP5jekL(iKkd02Oy5;o#fj zgUFVj)Pv5m3x|pFsl5>vTu*ZL2k~(9Zqhio&g^^Xw*`qy)#CQnZLdd5ZEhl|C^?dWY90V@PFR|6ytFMRs<-H&LSJ+>`2)A1a*d?DgrT5^F zTI22>1TA;SEm8IY4tps3O{sRjWSfi9`RNp!3Df4zxx_cwKhpYC3e)Q+ji_B154GWx zFVj{P%O+Ek+2nE;3K9Cv4rd|Bwz$vukaTD8nC=41!{2Uv02(eE3B?StNDUfe2vZ`J zTeRYCAF_ZL#rykQT9%M#g4Qybfy0H>h{5ct@TT2s!~+$lFgQ|~P&ij4?Pjl) z$ld@+%Lwv2wkd7lxT{=XuNil>bG=T2zA{JO#^LjD9nTS$TMusv-ct_we)1vL!x2t? zWHM&f!#&K{ZAgzsQD=Ckk9p8MTn}KX>b0Wm9FJcDUIco!a)w7tos5FdfNXvWQg%bcY9!gm>4C7g$KZ^~7Iff9wH z&XKNL_J!-GF$SX_j=xd6#k`WU-ID&|pQLH4E8&?ytLZh`u?L&6mgw{jh6XFkq)e38 z!+v0V_KhPwa>lIJhhWY=U|m}1NZ3d1Jq}2r9vO(vo%4k0R2n-Nrq($^Bs6uUc|B4w z)>&vx)}f@f+wfZz(v9zA8+JxxFvtrtH3XiscLeD{%D#puq>9FWBI!W;>ivP-mg`@d z#mw6Jk46NmrGqma0xfll8pv-DY$Utwp4TIQY_yq8iBMC5thX6;QN;VzjDh8um`q?> z_;uFB{0TZTu=e7X%o*x=@m4(U7j)dMcG?XO%eeNuKM_#H`wS5_kF5gfeF$Z{XrCS1 zPsluUl(*i;AbV-YydFq?yqbja93Mt<(rb^jngej%gB}Fj1}_By8)!!ZuV>G(5NX)x zM4a4-M$s^C4ix-26DKW7idj;jVjp@(QN!y=lZ=2LQT8ok2gIVnDB5HBZj8eKsC*X< zNE|XI%;PAW&yC^_A%)k8#pOUu00=5D)qq6#dUL=DWId2^YcB7PB&MJik&{&j0hkwi zXADp~1O_s9Qr#f*r#FghnGSFVV|^M%?`A+gO!k0DmTQ=F`T}Tn07oV7&nRRVTO~-r z{2S5&i$Hn;!9mz^;c7}I*Xt25;2dV34}rBI2)J7K-D3-!ASFc(#88irVoQ}tIFZ_P z2hG#zuVs8P*~1Mjf4?8(3Cqq&TY6+ERc{ObU)oUSzqCT*X<&=R?0%D(mZdlBiZUN|uj7J6|wp z$2J@_HuM;T&?fq$5SA@-t5~X3&XLkC@$O7wzM36lG|SU$*XmudOp}AzwQ=$G%PhcMzcE=!h(-qyW&ETrbB?QmpX z<&Qmw=retRGdR*%;|z(Aj#}S|m4r8d568FzBl=8w@*DY4q6P(EC82!Qo3C@tE}73LeBm zyIm|Cu#{~S%1N;vA!5f}+!JF+f|8Pit9Z7_uh!HYp5*ZNN<>eiPv;zQ$I{Rt!&b7{!0s3+}>9+&wihvaSVBXrR z>Zlc);@#4peG2@*tp_zhz!4Sj$?<}EB1_~JP!p-$({oxa>|2{Sril>kC5prK#P)Kr zOq~)g>&KZw2#4H{J-d;EDf4dB!gdpNyKZ~2UBg= zRb9Xl+p4zEJ!W4Bdrj1H9?%3jD3Z&;6z0e0=_>#I%YaG87)W6&@4kK4XsMpl7nSmi#>Ab&w;=sb8i)>;q@;2TtB!R=lPB z8ZtU1`7c+~u-uH6EhP?m^lyGekQ>pdDyo#$6S-y zkT?)Qcws=@jgDgx+u`5{@ryum7n`vUnO)fR{y=ub_Lg__R?L~1;ZHhI+5z5(#MZSgSQE<3>}c5?A3EfE9Vln2B+~nX8<`9W z;-g4SRbx|QR*gh@xR?iU5Qe5Pj-}c8Vj?vGq{EB=0G|1z5I})1hB*j9=U8T>AJ&B= z2|VnxY1%R`#DFpleeg{HqErrerSR;hayg`;0%jRNKnT6#(1Ae=1y|>f253v6jPwk9z^gru`x&#h5>l-2?`Nvt%-J10WpH* z#Sqgj945`QueaVkmUX75{pr*h$2{HtTEttEw}YO<5;-6wXj>d7btk}5iO7yjoJr#t ztePMX+7IidvrsB-_`I3iuw257|H0X{c6R z&!GzOqHI!?$~Gj7!cbPMZ|jww*P-J(&rP{Cw_u^At7>-D2p=a9 z4Xeghg<<;~e&xWQk&nC~6UOu1FMs*>i0{;sclB4t^J%JQF{}Uj_))cV@6BR4SN}>; z!h(FIG^scyjmu^ssfQ_lp-di5XN?|cukd0LVhNUoHiq54#r@-f8+{-*C_Q3qi=ARt zeuui9NO{ilDVR_i8BkOYywP$OamIUB`bZ<_LH zdXJ)MbNHp&N_!-Afbl+psgRx)Q+eR?ic`;`-yZ?uU;1hOej(gzDs)Y5 zTv<0ppt@Pyt}2^Q-CD<8q@2t*H%s6npk!wAw?dy%`uOM-$LqU4edqgYwLaNRssu=~ z;q`R7Om473TgWn*!f+4u&dxW-NIcUf{S+KJAQaKzV42XbaK;T872n#p;sS~pVy)J% ztDWmo^zKpEH{bgk|H(_h3!GJF?anx_i}ddGK44ofj4^)#WYMtS7GC!;1W7O5L-=fb zCEl>z#dy=%J;rUekTT@T1aV*!yg|zWtE~IF&H7+~IXCzc76I|a;f8gIGY{m^a@yEL z&`v50k{X>4ZYjNaBivW5z5frsa<>MJP%&3fazlEv46g)*)Se@&hw#!pq|NQ0VNenP z9!Wck@yNTNdz{AR^~Zk#{Qa;W6kdo@L}=2fW&0QUC3>hT z%g*9ey@s^2@JjbDwkTw1*jH*dogyjFH{uZYIq#a&B#)DFF%NqRUMb|mW~WFPGA3Qc zzh>{at)^vjkhz8lA5Hgz9O#_GPx0uwKVs;y#KT_W; zesji&7rVQ?kzPlKMwJvH$~^pOUkn|*Yl;les)xQGgp#rqiq5NB#4`ClUOrUF*GQ75rESD3B63ljWwF!{iDmF`jyo`y&r@R4>gJvt1X1Supzx=`XUJmOzqwq?mOF5pN2 zuE25>3w!_*t{L>A@S+ha;?q_6aqJcO{nH>PQu^~@i2J-_{Xmbehzk%=HY~xhNWsQp#Vrk?BZPOCkJ^=1Uq%lOVPZr~P8!lW=x57T?R+52auhi{lNepWsuX$$vb zQl7m21ay>UJUivT+crGS=esI6_i>Ela(r62cl+RHe-8frPT>7u?%wTexn)t7MHVlh zue(5QDeC}uk>S5i<PT-l!fgtRR>5%L=F3FES4j8FMT_J#Z62{z>P8zQ!= z5E8a-r@V=@&BXx}E&v0_bOXc68q+g{2<1PH`F`H&{Ak(_a#4dP;ZDM7ZgEIBodi}k zwv0$_>)-XFUjD3?l(epwHa6h5N1>pE7fyG?8uiR`ampV)P5Hw=_Zy!F-h&4NZG0wqX@HQo95iXB%upi$d&)NNC=K<2@*4KhQ+$1f5z=ik( z_a`Q=kif3X>Es>gvX6B+b3)IempAjdWKu4Xe4+USfnk&PGWyrQ`jv01-HYJQ*)3Oe zK9O&RPg`WiU7OP*q;1v`KV#?d$FPL&n=bRC1WZK#XZL^7Qto?jz)GEI=j$x0OrO(R zXvb<5vdbZCPI{P#vP{+Q6x#UJSd3*u}JlN{k*!Eo-id%Mzp-}%-Fec?;*VXPwN6D;N7c2dxy z_RR+df9YcPV|GWx7s;m%7a-3N!3KP~U{I)?XH(|6>OaaSRbKGbynKN7H{6(=W!=uGi<&RrIPB%!qO5tJ}!z~^b(#Dppi zwEj%tXfe$U*G!C=EhyxN{X*vJ$=GsUm-R^;;g9>G&mY%ikqoo&wPd5sAuLuatm)N; zX$yR?@W0@1%{q!UOmsr)ct{xXr!6e~H(jSYk0n3kiSK>s$DY>i#mxwK1`4bGG}%F7 z^eO9G>cfB2if4899mr#MdgwN&7v^ZH%rpX!||Vb0u#LhlqOvK9Lw z*|;`PADsH(?Uk554ZRCO9bqHU&G_qfwuAby=qdHPl=P)NSK61xLHt%+FX!p@bDNjc zNco0e3w*;l2V-)5@a?au-q*djdlJE<3gl!L!DBiJFhQx(DWfkLIqM?+{eDr)8Gfj!*a|ht#kkK zpzc8ViDEV6yYlyr`TNHFca~zgd_Lk89A2c;KLi5(CZtG2Yf0$fG)-a}H;!Rj@O3jBGXX zB*^ojkqn92rw(p~(l3m8J)QwtlypYSD)}%^ni(13Tlr9CFl^ZhZhQ*!1vkg)*M^C3 z{bBjd^Dz<;5`O{xR&o+M5a^K`Dj(>x_s33^@If4$g5aS5?-{@ac@WY7e^`zdO`{$`$b&@mLwnMaYZ1)CH&azUn4ZgCso6RY?@-9OXLgmN zUYl^0`>fiI@~^4#fa?)Xr?z{;Ig?!OqfPDGYfmCGx9Wys;2KE45r8Kw9zN#;g6(8HX?MBSThq*`LU0{ zb}So@9BOv${DS>WN2v!SwB~Jf5!O!-N#nV4J?*c&9%l!3MPir2ubosb_}(vpE)DQF zFOI^{*%Nx@`1KSC5D>}-?r6X-+)LcA&A-bbX><5R+#p~4MBV_Fxf?auwEl{ohw5~* z2Je<~$qZQ{*jzl%7tgF`FrT7Z4~mXwOu5=^KUw#eJ~H=`nl`tdxn_AUnSa+E0#ZKX zG#W$Eu7P)fhKV*%S08eCfAXRrlz!Zi=e3&B}IuX;|;2YS^D^n6JE&ZC#{D0F6Jd%9hH<+Xv4kpEE#;Mz_`#;Iz+ zjEAZ03ivT-2~mWg4)Z0Ko&OkS9{#i&b|t4(*+r7@>@z8HK%7ZYKf|nt?Zc0L7Rs8$ zd$aUnt2L%H%&+qHV!yu%@14qn3VKZ4KgL&C**LjowY2-;3C{j8ZuH=zL^Z1s(eo-` z&^u!D_zrLU9?}a+ro{!El;x;#Evp z<>IT}>FtW={>=K!=p}sc|8jjM-KOEjdDf?%H!^y7Sf2~zx5UxQuTPvemb@RG#UM6? z^@qh^LrRxd7$fuWrxKeqE3S6ko^>YCjy7@T2Ag$>y&&5@ZX-J$K*_8%7{6lun?xqt zzv~v>ei_mrUwsq&(E$F1&ta!3OD4ldmtd!Qrk~Q;nIg@{ENi>wv3@qk^^Scs zZKd|j28wEFV;dxG8NZMRSW2I2PsnBz=!fEWfBZh?8%{TaclVTkI7J?!{@sP;$;>?m`LNErK>qDHy>4ab0_l*@E9fsZ zBN6;cULCHw(9Q$uI>$en{F@_pKxBGY|01vIqUaR{QdB^enasWYK+o>1$bMAENB7V*601v z;co2|x_TC#K7oJ3ZZkzx!_!GOhp5Cyz9$ZHDlfb$+$K}SQvD#$&^E9xC0on?*he|h z@MBn4tONBz9kJW8XXv7~ENfQ4;3(Bcw59w1cg2XbNkvf4eGo&1O3EPweJKxG=a3luJ?bk;Oi^RhHV${)4R4+5XN_Wr?_Wqm>y7;n7`J0xEUq8t!?1rDcLpCUqWzCmrgo=Q^Qy9OyX5?_ z1NaQ+gmv@E{q)^|5B~8#mvsXz2{#8n|GII%D~7k^%Tjv_2`^mNgu^pmM|fFBWq+-< z!^b^H6FzJcaF3de2={*?H^i+I_&b&3;Z6zX4*P){(a!}hd0f?f} zePc!+2gB|7AeJr7B4*~TF|TKcRF#-YiK9JufanIY(T3P)_Pcp8(@OBo>j^XjS9Jm@ z$pKA^(93pDUl-+vu03FjAWhU!!t1fYE4hnX*{tUG&*0Nm1tQeuTQh@)UXOY+1v%sZ zv`8PEvx%Z%ag!!zU$Ry19v{6PlXD5v&oVwvIi>81JeGzKQm%^z%p`^Rr3J5tbLxnN zkiCV6fV~{cGz3FmHKN!XaH6AaPB+a^3#B`tV=P(ALqY$+tWVF*cAI#ZB| zJb*+|Iwp-^i;xpu%PYE;BJz@8_Kdp)qg;VZI+ zrm%uZ45m~xGkCBodM76vVY`=L5eTT$_p!U^jr0Nhp!S`R)U%m3-HDnqCZ@xW?J&Uv zYPf@0@cvlq@aCFkj-}56WuOk+ykZm9_PcQp17$4;Ndd1%AO}kzB+F;m1ceH_W6TLt zdvFSCV+625h_;GekLKeREtAYAH6y7;~ zy_k^l{xCaUH0D^OEHnZ_W>}L2V@=kJIDx13Q8M~QfR6xQ(riR{16j{a5|Gg#6l>Zj z0^buF!ovl@?%m*vh9N&NFv@GmA@?}DTH%pbr$HJx?AdysPLEW946cV!kR!wHa%>g8 zcR}CpmY-1k&BvsditafG!7p9t$WwddRq8x$JhE$F=U&u)W z1;gI3Ebp`*Avz5ElRm0rgn&7{8qGUfQMRjCPFyZJD%GDrEnrMwiz=h;`DV`bS}94YpI^XAN;d#uhoHL zI0KOLloh#b-(4!Vo?nmk%dE%q$gQR8f?Mf&6t((BtK*1~S&v*Y9H*2B!?u{?tpOv0 z^HF_Y+B6ZDIU0s;j|iAimnhIcM-Q6<`N-3MVW0YJsxP|s z!T8NLV4J`g563=Yx^FvrWm#UOxc69O?+XEseHR2 zajg|*MA&x5gDcDLEn6zjV&ADh4R#mr{l_Ed8_DD)IJum@?<_s<$#T!}fiRuTkAd_2 zY}XNyZs9t@!T=gN#)EgF6`JF> z;uvK2F|dR1WenF4x?oj$Gw2a>*|T9B^`S?{b)=9&nl@@L%je;D9pVe_EvYxa{mT69 za>v z+yLd)#S*{S&w5>)U@7|m`Ioo~I1d`ThEdlH%40>nB19&bIW;pN2dD)PP+eQ-PoSb8r&)Oco(OCC34Lf|?6i z7KGqJgVux)ZZQvkNaVV}b;F5Dav7t#q6!ocfnbgX?m_a0`v9$sIm3H+F?I*(BND^C zJcDULYuQ?qSm3#IoahgGH?#JbklBbjY$)ZQSWD;*_NkeAv_DK`B~mDEpU5+W1%3mA z859600?h~pGW9SgUI6a#HV$=iXv1bHhZ@wVN<77Fm{iDG-m3CRCNAYO;GFJ@55ha-YyDdvkI?}E=j=unKKgpn zp`1h*3VYXx2O*0j9K_`Fq)Rqr#p(_(5Flj7UN+m`>lMrD#h-KJDSp+1T>69RUy<_& z>@A_zd&YUcGFYg;xl@`yk1%Z&JVU#)^U0aVbw;OmG@E|Tv0l0C^beu_ivQ2x@7mW1 z=^EeBG)2SBjgnYwo&o;=BEbv7y6 z^Y{^3I7fhEQob2)&%n5yiyu#H^1akm$8(O>p5Lq&@+V+)wZ4<;h5qyCEzUFenPjQn zc79$lKeRX4G5;VLdp${;n3+4`zToM8GRUZHyM4hzeNfTBX*7lZ)B0ggWg4O~ z9NAo2rVp(Wan3gLDt^h3!>)vw%g^jSdOB?;13*Q0Dd8QncC|>?>R`nZ|If6 z*WdF={qhs$!~nn@7U=#yFN6L*Wpxu)8|26 z?#p63py|PB-kxSDe$UGjc1o9!C!7nv{bbWj-|Z2gm|UL_bv%|K%Hd5PlM=rFn)6AH z9R4@;uk?Rp_fN-5qMd2vBM9qg;pQ1EDMQboa`7v#^RTb(JPiBl-N}y$zlB*9yqwus z?O^|L?W#UON-jnyW#WpQ=g z-{{MIG|CBrN#qD=dJbjg7WBWXB3h`1aiRbLC8!}r;0u4(Ktc<|uSeW4?8 z8*%p^{n#PT6N(3M7y1y8#?qDvuiJlZ@Zg$G;EKb(&^()e#Rv8dcbMPVXSi?Xcf~pQ zII~@9exK&{`w>Vu>=AAG-pudEIdLo2eWCePhHCoYQIPw5FtcB0XteNyl7C+Qb6LJ_ z#Ub8g0|YKK&rYWwsUBUR(}XUq2t(v=2y-|xKFBub-cFoyDBFEe-)2} z3tK+FOXat6H9vFzy|e7y%x8T+0aj5Tzk_tc&!wGF`d$Z7RpqzHhasxiq6sfA@d&~< zloCA-nNJ8hRLlXJ5}1BKcBd!YKlI7|I_SW>{-WG7RN%iWy-|R32tfr3FjCd}^&+GP z=a3Htd2apDLq8Y1_tU?V#nTyauF<29?VfZ7f2?IWA;vAe%JOsKUc0v|nnWfT`8t@k zKlCnKicZyE@%b;b|DB(ZbKwX+r_8O+(s|GG8LI&Sbb|Nrd_Tec_N-R$TIRacyuKCY zb*=E<{861(Xr<5Chk=;q^&ZBshKGrN(n{hP1(}OX0M{($o8}g1R~>_1q@Jr<<}&m9 zU?<4+et+{n|4Gg-7)aRv*uoP25&QD0^NanPdJqp6_^)Hy+`Y_cb3z^gvku?bZ%3!) zyKdj+?CAgizO_aK3$x`?`R&{vdr1tT~c>9WFkW-_tGQ zJ7LoXLG3Kxc^Nym^XLr#rH}kpjyxtuCQJd+_3x2fkTqc^%D5%te+~KW&T_Ku^q@~APY$JaZ|S)!f4dd*n0KlR z))Ug^=qvH*=6>yKgXWjnhwHBfeVF&RYI48U;gg3z5#g(s$#Is_TeB@TdP2X)J7#bE z1aFqrD(ZjlNwHk3l?0bE$({TG=gXks zBo|qvYnH5{0-Oh2^)TP>>ln}K#S^9k8Q@AefIB^g^KSFM3X2Tk6F~o9-3W7hWf@k4 zThKSGzZ&d%*VcacU(!xP?*%XFPeP0;XZVJC5k6n@{nF8$ZU42zpTu;|53=-oAzlK< zY)HlmSWL7H1eX=HHir?| zw_!>o)C@{6s`_FNyKI>wiES7v*|t4hkq=J!-`4_NUVHQ(h&?V}b~_?HUSXfEmqaya z7Jrd8hrhG)toTFan`}C93+p#(!+{(fT{$h34(%T|;Xy9=$#K+VUljwP*rDZ2i|YJcDlrgzEZs5teYP!Y9zbori(`eNfT!68wVey){kmAVK;D&eH{Is#UsH}@k5|PGNVfypjvzj zGGl~3?2Ik67BZsR3*KV!S`r+PxySWWV0>*pEqjL%_-j_gJan7KCYTnRtsdD=Q?%W# z8g_5!zQ4W6U6((#K-k_ABVwG8GqxdK2?b^DSDE%h2-%W=8wHxnwko8&_sVsOU(7J=X%q^bTbus3iDPuy>IPabrr_qHn>S7a}V^Okaupi-_dDcT12rJG+^v1G|dYx$Z zI-V2BoR|OFnCIVjkT%yJ#hS?E%j6V#eYxt55D!&JcGYq#ut@T z4wtoGsw3^f_;nt>Xb{bgpE!*5O=>Gc3iMQB#^)Qr;A4g4aju^$!t+XHo5w?eV+ry! zp&q58>DrWvrfE|u+Wi6vrazenwuja}dh%HjKq+26xlcBO?>T<>Cq5AQac>B{D0}Yy zS?ga=zJ>a8_=8Tv0X-aL&!(?9mMfd>QuhK+gZ%04xBSNEc|YG9iSnCF_qq91e`Ckb z*>W#%33{_+KU?UZ09~)hf&lUuI{|;!Dowzsg!60pAHA8?*hnIl1%HHQ0tzVM_1r=f zcLA&eA=siYbOb|QT~2&2%j_x*eA1c%lR>YCcrEbFd`~Sct!$PDmCR{^*JHIf3yNFc zOsyW%gC`y$A-!dT@FLtB$@>jn4;?B%&q)9PnhOhQ=EKD@o}ZH-o~Ss+t3XVZpl0A} z4~Gd{kzLtEb;`h&(&N&)-{-={a~(Iof{mr3ai=9n`~%_pS{4_q+ zpT2pUF9m1l&ag3v>BW7oFv1O;lA)#hOa9z^%Cu!ZVgDQ*6|^CvbD6Iy9Ma_jeX}V#Imsq z;{z(GKMn7K7d|zM51CUm_&XAy1@hngddI#ievvMQ2iZ~Gg!2&KJnKFn=iab4EZ-A! zBe>AH_i1W}Quvp@Dfa;*++v^QA7I(J*L~mn{sTU=ewlYumz;YSzHcl{7B|6$z4Hse zDx;~&ChB3WF|wF^!bpeQBRL0zIr&LE0Ib49ghm02 zi}YIXYR>HWoNW-Fhj_tImIW6G#^i?=JooGGn@(j-_(d@@L$NjWu^l3EvO#^&Zn?pK z$F0d^e^Qa(SA)N;J!PxHITrIk{VaQ*o<{@sIfJ0B3NrLnI}cPhae*c$k1B#&w-sNe zQ&AgWl6kK|5Vl=G4g4&*XDV0vY>+FheeoBjO80>qh5h&lFMzfc@8|75@_c~9;5>hc z`hdp>+RsEsVjB*}&>jHucb|BBz=TZDcnT6CqvdI8+J$fF|r2-Ehe8(g-kh~7amyV0c}*IQ>){{ifHqE zWSg_E0+6s?C^K~Rs#3`|;8MvhuS+Gnx-OOM;+j0`mP*^ocJDozl*_5T2{vTmNz2s= zuE0gU2aeW?kY_dR7Y0oMM)+Mq5lNd`1S;GWs|Xxz$rNIiKswx$KX^Tr>*;!(73(eA z*Yo`Bl6G>*D$i*R<;@{rCEg9N9Ljyq()C>7Ya6|&9ESjV>-AL6DN=h9Xu-f{%n0)` zx}3Mi2Htb0zK=H?L0)F)GSklB!*t(1>CMhBX%6bevme6|pX@}%3161SV=HIWcfC*{ zcV3pk3mt-Ad%rZUY=NLGI5#eVRM@xc4}zZZ+M{3m3i*2Y2F=-ZqmsPcZ=R1^(oQZ} z@BsDC;enhx-*(MlY?syv;)KM2E3!jr*8+zZGU~<%*QN=45MI;$DhKR~`4dtwPwS6@ zz3=kRbMU#oh+*{V5_3PN_5eEZac8 z1g~UBuE_2q1bQ(Kf6C~E!MiGq$f8sJPwcc3m;E@|7-7*eQS9rwmklJlvfMX_j-c93?)JQ>|n{TEC+^j~Z$?OEoV{d@sx zFQRt~vYnQc*@we>VDJ6Ae^&e+Vd3IMRT3Hemf=BOJ_dS0`AHo#VoAVpWSbx0gQI_DOEgSJ`C=PurdbW9vF}aXCi@%NvPql z!%eJ^o6IMMJ%mFsK1O@PhYIlL{c|cGTDA?cR5qU+rE*nOI7{UX(~Q7=Ec%~(^aHlN z#$B$=->3L}|FPgP)EGYa>^~FyerF740e-MrhTjX$RgYh)!l4Y57l`0OOfgCk8g3iX z!w~X5!eoR`TYTX7Xjg!K%;w{oP(Dz*=xm_I6!CQ3Ko3eEAdusae1~gTzJDW3_?hjW z-n*;vHFpmv?_`>$GVTO%##wM4UNZI+pWX=Pmb-uJ6M|1*ha$W_bh_NA1P$W7xch0J zAETG|7RZg5c42z?fWqeVStox-anA1n@NbkHEyF(>k`T`r=WQ9F(7}LzAzASf)RXEl zH~5!9Anw!pZtL1z*MG@;UL}~~-GiX7y7q%Fd^hEl&{Ktu$Qkz>%jA^{?m2cA-E-)C zpS@3?&prlS7u;$MeV_LD*f5B|VcSX%@g^_?--eFZc{?G(Jp36j+{J-K%~^~Uv_#*} zEt=9**3%!x<6u0kka$NIz-_aPa? zFwb@SEt5-?O|y&EAELukg6g80qu|C@Y&%LgUaQI^7z48c;X%FZ_@f1>F~;lZGxa;t zb@k-)&L6CO_z&fNXgChH0HBYYP@bD+-Nt<4+4}u;JO|dG?SQTbJF@yXrE@p?{LIq1 z(0SO_X+3>Ef(1A9~S53?o6B8&u0bzBvU$vre*S513w4j zs#x%o`H6`kU(a-Dppe~0hgs|->4x_PdPri)*>ZDg zoXKZ9>VOxhb`CEx$RHSCjQff`NcWdo&_B5Q-~Wc37w|F>UMs!eJ;wt2va^W35Z6gD zF6h5>;XOyB-gQLQ!TRx=Qu-SnJHg15e7UjnNaB{Pkt6&8ED1+e;Pecl7+k&U&eyjB zFc%JbgsK+J6m5ec<=pn#3Qv}WT`?jeXNLDRKI_R;xR;iC*rsbNq8iu67>V1u44q}Z z>-by7pV5Zc{6LF6vAy0Z;fmd;z=l^SYN=u_uSykhki$9V4|gpU)8&D_pj+>jpp z5PHA@^|zG%Lmu@ry`T9nl;2Q#uwWlpUH_yy&v)z~?JT}y+Gs_G>}nR@IW(-x=nw|? zvVc#pL+Ls{qrPk{S3i7;{wy57In!_kIvMKZ@Z~JvDLw(A>h)l!ux576ByHSZ78*7S z(ZxUc^UN|i!K!$r>*3k%Hz#fvjexE;&~L6c>>;jzbQYklM?^l3_U7o4^9$^X%X*|=$_q3gf6)=QV6-cF z&d0Z%6I{<%_C@!GKHs4CA|E&VQrgU{V{bfTp2GNr9x+yb6y8yKudjZAWqu0wNSV@~ z`SVR4e?raY2#^LDKS}(^Jc|a`hES%v(VLwG=B4B&Ps2Q~{p~+4aI$dy}X41d=pk z?|+Y;zmwfD6h{@n%kVT$k3d(%lC!ix&jo37bdtF7tk2)>opzM$@*E>rK#Xkdjs-JE zl7U}ydWB8(t0k!GT3X0PD6pUWh0Rox0}^Z0(HM7zD5bcH>yJUwGKXH`=awBBx-JB? zb358B{N#6q*-+y3=O9*(+RZcKCr_1u4Ge`ze{rd6N!hme@oXC z>*6C=e#Sz3yU~$iJ>Z2D0wP=MbqxnOrs5IYD!5-aAP-bjz%SrY z{jH#%diRHZ+wkb*;(FVrPLuTuyK@=;Am_V>hUiZyXX}KxN8C~^R~1z@^y7)7Syl`+ zz>P%|Utv$?>aozOa5jOd%!A)F^{t4C1YB9ZL6Z#M`*1jlS5MBh&aX7;FOy5+9Xp|x zCAbC=YDDjZTZBG+6RM^+WR2?@#IsMJsgjBp@N`zDQz(GTj?T;EiuoyAhXhX&L2!9B zy}~+?^+EipzZL9J-~Sf%8{rdPh}uzjBwFe1$8!$4(#UXu!CmH@bMH~mkA39_zx#cW z*WxJv=zQu!U(4q4V)u2rFZOnC_O;WdIoPQ6|!!|SLJ00eO%DL_ni1soj;F0MA|dPpUE_jKaDuya+tvv#iPM)baaD9 zSv<+gF@*2HKUn{Af4Z)m2Cp6MDwEfacKyj~M`LYx#Ym_6!AQ=fvR5ZXZ#e&H3yCibWXIXb-=eds#Blk2%6W<$~qJXq-q*| zmW<2r{vfHWhYNnKXhk#&b>HT2b8hDgxGaaQsi+v>fMF`HzE4BFpvrD6S?A`jd@`-y zSGi_AAYyzc^SV}qH!G6vezKd4dLrUkwy!K(-y8FOaCVS(;eBQC`abm z9h|dhx(~b=?sf0lJ}`!ThpVG4+f4V+6JC1r^i1Z7u$u_G#<-= zxwhoc+!idPBhAzzmPI1j4ezALS4n~{A0w>bfLCH84UPPQ0gd^0p1*AH)}QHcA4<_u zc-W5{*w1m-Ci6OOOV6c`P?&aoKm_sr$UJ?^Nf;ZxuK2#EDdt?yDPcTzJa9%8p}l>u(1A zytRAZDe`SY*aC2r z{W}nUAG}&79@QNe;ychcfbNU<9c;(kw9@^R&NMimxNnHs@`M`jP3-s==>63f>63E4 zSzo=^+2!;lJ;<4QEr^-E=&CI!@Y zcdGuE#yGChm7M$(Po`5nx94YRmQF42gUGW{?`(eJ4DbxpLz{HoOk>J#2wI_HWRh-a zp5Cz2Q|*}LZC;-*7orme*!ulo$G-OAm;MF(V)pm({(+ml**Rc-f6MD{ErT}aIHfb0 zlWC4JEYZ_iXn!JIlwA$>aU^#5DfiqOWZxra+rTeLg2N7vr( z{vOr?4jRWizyU6hDx%!Q3nT3FDm?^uO6SRF4y&rez8PIdOltuhmsA}Q#t7Mn=11_@nrJA> zm|R997+P|`p?E!PLof?4Nb3NmwGs-23et%g)Ke;;h5GwmkD{e*Mf!0VnU%Oiho+Xy z2nIY##P_^3PK5S)d=!Ijg3|!TlIc`0#s82EG^anz#JnE!PQcc9uuMCRSO671WqQ?X zMdsZVrMw>W!IV;^s&tND6u=dvkMXE`oc5t}Y}+XZm)64pWt)Z!E(JmFa10G?sROUI<#I?$9ZwBs@A*Cp-s6mBsU`IO*U#MUTOmkxcswpm+->S;XK zT@M`slAdB1qhYET;js*J!XP29k(56UhMI)Q~|NoJbS z`-~K%2Hgjw^CNaCyG}^>)CI!PLHJ zk8YPXf|Wai<_!hncRfns+S*QD?(948yYBOw2QSM+3BSFsRo*V+CChbAPI^aW)@q9n?aRD0rM((#U+Szj;+a|va^47&mlMA8Y|oU|fg#-j02hT8z2>h*Mz zku4h}hKhu8%`k`GXJ;! z$QkZ7?Q+$<%a`1@JjttHh2pZ)oRe&AZYcG{IiDIt0Fly#rT?b#t%r4|n`xf}MVN2Q!Q5W1ivC7G^$xK7mF=joE&2&Ox7c!Ru*lvIe8J zZ`H(*fbYm*1c=GjMZv{P+*Y|~@aU)qf0FuxHnuKx>5q&-T4fZ&Vz}Gegc0a1bm7GqTbaz3;1BvUnLMU5@HVudP0$Ox0Y~@hy`pHn zWc`*%+9LhO*?MyKTZ$Lzp_{EJ5LB*;mW3vAXpgYuhh!`F&#t+KJKr- zlw2FQbe1MNl5!(B(yh^ z2`11o^&@rs3(2&e8917_p{^YmgrM6Y;K!Pz@AZJ)(UVAkfdqCV6`&Ug8ID*^EAolt zB#n7JO}krQeh$G~47esRlM48mP&8_z1-u^lVwA_KVqWLem}GjkY-vvqIa2Kb1UFfE zpCp1@g`R*~hj2JKNUpAl!dazJH}4OSLbCKTW7buIx?a4+{dmxOH`7WwFI035elkMK zNJ~M1h(Up-BASQhbOv8A3mCg3dw&wIzc&~XF!FJX4Z?zc9%~$1w299j{&IL)v&|Z6k~Y1bR(sryRCW%j`nVyLBwd~@IS9O5+ZU8( z-DG8P-NoQR4EMu%_+YXiWl!E=2E`G5~)3@=%$!EwBe!Dpr-^D`c9X9Ogo`1N z4hhB3rqj>TvK>Uc9<+4K69vjZa0(9@76R{Uw{n!H%DhX(LymKAETiL1h1cT{9`-S- zhKIOTRX`5MVa|tRoaISDq@6JySk|#=J+R{d!@%blr2)8z!NsYp1E{vpe||yIPoUT? z#pd~J-#0#vzdX#jJoHOH&EIbZ{bz>*_76x$t2kE6h6e*6c$`;f^a#3KbiG*Jx-G{C zWT=|9acOJ)cG>G8cuHGUE4sB|)opE>Ko$IeJ#kKd1THp($)DLOdp+f93G9UkDH*iB zFlZ0aF=!9bQ2=Y64Ip!cR|FK(dN?nYb@WfkT+`c??Xx2BEDMAU3tCHye4A)yYnUae7SMmL^BY$ z&^gQXjm@vnEMD|*eZ+UpMc)`LO(uDMPx(^Jy{x9}IZM)R@F6olU+duI@Imd|XYm2M z^s4wEBrk^#r}#t2umAkI&wsz659i0G3*iGcAhuM0CHPNS`{f`0*LUl9tRflV{#iKp zRF3y5Z?C`^#lt&bAE8?-Pq7cFcL#aQgIZDc;w)ZB+Cnr1{4w)m0 zJm?mKzcjx@?R>6smwj%NkQ?(4>*lx+71oV^m1k_U)$R>uX1R0e?yjq4MH;lz0;I-4 zf6ZM@?&AEQOx7;d6^vKp`-F1$uAk6oBh~{4CFJC;*)RUsPwdS85k?u_HhZd1urdV8 zU_EX!>?|WbXf2Zo^f1x^CMGeLf+Gh09fD+lSh!7*@a*{w+8%n;L4a2XGLZ*3 zr0dZQA%!WlZV>9nQWe4kl=ml1OGCmNAN0@x33Vc!LJkPxhPG>f>J`5N zV8D?x1kE9U*Tb*o5CH5s3>QV7O!j=BZ!)$KMV@5&w4m*!k?StfURN` zXO1o66TF(?kO7ffZfa9`;VU)wSF~2;yRPjBs*n-x^9sanvF~8n^xlH<IPXgnMDB?`qJa1p|C0Nt{1j9e~#- zZdKsObHnIHrHn(oPzc&fn>ql4_FgUy@#3z1Rs7G;iHE}Q(5~=X?|nPyMAB{QULxu2 z5YKNZe>BIRsab<`PVZS+1PV}k)F=1$z>Oiq077!A0fb8fERXR`SzsDGGVQO%&%Kgm zBEvqY{G48)$-Zs+&C_XHT?b+GN@|jBMNX!~+olS7g}p;qNDceQzLDPH+8OdfrBP5v zLy4dl81$#9rZ)2dik@IgyfJ`0!x@DsFuI4h!$GGey~I=Q#;b8-0JJoUc2#i*UMHO) zJZJ|$&C(o;Aq@kRjtnsf#AJZkIk+xi!nh*8uLk*`zTf%>A@1{lc?XXHsh!Bs7%T_Y z0=@^<30iUh`Wf#XDc=F1o1lNtr-Vl$+0ZG&+ty+b*qMlM9exYVQxIiEA2tRt zFUIx?qZkhwb6o)-#E)h4VKv;*bqU;q(;{t4;XIwDD^g{6*KeSr&S3K9{ z_<{$VX4;9bt^F$Qo!e09e-)Za%DOWc z@0sq*AdW`x**2nEfi`YqBlai%U9k`+g$cp)P#Rg72agF&vqkU{j zP(2FzulUG!%vha5z^HH!ulg!PSPBO--qmJ;g09qar~3`mBiJU1xLC%i)jt7yuQz{` z`p5r;W%SnE((pvKVP`MgofM6RBDiT+9XMTWDCy%tYYXpo@;99dVPuk-6q8)q)4~ke zD|Xu(B@pqA<@8eK5dUQOs0ZP^wf2AOI)QBzEK2pKbkhAG=B1RjPD*dSIsY!Vq%B$} zg1O7iZ~1h`d-wC<1K?jm#@2~+SuPBT<`PpZSLngk05UUIP~d0SOa=Ug{AI46*>x|m0B-1YnOe)T17Zhknge5WT& z=2X;x3z>ZMF-Uz|nbx>F#9jPhJd+uypPh3yWptKr;Mkyy)FK6ZYS4=z9|~#;EM!)G znN681%!D9X>;-$?06SwEGSCeE(6S&_Y)?mQ!&5$lQb~$JuPL3*>cM5_b%k(-P6j{P z-}-B`-vRKmjuwE5sBSWOnz8qwgkJF)he|y?rhEhsnhWoT*sJ+^^7St2yW^>J4Fci} zT3J_V$Dk#Nq*P-8q6WGDqB^fr+B3nEr|G@X+V9JL3Y(LT+$nQM#nfU3PSyVw>n(kM zFtzh4)#@sYpaX^nYVxIaUiMNU)xs@{$S6F|%W%AKZ@XyIJ|zv1ek`0=%DZ}cKFWMI zyn=1kA;&?~*`<+A+*J##2AqL24}U}G(g*=W8pBGyB;vO_5azbVdy)y9Yk-a<1Ud>c zd)E@SJT&*wJfTc38u(h&slAy@6!MZ0+C8|867fk>Yeu^)>_6=D6dL zaR&d6afk1lX>GcJh>B5K(?hUORB0)MP(1dP1R+d=OSfF?tSVf4(% z+Yy~bN-bEvyAEd$3m6&kdYD1SYZXbm8rCfc(rhZ=HTYT!%J{QDReZj{vxT&3 z8WxjLKC6}Q7t39OZ{xi)s>FGD$i<99bIS6_g*f>%Q>WzLaBglG;bVW;1>}pm2XNe= zSS~(UaIYQp<(7Ci(2pK#(LB7&CKrXt5wk(jB@65w_FL29rPitt3KR|Np31V!t0Gwg zelE(--TmXHdxMYxXt6+FrFAQg{25-5nr&>ss37xrZ{gdJBO|ru*!hE*C+~%ki#5_S z0T==1f-))Zb|o#01mDv(*~4((uJ>h4>RZZ{a5I5B3pm(CM}%fIkKtWdffgSeX87T~ zxXtFYHR}@05^I})1$?W-Q0W3+EB)R^2@N4znU%iL>UR*<9kLY5N;ye6VLA6;N z=%~62`RQ75GrgqI@xVUr&3krPlle>|_mB?bb_r__^L^6(ESGcS`=RAc{y=nu%NAb6 zus{4JadimOko$~=Mc}L1_c7)ry+TQm2YWRbzhAKg`wxK%Qk8xfkY*yvY1x;+3iWm= zhTNZ}A21vX4IV_@J#5xvHV&sP;9T6WU1F}!5AE3wb*{tsxB`27aGawzP;dfAF`?Zu zojLz`@L!2|XVRIx`gvUd{+ICLPuCkfO6!usdUGucT!3y7_+{L5h?K7kO>4PzDMQ6W zj*aE*byOiR!i|j7AlE%2>C^Vk0HEHJAXEKywa4;xb_a$fa5(@6Mk6r@<>tt`@^ZLE z^0zbEy!pHY0+*7reSc~XzxLM8->t(iT;E;H`g;T&JK_m}zPr>$6!?exjG7b4R1TqO zOZl|?eTCgqjK)y-YK&<&ri7XID7x`#T!*go4P6w{#;z(B1GvYKAIh4KwSRru)Rk}3$yU|eU!TECWzO@9! zu0(R`H~Kdg->YoG0z~hpK~L@6R0d&HqFLfWiG&rOR3ENn1)%YUoxAbOh{{1RRTeN=B{BnLKTR#QoO7-C%CwCEwcAMxT z;mE(?Jaw4CN3JK!XG4({f&3hpEGqi@7jPU)EvybN_c`;8@nv9jZG(&6?IUanI>46? zG?^YKgQf|Jpeugz*(TMdS{a@hyiENL^xyuyyF2g@lu@HIJ-W#>uSZ7~`_?)dX^zj{HJFu+?fpBiydGti+mFQRe+y6E2rH_Z_;vnB%#y_Gz)Vq7rJq{~& zPp4F?5b7)5hV3(uOVj7+s+PO3zQr`JZ_$k4>_10`94{OG9v-yz;Vx4J8_^-yk8zM! zw^VoDQV|ofXVLz?#UaQzfj$MK!}2*qQ~5b5BZTXy+3V0)r~<|n$CY{3qB7e)#y#BPppRJGhOJld;KF}!SY03ky|%jiN2K z_lJOBJ8T{X4pxtLMqs7E<2FVMmy#yUl0HdxuSYs7$vprtn;DK4qd@^Dd+E!#*@HeK zTO4;ac=h1erL!h1A8M8RbAROPN5Guf#As4NG4hN{9* zGSm~*F6JR_0dBNzayif#COLZUK~{#Chd&^c77l8-8s!;77m`%XsI7Zikm+fI7|8an z`;UCrZ$JL|@A{G7`X{+_hU}kIS2sZngNDisn(8W9FmABtfM?2gJxJ{r{`KGe&e{&{ z=oau@OYD$et(E2cleI6Dv^jh}ZH|dYz&DtYHPO1@Y^E2AHnyCn?~JKBg)6}G@eQXn z|J;8g{8Zoiw*&sDKK8GLIP;K30M1+ZnWF_bO9Vj_f!=my6MVcs1G4J6O!4TIpnvt= zPyPIxf=36$->i4k3#qgd@^N$GbQ0b*;5`K2u0NfzMUc4Z3^3`I8RiBfBS zp0Ccmw3tqn^ML*mTGlc+OiuD7o*AjhC&gBCXyS5A5@f{qdPfRr+E1} zeOH?2(SQFJzoWL3?8bP~YR+$BjhgFw6s`?LvIaZ=U-;6!z!zdHY$KBTe7aw|zQWW-ZD%Np z=@xzv^>KeL_G0iStukrf#^=^q4$jvin(~2vKTAIaBLIJ1aR<5Y2A=d1Qi@bO>LobK zARmgo5FeQFbA0!!|K#pYR^x*EpY&n{{T$abRWt@3LqEsTL_fz|*5@abIQB8?yJk&4RF!OO+Evet;&`S6c zQfv*Ov$Lu--k@xG24>Z>riTQc!>*}4*ID`|*dNTJS7~DtOGy?Dw+iz%R)#^0tf?~W z6Lrskb)xPWGU>n(h%fcF9M>^r4Z_|SF2^L5OO%_-JbljLd%ABtOzp%zc;~mU?y{#Z zS$D+DWpeNJT)j)8;6tR|#dJMs;6-Fx8s54fUmx;Cs}b6i)YUp`KU~uO)k@CEw{a53 z$w?$C44PFGgS-hm-#Imd7eSBvgYWq}I8P<1j~L$6IXzxxKdOAigIa0sd@gBo^C7 zhj<^zP)^<;z2^LLdXJsHf2?qJ`4Y5xguf)x+GRC^c3ll#m<|^OlUH2HDIUKb@OZ8N z>$um$G(qVx?f{4R10JJFyn`L_4KsdF{SC$6ozKqSH%r<={AE4L-|nWbG2~d_d^@GpOU$2{vRM#2Zo$_pgP z9y!u5j&SnG(fq!z{MpL#0>v-YiAGN;x7QIv%q~68?k9$ibdF}HGWe_riadM*v=QDj z6!8er6iQOKp31x|My;uMq@QNL;JGuX=4sVRFW@H)`V*h1cM)5eSl8VjN1+q%t{LKML1=< ze!yqv(-91MRC;5_+yI6@iX@v8U3>76Fw_RynK+DA6y+6_@GZb6fl@f%IFSN$Cqi{} ziyXovNyBgBIx>{K1)tBDD|t-M>w!T$HafRX0b}2TCOi9pw~-=%NP_fqhb~LFhiko~ zW4&{M>5bQuejn`NB~QtV_w+Ob|J}WVcvln|aDmx~nqZ;Kh$i5mCAKf{{s2A!xMCqayWCu!o!t$ zaHi`4bJPMAIjHT6l7G3p?g4$*&g;2VE{i{A$nD^pK=tTEc|-^<&R#f(X)4r@OzHobp~y-5;}N|JgK+B;`mT@8#HM zGmNY*I3H@c8N1AdFW@|M%RcZm&4T#BL~E02qMe43B23n3P_ArLfiKGnpOt|J+rm6S zl>wG;W-3JU8;ImEaxR)wJ^|dPE-Mpp8%(LCWRS3xWfQ46AYw3wF)|k)ur2-!s;mds zcWo<@iz>avXS{%XjJ$K9p11vo81t=}z4>KUXlEHB9#o&QIWq4Jz zH(JWojfzRvX)GALEN$RHOg%WP2oTx{NY?ugR4#JAg%=j^;uBC@e#+mUxxTGA*y**j zg8sPE&#wc^bo0j`a6!8ODSiL7z-OWtk)gH~_$g8iO*3z`|37x9kCIa&!+>B8LXkdVWhWxV>2^yJ9 zzX+r9dn6S_c16aKpgj?37Eg?VWv=f1vAC%$N#8$mYzOP?T1T-)c&nDX-!sSshNu6P z&S(EfuYvXoInxSzSFT&m*GdEE&7 z4ozUDKOSWM$a?J?*f%*$gz%NY{UrYH+)%p{vM10tWxIoTlV>66fZ8!=Xq|LcE4B;Y zi1X6G(P1-p(cv=}1dLiNE$$Y!*-i36v)5%AjCA=J!LOTe3*Z|Fz5?Kvz-ajAh^KRO z741%j7jgL9t*pStM0{N`>0G?cq#wadniOJiy@%T^@&!D8j$k(nG4}V&{=iqNw_1lD zUs%P7?|h0L&uAP#+Ihh-Snfm1 zqO5N{D(pI2IENIA7i<$-zO?TPKW5|nbHMnWNWIhteT!uy`(FDL^jy*25JflWKkZTB zOYMu0Ea834&20S$XU0|?!6|q(>-1c(P)?lVjjejf(b>hVh8TG8;Q&n1Oy``_Q7R0= zET+N`N#qQV*oDwMUl5a&-@U5oadP-G&P6_t9woi|ne|`(gmBquGqU6WT)teq;_yjbs(v9n^f=KUAAj`6zf`@|fk|f}u!;NR(}GK%?Ni~G zV?^GqvN8CFb2_zL2JsSVhXlEDC5VBJ_y8KhW%*T4Pt;?>#NfU$KL@A#uE@5!vMF|6!kI zBQ>mYus?<`p?Z>x*P0S(G+MB0e*PNY48urCzly%VAHmx^J;Nsj2M4{%(kh}>3iOyv zw)LwJC%Cf1(0(8OUXjmm`1tcWnWzUm^JoA1`YnVd%2B(3C(tLtPu8=!4k8OYb1>g& zX^;L|TnKf{Zu(5g;H92!t)}E^)Fj^)r6h3O?Y}V z7Jls+^hZMchKvz&8!&p!QaMUU_Ub8qm`Fhs?He~@t9=mf!@iTOh~Vt)!C{!ju-7|u zB9WhBpZSyg4}@qNZG}X#p80~=ZkNxCa9*ko8N0QDb{sVfDm}sVq<2J<$RYcDGHKsN zSCNW#Y_>6R&T!E{oH^4u4quj-L?-JJkRTId>?FN`T@cMS?#{7C^F}>bx%&6r%c54& zqIKgjA>N-ye^^v}m07sNj-D&qgH5!*#rz)J;pJ?!gQ<&8s}iS$bMc13(k$L%Q5q>i zNJk?K!<+OETp&zQ6YOC4#8F6_J^2GyvG}$M^1xA`5XvZVtVr^xzLl(3Oz~2dl55-vL6hwbG z68Os6hxpwlhB=6|$>QT|BUEzz0FPJ?S{GTB1JX38H<$1O`)m*DE`grEBnO&}P16rh zCMJiGqN88%=V2HJ(OXQ@Uvv3IxRx=&cY!;1+;{TXmohJwi;+n$q^GgwH zXntVj!lj|M=fGiTtM7pE30?}vjzFp zKywSB6BX^im5ggBSC&y*M+D*@;RI7{@6bXeMDGxshc}v~1w>~ zYoC?Rxuwrirx1 z_7I^Ejae)Gz8!S?y$(=~A!a%jC|ZLXEcT@A=eOMk`xbSGb7uBpIWEy~-saWmMC@x< z{KvLkj5y}2YcK~eQ4sd1(}~!33k)R4UABmQ8|_#@R9bWsfrUj6WXR~_ikpbn6iVDS zJd$p%7VSX81$aX!WMOGhLCWwccv5j?7{(-b^++Zi2_QT<{P%J%TRY%`(>!VZ-eG;rlw#ZvK3^f(%zB{FUF-#vqL=~ zUcfg|%w)6!Z}K}5MQBQJ_TsU1VWjfV_ zWpGNjeGDw;z{k0NpWe1qS9$SuaDe)sN@- z)r!Z-Iyte5IM2hT5XsOe!IAFd1=U16v>{J#C)b(edT?T$aK}0Av;;zH>Bt^`PRCm4 zyk_Rs(?YNH$A6aeIkdCG%WmRBP4u(--lL`Y>ihF6(ePRR=LmpB?0ZI5ywY%Uma$J$ z_gv@bHw`Xsz3=k%qdL^k7)r{1(|q@Jo#|%aTImEd*>4PiOl`6U0-a*+L z{T-BN5htNvd?c=})d8zjkr<4@$U6A-)3bFv&T|M|`8Z4h`z#-ARb%ME_U!m9;5 z&}H(ys=x|gQ;dW$e4OEqlz9RW#tBn(sAPzGQnJ|)X~Xnhq6?iHxt+T!nyv{(KFk%U z97cfiY;Y(oD_(l^v!vV0zFehr){p(QLBAuI1i{@B=pxBS33nd4nQ&JG+?aB{GThxw z{(fhF@Kf7>I~banrwg-JF$6WD_d4Zw2C8wbk3baD!|K3;E1uyw$34gS@pWD`N|)>G z8qHj1MSMCFosrl1UR5tb8v6ae{ovoK-fqJ7O>z-$&ptnq4xMg^aPFwx!S&_PFfQEb zb*}+V5RULXkwU$^M-}CMM6u27c6S@MO@yh?3C1G$bVc;JT)0!q@rfYJ$29MUCGn`^nbE`yNRo)j3yHN07OnE`lp=Jb*Ex{TB5W*K80SeknFHZoQCs0Zc* zyc)ma_x9nnI%}TuYWAx6d>hWQ4(AT|0{r&4bi=g|JZiaXmsNO#lb8&b@}wd%WnYL7 zRrU70d@uj_)3_fX6cX%twu5i}0y>NLg16?yb130iWh3xB*e~KoerGIxv`6)AA+E>- z`5yg_@&HO&7Xb=S`R-sZE^F?a{T$~k<_mB{JvaD>5*KL+oFfwK)6Q3Me&+k+SO1CM zBfNCz02gtuga83Im{!CogM)Jxy4f%J)YJ~TQAH3$oJa2kUVxU6%KW-;3Oyva!S}|( z4INCND{LN`OPhg}sAm1eM5pU-*53CVVF7C?{uj&->ErY=a>i1OjiS z@<)F~@n)h69UoR!AmJ3=p`siesAH~~bZT*Rg%^bL`JcXhFWVh_?Qi`G;Ja5iyaU{6 zLk-vojI%okWBYev|H<#58Q=rt;e*g6oWnQ>^|3Vu+JB)P!i~&fA@hxJrTsTWJWv=i z)2`ln;K;T&hEAY)sRBb{mTfM~k-O6BFaDUtLBW9G(_=7kw8`uu70wH>DZ=t0#rKSM zQuXpxqyzt})8Gflg4Qx>%W3HppLk%|Bx5KlL)j{w8|xY!r_}d(k)Mot?aAy<8}s9WC(rGPYgrq-@Y{HgV2L+W zqt-nK^t@p@@5#=p4e6`8zt=l3+<>i#0N~al)EZ&c<;`Pdy-nya zM#@G-{x!i+pTScO!6xWA6@l4NGy)GmmSV-T@kw7v1i`tn`%U)4KAiXYBRtbzkLx5s z?FoK`b!Dd9bJ6t)7yY1LfZ2xlfb`#Es)lL@vjoK{Q(1&x)Fpd{Ym#d{t-_ZZIoFu` zQzkUiy>C4geJgx(&+yIh0Sw9MDEPTWA7vmep zYh(TL2{=cNR*TMgR^=5W4u3Ce`=!CX~}7>ZLluZ}F$%sATWtBb|AV zV1$>3+XPBD7GC7qmmlNlAD^G@K5`25yrPd=C#?~E<1-E=@0%Ql1CHpmZ}#fs1KGCW zzCqIkpUW?dfG1oR@81};-&NVjy%iua*v=5uZ2LhBD2CMP+IV=M?4dt{c!2Olc!pMM zKoJB@;X}{fU>*K25;1YDl>99RN*iT@$-M^1$9M$ydS>2X{w&xR1n+XA5w>LHE$l)* z>S1$S75dQDWb`lPLF4sg#UG*0sE)Hxn#qHYxw6BK8F-y(5wdq z`Z)e%D=`8s9^?We8OxFc<#}qN9iu4$)A>=pdkuZwY7JP-@II$Ouz}|dolo!z2e*!n zpa(~IHFD$R@@E`*hVR?=c>K?juKCKp@J97E#7n$Q*d-$1yWgKg*PQXYs!rGd98!{% zK1C>#xz4twY}Ii-L(I;#KF@b9+dCJMTRnV|*7?o1KcjUH9L5K64nHzkA~>FQ5ZgJ7 zn1E*NNq&}=MzI5}>;B zG9PkQz;mOuo%E{7Lc`PwxP6MVX(*rIU-2ruK!O2`t~r{!((u1?(j1{jxrSVStRwwC zx_?*reOz)AHS&Y~c8DZYRnOW9DbCi-xivUxHynD?R`cYfCs163wpa36~$g^coX{bFI-=P zFLYISl3kAX3`^R1%RT`P>HW;v+@2JS;Y!rlNOCn?=;1k!&27M1MmUlgm{8X{+xbI? zES#R9II_LH7=LuAAsc&xZoCe)I=elwuXOZZZbZgL(*koiW{YhQZm)IQ8ju=?H}RD7z!1Z*eVOuE4k)-JM{wD_ zbuT3&#?`Qb@OVlK%X2RB#x0PZGi_r`IWL(`{-GrI{`fB~eNerP5Jj+FiEW?7>w_iv5rQLAj+JrG@-OfNm)%?&!swHA!SU=$YnH+*fE<0I^FA3wu=%VQz%%^d?k zOR^3jEJztVhns2b#u%w~2P9nB_-y4&^H_H0(xo$h;+K=Y>KO-_;q37TL2rEg$%Cf` zXAqVkOo2FNMsG}p3#{`UofR_tfA5YK6`d){1cy+=&;q`=pWu&i^`WR*)+40gI~$OX zB&Wl?og3DI=EQNfm$Nb$o2R-u650r3V60+(plP@rDau$h)_^>Ii@%~al7{@%HB@(N zHS4NgkGH)w93$2W@o-Vi4-IQ4W%zw>V2@@)M>S5qmqa`5!?Zh4A^MM`)tu#UbDx=v z7R(D}wBvo>ftL7|@dTNKj|zSdZcSk0;D^q(3#g=wV#islk>uUIJZ&iDOtJw>mUB8# zVnc2bl|+B|DuQwNM+3`!6MRukQ|5BDjoDc9;ar&~Awb z*SZLqg-{j;>E0B|F^y-2?br~mQfSB~lp?rYKC&J&JCIX<0K9<8RD-p3>ca&q$GZdP zAxcYa&cVszSxFRLA^BRg4-kJ5evv8pb-|6G%?R zlTSdG!kjco3GDoYoE&m`Dy?DuwvGDi!3|9VdfC=8z;7E1?HR=7)8KU*%Vqt` zIg*@q<{zc=csPH?v8VI-PBq{6{)-3yPW2A%CWSa4=)ivF-w({ z!LMER+$nZtWD~m92$LSfiOEU=n`!r5hMQ`kH}Z%7OTZ2E(Mo77eTO| z8lNHcChxaf>3sgeR&}F#2RfJmazxap?l;%b4tR$SN)<|=BX}C)(hfM|zUm`jBl

ha5@yZYo4A;b;)66}S17@``_WJT)SX{{ z{ws+d9It;U`hghV3I{!3DORQDsEy7a}CDPa@ zn?~)_N#~XJvODz!mhiMN_6Yu)Uy$-BQcLNPbYD<%P*cy9+OypZdq=*Gjl=JtN(h8; z0n3655L(F&NK2=eP#Da5b^!Wf5QK>FVP8mMyqv`zj`>%o9TFr#$hC~YVtGmmipN>@ z9PO}LSUxpj(UiJ`z+a7nE|jxd4e^$`_5B07j$+@L)=O6tU(o9O=laOUn6P1fX&$zif;0*xR*mVxWcIHrz(nj&xJDG;gGrB% zw6Gk`nc#3<=g-1&_-I;QGv(#z56(!qM^p<;x;Y<{jBJRtM6cpyqAZt-RF;>`t$nlu z*Nw}ICKy4=Jx5m7=HO6D16^D}lQz1gx#fs7wgjj6Yx+*KGkXnc)!7c!jj>P`wpep( zEAF9T738%$kAjm&IIhI;9{4lG>$!8w{J7rX4$|iO>~3Rc*YP6skP>Dvj4&Pk)%m(p zH$Qp!ziD^_FB`TvsLk>#+Q;d`R%F-3=;w5wyCSvHy&K4r`-JfBAeA8xpfCs&Hlb5a zQE_gjcnY(dpL`K?9lSw|BLY@>N4oaF`4yyLt!4opnf+ znh46k^1w@z^k>mO8XD3E2v*qSBV0pR#V4Uidd%3}Do^L;RLkvfSKI4Bb}xY2syFw% zlR{nfN1)b`U82blDW=N zuh#mo(b~}+Sa3cSB)%GzvVQ&7hwcML=fJ_b6aI)61s8ZaT9|b1F_YvT6G2Zo;&jfv zUA@8SoTa?#FaPLwR^P5|z=Lj3Il?Du@_cmgU~jngz&{|fpHV%7fTy%T11b3EJqq~H z!wxD!JC5m%#xvi9uphlQb%+2fD^NYb@;R5q-dG5hOkYIMDtV@v|xNLGHdMj$Mxwlmt6=hZ)G{y@BY!xRNsc* z5_7FF2$zLFlW~4ks`H|gN;&FVEE`A11JI`Tqw+{j)amM@JDcOVp7bZhbKO<{2jP-% z26#*(GkCPDQ$vgst6!=l6lksS>jr&*JD(lmS~~x!LGYhEk-$0xjR@4bHFuPPGWa9{ z#x{Vx%y4+x*tTIWIv6J@_!IDVE+huto1NMWIV6Z$h_Fcuuo}fx;Iwb}^L%c9{*C|{ z$M$cn{i#1!efxMP*@y~%`Fg#~a~mjf7lb^K8o>k%azt_iA;_GA*~zutW9aL$n%NZZ zs$WI=5K)R`Ns_uU`2@T><=kAFYUjdx?jQZ`4dYwfg~`AXsI1lwLb7pQ1rG!M zA_PCcA3R}Q&QstyE1MQBFU{P)%z>P19ev;4eJk6^{^URQM)fWfRT=Cq?)NX&`@a=b zQo(;x*(vLJ(r@THW6v3T1SbL9{7^sWLRBc-cfF=p3c%sI3m>8k`)j4L1o5qeqi`lX zzh=q@^eeo8L&3+YJ}N2gYHz;1 zG{Tou*$7;)|Czr%*{}ZacWfF&mo#9JL{I^->~cpuR90+D6z^L!RHlqS(AbLrz-)(o z!2IbkEV2Z5R=2)qbW0=IacT5AmJ|}wy{0iTOb7nY#Hu)GFy;$;WGS6vKK;|qzYXt_ z{vGn;$?50(QyvKiNdn+`h*#Xc3E~&TX_VxhNsnR;HYe2AbVWl5w}p8%f>A@Rzs`^X^>lERhCy* zZNI^(EnGV-M>_-q7R_60OfFb^7@^zoGB~%ljiF+&>iF6+eB#d9F6{TwO@WYuM3O7s zeRNCb>s{ZM*Kgf?N>AXnKl}ah`{t4Y*0*R_3GZTY0JjuJI~e%lPgry=;FMj|`f}~> z-Z%Taw7#8slM!hkMAo{WiidSCDCn(u;Nj`@&!+6|)v7jvzc75j!3(x=?A|l1KM)9K z_3o3;X`ONZTK}P~52|;&wZp=V$uxW~bMiQ>|3}A=NqS}HdMnTotvx*;8Xr`8rrThEcCw4vnem?%E z-n;|&fe?2(y*w$>nHF4$KknR^AYVqu&#ed74?Q@Dj?llc@TN!36HuCbB_r0l$*#@^ zCl-~pMV4vQ@~2?ZBR-RH>2oEJdQ;EunAN>JMZ8sv*LSw_Zh>&Aa|K5q;+Ke&V$$g> z_$32f1t;u7c;f{#RKRQY+duP#|7`tkx1F6fu{~{&0sg{uFoF`#9s5QOZh_lCc^RLd z-<_}Cc9(m_V=?zxKDzGQtAgjE?d*^;JD7Yr*8eT^9NhnHIcBzr{y_xlLt+(S-ecaK!aI)idEc2^Oiq_Gf5ghh-h?X- z{iZk^);6|a+-}!hxba5-Q+q{ativB5wAS)Z5nLG_wNpdW!m!$TNhZbI0b`gx>ml}? z-JGoz*tc{jK=qFyjgP1~OA0^N4k$L;aBK~`8CZz1&So8kpwW&M&|eTTkjpf^Rty6#`Ep^0rWiBT|{ZCHNBnP z)E_Jk#~|g1U0ov_iG@ta;@-AT4*FsL-V}AGr6{Lq=?F|$^Kc3auRX3h%t z8UHrgac&BfRxr72w1JZz^Wz7!0Kre^_C|svB1Hp`Xva!?xXk4C+R@Kw$JNSEt7+nU zq@tY`%)_K8kFu62_b}BUa9a16!Jxf^o{Odv9IB2phxmSu`K#t;%jP!47E(F7Z5CP4 zpD498O1V~yDfLMM9vN!xPfRrW!ud__J>y_fu2~E@*J*9#`AJoad4hYDTzOz_kcp|G zT5~JWVcrabH5WNUJX_!PAo``GlQeFbh{bmU?6 zFyGOvlC7?6?^}Las1n?~M{E0Oz2My5z+}JPaTb3dgq5_i9C^Gnx0cfYjHLxb_G)w$9tQCAwv7ee5D93?brz+1Ihz!2h zi2cPh@HEH8B%KXf{g`JI9suL00uT%gMf}s2NjW&hw~=C5+CrSRxX})bNoqaxAg0N3 zK4;K@Yo)FdSXR<4|_3puO$(`mXi_fsB&Y2 z2c9RjIW%}c+$`|1%^blG2r4Q;Pf^Ke2Tx;;Q4>BPyr%0c0!*O>rBMr@aUw;#IHr(} zcGRd9Ssy?L7~UgAfIUIFAf|f}H&2=$&H)a}ri*)(!DqZGj97KD9UMb7lVv^b zsm)^>Dl^faHn4^|atI9rZfR!TxOP~FS1EjM7Vo0j8bh6GU|enAML2T-&rUFMv~iDN z+vcx1`$HPe$M-?!lUp4uW0-}ykN$|AIGQoNzFqt+`c~{wzd0YZVy$nKden{B&hooU4E@tuHVnx|_uy ziKqi&J22^%Ez!;*I_hx;VCsU`^hc(p;A&ojWRmd!71qFq)L5;N`lI3UE35#ia_r>s7z64b$V3=zon1m&%)+-j2r* z06IHBT*-sk_V%oSEy>x2$+zBW?}3aHBJ8q)z2EPHo|@|YN&R?Tela_WyHArJyP28) z5cf6QpZ%6S;9rdJ;qfJg`3A-(72p^AF7ipo#8)=BGd{$N^!>*32L|HffP*R&#Q!$~ z@3f11KfeWhf`}`KG3jw*l)(!^hmfTU4)JHJ4Zo<|hf+dEg`*?p8Z9>N-mg`V^8?vv z2R;=B$|I1CI@xYLuX%_a=J_ephh?r=e}*@soogs!{2JlnX8Sn~N}Y%8mZS1+eGepu zCII2mVc1!3iauAS<@8d-nL-74PSA+F|8^X7W*arWfV0xrB?J8G%f7cb*Ta0|;e4zI z&n3j6ae37|P9qmL;sjcX@H04WLi)Kf2Of)^8#tjB)43$sXaz-n7*ybo(&e!ff-y`T zz;0y@JVCw9&@?=2e0fe=pTviGC;Rta|Kaa@T73ubEzL0SJopQK;3U697_U4NIrA^` zVc@NZjK5*nh<^*Twqf*)YNgvRbLfYMWz2UGwEx^5T-#^e(`zFRH)9DMm_*WX20vLSfH>%(%8 zF75l}$iVEOlAnV<{Ss&|y;nST9|l$~e+3IlM-m+$?jzxL^t5T|tlfU! zsC5Qm(=&})DfhU|{;)2_$x2yoUAd&6{)~0l)0j5hMp7MPs30qaUv>h*Zs-S(?$hD% zUxob6NqvI9c+ETS8?KqcWLyp^%P@GiTR~+t-3ylH!7%sB1q=xjUN^NE5c!L)7_;W_ z=@($0Z?_hl7WtH#fNHvrGf?~|U)`Sh0! z-v3qc+n?27en0&Es{oc$k1^yoe1UXG22w2e;6hJ3k4aDF-Kxd6P3wD|fr&wkg4yD9 zg8F&Bb)I^NSF$44^^CuKo)-2q-}|edslE%QU))nl`tAkyHWTOyu_U{$6Uci_b>Z!~ zg|}QwnHRhp=ABh0UT=Be0XmlU+V4emC%@=NLuOxmucR036g&O?cNYvgdIzqXJ9C%E zAO;>Ifk^F^2S3hapo&1OAAzNAcr)T>(8?ZG z#|La)w={nZpB%UivJ1FTs-xDGXeX^k>Y-gC{iMcwu)U6F;H^pTmCZG}V)8~iILc8N z7r|$UdZlY%vwqmt$BU~eXg{&h0VMK0g3fRzRW3l%}Lk#K;jAYX@Yx-Biv9*RN#t?C1SAhU|iku9#Z`5g@{V z_eDq4#NNSn#MLnZmcqN8aWQeglK}Ab?_XO$EE^HA3n0!#5G>Ep<&UTYCjG{Vqkx{t zZ1zX#+@T51=lfmbAHEA|NO?o_`{8MRYb!(TPRPRkzYguYg5aM}@pUm~;3DV3z3LO9 z|5@m*eeDOjPpkK^s!a-oRhsVo{YmyI?>$tRG>>d#&VwiUAA{b7y6)9SC(*@SetfU5*=~xiP3+6mzlrz zPyZOd3wx#czq@`97RP(-qxyD%H>hXzmTm_KPe-P4clP@$ovm4D+x=jiJJ|o= z8{UM&Nm2(TT&QduT!{Z-_-L{n)6?BXXX~^05~vnR(~aIk{0_UWqz>Wx=r+HN|G;wz zy3q1X836E*qFrKhZdcnv!xK-)w_8ir*o_!~f z7fYfa=4){mVXtc9x}R~qE>-n!_IDFs=8OZ&aC`rU1ff7*pZb~aII7;OZ^N$<2-X5_ zxzdx)JA+sFd>fWu(Kp-}`PGa1>G0HyE>Jnpf#Rs%Y9cd=7hlxgWq;;;4Gk0PKsylU z!>z$-CY7Q`SN;(2 z#$j?rPt*Z8!KA(*ena33ho?FE5419KzAw5clA~~Jubq`15`FD5VY{sR=lf&`=w#A3 zlscsGHz9+thy7K922VJ---MRD>2tzU8{;>z4u6H){;lIyE$YK~j!BW~^pvj?7T-)2 z`2Foh_74Sk6(FnJ8#O||nCPO%JY2)u392W3KSl1<%4|lH?d=18R$XAHy0u1!17?|h z^Z-|otUspB0UalEAEe!djfu!yK?kV975KyTC7nMrll_JWgyL$NrBOs=}<0wU|AKb4Cr#>Sw^Q^j~4OHiY7oh)!K++p&{GX4LX z@B+!8n_OXvPi2)qVYw1t``#_Hhq+gP+x2#bnxf=wowC0lSIrKlq+eAwk$xT4Z-OWe znum;BZMF@=&tqJ}^(Kt#bunh(Liqkcirf6PzwkFUgzurbn8GKVhVM;~T*3qHxubHk z*XwkK893K^x*wf;Pt5=Gy+&)Z{n_rmycQMo-6VQ{y6)i|WV_;5URUEmcQGIgrSj9Y zbG2%nYdvw+aF*`f&2)R~H*Z(9t|h-%^-fN*e$ikYHM_^%zU^Wv#z)fRBf45DTe7rB z=i!w>ef@I#)9Ej%pJ1Fr-&u;T)~?ZM03i`#1f_r? zHrOCTPeXwnP$;F64;v{e^fiHPkY4=mPHkU(i1D$E4t({dYByW;mTRpmpBwh9(RzFl zJ;?1CHRr{NbhCVlIKeEv5Rqqst>ZmoJH7z&_v`$a;WfFedCuW4{sMo$m*hsn`Iu+Y zVUQSwemZ!(rfC8_5z$>0sEJ5CQ~{|bqKtl2;7Em24yJI-GlWO-Wpv7%=6m#m6nA*$ zH$VAq?#DWXeuW$XO@Xg+M0$#bDUhaO2iQJ*KVs7tdV?w(M?YCR@JZJhRlAD#FNvD6 z@jwq)Q91QJ09L?a{W<1ML$s?!>$xD$|85Q5hp=N2q7$02Y(Rr>FhwTqJ6TJl3dZhx z-Z%t%P*0v8Bgxm4(5AAK_BfS?GXv%j#Ux<$^y5gl3Tf*V?kh9~pZd4D~(VD{h-#2<(S8 z3@W+@pM|hQiKH*1CBGp3(Fe$(;n#AGp>-I@UWnd!nB^Tazxq?__h2Gbh`mm^AKs@9 zGz*s9D-*L~%3_ZhSIdO~H z$-_5OW^4=&4Y@hqbN2hH{wBw-Fun}v0XI{tK&4X{t^y+hrw2UJZ3QZxW@AR5a8&V3 z@G!-^W;)R3S+++^7}x&Zqsoo>MEz{NkIwOm8B~ru0R{xxPo&Fv{G;c zH|4}-c>a9C`)~hq-}R;HJp^h+U_MfKwm$?wCnrzqG?cOjyx19C3-9*A>m?sZWn_|$O?Z8Ut+9CROv8198?r^tspI-KE{q(f z_5i30u+x!^cH%;a*~qoja=x54(_A^q50x%-DB8K!DmtpOLwU4hikFs)J|4o9o0F`( zR&?BaT=p`~ozcNrk8n6|^Bel#i_VruoIgYI6-3grje|JVW_AYSgfVtn6Xr7QkNXek z1=He<%*_4y_4_cMgzf+4EWm|#KjQn0mxsC6+9x;WmY_MT3#i%a@S6~)yGls$nD#m< zpG+T3qN9h)MTFryaW5>#$+_cx+B@Faf?U-!(&)sZ-t5-uaF5x89mp^eqHwTe&KijjAKpusrT=goEC5huU`9&BSB}# zXA%D~+a>GC8Nc(o`j{EG$i3=*HPMSRU-(OZ5BQ_AQ3}?9Kk&tq{&1XmqJsO?wQ2Q< z`%s@kyMy$V?{hu!h*egtkUz5yf7b?{=uR_G5|7*)~U5LfceSvW&?g`)24qat0zi8+}RCr0NGxuv1c;|CYui=2Uz$KKs#o@gkqz&GGB5` zwHFm-`sr4R3-Q&JnIEg($87gTxB$m?g*&A^4uuUqMUIP;egzwFCM)jq!fyg%|dW?SM!hPQUV#4E*8So*m~^5iuM1 zx1-PvtmAlvH4%|Q4{el1QpYsvMkEJR?x5}nzGQn>?T2VmNpG2R$sh1E^raSHi7hsq zVluc}5T)JD3$naLxBgz7Uj(;9+&ctZw^mM0Jl+9H-2Vbnl~l`(%b_jh8d%hsb%S*# zS0wk~dWiK0@7FL76W3%7&PymM^kaAu-cNFl`w#5gy&v#@9sW7trz{-k1BkTjSC?Fgs*-as|tK;Y56^eM3_ zbC%~?oJ&P5khP=yqk)F6NakF4!`Jct({#^z`<;L0OIUAMx}SwFu2ZJO8{mtNwFBg0 zOv@KP>CETeT&)+nX?IO_9T zgt>#=V;F6OsDLl;?=r@=NPE2uVrt8>JY=s3$c-K5IC;<5ijxa79xCh-fBY|gUT`^T z&ogjeA0H=nL~euo{}}yUTke7O&T;=o95t9#)WKoinw9!!r^mw=zjDa@7VzB$#O=Ie z5U4ibrq7d`bh*2y{@_p2_NxQtop~Uz+lDV(*Rb2G?ZC~kHN*|E=VDBzqa8R6OdH1L z(IrB9Aq=G)@uG<+iTx4nkzb7JzJ1v1wi%|hH6Aq#M-)5J4u@jAjQtK=3&RJr zB(I3pbliqY*eqOz+U|l=_fT8x(80TRJKE{iWAkAa5%QkV#-p)r?=YqX?r#xq)26`E z_VJ{r)o8;{Gz@3Tb-HY6&Y9VL{G+6YHJm@=n2Y^d#DDnCuYzBPRRk-lkgpc^-m&r{ z6AF!-ClC~kJx@sWhMvG^d*_l90ca7JKsRIdT$x&Ps}6}zz?*=wwzpSQ+=Kh+vZ_^q zd_q3yCIF1Gb9+PT)M(Z72XU)!%Yn{dj*$%KdXI{ov5?_!hN)7xwrDVKjoJ1BvJ zSJRBb`v|#U^%ychfCE|LRy|c1Xq6eZ!##>msXD^uaM84=S{?T36{kaXE+Rkl`MF>C z$(s53pCvwW-o2m4syA@nkE0)M&xxS|`qnQXbMtSdvL#E4wK9x1Q6Fy%wEseSqL4e( zy7gI)>wa=lha+v!x(5To2Mj^?CBz%hsR;lUP@oeH=k%~Y>;mbGdXq{YAtk_hOfUO_ zn9W2lH}_RRFvY_gXQhSM*lNI|RC<{{61H`8Yujx%YiOMkZ+?qELUR-PA$(t-K;Mdw zbF1annDbTPd(2uZqI)FnQDBdDPdKTlF4XD*{oF`Fl0-Yve%jdx;F3nOSDzJBWKzg` z6F4RN$Ir8aUU;qIb6#R!!PsliF0f7`bBtYX{V_jUoI|L;XnK&|FJ`2BjB~>~I2Nvk z;p|n;zYISR_n(?Q80na=|F@rLpHnZ}$!?bu_J4o)6@XrS%YoN220L7Dt_^@iRkX1P zI?4e~w7P@$f>(JhFVgo5@h{#tKW13|kAHIg4)2K#=qn!>w+i#?czamy;5_~1ni}5K zCtTcO--{JJPrH}(oeQmN8K2<3?h|0NgcY~e75i&4{f~93!cFCkdFkuloa5T@w|wLM zIjIE5iKQiZ@qklI?&3#$$C7X`o!*E0OMg*~V8LJmP_!V0HgAHS)Sw6F5#(cS@g9Nx@`-nV`R|e zW1n_Fub`1bxQ}35o1MmCe8g4zK=WXZ1#Hodwd~Ke0s)L{5d(YH^jJ?t!sl%dv7n+I z@2_OA_<;JOj|CwIv$Wa{+tf#zHaw*ntIz2OqqE9x1TspSBoREgmUt91)jw!UEFAsW z!{utjriJSe-9yrpi*dVY;esJsH;&jVz|kliM}h#0cFDnZh8;wdI4%?|Q~1 zv~ls_Zh(w3cH366y@3hWtE>e|*P}qixKz4VR@rxjW<8n3c;anvy0lH$u5}ElXorR` z-gKw&EVd3RJlk#OHlDRVOzk0rSxRTV_A^n!cn@)!?6IcSIa`2Z4{!xXDCY5ky*osd zL|4RCe}FlzeGzqW&DADF#3wBRsv?pQoHvFx(zhplLZ>zE_HLGR-^@(rXT^L2?;&mn z{H2;$9^!X*r;5NEt|$$uxekZQf(z^`kgn^xw=!2T>yzK>F%0{@|G!z|^GMSDGm&mQy}o zv{Dh8&{Q~@L!i#Mr5a&9JWp3C|IPk~X@A6gb3b4cxGUjG#RH915M;*824GQZyP@I^ ziz^IOt=&V*aH0J2CTC32kOxa}%6w;ilPBiK?|$AVjAT~oEoh-9 z?Uz%&QZ!^?>$>E+!{>#ECeQK$t7Z5F_-t%# z;xLAZ5uY~_j^u(b6z-?m`4r|BsZ%v+4Hns>&1MxK$PazP>uf0EV36mWNhat z&Y>xnU6L+l$O)#(%d4g3(qj0 z8Ghf&=ljeL<6g>WoVs}ktdm~)3*cAx$~j@(YPy%MMCfyi&Y*tU1ycjDPzqF z{ZYu#ZJB(-TE@tiSV1Qxkd2EZZmGJRfF5C=`NMYi^;S!`@SxvCQa1qHMGqUg#2xma zD`GS@&<{c_2mK@x=Q&XlNbu9o%U65D4)q>Vjgk0!LC@PPpD5nV%EHR35#$R?%PB7>-n zoPg$#nP$QPGvx#0q9FFYgSl-$tA7lBzH~Ae-6l2LLDcKlaI0-fd^&8$6!`Rv`#9sp zyUCtu=4(Ive}K+$V@e})E+|(y=>zO>VvmQn_>_Z-f7lM|z*|uVAav#NR;=-b@Ye(L zn~Q7Ns`P+C`b?<@EP8Z7c@exd-Vm05pIiIRfdZIdG=pb9~ zsr80QSMC`rT|ow&{-a)mZfbUjVr-tp7?rYe6bqP~UgcOwr*6Vc9BU~wm=mP!&atqM zk5_sRbe!$SYqJg_Ho|+6j4ZrsST^-UK1c@mVrlAgCs`@5B^M^W4OdH1YotGW$NaA8 z2_foNqivtUNFZHlqqltX5FS*WggyfEIHn+A>MH$DC6F3|O= zQt^PB6$BL(d0Ih8QNeu$fxpBmt1NoFPxuWBcJwN!Sv9b@wzA|-wU?IWm;5G)GI6VJ02M9)z!&meg148 z9qWyCAwN01k-|}_?*cbaB(ueK0lWZc7x0Qk_%;kXQf`vFUr=hBpOcj>BKh`xE8;AiFwKlqLH`;23yyVoFI41N~{5aGk0 zH30AL%q>>m9q|KZW#jQ8fbwRiw__}1gy^mvU^NeB;lJddw^8qG_L{&)av$yfZnskH zfQJ{qHJ*NM!wQ0S61>wHEJndzl1Jw!JHvJDO$S_`r2y6rVg#${zyszb4}q}afq!$q z0jB6SUF@nMWszZbA}tqumkvnJFrW*;^X(kR=F5NO4*?$@rI-eUSAZUR@`5-vLf6u3 z7T!@D8!IzErV<85a@5Y!(ABx(*dQ#LLFEyMaz}fVCu;aMO*JA^)vJ_V~GFT+Rb&mFY$g!wLEfw$8ye4e&}31CaX&mGpmLbL9J z!5c}ianbkJepNVkMmPUjlFJO|W1WCc;lvJvv4k^Bu7xAJIZzBHik_c?(*#{C7ZH+% zbTHOnv9hu>FMkJYOBEMEhDSVf1d8!6GmIItXe}}6bo%Pt5=awKB=iZ*Hn?TIBWo3q z;r1Q6iKbVF7t$-4KKY@nhy1A@jZ1?o2O|qx*6Y{fK_v>+Ne-p+^Jy8|qtXKuy81Y;{joB;L_XU%g;P^o`*@J)bFaGO4R(&ww{UhMG z|5D@Vy`W!L^3g@;f(O+khnSi9(?7lbpon$kcnEVkmM$=koat5E4EPb3ZjAlqix$S= z7m$OHt;V@8dZFzfc%)xE5Kpd*&17hUC5-3_jndlI>vOi4_=~|w*29_kbN@Zygl1i! z&di7wRn1Yu1!}lXU)l@GrkB_y?cq&HwL@{6(C9P&V0h34GcYul@M_ zegf;o@LHBz&fMbp#~?*V$&oei8oFNGTaEqVe%|lj81>_)vJre{@K&@lq;+ljgmfDV zQ41m@*?ftv3)CgUfuMtdJuLPB613rEec~42+1lPVd5u&Ebf?uI(VxLl0L;uwxzPqJ zZ9z)wsNCFzZll|$U)wx}b`=p1Cjz#=ktE)XG{40kKF^|hZxf15R@Ksmx*Dw(ZpLt2 zqDCU8%!kmdH2ZY5!&aX4x~UMGI43Y_tv_2Jt>J zhw8$m2FI`V-`$J&7ofjAppXaEd!MDJvrtGjJh1 z;PJyj|If_)@YmKK)J+{A*1Jj-83hIDLeeF@P1DEMdYAhADCSXWVNb->H3qM4HMl$9 z!4p<6t*E3SwE|73L4E$B1=^v52kf$&qK(JU=MTGesU^D}=@Xsr_(OgF6sN9Y-8DW=nF^7N(Q~=l{pCPdELhR<7gg zw9P;R`kkTA8UM$+0^iWib;+#wcyD&E(YQA+he;p8X$lrA2&O4Gtw6oVxXEZoAA#zT zpo;hAC0wr0dT)ME_*>fj``-Yh-p{$QMTtzi1_gS^LXEK}#J^o2l3^COZU=oNaW@j;OPI_p;W#(7NAF_HSSNk?KZO>wW--l5H5v^L)@c zyijie=lA=!M){^Hn|R-ugl`_eDG67%)|!P1LL>R-g(MN~WCqVGhofd4&Q9FkQ(%OM z!{!PYGDclR`{N<5U+3 zby;Cg03mX|}um_=DdBemcNCMFFQ1`80Iw z_5S?)xy}c!J?H>%`dSTPC$M0jC+$i&mFjIL|4vME894!pV__6q&9d{^bKj#>SvVH(+3gQuGBQ!o+iGQAEsjNmXO+)zr zeYgaQX=ROl!95nFwh6aDU<#|#ij`?6HPk*2;d^Oz%KJjGw6A`$Uht7)o&YC|hqq)G zE(F1wce`cA!z01x6E)@NGyLC8ehz0ooc}!Vbl^#1q%+`YT?9+M6!7$TyAE`5GTzVM zFY)xrN#JSBgF<3&U)NpV@o>LyZZHlE`Wy!Rzj@tAu?r;3;Quhk;yiI~wf}T3ur@Z} zvm(=ZR^WMKphCTxH4Hn$gBVW~zA3?&9Wcs5%2ni!(>{&^g)X@p>Mp$B!EY<*4z#k} zgSm-&^hlw?*&#G90ZiE+zG(em4a;c*N7mgpD?5}P@T+ST+^=rRsHxeMwTbgqp z)i(Df=Ztm`j}!Jh9&BCd+(wbr7nDzpS}xj&rEWF!VfI+ZJnWVEVY;#7vCga`PtW-g zAMJQ)phIO{WzialwN$Qt;4)G`t4&$7gU>;A-{gw1RrAOM+-y5f`(V+)x(`0`uEE)! z8sJD_50%q!>|TsB`h&wkRbu>9wl1p8BA{`Z2ZmR5w$4Dv=BEaY`Hq4=j@S!b@GT&N zH4!E~$_4QB=xn}j4(qTy&+GfxN6{aWOps9uD3D4YvvewF{BZUG#SliC5ob<on0T;Eeg8Zv-fb|(m$3tJxJvQ=&mu&WG zSlrD-&j?@u0BD3uzfpt#MtD|K8fJnh2K{1N9Bw9=1*c0OWZ8hfy2^MOWZ2u>mCPK? zZo)bc?;04A6%o#9s1~gkq8(xTtz%vv?5i{aj&vQdBm63|4Ls`nI=UWBRid43bu=9d za*M}7*$A4mVgBoRXFK}%P%+x^7pyP-IAJN}+nYXLmh0$nQ<`C)qMh78Xo9oK4$POL zS53D5G9srClVlzd5 z4223B({a&^Q|zDvn=^bMUUGcv2cZbb)J_fe4R713;aj;KHWPPiycd8DFRpAKpO1EM zC>4Yi-IcO}_ZwL_J=JHRgp+!PMWJJD?4^eJ6#+(89}&th?efFgR!Sek@hfdCfa<Ik#$Y5Se=bm15K%b>CNTaTUZC602wV-CSu54zJ{o`*T zPU3TK?F#PGd@uOz#4n9`1RPNgx$Nrh5DoeT!P!fdW#77$<+TtsF0WXM#*=;w^%w0L zfvW;l=tuX*(0(>Qy}+ms9zHgG#|#Lrmslt}rt_!YAHR==S|7$hz`5Z9?>=~XcLXkgn{j?odNu_-h&&jAhsr3O@ERVzb+CFa zc+h?YJbbPycz`zK7e4$un^oWo$bk^w!aZBseWTyM(}Z*Feca_;&+l6|y36~e3$5G3 z&&9g^^}C4c{Q&%8T!cVwsW{~N6Xm6fX!QQt(sZ-y^sz z*d!PsA5&si$TUMn30u}$K|9$WyT+%fG*X!23w~CufE!-sz&kf}ylBVBV5t3-wIC_j zhiJ8N*a&*Kn~RDsANI@+35(+1%k)hYyUQ~U3%T%k1{!+0^?S8zai7Hel1^T!z;CqV zoFti7T=x}b0H%1iGViqW%7RnVD;28)<=22)_~*l^b?W@_UaQG_@OfGT&CXJ7{9pUh z`_%`K8-mJdv16ors-SZe2%y;=j%NV9Z0KW)yPx8e_302(L!c9QPs-c7*OZs{D33a) z_Sg0)x+eH%7h}93FyUZ0m%O)v!C8a073*#_z_R6dm;p?O{r(9dU)*=NfC95qm9gF0 z2zr_7GhgPODF;3|8soS412415I_j9%?e;DCSI2j4iy}67a534wdShQ=8|=HadQF8; z7y>IPjTH>qQ|~)$;?n(iuOwVDPSSk~w-WO%KkIYL@OfkV1xeRb<<<$MRk$4Sdn5Ti zYv2Zr(DxH2E%ALG7XGSc{_an&KOErtoJLoI#}j%BTxcw{_&!!<%$`Uyu7MN@ied|K zKz8d0K4e>j_++0qbR!vmkJbKYOTnSNEtt1<`h8@@Fya5^wW7TpaL0~gUm>m@a5@3q zQaWx>9oHa}YqB06vxx|P7aSH^A)(wujSVHmXVFecd?j@Q?dl`eDddVSB4@{#J@msC zeQ!!S%f4`i7+Vc&d)w=W;NL<5%szsdrO{w&^_u_(m%5l!H02wfWggCCR~DU{v$7hL4K^ze{LSVm0*|!Z5zng?+^u8zZN3{0WU0V}FCtH`g#L;fWX#Va&1( zqAH<1kSuFNdv-!iIR%++xu5K3c7Ny7U#dRbg9cyW7$5MACP)3#1709+1uZfH$0|G1 zy7Ci{iVuEw%7I*kYTTa||KgXE+{Dh`q4;2!46Fko0EhxpF#e;3u88tehbOMJB5?76xOJexFV8pC6LLn+qb&)t!* zD{%Lr3Xv8HQU;8F*JD&R*UEN`Y#Fz@;(27OnRbiccRCZwfCudlO%ryjp`gju8}z&A zh(FSc=$jfU%dAANr%y*asvM7sPpjyo9`vO+T-CxH#n3_O%BHE5PquxfRF@gHrp!JR z@{c|JQ4gB4e8P#~|FxZFZ!rF`dO@~SdW9c0wIDqkd=UCLdX(7v)aGy{pBhZ3waou9gW zJCor94oMSXYyHy8FHRKeemAZA2S4AcK4d&|N;aH99_RY7Tm$`~9u;X(Ac9iPrLqzD z1HM9!CfiYz?UVIj$H~dbfKU`Y#djHUogd}@iEnp!HoE4;vvbLwCOEIMb)~8jDb)LNM(Ju?{ zs>{kd5eK$E|Nc#L-9m%K8}7xWs42OeSE27I$OgvBDNe&X@$%cDrEcFSyc zyFRDJJv^#y*p(VzM9Q=ttQE$kwjQ~p)G}0^FCAm2QoHNMlJU+Q?Kr<6)ePN=RN%rQ zQZ%{acbUA&rE_EZ zWc!8wzE%;MBuk1S+90&_r9)6zbq`<^Ev*s_(!G$eOIKH8Ui}n-)Q1kUPnC;jdC&V* z=>b0s;2F{aw)5hm@gYu508y{?fQd||_>tZ{5$%>0n_dl+}OpLG%Jl`lp+xOE@w@+Cu^ z-EPCQPtd=Ow%o;;6&8G95VbYv*-a@}IRlnWZwrm(GPCLce(SXAvV1sz!*2SVWtCnN z^s))t`O&tHBBV^tgvo(H;8?f=takTl@4`rLmUf8@Os zo#Ou6jJOB{IXZ&qHVhCUs)~LmX=n{Dl~RV@IgqitBlOI$3&h$Il@xQ$R+By`ICC^l zw(Z9xHoJDs7Bo7GM^IEl&g*S~-EYs5J}BC(?`?FB(J1acE~t&v&mH&v z%B~=dJssn+ZMw^5imyxhz!{rOAY=3ruE`Njn{Dl-`GKXmkw5S!QpBmP!>^9_9Mxg^ zXcz!^snI=tMhXhWAP|#%v;iqx!6yO`Yr#&8Dbhr$fg`V!^=@N|p>JgGt8x&17W3L( zJ>EAT_=1p5n3=`=fE>j%Sg})^o(_)%laTfjN8h3fjQ`ig>RvICoBK8gO=%y;Vk zDxB}<*AQWQuK}xdEe=2|fe{SQpZQ8eJ0j`f{EqhLst-3a&AeC$4A6sWG$EN|?DmS} zK8~++e@GPoh^Y?FlmIIxy+;T2ZQ9PWy#t1m&`_g4D8WHu!Ya%XoH}W8wS?4L_3Fy! zL0Xo*jCRzhAO|rjY*Sm#7TMBGTRCO4O6n4!HR-MG?Yn}RDm|+ygq_k5yEWRg9L5_M z2VUAE-`+;WocZO6{-{QJ+NLW2eyqJ;E*t`&59~Jt=<#`Vzb80vyMamYdN1WPT*U7M z#MtaRdu!yr8u<5H@qhgkf59u2HMb*#DjGbD=tQB?S;Q+}4KqUoY}P{>uFHirBeLolJr1CKkzH<4u>{t$l$jDSQ54PYR9dTwh-0vTyctoQ*S%Bg4(D99MPr8^5*ws9r)%oTHQcGr`Vj#C~37F9~jR z?(U;Yf`U36*93lntJQR#J3KXO8*NCiba}!%&W_~UAkAorn*O*ahYDN>YQKGW6u6yhV!h0AMqkDa}~d)K{+lWqeA)J zgg*Ycm3{ZszG5Z(Xa zzE%uMD6=>I-OcJFICkAbNXii9<7mPL9gwqkuY>*%!MdGyZ`~Tv|Cm?VIJ|`h2iiM} z+@5|DH5(8tH>j&LEVnPGiW>v{gNJh7SVYl5(hUY6b@EK;WB$!iFNW>xQ`Aq>AXZ&j z;0Q0*07?ryYFPAq_oA}zuX399#=rOr{C$%2n$9?$ByWE7z~qyU63AW8{ufBMI6xHo z9Ru(=-FLxXAnW+>YOmXAbLIC=?Lh1+C}YEeg7F8D%tsGwR?lunL%&q$z@sN-pkAyu z)M%+nQxhxV<*fHq_&nE(Bk96TLF?6~yTUd_nGPTo%F|KthXMC3mQZ(>VwM)8!ma z_IeR84{)MPaD}kMtiw;HP6V}(3W8cl1p<(tW<3IjX^$~)MKxZypJdMs9 zxF-(K^+qq?jya-#sIrlL$h~{X(MvgsNs81uo2(y6*WQ5tEvm{yGmxA?XT^j0K%L53f!=JAAJAn!A}FvKB;Apa z!XE*Fu@t&O@trMv)2c>09FLa6yPEQ@K~m;5ma+gxUbF)*MpS*WkzwHeZ5-Jei}X0) z4j#oYXI5vQ)eh^(+8arZQag%QVWORqcqJ6Z@w&I&W^46rd1ut?xy_Xi4-3PjGCo zFXaYcC*EMuY~B=J4Tgmo3ii{wLx&EXVMEaOp(jqCK*Ust8S3_;N*5|nUK>d@7yVHa zD6DsK6UVKCU1tgL19+P9nk_4^2CW^$<$+F3>JlRMv{8vKAJzd@Tbfucv$LHC_D#8m zzMaz-)i>3B_w6iqpZQ<^>iQ#qLE=zx32d?byqf|a$_AjkKLH;?<~lr&S|=dcf^TvT zJ{{PS+n4R?-Gyh2PALSpepBY0KE{4 zS^L1FYKAx`fPD`-f9!%D$Q^#*(3DX(k%IzUwBxl6OIaowH<@OJw8 zv_0ea=rrGv0TlM2xtb9AAzb5o?yAb;whMXhFub0U&+@nXDZa$le&YL|Rv#h8FqAYy ztt`=v)JGcUkMor8_+$8~uerV@4}JW~_qg_eR~W}0V!5T#Zu3sc~K0} zPWq@y{mj7}rVsCPLb2o23uV}{!95ZP>eDVv? z%a00s%fADCJK#S=drgXV#`h@n2uwXI+vzNFxyy3_b~9UVdQU;|P@F>HVXSGfb`Zf^; zey_eq2Sb8i*u>~9=z|AHg61`sSbIcX%vj|BynDJcL?D&jg5K$L;J^q&Wr%!7f z7Lgc7R7)mdg2RA6BB&WHWjD+D6K z7v}>Y=@w*8JONFF5j=W_7c=%Lu6V4e)w63KfGL)7nqyv;!y}Z^&P8f zmmMpxRzO!}>ZYhkwYXw0#kbgA6bl0^|Xs*HXQMiRN)H!`DVY9?0jRM zv99xT^NUd0kYG*ec~k13e#e?QH$)Qd%!Sgax4&x1%G%08v}4-&i*R@&HGTSn6{m#W zV5MS2U$FYb;=H%NIKSYP=PRF$cI>5jcSnl|U~m;JO8_QUtv-`$);#s?7Oh<*DxZbD zfGsFj8zp?Eqkm|bv%L4N>6Je!pp1@mLIOzO=exzdWniBVwfj1Iju{w*OY=iA?c$%| z{v!O&1%3KK#_ykg^Ls$IJAML!y3Qc>4gj|Pr{ej?WB7tByD**~jZb7dg*QyYb=^1N zd~mb*gR>j;gW6}Cl3df}M5Bd(Z!qNRh%zJozAkbf_z>gs{ib-vR$^*%W`;#igxo=l zpv=E^L>!2?I(W{5fy>M`bgr;LpRmBPP*!1*-w{OUvC%Bg#hY=0To14KpHcYNybj^w zK)~bi=OEr(nR7JQ4-9z96lc2Uaq>Sq^OYZmT}A_8U>(vj-SZkBo-&^odVHaK+v9tQ zZhd?C4+F1tnx^Bg;^6D`v;XQrf7mqczI}UbZn^bh0#Y)^qz<1Tv ze21bd*5MDgV!yAGZR_`J_{eY>ijC5*6rDPZl69?SknkK|nqTL&8|piDAfi!#t+nQ9qaUY`*sX*8zVJ;y{T>_duX7ZUDmHBsv`M06UnsB3e=5$6sY5 z>m%S8Y;On>2mN`Czi$IBCfv762;jFwCxJiHK5pi55rXz@pz04shyf>jSH6@$q ztAFD62)CimE(Ox5;daD+3vfH$ehV96U>}?VZciq{Ex-}|A3S#*emCJ62{I&;AJm)2 zt|%Y?-m>|oJggK|`D6g1_xyTM%#NM+UAXi-0%AVfxiw)~E=Mup+2RZQ#`*Qxu^^m{ zNB5Fl;ivxQd;ezjQ4?1+31<>Lh+6QEIi$a6`1H<=(RjNmn|7aQLD-S!^}Vf5V-T+N z@CyG)bRCuo^G(0O;U*7$gBJ}`(QmMO#aLUI3+vOhMcSl};UiC&&Wx|_CI9oY-~HeH z+to+yCY!O+b2cOKpf5Sovdayt}meb%U$Au!*k&7rd zRka{#fu}{zzV~FV68@`-s#a4qqC$c{1M|st;=|*x`LXkOL+7v2hk?KL+s!Ce#8Bjq zXH!W^Ac&}oe>i{4pi-R2oWdHY(e6H6rw{lSnXo!ntat~L9dQ8-&;5@H&&4`mKg_Qz z!pKAV`Q$$@Sd#o_LcZUAXl#unScQJVFU+Z)!3FM@iwpC9(l0FFr1xWHKz=@E`m_Dv zL*o-BIGVk2oiNdD!!HH=ZmrIhcog_H_LJ|MF>SvtI^zsnh#&Isi57_T*)RP2;Pb*| zOyO=i-76;PXXqTHzv*Flwv{D36hk8X>O6J-GiUQR4f+W|MA>0{7pfY@IANEGmH8WE zH%&iA5Mpy1bfIqvlp|fiE@A@Iw&OiK7wB6nSNkv5XgGe;aGrJe!#XTgR=`=2PZ3C- z;Hyf=hshN~NlY?;Ar^p1mzk~3EiEp6Hs(JVGpEdaKBpfi{fm#k{4*QXN1fVM3a1J9 z@N;@noS2nUzBBf*k9WV9zr-;eLU2pl`gFdHefbI&I{l`R15Q>zvw0NE)sKxE-R{7%XuWno1*qBf_Uu6q zy8oNKCLAFdfn)kvTd6i-iDP{6TT{=&l+$&&s%1TQ--K6;$^ zt6%%-PrMH}GO3WkPk*93=sYv)_=KVN+8{z)cN6M&on**J{=AxQWJOWNFk%G>f6nvW z%l6KN=-$V7g&%-6zFzyaZLT*wzJd?O87}a~Bsrk)#{6x#g&x8iRyH1QU{P~>Z%!2# z_X!XMVp7mWdZPuDVryvkb99*>2V8V>JQlyfv7WCuuGGpeVouP#KAH0cAC=C*`)T z!A51aHC!n;M^g@6bOKT7qav>4%pd(((2ea)Sd!ME71Vlu+|24i!U~ygI7OazE5%E9 zd<_{}Dnq;+rpMkZHE!(CqWu@jDT;bjUOJE8o!U0c4;>LORznu0As73OrA3`=qgFeF zX`jqxxGH>C^QTPb7`W43jCNSQRo^d!9SAK>ee@9DZDB{V7ryDXdhqy+RnU77Ek`@K zJLcOx^-ij;`ROwl?{E>-K(mf0RipjcbxWrBjdExT5Y(x=ljTEWE-iYAV?X5)@Rk*>0j&a%Er^@8ZN8DoC%)3Ya8%SFIoH- zfhhFmRlp0>;&^FtoyS>!@st1b|KWZwq~&MW-y?b(*wf?nHh=-XrTclK7QkUpr}6o* zB7Jk>$UJO6NYgafVKXHjz0}pReEfIQed3G*&iB!G6JP2JfA&|%m%@ZI*g(iR{G1q; zC!XDzICnA!T=_i~*P1_Ad6 zL>T7-65mts9d3@?9~P@D8-IU5qto&op6{R#qV zuozA+qlx|cb6g#~J?PV_NsSYK3}2$~IXHw{MK1M#Z}^N4KSrOT9V%F=UY(}}B&BH0 zC`Al(+X4o0%y6iciq+~?L-}aO>geN+x^2Ph)}Z2x9?J+leWBCXu5Gu?X4mzRA-|0e z0oCiP!tRZ3%mYFJ@lys!S7cvjyq@Dy$Gn67o5zNoH#HCHfmBS=x-hqhsHD;kS%8RT zAp(?AKr2}X6h)vWAMHqdiy~Oj=$%D`t&m865h_*U$t*4`nWf?4!m`^XF055Ndi#>K z)9){>z>d*Gy-0>wczF)*sB~>%VUcEyr`%@~-{!rW36HEl0iTxVL{A(~*r7p7eVZI~ za&EaP@pHOsBEO!hSK!(%Ou%1!UB8#er~T-zlLyU+Lj;n?ElU_A>F<5 z;6E@hI7#d$Pe?0iY%%}(XETuGi@^NY2LN;UQ8z$Fa^8(_!BJo^c1$i=iAxTgt1Gas z9dnLMnA>!&J+5Z^uaAG^ch(<6o(SAcU!?{7A&wSYGIfS%8Nug-54@2TWy1=L*OeVn)2SdfTfZ0BZwkr&g^6epu2|Mxj-QdoRe>>qjE9 z_iM+^y2k{7T*4wg!g}1NKmcu7!8!hLW~?CuOKtO8R>?E!Up(=?`92)q1i~~rzTdyoq{kbGnsClja{VHB%+GM2 zRD09b&u?C(RK`=HuVGSwGt$*Ec}9xG$Wr&-jU-f>VcanFI`lJs`XH_M7k>U9ZehKj z_rTVV(K87HuIopF!iofD}s)Zu} zvvAUPU74ZUv$K$n=)H12d3KzX4-+-a)L?#+Ve22z)VUzlr1myR}&V z`~5?zE2Q?1pgx2=JtsONV|d(GDgQF!^gX_NGvbtd<-`BE4g3XWYJ;`7uE+n?5l?-4%Fd zu{z05CJ@c^@=<;_=vcv*Cd25?7P!qaZtQGt7&Qcb9cj$Qwiz)J9`SQLWd7uh>(5t- zURb@x4D0Ymg+DR)Sqg{gxr#EvKDBP~NRz?|voA+Kd=`P64Dp<{hL`zymSc^#kDQxZ zh95k!o#&UqBsb3X{Bi{>a9zKdT(Rr-{2HA6+0ATW4i#+GPEL&FO%D2;F})WS=fF(Y z>kCWtvnK^$aL&=bWS&eqJ06^JwSz@iTC$2LT3SvX`=IYA=Y4C-^RS1Y_2q>1%J;sz zDW2(n5c^7gKr(%9=k00xN<4k+D+estKxBhtOAEk;`(xvIDf^7_AKzBkC;lNh)g0Pi z8>}grKUC&+8(ZeNzSh~sPK$N29oGrz5wtoYoSrEv7Py+ z=6%F>-FD6W$g&4WI+3s)0Sj2%+@hE*1`_?T(o~mNutw3ZgrJjVljCu!4#mX?Fp*r^D{V)ucuT-9EGOXt~ zoIm4$gdez-AK$twItFC@|MeezpPjn~HrEjhqqc`LxZS)Cc{8-oG4UZUJMA34KR2w; zu~=oz3Ws5Q*`s7!w1&2<0(^49v}`>aOYs2zH;>&6(Vjd(P>;*E5%( zsjm9Ex~A*VQ;)u<4-u|nVvNLu!G97A3<2>EK@k#}0fifhO4N*_@sWgp6BQ+nF*8C? z)T-<6w;p@%`l_nC`f=yZ?K<^G_x|>`zrEMqd+oK?UVA+rD84=A;0h5-kc)I2bCSvl z=J0usOzsf!OR{WUP?@Qwirts-wB~%ICBq}7?Y+`j0e3E5_2zIXpVUZ}Fn~x!1YxEi1mv>-VMb zh}#N&PalN))0O?gGm%?}*iX@B5xfyUP$junyI16P#ozkQvyz|^t%7FZveSfstMn(eHfMKL~h;v6f*0{Sdu#i(9d=zP`%978CPw#`s0~*n{97W_$O?lzu;l zigaG?oaiY)ED=3|01l<3b>D1R1>y4Dbm zN-PK&UaIX3P#Z44OqN69Yp(m456`2D-)xIN%|u%P&81~0&-eiE0$IkRtqw#@lP07R zbmLZ^dgu1~Ia^W*k|g^`<802~WRI8QDay5@e^Vbf;3xEn;6uxmh+M~-`b1?@8e4qa z;<|Yl?}NYj8^414V2SE_O?qRK^TrhbolhEHXYD?8dlrXxvZ5RMbS3`vVbGUf`GNoY z4d7pW9#Eo_xKt`eFEnYeVSh7?y$ih!Ne7n!$ba|`&d{r{fk0SceFoj6${sa@az7096hT$uEiiS{+42d3?C0i$E3D3dwCvqUaf0v#&WQc%| zG?rVpTY0w&D#I6{u<&JQ;0udYUfaBk{p-`juWs=#|3R#iK8!0d^GYr$N5VXv5idp$ z74bf#g!r&C?3HxBlX`Nhb$ZT$L39VAnNHR}W4&-kF(8Rj5{^>Q2ua6JgmP6^y2xW% zu$O5PWg+KYhf!p!Q5RX){CmO9QwGBh3V5h%n3{J0r@UcRct9i>JqpZ%ds*`0dEl3G zcr5!W@z{bume=SX3qx0iC7dX}lwk*_2o1AKL1=i<65pG8z*=w&#osr}K7FS2|0$Ts z!69NGaT^Ct1ClYPtOq0EQ8BsQ?^31QPS3no$Djt@gT-++wT4M?WaS!T#f|Q>1p0ygz_Em zJu#)PEP1o=4#P8_p62VHHI}56XtxbPjHvwe0<20C`Ka`CJeDpfaSWxDDvANT2}nQ& z&BOGp_LeO#^0U$Z>jlRk;MML<#H-KzmDhH5=_)f&wLsVA+VehnTq)hb&b(Oru!EBN zXP%FEJ}1LU8ilhG9({ksM~*K9E}Va~G9kf&S;_Oub5EQRp2vOsur6r^Zd@Ld#^*6f zP7i~>xl!3-U=5P0Sj(BI1fP;PfxRzp?^e}0yi+QpQ}g`NZ=Tsocu72By_4{`Slz&wb)Y8~cpPC=@?r9Vh-}uN=QU&NrK)FhnkkFx&o|Q7>6~pftwwBjGr^ zd&}|mDstrA`@tS`<@iUwy1kp#5ECJoQ~7yqE?@H)#NkeHW6}L@VnS^G4_Z`{ALzlp zukDK%muZ$E3Mfq6nXuWgjFxD2>fOF>IFMW5#Rbm|6Y$)$htz-e1^X81!oywJA87yi zrJwnY?OiCy31ca_ao^a%b#Avo=OAi{sr$xjcc$WHlq7G)zM*n~$$D}^DzrJ<{&O^P z`%ms408!9{pepqkk57~RgBXQ!@JYuD7T_;;ev82w8hcdP42h9|6_lAXBQVlsRRL_qSSnU zmaEh9*d63e;rrywfKQipa(p@pA)rGI{!0gw<(K>Ey7(T>|dtiW|whqbq)3jLKh7nI8C6OU625mpCFQTcbgD2gHjB! zbwra2^hQWj3r@NE>eHU$r(@KoUx*+|q7$idOgrhB8_sA2n^|G(f^#QpS*C`bDI zw>$^F;a>C-@^RDZP40bgZ$CpmeiodZa~cEE1)Vr6MIX;9zijVjoXhEM3mhm8;}T&+ zld$u}3ReVKaEu~8JPzlsm6adb z7cP*d{Wdzo_#L4S!inLzt2fnduL?hXp;GUza#hK<%2>UqHejM^!}}6HWfuM1ALZH{ zd;G+|WpQn5Lof4Sj}G~f@JC3l8qY)#rrrPHvW0TZY5mhVc%0yE(C=7z_w6qLZ>g6W zCE`FeAl&?T(t19C^6QjbN%E%nC8_R=`to|Zx}6~oY_&zT66%%oHSW`~;F;D3`Ukj$ zAt(HrfR?w?L6jl?NpoZ{11vx(rr>S0ZXdD?f46}3HUdHH4&nSn^=fH7U5+_gi^Q|i zgMqDvWK<=R&0sp;&L3>P%aG9c(GR9rQ{$chM`c-rc&Ykf>?JgT_vPfX%HVd}ovaUOS*P?0(7}#t zwmdMv?VN`FOgXX?dWvFBEfef5g``fFIFnuEP%-=HLCWt!x*6c{`m45^^E# zv++O-qm&+eLhN2Sj6?$!oh7g7gkSQf`BT!v%j1WhYh+6r(45TgyT@akYX)%9Bw9fI zf$m}h-MpY~t6wnEs*zLM$COWO$O~{+RYX2@0r0KbAsh*r9uMrIq)M1{Nx0UiqS46g zh}6j-f%5mq)&0<9O~f_64*<+u4W2=%assGwlg1<3H>WR}zW&^R>LZHER{}d-2R^R0 zzpm<`iCgWOx$A;j+Nz%Zd6Y6`HMsWLtmr;Ve_oZTI2lFTm&r-Gh9%Btwpqi;*QR;+ zMsmwMd?T^x@NoLe>lUtnkvepj2PneamDe{)=31=0S%P|}Any7WR0TwvbA$D8kctqP z%NIED+1ZcI#2E2l7GEfOocwUt;+LiC`_;o{<50LYU+3d-p58AuF}e;B4@|NAu%&*e z@G-h=2wh-nVHLpXzi5(5CLmv|o#iSO~aMwj*5; zyqTwOqUYYbGvcaC-pq3a{Xr%5<(SEj7ht1k3NQUaQjT$y?HoHAcMjnWbkOaIPzkX1 z1@1{YL>vWt`;5v}eW81?cMlu!EPDIlPv(aR!Sp^H;$N)WHiw`Wwzo0<#irRTApQk+ zQV!^X;77Sj^n?E1pDy%wh<{=FS)btP1inn@I~o4Dca=!DN_S`8!w@Gff`5+#F#W8 z+r}YWbHF_rWo;%PHM%rcACE`o`%g-9*cS>Wb@7ro#$Sy+ZCX$D zY7jEUmb&njYFGkcVJ3>mAjy}gLb{f|KFJ16d@2q+C;Pn|PnX3ile6MJ>|!b{EOuWMT42u{Dn`BZ zgVSqgfMAfl3Pw?<8}UIp4f0^&TclBD<~~@1U`603^3~wpIeiu+Bpxy!ViM7VsUwVZ zN4*!mT_j@)4@9QjvVzU~9~6 zH9tLcc+%347Rk~=XIZS1h2B7Dgz+Mc;EUrbbe8bQ2d{_WTXDue& zM5dB8yoLsfN0jZipvB~-?W7SpZAui5;SCPa0bh7MLDq!|y#K@pcrj^PP;z->9S#j& zYn?9lqn%4A78xKf1||!AdPR%K*txqS`G`a4@SqcB9m7^+aOHAK#)Mgeo+&!>A%z$L zEI>@X9)+jdfqssE>Wa?bxeimbz`_7VXsx2k!@gNPSRaBC%;#Cep5UFy78@%EuJkjJ zOAdNN1lC2N3-JkGFVr;Jq2~M{VK6|KD9kIHNB)h~lAH9e)2areP+q57BuOydnk3d$ zB3Ic8ax@7_i+Af=MLUpe6rp*lLHIzY&KV2g^JKq|{xMeG`?Zno_llI+ZTfKNJ{Ot_ z5=%Ne-b=_K=`6ST`^ELS?Q#A|pLc;~XVKN^do=x$h&}hakHejOt@Yih(qY9rM+^Bv^z=Suc2ZA@5X4~oK4g5v)iB(LLfw^!hLmcc z)tkh*5dQ$LBnP}Bi(wg%I;zqvQjJ!3UkNHcQbIp~lOl3IEI#aTweklY2xLv)Tj|^7 z_>6bc~9_B_|JbH_)lR8VeB6L2Vt0J@SivXb3RginEOxcOiW8`UN&9{PhanL z8stNr|I~ROjh$xp>x64^Kj0bwU99e#$0}YE?i)I`EWtATReMl5Ba0x|O3^4eJmCfS z(CZq4*0Wh-hg{w5ojqr_eyZ z4Owk+UIwS68_FC?8ga_K42<~%YUVRN!G|Jd^APNwtgd!eQ+9)u(<|@`Y%H?8Fn0K| z?u;&isNuGgfH^#5e>HcY@J^mJp(!sdblV+=7%rALJj!DCyq+rBP-uHNTp&sdI{_~W z;QO^h;JD@RD~H>D4Z8MVqNNlDFP>jzY`c8~Cs96iNR1}eg*NN-l<5x$%%r`NxsuNg z(N%{>25#~dyzyvnzUS&A%WE4@zOqz$^-Wi z&eb}1AYr1zg9UrRXTqcgzoJ~D$tWPHpMX2i^TMg8goVX8zfjaC0R|2`T_sn-mHSbm zpyW%1j;(wtwQrIxfF5jaY#=<;8pmUEW3#x1WGUWu%vK_&9%GcTeLn z&J(0a=6xLWa)j9L{<+U8-xiy4CmT=dyay4bBtt*pRq>^3_*?=};+Tw0n3p6{xLtoTK zaHD3R7`cLMVj#EFIF)nlc|C+w59+eg0Gz{*b7T-AkXi72AuDK{GgnRd67~!o4vdKs z0zLNfe5y;6U;}{sv%?d~5DN|tPbn@*kD)?cY>0jFXR(0SV*~>)!cBm{GjaS4y-0v# z0es^1?Mh~(MAVDPF zsN5P->L#lz=HRvW>yTLB^`kJsO2=8UCV^sBsL<;XLYf1EI~mSPwhPgBARl#)hvWo- zn{)}BVB>JQiBXpY{86Hthl&2{1>six6?7iwpH(uFyS8!40N*Cdj|maJUD(X?&prA0 z9ys@aK2FI=IBy@;Ip>07bmNO(>HP6}h@S|;i`0 zuo#M-oZjyj#iNDy)r0;EVtP91Y=ir1tu|z@NXM#V+rk6L5zFug*FLg!%DEW@glR)b z5>pDE`7sYB2%o6;K>M)pdQp{1sR60Apq^p1!Ls0~QKh$p0|>uUvISodLu0WesRxq= zIB$@DucvSe89bV6)8RoHv?s6@Y)YRDMtOksgx4d0!(RV6Xs@KXS;HpM(gg*Q)pWX$ zVOz(MMjeFT>(SxkAp`?BapT3PCUP`7=Iw>|81bl+^Ib2*l>{Wp(@+42+SoFamWxI) zaA8Nn#^4nS+i(!>4Fpk@v-VS-cCxOU5}0v2{2?2*=lde`XX}`B6!Ct6tAGhnWGIwf zw|(_sSdexIq|Bc!kc1`hdNA&x6ufP#7~CX#$yfLgRxV$`FwNDFC+Jg3t3HhM;pi~vbGRMO1>uP2 zv)3O4Iqb@Ru>AyMVl1-Dvu4Wq;WlvYxNyD};WuXQ6STjYJb$JAW8K^zFn7>oQz8}~ z1SP6Lj)EfHhThiKyX~st1X4|-=};jt?8r1J-)F5OWOJRcE>4mY|d+wPX*jWh57a z#>GOcYG;(w2#v&Y!SaT`7yFUVi>C!S>qLJ1fNOwxSS{1J{4~%}wE#eS{3NpHgaCA? zT?h<2bG!&)vuB4#J`DhQL0?zl%XFQF_IU74=jEoRuX()*-%q*AyMO!Vw|6;VE!=-9 zyMG?Pe=po~*kFrR%}oFEi><%e@?!Y6w&j=3DRBntu3l}O;$TN)I)FporVSE z@F*W3hpXqO$@`F>eiSpMEY+O69wi`HMA)!6Z3Yvb1o}d389wa?vG*dRT9WnRICEY8 za9H2&+i%DU;kx3@_<|L-7|zF_}T{$`DcL%dn}CF5^=gXMZuyqR^cjEI)F zj}vpH#2)beJqsnCyf)=V+A`(7MRfbNla-3TOU|FM3d@?Hy+Q}rc&j2aGe`7WCxwd z(Va15C30td14vDfa?7>E2@J*gQrJLuSeGhYZ<_`R+DU;FgmZ?l7MRkn|B$D z+E8THNbB_oVe)!znLdla3DIXbnIjF(4yyEQ0}siJ;)$aG#%r4Iy$-tawXP$**OhSr z0N}6Ji=_<<2E?R!SYVP)f9+tuAgqzzJxcs5{;P!EsZ8JHuCvZ1q-b}89-%cXa-cbO z>5K3=bL?0~u1DzdAdE-afd!rk~@V z-EuL@lP(hK_eqSRz(;oX7V~^bfTQ<%uvl~iCs!bqye2BW zp5AHk8Dh{ZsZuT_Vvg^JSR?z@qiO!rrtL=lOZ~h1cmfYf#Wj!NRw`Ancw~R3^+QFi zso|+)qolSD@D#aWzE0pu1Wv`g9^hGdebZcPuWzXjl=4PVEh8#hTc}}`bH?PVxg9C4 z!S9IV278Is^$oMR*eq7uSNCRd3%TMlZ_dQX`sLj2zW$&R_?3S>v3@CD43?2+$QQVd z@7djZVy6u&$;vdou>Xs!<4ee?pu|Z;=AhM1Z7Z%f=u1vSTRs_Hc*Hk}$38 z3Kc*s((FhsX_?ZjQ%kfmSfL%s?TgoQ3qn(i5rx%sA* z=JLUr_n-HQYje*zoX-zvy>jV+fd+~ZKe!vx_RyXjk2DuZqkE+9rIXivv7?S@AxG-L zpaw)sMn$*QLDtH+V3Yy6;P~ID;+K_Q*gmom@b3$8AL%|nH3e9{4d>rEcv${0@NmC+ z%EKE`hbDFK(IH37dX*%}@laj^V^L7fH=i1wxMl|T3;X7%Nqm;inH0q4mQW3J8p|?Z zyI#tfov?|8Atpws6;ZHt(kK{fmb~HKTvs{-nPe#srPsq3lPoWWdB%81?qrJspVz~E zCe+jNq0}>{k0tLuWysPFV~3-AT|W=#WXhrPIZ4D#TJYDh|Im*u2mtheMegPM4i4C` zvz<}{K64+se+~Q4Y&p01;fSg@4Cs-o?IRWfSbN(*UF(anq{0GJ#&O{-E5~}j4p(t+&*N&4m z%kU@ERJakcER7-jIz$m4+&&;!RU!%y{VAN|<0)Qi!F{Jxq~A+*B(M4yr3U&O$Q_7$ zP<8Zrgeo&PDP;je`Rb(E=&B+pp2%EDf7mvn*RWl$hgri&cZZ=4($enpf(bJy#Pef_ zr{w}M9nYJd&PLhQ^&8z!`0IOePT%Eh$@ET=S3952i+*J27OB;LI9gTVcf;@c#i?3%bh}3}FH`I9Zg; zZFUaAy^popatjcsK*EOzRBsBu>B1pOJzfO7bf3kkG9g9ieyGh+`{ zvpp%C$Km`j(K`G<_@*J%2>!AMI(DXF$yg%&Yd$Fycd8A$X5*V6U$b{E=a+Y0PcWj8Tt_(lf=@Eq@zHi=D-7QNUe83i zu4+qbDLsj4+Gf@2bNhL|^Lhplw&|X(Uj!#{^4Kdxm}G-#)=gPSpE{G{!^}jW0u^!h zP$h3BJ~lZkQId8$4i9I*Pi69g8MukS?Pxq=8vROH7TWD{OuQc9j|hA`Z|ai{99pI8 zCRXklU{tK$d_D1vv?xY6u*e`z!W9oOLu}`v@GI$V3sT{)NBQIx_mNW3`0~g9<}1pV zL+?$3PsDv>CZBwSa2dHjF5VGDlyg$;)nIHxRP!gt6Xs%mCHn-SVpZ@> z%eiJ3eunf#1}#V$@jcX)2WX=4N$Eda}SX5*kwL{|&$*g)kaV<)= zFBU76tU%C_d*)-Sxoy5&V22shziazHe; z>-qG4EIYtYOOpC%=+XNOTD5dtvxk(Bp!r}e|TqKaJ4#Gg)Bp}8@^t%tN2Gq z)+r68WS#zsuTx&EgD;Nz>AZD%XF9GI4q$M}o~Lb`$3^zntDL`ZuCay4GeWlpHdV-d zz1j%;VMn*iY`E{%s+Lqd1~Lt>=w-3m&9ScBV>m-5MjAefo;$+;2j>@ryk_c8=C zkk8E^i}BKwZ3KJXJcf;d*Q10(4gu*0$QTlA12;0x(vBTjxVF5WiRN_C=_Kl!C~!a3 zjJRNZCr;~;c@OKzznRLAaTNu(aGZj`8bU-N{+N6>=*{E7O?pn(pP)B7NBx^}5qfN5 z&r+#W5K0niCUg1D+<3(M^6%Th>eF@k-d{&tU{cKfkOyHoEKuo--(IJ_HF1f0WRp$V z+*|7`!*&G<=a5p!giE?v_fYKbWqwyW=e)TW=6~hajV@!s$*zbuXXrbryiC-vCgo*n zvXQ(th3u=?Q_ZH=GxV-;MS0kq#0$eWbP2jbIOhn}#gmF?gv5lnxU^K!0yRzQYn+dy zIFYo50FhRvK7=Oi5i{!)hyhR87JqQT-O7fLLJ2w6s}lIMaQPCXUDX2w%oR`=n^X@k zKJaNh?tjn(F&%SZ0?N&H{m}qQ9tH4l9a!;MIZ=XLwd*W^-v#+ zvk`ZjY63c|hDUVU9Z7Jym{#k9oWQ&uZ^Ih3;bg8z1q&h;gc3F~q#7A~`AEp5oQt`3 zF(t_DzR+Aey(13YP~Xk58za4uaYKJW$7v#B@#5%Wa9x!-ncN8BU@yKe;ao=pGVqJ< z{)PYiK<$G$vQRyN+kK}?GvzOLikoxWBitV_f4C1x1^6?^hRP&V1B_MR8#GC#s6#I%Tynv z2}`AAnVZY>GtfIAIr(lVyIYV;D!Z?%QaY5~5v)_Vp)z#V*SHYM&{!A$(B+LaQ*l?W zc07h&y0A%G8%5I2sdH=&&d9It?qc?pU;pOc|2x93o3KdouZLe({`?@^Z9osq0BV|` zKL_8-M~pxoPc~?iAcz1fBOKKv`~y*D!;B&jt94baCd$Qf(U7Nz_^rhtXD1dFQA)&= zWmFI-sPK*{G}|PQHq9=zvX>ECdyyHtZTw6 z>Pev9NqR%v>h=(W>7;u25|QEv1bjjk=uV}wx@rEKk=!aOX<@RYHZCLp@#`~F$-M6c zefeMcBY%wZ&U;;mrf`)V=Kb9GgiojCb9b3HMc0Ji05T3)2Pm>d4_|eyhSZzsmU568V z>8v>1uTA^wL>zdWw(>I~d?PAdl+R7d3G=FGH5yGYvFHK#RYWEcp*#QYJO5El&gHhx zWY70o%>#ApDP^U*Ce33R!YsAvK=>Y_1B0iRe5}rDIEP`xF#e1T@7qLaW7RhbBz>zW zZOCc<0^=9y&7E)#-`@Uv`#XEtelvFt7oaXjZ?r!z|IQwPE76y?Lmaun541DPo4Cwx z)`jZG`2>xQMsJ7&m)Z|d6~;~m*$^YhGUKS+*qr)P3`96g^aRlXnYL23r>{D5dXRtv=hZ#OTeDrJpDh2GXUa20dM$Z{z zvb3*w>#BJ7s{s#XT=55ZN6GS*o?2Ebl{GrP!SFL_T0(2(HAsm?3eDt}36+cGwO7}@ z9)42ZT(eh*V=VebWw`Xw8x3H#P%1SopuF+x_l%oZ=htc}ATtvo1ISSK8-Zf6M96%EQ0-8t71~dcx2%6c*!mE*%my zO64-3L$l*sp;y>1=j?MSUYtvZ)b9ZtoK#PAKOB!|@XI*CW$=2z6@Z(F4#dKz=$25Z z4EmTl$eDK5uUB5;BZei%A8+8A!iWzyy`qtc3Mq!rj!pd5O*Lde)Q$UK63_f^{nrP? zzvkc&WP@|1_=lMqjUJJffSt+uw;^bQ(@Igu=^MZGV1|59@@DOaLKMS8d%BLWS%p|$mWAPo&}rbIxRB!if#c)h1lq3LgeG3_F`#lQLPhoexR#{)mIzstEOnH;eru9wz=CKl^>ZwY`_Ms|WO3 zV3g45;Dgo>mPz8H3_9akU-|t(_1=p0!1B zc0kY^&svjsM!tcuiwU|?y4Vf**!Y66RAT*8@pIB)6-Oi)COlYtTo)Vtk7%iL@DzL- zE_3xdAF2VuwUr@}7X6SiSUS1ND5K1beR9r_L_ED8{b?WnuipiF*|y6Eqf3}z;#VSn znkDzzDXCI#;@1%ODNyLmw=eiISziugKVC@gZVQj&J#OJ0P;vnW-_N^G0loqi9pSn) z$Lmxtg)pF8Cu>yq)eM85;2Om5Qt+g3f=6k7JxN89yCo z;xAQJcyd5O6`tTUToHL|%@7$pfgp0FTmmXXH9!z>!EucE{Pd1|M>*~ne`W*t+=Br= zbg5(97{TWqP)RswY2ZA1n-mlL0d$&cq`&tN7xTW}52}B0!ccjM84O9|x)7E}p7dDqZA9SoNM;h2c3`;9w)m3@bSLnEwZ-9&CMK3~ zw~zTseGc&cQo6v`*8Gbq_-bdE)BY_>I_g1uagtBL0APMgMGBE+*)U0E9?UgY71h3U znM~lt8RM3$lOQiz`5RyPqg*G5Ye!A_;8!Y-zxj27SnP<$u8ZO|omIw{mAnhlL*fqohf8sX~o*Lj#!K-+W_U`Zf3i#e0s1U5{6|GDUN9iJIZsb%+ z-Ao=?-uYgf`7tkv96&os!^H5;tTg#tlJIx!9y6-8y-ZC!}~g zTf)gad98wUah15hpJFTDTOFT}_gWtVitH4HY(Lp8t|F~o1$K*Ttb^aO4h~&XG%4u? zKUUCE)BVf$SEoVo)QBjX5&a>)%Y@1zW(3AgUSJ&kKV@GmLzu{4kgaf07akDBQHGnv zgS|=vB9@>52VYaRZ{Eu#XF zy5V}@u-d~Fhm?WW0;)|BX8s7FG)`|NHB_gI6!MVJnDFhh6MJ0Um*r z4Zr}+@k|~OwH4ioOJrZiEa;EPvWev}zG2Ae9INVlU&!{IRWdrM z{<(Zxhil*18cY{4NHB*huwHnPw^5R!FHVmzY8=Eth=V;oqWiEuGW>;P_%mwo8AOy# zn+Kt&#M6)ZZrw$GG#Vg(U^4sE%YdcJ)i#x@!R(9e)82_P~yD=aSDBeCd7Fiu0aPdU==#8^ceR! zNjcKv#pY}@0)4V-rMd;bTdek*R_e0*D)*GVH-cVmvGRu|_to1t6hMp}Wayj;ZVucb z=H0&lZ=tvF)OWf>E+ly~`8d{>*XQTiJmnGd?{z=KeNC?1O`F^6?9XNKgfQ&gkNyC* zf9JQs-@{Gh^AA>El{5_abPO-qX4TGp#9EczZ{U7az{gv@i5|kU?O&+l*hCRb(yUxg z(APP>AJw|9gcsiv{e%>@p_fL>cx=`5pJ?<#h9$4xbeXX-e31HK>TE6xt49MI$Ao>sBIst!oUM+Y_EfSVpF2|2p}&)v3&_HlJ% zrvn&KVYEV-z)vzWltzV8iQ<62u&2=4Arz&(T$ry|xa;_1RfT6;$!M|q!Z6H>)WUg$ z-BRf$;pJI`_FLkh0X~pw1vTg5I}ITeLDmc(A5Mn$3q|{s+;YTvGjr2S4j`FXuZLrb z8klX7ee5xulJFcV2x~_=hKUdJWg-2-A&6Mv5F+`)?lZ#BGNJHexUe7{9!|Pe9>!HE zDT)msnihn%0%+cEM#N13Yt(wwp9Kd7K7aMnMFcLP_ThdLB6g_rKkLStHU{#id8je(W$Yd2XB z#|Gn4?X|0-s8EM(lX}+#_z1hj>6Y=spYTrlW-pu2gs>wZ&UG2Q|FPHnEO``k3jU#E zF`~36iGzw6bfV0>(ED9F}&JNK!AG~e-sdgJ-DKw@M7uw@;mBqE(K3l zqMc^`S?62U3)LoEK@dq-5k%6I1hI+`$xp8?yp41INBQzjAa6lCm-Le$VAomccjCIooWB2p{ zJK@XotxZPY>#*X<*Fn?If;%(G;LhMcn54Qok`RkRyXunr)WdkcUijVraeI#k2UR8_ zISTvKxq4Okd(aZ}s%GeUIo(O>yLP=Qy(m)MRHagg17(>tLqYb^<;a8y;|#SLJ3ZPM zgu?{#6>iLj=vf)+hM_V(4tFis&c*O!v2}H`OT9nthj>Xcemc&)8z`%N2a|RqfNO$^ z<(3io*vvGF6>~RK-cpkgujf{!SX2d*3LH=ANvF7Knpwp){hZekvO=Jg&1Ibm5R=#qdo(2pUa26N9xCd zc-yAKK;cq^Pm!{Zpd!J0xN2MFMP9+n|Cb+uOP)_;iudk3kr|>K=G||Ao?WvART{M; z;R~ZT%_T*6||qegSy{>z`b=+{@8Fwu|M>?lCfm zr;&v>EQ8;ekQtZhfEpX&kA7xD4batc#^S8OSeADIpD?2sZ%P{M1cW4`kg$4b_z$kQ6Q_HJnMunM~rOG8Y|b`%g<7cE>S zP26uGTxSd!NrjT`K(Ao?-QK5%xSp2!`=`kpREe0+u-65Iejkf?+Od_;rY$Atl6GOP zBjusA0`3g)goqUQCEZ_|B!dk#wEG3Y@8n*JI6%|_9#qO(t7at$VFOHPRGNXLtuN-T zf}US$eccWIMpwS=zrfC1ZpNvLqJY_cecnBkuau}CSKeXXjB_8mwfMaP?>it75jX!C zqH@Y|1BP%d`5MaO4@ZvchaNVL%;Bv(JU^`~D#FjV{hH6!A!WS^6xStD$8wP-1?Bl< zWmw;H)6#)&LzHO+J#CS0d!|M9wIUiyG`v#?@aUl7#y9A(j9I6}9`%`!_2LhXTO*ZQ55h|6^;_q+TE zUUGhAME4#>`@F%o{9&xy7Z`Z(I1~HU^{&@E{LB6v&H)$*?6>p>XI2~Z2WQeeBv<|N z5hQNGF^l~F8_^E_z0du|_FmVmxB`EIDyatszab4eg~Nsq&KmGQlJMG{qVWBYN8`t~ zlRPm|Q+c%~r{%i(UB3R@l_Wqh{y#vW%YHOcXhh$wqgUR_|2jNMC%U5jIzZoKvzI>V z&Q6$Fmi){S3h+I3SC2F(Gq@9e75N#yZ-95lkpcH7d^&}309-GmgCAuThp zi(^~-4Ght6c4(Pcjug4DS z($^*wJJb3A7wogr4^_<#U}zh7WIY_qj&SO{>-B1A0#J!4tWql49q{Vbx&@-CY^}jTI>9sa85eHhme>3$(IX)5hLdww zyoY$>dxSvk3C0p1Up;I#4o#jt9_Q)RV#p+PKybIf+7vFq>xk(ce}$~WrS?a0-k4sA z|9FtZE&DOZr4ZQiB7U(}{hrhit5|xpV|m<+?yHrxC#UzN$-Y6JB<(M}zfOL>Bv15D z@=O1Mzh6)3p7b93YpDpixcT+jST8}R>N0T<9)7!iP&Hq^0}9BOgn@ht0tDC_Fyw5Xg<#l-RIqD_ zSzX~5z);jx#z@wp?olO?lw(!kH;|w!icpUTF`3z{!TAo_ku*FMd0Ix^A85@lOb-m3 zAd5uRgqc6(ssiAYxFQmg+8Kcl>f=hmI#OedTs%lUs00TORHU_xMt}g8Q{I35N&%~9 z$SufN)Fle8)=(e9zTHGb{e8Fp8=-XqozbU&HbR8SEDt%5|aNR>I+d zHyY!Nnn$5`&CUU8l^&@-0(f&|m=)z0878WuV%=64=SJ0=MilsvgcpLYpb3PzVW64z z5}ponGG#ftC)&95vD-FhIj`J021;Tyw2u%;BZiuFnDS|kx%UfW1J41l^WrG=Ficji z*F_|H>4&7`H9`SESZD>nI-+dwL%`2*6%+slI}OV-$<@fd2vje;bAQ+f$O#=7!g!1y|Rw zzbRvlB>c6D$2xjqSW_k%wqhX|V-X&-g@rE{Hv?a;tTJ-UJ9ecM66TBn!Cv$bP(f2_ zbyhOQxl#&#xV7aBz0EKDr*GTYBgWgld|THuAJe$AsA4oT?(+R&Y3@0ZLBU9&RT ztAQ6rf_1O4dDi&E&vgsGEd*@P)_<}Rbs6@D_FwPt`cwP3oyM`Fhn=U|kk#b)#0sjQ zhQ5fa$FjGDXMPE%C$iRMYi`+|$}Jo2P||w%UadJL)ywMG@Ynz!jVx%=NR>RmC>D#} z>#@S!V(ihdH#$24vW$n$?cph;eUsBAWGEU>GLH8J4l1Z(neZ#zZ#x(mB-AE#K~5$7 zh?H(OkEq@xI27g`evmo?Z2_E-UMzNDU2K&V;ElMi9s;{@6Gin7p~C}a1RRMC#4$cs z{9#TQSP0l~WhHESsxZJqBWkJ3i^Chzuq~Z{aeG#1g(~4boM|a8SEWGN z2|f^@V3}Ki9wI?$(O$FBHB=_BhzH~OZJ`2eeh}zS+zr^h$RG{64P8f4M?fZd62@O@ z(Q)RULk`?|y0(%+HUuYE!bncthuc2&f&L3}dQ4)TkANgEWfKB>Fpnp2Jec19{)<OdS*DE zb*a|oDsNaY&?iVdLih0KH3GGvrDNZz|7gH%o|BR~(s?k9PqXxJ0)PJ6uJdVJ4DXz> zjpd7flO_5Jif5{ii8bi)uHBTV64ZQxl8>tROk&jBr)2%SA#!Ny7rpoJ%iCB#B2sWC zSh{|$dQS@ZqtrVoe>8m8S7aZeb3)HE{2Gr_>`Wna%u0ZkTlBd-U!oURl3%|S?SjAb z5B~@8;v^010KC9Rjz)Ps38klxXuFA(oZ9(F-Yj}5^;{;d13=PE8lVvx{ton7)a8x5 zcLpw*zofyi2U$USAEO^F`CqO>l`EVR*A0V=@q|PGXMee$U~)|l@4VbMi39fW5D06* zp^fzD&9I+;_P5@He=Qg|&WLMso_#=hv35b1r2d(7sS3PNU0L`EeQwv#2zdih-E);U zp%Efrn=y9!S`_s)vlFFCNcQO)DY^e!46GYk%J@v_9q@>EC>Ez}b7Mo;%=7NC!oUz; zY~eiOlWde0{DaW z^5tw_gL7ZRzI2bUO@T`f4yQq0IaWRjm4NwDtkDjnX=9b(SPHEr^lcVI%aj+-Ekc(_ zf!0ktiR6ZoDCSzQKiU~E_X6uN(xp$nF8)=(CcXP7J_9@KQ`{LSstNz3eA2mgORI~` z5Af+EyNi4#+N$DEOo`6exR{Pazq@0D-f z8*jgf5Yisj>boBIK-&FLj;ls*uF5CRf$C+pjKEd+*|%c+`jvP8)Guwn6#^T|@(uUy zX*@-{cZa8Y_iCTo2l-We@>-07JYRGMS2xKZcoL|RpGw`w=GzCQ@KCEz_o>l{vS_*J zj&WvBWOFfA*Y`6#%55kAINAL;yZza<} zTib$$n(cI38_1j}=v?t5`i_5ZW?PoSJY9>x?AWe`|4Tb+v3^e6}{$u_JqQ+^KaC;^DrvqjB2a z3hQ$s9Ima?m+^4(bmTgoFG*je>9-yRInuYk@*SVudCTHXxcq2mj-SHIz)jr4dcp<_ zxjhLIv5rqsestn^PH%X)RT6gkghEXzjFb>Ie&}hXo(8s;Z|f;zJZ3W_beDnmrhF6m zZKY?RT;@87uk}U0pEN>Z;2OWQ*q{Xd`>lt;4)IIXUp)YR^9K4`peLAcRyohkcCqGOmO5($E=eC`Ufy~m%-_n&4}Nv~Ev#LSOeW`NnLqVsIwxM? zClFES?v&pu&6`@6T>q3$I^BW(pN7rK1svSNg*NZ$T)$D*JNPR#zoy>h2|yJ>L6DuV z5?!Yg^#SMSf40f;xM7sbUVdnOOukphpu>S??PRaz{JM~z9qIdE{yfDuo;6Q5^&Lkp zum6;PW*Po4571F^%_MSO&Ltt~B1?F*C@R-eE|qY{BD%HZ(kd7-tz|qGKB)pO%h)5B zD{Yu*19gmyLE0>?!!r#Z$G>z2Up0We)iA)_-A(BhK{gIj5)OWAofGjKKK&0cAzzj&_~{v zm;cA`rvLs$hauPlz5PJv^KB@^fR(Ltf#uiV`IV2x*hB;`&M&*XB`z^f|L^|;*}&hc diff --git a/data-raw/datasets/antimicrobials.txt b/data-raw/datasets/antimicrobials.txt index e17bb3ab6..3590c958b 100644 --- a/data-raw/datasets/antimicrobials.txt +++ b/data-raw/datasets/antimicrobials.txt @@ -1,499 +1,499 @@ "ab" "cid" "name" "group" "atc" "atc_group1" "atc_group2" "abbreviations" "synonyms" "oral_ddd" "oral_units" "iv_ddd" "iv_units" "loinc" "AMA" 4649 "4-aminosalicylic acid" "Antimycobacterials" "J04AA01" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "aminacyl,aminopar,aminosalyl,aminox,apacil,deapasil,entepas,gabbropas,granupas,helipidyl,hellipidyl,nemasol,nippas,osacyl,pamacyl,pamisyl,paramisan,paramycin,parasal,parasalicil,parasalindon,pasade,pasalon,pasara,pascorbic,pasdium,pasem,paser,pasmed,pasnal,pasnodia,pasolac,passodico,pharmakon,propasa,rezipas,salvis,sanipirol,sanipriol,sodiopas,spectrum" 12 "g" "NA" -"ACM" 6450012 "Acetylmidecamycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA" -"ASP" 49787020 "Acetylspiramycin" "Macrolides/lincosamides" "NA" "NA" "antibiotic,espiramicin,espiramicina,foromacidin,provamycin,rovamicina,rovamycin,rovamycine,selectomycin,sequamycin,spiramycine,spiramycinum" "NA" -"ALS" 8954 "Aldesulfone sodium" "Other antibacterials" "J04BA03" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "NA" "adesulfone,aldapsone,aldesulfone,aldesulphone,diamidin,diason,diasone,diasoneenterab,diazon,didimethanesulfinate,novotrone,sulfoxone" 0.33 "g" "NA" +"ACM" 6450012 "Acetylmidecamycin" "Macrolides" "NA" "NA" "NA" "NA" +"ASP" 49787020 "Acetylspiramycin" "Macrolides" "NA" "NA" "antibiotic,espiramicin,espiramicina,foromacidin,provamycin,rovamicina,rovamycin,rovamycine,selectomycin,sequamycin,spiramycine,spiramycinum" "NA" +"ALS" 8954 "Aldesulfone sodium" "Other" "J04BA03" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "NA" "adesulfone,aldapsone,aldesulfone,aldesulphone,diamidin,diason,diasone,diasoneenterab,diazon,didimethanesulfinate,novotrone,sulfoxone" 0.33 "g" "NA" "AMK" 37768 "Amikacin" "Aminoglycosides" "D06AX12,J01GB06,QD06AX12,QJ01GB06,QS01AA21,S01AA21" "Aminoglycoside antibacterials" "Other aminoglycosides" "ak,ami,amik,amikac,amk,an" "amikacillin,amikacina,amikacine,amikacinum,amikavet,amikin,amikozit,amukin,arikace,briclin,butirosins,kaminax,lukadin,mikavir,potentox,prestwick" 1 "g" "101493-5,11-7,12-5,13-3,13546-7,14-1,15098-7,17798-0,18860-7,20373-7,23624-0,25174-4,25175-1,25176-9,25177-7,25178-5,25179-3,31097-9,31098-7,31099-5,3319-1,3320-9,3321-7,35669-1,42642-9,48169-7,50802-8,50803-6,56628-1,59378-0,60564-2,60565-9,6975-7,80972-3,89484-0" -"AKF" "Amikacin/fosfomycin" "Aminoglycosides" "NA" "NA" "NA" "NA" -"AMO" 54260 "Amorolfine" "Antifungals/antimycotics" "D01AE16,QD01AE16" "Antifungals for topical use" "Other antifungals for topical use" "amor" "amorolfina,amorolfinum,bekiron,corbel,curanail,fenpropemorph,fenpropimorph,fenpropimorphe,forbel,funbas,loceryl,locetar,mildofix,mistral,morpholine,odenil,omicur,pekiron" "NA" -"AMX" 33613 "Amoxicillin" "Beta-lactams/penicillins" "J01CA04,QG51AA03,QJ01CA04" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "ac,amox,amoxic,amx" "acuotricina,alfamox,alfida,amitron,amoclen,amodex,amoksicillin,amolin,amopen,amopenixin,amophar,amoran,amoxi,amoxicaps,amoxicilina,amoxicilline,amoxicillinum,amoxidal,amoxiden,amoxil,amoxillat,amoxina,amoxine,amoxipen,amoxivet,amoxycillin,amoxycillinsalt,amoxyke,anemolin,aspenil,atoksilin,bristamox,cemoxin,ciblor,clamoxyl,damoxy,danoxillin,delacillin,demoksil,dispermox,efpenix,eupen,flemoxin,flemoxine,galenamox,gramidil,hiconcil,himinomax,histocillin,ibiamox,imacillin,izoltil,kentrocyllin,lamoxy,largopen,larotid,matasedrin,metifarma,moksilin,moxacin,moxal,moxaline,moxatag,neotetranase,novabritine,ospamox,pacetocin,pamocil,paradroxil,pasetocin,penamox,piramox,promoxil,quimiopen,remoxil,riotapen,robamox,sawacillin,siganopen,simplamox,sintopen,sumox,topramoxin,trifamox,trimox,unicillin,utimox,velamox,vetramox,wymox,zamocillin,zamocilline,zimox" 1.5 "g" 3 "g" "101498-4,15-8,16-6,16365-9,17-4,18-2,18861-5,18862-3,19-0,20-8,21-6,22-4,25274-2,25310-4,3344-9,55614-2,55615-9,55616-7,6976-5,6977-3,80133-2" -"AMC" 23665637 "Amoxicillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR02,QJ01CR02" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/c,amcl,aml,amocla,aug,xl" "amocla,amoclan,amoclav,amoksiclav,amoxsiklav,amoxyclav,ancla,augmentan,augmentin,augmentine,auspilic,clamentin,clamobit,clavam,clavamox,clavinex,clavumox,coamoxiclav,curam,eumetinex,kesium,kmoxilin,spectramox,synulox,viaclav,xiclav" 1.5 "g" 3 "g" "NA" -"AXS" 465441 "Amoxicillin/sulbactam" "Beta-lactams/penicillins" "J01CR02,QJ01CR02" "NA" "NA" 1.5 "g" 3 "g" "55614-2,55615-9,55616-7" -"AMB" 5280965 "Amphotericin B" "Antifungals/antimycotics" "A01AB04,A07AA07,G01AA03,J02AA01,QA01AB04,QA07AA07,QG01AA03,QJ02AA01" "Antimycotics for systemic use" "Antibiotics" "amf,amfb,amph,amphot" "abelcet,abelecet,ambil,ambisome,amphocin,amphomoronal,amphotec,amphotericin,amphotocerin,amphozone,funganiline,fungilin,fungisome,fungisone,fungizone,halizon,nystatine,nystatinum,terrastatin" 40 "mg" 210 "mg" "16370-9,18863-1,23-2,24-0,25-7,26-5,3353-0,3354-8,40707-2,40757-7,49859-2,6978-1" -"AMH" "Amphotericin B-high" "Antifungals/antimycotics" "NA" "amfo b high,amhl,ampho b high,amphotericin high" "NA" "NA" -"AMP" 6249 "Ampicillin" "Beta-lactams/penicillins" "J01CA01,QJ01CA01,QJ51CA01,QS01AA19,S01AA19" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "am,amp,amp100,amp200,ampi,ampici" "adobacillin,alpen,amblosin,amcap,amcill,amfipen,ampen,amperil,ampichel,ampicilina,ampicillina,ampicilline,ampicillinesalt,ampicillinsalt,ampicillinum,ampifarm,ampikel,ampimed,ampinova,ampipenin,ampiscel,ampisyn,ampivax,ampivet,amplacilina,amplin,amplipenyl,amplisom,amplital,austrapen,bayer,binotal,bonapicillin,britacil,cimex,citteral,copharcilin,cymbi,delcillin,deripen,divercillin,doktacillin,domicillin,duphacillin,grampenil,guicitrina,guicitrine,lifeampil,marcillin,morepen,norobrittin,nuvapen,omnipen,orbicilina,penbristol,penbritin,penbrock,penialmen,penicline,penimic,penizillin,pensyn,pentrex,pentrexl,pentrexyl,pentritin,ponecil,princillin,principen,racenacillin,redicilin,rosampline,roscillin,semicillin,servicillin,sumipanto,supen,synpenin,texcillin,tokiocillin,tolomol,totacillin,totalciclina,totapen,trafarbiot,trifacilina,ukapen,ultrabion,ultrabron,vampen,viccillin,vidocillin,wypicil" 2 "g" 6 "g" "101477-8,101478-6,18864-9,18865-6,20374-5,21066-6,23618-2,27-3,28-1,29-9,30-7,31-5,32-3,33-1,3355-5,33562-0,33919-2,34-9,43883-8,43884-6,6979-9,6980-7,87604-5" -"SAM" 119561 "Ampicillin/sulbactam" "Beta-lactams/penicillins" "J01CR01,QJ01CR01" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/s,ab,ampsul,ams,amsu,apsu,sam" "sulacillin" 6 "g" "101478-6,18865-6,20374-5,23618-2,31-5,32-3,33-1,34-9,6980-7" -"AMR" 73341 "Amprolium" "Other antibacterials" "QP51BX02" "NA" "amprol,amprolio,amprovine,anticoccid,cocciprol,corid,mepyrium,picolinium,pyridinium,thiacoccid" "NA" -"ANI" 166548 "Anidulafungin" "Antifungals/antimycotics" "J02AX06,QJ02AX06" "Antimycotics for systemic use" "Other antimycotics for systemic use" "anid,anidul" "anidulafungina,anidulafungine,anidulafunginum,biafungin,ecalta,eraxis" 0.1 "g" "55343-8,57095-2,58420-1,77162-6" -"APL" 6602341 "Apalcillin" "Beta-lactams/penicillins" "NA" "apalci" "apalcilina,apalcilline,apalcillinsalt,apalcillinum,lumota" "NA" +"AKF" "Amikacin/fosfomycin" "Aminoglycosides,Phosphonics" "NA" "NA" "NA" "NA" +"AMO" 54260 "Amorolfine" "Antifungals" "D01AE16,QD01AE16" "Antifungals for topical use" "Other antifungals for topical use" "amor" "amorolfina,amorolfinum,bekiron,corbel,curanail,fenpropemorph,fenpropimorph,fenpropimorphe,forbel,funbas,loceryl,locetar,mildofix,mistral,morpholine,odenil,omicur,pekiron" "NA" +"AMX" 33613 "Amoxicillin" "Aminopenicillins,Penicillins,Beta-lactams" "J01CA04,QG51AA03,QJ01CA04" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "ac,amox,amoxic,amx" "acuotricina,alfamox,alfida,amitron,amoclen,amodex,amoksicillin,amolin,amopen,amopenixin,amophar,amoran,amoxi,amoxicaps,amoxicilina,amoxicilline,amoxicillinum,amoxidal,amoxiden,amoxil,amoxillat,amoxina,amoxine,amoxipen,amoxivet,amoxycillin,amoxycillinsalt,amoxyke,anemolin,aspenil,atoksilin,bristamox,cemoxin,ciblor,clamoxyl,damoxy,danoxillin,delacillin,demoksil,dispermox,efpenix,eupen,flemoxin,flemoxine,galenamox,gramidil,hiconcil,himinomax,histocillin,ibiamox,imacillin,izoltil,kentrocyllin,lamoxy,largopen,larotid,matasedrin,metifarma,moksilin,moxacin,moxal,moxaline,moxatag,neotetranase,novabritine,ospamox,pacetocin,pamocil,paradroxil,pasetocin,penamox,piramox,promoxil,quimiopen,remoxil,riotapen,robamox,sawacillin,siganopen,simplamox,sintopen,sumox,topramoxin,trifamox,trimox,unicillin,utimox,velamox,vetramox,wymox,zamocillin,zamocilline,zimox" 1.5 "g" 3 "g" "101498-4,15-8,16-6,16365-9,17-4,18-2,18861-5,18862-3,19-0,20-8,21-6,22-4,25274-2,25310-4,3344-9,55614-2,55615-9,55616-7,6976-5,6977-3,80133-2" +"AMC" 23665637 "Amoxicillin/clavulanic acid" "Aminopenicillins,Penicillins,Beta-lactams,Beta-lactamase inhibitors" "J01CR02,QJ01CR02" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/c,amcl,aml,amocla,aug,xl" "amocla,amoclan,amoclav,amoksiclav,amoxsiklav,amoxyclav,ancla,augmentan,augmentin,augmentine,auspilic,clamentin,clamobit,clavam,clavamox,clavinex,clavumox,coamoxiclav,curam,eumetinex,kesium,kmoxilin,spectramox,synulox,viaclav,xiclav" 1.5 "g" 3 "g" "NA" +"AXS" 465441 "Amoxicillin/sulbactam" "Penicillins,Beta-lactams,Beta-lactamase inhibitors" "J01CR02,QJ01CR02" "NA" "NA" 1.5 "g" 3 "g" "55614-2,55615-9,55616-7" +"AMB" 5280965 "Amphotericin B" "Antifungals" "A01AB04,A07AA07,G01AA03,J02AA01,QA01AB04,QA07AA07,QG01AA03,QJ02AA01" "Antimycotics for systemic use" "Antibiotics" "amf,amfb,amph,amphot" "abelcet,abelecet,ambil,ambisome,amphocin,amphomoronal,amphotec,amphotericin,amphotocerin,amphozone,funganiline,fungilin,fungisome,fungisone,fungizone,halizon,nystatine,nystatinum,terrastatin" 40 "mg" 210 "mg" "16370-9,18863-1,23-2,24-0,25-7,26-5,3353-0,3354-8,40707-2,40757-7,49859-2,6978-1" +"AMH" "Amphotericin B-high" "Antifungals" "NA" "amfo b high,amhl,ampho b high,amphotericin high" "NA" "NA" +"AMP" 6249 "Ampicillin" "Aminopenicillins,Penicillins,Beta-lactams" "J01CA01,QJ01CA01,QJ51CA01,QS01AA19,S01AA19" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "am,amp,amp100,amp200,ampi,ampici" "adobacillin,alpen,amblosin,amcap,amcill,amfipen,ampen,amperil,ampichel,ampicilina,ampicillina,ampicilline,ampicillinesalt,ampicillinsalt,ampicillinum,ampifarm,ampikel,ampimed,ampinova,ampipenin,ampiscel,ampisyn,ampivax,ampivet,amplacilina,amplin,amplipenyl,amplisom,amplital,austrapen,bayer,binotal,bonapicillin,britacil,cimex,citteral,copharcilin,cymbi,delcillin,deripen,divercillin,doktacillin,domicillin,duphacillin,grampenil,guicitrina,guicitrine,lifeampil,marcillin,morepen,norobrittin,nuvapen,omnipen,orbicilina,penbristol,penbritin,penbrock,penialmen,penicline,penimic,penizillin,pensyn,pentrex,pentrexl,pentrexyl,pentritin,ponecil,princillin,principen,racenacillin,redicilin,rosampline,roscillin,semicillin,servicillin,sumipanto,supen,synpenin,texcillin,tokiocillin,tolomol,totacillin,totalciclina,totapen,trafarbiot,trifacilina,ukapen,ultrabion,ultrabron,vampen,viccillin,vidocillin,wypicil" 2 "g" 6 "g" "101477-8,101478-6,18864-9,18865-6,20374-5,21066-6,23618-2,27-3,28-1,29-9,30-7,31-5,32-3,33-1,3355-5,33562-0,33919-2,34-9,43883-8,43884-6,6979-9,6980-7,87604-5" +"SAM" 119561 "Ampicillin/sulbactam" "Penicillins,Beta-lactams,Beta-lactamase inhibitors" "J01CR01,QJ01CR01" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/s,ab,ampsul,ams,amsu,apsu,sam" "sulacillin" 6 "g" "101478-6,18865-6,20374-5,23618-2,31-5,32-3,33-1,34-9,6980-7" +"AMR" 73341 "Amprolium" "Other" "QP51BX02" "NA" "amprol,amprolio,amprovine,anticoccid,cocciprol,corid,mepyrium,picolinium,pyridinium,thiacoccid" "NA" +"ANI" 166548 "Anidulafungin" "Antifungals" "J02AX06,QJ02AX06" "Antimycotics for systemic use" "Other antimycotics for systemic use" "anid,anidul" "anidulafungina,anidulafungine,anidulafunginum,biafungin,ecalta,eraxis" 0.1 "g" "55343-8,57095-2,58420-1,77162-6" +"APL" 6602341 "Apalcillin" "Penicillins,Beta-lactams" "NA" "apalci" "apalcilina,apalcilline,apalcillinsalt,apalcillinum,lumota" "NA" "APR" 3081545 "Apramycin" "Aminoglycosides" "QA07AA92,QJ01GB90,QJ51GB90" "apramy" "ambylan,apralan,apramicina,apramycine,apramycinum" "23659-6,73652-0,73653-8" "ARB" 68682 "Arbekacin" "Aminoglycosides" "J01GB12,QJ01GB12" "arbeka" "arbekacina,arbekacine,arbekacinum,haberacin" 0.2 "g" "32373-3,53818-1,54173-0" -"APX" 71961 "Aspoxicillin" "Beta-lactams/penicillins" "J01CA19,QJ01CA19" "apoxic,aspoxi" "aspoxicilina,aspoxicillan,aspoxicilline,aspoxicillinum,doyle" 4 "g" "NA" +"APX" 71961 "Aspoxicillin" "Penicillins,Beta-lactams" "J01CA19,QJ01CA19" "apoxic,aspoxi" "aspoxicilina,aspoxicillan,aspoxicilline,aspoxicillinum,doyle" 4 "g" "NA" "AST" 5284517 "Astromicin" "Aminoglycosides" "NA" "astrom" "abbott,astromicina,astromicine,astromicinum,fortimicin,istamycin,istamycins" "NA" -"AVB" 9835049 "Avibactam" "Beta-lactams/penicillins" "NA" "NA" "avibactamfreeacid" "NA" -"AVI" 71674 "Avilamycin" "Other antibacterials" "QA07AA95" "avilam" "avilamycina,avilamycine,avilamycinum,inteprity,kavault,surmax" "35754-1,35755-8,35756-6,55619-1" +"AVB" 9835049 "Avibactam" "Beta-lactamase inhibitors" "NA" "NA" "avibactamfreeacid" "NA" +"AVI" 71674 "Avilamycin" "Other" "QA07AA95" "avilam" "avilamycina,avilamycine,avilamycinum,inteprity,kavault,surmax" "35754-1,35755-8,35756-6,55619-1" "AVO" 16131159 "Avoparcin" "Glycopeptides" "NA" "NA" "firvanq,tagocid,targocid,targosid,tecoplanina,tecoplanine,tecoplaninum,teichomycin,teicoplanina,teicoplanine,teicoplaninum,teikoplanin,ticocin" "NA" -"AZD" 15574941 "Azidocillin" "Beta-lactams/penicillins" "J01CE04,QJ01CE04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "azidocilina,azidocillina,azidocilline,azidocillinum" 1.5 "g" "NA" -"AZM" 447043 "Azithromycin" "Macrolides/lincosamides" "J01FA10,QJ01FA10,QS01AA26,S01AA26" "Macrolides, lincosamides and streptogramins" "Macrolides" "az,azi,azit,azithr,azm" "aritromicina,aruzilina,azasite,azenil,azifast,azigram,azimakrol,azithramycine,azithrocin,azithromycine,azithromycinum,azitrocin,azitromax,azitromicina,azitromicine,azitromin,aziwin,aziwok,aztrin,azyter,hemomycin,macrozit,misultina,mixoterin,setron,sumamed,tobil,toraseptol,tromix,trozocina,trulimax,xithrone,zentavion,zifin,zithrax,zithromac,zithromax,zitrim,zitromax,zitrotek,zythromax" 0.3 "g" 0.5 "g" "100043-9,16420-2,16421-0,18866-4,23612-5,25233-8,35-6,36-4,37-2,38-0,6981-5,89480-8" -"AFC" "Azithromycin/fluconazole/secnidazole" "Other antibacterials" "J01RA07,QJ01RA07" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"AZL" 6479523 "Azlocillin" "Beta-lactams/penicillins" "J01CA09,QJ01CA09" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "az,azl,azlo,azloci" "azlin,azlocilina,azlocilline,azlocillinsalt,azlocillinum,securopen" 12 "g" "16422-8,18867-2,3368-8,39-8,40-6,41-4,41661-0,42-2" -"ATM" 5742832 "Aztreonam" "Monobactams" "J01DF01,QJ01DF01" "Other beta-lactam antibacterials" "Monobactams" "at,atm,azm,azt,azt1,aztr,aztreo" "azactam,azetreonam,azonam,azthreonam,aztreon,aztreonamum,cayston,dynabiotic,nebactam,primbactam,squibb" 4 "g" "101497-6,16423-6,18868-0,25234-6,3369-6,41662-8,41663-6,41664-4,41727-9,43-0,44-8,45-5,46-3,6982-3" -"AZA" "Aztreonam/avibactam" "Monobactams" "J01DF51,QJ01DF51" "NA" "NA" "NA" -"ANC" "Aztreonam/nacubactam" "Monobactams" "J01DF51,QJ01DF51" "NA" "NA" "NA" -"BAM" 441397 "Bacampicillin" "Beta-lactams/penicillins" "J01CA06,QJ01CA06" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bacamp" "alphacilina,alphacillin,ambacamp,ambaxin,bacacil,bacampicilina,bacampicilline,bacampicillinum,bacampicine,berocillin,centurina,devonium,diancina,inacilin,maxifen,penglobe,pivatil,pondocil,pondocillin,pondocillina,sanguicillin,spectrobid,velbacil" 1.2 "g" "18869-8,47-1,48-9,49-7,50-5,55620-9" -"BAC" 78358334 "Bacitracin" "Other antibacterials" "D06AX05,J01XX10,QA07AA93,QD06AX05,QJ01XX10,QR02AB04,QS01AA32,R02AB04,S01AA32" "baci,bacitr" "albac,altracin,ayfivin,baciferm,baciguent,baciim,baciliquin,bacilliquin,baciquent,bacitracina,bacitracine,bacitracinum,fortracin,mycitracin,parentracin,penitracin,septa,topitracin,topitrasin,tropitracin,zutracin" "10868-8,16428-5,18870-6,6827-0,6983-1,87603-7" -"BDQ" 5388906 "Bedaquiline" "Other antibacterials" "J04AK05,QJ04AK05" "NA" "NA" 86 "mg" "80637-2,88703-4,88704-2,94274-8,96107-8" +"AZD" 15574941 "Azidocillin" "Penicillins,Beta-lactams" "J01CE04,QJ01CE04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "azidocilina,azidocillina,azidocilline,azidocillinum" 1.5 "g" "NA" +"AZM" 447043 "Azithromycin" "Macrolides" "J01FA10,QJ01FA10,QS01AA26,S01AA26" "Macrolides, lincosamides and streptogramins" "Macrolides" "az,azi,azit,azithr,azm" "aritromicina,aruzilina,azasite,azenil,azifast,azigram,azimakrol,azithramycine,azithrocin,azithromycine,azithromycinum,azitrocin,azitromax,azitromicina,azitromicine,azitromin,aziwin,aziwok,aztrin,azyter,hemomycin,macrozit,misultina,mixoterin,setron,sumamed,tobil,toraseptol,tromix,trozocina,trulimax,xithrone,zentavion,zifin,zithrax,zithromac,zithromax,zitrim,zitromax,zitrotek,zythromax" 0.3 "g" 0.5 "g" "100043-9,16420-2,16421-0,18866-4,23612-5,25233-8,35-6,36-4,37-2,38-0,6981-5,89480-8" +"AFC" "Azithromycin/fluconazole/secnidazole" "Other" "J01RA07,QJ01RA07" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"AZL" 6479523 "Azlocillin" "Ureidopenicillins,Penicillins,Beta-lactams" "J01CA09,QJ01CA09" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "az,azl,azlo,azloci" "azlin,azlocilina,azlocilline,azlocillinsalt,azlocillinum,securopen" 12 "g" "16422-8,18867-2,3368-8,39-8,40-6,41-4,41661-0,42-2" +"ATM" 5742832 "Aztreonam" "Monobactams,Beta-lactams" "J01DF01,QJ01DF01" "Other beta-lactam antibacterials" "Monobactams" "at,atm,azm,azt,azt1,aztr,aztreo" "azactam,azetreonam,azonam,azthreonam,aztreon,aztreonamum,cayston,dynabiotic,nebactam,primbactam,squibb" 4 "g" "101497-6,16423-6,18868-0,25234-6,3369-6,41662-8,41663-6,41664-4,41727-9,43-0,44-8,45-5,46-3,6982-3" +"AZA" "Aztreonam/avibactam" "Monobactams,Beta-lactams,Beta-lactamase inhibitors" "J01DF51,QJ01DF51" "NA" "NA" "NA" +"ANC" "Aztreonam/nacubactam" "Monobactams,Beta-lactams,Beta-lactamase inhibitors" "J01DF51,QJ01DF51" "NA" "NA" "NA" +"BAM" 441397 "Bacampicillin" "Penicillins,Beta-lactams" "J01CA06,QJ01CA06" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bacamp" "alphacilina,alphacillin,ambacamp,ambaxin,bacacil,bacampicilina,bacampicilline,bacampicillinum,bacampicine,berocillin,centurina,devonium,diancina,inacilin,maxifen,penglobe,pivatil,pondocil,pondocillin,pondocillina,sanguicillin,spectrobid,velbacil" 1.2 "g" "18869-8,47-1,48-9,49-7,50-5,55620-9" +"BAC" 78358334 "Bacitracin" "Other" "D06AX05,J01XX10,QA07AA93,QD06AX05,QJ01XX10,QR02AB04,QS01AA32,R02AB04,S01AA32" "baci,bacitr" "albac,altracin,ayfivin,baciferm,baciguent,baciim,baciliquin,bacilliquin,baciquent,bacitracina,bacitracine,bacitracinum,fortracin,mycitracin,parentracin,penitracin,septa,topitracin,topitrasin,tropitracin,zutracin" "10868-8,16428-5,18870-6,6827-0,6983-1,87603-7" +"BDQ" 5388906 "Bedaquiline" "Other" "J04AK05,QJ04AK05" "NA" "NA" 86 "mg" "80637-2,88703-4,88704-2,94274-8,96107-8" "BEK" 439318 "Bekanamycin" "Aminoglycosides" "J01GB13,QJ01GB13" "NA" "aminodeoxykanamycin,becanamicina,bekanamicina,bekanamycine,bekanamycinum" 0.6 "g" "NA" -"BNB" "Benzathine benzylpenicillin" "Beta-lactams/penicillins" "J01CE08,QJ01CE08" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "NA" 3.6 "g" "NA" -"BNP" 64725 "Benzathine phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE10,QJ01CE10" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "bicillin,biphecillin" 2 "g" "NA" -"PEN" 5904 "Benzylpenicillin" "Beta-lactams/penicillins" "J01CE01,QJ01CE01,QJ51CE01,QS01AA14,S01AA14" "Combinations of antibacterials" "Combinations of antibacterials" "bepe,pen,peni,peni g,penic8,penica,penici,penicillin,penicillin g,penora,pg" "bencilpenicilina,benzopenicillin,benzylpenicilline,benzylpenicillinum,capicillin,cillora,cilloral,cilopen,cintrisul,cosmopen,cristapen,crystapen,dropcillin,eskacillin,falapen,forpen,galofak,gelacillin,hipercilina,hyasorb,hylenta,lemopen,liquacillin,liquapen,monocillin,monopen,mycofarm,novocillin,penalev,penicillinum,penilaryn,penisem,pentid,pentids,pfizerpen,pharmacillin,pradupen,scotcil,sugracillin,sugracillinsalt,tabilin,ursopen,veticillin" 3.6 "g" "NA" -"PEN-S" "Benzylpenicillin screening test" "Beta-lactams/penicillins" "NA" "pen screen" "NA" "NA" -"BES" 10178705 "Besifloxacin" "Fluoroquinolones" "QS01AE08,S01AE08" "besifl" "besivance" "73606-6,73628-0,73651-2" +"BNB" "Benzathine benzylpenicillin" "Penicillins,Beta-lactams" "J01CE08,QJ01CE08" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "NA" 3.6 "g" "NA" +"BNP" 64725 "Benzathine phenoxymethylpenicillin" "Penicillins,Beta-lactams" "J01CE10,QJ01CE10" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "bicillin,biphecillin" 2 "g" "NA" +"PEN" 5904 "Benzylpenicillin" "Penicillins,Beta-lactams" "J01CE01,QJ01CE01,QJ51CE01,QS01AA14,S01AA14" "Combinations of antibacterials" "Combinations of antibacterials" "bepe,pen,peni,peni g,penic8,penica,penici,penicillin,penicillin g,penora,pg" "bencilpenicilina,benzopenicillin,benzylpenicilline,benzylpenicillinum,capicillin,cillora,cilloral,cilopen,cintrisul,cosmopen,cristapen,crystapen,dropcillin,eskacillin,falapen,forpen,galofak,gelacillin,hipercilina,hyasorb,hylenta,lemopen,liquacillin,liquapen,monocillin,monopen,mycofarm,novocillin,penalev,penicillinum,penilaryn,penisem,pentid,pentids,pfizerpen,pharmacillin,pradupen,scotcil,sugracillin,sugracillinsalt,tabilin,ursopen,veticillin" 3.6 "g" "NA" +"PEN-S" "Benzylpenicillin screening test" "Penicillins,Beta-lactams" "NA" "pen screen" "NA" "NA" +"BES" 10178705 "Besifloxacin" "Fluoroquinolones,Quinolones" "QS01AE08,S01AE08" "besifl" "besivance" "73606-6,73628-0,73651-2" "BLA-S" "Beta-lactamase screening test" "Other" "NA" "beta-lactamase,betalactamase,bl screen,blt screen" "NA" "NA" -"BIA" 71339 "Biapenem" "Carbapenems" "J01DH05,QJ01DH05" "biapen" "biapenern,omegacin" 1.2 "g" "41665-1,41666-9,41667-7,41728-7" -"BCZ" 65807 "Bicyclomycin" "Other antibacterials" "NA" "bicozamycin" "aizumycin,bacfeed,bacteron,bicozamicina,bicozamycin,bicozamycine,bicozamycinum" "NA" +"BIA" 71339 "Biapenem" "Carbapenems,Beta-lactams" "J01DH05,QJ01DH05" "biapen" "biapenern,omegacin" 1.2 "g" "41665-1,41666-9,41667-7,41728-7" +"BCZ" 65807 "Bicyclomycin" "Other" "NA" "bicozamycin" "aizumycin,bacfeed,bacteron,bicozamicina,bicozamycin,bicozamycine,bicozamycinum" "NA" "BLM" 5360373 "Bleomycin" "Glycopeptides" "L01DC01,QL01DC01" "NA" "blenamax,blenoxane,bleocin,bleomicin,bleomicina,bleomycine,bleomycins,bleomycinum,blexane,nbleomycinamide" "NA" -"BDP" 68760 "Brodimoprim" "Trimethoprims" "J01EA02,QJ01EA02" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "NA" "brodimoprima,brodimoprime,brodimoprimum,bromdimoprim,hyprim,unitrim" 0.2 "g" "NA" -"BUT" 47472 "Butoconazole" "Antifungals/antimycotics" "G01AF15,QG01AF15" "NA" "butaconazole,butoconazol,butoconazolum,gynofort" "NA" +"BDP" 68760 "Brodimoprim" "Trimethoprims,Sulfonamides" "J01EA02,QJ01EA02" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "NA" "brodimoprima,brodimoprime,brodimoprimum,bromdimoprim,hyprim,unitrim" 0.2 "g" "NA" +"BUT" 47472 "Butoconazole" "Antifungals" "G01AF15,QG01AF15" "NA" "butaconazole,butoconazol,butoconazolum,gynofort" "NA" "CDZ" 44242317 "Cadazolid" "Oxazolidinones" "NA" "NA" "NA" "NA" "CLA" "Calcium aminosalicylate" "Antimycobacterials" "J04AA03,QJ04AA03" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "NA" 15 "g" "NA" "CAP" 135565060 "Capreomycin" "Antimycobacterials" "J04AB30,QJ04AB30" "Drugs for treatment of tuberculosis" "Antibiotics" "capr,capreo" "NA" 1 "g" "16545-6,18872-2,23607-5,25210-6,25211-4,25212-2,42643-7,48170-5,55-4,55623-3,56-2,57-0,58-8,61355-4,89483-2" -"CRB" 20824 "Carbenicillin" "Beta-lactams/penicillins" "J01CA03,QJ01CA03" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bar,carb,carben,cb" "anabactyl,carbecin,carbenicilina,carbenicillina,carbenicilline,carbenicillinum,dicarbenicillin,dipenicillin,fugacillin,geopen,gripenin,hyoper,microcillin,piopen,pyocianil,pyoclox,pyopan,pyopen,pyopene" 12 "g" "18873-0,3434-8,41668-5,59-6,60-4,61-2,62-0" -"CRN" 93184 "Carindacillin" "Beta-lactams/penicillins" "J01CA05,QJ01CA05" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "carindacilina,carindacilline,carindacillinsalt,carindacillinum,geocillin,indanylcarbinicillin,urobac" 4 "g" "NA" -"CAR" 6540466 "Carumonam" "Monobactams" "J01DF02,QJ01DF02" "NA" "carumonamum" 2 "g" "51694-8" -"CAS" 2826718 "Caspofungin" "Antifungals/antimycotics" "J02AX04,QJ02AX04" "Antimycotics for systemic use" "Other antimycotics for systemic use" "casp,caspof" "cancidas,caspofungina" 50 "mg" "32378-2,54175-5,54176-3,54185-4,58419-3" -"CAC" 91562 "Cefacetrile" "Cephalosporins (1st gen.)" "J01DB10,QJ01DB10,QJ51DB10" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephac" "cefacetril,cefacetrilo,cefacetrilum,celospor,cephacetrile,vetrimast" "55624-1,55625-8,55626-6,55627-4" -"CEC" 51039 "Cefaclor" "Cephalosporins (2nd gen.)" "J01DC04,QJ01DC04" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "ccl,cec,cefacl,cf,cfac,cfc,cfcl,cfr,fac" "alenfral,alfacet,alfatil,ceclor,cefachlor,cefaclorum,cefeaclor,cephaclor,compound,distaclor,keflor,kefolor,kefral,keftab,keftid,lilly,lopac,panacef,panoral,raniclor" 1 "g" "16564-7,18874-8,21149-0,6986-4,83-6,84-4,85-1,86-9" -"CFR" 47965 "Cefadroxil" "Cephalosporins (1st gen.)" "J01DB05,QJ01DB05" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefadr,cfdx,cfr,fad" "bidocel,cefadrops,cefadroxilo,cefadroxilum,cefradroxil,cefzil,cephadroxil,duracef,duricef,kefroxil,sumacef,ultracef" 2 "g" "16565-4,18875-5,55628-2,63-8,64-6,65-3,66-1" -"LEX" 27447 "Cefalexin" "Cephalosporins (1st gen.)" "J01DB01,QJ01DB01,QJ51DB01" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cepale,cflx" "adcadina,alcephin,alsporin,ambal,amplex,aristosporin,azabort,bactopenor,beliam,biocef,carnosporin,cefablan,cefacet,cefadal,cefadin,cefadina,cefalekey,cefaleksin,cefalessina,cefalexgobens,cefalexina,cefalexine,cefalexinum,cefalin,cefalival,cefaloto,cefanex,cefaseptin,cefax,ceffanex,cefibacter,ceflax,ceforal,cefovit,celexin,cepastar,cepexin,cephacillin,cephalexine,cephalexinum,cephalobene,cephanasten,cephaxin,cephin,cepol,ceporex,ceporexin,ceporexine,cerexin,cerexins,check,cophalexin,domucef,doriman,durantel,efemida,erocetin,factagard,felexin,fexin,ibilex,ibrexin,inphalex,karilexina,kefalospes,keflet,keflex,kefolan,keforal,kekrinal,kidolex,lafarine,larixin,lenocef,lexibiotico,loisine,lonflex,lopilexin,losporal,madlexin,maksipor,mamalexin,mamlexin,medolexin,medoxine,neokef,neolexina,noveol,novolexin,nufex,optocef,oracef,oriphex,oroxin,ortisporina,ospexin,palitrex,panixine,pectril,prindex,pyassan,rilexine,roceph,rogevil,sanaxin,sartosona,sencephalin,sepexin,servicef,servispor,sialexin,sinthecillin,sintolexyn,sporicef,sporidex,syncl,syncle,synecl,taicelexin,tepaxin,theratrex,tokiolexin,uphalexin,viosporine,voxxim,winlex,zabytrex,zozarine" 2 "g" "NA" -"RID" 5773 "Cefaloridine" "Cephalosporins (1st gen.)" "J01DB02,QJ01DB02" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefa,ceplor" "aliporina,ampligram,cefaloridin,cefaloridina,cefaloridinum,cefalorizin,ceflorin,cepaloridin,cepalorin,cephalomycine,cephaloridin,cephaloridine,cephaloridinum,ceporan,ceporin,ceporine,cilifor,deflorin,faredina,floridin,glaxoridin,intrasporin,keflodin,keflordin,kefloridin,kefspor,lloncefal,sasperin,sefacin,verolgin,vioviantine" 3 "g" "NA" -"CEP" 6024 "Cefalotin" "Cephalosporins (1st gen.)" "J01DB03,QJ01DB03" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephal,cfal,cflt" "averon,cefalothin,cefalothine,cefalothinsalt,cefalotina,cefalotine,cefalotinsalt,cefalotinum,cemastin,cephalothin,cephalothinsalt,cephalothinum,cephalotin,cephalotinsalt,ceporacin,cepovenin,coaxin,keflin,lospoven,microtin,seffin,synclotin,toricelocin" 4 "g" "NA" -"MAN" 456255 "Cefamandole" "Cephalosporins (2nd gen.)" "J01DC03,QJ01DC03" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefama,cfam,cfmn" "cefadole,cefamandol,cefamandolum,cephadole,kefamandol,kefdole,mancef" 6 "g" "18876-3,3441-3,41669-3,55634-0,55635-7,55636-5,55637-3,67-9,68-7,69-5,70-3" -"HAP" 30699 "Cefapirin" "Cephalosporins (1st gen.)" "J01DB08,QG51AA05,QJ01DB08,QJ51DB08" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephap" "ambrocef,brisfirina,brisporin,bristocef,cefadyl,cefalak,cefaloject,cefapirina,cefapirine,cefapirinsalt,cefapirinum,cefaprin,cefatrex,cefatrexyl,cephapirin,cephapirine,cephapirinsalt,cephatrexil,cephatrexyl,metricure" 4 "g" "NA" -"CTZ" 6410758 "Cefatrizine" "Cephalosporins (1st gen.)" "J01DB07,QJ01DB07" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefatr" "bricef,cefathiamidine,cefatrix,cefatrizino,cefatrizinum,cephatriazine,cepticol,cetrazil,latocef,orosporina,orotric,seapuron,trizina" 1 "g" "18877-1,55639-9,71-1,72-9,73-7,74-5" -"CZD" 71736 "Cefazedone" "Cephalosporins (1st gen.)" "J01DB06,QJ01DB06" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefaze" "cefazedon,cefazedona,cefazedonesalt,cefazedonum,refosporen,refosporene,refosporin,refosporinsalt" 3 "g" "NA" -"CZO" 33255 "Cefazolin" "Cephalosporins (1st gen.)" "J01DB04,QJ01DB04,QJ51DB04" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefazo,cfz,cfzl,cz,czol,faz,kz" "ancef,atirin,biazolina,cefabiozim,cefacidal,cefalomicina,cefamedin,cefamezin,cefazil,cefazina,cefazolina,cefazoline,cefazolinsalt,cefazolinum,cephamezine,cephazolidin,cephazolin,cephazoline,elzogram,firmacef,gramaxin,kefzol,lampocef,liviclina,neofazol,oprea,recef,totacef,zolicef,zolisint" 3 "g" "16566-2,18878-9,25235-3,3442-1,3443-9,41670-1,75-2,76-0,77-8,78-6,80962-4,85422-4" -"CFB" 127527 "Cefbuperazone" "Other antibacterials" "J01DC13,QJ01DC13" "cefbup" "cefbuperazona,cefbuperazonesalt,cefbuperazonum,cefbuperzaone,cerbuperazone,keiperazon,tomiporan" 2 "g" "NA" -"CCP" 6436055 "Cefcapene" "Cephalosporins (3rd gen.)" "J01DD17,QJ01DD17" "cefcap" "flomox" 0.45 "g" "100044-7,76143-7" -"CCX" 5282438 "Cefcapene pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefcamate,flumax" "NA" -"CDR" 6915944 "Cefdinir" "Cephalosporins (3rd gen.)" "J01DD15,QJ01DD15" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cd,cdn,cdr,cefdin,cfd,din" "cefdinirum,cefdinyl,cefdirnir,ceftinex,cefzon,omnicef" 0.6 "g" "23636-4,23637-2,35757-4,35758-2" -"DIT" 9870843 "Cefditoren" "Cephalosporins (3rd gen.)" "J01DD16,QJ01DD16" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cdn,cefdit" "cefditoreno,spectracef" 0.4 "g" "35759-0,35760-8,35761-6,35762-4" -"DIX" 6437877 "Cefditoren pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefditorin,meiact,pivaloyloxymethyl" "NA" -"FEP" 5479537 "Cefepime" "Cephalosporins (4th gen.)" "J01DE01,QJ01DE01" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cefep4,cefepi,cfep,cfpi,cpe,cpm,fep,pm,xpm" "anticefepime,axepim,cefepima,cefepimum,maxipime,pyrrolidinium,renapime" 4 "g" "101502-3,18879-7,31142-3,31143-1,35763-2,38363-8,42350-9,42351-7,42353-3,50631-1,58412-8,6643-1,6644-9,6645-7,6646-5,6987-2,8272-7,8273-5" -"CFA" "Cefepime/amikacin" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"CPC" 9567559 "Cefepime/clavulanic acid" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "cefcla,cicl,xpml" "NA" "NA" -"FPE" 23653540 "Cefepime/enmetazobactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" -"FNC" "Cefepime/nacubactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" -"FTA" "Cefepime/taniborbactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" -"FPT" 9567558 "Cefepime/tazobactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" -"FPZ" "Cefepime/zidebactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" -"CAT" 5487888 "Cefetamet" "Cephalosporins (3rd gen.)" "J01DD10,QJ01DD10" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefeta,cefmtm" "cefetametum,deacetoxycefotaxime,epocelin" 1 "g" "32377-4,35764-0,35765-7,55640-7" -"CPI" 5486182 "Cefetamet pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefetametpivoxil,cefyl,globocef" "NA" -"CCL" 71719688 "Cefetecol" "Cephalosporins (4th gen.)" "NA" "cefcatacol" "NA" "NA" -"CZL" 193956 "Cefetrizole" "Cephalosporins (unclassified gen.)" "NA" "NA" "cefetrizolum" "NA" -"FDC" 77843966 "Cefiderocol" "Cephalosporins (unclassified gen.)" "J01DI04,QJ01DI04" "NA" "fetcroja" 6 "g" "95767-0,99280-0,99503-5" -"CFM" 5362065 "Cefixime" "Cephalosporins (3rd gen.)" "J01DD08,QJ01DD08" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefixi,cfe,cfix,cfxm,dcfm,fix,ix" "cefixim,cefixima,cefiximum,cefixoral,cefspan,cephoral,citropen,denvar,necopen,oraken,oroken,suprax,tricef,unixime" 0.4 "g" "16567-0,18880-5,25236-1,35766-5,79-4,80-2,81-0,82-8" -"CEO" "Cefixime/ornidazole" "Other antibacterials" "J01DD58,QJ01DD58" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"CMX" 9570757 "Cefmenoxime" "Cephalosporins (3rd gen.)" "J01DD05,QJ01DD05,QS01AA31,QS02AA18,S01AA31,S02AA18" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefmen" "bestron,cefmenoxima,cefmenoximum,tacef" 2 "g" "32375-8,54174-8,54203-5,55641-5" -"CMZ" 42008 "Cefmetazole" "Cephalosporins (2nd gen.)" "J01DC09,QJ01DC09" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefmet" "cefmetazol,cefmetazolo,cefmetazolum,cefmetazon,metafar,zefazone" 4 "g" "11575-8,18881-3,25222-1,87-7,88-5,89-3,90-1" -"CNX" 71141 "Cefminox" "Other antibacterials" "J01DC12,QJ01DC12" "cefmin" "alteporina,cefminoxhydrate,cefminoxum,meicelin,tencef" 4 "g" "54908-9" -"DIZ" 5361871 "Cefodizime" "Cephalosporins (3rd gen.)" "J01DD09,QJ01DD09" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefodizima,cefodizimum,cefodizme,diezime,kenicef,modivid,neucef,timecef" 2 "g" "18882-1,6988-0,91-9,92-7,93-5,94-3" -"CID" 43594 "Cefonicid" "Cephalosporins (2nd gen.)" "J01DC06,QJ01DC06" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoni" "cefonicide,cefonicido,cefonicidsalt,cefonicidum,monocef,monocid" 1 "g" "18883-9,25237-9,3444-7,55642-3,95-0,96-8,97-6,98-4" -"CFP" 44187 "Cefoperazone" "Cephalosporins (3rd gen.)" "J01DD12,QJ01DD12,QJ51DD12" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefope,cfp,cfpz,cp,cpz,fop,per" "bioperazone,cefob,cefobid,cefobis,cefoneg,cefoper,cefoperazin,cefoperazine,cefoperazon,cefoperazona,cefoperazonesalt,cefoperazono,cefoperazonum,cefozon,medocef,myticef,pathozone,peracef,tomabef" 4 "g" "100-8,101-6,102-4,18884-7,3445-4,35767-3,35768-1,54166-4,54167-2,54168-0,99-2" -"CSL" "Cefoperazone/sulbactam" "Cephalosporins (3rd gen.)" "J01DD62,QJ01DD62" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "fopsul" "NA" 4 "g" "35768-1,54166-4,54167-2,54168-0" -"CND" 43507 "Ceforanide" "Cephalosporins (2nd gen.)" "J01DC11,QJ01DC11" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefora" "ceforanido,ceforanidum,precef" 4 "g" "103-2,104-0,105-7,106-5,18885-4,55643-1" -"CSE" 9830519 "Cefoselis" "Cephalosporins (4th gen.)" "NA" "cefose" "winsef" "NA" -"CTX" 5742673 "Cefotaxime" "Cephalosporins (3rd gen.)" "J01DD01,QJ01DD01" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefo32,cefota,cfot,cft,cftx,ct,ctx,fot,fot1,tax,taxmen,taxnme,xct" "anticefotaxime,cefotax,cefotaxim,cefotaxima,cefotaximesalt,cefotaximsalt,cefotaximum,cephotaxim,cephotaxime,claforan,kefotex,omnatax,pretor,ralopar,tolycar,tolycor,zariviz" 4 "g" "101479-4,101480-2,107-3,108-1,109-9,110-7,18886-2,25238-7,31138-1,31139-9,3446-2,35769-9,35770-7,35771-5,41671-9,50632-9,52128-6,54191-2,54192-0,54193-8,55189-5,55644-9,6989-8,80961-6" -"CTX-S" "Cefotaxime screening test" "Cephalosporins (3rd gen.)" "NA" "ctx screen" "NA" "NA" -"CTC" 9575353 "Cefotaxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD51,QJ01DD51" "cxcl,taxcla,xctl" "NA" "NA" -"CTS" 9574753 "Cefotaxime/sulbactam" "Cephalosporins (3rd gen.)" "J01DD51,QJ01DD51" "NA" "NA" "54191-2,54192-0,54193-8,55644-9" -"CTT" 53025 "Cefotetan" "Cephalosporins (2nd gen.)" "J01DC05,QJ01DC05" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefote,cftt,cn,cte,ctn,ctt,tans" "apacef,apatef,cefotetanum" 4 "g" "111-5,112-3,113-1,114-9,18887-0,25239-5,3447-0,41672-7,41673-5,41674-3,41729-5,6990-6" -"CTF" 43708 "Cefotiam" "Cephalosporins (2nd gen.)" "J01DC07,QJ01DC07" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoti" "aspil,cefotiamum,ceradon,halospor,pansporin,pansporine,spizef" 1.2 "g" 4 "g" "32374-1,35772-3,35773-1,55645-6,55737-1,55738-9,55739-7,55740-5" -"CHE" 125846 "Cefotiam hexetil" "Cephalosporins (3rd gen.)" "NA" "NA" "taketiam,texodil" "55737-1,55738-9,55739-7,55740-5" -"FOV" 9578573 "Cefovecin" "Cephalosporins (3rd gen.)" "QJ01DD91" "cefove" "cefovecinsalt,convenia" "76147-8,87792-8" -"FOX" 441199 "Cefoxitin" "Cephalosporins (2nd gen.)" "J01DC01,QJ01DC01" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoxi,cfox,cfx,cfxt,cx,fox,fx" "betacef,cefoxil,cefoxitina,cefoxitine,cefoxitinsalt,cefoxitinum,cefoxotin,cenomycin,farmoxin,mefoxin,mefoxithin,mefoxitin,merxin,rephoxitin" 6 "g" "101492-7,115-6,116-4,117-2,118-0,18888-8,25220-5,25240-3,25366-6,3448-8,41675-0,41676-8,41677-6,41730-3,6991-4" -"FOX-S" "Cefoxitin screening test" "Cephalosporins (2nd gen.)" "NA" "cfsc,fox1" "NA" "NA" -"ZOP" 9571080 "Cefozopran" "Cephalosporins (4th gen.)" "J01DE03,QJ01DE03" "cefozo" "firstcin,imidazo" 4 "g" "100045-4,53820-7" -"CFZ" 68597 "Cefpimizole" "Cephalosporins (3rd gen.)" "NA" "cefpim" "ajicef,cefpimizol,cefpimizolesalt,cefpimizolum,renilan" "NA" -"CPM" 636405 "Cefpiramide" "Cephalosporins (3rd gen.)" "J01DD11,QJ01DD11" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefpam" "cefpiramida,cefpiramidesalt,cefpiramido,cefpiramidum,sepatren,suncefal" 2 "g" "NA" -"CPO" 5479539 "Cefpirome" "Cephalosporins (4th gen.)" "J01DE02,QJ01DE02" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cefpom,cfpr" "broact,cefir,cefpiroma,cefpiromum,cefrom,keiten,romecef" 4 "g" "18889-6,6647-3,6648-1,6649-9,6650-6,6992-2,8274-3,8275-0,8276-8" -"CPD" 6335986 "Cefpodoxime" "Cephalosporins (3rd gen.)" "J01DD13,QJ01DD13" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefpod,cfpd,cfpo,cpd,pod,pod4,px" "cefpodoxima,cefpodoximum,epoxim" 0.4 "g" "119-8,120-6,121-4,122-2,18890-4,25241-1,41678-4,41679-2,41680-0,41731-1,6993-0,90849-1" -"CPX" 6526396 "Cefpodoxime proxetil" "Cephalosporins (3rd gen.)" "NA" "NA" "banan,cefodox,cefoprox,cefpoderm,cefpodoximproxetil,cepodem,doxef,orelox,otreon,podomexef,simplicef,vantin" "NA" -"CDC" "Cefpodoxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD64,QJ01DD64" "cecl,podcla" "NA" 0.4 "g" "NA" -"CPR" 5281006 "Cefprozil" "Cephalosporins (2nd gen.)" "J01DC10,QJ01DC10" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefpro,cpr,cpz,fp" "arzimol,brisoral,cefprozilo,cefprozilum,cronocef,procef,serozil" 1 "g" "123-0,124-8,125-5,126-3,18891-2,6994-8" -"CEQ" 5464355 "Cefquinome" "Cephalosporins (4th gen.)" "QG51AA07,QJ01DE90,QJ51DE90" "cefqui" "cefquinoma,cefquinomum,cobactan,quinolinium" "100046-2,76150-2" -"CRD" 5284529 "Cefroxadine" "Cephalosporins (1st gen.)" "J01DB11,QJ01DB11" "Other beta-lactam antibacterials" "First-generation cephalosporins" "ceftix" "cefroxadin,cefroxadino,cefroxadinum,oraspor" 2.1 "g" "NA" -"CFS" 656575 "Cefsulodin" "Cephalosporins (3rd gen.)" "J01DD03,QJ01DD03" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefsul,cfsl,cfsu" "cefomonil,cefonomil,cefsulodine,cefsulodinhydrate,cefsulodino,cefsulodinum,pseudocef,pseudomonil,pyocefal,sulcephalosporin,takesulin,tilmapor,ulfaret" 4 "g" "127-1,128-9,129-7,130-5,131-3,18892-0,25242-9,55647-2" -"CSU" 68718 "Cefsumide" "Cephalosporins (unclassified gen.)" "NA" "NA" "cefsulmid,cefsumido,cefsumidum" "NA" -"CPT" 56841980 "Ceftaroline" "Cephalosporins (5th gen.)" "J01DI02,QJ01DI02" "ceftar,cfro" "ceftaroine,teflaro,zinforo" "73604-1,73605-8,73626-4,73627-2,73649-6,73650-4,74170-2" -"CPA" "Ceftaroline/avibactam" "Cephalosporins (5th gen.)" "NA" "NA" "NA" "73604-1,73626-4,73649-6" -"CAZ" 5481173 "Ceftazidime" "Cephalosporins (3rd gen.)" "J01DD02,QJ01DD02" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "caz,cef,cefta,ceftaz,cfta,cftz,taz,tz,xtz" "ceftazimide,ceptaz,fortam,fortaz,fortum,glazidim,kefazim,modacin,pentacef,tazicef,tizime" 4 "g" "101481-0,101482-8,101483-6,132-1,133-9,134-7,135-4,18893-8,21151-6,3449-6,35774-9,35775-6,35776-4,42352-5,55648-0,55649-8,55650-6,55651-4,58705-5,6995-5,73603-3,73625-6,73648-8,80960-8,87734-0,90850-9" -"CZA" 90643431 "Ceftazidime/avibactam" "Cephalosporins (3rd gen.)" "J01DD52,QJ01DD52" "cfav" "avycaz,zavicefta" 6 "g" "101483-6,73603-3,73625-6,73648-8,87734-0" -"CCV" 9575352 "Ceftazidime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD52,QJ01DD52" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "czcl,tazcla,xtzl" "NA" 6 "g" "NA" -"CEM" 6537431 "Cefteram" "Cephalosporins (3rd gen.)" "J01DD18,QJ01DD18" "cefter" "cefterame,cefteramum,ceftetrame" 0.4 "g" "100047-0,76144-5" -"CPL" 5362114 "Cefteram pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefterampivoxil,tomiron" "NA" -"CTL" 65755 "Ceftezole" "Cephalosporins (1st gen.)" "J01DB12,QJ01DB12" "Other beta-lactam antibacterials" "First-generation cephalosporins" "ceftez" "alomen,ceftezol,ceftezolesalt,ceftezolo,ceftezolum,celoslin,demethylcefazolin,falomesin" 3 "g" "NA" -"CTB" 5282242 "Ceftibuten" "Cephalosporins (3rd gen.)" "J01DD14,QJ01DD14" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cb,ceftib,cfbu,ctb,tib" "cedax,ceftem,ceftibutene,ceftibuteno,ceftibutenum,ceftibutin,ceprifran,isocef,keimax,seftem" 0.4 "g" "35777-2,35778-0,35779-8,6996-3" -"TIO" 6328657 "Ceftiofur" "Cephalosporins (3rd gen.)" "QJ01DD90,QJ51DD90" "ceftif" "ceftiofurum,excenel,naxcel" "23709-9,35780-6,35781-4,55652-2" -"CZX" 6533629 "Ceftizoxime" "Cephalosporins (3rd gen.)" "J01DD07,QJ01DD07" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "ceftiz,cfzx,ctz,cz,czx,tiz,zox" "cefizox,ceftix,ceftizoxima,ceftizoximesalt,ceftizoximum,eposerin" 4 "g" "136-2,137-0,138-8,139-6,18894-6,20378-6,23622-4,25243-7,3450-4,6997-1" -"CZP" 9578661 "Ceftizoxime alapivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "NA" "NA" -"BPR" 135413542 "Ceftobiprole" "Cephalosporins (5th gen.)" "NA" "ceftob" "NA" "43269-0,43270-8,43271-6,43272-4,85052-9" -"CFM1" 135413544 "Ceftobiprole medocaril" "Cephalosporins (5th gen.)" "J01DI01,QJ01DI01" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "NA" "zevtera" 1.5 "g" "NA" -"CZT" 86291594 "Ceftolozane/tazobactam" "Cephalosporins (5th gen.)" "J01DI54,QJ01DI54" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "cei" "zerbaxa" 3 "g" "101484-4,73602-5,73624-9,73647-0,87735-7" -"CRO" 5479530 "Ceftriaxone" "Cephalosporins (3rd gen.)" "J01DD04,QJ01DD04" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "axo,cax,ceftri,cftr,cro,ctr,frx,trimen,trinme,tx" "biotrakson,ceftriaxon,ceftriaxona,ceftriaxonum,ceftriazone,rocefin,rocephalin,rocephin,rocephine,rophex" 2 "g" "101485-1,140-4,141-2,142-0,143-8,18895-3,25244-5,25367-4,31140-7,31141-5,3451-2,41681-8,41682-6,41683-4,41732-9,50633-7,55190-3,6998-9,80957-4" -"CEB" "Ceftriaxone/beta-lactamase inhibitor" "Cephalosporins (3rd gen.)" "J01DD63,QJ01DD63" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "NA" 2 "g" "NA" -"CXM" 5479529 "Cefuroxime" "Cephalosporins (2nd gen.)" "J01DC02,QJ01DC02,QJ51DC02,QS01AA27,S01AA27" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefaxe,cefrox,cefuro,cfrx,cfur,cfx,crm,cxm,fur,rox,xm" "anaptivan,biociclin,biofuroksym,bioxima,cefofix,cefumax,cefurex,cefuril,cefurox,cefuroxim,cefuroxima,cefuroximesalt,cefuroximine,cefuroximo,cefuroximum,cephuroxime,cetroxil,colifossim,curoxim,curoxima,curoxime,froxal,furoxil,kefurox,kesint,ketocef,lifurox,medoxim,sharox,spectrazolr,ultroxim,zinacef,zinnat" 0.5 "g" 3 "g" "101503-1,144-6,145-3,146-1,147-9,18896-1,20460-2,25245-2,3452-0,35782-2,35783-0,51724-3,51774-8,55653-0,55654-8,6999-7,74699-0,80608-3,80617-4" -"CXA" 6321416 "Cefuroxime axetil" "Cephalosporins (2nd gen.)" "NA" "cfax" "bioracef,ceftin,cefurax,cefuroximaxetil,celocid,cepazine,cethixim,cetoxil,coliofossim,curocef,elobact,kalcef,maxitil,medoxm,nivador,novador,novocef,oraxim,zinat,zoref" "NA" -"CFM2" "Cefuroxime/metronidazole" "Other antibacterials" "J01DC52,QJ01DC52" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" 0.5 "g" "NA" -"ZON" 6336505 "Cefuzonam" "Other antibacterials" "NA" "cefuzo" "cefuzoname,cefuzonamum,cefzoname,cosmosin" "NA" -"CED" 38103 "Cephradine" "Cephalosporins (1st gen.)" "NA" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephra,cfra,cfrd" "anspor,cefradin,cefradina,cefradine,cefradinum,cekodin,cephradin,ecosporina,eskacef,infexin,megacef,sefril,velocef,velosef" "168-5,169-3,170-1,171-9,18902-7,55646-4" +"CRB" 20824 "Carbenicillin" "Penicillins,Beta-lactams" "J01CA03,QJ01CA03" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bar,carb,carben,cb" "anabactyl,carbecin,carbenicilina,carbenicillina,carbenicilline,carbenicillinum,dicarbenicillin,dipenicillin,fugacillin,geopen,gripenin,hyoper,microcillin,piopen,pyocianil,pyoclox,pyopan,pyopen,pyopene" 12 "g" "18873-0,3434-8,41668-5,59-6,60-4,61-2,62-0" +"CRN" 93184 "Carindacillin" "Penicillins,Beta-lactams" "J01CA05,QJ01CA05" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "carindacilina,carindacilline,carindacillinsalt,carindacillinum,geocillin,indanylcarbinicillin,urobac" 4 "g" "NA" +"CAR" 6540466 "Carumonam" "Monobactams,Beta-lactams" "J01DF02,QJ01DF02" "NA" "carumonamum" 2 "g" "51694-8" +"CAS" 2826718 "Caspofungin" "Antifungals" "J02AX04,QJ02AX04" "Antimycotics for systemic use" "Other antimycotics for systemic use" "casp,caspof" "cancidas,caspofungina" 50 "mg" "32378-2,54175-5,54176-3,54185-4,58419-3" +"CAC" 91562 "Cefacetrile" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB10,QJ01DB10,QJ51DB10" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephac" "cefacetril,cefacetrilo,cefacetrilum,celospor,cephacetrile,vetrimast" "55624-1,55625-8,55626-6,55627-4" +"CEC" 51039 "Cefaclor" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC04,QJ01DC04" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "ccl,cec,cefacl,cf,cfac,cfc,cfcl,cfr,fac" "alenfral,alfacet,alfatil,ceclor,cefachlor,cefaclorum,cefeaclor,cephaclor,compound,distaclor,keflor,kefolor,kefral,keftab,keftid,lilly,lopac,panacef,panoral,raniclor" 1 "g" "16564-7,18874-8,21149-0,6986-4,83-6,84-4,85-1,86-9" +"CFR" 47965 "Cefadroxil" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB05,QJ01DB05" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefadr,cfdx,cfr,fad" "bidocel,cefadrops,cefadroxilo,cefadroxilum,cefradroxil,cefzil,cephadroxil,duracef,duricef,kefroxil,sumacef,ultracef" 2 "g" "16565-4,18875-5,55628-2,63-8,64-6,65-3,66-1" +"LEX" 27447 "Cefalexin" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB01,QJ01DB01,QJ51DB01" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cepale,cflx" "adcadina,alcephin,alsporin,ambal,amplex,aristosporin,azabort,bactopenor,beliam,biocef,carnosporin,cefablan,cefacet,cefadal,cefadin,cefadina,cefalekey,cefaleksin,cefalessina,cefalexgobens,cefalexina,cefalexine,cefalexinum,cefalin,cefalival,cefaloto,cefanex,cefaseptin,cefax,ceffanex,cefibacter,ceflax,ceforal,cefovit,celexin,cepastar,cepexin,cephacillin,cephalexine,cephalexinum,cephalobene,cephanasten,cephaxin,cephin,cepol,ceporex,ceporexin,ceporexine,cerexin,cerexins,check,cophalexin,domucef,doriman,durantel,efemida,erocetin,factagard,felexin,fexin,ibilex,ibrexin,inphalex,karilexina,kefalospes,keflet,keflex,kefolan,keforal,kekrinal,kidolex,lafarine,larixin,lenocef,lexibiotico,loisine,lonflex,lopilexin,losporal,madlexin,maksipor,mamalexin,mamlexin,medolexin,medoxine,neokef,neolexina,noveol,novolexin,nufex,optocef,oracef,oriphex,oroxin,ortisporina,ospexin,palitrex,panixine,pectril,prindex,pyassan,rilexine,roceph,rogevil,sanaxin,sartosona,sencephalin,sepexin,servicef,servispor,sialexin,sinthecillin,sintolexyn,sporicef,sporidex,syncl,syncle,synecl,taicelexin,tepaxin,theratrex,tokiolexin,uphalexin,viosporine,voxxim,winlex,zabytrex,zozarine" 2 "g" "NA" +"RID" 5773 "Cefaloridine" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB02,QJ01DB02" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefa,ceplor" "aliporina,ampligram,cefaloridin,cefaloridina,cefaloridinum,cefalorizin,ceflorin,cepaloridin,cepalorin,cephalomycine,cephaloridin,cephaloridine,cephaloridinum,ceporan,ceporin,ceporine,cilifor,deflorin,faredina,floridin,glaxoridin,intrasporin,keflodin,keflordin,kefloridin,kefspor,lloncefal,sasperin,sefacin,verolgin,vioviantine" 3 "g" "NA" +"CEP" 6024 "Cefalotin" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB03,QJ01DB03" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephal,cfal,cflt" "averon,cefalothin,cefalothine,cefalothinsalt,cefalotina,cefalotine,cefalotinsalt,cefalotinum,cemastin,cephalothin,cephalothinsalt,cephalothinum,cephalotin,cephalotinsalt,ceporacin,cepovenin,coaxin,keflin,lospoven,microtin,seffin,synclotin,toricelocin" 4 "g" "NA" +"MAN" 456255 "Cefamandole" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC03,QJ01DC03" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefama,cfam,cfmn" "cefadole,cefamandol,cefamandolum,cephadole,kefamandol,kefdole,mancef" 6 "g" "18876-3,3441-3,41669-3,55634-0,55635-7,55636-5,55637-3,67-9,68-7,69-5,70-3" +"HAP" 30699 "Cefapirin" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB08,QG51AA05,QJ01DB08,QJ51DB08" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephap" "ambrocef,brisfirina,brisporin,bristocef,cefadyl,cefalak,cefaloject,cefapirina,cefapirine,cefapirinsalt,cefapirinum,cefaprin,cefatrex,cefatrexyl,cephapirin,cephapirine,cephapirinsalt,cephatrexil,cephatrexyl,metricure" 4 "g" "NA" +"CTZ" 6410758 "Cefatrizine" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB07,QJ01DB07" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefatr" "bricef,cefathiamidine,cefatrix,cefatrizino,cefatrizinum,cephatriazine,cepticol,cetrazil,latocef,orosporina,orotric,seapuron,trizina" 1 "g" "18877-1,55639-9,71-1,72-9,73-7,74-5" +"CZD" 71736 "Cefazedone" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB06,QJ01DB06" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefaze" "cefazedon,cefazedona,cefazedonesalt,cefazedonum,refosporen,refosporene,refosporin,refosporinsalt" 3 "g" "NA" +"CZO" 33255 "Cefazolin" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB04,QJ01DB04,QJ51DB04" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefazo,cfz,cfzl,cz,czol,faz,kz" "ancef,atirin,biazolina,cefabiozim,cefacidal,cefalomicina,cefamedin,cefamezin,cefazil,cefazina,cefazolina,cefazoline,cefazolinsalt,cefazolinum,cephamezine,cephazolidin,cephazolin,cephazoline,elzogram,firmacef,gramaxin,kefzol,lampocef,liviclina,neofazol,oprea,recef,totacef,zolicef,zolisint" 3 "g" "16566-2,18878-9,25235-3,3442-1,3443-9,41670-1,75-2,76-0,77-8,78-6,80962-4,85422-4" +"CFB" 127527 "Cefbuperazone" "Other" "J01DC13,QJ01DC13" "cefbup" "cefbuperazona,cefbuperazonesalt,cefbuperazonum,cefbuperzaone,cerbuperazone,keiperazon,tomiporan" 2 "g" "NA" +"CCP" 6436055 "Cefcapene" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD17,QJ01DD17" "cefcap" "flomox" 0.45 "g" "100044-7,76143-7" +"CCX" 5282438 "Cefcapene pivoxil" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "NA" "cefcamate,flumax" "NA" +"CDR" 6915944 "Cefdinir" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD15,QJ01DD15" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cd,cdn,cdr,cefdin,cfd,din" "cefdinirum,cefdinyl,cefdirnir,ceftinex,cefzon,omnicef" 0.6 "g" "23636-4,23637-2,35757-4,35758-2" +"DIT" 9870843 "Cefditoren" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD16,QJ01DD16" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cdn,cefdit" "cefditoreno,spectracef" 0.4 "g" "35759-0,35760-8,35761-6,35762-4" +"DIX" 6437877 "Cefditoren pivoxil" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "NA" "cefditorin,meiact,pivaloyloxymethyl" "NA" +"FEP" 5479537 "Cefepime" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams" "J01DE01,QJ01DE01" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cefep4,cefepi,cfep,cfpi,cpe,cpm,fep,pm,xpm" "anticefepime,axepim,cefepima,cefepimum,maxipime,pyrrolidinium,renapime" 4 "g" "101502-3,18879-7,31142-3,31143-1,35763-2,38363-8,42350-9,42351-7,42353-3,50631-1,58412-8,6643-1,6644-9,6645-7,6646-5,6987-2,8272-7,8273-5" +"CFA" "Cefepime/amikacin" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams" "J01DE51,QJ01DE51" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"CPC" 9567559 "Cefepime/clavulanic acid" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams" "J01DE51,QJ01DE51" "cefcla,cicl,xpml" "NA" "NA" +"FPE" 23653540 "Cefepime/enmetazobactam" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DE51,QJ01DE51" "NA" "NA" "NA" +"FNC" "Cefepime/nacubactam" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DE51,QJ01DE51" "NA" "NA" "NA" +"FTA" "Cefepime/taniborbactam" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DE51,QJ01DE51" "NA" "NA" "NA" +"FPT" 9567558 "Cefepime/tazobactam" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DE51,QJ01DE51" "NA" "NA" "NA" +"FPZ" "Cefepime/zidebactam" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DE51,QJ01DE51" "NA" "NA" "NA" +"CAT" 5487888 "Cefetamet" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD10,QJ01DD10" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefeta,cefmtm" "cefetametum,deacetoxycefotaxime,epocelin" 1 "g" "32377-4,35764-0,35765-7,55640-7" +"CPI" 5486182 "Cefetamet pivoxil" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "NA" "cefetametpivoxil,cefyl,globocef" "NA" +"CCL" 71719688 "Cefetecol" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams" "NA" "cefcatacol" "NA" "NA" +"CZL" 193956 "Cefetrizole" "Cephalosporins,Beta-lactams" "NA" "NA" "cefetrizolum" "NA" +"FDC" 77843966 "Cefiderocol" "Cephalosporins,Beta-lactams" "J01DI04,QJ01DI04" "NA" "fetcroja" 6 "g" "95767-0,99280-0,99503-5" +"CFM" 5362065 "Cefixime" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD08,QJ01DD08" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefixi,cfe,cfix,cfxm,dcfm,fix,ix" "cefixim,cefixima,cefiximum,cefixoral,cefspan,cephoral,citropen,denvar,necopen,oraken,oroken,suprax,tricef,unixime" 0.4 "g" "16567-0,18880-5,25236-1,35766-5,79-4,80-2,81-0,82-8" +"CEO" "Cefixime/ornidazole" "Other" "J01DD58,QJ01DD58" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"CMX" 9570757 "Cefmenoxime" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD05,QJ01DD05,QS01AA31,QS02AA18,S01AA31,S02AA18" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefmen" "bestron,cefmenoxima,cefmenoximum,tacef" 2 "g" "32375-8,54174-8,54203-5,55641-5" +"CMZ" 42008 "Cefmetazole" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC09,QJ01DC09" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefmet" "cefmetazol,cefmetazolo,cefmetazolum,cefmetazon,metafar,zefazone" 4 "g" "11575-8,18881-3,25222-1,87-7,88-5,89-3,90-1" +"CNX" 71141 "Cefminox" "Other" "J01DC12,QJ01DC12" "cefmin" "alteporina,cefminoxhydrate,cefminoxum,meicelin,tencef" 4 "g" "54908-9" +"DIZ" 5361871 "Cefodizime" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD09,QJ01DD09" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefodizima,cefodizimum,cefodizme,diezime,kenicef,modivid,neucef,timecef" 2 "g" "18882-1,6988-0,91-9,92-7,93-5,94-3" +"CID" 43594 "Cefonicid" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC06,QJ01DC06" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoni" "cefonicide,cefonicido,cefonicidsalt,cefonicidum,monocef,monocid" 1 "g" "18883-9,25237-9,3444-7,55642-3,95-0,96-8,97-6,98-4" +"CFP" 44187 "Cefoperazone" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD12,QJ01DD12,QJ51DD12" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefope,cfp,cfpz,cp,cpz,fop,per" "bioperazone,cefob,cefobid,cefobis,cefoneg,cefoper,cefoperazin,cefoperazine,cefoperazon,cefoperazona,cefoperazonesalt,cefoperazono,cefoperazonum,cefozon,medocef,myticef,pathozone,peracef,tomabef" 4 "g" "100-8,101-6,102-4,18884-7,3445-4,35767-3,35768-1,54166-4,54167-2,54168-0,99-2" +"CSL" "Cefoperazone/sulbactam" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DD62,QJ01DD62" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "fopsul" "NA" 4 "g" "35768-1,54166-4,54167-2,54168-0" +"CND" 43507 "Ceforanide" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC11,QJ01DC11" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefora" "ceforanido,ceforanidum,precef" 4 "g" "103-2,104-0,105-7,106-5,18885-4,55643-1" +"CSE" 9830519 "Cefoselis" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams" "NA" "cefose" "winsef" "NA" +"CTX" 5742673 "Cefotaxime" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD01,QJ01DD01" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefo32,cefota,cfot,cft,cftx,ct,ctx,fot,fot1,tax,taxmen,taxnme,xct" "anticefotaxime,cefotax,cefotaxim,cefotaxima,cefotaximesalt,cefotaximsalt,cefotaximum,cephotaxim,cephotaxime,claforan,kefotex,omnatax,pretor,ralopar,tolycar,tolycor,zariviz" 4 "g" "101479-4,101480-2,107-3,108-1,109-9,110-7,18886-2,25238-7,31138-1,31139-9,3446-2,35769-9,35770-7,35771-5,41671-9,50632-9,52128-6,54191-2,54192-0,54193-8,55189-5,55644-9,6989-8,80961-6" +"CTX-S" "Cefotaxime screening test" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "ctx screen" "NA" "NA" +"CTC" 9575353 "Cefotaxime/clavulanic acid" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD51,QJ01DD51" "cxcl,taxcla,xctl" "NA" "NA" +"CTS" 9574753 "Cefotaxime/sulbactam" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DD51,QJ01DD51" "NA" "NA" "54191-2,54192-0,54193-8,55644-9" +"CTT" 53025 "Cefotetan" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC05,QJ01DC05" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefote,cftt,cn,cte,ctn,ctt,tans" "apacef,apatef,cefotetanum" 4 "g" "111-5,112-3,113-1,114-9,18887-0,25239-5,3447-0,41672-7,41673-5,41674-3,41729-5,6990-6" +"CTF" 43708 "Cefotiam" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC07,QJ01DC07" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoti" "aspil,cefotiamum,ceradon,halospor,pansporin,pansporine,spizef" 1.2 "g" 4 "g" "32374-1,35772-3,35773-1,55645-6,55737-1,55738-9,55739-7,55740-5" +"CHE" 125846 "Cefotiam hexetil" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "NA" "taketiam,texodil" "55737-1,55738-9,55739-7,55740-5" +"FOV" 9578573 "Cefovecin" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "QJ01DD91" "cefove" "cefovecinsalt,convenia" "76147-8,87792-8" +"FOX" 441199 "Cefoxitin" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC01,QJ01DC01" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoxi,cfox,cfx,cfxt,cx,fox,fx" "betacef,cefoxil,cefoxitina,cefoxitine,cefoxitinsalt,cefoxitinum,cefoxotin,cenomycin,farmoxin,mefoxin,mefoxithin,mefoxitin,merxin,rephoxitin" 6 "g" "101492-7,115-6,116-4,117-2,118-0,18888-8,25220-5,25240-3,25366-6,3448-8,41675-0,41676-8,41677-6,41730-3,6991-4" +"FOX-S" "Cefoxitin screening test" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "NA" "cfsc,fox1" "NA" "NA" +"ZOP" 9571080 "Cefozopran" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams" "J01DE03,QJ01DE03" "cefozo" "firstcin,imidazo" 4 "g" "100045-4,53820-7" +"CFZ" 68597 "Cefpimizole" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "cefpim" "ajicef,cefpimizol,cefpimizolesalt,cefpimizolum,renilan" "NA" +"CPM" 636405 "Cefpiramide" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD11,QJ01DD11" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefpam" "cefpiramida,cefpiramidesalt,cefpiramido,cefpiramidum,sepatren,suncefal" 2 "g" "NA" +"CPO" 5479539 "Cefpirome" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams" "J01DE02,QJ01DE02" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cefpom,cfpr" "broact,cefir,cefpiroma,cefpiromum,cefrom,keiten,romecef" 4 "g" "18889-6,6647-3,6648-1,6649-9,6650-6,6992-2,8274-3,8275-0,8276-8" +"CPD" 6335986 "Cefpodoxime" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD13,QJ01DD13" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefpod,cfpd,cfpo,cpd,pod,pod4,px" "cefpodoxima,cefpodoximum,epoxim" 0.4 "g" "119-8,120-6,121-4,122-2,18890-4,25241-1,41678-4,41679-2,41680-0,41731-1,6993-0,90849-1" +"CPX" 6526396 "Cefpodoxime proxetil" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "NA" "banan,cefodox,cefoprox,cefpoderm,cefpodoximproxetil,cepodem,doxef,orelox,otreon,podomexef,simplicef,vantin" "NA" +"CDC" "Cefpodoxime/clavulanic acid" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD64,QJ01DD64" "cecl,podcla" "NA" 0.4 "g" "NA" +"CPR" 5281006 "Cefprozil" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC10,QJ01DC10" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefpro,cpr,cpz,fp" "arzimol,brisoral,cefprozilo,cefprozilum,cronocef,procef,serozil" 1 "g" "123-0,124-8,125-5,126-3,18891-2,6994-8" +"CEQ" 5464355 "Cefquinome" "Cephalosporins (4th gen.),Cephalosporins,Beta-lactams" "QG51AA07,QJ01DE90,QJ51DE90" "cefqui" "cefquinoma,cefquinomum,cobactan,quinolinium" "100046-2,76150-2" +"CRD" 5284529 "Cefroxadine" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB11,QJ01DB11" "Other beta-lactam antibacterials" "First-generation cephalosporins" "ceftix" "cefroxadin,cefroxadino,cefroxadinum,oraspor" 2.1 "g" "NA" +"CFS" 656575 "Cefsulodin" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD03,QJ01DD03" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefsul,cfsl,cfsu" "cefomonil,cefonomil,cefsulodine,cefsulodinhydrate,cefsulodino,cefsulodinum,pseudocef,pseudomonil,pyocefal,sulcephalosporin,takesulin,tilmapor,ulfaret" 4 "g" "127-1,128-9,129-7,130-5,131-3,18892-0,25242-9,55647-2" +"CSU" 68718 "Cefsumide" "Cephalosporins,Beta-lactams" "NA" "NA" "cefsulmid,cefsumido,cefsumidum" "NA" +"CPT" 56841980 "Ceftaroline" "Cephalosporins (5th gen.),Cephalosporins,Beta-lactams" "J01DI02,QJ01DI02" "ceftar,cfro" "ceftaroine,teflaro,zinforo" "73604-1,73605-8,73626-4,73627-2,73649-6,73650-4,74170-2" +"CPA" "Ceftaroline/avibactam" "Cephalosporins (5th gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "NA" "NA" "NA" "73604-1,73626-4,73649-6" +"CAZ" 5481173 "Ceftazidime" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD02,QJ01DD02" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "caz,cef,cefta,ceftaz,cfta,cftz,taz,tz,xtz" "ceftazimide,ceptaz,fortam,fortaz,fortum,glazidim,kefazim,modacin,pentacef,tazicef,tizime" 4 "g" "101481-0,101482-8,101483-6,132-1,133-9,134-7,135-4,18893-8,21151-6,3449-6,35774-9,35775-6,35776-4,42352-5,55648-0,55649-8,55650-6,55651-4,58705-5,6995-5,73603-3,73625-6,73648-8,80960-8,87734-0,90850-9" +"CZA" 90643431 "Ceftazidime/avibactam" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DD52,QJ01DD52" "cfav" "avycaz,zavicefta" 6 "g" "101483-6,73603-3,73625-6,73648-8,87734-0" +"CCV" 9575352 "Ceftazidime/clavulanic acid" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD52,QJ01DD52" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "czcl,tazcla,xtzl" "NA" 6 "g" "NA" +"CEM" 6537431 "Cefteram" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD18,QJ01DD18" "cefter" "cefterame,cefteramum,ceftetrame" 0.4 "g" "100047-0,76144-5" +"CPL" 5362114 "Cefteram pivoxil" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "NA" "cefterampivoxil,tomiron" "NA" +"CTL" 65755 "Ceftezole" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "J01DB12,QJ01DB12" "Other beta-lactam antibacterials" "First-generation cephalosporins" "ceftez" "alomen,ceftezol,ceftezolesalt,ceftezolo,ceftezolum,celoslin,demethylcefazolin,falomesin" 3 "g" "NA" +"CTB" 5282242 "Ceftibuten" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD14,QJ01DD14" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cb,ceftib,cfbu,ctb,tib" "cedax,ceftem,ceftibutene,ceftibuteno,ceftibutenum,ceftibutin,ceprifran,isocef,keimax,seftem" 0.4 "g" "35777-2,35778-0,35779-8,6996-3" +"TIO" 6328657 "Ceftiofur" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "QJ01DD90,QJ51DD90" "ceftif" "ceftiofurum,excenel,naxcel" "23709-9,35780-6,35781-4,55652-2" +"CZX" 6533629 "Ceftizoxime" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD07,QJ01DD07" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "ceftiz,cfzx,ctz,cz,czx,tiz,zox" "cefizox,ceftix,ceftizoxima,ceftizoximesalt,ceftizoximum,eposerin" 4 "g" "136-2,137-0,138-8,139-6,18894-6,20378-6,23622-4,25243-7,3450-4,6997-1" +"CZP" 9578661 "Ceftizoxime alapivoxil" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "NA" "NA" "NA" "NA" +"BPR" 135413542 "Ceftobiprole" "Cephalosporins (5th gen.),Cephalosporins,Beta-lactams" "NA" "ceftob" "NA" "43269-0,43270-8,43271-6,43272-4,85052-9" +"CFM1" 135413544 "Ceftobiprole medocaril" "Cephalosporins (5th gen.),Cephalosporins,Beta-lactams" "J01DI01,QJ01DI01" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "NA" "zevtera" 1.5 "g" "NA" +"CZT" 86291594 "Ceftolozane/tazobactam" "Cephalosporins (5th gen.),Cephalosporins,Beta-lactams,Beta-lactamase inhibitors" "J01DI54,QJ01DI54" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "cei" "zerbaxa" 3 "g" "101484-4,73602-5,73624-9,73647-0,87735-7" +"CRO" 5479530 "Ceftriaxone" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD04,QJ01DD04" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "axo,cax,ceftri,cftr,cro,ctr,frx,trimen,trinme,tx" "biotrakson,ceftriaxon,ceftriaxona,ceftriaxonum,ceftriazone,rocefin,rocephalin,rocephin,rocephine,rophex" 2 "g" "101485-1,140-4,141-2,142-0,143-8,18895-3,25244-5,25367-4,31140-7,31141-5,3451-2,41681-8,41682-6,41683-4,41732-9,50633-7,55190-3,6998-9,80957-4" +"CEB" "Ceftriaxone/beta-lactamase inhibitor" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD63,QJ01DD63" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "NA" 2 "g" "NA" +"CXM" 5479529 "Cefuroxime" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC02,QJ01DC02,QJ51DC02,QS01AA27,S01AA27" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefaxe,cefrox,cefuro,cfrx,cfur,cfx,crm,cxm,fur,rox,xm" "anaptivan,biociclin,biofuroksym,bioxima,cefofix,cefumax,cefurex,cefuril,cefurox,cefuroxim,cefuroxima,cefuroximesalt,cefuroximine,cefuroximo,cefuroximum,cephuroxime,cetroxil,colifossim,curoxim,curoxima,curoxime,froxal,furoxil,kefurox,kesint,ketocef,lifurox,medoxim,sharox,spectrazolr,ultroxim,zinacef,zinnat" 0.5 "g" 3 "g" "101503-1,144-6,145-3,146-1,147-9,18896-1,20460-2,25245-2,3452-0,35782-2,35783-0,51724-3,51774-8,55653-0,55654-8,6999-7,74699-0,80608-3,80617-4" +"CXA" 6321416 "Cefuroxime axetil" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "NA" "cfax" "bioracef,ceftin,cefurax,cefuroximaxetil,celocid,cepazine,cethixim,cetoxil,coliofossim,curocef,elobact,kalcef,maxitil,medoxm,nivador,novador,novocef,oraxim,zinat,zoref" "NA" +"CFM2" "Cefuroxime/metronidazole" "Other" "J01DC52,QJ01DC52" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" 0.5 "g" "NA" +"ZON" 6336505 "Cefuzonam" "Other" "NA" "cefuzo" "cefuzoname,cefuzonamum,cefzoname,cosmosin" "NA" +"CED" 38103 "Cephradine" "Cephalosporins (1st gen.),Cephalosporins,Beta-lactams" "NA" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephra,cfra,cfrd" "anspor,cefradin,cefradina,cefradine,cefradinum,cekodin,cephradin,ecosporina,eskacef,infexin,megacef,sefril,velocef,velosef" "168-5,169-3,170-1,171-9,18902-7,55646-4" "CTO" 71402 "Cetocycline" "Tetracyclines" "NA" "NA" "cetocyline,cetotetrine,chelocardin" "NA" "CHL" 5959 "Chloramphenicol" "Phenicols" "D06AX02,D10AF03,G01AA05,J01BA01,QD06AX02,QD10AF03,QG01AA05,QJ01BA01,QJ51BA01,QS01AA01,QS02AA01,QS03AA08,S01AA01,S02AA01,S03AA08" "Amphenicols" "Amphenicols" "c,chl,chlo,chlora,cl" "alficetyn,ambofen,amphicol,amseclor,anacetin,aquamycetin,austracil,austracol,biocetin,biophenicol,catilan,chemicetin,chemicetina,chlomin,chlomycol,chloramex,chloramfenikol,chloramficin,chloramfilin,chloramphenicole,chloramphenicolum,chloramsaar,chlorasol,chlorbiotic,chloricol,chlornitromycin,chloroamphenicol,chlorocaps,chlorocid,chlorocide,chlorocin,chlorocol,chlorofair,chloromax,chloromycetin,chloromycetny,chloromyxin,chloronitrin,chloroptic,chlorovules,cidocetine,ciplamycetin,cloramfen,cloramfenicol,cloramfenicolo,cloramficin,cloramicol,cloramidina,cloranfenicol,cloroamfenicolo,clorocyn,cloromisan,clorosintex,comycetin,cylphenicol,desphen,detreomycin,detreomycine,dextramycin,dextromycetin,doctamicina,econochlor,embacetin,emetren,enteromycetin,erbaplast,ertilen,farmicetina,globenicol,glorous,gloveticol,halcetin,halomycetin,hortfenicol,intramycetin,isicetin,ismicetina,isophenicol,juvamycetin,kamaver,kemicetina,kemicetine,kloramfenikol,klorita,laevomycetinum,leukamycin,leukomyan,leukomycin,levocin,levomicetina,levomitsetin,levomycetin,levoplast,levosin,levovetin,loromisan,loromisin,mastiphen,maybridge,mediamycetine,medichol,micloretin,micochlorine,micoclorina,microcetina,mychel,mycinol,myclocin,mycochlorin,novochlorocap,novomycetin,novophenicol,ocuphenicol,oftalent,oleomycetin,opclor,opelor,ophthochlor,ophthocort,ophtochlor,optomycin,otachron,otophen,pantovernil,paraxin,pentamycetin,petnamycetin,quemicetina,rivomycin,romphenil,ronphenil,septicol,sificetina,sintomicetin,sintomicetina,soluthor,stanomycetin,synthomycetin,synthomycetine,synthomycine,syntomycin,tevcocin,tevcosin,tifomycin,tifomycine,tiromycetin,treomicetina,tyfomycine,unimycetin,veticol,viceton" 3 "g" 3 "g" "15101-9,16603-3,16604-1,172-7,173-5,174-3,175-0,18903-5,25247-8,29214-4,29346-4,29347-2,3455-3,7001-1" "CTE" 54675777 "Chlortetracycline" "Tetracyclines" "A01AB21,D06AA02,J01AA03,QA01AB21,QD06AA02,QG51AA08,QJ01AA03,QJ51AA03,QS01AA02,S01AA02" "Tetracyclines" "Tetracyclines" "chltet" "acronize,alexomycin,aueromycin,aureocarmyl,aureociclina,aureocina,aureocycline,aureomycin,aureomykoin,aurofac,auxeomycin,biomitsin,biomycin,chlormax,chlorotetracycline,chlortetracyclinum,chrysomykine,clorocipan,clortetraciclina,clortetrin,declomycin,declostatin,deganol,demeclor,demeplus,demetraciclina,demetraclin,detracin,detravis,diuciclin,duomycin,elkamicina,flamycin,isphamycin,ledermicina,ledermycin,ledermycine,mexocine,novotriclina,pennchlor,perciclina,periciclina,sumaclina,uromycin,veraciclina" 1 "g" "176-8,177-6,178-4,179-2,18904-3,55655-5,87600-3" -"CIC" 19003 "Ciclacillin" "Beta-lactams/penicillins" "NA" "cyclac" "bastcillin,calthor,ciclacilina,ciclacilline,ciclacillinum,ciclacillum,citosarin,cyclacillin,cyclapen,noblicil,orfilina,peamezin,syngacillin,ultracillin,vastcillin,vipicil,wyvital" "NA" -"CIX" 47472 "Ciclopirox" "Antifungals/antimycotics" "D01AE14,G01AX12,QD01AE14,QG01AX12" "Antifungals for topical use" "Other antifungals for topical use" "cipx" "NA" "NA" +"CIC" 19003 "Ciclacillin" "Penicillins,Beta-lactams" "NA" "cyclac" "bastcillin,calthor,ciclacilina,ciclacilline,ciclacillinum,ciclacillum,citosarin,cyclacillin,cyclapen,noblicil,orfilina,peamezin,syngacillin,ultracillin,vastcillin,vipicil,wyvital" "NA" +"CIX" 47472 "Ciclopirox" "Antifungals" "D01AE14,G01AX12,QD01AE14,QG01AX12" "Antifungals for topical use" "Other antifungals for topical use" "cipx" "NA" "NA" "CIN" 2762 "Cinoxacin" "Quinolones" "J01MB06,QJ01MB06" "Quinolone antibacterials" "Other quinolones" "cino,cinoxa,cnox" "cinobac,cinobactin,cinoxacine,cinoxacino,cinoxacinum,clinoxacin,noxigram,uronorm" 1 "g" "180-0,181-8,182-6,183-4,18905-0,55656-3" -"CIP" 2764 "Ciprofloxacin" "Fluoroquinolones" "J01MA02,QJ01MA02,QS01AE03,QS02AA15,QS03AA07,S01AE03,S02AA15,S03AA07" "Quinolone antibacterials" "Fluoroquinolones" "ci,cip,cipr,ciprof,cp" "alcipro,bacquinor,baflox,belmacina,bernoflox,catex,cenin,ceprimax,cetraxal,ciflan,ciflosin,cifloxin,cilab,cilox,ciloxan,cipad,ciplus,ciprecu,ciprenit,ciprine,ciprinol,cipro,ciprobay,ciprocinal,ciprocinol,ciprodar,ciproflox,ciprofloxacina,ciprofloxacine,ciprofloxacino,ciprofloxacinum,ciprofur,ciprogis,ciproktan,ciprolin,ciprolon,cipromycin,cipronex,ciprooxacin,cipropol,ciproquinol,ciprowin,ciproxan,ciproxin,ciproxina,ciproxine,ciriax,citeral,citopcin,cixan,corsacin,cunesin,cycin,cyprobay,cyproxan,disfabac,felixene,fimoflox,flociprin,floxacipron,flunas,globuce,inkamil,ipiflox,italnik,keefloxin,linhaliq,loxacid,loxan,lypro,megaflox,microgan,nixin,novidat,novoquin,ofitin,oftacilox,ophaflox,otiprio,phaproxin,piprol,plenolyt,probiox,proflaxin,proksi,proquin,proxacin,quinoflox,quinolid,quintor,quipro,rancif,renator,roflazin,roxytal,sepcen,septicide,septocipro,siprogut,sophixin,spitacin,strox,suiflox,superocin,supraflox,uritent,utiminx,velmonit,zumaflox" 1 "g" 0.8 "g" "101500-7,14031-9,14032-7,14058-2,14059-0,184-2,185-9,186-7,187-5,18906-8,20377-8,23621-6,25180-1,25181-9,25188-4,25189-2,25248-6,34636-1,3484-3,42644-5,55194-5,7002-9" -"CIM" "Ciprofloxacin/metronidazole" "Fluoroquinolones" "J01RA10,QJ01RA10" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"CIO" "Ciprofloxacin/ornidazole" "Fluoroquinolones" "J01RA12,QJ01RA12" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"CIT" "Ciprofloxacin/tinidazole" "Fluoroquinolones" "J01RA11,QJ01RA11" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"CLR" 84029 "Clarithromycin" "Macrolides/lincosamides" "J01FA09,QJ01FA09" "Macrolides, lincosamides and streptogramins" "Macrolides" "ch,cla,clar,claryt,clm,clr" "abbotic,abboticine,astromen,biaxin,bicrolid,bristamycin,clacee,clacid,clacine,clambiotic,clarem,claribid,claricide,claridar,claripen,clarith,clarithromycine,clarithromycinum,claritromicina,clarosip,clathromycin,crixan,cyllid,cyllind,eratrex,esinol,fromilid,gallimycin,helas,heliclar,klabax,klacid,klaciped,klaricid,klarid,klarin,kofron,mabicrol,macladin,maclar,mavid,meberyt,pediamycin,qidmycin,veclam,wyamycin,zeclar" 0.5 "g" 1 "g" "100048-8,16619-9,16620-7,188-3,189-1,18907-6,190-9,191-7,20375-2,23619-0,25190-0,25191-8,25192-6,25253-6,34638-7,43987-7,43990-1,43991-9,7003-7,80559-8,89485-7" -"CLA1" 5280980 "Clavulanic acid" "Other antibacterials" "NA" "NA" "amonate,clavulanate,clavulanateacid,clavulansaeure,clavulansaure,clavulox,serdaxin" "NA" -"CLX" 60063 "Clinafloxacin" "Fluoroquinolones" "NA" "clinaf" "NA" "32376-6,33284-1,35785-5,35786-3,7004-5" -"CLI" 446598 "Clindamycin" "Macrolides/lincosamides" "D10AF01,G01AA10,J01FF01,QD10AF01,QG01AA10,QJ01FF01" "Macrolides, lincosamides and streptogramins" "Lincosamides" "cc,cd,cli,clin,clin32,clinda,cm,da" "antirobe,chlolincocin,chlorlincocin,cleocin,clindamicina,clindamycine,clindamycinum,clinimycin,clinsol,clintabs,dalacine,klimicin,klindan,sobelin" 1.2 "g" 1.8 "g" "16621-5,16622-3,18908-4,192-5,193-3,194-1,195-8,25249-4,3486-8,42720-3,55657-1,55658-9,55659-7,55660-5,61188-9,7005-2" -"CLI-S" "Clindamycin inducible screening test" "Macrolides/lincosamides" "NA" "clin inducible,clinda inducible,clindamycin inducible" "NA" "NA" +"CIP" 2764 "Ciprofloxacin" "Fluoroquinolones,Quinolones" "J01MA02,QJ01MA02,QS01AE03,QS02AA15,QS03AA07,S01AE03,S02AA15,S03AA07" "Quinolone antibacterials" "Fluoroquinolones" "ci,cip,cipr,ciprof,cp" "alcipro,bacquinor,baflox,belmacina,bernoflox,catex,cenin,ceprimax,cetraxal,ciflan,ciflosin,cifloxin,cilab,cilox,ciloxan,cipad,ciplus,ciprecu,ciprenit,ciprine,ciprinol,cipro,ciprobay,ciprocinal,ciprocinol,ciprodar,ciproflox,ciprofloxacina,ciprofloxacine,ciprofloxacino,ciprofloxacinum,ciprofur,ciprogis,ciproktan,ciprolin,ciprolon,cipromycin,cipronex,ciprooxacin,cipropol,ciproquinol,ciprowin,ciproxan,ciproxin,ciproxina,ciproxine,ciriax,citeral,citopcin,cixan,corsacin,cunesin,cycin,cyprobay,cyproxan,disfabac,felixene,fimoflox,flociprin,floxacipron,flunas,globuce,inkamil,ipiflox,italnik,keefloxin,linhaliq,loxacid,loxan,lypro,megaflox,microgan,nixin,novidat,novoquin,ofitin,oftacilox,ophaflox,otiprio,phaproxin,piprol,plenolyt,probiox,proflaxin,proksi,proquin,proxacin,quinoflox,quinolid,quintor,quipro,rancif,renator,roflazin,roxytal,sepcen,septicide,septocipro,siprogut,sophixin,spitacin,strox,suiflox,superocin,supraflox,uritent,utiminx,velmonit,zumaflox" 1 "g" 0.8 "g" "101500-7,14031-9,14032-7,14058-2,14059-0,184-2,185-9,186-7,187-5,18906-8,20377-8,23621-6,25180-1,25181-9,25188-4,25189-2,25248-6,34636-1,3484-3,42644-5,55194-5,7002-9" +"CIM" "Ciprofloxacin/metronidazole" "Fluoroquinolones,Quinolones" "J01RA10,QJ01RA10" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"CIO" "Ciprofloxacin/ornidazole" "Fluoroquinolones,Quinolones" "J01RA12,QJ01RA12" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"CIT" "Ciprofloxacin/tinidazole" "Fluoroquinolones,Quinolones" "J01RA11,QJ01RA11" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"CLR" 84029 "Clarithromycin" "Macrolides" "J01FA09,QJ01FA09" "Macrolides, lincosamides and streptogramins" "Macrolides" "ch,cla,clar,claryt,clm,clr" "abbotic,abboticine,astromen,biaxin,bicrolid,bristamycin,clacee,clacid,clacine,clambiotic,clarem,claribid,claricide,claridar,claripen,clarith,clarithromycine,clarithromycinum,claritromicina,clarosip,clathromycin,crixan,cyllid,cyllind,eratrex,esinol,fromilid,gallimycin,helas,heliclar,klabax,klacid,klaciped,klaricid,klarid,klarin,kofron,mabicrol,macladin,maclar,mavid,meberyt,pediamycin,qidmycin,veclam,wyamycin,zeclar" 0.5 "g" 1 "g" "100048-8,16619-9,16620-7,188-3,189-1,18907-6,190-9,191-7,20375-2,23619-0,25190-0,25191-8,25192-6,25253-6,34638-7,43987-7,43990-1,43991-9,7003-7,80559-8,89485-7" +"CLA1" 5280980 "Clavulanic acid" "Other" "NA" "NA" "amonate,clavulanate,clavulanateacid,clavulansaeure,clavulansaure,clavulox,serdaxin" "NA" +"CLX" 60063 "Clinafloxacin" "Fluoroquinolones,Quinolones" "NA" "clinaf" "NA" "32376-6,33284-1,35785-5,35786-3,7004-5" +"CLI" 446598 "Clindamycin" "Lincosamides" "D10AF01,G01AA10,J01FF01,QD10AF01,QG01AA10,QJ01FF01" "Macrolides, lincosamides and streptogramins" "Lincosamides" "cc,cd,cli,clin,clin32,clinda,cm,da" "antirobe,chlolincocin,chlorlincocin,cleocin,clindamicina,clindamycine,clindamycinum,clinimycin,clinsol,clintabs,dalacine,klimicin,klindan,sobelin" 1.2 "g" 1.8 "g" "16621-5,16622-3,18908-4,192-5,193-3,194-1,195-8,25249-4,3486-8,42720-3,55657-1,55658-9,55659-7,55660-5,61188-9,7005-2" +"CLI-S" "Clindamycin inducible screening test" "Lincosamides,Macrolides" "NA" "clin inducible,clinda inducible,clindamycin inducible" "NA" "NA" "CLF" 2794 "Clofazimine" "Antimycobacterials" "J04BA01,QJ04BA01" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "clof,clofam" "chlofazimine,clofazimina,clofaziminum,colfazimine,lampren,lamprene,phenazine,riminophenazine" 0.1 "g" "16623-1,20376-0,23620-8,23627-3,43986-9,43988-5,43989-3,55661-3,55662-1,96108-6" -"CLF1" 2799 "Clofoctol" "Other antibacterials" "J01XX03,QJ01XX03" "Other antibacterials" "Other antibacterials" "NA" "clofoctolo,clofoctolum,gramplus,octofene,phenol" "NA" -"CLM" 71807 "Clometocillin" "Beta-lactams/penicillins" "J01CE07,QJ01CE07" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "chlomethocillin,clometacillin,clomethacillin,clomethocillin,clometocilina,clometocilline,clometocillinsalt,clometocillinum,penicilline,rixapen" 1 "g" "NA" +"CLF1" 2799 "Clofoctol" "Other" "J01XX03,QJ01XX03" "Other antibacterials" "Other antibacterials" "NA" "clofoctolo,clofoctolum,gramplus,octofene,phenol" "NA" +"CLM" 71807 "Clometocillin" "Penicillins,Beta-lactams" "J01CE07,QJ01CE07" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "chlomethocillin,clometacillin,clomethacillin,clomethocillin,clometocilina,clometocilline,clometocillinsalt,clometocillinum,penicilline,rixapen" 1 "g" "NA" "CLM1" 54680675 "Clomocycline" "Tetracyclines" "J01AA11,QJ01AA11" "Tetracyclines" "Tetracyclines" "NA" "clomociclina,clomocyclinum,megaclor" 1 "g" "NA" -"CTR" 2812 "Clotrimazole" "Antifungals/antimycotics" "A01AB18,D01AC01,G01AF02,QA01AB18,QD01AC01,QG01AF02,QJ02AB90" "clot" "alevazol,bisphenyl,canesten,canestene,canestine,canifug,chlotrimazole,clomatin,clotrimaderm,clotrimazol,clotrimazolum,coltrimazole,cutistad,diphenylmethane,empecid,esparol,femmesil,footlogix,fortinia,gynix,imidazole,jidesheng,klotrimazole,lakesia,lombazol,lombazole,lombazolum,lotrimax,lotrimin,monobaycuten,mycelax,mycelex,mycofug,mycosporin,mykosporin,nalbix,otomax,pedesil,pedisafe,ringworm,stiemazol,tibatin,trimysten,trivagizole" "10653-4,10654-2,18909-2,54177-1,55663-9" -"CLO" 6098 "Cloxacillin" "Beta-lactams/penicillins" "J01CF02,QJ01CF02,QJ51CF02,QS01AA90" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,cloxac" "ankerbin,austrastaph,biocloxin,brispen,chloroxacillin,ciclex,clocil,clossacillina,cloxacilina,cloxacillinanhydrous,cloxacilline,cloxacillinsalt,cloxacillinum,cloxapen,constaphyl,dariclox,dichlorstapenor,diclocil,dicloxacillinhydrate,diflor,digloxilline,dynapen,ekvacillin,gelstaph,novapen,noxaben,orbenin,pathocil,stampen,staphybiotic,syntarpen,syntarpensalt,tegopen" 2 "g" 2 "g" "16628-0,18910-0,196-6,197-4,198-2,199-0,25250-2,55664-7" +"CTR" 2812 "Clotrimazole" "Antifungals" "A01AB18,D01AC01,G01AF02,QA01AB18,QD01AC01,QG01AF02,QJ02AB90" "clot" "alevazol,bisphenyl,canesten,canestene,canestine,canifug,chlotrimazole,clomatin,clotrimaderm,clotrimazol,clotrimazolum,coltrimazole,cutistad,diphenylmethane,empecid,esparol,femmesil,footlogix,fortinia,gynix,imidazole,jidesheng,klotrimazole,lakesia,lombazol,lombazole,lombazolum,lotrimax,lotrimin,monobaycuten,mycelax,mycelex,mycofug,mycosporin,mykosporin,nalbix,otomax,pedesil,pedisafe,ringworm,stiemazol,tibatin,trimysten,trivagizole" "10653-4,10654-2,18909-2,54177-1,55663-9" +"CLO" 6098 "Cloxacillin" "Isoxazolylpenicillins,Penicillins,Beta-lactams" "J01CF02,QJ01CF02,QJ51CF02,QS01AA90" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,cloxac" "ankerbin,austrastaph,biocloxin,brispen,chloroxacillin,ciclex,clocil,clossacillina,cloxacilina,cloxacillinanhydrous,cloxacilline,cloxacillinsalt,cloxacillinum,cloxapen,constaphyl,dariclox,dichlorstapenor,diclocil,dicloxacillinhydrate,diflor,digloxilline,dynapen,ekvacillin,gelstaph,novapen,noxaben,orbenin,pathocil,stampen,staphybiotic,syntarpen,syntarpensalt,tegopen" 2 "g" 2 "g" "16628-0,18910-0,196-6,197-4,198-2,199-0,25250-2,55664-7" "COL" 5311054 "Colistin" "Polymyxins" "A07AA10,J01XB01,QA07AA10,QJ01XB01,QJ51XB01" "Other antibacterials" "Polymyxins" "cl,coli,colist,cs,cst,ct" "colimycin,colisticin,colisticina,colistina,colistine,colistinum,colobreathe,colomycin,kangdisu,kolimitsin,kolimycin,promixin,sogecoli,totazina" 9 "MU" 9 "MU" "16645-4,18912-6,204-8,205-5,206-3,207-1,29493-4,33333-6" -"COP" "Colistin/polysorbate" "Other antibacterials" "NA" "NA" "NA" "NA" +"COP" "Colistin/polysorbate" "Other" "NA" "NA" "NA" "NA" "CYC" 6234 "Cycloserine" "Oxazolidinones" "J04AB01,QJ04AB01" "Drugs for treatment of tuberculosis" "Antibiotics" "cycl,cyclos" "cicloserina,closina,cyclorin,cycloserin,cycloserinum,farmiserina,levcicloserina,levcycloserine,levcycloserinum,micoserina,miroserina,miroseryn,novoserin,oxamicina,oxamycin,seromycin,tebemicina,wasserina" 0.75 "g" "16702-3,18914-2,212-1,213-9,214-7,215-4,23608-3,25207-2,25208-0,25209-8,25251-0,3519-6,55667-0" -"DAL" 23724878 "Dalbavancin" "Glycopeptides" "J01XA04,QJ01XA04" "Other antibacterials" "Glycopeptide antibacterials" "dalb,dalbav" "dalbavancina,dalvance,xydalba,zeven" 1.5 "g" "41688-3,41689-1,41690-9,41734-5" -"DAN" 71335 "Danofloxacin" "Fluoroquinolones" "QJ01MA92" "danofl" "advocin,danofloxacine,danofloxacino,danofloxacinum" "73601-7,73623-1,73646-2" -"DPS" 2955 "Dapsone" "Other antibacterials" "D10AX05,J04BA02,QD10AX05,QJ04BA02" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "dao" "aczone,atrisone,avlosulfon,avlosulfone,avlosulphone,benzenamide,benzenamine,bissulfone,bissulphone,croysulfone,croysulphone,dapson,dapsona,dapsonum,daspone,diaphenylsulfon,diaphenylsulfone,diaphenylsulphon,diaphenylsulphone,diphenasone,diphone,disulfone,disulone,disulphone,dubronax,dumitone,eporal,medapsol,novophone,servidapson,sulfadione,sulfona,sulfonyldianiline,sulphadione,sulphonyldianiline,tarimyl,udolac,undolac" 50 "mg" "51698-9,9747-7" -"DAP" 16134395 "Daptomycin" "Other antibacterials" "J01XX09,QJ01XX09" "Other antibacterials" "Other antibacterials" "dap,dapt,dapt25,dapt50,daptom" "cidecin,cubicin,dapcin,daptomicina,daptomycine,daptomycinum,deptomycin" 0.28 "g" "35787-1,35788-9,35789-7,41691-7" -"DFX" 487101 "Delafloxacin" "Fluoroquinolones" "J01MA23,QJ01MA23" "NA" "baxdela,delafloxacinum,quofenix" 0.9 "g" 0.6 "g" "88885-9,90447-4,93790-4" +"DAL" 23724878 "Dalbavancin" "Lipoglycopeptides,Glycopeptides" "J01XA04,QJ01XA04" "Other antibacterials" "Glycopeptide antibacterials" "dalb,dalbav" "dalbavancina,dalvance,xydalba,zeven" 1.5 "g" "41688-3,41689-1,41690-9,41734-5" +"DAN" 71335 "Danofloxacin" "Fluoroquinolones,Quinolones" "QJ01MA92" "danofl" "advocin,danofloxacine,danofloxacino,danofloxacinum" "73601-7,73623-1,73646-2" +"DPS" 2955 "Dapsone" "Other" "D10AX05,J04BA02,QD10AX05,QJ04BA02" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "dao" "aczone,atrisone,avlosulfon,avlosulfone,avlosulphone,benzenamide,benzenamine,bissulfone,bissulphone,croysulfone,croysulphone,dapson,dapsona,dapsonum,daspone,diaphenylsulfon,diaphenylsulfone,diaphenylsulphon,diaphenylsulphone,diphenasone,diphone,disulfone,disulone,disulphone,dubronax,dumitone,eporal,medapsol,novophone,servidapson,sulfadione,sulfona,sulfonyldianiline,sulphadione,sulphonyldianiline,tarimyl,udolac,undolac" 50 "mg" "51698-9,9747-7" +"DAP" 16134395 "Daptomycin" "Other" "J01XX09,QJ01XX09" "Other antibacterials" "Other antibacterials" "dap,dapt,dapt25,dapt50,daptom" "cidecin,cubicin,dapcin,daptomicina,daptomycine,daptomycinum,deptomycin" 0.28 "g" "35787-1,35788-9,35789-7,41691-7" +"DFX" 487101 "Delafloxacin" "Fluoroquinolones,Quinolones" "J01MA23,QJ01MA23" "NA" "baxdela,delafloxacinum,quofenix" 0.9 "g" 0.6 "g" "88885-9,90447-4,93790-4" "DLM" 6480466 "Delamanid" "Antimycobacterials" "J04AK06,QJ04AK06" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "dela" "deltyba" 0.2 "g" "93851-4,96109-4" "DEM" 54680690 "Demeclocycline" "Tetracyclines" "D06AA01,J01AA01,QD06AA01,QJ01AA01" "Tetracyclines" "Tetracyclines" "demecy" "demeclociclina,demeclocyclinum" 0.6 "g" "10982-7,18915-9,216-2,217-0,218-8,219-6,29494-2,7006-0" "DKB" 470999 "Dibekacin" "Aminoglycosides" "J01GB09,QJ01GB09,QS01AA29,S01AA29" "Aminoglycoside antibacterials" "Other aminoglycosides" "dibeka" "debecacin,dibekacina,dibekacine,dibekacinum,kappati,panamicin" 0.14 "g" "55669-6,55670-4,55671-2,55672-0" -"DIC" 18381 "Dicloxacillin" "Beta-lactams/penicillins" "J01CF01,QJ01CF01,QJ51CF01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "dicl,diclox" "dichloroxacillin,diclossacillina,dicloxaciclin,dicloxacilin,dicloxacilina,dicloxacillina,dicloxacilline,dicloxacillinum,dicloxacycline,maclicine" 2 "g" 2 "g" "10984-3,16769-2,18916-7,220-4,221-2,222-0,223-8,25252-8,32380-8,55668-8" -"DIF" 56206 "Difloxacin" "Fluoroquinolones" "QJ01MA94" "diflox" "dicural,difloxacine,pulsaflox" "35790-5,35791-3,35792-1" -"DIR" 6473883 "Dirithromycin" "Macrolides/lincosamides" "J01FA13,QJ01FA13" "Macrolides, lincosamides and streptogramins" "Macrolides" "dirith" "dirithromycine,dirithromycinum,diritromicina,divitross,dynabac,noriclan,valodin" 0.5 "g" "35793-9,35794-7,35795-4,7007-8" -"DOR" 73303 "Doripenem" "Carbapenems" "J01DH04,QJ01DH04" "Other beta-lactam antibacterials" "Carbapenems" "dori,doripe" "doribax,dripenem,finibax" 1.5 "g" "56031-8,58711-3,60535-2,72893-1" +"DIC" 18381 "Dicloxacillin" "Isoxazolylpenicillins,Penicillins,Beta-lactams" "J01CF01,QJ01CF01,QJ51CF01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "dicl,diclox" "dichloroxacillin,diclossacillina,dicloxaciclin,dicloxacilin,dicloxacilina,dicloxacillina,dicloxacilline,dicloxacillinum,dicloxacycline,maclicine" 2 "g" 2 "g" "10984-3,16769-2,18916-7,220-4,221-2,222-0,223-8,25252-8,32380-8,55668-8" +"DIF" 56206 "Difloxacin" "Fluoroquinolones,Quinolones" "QJ01MA94" "diflox" "dicural,difloxacine,pulsaflox" "35790-5,35791-3,35792-1" +"DIR" 6473883 "Dirithromycin" "Macrolides" "J01FA13,QJ01FA13" "Macrolides, lincosamides and streptogramins" "Macrolides" "dirith" "dirithromycine,dirithromycinum,diritromicina,divitross,dynabac,noriclan,valodin" 0.5 "g" "35793-9,35794-7,35795-4,7007-8" +"DOR" 73303 "Doripenem" "Carbapenems,Beta-lactams" "J01DH04,QJ01DH04" "Other beta-lactam antibacterials" "Carbapenems" "dori,doripe" "doribax,dripenem,finibax" 1.5 "g" "56031-8,58711-3,60535-2,72893-1" "DOX" 54671203 "Doxycycline" "Tetracyclines" "A01AB22,J01AA02,QA01AB22,QJ01AA02" "Tetracyclines" "Tetracyclines" "dox,doxy,doxycy" "abbocin,alamycin,aquacycline,biosolvomycin,biotet,bisolvomycin,chrysocin,dalimycin,dalinmycin,deoxymykoin,dossiciclina,doxiciclina,doxirobe,doxitard,doxivetin,doxycen,doxychel,doxycin,doxycyclin,doxycyclinum,doxylin,doxysol,doxytetracycline,elinton,engemycin,hydrocyclin,imperacin,intaloxin,investin,jenacyclin,liquachel,liviatin,macodyn,mepatar,microdox,mondoxyne,monodox,morgidox,ocudox,okebo,oracea,otetryn,oxacycline,oxamycen,oxatet,oxlopar,oxybiocycline,oxydon,oxyject,oxymykoin,oxysteclin,oxytet,oxytetral,oxytetrin,oxytracyl,oxyvet,stecsolin,supracyclin,terraject,terramycin,toxinal,unimycin,vendarcin,vibramycin,vibramycine,vivox,zenavod" 0.1 "g" 0.1 "g" "10986-8,18917-5,20379-4,21250-6,224-6,225-3,226-1,227-9,23623-2,25223-9,26902-7,7008-6" -"ECO" 3198 "Econazole" "Antifungals/antimycotics" "D01AC03,G01AF05,QD01AC03,QG01AF05" "Antifungals for topical use" "Imidazole and triazole derivatives" "econ" "bromazil,chloramizol,clinafarm,deccosil,deccozil,econazolum,ecostatin,ekonazole,enilconazol,enilconazole,eniloconazol,fecundal,florasan,freshgard,freshguard,fungaflor,fungazil,imaverol,imaversol,imazalil,magnate,spectazole" "25595-0,25637-0,54178-9,55673-8" +"ECO" 3198 "Econazole" "Antifungals" "D01AC03,G01AF05,QD01AC03,QG01AF05" "Antifungals for topical use" "Imidazole and triazole derivatives" "econ" "bromazil,chloramizol,clinafarm,deccosil,deccozil,econazolum,ecostatin,ekonazole,enilconazol,enilconazole,eniloconazol,fecundal,florasan,freshgard,freshguard,fungaflor,fungazil,imaverol,imaversol,imazalil,magnate,spectazole" "25595-0,25637-0,54178-9,55673-8" "EFF" "Efflux" "Other" "NA" "effflux pump" "NA" "NA" -"ENX" 3229 "Enoxacin" "Fluoroquinolones" "J01MA04,QJ01MA04" "Quinolone antibacterials" "Fluoroquinolones" "enox,enoxa" "abenox,almitil,bactidan,bactidron,comprecin,enofloxacine,enoksetin,enoram,enoxacina,enoxacine,enoxacino,enoxacinum,enoxen,enoxin,enoxor,flumark,penetrex" 0.8 "g" "16816-1,18918-3,228-7,229-5,230-3,231-1,3590-7,41692-5" -"ENR" 71188 "Enrofloxacin" "Fluoroquinolones" "QJ01MA90" "enrofl" "baytril,enroflox,enrofloxacine,enrofloxacino,enrofloxacinum,enroquin,enrosite,enroxil,quellaxcin,tenotryl,zobuxa" "23712-3,35796-2,35797-0,35798-8" +"ENX" 3229 "Enoxacin" "Fluoroquinolones,Quinolones" "J01MA04,QJ01MA04" "Quinolone antibacterials" "Fluoroquinolones" "enox,enoxa" "abenox,almitil,bactidan,bactidron,comprecin,enofloxacine,enoksetin,enoram,enoxacina,enoxacine,enoxacino,enoxacinum,enoxen,enoxin,enoxor,flumark,penetrex" 0.8 "g" "16816-1,18918-3,228-7,229-5,230-3,231-1,3590-7,41692-5" +"ENR" 71188 "Enrofloxacin" "Fluoroquinolones,Quinolones" "QJ01MA90" "enrofl" "baytril,enroflox,enrofloxacine,enrofloxacino,enrofloxacinum,enroquin,enrosite,enroxil,quellaxcin,tenotryl,zobuxa" "23712-3,35796-2,35797-0,35798-8" "ENV" 135565326 "Enviomycin" "Antimycobacterials" "J04AB06,QJ04AB06" "tuberactinomycin" "enviomicina,enviomycina,enviomycine,enviomycinum,tuberactin" 1 "g" "NA" -"EPE" "Eperozolid" "Other antibacterials" "NA" "NA" "NA" "NA" -"EPC" 71392 "Epicillin" "Beta-lactams/penicillins" "J01CA07,QJ01CA07" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "dexacillin,dihydroampicillin,epicilina,epicilline,epicillinum,spectacillin" 2 "g" 2 "g" "NA" -"EPP" 68916 "Epiroprim" "Other antibacterials" "NA" "NA" "epiroprima,epiroprime,epiroprimum" "NA" +"EPE" "Eperozolid" "Other" "NA" "NA" "NA" "NA" +"EPC" 71392 "Epicillin" "Penicillins,Beta-lactams" "J01CA07,QJ01CA07" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "dexacillin,dihydroampicillin,epicilina,epicilline,epicillinum,spectacillin" 2 "g" 2 "g" "NA" +"EPP" 68916 "Epiroprim" "Other" "NA" "NA" "epiroprima,epiroprime,epiroprimum" "NA" "ERV" 54726192 "Eravacycline" "Tetracyclines" "J01AA13,QJ01AA13" "Tetracyclines" "Tetracyclines" "erav" "xerava" 0.14 "g" "100049-6,85423-2,93767-2" -"ETP" 150610 "Ertapenem" "Carbapenems" "J01DH03,QJ01DH03" "Other beta-lactam antibacterials" "Carbapenems" "erta,ertape,etp" "ertapenemsalt,invanz" 1 "g" "101486-9,35799-6,35800-2,35801-0,35802-8" -"ERY" 12560 "Erythromycin" "Macrolides/lincosamides" "D10AF02,J01FA01,QD10AF02,QJ01FA01,QJ51FA01,QS01AA17,S01AA17" "Macrolides, lincosamides and streptogramins" "Macrolides" "e,em,ery,ery32,eryt,eryth" "abboticin,abomacetin,acneryne,acnesol,aknemycin,aknin,benzamycin,derimer,deripil,dotycin,dumotrycin,emgel,emuvin,emycin,endoeritrin,erecin,erisone,eritomicina,eritrocina,eritromicina,ermycin,eryacne,eryacnen,erycen,erycette,erycinum,eryderm,erydermer,erygel,eryhexal,erymax,erymed,erysafe,erytab,erythro,erythroderm,erythrogran,erythroguent,erythromast,erythromid,erythromycine,erythromycinum,erytop,erytrociclin,ilocaps,ilosone,iloticina,ilotycin,inderm,latotryd,lederpax,mephamycin,mercina,oftamolets,pantoderm,pantodrin,pantomicina,pharyngocin,primacine,propiocine,proterytrin,retcin,robimycin,sansac,spotex,staticin,stiemicyn,stiemycin,tiprocin,torlamicina,wemid" 2 "g" 1 "g" "100050-4,11576-6,12298-6,16829-4,16830-2,18919-1,18920-9,20380-2,232-9,233-7,234-5,235-2,236-0,23633-1,237-8,238-6,239-4,25224-7,25275-9,3597-2,7009-4" +"ETP" 150610 "Ertapenem" "Carbapenems,Beta-lactams" "J01DH03,QJ01DH03" "Other beta-lactam antibacterials" "Carbapenems" "erta,ertape,etp" "ertapenemsalt,invanz" 1 "g" "101486-9,35799-6,35800-2,35801-0,35802-8" +"ERY" 12560 "Erythromycin" "Macrolides" "D10AF02,J01FA01,QD10AF02,QJ01FA01,QJ51FA01,QS01AA17,S01AA17" "Macrolides, lincosamides and streptogramins" "Macrolides" "e,em,ery,ery32,eryt,eryth" "abboticin,abomacetin,acneryne,acnesol,aknemycin,aknin,benzamycin,derimer,deripil,dotycin,dumotrycin,emgel,emuvin,emycin,endoeritrin,erecin,erisone,eritomicina,eritrocina,eritromicina,ermycin,eryacne,eryacnen,erycen,erycette,erycinum,eryderm,erydermer,erygel,eryhexal,erymax,erymed,erysafe,erytab,erythro,erythroderm,erythrogran,erythroguent,erythromast,erythromid,erythromycine,erythromycinum,erytop,erytrociclin,ilocaps,ilosone,iloticina,ilotycin,inderm,latotryd,lederpax,mephamycin,mercina,oftamolets,pantoderm,pantodrin,pantomicina,pharyngocin,primacine,propiocine,proterytrin,retcin,robimycin,sansac,spotex,staticin,stiemicyn,stiemycin,tiprocin,torlamicina,wemid" 2 "g" 1 "g" "100050-4,11576-6,12298-6,16829-4,16830-2,18919-1,18920-9,20380-2,232-9,233-7,234-5,235-2,236-0,23633-1,237-8,238-6,239-4,25224-7,25275-9,3597-2,7009-4" "ETH" 14052 "Ethambutol" "Antimycobacterials" "J04AK02,QJ04AK02" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "emb,etha,ethamb" "aethambutolum,dadibutol,diambutol,etambutol,etambutolo,ethambutolum,myambutol,purderal,servambutol,tibutol" 1.2 "g" 1.2 "g" "100051-2,16841-9,18921-7,20381-0,23625-7,240-2,241-0,242-8,243-6,25187-6,25194-2,25195-9,25230-4,25404-5,3607-9,42645-2,42646-0,55154-9,55674-6,56025-0,7010-2,89491-5" "ETI" 456476 "Ethambutol/isoniazid" "Antimycobacterials" "J04AM03,QJ04AM03" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" "ETI1" 2761171 "Ethionamide" "Antimycobacterials" "J04AD03,QJ04AD03" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "ethi,ethion" "aethionamidum,aetina,aetiva,amidazin,amidazine,atina,ethimide,ethina,ethinamide,ethionamidum,ethioniamide,ethylisothiamide,ethyonomide,etimid,etiocidan,etionamid,etionamida,etionamide,etioniamid,etionid,etionizin,etionizina,etionizine,fatoliamid,iridocin,iridozin,isothin,isotiamida,itiocide,nicotion,nisotin,nizotin,rigenicid,sertinon,teberus,thianid,thianide,thioamide,thiodine,thiomid,thioniden,tianid,tiomid,trecator,trekator,trescatyl,trescazide,tubenamide,tubermin,tuberoid,tuberoson" 0.75 "g" "16099-4,16845-0,18922-5,20382-8,23617-4,25183-5,25196-7,25198-3,25231-2,41693-3,42647-8,42648-6,7011-0,96110-2" -"ETO" 6034 "Ethopabate" "Other antibacterials" "QP51AX17" "NA" "ethopabat" "NA" -"EXE" "Exebacase" "NA" "NA" "NA" "NA" -"FAR" 65894 "Faropenem" "Other antibacterials" "J01DI03,QJ01DI03" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "farope" "farom,faropenemhydrate,faropenemsalt,fropenem,fropenum,furopenem" 0.75 "g" "73600-9,73622-3,73645-4" -"FDX" 10034073 "Fidaxomicin" "Other antibacterials" "A07AA12,QA07AA12" "NA" "dificid,dificlir,difimicin,fidaxomicina,lipiarmicin,lipiarmycin,lipiarrmycin" 0.4 "g" "73599-3,73621-5,73644-7" -"FIN" 11567473 "Finafloxacin" "Fluoroquinolones" "NA" "NA" "xtoro" "73598-5,73620-7,73643-9" -"FLA" 46783781 "Flavomycin" "Other antibacterials" "NA" "flavom" "bambermicina,bambermycine,bambermycinum,flavofosfolipol,flavophospholipol,gainpro,menomycin" "NA" -"FLE" 3357 "Fleroxacin" "Fluoroquinolones" "J01MA08,QJ01MA08" "Quinolone antibacterials" "Fluoroquinolones" "fler,flerox" "fleroxacine,fleroxacino,fleroxacinum,fleroxicin,megalocin,megalone,megalosin,quinodis" 0.4 "g" 0.4 "g" "25411-0,32372-5,35806-9,7012-8" -"FLO" 65864 "Flomoxef" "Other antibacterials" "J01DC14,QJ01DC14" "flomox" "flomoxefo,flomoxefsalt,flomoxefum,flumarin" 2 "g" "100052-0,53822-3" +"ETO" 6034 "Ethopabate" "Other" "QP51AX17" "NA" "ethopabat" "NA" +"EXE" "Exebacase" "Other" "NA" "NA" "NA" "NA" +"FAR" 65894 "Faropenem" "Other" "J01DI03,QJ01DI03" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "farope" "farom,faropenemhydrate,faropenemsalt,fropenem,fropenum,furopenem" 0.75 "g" "73600-9,73622-3,73645-4" +"FDX" 10034073 "Fidaxomicin" "Other" "A07AA12,QA07AA12" "NA" "dificid,dificlir,difimicin,fidaxomicina,lipiarmicin,lipiarmycin,lipiarrmycin" 0.4 "g" "73599-3,73621-5,73644-7" +"FIN" 11567473 "Finafloxacin" "Fluoroquinolones,Quinolones" "NA" "NA" "xtoro" "73598-5,73620-7,73643-9" +"FLA" 46783781 "Flavomycin" "Other" "NA" "flavom" "bambermicina,bambermycine,bambermycinum,flavofosfolipol,flavophospholipol,gainpro,menomycin" "NA" +"FLE" 3357 "Fleroxacin" "Fluoroquinolones,Quinolones" "J01MA08,QJ01MA08" "Quinolone antibacterials" "Fluoroquinolones" "fler,flerox" "fleroxacine,fleroxacino,fleroxacinum,fleroxicin,megalocin,megalone,megalosin,quinodis" 0.4 "g" 0.4 "g" "25411-0,32372-5,35806-9,7012-8" +"FLO" 65864 "Flomoxef" "Other" "J01DC14,QJ01DC14" "flomox" "flomoxefo,flomoxefsalt,flomoxefum,flumarin" 2 "g" "100052-0,53822-3" "FLR" 114811 "Florfenicol" "Phenicols" "QJ01BA90,QJ51BA90" "florfe" "aquafen,descocin,dexawin,efnicol,fricol,hyrazin,loncor,macphenicol,masatirin,neomyson,norfenicol,nuflor,racephenicol,rincrol,thiamcol,urfamicina,urophenyl" "23740-4,35807-7,35808-5,87599-7" -"FLC" 21319 "Flucloxacillin" "Beta-lactams/penicillins" "J01CF05,QJ01CF05,QJ51CF05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,fluclo,flux" "bactopen,cloxacap,cloxacillinhydrate,cloxypen,floxacillin,floxacillinanhydrous,floxapen,floxapensalt,fluclomix,flucloxacilina,flucloxacilline,flucloxacillinum,flucloxin,fluorochloroxacillin,galfloxin,latocillin,orbeninhydrate,rimaflox,staphobristol,zoxin" 2 "g" 2 "g" "NA" -"FLU" 3365 "Fluconazole" "Antifungals/antimycotics" "D01AC15,J02AC01,QD01AC15,QJ02AC01" "Antimycotics for systemic use" "Triazole derivatives" "fluc,flucon,fluz,flz" "alflucoz,alkanazole,baten,biocanol,biozole,biozolene,canzol,cryptal,diflazon,diflucan,dimycon,elazor,flucazol,fluconazoli,fluconazolum,flucoral,flucostat,flukezol,flunazol,flunizol,fluzon,forcan,fuconal,fungata,loitin,mutum,oxifugol,pritenzol,syscan,trican,triconal,triflucan,zemyc,zoltec,zonal" 0.2 "g" 0.2 "g" "10987-6,16870-8,18924-1,248-5,249-3,250-1,251-9,25255-1,7013-6,80530-9" -"FCT" 3366 "Flucytosine" "Antifungals/antimycotics" "D01AE21,J02AX01,QD01AE21,QJ02AX01" "Antifungals for topical use" "Other antifungals for topical use" "5flc,fcu,flucyt,fluo,fluy" "alcobon,ancoban,ancobon,ancotil,ancotyl,flourocytosine,flucitosina,flucytosin,flucytosinum,flucytosone,fluocytosine,fluorcytosine,fluorocytosine" 10 "g" 10 "g" "NA" +"FLC" 21319 "Flucloxacillin" "Isoxazolylpenicillins,Penicillins,Beta-lactams" "J01CF05,QJ01CF05,QJ51CF05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,fluclo,flux" "bactopen,cloxacap,cloxacillinhydrate,cloxypen,floxacillin,floxacillinanhydrous,floxapen,floxapensalt,fluclomix,flucloxacilina,flucloxacilline,flucloxacillinum,flucloxin,fluorochloroxacillin,galfloxin,latocillin,orbeninhydrate,rimaflox,staphobristol,zoxin" 2 "g" 2 "g" "NA" +"FLU" 3365 "Fluconazole" "Antifungals" "D01AC15,J02AC01,QD01AC15,QJ02AC01" "Antimycotics for systemic use" "Triazole derivatives" "fluc,flucon,fluz,flz" "alflucoz,alkanazole,baten,biocanol,biozole,biozolene,canzol,cryptal,diflazon,diflucan,dimycon,elazor,flucazol,fluconazoli,fluconazolum,flucoral,flucostat,flukezol,flunazol,flunizol,fluzon,forcan,fuconal,fungata,loitin,mutum,oxifugol,pritenzol,syscan,trican,triconal,triflucan,zemyc,zoltec,zonal" 0.2 "g" 0.2 "g" "10987-6,16870-8,18924-1,248-5,249-3,250-1,251-9,25255-1,7013-6,80530-9" +"FCT" 3366 "Flucytosine" "Antifungals" "D01AE21,J02AX01,QD01AE21,QJ02AX01" "Antifungals for topical use" "Other antifungals for topical use" "5flc,fcu,flucyt,fluo,fluy" "alcobon,ancoban,ancobon,ancotil,ancotyl,flourocytosine,flucitosina,flucytosin,flucytosinum,flucytosone,fluocytosine,fluorcytosine,fluorocytosine" 10 "g" 10 "g" "NA" "FLM" 3374 "Flumequine" "Quinolones" "J01MB07,QJ01MB07" "Quinolone antibacterials" "Other quinolones" "flumeq" "apurone,fantacin,flumequina,flumequino,flumequinum,flumigal,flumiquil,flumisol,flumix,imequyl" 1.2 "g" "55675-3,55676-1,55677-9,55678-7" -"FLR1" 71260 "Flurithromycin" "Macrolides/lincosamides" "J01FA14,QJ01FA14" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "abbot,beritromicina,berythromycin,berythromycine,berythromycinum,flurithromycine,flurithromycinum,fluritromicina,fluritromycinum,flurizic,mizar" 0.75 "g" "NA" -"FFL" 214356 "Fosfluconazole" "Antifungals/antimycotics" "NA" "NA" "fosfluconazol,procif,prodif" "NA" +"FLR1" 71260 "Flurithromycin" "Macrolides" "J01FA14,QJ01FA14" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "abbot,beritromicina,berythromycin,berythromycine,berythromycinum,flurithromycine,flurithromycinum,fluritromicina,fluritromycinum,flurizic,mizar" 0.75 "g" "NA" +"FFL" 214356 "Fosfluconazole" "Antifungals" "NA" "NA" "fosfluconazol,procif,prodif" "NA" "FOS" 446987 "Fosfomycin" "Phosphonics" "J01XX01,QJ01XX01,QS02AA17,S02AA17" "Other antibacterials" "Other antibacterials" "ff,fm,fo,fof,fos,fosf,fosfom,fosmyc" "fosfocina,fosfomicin,fosfomicina,fosfomycine,fosfomycinum,fosfonomycin,infectophos,phosphonemycin,phosphonomycin,veramina" 3 "g" 8 "g" "25596-8,25653-7,35809-3,35810-1" -"FMD" 572 "Fosmidomycin" "Other antibacterials" "NA" "NA" "fosmidomicina,fosmidomycina,fosmidomycine,fosmidomycinsalt,fosmidomycinum" "NA" +"FMD" 572 "Fosmidomycin" "Other" "NA" "NA" "fosmidomicina,fosmidomycina,fosmidomycine,fosmidomycinsalt,fosmidomycinum" "NA" "FRM" 8378 "Framycetin" "Aminoglycosides" "D09AA01,QD09AA01,QJ01GB91,QR01AX08,QS01AA07,R01AX08,S01AA07" "fram,framyc" "actilin,actiline,antibiotique,bycomycin,enterfram,fradiomycin,fradiomycinum,framicetina,framidal,framycetine,framycetinum,framycin,framygen,francetin,jernadex,myacyne,mycerin,mycifradin,neobrettin,neolate,neomas,neomcin,neomicina,neomin,neomycine,neomycinum,nivemycin,soframycin,soframycine" "18926-6,257-6,258-4,259-2,260-0,55679-5" -"FUR" 6870646 "Furazidin" "Other antibacterials" "J01XE03,QJ01XE03" "Other antibacterials" "Nitrofuran derivatives" "NA" "akritoin,furagin,furaginum,furamag,furazidine,hydantoin" 0.3 "g" "NA" -"FRZ" 5323714 "Furazolidone" "Other antibacterials" "G01AX06,QG01AX06,QJ01XE90" "furazo" "bifuron,corizium,coryzium,diafuron,enterotoxon,furall,furanzolidone,furaxon,furaxone,furazolidine,furazolidon,furazolidona,furazolidonum,furazolum,furidon,furmethoxadone,furovag,furoxal,furoxane,furoxon,furoxone,furozolidine,giardil,giarlam,medaron,neftin,nicolen,nifulidone,nifuran,nifurazolidone,nifurazolidonum,nitrofuradoxon,nitrofurazolidone,nitrofurazolidonum,nitrofuroxon,optazol,ortazol,puradin,roptazol,sclaventerol,tikofuran,topazone,trichofuron,tricofuron,tricoron,trifurox,viofuragyn" "69574-2,87794-4" -"FUS" 3000226 "Fusidic acid" "Other antibacterials" "D06AX01,D09AA02,J01XC01,QD06AX01,QD09AA02,QJ01XC01,QS01AA13,S01AA13" "Other antibacterials" "Steroid antibacterials" "fa,fusaci,fusi" "flucidin,fucidate,fucidina,fucidine,fucithalmic,fusidate,fusidicacid,fusidin,fusidine,taksta" 1.5 "g" 1.5 "g" "NA" -"GAM" 59364992 "Gamithromycin" "Macrolides/lincosamides" "QJ01FA95" "NA" "zactran" "100054-6,88376-9,88378-5" -"GRN" 124093 "Garenoxacin" "Fluoroquinolones" "J01MA19,QJ01MA19" "gareno" "ganefloxacin,garenfloxacin" 0.4 "g" "35811-9,35812-7,35813-5" -"GAT" 5379 "Gatifloxacin" "Fluoroquinolones" "J01MA16,QJ01MA16,QS01AE06,S01AE06" "Quinolone antibacterials" "Fluoroquinolones" "gati,gatifl" "acorafloxacin,avarofloxacin,balofloxacin,balofox,bazucin,bilimin,bonoq,gaity,gatiflo,gatifloxacine,gatifloxcin,gatilox,gatiquin,gatispan,kinome,tequin,tymer,zymar,zymaxid,zymer" 0.4 "g" 0.4 "g" "31036-7,31038-3,31040-9,31042-5,41494-6" -"GEM" 9571107 "Gemifloxacin" "Fluoroquinolones" "J01MA15,QJ01MA15" "Quinolone antibacterials" "Fluoroquinolones" "gemifl" "factiv,gemifioxacin,gemifloxacine,gemifloxacino,gemifloxacinum" 0.32 "g" 0.2 "g" "35814-3,35815-0,35816-8,41697-4" +"FUR" 6870646 "Furazidin" "Nitrofurans" "J01XE03,QJ01XE03" "Other antibacterials" "Nitrofuran derivatives" "NA" "akritoin,furagin,furaginum,furamag,furazidine,hydantoin" 0.3 "g" "NA" +"FRZ" 5323714 "Furazolidone" "Nitrofurans" "G01AX06,QG01AX06,QJ01XE90" "furazo" "bifuron,corizium,coryzium,diafuron,enterotoxon,furall,furanzolidone,furaxon,furaxone,furazolidine,furazolidon,furazolidona,furazolidonum,furazolum,furidon,furmethoxadone,furovag,furoxal,furoxane,furoxon,furoxone,furozolidine,giardil,giarlam,medaron,neftin,nicolen,nifulidone,nifuran,nifurazolidone,nifurazolidonum,nitrofuradoxon,nitrofurazolidone,nitrofurazolidonum,nitrofuroxon,optazol,ortazol,puradin,roptazol,sclaventerol,tikofuran,topazone,trichofuron,tricofuron,tricoron,trifurox,viofuragyn" "69574-2,87794-4" +"FUS" 3000226 "Fusidic acid" "Other" "D06AX01,D09AA02,J01XC01,QD06AX01,QD09AA02,QJ01XC01,QS01AA13,S01AA13" "Other antibacterials" "Steroid antibacterials" "fa,fusaci,fusi" "flucidin,fucidate,fucidina,fucidine,fucithalmic,fusidate,fusidicacid,fusidin,fusidine,taksta" 1.5 "g" 1.5 "g" "NA" +"GAM" 59364992 "Gamithromycin" "Macrolides" "QJ01FA95" "NA" "zactran" "100054-6,88376-9,88378-5" +"GRN" 124093 "Garenoxacin" "Fluoroquinolones,Quinolones" "J01MA19,QJ01MA19" "gareno" "ganefloxacin,garenfloxacin" 0.4 "g" "35811-9,35812-7,35813-5" +"GAT" 5379 "Gatifloxacin" "Fluoroquinolones,Quinolones" "J01MA16,QJ01MA16,QS01AE06,S01AE06" "Quinolone antibacterials" "Fluoroquinolones" "gati,gatifl" "acorafloxacin,avarofloxacin,balofloxacin,balofox,bazucin,bilimin,bonoq,gaity,gatiflo,gatifloxacine,gatifloxcin,gatilox,gatiquin,gatispan,kinome,tequin,tymer,zymar,zymaxid,zymer" 0.4 "g" 0.4 "g" "31036-7,31038-3,31040-9,31042-5,41494-6" +"GEM" 9571107 "Gemifloxacin" "Fluoroquinolones,Quinolones" "J01MA15,QJ01MA15" "Quinolone antibacterials" "Fluoroquinolones" "gemifl" "factiv,gemifioxacin,gemifloxacine,gemifloxacino,gemifloxacinum" 0.32 "g" 0.2 "g" "35814-3,35815-0,35816-8,41697-4" "GEN" 3467 "Gentamicin" "Aminoglycosides" "D06AX07,J01GB03,QA07AA91,QD06AX07,QG01AA91,QG51AA04,QJ01GB03,QJ51GB03,QS01AA11,QS02AA14,QS03AA06,S01AA11,S02AA14,S03AA06" "Aminoglycoside antibacterials" "Other aminoglycosides" "cn,ge1000,ge2000,gen,gen128,gen500,gent,genta1,gentam,gm" "centicin,cidomycin,garamicin,garamycin,gentacycol,gentamicina,gentamicine,gentamicins,gentamicinum,gentamycins,gentamycinum,gentocin,lyramycin,oksitselanim,septigen,septocin" 0.24 "g" "101494-3,13561-6,13562-4,15106-8,18928-2,18929-0,22746-2,22747-0,266-7,267-5,268-3,269-1,31091-2,31092-0,31093-8,35668-3,35817-6,3663-2,3664-0,3665-7,39082-3,47109-4,50630-3,59379-8,7016-9,7017-7,7018-5,80971-5,88111-0,89481-6" "GEH" "Gentamicin-high" "Aminoglycosides" "NA" "gehi,gehl,genta high,gentamicin high" "NA" "18929-0,35817-6,7017-7,7018-5" -"GEP" 25101874 "Gepotidacin" "Other antibacterials" "J01XX13,QJ01XX13" "NA" "gepotidacina,gepotidacine" "NA" -"GRX" 72474 "Grepafloxacin" "Fluoroquinolones" "J01MA11,QJ01MA11" "Quinolone antibacterials" "Fluoroquinolones" "grep,grepaf" "grepafloxacine,grepafloxacino,lungaskin,raxar,vaxar" 0.4 "g" "21316-5,23638-0,23639-8,35818-4" -"GRI" 441140 "Griseofulvin" "Antifungals/antimycotics" "D01AA08,D01BA01,QD01AA08,QD01BA01" "NA" "amudane,delmofulvina,epigriseofulvin,fulcin,fulcine,fulvicin,fulvidex,fulvina,fulvinil,fulvistatin,fungivin,greosin,gresfeed,gricin,grifulin,grifulvin,grisactin,griscofulvin,grisefuline,griseo,griseofulviin,griseofulvina,griseofulvine,griseofulvinum,griseomix,griseostatin,grisetin,grisofulvin,grisovin,grisowen,grizeofulvin,grysio,guservin,lamoryl,likuden,likunden,murfulvin,poncyl,spiro,spirofulvin,xuanjing" 0.5 "g" "12402-4,54200-1,54201-9,54202-7" +"GEP" 25101874 "Gepotidacin" "Other" "J01XX13,QJ01XX13" "NA" "gepotidacina,gepotidacine" "NA" +"GRX" 72474 "Grepafloxacin" "Fluoroquinolones,Quinolones" "J01MA11,QJ01MA11" "Quinolone antibacterials" "Fluoroquinolones" "grep,grepaf" "grepafloxacine,grepafloxacino,lungaskin,raxar,vaxar" 0.4 "g" "21316-5,23638-0,23639-8,35818-4" +"GRI" 441140 "Griseofulvin" "Antifungals" "D01AA08,D01BA01,QD01AA08,QD01BA01" "NA" "amudane,delmofulvina,epigriseofulvin,fulcin,fulcine,fulvicin,fulvidex,fulvina,fulvinil,fulvistatin,fungivin,greosin,gresfeed,gricin,grifulin,grifulvin,grisactin,griscofulvin,grisefuline,griseo,griseofulviin,griseofulvina,griseofulvine,griseofulvinum,griseomix,griseostatin,grisetin,grisofulvin,grisovin,grisowen,grizeofulvin,grysio,guservin,lamoryl,likuden,likunden,murfulvin,poncyl,spiro,spirofulvin,xuanjing" 0.5 "g" "12402-4,54200-1,54201-9,54202-7" "HAB" 175989 "Habekacin" "Aminoglycosides" "NA" "NA" "amikafur,amikan,amitrex,arikayce,biklin,biodacyn,chemacin,fabianol,habekacinxsulfate,likacin,pierami" "NA" -"HCH" 11979956 "Hachimycin" "Antifungals/antimycotics" "D01AA03,G01AA06,J02AA02,QD01AA03,QG01AA06,QJ02AA02" "Antimycotics for systemic use" "Antibiotics" "NA" "cabimicina,hachimicina,hachimycine,hachimycinum,trichomycinum,trichonat" "NA" -"HET" 443387 "Hetacillin" "Beta-lactams/penicillins" "J01CA18,QJ01CA18" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "hetaci" "etacillina,hetacilina,hetacilline,hetacillinum,natacillin,phenazacillin,versapen,versatrex" 2 "g" "18931-6,274-1,275-8,276-6,277-4" +"HCH" 11979956 "Hachimycin" "Antifungals" "D01AA03,G01AA06,J02AA02,QD01AA03,QG01AA06,QJ02AA02" "Antimycotics for systemic use" "Antibiotics" "NA" "cabimicina,hachimicina,hachimycine,hachimycinum,trichomycinum,trichonat" "NA" +"HET" 443387 "Hetacillin" "Penicillins,Beta-lactams" "J01CA18,QJ01CA18" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "hetaci" "etacillina,hetacilina,hetacilline,hetacillinum,natacillin,phenazacillin,versapen,versatrex" 2 "g" "18931-6,274-1,275-8,276-6,277-4" "HYG" 56928061 "Hygromycin" "Aminoglycosides" "NA" "NA" "antihelmycin,destomysin,hyanthelmix,hygromix,hygrovectine,hygrovetine" "NA" "IBX" "Ibrexafungerp" "Antifungals" "J02AX07,QJ02AX07" "NA" "NA" "NA" -"ICL" 213043 "Iclaprim" "Other antibacterials" "J01EA03,QJ01EA03" "iclapr" "iclaprime,mersarex" "73597-7,73619-9,73642-1" -"IPM" 104838 "Imipenem" "Carbapenems" "J01DH51,QJ01DH51" "Other beta-lactam antibacterials" "Carbapenems" "imci,imi,imip,imip32,imipen,imp" "imipemide,imipenemum,imipenen,primaxin,recarbrio,tienam,tienamycin" 2 "g" "101487-7,17010-0,18932-4,18933-2,23613-3,25221-3,25257-7,27331-8,278-2,279-0,280-8,281-6,282-4,283-2,284-0,285-7,35819-2,3688-9,54170-6,54171-4,54172-2,7019-3,85424-0,93232-7,96372-8" -"IPE" "Imipenem/EDTA" "Carbapenems" "NA" "NA" "NA" "35819-2,54170-6,54171-4,54172-2" -"IMR" "Imipenem/relebactam" "Carbapenems" "J01DH56,QJ01DH56" "NA" "NA" 2 "g" "85424-0,93232-7,96372-8" -"ISV" 6918485 "Isavuconazole" "Antifungals/antimycotics" "J02AC05,QJ02AC05" "isav" "benzonitrile,ravuconazole" 0.2 "g" 0.2 "g" "85381-2,88887-5" +"ICL" 213043 "Iclaprim" "Other" "J01EA03,QJ01EA03" "iclapr" "iclaprime,mersarex" "73597-7,73619-9,73642-1" +"IPM" 104838 "Imipenem" "Carbapenems,Beta-lactams" "J01DH51,QJ01DH51" "Other beta-lactam antibacterials" "Carbapenems" "imci,imi,imip,imip32,imipen,imp" "imipemide,imipenemum,imipenen,primaxin,recarbrio,tienam,tienamycin" 2 "g" "101487-7,17010-0,18932-4,18933-2,23613-3,25221-3,25257-7,27331-8,278-2,279-0,280-8,281-6,282-4,283-2,284-0,285-7,35819-2,3688-9,54170-6,54171-4,54172-2,7019-3,85424-0,93232-7,96372-8" +"IPE" "Imipenem/EDTA" "Carbapenems,Beta-lactams" "NA" "NA" "NA" "35819-2,54170-6,54171-4,54172-2" +"IMR" "Imipenem/relebactam" "Carbapenems,Beta-lactams,Beta-lactamase inhibitors" "J01DH56,QJ01DH56" "NA" "NA" 2 "g" "85424-0,93232-7,96372-8" +"ISV" 6918485 "Isavuconazole" "Antifungals" "J02AC05,QJ02AC05" "isav" "benzonitrile,ravuconazole" 0.2 "g" 0.2 "g" "85381-2,88887-5" "ISE" 3037209 "Isepamicin" "Aminoglycosides" "J01GB11,QJ01GB11" "Aminoglycoside antibacterials" "Other aminoglycosides" "isepam" "isepacin,isepalline,isepamicina,isepamicine,isepamicinsulphate,isepamicinum" 0.4 "g" "32381-6,35820-0,35821-8,55680-3" -"ISO" 3760 "Isoconazole" "Antifungals/antimycotics" "D01AC05,G01AF07,QD01AC05,QG01AF07" "Antimycotics for topic use" "Triazole derivatives" "NA" "isoconazol,isoconazolum,travogen" "55681-1,55682-9,55683-7,55684-5" +"ISO" 3760 "Isoconazole" "Antifungals" "D01AC05,G01AF07,QD01AC05,QG01AF07" "Antimycotics for topic use" "Triazole derivatives" "NA" "isoconazol,isoconazolum,travogen" "55681-1,55682-9,55683-7,55684-5" "INH" 3767 "Isoniazid" "Antimycobacterials" "J04AC01,QJ04AC01" "Drugs for treatment of tuberculosis" "Hydrazides" "inh,isonia" "abdizide,acetylisoniazide,andrazide,anidrasona,antimicina,antituberkulosum,armacide,armazid,armazide,atcotibine,azuren,cedin,cemidon,chemiazid,chemidon,continazine,cortinazine,cotinazin,cotinizin,defonin,dianicotyl,dibutin,diforin,dinacrin,dinocrin,ditubin,ebidene,eralon,ertuban,eutizon,evalon,fetefu,fimalene,hidranizil,hidrasonil,hidrulta,hidrun,hycozid,hydra,hydrazid,hyozid,hyzyd,idrazil,inizid,ipcazide,iscotin,isidrina,ismazide,isobicina,isocid,isocidene,isocotin,isohydrazide,isokin,isolyn,isonerit,isonex,isoniacid,isoniazida,isoniazide,isoniazidum,isonicazide,isonicid,isonico,isonicotan,isonicotil,isonicotinhydrazid,isonicotinohydrazide,isonide,isonidrin,isonikazid,isonilex,isonin,isonindon,isonirit,isoniton,isonizida,isonizide,isotamine,isotebe,isotebezid,isotinyl,isozid,isozide,isozyd,laniazid,laniozid,mayambutol,mybasan,neoteben,neoxin,neumandin,nevin,niadrin,nicazide,nicetal,nicizina,niconyl,nicotibina,nicotibine,nicotisan,nicozide,nidaton,nidrazid,nikozid,niplen,nitadon,niteban,nitebannsc,nydrazid,nyscozid,pelazid,percin,phthisen,preparation,pycazide,pyreazid,pyricidin,pyridicin,pyrizidin,raumanon,razide,retozide,rifater,rimicid,rimifon,rimiphone,rimitsid,robiselin,robisellin,roxifen,sanohidrazina,sauterazid,sauterzid,stanozide,tebecid,tebenic,tebexin,tebilon,tebos,teebaconin,tekazin,tibazide,tibemid,tibiazide,tibinide,tibison,tibivis,tibizide,tibusan,tisin,tisiodrazida,tizide,tubazid,tubazide,tubeco,tubecotubercid,tuberian,tubicon,tubilysin,tubizid,tubomel,tyvid,unicocyde,unicozyde,vazadrine,vederon,zidafimia,zinadon,zonazide" 0.3 "g" 0.3 "g" "18934-0,20383-6,23947-5,25217-1,25218-9,25219-7,25451-6,26756-7,286-5,287-3,288-1,289-9,29315-9,3697-0,40371-7,42649-4,42650-2,42651-0,45215-1,48171-3,48172-1,55685-2,7020-1,89488-1" "IST" "Isoniazid/sulfamethoxazole/trimethoprim/pyridoxine" "Antimycobacterials" "NA" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"ITR" 3793 "Itraconazole" "Antifungals/antimycotics" "J02AC02,QJ02AC02" "Antimycotics for systemic use" "Triazole derivatives" "itra,itraco" "candistat,canditral,cladosal,fungitraxx,intraconazole,itraconazol,itraconazolo,itraconazolum,itraconzaole,itrafungol,itralek,itrizole,lozanoc,onmel,sempera,sporamelt,sporanox,sporonox,traconal,triasporin" 0.2 "g" 0.2 "g" "10989-2,12392-7,25258-5,25452-4,27081-9,32184-4,32185-1,32603-3,54179-7,7021-9,80531-7" -"JOS" 5282165 "Josamycin" "Macrolides/lincosamides" "J01FA07,QJ01FA07" "Macrolides, lincosamides and streptogramins" "Macrolides" "josamy" "jomybel,josamicina,josamycine,josamycinum" 2 "g" "25597-6,25702-2,41698-2,41699-0" +"ITR" 3793 "Itraconazole" "Antifungals" "J02AC02,QJ02AC02" "Antimycotics for systemic use" "Triazole derivatives" "itra,itraco" "candistat,canditral,cladosal,fungitraxx,intraconazole,itraconazol,itraconazolo,itraconazolum,itraconzaole,itrafungol,itralek,itrizole,lozanoc,onmel,sempera,sporamelt,sporanox,sporonox,traconal,triasporin" 0.2 "g" 0.2 "g" "10989-2,12392-7,25258-5,25452-4,27081-9,32184-4,32185-1,32603-3,54179-7,7021-9,80531-7" +"JOS" 5282165 "Josamycin" "Macrolides" "J01FA07,QJ01FA07" "Macrolides, lincosamides and streptogramins" "Macrolides" "josamy" "jomybel,josamicina,josamycine,josamycinum" 2 "g" "25597-6,25702-2,41698-2,41699-0" "KAN" 6032 "Kanamycin" "Aminoglycosides" "A07AA08,J01GB04,QA07AA08,QJ01GB04,QS01AA24,S01AA24" "Aminoglycoside antibacterials" "Other aminoglycosides" "hlk,k,kan,kana,kanamy,km" "kanamicina,kanamycine,kanamycins,kanamycinum,kantrex,klebcil" 3 "g" 1 "g" "18935-7,18936-5,23609-1,23889-9,25182-7,25213-0,25214-8,290-7,291-5,292-3,293-1,3698-8,3699-6,3700-2,42652-8,47395-9,49080-5,7022-7,7023-5,7024-3,88002-1,88705-9,89482-4" "KAH" "Kanamycin-high" "Aminoglycosides" "NA" "k_h,kahl" "NA" "18936-5,7023-5,7024-3" "KAC" "Kanamycin/cephalexin" "Aminoglycosides" "NA" "NA" "NA" "NA" -"KET" 456201 "Ketoconazole" "Antifungals/antimycotics" "D01AC08,G01AF11,H02CA03,J02AB02,QD01AC08,QG01AF11,QH02CA03,QJ02AB02" "Antimycotics for systemic use" "Imidazole derivatives" "keto,ketoco,ktc" "brizoral,ethanone,extina,fungarest,fungoral,ketaconazole,ketocanazole,ketoconazol,ketoconazolum,ketodan,ketoderm,ketoisdin,ketozole,kuric,levoketoconazole,nizoral,normocort,panfungol,piperazine,recorlev,sebazole,teryzolin,terzolin,tocris,xolegel" 0.6 "g" "10990-0,12393-5,18937-3,25259-3,294-9,295-6,296-4,297-2,60091-6,60092-4,7025-0" -"KIT" "Kitasamycin" "Macrolides/lincosamides" "QJ01FA93" "leucomycin" "NA" "NA" -"LAS" 5360807 "Lasalocid" "Other antibacterials" "QP51BB02" "NA" "avatec,bovate,bovatec,lasalocide,lasalocido,lasalocidsalt,lasalocidum" "87598-9" -"LSC" 71528768 "Lascufloxacin" "Fluoroquinolones" "J01MA25,QJ01MA25" "Quinolone antibacterials" "Fluoroquinolones" "NA" "lasvic" 75 "mg" "NA" -"LTM" 47499 "Latamoxef" "Cephalosporins (3rd gen.)" "J01DD06,QJ01DD06" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "mox,moxa,moxalactam" "dilatamoxef,festamoxin,lamoxactam,latamoxefum,morrhuate,moxalactamsalt,moxam,shiomarin" 4 "g" "NA" -"LMU" 25185057 "Lefamulin" "Other antibacterials" "J01XX12,QJ01XX12" "NA" "lefamulinacetate,xenleta" "85425-7,99281-8" -"LEN" 65646 "Lenampicillin" "Beta-lactams/penicillins" "NA" "NA" "lenampicilina,lenampicilline,lenampicillinum,takacillin,valacillin,varacillin" "NA" -"LVX" 149096 "Levofloxacin" "Fluoroquinolones" "J01MA12,QJ01MA12,QS01AE05,S01AE05" "Quinolone antibacterials" "Fluoroquinolones" "le,lev,levo,levofl,lvx" "aeroquin,cravit,dextrofloxacin,dynaquin,elequine,iquix,levaquin,levofiexacin,levofloxacine,levofloxacino,levofloxacinum,loxof,ofloxcacin,oftaquix,quinsair,quixin,tavanic,unibiotic,venaxan" 0.5 "g" 0.5 "g" "101501-5,20396-8,20629-2,21367-8,21368-6,30532-6,30533-4,48173-9,53716-7,7026-8,76040-5,76041-3,76042-1" -"LEO" "Levofloxacin/ornidazole" "Fluoroquinolones" "J01RA05,QJ01RA05" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"LND" 9850038 "Levonadifloxacin" "Fluoroquinolones" "J01MA24,QJ01MA24" "NA" "NA" "NA" -"LSP" "Linco-spectin" "Other antibacterials" "NA" "lincomycin/spectinomycin" "NA" "NA" -"LIN" 3000540 "Lincomycin" "Macrolides/lincosamides" "J01FF02,QJ01FF02,QJ51FF02" "Macrolides, lincosamides and streptogramins" "Lincosamides" "linc,lincom" "albiotic,bactramycin,cillimycin,frademicina,jiemycin,lincocin,lincogap,lincolcina,lincolnensin,lincomicina,lincomix,lincomycine,lincomycinum,lincomyocin,lincorex,linocin,mycivin" 1.8 "g" 1.8 "g" "18938-1,298-0,299-8,300-4,301-2,41700-6,87597-1" +"KET" 456201 "Ketoconazole" "Antifungals" "D01AC08,G01AF11,H02CA03,J02AB02,QD01AC08,QG01AF11,QH02CA03,QJ02AB02" "Antimycotics for systemic use" "Imidazole derivatives" "keto,ketoco,ktc" "brizoral,ethanone,extina,fungarest,fungoral,ketaconazole,ketocanazole,ketoconazol,ketoconazolum,ketodan,ketoderm,ketoisdin,ketozole,kuric,levoketoconazole,nizoral,normocort,panfungol,piperazine,recorlev,sebazole,teryzolin,terzolin,tocris,xolegel" 0.6 "g" "10990-0,12393-5,18937-3,25259-3,294-9,295-6,296-4,297-2,60091-6,60092-4,7025-0" +"KIT" "Kitasamycin" "Macrolides" "QJ01FA93" "leucomycin" "NA" "NA" +"LAS" 5360807 "Lasalocid" "Other" "QP51BB02" "NA" "avatec,bovate,bovatec,lasalocide,lasalocido,lasalocidsalt,lasalocidum" "87598-9" +"LSC" 71528768 "Lascufloxacin" "Fluoroquinolones,Quinolones" "J01MA25,QJ01MA25" "Quinolone antibacterials" "Fluoroquinolones" "NA" "lasvic" 75 "mg" "NA" +"LTM" 47499 "Latamoxef" "Cephalosporins (3rd gen.),Cephalosporins,Beta-lactams" "J01DD06,QJ01DD06" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "mox,moxa,moxalactam" "dilatamoxef,festamoxin,lamoxactam,latamoxefum,morrhuate,moxalactamsalt,moxam,shiomarin" 4 "g" "NA" +"LMU" 25185057 "Lefamulin" "Other" "J01XX12,QJ01XX12" "NA" "lefamulinacetate,xenleta" "85425-7,99281-8" +"LEN" 65646 "Lenampicillin" "Penicillins,Beta-lactams" "NA" "NA" "lenampicilina,lenampicilline,lenampicillinum,takacillin,valacillin,varacillin" "NA" +"LVX" 149096 "Levofloxacin" "Fluoroquinolones,Quinolones" "J01MA12,QJ01MA12,QS01AE05,S01AE05" "Quinolone antibacterials" "Fluoroquinolones" "le,lev,levo,levofl,lvx" "aeroquin,cravit,dextrofloxacin,dynaquin,elequine,iquix,levaquin,levofiexacin,levofloxacine,levofloxacino,levofloxacinum,loxof,ofloxcacin,oftaquix,quinsair,quixin,tavanic,unibiotic,venaxan" 0.5 "g" 0.5 "g" "101501-5,20396-8,20629-2,21367-8,21368-6,30532-6,30533-4,48173-9,53716-7,7026-8,76040-5,76041-3,76042-1" +"LEO" "Levofloxacin/ornidazole" "Fluoroquinolones,Quinolones" "J01RA05,QJ01RA05" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"LND" 9850038 "Levonadifloxacin" "Fluoroquinolones,Quinolones" "J01MA24,QJ01MA24" "NA" "NA" "NA" +"LSP" "Linco-spectin" "Other" "NA" "lincomycin/spectinomycin" "NA" "NA" +"LIN" 3000540 "Lincomycin" "Lincosamides" "J01FF02,QJ01FF02,QJ51FF02" "Macrolides, lincosamides and streptogramins" "Lincosamides" "linc,lincom" "albiotic,bactramycin,cillimycin,frademicina,jiemycin,lincocin,lincogap,lincolcina,lincolnensin,lincomicina,lincomix,lincomycine,lincomycinum,lincomyocin,lincorex,linocin,mycivin" 1.8 "g" 1.8 "g" "18938-1,298-0,299-8,300-4,301-2,41700-6,87597-1" "LNZ" 441401 "Linezolid" "Oxazolidinones" "J01XX08,QJ01XX08" "Other antibacterials" "Other antibacterials" "line,linezo,lnz,lz,lzd" "desfluorolinezolid,linezoid,linezolidum,zivoxid,zyvox,zyvoxa,zyvoxam,zyvoxid" 1.2 "g" 1.2 "g" "29254-0,29255-7,29258-1,33332-8,34202-2,41500-0,80609-1,88706-7,96111-0" -"LFE" "Linoprist-flopristin" "Other antibacterials" "NA" "linflo" "NA" "NA" -"LOM" 3948 "Lomefloxacin" "Fluoroquinolones" "J01MA07,QJ01MA07,QS01AE04,S01AE04" "Quinolone antibacterials" "Fluoroquinolones" "lmf,lom,lome,lomefl" "bareon,logiflox,lomebact,lomefloxacine,lomefloxacino,lomefloxacinum,maxaquin,maxaquine,mazaquin,okacin,okacyn,uniquin" 0.4 "g" "18939-9,302-0,303-8,304-6,305-3,41701-4" -"LOR" 5284585 "Loracarbef" "Cephalosporins (2nd gen.)" "J01DC08,QJ01DC08" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "lora,loraca" "carbac,lorabid,loracarbefum,lorafem,lorbef,loribid" 0.6 "g" "18940-7,306-1,307-9,308-7,309-5,7027-6" +"LFE" "Linoprist-flopristin" "Other" "NA" "linflo" "NA" "NA" +"LOM" 3948 "Lomefloxacin" "Fluoroquinolones,Quinolones" "J01MA07,QJ01MA07,QS01AE04,S01AE04" "Quinolone antibacterials" "Fluoroquinolones" "lmf,lom,lome,lomefl" "bareon,logiflox,lomebact,lomefloxacine,lomefloxacino,lomefloxacinum,maxaquin,maxaquine,mazaquin,okacin,okacyn,uniquin" 0.4 "g" "18939-9,302-0,303-8,304-6,305-3,41701-4" +"LOR" 5284585 "Loracarbef" "Cephalosporins (2nd gen.),Cephalosporins,Beta-lactams" "J01DC08,QJ01DC08" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "lora,loraca" "carbac,lorabid,loracarbefum,lorafem,lorbef,loribid" 0.6 "g" "18940-7,306-1,307-9,308-7,309-5,7027-6" "LYM" 54707177 "Lymecycline" "Tetracyclines" "J01AA04,QJ01AA04" "Tetracyclines" "Tetracyclines" "NA" "armyl,chlortetracyclin,ciclisin,ciclolysal,ciclolysine,eficiclina,infaciclina,limeciclina,lisinbiotic,lymecyclinum,mucomycin,ntetracycline,tetralisal,tetralysal,vebicyclysal" 0.6 "g" 0.6 "g" "18941-5,310-3,311-1,312-9,313-7" -"MNA" 1292 "Mandelic acid" "Other antibacterials" "B05CA06,J01XX06,QB05CA06,QJ01XX06" "Other antibacterials" "Other antibacterials" "NA" "amygdalate,mandelsaeure,paramandelate,phenylglycolate,phenylhydroxyacetate,uromaline" 12 "g" "NA" +"MNA" 1292 "Mandelic acid" "Other" "B05CA06,J01XX06,QB05CA06,QJ01XX06" "Other antibacterials" "Other antibacterials" "NA" "amygdalate,mandelsaeure,paramandelate,phenylglycolate,phenylhydroxyacetate,uromaline" 12 "g" "NA" "MGX" "Manogepix" "Antifungals" "NA" "NA" "NA" "NA" -"MAR" 60651 "Marbofloxacin" "Fluoroquinolones" "QJ01MA93" "marbof" "marbocyl,marbofloxacine,marbofloxacino,marbofloxacinum,marboquin,zeniquin" "73596-9,73618-1,73641-3" -"MEC" 36273 "Mecillinam" "Beta-lactams/penicillins" "J01CA11,QJ01CA11" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "amdinocillin,mecill" "amdinocillin,coactin,hexacillin,mecilinamo,mecillinamum,selexidin" 1.2 "g" "NA" -"MEL" 71306732 "Meleumycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA" -"MEM" 441130 "Meropenem" "Carbapenems" "J01DH02,QJ01DH02" "Other beta-lactam antibacterials" "Carbapenems" "mem,mer,mero,merope,mp,mrp" "meronem,meropen,meropenemum,merrem" 3 "g" "101222-8,101488-5,101489-3,18943-1,41406-0,6651-4,6652-2,6653-0,6654-8,7029-2,85426-5,85427-3,88892-5,90980-4" -"MNC" "Meropenem/nacubactam" "Carbapenems" "NA" "NA" "NA" "NA" -"MEV" "Meropenem/vaborbactam" "Carbapenems" "J01DH52,QJ01DH52" "Other beta-lactam antibacterials" "Carbapenems" "NA" "NA" 3 "g" "101222-8,101489-3,85427-3,88892-5,90980-4" -"MES" 176886 "Mesulfamide" "Other antibacterials" "NA" "NA" "mesulfamida,mesulfamido,mesulfamidum" "NA" +"MAR" 60651 "Marbofloxacin" "Fluoroquinolones,Quinolones" "QJ01MA93" "marbof" "marbocyl,marbofloxacine,marbofloxacino,marbofloxacinum,marboquin,zeniquin" "73596-9,73618-1,73641-3" +"MEC" 36273 "Mecillinam" "Penicillins,Beta-lactams" "J01CA11,QJ01CA11" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "amdinocillin,mecill" "amdinocillin,coactin,hexacillin,mecilinamo,mecillinamum,selexidin" 1.2 "g" "NA" +"MEL" 71306732 "Meleumycin" "Macrolides" "NA" "NA" "NA" "NA" +"MEM" 441130 "Meropenem" "Carbapenems,Beta-lactams" "J01DH02,QJ01DH02" "Other beta-lactam antibacterials" "Carbapenems" "mem,mer,mero,merope,mp,mrp" "meronem,meropen,meropenemum,merrem" 3 "g" "101222-8,101488-5,101489-3,18943-1,41406-0,6651-4,6652-2,6653-0,6654-8,7029-2,85426-5,85427-3,88892-5,90980-4" +"MNC" "Meropenem/nacubactam" "Carbapenems,Beta-lactams,Beta-lactamase inhibitors" "NA" "NA" "NA" "NA" +"MEV" "Meropenem/vaborbactam" "Carbapenems,Beta-lactams,Beta-lactamase inhibitors" "J01DH52,QJ01DH52" "Other beta-lactam antibacterials" "Carbapenems" "NA" "NA" 3 "g" "101222-8,101489-3,85427-3,88892-5,90980-4" +"MES" 176886 "Mesulfamide" "Other" "NA" "NA" "mesulfamida,mesulfamido,mesulfamidum" "NA" "MTC" 54675785 "Metacycline" "Tetracyclines" "J01AA05,QJ01AA05" "Tetracyclines" "Tetracyclines" "methcy" "bialatan,metaciclina,metacyclinum,methacyclin,methacycline,methacyclinum,methylenecycline,physiomycine,rondomycin" 0.6 "g" "NA" -"MTM" 6713928 "Metampicillin" "Beta-lactams/penicillins" "J01CA14,QJ01CA14" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "blomopen,bonopen,celinmicina,elatocilline,filorex,magnipen,metambac,metampen,metampicilina,metampicillina,metampicilline,metampicillinsalt,metampicillinum,micinovo,ocelina,pangocilin,probiotic,relyothenate,ruticina,rutizina,sedomycin,serfabiotic,suvipen,viderpen,viderpin,vioplex" 1.5 "g" 1.5 "g" "NA" -"MTH" 4101 "Methenamine" "Other antibacterials" "J01XX05,QJ01XX05" "Other antibacterials" "Other antibacterials" "NA" "aminoform,aminoformaldehyde,ammoform,ammonioformaldehyde,antihydral,carin,cystamin,cystex,cystogen,duirexol,esametilentetramina,formamine,formin,grasselerator,heterin,hexaform,hexaloids,hexamethylamine,hexamethylenamine,hexamethyleneamine,hexamethylentetramin,hexamine,hexaminum,hexasan,hexilmethylenamine,metenamina,metenamine,methamin,methamine,methenamin,methenaminum,metramine,naphthamine,pellurin,resotropin,uramin,urasal,uratrine,urisol,uritone,urodeine,urotropin,urotropine,vesaloin,xametrin" 3 "g" "NA" -"MET" 6087 "Meticillin" "Beta-lactams/penicillins" "J01CF03,QJ01CF03,QJ51CF03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "methic,meti" "belfacillin,celbenin,celpilline,cinopenil,dimocillin,estafcilina,flabelline,lucopenin,metacillin,methcillin,methicillin,methicillinanhydrous,methicillinhydrate,methicillinsalt,methicillinum,methycillin,meticilina,meticillina,meticilline,meticillinsalt,meticillinum,penaureus,penysol,staficyn,staphcillin,synticillin" 4 "g" "NA" -"MTP" 68590 "Metioprim" "Other antibacterials" "NA" "NA" "methioprim,metioprima,metioprime,metioprimum" "NA" -"MXT" 3047729 "Metioxate" "Fluoroquinolones" "NA" "NA" "metioxato,metioxatum" "NA" -"MTR" 4173 "Metronidazole" "Other antibacterials" "A01AB17,D06BX01,G01AF01,J01XD01,P01AB01,QA01AB17,QD06BX01,QG01AF01,QJ01XD01,QP51CA01" "Other antibacterials" "Imidazole derivatives" "metr,metron,mnz,mtz" "acromona,anagiardil,arilin,atrivyl,bexon,clont,danizol,deflamon,donnan,efloran,elyzol,entizol,eumin,flagemona,flagesol,flagil,flagyl,flazol,flegyl,florazole,fossyol,giatricol,gineflavir,givagil,hydroxydimetridazole,hydroxymetronidazole,izoklion,klion,klont,mepagyl,meronidal,metric,metrolag,metrolyl,metromidol,metronidazolo,metronidazolum,metroplex,metrotop,mexibol,monagyl,monasin,nalox,nidagyl,noritate,novonidazol,nuvessa,orvagil,polibiotic,protostat,rathimed,rosaced,rosased,sanatrichom,satric,takimetol,trichazol,trichex,trichobrol,trichocide,trichomol,trichopal,trichopol,tricocet,tricom,trikacide,trikamon,trikhopol,trikojol,trikozol,trimeks,trivazol,vagilen,vagimid,vandazole,vertisal,wagitran,zadstat,zidoval" 2 "g" 1.5 "g" "10991-8,18946-4,326-9,327-7,328-5,329-3,7031-8" -"MEZ" 656511 "Mezlocillin" "Beta-lactams/penicillins" "J01CA10,QJ01CA10" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "mez,mezl,mezlo,mz" "baycipen,baypen,mezlin,mezlocilina,mezlocilline,mezlocillinsalt,mezlocillinum,multocillin" 6 "g" "18947-2,330-1,331-9,332-7,333-5,3820-8,41702-2,54194-6,54195-3,54196-1" -"MSU" "Mezlocillin/sulbactam" "Beta-lactams/penicillins" "NA" "mezsul" "NA" "54194-6,54195-3,54196-1" -"MIF" 477468 "Micafungin" "Antifungals/antimycotics" "J02AX05,QJ02AX05" "Antimycotics for systemic use" "Other antimycotics for systemic use" "mica,micafu" "fungard,funguard,micafungina,micafunginsalt,mycamine" 0.1 "g" "53812-4,58418-5,65340-2,85048-7" -"MCZ" 4189 "Miconazole" "Antifungals/antimycotics" "A01AB09,A07AC01,D01AC02,G01AF04,J02AB01,QA01AB09,QA07AC01,QD01AC02,QG01AF04,QJ02AB01,QS02AA13,S02AA13" "Antimycotics for systemic use" "Imidazole derivatives" "mico" "aflorix,albistat,andergin,brentan,conofite,dactarin,florid,micantin,miconazol,miconazolo,miconazolum,micozole,minostate,monazole,monista,monistat,oravig,vusion,zimybase,zimycan" 0.2 "g" 1 "g" "17278-3,25607-3,25722-0,54180-5,55686-0" +"MTM" 6713928 "Metampicillin" "Penicillins,Beta-lactams" "J01CA14,QJ01CA14" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "blomopen,bonopen,celinmicina,elatocilline,filorex,magnipen,metambac,metampen,metampicilina,metampicillina,metampicilline,metampicillinsalt,metampicillinum,micinovo,ocelina,pangocilin,probiotic,relyothenate,ruticina,rutizina,sedomycin,serfabiotic,suvipen,viderpen,viderpin,vioplex" 1.5 "g" 1.5 "g" "NA" +"MTH" 4101 "Methenamine" "Other" "J01XX05,QJ01XX05" "Other antibacterials" "Other antibacterials" "NA" "aminoform,aminoformaldehyde,ammoform,ammonioformaldehyde,antihydral,carin,cystamin,cystex,cystogen,duirexol,esametilentetramina,formamine,formin,grasselerator,heterin,hexaform,hexaloids,hexamethylamine,hexamethylenamine,hexamethyleneamine,hexamethylentetramin,hexamine,hexaminum,hexasan,hexilmethylenamine,metenamina,metenamine,methamin,methamine,methenamin,methenaminum,metramine,naphthamine,pellurin,resotropin,uramin,urasal,uratrine,urisol,uritone,urodeine,urotropin,urotropine,vesaloin,xametrin" 3 "g" "NA" +"MET" 6087 "Meticillin" "Isoxazolylpenicillins,Penicillins,Beta-lactams" "J01CF03,QJ01CF03,QJ51CF03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "methic,meti" "belfacillin,celbenin,celpilline,cinopenil,dimocillin,estafcilina,flabelline,lucopenin,metacillin,methcillin,methicillin,methicillinanhydrous,methicillinhydrate,methicillinsalt,methicillinum,methycillin,meticilina,meticillina,meticilline,meticillinsalt,meticillinum,penaureus,penysol,staficyn,staphcillin,synticillin" 4 "g" "NA" +"MTP" 68590 "Metioprim" "Other" "NA" "NA" "methioprim,metioprima,metioprime,metioprimum" "NA" +"MXT" 3047729 "Metioxate" "Fluoroquinolones,Quinolones" "NA" "NA" "metioxato,metioxatum" "NA" +"MTR" 4173 "Metronidazole" "Other" "A01AB17,D06BX01,G01AF01,J01XD01,P01AB01,QA01AB17,QD06BX01,QG01AF01,QJ01XD01,QP51CA01" "Other antibacterials" "Imidazole derivatives" "metr,metron,mnz,mtz" "acromona,anagiardil,arilin,atrivyl,bexon,clont,danizol,deflamon,donnan,efloran,elyzol,entizol,eumin,flagemona,flagesol,flagil,flagyl,flazol,flegyl,florazole,fossyol,giatricol,gineflavir,givagil,hydroxydimetridazole,hydroxymetronidazole,izoklion,klion,klont,mepagyl,meronidal,metric,metrolag,metrolyl,metromidol,metronidazolo,metronidazolum,metroplex,metrotop,mexibol,monagyl,monasin,nalox,nidagyl,noritate,novonidazol,nuvessa,orvagil,polibiotic,protostat,rathimed,rosaced,rosased,sanatrichom,satric,takimetol,trichazol,trichex,trichobrol,trichocide,trichomol,trichopal,trichopol,tricocet,tricom,trikacide,trikamon,trikhopol,trikojol,trikozol,trimeks,trivazol,vagilen,vagimid,vandazole,vertisal,wagitran,zadstat,zidoval" 2 "g" 1.5 "g" "10991-8,18946-4,326-9,327-7,328-5,329-3,7031-8" +"MEZ" 656511 "Mezlocillin" "Ureidopenicillins,Penicillins,Beta-lactams" "J01CA10,QJ01CA10" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "mez,mezl,mezlo,mz" "baycipen,baypen,mezlin,mezlocilina,mezlocilline,mezlocillinsalt,mezlocillinum,multocillin" 6 "g" "18947-2,330-1,331-9,332-7,333-5,3820-8,41702-2,54194-6,54195-3,54196-1" +"MSU" "Mezlocillin/sulbactam" "Penicillins,Beta-lactams,Beta-lactamase inhibitors" "NA" "mezsul" "NA" "54194-6,54195-3,54196-1" +"MIF" 477468 "Micafungin" "Antifungals" "J02AX05,QJ02AX05" "Antimycotics for systemic use" "Other antimycotics for systemic use" "mica,micafu" "fungard,funguard,micafungina,micafunginsalt,mycamine" 0.1 "g" "53812-4,58418-5,65340-2,85048-7" +"MCZ" 4189 "Miconazole" "Antifungals" "A01AB09,A07AC01,D01AC02,G01AF04,J02AB01,QA01AB09,QA07AC01,QD01AC02,QG01AF04,QJ02AB01,QS02AA13,S02AA13" "Antimycotics for systemic use" "Imidazole derivatives" "mico" "aflorix,albistat,andergin,brentan,conofite,dactarin,florid,micantin,miconazol,miconazolo,miconazolum,micozole,minostate,monazole,monista,monistat,oravig,vusion,zimybase,zimycan" 0.2 "g" 1 "g" "17278-3,25607-3,25722-0,54180-5,55686-0" "MCR" 3037206 "Micronomicin" "Aminoglycosides" "QS01AA22,S01AA22" "micron" "micromicin,micromycin,micronomicina,micronomicine,micronomicinum,sagamicin,santemycin" "NA" -"MID" 5282169 "Midecamycin" "Macrolides/lincosamides" "J01FA03,QJ01FA03" "Macrolides, lincosamides and streptogramins" "Macrolides" "mideka" "macropen,madecacine,medemycin,midecamicina,midecamycine,midecamycinum,midecin,momicine,myoxam,normicina,rubimycin" 1.2 "g" 1 "g" "NA" -"MIL" 37614 "Miloxacin" "Fluoroquinolones" "NA" "amiflo" "miloxacine,miloxacino,miloxacinum" "NA" +"MID" 5282169 "Midecamycin" "Macrolides" "J01FA03,QJ01FA03" "Macrolides, lincosamides and streptogramins" "Macrolides" "mideka" "macropen,madecacine,medemycin,midecamicina,midecamycine,midecamycinum,midecin,momicine,myoxam,normicina,rubimycin" 1.2 "g" 1 "g" "NA" +"MIL" 37614 "Miloxacin" "Fluoroquinolones,Quinolones" "NA" "amiflo" "miloxacine,miloxacino,miloxacinum" "NA" "MNO" 54675783 "Minocycline" "Tetracyclines" "A01AB23,D10AF07,J01AA08,QA01AB23,QD10AF07,QJ01AA08" "Tetracyclines" "Tetracyclines" "mc,mh,mi,min,mino,minocy,mn,mno" "acnez,arestin,borymycin,dynacin,lederderm,minociclina,minocin,minocline,minocyclin,minocyclinum,minocyn,minomax,minomycin,mynocine,periocline,solodyn,vectrin,ximino" 1 "mg" 0.2 "g" "18948-0,25225-4,334-3,335-0,336-8,337-6,34606-4,3822-4,49757-8,55156-4,7032-6" -"MCM" 5282188 "Miocamycin" "Macrolides/lincosamides" "J01FA11,QJ01FA11" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "acecamycin,macroral,miocamen,miocamycine,miokamycin,mosil,myocamicin,ponsinomycin" 1.2 "g" "18949-8,338-4,339-2,340-0,341-8,55687-8" -"MON" 23667299 "Monensin sodium" "Other antibacterials" "NA" "NA" "coban,elancoban,monelan,monensin,monensina,monensine,monensinum,monovet,romensin,rumensin" "NA" +"MCM" 5282188 "Miocamycin" "Macrolides" "J01FA11,QJ01FA11" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "acecamycin,macroral,miocamen,miocamycine,miokamycin,mosil,myocamicin,ponsinomycin" 1.2 "g" "18949-8,338-4,339-2,340-0,341-8,55687-8" +"MON" 23667299 "Monensin sodium" "Other" "NA" "NA" "coban,elancoban,monelan,monensin,monensina,monensine,monensinum,monovet,romensin,rumensin" "NA" "MRN" 70374 "Morinamide" "Antimycobacterials" "J04AK04,QJ04AK04" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "morfazinamide,morfazinammide,morfgazinamide,morinamida,morinamidum,morphazinamid,morphazinamide,piazofolina,piazolin,piazolina" "NA" -"MFX" 152946 "Moxifloxacin" "Fluoroquinolones" "J01MA14,QJ01MA14,QS01AE07,S01AE07" "Quinolone antibacterials" "Fluoroquinolones" "mox,moxi,moxifl,mxf" "actira,actura,avalox,avelox,avolex,izilox,moxeza,moxifloxacine,moxifloxacino,octegra,vegamox,vigamox,zimoxin" 0.4 "g" 0.4 "g" "31037-5,31039-1,31041-7,31043-3,41502-6,43751-7,45223-5,76043-9,76044-7,76045-4,80540-8,88707-5,93497-6,96112-8" -"MUP" 446596 "Mupirocin" "Other antibacterials" "D06AX09,QD06AX09,QR01AX06,R01AX06" "mup,mupi,mupiro" "bactoderm,bactroban,centany,mupirocina,mupirocine,mupirocinum,plasimine,turixin" "20389-3,35822-6,35823-4,60542-8,60543-6,7033-4" -"NAC" 73386748 "Nacubactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA" -"NAD" 4410 "Nadifloxacin" "Fluoroquinolones" "D10AF05,QD10AF05" "NA" "acuatim,nadifloxacine,nadifloxacino,nadifloxacinum,nadixa,nadoxin" "NA" -"NAF" 8982 "Nafcillin" "Beta-lactams/penicillins" "J01CF06,QJ01CF06" "nafcil" "nafcil,nafcilin,nafcilina,nafcillinanhydrous,nafcilline,nafcillinhydrate,nafcillinmonohydrate,nafcillinsalt,nafcillinum,naftopen,nallpen,naphcillin,naphthicillin,unipen" 3 "g" "10993-4,18951-4,25232-0,346-7,347-5,348-3,349-1,41704-8" -"ZWK" 117587595 "Nafithromycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA" +"MFX" 152946 "Moxifloxacin" "Fluoroquinolones,Quinolones" "J01MA14,QJ01MA14,QS01AE07,S01AE07" "Quinolone antibacterials" "Fluoroquinolones" "mox,moxi,moxifl,mxf" "actira,actura,avalox,avelox,avolex,izilox,moxeza,moxifloxacine,moxifloxacino,octegra,vegamox,vigamox,zimoxin" 0.4 "g" 0.4 "g" "31037-5,31039-1,31041-7,31043-3,41502-6,43751-7,45223-5,76043-9,76044-7,76045-4,80540-8,88707-5,93497-6,96112-8" +"MUP" 446596 "Mupirocin" "Other" "D06AX09,QD06AX09,QR01AX06,R01AX06" "mup,mupi,mupiro" "bactoderm,bactroban,centany,mupirocina,mupirocine,mupirocinum,plasimine,turixin" "20389-3,35822-6,35823-4,60542-8,60543-6,7033-4" +"NAC" 73386748 "Nacubactam" "Beta-lactamase inhibitors" "NA" "NA" "NA" "NA" +"NAD" 4410 "Nadifloxacin" "Fluoroquinolones,Quinolones" "D10AF05,QD10AF05" "NA" "acuatim,nadifloxacine,nadifloxacino,nadifloxacinum,nadixa,nadoxin" "NA" +"NAF" 8982 "Nafcillin" "Penicillins,Beta-lactams" "J01CF06,QJ01CF06" "nafcil" "nafcil,nafcilin,nafcilina,nafcillinanhydrous,nafcilline,nafcillinhydrate,nafcillinmonohydrate,nafcillinsalt,nafcillinum,naftopen,nallpen,naphcillin,naphthicillin,unipen" 3 "g" "10993-4,18951-4,25232-0,346-7,347-5,348-3,349-1,41704-8" +"ZWK" 117587595 "Nafithromycin" "Macrolides" "NA" "NA" "NA" "NA" "NAL" 4421 "Nalidixic acid" "Quinolones" "J01MB02,QJ01MB02" "Quinolone antibacterials" "Other quinolones" "na,nal,nalac,nali" "amfonelinsaeure,baktogram,betaxina,chemiurin,cybis,dixiben,dixilina,dixinal,eucisten,eucistin,innoxalomn,innoxalon,jicsron,kusnarin,nalidicron,nalidixan,nalidixane,nalidixate,nalidixateanhydrous,nalidixic,nalidixin,nalidixinsaure,nalitucsan,nalix,nalurin,narigix,naxuril,negram,nevigramon,nicelate,nogram,poleon,sicmylon,specifen,specifin,unaserus,uralgin,uriben,uriclar,urisal,urodixin,uroman,uroneg,uronidix,uropan,wintomylon,wintron" 4 "g" "NA" "NAL-S" "Nalidixic acid screening test" "Quinolones" "NA" "nal screen" "NA" "NA" -"NAR" 65452 "Narasin" "Other antibacterials" "QP51BB04" "narasi" "monteban,narasine,narasino,narasinum,skycis" "87570-8" -"NEM" 11993740 "Nemonoxacin" "Fluoroquinolones" "J01MB08,QJ01MB08" "Quinolone antibacterials" "Other quinolones" "NA" "NA" "NA" +"NAR" 65452 "Narasin" "Other" "QP51BB04" "narasi" "monteban,narasine,narasino,narasinum,skycis" "87570-8" +"NEM" 11993740 "Nemonoxacin" "Fluoroquinolones,Quinolones" "J01MB08,QJ01MB08" "Quinolone antibacterials" "Other quinolones" "NA" "NA" "NA" "NEO" 8378 "Neomycin" "Aminoglycosides" "A01AB08,A07AA01,B05CA09,D06AX04,J01GB05,QA01AB08,QA07AA01,QB05CA09,QD06AX04,QJ01GB05,QR02AB01,QS01AA03,QS02AA07,QS03AA01,R02AB01,S01AA03,S02AA07,S03AA01" "Aminoglycoside antibacterials" "Other aminoglycosides" "neom,neomyc" "NA" 5 "g" 1 "g" "10995-9,18953-0,25262-7,354-1,355-8,356-6,357-4,41705-5" "NET" 441306 "Netilmicin" "Aminoglycosides" "J01GB07,QJ01GB07,QS01AA23,S01AA23" "Aminoglycoside antibacterials" "Other aminoglycosides" "neti,netilm" "netillin,netilmicina,netilmicine,netilmicinum,netilyn,netira,netromicine,netromycin,nettacin,ntromicine,ntromycin,vectacin,zetamicin" 0.35 "g" 0.35 "g" "18954-8,25263-5,358-2,359-0,360-8,361-6,3848-9,3849-7,3850-5,47385-0,59565-2,59566-0,59567-8,7035-9" -"NIC" 9507 "Nicarbazin" "Other antibacterials" "NA" "NA" "nicarb,nicarbasin,nicarbazine,nicarmix,nicoxin,nicrazin,nicrazine,nirazin" "NA" -"NIF" 71946 "Nifuroquine" "Fluoroquinolones" "NA" "NA" "abimasten,nifuroquina,nifuroquinum,quinaldofur" "NA" -"NFR" 9571062 "Nifurtoinol" "Other antibacterials" "J01XE02,QJ01XE02" "Other antibacterials" "Nitrofuran derivatives" "NA" "levantin,nifurmazol,nifurmazole,nifurmazolo,nifurmazolum,nifurtoinolo,nifurtoinolum,urfadin,urfadine,urfadyn" 0.16 "g" "NA" -"NTZ" 41684 "Nitazoxanide" "Other antibacterials" "P01AX11" "NA" "alinia,benzamide,colufase,cryptaz,daxon,dexidex,heliton,kidonax,nitax,nitaxozanid,nitaxozanide,nitazox,nitazoxamide,nitazoxanid,nitazoxanida,nitazoxanidum,nitrazoxanide,pacovanton,paramix,phavic" 1 "g" "73595-1,73617-3,73640-5" -"NIT" 6604200 "Nitrofurantoin" "Other antibacterials" "J01XE01,QJ01XE01" "Other antibacterials" "Nitrofuran derivatives" "f,f/m,fd,ft,ni,nit,nit16,nitr,nitro" "alfuran,benkfuran,berkfuran,berkfurin,ceduran,chemiofuran,cistofuran,cyantin,cystit,dantafur,fuamed,furabid,furachel,furadantin,furadantine,furadantoin,furadoin,furadoine,furadonin,furadonine,furadoninum,furadontin,furalan,furaloid,furantoina,furatoin,furedan,furina,furobactina,furodantin,gerofuran,ituran,macpac,macrobid,macrodantin,macrodantina,macrofuran,macrofurin,nierofu,nifuraden,nifuradene,nifuradeno,nifuradenum,nifuradine,nifurantin,nifuretten,nitoin,nitrex,nitrofuradantin,nitrofurantoina,nitrofurantoine,nitrofurantoinum,novofuran,orafuran,oxafuradene,oxafurandene,oxifuradene,oxyfuradene,parfuran,phenurin,renafur,siraliden,trantoin,uerineks,urizept,urodin,urofuran,urofurin,urolisa,urolong,uvamin,welfurin,zoofurin" 0.2 "g" "18955-5,362-4,363-2,364-0,365-7,3860-4,7036-7" -"NIZ" 5447130 "Nitrofurazone" "Other antibacterials" "NA" "nitfur" "acutol,aldomycin,alfucin,amifur,babrocid,becafurazone,biofuracina,biofurea,chemofuran,chixin,cocafurin,coxistat,dermofural,dymazone,dynazone,eldezol,fedacin,flavazone,fracine,furacilin,furacilinum,furacillin,furacin,furacine,furacinetten,furacoccid,furacort,furacycline,furaderm,furagent,furalcyn,furaldon,furalone,furametral,furaplast,furaseptyl,furaskin,furatsilin,furaziline,furazin,furazina,furazyme,furesol,furosem,fuvacillin,hemofuran,hydrazinecarboxamide,ibiofural,mammex,mastofuran,monafuracin,monafuracis,monofuracin,nefco,nifucin,nifurid,nifuzon,nitrofural,nitrofuralum,nitrofuran,nitrofurane,nitrofurazan,nitrofurazonum,nitrofurol,nitrozone,otofural,otofuran,rivafurazon,rivopon,sanfuran,semioxamazide,vabrocid,vadrocid,yatrocin" "20388-5,87793-6" -"NTR" 19910 "Nitroxoline" "Fluoroquinolones" "J01XX07,QJ01XX07" "Other antibacterials" "Other antibacterials" "NA" "galinok,isinok,nibiol,nicene,nitroxlina,nitroxolin,nitroxolina,nitroxolinum,noxibiol,noxin" 1 "g" "25608-1,25723-8,32382-4,54181-3,55688-6" -"NOR" 4539 "Norfloxacin" "Fluoroquinolones" "J01MA06,QJ01MA06,QS01AE02,S01AE02" "Quinolone antibacterials" "Fluoroquinolones" "nor,norf,norflo,nx,nxn" "baccidal,barazan,chibroxin,chibroxine,chibroxol,fulgram,gonorcin,lexinor,nolicin,noracin,noraxin,norflo,norfloxacine,norfloxacino,norfloxacinum,norocin,noroxin,noroxine,norxacin,sebercim,uroxacin,utinor,zoroxin" 0.8 "g" "18956-3,366-5,367-3,368-1,369-9,3867-9,41504-2,7037-5" -"NOR-S" "Norfloxacin screening test" "Fluoroquinolones" "NA" "nor screen" "NA" "NA" -"NME" "Norfloxacin/metronidazole" "Fluoroquinolones" "J01RA14,QJ01RA14" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"NTI" "Norfloxacin/tinidazole" "Fluoroquinolones" "J01RA13,QJ01RA13" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"NIC" 9507 "Nicarbazin" "Other" "NA" "NA" "nicarb,nicarbasin,nicarbazine,nicarmix,nicoxin,nicrazin,nicrazine,nirazin" "NA" +"NIF" 71946 "Nifuroquine" "Fluoroquinolones,Quinolones" "NA" "NA" "abimasten,nifuroquina,nifuroquinum,quinaldofur" "NA" +"NFR" 9571062 "Nifurtoinol" "Nitrofurans" "J01XE02,QJ01XE02" "Other antibacterials" "Nitrofuran derivatives" "NA" "levantin,nifurmazol,nifurmazole,nifurmazolo,nifurmazolum,nifurtoinolo,nifurtoinolum,urfadin,urfadine,urfadyn" 0.16 "g" "NA" +"NTZ" 41684 "Nitazoxanide" "Other" "P01AX11" "NA" "alinia,benzamide,colufase,cryptaz,daxon,dexidex,heliton,kidonax,nitax,nitaxozanid,nitaxozanide,nitazox,nitazoxamide,nitazoxanid,nitazoxanida,nitazoxanidum,nitrazoxanide,pacovanton,paramix,phavic" 1 "g" "73595-1,73617-3,73640-5" +"NIT" 6604200 "Nitrofurantoin" "Nitrofurans" "J01XE01,QJ01XE01" "Other antibacterials" "Nitrofuran derivatives" "f,f/m,fd,ft,ni,nit,nit16,nitr,nitro" "alfuran,benkfuran,berkfuran,berkfurin,ceduran,chemiofuran,cistofuran,cyantin,cystit,dantafur,fuamed,furabid,furachel,furadantin,furadantine,furadantoin,furadoin,furadoine,furadonin,furadonine,furadoninum,furadontin,furalan,furaloid,furantoina,furatoin,furedan,furina,furobactina,furodantin,gerofuran,ituran,macpac,macrobid,macrodantin,macrodantina,macrofuran,macrofurin,nierofu,nifuraden,nifuradene,nifuradeno,nifuradenum,nifuradine,nifurantin,nifuretten,nitoin,nitrex,nitrofuradantin,nitrofurantoina,nitrofurantoine,nitrofurantoinum,novofuran,orafuran,oxafuradene,oxafurandene,oxifuradene,oxyfuradene,parfuran,phenurin,renafur,siraliden,trantoin,uerineks,urizept,urodin,urofuran,urofurin,urolisa,urolong,uvamin,welfurin,zoofurin" 0.2 "g" "18955-5,362-4,363-2,364-0,365-7,3860-4,7036-7" +"NIZ" 5447130 "Nitrofurazone" "Nitrofurans" "NA" "nitfur" "acutol,aldomycin,alfucin,amifur,babrocid,becafurazone,biofuracina,biofurea,chemofuran,chixin,cocafurin,coxistat,dermofural,dymazone,dynazone,eldezol,fedacin,flavazone,fracine,furacilin,furacilinum,furacillin,furacin,furacine,furacinetten,furacoccid,furacort,furacycline,furaderm,furagent,furalcyn,furaldon,furalone,furametral,furaplast,furaseptyl,furaskin,furatsilin,furaziline,furazin,furazina,furazyme,furesol,furosem,fuvacillin,hemofuran,hydrazinecarboxamide,ibiofural,mammex,mastofuran,monafuracin,monafuracis,monofuracin,nefco,nifucin,nifurid,nifuzon,nitrofural,nitrofuralum,nitrofuran,nitrofurane,nitrofurazan,nitrofurazonum,nitrofurol,nitrozone,otofural,otofuran,rivafurazon,rivopon,sanfuran,semioxamazide,vabrocid,vadrocid,yatrocin" "20388-5,87793-6" +"NTR" 19910 "Nitroxoline" "Fluoroquinolones,Quinolones" "J01XX07,QJ01XX07" "Other antibacterials" "Other antibacterials" "NA" "galinok,isinok,nibiol,nicene,nitroxlina,nitroxolin,nitroxolina,nitroxolinum,noxibiol,noxin" 1 "g" "25608-1,25723-8,32382-4,54181-3,55688-6" +"NOR" 4539 "Norfloxacin" "Fluoroquinolones,Quinolones" "J01MA06,QJ01MA06,QS01AE02,S01AE02" "Quinolone antibacterials" "Fluoroquinolones" "nor,norf,norflo,nx,nxn" "baccidal,barazan,chibroxin,chibroxine,chibroxol,fulgram,gonorcin,lexinor,nolicin,noracin,noraxin,norflo,norfloxacine,norfloxacino,norfloxacinum,norocin,noroxin,noroxine,norxacin,sebercim,uroxacin,utinor,zoroxin" 0.8 "g" "18956-3,366-5,367-3,368-1,369-9,3867-9,41504-2,7037-5" +"NOR-S" "Norfloxacin screening test" "Fluoroquinolones,Quinolones" "NA" "nor screen" "NA" "NA" +"NME" "Norfloxacin/metronidazole" "Fluoroquinolones,Quinolones" "J01RA14,QJ01RA14" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"NTI" "Norfloxacin/tinidazole" "Fluoroquinolones,Quinolones" "J01RA13,QJ01RA13" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "NVA" 10419027 "Norvancomycin" "Glycopeptides" "NA" "NA" "NA" "NA" -"NOV" 54675769 "Novobiocin" "Other antibacterials" "QJ01XX95" "novo,novobi" "albadry,albamix,albamycin,biotexin,cardelmycin,cardelmycinsalt,cathocin,cathomycin,inabiocin,novobiocina,novobiocine,novobiocinsalt,novobiocinum,robiocina,sirbiocina,spheromycin,stilbiocina,streptonivicin,streptonivicinsalt,vulcamicina,vulcamycin,vulkamycin" "17378-1,18957-1,370-7,371-5,372-3,373-1,41706-3" -"NYS" 6433272 "Nystatin" "Antifungals/antimycotics" "A07AA02,D01AA01,G01AA01,QA07AA02,QD01AA01,QG01AA01" "nyst,nystan" "biofanal,diastatin,herniocid,moronal,myconystatin,mycostatin,mykostatyna,nilstat,nistatin,nistatina,nyotran,nystan,nystatyna,nystavescent,nystex" 1.5 "MU" "10697-1,10698-9,18958-9,35824-2,55689-4" -"OFX" 4583 "Ofloxacin" "Fluoroquinolones" "J01MA01,QJ01MA01,QS01AE01,QS02AA16,S01AE01,S02AA16" "Quinolone antibacterials" "Fluoroquinolones" "of,ofl,oflo,ofloxa,ofx" "exocin,exocine,flobacin,floxil,floxin,monoflocet,oflocet,ofloxacina,ofloxacine,ofloxacino,ofloxacinum,ofloxaxin,oxaldin,tarivid,visiren,zanocin" 0.4 "g" 0.4 "g" "18959-7,20384-4,23948-3,25264-3,374-9,375-6,376-4,377-2,3877-8,41408-6,41409-4,41410-2,42653-6,7038-3,72168-8" -"OOR" "Ofloxacin/ornidazole" "Fluoroquinolones" "J01RA09,QJ01RA09" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"OLE" 72493 "Oleandomycin" "Macrolides/lincosamides" "J01FA05,QJ01FA05" "Macrolides, lincosamides and streptogramins" "Macrolides" "oleand" "amimycin,landomycin,matromycin,oleandomicina,oleandomycine,oleandomycinum,romicil" 1 "g" "18960-5,378-0,379-8,380-6,381-4,55690-2" +"NOV" 54675769 "Novobiocin" "Other" "QJ01XX95" "novo,novobi" "albadry,albamix,albamycin,biotexin,cardelmycin,cardelmycinsalt,cathocin,cathomycin,inabiocin,novobiocina,novobiocine,novobiocinsalt,novobiocinum,robiocina,sirbiocina,spheromycin,stilbiocina,streptonivicin,streptonivicinsalt,vulcamicina,vulcamycin,vulkamycin" "17378-1,18957-1,370-7,371-5,372-3,373-1,41706-3" +"NYS" 6433272 "Nystatin" "Antifungals" "A07AA02,D01AA01,G01AA01,QA07AA02,QD01AA01,QG01AA01" "nyst,nystan" "biofanal,diastatin,herniocid,moronal,myconystatin,mycostatin,mykostatyna,nilstat,nistatin,nistatina,nyotran,nystan,nystatyna,nystavescent,nystex" 1.5 "MU" "10697-1,10698-9,18958-9,35824-2,55689-4" +"OFX" 4583 "Ofloxacin" "Fluoroquinolones,Quinolones" "J01MA01,QJ01MA01,QS01AE01,QS02AA16,S01AE01,S02AA16" "Quinolone antibacterials" "Fluoroquinolones" "of,ofl,oflo,ofloxa,ofx" "exocin,exocine,flobacin,floxil,floxin,monoflocet,oflocet,ofloxacina,ofloxacine,ofloxacino,ofloxacinum,ofloxaxin,oxaldin,tarivid,visiren,zanocin" 0.4 "g" 0.4 "g" "18959-7,20384-4,23948-3,25264-3,374-9,375-6,376-4,377-2,3877-8,41408-6,41409-4,41410-2,42653-6,7038-3,72168-8" +"OOR" "Ofloxacin/ornidazole" "Fluoroquinolones,Quinolones" "J01RA09,QJ01RA09" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"OLE" 72493 "Oleandomycin" "Macrolides" "J01FA05,QJ01FA05" "Macrolides, lincosamides and streptogramins" "Macrolides" "oleand" "amimycin,landomycin,matromycin,oleandomicina,oleandomycine,oleandomycinum,romicil" 1 "g" "18960-5,378-0,379-8,380-6,381-4,55690-2" "OMC" 54697325 "Omadacycline" "Tetracyclines" "J01AA15,QJ01AA15" "NA" "amadacycline" 0.3 "g" 0.1 "g" "73594-4,73616-5,73639-7" -"OPT" 87880 "Optochin" "Other antibacterials" "NA" "NA" "aflukin,auriquin,biquinate,chinidin,chinidine,chinimetten,chinin,chinine,conchinin,conchinine,conquinine,dentojel,dihydrochinidin,dihydroquinidine,dihydroquinine,hydroconchinine,hydroconquinine,hydroquinidine,kinidin,numoquin,optochine,optoquine,pitayine,qualaquin,quinaglute,quinicardine,quinidex,quinidine,quiniduran,quinindine,quinine,quinineanhydrous,quinora,quinsan,rezquin" "100055-3,73665-2" -"ORB" 60605 "Orbifloxacin" "Fluoroquinolones" "QJ01MA95" "orbifl" "orbax" "35825-9,35826-7,35827-5" -"ORI" 16136912 "Oritavancin" "Glycopeptides" "J01XA05,QJ01XA05" "Other antibacterials" "Glycopeptide antibacterials" "orit,oritav" "NA" "41707-1,41708-9,41709-7,41736-0" -"ORS" "Ormetroprim/sulfamethoxazole" "Other antibacterials" "NA" "NA" "NA" "73593-6,73615-7,73638-9" -"ORN" 28061 "Ornidazole" "Other antibacterials" "G01AF06,J01XD03,P01AB03,QG01AF06,QJ01XD03,QP51AA03" "Other antibacterials" "Imidazole derivatives" "NA" "levornidazole,madelen,ornidal,ornidazolum,tiberal" 1.5 "g" 1 "g" "55691-0,55692-8,55693-6,55694-4" -"OTE" 77050711 "Oteseconazole" "Antifungals/antimycotics" "J02AC06,QJ02AC06" "Antimycotics for systemic use" "Triazole derivatives" "NA" "quilseconazole,vivijoa" 21 "mg" "NA" -"OXA" 6196 "Oxacillin" "Beta-lactams/penicillins" "J01CF04,QJ01CF04,QJ51CF04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "ox,oxa,oxac,oxacil,oxal,oxs" "bactocill,bristopen,cryptocillin,micropenin,ossacillina,oxabel,oxabelsalt,oxacilina,oxacillinanhydrous,oxacilline,oxacillinhydrate,oxacillinsalt,oxacillinum,oxazocillin,oxazocilline,penstapho,prostaphlin,prostaphlyn,resistopen,stapenor" 2 "g" 2 "g" "18961-3,25265-0,382-2,383-0,384-8,385-5,3882-8,7039-1" -"OXA-S" "Oxacillin screening test" "Beta-lactams/penicillins" "NA" "oxa screen" "NA" "NA" +"OPT" 87880 "Optochin" "Other" "NA" "NA" "aflukin,auriquin,biquinate,chinidin,chinidine,chinimetten,chinin,chinine,conchinin,conchinine,conquinine,dentojel,dihydrochinidin,dihydroquinidine,dihydroquinine,hydroconchinine,hydroconquinine,hydroquinidine,kinidin,numoquin,optochine,optoquine,pitayine,qualaquin,quinaglute,quinicardine,quinidex,quinidine,quiniduran,quinindine,quinine,quinineanhydrous,quinora,quinsan,rezquin" "100055-3,73665-2" +"ORB" 60605 "Orbifloxacin" "Fluoroquinolones,Quinolones" "QJ01MA95" "orbifl" "orbax" "35825-9,35826-7,35827-5" +"ORI" 16136912 "Oritavancin" "Lipoglycopeptides,Glycopeptides" "J01XA05,QJ01XA05" "Other antibacterials" "Glycopeptide antibacterials" "orit,oritav" "NA" "41707-1,41708-9,41709-7,41736-0" +"ORS" "Ormetroprim/sulfamethoxazole" "Other" "NA" "NA" "NA" "73593-6,73615-7,73638-9" +"ORN" 28061 "Ornidazole" "Other" "G01AF06,J01XD03,P01AB03,QG01AF06,QJ01XD03,QP51AA03" "Other antibacterials" "Imidazole derivatives" "NA" "levornidazole,madelen,ornidal,ornidazolum,tiberal" 1.5 "g" 1 "g" "55691-0,55692-8,55693-6,55694-4" +"OTE" 77050711 "Oteseconazole" "Antifungals" "J02AC06,QJ02AC06" "Antimycotics for systemic use" "Triazole derivatives" "NA" "quilseconazole,vivijoa" 21 "mg" "NA" +"OXA" 6196 "Oxacillin" "Isoxazolylpenicillins,Penicillins,Beta-lactams" "J01CF04,QJ01CF04,QJ51CF04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "ox,oxa,oxac,oxacil,oxal,oxs" "bactocill,bristopen,cryptocillin,micropenin,ossacillina,oxabel,oxabelsalt,oxacilina,oxacillinanhydrous,oxacilline,oxacillinhydrate,oxacillinsalt,oxacillinum,oxazocillin,oxazocilline,penstapho,prostaphlin,prostaphlyn,resistopen,stapenor" 2 "g" 2 "g" "18961-3,25265-0,382-2,383-0,384-8,385-5,3882-8,7039-1" +"OXA-S" "Oxacillin screening test" "Isoxazolylpenicillins,Penicillins,Beta-lactams" "NA" "oxa screen" "NA" "NA" "OXO" 4628 "Oxolinic acid" "Quinolones" "J01MB05,QJ01MB05" "Quinolone antibacterials" "Other quinolones" "oxoaci" "aqualinic,cistopax,dioxacin,emyrenil,gramurin,inoxyl,nidantin,oksaren,orthurine,ossian,oxoboi,oxolinic,pietil,prodoxal,prodoxol,starner,tiurasin,ultibid,urinox,uritrate,urotrate,uroxol,utibid" 1 "g" "NA" "OXY" 54675779 "Oxytetracycline" "Tetracyclines" "A01AB25,D06AA03,G01AA07,J01AA06,QA01AB25,QD06AA03,QG01AA07,QG51AA01,QJ01AA06,QJ51AA06,QS01AA04,S01AA04" "Tetracyclines" "Tetracyclines" "oxytet" "achromycin,actisite,adamycin,artomycin,berkmycen,biostat,bristacycline,cancycline,cyclopar,dabicycline,diacycine,dumocyclin,embryostat,fanterrin,galsenomycin,geomycin,geotilin,hostacycline,hydroxytetracyclinum,lenocycline,macocyn,medamycin,mephacyclin,nitox,oksisyklin,ossitetraciclina,oxitetraciclina,oxitetracyclin,oxitetracycline,oxitetracyclinum,oxymycin,oxypam,oxyterracin,oxyterracine,oxyterracyne,oxytetracid,oxytetracyclin,oxytetracyclinum,paltet,partrex,pennox,piracaps,proteroxyna,qidtet,quadracycline,quatrex,remicyclin,retet,ricycline,riomitsin,ryomycin,solkaciclina,stevacin,stilciclina,subamycin,sumycin,supramycin,sustamycin,tarocyn,tarosin,tefilin,teline,telotrex,teravit,terrafungine,terramitsin,terramycine,tetrabakat,tetrabid,tetrablet,tetracaps,tetracompren,tetrakap,tetralution,tetramavan,tetramed,tetran,tetrosol,topicycline,triphacyclin,unicin,ursocyclin,ursocycline,vetquamycin" 1 "g" 1 "g" "17396-3,18962-1,25266-8,386-3,387-1,388-9,389-7,55699-3,87595-5" -"OZN" "Ozenoxacin" "D06AX14,QD06AX14" "NA" "NA" "NA" +"OZN" "Ozenoxacin" "Quinolones" "D06AX14,QD06AX14" "NA" "NA" "NA" "PAS" 4649 "P-aminosalicylic acid" "Antimycobacterials" "NA" "pasraa" "NA" "NA" -"PAN" 72015 "Panipenem" "Carbapenems" "NA" "NA" "carbenin,panipenemum,penipanem" "100056-1,53823-1" -"PAR" 165580 "Paromomycin" "Other antibacterials" "A07AA06,QA07AA06,QJ01GB92" "NA" "aminosidin,amminosidin,crestomycin,estomycin,gabbromycin,gabromycin,humatin,humycin,hydroxymycin,monomycin,paramomycin,paromomicina,paromomycine,paromomycinum,paucimycin,paucimycinum" 3 "g" "51719-3,53824-9,55700-9,55701-7,55702-5" -"PAZ" 65957 "Pazufloxacin" "Fluoroquinolones" "J01MA18,QJ01MA18" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pazufloxacine,pazufloxacino,pazufloxacinum" 1 "g" "NA" -"PEF" 51081 "Pefloxacin" "Fluoroquinolones" "J01MA03,QJ01MA03" "Quinolone antibacterials" "Fluoroquinolones" "pefl,perflo" "labocton,pefbid,pefloxacine,pefloxacinium,pefloxacino,pefloxacinum,pefocin,pefran,pelox" 0.8 "g" 0.8 "g" "18963-9,35828-3,390-5,3906-5,7040-9" -"PEF-S" "Pefloxacin screening test" "Fluoroquinolones" "NA" "pef screen" "NA" "NA" -"PNM" 10250769 "Penamecillin" "Beta-lactams/penicillins" "J01CE06,QJ01CE06" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "havapen,hydroxymethyl,penamecilina,penamecillina,penamecilline,penamecillinum" 1.05 "g" "NA" -"PNO" "Penicillin/novobiocin" "Beta-lactams/penicillins" "NA" "pennov" "NA" "35872-1,35873-9,35874-7" -"PSU" "Penicillin/sulbactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA" +"PAN" 72015 "Panipenem" "Carbapenems,Beta-lactams" "NA" "NA" "carbenin,panipenemum,penipanem" "100056-1,53823-1" +"PAR" 165580 "Paromomycin" "Other" "A07AA06,QA07AA06,QJ01GB92" "NA" "aminosidin,amminosidin,crestomycin,estomycin,gabbromycin,gabromycin,humatin,humycin,hydroxymycin,monomycin,paramomycin,paromomicina,paromomycine,paromomycinum,paucimycin,paucimycinum" 3 "g" "51719-3,53824-9,55700-9,55701-7,55702-5" +"PAZ" 65957 "Pazufloxacin" "Fluoroquinolones,Quinolones" "J01MA18,QJ01MA18" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pazufloxacine,pazufloxacino,pazufloxacinum" 1 "g" "NA" +"PEF" 51081 "Pefloxacin" "Fluoroquinolones,Quinolones" "J01MA03,QJ01MA03" "Quinolone antibacterials" "Fluoroquinolones" "pefl,perflo" "labocton,pefbid,pefloxacine,pefloxacinium,pefloxacino,pefloxacinum,pefocin,pefran,pelox" 0.8 "g" 0.8 "g" "18963-9,35828-3,390-5,3906-5,7040-9" +"PEF-S" "Pefloxacin screening test" "Fluoroquinolones,Quinolones" "NA" "pef screen" "NA" "NA" +"PNM" 10250769 "Penamecillin" "Penicillins,Beta-lactams" "J01CE06,QJ01CE06" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "havapen,hydroxymethyl,penamecilina,penamecillina,penamecilline,penamecillinum" 1.05 "g" "NA" +"PNO" "Penicillin/novobiocin" "Penicillins,Beta-lactams" "NA" "pennov" "NA" "35872-1,35873-9,35874-7" +"PSU" "Penicillin/sulbactam" "Penicillins,Beta-lactams,Beta-lactamase inhibitors" "NA" "NA" "NA" "NA" "PNM1" 54686187 "Penimepicycline" "Tetracyclines" "J01AA10,QJ01AA10" "Tetracyclines" "Tetracyclines" "NA" "criseocil,duamine,geotricyn,hydrocycline,penetracyne,penimepiciclina,penimepicyclinum" "NA" "PIM" 65453 "Pentisomicin" "Aminoglycosides" "NA" "NA" "mutamicin,mutamycin,pentisomicina,pentisomicine,pentisomicinum" "NA" -"PTZ" 55250256 "Pentizidone" "Other antibacterials" "NA" "NA" "pentizidona,pentizidonum" "NA" -"PEX" 16132253 "Pexiganan" "Other antibacterials" "NA" "NA" "cytolex,mangainin" "NA" -"PHE" 272833 "Pheneticillin" "Beta-lactams/penicillins" "J01CE05,QJ01CE05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fene" "alfacillin,alticina,antibiocin,arcacil,arcasin,astracillin,bendralan,beromycin,brocsil,broxil,chemipen,cliacil,darcil,feneticilina,feneticillin,feneticillina,feneticilline,fenocin,icipen,isocillin,ispenoral,kavepenin,maxipen,optipen,oralopen,orapen,ospeneff,pedipen,penagen,pencompren,penemve,peniplus,penova,pensig,penvikal,phenethicilin,phenethicillin,phenethicillinum,pheneticilline,pheneticillinum,primcillin,priospen,roscopenin,semopen,suspen,synapen,syncillin,synerpenin,synthecillin,synthecilline,synthepen,triospen,vamosyn,veetids,vepen" 1 "g" "NA" -"PHN" 6869 "Phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE02,QJ01CE02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fepe,peni v,penicillin v,phepen,pnv,pv" "apopen,calcipen,fenacilin,fenospen,meropenin,oracillin,oracilline,oratren,orocillin,ospen,phenocillin,phenomycilline,phenopenicillin,rocilin,stabicillin,vebecillin" 2 "g" "NA" -"PMR" 5284447 "Pimaricin" "Antifungals/antimycotics" "NA" "natamycin" "delvocid,delvolan,delvopos,mycophyt,myprozine,natacyn,natafucin,natajen,natamatrix,natamax,natamicina,natamycin,natamycine,natamycinum,pimafucin,pimaracin,pimaricine,pimarizin,synogil,tennecetin" "NA" +"PTZ" 55250256 "Pentizidone" "Other" "NA" "NA" "pentizidona,pentizidonum" "NA" +"PEX" 16132253 "Pexiganan" "Other" "NA" "NA" "cytolex,mangainin" "NA" +"PHE" 272833 "Pheneticillin" "Penicillins,Beta-lactams" "J01CE05,QJ01CE05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fene" "alfacillin,alticina,antibiocin,arcacil,arcasin,astracillin,bendralan,beromycin,brocsil,broxil,chemipen,cliacil,darcil,feneticilina,feneticillin,feneticillina,feneticilline,fenocin,icipen,isocillin,ispenoral,kavepenin,maxipen,optipen,oralopen,orapen,ospeneff,pedipen,penagen,pencompren,penemve,peniplus,penova,pensig,penvikal,phenethicilin,phenethicillin,phenethicillinum,pheneticilline,pheneticillinum,primcillin,priospen,roscopenin,semopen,suspen,synapen,syncillin,synerpenin,synthecillin,synthecilline,synthepen,triospen,vamosyn,veetids,vepen" 1 "g" "NA" +"PHN" 6869 "Phenoxymethylpenicillin" "Penicillins,Beta-lactams" "J01CE02,QJ01CE02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fepe,peni v,penicillin v,phepen,pnv,pv" "apopen,calcipen,fenacilin,fenospen,meropenin,oracillin,oracilline,oratren,orocillin,ospen,phenocillin,phenomycilline,phenopenicillin,rocilin,stabicillin,vebecillin" 2 "g" "NA" +"PMR" 5284447 "Pimaricin" "Antifungals" "NA" "natamycin" "delvocid,delvolan,delvopos,mycophyt,myprozine,natacyn,natafucin,natajen,natamatrix,natamax,natamicina,natamycin,natamycine,natamycinum,pimafucin,pimaracin,pimaricine,pimarizin,synogil,tennecetin" "NA" "PPA" 4831 "Pipemidic acid" "Quinolones" "J01MB04,QJ01MB04" "Quinolone antibacterials" "Other quinolones" "pipaci,pipz,pizu" "deblaston,dolcol,filtrax,karunomazin,memento,nuril,palin,pipedac,pipemid,pipemidate,pipemidic,pipemidicacid,pipram,pipurin,tractur,uromidin,urosten,uroval" 0.8 "g" "NA" -"PIP" 43672 "Piperacillin" "Beta-lactams/penicillins" "J01CA12,QJ01CA12" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pi,pip,pipc,pipe,pipera,pp" "penmalin,pentcillin,peperacillin,peracin,piperacilina,piperacillina,piperacilline,piperacillinhydrate,piperacillinum,pipercillin,pipracil,tazocin" 14 "g" "101490-1,101491-9,18969-6,18970-4,25268-4,3972-7,407-7,408-5,409-3,410-1,411-9,412-7,413-5,414-3,54197-9,54198-7,54199-5,55704-1,7043-3,7044-1" -"PIS" "Piperacillin/sulbactam" "Beta-lactams/penicillins" "NA" "NA" "NA" 14 "g" "54197-9,54198-7,54199-5,55704-1" -"TZP" 461573 "Piperacillin/tazobactam" "Beta-lactams/penicillins" "J01CR05,QJ01CR05" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "p/t,piptaz,piptazo,pit,pita,pt,ptc,ptz,tzp" "piptazobactam,tazonam,zobactin,zosyn" 14 "g" "101491-9,18970-4,411-9,412-7,413-5,414-3,7044-1" -"PRC" 71978 "Piridicillin" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA" -"PRL" 157385 "Pirlimycin" "Macrolides/lincosamides" "QJ51FF90" "pirlim" "pirlimycina,pirlimycine,pirlimycinum,pirsue" "35829-1,35830-9,35831-7" +"PIP" 43672 "Piperacillin" "Ureidopenicillins,Penicillins,Beta-lactams" "J01CA12,QJ01CA12" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pi,pip,pipc,pipe,pipera,pp" "penmalin,pentcillin,peperacillin,peracin,piperacilina,piperacillina,piperacilline,piperacillinhydrate,piperacillinum,pipercillin,pipracil,tazocin" 14 "g" "101490-1,101491-9,18969-6,18970-4,25268-4,3972-7,407-7,408-5,409-3,410-1,411-9,412-7,413-5,414-3,54197-9,54198-7,54199-5,55704-1,7043-3,7044-1" +"PIS" "Piperacillin/sulbactam" "Penicillins,Beta-lactams,Beta-lactamase inhibitors" "NA" "NA" "NA" 14 "g" "54197-9,54198-7,54199-5,55704-1" +"TZP" 461573 "Piperacillin/tazobactam" "Ureidopenicillins,Penicillins,Beta-lactams,Beta-lactamase inhibitors" "J01CR05,QJ01CR05" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "p/t,piptaz,piptazo,pit,pita,pt,ptc,ptz,tzp" "piptazobactam,tazonam,zobactin,zosyn" 14 "g" "101491-9,18970-4,411-9,412-7,413-5,414-3,7044-1" +"PRC" 71978 "Piridicillin" "Penicillins,Beta-lactams" "NA" "NA" "NA" "NA" +"PRL" 157385 "Pirlimycin" "Lincosamides,Macrolides" "QJ51FF90" "pirlim" "pirlimycina,pirlimycine,pirlimycinum,pirsue" "35829-1,35830-9,35831-7" "PIR" 4855 "Piromidic acid" "Quinolones" "J01MB03,QJ01MB03" "Quinolone antibacterials" "Other quinolones" "NA" "bactramyl,enterol,gastrurol,panacid,pirodal,piromidate,reelon,septural,urisept,uropir,zaomeal" 2 "g" "NA" -"PVM" 33478 "Pivampicillin" "Beta-lactams/penicillins" "J01CA02,QJ01CA02" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "pivaloylampicillin,pivampicilina,pivampicilline,pivampicillinum" 1.05 "g" "18971-2,415-0,416-8,417-6,418-4" -"PME" 115163 "Pivmecillinam" "Beta-lactams/penicillins" "J01CA08,QJ01CA08" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pivmec" "coactabs,melysin,pivamdinocillin,pivmecilinamo,pivmecillinamum,selexid" 0.6 "g" "NA" +"PVM" 33478 "Pivampicillin" "Penicillins,Beta-lactams" "J01CA02,QJ01CA02" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "pivaloylampicillin,pivampicilina,pivampicilline,pivampicillinum" 1.05 "g" "18971-2,415-0,416-8,417-6,418-4" +"PME" 115163 "Pivmecillinam" "Penicillins,Beta-lactams" "J01CA08,QJ01CA08" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pivmec" "coactabs,melysin,pivamdinocillin,pivmecilinamo,pivmecillinamum,selexid" 0.6 "g" "NA" "PLZ" 42613186 "Plazomicin" "Aminoglycosides" "J01GB14,QJ01GB14" "NA" "zemdri" "73592-8,73614-0,73637-1,92024-9,94719-2" "PLB" 49800004 "Polymyxin B" "Polymyxins" "A07AA05,J01XB02,QA07AA05,QJ01XB02,QJ51XB02,QS01AA18,QS02AA11,QS03AA03,S01AA18,S02AA11,S03AA03" "Other antibacterials" "Polymyxins" "pb,pol,polb,poly,poly b,polyb,polymixin,polymixin b" "aerosporin" 3 "MU" 0.15 "g" "17473-0,18972-0,25269-2,35832-5,419-2,420-0,421-8,422-6" "POP" "Polymyxin B/polysorbate 80" "Polymyxins" "NA" "NA" "NA" "NA" -"POS" 468595 "Posaconazole" "Antifungals/antimycotics" "J02AC04,QJ02AC04" "Antimycotics for systemic use" "Triazole derivatives" "posa,posaco" "noxafil,schering,spriafil" 0.3 "g" 0.3 "g" "53731-6,54186-2,54187-0,54188-8,54189-6,80545-7" -"PRA" 9802884 "Pradofloxacin" "Fluoroquinolones" "QJ01MA97" "NA" "pudofloxacin,veraflox" "76148-6,87800-9" -"PRX" 71455 "Premafloxacin" "Fluoroquinolones" "NA" "premaf" "premafloxacine,premafloxacino" "73591-0,73613-2,73636-3" +"POS" 468595 "Posaconazole" "Antifungals" "J02AC04,QJ02AC04" "Antimycotics for systemic use" "Triazole derivatives" "posa,posaco" "noxafil,schering,spriafil" 0.3 "g" 0.3 "g" "53731-6,54186-2,54187-0,54188-8,54189-6,80545-7" +"PRA" 9802884 "Pradofloxacin" "Fluoroquinolones,Quinolones" "QJ01MA97" "NA" "pudofloxacin,veraflox" "76148-6,87800-9" +"PRX" 71455 "Premafloxacin" "Fluoroquinolones,Quinolones" "NA" "premaf" "premafloxacine,premafloxacino" "73591-0,73613-2,73636-3" "PMD" 456199 "Pretomanid" "Antimycobacterials" "J04AK08,QJ04AK08" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "NA" 0.2 "g" "93850-6" -"PRM" 6446787 "Primycin" "Macrolides/lincosamides" "NA" "NA" "chinopricin,debrycin,primicina,primycine" "NA" -"PRI" 11979535 "Pristinamycin" "Macrolides/lincosamides" "J01FG01,QJ01FG01" "Macrolides, lincosamides and streptogramins" "Streptogramins" "pris,pristi" "eskalin,micamicina,mikamycin,mikamycine,mikamycinum,ostreogricina,ostreogrycin,ostreogrycine,ostreogrycinum,pristinamicina,pristinamycine,pristinamycinum,pyostacine,stafac,stafytracine,stajac,staphylomycin,stapyocine,starfac,virgimycin,virgimycine,virginiamicina,virginiamycin,virginiamycina,virginiamycinum" 2 "g" "32383-2,35833-3,35834-1,55709-0" -"PRB" 5903 "Procaine benzylpenicillin" "Beta-lactams/penicillins" "J01CE09,QJ01CE09,QJ51CE09" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "afsillin,aquacilina,aquacillin,aquasuspen,avloprocil,cilicaine,crysticillin,depocillin,despacilina,distaquaine,duphapen,duracillin,hostacillin,hydracillin,kabipenin,ledercillin,millicillin,mylipen,neoproc,nopcaine,parencillin,premocillin,procanodia,prostabillin,retardillin,sharcillin,vetspen,vitablend,wycillin" 0.6 "g" "NA" -"PRP" 92879 "Propicillin" "Beta-lactams/penicillins" "J01CE03,QJ01CE03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "baycillin,propicilina,propicilline,propicillinum" 0.9 "g" "NA" +"PRM" 6446787 "Primycin" "Macrolides" "NA" "NA" "chinopricin,debrycin,primicina,primycine" "NA" +"PRI" 11979535 "Pristinamycin" "Streptogramins" "J01FG01,QJ01FG01" "Macrolides, lincosamides and streptogramins" "Streptogramins" "pris,pristi" "eskalin,micamicina,mikamycin,mikamycine,mikamycinum,ostreogricina,ostreogrycin,ostreogrycine,ostreogrycinum,pristinamicina,pristinamycine,pristinamycinum,pyostacine,stafac,stafytracine,stajac,staphylomycin,stapyocine,starfac,virgimycin,virgimycine,virginiamicina,virginiamycin,virginiamycina,virginiamycinum" 2 "g" "32383-2,35833-3,35834-1,55709-0" +"PRB" 5903 "Procaine benzylpenicillin" "Penicillins,Beta-lactams" "J01CE09,QJ01CE09,QJ51CE09" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "afsillin,aquacilina,aquacillin,aquasuspen,avloprocil,cilicaine,crysticillin,depocillin,despacilina,distaquaine,duphapen,duracillin,hostacillin,hydracillin,kabipenin,ledercillin,millicillin,mylipen,neoproc,nopcaine,parencillin,premocillin,procanodia,prostabillin,retardillin,sharcillin,vetspen,vitablend,wycillin" 0.6 "g" "NA" +"PRP" 92879 "Propicillin" "Penicillins,Beta-lactams" "J01CE03,QJ01CE03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "baycillin,propicilina,propicilline,propicillinum" 0.9 "g" "NA" "PKA" 9872451 "Propikacin" "Aminoglycosides" "NA" "NA" "propikacina,propikacine,propikacinum" "NA" "PTH" 666418 "Protionamide" "Antimycobacterials" "J04AD01,QJ04AD01" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "prot" "ektebin,peteha,prothionamide,prothionamidum,protion,protionamid,protionamida,protionamidum,protionizina,tebeform,trevintix,tuberex" 0.75 "g" "NA" -"PRU" 65947 "Prulifloxacin" "Fluoroquinolones" "J01MA17,QJ01MA17" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pruvel,quisnon,sword" 0.6 "g" "100058-7,76145-2" +"PRU" 65947 "Prulifloxacin" "Fluoroquinolones,Quinolones" "J01MA17,QJ01MA17" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pruvel,quisnon,sword" 0.6 "g" "100058-7,76145-2" "PZA" 1046 "Pyrazinamide" "Antimycobacterials" "J04AK01,QJ04AK01" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "pyra" "aldinamid,aldinamide,eprazin,farmizina,isopas,novamid,pezetamid,piraldina,pirazimida,pirazinamid,pirazinamida,pirazinamide,pirazinecarboxamide,pyrafat,pyrazide,pyrazinamdie,pyrazinamidum,pyrazineamide,pyrizinamide,rifafour,rozide,tebrazid,tisamid,unipyranamide" 1.5 "g" "11001-5,18973-8,20461-0,23632-3,25186-8,25229-6,25270-0,423-4,424-2,425-9,426-7,42935-7,55710-8,55711-6,56026-8,92242-7" -"QDA" 11979418 "Quinupristin/dalfopristin" "Macrolides/lincosamides" "QJ01FG02" "Macrolides, lincosamides and streptogramins" "Streptogramins" "q/d,qda,qida,quda,rp,syn,synerc" "synercid" "23640-6,23641-4,33334-4,35835-8,58712-1" -"RAC" 56052 "Ractopamine" "Other antibacterials" "NA" "NA" "bufenina,bufenine,buphenin,buphenine,bupheninum,luteonin,nilidrine,nylidrinum,optaflexx,paylean,prepar,ractopamina,ractopaminum,ritodrina,ritodrine,ritodrinium,tomax,utopar,yutopar" "NA" +"QDA" 11979418 "Quinupristin/dalfopristin" "Streptogramins" "QJ01FG02" "Macrolides, lincosamides and streptogramins" "Streptogramins" "q/d,qda,qida,quda,rp,syn,synerc" "synercid" "23640-6,23641-4,33334-4,35835-8,58712-1" +"RAC" 56052 "Ractopamine" "Other" "NA" "NA" "bufenina,bufenine,buphenin,buphenine,bupheninum,luteonin,nilidrine,nylidrinum,optaflexx,paylean,prepar,ractopamina,ractopaminum,ritodrina,ritodrine,ritodrinium,tomax,utopar,yutopar" "NA" "RAM" 16132338 "Ramoplanin" "Glycopeptides" "NA" "ramopl" "NA" "41710-5,41711-3,41712-1,41737-8" -"RZM" 10993211 "Razupenem" "Carbapenems" "NA" "razupe" "NA" "73590-2,73612-4,73635-5" -"RTP" 6918462 "Retapamulin" "Other antibacterials" "D06AX13,QD06AX13" "Antibiotics for topical use" "Other antibiotics for topical use" "ret" "altabax,altargo,rebapamulin,retapamulina" "NA" +"RZM" 10993211 "Razupenem" "Carbapenems,Beta-lactams" "NA" "razupe" "NA" "73590-2,73612-4,73635-5" +"RTP" 6918462 "Retapamulin" "Other" "D06AX13,QD06AX13" "Antibiotics for topical use" "Other antibiotics for topical use" "ret" "altabax,altargo,rebapamulin,retapamulina" "NA" "RZF" "Rezafungin" "Antifungals" "NA" "NA" "NA" "NA" -"RBC" 44631912 "Ribociclib" "Antifungals/antimycotics" "L01EF02,QL01EF02" "Antimycotics for systemic use" "Triazole derivatives" "ribo" "kisqali" 0.45 "g" "NA" +"RBC" 44631912 "Ribociclib" "Antifungals" "L01EF02,QL01EF02" "Antimycotics for systemic use" "Triazole derivatives" "ribo" "kisqali" 0.45 "g" "NA" "RST" 33042 "Ribostamycin" "Aminoglycosides" "J01GB10,QJ01GB10" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "exaluren,hetangmycin,ribastamin,ribostamicina,ribostamycine,ribostamycinum,vistamycin,xylostatin" 1 "g" "NA" -"RID1" 16659285 "Ridinilazole" "Other antibacterials" "NA" "NA" "ridinilazol" "NA" -"RIB" 135398743 "Rifabutin" "Antimycobacterials" "J04AB04,QJ04AB04" "Drugs for treatment of tuberculosis" "Antibiotics" "ansamy,rfb,rifb" "alfacid,ansamicin,ansamycins,ansatipin,ansatipine,assatipin,mycobutin,rifabutinum" 0.15 "g" "100699-8,16100-0,16386-5,16387-3,19149-4,20386-9,23630-7,24032-5,25199-1,25200-7,25201-5,42655-1,42656-9,54183-9,96113-6" -"RIF" 135398735 "Rifampicin" "Antimycobacterials" "J04AB02,QJ04AB02,QJ54AB02" "Drugs for treatment of tuberculosis" "Antibiotics" "rifa,rifamp" "abrifam,archidyn,arficin,arzide,benemicin,doloresum,eremfat,famcin,fenampicin,rifadin,rifadine,rifagen,rifaldazin,rifaldazine,rifaldin,rifam,rifamor,rifampicina,rifampicine,rifampicinum,rifampin,rifamsolin,rifapiam,rifaprodin,rifcin,rifinah,rifobac,rifoldin,rifoldine,riforal,rimactan,rimactane,rimactazid,rimactizid,rimazid,sinerdol,tubocin" 0.6 "g" 0.6 "g" "NA" -"REI" 135483893 "Rifampicin/ethambutol/isoniazid" "Antimycobacterials" "J04AM07,QJ04AM07" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "isonarif,rifamate,rifamazid" "NA" -"RFI" "Rifampicin/isoniazid" "Antimycobacterials" "J04AM02,QJ04AM02" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"RPEI" "Rifampicin/pyrazinamide/ethambutol/isoniazid" "Antimycobacterials" "J04AM06,QJ04AM06" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"RPI" "Rifampicin/pyrazinamide/isoniazid" "Antimycobacterials" "J04AM05,QJ04AM05" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"RFM" 6324616 "Rifamycin" "Antimycobacterials" "A07AA13,D06AX15,J04AB03,QA07AA13,QD06AX15,QJ04AB03,QJ54AB03,QS01AA16,QS02AA12,S01AA16,S02AA12" "Drugs for treatment of tuberculosis" "Antibiotics" "rifmyc" "aemcolo,nacimycin,nancimycin,otofa,rifamastene,rifamicina,rifamycine,rifamycinum,rifocin,rifocyn,tuborin" 0.8 "g" 0.6 "g" "NA" -"RFP" 135403821 "Rifapentine" "Antimycobacterials" "J04AB05,QJ04AB05" "Drugs for treatment of tuberculosis" "Antibiotics" "rifp,rpt" "prifitin,priftin,rifapentin,rifapentina,rifapentinum" 0.11 "g" "100059-5,76627-9" -"RFX" 6436173 "Rifaximin" "Other antibacterials" "A07AA11,D06AX11,QA07AA11,QD06AX11,QG51AA06,QJ51XX01" "Intestinal antiinfectives" "Antibiotics" "NA" "fatroximin,flonorm,lormyx,lumenax,normix,rifacol,rifamixin,rifaxidin,rifaximina,rifaximine,rifaximinum,rifaxin,ritacol,spiraxin,xifaxan,xifaxsan" 0.6 "g" "73589-4,73611-6,73634-8" -"RIT" 65633 "Ritipenem" "Carbapenems" "NA" "NA" "ritipenemsalt" "NA" -"RIA" 163692 "Ritipenem acoxil" "Carbapenems" "NA" "NA" "penemac" "NA" -"ROK" 5282211 "Rokitamycin" "Macrolides/lincosamides" "J01FA12,QJ01FA12" "Macrolides, lincosamides and streptogramins" "Macrolides" "rokita" "propionylleucomycin,ricamycin,rokicid,rokital,rokitamicina,rokitamycine,rokitamycinum" 0.8 "g" "NA" +"RID1" 16659285 "Ridinilazole" "Other" "NA" "NA" "ridinilazol" "NA" +"RIB" 135398743 "Rifabutin" "Rifamycins,Antimycobacterials" "J04AB04,QJ04AB04" "Drugs for treatment of tuberculosis" "Antibiotics" "ansamy,rfb,rifb" "alfacid,ansamicin,ansamycins,ansatipin,ansatipine,assatipin,mycobutin,rifabutinum" 0.15 "g" "100699-8,16100-0,16386-5,16387-3,19149-4,20386-9,23630-7,24032-5,25199-1,25200-7,25201-5,42655-1,42656-9,54183-9,96113-6" +"RIF" 135398735 "Rifampicin" "Rifamycins,Antimycobacterials" "J04AB02,QJ04AB02,QJ54AB02" "Drugs for treatment of tuberculosis" "Antibiotics" "rifa,rifamp" "abrifam,archidyn,arficin,arzide,benemicin,doloresum,eremfat,famcin,fenampicin,rifadin,rifadine,rifagen,rifaldazin,rifaldazine,rifaldin,rifam,rifamor,rifampicina,rifampicine,rifampicinum,rifampin,rifamsolin,rifapiam,rifaprodin,rifcin,rifinah,rifobac,rifoldin,rifoldine,riforal,rimactan,rimactane,rimactazid,rimactizid,rimazid,sinerdol,tubocin" 0.6 "g" 0.6 "g" "NA" +"REI" 135483893 "Rifampicin/ethambutol/isoniazid" "Rifamycins,Antimycobacterials" "J04AM07,QJ04AM07" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "isonarif,rifamate,rifamazid" "NA" +"RFI" "Rifampicin/isoniazid" "Rifamycins,Antimycobacterials" "J04AM02,QJ04AM02" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" +"RPEI" "Rifampicin/pyrazinamide/ethambutol/isoniazid" "Rifamycins,Antimycobacterials" "J04AM06,QJ04AM06" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" +"RPI" "Rifampicin/pyrazinamide/isoniazid" "Rifamycins,Antimycobacterials" "J04AM05,QJ04AM05" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" +"RFM" 6324616 "Rifamycin" "Rifamycins,Antimycobacterials" "A07AA13,D06AX15,J04AB03,QA07AA13,QD06AX15,QJ04AB03,QJ54AB03,QS01AA16,QS02AA12,S01AA16,S02AA12" "Drugs for treatment of tuberculosis" "Antibiotics" "rifmyc" "aemcolo,nacimycin,nancimycin,otofa,rifamastene,rifamicina,rifamycine,rifamycinum,rifocin,rifocyn,tuborin" 0.8 "g" 0.6 "g" "NA" +"RFP" 135403821 "Rifapentine" "Rifamycins,Antimycobacterials" "J04AB05,QJ04AB05" "Drugs for treatment of tuberculosis" "Antibiotics" "rifp,rpt" "prifitin,priftin,rifapentin,rifapentina,rifapentinum" 0.11 "g" "100059-5,76627-9" +"RFX" 6436173 "Rifaximin" "Other" "A07AA11,D06AX11,QA07AA11,QD06AX11,QG51AA06,QJ51XX01" "Intestinal antiinfectives" "Antibiotics" "NA" "fatroximin,flonorm,lormyx,lumenax,normix,rifacol,rifamixin,rifaxidin,rifaximina,rifaximine,rifaximinum,rifaxin,ritacol,spiraxin,xifaxan,xifaxsan" 0.6 "g" "73589-4,73611-6,73634-8" +"RIT" 65633 "Ritipenem" "Carbapenems,Beta-lactams" "NA" "NA" "ritipenemsalt" "NA" +"RIA" 163692 "Ritipenem acoxil" "Carbapenems,Beta-lactams" "NA" "NA" "penemac" "NA" +"ROK" 5282211 "Rokitamycin" "Macrolides" "J01FA12,QJ01FA12" "Macrolides, lincosamides and streptogramins" "Macrolides" "rokita" "propionylleucomycin,ricamycin,rokicid,rokital,rokitamicina,rokitamycine,rokitamycinum" 0.8 "g" "NA" "RLT" 54682938 "Rolitetracycline" "Tetracyclines" "J01AA09,QJ01AA09" "Tetracyclines" "Tetracyclines" "NA" "bristacin,colbiocin,kinteto,reverin,revrin,rolitetraciclina,rolitetracyclinum,solvocillin,superciclin,synotodecin,synterin,syntetrex,syntetrin,tetraverin,transcycline,velacicline,velacycline" 0.35 "g" "18976-1,435-8,436-6,437-4,438-2" "ROS" 287180 "Rosoxacin" "Quinolones" "J01MB01,QJ01MB01" "Quinolone antibacterials" "Other quinolones" "NA" "acrosoxacin,eracine,eradacil,eradacin,eradicin,rosoxacine,rosoxacino,rosoxacinum,roxadyl,winoxacin,winuron" 0.3 "g" "18977-9,439-0,440-8,441-6,442-4,55713-2" -"RXT" "Roxithromycin" "Macrolides/lincosamides" "J01FA06,QJ01FA06" "Macrolides, lincosamides and streptogramins" "Macrolides" "roxi,roxith" "NA" 0.3 "g" "18978-7,443-2,444-0,445-7,446-5,7046-6" -"RFL" 58258 "Rufloxacin" "Fluoroquinolones" "J01MA10,QJ01MA10" "Quinolone antibacterials" "Fluoroquinolones" "NA" "monos,rufloxacine,rufloxacino,rufloxacinum,tebraxin,uroflox" 0.2 "g" "NA" -"SAL" 3085092 "Salinomycin" "Other antibacterials" "QP51BB01" "salino" "coxistac,procoxacin,salinomicina,salinomycine,salinomycinum" "35836-6,35837-4,35838-2,87593-0" -"SAR" 56208 "Sarafloxacin" "Fluoroquinolones" "QJ01MA98" "sarafl" "difloxacino,difloxacinum,difloxcine,sarafin,saraflox,sarafloxacine,sarafloxacino,sarafloxacinum" "73588-6,73610-8,73633-0" +"RXT" "Roxithromycin" "Macrolides" "J01FA06,QJ01FA06" "Macrolides, lincosamides and streptogramins" "Macrolides" "roxi,roxith" "NA" 0.3 "g" "18978-7,443-2,444-0,445-7,446-5,7046-6" +"RFL" 58258 "Rufloxacin" "Fluoroquinolones,Quinolones" "J01MA10,QJ01MA10" "Quinolone antibacterials" "Fluoroquinolones" "NA" "monos,rufloxacine,rufloxacino,rufloxacinum,tebraxin,uroflox" 0.2 "g" "NA" +"SAL" 3085092 "Salinomycin" "Other" "QP51BB01" "salino" "coxistac,procoxacin,salinomicina,salinomycine,salinomycinum" "35836-6,35837-4,35838-2,87593-0" +"SAR" 56208 "Sarafloxacin" "Fluoroquinolones,Quinolones" "QJ01MA98" "sarafl" "difloxacino,difloxacinum,difloxcine,sarafin,saraflox,sarafloxacine,sarafloxacino,sarafloxacinum" "73588-6,73610-8,73633-0" "SRC" 54681908 "Sarecycline" "Tetracyclines" "J01AA14,QJ01AA14" "Tetracyclines" "Tetracyclines" "NA" "sareciclina,seysara" 0.1 "g" "NA" -"SRX" 9933415 "Sarmoxicillin" "Beta-lactams/penicillins" "NA" "NA" "sarmoxillina,sarmoxilline,sarmoxillinum" "NA" -"SEC" 71815 "Secnidazole" "Other antibacterials" "P01AB07" "NA" "flagentyl,secnidal,secnidazolum,secnil,sindose,solosec" 2 "g" "NA" +"SRX" 9933415 "Sarmoxicillin" "Penicillins,Beta-lactams" "NA" "NA" "sarmoxillina,sarmoxilline,sarmoxillinum" "NA" +"SEC" 71815 "Secnidazole" "Other" "P01AB07" "NA" "flagentyl,secnidal,secnidazolum,secnil,sindose,solosec" 2 "g" "NA" "SIS" 36119 "Sisomicin" "Aminoglycosides" "J01GB08,QJ01GB08" "Aminoglycoside antibacterials" "Other aminoglycosides" "siso,sisomy" "rickamicin,salvamina,sisomicina,sisomicine,sisomicinum,sisomin,sisomycin,sissomicin,sizomycin" 0.24 "g" "18979-5,447-3,448-1,449-9,450-7,55714-0" -"SIT" 461399 "Sitafloxacin" "Fluoroquinolones" "J01MA21,QJ01MA21" "sitafl" "gracevit" 0.1 "g" "NA" +"SIT" 461399 "Sitafloxacin" "Fluoroquinolones,Quinolones" "J01MA21,QJ01MA21" "sitafl" "gracevit" 0.1 "g" "NA" "SDA" 2724368 "Sodium aminosalicylate" "Antimycobacterials" "J04AA02,QJ04AA02" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "bactylan,lepasen,monopas,tubersan" 14 "g" 14 "g" "NA" -"SOL" 25242512 "Solithromycin" "Macrolides/lincosamides" "J01FA16,QJ01FA16" "NA" "solithera" "73587-8,73609-0,73632-2" -"SPX" 60464 "Sparfloxacin" "Fluoroquinolones" "J01MA09,QJ01MA09" "Quinolone antibacterials" "Fluoroquinolones" "spa,spar,sparfl" "esparfloxacino,parox,spara,sparfloxacine,sparfloxacinum,zagam" 0.2 "g" "20397-6,23610-9,23628-1,35839-0,7047-4" -"SPT" 15541 "Spectinomycin" "Other antibacterials" "J01XX04,QJ01XX04" "Other antibacterials" "Other antibacterials" "sc,spe,spec,spect,spt" "actinospectacina,adspec,espectinomicina,prospec,spectam,spectinomicina,spectinomycine,spectinomycinhydrate,spectinomycinum,spectogard,stanilo,togamycin,trobicin" 3 "g" "18980-3,35840-8,451-5,452-3,453-1,454-9" -"SPI" 6419898 "Spiramycin" "Macrolides/lincosamides" "J01FA02,QJ01FA02,QJ51FA02" "Macrolides, lincosamides and streptogramins" "Macrolides" "sipram,spir,spiram" "formacidine" 3 "g" "18981-1,455-6,456-4,457-2,458-0,55715-7" -"SPM" "Spiramycin/metronidazole" "Other antibacterials" "J01RA04,QJ01RA04" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"SOL" 25242512 "Solithromycin" "Macrolides" "J01FA16,QJ01FA16" "NA" "solithera" "73587-8,73609-0,73632-2" +"SPX" 60464 "Sparfloxacin" "Fluoroquinolones,Quinolones" "J01MA09,QJ01MA09" "Quinolone antibacterials" "Fluoroquinolones" "spa,spar,sparfl" "esparfloxacino,parox,spara,sparfloxacine,sparfloxacinum,zagam" 0.2 "g" "20397-6,23610-9,23628-1,35839-0,7047-4" +"SPT" 15541 "Spectinomycin" "Other" "J01XX04,QJ01XX04" "Other antibacterials" "Other antibacterials" "sc,spe,spec,spect,spt" "actinospectacina,adspec,espectinomicina,prospec,spectam,spectinomicina,spectinomycine,spectinomycinhydrate,spectinomycinum,spectogard,stanilo,togamycin,trobicin" 3 "g" "18980-3,35840-8,451-5,452-3,453-1,454-9" +"SPI" 6419898 "Spiramycin" "Macrolides" "J01FA02,QJ01FA02,QJ51FA02" "Macrolides, lincosamides and streptogramins" "Macrolides" "sipram,spir,spiram" "formacidine" 3 "g" "18981-1,455-6,456-4,457-2,458-0,55715-7" +"SPM" "Spiramycin/metronidazole" "Other" "J01RA04,QJ01RA04" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "STR" "Streptoduocin" "Aminoglycosides" "J01GA02,QJ01GA02" "Aminoglycoside antibacterials" "Streptomycins" "NA" "NA" 1 "g" "NA" "STR1" 19649 "Streptomycin" "Aminoglycosides" "A07AA04,J01GA01,QA07AA04,QJ01GA01" "Aminoglycoside antibacterials" "Streptomycins" "s,st1000,st2000,stm,str,stre,strept" "agrept,agrimycin,chemform,estreptomicina,gerox,neodiestreptopab,strepcen,streptomicina,streptomycine,streptomycinum,streptomyzin" 1 "g" "18982-9,18983-7,20462-8,23626-5,25185-0,25205-6,25206-4,35841-6,4039-4,42658-5,42659-3,459-8,460-6,461-4,462-2,46719-1,48177-0,6933-6,7048-2,7049-0,96114-4" "STH" "Streptomycin-high" "Aminoglycosides" "NA" "sthi,sthl,strepto high,streptomycin high" "NA" "18983-7,35841-6,6933-6,7049-0" "STI" "Streptomycin/isoniazid" "Antimycobacterials" "J04AM01,QJ04AM01" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"SUL" 130313 "Sulbactam" "Beta-lactams/penicillins" "J01CG01,QJ01CG01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "sulbac" "betamaze,sulbactamum" 1 "g" "41716-2,41717-0,41718-8,41739-4" -"SBC" 20055036 "Sulbenicillin" "Beta-lactams/penicillins" "J01CA16,QJ01CA16" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "sulben" "kedacillin,kedacillina,sulbenicilina,sulbenicilline,sulbenicillinum,sulpelin" 15 "g" "NA" -"SUC" 5318 "Sulconazole" "Antifungals/antimycotics" "D01AC09,QD01AC09" "NA" "sulconazol,sulconazolum" "NA" -"SUP" 6634 "Sulfachlorpyridazine" "Other antibacterials" "QJ01EQ12" "sulchl" "cluricol,cosulid,cosumix,durasulf,nefrosul,nsulfanilamide,prinzone,solfaclorpiridazina,sonilyn,sulfacloropiridazina,sulfaclorpiridazina,vetisulid" "NA" -"SDI" 5215 "Sulfadiazine" "Trimethoprims" "J01EC02,QJ01EQ10" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "suldia" "codiazine,cremodiazine,cremotres,debenal,deltazina,dermazin,dermazine,diazolone,diazovit,eskadiazine,flamazine,geben,liquadiazine,microsulfon,neazine,neotrizine,palatrize,piridisir,pirimal,pyrimal,quadetts,quadramoid,sanodiazine,silbertone,sildaflo,silvadene,silvazine,silver,silveramide,sliverex,solfadiazina,spofadrizine,sterazine,sulfacombin,sulfadiazene,sulfadiazin,sulfadiazina,sulfadiazinum,sulfapirimidin,sulfapyrimidin,sulfapyrimidine,sulfatryl,sulfazine,sulfolex,sulfonsol,sulfose,sulphadiazine,terfonyl,theradiazine,thermazene,trifonamide,trisem,truozine" 0.6 "g" "18984-5,27216-1,463-0,464-8,465-5,466-3,59742-7,6907-0,7050-8" -"SLT" 122284 "Sulfadiazine/tetroxoprim" "Trimethoprims" "J01EE06" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "berlocombin,cotetroxazine,potesept,trimerazine" "NA" +"SUL" 130313 "Sulbactam" "Beta-lactamase inhibitors" "J01CG01,QJ01CG01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "sulbac" "betamaze,sulbactamum" 1 "g" "41716-2,41717-0,41718-8,41739-4" +"SBC" 20055036 "Sulbenicillin" "Penicillins,Beta-lactams" "J01CA16,QJ01CA16" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "sulben" "kedacillin,kedacillina,sulbenicilina,sulbenicilline,sulbenicillinum,sulpelin" 15 "g" "NA" +"SUC" 5318 "Sulconazole" "Antifungals" "D01AC09,QD01AC09" "NA" "sulconazol,sulconazolum" "NA" +"SUP" 6634 "Sulfachlorpyridazine" "Other" "QJ01EQ12" "sulchl" "cluricol,cosulid,cosumix,durasulf,nefrosul,nsulfanilamide,prinzone,solfaclorpiridazina,sonilyn,sulfacloropiridazina,sulfaclorpiridazina,vetisulid" "NA" +"SDI" 5215 "Sulfadiazine" "Trimethoprims,Sulfonamides" "J01EC02,QJ01EQ10" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "suldia" "codiazine,cremodiazine,cremotres,debenal,deltazina,dermazin,dermazine,diazolone,diazovit,eskadiazine,flamazine,geben,liquadiazine,microsulfon,neazine,neotrizine,palatrize,piridisir,pirimal,pyrimal,quadetts,quadramoid,sanodiazine,silbertone,sildaflo,silvadene,silvazine,silver,silveramide,sliverex,solfadiazina,spofadrizine,sterazine,sulfacombin,sulfadiazene,sulfadiazin,sulfadiazina,sulfadiazinum,sulfapirimidin,sulfapyrimidin,sulfapyrimidine,sulfatryl,sulfazine,sulfolex,sulfonsol,sulfose,sulphadiazine,terfonyl,theradiazine,thermazene,trifonamide,trisem,truozine" 0.6 "g" "18984-5,27216-1,463-0,464-8,465-5,466-3,59742-7,6907-0,7050-8" +"SLT" 122284 "Sulfadiazine/tetroxoprim" "Trimethoprims,Sulfonamides" "J01EE06" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "berlocombin,cotetroxazine,potesept,trimerazine" "NA" "SLT1" 64932 "Sulfadiazine/trimethoprim" "Trimethoprims" "J01EE02,QJ01EW10,QJ51RE01" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "antastmon,astra,ditrim,ditrivet,sultrisan,triglobe,trimin,tucoprim,uniprim" "NA" -"SUD" 5323 "Sulfadimethoxine" "Trimethoprims" "J01ED01,QJ01EQ09,QP51BA01" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "sdimet" "abcid,agribon,albon,arnosulfan,bactotril,bactrovet,deposul,diasulfa,diasulfyl,dimetazina,dinosol,dorisul,fuxal,lasibon,madribon,madrigid,madriqid,madroxin,madroxine,maxulvet,mecozine,memcozine,metoxidon,neostrepal,neostreptal,nsulfanilamidesalt,omnibon,persulfen,radonin,redifal,rofenaid,roscosulf,scandisil,solfadimetossina,sudine,suldixine,sulfabon,sulfadimethoxin,sulfadimethoxinesalt,sulfadimethoxinum,sulfadimetossina,sulfadimetoxin,sulfadimetoxina,sulfadimetoxine,sulfadimoxine,sulfastop,sulfoplan,sulforal,sulphadimethoxine,sulxin,sumbio,symbio,theracanzan,ultrasulfon" 0.5 "g" "87799-3,87803-3" -"SDM" 5327 "Sulfadimidine" "Trimethoprims" "J01EB03,QJ01EQ03,QP51AG01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "suldim" "azolmetazin,bovibol,calfspan,cremomethazine,diazil,diazilsulfadine,diazyl,dimezathine,intradine,kelametazine,mermeth,neasina,neazina,panazin,pirmazin,primazin,solfadimidina,spanbolet,sulfadimerazine,sulfadimesin,sulfadimesine,sulfadimethyldiazine,sulfadimezin,sulfadimezine,sulfadimezinum,sulfadimidin,sulfadimidina,sulfadimidinum,sulfadimidinun,sulfadine,sulfametazina,sulfametazyny,sulfamethiazine,sulfamezathine,sulfamidine,sulfodimesin,sulfodimezine,sulmet,sulphadimidine,sulphamethasine,sulphamethazine,sulphamezathine,sulphamidine,sulphodimezine,superseptil,superseptyl,vertolan,vesadin" 4 "g" "NA" +"SUD" 5323 "Sulfadimethoxine" "Trimethoprims,Sulfonamides" "J01ED01,QJ01EQ09,QP51BA01" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "sdimet" "abcid,agribon,albon,arnosulfan,bactotril,bactrovet,deposul,diasulfa,diasulfyl,dimetazina,dinosol,dorisul,fuxal,lasibon,madribon,madrigid,madriqid,madroxin,madroxine,maxulvet,mecozine,memcozine,metoxidon,neostrepal,neostreptal,nsulfanilamidesalt,omnibon,persulfen,radonin,redifal,rofenaid,roscosulf,scandisil,solfadimetossina,sudine,suldixine,sulfabon,sulfadimethoxin,sulfadimethoxinesalt,sulfadimethoxinum,sulfadimetossina,sulfadimetoxin,sulfadimetoxina,sulfadimetoxine,sulfadimoxine,sulfastop,sulfoplan,sulforal,sulphadimethoxine,sulxin,sumbio,symbio,theracanzan,ultrasulfon" 0.5 "g" "87799-3,87803-3" +"SDM" 5327 "Sulfadimidine" "Trimethoprims,Sulfonamides" "J01EB03,QJ01EQ03,QP51AG01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "suldim" "azolmetazin,bovibol,calfspan,cremomethazine,diazil,diazilsulfadine,diazyl,dimezathine,intradine,kelametazine,mermeth,neasina,neazina,panazin,pirmazin,primazin,solfadimidina,spanbolet,sulfadimerazine,sulfadimesin,sulfadimesine,sulfadimethyldiazine,sulfadimezin,sulfadimezine,sulfadimezinum,sulfadimidin,sulfadimidina,sulfadimidinum,sulfadimidinun,sulfadine,sulfametazina,sulfametazyny,sulfamethiazine,sulfamezathine,sulfamidine,sulfodimesin,sulfodimezine,sulmet,sulphadimidine,sulphamethasine,sulphamethazine,sulphamezathine,sulphamidine,sulphodimezine,superseptil,superseptyl,vertolan,vesadin" 4 "g" "NA" "SLT2" "Sulfadimidine/trimethoprim" "Trimethoprims" "J01EE05,QJ01EW03" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA" -"SLF" 5344 "Sulfafurazole" "Trimethoprims" "J01EB05,QJ01EQ05,QS01AB02,S01AB02" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfsz" "accuzole,alphazole,amidoxal,astrazolo,azosulfizin,bactesulf,barazae,chemouag,cosoxazole,dorsulfan,entusil,entusul,ganda,gantrisin,gantrisine,gantrisona,gantrizin,gantrosan,isoxamin,neazolin,neoxazol,novazolo,novosaxazole,nsulphanilamide,pancid,pediazole,renosulfan,resoxol,roxosul,roxoxol,saxosozine,sodizole,solfafurazolo,sosol,soxamide,soxisol,soxitabs,soxomide,stansin,sulbio,sulfafurazol,sulfafurazolum,sulfagan,sulfagen,sulfaisoxazole,sulfalar,sulfapolar,sulfasol,sulfasoxazole,sulfasoxizole,sulfazin,sulfisin,sulfisonazole,sulfisoxasole,sulfisoxazol,sulfisoxazolum,sulfizin,sulfizol,sulfizole,sulfofurazole,sulfoxol,suloxsol,sulphafuraz,sulphafurazol,sulphafurazole,sulphafurazolum,sulphaisoxazole,sulphisoxazol,sulphisoxazole,sulphofurazole,sulsoxin,thiasin,unisulf,urisoxin,uritrisin,urogan" 4 "g" 4 "g" "NA" -"SLF1" 5343 "Sulfaisodimidine" "Trimethoprims" "J01EB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "aristamid,aristamide,aristogyn,domain,domian,elcosin,elcosine,elkosil,elkosin,elkosine,erycon,isosulf,mefenal,solfisomidina,sulfadimetine,sulfaisodimerazine,sulfaisodimidinum,sulfaisomidine,sulfasomidine,sulfisomidin,sulfisomidina,sulfisomidine,sulfisomidinum,sulphasomidine" 4 "g" 4 "g" "NA" -"SLF2" 9047 "Sulfalene" "Trimethoprims" "J01ED02,QJ01EQ19" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "dalysep,farmitalia,kelfizin,kelfizina,kelfizine,policydal,solfametopirazina,sulfalen,sulfaleno,sulfalenum,sulfamethopyrazine,sulfamethoxypyrazine,sulfametopyrazine,sulfametoxypyridazin,sulphalene,sulphametopyrazine,vetkelfizina" 0.1 "g" "NA" -"SZO" 187764 "Sulfamazone" "Trimethoprims" "J01ED09" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "sulfamazona,sulfamazonum,sulfenazone" 1.5 "g" "NA" -"SLF3" 5325 "Sulfamerazine" "Trimethoprims" "D06BA06,J01ED07,QD06BA06,QJ01EQ17" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "sulmet" "cremomerazine,kelamerazine,mebacid,mesulfa,methylpyrimal,methylsulfazin,methylsulfazine,metilsulfadiazin,metilsulfazin,percoccide,pyralcid,romezin,septacil,septosyl,solfamerazina,solumedin,solumedine,sulfameradine,sulfamerazin,sulfamerazina,sulfamerazinum,sulfamethyldiazine,sulphamerazine,sumedine" 3 "g" "NA" +"SLF" 5344 "Sulfafurazole" "Trimethoprims,Sulfonamides" "J01EB05,QJ01EQ05,QS01AB02,S01AB02" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfsz" "accuzole,alphazole,amidoxal,astrazolo,azosulfizin,bactesulf,barazae,chemouag,cosoxazole,dorsulfan,entusil,entusul,ganda,gantrisin,gantrisine,gantrisona,gantrizin,gantrosan,isoxamin,neazolin,neoxazol,novazolo,novosaxazole,nsulphanilamide,pancid,pediazole,renosulfan,resoxol,roxosul,roxoxol,saxosozine,sodizole,solfafurazolo,sosol,soxamide,soxisol,soxitabs,soxomide,stansin,sulbio,sulfafurazol,sulfafurazolum,sulfagan,sulfagen,sulfaisoxazole,sulfalar,sulfapolar,sulfasol,sulfasoxazole,sulfasoxizole,sulfazin,sulfisin,sulfisonazole,sulfisoxasole,sulfisoxazol,sulfisoxazolum,sulfizin,sulfizol,sulfizole,sulfofurazole,sulfoxol,suloxsol,sulphafuraz,sulphafurazol,sulphafurazole,sulphafurazolum,sulphaisoxazole,sulphisoxazol,sulphisoxazole,sulphofurazole,sulsoxin,thiasin,unisulf,urisoxin,uritrisin,urogan" 4 "g" 4 "g" "NA" +"SLF1" 5343 "Sulfaisodimidine" "Trimethoprims,Sulfonamides" "J01EB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "aristamid,aristamide,aristogyn,domain,domian,elcosin,elcosine,elkosil,elkosin,elkosine,erycon,isosulf,mefenal,solfisomidina,sulfadimetine,sulfaisodimerazine,sulfaisodimidinum,sulfaisomidine,sulfasomidine,sulfisomidin,sulfisomidina,sulfisomidine,sulfisomidinum,sulphasomidine" 4 "g" 4 "g" "NA" +"SLF2" 9047 "Sulfalene" "Trimethoprims,Sulfonamides" "J01ED02,QJ01EQ19" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "dalysep,farmitalia,kelfizin,kelfizina,kelfizine,policydal,solfametopirazina,sulfalen,sulfaleno,sulfalenum,sulfamethopyrazine,sulfamethoxypyrazine,sulfametopyrazine,sulfametoxypyridazin,sulphalene,sulphametopyrazine,vetkelfizina" 0.1 "g" "NA" +"SZO" 187764 "Sulfamazone" "Trimethoprims,Sulfonamides" "J01ED09" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "sulfamazona,sulfamazonum,sulfenazone" 1.5 "g" "NA" +"SLF3" 5325 "Sulfamerazine" "Trimethoprims,Sulfonamides" "D06BA06,J01ED07,QD06BA06,QJ01EQ17" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "sulmet" "cremomerazine,kelamerazine,mebacid,mesulfa,methylpyrimal,methylsulfazin,methylsulfazine,metilsulfadiazin,metilsulfazin,percoccide,pyralcid,romezin,septacil,septosyl,solfamerazina,solumedin,solumedine,sulfameradine,sulfamerazin,sulfamerazina,sulfamerazinum,sulfamethyldiazine,sulphamerazine,sumedine" 3 "g" "NA" "SLT3" "Sulfamerazine/trimethoprim" "Trimethoprims" "J01EE07,QJ01EW18" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA" -"SUM" 5327 "Sulfamethazine" "Other antibacterials" "NA" "NA" "NA" "87592-2" -"SLF4" 5328 "Sulfamethizole" "Trimethoprims" "B05CA04,D06BA04,J01EB02,QB05CA04,QD06BA04,QJ01EQ02,QS01AB01,S01AB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfmz" "aethazolum,ayerlucil,berlophen,gliprotiazol,globucid,globucin,globuzid,glyprothiazol,glyprothiazole,glyprothiazolum,glyprothizolum,lucosil,microsul,proklar,renasul,rufol,salimol,sethadil,solfametizolo,solfetidolo,sulfaethidiole,sulfaethidol,sulfaethidole,sulfaethidolum,sulfaetidol,sulfamethizol,sulfamethizolum,sulfametizol,sulfapyelon,sulfstat,sulfurine,sulphaethidole,sulphamethizole,tardipyrine,tetracid,thidicur,thiosulfil,ultrasul,urocydal,urodiaton,urolucosil,urosulfin" 4 "g" "60175-7,60176-5,60177-3" -"SMX" 5329 "Sulfamethoxazole" "Trimethoprims" "J01EC01,QJ01EQ11" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "sfmx,sulf,sulfam" "septran,septrin,simsinomin,sinomin,solfametossazolo,sulfamethalazole,sulfamethoxazolum,sulfamethoxizole,sulfamethylisoxazole,sulfametoxazol,sulfiodizole,sulfisomezole,sulphisomezole,urobak" 2 "g" "10342-4,11577-4,18985-2,25271-8,39772-9,467-1,468-9,469-7,470-5,59971-2,59972-0,60333-2,72674-5,80549-9,80974-9" -"SLF5" 5330 "Sulfamethoxypyridazine" "Trimethoprims" "J01ED05,QJ01EQ15" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "altezol,cysul,davosin,depovernil,durox,kineks,kinex,kynex,lederkyn,lentac,lisulfen,longin,medicel,midicel,midikel,myasul,opinsul,paramid,petrisul,piridolo,quinoseptyl,retamid,retasulfin,retasulphine,slosul,spofadazine,succinylsulfathi,sulfalex,sulfapiridazin,sulfapyridazine,sulfdurazin,sulfozona,sultirene,vinces" 0.5 "g" "NA" -"SLF6" 19596 "Sulfametomidine" "Trimethoprims" "J01ED03" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "duroprocin,methofadin,methofazine,solfametomidina,sulfametomidin,sulfametomidina,sulfametomidinum,telemid" "NA" -"SLF7" 5326 "Sulfametoxydiazine" "Trimethoprims" "J01ED04" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "bayrena,berlicid,dairena,durenat,juvoxin,kinecid,kirocid,kiron,longasulf,methoxypyrimal,solfametossidiazina,sulfameter,sulfametersalt,sulfamethorine,sulfamethoxine,sulfamethoxydiazin,sulfamethoxydiazine,sulfamethoxydin,sulfamethoxydine,sulfametin,sulfametinum,sulfametorine,sulfametorinum,sulfametoxidiazina,sulfametoxidine,sulfametoxydiazinum,sulla,sulphameter,sulphamethoxydiazine,supramid,ultrax" 0.5 "g" "NA" +"SUM" 5327 "Sulfamethazine" "Other" "NA" "NA" "NA" "87592-2" +"SLF4" 5328 "Sulfamethizole" "Trimethoprims,Sulfonamides" "B05CA04,D06BA04,J01EB02,QB05CA04,QD06BA04,QJ01EQ02,QS01AB01,S01AB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfmz" "aethazolum,ayerlucil,berlophen,gliprotiazol,globucid,globucin,globuzid,glyprothiazol,glyprothiazole,glyprothiazolum,glyprothizolum,lucosil,microsul,proklar,renasul,rufol,salimol,sethadil,solfametizolo,solfetidolo,sulfaethidiole,sulfaethidol,sulfaethidole,sulfaethidolum,sulfaetidol,sulfamethizol,sulfamethizolum,sulfametizol,sulfapyelon,sulfstat,sulfurine,sulphaethidole,sulphamethizole,tardipyrine,tetracid,thidicur,thiosulfil,ultrasul,urocydal,urodiaton,urolucosil,urosulfin" 4 "g" "60175-7,60176-5,60177-3" +"SMX" 5329 "Sulfamethoxazole" "Trimethoprims,Sulfonamides" "J01EC01,QJ01EQ11" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "sfmx,sulf,sulfam" "septran,septrin,simsinomin,sinomin,solfametossazolo,sulfamethalazole,sulfamethoxazolum,sulfamethoxizole,sulfamethylisoxazole,sulfametoxazol,sulfiodizole,sulfisomezole,sulphisomezole,urobak" 2 "g" "10342-4,11577-4,18985-2,25271-8,39772-9,467-1,468-9,469-7,470-5,59971-2,59972-0,60333-2,72674-5,80549-9,80974-9" +"SLF5" 5330 "Sulfamethoxypyridazine" "Trimethoprims,Sulfonamides" "J01ED05,QJ01EQ15" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "altezol,cysul,davosin,depovernil,durox,kineks,kinex,kynex,lederkyn,lentac,lisulfen,longin,medicel,midicel,midikel,myasul,opinsul,paramid,petrisul,piridolo,quinoseptyl,retamid,retasulfin,retasulphine,slosul,spofadazine,succinylsulfathi,sulfalex,sulfapiridazin,sulfapyridazine,sulfdurazin,sulfozona,sultirene,vinces" 0.5 "g" "NA" +"SLF6" 19596 "Sulfametomidine" "Trimethoprims,Sulfonamides" "J01ED03" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "duroprocin,methofadin,methofazine,solfametomidina,sulfametomidin,sulfametomidina,sulfametomidinum,telemid" "NA" +"SLF7" 5326 "Sulfametoxydiazine" "Trimethoprims,Sulfonamides" "J01ED04" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "bayrena,berlicid,dairena,durenat,juvoxin,kinecid,kirocid,kiron,longasulf,methoxypyrimal,solfametossidiazina,sulfameter,sulfametersalt,sulfamethorine,sulfamethoxine,sulfamethoxydiazin,sulfamethoxydiazine,sulfamethoxydin,sulfamethoxydine,sulfametin,sulfametinum,sulfametorine,sulfametorinum,sulfametoxidiazina,sulfametoxidine,sulfametoxydiazinum,sulla,sulphameter,sulphamethoxydiazine,supramid,ultrax" 0.5 "g" "NA" "SLT4" "Sulfametrole/trimethoprim" "Trimethoprims" "J01EE03" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "trsm" "NA" "NA" -"SLF8" 12894 "Sulfamoxole" "Trimethoprims" "J01EC03" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "NA" "enterocura,justamil,oxasulfa,solfaguanolo,solfamossolo,sulfadimethyloxazole,sulfaguanol,sulfaguanole,sulfaguanolum,sulfamoxol,sulfamoxolum,sulfano,sulfavigor,sulfmidil,sulfono,sulfune,sulfuno,sulphamoxole,tardamid,tardamide" 1 "g" 1 "g" "NA" +"SLF8" 12894 "Sulfamoxole" "Trimethoprims,Sulfonamides" "J01EC03" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "NA" "enterocura,justamil,oxasulfa,solfaguanolo,solfamossolo,sulfadimethyloxazole,sulfaguanol,sulfaguanole,sulfaguanolum,sulfamoxol,sulfamoxolum,sulfano,sulfavigor,sulfmidil,sulfono,sulfune,sulfuno,sulphamoxole,tardamid,tardamide" 1 "g" 1 "g" "NA" "SLT5" "Sulfamoxole/trimethoprim" "Trimethoprims" "J01EE04" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA" -"SLF9" 5333 "Sulfanilamide" "Trimethoprims" "D06BA05,J01EB06,QD06BA05,QJ01EQ06" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "albexan,albosal,ambeside,antistrept,astreptine,astrocid,bacteramid,bactesid,collomide,colsulanyde,copticide,deseptyl,dipron,ergaseptine,erysipan,estreptocida,exoseptoplix,fourneau,gerison,gombardol,hydroxysulfonamide,infepan,lusil,lysococcine,neococcyl,orgaseptine,prontalbin,prontylin,proseptal,proseptine,proseptol,pysococcine,sanamid,septanilam,septinal,septolix,septoplex,septoplix,solfanilamide,stramid,strepamide,strepsan,streptagol,streptamid,streptamin,streptasol,streptocid,streptocide,streptocidum,streptoclase,streptocom,strepton,streptopan,streptosil,streptozol,streptozone,streptrocide,sulfamidyl,sulfamine,sulfana,sulfanalone,sulfanidyl,sulfanil,sulfanilamida,sulfanilamidomethan,sulfanilamidum,sulfanimide,sulfocidin,sulfocidine,sulfonylamide,sulphanilamide,sulphanilamidum,sulphonamide,therapol,tolder" "NA" -"SLF10" 68933 "Sulfaperin" "Trimethoprims" "J01ED06" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "anastaf,archisulfa,archisulpha,avissul,chemiopen,demosulfan,demosulphan,durisan,isosulfamerazine,isosulphamerazine,methylsulfadiazin,methylsulfadiazine,methylsulphadiazine,novosul,orosulfan,pallidin,retardon,risulfasens,sulfaperina,sulfaperine,sulfaperinum,sulfatreis,sulfopirimidine,sulpenta,sulphaperin,sulphaperina,sulphaperinum" 0.5 "g" "NA" -"SLF11" 5335 "Sulfaphenazole" "Trimethoprims" "J01ED08,QJ01EQ08" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "depocid,depotsulfonamide,eftolon,firmazolo,inamil,isarol,merian,orisul,orisulf,paidazolo,phenylsulfapyrazole,plisulfan,raziosulfa,solfafenazolo,sulfabid,sulfafenazol,sulfafenazolo,sulfaphenazol,sulfaphenazolum,sulfaphenazon,sulfaphenylpipazol,sulfaphenylpyrazol,sulfaphenylpyrazole,sulfonylpyrazol,sulphaphenazole,sulphenazole" 1 "g" "NA" -"SLF12" 5336 "Sulfapyridine" "Trimethoprims" "J01EB04,QJ01EQ04" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "adiplon,coccoclase,dagenan,eubasin,eubasinum,haptocil,piridazol,plurazol,pyriamid,pyridazol,relbapiridina,ronin,septipulmon,solfapiridina,soludagenan,streptosilpyridine,sulfapiridina,sulfapyridin,sulfapyridinum,sulfidin,sulfidine,sulphapyridin,sulphapyridine,thioseptal,trianon" 1 "g" "14075-6,55580-5" -"SNA" 60582 "Sulfasuccinamide" "Other antibacterials" "NA" "NA" "sulfasuccinamid,sulfasuccinamida,sulfasuccinamidum" "NA" -"SUT" 5340 "Sulfathiazole" "Trimethoprims" "D06BA02,J01EB07,QD06BA02,QJ01EQ07" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sulthi" "azoquimiol,azoseptale,cerazol,cerazole,chemosept,cibazol,duatok,dulana,eleudron,enterobiocine,estafilol,formosulfathiazole,neostrepsan,norsulfasol,norsulfazol,norsulfazole,norsulfazolum,planomide,poliseptil,sanotiazol,septozol,solfatiazolo,soluthiazomide,streptosilthiazole,sulfamul,sulfaplex,sulfathiazol,sulfathiazolesalt,sulfathiazolum,sulfatiazol,sulfavitina,sulfocerol,sulphathiazole,sulzol,thiacoccine,thiasulfol,thiazamide,thiozamide,wintrazole" "87591-4,87796-9,87797-7" -"SLF13" 3000579 "Sulfathiourea" "Trimethoprims" "J01EB08" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "badional,baldinol,fontamide,salvoseptyl,solfatiourea,solufontamide,sulfanilthiourea,sulfathiocarbamid,sulfathiocarbamide,sulfathiocarbamidum,sulfathioureasalt,sulfathiouree,sulfatiourea,sulphathiourea" 6 "g" "NA" -"SOX" 5344 "Sulfisoxazole" "Other antibacterials" "NA" "sulfiz" "NA" "11578-2,18986-0,25226-2,471-3,472-1,473-9,474-7,9701-4" -"SSS" 86225 "Sulfonamide" "Other antibacterials" "NA" "sfna,sulami" "NA" "17674-3,17675-0,18987-8,35842-4,4040-2,4041-0,4042-8,475-4,476-2,477-0,478-8,75650-2" -"SLP" 9950244 "Sulopenem" "Other antibacterials" "NA" "sulope" "orlynvah" "55289-3,55290-1,55291-9" -"SLT6" 444022 "Sultamicillin" "Beta-lactams/penicillins" "J01CR04,QJ01CR04" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "sultos" "combisid,sultamicilina,sultamicilline,sultamicillinum,unacid" 1.5 "g" "NA" -"SUR" 46700778 "Surotomycin" "Other antibacterials" "NA" "NA" "surotomicina,surotomycine" "NA" -"TAL" 71447 "Talampicillin" "Beta-lactams/penicillins" "J01CA15,QJ01CA15" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "aseocillin,phthalidyl,talampicilina,talampicilline,talampicillinum,talpen,yamacillin" 2 "g" "18988-6,479-6,480-4,481-2,482-0" -"TLP" 163307 "Talmetoprim" "Other antibacterials" "NA" "NA" "NA" "NA" -"TAN" 76902493 "Taniborbactam" "Carbapenems" "NA" "vnrx-5133" "NA" "NA" -"TAZ" 123630 "Tazobactam" "Beta-lactams/penicillins" "J01CG02,QJ01CG02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "tazo,tazoba" "exblifep,tazobactamsalt,tazobactamum,tazobactum" "41719-6,41720-4,41721-2,41740-2" -"TBP" 9800194 "Tebipenem" "Carbapenems" "NA" "NA" "NA" "NA" +"SLF9" 5333 "Sulfanilamide" "Trimethoprims,Sulfonamides" "D06BA05,J01EB06,QD06BA05,QJ01EQ06" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "albexan,albosal,ambeside,antistrept,astreptine,astrocid,bacteramid,bactesid,collomide,colsulanyde,copticide,deseptyl,dipron,ergaseptine,erysipan,estreptocida,exoseptoplix,fourneau,gerison,gombardol,hydroxysulfonamide,infepan,lusil,lysococcine,neococcyl,orgaseptine,prontalbin,prontylin,proseptal,proseptine,proseptol,pysococcine,sanamid,septanilam,septinal,septolix,septoplex,septoplix,solfanilamide,stramid,strepamide,strepsan,streptagol,streptamid,streptamin,streptasol,streptocid,streptocide,streptocidum,streptoclase,streptocom,strepton,streptopan,streptosil,streptozol,streptozone,streptrocide,sulfamidyl,sulfamine,sulfana,sulfanalone,sulfanidyl,sulfanil,sulfanilamida,sulfanilamidomethan,sulfanilamidum,sulfanimide,sulfocidin,sulfocidine,sulfonylamide,sulphanilamide,sulphanilamidum,sulphonamide,therapol,tolder" "NA" +"SLF10" 68933 "Sulfaperin" "Trimethoprims,Sulfonamides" "J01ED06" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "anastaf,archisulfa,archisulpha,avissul,chemiopen,demosulfan,demosulphan,durisan,isosulfamerazine,isosulphamerazine,methylsulfadiazin,methylsulfadiazine,methylsulphadiazine,novosul,orosulfan,pallidin,retardon,risulfasens,sulfaperina,sulfaperine,sulfaperinum,sulfatreis,sulfopirimidine,sulpenta,sulphaperin,sulphaperina,sulphaperinum" 0.5 "g" "NA" +"SLF11" 5335 "Sulfaphenazole" "Trimethoprims,Sulfonamides" "J01ED08,QJ01EQ08" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "depocid,depotsulfonamide,eftolon,firmazolo,inamil,isarol,merian,orisul,orisulf,paidazolo,phenylsulfapyrazole,plisulfan,raziosulfa,solfafenazolo,sulfabid,sulfafenazol,sulfafenazolo,sulfaphenazol,sulfaphenazolum,sulfaphenazon,sulfaphenylpipazol,sulfaphenylpyrazol,sulfaphenylpyrazole,sulfonylpyrazol,sulphaphenazole,sulphenazole" 1 "g" "NA" +"SLF12" 5336 "Sulfapyridine" "Trimethoprims,Sulfonamides" "J01EB04,QJ01EQ04" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "adiplon,coccoclase,dagenan,eubasin,eubasinum,haptocil,piridazol,plurazol,pyriamid,pyridazol,relbapiridina,ronin,septipulmon,solfapiridina,soludagenan,streptosilpyridine,sulfapiridina,sulfapyridin,sulfapyridinum,sulfidin,sulfidine,sulphapyridin,sulphapyridine,thioseptal,trianon" 1 "g" "14075-6,55580-5" +"SNA" 60582 "Sulfasuccinamide" "Other" "NA" "NA" "sulfasuccinamid,sulfasuccinamida,sulfasuccinamidum" "NA" +"SUT" 5340 "Sulfathiazole" "Trimethoprims,Sulfonamides" "D06BA02,J01EB07,QD06BA02,QJ01EQ07" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sulthi" "azoquimiol,azoseptale,cerazol,cerazole,chemosept,cibazol,duatok,dulana,eleudron,enterobiocine,estafilol,formosulfathiazole,neostrepsan,norsulfasol,norsulfazol,norsulfazole,norsulfazolum,planomide,poliseptil,sanotiazol,septozol,solfatiazolo,soluthiazomide,streptosilthiazole,sulfamul,sulfaplex,sulfathiazol,sulfathiazolesalt,sulfathiazolum,sulfatiazol,sulfavitina,sulfocerol,sulphathiazole,sulzol,thiacoccine,thiasulfol,thiazamide,thiozamide,wintrazole" "87591-4,87796-9,87797-7" +"SLF13" 3000579 "Sulfathiourea" "Trimethoprims,Sulfonamides" "J01EB08" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "badional,baldinol,fontamide,salvoseptyl,solfatiourea,solufontamide,sulfanilthiourea,sulfathiocarbamid,sulfathiocarbamide,sulfathiocarbamidum,sulfathioureasalt,sulfathiouree,sulfatiourea,sulphathiourea" 6 "g" "NA" +"SOX" 5344 "Sulfisoxazole" "Other" "NA" "sulfiz" "NA" "11578-2,18986-0,25226-2,471-3,472-1,473-9,474-7,9701-4" +"SSS" 86225 "Sulfonamide" "Other" "NA" "sfna,sulami" "NA" "17674-3,17675-0,18987-8,35842-4,4040-2,4041-0,4042-8,475-4,476-2,477-0,478-8,75650-2" +"SLP" 9950244 "Sulopenem" "Other" "NA" "sulope" "orlynvah" "55289-3,55290-1,55291-9" +"SLT6" 444022 "Sultamicillin" "Penicillins,Beta-lactams,Beta-lactamase inhibitors" "J01CR04,QJ01CR04" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "sultos" "combisid,sultamicilina,sultamicilline,sultamicillinum,unacid" 1.5 "g" "NA" +"SUR" 46700778 "Surotomycin" "Other" "NA" "NA" "surotomicina,surotomycine" "NA" +"TAL" 71447 "Talampicillin" "Penicillins,Beta-lactams" "J01CA15,QJ01CA15" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "aseocillin,phthalidyl,talampicilina,talampicilline,talampicillinum,talpen,yamacillin" 2 "g" "18988-6,479-6,480-4,481-2,482-0" +"TLP" 163307 "Talmetoprim" "Other" "NA" "NA" "NA" "NA" +"TAN" 76902493 "Taniborbactam" "Carbapenems,Beta-lactams,Beta-lactamase inhibitors" "NA" "vnrx-5133" "NA" "NA" +"TAZ" 123630 "Tazobactam" "Beta-lactamase inhibitors" "J01CG02,QJ01CG02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "tazo,tazoba" "exblifep,tazobactamsalt,tazobactamum,tazobactum" "41719-6,41720-4,41721-2,41740-2" +"TBP" 9800194 "Tebipenem" "Carbapenems,Beta-lactams" "NA" "NA" "NA" "NA" "TZD" 11234049 "Tedizolid" "Oxazolidinones" "J01XX11,QJ01XX11" "Other antibacterials" "Other antibacterials" "tedi" "torezolid" 0.2 "g" 0.2 "g" "73586-0,73608-2,73631-4" "TEC" 16131923 "Teicoplanin" "Glycopeptides" "J01XA02,QJ01XA02" "Other antibacterials" "Glycopeptide antibacterials" "tec,tei,teic,teicop,tp,tpl,tpn" "NA" 0.4 "g" "18989-4,25534-9,25535-6,34378-0,34379-8,4043-6,483-8,484-6,485-3,486-1,7051-6,80968-1" "TCM" "Teicoplanin-macromethod" "Glycopeptides" "NA" "NA" "NA" "NA" -"TLV" 3081362 "Telavancin" "Glycopeptides" "J01XA03,QJ01XA03" "Other antibacterials" "Glycopeptide antibacterials" "tela,telava" "arbelic,nvancomycin,televancin" "72894-9,73630-6,85051-1,88886-7" -"TLT" 3002190 "Telithromycin" "Macrolides/lincosamides" "J01FA15,QJ01FA15" "Macrolides, lincosamides and streptogramins" "Macrolides" "teli,telith" "ketek,levviax" 0.8 "g" "35843-2,35844-0,35845-7,41722-0" -"TMX" 60021 "Temafloxacin" "Fluoroquinolones" "J01MA05,QJ01MA05" "Quinolone antibacterials" "Fluoroquinolones" "tema,temafl" "omniflox,temafloxacina,temafloxacine,temafloxacino,temafloxacinum" 0.8 "g" "18990-2,487-9,488-7,489-5,490-3" -"TEM" 171758 "Temocillin" "Beta-lactams/penicillins" "J01CA17,QJ01CA17" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "temo,temoci" "negaban,temocilina,temocillina,temocilline,temocillinum" 4 "g" "18991-0,491-1,492-9,493-7,494-5,54190-4" -"TRB" 1549008 "Terbinafine" "Antifungals/antimycotics" "D01AE15,D01BA02,QD01AE15,QD01BA02" "Antifungals for systemic use" "Antifungals for systemic use" "terb" "afogan,bramazil,bramizil,corbinal,lamasil,lamisil,muzonal,shoprite,terbina,terbinafina,terbinafinum,terbine,terbinex,terbisil,zabel" 0.25 "g" "10720-1,10721-9,18992-8" -"TRC" 441383 "Terconazole" "Antifungals/antimycotics" "G01AG02,QG01AG02" "NA" "fungistat,panlomyc,terazol,terconazol,terconazolum,tercospor,tetrazol,triaconazole,zazole" "55196-0" +"TLV" 3081362 "Telavancin" "Lipoglycopeptides,Glycopeptides" "J01XA03,QJ01XA03" "Other antibacterials" "Glycopeptide antibacterials" "tela,telava" "arbelic,nvancomycin,televancin" "72894-9,73630-6,85051-1,88886-7" +"TLT" 3002190 "Telithromycin" "Macrolides" "J01FA15,QJ01FA15" "Macrolides, lincosamides and streptogramins" "Macrolides" "teli,telith" "ketek,levviax" 0.8 "g" "35843-2,35844-0,35845-7,41722-0" +"TMX" 60021 "Temafloxacin" "Fluoroquinolones,Quinolones" "J01MA05,QJ01MA05" "Quinolone antibacterials" "Fluoroquinolones" "tema,temafl" "omniflox,temafloxacina,temafloxacine,temafloxacino,temafloxacinum" 0.8 "g" "18990-2,487-9,488-7,489-5,490-3" +"TEM" 171758 "Temocillin" "Penicillins,Beta-lactams" "J01CA17,QJ01CA17" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "temo,temoci" "negaban,temocilina,temocillina,temocilline,temocillinum" 4 "g" "18991-0,491-1,492-9,493-7,494-5,54190-4" +"TRB" 1549008 "Terbinafine" "Antifungals" "D01AE15,D01BA02,QD01AE15,QD01BA02" "Antifungals for systemic use" "Antifungals for systemic use" "terb" "afogan,bramazil,bramizil,corbinal,lamasil,lamisil,muzonal,shoprite,terbina,terbinafina,terbinafinum,terbine,terbinex,terbisil,zabel" 0.25 "g" "10720-1,10721-9,18992-8" +"TRC" 441383 "Terconazole" "Antifungals" "G01AG02,QG01AG02" "NA" "fungistat,panlomyc,terazol,terconazol,terconazolum,tercospor,tetrazol,triaconazole,zazole" "55196-0" "TRZ" 65720 "Terizidone" "Antimycobacterials" "J04AK03,QJ04AK03" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "terivalidin,terizidona,terizidonum" "NA" "TCY" 54675776 "Tetracycline" "Tetracyclines" "A01AB13,D06AA04,J01AA07,QA01AB13,QD06AA04,QG01AA90,QG51AA02,QJ01AA07,QJ51AA07,QS01AA09,QS02AA08,QS03AA02,S01AA09,S02AA08,S03AA02" "Tetracyclines" "Tetracyclines" "tc,te,tet,tetcyc,tetr,tetra" "abramycin,abricycline,agromicina,ambramicina,ambramycin,biocycline,brodspec,cefracycline,centet,ciclibion,copharlan,criseociclina,democracin,deschlorobiomycin,economycin,hostacyclin,lexacycline,limecycline,liquamycin,mericycline,micycline,neocycline,omegamycin,orlycycline,panmycin,purocyclina,roviciclina,solvocin,tetrabon,tetraciclina,tetracyclinehydrate,tetracyclinum,tetracyn,tetradecin,tetrafil,tetraverine,tetrazyklin,tsiklomistsin,tsiklomitsin,veracin,vetacyclinum" 1 "g" 1 "g" "101504-9,18993-6,25272-6,4045-1,495-2,496-0,497-8,498-6,7052-4,87590-6" "TCY-S" "Tetracycline screening test" "Tetracyclines" "NA" "tcy screen" "NA" "NA" -"TOL" 54691494 "Tetracycline/oleandomycin" "Other antibacterials" "J01RA08,QJ01RA08" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"TET" 65450 "Tetroxoprim" "Other antibacterials" "NA" "NA" "primsol,tetroxoprima,tetroxoprime,tetroxoprimum,trimpex,trimplex" "NA" +"TOL" 54691494 "Tetracycline/oleandomycin" "Other" "J01RA08,QJ01RA08" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" +"TET" 65450 "Tetroxoprim" "Other" "NA" "NA" "primsol,tetroxoprima,tetroxoprime,tetroxoprimum,trimpex,trimplex" "NA" "THA" 9568512 "Thiacetazone" "Oxazolidinones" "NA" "NA" "acetanilide,aktivan,ambathizon,amitiozon,antib,benthiozone,benzothiozane,benzothiozon,berkazon,citazone,conteben,diasan,domakol,ilbion,livazone,mivizon,myvizone,neotibil,neustab,novakol,panrone,parazone,seroden,siocarbazone,tebalon,tebecure,tebemar,tebethion,tebethione,tebezon,thiacetone,thiacetozone,thibon,thibone,thioacetazon,thioacetazonum,thioazetazone,thiocarbazil,thiomicid,thionicid,thioparamizon,thioparamizone,thiosemicarbarzone,thiosemicarbazone,thiotebesin,thiotebezin,thiotebicina,thizone,tiacetazon,tibicur,tibion,tibione,tibizan,tibon,tibone,tioacetazon,tioacetazona,tioatsetazon,tiobicina,tiocarone,tiosecolo,tubercazon,tubigal,tubin" "32384-0,54184-7,54204-3" "THI" 27200 "Thiamphenicol" "Phenicols" "J01BA02,QJ01BA02,QJ51BA02" "Amphenicols" "Amphenicols" "thiaph" "armai,dextrosulfenidol,dextrosulphenidol,igralin,racefenicol,racefenicolo,racefenicolum,raceophenidol,thiamphenicolum,thiocymetin,thiophenicol,tiamfenicol,tiamfenicolo,urfamycine" 1.5 "g" 1.5 "g" "41723-8,41724-6,41725-3,54169-8" "TAT" 9568512 "Thioacetazone" "Antimycobacterials" "J04AK07,QJ04AK07" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "NA" "NA" "THI1" "Thioacetazone/isoniazid" "Antimycobacterials" "J04AM04,QJ04AM04" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"TIA" 656958 "Tiamulin" "Other antibacterials" "QJ01XQ01" "tiamul" "denagard,thiamutilin,tiamulina,tiamuline,tiamulinum" "35846-5,35847-3,35848-1,87589-8" -"TIC" 36921 "Ticarcillin" "Beta-lactams/penicillins" "J01CA13,QJ01CA13" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "tc,ti,tic,tica,ticarc" "ticar,ticarcilina,ticarcilline,ticarcillinum,timentin" 15 "g" "18994-4,18995-1,25254-4,4054-3,4055-0,499-4,500-9,501-7,502-5,503-3,504-1,505-8,506-6,55716-5,55717-3,55718-1,55719-9,7053-2,7054-0" -"TCC" 6437075 "Ticarcillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR03,QJ01CR03" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "t/c,tcc,ticcla,ticl,tim,tlc" "augpenin" 15 "g" "NA" +"TIA" 656958 "Tiamulin" "Other" "QJ01XQ01" "tiamul" "denagard,thiamutilin,tiamulina,tiamuline,tiamulinum" "35846-5,35847-3,35848-1,87589-8" +"TIC" 36921 "Ticarcillin" "Penicillins,Beta-lactams" "J01CA13,QJ01CA13" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "tc,ti,tic,tica,ticarc" "ticar,ticarcilina,ticarcilline,ticarcillinum,timentin" 15 "g" "18994-4,18995-1,25254-4,4054-3,4055-0,499-4,500-9,501-7,502-5,503-3,504-1,505-8,506-6,55716-5,55717-3,55718-1,55719-9,7053-2,7054-0" +"TCC" 6437075 "Ticarcillin/clavulanic acid" "Penicillins,Beta-lactams,Beta-lactamase inhibitors" "J01CR03,QJ01CR03" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "t/c,tcc,ticcla,ticl,tim,tlc" "augpenin" 15 "g" "NA" "TGC" 54686904 "Tigecycline" "Tetracyclines" "J01AA12,QJ01AA12" "Tetracyclines" "Tetracyclines" "tgc,tig,tige,tigecy" "tigeciclina,tigecyclin,tigecyclinehydrate,tigilcycline,tygacil" 0.1 "g" "101499-2,42354-1,42355-8,42356-6,42357-4,55158-0" -"TMN" "Tigemonam" "Monobactams" "NA" "NA" "NA" "NA" -"TBQ" 65592 "Tilbroquinol" "Fluoroquinolones" "P01AA05" "NA" "tilbroquinolum" "NA" -"TIP" 24860548 "Tildipirosin" "Macrolides/lincosamides" "QJ01FA96" "NA" "zuprevo" "100060-3,88375-1,88377-7" -"TIL" 5282521 "Tilmicosin" "Macrolides/lincosamides" "QJ01FA91" "tilmic" "micotil,pulmotil,tilmicosina,tilmicosine,tilmicosinum,tilmovet" "35849-9,35850-7,35851-5,87588-0" -"TIN" 5479 "Tinidazole" "Other antibacterials" "G01AF21,J01XD02,P01AB02,QG01AF21,QJ01XD02,QP51AA02" "Other antibacterials" "Imidazole derivatives" "tini" "amtiba,bioshik,fasigin,fasigyn,glongyn,haisigyn,isotinidazole,pletil,protozol,simplotan,sorquetan,symplotan,tindamax,tindazole,tinidazolum,tricolam,trimonase" 2 "g" 1.5 "g" "54928-7,55720-7,55721-5,55722-3" +"TMN" "Tigemonam" "Monobactams,Beta-lactams" "NA" "NA" "NA" "NA" +"TBQ" 65592 "Tilbroquinol" "Fluoroquinolones,Quinolones" "P01AA05" "NA" "tilbroquinolum" "NA" +"TIP" 24860548 "Tildipirosin" "Macrolides" "QJ01FA96" "NA" "zuprevo" "100060-3,88375-1,88377-7" +"TIL" 5282521 "Tilmicosin" "Macrolides" "QJ01FA91" "tilmic" "micotil,pulmotil,tilmicosina,tilmicosine,tilmicosinum,tilmovet" "35849-9,35850-7,35851-5,87588-0" +"TIN" 5479 "Tinidazole" "Other" "G01AF21,J01XD02,P01AB02,QG01AF21,QJ01XD02,QP51AA02" "Other antibacterials" "Imidazole derivatives" "tini" "amtiba,bioshik,fasigin,fasigyn,glongyn,haisigyn,isotinidazole,pletil,protozol,simplotan,sorquetan,symplotan,tindamax,tindazole,tinidazolum,tricolam,trimonase" 2 "g" 1.5 "g" "54928-7,55720-7,55721-5,55722-3" "TCR" 3001386 "Tiocarlide" "Antimycobacterials" "J04AD02,QJ04AD02" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "NA" "aethoksid,aethoxydum,amixyl,datanil,disocarban,disoxyl,ethoxide,etocarlid,etocarlida,etocarlide,etocarlidum,etoksid,thiocarlide,tiocarlid,tiocarlida,tiocarlidum" 7 "g" "NA" -"TDC" 10247721 "Tiodonium chloride" "Other antibacterials" "NA" "NA" "tiodonium" "NA" -"TXC" 65788 "Tioxacin" "Fluoroquinolones" "NA" "NA" "tioxacine,tioxacino,tioxacinum" "NA" -"TIZ" 394397 "Tizoxanide" "Other antibacterials" "NA" "NA" "NA" "73585-2,73607-4,73629-8" +"TDC" 10247721 "Tiodonium chloride" "Other" "NA" "NA" "tiodonium" "NA" +"TXC" 65788 "Tioxacin" "Fluoroquinolones,Quinolones" "NA" "NA" "tioxacine,tioxacino,tioxacinum" "NA" +"TIZ" 394397 "Tizoxanide" "Other" "NA" "NA" "NA" "73585-2,73607-4,73629-8" "TOB" 36294 "Tobramycin" "Aminoglycosides" "J01GB01,QJ01GB01,QS01AA12,S01AA12" "Aminoglycoside antibacterials" "Other aminoglycosides" "nn,tm,to,tob,tobr,tobram" "aktob,bethkis,distobram,gotabiotic,kitabis,nebcin,nebicin,nebramycin,tenebrimycin,tenemycin,tobacin,tobracin,tobradex,tobradistin,tobralex,tobramaxin,tobramicin,tobramicina,tobramitsetin,tobramycetin,tobramycine,tobramycinum,tobrased,tobrex" 0.24 "g" "101496-8,13584-8,17808-7,18996-9,22750-4,22751-2,22752-0,25227-0,25800-4,31094-6,31095-3,31096-1,35239-3,35670-9,4057-6,4058-4,4059-2,507-4,508-2,509-0,50927-3,510-8,52962-8,59380-6,7055-7,80966-5" "TOH" "Tobramycin-high" "Aminoglycosides" "NA" "tobra high,tobramycin high,tohl" "NA" "NA" -"TFX" 5517 "Tosufloxacin" "Fluoroquinolones" "J01MA22,QJ01MA22,QS01AE09,S01AE09" "tosufl" "NA" 0.45 "g" "100061-1,76146-0" +"TFX" 5517 "Tosufloxacin" "Fluoroquinolones,Quinolones" "J01MA22,QJ01MA22,QS01AE09,S01AE09" "tosufl" "NA" 0.45 "g" "100061-1,76146-0" "TMP" 5578 "Trimethoprim" "Trimethoprims" "J01EA01,QJ01EA01,QJ51EA01" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "t,tmp,tr,tri,trim,w" "abaprim,anitrim,antrima,antrimox,bacdan,bacidal,bacide,bacin,bacterial,bacticel,bactifor,bactoprim,bactramin,bencole,bethaprim,biosulten,briscotrim,chemotrin,colizole,conprim,cotrimel,deprim,dosulfin,duocide,esbesul,espectrin,euctrim,exbesul,fermagex,fortrim,futin,ikaprim,infectotrimet,instalac,kombinax,lagatrim,lastrim,lescot,monoprim,monotrim,monotrimin,novotrimel,omstat,pancidim,proloprim,protrin,purbal,resprim,roubac,roubal,salvatrim,setprin,sinotrim,stopan,streptoplus,sugaprim,sulfamar,sulfoxaprim,sulthrim,sultrex,syraprim,tiempe,trimethioprim,trimethoprime,trimethoprimum,trimethopriom,trimetoprim,trimetoprima,trimexol,trimezol,trimogal,trimono,trimopan,triprim,trisul,trisulcom,trisulfam,trisural,uretrim,urobactrim,utetrin,velaten,wellcoprim,wellcoprin,xeroprim,zamboprim" 0.4 "g" 0.4 "g" "101495-0,11005-6,17747-7,18997-7,18998-5,20387-7,23614-1,23631-5,25273-4,32342-8,4079-0,4080-8,4081-6,511-6,512-4,513-2,514-0,515-7,516-5,517-3,518-1,55584-7,7056-5,7057-3,80552-3,80973-1" "SXT" 358641 "Trimethoprim/sulfamethoxazole" "Trimethoprims" "J01EE01" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "cot,cotrim,sxt,t/s,tms,trisul,trsu,trsx,ts" "abacin,abactrim,agoprim,alfatrim,aposulfatrim,bacteral,bactilen,bactiver,bacton,bactoreduct,bactrim,bactrizol,bactromin,bactropin,baktar,benzenesulfonamide,berlocid,bibacrim,biseptol,centran,centrin,chemitrim,chemotrim,ciplin,comox,cotribene,cotrim,cotrimhexal,cotrimoxazol,cotrimoxazole,cotrimstada,cotriver,dibaprim,drylin,duratrimet,eltrianyl,escoprim,eslectin,esteprim,eusaprim,fectrim,gamazole,gantanol,gantaprim,gantaprin,gantrim,groprim,helveprim,imexim,insozalin,jenamoxazol,kemoprim,kepinol,laratrim,linaris,maxtrim,metoxal,microtrim,mikrosid,momentol,nopil,oecotrim,omsat,oriprim,oxaprim,pantoprim,potrox,primazole,radonil,septra,septrim,servitrim,sigaprim,sigaprin,sulfatrim,sulfotrim,sulfotrimin,sulmeprim,sulprim,sumetrolim,supracombin,suprim,tacumil,teleprim,teleprin,thiocuran,tribakin,trifen,trigonyl,trimedin,trimesulf,trimethoprimsulfa,trimetoger,trimexazol,trimezole,trimforte,trimosulfa,uroplus" "101495-0,18998-5,20387-7,23631-5,25273-4,32342-8,4081-6,515-7,516-5,517-3,518-1,7057-3" -"TRL" 202225 "Troleandomycin" "Macrolides/lincosamides" "J01FA08,QJ01FA08" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "aovine,cyclamycin,evramicina,matromicina,oleandocetin,oleandocetine,tekmisin,treolmicina,tribiocillina,triocetin,triolan,troleandomicina,troleandomycine,troleandomycinum,viamicina,wytrion" 1 "g" "18999-3,519-9,520-7,521-5,522-3" -"TRO" 55886 "Trospectomycin" "Other antibacterials" "NA" "trospe" "trospectinomycin,trospectomicina,trospectomycine,trospectomycinum" "NA" -"TVA" 62959 "Trovafloxacin" "Fluoroquinolones" "J01MA13,QJ01MA13" "Quinolone antibacterials" "Fluoroquinolones" "trov,trovaf" "trovan,turvel" 0.2 "g" 0.2 "g" "23642-2,23643-0,35855-6,7058-1" -"TUL" 9832301 "Tulathromycin" "Macrolides/lincosamides" "QJ01FA94" "tulath" "arovyn,draxxin,increxxa,macrosyn,tulieve,tulissin" "76149-4,87798-5" -"TYL" 5280440 "Tylosin" "Macrolides/lincosamides" "QJ01FA90,QJ51FA90" "tylo" "fradizine,tilosina,tylan,tylocine,tylosine,tylosinum,vubityl" "35856-4,35857-2,35858-0,87587-2" -"TYL1" 6441094 "Tylvalosin" "Macrolides/lincosamides" "QJ01FA92" "tvn" "aivlosin" "101526-2,87586-4" -"PRU1" 124225 "Ulifloxacin (Prulifloxacin)" "Other antibacterials" "NA" "NA" "NA" "NA" +"TRL" 202225 "Troleandomycin" "Macrolides" "J01FA08,QJ01FA08" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "aovine,cyclamycin,evramicina,matromicina,oleandocetin,oleandocetine,tekmisin,treolmicina,tribiocillina,triocetin,triolan,troleandomicina,troleandomycine,troleandomycinum,viamicina,wytrion" 1 "g" "18999-3,519-9,520-7,521-5,522-3" +"TRO" 55886 "Trospectomycin" "Other" "NA" "trospe" "trospectinomycin,trospectomicina,trospectomycine,trospectomycinum" "NA" +"TVA" 62959 "Trovafloxacin" "Fluoroquinolones,Quinolones" "J01MA13,QJ01MA13" "Quinolone antibacterials" "Fluoroquinolones" "trov,trovaf" "trovan,turvel" 0.2 "g" 0.2 "g" "23642-2,23643-0,35855-6,7058-1" +"TUL" 9832301 "Tulathromycin" "Macrolides" "QJ01FA94" "tulath" "arovyn,draxxin,increxxa,macrosyn,tulieve,tulissin" "76149-4,87798-5" +"TYL" 5280440 "Tylosin" "Macrolides" "QJ01FA90,QJ51FA90" "tylo" "fradizine,tilosina,tylan,tylocine,tylosine,tylosinum,vubityl" "35856-4,35857-2,35858-0,87587-2" +"TYL1" 6441094 "Tylvalosin" "Macrolides" "QJ01FA92" "tvn" "aivlosin" "101526-2,87586-4" +"PRU1" 124225 "Ulifloxacin (Prulifloxacin)" "Other" "NA" "NA" "NA" "NA" "VAN" 14969 "Vancomycin" "Glycopeptides" "A07AA09,J01XA01,QA07AA09,QJ01XA01,QS01AA28,S01AA28" "Other antibacterials" "Glycopeptide antibacterials" "va,van,vanc,vancom" "vancocin,vancoled,vancomicina,vancomycine,vancomycinum" 2 "g" 2 "g" "13586-3,13587-1,19000-9,20578-1,23615-8,25228-8,31012-8,39092-2,39796-8,39797-6,4089-9,4090-7,4091-5,4092-3,50938-0,523-1,524-9,525-6,526-4,59381-4,7059-9,92241-9,97657-1" "VAM" "Vancomycin-macromethod" "Glycopeptides" "NA" "NA" "NA" "NA" "VIO" 135398671 "Viomycin" "Antimycobacterials" "NA" "NA" "florimycin,floromycin,vioactane,viocin,viomicin,viomicina,viomycine,viomycinum" "19001-7,23616-6,527-2,528-0,529-8,530-6" -"VIR" 11979535 "Virginiamycine" "Other antibacterials" "NA" "NA" "NA" "NA" -"VOR" 71616 "Voriconazole" "Antifungals/antimycotics" "J02AC03,QJ02AC03" "Antimycotics for systemic use" "Triazole derivatives" "vori,vorico,vrc" "vfend,voriconazol,voriconazolum,voriconzole,vorikonazole" 0.4 "g" 0.4 "g" "32379-0,35862-2,35863-0,38370-3,41199-1,41200-7,53902-3,73676-9,80553-1,80651-3" -"XBR" 72144 "Xibornol" "Other antibacterials" "J01XX02,QJ01XX02" "Other antibacterials" "Other antibacterials" "NA" "bactacine,bracen,nanbacine,xibornolo,xibornolum" "NA" -"ZID" 77846445 "Zidebactam" "Other antibacterials" "NA" "NA" "zidebactamsalt" "NA" -"ZFD" "Zoliflodacin" "NA" "zol" "NA" "NA" +"VIR" 11979535 "Virginiamycine" "Other" "NA" "NA" "NA" "NA" +"VOR" 71616 "Voriconazole" "Antifungals" "J02AC03,QJ02AC03" "Antimycotics for systemic use" "Triazole derivatives" "vori,vorico,vrc" "vfend,voriconazol,voriconazolum,voriconzole,vorikonazole" 0.4 "g" 0.4 "g" "32379-0,35862-2,35863-0,38370-3,41199-1,41200-7,53902-3,73676-9,80553-1,80651-3" +"XBR" 72144 "Xibornol" "Other" "J01XX02,QJ01XX02" "Other antibacterials" "Other antibacterials" "NA" "bactacine,bracen,nanbacine,xibornolo,xibornolum" "NA" +"ZID" 77846445 "Zidebactam" "Beta-lactamase inhibitors" "NA" "NA" "zidebactamsalt" "NA" +"ZFD" "Zoliflodacin" "Spiropyrimidinetriones" "NA" "zol" "NA" "NA" diff --git a/data-raw/datasets/antimicrobials.xlsx b/data-raw/datasets/antimicrobials.xlsx index 127c20e44791df7ee3cc1e6a3930e71c2e2e55e9..cb103470c2c78c12c5721a74311de6fb16a5792e 100644 GIT binary patch delta 76162 zcmZ6xb97(bwm%%(joHSw8{4++G&Xjeh7G?_V>ht-Qh=YH1C8j`< z0ps6#n9)KEDX#fzK0%3SU=%cNs};x;+RSCxG8u8a#h-Cr-g5*(*hAyv1aD?!4^T=Mu#B~b>)leJIl5>U2aE1VLR0}w?lw1kaK2&7z38N+1Y)KKo(I z8?cFsuapx!=mpx5<6>wn^m2LlK3?}$^tUBLXig^ODMKe3-eqXzn3j}mqoYpD@_%Y^?He2|#p zJlN`6|0{8)m4DjUaevnF_A`h4S7aHrN>tv63jb?L8W=Sw1WK&onYc|>3PZ?wq%Up< zcoAGNzdJ9qS}<3AKTup}I#;}i^qwCZeZCR|o(B!H0R_Oj>HOL|OH*F|EmbXL9Oz9bwA7fd3pi*9LT+R6 zt=5;1e3N{5{L{8~3as(X%V#LkJrX;bKAo;Lh5`aF(7^-~mK#o^PvwKNS>XeSTYuV< zq_lk0-qM=$h*N$`V*iYwKaYnNd|haJPfZb$^SrHOz{LUEl z8(4U62;Zp4PXGP8e($BT9PzW?1r_g&Z2T7Nm+zH77`n|->a zm@{N?z=A=B#nS=(Ak$F`qu!06Karm5dY2_>^u~(EA7A}0j<*fxb^g}_#jdm)lX!<; zD2#skNk0^cjKC3c9o~QMxBck%hOvXdc?SA71SbaDN8e8bm-jC`7}n>2*FmH}y7rCt zm(qZpl=tU%dH;^*ABKjT78bS79VLt>2w6{)m7x|C?TP2VE%sgn{m*hJi0{V*9mh|6 zwXK$c-DSbXaf`yE%ZQUW4>tLm$*}$RjLI!*Z@-%RYmSb}C4)aSGnu&M>_iUDvA~J` z+H6~4_GT2FnQ4W!^QHnu5?tvqtK^P^QlMgpnEE~Z6xGGmBZZc(j0)sKZjqs zfM2p?*5lW+W_(g=}roOW_u^Rc#-8{N0pmBI1Vy`?w$b)F0MMdDvq)W%z9*Sc}; z-+qw16Vam?G24vddp8OY~q-lMlrbOnXlSaMnyJUvTM|2 zseLyawL?S?@x*RB;SN8Ih=H-WMAg!R@f@_u}h$9JDF>KI7fiaMag8aSpmx z{RaAjemSM!Z*rTwg1gm@r8!mZ^l$^!69-+7l)qEUswDMKEYwbPZwfEQ<{tKsVO{RX zxx)i`vI0cT%if>bVgp22%FLwGn>&4kgmdGA=DTwFz(Xz3mAE4VL;yDMw12%J%rlkgbbk(tmAoC^gO-OGmUkhPkb=5a9)46bO?f_yzRBbPeYvd^&!f?IEF|@ zuK`y6upaxzJ}!5`E#4SeqQlCH!|0NJ55O@sPu_}D9W`H$3AQ4%SaaZ-oql`ou=rmH zLFW$OBr8%wvIiabP3#Tq!SM3N4pfByGMU?N4V??PXWY#TS<~tYyg_MSf`~LxF>e+`5Q9n7qaK10!safPZ zOD(&A?(l}C$NFJ33BRxi>12rgLdcW#;Ii#0AksYv{vu`^ZP}B}KNz)2-ycjKIOEpN z9;45FzxElv8p%X3xOVr%kCGWu;V>l;r#YqvX~ROARv&(d&sKs8 z!4!NhyxFEj@aX9vj5+AZdAlS*Z+i6?u+wrqtu^NovAPW19suhm8a1a+kn=;|s zsVbiEZ|-0p*`JtVo8;n*9awIs^98AXXmx zMJIm%u$kvBOkz7jON!PpPA55vYI*jaZTKe9(8*!=JfY|3Q0dRCshHqmQB_Y>mXz7y z|0iBurU@OKgz#KZOH5YFap#v1U5`BSc4dE&zuB%H%~uaE&1}B(I=HF$Y4{Y((K-wD zpt#pHi;A`zrcy5h{LoWg^WqeVrpgYMhT;?;#w8BQ_&5!Fk~w)6Wh5$cB+XtZAvrk7 zT6vcGmL})uSehs~Js+Y;ei17R{uW+gZY&bJPg~3Vvw|*Yu3bAx7i^vgE`;cKZu5+1 zyuD;g2l=#;li55%ciKtWW}npMuA}9-TaRCQax1U=ATN3^&w-b5qz|9@dq=SOMR+uD zkY`UbkH^b7BDcdrjbN^c8wY#o^XMuV%v?R%pcABs*XDICpx2Unb0-TmD#(=+`Xy`H zi6Gp}@hVt6=jNMZFYm;T5=z$D+J^bVZRKLmwUxox23|qZ0wJdkN}gWoIv=Jk5!rPI zSM@9Ubx6AooLpCoiw@!T037<{ub>gYOL)P{Amvr1HopItl6Xt9WtNmbvUiHk>d$uZ z#aU@M%-<$pO600Ys8%!xk~u$9gub8;?;xn{K&WV81|{3jfNI9wn|>QY2hVEF^NTXY zMMhC+S6N{Wef5>mS#M-koAOD+az(b(P$(;Mv%tE8QRYilnsrreCW5Ybl?%KDI&;+F zOLY5G=?@ur`e80yl%?wtsD+YHFESXP7H42^pdLR%R9QlOE~7V&e}#IO8!8K6k62ET zbz8e`DCMw1TX^dD> zZegBb;a}CfcLZ7%{k2DQf-(E6uRtX<8DhWiv~k?MuxF}Z3NJLOPVq~2(Qm30nHXXf z!P_a|9(o!wpkJb<2(k^I?@9#@lj-q0+)GFAhUOLdq9ZEy1l|4gIGzbPaOWR^LK$Tj z{V0So2+KBri(t0yj4RnuKh{C`8$=#2P8o;xjeD|r^ zW1)U|_(uovgd5N-f*%wx@7UGxQa-r-GDTlZ?IH>ZoB}KlMlc-oS^CXG!ijs_-qnquIcnrShrbg%LmR zRsy}Sm`cV0Q`xy9&1*ue^es!p>m=(zM+OUo7?0}Q%FRozzTN}v-p-xgn|HG2!w~a) zApP~x|MQ+F>em`NuD}?rZC|JUu+#aw>D9rfU--W244uF)N<(u3hK}XvIH7LZKKzrl zRyrfoNqFh#)Q}<#LD(x0A7bh!Y}H3_JaL68y-`Sdh&Yom#|KvNP)2*xqWY^e(20dM zToT*z3|IhbQu@90t-U2e&JTK2CCoe&1LZAo!&*k`tw`o^9H=QQ@&ek@(NFZR%E=nN zf5)sTRndSk9>*3=97&zGSmFMpk@j7kp-0|y>fMNx=DEqge_-5i2Q-SqZgsB=&q zdFaF*sIz}aKN3SbLPVlz{Lam2hG!3A6+ss$FUUtKJi>!p;Qw@SVeiQ|f4#q@Gy2ye zDh`#elk4>TM)m2jfCw^(Z7{%TpAR(nXj1yyf(aHFTWHVd>>Y$m020b;1lc^{$LN~z z9;ll@x*c`18@k6N^mm^w=*d1iI6&{#6n#b2Vf(DO2p*_&GS!+iSg(gy5FGYx;|sA_ z4T5z}abFOe7{=$&niQVeS(R^(koO8(;^JZSt%TyXbT2o0IEaRr6t8143|!Si`&OrP zd$!2{T8I4fIW~CQ{T9>gwktKX%W+d7JTl{>nv{?<6jn0QmI<8fQ6{edH~I8drOfy*!vFTtn420igR@6D5A9MiOo*HNLAC_ssbXMoTspir;cdsfm-3TFoL0@ zmuFR@Y=UD_pUGbAEEI|>K%$3Q0@HbX5P3GZ9Fe#H7O|KX2U>tm>cKe_8-xjM@GGnk zdY$%M`D7fCU%jsUh;yi1vmKk8T-sVyy807o2MruaHaZwgKqjLw+jBY`!!#}Kh^7-D z4|a7|rDOqLB?d}{aL2%CHs%+p74wAf8igQl`TU*G_U_i61;+z^yQksN7dlABNbB~( zPQRXszg-(dx48lH8H4EDMwmgrCRtucLXVSQubZ|!sP-Kft|vTW`tMOeAI2fX5JpOp z$UU{;#(tU&7uKw3VUW_>8!0Z#H@R)VkLKX`7jW_YXZ@de+)UJpbZyRgrp8?~fEz1D znAKP}e+qrq|FeVGXYn+$@)nVn`$(mNLzvI<(L$Yv1JsF7TSU^Neo5E~(81Zccfqn@ z=*`TcEoNwO#$uQe$@oLGPNg8PW=cdfKimTA07NcoQ6WUchUju)6|p4B8blm`Lq6Rn zSoBBT$n%Yit?wDUEbHW`k)9ZnvsY1;4n))9yY}$~!yPKO~^rY6t~F# z6?Q0-E4+V2wBCxA;uMo@F@G0@{;H{PeQC}l)3Wq;%I@x)vlZm1K&1b7MXhOfwCy|^ znN@lbbPxQX^97fLzF;gs!)`mi1220}r{UGVY7gCb2xqXe3U5f;tgM~&JKjuu8975+ zf$6}~q=60Iyy|H6gwD)#z75Uds<@rSUmSHLqneC!)WB%Esju!WARC5xN6@p6>}znL z|8}N1`oWp}Hs3tuna697h>me{DNd-Q3=a0v$mab%-uU*|I=UTTm@6}!^i^y>!4naj z!OsHwd5r#c7(aD7*!C##toG-*)DDWiI*tDNwfaThe6TkO=P2^Vf5Hj>*R}dH%%0FG zxzhFkrYx=oa^LZVy@Bt1>n>_V*c1-_BX`UnQAI;y^{)(Cg2WsA*=l~lr6Va19Xqkb z`Z%K#^nrlRan(}P!EG}yM1w0jRB4w9YLDj=luaAREBt@%z|kMaZ`&l^X+K!YjdWoJ zyvv~!FbjxzB0`7>Guj1TIvPSJb);S@IauyPc?GU&$(-PR*mSV!;QckVr>~#2sVxv% z>(Yd`DxEWtHvZ?%&8iAXX6gWEn6BlYlLg3X&o+z0TJ9-vjCYBa(XNN)^<@*h_*+JO$}%Qxa0B>N+GMVqTpn!8`lOyHo)F zb7wBQ8@-M+ab3*lmWzr#i*x$B2hcOD>}#K(?9s(V@|!@J%ezCx)ClUHFA-HZ%O_7Y zCiDIa|HW_RM#*Pi9{A!x<@AAq0R7#=neY)$Nj`lRM~x1NEBYMH*gwt`~7^-WYmUUPb^7cEwk@k;&`Tp?H*p zAnDHIkbM@?77D@B@it88&K(s8GBp}vbSV)@GWaq_lIK*V^X!KH2jL6{^Iz&Hi7^$x zp%kc|ReY&~aDMd31WnTBy*(+*F0c*=V^SEqlOyldblk&0>WsuP)#yedw-qW{EzyB9 z3=iI$4`|I@(g55}N3{coCAjmGL6^%U#agBr2iLY!i@)Dl9Z({-z(3V1%=E-_vO>b(kn!g)dgqpHX-_}t7^Ud$%5pf(fcyWE4SepzsuYx zE=hvpjkAn~T`{^ZUQ~aB^8|C|fzdp#uskxh=LI4p@d?$Mq{J1B4a&|$^OmrF{B2#3 zE-R}aLpX8LaCK<;o!LQH#Tl z9J~Aq*vrvdH+G&p}KMXUJl9y0c;^@oL zeAWrXNq)RmG=fyNjH1M9#56R=cN&QwBu~OZwt#|`BaGIkoMe9?aEDq7+dVl z3%3-3vTrZtZrpd{zsf!k6!_X(YYAsv(S%{fuSYliF`?gb)$X{mk{1Ok{!o8|UmVGE zh^m_>!sj*bH?>nl-Oh@4_K%du9T+xlC;oSj%x1nBtR2<04gfY-mz_!;1I9oC_*Wto z=BU#K)(Y;HZ|_!!TK7L~4=*wx1F0iA%2F2J1HeANnUe)nA6iKaXxG>rN;;q#9U4rB zXq=@K&KZ6AWn_#sMbZ<3&^ry&dwu9(i49#|_-25SxP7dMX&6>~W+Hsq(T=X2BGWuk8f$snR}ol#UifjfI( zTpk~*QE)J0hyE6FvabP%-(HrQY``vTD176^J$MuRU>keK9{)*V7(WYbP+s_HYHijd z-2b9IVyoO%6lfjP#ROu%lE_BAJxt|^E8Ca;Mj4>k#a(!rcfR}jG4sN=ZWTfJi5Uji z;Ar%66U~bTOemG(edwj!ImjP$*?SUzVdFunx?q$TJ#cT@aJ(?G8uSTs)l~Dfm~Za; zNB=jODoxq(a+x*^fn3t%jdekGLj*G@BQ175v4auocler7*GJ)~rf{p1%GjDptK=V~ z7Dvl*gGcS2)jv7h!#UfmjE#L8|0%ack&-eCE z+9@?PfUO2;2aG;jm*`aq|6v^%l!DurDgFdMHyve7qtRt!*_Cd6WKG%nPtwe(E|G{| z&rcN<0dI3Hp(6#=Vf1I1dpWd{PD%C(FkoGz3g~eF3ZW^kdd+)@R@Gx3oJM$HW0MoMoqZ*9rS;IQ6*n;nb5LMEnwdJK? z7%a?Xo^1-9x=Bny!hwc5Cau>_kn|EtGzw}Ib_8PiHel~<4ph~9kj=PVGn+Dc=!J0@ zP-on&h6k)V`Mfc#cCL;FrJpeR;K20T1YcW?rFZAA4KDtZqsTY?l2kE}HU%gFtQyo$ zn5ca;r;1Xs(dW^Jtc1Awc)=Y!qFvrS{x84wq>U%gpsmweuD-}#e`~lQ?BvUuzurA0 zqzL>XJv^7W$p=yIYhGjX@dL0s<@f^}zmpxfV^B+DMe|YR&Ah&UB*c&oz2kv`R-t7? zBadhb3A|Aeq{cK}?bDVBI zJW>&i;kr+tGZ|dHtCdq#!@oWR1|cdC+nR=h>!;O0rNuUmhTS?;>KW*O;_hrcM{+0+ zNk92-2(kLQH>Jskn=DVpJ<9%hF#`tbC(Pxmm@OEAmb3KbV{m=(KS85LDb;XP?F1Vm$*sK;aaUJ3R`Y-`$tUn zUW5SG{Cql#olU7Dd7w^q%F}{ygr6g66wD?29(;dSWA=}Zc&*i7hNd3M97mLmPC0cE z&Kc6t!CL;i!KaPi64V zX{oyFZyd#dWf`>>7=3dqc1#04x0?hmz>Oy{p!8sl1R5~SNnKPHADhidg7a3 z+PjkzI|8bGsx7oSPe_VwzH9ZW)O75BotZhHDC`3G+iet?v-E3;3kwo+o~}mDgV{A*h!94>zSo!H zZ*hp@v@58&KHEwU-}r42ku)A2E9vH2yLw5U+6Vxa>(KMmmW#T*r%tU8C_LJoI4U`h zOtf=;J@1V3-+R#c`mB?py<_6*?ILn#)~T71+d^;1M0lADv2G0`PVx|Pej#(^&VkLJ zdSn@jj9;Zu4L1$24PpaZxzdhA))&968N!P{x)}V)1Jlu9&|q0J)(2<^)F?|9n(4xp(5g`p2CiY!bADA zPQn^i6%4?l0?D;IZEGg;7JkwiNmb$f2MyuZAuMC~z@`1gw~IQYY#uZ^(G+@o&N^R4 ziPk>2hp5E(U$j`|8->MrtBNol->U&@b$Z1__be8P$Q*>*qLjZ8LS_oYA@u zhcWAcS;$`qJsRqRe@tt9P@G<;WtqmOq-&vlU084}YqF*86H=YN1&vN1&>39jT5Z!C zH7`a%9WA|8P`Wcj=eeO-Q}=&3tF$M`$E{h@HLTqEI$xun7@~#eS zL+2dm`C~2+9IJFnq8fz{sP>L!O3xZpIeNTiVAyj-wn;!92yy~Ra_qjh&nUY?$_x%t zNcK9y{6&F&=Ye~UV#T-h$obCs=h2%yvhnB1LH)Iy?qmRj&ET!@-<&_rZ-OAZ0&^WDos4SZ@YJMkRWwzN&z+rw;K3$tsvNA9)^wrV6jMqE*Hlw5Qou1 zl7j0v@9+Y4Tt7&Kyce*&!g(x|e}DL~Ii|}-?vxdI%_Q$$$@wm&e)%Y zQHREGNsek7_J}cjTE|pd+L3uyRn(D-(Zia{ZZ_m~H!#YWlIPPp$&x8mI=u!_XCC-O zl9hq68?co*reLms>zKPhVr@J>;unl#I!MAUl4sNhCcjX<)uJCqsOwSgQd$z zT1gO*&E-McVi)bpT}&I~VmY-&pgxx@#4A}neLE)6iMj+zn0@Pp)yP}Ll(vR&)wGcA zp{&yS>dFKL(nT|`)yRG(Yq|a*Tq@3-K~0yHYq0BsVXAcTEzzfV&R;a02bhz5$HKBN zHmf~-q~0VQCc3V=49sf0PH*!Ru%0Fuzj>x5!twDEo=pFo{1C%!SG*vrp z`MMBS-tx}*A=K1jd%M7R42EuV@abRB?yl7WmJ9Mxh@Tit;YZ+6pN2{5c%$jPWo2K< zd1W2&&h9|yWnAqu`&1Dj6NvkcT+yf3Mc(1qV*}dV#eJac_Yt4!qR=%6HP6M+) z63Mu}5aU@8Y`Ub?ywdmdeph^orWq4S9+k88ux&pq(X)tGF5?wQ!HaT$shUokZktVD z+o%eQ@$CfpiOaAt80)&Gec)wjqIe&vrPWM^yMpnswEJMFIysYH7}1}CDZ(NHSqs;s z@V(PmEad7Jd?f5NlshI}$#1jLU;*7M(H=`>tSDcN00jN|H^!N3Qt{C=WpH0P@ZAKztrsy{o&KSm(xis z%SugO>Y3I^>Y4wwi&Wz|&rNw-!GwCdZ=1hVzcF@%lvJr#B;Zt(92>PEg)x zv09Q#aS(ssM5$4+fQwNRN>g=L!m7YBA={j7>4}C)na5CV{%vo(xS(BWcC{uXxB+31 z5K7Z|vn8yPerkjfG%hq(zmP4BgtqLoC-OvEP=uI|pL5?4grF}l?;xHez!Qa9G2*3m znR#GeH#cDaWOe9X>czq`9yQW)&0kll$T&PV3|-vY$J{g?=!bn%VYb-<3e-mC3M*ym z>-!$7XbWvWhe>19-B`gV@|cX!?Br$BX&v#JLti82Uxes4@pm7xt_VT?KE?-$o@)Ql{vnYVD5+|wORyZdIpO_{kE zXX%A6Xi{8{shu|r;aA@sO$m;)p+^;*u!ELi0bozItF^Ut!-O9xE0EJJT|%&qFlb{M-SB zcJ{D!=%FE3S))T|r$<(3$#$z}?;-j!X0cQgfH5NjM!~d(Ik$~qISlCh%N5(Nq!zgz z_C_u0m8J5kpER`mBj~;cnS*VxW=FA&5`Kq$P#^V8D^rz)$8=SOpGGW?f;mSk5Br*-Atd$#7-j_i61gy{q*& zItzv>0c+$IleEk=epb~jmI${W{_5X=L$};OQui20@f;Y0idPxm;c_tgS~eI2?3BYu zXU3OOSCdtOMwd5{bu;I}XEl^=6EMWWrsv8hV*2~d70$j>YK?VNcnkn_6y^2GKa=;g z-eKW8S|(gaTn@(znkr6t(-w{-}DK@Q+$y7w_{Aa9`a+b!_cI{)}!ql%d z$TMkJ*H^58bqbG->HPJw}iI7FiWOLwg2 zgZ?Mnq6BaD<(K!EB&y@mY6Sz#w>d&()kt?0%7h_SC-CMW;AOedp?!2xN`0X`{M(o| zIbOTumC95Ee|-ja#;hvuIA?0AU*T7|zp7Eyl*CS{3$Q9HjCsNA(}_x$--nCbJ4ph}^vMTBDA%NG zl;7x!XMk>$tght4rQm+zQ%eKh1iGi>gmAYCO#Uy`i4gWSJYZ4a?b#_c;TVCV>#}M% zlbjXq5rn!Bj#|eTriOxn&-nwvb>&Oj9UQu2_&KkIcQ8?f9J+@s(ymq-ePsDeK^Y9M zNcb;~1}M?(KdG_j_tgQjui5=A-OxN-%wvJi&G&XGrEyxylf@XBaab$e;i`P0h94Q! zhBGw(MV%Ep5;H!=Xd#lekXAFHqX=iKI})oBMt0t}p_`&bsEETg;nuxmF-Ed5^gDy~ z7y7%z#W-wI=@4^?xNf<0Psg}NxLimWY9F#s1m_ihP3Au}N!8O~$_9m&^?c}IoIJ@0bUBOkMAlPyJedk0OrB2u=|Koho%?|9o zH&5GY)YV{d)Ra50z6l+eIxP&H;|mH3Vj1s6%UMNJ%TS4k2g)E8+w6zQjrtcdIjCTv zI%M`VxIC9y|Bw5(7a7VlKQM>Y0RyZ;q`_U`iUJvG2N54`fYSE2W~wW8)gvq$V$xwP zs%7SZCIjG9V&!nqMKoLJtK_!OV>xzzl_0Tw*{|(GGcHV+;faO3KiNR24w5G*6u;=hWqW z1s^BSM`yRQkMH#inA88G42YG>s2N%h!bYhVd?>q4%Uh3VG592;!4$B(?Av0|+G)%g z=H!jt0&@LIP^3t>r*_5`u{kt$iTbb>XS0FCHHod-r-?^c``H|LsslczBdHt~AIf$> zbfH&zHX!zv+bwBVUG(#tknfKt**n$7X$$4AVYu?-{1j3%#mC%;0{#p7J1SKAK_DC#blWLZtaOjK+`{3u>lWh*=4VgGNb!P*6Nwx?QI*s zY&rf1nzds-%V62YtVAri2aRjU#%#AW{|*W7#@<%ubO#lCefTbmWnPshVOF>4eFjzv z{a6>sM<(;JXTkGvjM$vW@!8MDj^wdY_PbBt)H@xEDx98shh6okGZryM2L5eg0Zuk~ zJLc(N6gO0_NxoB64$;k)Z-jx=V&tF*{L5U zMyNvvh(z);>2gP)(MAH&24QrO7TPI41!xk<9*q;)Jk{!dE@ChY{)3M8VM}NcSeD`T zS`qWeWj1j~XK`uBmvoKD?FiEd?EBiptdi^4o&H=-8PPe(+s)=)iVjLe{LROsaf*q? zq?4GDX-tsSF|Hn(Fe1msaYFBKCOWuWd#;)ts_**w5KsW2wF(ecORx^KZVJ?p`~NGP zUl4QNQIcv938d-y7iCSX*F`CP{)G0KYKykbO7k^fC<-0=4&i4dbI93d_Wj+W-;U8a zAqTOegPu>EQre{X5XTebUEqI6dR3QMXx>S$)I-_TU{(K5B}rl;$vcD7v(L8K-Kh6y zix@QjFb+It_PmFv8)gzu9Ymvw=U-|MYUl{qhLpAhJ(*;p8Qq=rNlQ0zGW-dEmcVW1nx+P)jQ(HyR^PCh2^R`eht(rddj=llA26#rRMaB+YiVCF(O3TIH4X~9=ncztXi|?ckNk0K)qds?h{W`e^gg!$ z92{JK{T|J2RTzLC$NO*)uDky$UhVF#_{nbh5PA35R09hV+)^R?tWn$Kkti`U2~!g5 zb+o{e+F_!?v}S`E@tY$p>hJIo1|Ff0!x|y{1KD9PEf58v_>;XxB{`vFCN{^1!LhFL zZd960ZfRYT*b&BS>{j?20A^H*r!uXrv zdQhKN+`~+n@NSLi4FATk^v@@To9#aDq;Kd{`hRG_O|ya@(gW4TxvtC_9oHv?!CS99 z5=qlhnJ3KVx2y$HO>F}!HJ0u4-BQ} zbLsE|rQ04IxO_zP@~Cs^(l*7aJMGzTB;+%D-ZuQif#Ds0`H! z5l?-v^|8#7YkI-amQgysYori!b@)uY#dEKEWT|%HA#HLVCxVr?bh3%JaI%Tb6mpMz zF3{|`WZgdr%DT*Cju8rUiW6cB4h-Q%;|^|a5sF%rxq!^H`QyG?m|q`VDn4rU554Qf zZB^MK4p&*B_Tv^^uu@7sZ-}NTTl)JdF-o6h0$P+s%|9s0iqV#n8MqCn!~5eTGccQH zRzGX_qit3Gcu7jDlg}(ze~<6O6*6WAc0syr|B+x5Z|R{;k1viA)Gz#+7iJ2l_Q(yk z&9APgzs)ea_m@w9+C|l5DcZr9Ee1i|eJsRm&U40I>a!AEB#}o-6R55E|GX%B!LPoDGe~Dv?qg=`gpw|LE;-HGD=%~lGa2F?W*_=^_62jZB<~1ff_-N92r65nd0KWW zpe9kNeU*KVrASk@|5QGXpM9^r%r*KlX zRjhVsVu=Ayk95mCA0G83*X7LwF(Z2kLLah8p%huoR#<}btJXfk;*csW>xnmo$r69W zC-Vgr(grW(-@6s6y`+e!xz}ltFj03Fz}&v>?S&*)ul#uYPz8CbY1E`^boQp7&2;7m z4JjR-MB|x)gb$)qVS=ftzY=cyNiK>bf+O$3X9ap5s24agSOQ&J~;9CyHPdCI4a;QDQ9(N?jQg9Pr<}OA;)9_#$q+3Rj%}XqBJV{~coBLsaz!Z8NOV zt*dB^-sLptDTG$xkC}YKAi@tXf~i=kEg^7MdD=1vDV>f|3iTu1R9t9lMc{*aDWhX@ zn}zo(r+Ag!r!}-?9m1(o4@}mJ_<-?uGXfu~AFZ0F)graiNbKx>a=}-+c#yw(qA(c-!ZZD3& zFUHH$#n4jeormsmwbLHCQL+>{oG#L@RPM&<>8WBTxTZ%U%J}z2Yytf$a)dc#BH_ww znVOLlxj!~CbdusfGP<};_-bP8HgRRcfp{N(b9#?eXm$EEiyk1Fo}vVV>ZxX?lzSM;c}{37?_3$&|#S0t14?2S%}R z{HAyO`bAX$#zS+c*?{dSEX(}{do6g5Mduxd!rJ&}<>t1n&bQ}}G61IEN9e<`2t4DB zu{~q*F&mu*59>xawu2<$9H;IjXsHketkdE##??;Y8gs7LGO}stmnh!G z4Npx7ClNhwSi*Fe2S=1O%>P|N{c-X$ZHITz#=hW=V1f~Efv3$(?_ezFFl3>^oXiF1 zQG`7cu6ik$cJT*yPec*=lYPmo|H8^x-q#PEO;+RvWywF9dBwN=oY0tD7_CZ__j{lCa;E)p6)1Ur(BCJsC3}&XaKf?NZOsj8ZQCEbuRxHAKkPa*f=y zI_6HBDZYKQ9o3B8Ap4TVKo{YX0c=*y^MPOk@8#GwN;))EH2m*ME-Z(OH0TsUq5)vZ z$AZ#f`bP~um&vQ6)9~XIeXUCvA_|T##v|skvGLD8C86~H)K+Qd9F!Sh8ah=loSJMW zbx;bLx*dLcx3J!nSkFChvtVYin*S`OW9zk>H&L!bjJF5# z%u~l*`jO??f;))~f70bCgB3_DQfRZB=8 z4oc#EVGF+2TTZmKzEFdmyJ_N(AZkNUzfmUnMH$7!BQS`gmxY`6moxAJj?RB^ioIG` zYieV@8;M0}ljre9D6qL-aEjVQIatX4>z`kSi)F)LoFm3UK?;Bk>Yk6|Z~NTdCP~(2 zj}866fc6pV^PK1oBEX_qf1bwxc^_RXgO{Pb2J6thwP<-<4gP?o>_qnIm$`8iPv8gZ za_*bvW20qcS;6Pz_<}e1SqO$TE9xuWWPfPdfyq45q>IyAU>dBbSNwZ*An&LN|fOVXSRuZ7-+n*@poBU*Pk?8JLCv?`NPZ& z3EKb-i(@Sbu>=pBHm08=h@sXUYYK@te}oXq(JX(ssP(pzw|wM9OP;~mGvY))N!5J_m5<3_Y=7Kr*5F^ zzlEF917(*j$zT;=NB}v~^-@+C`u=yV6MuT%eD{qz)bS(aAuGQ{YgJ`mcDJ@TvG2b_ zl%yqOxJr>xCLRPVC%a9*N>cZk=HGp#Rp!+i4IY5lLK#JYab~C`AlB|A&4j|tlq#bV zC|+Na&NWUOnBO!|UfN>K`Yn9Mo8@rs)jV>~7wLIq93V5<>jtnfu1vEMr<^rsg_-jb zZ#xqvziGiZdl9RcEcZ=P$C>Zrrz}+);$9M#MZTZZWgR532sxY4S__4dl+G$*7a8D~ z^3?GNWahihskgx2 zA^vP-%XKGAy1^&$n(bRF9#1ZTRa4;FDr^g#J-RDrtH2We>Iy#JBEH-s)gy5NG7R}> z(cJ6V?>lmWk`8fvBKROLSE)KC=udNtvu7rKBl;qzxU7nbwSh5akOaf{dM#Tqhr{!$ zmPHAqoOg(D_0IfPFr3@Sc6|hk-?^&MnH~sJR}k3Xi=-3M^xuU3aDLX9=Xq&z@HR)Gm|`Z+uvjD$$mY55@p@h_fyK9tf?us049-zjU=J`dRVDZb8_!BAMIg*0+* zjfye*jmC%Bijf8o2rjw*3U5Mn1j3K@4}>_`xUM7uH5|?RRouGemP4soSqy`revNB`nHAj~72UxV z-Mhf8kHF^%PobYbDKD~rzgAL>YcUiE6(0~!7fKhtEtl&k^tesuOnS?(54gKSCcjfm z{V})8A6=A4p}c#r&8L#7oP=QewgYC!INWBam{$`cW=aq-Fb2a#%w=?QY_dQRwLmT9 z=MwjIiVU>`H0SC6R-9#HZm_~Wl0cTuL2V3ZUi$M`>ZlGzF}x?n_gb2e{pph^g7I+l zB=Bb4d)|Gg-HVjy90Fg=P#ZFhCn_m-wz!L5{LWK@?qWjV@M*;}<0sd85#)&ZUH)&u zLmEwL`<>4yYo>l8Hl%BuhOCrDMX@+!`uSNJcxnE(scT&n`rTf3mZ>aPLvbLNFi|%BnfDtE^W|_W7>B4VxW`lnr{%6tX^g1~!64l7%@14(BCeO>gBp2GBLWSt zzkeOP8_`?M;&abEQ8V$LinLkvT&B_HyenBG^4$FzWUlV?67`d87vZ)ncT0C_zF2d~ zx|-SCwfDOHY(y@y>Z?|-FpINDdx%>EFd#SiaLi#>gErg-j-Xfx>dZJThEp3W)-diC+}+*%!JXg^!9755hYTLv-Q9z`ySrO(ch^8Z&bjxkTi=hKp4mU9YIe<@ zp1peY>MPxUu(NnHrKDqX6n1`=Gal9Hd<0j+3pc79iIymBM5TCg-4xf%<#&(F$MaJZ z6q*?n6~HX&R|c?cyl2F$Bm*P!-X-amIMy2dS}~DvOX8HXldBfwKQ8)I1VR`cS;F1o1qVT57x`l7@$ z3(|hGVH7zXP_Lw1S@cOo2ZZkyT^uMP1LG&9Tbt#|bnn z+I!Q;ZLWJ0%u^E#Y7>Fgh44j?f?s=;l>WXqc!9veo}gjj717|lz2bNe>9XA7+n z92bBzzx>s)r{5WLdLob>y-BrKmagW};IND=>L9t?oir3{abwuQD2RUCjbI;!?(Fb1 z_JSama z@&Zp6_w=XHvgvZTfg5e)7YnQR3?Mi@1ZgsS90}hOR=V7Ux$k%EP*KBJEM{z4r@vsd zxDlvFIQd8v;W6!dh)y3=bAow5Vdcb zPh)sZ(JG3w2ylPDMbdp_ws(XdkKHNLeLVjAJ5YA~XTg0iPh{7Oyxo5K+Q?$=N{Blo zq;Ca}U7d@q!`G{DN$A`=-KB`)MFKugZl-3-c_+R93A%u#Y`}^nEHNV+1b?E?TA@jp zW|?wG>3kr&*rXUlIpn&5NiNot$M5H)>=`D$Ok~`r!VjAd)!QFS)R>lN@4Uh`AG;eK zS*y6D^=u;CP94NY26pZK0(ybodV#Qdf$+dI=Tn1PQZ5@_eaQs~R;1#xO;v3Ytr7b4`>jFX<2#UeWs~{uCFQIV_))2*X52VRg z7@@_kjk_=5OJFktXIeQwxA5eik%C08qWj|`vd7~7=G42iv6Jx0r4%u915rU0JlMRP zP&FAnd1UBngfE{ei%FuZ;(UAD2yf8p6(UXq(z3_utHcP`^8lu<^>vi-H(zK9; zHb5=-FaPx>4kO#%iTodKnIo0S5LO29pXQU<)w5~rmx%0o9qFqSqG-J8>!z^L2SV$4 z_cw0eX39_s8cHB@o_oFHNH`f1>VSZ5lSElChhOjN^c0b*0`6{~;Gw7f?srhib;C}{3{$Qc(J&_$|00lFuAR)tG{n)!m>xPLjwstyb8#q6csxmxD|i|J^GT#;rwoA$c;wd=_+3 zj%Qv~NlOTxugB3;*)>_T*4(NtFNYMpVi8I0)5p`yIx7-$apym_b(SV0MgOEmvhYLN z)=b$9($%g_ta{`T=pbL`p|1m(cbuL?X}w3#*S*Wr*XfvXjKu*^Jdp8~CqrqjYO!Pr z4?cqx^+)8#9$Ji4+HI!1&@_E zgWV6+bSY?DtgC;{_J7@Z{j=!qSnfj^gG5;wOS2Ojqbww7JF6alu|U$K}sC3?QSM| zip*sxdoioN;4P)EU+O$A-ftJ0FSKlTwVzLZ??|#%uw|J1X{K9xPn`9QbSAOP@CIM| z{1{*Muz5lq3qdS=awRB&=G+6JoW-7dkh|{J5oyPX>DG;PWhZ`keuykz)_=bMP9YDT zeL3#{&gd9urL-)(tpkl88?BbY*(}nh^S&8EpDS?wJ?_;7DE#l~|BigR_kHi5^3lB_ zuEY)qy-$%>Dx{ckxe!PnB5QrnKE=q7?2Q5`JT;TXca5>IY!bF+!sy5f{hO)MJko33D7P6|o9g5U zR!OO5lOO;T?*+375A_y3H*(0t5dgCpL!+M%@F)d6*kK%C0)rEEYuEee#s>*^bfsCd zqI0Un-7ACoz3JWNCV*TM6tS|<>96poV&pjGIFx6I&L{A$BNKoGdY~%D?sL5Q7etQ# zsA^Ao4|`rBKgU9sA97Vk7>Z`B;8x;5{EKH~o%14NrSq^SrxSn>nI^>1xYn(SGDF!c z(7lovcJp9bv+go)=`UVEwhh;pHIjyyH_9~O*;do{HpWL77g@%!5EatJ%VUG8TA#%w zXNUbjggM>vTLd~j@^CJp<_^+#MTm6VV5uKiV#kt4ZS7Az%8J~L7Qou&s!rKE992rr zwgYs^J(g&+Yc)wrn+Y)bKvvunj^c9DW4W72$|b`U~q{osKDeQig*~TF7=b*M%Bw#GhA9ir3Lq@HoouslubrAE)}@S``79=})4AmD=B@^^ zpVXa0IxL4*!YgPnr$6A=R#e~exCN6?2l9?G8O%nQt?_)SlmKmS>XEqGQ! z2%s)kKxk50&HDZ9$!Zz0(MeDPPjsz%LQMX9NPH=A^~_VP)e94uB+fcD=5L2$<3CcA zXipYC+lhAM%My9=l{~)3++)Ap_&l6&YG!D-bqmL9eF4X70~4}O!eG}_P>wc1*$V}# zFM$*x_$Q8UYyukC26{_vhRL%W&!er4Kj1$o*^|!iGw%%p#qK1s-9L6fi?4>JH{9*c zN5aVx3jAfojlm3G6I+38LVG;NvSfuh8BR*ePO{TY2wG{^F7P~lJ}m& z1`=E(cqId?EuRj%aQZ1Ea3OofYL;lTJKzv#IN-CBCFJZ;u&-+3|sJz+J zMrL*aSM|WmkvAhJt>Z%JvF8ZVK=vXBVY$L*5QAl$n5Q7JmugG8>%8EYAK-EJM`qBm>Fo55Twf^!IWl21Gp z!X*@xyN1ve!*+WuCQpa7G!k`^jx-| z@Po7G@RuaaDDQ9>=xIiRwtlcl+TIWw+_%KwkP~|-AW3m^Nz{P7;B&?xt8k_h84z6G zJA=JN2B_oM>G^LKB!$#go6cyiD}mZ}=fcCRaM6lTb3BRmiJGhS`z^6=_%sgODxe+G#R zU|j~nDO(egVDmeT-79xq`RL*t zB|w+w*cw-U{32ygRGPi$WTrA2))KU+AWUN_M6JTI-D}N8+n3)=26n{g0q01;YPn!i zr-OA-DGa}eZV=d}CqnSRX1u0?noptxT|qKvi#mMJ3vcJ?Af`u5_!vN3)b&IQ+;mEN zP6>`Vg@{vIJBxZp_;1cpy6M+@|KP3JM$#D{CGagSQ7#6JZkWo_#UL4genit#_Xw=t zxPQw~?#3w0W5iZ8Fhv~4SnIp3(UMS{w0yk@Z48}Y`{f}?(9)4lHTJcO$K>E$fH4G? zm#~x~pxq*CzRPO4`3oy6io;w3(8qJid6A!(37IjjReS8IelZ&>*30tt=0&Hq@N)GB zk+J2WswZ!=JQW;D^E2NzOrD7F!!W7hjEr0<^bYu~=M7al%tLGOL3 z9>~z)y-I|?d!^@Tmr{m|LG-pNH=R;?i?uwQ|3)Kw)_Dy6>E_35!tF}r%QD+FGT+we*%$Yvz_g?(U%#us)zCtt2VKEy4`LCC5OqU zY!zlCFPo`Ki;an>&YdnIKqsD3*4N(z^%DXt`6Wlxqh7;AA{rS`QHZaZu zhmEr7>LcDI_9_Wu){n;fdB)5%p%l^x2#M^KS%28vb}R5crIW7_-_z#ZED*$)Upr_o zXd>2igW=IbT54Lv0+)4KNj1PQDM93Z`|G*nsk;><_bB?I=HmqZ@Avm+gqx-fNKe!q0Uuzb_h2J3|3Uc_?_4ly=FGK7L_hMClW{MU6o#}_-0WQ~JJQD%NCLof*mrWH}P1*hDvMtlBsRvWl zC4!zj2w$|`CO=EzDEGS`v2!QAK-+a2MZ{Hs>Rmoalaul2Jy0`WR}AJ9~@18ryAANT2H^j2oDl^7caF%a#fYVs!GxCN)-xCwE4Ln;^PG5#`t zwS&seme?+>=23C?qB~WLTDV|1wHQD+fi4s1By}yJC=(!({lm?$K4W1{uvTd+o{?nd zk)346TT_Ru1G!A#`!{kX`6_()Ii$@v%oHfRJXc-F!Yf->TlkHN-7h?Ww~(bD+a?`y zkMJL}$w!$wO$sI zV>B{KibAJ%YB-f3(JPtD!tw+g2j8eENhWBXd%>lTzcFi>B}m=pj%lv`>HuxZ*m}5& z1&04371t)4;c>S3y>fU--(gJ;oVEsPz8u3v3K*<_F{8mR1+H|`OAeRh2mE39n|!aE zBT5L~er$OYs$PizaV!c&8nNd21G@#<;BeQKuQZBE&kI7A)@T{QTNf>1yGadSa;K{< zlfjj#OGuexG+aw?>1aLqTggp&_|X1+n^tH?f2{>(I{a2H$19AmkIfYP(>S&_Ic5y0 z*-d+Q3FXlW_msl50Ir{}1WyW|E#z+)Ow-~Q8&qGQD25P6cJI5eE7$5bPahgeP)Hecg3I-= z1a`lrICjcdp9(C`feVNyX$>;@*S_xu%fO|H2We7gk#1pMI~faf?EKL@*GA5_Qlb9z zm=411G8VY`9cKC;KVp{*yPu_P`I(WmV~%CiiK7tnhPa0hlB7Q(aeriDYcr=!n&Upt zjE@lWQP}J==9?#ySm25>eN_=5ehs^lYj1^W`4R*^SVrR3uxjgKhIMm^<*cdn-+O6!lS( zO}3_SOzXJbl9V6s1hErNF1y>3C#xQXcq(Qb6ydfO5^%H|~ zC5^7RlnWuilrpTrl}O%ZhIF(VZ50_J#47c&Ow;x6H-Q|gEco$g!r6Q6A3?c_#-oYclAL3Pewvgu44go+p`;IY#`o1V+=xBsVWde zArEx=*H4p10}l?0a_-!!chn|~bgH^kQhKBz9i(kN%Qr~Te^J$DHMqm&AKg--! zeTbtC9epFpdz-J~CM` z*@25lE>{UvtfQ=nfUIZwF39>6>gkNyS!Qr9=Q>+!l|4*_DS2L=c;QhW5`CTJwrJFN z7^zz^1mhfw>f{2bh){xugY`u6Fm_$(bY=%&YE?5S3k+QyS5|0Y??rYH9S2$sb2ph9 z2;*EdsI%p4b89MLp2_0g7FfgSIK|TZYcibfV>Fn7p8b?Wx>~NIPjOf2^1sRbxi(3+ zKecVfCa7%l=b{G(H|F?NL7^E&{EBdr^V*SZ8)*Y8n`H)YHa8f1BNH+1t;ql38Ex^n za{MLd>o=dS3V83EzxmncwWR|BJz!IP!yXw*dA4hGd|j1Jwb8?&4Dz<5m-4#9MuJHl zMe_*x!>8fHA$rB~n*yq01AAYE?yZQ2^3tv+Rg4nDYp99&%FNkT-6#t~NS)umYP&pt zf%!2^#=w~Ym<&LwMW%9PJu8qLGAAeF`X9B<#)%|L!_N6;7C(q%6YQc$F@!G-B1zlc z^YEzf57=KhJ{0^%kG$tO$nU52ZI_mV%O-~Y-Ma-jJ^y>9zoCCl?F>tq2V)fb6uQS) zvr*MHxcYspHX)ZnlfjMr8yPWGe9 zQeM<>^^2a<^!+s|$ng7(VB`SD&N`%NNZj?8hY^=C_Ago%xu5v#@qy!A(R9IKu@(5s3X`Dnd>nxhsio z4XT4^VU=`h6EyRP)tmBI8(0DZuzQ%6e=Kwx>XBbp*eQM*t!zY?BXI0z>~<^9Bw75X z`PO7ww#m-~y{vvIfhiJJReYD64G zwdZ96F@mhzw4ZA0+Dvpu*1GQ+d-5%NM9N>{DV+a!WP;1uBBEog2Mi2!9LVg-MSMYZ zPwx7qE3kz)!-76Vc^y#?d;Ctzfx@`8A@MBJR;E4GnpQ&_CMeglXU;mheaif@3UIN% z^hi)zh_`%Ws}M+gW0d*Jsu0an#3&R?xzBQ3GhTV^!4Ru)r|s`z68xjX3gOn=qwvT_ z{6~kq7JC#mgx6H_ub5h?t?tqpaoK z;B}-`TX~ZVyRbq+1=T~3Z<~Tme86Fbgk~@L#YP?_qWgrfb!~1W>>~}E4ZC9zswsxF zsy8l_^eGatjzLDCa}8)X{k|?#LOJ^D6*r!AldGngo~0xs@@~P|N%EvL500bDQQ)#> z2jBNiLc9Ao3q~GaOB)A!n`{S5B_ZLhp2$5f~3Squ73(asU;j<`BB46YaZ=o^8by# z&b~`TP2xfY69arQ3(HU)J@__iOzB==k0qa#-(Y>U%lXt4W1z^R@y72gBC|eA+ybr! zefcJeTl(0oj67EUNaYYfC5v+&SR9Xw!`~+Gd_jH{86vqZ%^KP#IIvT2o%XaQ2LV#& z4L@!0Y0TV~5xO&iO=BuZ6;otJT()R<5X|nx5mgrTeJi6o)`q5jJZ5}Voqe!&$RepE zBb)7+#irlL%IbppsWefqRh&2HnnRA)Xr;8>5?AeHTS%t~R00){j%z8Ks$CceDWAb> zd?Y6YM`lN2!U7j~?y({J>{!ClQa!YHH#`VapKiZZctj8J8b|$dDY@(ZpWqIbMDfe* zeotCmf*C7nQz}6+n7EMKZMFgP?n(|j>lPvFDW@2>hnE{O#NMr<$~rZ|ZimMtX<|y4 z{W@lNW$x?q;V}@DAX7qUhRQh0PO_Yw9jpXn!Omuxe|=NGslV%e`%3Z@GqLr1UsKNEI$sBurI3fKNc+Fd+*-4; zn0-p&=(q7&G_TAH`50QE{4E#4cc)3UXViWU^B=hRQnUaf`U(c#yv-nFdupm$Bw)r! zXKIXt@vDqrNE+VF)8+axg|+?^}U}SwHbDt4RsvG)!slklSyj-6MM~u zm?^#~n+^%o_9ro}%KZBbi2TEr@Me92+azNZ#=DnMMwAvi{)>-A@uQhhcANwMQcTYM zLN?r=sv5w2B6?%W(}x_TYc!pWPq>H>&>0)w9*soy&4)4H9Fggp?n+=ea_>BBS4Hv9 zO3t42Ew@ND&jsEi3rQUx#P5gzEKnLvlbLH6la79$wD*W=_&6;4e(3%Xn`}HrBC0no zOdm}i>vvq0q0E+CH_ow;1ph-}V~l}6oy*RFGeBubSO(Es(5F_6_00scHo6c%P^l!t z+F^0fV{1wJ#Bz0jZU|-;v~L;B_z>x^)|pxNti%Wdwe+j~P-WsI_!KYb0z+-@YPZhRyQbmuvks7`-y!1W@ zi2Ay#$2&;kfKX!hKC<7OJ5__I7Rj3mO2_F zeg}f_Eg>bcoEbKeAmFwhDL!HqA8u~)3NkawS=Jk#eATtCemW!tY^2;Bv^zip3N3=k zoLH5LhxWOcv zOu2|XqhxLcVB%cVKN0>KWmCc&g2PwLekfE2$e2)V$O#&XzcF@Mw0}wQq_=xJNrquIt_OHL%AAixWeyMVH$@Wi?7S0Tf;6h1N92KF~(qUzD?9hEs8iz^T zVR>7~)t}AV1OP=!;0?1JWS$zM{5#&Wk7?Abz&Ta_l{3|$!rmyHIRvb9_z0?Fq+{n= zCYX_}mJ__(gyvBY6grPjSej5eGJLBrq>4lWLl2ack|5$KVH2fMRynoOOFSwgNm6GP zkG%#9ie>>=jS_q6R9(~^c?cGYPWnMis*njK^^77D{&8jiTMy&U40E+T{cYy*vV*k8 zT8Z2=yHXG4;;8wa;E0Vps0so0?;1~xmAZ)hzjAU{H7606!L?_bE9@IHOy$llE)55f z2+DY3s`D9+y9U=C7Uat?DJ!nIX8AncP#$&EGzsO5$#V!p?zl@3(J1X~=^7QNI3(3# zH@vc&p_0^q#qX%tVBI}|1^T1%9Lq7a^v0ucB_8a|cksWCjS2JNw+MNX6Tz{#6X9E} z{o0V46Nz6H{Ye*5PjK$U-h_&2Z{DGxtIcX9hgya3t^?S?pzCWmYX`PvVTLf_OM*V` zMX!j`;ojZ1iM)T^wpb`kdgs>vu_ZpXmEJKVmYKc-WcV^+$94qgVkT%dhGknxbtHJk z{-i%b^ziN)8RWLJhcFt$*rOP-&3{UP?RbARp3Uw~PIA}{QW&W~%1SLL105Xu{S#1Fm{&&dY+m`kTKHZYt++P5Ez{xV8}MU;6FkmqD6o}yADjb$o|jK zqZ|nUX@^higdxJcIZltRNHwdh(fx&VIA(`IuU~w9*Jjw{K1FSs4`ov>O&HTL{2S;m z?HGAoWens(Zf;C7(oiZ?GV)N*0>zH{O^y)99JwApHu0W`iru}e{;E)is5<*t;cop! zSN973w>vFH?0d5-&5R-;$ITY+&c;7upEP*je|hkqH2B=#{(Mq>bREJ9saze(ORyh~ zO>o31biLo5${J|G$Sy_$Z)ZKWeK=P(3vPw8|FXW8`JL(aAi7-tQt7L``C7cdQJriK zYf4|FH>lkT(PIl+53@(Cy7`ueCrBt*ZJic{^7NwmEpuN~5@bbru^-`EtOa+fJ5ff+(8Jt+ z;a6Q|N7VkDie;wb*+#*E$FxJB=B2kW-p3Aw~!R(MeZM zzlFdu(B^Naf6&1_KdEU?Ztl7Ne;dJnA%DRJ_*94e4#~Bt_eE08u#2?$YfxlC$*=$P zl-|X%uAp%@_^)FyO$Ga2i#SUOSANpq!xneM!Fjex(_oGlHww#E|PHCigfNdD3OBR0r zkX34Lnt>OTnjn_XKK0rqB4H&X!eb?Cg#IdH2aYip_dlkp*AujW{eQ!E5Y&Z`0Ea)P zQJI`QbRvus2+d4d6w1@AV$KMBz>UECEa5f|qXSioewQ&NBkSTFL@iVzxYFJ&%J%x% zXa^I-BGMgE7piHq={dQ#XO-S4K?{QoqV%6iImO_E7UevzdY!2O!39>urqqz!YtD|u zNhzdONI{p`%cFv26J@i^XKGcN_d@5?5*J zR2e&XYE`{}FvtJY&)}TuqhTS`tOQ2BJAZe6R=i|^A5xhLJKOKe)1t`n;`A5K4kWt%PrM)n6b zh81GH^S<*2+t;^+;%=q4Of+fDp%Y$cq4mso_WU$Q{NO_Bu>eZNiRkwe5$7DI({d$% zO}tn+(KC*~TUwD$u&HU>GXtw>oi-zBA+~yFuW@48&o4WEaur)@tupgg!fP&CXYSG{ zvS|4jGt0oq?wpZ1+@B5*)yi6~_DXN2vX-%v#mDp|{PLHV>-$)RN@r|*V(wRPc;Qgh zWhx!<({Lk6x?}0dx)6U8PV=NR;BQPecwq`(sZ;bxj^xti#88y2QiLPLx)Nm-MMcuI z*4tONF1d6@+Y@M!XgY)45!GpuM*_iVl-mxP?!z}@Kilm@q7P`GOPtT^M%o^KH2tgve}LfnTY+ZEKAHA_LiX*p z7R+Md;?<0RhiM<=3el0Kpd{L=(*eV-)0^QT8}A3enej%ptbU=->cacb7i(uEU@Xg zMt}Wl(daln$Lf@k4UAnAO4;fO=MXQ8r2ss?B!6;3F)7LD_L9c=LrWo?wd+hu8 zzqTbMZ1xz*W2xbBUu+%Nd%iyoWtA&GOAw0G0+nACC(xjdkHEQw2GWSn%4XBIZDU-q z?P`PA5I0%h8B1Pe{m(LS-kbBlB=6#lka#JlAeJaf0msdI-Ana|#p2*N7#QtHl0ro{ zs;3isZzul87^Pw8U)yM)NO8`c42*(;dQ4WAP@VO-ICJjjg@n-~@=xjS-{Sl@`3y-U zFp0>-QeRZ!1KE=ILkaV|u<-Z?HU<^Z+O4Q@UU9#ymY_=q(B9@N>#pP)6ICwxH1x=R zL#sw$qgwcUZmo@|ME+tW1)Q&!e&v9#bUU$rS#hYw~he! zr9CErxYZ5;_X$)aO!S?s3J^t}x=`YDrPzsY0w=1r@7N*+ z#-5CJ7>y{D!-p8`;Ez?#+wWI9Ss>wJK}&L$?io4A)jw*t5goh zv2cBIt+!+#Bi`I!gyIKL9^WP!g#0WF3D`W|sN$`l?ZEn9tkQ_ zCb^Hf^?A!aF*3Ipij}*Twi1h^db}^}pZSfji`$2%k@nZ2k)P}tWO5c95~CfCz#Yqa zmvXg)(hRqF{Dg&!iS>Wb625m8)X;GfG#s0o8wGpu_*GjOkH~e1;yIs5C5Ax4Z7KwiI^Wyal( z@fZLvQ^+COLrN178q3srU+2#zH&pD>GHaPUV&(vj3T=ijW^t2;kvD2h+OF;dkNu@N zu?8qg8nLye8q&WBvF{GP&@G^m%+QdvsHY#b)gfosOAcjZpE07hns%3L3Z01$;3mLL zFw30#xO-2^h6%0}!KJZ|CHz&fccbwVA)1yQrG(wi&0P<`lL4^EIPqdMi4-5H-N_jlua^?=OG)5jj~|C_Xh3(t!Y~~^0Y}s z%K9RL5!(|O#Sb%BC;`@w5%grEw5a6!aMb+$P;H%W8nfvkHk%NHjs==5Cmz1MSDyQxV+)^9MSx&C4rO6 zBi%1ozw?p)pqpmGWQ*UkqRa-_qoi}7dqSsLN0IjzG3%=PQ%;!hCLz1*;1OKrjPhg` zeHX?fx%x~;f=|}1Vk3giBHbmXky@dJeqNgyRiI{Xa`D!;7FlvPyF9)kdMSfkGu|)} z3oXIJe6s~f=cL^AexNn;RatTmy8g1-ClW=C8HSHX8ha&nJwNuMa zk(Cq)5j(68(J5pd4DRzL)W7gd%X;1ZzRTX5z&I^|6ItE8YaGU(Yowo;p3rMWP64qiMsHL{G7${+E2&6xTceQKXkx$hATFUt90weSUamBh62(Hsu z3zc;E_7hOHCTUy z%y+o|!^=AyQi#3s3Y_gRl@0`sr6HAm1neGLv0ftu`jheEZq1?-MqbI(_6Sbg9vk|i z!OISWRo_Nt|FI+fmnxURD6)jhf?ABpEQlL(T8#l2aDy9r8TL$&|5xkTbCHAl7dRhe zTQ|SwL*_W3ZBS}e3>RHb=w=NUI-fsK8ReWTdaMSnwj=RzcZ_t7V#kexZEv77d?IL5?66vQ&^$DKaF8tWi8 zHcj#|hf3LnFSA?VKfr@T*^ctGHzBf{BM|!>;=iA8H7jzffK2JJTOn9LBBR(6qn3|! z8~O;e5-Lf%PZmUAV@1-{BiHUmKgVh!3B330)!K7i5fT>)HTO4R4S50}GLYhoL4nc#b~+>B{r$4%E44tPPNSw@ zY%P+%-FD*K58X2kJdA4f;F;BGyJK2-K$isfBX9l24>o+x$pkD)Geg!po(YPaM%0>% z|6UBH<>N3ZgGF6B4oz$Q`{tT}$SFYoF^Yp-`9kNU{P+J>ALH~d@5VMCLm;k1pM*`D zcp3e_90uR}4r(YfF&dE#*7bUhSAK#fj4@Js-sgWbvVSO>(wYm}G8>d7oZ8Jr z##c8QKVf5l?C-7b6ibe@`}ex%t09L;Q*Fjf=*Wl~O>404OV5CG55#Y*46Y6X(C9Es zJdWZOL|Dz2Gf`LF=&jEdd*P7QbK8jz`69j4KJ?PM!n8a;T~|s8p*ar@yh6}}un2Ed z1b@)tSj|yb;A61|+DG>eo62e6Nc%6~n_(7lJbW{a$JtVV@fkjSBoR7&QM9Tn7!WpT z3$oKEg>7Fs&lSx2+c*Zp-h_`59OwzRRLtcTWy z?v81&XGk;Ut(oFqCQUuqI$5#9USo=OiCJs38331L&&)QWm#i1MCFs?~rK{M4x^XeU6+ZsdW>*Wk*LQ*R zACNLDn*NdfNJ`NwXV;Oj=E2i=^W*!T{*o=^zyw?CB_ixc;>I0o2EA?GD37ord%<1j zl?5b>Qx2BS)nbl}R zs~_Q#y2bY7=X}Z?n?Ggqb}Z@S18qK}LL2az2J3u_sk~&3eHjnpwGPP9CIsGQ1?jG9R(J^9mLCEVE>885I?rECK%MOmtGU ziCDL{QEfi+h99*P>wIvLwUtIc^|9{=bIO^q`__F!)(mNJ2wr&MOsrT`9+h4WW2w1i zS)ALv0N&&4$BA6j2P@6Qt5IuR6`+dS zNf>4qq%wpH(@{}jRgA#9jA>rW|DjJxxsKRWxTG`+tnPMJg!V8NB*Zr5H~$}1?-Uwr$&XCbn%(?1?+JC$>GYZQHhOC-dfh^#1+_{n_1hSXEuuu4}LLU5K4ngTKuQ ztIppfs4?J9IBM?bEv|)rGcU(-7JO%UGZ1d3x-=N~%FZHoOYH+CU{n|G@iV+@Dj+4rzgh(#)2t0sy`Abm3`gu3}L%~~l`#jVR123K+ zlHMLx^oyfwUs8dB0GXS~BkjTTj)h+gf+GUX25l5T(|HPiQkHNH3QK*;c#Z@T_;L#T#PoM^6BG zk)EhwXFz8!YjH=wBed2O*CxU~e)m;!>&s@J_7VE@sRyg6hjZrLe>+(McRN3&nwkMB zO~nu_3Q(DcSJ+M@4%pgwGsp&?3(VelwKU9V z6U^Y#5k*h5f41%|Y81kLi!5tOr5d;_n2Z_yu zC+mOa6+<6%!+1X)AO=SptE6s_UAnGBCEh4tH6T$H4p!C?1G)OPD#UJPa0Eet&2YJ? zMwiDOKW_Y5Bh4NNz}Sa8=ly3Q7#Hkdix|uZ!>8iq8zDwEh`$4p=SN%#8XXGM~BVS$&YyOR_hXe~ANe58`|3jJI+;B@`{PECS zGYPu?`6rx-*1J>~x8ip~O{uS}67@b9KcjJkEVhZCS861d`4mGsH9k3+G^|hS8o8o)@K)$rwMJG5AbP(a8ug|NE>S8q6JrYdsh# zTv1KLFc;8IjN)uFdZrrCTNJmr_9a9ob5cJ_$K1)NsfW~ z)sPwuZ@O&5pL%>!fG_V*L_Wj*UlXt`*spNSO*$R_6QkTbSGGtfed3O>E1&d`49IA~ zeCjFWvBUt^)TI!-i+-n9sRep0thTzl_`!6+YJrb=+d!S1&YSP^;X&c`gPJ*-eK@tRvOz zwkXU})+o$|Y!gbFq&z9Pnx0#1=gJTZ46r23XV^7&3+t6B1) zu)_mhL^A|MUBokNr(t6|?A&c^TN#9Y>vS@C?`GV=q;7z%#1M{dF@Q%GJby`hgeo`C zdx(!?bxjWSHm`EMT(vl++vYHGIwqYdH#)ye^WjLS)Gy2ojLjG>}9TR4*aXbio(&bWQ_9FX)_;5KoiHu6P!SSHBu6=csUd1DI!eE|+o z`V+)kKoz9N=y@g_eg;D4Q(uxT$fS6~{paFw(d#pn__0?iu}C5Ugg{4tK6^Dh@zQPV zs*e!;@vGj-9t)jsy>urU4}IkYY5WfRPX-j}p@4#=*+V#g`?c6~i2Vi!9R?>l59;Jf}6yU$ijL}p3TR-8W(-xB;Mu$<7os>D1e- z#qh#04*s{}1?;Owy!SY9^qcJ^Z6Fv&+e5_lw6_eTBNbB^6*x82zb2ceLU@kt_kvkB%(ij zVp{V%I_v2b@_DV`@dQw>u?HiP0v(g`4?~S{&+)wO!%=x>00-N%<{C0WDOUlRjS%4s zt?)_(ZFwXjEGp2QQ2-1jcb(U^&;P#WA5;I7L=G%ni|!Hdu&Rq*jw zu;M91OxaS0EINv-r%8gsC&2c%>~qHz6BoIk0&i(A%!)SOYz082M~0bHg3M#aagS-7 z^?$y6S$TjQBp449?hUuk`J`7T*F-E`IS9c%T1X(C2Af#>oXTk{F^Kn;Y7b_)0`$r0 zA_h}WGdSFh1Oyz`^4F3Z=>OpmUBCLRK#cv$QQ6$|o`Ed530^|_p=;-E3O;I*0Z`+n z_*$A@Ihg?U#?%z`ZcDf_f;uUqZBo*(DPXvIBj+#8?wjx#BM*@arB2Vvv&AvkF1~I2 zmk|ACI!@8bLE3lMjHF)iBxCd7)8BL9SXGC!`&_QbJI!emetu_!IBmFzZk12RyBaao zTGcd&$0*HOlIrG`2c-@G_K*np`LIBk=6PO7Imc+)8guBR&Qqh(-;MqWCV*bkMVCU$ zzj;5BOL(|LclgWSwGzxaN;teYI2W0UY1JAwp|5J7Fsp87&ZhJn`(>cGJZZqylKd)>Y3>KT>pLBe~*7-JHFM1|F78a z`}sZsNXk_D^^?NR1|wI3{ZG&=T}_sj}7% zQDoh}K&@DnuqUzf_+o5=SpInAuA3B3ur()LpAc`tW^JI845eK_y$o0Fgkwjy)+3wj~)QcNZ_oY_E2QYTP&FwXh9e%!{+{hxQ`_Fa`Y3e&{8n14-md8PKRZQ2^w1@ z|G7Xw^=x4X@+{doQlNuL8`$V}!~Z7M#EPx&MWc^olIgrxq@a}riSc}bT3M=vM&2m| z;IGAfSIp%E3kqw!5d0zF7kVr#*Xk+4fB1#AzlOAunCLGjgdb5H;a3*jdN50huUAWqIR3&5hH1C{r1W}UUZ2^2#9if>C8ZVchZF2Fw> z6{v~JaMb)7cJsP>5SCyhTDS@C<&;F84gk2&uLF6F8dxk z2X%$ae)bG}9TW&(4Vsb%522WA@Sr*a!>H@WLP$Q6!C)d3bD4^o9@V*IqYKm~R}=-Lo2HVq61x@Xdasgrtxn214p!Vwxg zb1E`tMzkJy^9qG?GCE5T{xSEKrg`Jw#3f3SGE?Bh_@* z)segurO|+}jYCU%_^*%ivc(f(UR=R-n7gPR^QBBUo}HOQGfk`-<%iHoml&r%5WD74yEpVh z@ac=&ymyugo9K`4{g32)T)X5RA+S!xgVN0GGJqF5gvA6cU3`dh1br|k@z#WDR)P(w zP@6KhHCc$qmJ%KHtM;xLd%kWsksAI`UteA7k&jljh5VncADud|FnUJmBs4n6ugzWo zNrVyBMz70#2e4u4ydKvT_))G4o}nBSFNsi-qrT|GFj|lRURrNRc#wrZ^gNEow&4^G z^hda)Abn2$mx|I+yP?o$OPb(?T?{lZE@E*&&E&;OLCdpz;U%HXjZ>U{iB~dyV8HAV zk$cCzk+T*w7OHzG0d+qRLhH2p8OJ=rhT8VhhOl*SVc`zZASvm_zht#&fmE1{UzMxM zROvZh7I)SGNqf!6)dHcQv&Nz)YEqOiI}}P`;XhROFVso>5=G3!XxxIxLd>;P<(s|y z3*b@4Y#^baJ;hGQ0pu)TrG9GYhP}N0!ha_4y+b7#QZJydMY~s&khx>};2`$lq`Cg{ zte|qCRBFX7Ozjy(tc&}AC*78z8vlJ=L^6#EkR%s|A`C``Uf(ApxgJQg`7|Pg5Acku z7L7$yGxWu9M;1pEvbS7@HbT4*zMqK|ec%aVaWaC9A?HC0@gta*45o(R1*P$6C5e>e zx-QUTdc!X^AJk^5af23dqs(t6f)$B`OB^l@`D-xhq6V?rAN*R4Z^gNb>I0-38?g1` zU5fq(;SVQ9C%mojVQ?LRdxj5P&~ze}2qhnK@kJdNTt?n0%b3e}N&@~jagGOaWL zCODa4fgjj@zF*BGvmOb}IbSNLPdWj!o9mBxvY!R0oJB1fOn}Ic)DUdx%wrHiH>Kfd z>CUK*Bp;iQQ&j%?ZW*Q;0~k$FB8qA$qKgy~#U!ucGEEPc)Yb6DL(^|q1|$RoYw@%O zOX#`<1Is7020tV1qDQRrf9!}?ShSpc;7kHTNM-nx*Uj>%&z@2l)AJv~k|J5jP%RS&byAVwP?6Ti>|e-9@u zQ=I+HHbn8Zh)UWoW^tFN3OsHpi-*4Y}`Bqnum27TE!DJk~qjTUzl$@>l|7Bjn z>9Bs&y2`W=5AHY0vkTD3UZkXb`p)|7V}oS!DB;%_bOETJIpawib8iih@2^N|pW{1D za|M?7AOVpI@lw(i?Kegm84G2QHW|mKjJ1x!I#fWKg{iBgMOv`JUF=z4p+a!ja&Z#V z7HgW8!b$5kD%~@8sG*p)RKv1jx`-gl>vpAfgE$5O+s`eyIzB_3sbS*oH%)T#QiFlw zmJ^w^rUT*&)@@4Nqaw&&ESYFg6&f{*wVTOk}9U;_jk};(NF&a^To9-h>YW7WEl>%rtxNuIhd`ts=r1*0a5Xu)0-af2CQsl$v)h z*?)SZE61GxcAXo_7Q2PB-|#42zT*4!cA;)_Ol?=~D1k^KstW5jW=lJ#vYTQV32>D_ zV)qaylx*xSfj#O6ZCxeoX}R$);I3+@q0@HE*Das`A)fUDg@G-h(N7mPP%R4Mt;ld& z&25_1I&4HktQ6DVs)!_(L16bj9&s52uCv>0h^0lOF*?E8vNBU=mN0kcF_#R6-h&I zyJ58sdIt7+jc5O}$x-Qy`8E35MW=|4V#EwaA_*TOmDmX)RWxf_YxkT?>No#o9KDx- zj6Y^?q5zbn0*7H6c0Kwz-lX08lmBk39yN-dUCdHO4mqZw&UpQp=@E_9V$F~m7VGz- z7tNDlJtTFk1z#5i5?s9(_3nx4)bv~mN(b#7L-7u}h`m;JGA^kxzr8(G)Oi&F6`KvYO!El&xIdrmNM z@M&3PbqWvyNf#tG-M*SpvY^5j3a8%;3gG@!&9q;Dk2Ta+Kdaz|)%+x->L0X)&YEBD zKl5E}xSWTui28iARPO07s`sVIFq=Bv6v;T_Z7AzPS0kvMX~9F^^?18>_)hlWj^6z2 z7kq#tcL}DVi{3Z^xF7cI(PF%!6u_Q&(BO1CF&C!2JWbxKaT%C{n?&LxuNg}Ok(x-< zT+%+8&zNIKIq58@^%lCr+9H#S===zu!B8S;5KA=70ozECmYlR;6mN6a_?`he$xmFNVIzC zi)ao#8Hy8po-J?yQ!^ZwfNpQ(AOAnIk7ZY(T2LRWk<-+xzdD3Il!2BQ@xwvN{ucJgp;pZwn>!jO-}MV@jqH#=LLe>-l5dqBBe= zfRu6IF-t3>J28tDa(AETddXYkSXECo5x&BKNn;6vk#cI@bzG#O3L>Y~-Fcyd8>ASt zREx{ST-+x^ECto-NBh(`1~AKykZ5Kc3VSQ;(pe8+h%FW=JaQkafbEd|#1_2#P{%L| zZ|CVpk`$L(yEr3Hr0r;*26~V`wwXK3fJAC5(@m-yGwfV?+cR=tPkQihOjtcSHwEK~ zZFHq@ibhTCfVm)0a+}n;-zi&>j1AOA9#Np$FO5H~sr{B?;ZBRhAw-vg1gnAyIDp^$ z{h})!4Uas>92}T+m-!g%#_-CX;cY#?XFvZf{IA)FVP3fh@Z6W1p9g?~>=v<|Ah;)p zE5{LX0(?cctm#SUvpyL!eW>U(%nwEAn1?2jJh^M!wTG@<$xeGN<$rzs&yjyhcFA)z zgy;5%nOX9iE^E9sww6bf<=+?9U|X}W*vm0{#R4S{FoAWuzmb3bq42@vD5NTmgtC=7 z3~fID0bDj+*}z}f{)=;4vV9NS3ZEE^Tms(KJ$o%eirxgGB1`CTaDVb8_{buH~PLO^4%gfQ*oi`3h`jTHFf0K z_2BndvXm^ZKf}5FZL#cTTX(ty4*?4qqoJ*00W%KEE0;v!ZuzbV8M`o zT}KRYs}>R7O92j+`9D+h&xzO(aP+Y-x`f%#A!m>mM7bEyZ|qzpSfstIz$whTc>_ZX z^#~Su5nJ7okQrVr&DJ#FjY(d~P{$XX&ns{Fxa}RA0|?CFw+WLkI*0V|+v*dVfen1s zD{UV$Ursi#_~zlCON#&ZdPT!8v?5pdf67%)MF;KCjr0{vlE+qPVGKo+uRC81vB1dT z%AA&w0}=DX7on+j&zsIhC*)^;xV+6~o$JwK0*Io2gdf!95>hboL>i_yi-E#sAH_F) z27wZak(>|a1r{7lB9}V~=StnFg8K<@0?k-k`HoK~h+-+Y^UZ;Dg;!L4geu4eQS(*%aT!E7PAiJJ+4b7P{hdLS`Mo z08#{cpl7)qSuDk9Hr=8sFx>*ni6ktg;orf&uykM#be0P;vFt^LwVzrO>7JGJ;E{g< zQm#}Vjvnbod1ae#z!qF1U@O1&%r7c)?;eMy00)9z=!n+O7Wc>|I8!ilVOl=8I!P8Q@d2t&z zZpzsG$uH`N|CeT_LifQGYjDTh+w~Bpj0(h4ocp=YVCvd)@|PJ|naz8L-W83-6PW4d zWi<>6Fx3)@WjQ_sf+CST$6$UT1r}e0{s9aGwMcDfUJ)9H>gRHQtIVnr@8eFw2>{Fw z8BDq(5$Lp>aj;J%+$`e0)G^N zJ+>gkwd%k6E+O{|R$j~HC8_u&O-Z@F?rj0gs1Qj@cTf=@QqzS(q734or5bT>fgQoi-Zr65Bgi{oU;A zS#I^tSskJB6i9=SA+Z?%O=* z)DP9C;VUs~2BjEqPJzE~3_sEgNC!4$NWAC;Uz+m zLS6X8&xA83hP;xFMbjePHY;DI450PH_}5g6su)M3y{XE3-Ll?X{rS(S707yB#!$v8 zcdwNW{z7MyAU!TbzTDV&NE@e-(2={Cdej60gM2JB107!!-QmeSdB4Bh_HU zoQEnVKlrn!3y&7R~>bLZLRawEKhIv(4 z%lkFK_!_2Sp1jkR9x^M$aOt2F{a5w~nSCs(pdsljDI8q`0~1hh=5FRnF=q{;$D|_)B|RPKW>5NVz|=5uv_?k;&62$@+#U&z?F&e@N?$Yte1{kMB&{qov=` zaoJkF9Z{>`Af6HTjMRpFhv5(Xbjyy=B;97Sd*6gST1}J6OtT7weT$y?z5sv?wbDX) zp^Yz4bMO`5C@^I6qkg*|GuNPR#WS-XIJc*#@KQwGdy%pE(FzakC2k3HB#V$ zzz|j!F-B=|FbNVR^9b4q?raD)za?GPYVr!-NBwC{FdWbZsqgHMdcRlgH<<>)b%RToX zTGXv_*@8CGcDBePil4dbV7{1L$>b%lZ1$kn3%^W@*w{Qc((@+!uJTRG$Q16>@%y|H zzD<2+kIbamxey*pj&lHb+bTLrOeBu{_t;}J&0kce;Y88^N92y_1RgQBD=^6VdW0T- zNw?!MwTEX%ZWoV?aM$^4_TvefY~IcOayVHaa)PEp1EZ{W*qUTC+uEoY4RN3!joR<} zoj{z8rou12W7gv-o{e&aCz!Yj#v+2+VlVu@eLWjpsmzW_^i;kMMa!wqj+)j`sMBMf z?v*7xOTAkxztsD*Gu79}i-+zDnVVKPqePy}gHHX9?fF+Iy({gW5c39JVrdO->!2-gS zh_Gn|ERK)eXf*$y^&(dR^ykDlR>I9}Qb-5*O} zwn~>csa4hsu1y*88{8ly{z}BJSh;TT5_nm2hkPe%bG4^&q3g+2=)74=em! z1SJ5v!+*&GxU=98QUSTF(OU4w25&c`3)rTLTeZhPu@$+D4WbEgxWCGUn)#bStf23mQz`DvU<6u(YBQHe; zq-3krnH-cwP{m3D?b-Y(=IRVT4KX#_8>MyQO_v&INC(m@L>M;1fcyeoqZyk`zz%cq zGAU`a2l3Q3?>AF7(kM!RO9F8U+%zG|1I;hH2-n=9u58^Tqm5rcVUqxH;gY$6*diZ) zSb8&?APxDhC1R=tYxixlQmn2@k3ID%%TWd`@cuD$nxwAwpZ=_0^NDnchLT8Z6%mR1 z2)&#acF3B5^iEX@HcVOYz!4u%BG#x#Bdv*V_#_OX?&RuE3)w*{tKFu0CKnaj6c_nh zEJ*sVu7>h%R%2yuV{%wAutIZLEI}U5PaUDkxiEd ze`l>A0C$?x7WfzN3_>WH_Xx^28bPznLi5@R^v`xVrtQk!x-32!C;>RY*+h`IKA(Hq zL;yRLgRGLh&%iVG^~Xv2KHFGKq7@&@3ru360o}bo=hOB)j}cTkO>$t zmx{}@kcxW&9W!zLD+@CGLmS0?cuAL!LDP$4$X(_;HEi7`g%-)Q>lx*^0Jr<^(KqQ7 zEV1R!JJjK|W-RxST7PxCqra z!BF2)b(!_VW|z=5Wz=EFC^p`Tr&7IfU^}kmo92udRG%3XND-BrYRBBD2p%xa*kg_5 z(mB3rPjqkR1QekBc8t*sb_aGh4&w4YfkSXFxcv7xu^f+s%rtuOqI&nsk8xwMXQ3g? znY#RC>f|h2&}T~jtWrxwY7*h_77u5#W&jx_isEu5&`Pq(1*E-y6$JU)!~%DltFZ>3 z4rk47KR5|Y6WMnf6p&h_bIH%a`>J$lu?ihxC+RKd@i73UJ8){JSJt#C^c=nHirn>8 znHGpF;?m*tOBK#o7PnV^B$BF)*s83Kt8`Fk3e?;0ijL3&Zlpd}5KUu$yQ2JURwZZ< zpZ((_1DLoJeT->qI)fAa6K16|2y%+QzN6N!zy=Xbq$N4s&SNs#yw$In*?-Zy#$fj! zNg?Y=2}1y;x;G%<;-twkLusRA9ci-39;Fg;^-RTJIm|`xvNQWr67^|45|37U5XmF8 zqdimPMt_tAPWu65BsiXUgYmz}2EIqb)oLayjP>|`XEAPWr?zM*{gpDWX&k#M2sZ-> zYsAdsv#F;nZs}pMZg)H95#dB9R;FEZj%p^!PJO@me;{ufwZ~`%$~J88)!J}~2kP~L z6b7B;)^Hgk1LkGFSLj^Pj0kSGTRtAci2*)g(5?YJMRCN5Hk>_)LBf8}9svu#m~HbY z@1n%>Qu3U+ljBFaGX{@p_(ppUD2?DKO3`G!72`x5UUeiLGV5C0~W^G%57 zKBNase+(||q<51jGIqf74@Wi3O4)Gmginf7){2Qq+9)BfcnO5cLJo03TMIbfYbg}> zVL?7s?mEh&5$JFiTdzel9Dq zt11|Q;Vj8?zy(YGlo*Aq!FvD2DsS|wqRJ4k1DPSEnBPZ=XVxY+WTs=0At8Kb)YL!) z&#$XJsD#vJs&^4mw%W^soeEE0nKlh+?utJC$JLW=Hr(TgiCoY0T`P^0yb>&EZkCOUOK1wfMl=&9GOob%tn`p%ovB$>&fep$Ki=@ZgV}JLN0u)MBA8E#9Rypn7TJuP>$;_1usl!ti; z<**#s2t&)mN3(^O7i;`QrQA^vRY>dZEHLi8`Csb3?8~wtG66<4Byagbx`5 z^gFFv-1oVdvvk`q;>h)94F9>w^;;*-}qb zN(=jJgxe_b%5L4gPj2iT6byO49fvDb4UspX#|6iI$;6I9DF6|gW=zFfwM9ut2p^)p zdi%?NJNRX0i1~qicuWbYEYY{=sm^wCvR|}JUn?Pu7!PfR=|$(S23BIU5`XxTt;i`N zxV42j`6vR<)uOR%eBC4TL|-(bQl`ABCmKJkAR{yw*vN!~tGdJMVxzIJvT?aIkvA>h z@XAPJSh8$U zddky<0x(E@a9D6O1tXEh(%muGNm1VXOfXVfv@wXD*AWZr)!*q?uQ;&?0$D~%$=TR^ zBDR-WsWq3vkhB1UW>ITawtW3L${sQ8zw~j085WC3 zO?K#2tq0ohY@Ml8y*rkPo*MzQ_$li|jap@e9JJs5)&-)%9}vRQe8B`CR6jwpVfc+R zxa20*CKd>9V6A=cG6X=SXd1hP@hHC>eN6}qz8j7X9nO2Fg5~7GeR%CTCGO2{dCCV4 zT_eCOp77ToZr5jJT0*ddJ}eZNl)DhQ*@L3cmZ%t_lE7}82Q?4m(^)?M2`}`_d=q`S zm{p`z{2I%6Nz=p~Wp^8>C%)yjin_rUq-Zq@Cbwiv3Vl@%6QwCu3 zf(oO93ZDpxJJGr%Sw;F5it^)X%`K-q)cYk(sS{4ei}~#yuWk4n2M)rnP8~7^Q{k|+ z&>AS=`Dsw;JA35mTQYHpG|yJ~k(1dN5isv}f|euE2!8@!rgDeN1;oY31oRMlVuf1v zaU$}i3jO#vAu3pzO>Je*W69NpiU&l78}t)}-*`i1WDA+Q4}#TbhNJ>vNN>OurFO$7 zTc=V%-kJknc;yOGOx)6sH~X^-kDdMfoA=x$S;Q`kB{3|O=V6nfw#q^G9D{h#>-Ksw zq_M3CyaoyY0vPLBX`Q_;U_6sH4t^TiTefO(-)PJ!j7ws-OmQ)>k%{GI+5;LUGUDBw zC~u*$>p&v;!?wiLx)??mk+B*~(?-nk;?|--m32De7BCote1N-f6~Quy`X+s3$&bWh z{6Cln;FEzfLl3nK5iEZrM1d&_zyu03NzyD7K-;A69dJb>#!lnuM_qDGh0)?CDeZhK z)^eX##4kymv7)R2*6rUpO@RLdHI1G=dka~Bvb&C1LqF1VvBeiu{5n`0+OIn#l2?$E zve(0N3=3l8QZ_c~yi~WE*C^reaphr&f>$m7Q(|Eb#>7^E>^J!Z>ssJ(uFPoX6q9`9dFQSQ(P;*1OoiKYiAMues6bb z96VF7t$kZPUw*jpOkjU@v^quE1Z@o}&x>>hl&=JiEw>8#@8uNyHkDZ+MBZfNnKNDX zPz$g7rGn9mmRSE7vNv(U-Jh&R)M$n-**J?r@bWxJH{E)4a^`;y6Bnc0p)$h_me@cy zK$i#*mXvu$qE9uEz#Pvq;mu- zFd+P~Han(>$edr`2)*{oyduHaj&sb=me}}`Ov1dzeJd` z%1MdJ&zyQivC+YVsIHuV+5xeXk;+_cOSzCR;$uF{tH@hcwP&%cM@PaCyyP##c@=Vs zh@w54$2#lA?n^@SEFkea!05yB_i8?c>9LsH2n5Vsl*Z`R-;WaC4rW?fK`e(ZY}c(n z7PkI*1_b{?ewe6q{$6W z=rOoHJMdRVD=RDyvYJJL0Ax z&i11g)0nx1>Vy~$i~#XL63X}lgbR#YI_vC75%=ZEt_ zXk4_)oOzxw44Qu(dXbQS4PP|%h7el*7)Qj69Ycf^Vp47ywWNQ34k;-lLgF86T=X31 z-)Yolw8a#>d%_sF;@*dPOW(8)$2?+IekS>RE~@ybeaN{`xodEjz0S-5gxTkM(SbUE zs0I&vr#e4xDi4g(&%bha-+MoXiH&=`@@#fxdg~YK)G0hb?Yf0KTN=-emca6j)mS<0 z2Xtzzhtv4q45SwCXS(80$JFonmZ`)9XYhrjqhLN-w0Z#?cmuPxFj#GVOs#5q&!N~utXK!dxV zjI$aKba?-nn3R1WO-}Utst>G6!ZWXT6{qZmi42^a87L6%kdK9pY1N}A(W^fKHT_Kc zBro~1lrG&VtOrLN7ul8F6MIzUf)Hj|umbg@`_ z%BK9#rqC+QHb-IHOx|g!4WRR#UvHExuXYb1fBJK-SYpb?^I+oN<${mjiDQP;qVnpQ zm9$3cP%+Kj&YP}IN=|i^T~g7r{D8Nw658iJJx@esDnLP*@!Q!)(ameo3(aW;# zCi9yc4V#v;Dsp6T%*|o}8tpK2_W3n8TsCStV8$4lf2Vr z7`AL5WuaxR0%5^n=D?whJ<$Z2B%*heD_mg^{Q3nK25|I`S2w@31HT?mJH|3}jlr&u z{BsWm(}KWmeAodjhc@F-;+vu2T`$^_8@OyOLL4c1)|8(uki@U;miDn6%Z(f$a(gG6t^h1nNzWy3AU76BNFNB zsmgJ;7Q{`ds8^60DSpSt9ZapcwQEA$ovz}hN_W2s~W;M_%0Q0^X=y@D0P8A8plZ4FAnD)f*CgGg(BAE~m6LQ$S^GIyV z9WZ}{vU2pPC*6_^d6;Xw+|QI9kzGOQ4iOJpN>QiTZ;ou6%Oqa+v4J}g8iX95w`*N{ z7UT%D3I;`n`}oFTDcCqwW^*QCaWAqO^u<7<^mi>RqzzaXUSqhn!yRH4VYi%{H|SsC zvH4^aBG9r?*-yZdCPE0Pp=6=ql1CtbJuIiz*l6N+kY!xBi%O@LqntN?y|#@|BandE z0{_kWXvgYkUr;X*4Le;z3;x`-`f*~NZ%121593?(A^bLFjxEy%mz{Jl8nT2wP0EPi z6kATd!YH2jrdHKfE-QKg{U{r_E|eD;`<*~M_+(|C0GO>P}ps2Bsi z;0G;}07hf!A0`|~V5X??S{;t!2V>(Sp%mO%UwG0%`Al8Gaj(;*PrdHs&qn=s6(462~`b5IwfOwzQLcF+7o3L5P#r4&G>pO6b z<8xzXRM8Jv_=5%;JsbUuUUxlsp;osf%+ z&WaF`f$%YQ`L~;$8;qS<1GK!Z183liyBKG__D09m|H&DGECA9jK7B%^KNC#-nf;`8 z-U4S6*==W!F_5#2_T$X9ZZ*#`AO`5)I9W-{0N6@Iv62UovZ{L{KLn?I?d#&c{j9d` zp&D;W>67|?yvs+c)XS<1Bgg1zLNo&F>Yp$XU6Vj~*~MZD>TbsyTApoOd(eOltAS?6 zF#CO^tAOuUIzTWy`S%;1BJ2Sqbubb_=R*I;ni3qI=~1R(4|iqspgr6%)Ot1(OdaWv zkt6$`QLV^pu5?FPH-3$|cQK&8z|EBGi>~b73`Qr;Z}X?z;pcjs^blgYGl&t`Mj5q# z9ybOl4SLXlCwS*|Wz}oE{YQh;nP6zpB=4QXD28L1oB>TFdzcNmxMft@NIk7I&H061 z>!?D^eC{fuc+&S6N$WmRKBe%oK3GBpKe)?J4sCea0ySn;rx*P<%nBvE@uT+7dxn<% zqpRUP2=lS@Y=x8}y`qB*4<3l7Bzs{?Se()jjX)FPEIQ-I`+-wJ`BKg=Q`9h*d{_OP z|4Jz^=>v{#qs+e?f8yIHy!>k;$~Zc&SIhb+{+Fk9d;I@dN50$h;8{Nyt^KS}1y7tP z8#b)fpEt`z^ptq9=4{Y7birSW@v2BOsAS9UqV<`5R>ia#p3zD{@@Xy%A?Is1$!UYS zYzZBtxE>N5cQG~x_^TtlJh2`70AP=L3V6Wg$tZ7A{4Z}1kNyXX!pj%s27KI~yowF@ zCqH?+h-`;33oqTtY==pI@;1%7*%Vx^h_Ba1H|^hB@?y_$SmWGoYk00&D*BLN15n3xw{`w3EiJ^@Xatz4~sbHZE8fX%cw4n_$CG+@R^k{420UE}n)dS-C z;n5ul_an6UahTRRH|v1&QJG@!+@87HTlvI6NKZ5*;F^Y{m`1prb|`E)j8kgbMkRHt z0y+*$5I&OA$l{{x0cG`jE^y#Igx~#fTUpWxQ6|OH0UW^|yo@xCPCzO^!CG7V?D-%- zvk(v_w@rue;UjWhEm%Dy02omKRC{mJH84y$0oY|y-8=Z9`C<+xu*dnGSmC_8vt)|_ zhgy!GP*0z`y9$53aQOFJZSQ-owzag=yJXl0U}1zt*&x|FV($H8yq7ORbL#+`_R0H0!n(2tCfxb7~4w8vNvXm-BxHV|a*T8>0^ONXiFKV=Fch zYdSN6=jmuZtWPX5L~9qFs3Qwj=5(ndKv*l}ikdKgq$E*U0rHY7snQ;6HeiaJ>oE&C z0)_HHiOcw zf6I^54=5H7A;fZX&$PPd6wlk!0ujSvdSdY_W*-C6ge#B$nkEAkDp7_$d0lVMgxhgy zsq)aBps>|_*ICEx`kzrS^P5_oc!@}ru?Vw$KG>YCSWMxYia%{eS64oA-fHxB`iU*{ zZtp!j$~Inlvv|Aan;BYP7nJ$>%?t%}hv?^KJACKQdKt5-K3;EW9d!cCNV~&Vc-aFP zRXe!z`Ei@dAG~|0mOCBCT&Ih5pKZomp8}W)1{f~0m>?D66sO`A$T?-A;vgft;fkS1 zhv5>>32^szcLTFcK**Oy5_)1|QbPutCyrZ*jWD+7)0rZ#rL}50B#Zm+u(|-ybQ$FT zSj68pPVj1e*m+AepIx?hgGr$A$jfbz-o;2d!~NrA-Gp%%4YUI5+b~) zHA3@UZbx@#p%YIimUvR;W5IeeSJ+@8h{0&|AVu%Umg_xVMeF#NylxtE5dxm%UQTDv z3HFE80rG0RD|m=Tg_jT@TN|cdE?qd3C+-HVgd$5T+2}`}2ULSeExlJzbY84G|mi@1KMnD+X?^+=F z0`tAK6JG{-<{AqRaXakAuM$ZGQH$F?tO6eiM^8nF#$5>E}rgv%z2s%dXfDak%4 zGE1ODvClV7Ks^Q$8cjSM$0yH*2)d@)N?nt8_5>W)0`HFEwV!AwD8eI!J#M33?UJXI zMUR8&i+C>-45Fkx{Pv}yd#-3LrEuaw?~g#)=H))5KtE#gDAhsxMRgBxX1~1Q{?J}H zkgw2H;Sb>}B6EJt%!Xq*c_9IXwHu1U2K8K%s(<)uqQsW>MX!n#3qr?e*9#;>yV#b(POM?_KP zKQB_7m|8Jd9z8|}z@hPw-`{q^;vwn)&fLLnf0BR-n>OzhV}W@SJRZU}Wx{6i<9N4Ml(*LaZw*$Tcp-+%lwI=X9-&x?x zk{g|!0~upW%Q@K0J(QV2rE!$pW*Puj2n|og1*tn4+yjS5E$G~2|8-E8^6u}SXT!cY zvh9$U9Qha0D>Rc2an7|ib$ggSvs-0XM5s^tOuw|i{NAm~0#x0?)&h>M7OQA4H~p>7 zo||}TIS*nw{b>++!`^PXfEPR~zvj{0;x!D|GRyJGhL(dyoc)}8fTt)0ziI(Op`>)& zWVhRb7i1lZyn#>@O6TTlo-`*!>@JPdS=yl&%=%+URYT-1@S9B$nxwKPII;sQM(Cb( zX|wPhsX!eX1sP2df2pI5XX=_R;uvdB(=e(}Ffu3=0>*Ff4+w!mkcWc>vl?^a;77SU z-C?)##g>tCEI}>YT%HtA+|yvh$7y~YBz)tUuG9wOTi8}h9&%CG|{~uRh0h>pxb(w~lnVA{CK$C{CNyAN(G>i>1 zPnemRnVFfHnVFfX>7VzsyVAeXwd|R(G-HiroqK$JPf+EkDRmzn?aOP08l+w?v*o#} z!b+C^9rr5YL`eCD0M~Wvd96(DQ1K=(#8aV#Y8gfYhEwlo+_Kp;?f3_U&E^CZ;_}Qa zih6w&NB(Xat73if{^@6S|44BxvQ?_MvTMXgxHolnnQl6~nw^MBNa3JH_C`FDg_jdM zyI)h;&Vwq$y*30+pD0UFp7t6dTzPZcz&TMwcc~~(Ip2QuX>?y{-*x*Yw{H$0iq8G9 z2V8Vmdgsi6zSEq$wRRMF3iZZacwTx?rk2xZtOwQHdqv5gV7c==P_jm(Q7Uh%EAOf+ z?=LCT6uu(|boKM)c&sB_oMryB%zOi7O;)*yt6T2lR6FaS?Lmh=!&v8BDm2$ipRp->Zjj=h2lHV%o= zd3FAg4vEt<3c|xP^dgaJXm<6X(Rr%=M=x}+l47CJA_IV{s6~q7aIBczl8m8dm5~GT zkMQnc#i>greF-3pzfJl1+ftEJAE6)lJ}%}yR+IP=c7XOGVFt86p(pwNF$S4r7A)_p zm`moIw@rUMEQZozu<&;_s@Z82>U^Ts8j-;g<|U^u6c;CK`~Kz5p|e!Bn05XbpT;4% z=2so`WvSp=v|fFXX}_OmYpl4xEB?$Rv$ndD%serHo0( z%2tH!7{eaOkV^X}&xesex!W336tlSYt%?M?;@`m8MC>LsmvI;sQ3c8DvnA#n;QsvM z07St95VaW@l_u{;9y7?uP?wwEu7nsd4)wzFVne(3fTSR_V)Oywv>K4Srw$23i~je& z(HbR@Kk@V=9x2-Fw|+mDvOgM@9l&@!?1I?3a>*%`1~UmTs}nE$VBjTCeAxfUO5y$g7@zrA^heZvtI;T+w2UczX z_^ml%d6^Wm`=<4%k#=SriEp#$LpUD-01Lh%A9>cLD5N04OSqb!Rh`4l7_RoHCD;mT z4Vy0UHHP|jXeYVU4k7-TQ;|+H!OJMt^B`99A^iF$9A@#i5kn8A{q~fU_NNWD^e3bb z$zbQe8~VoYmM;${h#jVthbPwnr$GVmap|`Sq1(&srE)>CgOV{zdm9Ay1ooce#;Eb} zF06GWP~*&edqG zoL>UkLaMZUthIdpRCXhIPE`j>iQ<{^%Rc0iW8EdT&%mxl(f&A0+WIiV84Si448|F> zQfJA>T`^*_ix_yjnJ|mLUodkEIgkp7ESUN;DRsu?mQQ~thf!N<=eSLf1=Fd$ zIoWYtbXWF!MwJe)V3cL8lp!YStiq`{fRX9}d<4ubMtA$qeEd^tbu|}>nBTv(JQOh| zL{K~H?sac)9|8q3OZa3TLLS<0+!)*~6aByCNL2=C3WR&p5ee0Y=lJwM`(O9gLjn~N zS%am>ddmnx;oe{fI0|G+hqhgl)_1ohhNjF+Il7GdV8oSS=UC8p`AQ0PU zYvguq$I^5r&P-+=L<+F&diMuIpi>}A3A~Kx1h2yKg-cam`E5)Y8D{s9!i$cvN;Rqr zsyYu8k`8`zK4!J!bcqCov+lC?4x>>}jDv$kiPHO|-$XTWeuLB}MZ%4tRo8-u@ z{4X&&Qp>O^VN!(WqgIo6X39sL=mul=wGk( zZHOYtFxue1@8zGV;z?@Y4=*HGm_Q+^;zlVW_#rCu#)jvO-zZQW?tkxrv%tV6XjNK} zwr|LNBn}-?N&z-2!e}%~R~}D;g}EI?h^ysY-4T>WWU#+QtYz@w@0RYD3zVupH*Pv6 zn-U+K}QxReu58;Za`b+~2Qeu9zn!;j;V$l7On&5G{}jj>H94d0vQsROiI)VSUF zUu2uMFkg!qgi9?PSN=i|9`(JDDW9&Z4N@=SxH2vxr2~(|vdtN)MHgOaBr{c`YN zF8qmVA5kLwUIvDG(g|UjN|!p_?vW#OB}U$zAf!bQWEwOq5=yKU%XVNSC@^?&1uM^m z&+J&=i2#WaGFAOrb!rX2kjnBvif!ab@xww|Jw8do>=WCGfqJQ+FI9V-tSuCO)V= z4-q5>^=sG!*KMPk^pH*N3iNA)qnZfsws*DHIHN$3g)*kH1|2u*-fOCt@tS|tNXp?1 z#smC6F{+cQ51hNTUX>fXMzF;JC4_G6W8-S?*{9a5U|-fzM#mbIVUwmV>oat#rZNkg zzJ+R^$UEF(+XeC=0^XCScIAw0Nz+OL>CKvmJk52D+JF-Ak`$McBXnO>bQ@?` zkMS2ss!d<(>ZuLe(tRnGK8$UD#*dzm1b|DD`c=-DPq70nhk%@nO~}eL2~j8xI#s2F zet*GnuYy;t3XL_JCT?YWhP_CS!mT|NT0_UwGjVrBx@s#U_I z$-b=mD1CiXKfnmyE!FDq4VbUBt{ClRXzi#tk9k&j0Dmb8K-yf~6f*ho&~R!!4M0rD zR0??fP@v*z_3ZnH>v_AUdnr89W6PuV<>JkfA@bc<7!B&ZXt5eab)1+)BT1ev-< z(m(9)2a>kHHAKuCyF4l-I2JAKhz^a5oM*TMdXRJ=o1|U$ld{5d$$MHybXQzU z$PNYQ*{6I)46)}w-aWGVX#2R=ct8}M()3PpUzLh#`z1}D$u3rRol*^|S-eubi768yV416v;sV~J6 zI)htyUC1tzMt`H!5rTrca;xh9mJFRhb|wmP9^3rp%Xn(EIoB&a&+7O{Nv44602h?< zPA}rNQK8X=c9+=5>rl6IfbN;WtH1u`R$z0Mpl`K0TbGbtP<(Ra?`qWVjY?^@)An^b zRbBZ+w)a(_cafq(lZO8GuTNCGy$w&#S24K1TG-AZzi9x~xR`?c25CeW&C>cfae5!sg~= z*4v^S{D%vF8+SA8AJOp|?oHhKTO=Q~&@R6Q+fhH>lWfB81tYhb&(w}}RVXBbYsgvB z6L@)1YQ!dRjp?j{=S78Ly-0I7goP|1xvX~5$_fZXfRZ3vNC%CQec6Iubi(-V<7@!- z8i%se%aTR_j!1_;*w3)_VdA8cW7!FfU^5KtFZrjwY|06r6Ak$871*nSD{E0@+?@88 z&6^@6|s4_rqkL0~hZMR13r}$eY2}k?Q11}hc z2$rhcI&+7SwF%CI7&hJ7ZUO#_JZrds{<(IuG(BJh^>%< zrBqemRSGro&unVmWux&Tn(QW4qsl+hx<|Q7BM~A0)XXEgPSqJld2QEjJ&L)+a6&)o z@MmbVE*10y~wGX7QQIulz86mW=0&K*z7>8hCs&kMFI??RO?`^1 z5S$@&TEMrO!I!jr(&nyS0*WK1=aTyYI-oJHs0MsREOy{UtW2~CTBd)+RLSsro zPCHw0JnKw;u=wD*(MGOx%=Zk!@1Ihw2-Z_;qw1zf+NI=t?;RE9Rhqr|N|u-HRtP-y zvi-GDBR_X)((H{(bN)01S{?7&#`_+!3qx|t>J|?egzhYCC+oRzfyiyi?hMd?sXw4S zGH+3p^~(Qa(U5C1pUj| z(fXwhMFfAw9NAc+l0vismKyiNC=$0)U7GP1cItk+fdBIH1kA$k zjD>To4Mr|f{=tF8ti^vrkh^4>iZ2lY5GTu8U8wwNZoA-G7dJ_LAa zJ3$H_%Jmscata)>4kq{E0(*C?gD(DTgOreuf9td#Im0pc&4?xET7>cfs?HR9~^L^!6;Gk3XjO zf4@tSmb4Y@!(zJTuV**q-wjN)bdb77lcLxi_eqtO6E(NW#A4afhi)El;6W2rqD>HGu@`$eU zn)}JKZUaHMg$g8phC~`(h8Hb%0{d9y*n%#5-JqZJ)gQAtpo8up!9%|QP-S{x*h&{h6|gWPE#0+i{C9ji`~NG8#P>k3lq7v~X{q@f? z@3~bcC{o2;lMu0SXwm7>-B-^1@zJ!TyeM^M(Q>V9`@jSuvV(Y157~_gOwceQvQt0P z3%`DG)@<<_kQ@#2U4$c|_XLhvV7z8`WE1uf+49WIuK&e!okN9a_TTu6wqPJ1$WL<2 z$V-4ZiHH>HT%2xDPM>aYV&3%2q*)TpkkyXqJR7{$Ql`%&b*Q`ZrBovry6Ac0t!!UCsru?YF==Lp(8*2%lxrl)GJYJg!muknp~+8=3B zUA;jAnB+f%X5nTyZ4tg?+Dtq43NMYgPCK&uR$`!Ad{{YSWYYd*54kJh!Edc`Qdh5= zhSgZW!k0FsC7@6&pr%Y9s-^hDze1D#&iW|0Z%QGTxYgJ;RQtGXw*ifW{9*o!|AHgr zBP`pK+A7(xmzO{RWU{vpWppf3k0XJ|nt8MaP<^t{WIKBR#u%2R`AHbumw2l`Te%Q% zDJvrH+ZJTTGYQ?<4E+{l%wIKwyP&km(l&bE8pZ@w^NQ6^-CaaW??)@%D(4xMkg{CU1z&SGQ_xMm+pHvtSjXR?+Ts^5An{d?#%i?06jZm)uxgwUG#U?sDbZ) zhy5`U+!6hQ_2!Ak3E`huTdcyn%dTdq6=It zY;M(EXJ8~SgD9!qyfb#A!#&m|XB^D+lU4E zQ}9KrTO5e4y8F**d+k{5GN^A8sBfn-*obb`!P;>7Iw3dXhwQV(M*>~5w4NCg@LR!q zpTj?S0x)`uc#*v_CG}WUhhs0Wrua`3)|uT^8k~y-Vjtv%Y1k#%#zFrzDYpKh&-6%# zw1HYSNB#(x={BZry*VfQUn$&Y)XT+Dg~(RIZak#!4E=LyFxwyhI)f9;Z4TX$VvIOI zedC77g}9rF6a$9rp0L1F4?42iUnsz61?oUibl35SOz! z56p0-cB=HZcIa{(YCC~OXQXd^2zPLla^-UY+K0T5pdHk0|2i^x5W()gz%dVza94>! zWaZ<}Lpq#*6ssB!=4q)Q)a!e#tc{Yqsmu5}JbB)<9bg{K%aP$EvASM*f}%{1$}pUG5pXk( zPmB!=m1)u?PBQW9ez7Tb6<9?UC?kh|=Vj&oiW2_4F9uQ> z0Gof>@@kT;7MaQ&#!F;CgH%^Oj0lQvTrIAn^G?1WG{+mRJTw^%*9Q9=e@_ky=<2FN z>7}G@`GRYB)zE|hd3)|9bUeyFPSl;U9L#yDI5EN#KGL~*8pp2cCT=1>niQ4w13Z{r zJi5O=UT(w7qu?t1XO_*i?r4u6-9_25!YyGo{B+i9@Eepgq>C*fd9tx;=&(^);%KLNlGtdOm$ujh zJ+ZNeHXuPfQD7v(&620lxPaf#kw&JNidl=TQp+wa;Pj&{;K`3rfE_XTk_EdH{lzv| zIMnobwIYY06~vJjqIgtu-~)^jI?2AU_@c^Oz3w9MSBUV~|55!0%tkkBVXLc5)g0 zv9ZxJ)BV-4-$NPs?mO=|&jIUJe4oeMo!rtKT6tP5>p9E3N3^Ye){VYUE_otyov2gG zW%PtoP`^V^|0YqbtaH%$)g^M|?*?VbbKZmMqxil|Wn_1G-t(7zcdr>D308ZV-QF(L z4zeRR(aU9mWaelcpb}xfPMeflyPJ3+q}P2ErCHgGv(q@h|0LLVu8!Erb5jw)z{C_C;~XpEa>2(u(t3~@_e-3i z;#G(mY9Y`JHrO1eVDMRAaPC*6ubHv`lj{H=HP9AcujMO^1;WMkdljwa zYEKCAPH0()D>voC9iZO)N_B-y;qfcLO<9?_FK6l0`%~E5GyA6}*2go00;$^^ivHtj z$rGb0QGYjwYtj%e%$Qo(-+6kidW#fYH0CCE1{7@Y{{yZNE_pVJJAhOmjHiH zi)Rq@jdj!SwuZYb_SJcOOzn=_RL4K{N2hV&u>-W*!JH4gpw~E@ zcxWfwV2o6-)N&dZKJ->aE$KV9Vw9Ff{3y zUtp`{e%q7PnX%vCYi+D?NjMsYZh7Bpj6Lu&ZhWWbWzxN=7w zS_x^MG?Y{8cjNGeIMdY`QxRdE83F6sRE#NpdrDkG!XDB+Sm+dr9@0EG=+_4a@r^aA zn7q&X1EhPj(0Gz;!;_y^6rsWr%82L2ktv0^l!~zm%i0cq4m~@4<^LHzlzwDZUQj#s zDxQL1Ht~+S*DgY{PHt}jw6Fs0O;FMX-cc?8UiWJ_#F>KEG|nxz?*s>W#m7sT_9mtq zPLPIajX_S@AL3G8ZoNUxhSh?wz+u0rX0*SmH0QOC&MUK-Pat)N4z*69w&z*mt~93N zkVi-D%fyHr3}!ACR829fF!Pp0$vTX$9+h_KIg6`oEoTmWfgF@$Rt@xv*dor$x|TYKhfwrF%3qqdR89S~ReX7+n^$O`179 zw>r*l)E_LZq$|JXCO}f7li^G06GMNH<=Tz)5!_>3CRR`efIpLjUkqvmCY@ig+zXsK z5r?qcG`Qei#$?#4<#ukPEs&+xt3}Kksyez#BdoBM+8W8Yi%Za+rFCo(w$g2%9R_#i z_MvKq@{f6_MrX1@zgg3XY^$llaw3aQ(V@-ROOQHA?Dhhvb2veIb4Zj!E*0d058sa}^>6$*m23Ab5_vlh46 zG2``MovxWc#ZQ;r(<>%rZ$79dtd*i#E>XvCw(f2f*!XlY$Tq@fkKZ7*?Q&+(55KSv zs~M+jDzu-QSlK3WASX|PbouyEk|!m*9prn=yEEhP+^&D&GiSF?ZkJfcuk59P(14j(|&KmP$gCU?zvj z6!jw@-PQ3wb-F9pOZ9Of{L+n!T*Dgu&oOrm{G%C<>mU#Ry~8hbbz2wgWvuNWxW6Mm zzVoQn-=Xacr&juLtwcxuFhyxgu=lF4pRD5g&l_8{qf7Y8PFahIXIYC&!?ATt)#01n z8botJ?*g3clZw5QEd!IhP0PGNBZq|4fNUpfe;9iJhV)QCFpjMVaio8GZ;scSl{0H} zkl!QiFq0ketljTPy2#Cn7xD=e4C|2z51`G;?bI@K#+Pe;Fo)@cVL zJ@W40>{~6HOzLIv26-MHt;ioyBy&Vb)iiLx+dVK8wQLq04B=ebwSVgO5 zh*<4M>Y7aYWbnc`9Y*TXXml!96|14U49D*wa@E?gnojm)^TPNY5+bH%eO45>oJG+U zTY{*5#lFJAPbM+qwKaAvC2I9(0Q34%V}6r4F6$Qhp(-zo>mlKO3cpCE;maES1(Ex7 zmE-9FBAknCG0c!$1UBGTR>+{pgbc$kQYtiJ*p$$=!g)j}muk;y=0z-*8l^j%ejo9+ zQW-IcMIIO*C(TO!$=WNo!L)J4sx{Gov_?#9W)-Ye^M8K&=f`GAg5oXTxE)*juxdk) zH?x9(MfbM(xx=9`7|U%G{szed&jt=1gLp<1>2pN(j+rE_QXu{VFLr9b@g=M!A;mWJ zPA#2aoC`CKc*j^$7F$xBC>A5&8w5bc?(ZlTS$ev>RM`Pl$4MG(y-losD#Fi9C znmVZUxewrG{4Yt%{9n>I-I)l|T{|3H0QAus=*WX0Zs}^Dq5A0y`k~*0eVoe9h*Ik<};RI1+oVsUcfq-swbpuz3&=f#tHHWBeDH<%yHf!!;i z5NrKPsXXrM|B^zgCy0O!4NZx7PO3NA!ZyjvGuV=cN2k#lS5=&kiImP|HmMPJNSK^t zulrkYZv-TpkchYkCTpnyLQy-SxMwbkj^6Sjn@3)aW7GB5C-*fpSj)}OLDz!s8Z)`! z|K8FH6w<1{h+nt82VL{mIyD6ZutMV;@2}O%f>c}1C9<-6z*>sM14VZtfKRrry5EcW z5?*9ZxYxCXAU(<6=J#Ze>pqkyiG(@UBZSJxER9-lm}$R)p~;P&5tH$2=ru|-NnuH+ zzP3==DC=5(jmyY1Vio>~AdQB!i#226Vv5e>A~F-I&lm`bOqOK&rF-|<%7EkDYR?G|tkU0r zZK?i=HS?gU8hNA*2SJ!d8vhPV-lZgXq?0vlDf{X=lxw0%9I_O55cW@w4i?a#8nGp1 zG5WrE^~rt1-c6jBu`KZlzPpynV>j&vOCy?+Uq%a!jZZSAf`c>ze?y3L-t+~nIb+;u z&XknX)4iI(dG4WVARv{-4Ja`N;bLuoJxpnJTj)8IQ|sLoREu5|Ng{7Ca-gNr+1qvf zbVDvol;qhAX;_D&sIW*gB_+xjZ1T$b-oqcxog~}5%VE-Xbljn)vGTa_{0(jBR;T&u zC4u2Og2842tNAlmna;2+XRHBw+WX%&?MMpw$Pw&?=B8DyeH-G8s)ZtkJoYUh{3L5Q z=l#>Uq#PJW_)&>=E<(TyZ@Eufk4Ez!Ta|tmQ`6qP-%R(~W1& z8KzNUkbgFH%E1yMuQxQRe-5fqA1Sx}k_}@ZV34G5%S(rSB+I7S;OEHY=ISk4j9g85 zqWP}wX0Bm~V?RstK(u(X4P7`p1#^3GEm|lM;6wWA8u&&J-KK{wa;0-Sj60$_##j z+7*+mXdGua%^$+*-^@UR?&H6k;-|Rgn=AFlNfP@zH4oqJuFk5<%Zt8m?-YIC&eh zjFSxShLlB=?7$m;jiNk=_q%-bT$ZsX)U0KCVD-#Hf=+ig2$s^g1i}4BAwhez-?vxr z`Bp~Ta~QZK6!c0GN-ZI&W-lA;M86&-?T%;*$u2o^$Brf(DJRmvP*h1OD3m3e6!nWdQ5d!ejSIeb@_C=6R@9VcgXM z^E9Qu)~cy+7t&ri$VfKbb~8+6;+%^)(vZ-1xmilOOWj+P#P+Vtx%R|9=J1+%^BMy4e2hEIj{fIfHoSuLBCH5{U z_*gx#BFIwnPg!aTrKRk;Kc(+uE!pN4k^77{mcF-bG$p_%7-02u6G>5*ZF|4(sJCU& zD2HM56?S8JYR9L$GvN7F)|ES3225h>0qqcmvcxk9d*(~nHiy{t+)Yd$hnB2i&E=55 z+%(q$kAVcQ0oKmm$D++V0ROKh$A>LX#r4m}g!V6G!!U&11U6tS%Kv5Y zxL?DvB|)_QIDr4f2TQ><_}L7ZE;+mC9&6jKw_Z_Eb+w~!Xb3E-)J@{ry7)@VcxA|_=5iG~nKr<1KSiV3 zqbCi9cK|nTQQ0!0!klWgoB5jrmHM#DP(Q`IQW0^GU6fH7iaF}ZDg5klMk!uC_6h}( z;XRSlHIkzzua#7WuZ+RV?0YtS)Z73lPt6f`4v|=fFJE<~<7*kg#hPb@QXf$_`Jprw zcSdTZb-@c7Bi>a|6Y`Ts*d=f&AYDK>xjCi~+O(br<46^ld^yTR=rq9*a1ApU;J}Xe zy3YFH-S-TEyoYkg>gDr##)+7}Rzcb8sYRaui%&w;G1fbmZ&De}*O+DGuL}DoEMA1E zgzcTdmD#;_igGDsXKd_a9WO)(y7pJRr*TML6i|eic5lU6LURm+zXo>vHhQMtDL}~i zMd)CyErnmFy&2B{8v(ah^ZwlwMif7VjbmHAmEx!ZzIALnA`z9_k5%8x--H>Y+sBY! zBxztle8Qj0IVtW8oNw?Yq0*s)y~1DjiSd?ga24Q z(**TAq4@LJJPH%GNdfmjLl_7hefTzehYsvAfD4T9*H1$g7yeT)S?lx;8*KV$Q;m&< z36V(|(;v%MiKmIqX`wC*I^&KettgTfy8jKLl?T*WTBm~NP@}Wogtpe)qozlrZE^*R z)|4_NM|&|^Byez275n92+^QCiNxa0r!|@5^1|!v>>@E8M#f6<*X>D^jCzM0Nof_^( zq-KZ+ct77NE3lV^&0m@}IL*7xa*Q#T#v0@rkRFp%TN2#$aUqT9;+FU5n!j|!OVV?d zqp5!nOVhk^dV(A~X+7Q#SZwYmLU*=7V81Dn&$dB?`#FT8(1y>_!JHKFYsJ8ZB;zz^ zTBh=v01m4UFp@(jq9?K5n6d3xD(AV~U8@}+VXLs@epOq~oXZ!o%G7AIp)~oM%ya4f2$~rGO}zgLAl~fem>;;Q{h@D8g7%&C!G#@@ z?}du(hnz}kE ztrXo4=l4aSuTLf@D($Z{vvVUnJ;>He%88waw%QCuXw%5@vo6?h}zQ#tH|jTdGsh~ zqWz{(6T<`M?ovR$Qd+%}rUw$SjWO0DXzsD&EDu+OP5#UwD&>5y40Kh&EClkt2rvu1 zm~m?f9@e*SJAA?OM&>L8bk_8RsjT?z=Hdw%aC9CuxG|Ww6VQKC z^Xj@3|8Pww(MG(>8{K2r_6M&+o zDFeTIw-`%ts2Dx1Su-stXE#sLI&!1y+8fBo3y3C;TMg@Xklj(d;ihO=g$pFuJEV95 z$rNAcY$!>g2*1#6!%BUT{00vKSF$1gLWheM4IayWf03uXuiU|osyv~^M|0lfEgxgU zuCd@~6g^pqs9(n(tU5i@)EUb4npka{>`5+pqQFuoLRuo#v{9#BZMO9~M&yOMEZDQ2 ztz@$U%_E?6;0+cC1KbqSw}gJ{4Ov$O7~!8=XsO)WSFoIeg>#`%2z)ByHUksVyn^^q zT>U5JiP}rR|K;w2uM#K~NOKe1z16*R2xCbGRODGfEMa|T!Z>x?EOb?IhKHjqv)0cu zZil!J5mr&Jc2w$?gVQY3Yl6*2E)KPQx~FswcIg-3gjOgxluBkc;%YIU$wh1f5L?t$ zo&u*~-5ykFN;^MQc}?e8JZom`+txF}`T7+H%egM^f5U8)l!$S)>!ei7#QyFjnTY0G zmax^rygH2LD9bG+Ku$;cj5T3*8IH^iZr zWz1VP7+4;zR;2ugvwn{%b{3XE`RD)0%dz)Q1xTET_=okF(=wswltV|FmH{4Iq3hJ* zBiJ_nEsM8Or}#D?+^}B4F-1Coer5gQORd$SI28(3KkEq*pw${8_&-SLL@p= zcVC(euFPn0ya+#Dwc_mA7D&})&4q*J-Dn8e2;YS}>`bQjyltt}PEyI5WSK9z)5v)4 z)~tzxHnHBUu|L954B!XsP)BadayR>|Hrkk0xdL~};O9q+OI9e6i%_-1m&_P86cly5 zDXU^`bGgTmq&P)K9b_M@9xq}9As(vUMn=roRApj@9D>TnYEE~5Ksg-tZLIN^-E3mW zwf?zW)aLzV)ICG*cW0Wg6Rd_8t1=Ayv$!bEc^rpW-3}orOIZZ=gJ`3{OfSj}#fK*G zU+Xd!HYH82Rx6@nzw)cRA&e_Sau39R$7->jYK_3{Z${Ne_!gO5xdw zjb00o8-d7`0>6AE5_h6QL4;=0Qwpq;8^v24c5f{$i&wsAe~N3u)t8fYr>B_i;$j=p zjg+~#1$eEfR^oxQ_bD5Cy5_|4ycy`P?F`%5T-`n38~fdgPRI&$cSuo+2Z0f1wraV> z5L$ZhDnYxrrga+32OlJdiNB!A7ly%l%W=g~F}^pE6pC>W?Pk_#(PfJi1h$kjMcPBm z+7y2sjWC&_NEVTI?_(@s)+2#~)e+7ih+^G$@h2Oipkx7t!y$G|36sen(D%TOU}zB) z@Q_@n++EOVrUmiG=fITv+(yqc{@HnSU;m>gVRhJt2#jR*6N%izu_Nq?-g^!p9AXiO z+QW$id67vQzZDUAp-`ZEq2#&hEx~4McbBx*56B&3!w$q3SsEpSt4IF-u~>i)!D}WP zzr&H)m~-|h`*Nl2)OX_we;v+a4ce86l-734~h8h6vOCF4vrvldAd?b zytukd{b@L16|&KY+jd#n3BN~LjY{80a?fp4UcjPggQK1H*BUT$I%9*piWYMBm~F={EFqC|X0a3k~l)(?K2 zB;w1|rU}^39eZ{TwU^uf$9gY`U05waJjIM!{IYc9jtOicr)G< zi+$d~>dw$bXE_%OvPyAiK6r3XbtHj~G6owa{w&T#Y41XLJ!_2cu6icW{&G+`;4iXt z>XQ+8?WZ*J4SXUSKSV0|saZKu7?MEr=`sYJ!-1kYfY66&AJ$?Y3PVVWO^tLwjgmBbsaRuFK{S8qkDX;o7e9b6U zvJpBjxprW-V_Yydra=#=Tf{bhS{!BNJ(F)`9n2TRpDn8;A0UBpX-Lx6bfM3TD{R<+^*To1SEW7uT=skrP9K?62!59=@ z(7Lvnb{_c5Qd_qSY1pX>$Oxco{EadSQ#?@PzyJ9Rwm{71>OD^U zZ;|TUfDA4KX;7;YU?^~V(3RjCGtJKa`$L@vTSkwF6ADICOprlM0AUytAP_Zx9r@E@2QiGP1_gSR zONsah`4uxmcj3*s-cg^TD34H8AT?s)Q4Mk_5Tk*O<-vq3BJIXtoBrL=V7zRvRRd7 zuS^oS0FFF<`Qz-q`L9?=*1YMWunawsrP-a)MmmtxzUMCQE&j5)V_3JS43)|BCWZ{! ze4DydMBlUt?B61xKUX^~E)+WuGp;|?h=POARwsHf_qI3Umm#+3Geo#RDD9R#>|TcH zpD9Ti_??J{h5OeDvWZZK(0-33i+YMofk+v95XhuG-L39Wk1B6^m3(SfErV>y0&1hE z@pzwFVyxa&BzRy?kr{7| z-GmPpeh}jZwf@?2>WAJ4>A4Sh+y7r%m_HZu(3ELzPvAJ~M&0tI3H1^Ig=D@N0c9Ao zxyKTYR@BdjCXNbDbWzMh^JHm!vIm&F>`ueCRKGjE{I&QJS712aOMNY^88PO1ZKZAz z{u^IVWeLfR+91LupF?S2=p>IMPyn-fw!cd6x zXq3vgF}M-Rb4&<|B9=G6XkUV>mgkcX9iKSKx)oO^x``l9wZ3oD7Q%!Yug8S)01iwF zXhH63p}s2`Bc1aR%tMUiX|I~b1++HjQ$B0y{T^5UJ9J~ZFD84=KQ*dFds;LPHY3?a ztWE{r;JZ=M8G`FP`I;h_b$QNKKWV4m_pFU2K+S>I3TY!Aqnm&?)_C|xTs3H<$##BRHeC^4 z;04)0winv`ezo1)UQ^$_p`N(>Nt?pVV-$&;dPgvI25Fn<;Tk*N{fiX1DTQ)|T|usL zYkoW3eY}fl1H*m*7R?X%mLhu0RN~;MY?4Akr35D*&@yiCT$yn`KaPFrdhVAzH;w^q zgIs??na9~`MVhu8?{}3TLtYsY{nJlRGnfB;7V#+PSzv8v6ge*64nLpC5s=~j_0BcG3Ndq_N;#e>^;j$ zg+3Hw4-!Lk6O9`Kep@(alZfM_Lgi{y5VI}nOqvm{#K)eyJHj-pOp~4x zR)do%rMh4={g4%@IEN}zEkl}@SCe_pC?C;Pz|~eWTM6O}9zxhCT>BdYqsyYE!r>zb zOJw*h`X_$b!>r|28dXV9mWvkw>J@ImmFo`p3nC%(5+`=?+@`d*f#6k#{xwzGr`!n6Vu=jZ5q~wEsp#v@`lyHFB$@;B^t(Dip^d1Eo}xna+}6q-4MP^ALBTS_A+LtgEGKfSfPgV4o> zOqXnNW-+%?%$E(4`l911xC_sQB!0){fXGtv18!n3wT-0$4dPPtMtG296x{S&T8yCB z3L75LFgOl#Ti;1uII}_jA&AGtL+xdPtf{K0x?iA_v_dRcIY_*(7%}pT#4puM>q)S6U&y|fd+|*uCfP-{7!iPdMJ#BC)#5lx0HtU;@*G#}q`JsucvO=KMQYy zy*8Z5R~wS0f9P`w`8E8bj0(nGXD_a|Y3)rS$-rDZ>4p(|0+QFC$Knb;-@4}LaEi!c zT6ggqjJ_Qww4;8>A-3oIWnX^NKcj|dp$aGQErISF2}@-_BdIMxg-1rpN|8%RM}7Bq zb7>ApqEZcEriXL@q&R4KDbYrLmY>C%;3X)Zw1+s(eQf-bPGm+S&^8S2s6IoE=XlDd zQJIDcwOQG@nz-atx0Aq1*0RajxQ4HqKSE<-MwAf53Dbw4K!oL0?#AKBeJv5hb@?3o z6ZcMHj&1|c(Sve)T`3+Zm7w_-`=Naz&h~k>2}G{dkG4Y|2`dRtgg>Q+Xz37}PWp)r zPR<;hy76oFa(Q)rI?er0TVDZ`N3*PrLmo7-rjoIzzrw8sen1s5O|tsLRIR(fE!pJhOdgSZh|&i<9sdSc z9FXA5Jbu1@3H4iMiUPZ&KMYt8AC(tKpIF7V2GswP zQ^acG<_s`INmbT{@2b7n^V~!##E+C4Pus+%ai!lcKAE1k`+F2hL2kP>Znc5Thz*Uz zo`Yo*D2C{r0fzKuBrlA1F9z_7BDPaIsUSxQ zk-n4J5q05oG-W2KZ>*x2xqeS$43T09CJ=D)mnsa}>e9+Yy44~>J{(q3}KO#Q9jwa)5Faf&&?yI5N)-jamPbgA8(0he@B84TWi zq4&vN!2A6(Hc4L0Um!pTJi}OUC=J7}!aKzi0ct^I>9jIyO42M}JcHCkmowJPda_f! zttPIQKa7sc^W10{2VsG|i|yWIG(24@n(|b|L;aeZy&f1J<;sX{_`g~g91nH^IeK&_ zaTT7mVaf(1)}Hud?{jDu1=2C;qrMAXk(_=8jJs6%;H3A^4^;Vj!-vUjJViIoKFJj< zP{{fUE7Haq9^Qc+W_V6s5|35SUju`SI>@^IqF`oskZldtkd1gAJ7~yLNA-NK`78!^ zASL7M7z`(kgHEI=k`3u7EBwizA9*%TYfDU~IMLNvyWGv;E1w(df|{I(+RmnV#IXRc zdm0rDRfR=M)n{Vyn|Ek;$3H7N08OFWJuA&BBaao=r6w)+%}B>MOwVaP6>aY0N2t3Z zxA(HUCt<81zw=3frYqhknmYK8PHmq?$#zR$%&4rkx5a)z9|gir!y|r6!s~_qf*_J5 zYqj z!@oDDe}-MrxK|WbCa?y*EEEG6k<+Ozemic(hq6Ky&*0yb3E%()+yl)~hDj zEX!^9?tny0-s)x-clNO(A&4~WfiY^YzpCdbAdA1J` zUSpwsA;Pan$phkm!XmW;Zo*gg<7LEUQv0n)$AYjlt2C`zshQN-&#z`exo>et z`$Np*@8%{O^u>AHFR>>-^sZ0SU1CH9nfLnJUm{sV$)+KYuIujc&!_IoqQiUh>K;y? zrOc`IW71+{SoA61k}yz^hEwSGa-3tovPH8g=)eoy0UFiHEw}2xZkBx+YnqX<)`K!l zzUI$?H&K`BH63bUu*97i>QWS+g|d9;TbwL<)#4Zmv@X#tJRcKwH*YLl{;-!sp(7PV z=c$kPD8|gSBoz)ahSf*%8FsPhNlh5m+Z`w+OTS!;pFvBxAH^Qbrh!g@R*t{v*Plfo zd@;tKqJ1-RSmXVG5M_K!_M{V0K}UMfs~PHJ6tN*nZ)_F38R|t8UnlE6R7X1O^Y*m? zO7E7;tW46Y(_3v+X16JYFiN3C;MvqzipOO*v|a>xM#cS)Wo}RN%PS@HMrUw*>?oOo zr=R$|kZ(LHE0;{zE}0?T;TXD6xna620CQGYX=<{u*`xw2hTTNU_+_$|`~Zm_M3Dn2rSm5Pds2`ocR|hz&2c?m5`L-(786O;$+$rsBO6ev&4>1EKy|Vv-%6&rD zGRWHeTo1?#Xei9|HD zAau-uk55S=8ps~8jUjYr4u3&K_Xo?CmXL9wkGW-tA|$8cZ_PTF1EnuZ5n<%`lZVW5 zF@S*G#{Fu}W}4<#apydjB=w?B+Rt(ki2cBYdJ8WULlR4j zsm4xT*@{+sVDeP5?pL>`_dITcDp}J`TbU$<=r;W(MNPO!zru`9AQXm6>liB(x{-!! z{_206CX1nc|DmP9b!{|%-{KSPEac-^0$(l2Ro1+g7*Y8`Ieei`G78T{y8>IDTKK_f zX&neEi_E&J(!nM)Y?}Wq4OF_c5EYmE^#nk8Z(4Ronde@H(Yg?{-Qs5|U9JK6;CvGic_j*fV{?n$-!aS(VE4%x z12s<)IfXMv>IEF>FCRdIwx2NGp|C@l(T4VOo%DQWKF zclk5Lq3I57ny#3s@35drYGk_I^^6cwrzrH4*satvxTin=mNZv7>)FlVo{i?~atMuT(+yZa{HXfPFeDwv~X85#Kbb`!*VcW{s-nQvS*oP??4ebs z?OvzhG;}Ci@`WjRp?cjXV>|wvmKxD8p&OmkD1_4)cGZ7S&~}Nm7bB|y+^xMWQyb|E zM^eSixNp~lIVy)ztwQjgA?|XDV%y~vPHZIB=%!2)Jp8E;Y;l&U-^1K9#lRg;Gg<`x z2py6l&MW3guhW%6Yy>(ch=xLU@!8C8^5E>#=_=xjyWbpRi(OnDEb7yP6a7J?kuvOE ztOS?FrkQ+&E4k)T)@3BnI?uKi)nE`CGhNI1s5cpc=TO(ZmeR!J6m}3Wis0m=D~gL; zG*WQpI|ZY+%e*3&7?tMA82pNuhW~(RhyfmXYDvf?nzfWmA9cTK4_H!dK&|*yx+Uh( zz=C!p?D>c=6_mmEn?&u9Op6x!N6U=m6#qze=#qBM>aa}KG06(BU-R*Ph3nS5$bI9Y z5pS#??%d!wXKkyf@XvA~>%hToJ+oWOdIiyPH*em@OC1uJK%qaR7ZFcYUqsN_3^!t2 zKf)I8t$byA+M>9dQg-`96O>D++xhPVWS5<2X2yrbOfcW@<=7-3Jab=aM^^Us{7!0^ zXUP%S1jOYP4nK%nm8d;=U6$&#JCf>Opa(4CW)u#^h zHVl=#`0B?A@JuEZTap(^I6Zm1qZ1XQa91eQW*P_`pm%8+Q?%Mf^#O{0JDGK}c$G?h z;1!MYYyJmR6y9LBEdwLNiz(8b0I>`g?@Z;tD~KtA8QYsKaVEUDH93Hg-41 zpFN7;wv!d}EdM}^I2cbzChq9(esijvnzrss(4aHvRE%#u?1G?8FWuBjpV+=`f+_MH`aS^f9kk^P>#uyS7l$GijYo zu%tPbf;o~Dc{!GPrxa3|SdE8EDlGFO!breJgsVK*AGbfzFyaSWB8QncL9YZq$%TOY zZ`_KqV~F?i*$#0?z71?x78~)|)0zM^B7pY3W7_asjj2pr(u+z z_g8dHP|l`0c2089>-8dGyR|fx&nr^rPY*pMjJ{q zF-@PHqCjtmdi6{!JeWLHi2vShx$FwdB5)IhG+vA0a^G}QgPExLAv}wLP&j%ul^9 zo*@i7z>SKinS5*T!#in58D3Y|zwv`DN=5^TzB%0tuyG(g;%_efKe(m7g$3`@`!rsI zG0&p-hf103Ti91o$I%srB9-7~Ec#JyTX{q+kV?Sku)0suNF}9$=_p;v_GkgC$gcxE zwei4m@$VHNUeScuP@O{&E$;`BwR3^-R)nT*(u_$lsoa=f=3LNQ&V-~&JBFrmzummbOu}h z9L%_KcW?$mhC4W-iqth2cgmHbFKYBEF%d(avOpIgkigUIw4*4TRi>>9INC=geJHgw z6g0CBw)-1-5&DqpcqkUjmIQ)*g*cq=h-psO_}&Cs-2AqWkHd&f6Sa?lK$iC8H6Ps( zmPkUo!+5T#HQE0DbJRbHhh5pE=fT%KKSCy_gVr`*b~Vtp2Z-s2MX%{2{D4}|e2ok+ ztQe3<-7G9Bb97hH>KeP3oQu{|$|3dUvMI>wHzR4KbjKq=tFb(bx*e^XUUEk`EG}-9?=KkZClW zSeg5XU7mE#PE88$y?;?3pA`1!eNdN<7T#lfP40P6N8M58ix&QbwxisWkeyKdykdOj zYQ^@-n@7ie)DP9d(HIM+FS2XN^hx~iLIElO%TFZtys4wUDHC4;wLZdM)O$&I_khXg zWbtct)G=i~PKd2BWoa8fx$ZxCXG$|_A^Twz@+LJxs)Lhfnzt3pT2M9U`fE1|J6~#Z zKUPef6%4DRPAc<>2z$WY3|&pMI_L{=gXwoBXOqR%)ln4{`8ZSBE<5jEdc)QXQYCGf zhy^6*u`U>iyUOV!{QVlSZq$gW0D(~xZGP3-$uUi?&hz@s2o8AVQIuRm>U3nK3piS@ zK$3<{zO!!Wxh}jQj5`Y?U4@&Tk$?TDO_f8Xd(pWAXW(RyA}d+(U0)}22-D`_H3XD7 z`9zPXSL&I&m-%(!tQPV z5L<8_aILc~o4Mc51$pYbSASkE+wt33>q16~yO%6hf-0OxBOP0rFFw`79}V^%|QV<7(>in3KbQ zbHqKfxYXGtfAkBVl2IXrEhc~8<1MGeFQ%-HdF*2yHM0;8#=G5sN$?@1i z=5;DLPq)lv(E&KNX~~_|`RPXw=G&QEOcpm+M~#6zId{9#zT{?2G#~f2@Tn|q_O9%>f^qi!_9w`h(C0w6PyyQDr*Lvl-tdpX$%)+(udiVWKVex zgM3R5AVSH@PJP)i0p>w07jrE%koZgG^L|b5_PvuEARcRfj^U&}5Z*+Ocgej+vEE{M zS!e#2b@hYK|0Ib#{3@lqQgc;(Mp*(i5Ko?JK{?4x=~9$;)}HneK5tW#CY*3h$DC>C zhnm#<*Sb(tR^Jxzw{6O-fK{R2w{upi)P6H$t471Dn?>kP@q(OYD?`>C0 z%}N-xKZ@#fTM~UscZoN%BI|SBc4c-0da&zs71*KQvy0?lkj#t@5Ho%>$GqVuDPa#~ z?4pE-d0CNh=~epQhp*TVeADZf;q{(^g-@4ss6_^tvx(T=oZX1wm@ya71<5{yaGd6R zy}i@L!0CZa>-Isxw@Emm>CfGQT^D^WB$n;9Q_^WghcklS#1pZyl-V3bip9XsQ*+EP zw`pe7?yJZ4me!^?rLMSWrC2iS{(x){qHCgdvhNm-(0*AQ#GlG(%iyEP2Zi}t5y51- zAldYj=P!99+2F=f#ltZRFXyaVAw$E90JS%TD|Rhwl@lwcYEU-ZJA2QMiuiVUP3fKG zmqG4{lyP9tUj9^ckkk<2F|a346J>Tt7g<1(+}BG(?}h@K?J{Z8FIuzz->wuZZ$dVgOJdX?pRmyqou_PP~g)Nmxhgauap76e*o z8Z-t8#@}C~T_4qlB`CT?O4SyV%-idued1|Ina%zREJ^0nHyUAk0eB?#i(foWi#eb? z>~jTmTz^b9(bS4Y=@H8-GxvthRVZkVsL_g$Gh$sqTgrX0m5w^4K7MiWE@O!r?5PT+ z&P6==jhfFd*xbgtkS>;{>_MFnXjzxArx}4c2D0>{RwSCbo~cUU(E>+dDs`#WmQTUX zI@0Si=gqPRmv%R40Qm`gG$w&;v`=4?{2Q43 zxqdtr{~W$;yr~b?K7Q@LG9uXnOAB+;@Kjm(D46Wa{>?B*Ti)7jNuXK4ytkdjAcey$ zfqr&8uC^bISP?5VY4~%ttkxc6$e4hXA%TZG{aw>A-~UB(UPZr=mx^ayeW}82qVJ2S z#~!Oybyn~5UqJ4j$!wRFpauN-FqDO5;damz&4i(|OjI;8Qsd{z7&|N#!%flqYg0H5 z_>Wtb5q@f63Te9@zi@D^#7WP!~ia35Hk{P*%N;{~b=wW1N zqv;-)rXZgG^PnF2H2^8~lHH#EBE5&&S{&Pw(o9mSU<2rQF>Oj7!>)l5508kb%C&b8 zRCxPFr9{EPY2mA;-h0Dk-uAi$%cUDJqNt^z&I&qTGnfgz9#^uNopYv}n-RH(t6Nbf z9(7(beSZjkK;*v9@y*4$5iIq=KAtN0rGBs9sjW%d=*pl9;;PB;{=qV*fv8+`z?I^( z>@CIftzA z@De?am%MvchgdN&zM`=qo6)5u^$%*5YGzXz>iwR&>PbE3W>GZ#2X!nc;A6~0OU2Ex z$=vy8zM;mDT>KG&Pw-CY!KXK6dSI^6Y~CI4?@SuBlY;hT0xLw+bVG-EApaA zS+CYhi5g)>qV>(BkMVq5g=n_mF3}p-#I$D@AmAKZM zQ2>z5&EDI^3KXgkUBnf(&@T(hZdj4Ng>D@l9b>4uM7^Rd-r+6wGfuPGpC90Qw5_mo zMUi7)(zYa^9XD&%r`#*A)a1%hAt6X@)l#e_OHWZ)O}%nn*tAaB@Gkb#k$3r&dA0XD zv-zdU{&v*SM`onikQviCqgbsXXp1N&3JZ7=9C7*nF;+jtWwj!DM=Qa6(9|ktJim9e z{6Ow0yNsr5N!CeXXjq0|&Ql7D&QlzaPs zg1_hD(H#GaNQyy*q1$dlqB<7c&!7iwB!tR;>@kH_<$jx{N^tCg@FMZa!~*uT3b0fs zd;v#QC56V5S92~5JIKt{US~Nu499i&{-r?s{yZ?eI&b{dzSmK_1m0pa0e9QcJLHk)C zL`UGS>1mRr9Lg0XGHsjOSG4r+;pPujzEs^4hd=Ei&K0@kqI)I87a+KgNubXZ9-grT zU0aPptpI*Ur^{F2aNAy@W>`jRRycw>u~26ZRJr(EZsu?Ah{#a9B$H{O=@=m~H^Yqw zwiW|P{~YH1g7c3%S7G?EoF86hp9CD`a2dQQz%(S%{17Y;^14HPng4TK;ls37bAlv) z6K!s2Np!-nqoWNPXrUklFuGC<9wU`qXxSL^DUr1xr7T|4&{c>%DMx+CX;^TN_V2iC zQ6;ptB{=f%6pgnTAUs|=>EU5sHC%7lPl7)T#mWhq264T$s5~si3%8ZkPJc6hr_&Lcz^48(`kM&hnQDvHx(uTzv|xwK4)L-Q<`a? z&vbwG+)ZV~m8XDHlQ5EFU0Ww%L)G&i`VtM5bXyO#vZT+4H&1rZO%T6uMtXMneh^vm zR_1pq>#Fbn+A9eR#1omq)P{Xb8%1;-mF~^SHZyv@ddUkOEhj@1rDM`Vt8E76Qy^HL zN5Ib(faGj=`qcyY<0}KCW6cN$_y@wl$$(YyQEi?P|>LDIDOcI3^TM*(#r`SG^(`jW7=5 zNNggo$`x9Mcj4yjrq?e`A~{cvC$JEY3kd_V$RC=L0RjOBj}oET1on7jSyi1Qtz?!h zmk013o#G*Sy}QDlK{KJ`;D4$LSoqT9!}LHB*$KNDe-S_trO%<~zL8Ni zbBL7ixr({5qKOA2$Xs&<+zy|fvy!r>Uxl9z+{G{bZL{|GyU=sAqhd1iOqFVM z5gP!%-;Q?^B6S@<5I;Y>?)veJcaG5hKWwwojcXKH!b>z)Wb(%a>(+Ii1);$r-r+i` z92_z)!%C*q1c@|y*w-z>rj1yryGRk@|ReR_MVN2C|c zNRnV2nm$f&^v8 zN~WN<$BcMJ2XzvE9p&Ii`%2Lb434g@YplTe75FHyK6<-%sbIozu;D0g={w&Bjdhe3 z-v#r-Y;A$>D^bes>K#27eu)d{wIR}8U)PI#Le?p__|vO=^c}TY8UbWBA-SS)g*_?| z+zi@{^`n_kdx%9wYcqEKzxM>FUIA2++Z6m73=I<7xVp)O19Z@o=COVRL6d2lADOaT zsI#SHBO5hke0m$4_i0_&(0C6hO;}4Wl7!bWUu4O7Z1Ka(Ut{bm^*EXL#92M>72+rI zJ%Q(fohy^>bs%b*blvaO1V!5&W!70aC9R5S?-*7QeRAArPnfJQDnK`JH$bK;7u|M&jj9;~ZnVwhWW%7LTpG8zn2$=H;dD-cAz^R;KGO459|@)L&(Dhez_>YKEWM(*b-NN z;(|x_vLpTNYZCZ(ab#o3KEH+XF%rX8L-aK_-v^Eqg@nh4S2&VD-Tfb>EuZvn4PNhoF7Ynp%GI01k++Sv2Fa(=!sCK+1lyAf@fSb+mwP}` zsFN20gAE`>wa#D4d$n6e{9FBY4M3^LBN8L=X58lgq=JSrR6u|zpkeS}v7wNVke~>g zX$;b)Iib1W{xw43g8ua1BLyyK{&)ZA%yxeq(5J<5L35M+Go4wiD4K$Tf?|Y$f+B$Q z|2e)vU&1A!!V{tYf7UU$p$VXo)0nuSiT-W+9|dljH8(WHe=B1CQM^kl1O0v)}I1mU32oO-ZUb?ktWRNibEb3VyJ^yEwQ~|aB zpRJ@+XiC6Pv4;hxzjJ8nuJQ=NG{c_C#w)Q;EarFfl0mNXOHvcx{Vli~F1qbv!FBBA zW^E08_1z}X(8+*M|6}4VE#zqIHy_o!=2?n%$w+iLY`4~#T!9P_{F@U|xHYs`V?OnV4??|^Vz7#c03dkDD`A+b+C zHlU|oTZ*6&;_@J2`Ml)Vg2xvj6duZ9zq=-=u^of-VsH1pt$FjpEH{lVN#n=9U_aOT z1)NC87k+8OfmcfnRy_@b-L^@2I7TM6+LZOnOD(pDhl-#w5Qzufj6LmKST_o}C*ap7 ze`}CRtCCWPrW>`)fuAdRMNxD1xAlgug?ICHNJAe^It8B&&*z`oY~zNoe>$NIryZTy5RaIZSLsPeeL>WQQ&jH@UiLboxR!5FC|_{MsnFn-j_K*ZINMtUG;hi&Xo(`R(;Q=L#zVvHD9x|5oR#$L`Aj)ks~Z z|5y6I*YS1tw!q7}?|tuM>BEt)?%3IIE5y{@tAuBO?d#);+Wa}~22Jbo?(}+eS(5zK%5Mk@0#8r#4~d=+z?@-F#BkpTljtI@3oUmAR)`1;&RSfPmv%YJ=NR zLD$hEKW(ceU~@^ZY1E?d@I2+{n)uO>P-PHHA3Jwy- zmbfE8e|6?pVbwTj9)2(U@7u_JE7|_of~9Ke_fzRRz3R(Q@3D|P_`77p`C^-)$Bon% z1dbK#x^?WjaibQWmMQ-8Bt;yu-^RD#EkReWo}5c_ZSJEsddtuEcOU1ky6`>7-8Gp! z>n$>RM<&4Dg-;lUKi8Tayxe#H4&D&W@5=rHy!C*<-Ca?5cH?l_{cwwmyk)s)kEYTL z_fn#6Pmkw;>NiL(1eOntyU0p+vU#GOqj{MJ0brsk&VVOk(&LHvnju}u7s9`5bAL2h ziiXnhAu1pP??4bPqzTYO!AosxW1eZsYP)33D{5un0M^3Wa*PI2`-!77l&WnP zvXzUAhDwJC9YzQ(Z<2dOE@He6IbDlE2C{yzUWANZN?i;opf*Bb`$&xILdQCTZkbsJ zaI3ZiOXPm1dBW#YNuQZfvJU4UZx%pPQK2xKJ4s|h5eZUqIETzFNkphOqIb|8-SCk; z+D60emyPyVbb2n_YF3wfz@YKAitzf4WJw0(pN|wLeHbyD1&%=%^#RA5uabn<1$2Q`^=;>S~`4%6!H?X=DMo*IYWW7;vy#; z&QJ>*w*Pzs>O5cdh0u%}i!R>QRWi>F+Qv#yW0m$+kJ^;pJw>r)uvm0RCIaqQhR0EC zODEH7dxHFJrwD7{jcVZo(aOI+?1iQ+DWEM$Otig;BOD97|Pjy+YM z?9B2TR#J1cMW6pgWHyqmr3!$A&>6~CqCU+N+6hdpR*Np)JEf~eByv*I^}UzQd7O^b_czco?JOhLi;zgAfUZTocegOk z%YHOa5{0N!wd2`UV2qu>~q3DEp2(Embp*7n8=diL}JJy-KAuy70Wn0J%VmmGg2IEP~3DnN#KT$1*lE>KXJVEg;|r|}C4ZrKY8 z>0CDwW_eTmDt~S%D8`Tl^vw=3Z|QqgDRY>Yniv2WDv_%pNv7k697Z9<@^SzR34kNW zhEe{8bPebFV%#&$!F`DXMQjnAg#{2lI(?QCXi>--l-GYNP9EAQUI?-XKsw21lya)6 zCFo!BHw=(N+IxdG^Q)&6g~#y^Q#1i*~Dp zQ47H3wIL~H$t=Tg``6D$pP70GiN+32!N)N@f5)l-7EQ%OSB;8>Pld_)wE>d}Dl)wh zfw$=642=2I$3LAv<))k!!D%m;s0#LooU^97ur4gxmeQKzGoSq}myE`PI;F!Q+Y*6kMDIyveSR9W@mux4t^#PtgnrhI{dvlDxYb!>FF(-Ak#I` zE=$Cf3%p7Ki^@N_tJ_o|@k8(82ICUJTl>*VeeQPEPiw&V zhjEo<6*~?${(ko-n9eap@(;(CyN{G5c+^NBMe}3hKTm$UVPo-Un09w7fn32}k^_35 zPt-dETsVMi_<$t_xOA;ZUZJ6H0dOegk)FUCxpb z*q1gRSs<@Qt=S{sKZ@~}Bhl}}3hV>k`nS3R5_shzxVsu_-W1(jv}QJ}JiKB&ebNXV zJ;Cd^p*X$BOFligRwvX-Qeu~_P~U$B;^2iE73xIU+t#n143ryTd>U@GJb>MDxu7}1 zW%Xa%)SdEZ3QZ5{7_P{*Ch|N2Up9_ z3O`vcST&;#K3^0Ou;QFhz8FDt$#8lKu_LQIdPnPCL+t@L-JfM|U~|zODoZN*42h|s z^j{G&;1)(bd049t@3VUGkF0=Ky=p6^+&{EVKT7DexMaSwI3A{o-2_%7pUKtH@ey%s z4ZPmLt)>57#@j+ec=?s(5D0~|Ty@ns6J0$ldH=D-MW0DCrG#m-LAaUA3(<+;pdWGx zUkn`rkElNbEz9Kmx9mrywhab~^LezljwtT#Fy9&{gW7n9NDS=aJ6AWLhRe*f57y;Y zK#Tl$ZkkyUr99FA26M1!5PolZS2Xm}lP}_$!X`(cBmp}5XQeGx2sC1+0OvetVlI<` zyF-HQPhKwPlssu&?igP`l1Jt*^e$^jToT61IMqZzQsN+HGw3lR1YDvrr0(C!;s>rQ z-Do#^D9@+9g}G`H_Y1oKH31h3x9n4rMh~g-ur{9zjEA;9)aTbqIYB;+;!>c(G+02L z?xwQg?eAOgig$m=fX?M{3LJQVFnRjBk3Rik8Z^JThdrX9KW!6AdK_{Y-_kVd^tZY% z5ytg(Z*oyXhXE#a-BLx7erE~XSt2eUyzKr^(e=GWdw4%@0s9FNC?OWAiLeu@LVHxv z`5*?W#5`|82>fb**8+xs@P`pfnySFGCHsPQ_fuAj%!%!{#CSg;ZrM1;QvxH|9ioZN z@@(!)*hA?^X?a&}W1UkvZ^Vn%lC)GlZ&s+p$Ml-Y*kuhzqr=`sExni0lq*$Dj)aJw ziO**KXE1Z{*5}DqfY$K!8g<&5FZy(*d`^e%-|EHiBXP9tjP;@F>W>1BIEUUoQ&$oR zr1Kft`Eu6>XNL*R3lBdEC5>Y-9>`Uq3q*r=Dm6CjqFlL-Q@{94spJEYA7SHRzGCNW zh`I05IOWP@omKH@t+swyy5bR33n44(N1xpZw=1AF$V|aR1CoDW9<8=AZ19i$;fhK7 z+N0iid|t$dtObXsdJml+n$^(>{-^~*?w7VnXBOq7%@-$k2*D1TAFacnwRGcvgb*j= z{O)-Wo=q1R;OrfQh2nk@6-EE3eU!+Ri!hBP3?U#aQkK}t-;GDAZp7&~o`uH@+sy_Y zZ|mw@Xl`L`5A2a%vfUwqeJt>-{Kf^$_LaS8>|7T*X=srKR&4@%E5VV3>GI0(O#KzIWprcMOcSX#Q+OxfxRd z97}6lu zLPV0h0--v3NQF-FFZR}~A@E;tv6NH<#BoGh2zpeYimT9>q@SB9v~eKEu>>;`Od=C$ zpw91dYm<-C?V!Uc=nXF`X{}fF6Ow8ien^k>V!sNBq1jtxFkYzB|+f}Sv{rT|XwEH2%tfxt$`{UrL zkVS-0l#A$sW2nnIZl2Zzst^T1P|QTEauos;Pa@4D?FD5yw4i7-Y--F0C)KdJesXft zFj}l%9N)ONxIkA2gLRfMjK066#%m^N!(!!7%I~jH0htc|o$i`_ zdTj2K6C{DPnsaUtH==AM3_2+*gyT{*#{=jeCTuYn9-e*=o%7^qITJ5-c_!q-I; zsNJ2wj!){k0Q=ut6DudjLKs*b!7_ibHG<9ftfur!dpaMgM(af9axn-mFhQt=9pC5< zX3G3;X`yFyUUuQ@n#!9|X-?Mj?wZQ+n%Jo6Xb%myPLzD#GkVmI^9cg*0HB`gn#Lss zS0G4Boyt@C>A3IA@FkL~25TbG$%U0y&&0f&^}b5mkNhrp8^T`)l$!Q<(nHIGvS zx$@h-N>rB>8oA;-XPpSDu?F^gw|2s?RS8Wl?CO*?rqyWwJp{y#4scUm`oz4&d*qJ^u-fwuc4cj0!ONg}-=y z7PF)B~!yL^PNwQQ#s|6-wZZVUT-Yz z)Nh`RGWg9=ZE05O*D!NjMW&Jv>?l_ z{#wc84+)yA6PT5xtUKv6GC*gFh=JD>`f~+XXj;DzfU2D=OFL5q{k)`l3*^|IRV$^} z63aV3X=^K_GYv#XKTMYjAaLr;ZFi;TpC+!06Ek{R zY0lyae)N@n2`LQN$|>BryORmXQ6GI1W$3yT{i!$b$9M&rbXHdTBAl#gxs**4FNhyf zT!+5C@3LmbupWK%(7Z9(;%uY6E!22)9E}9t zGV<^FtqAbZ4Tv5anfOlfe-e#%YE-Y<^D!(>Ei(167!3a{+k`2>w|6XeNR%y z%PL+U#AWB%6ohf8jXkJ{c5B;j;b3%z;+Si92Eyv6H5)Ed0>L|q1l?NHmvlVJqHVvG zN(g$#gU^@9id{{C%>B#x+@HYPaNAGXFnqbMeA3907MHJSHMn;j;yD(jIro-_)6eZ+ zMlElo-e#6m??v`8!y<`DA91f*42DljcSQwiNF-tKuDtCt?oNhWBcWl)MTYv=8e%ls zJ$fRt(0e~Bi^=c^b&Je=`$XG|=h3FKW$A8OEmd}3T_C6kfN&m1F{1N9@cZ2!S7lz5 z@V~_rFcg}qccIWCw6>0ne~#ox`^v|kG%IZt(_r6sR~xkbTvB>-Sg)XF)<*o3aLgR_ z8m#k19liG<}Y*5puU3ETOSQgQnow%>P)*_K0<}Xu#^u{CA}_^uTMBooJi_Qoc9?!S`q(-T zmMsQkp<1^VgM_1LmL9|p@z6sw9{!X(i04J3eF7`f%QQ9ax3Zw;!fMB~O6SNZhD}6H z4sb-!9mJ762n!J@E%?J}Vdp*s2w~dQ;hbo(sKnX=;Ni2`j4$Pp&qX)1H={b0@5Bjm zH9$`-Q(JYvT3+2x51(C00K4M*^l|NH#^Q?PoQVKRfCSNMpSkKP4>eVQXKq(X|LL%W z(@*V6cUaNyUzdH=j#37y32wA2cLW>Dd<xZKR_1^j5G zJIYgc-k87Moih`yhlooKvob}hivrgkP+_OIl@_xBAv&l{KalX|pkAmeidgXNS$@a8 zW?3kY==?pSPWP4^s#cyvS(s}vG4f;AW3`e-*uue&ifL;zYD5sw0*NrkIqM_(n~nq- zRsTfQ>OUlVBp4C-18@0R5H&8C1*ji1f>-HE%uU&=YbVWU#jI2CA2bhHyB+4X#)=7y z0~W?iHq-0$ewb#luWw|Wgc}?2t-Nju{@5BT&?kPOBP98C-eO=4(ITEA7#z|qQX0sq zyPC(Rz9(yxs@MQAlq(qE`MFhX?_0sXGK0+?7Lr0tUX*tJag`1OCi*7acDGu6^eTZuVO*RO|2#cfo za=sOJ^#%Ekx^wNR7wg^*0p0@)7Kx z2v$8*?jHUNURXd@p#s{oKx}QG}w5L6$V&Y{^hwR8x#W(BNvu>K*W0j zh#a$#yyo^V%W|k`&TDBl4E1BMTiFj9yBV}`>`bvTUuD23n}fojFDvbTVyu0SS7!%h z;hOi9PRP14^)yN6VpV1OvflAk|G`%0(Vt3%fm|RCDNfL>1qVUX9e=rYFcbW)L4doE zXthvhc(YvW%XO08@%vG2j*A&!VJ@YyHZU4itO)CzFjRk8sG7kdmew&SW1TUKCbm+b>mft z_<-Yk5`>RSjzobrlppS{$S1QV^wRXR`?L-k!UwvmyS{)fj2>Db<0wmTxXZ9^U-FeX z1K(Dgu@^2O^-zqg`KhxbOhgfb9f-b{x_%H;UX{pWZ)K>SK}F0L1m;g2I~}y5em45e ze}1Pvg|FQzf{0%6+sSBGUKrBi96d1c*Um`rC|J+=%M^SN@Di#0MvgHUHKf&s0an^- z1OTO&aE670-(X(b(=mUzA*rLS_I10oD3s{jxAM>35inMZBPRJqrJZQM(`jRD0~iFo z2+6QMhD(sS4qjrtQy#>pmYG=To4_9gUDo)rG1TBt0#tVQx&>G40z!&~ObnQcjHhxg zc1iM?-^Sly*YZA7#Fu-G*^0(hdr}=Bpa34w>w?}vmly~QZdT3(jWdSu+iH(NAB81W zN03p_D>|@`ODqtO^|#dgy14N_|GfCieC-o3{P~|mzKeeP>UTgv8YAO~nN_%te(UoZ zIKAPYVP&riE$aeLYN*_~w~D<2t8DtxT7LTkfG%iKd1eUQ-f}uyOX~up8`b=J00ap# z8-*_3p+{oK3GUldhr{wS++sO$N*i$;@vZY(D zGhU}-Gbg&Xorv*JC(ffjIu6r1%}`ySY+9_qx+?KtbD8A`)Up6667c@)|iMzZ)$b% zlW}g$M!5rz!z_XCXFN~<9v2^}*PhNhcWC#vdm={kO}l<2v0}V$+kaNOY z?JRsXP{7Sd@lU?YvA0(U{H3`U&Lr6Xa{bF85qXq;VLZ=wOYP2Bz!o`1?Cw5~VXifz z$FN713JYPC)pnhG_{qQdop{BE7!PUA$&+kLc-wyH|Nc*T0{o{w;a_R~+B|O@USWBq zDX{qG{IDu~F%{i2g}=!}pNT%9Otz?CY&5VHN58K&GpB^y1}v@p(0CPg?fQAY$;ozC zbi0-#&1g_H-4b;n{>ex;ZI&fh8m^~dm;;e4A+Z$ygprWxiZy-vYg=!mt_g6sg)q0wqhHd%Zq zoyT3iw~kUgd4coCW4P@JL=;6I$eyo`Ez%G|nXw4a77FfFGs3z-1gO1XQlkdJV;&hXto(NE?#>ucrU)LoeKcp_ z3xbJC5{!*rA=06^)A?IHAaH8&4;oING2YyPAK_(RsQ6`d2~HbBKbCj4&XaAkNApMa zhi}Gk*VN^Cqa849@Tl*84`>}mnI=(i28ZBObD*e8h(a~&{C0nxav&8Sys83SqD}YZ z>r^kx2{$%$$H?lu7y(u>AjZy+5gEU!vYc4TeLG@a+5NFz7MjfxyLmi9@ApPrPyMy% zq=6t#t#o{K!_$lu%>rsZZQM#hJAFKpVPjZ5-trj-Uz{E^34o+0JOFWUkaprnLqfFP z|1Br!1m0#7&%HM$(~?7>9!Hx)_T4JtknqWbu`bZ2#8t4I?@Y-YSRW zt#$D=d?i&8pu=U-i#gBRF;j*0qI}GH1h6Fgjf4rVcbi|_CT1nBtpptfr4O21E$sI& z49acRru=!!_HbI|Bey@)&(@&k)IQmOqZyz^z%CU1IaDe#S8%WU`Gc0*yI=WApGba0 z%U7;VSe)ZQRyti`K`89x^bu83dt89kh!c?0KOzzZ0wiCv)BVBejc|rDH@lsad(RQ+ z{@LlnKG{TRi=8m+PZAb!IPA9ZCB-pD9PCf2=6lX@jdoYsZ?;l%D{oxyG>r|*#}!_2 zAaskfP5+F3XSL39UOt)#8)S+&goys|hphf{3}c4uyZ`XXx_&s}OvNncZJV+nj{J&* zGUo(v$DsR%QG^h>)bEG{)wDA@Y$iy1KgbWUU{0__hrUAJhODL5PmzP08#@s_f%>AM$V=?2DIXpE@U~m|3q4-^;P64vr-w z4Bvz&u8TQ9put!|KY4EGn5*tU3G}~l`qkf%KikyKosqSP56sron)8g4L112O6w6~j zyI<`ifhp58=o%kW=B0LztOm%J?Mjt*rc)ZPloJ-DR9-CZf&V61Va=K-9@iFw?6G4Qk! z=Or>t@w`E>t1?m7Xp1h%Q`~j5{-7J|TWj)&XisT=9pwAJR7Q1^=ryGEY&x#Gu0p^|9NEd4`S?hJMTzUmH0CJRk4 zJ*i;ZsKCbH%6eKQH@oU1vy`Qdnt5D$9?=d1hQv%6E88&+`{f_`vW*SB%Vs+v(KJkN ze*Dj{mFD*9K*jtM-0}dN*_N$4X9>CRcc}jBZ<{$P`pfRL-GAi!* zOHc*bmB%UL&JpN@OGkayTUx*9FkE(L8xvcwBAp&x2cMKE%#4kGFnPYBb}{$e?n>r9zy86gp9Th*!{SWwW=2|aA8mwZkq7E!s|prj=O;&My!%Vl0gPY9Pmt^~V*{|NJC5lm zK<>vZbY`w6i|TxBYR%Ev-0HwtlYG1VUG?>nPA^^RIl{EMoebq$^PoH^nY5(uKYf@+ zdSPRo^DqQ^ralSBeEK$Q{ypxOD{O-=P?AhODvT>PcOAgu-yK7%(#uG@u!hXYJ6n*( zWFYhWkp9rMW$<1>r)J?2k3ke<9Tn8a6mPX(sEz1+_MatG>}MPJ>1#&VV~XWV^m4j1 zVcTbh@$2^=a;2o8IVP$Ovk5=E#Scl4(XwvhKe1m+-SVf2np|H+40K!u9@Nmf0TT#h z^SZ~AO98Fp?q>UlJmutHmcEgl;pXA5KAr2t9!t%(Vi0m)4FAM0-tK=kO}`Nwg-~k~2W7txmi^F`jVa2-W$njHqW>pDRrj{AUeHFDEtn~X4*elV5ulyO zrx(>X$ASO2BrWp67{-d$^kWbb77nkmPBc#_p%p1_r0tC5@7L^~JlM&$K)b&)@ZV9-X6!R z2{|G|hfhmUc%*^Wnk+VV!A3#)R?LOktnWL{_RhGA^fP`|38G$P_CK}_fGuSBd1OHM zpf)d~i~;qTPOJzFT|)qLJ>B5?($>}=w~MJC*-hIt*Vj^ug%-YkxxGQo6O7s)ue*)9 zn=@dw&Akbq)1?Q`8RYHLOy;4Y#m59-@)I0t_H0l*6B0adD%+KfLJoR-iT)gd>|$y3 zuB&6NEi$Qoq|VP)r1sgRp9?0Fyg+@G8HLa&r_kH2PV`oa39kU4ilx+M)qW-xakej@ zc%+_lEEw#SqdMfkvQ^f`|0oqLwBn~X6tVl0`d)JNh4~>$Q!wHOqiFQ?g+%vBB7DaX zQYK8-vUfbitH-l>L|LjGN!_6C&eNuT&pu6>7-4LFcm`j`MJRLnqsAMwmAB3l-#5OE zi$LeJIjvynxH_DmSroA&BS)0$v zRW)ZNhH+y^kXUE(n{riruaVt8J|)LpdkRg9HQF z+6z%zl|qzcR_OzNOoD`?amMe1GF3)FaEtPKb?a zU*G>11K_}y1)Z<#Dr8pUCbZA5r^I@KL8BGZS346>@c0#zeq8a1MywXi7QkaPKD zaoez8qFh+baxrN66D zp-N8|&2XX`rA|l9PGQaa4J7hhr$*>>2P5i1{VV-WiFE66?+3xwL#e(kpoblyWc94^JoP zs1ut~b7&1@v}*1oL2!~|ZSuI*9#UW|>JW74ADj6mk!-E^`I@oxoCmI2+VAhgKhoeZ zD@KK{zEWU5T8~W3hjy#?$5zmOs8=jC4fAhpfi8Ik!f${o0+tYdXn>Lr!6dQ_($?;8 z$TDDYB6dwuuq3Tj6f<95hB&_+3CF4mtCtCmedaMYNwx+d2I;3+^^<~D;}y5P(?DN^ z$a5A9-tQL#`guzxTX`(KuOad>=hX>Y8&c!l#~2cy0)7#f9hvDFrTilo2>$)IUzPRV zWK(O?WcXB}a;I6T>PLa&uZ{BwP-%m973TTqJ^Ti8NGNxN}aCOxzKk2s(V% z8RjE}8<7pW(u0QJQeo|7il~SsgYZTx|2tbiWl3kB)IP;!tRCGNFsqWQ#NHjrjg)`R zl4XUpC{ZtI&$6}H*9m#Lb&PIU$%s^KUkosWsZ)fGbPJeH$?CflIP`9@C zfQ&`ap3Cr$i$X?M^LjwiCpeaR>hD3W`$+0iPrLDMj6XcED=mA?;NtcF&KyX)yjQD> zk5)~-@vNwY(79L-W~=Uw{#6s{d(AL)K|AK`v=n+c)r zT&1+1#|=HovWoX07ABvdATuHEzyvKmjPPKV2BG>vnKQo(n=6c!!U8w#Qt?#te=wjo zH&?}-C|sqOn&e1i-pT|>I(65kD;Ipckr>9vHi=k}MehwN%8vagS5|RNQC8uWMbFS! zQun{%=)=X9LWUsiugUwa`q&fbmz!Jt+dNFnF8nR?B5+bG^JDx@X9;`hYoBZz!gU!S` znIPcrp)6mRIV77lh}6TRzxS8peOKfO z(=50jr5CLgkHMo}dxlfWe%e&1KqEC|`e`g8CtsdN~r5mSbr*97AY5PK*w)jmYKTQFej zFRL0oL>mi|yRWrAav3WEDXbr1fioJ!4JrDg60&g@C*zxLTHevcEep-&p9o_1`9F8Y zSK?M3BBLET9x^wrh-xIxR4jpO@s_a!7sxy(R%Xfa-Y+B+|u z{jCN_4e&I}FU-+O6;OT5lk`T&pBRY6L!9Ej3bU=|lhwAL4bezV7~6ei1zNW})^E2E`NVjIYwKXHnlxtiehkNS z+Y!QVrul zGaJ8~W_&ve{UElgz6mE=T!sjo?1A`v%WNA+m}RCCdGxzssT)up-;t6T*rG%t#dS=z zCkai@B*Y#x^933IermSfzZ_8yw`7(_J7j0KLd^7j7_#%Ni!MQAFUU}m-!r^U^7fGC zH1-hYH0Giwd62i5K#ejCv@!$&P5w#{B!^tpb*&G0GYxJ|YxlgQx}aH_3`I={lk}pd zQ#-t4y+Pv4X51$t+-9(S>=n=0x-(o7w-mT7hwYOn5QcImplyZHo_^98{-L~XTC#lH zOmCTd2u+}fJ>;~e+pa}t`RtfN*q+^0X<5tOyTKrLkve3_A{E6Z^8=6^doJBrVR8!9 z2?auivb)ViDx|1#>b4T2K%;N$T(!5DH2i1IfYm#kk&Qme-Xg*z6OPReL!t;(B+4+z z63UHrh+-#`;8slgQuWxZbkdvS>W;COp19N6|Bfy18bwq~2Tl8T?uDJ)WDwgMg>Cd7 z-?Qi?C`57!q2Vv7ZoszbyVng8Bv+vF9fJma&t}tw5n)%{HVSNiMu~EQp4KB5H%hlAG12YS(}!71k(h4rH2RZQPIs@pr^HFh_{YiK)?sn7Pv7=2t(nb*CE(NPNi zJ*schNJfP*m#99R9m{C*KF!;npCWomR_I}=>&w&{PA?(l&@d7L=cSE9iK3NnHzjm18d5X!txLZtE z_mfO;5EN*w*N<2|1;(yJ95jn7o#5fnul9p!6xdB^?0G&(=w841fHAH zdE}eLooq{Cp-)w({l@&LM7~H}pIkpUwkSi8pU4$-hVa>qM}ngUWH`}T86r)W+vN+K zk3&~3;k^ZAphgq+DKDpM7$)b*uZ4|(c^((h=any!LHupFL!*e(qXeWlP~#BQ)SBpb(kgkRn2vK zl_{twF<}Ok`dlxbH-5H6Uh1K2op}RQgRa>oVkS6rKPdF11MO=@zD9h+`?zS*8j}d~ z%NWr{3Q0XCm@h^n_yK}q{fbqN^>|n)Q1XfW+vZO-lZGVP%PF}sR=PN8xKuiE&amEi z>)=IQ2s1>%?&s@Y9#OUTc@~lG;D?&*Mpz4M-{*;-A??qHdVRFyvcEw#c>Aire+IIR zJRin%nn?G*+WfC9`;WkBX33jp;VbX+yR7zYVrj}^2$3@~_`ph8wsOZqCMMySV$+a4 z$>t^c66HDn4rPR~qXhhDd%IZ=GCx{1$;H&tzJ_0M&MpPl{(p(s18iy2G_Pn`q4I$K zQjtnWhyo;;5{?{mSb^vCs95a4?ctA%^tSIlz%|C~{x3=UANgy0c5G!y&bBUyKv-c> zm9mGJ*Jf2i+;T?h*J~bYGvtSp1wMPFC*~pt${jj>!aS4cA~k2tB& z0f}E0Y6NaIA#jKMJtSZfxnDYF05^Y~pZKLGEnkAJ?6a9qCt+xqIf`zGuefx0re#3j z(klD<%9WGjkvGo3cyEnwcK9##6~+R6E(fqPK60jMTc11&eOWEaP7%)!#-zv`Wv`AA zP6r3$)Gr$h8vf4%+yaJlupTaEjg~@Tf-0psOY-d!wJF-6-)WmeUpV)6K`7BXw=Wsvxqj3bpoe>GdTW<@Q5iG+_4rXz0{VOp`p zky6=gCf>1o{!Xn3HN06&`~`Vrv@!6Eq!)};_}S%571vnA&*%c(@Z)m6;H;uRFT}^?9ew%6N zC5F3*TREhyd5c+>#DZv;@^`yXVFnH1VIEjBH%%JY6$m7;-8D{Plg?WPSvxuBGo|j- zSAObUkO->h?A548h zwJ3)Bj;zifrQ0PZUTiLea&|w`7NjOOW|18$K8aT;zE-Q8e%Toy3~a{?Y{PpH8KSrJ zK#Ght!Y1mbY4T>T9nJjXePzLytDv!bcNCJ%7mCD&25e0TfSZeHF72+UO}niA@PVXR-1nP$?5AEI?ACra*6XDd^%?!Z#BzfvC~T#ZRex8w>Nv_nZ?eaf&S7IhlEXiMwvW{wkW*bSz@Ma*N9LBRc~mD-(<#3q~v zg%lOB1-;ol*(bjyRDD#-H*46aahcD~#37sv6iQCHjOQ-ubGmZ%MU`%+rTk`xr$(ER zDOk_*#h*R#!N2C-OThd*n(+Mqoe>>kgXA8ckD;A>Ft`%Eg2LFS(j@f%5%pF9aRuAf zF7ECGcM0z98raCdii2=2ihg1fsz(8eW~efIh9d8nS<_1IlCyXIVDeC3~- zCcv~${SU9}W2|wIu7xxG8Wk#n>P7!~lr#6Lz;0N237iSi-d<)7Z=xr3FBPk%ej=Zk zNKqeSgfbb(L*`);nf}TREd+{|=Tg4)@(DNVDqc)_=A#fsX)vR{yO4h{S>)=}9lv85 zu-_*qs(N^2;%dYJE=3d!2*M0Xo~>Z6>*{rf}Y{Y%O=stw6I6a8a2J>q{E=?zIm`cp#`}+_Fmf4rD69TBs)4G>ag2lO3$Cx+NeAY;i%Vr zOXn==rN-~3O2jYVCMe0jh^vm??zsg`5G-sD%1D*@a-EUKHPeX=+rK}kTU6{kN z7p?;25%cadaGth~?QH_(=vxJXY;d~2URdbvu6EDO^DGNG8vUUPPbjr-*JPC%x>~pp z6<}#%lY!dkGc|A$KKfONb`>rd=zL)^59!S%$nq*OJ<=6%9M-fLF;hMnC;3B{4LoF0 z&YBk=X<>l4D&ze{d|IqPz-q(kyNc(E8xd2(OJT5R;WK)#i~k$L2ZG- z{5X_piu;g}z3B5?=2pEFIX|uM7}`!}w=bst$8sA-DUmC>3$HieW4MHLnp?RKTFL<; zTou5}h3QUDX{5Z)Byn>-bVAr{l7^=~U~t!K%oS@wg>FZj9*jTt8>2B@@68FX=#lmN zvqxauu);N0SC!TLZ?EH1gRX$BMKkQ&ZIBJXoJupr^DXw+A!zMqS4AeT*~Y%XAZwa5 z1>uhr8v6UxK^TViwI4v)P_%jJKKuTOiG@K$GYCiZnr~ zu8SBo=Eg}u5(VMeNzR}i>xWZl>+XH%+zp-Qeo0cwuobwH=A#gs{GbQzzgNH&uf7Z-3uhj7y`*N=-7(dk=ZrQ29f3u)9!c353=PG*n~> zW_7GK{x|R|ZC)TROcK{REP1Nuu0mDo`i&ie(RAr`Glxgr z=bpYwgsPA7Bh@yQx1#msNE^gJrY=BIxreq0?tg|VzH0gVPekhfWOU--c%Fl@keT#(2 zTP(qAgO7*)Bd0=%E(x#fHGEOzJzWrr(3V9ua1Hyyb`-D!bM_4VxMaEWOPvkt7=`iJ0 z$Sg8VxWfpv0~>2V}encaYjGD?d}rZDe6fR5`!xjt{#6*| z`xKx|>Bm=x2Do!DdpvmdH3&SXsldHblk6}jWRj6vhSpVt`DS^g`+nFZ^qhDm-_QH5 zl0EkHyHmI=-lZzUoUbpm-IfX7%H51SZ!}DLE1G`SnW;-~dk6n}i|=x87~MVdHFAaL z1O4=c28h3;J2U*pc4oK@;DW#68tlEvF*#QgKc|>pb*f(ETsF_SjLBFuINlxK+kbQ> z+QmNilZ@aVS0ug%(63shv>Dx(uK1BkR)`j6RU=oL=fgPobw{t)I3lH8R6u#XAemLR zn)tP}U%kNiI+n%hJDev)IR!$&W6so^T-W5X07H&N^*^phDx7_@zAU#^IIqGct|3yy z{)??LUK@OK_NQewE9jYvv)WN@;N`y|_iYari$}ThrMmwPH57t^SA%*427vT4 zFBD!X8t;joTjc&~;9KHq!3BY<(eaX|-tj_RV%tY(-Y#^_fP}!G)FXomQvB+=2tres zVG&YCn~buU75rO?e^^{KYDPHw3qMJA`w0DfUBHy88CtrURjQAFH%kxCB0u;3xqK`S z6iq%r{aS&VSxTYFdSVsO!DUde3{1bI%}&2ay;qmnQ3`g&6ay;n)qw0fLzJD=cU5B+ zQrJv~Y#nZB_zCrC{?1f4CUR2uAyv}>l1jYZNwBR8f`o{HN=96~gEsvnuZMQpG=B$$ z6VMxGqh20s$DH@#M%}_-OG&6V>9{Qhx<8L7FLEkv8Mvps-2@zr%^J8nP`_&H2qHG^ zRua^>vrD~Ykyey`1%&r);2W0^#_B4n9t77jpmk@xhpK?)Db&P z4}8F`dl(}Ra+akWhb;R;dJ@vlEN<3*n^kPrZW~0{?&da!qV`>6+l?D*hr+YCOfyVGg+|Y<>=yELWj#WYuHHAfY!uVwuFx%|Vl=}{1{LItdD~98fS#if}j_(se z#IK|8aYW6{rS0OD@T6o#>ckAcg|u*+(6gjQ>iiR5CX4P_vv6lpmujX$>hvc~|K(sz3?TdTkx7${D}JJp#mipGuX-4TjAL^#Fhl} zsoz~^g2gK+wUYdktw=fR3&{Zr3UsoEGR1h&YHBb(HQLJCVg0ug_dtkjWE>7tdH2XB zTjdpn%R-}Z{sfY?;GUz`tPJV9DV@huLXM-cswG5)T?S~nG}er(Ge9Nplzyz}&&)qb zL9-x4YX8H8KANAFstzlrpye7#W=$TCmZ`!JH7h;UOs-y}$XP|;&AeXe4~%Qsv~5D4 z&PO053rVjkDLig+Dv&{F&6;RSVOR?b3)Z45h^;5cz9z;1+k*BdQ8Ug|9lDRl5=njn zuRu^YyiAceV_B5 zZrC;(2Fr&M{d94I2aa~8Ep2S2_9Qg1!wG|P#2*>PX4n65A6Pv90?}A{-3Y#)doGO9 zMq`9aGX7GLooY~&mI9MDivwFqJ7Z*eNQ-k$G!z&m6<}GP!$}ma{w>ZHuzel7`mBbb zhfX~l^?eR^1gKnDl*M4HA)b`Fx)jm=rnQ-Q+88T~JL(!{f6=GzbvB+82Q;~sKk;MN zzt0T}o+Bva0Ks}Ab@544{;%{B#>y(k>tZh;)B3&?)U+;qe{uxA(92aOqRwF{Jzq4b z2XxPz+KyXjEZaJqsd4-oGqpKwj_LDFj9nqwQ!yE9?mzk{rSTRzV|^8(<49!?o$H>{-e zi@1nH>y2xy$C47SVT~5_1%tA1Tx@oZ$FQwV(hYC&&l>lOWPwBC+<%u(%(YrvFws*& zcx8=NSp%8G?a6m^5~7W`doO=OST|)QaLSQteYm3y68Ny!p4viR#l$mS#LO~GK{2Cp zK1jo`fCa`k#5)n~Z0Uj-^Fqw;7!dyJ?%Zx_(VNG^x%LVqE2vP_dml<&(4M55zadH7 zNTqk}16TM)d`F+HO+|e&Dwv4rRGWt8QS5G-R%xb;b7!XsSbJO?G!UQ*^23vW*9-_}X42Sv_FuED!Vd<4}fTVfnc52NDb zvZHMy^QUAtF!xn$4Gep3@vQ%9X`bfcSGj&LW*%aFhfF=Z53_Wh69ZWFmj##{)cBbY zfqGJu_bzvPyv&nq&(A-{CMf`P}!HDydHVb!Y}f`BHX_TKP`+|Fjsm5a+CB* zuSySH4;UO>hEeRMRsuvQoE+Fcrt7ds}n{cq$XC23s-6cksIf3GD*uiw}B9TO+KnfZP?0HUeM zDH4o`F_)ZenMTDB$qI2_NSJU1IoM~(qN_~^%MB79OqvT)fK34M^18h0n4@K%Hqb{BPB!HK@j7qgc9jOKk4C{_!m^&#vpl5Jn?-) zu0zX&zP~ilu|eV{+uvCI@U9yIhGBhPvbjfjngPXeM~vpO+6C!E{93m_LQt0%(`hv> zpJ}(8Hj!fPXQMQYCESI}+h9_>KA3}lH^;+rS6#;XpJ3;O_ zP#n{-S z3szECuZV-FU3)O<)=xt?xk)=0w0*O^n``xjnOv8f4GeE}Tnh@hdkaOsuDtkBHXen` zi9mW&xgzifHH35lI1r?C=;o-rAR%Y!;6yH5+o#a>p$=ZUor)?y2aMr&kI*txL268Q zn@xAY#yNY!@|Uc`-3H@@lXkNB&i;9!CGSoDUAJpZWOdymsg)iI(5hA zgy1REQyEm?injeb_{1ZI;ToU_1INA5v#k!A9LJnhVpvMRW>WE2_<=YDW1uxDul4kH z6_bSy3?v{Ax7`P8O9y8byC;Z`C?#kM?XzX{=H2-3aQ#-2Jfv1`{})&#RTGnD;1|}; zyo&&VQojXmTxIAx5~R+bO9qCISM6JiPHNs77tD(xgbG@n6Pd)?YCEGLm1@f1JGtxO zNsG!I2HTc^T3TgR29u;gWAC4B~uR z$}Ovuy>~E&|88jCQFA#UGK_GN#9r~k-)7B)5U&qJEyzK*@tk_E z`&E8gCvuxM+4;81vr{wNf02Io-H7#YgQkVkoeWHXTDSYLN5Tyl!#=L-)CcD}M0IRo z^_XZvralkw8}x0*?A z$@QS#N+(U-OM3VuF-|R9K}r|~CK!XX-^WtDb$>EM+cg&J`ueG)#9kQ}{a`sLiJfho z!rUBzzYZ}<`Cj$yx?}Gl)^sD44l|Y}n)d_%cnOpYr0a)5n-@=;qV2;j$V8z^+qZWiY7UOlI>CZ%Q!`l zQe0S3WJL3%+gnqbOpS1jQ<0cV`gc}5y4w1XV0e2nlNB2BvLp6)pTRZeqx8A9LP&i> zU>3)Mx`&|t_JaUt05Kb70lUwjaq3jR>3kgyubaeauBkungyU~vayDexAFcXRPxZgE z`eJ>|ug+b`U(eo_FQK_MyjquMED`Y6WQ03 z;82_VVCX_Zj-EA!8U2;Z+~%i6nqy?Q13XqPk*KJ~=>aR8Y(D4>dz4oQm9o(wnowvJ zZog4}uNGbtWfB~PSMY~-D&^a-$&MLED6uM`OIO!r0X}Vldl>Xx8M%QO%kOw=49Mbo z#aS~rr_=(|qb!7Y_@UK5w_^+m2*yDevOe;w3`{&(4$g7;GIbb^Jy_faLA~ z4R`5Z1_-b5W}$nmW-aR$p|{pk?&$Rds)&>YX61`MOVmAG zl?p^{+?GR%QFW(3>I0hUO8?Ls<-S;i@0BtRqRP!8;0(X%kA>AQSX|HJhtm#5`qr9mttfMHPz1LXdc8~K#! zdqxrgK*b_`UJ{FUV`)8ZV+^e*hN3@~TPr0lR#0)zyblc+q5fh}<*b0#wwQo}NZj-K zpS`~pcMpjzc^+K}PsDPpGe_;1`(;jd7}k`eO1*GPAwHeiDR71rCXspiy+Fm zN0BXY9%Im1udlP{7|0j^Ix*TRZ0Bo+inxB(`)I!=QtfK0aLZSU1Pqc1_kH-J+j``-+w!ouBkR1XQ-|uMua)x&MpUXOIFg@&3@CHH$gXKoPRbz9Att(di6$ya zC%W<_76bO0jRli7TunNYp^RL1HUz@?qDfmSz?zaj)@0f5p1dp;8)atXsQAFB#oCRvb<~u+%Im2mJ;J| z*0RsRWIQCHX8Cxub@(F+{NphozKp9f(xo|;b;pMT;}+Pb_9-(|z{zSD)uWUTO4v`FN9Q&A3(a!3)t4hmFTo$SkJp=J8GRGTdZ zuxSVbkA7?%Ml#HV^Qf=V+s3yp6GR|O(|}4m;BN!5A$-}bmLe(s*7S?2sZ0|!^+_Ka z3T*b9I0nen5g(js(D4ajV`r=HI?CqV<4d4Anfl?>$_!PK`Ws4sHI(NZTLz45S}+Nv z1$AgOWYgq_Kq!_w`9UYZ5wn)SW95xIWQfurO>O)E(+X~bPDGkdi0EQ;YnZ?+uFd|TbyQ2djK$|p%7o?HLd1u2rq zmQ+6&rQ7DyXmx;e=%;n$0LcC8HTS@AE1g*7NTIbYRZ|^+-Bp=uE`6jGX&3N^TyLjg z)Y1}jb;53i71l3)kmnbSUu0?|-WTvmo4V+bu>z_p1&+F!2<@QsR{}wNg!4?6=%Nc+ zS*|!_+?S2IJ|w34zJqu;EleezB7bwl$BgY!d`ZnWWlmx9lw6O$L4be@;y771ch4>7 zwhPRRNYQbDyZ<#4dR$~eK^nG?ej8xUEln1@t`w5YEQSZBk#%Q9ST{HRx@NDWq zmh!t~t+BtA3>O-0_IRE%TIo_R&jeA131xZ#_uzyjGE$GA_;h*t1AQd+kMJS|Ut*&4 zeqm1iq;u!);bKshv7$5OO6Ti+xtCN&J-Y} zZ3<#zVBdwu|DA3#Kk%2(zJc6j=FQqz7c1ng`g;EA#j_7*DSD)xCK46Q-tw@CUZ~p2 zK7f8~1l6Ga5|kw65g}`4j!-?C3h}j}q}Mbre6Z&qM50ct13>6QD@YK>K@e$YDV{KC zN86BrEXmbaa3auHU~SBWRbMLfxDAr1nh1>@n7M7M3~l(ty)6o?-+a^UTU7+>1XrQm zq=3$+QL1@NbGxJcwXjBhB@#YUP*(#H0@N5KGX=-+cc^0S5(j z42id#R(eLz2iy?-LQ~h_Imx6DgKAzWJgvP)Dui$#sxT^YPL)iUY@lt>!Kp_bOrgwI z)@>7Ym9;X`DKFgzGjv00kL!QjZKOt2HVfN4?7 ztk%b~aXA^VpW`tf(fU2MuNwz~j`M25?IZki&$pi6fUB!vr%AJ&shj$MucvBBVdY?~ zdVC$ng$Afw+O#+}AnK(A#uE*5L@(^sKtsuve63ke(b~d*TVYeq`A4rqfHIJr%J7WX z)9hxHg_%S*wQdX6ZdqjuHbHd%-*eRjQLumRuoB(?cn%-Qg!qdehHA9qZ>F=Kt0~MO z(EFTmK*Fc3sBYL8VMvOXcE;l4=*utb;1nD; z960JGGOR1y%uL|w?m@OT4Q!;P%V^2e3U%8H_3W?8=PyKi*$CFM7w#C6g@B#~Mw{vf?{9cJlDO-yM=$-J!_wq zU&9Tnz7i8SxHGk1$Y7(#HA2o7dE$jx_H#?utI(5Yc>o8QsYB-13Gr-!7x(NYN4wH^ z1w=GuGj@6Cs2A*}OSyZvzQw<_Gp(R-^J8C`>~^c$@!=bFbc@4pK;9fV2Ej0!T6M3 z8Q1K9s{^3;6&OynWP0IQ`|n&2*~@WtyemA@;f7Guo|k#SD7yX7Wu6QtL>;B#Dh@SP za-v47=z2e{K-cbqMm9GB(Sz)}>yT!l3D-#Xqq*bAV{|Yn@7+`V$->to*l5RJECK!WwtJtm9|YV;J_aJTzzIhzE;tS@OlFb%CX#PG z-D!)*RBwJnb%ojl%>ZJpkZjimHvc~Ce$)3&OWmeMFser3E= zOW+rcev4T}H{V~RW%Wx5eUXSd55#_XB{D(_8Xjj<=bgikFdy%ThT^x4mHI$1BbQ&lGFYH3-46Y)Ll0`Rf#J&T+}TgF%h0FiGwMY zl*GhzzNi|W-MIOAlpC@;%uLkzNX5}SbwHL2<}Ukbsj2(1W&Z@_E$vNg82+AfW7^xn zmkb|cZj44}{hIX2+zDG8O22gKkunt=l5n(JT-O~7E+74oE9`Je&6Bx5_`!pr4DNv8 zSaBNM$+LjZHp0VuQ$b!KnmPL9?tVc4wvVV_Q5N5LZ7u}_6r$DdqSqy1Ru|o5Cr0eRoS-Q^2jFyHfQIZ1RS!4vy==F<~ifO=bks7*Ad;~ zA7V_2dUR9oK)Y#V*~~6L*7bCG^&`f|cHwa1D_@#)8r5icgGU}UwyXjbuNXMkF659p z2MrtfWNg;Zb=?yoHR32IJ1_Q-5}vL_@n?xXzl>Eb(ZLoV8{F9KO?XIMH~jU%udwoq zM(G|2V(Sw7%IjfT!tus}4I!P6?h+j^U-VOdBZO+CQHBtbx#&j4_Rr@(g=@0U-+6b>~zRA@N+O z^|-;JZUV?uZyXEw0{Z*zRtZtaOPs(5-KHM;jFP~W&&Q*?S=$jS*eu0>8)zi1JY1jt zOV=TF6vC#wBumkEI?dx02EIc+zAK=@6l`Bz1<$Wv?_Pf3n>~OyiC&fL_K~m(2n-kh zCoeJQNO=7vZ8iSH6|`-F80^^VQX_cfLYTKfTW0lj_5R|i$6nI%1E!F_YCQ9vYdnbR z`*e?X$5G8UxQ!fL@z+(ChgueX-pKsHZF%R|p4wI8z3Y2~2z-BpL8g-P6`*;JY7-`r zD;!zv0)_8U0EG%8=#0w(A^%L`ODB-U)e$X3A*?9OGJkm(V`92^T{A~xTQJy}?y>wF zc%sc=ibLuCz|hp{a&)k3h~VvG5}rc3?cqmXNdgnBw@gd@mw|aWIW6WrStL2P#2!*0 z-I~S5)+|5SBt7^^m+{L=k+N%?GbTxgrVH;EYY3a302XqQs#!4Uq>iRQLSkn!>P+`ji@CR zKt@WmR&jA}k)S>s6HN^9t6Ro4Q@ z`vRmlQc2iv=1$tMG0_5bt}@yh|6;ZfdC?J$XdgC<22kRvIfy4#{b-0LR<~5aiIG6DEG5bYjXTul=+raTjR3mL2RX^(+t021}d zsiZUw(r%{=6AkGSGimjBj!;?d^`!5Mvaci4_ec_$v#c~`k7mQ9MUK$8TGk3CVE7Ff zs|x)yz*r%UdBg-iqVUnuiypz~1obL%5HB*S&EDkShhcBL1C^v*dKVxiY?5-_!xBxw z`6B9+4Ma;XDR&N;R#@S4;Yr4}JJ*v8P>0%a7}b=pB0_j^u^uO6GN#0NkgYb?ia53%%^6y@bC>GV@af)(Jf~-iu1qc( z*PDGz+4+R>IX%d9=WX9-Uhzr8;y-zS!jg>ZU;dpY%bWg4xxly^sQUE*G}(!4zc);S ztzi>YK0H23C@K}ys0}~DEz(=jAjuwKKP&%?YXpAQ=Nirp~y zHVaiAnZt7eBCRoZDsU*QA^yW1AVW_f&T`uc#bmkk>%$2on}<{FR9<08v-?PjlObdt_p9eX}PLpG(z< zSXfePrfq21X+gRIi?ZsPeOB=41?53U?TlbtjeMK1^p2|x7L5`au%ZJLs4&IUTsORO zTcJ|a7Hv>*zA#L8V0y4Ib-{<7m=G4iZxbpdC7)m^Ccw9w`g0*o zClJ3#2V^gxo-&sL555!Pd#~{08e>vX3=X~xB`5*2NoF_AZOm`-$-!VU!tm@&GZ$$V~q{q_)l)DcS{4#}1lxa$Q%+WV#m2CJB z!Ehs@JOgq^@iK!m#&~^(5}`EbsP9Un%Pg0v~3L*hzcR$WgRiKLE1 z%bm0T8iwn3Dl1-6?~h)*l^>MZYwzdWQikS#hWgF)87gCh627j7J-m3~5L*b{OmbcR zSLPlC4Ro!BEm~G6rEoh`x3(1gU;XkQrMo?{JTr!3`}@y+yOR)8q3bwInd>%rPxU1C z5@A`SQzhbL_F>55=)MQyl%pF#N2ke0rkyI@r?AVBdf!gmyF%I|7s(?Utu!y9fHKqN2lrN4Z6yjM6c2_IUoi_< zWiJTXi%Zpw_!RwLbmN_jof~n)gKp^)Q+m1eHw1TUr-jPl6naYXFPx*8k{_ z^k!ad@WcMHPwq|x{U(3@!D4%I9mykdlqO+p;8ysIQ}^zzrmoSAO&szQvaEgF z)4nw8*Vgse?YMgj%wx-c1;B{U;4;p|HsCQLb@HS5EMp7^b*{#D30@3i|HPGU#bmFb z@w)h~;otiJ#&el(eHC7q|RUN6Jrhgy!eX=|!3#Vrej7k6XPaX+jZ9f5&I zrjx3aA4gh7PH>;J>~i2AkD$VOHHT_eN+`KMg(|UCVM1( zZ~{^jNOFe9UVFao48gAE48aRHh-A$}VlvXh{~h-AXsUqT|IJTFg~X#UK+XA6v2|4_ zeHj%LjVF?X|74DT3(7!Uw@=Pc8i$p<7BZ@cZ_xkppf=31))6N8a^Afk)+0jkQn1n= zDab5RA0-y9X*=LKxxa6n*(^;9Gb}(EHkEcp^8+E!8prUy-slszZcIjN0?g=1Qb+^C zJg04V&|Vy<`!n*2|7>9O+3K`q#8c%!H6|5J+9G$k6io1*Oy3FQy=spWuQ!vfN8d0i z7<(ja{xGv%MsWMQiurya{|1iZ9bfOMXg~E)F}W(-oB>t*DRoE^?gPI^UihFZvw43Z zXpF%AwnZ!dwlXh2&(O^Uj45;|x0C?}xS3xT{%MVWJBn;fIp3M&I z&Q^2vDrl~6^q_?)fXex4*mE|vks3zUd}yLf=`69ozfeI}t9UQ=O)gLjrud%pn?YJI zYQA6Q(49q(!d{rNI0|`c zt7B#P>NyG80(pygBGsf|%_+|=jFVDeVnykNev>Knhz_B;^jhUE_I%DjqXa%F{B~L# zvt)%{#!8R!looBf$vRTI`Mxfdf`HwB-MB2+Nq44b@Od{PG1IXi zEwo(FS5~2!QMK7`%Y3jY)6X_BRKEDM79izdw|?WWP}M^szrXEj*iK#ja0f$YvL6!H z4df5&5Y(Q^Ebg`-uCqZv4z9eUx98`-%>rh$UNegR$o^q1yqE#MRy(YfS?vN*J=c{Q z`_efS%a{l|D<{<;F1@gYzpexW>1mBQ!NJH1?SX3GitlwY-c+L32U?%<8QHsHr!3PDp3m zSjd`Wz@g75!$y~~34yi`+j^b#7q;mGWJ6cP%o%kbTZA>^7{+d;weyAotk+ZWV&*^R zUq-ypVw=^j&mpyoY z?fD(YGFMWPpCwU7XCPD<#2c?xu!vH`BOgnpkdbmHyccP7RGWS9FDHRsRjoJ@*4c?% zL>N||PZc`q+NCkOzhgNCS;icEezj4QOLd2{^8J^MBag)DkBDNf^N!dkRQMqlq5zJG57i7@8&5 zHR=-*dot=yTHTk(25VzqI_CsBd~cP{9vny*s#@Mt)a0?=BOtI^=f<1@90^fI`cwPU z_kk9_%=WfT;JR0MVe5u1Z{y?$6jczwr@11XIH3YDso&txGX;~c`o#PXyG4!mJpSW( z4Qccb5~1oyw&yMT#RF=M*59Yo_{@>SWbumO_jcF7$baND-#DoW6|C;z7dEi%5r z2{{0YBRt6eXVEgO1^vUQ^U9f>{&m8HrE}scgCd*Ib9mNRkSJaRC1p2r^qHE`LCrnJ z8mhk({FQWiE@gpgXg!J(NuZQYIx7)39DIp%oVWmSZzxzRF}}QUjgCVmGLkmi($)cL zSAs9~1+M8MkEUQ;mA8#1Zx#ZXw^d|(tpE^8(j&FCm={e;+o=+1;k&#ec(f~6%p z&6wR0<*JNJqFphs?Eikun9QbZ%t$gn{v41liP16lP9@x|ljb%tw1U8t_cX<6v!KKj{6iW!F^Kcb7kRijEK_A$US-bri(bJz;5_xQZm- zkN`uCPf~6w%5O(s)j;Lno!z(s3~f}13uE0{0R!>0*2Ej3sceETV|ABF%$Im+5mCAD>PwImc0FraQpJWb&`Gr#B23;8N z(yVN4T=u8hlQ&vq;XMu#bid=oI>zLF*lAK{Opa4FQpJthjZrj=ig;9z@@!+vQi{nf zt=bvuCpv$5cYM_H>c>olGRZC${Xy6eJEC>S45Q%va7l>4022!`B{&`8n%mE9%XeQ) zB3Xt#kfX%U2P#wz;SA1qARfWOy=SX&N$GS7%$N;pbBzh^D6a&LERelqXR?<DWD&lfRGhTss|> zj`OlDs7*6(2Gx`=(JYE0p0+wKyG&_=X(NM&9m8;@-Z9!lY ztlx_AY=^pABMDu-qnvd;|6jVZo|i$wG0x>gAWQ48{sBG58fBruH4|rLR}D~4enO1R zEPZ??4lrRk{#fcUfZh_jy=%CO37>9PlfdhRyuHHqCXV`YR|Qs9kC{)p?gu~JWDM~@ zCp2X&a2rTVl;heSv2nDYyXv!X$m~;WH8p&i!CsV$59uOBiV`ZGm!J;&Wi$HcYPS_7 zdBz4-ScQ8h`z}#$77nJs1fCg6%YLm=A+C5)^*Z0oQCZal)p@s4_PTxQYB)zD`uAZ> z!p^!}86DsraJ+?<`Uz1I3P-GAch>_bCpG3ff{7u}=ejY{6&s`E2Jo3@Ol#hL1@DA8 z#9Gr|gtn7s0ax1uJj=F}SJ08l7asjvtc_&oGpV*#nh-54LkiKx2}-OGvKqJ>>Aczh z8&)0R@7%+W(0KxAux43)IwR&$dxUc2;QPAQ!b_!_q5k@paf0M?3B3iFXv0A^*qB9d zPCgRt2M?Q}la*3n+w!T_mo}3HD}I^Kc5F(DkB#J;aypoDMQtuKNgFm$uKAM{>_lEx|qrY#!Z_ zGQ*s$seN4b6Gq&-z_+~_w*MJSKjsSD4$h*ld&9JF2cz!u$HJ2gn-y4_5Fh!1YK5Xe zlzYRdp3>8=Ei&LdXbs3ZW*&mtvTb0d0+qswNch8MBGjac*5LrM;qG)*?jK&HQR_aC_aghxisw3wK+enV3OU<09Kz0FePb1#^w@d2neB5Xa8U7c8^V8Z^_*>l(uqeg`byWVL6GFG`?j0hepmbhPA4ELq(zwS;`E%=c`~7 zB~Kb8Dc!_pO$uwsQTU!U#UlLKct^r=sVcvonZAhy7(;XJJ&1>QKLr(x=iV$k5}NL{ zNgN*F9i|Jv_u-i8^mkNJ%$)+oz#h7u08bB<9^Q03XA0CY zt;@ba#GU|ewI8F^RD;i?p5QVaVhF`N!ABQf3!=Rp?%E2IfFpDyO!m+kn9uKJfL)W4 zO77DQdj+Fomp{}*#9kC-2REWaRsK+YvAFcVHsh#W?jNI@t^v^5YoKK7dX2jO_Y@=h z;}#YR50y5alj7;nT@dltXBuDcNsMf=lc79dywelniAa&S zzkd6e@YU0`tTY7xxI=A;2TXSvj1z+m$dO8r)!eSf$Mi_N0=UDfld$RgRJh_sf&-Z(7SJj`#s*_LMmO^E+qYUo!YL0bJFG zgf~DM2@YxX{inF$IURqqiknT5-I4=%Q5^FL#i?xe{Y>7^hWLXZ|PJnh(FvkUJ=)}XzdeVFxXR{BDrk^Of_O2g! zDrY1op=&l5qNr3u_f3o)ivHMVMapS8wG}|R>|%?tL11xB){}-POYD~>7`8Q;`MB?> zY=t!o!@nzH+|>xKO1ZWy>;*)4h}3Ao(9uY#+=VCR5v=TQ@8gmtPA0B?ulo1tn8oz` zE46Ymc?l@Iurnoe zHzFA$$B*Kf>+{r-K2Bk@!g?vW4!gWhpkcRGdNQP>s7M{y1zdVsdwJnvEn- z^76&U(ytor8ro`8JvyIyyDafzZLhl>~B1@N9+ zKTPGL-dk%X>x_TbRjJ`JWpvOO^3ptH-a9w5&b4Cw#p?tTe|Hld-z$@PlPTsQ_Q%M# z;$^1#>AP`SMu<4H`Tz4NJRo8kY5ULwz6a|35Z@nUucNxrevRunKV-;lqH;D^7XEf) zEYcd#<;436_AS2MZx6WH61=%?p=AB;JrtYS&-g)S|IM@n2Iun%=*n#i^Udw&-i|Bc zTX*7tE25!L9!aKwJ?))^`cTwZ$%?#7d1`td=KKtpi}G1cjg3)k(o0vR^j>QzrTEDc z_u)L9{$~0B^tr^TZ5{qmWZE7-t5Po$YDqVbZ|>9OK>6rE|NI*S% z4&!9q(sP@u{k3^@vt{znM$c$4k$7ntNv}u&GK2c9%NTwphF31#!>bdzAf+5<196*< zvqS_#a|a`W&cRcB1&`cyCty@~Y`nB2HRE)YvW)RJAu7e7jgYsFy@ z3|m{y9(g>}*#ty|h1V8d@)dth3!z9(5`|qV2pUBecJ_#sfPe48ZUB~TflR_5;?nRo zSRT9d@-82IOgsw2Nr;n24Mj_s)%QQaRgmbM*`$kej}aXS*11nU1^_~pPX*>47gB_3 zW~57I^B-Ml9=zZ)|Tfq*nSzA1tNc(i%f6`l@+QS$p=(pzC%}3Y{c*2DLGd>r%+5jnW zFo~LNE<|93fCi+WNaOgB65yJW7a+xg3n;a}zS9G1P=`RBMXm)NWw^&n=+m*j#cd5% zCnaf;4^~fCE7 zYk~wC1?lFc5){R!qu<}c)C};V+#!jo)mh05OnH?6$P-u{nTLp$1(Z$WCVmq*3`~jN z5A4nHy0&S3Xq$mN^wdZ;B`S`Jy*3RW7I`Hq6(z!7B)PKN-wSR`uNWs% z04g;0ve&`)QW6xIf3G0YdA!2iK>hSM+Q&} z$*zWqxjoII(p(Ul8GtFT(0w+Hal@trnDHhr|CPZiH63BW)4!9UU7W&^4!Q$=w*Xf` zwonD>5<41F2ve^~U}pY@#7!Nc1e1ygYSfdAyIg;mL=5D+UUU};n*<17wwP!@xnsI< zY%#{eIgSd+WZweN9t4Vu%&qr<8T--c!nu!*5enLll0fw4u3E2XK&}v-jJWYp~S#FBFTFvnq`?H z@LLpS3)(v^!LTtHn4U31p9{&}efn>RM-EoYdyi6WJFJPIMHBDgf%*ClOT_t;FCqRy z)V^kBQWwIQwS4bkTT8vbRX#5+fFAU;<@wI4J)u&-J-8S_CaV`Nz2~dCa-`VLyr-gY zI306``mssrvI_(0vI#GZn*~+bze2+gM4lQx!}$8Qoy5EIya{*jcL(-onaD`e{o_Mb zGi?6vvASb^@He5@Z#C3+v1#P7K(i}*4}|>5_#l50sMtu_7-a-7h%ebJpoCBk4%l$* ze1IHF;J3uK!|f1^G>hxdCde#sv%Fj1bl3(W>3HAA65=GM@7$ma8gmG*vtL%|cqe2) zORXNgPx;rnb)aRH|B1^NdYh129e8xpB>skEKx9=@vfatj;AZIi&}2OXWA3j+(EcJSG$3l3a1HR{yMU`a(hLM#r%8ZY0} zRMHf3Vo3l==L8#9q;LO`?E}TQl$oXVmWH{mX!u$4gSZJjvJMS`0AQo^?gGl>m*W!b z#I9sa9BE4-KqpB`5Hh=qEVqDRe40b}@fK7cJY8j8S0{8zjZ%f6RLmeahkCVgV{<*h zRA%3z9*_S~S@`nB5$^x7vuX+Hbnv5RC|5gu+WPbWMFdy64eLq3Y1fszUj}^|6ZSNR zcWs&vSYb-*_Z8S63t*+qUx?VO?1DyB}}^j(e=pmY^;HjpuLAD5 zGJ)lnv-ffax*=`X%;0o#l zP-ief1rG~Y!e_6?wM)DI@CQ8AT;vO3tk(wmkG}Q$Xil_!t66LP0?KBgmw?dA6`zWM zln?*`5F4YGh*=&EEo>wxkO`y3MfurUT5Vj=-#n+hQYuqPN@K)UGP~;tw0=3Hkgp<% zL69^iP`#{BkFsQU=Oqe10!&q z^BT?YFr{{KY@JqE!fkLU4Jog888>zd8Bgw~=C*9abe1z7ZE+^+tNZw0smB5#^!| z(jaDx611858pee{CwR`C1O!f&+V`IhApgb5Qs#&KMC`#AJEj4&4~|0TX1Y&e6)=6w z+yZPt2lbQH1a9%?HW!_;NL~oP%AR~E-$zkq(Dm%en^&alH*V#9oCJHbUQ^`}mXPSV z+Kty2`nwbb?QQ;L8L&-SL~)qv(LXL>STe)?y8a4oP(6Lx>-fc~Qh#Q9ZpSb0O`>N{ zaL{Rx?S3*W0I;6Z=AfO^Z=;6P8A*#V2L|TjOd5XdyZYz7{=*q?<)tU&soCwue24X; zGmg+<((+L|P7)QC1JNBT0P|=-`@uRvxrQIyT-c)kWQ0L#M`I5k3zpw2%C|B`%%Rho zn@=)H6Q;8P-6oi%QZq+MXz)>YoC%zuDwObrnn1(@L=qHsQIEl_zsiE-7;iiktA-UM z%1TDNu)L>o4bz%ltM?^^Yv9Y)?8jbE%%w`iUKvj?B9%##$uM6R;Yo$;vZ|qoni}D# z2Xc+;#I|Cpk-s8gOa_cK{M8bCEpH}Nur=9DFzSADDLdZ3(-$Ht+kdz8jrs@uB`@$| zZ+Hj%@4p2-U?N%!caCFjOQhw(?W`>ax-+JuVAYx#IBTe6$RWQ7uQ zz_c>NE0;DI^>#mh8zf+5`VENm;C4ogXq$ElRiS=;i>U?6JknN)v^jsuU{ggg6e|`lwa`ndgQxLzkWjB*Hb7E!4tfE-y&hQ- zATA=4F#ZuS0)2HQR7tL-T$!-3ZR&>y_C=xkMN1Bj$^9{+#*1@YIKdTxo9i+1Yx>H- zMDBE7i7(o8MHpI2=o;E@59oIjldl}w$0idWa(?rBDbAa#JF=OL#fIL6OFHj>8)LBw zU-*Df@H6*EZYj#29{|hbK{wa%?hqif>~m%}M?%=g9qx*ILXhGk&cDk@ z7phu2b+CNDY*Mg%1r84C_)LQ?0!9jGMQLl+$>M`(;qM(8#?gJurd*UrwSb$6WkSgpf$`H*d)9?bVfV`cT zw0m?k#xK6)B(Qh2;uekg_yAbEu37ei%0iS!04qWnXcyZr4vf{7L@9mr8+wG`8r9?Y z-unO|BCXjMhg1Q19bLh`H-_m-HO#xBe-@j7@d*q z&&EJiGr*s80`WUzzHo2eO?P*@pr}j2*frJ^5pqx*fuZG`J{VA!S<^8EnjH@$O7~#} z#zFW^LkxrZ6&`pLRaK%a>Nm2dJGsE8RfykJZTcXU2icrY-%^`p-!L<7{+v7hNp(lJ zBp86osL6V=wBB5v#Y18osP5F@oYY`EKpetBl>~^^c$fHap1HU`>TJ|_Xe{7J>x1aY za-tNSS=>pCE_$?c1UZ zHAGblE&q3`Pc%4QpTtP!1bfL@ zaNAL0tabzJ8@82bMN_TjLkJJEV4ZwzFr3cSeMh@@WTbHqdycQPm$cvc1KS)#lN#1( z3?IWxqI-F;qQ#$iUU`p%sCmtZnw>IBCx!v&K#JFSLd1ip)YEe}J#dKfaALG%B?s$s z4Z2jpiUo~^JzLU-EbU^Vi*}bx1ZklxHwm4d6^LqysB44IjCp^j&`Dwf&S_Zk5Z z1KQQz90n?;cf}f4P<%A!;=q2(VwjSmF8*#?gdr(Y(Mh5sB#kQ4!AkqO|L@p_gtD!J ziUk{@`ivSyA%M~uYe8x|Q?OK}wT5h?j6wpXc6sh{2r+~9X?BcRrkq3nbESwc{*D&e zE*hOx_(lRhdd_mw89FEVY)A({lL{h1lekpHNs~)+vf|oZ&qNF@ti$i^z~t43Fe%hJ}ukwyo3CXgG?+&7SNAe8u#=&f&@7>I~~ z77LHi$2Ck5TlwSG81>%f=fKJm>d&mwK&6e;V1Qw7GM=fD6^+X*{M(9T6Bpe*o2&6d zJua2S-2@SHZ;v&t@uYty2Tc%*ZnOyhA3`hN!&#FJ;ibToOD-xeW8+`?FCLWa{r>xX zD+Mf}w{v=Vf!fn|`rUxpiiKPLZD=I*9Zdt=bfNR_a3rjj24|z&Ey}x^&2u=$KHPPVQfy-f26y_GX zeemDddiMjWq$K@_tst#)=rMXvWm$ZYVJ*pJ zXDs};29fXMpI%WQU90d z+4OovWX@ioD+0Sd0nVUAN)Qw8`?OoF!6*9*<&Moq$_@Asl(0q&arG$js+4@ikVyjn zHL%i=#dkqgIsj{s-7nxcD**hsb^dtJlwbLJC(g=0k)ikjgu_iQX$1}dNN?8mgiuYf za*xuW2KX2YbtIYwg2uL!{LbEQh957+n8Q~AP&NpJxpBZY*P(E47^gmR^zzEbNoiRMSBM1Bo87Ld*`H+d_AUI5lK z8qq*VdbWa~zMy;E5uNvqO_upcE1h3nv4xWCQIIR~W&>ahXj$qae@8IZ_Dn;Yf8$)Z z)tIuI<>@#*1x%b_t|1JG<@9P>#~7ln6>EhaOV+`>gRZ(*ay0U$5m`pr~7-vH;M%ZbSQn9GEUhP+P* zW>pxw0%Rcf-^vPGBwRl==#Rs@iaq@@M=yxm2DR>3U?8J#Fk8Sz`V6nXp#5ov;<}K7 zGwq6Sf~9YVKHqsogU(Sd9#do0pm>h1zUmfgPOQ8EYJLSiGIZN@qWaFJ@SDLjhuHVX zy}6ONcz`DjLzih1GwViSzEiR1Uljyz+K;#STg@IL%L-F?YSgtp*--L+*?Y6i=ktPwKHcpJihU*#a*;>5@PE(#ucY&}suVv~K8M675e zhFlTKj0l%6vQAE1gTDE^vho`PmeentHB-gVW`H*Ozr1_uUcMHsskTqO(JdJ#*NMW9 zpk>Ztn#SYMNbOCX3R+E*I zg0CfS2%HGTcC~wqIVZC0)OpiwRFU6 zaXcY<#v?PzxxL7%iH%7)Mn|Af(lj_6^?J9_fbz4Z*GcbRqeajP&;MQX z&SHaOix?1Gy8bF`#0>5xgq4#HkY&d#h4^F|PE?nEmumh0p!coEK1uR;I@}{HQIUU# zgtGC2{%|Q>;Q_`l?i(C2o*EElmbmVdK{~U82V%mcu-d6v%O9dEB~tVl7-y~fg6Oyu zRx#!O-e9k3)C&xOGWyxC>B?>0&x^j)p7tb)?zYhHjwuG_zpfVIK{wY`On_qdf1ljn z!x~Pa+ny=EL3H?UN%`9P&Vs)?j?n)3Lu~}O!(iNFFn6YLP5@`PJ_*b{_j6Rz#_pnr z7q_11+li3FC~ZN6bMV=kDL+P(KJ)HR`uEfS9Qi6&0)kE)Gq+Mq^gav6`BD1g1Y>3r zhhxeZm1#vh&F7=Tv(_5lf}EOLo*nI+Cxw&TW&47~x`3j}?2a2P%>a}C3m*JK`TgQc zhM-oQwRX=I@RDP0fT1f8KVROSynK26dS<8~N`;ePZ+F3BgF;F`oY2k*rQa$|KOwJ@8?VYd$$+A7H|_g zPD8FF_3W&VEeN8YppY}0%;urul9uVYlO()j^o^D8xgsABmd}aMd9@-JISjRI9b2RY zY}gDS{mXslY~e|3ZFd4Td z4S9p2)H2>Q><+-%k3hu($DDE{#w=S-OPjAG&qaZBjK;q#sR@d2H*#?|V1C#?8UVIF z#IUmpFDU*Mdh1L?5~xQV;`w)4s!FT-i>ufEvzPNz;&=G+;%$HB|Lcv&>puZa!98;z z_2cFqyOW9=?WK_fJ|R9|pw?0cCn3*%Iwd|&)tb*kuA31QhSrv*tm?&$CdM(9IqFk}LD?n$4m@0-Z#yGo05LX?0m2|q~>T6v)Wzsm#nKMWS}EA z0J8-zi3v8wAZ|~kqvp8q%4vwC}9Gr_7r!7B6~5uCv{u#6j`_SE|o#IQ_s za46#mV<5RKhYG0lkFf{rPG5Hljh>`}@L3lGIU)n_Hb7xV9$PuOeYf~LY&Tbyk_43C zRmQX{d01fncE>GciH^q_0 z)~tvmA)sFO@Y4i~=G2IQ%5jfU`Ww1H*JeZJrKOkNG>87MFq}IbwqO?I*p9Z}_d~c= z8ZaLz-pButge}ag>|Z+!{?J)HK$ve{7Qj&hXqM2ds|kk?RY;g<28&CnaAax>58$9| zMC&7p$}s3O-s>XHQyLOH&U(pb=ZL{!QUOmipmXX*(KbMdgi}0E9U}3}5M_1?i zkMNqE(Re?uhV);J#tFq70K66w@`%sE1>Vjl-?#V+|08$DNztrk_Ds0#0FaFfywEOr z*W18Di$_P{Ylp#3cwn~PA=a|8=>s=u+p84U8Qd(7IyTXVQD0-#J*1-?Cgtqyma4Y@ z1ad;bokY$*3HmML7fNtJawM?UX`gJ*!5_ z-{S1Yj2>F$eM|(4a9@q9&kwKcFrAolS~A>O!tMB=y0OYr>J$?QR_{iV{#`C=%-Slo zOQUX7mZDCJ1%T~70xC?yx#3s4HCuI*Sn;W%7l1FRe2nB0jooVzOd_DqcHK)Tpk4)!iYWJI%6_D% z06^%e65kM;$Vd#EC_#aMc%8u9EGOh2E8kdqfE|9%|GM+C602kh7qS(Uv2{XF{=sY( zv6AK(GNoS&pWYev03I4dBd)D6FV78tfeI!)XJD}9KmRkpq>Ow|myG$udjSRu4vpzF zza02O2{77^q@zjxlpEUxKs)Q55ZapMh&$N3Ri-t%V$kpqRRme&_|_i3R@#;^_~R@k zg2WmIHXtD&hj~D<${d@;p5mJZ(dp2DxuA>72ThVb=}X@EJxYi zeqMZtOYmUSXg3fFnr|pG?$;|cFrS{#ELUQ*-Y|bSg0voiZ|KR7(9C{`RZ4ES@{u%p zdYN_T_#9`oHuJY}d4kHsLsoj__=wBj_4~6vfW>F84f%#3?fpIoQ#f|RD$*@X)!8C? zB}E!8>jm%_vEUD%<@c~_9s?8m+vYfjt>$a*uZIXS4zP`%YD$`+A2%eF>^1>mz{~xL zJxg$4wRWGvCrY&#n=UHf5EU?n^Tkw1hL^vSs)k;Dn6K8E({Wu}(3oPGPiXuly=e?6 zd7Hqze}(=Wic%sZ zC--VjA(-9s05`MMno&W1BtTN_x*z4Bl?Ru*Msr${)0q%bs^?Hb!b;|*0!|P~Pu^FK z>@c2MSaKQ*347{D8X-6^AgarA>tNB&8&0~r(+6&klwADe5ydtx>}>c%Vdeuxb-p>( z_oac{3er5n%QwZGI7OX-(r}^wv{pUNY*Fl~DX!*vs&=S%R>O;Ts_p-FI`Gz(dwtb*xECAkkK-H;_KOWug4Y=2uy-ja7onFLgY}lyKit zaD875mMgz`EEc#x4<7Fw`E=`e^^;&GG3D zD}|dt0M>wDDv!{=NJFm_JYU3YP-HUZ_OYzKRwNG%7FPEug87>MDN{oRmJ9ma*X*{T zfeUzd%RUkNOts!1H*8LNF0aO*@&ri1P?C)-5|wCE=|TEUh5^jNVg$q(%g!xPNCbo- zHuB0L>h4s=K;}^K?9yp@zUN5fYDcCBiZeh@Vm|#u*3XYUe8w2exF81FLJP?P^$Ur0 zs3Gd0yh>{oQ8Lk}-`;MN(*YFhXe!G;KvvS#FQAQr@}VgCdKY+KOii^q^theZ`UT11 zS}BAowm>w0xK-E;zSd^Tg=OoJy2=f~@=sDffn;X;=1rT!CNoV8DQ^F%(g9OoUOEI! zKmEiT3*+@IjzH0{mt0lQ`z{aRm;v*WQ_~S~Ac!*Z9ZcIasH?Den_U$a%zyv*$OtYm z!4PZOj={*9;VzpdC+ zcO^JloRmaHEYMrlD<^~DR%I~T(nJ9O%Wo#PomB{*m%zmml#snVfXGm9m=ZKA*O#5? zw>W$$BQbKr6HWeCrf}Gd-mqrKS=*97o{xb#NHy^hpK z&l{3a)<;ii|HPgCqYcurLh|`BKWR1qGeYUQJu1cW^B0AzpGi?KO*%%^AgfWWoTrSDI!36tB)Ig!?iN(ohoCQV0 zv1L84j}jZpnXEQ??)JTC4|jl0+^FG@ZVC;AgSHBdq37W z3hMf-0}8H`+ySh7lKLKeLwvq#ktsfcn+#`seH3S-m|NyibYSOvlNqAQpC(y8wlqiaX0)ea#&4WD5*pbX`& zo3Zm#o7L1fnf;cZDV2dx(yP`fE~m4rN2-ZFnF9=R;>eFmE*PNzrd65D<1zVnr7+vh!xj!<12B#!a}3(@EwN= zdOQTjCwP$2D`-;yA2)qVJw7UN?A{bkK1D`M)r%raWH>jNBwW%-?!#!%+!+%V- zk6Er+9g!JgQt|ns_c*vB%;ce#lws{^@3NBeN8dIa6Q2Nok{sv~Y9V&z8H2UXo<9U> zH&>_FOxl^zo6iyJQU;o3PmhR7-Blr&UCT>FnCv0 z$>uOSNDB@-|5rGe)i0SqXej|$J1@7A1g3nL{lF1re`X=WR&93?0J}JqQrA8VcK-mt zceRwJ`V>){FRE#At?BlD;3^pM_~em*Tc-eHTi82d9&y%pc-AM@zKF$@KZB!9{#&b+Lx*YYxFSPzqAEFq3z$5NG$RUMJ(l6lj`qSrq=z@5o` zF9#+qx-iSM**rqQ<1p9NOhMBOz?GpOClG$Z=Q%`OHoZ}w&hVS_e*jOhgBKQwg^0Wq zUdp}{fndhbiA2u_ey zvlnu5BV+_owI$bm;1-bV{^7OZPUc~#B&1;K7o$8g>N6>)g{X>)T9=E9ni5W*_j&_5 z$~mrYX%p-^5yr2Zb^bfmpHNI zP;S_QLdF4$zG~8xlCzWyhW1?~5iO+XOG3RH*ejOcMWcicq+`E_p6Jgmek)ccO_p19 zLK%(%tR1$!!>bleBP0I(ZbW<#7Ee<=A(#EJSX$!BFw06^7(fsz88qfxQLukFH z{>}3PU%ZRWn`a~~UI{~h4Z&%GUjX=?IGB8M}Z*MJ~v!AjLORS@GlJHAjfV zicXBeE2)5xn)RrjQ_t9_#2w|k zPLHEi4Ip7^gsjKd)!~mweeYga?D0*87zU#5Mp_*WaSt^{U8|o8vm}mw5weX|4;R`L zM?xlW3-l5utq`@h@xf=wL>;?yUk%&&Ka5&%7?aOVQ9+Iv{WV`i~#)d-=ZBlAkd^I3001M<5-TyK3}~B23Ynr zFP*z1i7nX|m=b87thUEbx7a4U3mLo`jH~;Qz_dYrgSv=LDz~Vz($iB&T);vPC7f{u zy6zas0(7O|dcP0V%_OD8qcAmO9Xd~T!Ymfl%TKBUcI1c=%K zDPAw(Q=yknrv#+|6S&98y8PS^zv@b_&P;R=@vq5(upAZ4_%Umod%O^e3Dvc z3adWe6w9+jM3ifrBVVf+_k>>GvJDND0S!k&N{oVKz9bncoOgbIoG^V=T16hYRW97z zQzj5!>5E?_rRgsD>gZG-w#Lb_gKv7bR5ox0tyWyYOPe=9s<`y~z&|@P3Hg=@HU*uT zLB-VIjNyDD0~_MPGR4?nY#xb<4bbhIXt!+k!qf8}L;!iNawC9`Zcm?lv=_T+fIOK3 zqA$i~tRzgVrib!R(o@%L1F=mOwYJi#xKJ^A|f|KwHu!?F4rJvz}c;-6Hr zZwc!<(I&OJ7VHu~V_*Mvo%qwvS%zr(`oZ#-l})_kGeVhdfdfpJ4Jdq%ktA;!k7kV8 z`m58Xc8Hb$i{-5*;b#)yy7vv6W@VT+TMa_-)~d+YjpgPHD#|G^*ub`8@ua;6({^f_D~mBz%)^i-%)U@`+Kcn@ zUAg=G7#|3B3j{p|`y=Y;d|Gnb1UA)mx+ft>y9V=wZHFJa;1E4>=I;WA=xue{j& zvcm=s7kRpiQeCs)>U6W5=Lb&zJpF!eJ~Sj?eO8+}XRf#ns8$gv0cm^;2%kLBRZie? zaJ8JLvif%cGDGwK9pH4j0S3wOn%!F~#3wK$=J@gWQtT#WMhr)Q5+JA%HSf!+$FvT>pgAtHPUr5kNnQ3L z8hJp-fy~+DJ{^LzYV$I!5T~EjO|1NA7?QEHIp!om5u_M4-``j2)Nj?{!W!em)u+gd z57OIDEuGASy1h_yRZ0|%$d&E3#k!SHUj!KD3jg4g%%R)@(w2aEJ0eL$;S%+Erz)$W zB%;ma)OfLb%YBU&w8^9hF)k&SoG_?*6$k*FHU>Oop8#ihC4_3E?FNmQZyODjg+}m0 zB?(q^Ky)ktk4lfF{fZxzvt>EPuS~y-NN62<9Pso<`!8DMKv?+OZ4Xb>UZDhAJh6-x zcPC&b%8WOPu=o)uKF}bp#mDLYO^`p64{p`wGv@&OH%5o@65sLn6TF=zpvqfr-~OC1H|eU^VF!SR`@aH~muAriEBKq*`~ zd$Yz^7*pgdHpnE0aLI6m9I2B)JgTp@u*Digg+dQvOJ9a9tAYzWjAIZ`A-4KqdnHvT zG!^>76SGmW(jrjn8ZPT%$O{#}4e-apt>T)px80v8=bDnLj$3`;^v9RRAdA=fY=Q%2 zR<+ld%KlktUtbOVOL5$9O>f=ze|f}wYCvo7%?Mfj&`pG8ONPC4+q0Rt^)f#+C6CAU zaa+DHSUYCGl`Y}&|2p}&t;p{u?O*+LncR|Fmfoqypji~|-2pY(+|KgKkz9wamg-Da z|0&0`8NeV{UNg+TZJb_3x{C1uw|%o&Mcc1P7}4Oll)ZL!JoEBYD5J9CuVJT47k^pM z?xM+MM9Z|DU1FTQxf*!0zh*}y53a<#JSu%XbPVVQg7L=g1)##x3sf`5BWYUpM9G3Q zkdR#&P~keiOL+J;I>akz)g1Yf#aJBRk>BmcHG^&SgX{{~zc5E3{P|(;ZiGKb`kTiU zd*EL9t+KIi{uCtvR4nW(^?qFXYU*H?qE2p{1{UyA^iU;(*Lvkl%Vb{|d`;i@SGrES zUhlEn5wDbao>|w0>A65qaIJWp4zH7lIwZv=psIV4KH!8@e`e4Qs9EME(fO$p?kvChxoQ2#vtCzeG22$*H&lmHGfP(0II&v%eHD3 z;5y%4@cEwF(!$6o5FZA7`t6S8W;F{cORl*u%uMxCF09LMLu6t&8<}WTfVt2WMngN8 z`zLWszau21+8OfCfKNE@cR9GGjYE}v1}kNNJ@D zKSIsZm@rsaKk5G9Gm#Ye%J&_W^6x^_HTda9m-8~a+M$A0+#M~q(9Km`FOna4}XBCe#xN$dMaw)c8-JVne6TsL?lU3u77<_4R4B4;D;?>v77m)Qb#B z1e?mPDI&uZ_|`Tf>=-~+=DC%vR7Ko{>FpW<)gN1svCSWTBSZuf`*rOkr~iec_43*e12Jaf<2e#VXe-z~6!dT|Rz zxUOOf1$->4D%diyLd_4>SRuWr69nlfhTC{*&25edq0YHLEc_79^lu zDm_6EYj)H#G!Yb+g=j-wjN|Vr5)?BW6KZV!mt;!j8oq_iwGMfAA}JBOE2*g;)Gk86 z?%W|q6MLz7HPG!dCEs{uVxKo|f0#1rSLc$aUWnaC6lXZP)ntxz{M`~);{Rx80bk+6 zWx>L{52=h75A zhXTba7?{6E77kC16NZddH^(p=f`_8f$H((~7W{Uiv&br`;8RCjywlNG6%Yj21=1eolm z@TcLl{K7Cr#G#K-ePLd*<522j?AXiUHPu^#?h^lfI0@O@_wwDU2}6?lOGvbJLlRtB z!%>+VIs1dOl@a>-BrQ|&x&wh5Ip~8yUDUT5WI^xIQcw(cJ|Q84h9?nr0NAikdh?bY zZNC|cX(q!Qx~?sGYpXib6<2&|42f zjlCm~^51a44qsadNRVR0iOIeFanL9dCEu@g2HBUk1J;r!D?7e3wVm;e@WiZ&w*G(#%2O0zAeW(y&{lwF>A)vWR??zJ z%#c;6tgtQFCa+H7j8^qpeDN(&(?@E`J~nq1Ckx*M(FicyE6nTWcfeO1O)f3{UZb(hRtF!Xd0B~^{dnyVJ}gDV@*BpET{F)iAN()Egz z93O(`Em6$fNjNZBO#4)@tuunWztW8Fp{tXddjR%JoHb9ksk4J7D9|5GcMYol<2G_b z&evVY$1>0(C5jb&XCI(IiS((3EN1NR>}%9SUm33~Q}hLJ>IVjJNJfB@5z{Dkn0%0N6UD z0L}P^t7IB)yT7)*7O?a`t@-cHv;v4s{pfl$WUjpr&E~l7zwlZ#P12M!oJLdwX+DnZ zF%&>cT4Yo^-MouvMh|!XMwFzEa!#9hzC5$M@MXLL9ZroTq4_D!Gv4voXn%lAF{M1Y zb4<6TKii6^r|DA;Fm^xL;vsCanlJL@BIJ7&(N;Ijm{QJcpq8PjkvU85r-Ygg5j28| z2~F~c;&V?xe7L&OnHCC4b~l&Zk(MSH*wZ_@-AFWw`D-&-H|SYbs$)n2wDLyShDc{m z{t|kB`Z-o3X_IjWlJlk3rZxf%HbsU4M&x9RCGA>W*Gd$`g^|bz28E2#Qf%JIqv9 zMJQ)NxAWet=@brZ zw!)i9m!!}1{DPR2q`?6rWMz9Z<2BN+@u!0u9qW;yUI$sFm0ynQCXjYn@IOUJE#h1% z$r(eeC4f8uS>uujpK`B7*@p;w7txg41CXFagoO)ZH7OS1NxQVVCAQKdv(h;-bea@5 z-+Ih-*X85LeK&d^%radL`e={m{GZ~nLUR&b+7n|6DQ;8Gb^~SWk`T9fm1D^GXY}o| z9(y3mlS20Bx{0N(kSM97=gFS1*h(ejvuX+f&|nqrDOL9rur{O2_jiZ^;E+yYT+Cca zeU?P`_2FQT_Wvy&6P0kXrE(OMx2*$`sA#F8Zz*=A7eN6V^4eodH8LNcot>+$`$G*} zFLZ>jXSpzq_~ItfJigME$FdEZ&CAz@o+Plc+F-DFAQr01pH@pCSYdJ$qNCmYj2J!D z5}+eLNV^Gw0jcUYi5Pk|ZH*2!_c@MQMkVrtjIqs)4b=V*4YpK{M9#mxdv=d{6*dGi zqjI1L{^tN_L{5tTP+G?Vci$I}X~>zfKvC*63JhKWSq5c2?^2nw>$8C6HpO@#oPt%V z|H+;ruQc!p-;$%p<)M?vAXP7o!O7$_Snp)%5jrbEV>x+F5&O>9O%8N^=Sjg z{aG`OAAg^Oan0HLNdQCWOma7x0GQY;3S*9-pn9uVw`N{&Aq`gTYlqcEhRoXtcjTgO zMO2hLY(%AMMZ_}Iac+2|>ma<68$Pe|eINy#NBe$B2}?|nrvhTx?C z0UC+}YVb7AOBqZ-0X#Rs?vRWzAz@jJL%5!^u3P0S7wie>!pif9xzk+hPVY4c{wheSK)XIgY_3t*ApfOvwsB1YMU_ zc|09gh}JO)(u;&B>Kuz6AOODrjLHS$_Ucdo#b%oBOjozDSkQwcIQLGi$= zg($N7oEAUPdF?T~-kwa48yT^KiMuY@nU(J9TCt`_Y<=%bE`AxPQ~Ss$V|PhgTvEccI?YsAqG<}_sjRIxm<@MZTVyx#tT#mc1RRJSs?__w6-PqyRNv} z_s5c&oz<%y&(Nr;FOtKVUEt1jZ?$Psr6-(UXOhtxf`@Plyh0o)7m3%I4`Dim3*Hk+ zHuq`z^Sk_dAb*8Rc09v{jSuqc7FgmYo2Ss70$1AgWxqC5*Ra>!m>l;#1zH?FvHGr- z`o5O>;j(f)*CinxAnrRrG^_=iZ$hxXR^ZV^C~y0YeX}visE4tO0;P+?=8k35dr^~w z1SIa9-k}cApJ=K=SB4ze_SUgTPDdOkCz{64xGIN}!GqCr)?{LEchxl2 z)P>McF$~``oxj3vwZ}u5#F2sfk~4c%-1=KCh~nE=``|I7Rcc&Gt)4F7@|Hl9wAk18lJ4JnIq(38g(H<^1 zHpcWotKke4R zDmJ5f6vGJ4wT2PJ-Yyw^vsSNXFGt{VO*KiR*0bLFUUB7hLC#y_m#Y_Gk~iJc!M<})Q@?`T%;xWv0lurSx?ZGEoc;} z-9mR2ZG^igRV8kCCVzKXq1L?p2a8JiD!P^d49SrD^$!6$wILHXwdc0U4LLCLA;NpP zeL47-7vX70lfA&uZ6rknhm{!3mMRB!A;~Sa#*%5Ed)AFRffy1qV_G5?`b)chJF%N8f=zV7q2xAs{0(e& zgF<@<%5K+gzB*tkHL+RYtN*WFc^KyqYFKW#s&)9-!aGeR;j(C)+|$SaS$EF zK`h1pz~KELL|FQVL}p@-bga?jCpq$mi3LyslhFd`cII|z#kSx}axXjX1!Yam$;Y?{ z_%i!)XJK7Z%1=4Vqm>>41C9Y~fOlVcy}@yxD|VkdHcKah_QSpGTRoK35}rl~ddYor z4c1`lfk->!w~F596aWdK@4}J^dV7Au7HWZGqNtk6c6OBOhJuH5`6h86+ z7ijxabVd6JZ)`DhD-|g#kZ%8{ zn%4WqkT>HcX6LWp%#4e}Sl(eLbmjQE3MsQnH9CBdF^QZFWX^c7wm~tfT}X@;RFEYb|zU{Dx5 zbUT$LYw@iAD5ih8zIsz;5@Nz_M0ggA?&sH~21*nJJHQXsjq&IU&! z+(ar4sc@IBKKY63t~KR3T(%D1%&Xv1X7Ll9!E+*+3#k=rrXog_hJQkuI_;QKL z%PCF7DJ{t9)$K>FJ2?|G9|OEG<4VEhqrLs%j*(!+A2nP3FYUaaw{Fn8Zjf4g@9aTX z#FP(FH3q8J0B%$8=i*unm3)XpX@4Pn`bm>uP^ptu3Bi3jxrI7*Oh2y}yg%=+yzl$U z$Gjg3yk$PARlgjn>m=oMom(X|&FB@W(Rxk|p@VS7xQOcX_RvrgAjvH}c0O>yGZ;!3?@?DOrusiyUg3`MAF4N`N`CeeEE zih<@lLv`XAJorEX%_IKwct=m_)0!Za@JbGD&T*t<9BZOHqJJ8HvM#U;M6(;P=HsfA zy0Wlay|p(pCM}%|1;_Pf+O%b+ft84NL5`E>_L;g`O%QflPD}HdMc)|HzPC#6taPIw z&h+NScAdeXJ}ndTi^?ALX`)&b#3`e(ZRJ zls*?OdBcUzq*WO74ZVK_@4dPN0O%jrw2n|$csp5FkPZG`$)A9#?hkT2Py>`~9tdYF z!_JZr2T5GTewW<$FONfLQ(~ZgT=2lgco;lR7nRM@O8*i=_fK?s0%ZOg2V^S8hZf<( zZt?K_d@u!mevLf?GE??{|Qi8IC`De3?bb{*023FDb})(M$yR$nz~GbOzeh^yYp|%=;UR zG-St9?flzNIGYQD+mBc&1b$euw5+p3B!V=dM>i9yNPzLBx=m!@>Q}1 zFH@{el?Z7XQWF4pR7E6VaRKZFsUA2UW}4089YZL;Bp>t++^Dbn{+B}arX%3#40v7j zD?n2iY`=DLnNdfA`E8{V=UriO^(3w58A(^ukx;BY$!Ov(y z#hpx`4(aoAjUYc~lHP^A+vJ8>;Gv#;>-)&LWhRc9(*BL#z}{naLa6FC8v7Xfzvw!W z=iu>xtlzK*!IKv$2lbeO<-%4NQNSUpA%Akd{u?KiWJ4@86#OO7l@JdBq!Uzb za|>q9LS{5A)-xzou0h+!O=`z3 zcQ3G@tbdAbdoz-*&p0kR{++b5qRY_IW!czpItIB?0`8#)vRL6j{$egihzCPOj7oJ# zc9h2WOVR@^Vzmtp1W>l2H{o;Z<$9Rd34GjTe64$2s;61m6&`As*!YU68@_SB&gHTz z9(1!SvdYmd0xqb55q~RtF+wGS?@nRJ_lVQmMx@VU*J1VzotJS3F75TdicI@i+6#q3 z3cPIS;m9yfxwUnQSZQfW2HgUU0 z`(@yAH4s$Z0-ZcQ=<0~W?28iDxp7=KuaXRnFlMHbLYLBrI|iqe>`Ua ze;RIU9nxAsVQQxBuqaHCzu*}6K|TZEw;_;!CJ6tm^Y=g0g2T*Wi&3celyeN&^AJ-S z>Cp9(B|XZwrzOu-)`S9NM>p1Taq$h>PLu!MTf#-wHU5w&Qi*y(pLr@EyWDbj}VSn zIRb7S#~t81y?4+k;=DwAE|Pw(sn55@awK|`37G{nN3n?KOU%09J?cvum@a|BBI}zD z2yKMCpUWuHa|XPP*Mu4`O3slLNt1a-sWu zh%aairXrBw=rWn+P>U~lIaH%G69A_DrP+l(Kgpg4=1?I~={#*&^__I}n`w}J8JmBe z0)n0mJOOUTHh)Nz_qxNth z$N+QVz??(ZTaZQ0kEpD0Q~}Lw1_RIgHq%U)6JV7&ixh7IOnhnl@pCz^ z5xRGjO6PUR(Fd2Y6j4jSG(ApRfU2`ihdYJ6d%T<$8lOV{oak4jK3+%W1UoJ#U;b%= z;>yky%Jo<`Z0>6|LISqCjpcMv8v8L&nb`ev>A<|S0d6)Cd2!l0#CQY;1%DAxx{<=h z11QC--m*1w>|`m=y3vg)-_HWGm^r7p5DtpKz0wB46u5$+{hL*_xcnt|QwSaBHLOz?~IjTIQ}n zaf4&I%HGp29%DoxJa>S(KM4p=A7HL9Xd=?rfv+kdCzgNY%9a1YnT^>^l6Ju*V8uER zk14x9rp#}Rg|j(5;XUx(@(H}f2F$77rSp<-I$c_fhH7u8qpjfdi~lIhWPsbL&bh6O zu=J+AoC}_hJ74PR;;c+ps1(Fvr^OJaeo)uswPuh{_EaOuqbId|+=4CQZxHkKk8ZUz zqkq99s*foXym<5K_)F^P_`SPcQHv6=!F%+CL%5}V8HWN4q)V^rsZ=nISd@@*|9c<< zp|#w^mY;rPTE!k&ISM2y|F+GB!2VIOKu|owPck1wtQdB``guTS`t^mV=MS=_JN_Dv zs{}O7Y^@C@#E!pqs!k-jJIBvbbIU&KPkg+6vz?O~NYGCmx61uBw=n`@W1Q+9DUUJd zO0Xf%_SWwj9`gpvVzAL~1m!yTr%2}$sIi?f-Q=-DRhv8#jlc~8H^ymoSPzCQf2Z$^ z61X*9q4lwobU&v~UW=!^M~c8k6MWS(5Ie* zvrCU|a#dH&t;OK34-xc9bT5!&I>mUoG+k*XhEpjjsp4 z5KXSQ$987ov}6M&zue0w87r)L*-!?)59dCT{wa#j_ z5$@rv;#M#3NSyke=Yrpj2?FQaBT7uU|MEFA5e&JHkLH{Y@iGfp4D{GoSz9~DP$zje ziG!nGH@4suN9d6SW7fS#QE%f&tCQ{fM! zS5x}HiSv)z7YZ3`HxZg&>3lc~-TzcrE>a{sk)l<7Trx1WSJy*vy^IIOzTX^dFl?zr zS<(Lc>0#lSJuN?x=K}B=-1|M@3-B`A`wbr@_|FCQO$m!BYxo6_kEB?$wY*IAO`Jyv zo?6c4onTR_jK(>Yu!&NC_D;nI^k17Q_mDt%_xA3$roX#hTQG(wpH6!1d)62qxTeop z(~wn|EFnIFQfRc!bnZySxNK%Yw=E-vW@2;jQTYFIbV_Wj<&9$%L~Zrna3tas6wv=< zsfT4k=|MoYps9!XoYITGQ;H(Wc_Ch}&b(>F6dP4u?;)2hFt*=)^+%BE)}jnt=H37n z-?OC_<mlpy0#d|Gnnpsr`X0-_`RS#Y_PyRVVJ$ zM89^;(_XRD1cLhqU&Rb!Z;~j`ZoUc{1XKA#)QPrzoX9vL2vw7w#K3>#us&} zoCZE!D&pWnR)eY52*5~rw#B9HK8KrCWV&W8=FhIRY77c9{h;!*yFGBMv9~U!(gi$^ zaU%i$&_M=?n6@)Q2Lq%sH#*ZhX)Y<>8?WDmkAKfj(g{J(f_n!2m>?{QJq2>5PX=Yl z!KM&dH8rYDEwm`?0paLTOlY}!9o~(u-zuDt%U76Zqit-73&8sUh5N`bPM|E{9`-K2 z)?c<=a{BC0yAE@w17W8VA;Tb?v1^v1UlYMkbeDlTc}xZ7{#(g|C(nd``k{olX}QR! zB3nV5|INK1LTIB`da1VHm4%NB@3rd8b`gzS8zq1>XTleM?7wWn_c_eztANIhBqNq@ zFPWW|C>xmXV#B{?-D3NY#!Tswo5&M)>#==1EIyBkVDxq?5FB^!P{-LXM`teoriIeeyjU3PmNIC)dHG>o%p_J=wYHk@zU3x_+$Nj6tvprq#O)6GLsZiuA=C!g*`kE(~ozA$KYT{>D^b zi?Kwf0MU#p)jK3e($043?37vrr2iovyd#EvNUQp{qV_R(vV?OEc~kpn`1|kGXT-Er zvct^?b&#V@vo>3DxbJPw;yv5y(x8Dl!qw~TVXwf3V^zr&4On-?{!KWS7?PUta?2ar z+TDSsJ3pta+a$D{QYYEOsX|3+%?`+FzGv8t1d}^q)a^P=T;DuFiQ6<^h zjN@^xT?<`wiJ<(*`0p$lIN4=088Pfr&b>Jg1e9fXc8h@-Z&u_;CE@t(qE1*djJ{1U zm8Pflb7-@`D>8Bq^Q>`{L}e<9ULaN{HH`kKnX%)elrBSWF(>Zf)YvsmqqHtX>^PTw zta+G!$#>}*RR9(HVd8Kq5XIqw))&PDra~hi3@(%k;)E@I3@g>XK@W!yX6fnHkA+;C zv~W=6nF9%4G>&id4eG~y#_HaWIV!Li*Vu1-02&5qUmR1xLMpgoTanJC5RAo4ELk&5 z{0#`czskk%gU6|+4{%Yj1@uX`rIHcS6qa~ox-KzR?+eBF1&rD3Kt4?aTs6ST71$q( zAv1D)Q;3NTyVkMT%X<|L zkZiV;B-EpKUrrOmj=3#D(JTFju$xS@{R2 zskAR;1y#3@2v?^2WkM5jAG+OE$Aje<>lOP5SJUwh}IZ;ct z+nn8`SoNvzoSmImH9dTIAXO>(VM{$dD@rU<>1=AShuRn84LQ7&)z^Yl`mY6P+QUQH zy10iv@~)g{GRKY1d9tYI)R*O=68fN=>gE-Z`_7uE-deC;UpneA)|c#iIg&*RM?TKIZwrzI@IS{us?Gxq=cuDNEAjR49o`(J4&^9c-DBc66dtAyhXB9y#g8S)3g{t_ zc8+Hc-u#oV&4-?@43sR+n_qiTjUfQu!`C4ny#a#ko%cOEAHT>Nd?o} zJ>m?kKU|}J|NLk;bbc`E8_-zp*eWkZu^z4TOoGn2F!5UGJ>MR83N9VgmBy&Jwg~^sUg6uys6;!I_d!JqM<0<`}7+&N-s6 z3httY3x6qG9EPPv@a7!*=DFst;vf4eZlld*F==bHENmdv+K#k*cv)q^ShUy%ZP?Io zUj3HiN*7pXDy+BJcWlD9?#Y|sf*uE`2gPzik6UF!ShUaw1yUNSJ~v;W_qnWnmK~&%Fl5}wtXL@F}$&OJ$DyP?{D@-L(S+S!d2cVA3&HJn8 z@H*ClDxEIf*qFgQSJe(q6pdMc%Etk0z@QmUPhOJE!|cu`Q#n{WU|Kv95kax8v$~w= zUsHxl+>Ff+f#)A@v&NnSGd}-PV=myswh&=3cGFpbi!)OmF4tCw3`GHk8QqrV7hoCd zg{bt!V$sD0=Ot@FBz=aq1uE5-nVSxvAumo)Gta)Dee=EO)-;4CCr0RplEU4(trnGT zW`YoutzSQUK$NTW(^U4Rty(RxT@PbWY`?w3M=O}7aTh1v-TD3Wy}aPGd`VX6b*osr zPoWkF#;B`PYJOT5;t5QsV}HtIfJ(Sy^M`He%D4bNn6gP3tMBB@#cnypY#++&Zaa&n zG&5vWZOS(_frSo-(hqRUDQ#gR=b#? zAL#@*DcyPUlK9y0v!V>oV=OE{`DsafIq;AvkFI@-^}iWCB`pDUY#vqgg03#n3N@wu?ISH9@2ltff$RpkqV1grq^>jZ8O6Z*VKQit<`Ur(=cSQH~%~+ zk7$boH|V#?W?1>;jqltjZHe<>T7x)}Uyh*>X8|32`@2UD4B(v7XqXTZ5s2iaaKm>9 z>rg+1iD(qPIT4dVvS2U!-n`f6nR~!5v8Yu?s>Usg8o{P5xyHMusFU3c-1VREh)!0s z#uisT|4sk8!)gMNvq2zx??@=ANH_B|_GoyREpbKaX($VV+UemM66o34qeC?i0FQs) zz zvoG&enz&wD+UCkE(v!F$&dxw4hXXrwbq4%gF>h<9#a*9$$;=8=i9k|4pw1tw ze33IpL_G3+Xi(7{&}b7kVQ^Tkxx{+8ir^~0K3rfC$A`osu?|pCrMjTV5MU$dOP)d-Eh68CA>qMS_%H36G*qL5GcnmEUggY)@d{f>xE zvI>r0bM>FCNRk}R+nC0&`?8KzsX~(W2^H&XR@sb|EEdUfK$GQ3vtfenD0kC*QP>iUe z(xwz!i-7?*?zb0@%=pCwqqFT{ZyKQBVm{dDBTg~Zrcci}rC1@lE&j*42#6jojre`J zIH#cMaz<5c6jrXXK-w^{__GPtScE4xEO@Nb z#LsXsXQc|~v5ZS0Q6qCu@hd)ncvhbc(Gt;N22<_F=K7hzv4K*EO|JVF1MoOa!sfd| z0%XflTMs9=>4bw`tZfiRUR11=?cHiGo9OsVNfqZL@ zj=vmdGE+Ts+F5ex*`OrW7H<5=Cqp{fUTfK@7KTIPgXzh09&;+rn!n~q9i}K50b8^Aazv8M@a0g{YsUwZfFW*azYT_5rg>tB51;T9Mqc& z`FET!LO6Drp&6Dg)l#JzZ50HB%aet_H5Fr~fs%ZNy+NHy4FY7$RIyLa*S?$IyeS>CLZ2aDp+iZbapIKW#<$dnnnY^tK4vrzF$^D`|{_~>_CFl3FcI9bWrzX?>*huF1w_$WATXXi) zMB4ZMWN8dP4;gWlxOsBc@n%872}(JXk4Bm>cAw9)D4Jr2npmk`1Oi$_r-6evxAf&@ z`mimvZ-ZsaZD|?q!Ebhbo?I9qx`7qt{CwQ5*mWm_#avLy z$L3u8v6x&daq2B&(VUstDrK0;fha*>tEoJLtiYwN0iZpXOW2{S{XOj{YFx&EQR&&nsT_OORIiDB6eg%q`?dxi z2UrMe-t*_k?AFbI33O~$WeaQXgoFwnsX}ZLzR><$|FFa`F>_?`eoE-DKOhEMsJoqR zpQYWq6vNW1*+K6r&_^$3?ilzb_3AlGZ6lXp@4Z5qE@R#Oxc88>P6wwn4n=Dbg2utF zJU%?UKo_>fPeO^rjf_x^*1S1*C8SzZ0c^%=-W@F>t*&VgEJmV8gN40#wS3)x(o$m( z_hfm(!~3U4m3fA_cp{EWhIn2}h0NB}Iv&CW-6TgMWfOLU*ish;X@|g;+iIc#-AMgG z)%5;m-F`E+*@Iose^c*VoumK6h9+W-_v1KrpR_abWmxlBVW;ujnQ`}aW1a1l5$JzF zN$w-n6UNF}u+O+U^S_J>_Lemzal|>QLyj`Vz@RddFm>a`PL!g@;H|A2L_uFxEV=9= z06D&7qk1klIEq|$T8))RB8%o(oE_?vQ02VIqMV2-_y1Zhv>>8LYi6Eg^uOmTE3Y_Q z=|C(=N@-eP<>gs8SDME?&$2^&9JL~Jy79HJt+h5&2j6>`u%K?3Z+&_9!&inb*h?S8 zp>=D;YdN(~7RBPk>e-Psh7-$ec|wCM$Ih^0k1d^oi_fI1&o`!ME3qjLPldpoT|4Ob zj&B3z5$9QCBg>#tB#U&UL_niJQNA5gNAvYqBPlhIl75_~)MOX0oyvlh0v@yfUI0?? z7iG|K$}5{O23_$lB7(kGLX{)!LkVLiE$R~!)$1Mptb0zy`jqS6%orLu-D+LIt9V(a zbT~%5{&oA!dQR*Y>YL^lXO6n+Z!xi$WwDslc|bmr2{j(&^rrjr*i8&vjM2|fG~CM# z0%&t!82L{r%QXiYj|z42G-X9$Id$J_Slnwg{8i}o!h_9Z;p6m&dqIuU*R7kb9*HD^ zRrh%O|CrNZvO8l&^QMxN3HdBIJkGzp*nuhn$dxonWoAwqn@cvs700cXjR5^h2R@}h zr2IIM6fBp9&zouiw^UoHdouMs&H!VJQlS1%Ip{4b-RpG(N}j|E2aadLhf?&K$zGxcBbG90{rI<&WibiJ=?9v4`p zq2jiIPu;|jYSra=J^Vh^WNRprg^tJ3ojJs_rJfIlIH}f|V$v2oL&7a?&DuFcX?QeQ% z5hVTDM`GAKdD#v1W!)GxWX_T8C;@$=nZEg4Jw$celgiPCSM0A{W)e)^hXg3yM@b?7 zATgu(@#DPik-#88U}U>UU?KF7V8QDbTu2rdbyS0nh7_gA{L&+y$wBM8yUGoy)7ib4hsvK?M%_!^)YronG zsiT`|;Q-%5g8mzJ1;2;%H_^gT=#gwzI24A;#RwwE+@a-Bp#m2T9`kA3LqsK0Ad0lH z|NV+J!GaYLMnf2wfX$+(nE$7Vo@JXPx)P}<5AMUN@aAG;YN%@Jy#$W)8(_LOtX_z1 z<*Ck#$cJ7uYx+ySishOI`&O$j`%UQws`XmGM#lkzLEdLw{*MI9CA7qfH`42^1}Gc%|1t_yWy zeG2V@iRFlhS%A0lS{ype*7pr3g4U!*7hpp5AHDQ-7%2-)r$Z~;Q6b$atiL|+{Drs| zHhRd61DcC}>Xy5=h5Cy-S@?ZRxLGVB2a!F*a6T8H4$g2q9-*-Wg&^s554H>#ZI~RH;tzDD zY<$|+>kslqx<@5r<-ZeU1?m{F3#&D5XBY%t2k zO6Hxls36n>%$Tq?b!4~Lvgf@^RvByAE=PQ{VzHXL9&IeqVau1t22o`RhFaDo0`138?pdOQ@{B zW4W}+i1}|v&vURLVE7GTcgaYD27l1lCL{o99lDe6VW%wIHn7hfGe|qf#t#lh$JG^M zjI7$Z7eREHw$@lKUee&!{|mWaq0ZNcE&jttNzS2qFCLnCnm+%?#cB{&QUm+i1JtJy zEiPoEF48c=%Za}6AyI(**VGXnR)|nGwo(<tYzi3l%E}RzZvqc(JowB99*r?(;(8v<_Xn;-#3=5ylvL3oNd;e z+VmP9;#Qn`z!H+_)Nh&&PJe>{yywNqkqEG-1VVHX=J4U&((&te9qcmG!%fCKZcORL z%`ElQ<#7_lNapSQE1O7f1doRaZ7#4@Y?S#$Y)E=5Sud9-r2u|`IzTMWk#;+mbr_fR zeJLMhsc-(gvCEg6;D12#G0zO=OX+?b_TkyP-_ZkY>*T-1-rtV^3YMHv(`lR}eocIW zQjg!Imex5hVJ2Ryi?@e(HoIBYxvh4p5j5H>;D2MGWS|j_0BjkVvn$|4<(cFeRdb}E zv9gOSs8oA%0=}14h#H;+dbk=WF00`f>A{>YtjG~%2Yr4&>D3ojEX+5dDtZxwKU5%x z1YrR=0JB&eEehlk3;wq|A_A72OJY8v%>oGO++vD>KOkx!a_{7L4h}gVXb%^e(^H7^ zXw#`Gbl<@p|e&*!&|JDF5J_X+4s7KJlC|gRuw9`c5O-okh92$eZ zl*qXg4rv{T>4VZ7N(LZ=elYd|?H@i7V;v!7=uz_*MhM@;J$W3&6O^g1_zIEB#XT$H zb-8j5)vgXrVJbCw^lE?0m|&?xnH8P>9U8W#5!w_btT-<$9d^OmokvV-@?E92!s!#zWV0(N}VCAa>fOh?-HL-j|vajRi4_3&Iq z`zxp6tk&z&DcNOK*egbxM2rYTPzGifqXz#D7qO%CRu`*9_%%OY2sA zhDqwHLP?4jD&Q{?{6w?uYW+n&^)(?S$(51QizfnY-o-At} z*F=E=RW%Bt|3qpIF238zBZNCXNOf1a2r&kTSfD(o(F*+9Y}HZG(G}83CC@C>U{?`^ zEtCF(cqDX{I*VeeR0Qo;T7YznpBJ7xuRD&Pm&B{^PBwDU?K2D}91ZdQEinTZOy zjOCvPs%z-&8r_@@p1VYDM8sz3=F4B}z0?ojTK510FPU^r2B!d}T;3t6j9O^0JfF1f zfE%irh5hfM*6{VFR*tcmu9T$6#)<@K+ci%DOJXgFR%m+?;nSo)3#0tYESKw7FW9_0gMNRi~My-+eG_78?v=aG7# zM67T+Og$&-U<97kbOMFKue=Dk=s=S!(y3VC ztb(5kcn5PF4G6Z7)d`LIub9jqNg~OgVHux7`@|&q&RWTP0w=Q$nEd>OV#h(KgONpmAF!v{UQQbFlZ^MO_LkU~PY=E9`>-tEgc> zaKf{!rHVvhlUI!o%H1i7F=^-)CE+{YCB$xH(s_!wU*VTblD5{{!Ur}icGk2gA#Yom zxcqI!k-7RNL+FGai&yHes`=X>7Q2#1ZH|^4aaEEBgpwvUv_t1EelY42Yv(|qee7pP zy&lxJE7SI?cP3-xe*)8ULl)a6L-;x2xsAF$`Hi|ZUm@nGRh0gxXKAq@NM_G}Fclvx z8-6kL#y_-~Eicu-o!Ii(&B~Ih(ifrtgymBuJjq$kwfedxttXvR+*aE3YivMaUHtj9 zz_k2&s>=YAoKl7eVeXATt z-+Qs*Gv%Qtyy`gKo60&&EIpbSRj4Lv`Yisv&!g+K#<&Tni~eQ=Run98{bB9RsyOdL zGQ4xmkV@sLfmsj@GGn%0;ThlYTvnBY>df|*tT9LN5 z;jvZ7$*~3?RgZ06-_jRk>pDh9siCE z9Rdw4#nTy&AKxNb@{$M#y3~MzFUpak#PrkWsOB?B^S>4%+sCxABzmz*`osRyTd^br zWk=({0*dUGaP~Syr#|7G_i%?QvNfI1)~Ep+*aCiUwCaKDjyE z>L&wtM^kXkoJVhyTd}{dn(>T!usiM5zV4RJ-mXjx(FqIW(t>S}5$b_Hokx}GH?XKw z2bcGdTTRUytO$jzG9-7dxp<~B{$3?kr1*M+{xFm(QMs@O1xqU8<0mBzqsX2y$;^)i ztm0MQ3lpa*iBFv-ZDjU9d z_I9Dc1csUHBIMvd6M?ra&uJi_v8fRWfk77!(g=#2nQt{!Rj-}N%Q-BJRF?|C_t*-r zv=GoD$s_ocLw-OGqq{aZG)NnUKPq$wboVkvx5mYB{cp(o3U$9i;=;=kPM$OU<@Zlu z@>e^skCbv#{X{cwhu4$$LE!IPx)`hVOeqf&ZoGyV`+A#<_Ox}U zObWIhSi&F_G4h9?x@^a&hLv?6taAzk7`rEi%fZbxo|@MXM}R|?B#_jhFri*2tp-rK z@Q80(zw%(BztoCl0o9}zOS4=Rc`~W^Q;goCc#t7OYb_RujZL#EkTXm}Q#_#~H$8A| z@asn{DhXKKyq;^7a(CMf;9aI2E@)nh0U@&C>K^&chjkk5{wb9D zjs1rcS1vCnlB?{wZvH&OvRcPELu-B8gW`7;!4ErREX3(BKrLdd??Z)WxkoGY(r}|y z@xDAx=+^r3`q*)|J>ih5WonT8&H-1=O^ijHjK z)Jue{)-yQ03TUl#`Ft>m;7ca^;l=Uaae6O|O+8RHy)JP$%EN?1e1hS2rNwe`WG8;F z@J~Vq@>!-d0eOG5TK1~YPy#&LI9y6L!5qE0rM=P?MBd|t6^>RSYr{?9ralkYx~q5M zl@zcN25PqvsI8Voa?>XJG#yXYDpf zzc2UF#UOUkv|&0$hHzxK6N1k6V>dFZlau!r-6p z`=2_(t7l|iWl+pd+zMzq+!n?^Azo6s#G1ovs#3>ao=&VONek;CGno)kXh_L9X|oVL z=>y-vcjr&Y&{V0$7NNHf=-9~?MeE!6`1(&euR5{(Isj%R_+D98X93d2pSihxtYS-0#ny zPi0=-wcp3-eP63y0qU+Ok}7^gX)M5TIix*W0iWXHEjD8yBzYcil8Jn&-!Y>4!w(sQT(xXOwr=vBGwx*51`V<_+GWaGtP!>jY{oAm*3=t?;mm+ZN`N+7M^8al8ACpPZwu}#% zBW*?*WEZRJ=gR%$-9seJTE+#Zp}*fVgNY^BSFSWO&r0PVNnNtd9sX>I>1(LThH_j! zP;z3>xX2Jp_;3+yh=$)FgUbBY4v)EZ;jxWub?4N7`(;;>q7*(F|EH|4j*6rCwqn~e)rxdy}H(^I<>m0 z|LL_(pW1sL!DVfiETCo0?IgxT@Y2IaE~Jr_Am>fu#!>We-jI8SGuW}DKeQCLb{@i0l&ofND@#Hc?7Q}NvcsOOt^MMe4?Pjd zp^npQjn4z|j)4bAnP8K+Rm;u6F`kBsgp_&4AkWE{0b_@=OGbdmmwYk*;fouu z2v`qSUa(0l(Uy?(d}08UGXllFnnuV3$35>;c)c?}G6j4u!o-zGpFL^z&x{w5Sy)-C zQ+Bt}X?n_v=K1NXE)sP4{CO{&itga6YG{`yJZb(-|X~8E(}(9F-a33^%GX#XoYf*Jo1WIwX1?Nk^s0Pp;wV(#*e( zPxUGDi%y+_?F82-Aw(B5f&5_JXhoV`se_OYvj7TOWwKzu+&k2pY(>upEK+dIAa5); z&F8ab31$`IH4ep$Y-7O5h9`;^U{mF0SLJc#-jR_M5Dj>dV2``WEf_hpLM={6oNw^| z^K~qVH(7_DCDjdFadjfyvbO8tqYC=Dd|wa=g<7zLciY=zRWpE47R`1s`V1$?B&$$? z0aTI`HgvCceHo>irF8 zpD7JFpL}WCjw1?cVqPXikS1a8zNioA{iZWsidcd0lVD+kW~&x&-SU4Qi488^2sV zbN>)p$EK?KksJN-SRI3d2twS`gY|A3pI&VSV6}}DF1OneTRpPJC@I`|)5wgmmK7Ox zwwE7_DHe$$ST05wcYo!KneT`x*2O2-n#7*fQet*#aC!caKe${3YnNq`PQOHdGc~8v z!|}pFrMO>V11BE;L&X4b5pgmNx_Fo8g?G(re=;@Zg?q>QEHfi^+Y=Y*0ZD-e-P1xE zAnU0HeK4NUisr!)yQhA`=I95&VVysFt#gx2Kbx*n$I1G@h$T69cn)Y{I18#zB-n5I za7Qc;fL+Ul;ZKe!%Pe^$(m^%xSwY}=R7m^pYz)8QQjT5^1wYS5 zI?cL2UrHB|^PfUPwt;yzbsvu46jFE4|j*sQwqZ&8qElXGm@<@Vl8k&7EJFE zvN9%nVTJoGMwp&6kBo%+pSF9}nE^kw!u=W}{J zDg4-5ulz4D;U6tAzu}$FO=ej*P3#Nr1~p|MO%LxWanloE54N41xf{m0`{8t9KdO|) ziCbgY#wZzVpSr@Ygr-GLBc#NqohP?9cK);;Bag`oeCaQ2lg|T?B-pd#o3b7x2|?XY z4)yT~MDy;_BwYqRR3&nNLwRhj8&@r;a9!vbQiV-xj14skIh|!k)rEI{<~$X(xWA7^ zuOoStzV6(Aa%mc9jXM$}%#_eYLyl|d zI;337Sr}c|+x4ijY+Td58S%EhK8Y!Ay!cfkEJ8;FyF2Wpx2Akc;#u)#tkCBi`E9z2 zNe7#pwT9%GB#Xs0<$J_h4M;#F`z!~nc^b@8m?%nUePlQun*_yXOQap(x6A*dO*c(vihw+z`AK$o{l zf;9aH($HC|7(As~XOc7iTGqaS9A`h!!@DobD+rC_ru3hO&e|tzDFP7pIjT^7y}~AG zWG#XD%Ce>(?AcKp95!&6m4enSvNpuh_zhIWXoNXVTiub5cNM{iD!(m>xvOQMY>Qj<;xFnN~h%}mf-Y;U@mw$@vT!6Kh--26H(u8m#X~ zgH4woVmV3WTK&PW6FxvKPv=v{Jx7dM@iH|g$Jw_~IHMsu+7VE7KUdo?c?QN0=^p+$ zK9P?*ssGDy=iR zd2karTg!mIx5hn<6Ydfe$2*OC)?|U4FZwh<&uIBmX6313x0%mxFYTwK zArI-OadNTRy|9!Y$I8_rjIRfAOFX;{Otik2JCUIo6v0&0N&Pz5ahBbcWK9z)9Ui8r zFYq;k>dLz{H21#XUl82V)=>~#{Ly3tXfIlr2{QS}B#lzrRgy)boO%*#u+lV`^~G?s zIa4pKnR_^-w#y;=m4r8Q#q4f(atpGrXI+OA1lJsSiw z8df#Et}qipp3n~+Y8c6x9BTqxuUQTXGT)QB>KYtgXg)fXzm7Z~8QZzm>?^420MOg! z;%Z}D4R(3Px(_z>cRO_hoU`vou3DWA?&bFfe!6gG#VO^t&%W=5D-8HG$(b)LY&Wrg z_v+LWp6qkZ{tPvzoc0huIX#QIukCs%M~d_Aatw9F zhGQ?Wy{H;3@Ws7!ofAIGz)>JgA5bD*!Rfvg#r%ZKfxp4|PB9v+Ru2-!u{Dh#^(p)| zYnWvyfEuNdP+A9g#+OBXwS9&JIE8{FO1Gxz!8=_eNT@x7m#-Me#04vAYI z>^#Xg6r?OsqU{VvL z=_@uf7}6_5Noxo~+4iD%+c#N(U@8)kD+uw5zu#MqAVQ)OPK9UmP>f**g!dB?!Gs9) z&zk=-NtZQ9Nt2sz2_~L4-xn9p89Suy z1ioTNKLy*WnQZjmvFUR`MhT)TT7%U3T}lbCByStE0Pf-Vi2@!6iW8fwb=y)iVP^r0 zKMg&KyL!PiYZim7Cz6mV;}f~JZ4EW8wI@4q3-4hmuaMiG>%IyylsOn%hbC(Ck27)!JCDl!bMS9{j2 zBpi*UqhaS12i)-jmTrlgO13hMRI&Y?Vw2zWF8e0xP8 zRLNU7<6V6r7jP(`O1n&S+)*K^aWPqag$}h=_2)JH_@n2&f-#LM3f z4UJvP>wooFho4|M=D5e;jY>c7N#5PY9!NmZAo6X9c!iI9g+l#DWfG44VkLwyxcXTN zC9y%r`;~GIFdebzQ$;_;d#tPUF7i(QOoB2k>|usu)k-F*N1&rrz);M;<@x*c2Equ@ zn+3AaL!OC({OSt%Ek-Pzk5^Sm#jor z*3YxA=#Y#nE&Gh@k7T-@(Ymq7TKS3e)#y2tROV6OCU@yPp(4YW!(c`#QvGlEBHyT?^E>u8boQDNc#OzxtG7k2WX*v+ zMDWf54fQyNKsHEa*nBxX_2V~oNae*n>Lj0v2Y{S4eN~n1F>=N%MwO|-NQ-D{iaZ#} z3}vmK=sqvM%nmHe{w+BCRq&=R1xS0(csh+-AJ>peX4au6YB;4UsOK`~b@vws71ztd ze}oLZBqvz%Z4pXrtm!mt3UT-#m};Yo@Et7>Yn5Yp7U_vi>7LeW9et?{?q9qTO)}O; zVRl4;?&Dsjc?2UkM4v^?lSZ$xQ|mU4+F4u4whvgBZ2=>~kL5XAfC%A|hQ0JXGum-E zxGCRbGH^ud{+U1(NN!vsS9IPXx>V6@ z!KHr`m!)T_5A>QpAxO{&)b6X?tR%~()CHVODCK!fK0o(oU-egB%~RWQ%TB>n(k$&L(!xHt?MB-y8 z#9$7ge#Vr^ECg$SkEBBnsN87Ngqkw_I>)A58jsR_<*$zz{_(2$E!{ZslvD9!}{8u)n@gk;$Dh zicOxMYO0DGK~{Cn&ZDr%DhcYQrh+4^%02p@Mo_B%a*IQven#)z?kt$6v_@tx3Z1dgei0jVDt935d_l;M5+)~9>;MQu7Hbz3L zTqy@a?L6N47hIICuqXhjG;*Q9oM_-GkN z$^eZsSftfG$gWe%3+`n$ZL2nDN&a!-GJ>&sh!&6ALpC-(^p2Eiz=Bl$)ouxKcve!- z-fLgX1YKcfg>EX@#o^2t2;-;Xw=C|4cdEmDxgo0StVk5kG{jXEK&EV;C|0z@e4D`? z!lgXV$@N_167o5*G(rsW?im1jDx?-)h@uTfa;wd+g_lmx0b?uAMN)-5mIC+r7q3Rufhg*x_1C zf!k;V&N71Sduy4aQXZ9{D;pVkajkWHMv_XEJd&nd3Zh zK{Zu0etP_5Z7e$o<0(jdIupX8J2~)~%N)24mXfN{FW@xhHCVc8BbSLpOI(>jMyHzc zr;F?G)bZl2`%LDoyAFqh>&VVf?z6ZY?;)@wa`xX8zoPrt!Vc?~Mav2+pm-WDiOvtgwwPAEow1t2S%%i&$y`;1mQKSD59=0QbMd-yHiY#n<*nUI5>X2RVlkx3P)V_aVC6VtB@L%JTD%^$I=ty6r zW$7QVqJfb&VFMG(DOg_m>r5p0qFEmi1ELt`e#)jpw+iEr3+tsL_>F?HGh>?D(cf!& zs)cjZM~5*NKMkLa2Ex2(_u>j;O$6Us8~GNE3&=Vo2uXi*>Fx>~GrmNVrDVaal@a2PBs+NLOF z>*^b7vgyxR?-&3v$C{;#=mT3pJ$#Vbb=tF6f6-JDf#I&d2`)fs2stn;SLEnn+ zQ`xeb{KR-(ScV$Jk77 z=s_EJ8-evjcP7k`c%?>hPo%bPs@@jeY)wOAtbB%2K53IEo*pQrBz|jxS1j6`I$Q7_ z=rqc``eH`(0}D^U<%`H~9=;$E0X)i@Mt#y0!Z@iIV+s|GPu<}RRcv~r+9Zj3fCC){@QTwT(p=j+!vxn|M=HM*^a6hW$hw}hd&8$L{n`?~eI_OfF& z?j4K23Q9+gHOLOdv*9a0ieV3;!%UU=U6rYuiiW3O>7D)Mdze?t>$?VSdmmmxcSH?J zUDXlq$`3lVul9r3&-3Le&ZP=0&^LT_B5bWWOi4PBRs7u+(k>{DjH48XX;GU#;@2M_ zk{z9X4xdi~HZ@oL@NBDV#fT447)H#;Ed)o1uHw?zthO2dLwin-f$>@5S+Mk&%1C8J z>vHanb0f*JToq$~hojqJ@`a|u+N{Woo>LqCq*0o?5M_66j)$>yd$KaxXrybB4^9K1 ztd^nRD;Yef8YQcVpDjk+@rLz&K5mT91M>iYBZ=(vhx9kT-`LNz948CS!=uSmas4E(ae1Bawg?dDHArcpD^{=U$J=`K0%Hg>9LTT>KyerqP?4YUMgy{p0SmWM`9KKvY8wchwnc@34A8m8}7MEQ;54p?a}>#k=aS zcjek7j{NVz<<*|Mq9B}b7Uwy)s-{E+m>k}Ct8G9X`sOyx-mh9%N+R~7PT%WUJTEj( z+4&CE);3r$S;w3X{~0IOM>KM3eqOkL=qZwy#HYOK>eqbNCcPzb7Ce06i{PFGplr4d zzsx10`IQ($CK*u~v)HK1tJu8lZ$|3kG)#r$p>F3gEny_sOqc7R%$R`o%R4p zuj5q?{&+juxdxb8&z2bzw-#U|e`XmKawi^LC1)=jG3K8^d0A)K?lkvYea7fppEom} zAWoqEZLYyVM6=C8F|+yaxv^tGTcFzBhtSP<;`nW1&?uXpHe$FZABXzNC7ZoRsyoDh z>|e7@>XBhI#LL9(dC)#B##p5U^_XsCYv!5mIEYx@NFWL%6TYpPVPx@YtrkW%@=aYut%_o%9@ z;F52FUio?~A?UM-K=Tx|l~m7hSQ_!r>(g4eHoF4i%NEfJYxh5E8 z+zVxp9F(gbZgY4^W`CaIPOPyABi6{YJx@s_R(|qOs2=ueisnjCApXkN(9)hiu_7-Z zruLMhzMtO=e`44<(`d;{Z9f*)ILma!8S_g3W1M~;|E+`L4uIF2|H#t5`pZnA)TdO` z@1Xi0Sz%li7DMT-zdq9(B(t#10TKW6H`ki2Rw;l|zfbu)$>luAPgIn*f|3gAg2Y(_ zN5ARp09Z~{U`HZ-!D3rSpLr%YSpPLK{<5KF9%SC)0|9;Xt;X`kWRCjRUy)l6uqiEf zvA8jZ6qA=1N@VaC9fs;3KLj=6&W-bHjt8kB{4Q3a_XVOsyOVT#vNRVhE>; z1b4XsrxTfy0!&r!4=4h5?#}-wV0s_#DA9*ZiciLssZN(^qAxCNTLzquCP<*8>P8WT zXbLqk(6>t*jMR9T|CRXK)Cu2zI4$pgS8wX(u$u|rc%p&Xqt`5WZ)DWJa^Uij5KAt zN=exzd{*fL;4d97$?fvQJIKy6_esQae?!Ylj;S$LNhnj5LbJ*-YHT5YV%u%eQx!_UotM6QGg9blYMS7TjpmiV zie3X09&sh^Ar{}quoFFhGI(%w$%^xK_5UMJf$P7;;=lJV-tF{~P`z=C)B_W6xLY7; z9TZv!9xoOeX{4vvXLJaeo6V6zZIBorN_W;cCm|7{-9uCu>)aygc;xS}VxizBZtl3D zlu`bZp}F1t_6lW(+X6F;Z9lOqi*iU?j5-Y-l1B1K_yyRr)VgUn&J&=BjOot^U4B^$|_3vyT7g zwhxKCJovw2?|(G9e~d{ld0?X4E__GMc1*ZNX!Gy4rf)!{(^1`K`Ce{Cmy=U1T24nF zN^+`8q-zAd1e4^0PFax{yzXmR@#>~K(@$qQ8AAwX z;_61nm0R_1CqD5UEX`&%3HDx4{2lKmSBL&^-@Pm%(G2C-`$sO__DQT;*z*tzXN*GY;_&TpO*ESeA1MqxdA-A3!)(Ix zy>P_w&fb9OFuM?Exnvpu(EniHBf_8`kY~v=C}~EKxkFOR+GN5l9uv+Q zm)9Q_E@0maYRN%b^1yX?-Tpl~Zq2LJcJV9c-6rrT!8dyhtg&?7XSWy!pb@MBz!Ql> zRYc?Z2qkA%@X~-9%xI&w;=Nw_0(9{SLw>BKqn&@JdvSz-t%pQyUC_zX$Aq}P3C=s| zXey}Yrq1`KZPfMtt%>vK@79BchtsE!h>$S-_We?W9^h$#SgbO-3QZe_ya$eVeeZI; z{`B$|;bhR=1wrH>l5`V65beK?;C~#L={bTRO6q^M h{6Alo^nX@CC;|1oNM3zGo_-|=dV$)<_q-Fr{{kjY-*Nx| diff --git a/data-raw/translations.tsv b/data-raw/translations.tsv index 0ecfeeef2..386eee206 100644 --- a/data-raw/translations.tsv +++ b/data-raw/translations.tsv @@ -280,7 +280,8 @@ Antifungals FALSE TRUE TRUE FALSE Antifungals مضادات الفطريات অ Antifungals/antimycotics FALSE TRUE TRUE FALSE Antifungals/antimycotics مضادات الفطريات/الفطريات المُمرِضة অ্যান্টিফাঙ্গালস/অ্যান্টিমাইকোটিকস 抗真菌药/抗真菌药 Antimykotika/antimykotika Antimykotika/antimykotika Antifungica/antimycotica Sienilääkkeet/antimykootit Antifongiques/antimycotiques Antimykotika/Antimykotika Αντιμυκητιασικά/αντιμυκητιασικά प्रतिफफूंद/प्रतिमाइकोटिक्स Antijamur/antimikotik Antifungini/antimicotici 抗真菌剤/抗真菌剤 항진균제/항진균성약물 Soppdrepende midler/antimykotika Środki przeciwgrzybicze/przeciwmikotyczne Antifúngicos/antimicóticos Antifungice/antimicrotice Противогрибковые препараты/антимикотики Antifúngicos/antimicóticos Dawa za kuua kuvu/antimaikoti Antimykotika/antimykotika Antifungaller/antimikotikler Протигрибкові засоби/антимікотики فنگس/اینٹی مائیکوٹک Thuốc chống nấm/kháng nấm Antimycobacterials FALSE TRUE TRUE FALSE Antimycobacterials مضادات الفطريات الحمضية المقاومة অ্যান্টিমাইকোব্যাকটেরিয়ালস 抗霉菌素类 Antimykobakteriální látky Antimycobakterier Antimycobacteriele middelen Antimykobakteerit Antimycobactériens Antimykobakterielle Mittel Αντιμυκοβακτηριακά प्रतिमाइकोबैक्टीरियल्स Antimikobakteri Antimicobatterici 抗マイコバクテリア薬 항항산균제 Antimykobakterielle midler Środki przeciwgrzybicze Antimycobacterials Antimicobacteriene Антимикобактериальные препараты Antimicrobianos Dawa dhidi ya mykobakteria Antimykobakterier Antimikobakteriyeller Засоби, що діють на мікобактерії اینٹی مائیکوبیکٹیریل Thuốc chống trực khuẩn kháng axit Beta-lactams/penicillins FALSE TRUE TRUE FALSE Beta-lactams/penicillins البيتا-لاكتامات/البنسلينات বেটা-ল্যাকটামস/পেনিসিলিনস β-内酰胺类/青霉素类 Beta-laktamy/peniciliny Beta-lactamer/penicilliner Beta-lactams/penicillines Beetalaktaamit/penisilliinit Bêta-lactamines/pénicillines Beta-Lactame/Penicilline Β-λακτάμες/πενικιλλίνες बीटा-लैक्टाम्स/पेनिसिलिन्स Beta-laktam/penisilin Beta-lattami/penicilline β-ラクタム系/ペニシリン系抗菌薬 베타-락탐/페니실린 Betalaktamer/penicilliner Beta-laktamy/penicyliny Beta-lactâmicas/penicilinas Beta-lactame/peniciline Бета-лактамы/пенициллины Beta-lactámicos/penicilinas Betalaktamu/penisilini Beta-laktamer/penicilliner Beta-laktamlar/penisilinler Бета-лактами/пеніциліни بیٹا لیکٹمز/پینسلنز Beta-lactam/penicillin -Betalactams FALSE TRUE TRUE FALSE Betalactams البيتا-لاكتامات বেটা-ল্যাকটামস β-内酰胺类 Beta-laktamy Beta-lactamer Beta-lactams Beetalaktaamit Bêta-lactamines Beta-Lactame Β-λακτάμες बीटा-लैक्टाम्स Beta-laktam Beta-lattami β-ラクタム系抗菌薬 베타-락탐 Betalaktamer Beta-laktamy Beta-lactâmicas Beta-lactame Бета-лактамы Beta-lactámicos Betalaktamu Betalaktamer Beta-laktamlar Бета-лактами بیٹا لیکٹمز Beta-lactam +Beta-lactams FALSE TRUE TRUE FALSE Betalactams البيتا-لاكتامات বেটা-ল্যাকটামস β-内酰胺类 Beta-laktamy Beta-lactamer Beta-lactams Beetalaktaamit Bêta-lactamines Beta-Lactame Β-λακτάμες बीटा-लैक्टाम्स Beta-laktam Beta-lattami β-ラクタム系抗菌薬 베타-락탐 Betalaktamer Beta-laktamy Beta-lactâmicas Beta-lactame Бета-лактамы Beta-lactámicos Betalaktamu Betalaktamer Beta-laktamlar Бета-лактами بیٹا لیکٹمز Beta-lactam +Beta-lactamase inhibitors FALSE TRUE TRUE FALSE Beta-lactamase inhibitors مثبطات بيتا-لاكتاماز বেটা-ল্যাকটামেজ ইনহিবিটরস β-内酰胺酶抑制剂 Inhibitory beta-laktamázy Beta-laktamasehæmmere Beta-lactamaseremmers Beetalaktamaasin estäjät Inhibiteurs de bêta-lactamase Beta-Laktamase-Inhibitoren Αναστολείς β-λακταμάσης बीटा-लैक्टामेज़ अवरोधक Inhibitor beta-laktamase Inibitori delle beta-lattamasi β-ラクタマーゼ阻害薬 베타-락타마제 억제제 Beta-laktamasehemmere Inhibitory beta-laktamaz Inibidores da beta-lactamase Inhibitori de beta-lactamază Ингибиторы бета-лактамаз Inhibidores de beta-lactamasa Vizuizi vya beta-laktamasi Beta-laktamashämmare Beta-laktamaz inhibitörleri Інгібітори бета-лактамаз بیٹا لیکٹامیز انہیبیٹرز Chất ức chế beta-lactamase Carbapenems FALSE TRUE TRUE FALSE Carbapenems الكاربابينيمات কার্বাপেনেমস 碳青霉烯类 Karbapenemy Carbapenemer Carbapenems Karbapeneemit Carbapénèmes Carbapeneme Καρβαπενέμες कार्बापेनेम्स Karbapenem Carbapenemi カルバペネム系抗生物質 카르바페넴 Carbapenemer Karbapenemy Carbapenêmicos Carbapeneme Карбапенемы Carbapenémicos Karbapenemu Carbapenemer Karbapenemler Карбапенеми کارباپینیمز Carbapenem Cephalosporins FALSE TRUE TRUE FALSE Cephalosporins السيفالوسبورينات সেফালোসপরিনস 头孢菌素类 Cefalosporiny Cefalosporiner Cefalosporines Kefalosporiinit Céphalosporines Cephalosporine Κεφαλοσπορίνες सेफालोस्पोरिन्स Sefalosporin Cefalosporine セファロスポリン 세팔로스포린 Cefalosporiner Cefalosporyny Cefalosporinas Cefalosporine Цефалоспорины Cefalosporinas Sefalosporini Kefalosporiner Sefalosporinler Цефалоспорини سیفالوسپورنز Cephalosporin Cephalosporins (1st gen.) FALSE TRUE TRUE FALSE Cephalosporins (1st gen.) السيفالوسبورينات (الجيل الأول) সেফালোসপরিনস (১ম প্রজন্ম) 头孢菌素类(第一代) Cefalosporiny (1. gen.) Cefalosporiner (1. gen.) Cefalosporines (1e gen.) Kefalosporiinit (1. suk.) Céphalosporines (1ère génération) Cephalosporine (1. Gen.) Κεφαλοσπορίνες (1ου γένους) सेफालोस्पोरिन्स (प्रथम पीढ़ी) Sefalosporin (generasi 1) Cefalosporine (1° gen.) セファロスポリン系抗生物質(第1世代) 세팔로스포린 (1세대) Cefalosporiner (1. generasjon) Cefalosporyny (1. gen.) Cefalosporinas (1º género) Cefalosporine (prima generație) Цефалоспорины (1-го пок.) Cefalosporinas (1er gen.) Sefalosporini (kizazi cha 1) Kefalosporiner (första gen.) Sefalosporinler (1. kuşak) Цефалоспорини (1 пок.) سیفالوسپورنز (پہلی نسل) Cephalosporin (thế hệ 1) @@ -302,6 +303,7 @@ Other antibacterials FALSE TRUE TRUE FALSE Other antibacterials مضادات ب Oxazolidinones FALSE TRUE TRUE FALSE Oxazolidinones الأوكسازوليدينونات অক্সাজোলিডিনোনস 恶唑烷酮类 Oxazolidinone Oxazolidinones Oxazolidinonen Oxazolidinonit Oxazolidinones Oxazolidinone Οξαζολιδινόνες ऑक्साज़ोलिडिनोन्स Oksazolidinon Oxazolidinonas オキサゾリジノン 옥사졸리디논 Oxazolidinones Oksazolidynony Oxazolidinonas Oxazolidinone Оксазолидиноны Oxazolidinonas Oxazolidinoni Oxazolidinones Oxazolidinonlar Оксазолідинони اوکسا زولڈی نونز Oxazolidinone Penicillins FALSE TRUE TRUE FALSE Penicillins البنسلينات পেনিসিলিনস 青霉素类 Пенициллины Penicillins Penicillines Penisilliinit Pénicillines Penicillins Πενικιλίνες पेनिसिलिन्स Penisilin Penicilinas ペニシリン 페니실린 Penicillins Penicyliny Penicilinas Peniciline Пенициллины Penicilinas Penisilini Penicillins Penisilinler Пеніциліни پینسلن Penicillin Phenicols FALSE TRUE TRUE FALSE Phenicols الفينيكولات ফেনিকলস 酚类抗生素 Phenikoly Fenicoler Fenicols Fenikolit Phénicols Phenicol Φαινικόλες फेनिकोल्स Fenikol Fenicoli フェニコール 페니콜 Fenicoler Fenikole Fenicóis Fenicoli Фениколы Fenicoles Fenikoli Fenicoler Fenikoller Фенікони فینیکولز Phenicols +Phosphonics FALSE TRUE TRUE FALSE Phosphonics الفوسفونيّات ফসফোনিকস 膦酸类 Phosphonáty Fosfonater Fosfonaten Fosfonaatit Phosphoniques Phosphonates Φωσφονικά फॉस्फ़ोनिक्स Fosfonik Fosfonici ホスホン酸系抗菌薬 포스포닉계 Fosfonater Fosfoniany Fosfônicos Fosfonați Фосфоники Fosfónicos Fosfoniki Fosfonater Fosfonikler Фосфоніки فاسفونکس Các hợp chất phosphonic Polymyxins FALSE TRUE TRUE FALSE Polymyxins البوليميكسينات পলিমিক্সিনস 多粘菌素类 Polymyxiny Polymyxiner Polymyxines Polymysiinit Polymyxines Polymyxine Πολυμυξίνες पॉलीमिक्सिन्स Polimiksin Polimixine ポリミキシン 폴리믹신 Polymyxiner Polimyksyny Polimixinas Polimixine Полимиксины Polimixinas Polimiksini Polymyxiner Polimiksinler Поліміксини پولی مائکسینز Polymyxin Quinolones FALSE TRUE TRUE FALSE Quinolones الكوينولونات কুইনোলোনস 喹诺酮类 Chinolony Kinoloner Quinolonen Kinolonit Quinolones Quinolone Κινολόνες क्विनोलोन्स Kuinalon Chinoloni キノロン 퀴놀론 Kinoloner Quinolony Quinolones Quinolone Хинолоны Quinolonas Kinoloni Kinoloner Kinolonlar Хінолони کوئنولونز Quinolone Rifamycins FALSE TRUE TRUE FALSE Rifamycins الريفاميسينات রিফামাইসিনস 利福霉素类 Rifamycine Rifamycins Rifamycinen Rifamysiinit Rifamycines Rifamycine Ριφαμυκίνες रिफामाइसिन्स Rifamisin Rifamicinas リファマイシン 리팜이신 Rifamycins Rifamycyny Rifamycinas Rifamicine Рифамицины Rifamicinas Rifamasini Rifamycins Rifamisinler Рифаміцини ریفامائسنز Rifamycin diff --git a/data/antibiotics.rda b/data/antibiotics.rda index 65116b3bffcbac278dfebf9553bea9b476e6131d..0d7b725fb7eec359849a0960c9871ab346c74749 100644 GIT binary patch delta 41489 zcmV(vKjLoY0+1O5@_n|mu^kr{f0fG$@J|!M;+o@MAo0##w$%uNvGD7XUMW>a z>LJ#2{G%6l93Tx#fL295vD=l%(b_qpudx+*Xg?PrHt^eWCOInTGy2E>Ux3T-<$~~V ztoa2z1Hwr$IM99K3m+o#QMSOEAMKQ9JBV95v!~ekRRaZa9;miKJbyy4}*E9_-o%cI^HeD(P(VnE)nGynr7M^N~}Eyr1@YEwjJ%rkCqSPdLG=2h>bIfdqpn4bdx=^H9;?Z6gLJ} z=BzOL@{kEDk~ITsJ9KCS98D{3-qV;(7DPBcTc8@sZZar z+w(U;W~271mV?n<|Dj0%(6N^;|AhuHbEU^v4iOJY3TJmd6izUwNpr(uS!7av4swZ> zBMy9`Bf#G*_x2QMe^Ll)AQOJ0pd|P+7ei)?gP**QuR zT_x32*OK*L;>tkq#K57K*3J7eNxP7XK(77xwQ!rUurzmHP_}c5)jNW4gFPVdeF7}P zGp3a6L~%21f3$Hb-fDXu*?kYrBXhj^-7?B$P^*>1aOLRd{Oj&f z-i3O^4*u&=bwV@~$_Cd`^x-)LydFk*SJ)|Uftr%B`b|e_0ynCkVKW-3LO}z3%*Mr! zZ~RP>Vd{nn;)u^#_P$39nY+0d3lZTx1f^Rvr5lx;fAIP0Mn)u7)0at7*mMr+yIC%TS%t_g^#mJD)08xANS{rd$)5@L z`x#eif1`PC-LLgdI4FYf4U6mgDC`gyqF4p9DhraBSisyDeDS`SwS@?3y~8$f9~sa} z=z~nG>!pE7$|kBd7IN^Ff(6kJ4z4eiY0q}2zgVC?d2$<|_v2ZyTb*ip%mmS%HBDT+ zbnV{&4?8b>djKH5>$2(ni%Q0zf#1L^_P0o)e<;f2xX-W#@Cjz{T-0#uhbF!|R-06z zWk}`d$ReJQp}%FIwZITGnn7hEf2Wsk!3~kAi8hseWY|wa^Nh8XLFvQzNSx4PPGHG7 z+`Lr5cwYYtATdoew*(Fs+Sf9VXiy){(+2?DLXLjo*!XSiQ8&Uus}UUb-$@5H_XAAR;0A0 z15>E=$I10tjeu;s2ToV$H7Ph`)I&bbP)nQCaw`gsCG6#mgDG1$0PwO9r|qZ3?9;Ol zi*4g6CH4F->PqF97yPZ~d`4q+$a0y7e|{t9XG7B!J4+>jid%33N-a$+I18Us#(2Nc zW8~QtfIrRDPVW|x(_#pd|HAASB%t9f0@LR2k=LS)f$_2y>SkVf;xXqCkPeWGNPj_zncn-ewET> z_h$$aoP^aGobi*EZDpT|=?;<;Q`Yv}ThgBms2zfX%MTSE{kB`b^Y7+ct?h?R+xlPw zTWOLaVEpwT=6H{bxfaAy)z*LumO_wio8#vw_g0tXB$p}i*IzqtEyDPAShI2M2(`GH zdqP)%Uaz!cCcRzkzV9a>$ZEl36?48-a~o2x3#}A|L3`k&_8;CR1BveB&SS#aaI54f5-#XZ!z12b9PvV zCF3*87{aVgJr+ALx^EMcn9!O!Dsqe60MpB(xw-&DNH$||yue{HTV#CC5HtP1pP2Xg z^DQ_~PPT;m%5ABI9cD4u~?f6w3xZ(VT=4y-&?GovUyz&seQpoKPY# zyXQyg`EP?DKR1rde@$vqIE7fO{-Nlh0fbENA`XN^e7#57!P#hALssNPZKa(j{l(06 z_%(o*uLLu{cd zapu8Q6NAWwdnvm^Uvu=Cj+rMTH@)>?-p}Se$U51YuosMN%_Ghy)6><2c{KZ3(2cyF zV*|oh!7Fpd6+EL%3?iA(X9#}(kF3nFsORgvjbC)@bbBmtf2L+z5DbJMWOeW7Z_NrL57VIIYxr@NRAb5H)ryspgNXR1ih?KQkRZ=I z0XmU@?H;XE{(m@4{N(#xQ(`jr++8S|)8M~Vz?M=nx&M(j3jaiPDF7^d zI;05|AU?5Ak-gI6^N>MzsX`b<% z0G`4h{ISei6vVKF=DTt$*V3W;0;+DDHqY0N2h8fx^)g-IpW7>r0xco#_vwW>4Eu3- z8b-1se|ngZnVKOZB==Ye#-#K9nNG8gUPl(o(pPZ#P(9;r)t3Sr(>y=u!xSFvpx_0= zgEYF6{`lwka}USaCNhPEAJ*>cpbS$WHMp0Rz!ww8c$X7N7sayaa*_gMg7L0Qb4SBH zLkK}p4&m!=z*Ex8w_w8Th|qEj;yf0{FUDV7f8qjfNy`vC&61Kf=bDh>>R$8+KoWPq zNg3id8tCI(ZvZ+zFA1-P%YbHj;f)%6YmgQ|eiq%jZ)GKem{x1v*@wwUAL|tg3bq>iy;BV`jf$bfhihZofKxR; ze-&FQgeAlQ;R0`xXjz5bQEgs*g!WHocf?Wi!GVu*2Ic$<{o0Sa<+Pp{8xDH=V2JoS z|Mh0OS530dp7Esv6J3k@B!Tr}HUWJqF_|@7#vXq zfy6hlxAyp5i`d`k3?#R|BxF%dN8wt87)I!Cm^Gm|^x7Uj+%7NflVREdj}c)@ik0@; zcp-|&TO5K+K5g;Y=jyRBXSE(-v;FEM8`Tq~G(O?-xc)vrO=0>ofQYWS0FqAhf6`Fj z%KOXu{Z7LRk@4^B*ocwe^y!>FBor;b2rF#!{Za*V7(jbEvcO@bY8e)y*%G?(8v4 zIMVH`%_Fb?)8*XO{`vmR`m_Yf3eQsY7K)NQ4!pTw*aXS?IwUz6NlKKgV~OE?{c6|q z(gt+!xRwy$2Y(hdN15FNNH+Z7eS!Y%RgT>kw2ZxP%-u{C476h*=q+)QER!QP+`@nKd-)) zYrh?EqsvFXls5O6R3i`v=Lgerse(fJ?19hYrN2S|GDV^9F;klgKlK)Km`-;}1d_6| z;F_=eS1rF3oZ(S;Zjr#Uh+BE(pUx8A{&7i0w+U$8^h=544g%lNfAM{-c7`dg`;gRb z!NAZ6SeF%~r_J~)dYH6eV;(Tm2th|$&%N;ttGvP5BT&}W?3xc z*Vnm7&n<)NlAZVV78X}r!Rf3vsRp$-)wbpGPClwTD-9QBS(&Vw$%_$;I40%j6&H)& zRjN-Os{M_BI|v}Ve>@v=K(KSABj`AKk)xxF=Ajk@lp3INGfT&(VjEkY4N4p``g&uF z3)x3SPR)+K1Lm-H8fKzm*Wk}vPdU0jQo8t&K#mG?l&n#E{~j+7VmrN9QH2c>&m?ZI zwoyIT5t2;jQg7rN+Rob}gUB&;Na)2GR_@r|7+r2e>BS&5iF`vqEy(SbUD&vOai-u`(&SXyW ztM3@N>+V30T(uXfnJP_wsrvymS6adVW~vd}b=aioJd~>|4(y43I_-xI8fNv-rf6A;g-#bto;Q#{tP zLm}se(HB5xcgU(>b7!+9>bITff2EjqP(8hq>v$EugqWrPLZYRp3mc=>T{#*K$^M@pS{qmN%AS-kT0QcnVVPU& z{?X?F!a=&p(taQCZkUS0zji#MHS%TIqrhn;cp88PZb$I!w9-TOqF$sUS_>5cfNlg$DZV0yYbOu5J9xe%SNEX#;SD?tMJf8J4}Ad)1bW=|ZEaR?k23N`2L=OKT|sd*OS_=nEQ z=;=K0y`y_Xr_+|4j-+JKAlVd?`e_pN1q?D{o+G$TjB71Dcew;FXn%Y=*L+gbw?e<|hYbIN{ za{<&)aj2ZP;t#bc3gnG5dGKEX$wM?rTRH_Q+C88wl$S%<5k=XK4u(L#M|+u18q2SgiWK*OUS9 z$NTW7T94PO#ze_=f0e7-(yG()RyME8_VAPf%b@{3f=&v}cVu?a69xE9>wUY}_HFbi zXS20YAe1Y~mPET#F2&5msfC;l3IRV<<0JKx1jOEudNMv4^XUsbX$DBzKMw@hNz;{; zs4)UoEdy|V=70?~0Vg|l@I9Jj%${|nL|&zm_KjV-XUeUAe=&O|a?S$N;@y|}G2I+m z+noWA$HkI`rRRNg-@jL<&MT!^gw9Qg1+hSMsGJ;EFcw&{aB{_CMH} zZloPcrM!}=E+eoczG(2#OqGN~2!o2Z2I`On7g0%Qck{e0te-s?be-HtU5O&Y7%9IgeaCdHZ zK(EA$NmrTIeNo;L7XC>x@@uMOt)2}o$d0+;j-}@la0t|cIO&zrs))&gdoau%zPJSh zHD9Q`5ct?F@(qkri{!yr7%t9mRq)i6L;$k%l&TumO^U8um8|AEPh?2Kf6$xf$z~n?0cV%G+mc7qR-tOmp5%E?_Y0jn5NPg^j{w$ zwHYqO=-OQ(sj=#=G_!i8Yl_z?a0#?|o>Wtwe20}ZrI}ctSCK<-R4{x&Aiz@<86 ze_Y|$&0%9bCf|XY|fZWArZr&rMqC9=7Ye{fTVYAG& zLN3^oVVIbnniI+IE^`!jMw$dEF3>h4c<4Ce(}a-kQPw*E7c7Ch!-16Q4?&huf5Pnj zm#tiyGFz}hV?ut78i44o0o^WwTJw4U#b6X6Ss*Q9E_4wnhk-Q5&juJ0cFprsH(rc5 zLw)%NL^e((8DZ()dNRy421h!RzqbckU=Rj6M0E}BjzY#|tHf7) zwtzyQkQzr*?>vKiF!oXnP zr@f2+GVQZ9u{|Tb43qWV6<~JCTFS7c31{w%+=V{+w5*nF=E&{T6BRTi-3$Hm-Dd$b zuTPn@<=ia=Aq4^V6ncLNuAy(rvQHL!_7YGa+gOt;y?n+FAL5z`RT`YDe}n4m^e*@4 zj8^@nd&$&9fnB_NF2ejaFZx%=?TCcUVGQ-bqc1Uh!co8Yq0cq-8xv;MT?`CH{e92H zH%4m@&Wbn^gNcKC(q4TJ(~GG_y7fKq-51L+m};B;bL4(EtT-&kXdg>Xb8bBE;`W5= z?I}(?*A^!2%a7&l;l`{EfBI_h_^G10S2URB{xogxIo{|*uWjLRzjcUe6nqr2-MnX~ z97Tige{e`Efj>g=gO&zSfhv)|kZ@+=>h(q5xLB8s-;z+E8Z`%oAg4 zn}SWwG?ybRWAU<7HN6*<8z=jn=Fi%q;5N@Tz_YDvbRm)Sf25|9RIMW0_0)TDo1{Db z3C=+>Eb4kNNn4)!jL$m;17{!Q<#L*_Q?BMS2?PZ~#Z61~UkB4%fEU`p*EgQ0Ms`Tl zO6(U#2;su!@`;mA>Jzt*E1r}PyI5{PmQjA5ZIPd9HU3K(_M@vZ*k@?npi5RL7XG^X zc(79XFDiX|f06>(^^>8%T_`55dV-??O8v=OgXzt_otBthf&&=pnM%N&Z5_Zsz~GaY zGciR^Sca^hj1|!aX{&&F7}UjEm@RZFze5GcH#xy4EXDSfn6|Mc4ml${+qsO-w=!S4 zM8o`w$N$o3|GWr&N-R!!rhYncWmsIY;j8nprJXmvf3&jerJS&roiWqy1gDSOG13N= z@GlMi*a7VYJQ%j|`dm=wmS+$8D(+QfU{vEhelwh;FKz347COm6;1BUs3C9&B(?Pao zNND!~rNhtvJRUj`qel{)3nC<0<;p{?eCJCnrYz){s5P6d_4O1lNIhaW_;7nd-yRxG z&->>}e;Us}W)RbK3Mkj;g7Q5_S=M9O4H|HNxfXXY@Id|so<0b7cAo3g$5xTirBNQC ziqxwyedlQUdEb}Y_cghu_-zBp9NJPrTnQ3Sz0Jf3H={BJgn4kXRh}cx^F>PE0t!ta zWHK@uWHuTm@!h+smZL$mdd>lMM7RUyQS79afAf$NP%Jcv*P>WD@!DstPOAUMmFzl| zwaE(nYfZ{DIOVv-OJ;}LwdM>sW6``&!D0DA_J?=u!y&)Cl(K2@tf+3oMJ>+u?+HwG zp!Ddg$a*6khh7iiQA zE63+Z^0m|bAea_#1c?#zp>+}?<69et$ADK}8u4=J9FMNkjm7l0Jw$)$#7(zH$u zdm3+f$AP~Q;fp^QnPMTQXtYbMzf<@u+aJ`7)6m&~R5F_*L&OB1`{bYKaGfAyOz zPKr4c3MO=KCE0j07K&`ozq~VB_EV;vYcAOY2=Ix*eC{Ob;iKmtmu|8TxEfb>&*}@L zMd>@pe3#RI*}=1p+~ zeJZ#t2Vq0hpl7rK@MeXK^2KONf3+ii_<$UqjD6k9HIT}<*?ov38U7A!AAgz9dY>Rv zo5^s*YD2ZnlYL{tf9pQy7~5`@ zg%!Oi$VSyebHPVx#9z%4H{8aizK?nE5NC-;3BQ^s_1 zN`gdyF}Qj6=mAx+0jrlZYHdL@437OPMw99HiMLU8~b6jzL~&Ze^WEx zho%F~QQOClmtk;7DRe8De*`;7)IO#c^r2EUl6fc>W*CidvD^T^t_i5Z=vQsVAjo z*(idMNcl4C;6M*df&`jl+Se(aY6LHQnV7TiDb>V>^ZmL1Ik;vJe=n+s2LI~Hal@;* zLJ$|!0Rg=rI-@wdHJgl>9?c{6$YL)K+mjtHstGs5A* z*w|9v$<)<>$RS&1NuLmhQz||_8i2|e(?qkzaqd3w-l8#4N6SPviBQY8friY+Sl;-W zzlG&L-1-utfBXL#g^toexq4Nm5!NLl0gQn-OeTBN5(&>z+UfJ~Uxn!(BOuhUJ153W zVp;d$Srvdx0sbCnC7aX!?{pluj?7jQqhMA?gwn zfHJNg6xFkvJztTHmY}Wz=}fO0Wq6hA@|~12#_SH^e*yEiwR0-qvpviN&u(+>VQU?* zW!v`{eHP*cE#e7OI=C7P$52Wo@p%nc5ZEWzWIsmNFN4|wd~s<{muy@EzQ5aRLkS9q z42_tkN~Y91(=?6lt1RQHgGDk2-DTCN97d(vc*S-u-BQ}Xk5X~N8bCijxy1=`(_|6| zb8B6-f1=;mppbduU!@R@A1w=z3<&CRWK`wmtNL}11>NQk^3} z*%@-*cULxwp1*qTAY$#CAdjjre?rZw*m>B4{2yG&erjlZ4 z_qzNr>*uXIXxQ&LGbH!uSVxTvCQ%|Mt*Ik}e|$Di#V-9Q4bO;W0n0baUN}M1q)vQt z5RmJ44>eG!Le$9D9AsW}$mKCG*smy#uh{P5+hxxgGnBiS_+y5{2QWS(mRe+>#LFId6#*Ng|2hrb?|hyzoF4F6OjiQ(<| z?%TAOn_BgQw;{Z81U4&-Ys!v>W>%sJaL59F@B(}iDdviZ2%oibfa-_%OfTq}P=p)+ z(27*(;13~VQumZI>6Stlk>$ia9phu7PpVYHo;V22GjeTK7z>nJIXej2zAi+(e>+WV zB)fYh!Lge9hsDi{56BqliF3fI4aT%5^i!AE9I%JXz0>imJpN*vB20C9J{9xL<_OF1 zsYh+VL&-t4;S=rqFE{#xUqLbP+yGSswbzcL`ICkiX{O=SWCwC_mP|-G-~2Gllm_<3 zrGk?tBC(qG(+R{+{U~F;AU$Qif1Ec*dvEB1i-mEA%pwpokp{4^4rp<4y?^mhEVbST z>UFm(pCKUwd3YbsueMi&?1>!q#xN6FHxiMF*5xD$iMex^E(y!}Q^?B$Q3)S+*PeZjjIrj>U`o<#wkURf5G^EHi)(X>hc9ftoJT&bprqIbh`qVi*7ex_YjU!GHfX= ziVBZ^Th;2BwQ&W+Pi1eW9Ac&q?4}cA!I4LnI3{P_Mg-Tz_z&ha^2tf9i= zC6<9#evH0>)v!-63%tR2CeVTtI%!=x3^=Xd7DB*MA}0y9e!)zof8-j^b1Br|)SYE| z=qnFI465|8e+FTqX!%NWEe@Q_r4{<2eOWnVi}O=!Gl?nql=Mu);%#WYaoXV9?9ouPNM@l-9c)_)}M`rEFyt$CX z;rHGke?|&(MqL}Df8(14A=KniwV0gWC&|7&MY7=tTc5bWqZ>TLt{|jEQ1$;lwC%5N zGpL~=9U?hK?L+EjcPnYL^|RVa*UMX0`MX>dCK ztNhHe)@tql>rZ*_q znVeq-f$P8MD7F7;P3>ETy@edq>%xnxV3=k_(3`0T(Qjh0B16{_V|W+cL0w$TMzM{Z zFY8pFmQ{${xTow_<@i(2?}UP7Z+BskIAq0#{GMM3Znr;!i5>WOJhzkL-Au-IJ%yvD zno6S>K2Gz2f4$%P^=dVDMo*0!QPVulfi>Iot_Ez9Q8+1MiFq3Jo^gNs@Sw)8d4ryr zuI(f9paF#TZKuRKO)|iNjPRImR_IdFC-?MzI3&4ig`#1Eu4YRzX(F0}vt$>O6mQ#^ z9w;P8E^~bNBxnVHVl5(=PjMA2xg#<$$(e?i`!%FXe{Y?vfQ4k$qZAv-YQ+XRx(OUz zNLV42zcu!VjN90?hWi1kO}6Cga5U`E*<(vpW=S)9Q^6}l=Pn=PN`oP?>2RQ<_(WdW zE)zdiYW45)ILSithRdAuhx*bXS$A8il2{8EysO^K9hl~5nNc*%bX=nW^Fhf5BOwou z=!T?yaEwTSAlhcfgH4HyQ!F?*RRyf zI+;AfNw7fHsx`Jd9O-jmKo@A%NCW&?LMp8aa>iv5uTZCM zc(&zu_9i73fZ)QY^o`igk||Dx`Y_)qf1>)I*sc*ML^w&owO#_S4r(pj-;47uah(L_ z>w@Qt;@~=KkZ8?&o-47iUO_Z5GUc^_WgLLtt9k|X9S*Jk>YYa6S&HD?@lc|k`BSL7 z5Yu2)>Yfovnr1@;5e({L*l#Z#(<8ccSe=EF2ZcCLYG7~An=d=w0B!*Bw*%{E)&|(sIEZ(PTpDI&ty2e>tBc5Z6%k zS1iJ6!jQF(AT4mF@<8Gm`-K~f1vp@hFd?E?M;Hc5%UC5S>r@Zg<>-8$bki~H`x)4R zLKCUg8X;$#_#{x!cs3ae#{XdZfcBkF&H5zyBMpd=i{7T}=<*+-2wA#Gi9Fy^L0g~x zs?qU~kw01WQlkjg5-;PSeG^tQ{UUaPXL_ervfur^*IRpR~S~=A-_t##y8`I!iE_MRoe6gwYV@^SRsm-zuZC zChaZ>T_U5aOb~Lqe{R`}!#|_WNtwUFzu&0@e(=1TaOhd;@pFw+2uLPJkQ1zX3PZ!D zeTLhiNqmj0p*)pvsW-+u%<^=0B>#IeSN{hfML>2!2)vW7dc(Q5T+%$xcRLXAJ-J~J zZ&^rcdsrxaD?Z{jz@%~nb^gycBw~T@S|o0~sP<}OHE6?je--A@xcaS%NSG6S`Egma zMI%-3*=M~$6!ImcywvKcn5Hmc(j`9oRUAgLgK2;cx9kyNE#jd`>hB3Gx^}AUW+v1{ zY5oB6>R-Su3@d?hE88aCtwcvjc%rDBN3`q4S!TU~gj)4@!9Creo5u^VQii75- z0n_@w6=p*HviM>D+_46m+07annk9YhXIMkgZ~L~Hf2>wiIuxF!x3nU8p>PF?&Uaf1 ztEJ6TDizdtQ#CF}forg?W6V7SZNvjy&DHN_a$ixL-l%sNJ zb;Y;&?>)KcFfmekwApl`f--?Uob^7A6qx8Ab1fM&PXJcsAQ;=dm8ta-MD}CbU;}p# zgAu6R#T3Qx;deb4&(>9=fJhGyIR=o&&A>08fAMHnwtLg>q1>(JikvFyqJUKlTOi=tYL(h1(W*`CZ;X-FOSIEDh@bc0*B&l&O)4i74Z) zze7!|`8~8t8Rp2eg0a|;zi0K4L(fQkKAI#I*W{zIx8c*t0+CBV(B^0P0p?3UgDRk- z8cVBWMIFNb-_rJ6uFE9fw4E(V&-5?ae}ht3U6fJosc4Cdi87P6s|Dg6>pWjwbWG{R z``Y%D9Z*V!h0NA-k1Ca`J2ofWwqj%AJ`QhjM&=BZ@hJa|IZKuRI%Plu=IYoKfP+}a zsE;&=r2&uTbwNfbV%!+PN8sB_pWWdXnYjga#F6?p-a^XRx`dZW+>(82iZ%|if4%6! zFKUQLasNHXoC7Eo1mfUg*7R;81RE9|0fp#_-ax*4wQXs*CsfYF(J);021f2O9)v4p zkSrf<0|sWN2S)ucE4DHa?ZANEzafzs#$=U`5l9@Qa;9rmE#I&xBJR8U`V|By$Vo+9 z@o{#$yE`+|<NFbdTVt*Z5^J<{4m)fOQ zZ~NT3YAu$vPTpb}T_zUfe?&#K%)=WBgIkjSl_WZO3q?hfA)d(Im+c_Ei{2WZ>QJBY z1Ig`bPfX%Bpv4;O&4xfwOoZ6 zCa|?2)2xF2Z{FFJpapQn-5}s?%(TCkLD#htbZYyoM*{vk2iMnT0{R*1JH9QhC6??I zI>$wzxB5S8{$ZP@qqZ?raZT|3{8~EUv7a$T0yO&c7xEU2ET0-`+UA?SHHG3_T)bk@=QPz@c?fQS!j25dqAF zUJV*HxCG7*8qflm(%vQ(ni|A$3YeifP?5Nvy#W|d8kNbDyTSqgxHyK30K=sC-A*-{ znMwf%CL?Z2qmdptcpvHn515&R?oFXG8(Ip}D)`xsyCPfge@=JF^CFcW$d0Ac%EXg6 zHny&vG3x@AI86IDCuhxi3(~xj{GX~_g_3C{;2s8OzuGxoiWA}1YXJH@CJOeyyn$bR$B3&0I!UH_x3St+q=uTF4j6mY{z=&Q0Squ8*G41J zh#_-`skHxbnZBY(z%&6h{2cx;L4m!?yj=BnlDP7 z+y$xWi&=@%O^KoVQo`tO?P?(-FLtKMa?M9werA{cE8IybOnJVccG6_&_r$whm-<^6 zouJ;Qe|&srjK&NjgiYpeW*K1gac^R#{jnp@(4u zTS?gOF)Z+qp$nR#A+w+A+{eJzVi7)0Q+^bce{G4wvu^-YCwv{8F>GcO4*RU_Lv)7a z#p^iaSU7C9q%G9zv`Bko^?&zId=lF!9rnsJy3qxcP^T>JfweN`kdaZNEpS(p@CEd2RWU3knQcYe$Ad&O&V zUJtY83()yl5%|UaFV61RY9grGr~9;)f97%kn14%nw(+Q5&yVmXQwjX$XlFeN1$)ZP zn8N`V29bN%u5O!JDrJ3v?&jurWIT>UxI4tb=^FL*4ve#jqPf^@;Zbel;*-;NQO^0# zMTw6T8i^2EHJ>UbQi2R%#Q|s4nl#I>H)>NuXL#)Ycq$DlS;E;Ey6e*`e$ zs`c}3kxEB@LBei%Ybw6?Rai(D%WL`@Hce1c#xZ`LIk!WRrG1^~LWoq`pyOUGxk zEea+pbO_Yna8z-m?cB!37JlpxqV-aWZ+DF_1jooKS2NQpmVVnWw!Va(9w;%7P;fu6 z8&V7oLjAH#SrPhz0ggGQtMqh!e?r8RiYX0u6+h<|ESPHJYHGICUdUxLhawWi|i?Zez87%`LS#_v& z7SZP_+@rSH2+=UTVuPILkKS1B{LiB=&SX0qg#QxIydf&0@}*vMZ{xPye}(x=em?vH zBfl>$9X>^K59aMRgH~45ZD&sU6m3sbwj>gcDPj`G(gmY_R2>qbO7&{p%ID4{=Q=rF zUT9w{1_2yVgdR&6NR1YHAk?94iGr5Ip^}7Q!fOCU$?oO=A9pUaDDE1@o)t54e00_?v)IG7fGCT+y4Qea3BxGr+;l@ z(#scY$y4VL)T93T&F2%-Ale^+jKsYjr1Z_$sl;4V+w$95Y9FTJe^2CY4fYkXST2 z`&jtr1YTVO2Vp@sQ1HexeM`{s6PL4S5adM-W(Y@P>h{j~a=?kms0UWxCk4Wvm%*$o zck4!0peSy!S>Lgr#NkD=SCyE~?v z7;~8H(?CP-3zf-T3^anKAl5Z>5++-U_-o=`JVv?t5YC=SR|taNmEhSXu00fJuMl=> z@b?w`lyrQMf7*w`#(`IkZ6|D-dQIAjl;o?Vk*;RyvpkTCjlQmnx=Tf6D$nsG&ujzS`M&q?f(NRHD5VQE z5);Ns!8OcoO?UgH%%CFGUqJHlK9`ni(4YCy8Khe5e`8K*N3D|@SVJyqEC+Fz6z?EqvJ=c{>n@Jl}w-!DHGtN6R+t-XQ%S7h9I&^(t7P(+rF zA_Hj=(L@I5lZQ-C1N6^Vt!Kw+jnrMnjT#sR6eV>|-?8+`u;nbmQuap>QNn(dQ@Hte z%jGhH>3%Q3JH+S#4-y<`h2->a8}lx{imzX?S4NrU2l zQDOqVCm6fHZpqKEgr-_vD3_ig37NB_kUKWgf`9l`Ef{2%qtaVcM+<)<_}Vbl93SPY z6-9~fOJ#KkF;9B~LgMI>4?hzKnHaIMX8VRU5*Vu$A)}R0b43uW<(l=1DE9C$bl7D~mjwE4NyEnhP{Se* z#x4+l&^we~YpivQ@+j8tfn0e`V$ z&JQrk!2{rG6GLlrrtEn5c6c)}`s`|{_IX~1%{?EL4(|Ap5UZ|f4xV>wJl4jryRLyv zn;ZyxkDC;C^t2Q?J5cHSglrz4HgZ5uw_ZC!=X}(oS#LTpSi(_3 zkP_~ZJKMGd8za~Gh~(G0`#NUaXoif636qx4YbR1o92|3BUKSqk{;<%vEiHr)|o4 z+DOu?W<{%{ZpUP0*SXu#8h;`Np<)(2f&@uF<&a$arecBPGl$=oWh2TC{uH=-5Aa2F z?kNWJIubGF%N3Y+WUJO+9VtS&C*#}-vz?h?Z)GCtJ)zYYzbb6O`rz_mapFJ=^u0*W zv)Kzv4ga6DeYo$fN@K7^VYdtxmhKUfa)%Ku1ril;u#H40B=wia5R{L_t#)0=z745|B6lg&fZ_PgE&7-r^ zD8pDrK>z~fvn*1=OMl&>brO4~(osEf&P>~zcO61g=2HMxWaWG#!*RC+L82`hX%@nu zNt)=IC=knd99($0%q?dZJA`XSxtIL0Sem?2ns<^(kHyfLh88cE?3;zG389xC$LawU zau!qfJg!-6-b*11>@IF{+*IJkl5b5k!<3@03FLG}?wu9@1b^c4*C!_qBh|JKYF>7( zZY|NBlh9Xf`tq9clpB1s^z|i_>%I63QZo#BVNg0rE}r1eHHyaCX+0Aay8j%gC^i2y zl{O|1!*DPl-%~W1;I7dM#l843GyV3K{t{YR%BJ6eI7Y`~qiE)YaKSbMP2ckp^Hf#d$6=qrgwyy^RAHF|H$f3t4k zq@Psj>X~PIF@#y3Zv4HD%eUE}g^7HA<8HgfW3Al7SeZk{te8?#6Z_PIgs;)Y7iV29 z`xYRDc~*-D7AvdzX|&A$Pa$bPR47Q;>69ni*k+dquzx*1Xd%Z9PvT;BI4K2Nm+rTQ z%vG1MJ!n}O*utPy7A__hL*1;hGSs?arTT0l!ur=dptYhhmbNg6=XaSx2zj=5lOSY) z#9F`RM$FY2EePsp$U;}I&v0E6{F2d9+0q8{JKCH0kDB zTE>s>>R8Vp>H=8*94dF#4;fI|9=>M&(7}U{tH!%~S(mVlAH_%J z>D;J?SONxXY#?-~tXC30d(3&e4{*RRbj`;eI>;JNrps!({$|Xny%QhDo@c)KWr}F` zZGS#{yS6l{Uc%Ze&Gww=>q8Z7$4mw<5T9Kv(`9rR38S94oi^+n|8hFj9V1NQlDwZ< z87o$QU3;O5MBZw=1eR|n`m|G7fg}7A^ny8r@r_wJS8l$~k~GC)^0Z(mpQ3$*uW5#;+m4S&`) zlD~Xgs+kWyP#r(LdbX%|6xOyU%x*l(`Vsyl=BEm)LT|Pj09vntIo+w!v+-FEnf8jt zmMg>*Q4iLL`_B6@1KN!1#n0kQ{`KSxb-bJ8eAGRUt!~qoyC(75T|ypLjBQv_E$?KF zTfg8L2EGzeL?w^~HtjKpAi)0Fkbn9e_)2!gEyZN)N#hj#n*wKJ=g>#RN3-L=jVA;S z0qf~{L|n)SjT!BDpz8cy+qrUzW5a}T<6uLXJ}XLZ^Kzj^6eS*~Pt%uteq3~E=xoq3 zBgAtwQNI+?C!r()1S`0_pEQt0^bg*tdhj>x7D`KHjjpZNJx!SLOAyPV$bZYKAx1$Q z41I#66&+dKv&_*$+Eo^nc<&2g10fE8rPR%bbrV|8EsHx#9SbKN`?*jeBgC++iBTKi zzt8uY+cb4h1D>)WJOY`Oi5?u}4iOW3)UtI+Eq?#~xs1fgbZJm%v7CY^NjK)$c5#P< zB;)59@B&@hqk0-0bmhqWr+=8f=k`b^pN;#Qd6E~?3W)WQu6JcI1kqHoU^EW87&h0k z-sZ?%=g-c-Ep)`j>O$xDX;UrYJz^Ma*9U#*3X3&3D9UD}a@2md!T>~FY){#%)k5hvk_y_*r2t1r{%Sj#WaL9*K7a-!Y2$R+_(@h=GA9JJRw~v*x zs4EJZDA7_{=kcCG#mL@|YTCiQMf|K9v)3I}#}}@p(-haJl@VbQBCX}|^Ty6ovJgV6 zC@Wq$I4j6hiZekwLx1bHJ!o()p6g`Bv6+~&Q32D=NTC5KnTmaf;Ni3I5!=b5nsSY_ zM`IhsK{%#ROKMf^tYdSJe?mlgtJ)$I1G^TJ;Osg(1Uj&;QWVVCb9{Pc!u)m)gH}J7 zb4FnOgaA>;I6%QvO4&MsWFim1cnG1O!Y=>9S^1!Y#dxWm+JDd-P`d{5_~n8LutI0Z zoE*V?FljT`;?Gw4$!@Sv^nh3xq1_rx{%z*cWsaV?$_SP&nlG5c9$*N+edo!{8!Zgy zMS+v<@Cq&H_<`^vt(-gN&Alyh!M9uBy7)`vA$uT>(T6Luj#Hnd9rf!Wez%i!x5wg3 zJ_~f{a|mO0zJEJQ{2&nTB89Tu??Q@}c?-O82qM^9FFVyKaaPY1JOR+_#h4kXo!!Jt zvf%dmk_GBzsc$iRTwlei1L`{IZkuBR;P5&T?e=E=n7{O|JQK4LN0B;FYrOr)a|@cS zWf;wKP~gzUDqOOc!cTsln4)B2MB>6D!3;tBDf;%Jf`1ndcM{PJjt$`@Wa$zcYUO|9 zxJ8oWUsVR~RjfQ|v=xJ3AL^aVQ z`Zs{nr^SNF6e+A+b?xXV>+Rt^j%O{mi&mM27S;8B;NW{?(5K4fTlxuu>UW610 zrJ~lXA~V-GRehJ{8cn%wLQX_3F^o|KNxAn4vZ$+~fUNx}>AP$|4;ZkWaZ!CT_a@u?^G;uM}VQ#UhW@v`j5hJ(>UFO$`v2~Bd zVSqD(07YZ~kID-9hyl@N5xf`^D-&8GcGN|5d901+wJ3 zIa;sw6+BJgY$R$jYS7)_oUL6u4TydCqygK0JLJgU69#Q(kIcJG@=ZW5IcC$W$A3++ z8I4J#k1O5b!UCDzpfTeN)JnSRT*f~WY#xO&y%T!~uwK=Wvfp+NJUYE<7h;oKq6Xn< zjugSurBhu&7)SrQpNiWtj@<4mR*%iyBVxfVOz~kvvcR)W-B4xM4Gsf^&^(&`)Hr|E z))F{~i8C|-UEYFZmU@^fBRYQnbbsSYGq5~aks$JSNmWi^Mh8T41PUY+X8|oM{+(FO zil3KWK=S1(K3mTi@;G}LiW#AA54Wz53YINazQAmh=I-&jdg9fv)TNWAMa1gW1`T@6wVWEwGX(9JOjU{Xy@*Ol1YT}oWx@Y>Z^mWgH|1tQ8 zbwiM-lZtJ8q2FX$=~sZH7APso$Y|OBID372>ZO{7@ZGceRHWodU)kLXOfYwXM+oIHEK#Ne)nxLa>)SFBlzCp`#b=#3k>0i!hpe{o7>h*3sfYK}2Q!r>THYN4Xj1+4(NDBK7j3;7%BA zhP*$#e2u{R2!5o?9`m72-pVjVrfl~bghfe!#ess!F?dF6FFUrB64PDh9@(8VT~Y)g z_>xi{0=bDL$RsuAb$^(Q#&?NPqe@w5Oe`!@ zVqaAdIcLBcNVM;q$su%#_6#kxQS+cmT>q=lG@u-3ngPyoHrh5Z8mn=mE37cHt`u1@ zG2zNva0cdxgPO24)!CH6nbE+q!~Rm8>JJl_H_6bw7VgN8zkh#JLl=t9vwK)pI0t=- z>~2|fI!0&dDHHL55oj|=F;Y)XD#!{~7K0#=J3#T?#hG_eE{g$UQ&bw;?Z2|v1RZ)k z)f_6^Y4A=^XKn5Z6Hf#?JxzGQ6r~G^~Fde`^zu=wOK!5<(ws24(|lJ_6$zQ z3F!Etmc1h&Re#jGa9D&mzfLKmL8D^-8@LCjmHVwqr%Ikwn>GlZvjZmfZbOIgk8~$_Xxh>kC>d~s(%nfuL~_qk(qJQam<`Kwpa+a z9Awj6A3nKuWN0^cAB{uaSRI78ZRxI$4`Jkdy)~TKp_$M&^Zf?8*0)kO%M2XGE5fA--K! z9&Y|K${Hi8^>P4II_-qXtLqkKe|gsCB7<uCJm z1Vk+^bbroCn70_RpnR@}CwY?44tC_4{eNC~8uuTiZySQD6y5kEbabmV!E9k9 zSbvzL$7@b@aC>MCW54U&qA(1r1_nSqumZ5ah1?{mL%_N)jo(7?hw{plC|SfRGRZQ3 zti6uE?AqP&p%w~MU<#+>qdTwnRvJrzP?f@{F}O}EG>0Y*t%BDk*#i`|D$)FTGC**p z-gP|uKlo*5UVJb$ODl9EQ@!*aG9@-@j(=_qc$LsyLWr_s)2wnL<)XlFKc22k)vgBQ zeH!A661G>wg~Q3MG4fz(Sk78=XrZHM$$;WJLubcROc@g?U{P^sbv z8syMO-G?Mvc?&**G3KfOzZyg7W-hxvOzCkVr@Lv2hW@%O#0MIIysCTf-1ZEU2Y+9X z8lgo&6J)7?(Cu!a^kFMO=bPMcdoNH-&*Rjlh;3|ON2EDv(4rB++J~~#%oJxPtwt%H z!1lC!{$6+A=&V|NhCZNX7u%7J+O)cmN)D}P{c6(EwFUy#flVplNyB#%KW7;=qUN{W z29!_Dh`a|x^J*oZf7d3`Htp|cvwv>sT*86|$~dJ<#QdO8GgXc1fLj&T-6h!ag?^YZV3hs@y?@{eN#-gT770 zCjm&Y$95_EeDAlR1A*jdXCyfR+Wri&6+$;E_+El8l686MAA`B+*Jp>wGn~CpzxrtR*i8@{=R*5+gXl+t?+U?M{np($?VZ148YvKuQ$8A+nU3`)7@e|_p_>6y*g6{ox1&@8MCG`G^ z5@)df^$f&?5=GV=j+um?A&s=*&Tu3kCtLmHX7M^}DD1alB%it_o_`~`88cu%Z;n#U z-vc-hE$nb$+iHX@Uu>vLnS4V$8Om+C_vB(@#Um=0=`pZ9lb?z}3<=cMIRl0+4VugT z`hFHlkX(*384$C@D)TO_VV16gEvTBT?KQ8YX}=5jEgZ^Ts2ChgVkzISq$43YOnEsc zW7`ux1t z@xO#vx3Naij*i+FGt;f3%O&MLy0-1v0|TP`*u^WYHR5>cF+}Lwt9uGV5<@0Zgd|AB z(RRh&&1DkjV0sOY+7@e!9cN_tX*qrLIik-(*9v~-zyziZBY*t{I+}ESNS?2$ImhE$ z+dhyv)oIsX_iblN)6wg831VhAenxyNw} z52dz=j&qx&C6?6zj;f{_04*70O@qpR_=OtZ0~a0I%uB!|Q5!>Y?0b1r@3Ok!w1zhtJ=TqBYe5Q5ppOo5cvgINlKtIOXqA z7sE_rJtYegA1UEN0JVeX>yNAMg1l-_ul zXyy6@;J##LZEb5eKTvx4go0=>scf}QN0~J3`N~V;nqB~F?heJPM^}EL+!30k#oT?Zf_>F? z4}V1i+R#dm`y046sfT8h?AjMtx)aITV_C+`G*@l)8bN$cX^Qvl_`?7XZv@qhmMXJL zwex&^mK(Qj{9iV0{7;eNB-o0ZF=x)OLB`uuW!U+~y=F2jjz%+9O0A!sfSVlm>@;0V zMN-j^G@GfU&u-lVp)XE8gkW7d-D1&dMSo%FIE4_v=PTX+U2ZgBl@%`~s{R&A3zAy?q|Q*e<3MAQA#`l_#GcDQF<4+(xb}IJ*KWqpS56$>&{i$;D)rG zD=3m&71oQWW*@H!W~UK0Ifqt$jv})^dd6ZDNdD04Zv>dfZEx-Fg_>yS`_`K?P=6+B z_9T_G)9#_+!Mavy-LlI~&n5K%9#G)b4w~}4Dwj+m;zNU&3TFN0rz|~&pqU*6%!FV}A(oEH0t*zfxJ%%P?5C3{JLy4%rMsrcn@|d9Jsw zmd@>htQhACVgBb2i0(?9=8o&HKDM4Z?$ZPPebcB7+@5}nfogU(Pac*awmV1l%^Q2H zG|Rq~9tZbG?);mfoBl@Idm5UuO3~<+XA@6ZpD_jh|X;8CEB(WPg)#FXlQlrO=(*@8* zLU+oGdaJxgcrjGq7!1oN2>Pf)f^DDv@{qh9L5FGsm~5RpiO@bU+;ytomHwCYjD(1; zCZB7I-sPpWsXeTW7X45;t$*+Q#g%J?0)54#s59K;KLd?>5ML}@RnC&jGH z3RYN04z}*?Ka7Ta)}K>K=Ef?Fh@9K*pO))5WHpB%BgY6(b^85VLyQca2IW!&O`0*O z{btNgvIR5B-HCEHpAXriGVKs+?9E`6zT|$w#q)sl$4o&S>Bv zTJNs^o`Ccy9H`GBxR>Q^ACqG`qWB6f(k&o&^=g?65+G<7mV$+}VrTanrYQT7$M4Rk zhK|K8uN!RX{jEv}w10EXbOw1}XWd0uPF3P4|Z4&Asg~5hDmfh zWADvg&B(MyNMfL><;)z^HupMU6MHK!>qlxwKDuU*b4 z9J79KWtk5`6KO*KxUA+shr;VU%~uC#0k%y5Hs{#;^0zZ8nTFSBoqP1#4oeel*oHV* z-(wMbS@MGmr|SMCx&YYcEN=n{(hwei;v->v^2(>##zvQ@ey0>+20)Yhf{7;jlxMmi zK)IGHZ%;W=)_+F=;{Pb!8!=&2qbPXBW@vyMrxq0Y6f_%4@)ADJO9}(^1l02PnN74{ z`w%6;?h`f_&X4)j{v}WA@6&X*I7{aXaS4kqHJ}RaO@DxiC(^Cc4YmbZJC`Nhoy@6M z+OS`T;3bn^NEvR3ouv>4M7yH`UqmK!1+2wA$QH%6J%2h2JWdc7**jw~h%7-gOD*(2 zHN(kwP|3eGN`rBUDH9)Lu9AoIrXnJ4?^0eMC}Yt>;L-nH^POL8J2V1TlEY0VbUq-Q zQ!(U?TxbN__AdD;lfm`x$#lq3FU|#K+w`UemzHZF9vY4wBL2yXal5MGs`oXvXNJBH zeG6^ERev9ku`JgV%yvCq*_JVlyWoQpsq$~)mfA&sIk~RZhNoFUpKumeaA%7<874lF zZ&pj28Qgf&u_V_JOrax^P{Io`N`PND3{g!dYp@@W6m-rt`^g(T>8-8Ji~UnF$)c{* zbW}T_O;f;64GZXrjJ4eWlkExHN0~(qs!MbR_J92r2rPKL|KLTwtyoQE-)}7pqnTLpcvpt9 zl7AG`q#Gk8x9xwol;a9(MC?oGm#reX;e27Zw|p$1Tz^}Lh-eF!rY<8We{(kq z*lsV3CP9hXZ}fYT2DP4+2@a!>z(4XkNq?5uC;|gsKb>udSj7FxM8TBb;mgnoJgficsE6L-ytJguMb~*$3am>;b3uptSU32QevfNO6G@^m zu$-75mh<6d0s3(C^a>cV1;t(IMlA+X2P*FKQdXyB7#+$SG&+ia&gSH(0C9d$W79)8 zu*@|RR5xiY0!s31A0d9%U~NH~+<%^UWmS3F_tZ1r@D`uFj8Aj!jSlNXk+_5#rPy+r zoSz60^XIqZT`|MWAu?`g-^~nUyLpCc3JMwKX?iPv6nMw?zR;o^Q4O@CYu8#gG7;)q z(65P#sh0Aq`skE2%R?gJ{S*zBP2r{-q3x;QD>fOu68s4b&xq1xbxLwk{D1ZRf=i}E zL(-SRi`qGWxYt{uzxg9T*r>`1b1fnYA0y6wCNUiLTSyYU?V>Nw4{tEhJ;C0I@e%0V z6##o!1X_S8=@SW9f{DgH8X=0UUQ#9MG;`0VGFqwJZZ%mA9iEHZNtKSH``M*UmZ=?L z@~wM+CniuUS3(o}bN@GRDSzK|31Mh3#ICqr5M*8(FZuZbf@93BQcMq}vH>=R`alvt z{SrL8St9tXibtfRMy5{5;~hGwP>2FJNJ2@J{cOp=0l7HSa z$5ok$FgoUkJnOxC1d@nK5yI&jb5`;jupno^!%UkeEd|-&98^&zjDOV8rM}-$S8bwH zi4sHdIj?B-6|6<^is*}iMmB_kswqC@fXcUZxPrg6kxImeZ&@A!1ION!2?E!~SCm!+ zLbDUu-l{8JeSPNa%f^4W&7wkR>}y{rHzPR(EQTSrH-o(07QhDcnxK1~Cs|1)zv6{# zV6`aO+zAiEa_&G8!hdF2J0=QSm6cM>dn>_he!l?iSKxU<^@t z|B~2JZcUEEfL=K!bw5ECFJf6veMATGV27-ME{Q6-P{ zQz*L@H(c%i8l0Os$&@gty_A}Kmk*E&R8>b9Fo+n4itxj`@qa9O{6i;_iD+|xk8_ZJ~0LyAL0urE6S12FH2k4lkP5zt~ld|^uZ+#@Hpx>3qH_T5zRCWgIHBeM0^ zrTi|DC=;u3qJM3r$9`PUwA zumyw=bPoP!wG7Mp!~Xb;JD!^Dr|ti*LeS`L>q>|A-+yvCyrk$tFY@#^>P4jeY9oll zLvOT9RgaCQDUB#PLV%k!6dkio55f?8tyMlaGQneIjj%>fVWa+ORdwgo@v_6?)~Qkg zJGr7BfsQi16g52&qmznax}!`b?}9J6qmv$tnyS<2LHL3FGn-g?!`_=@M(ml+jk3YoF7=Mx2(L5$<1=q*Bm~3L>a?A0f#G<(#Ud-A|-3GQh_I%nQuNjeRvGZ~m__ zLw|3(F~6S~%u3Qdxea)qiD;7bR1j$?R1E+cn2dVhKpP#YWrPR2Pb z>=vg=;8pq6lL(oGlje#9)9%{&;Mys~%r~EeUMCo(H&AmfZVZs-W^SNa+2~e)F3!#s z_}6Id{d?*XCw>kA?VL#KAs6#{Txq2kE`LRsnbRA{oXo0aVB~h*0kZW$>}p^Kv?&s~ zp?N>Bgpx!~V_Nr?c{Q^edY;tP77Ya8?g^yPx^k?|81VunF$XNwL5ynE1CbAM$u8dG zXVQ21L8eI$pk0BE_Wb{Uw*80?9@+;6n|xRznLMk^bh9Zga=WD6!0Z!e2p-U4p!#uc z#*eK?t9=}9#AMujRlKA1QD)}rCVvOD@3}D*mgE9!nObvP9E)rHB@8R$#3eVZHeGes zW3g*Kp+&BaV0%?{d1b(fvYin-2eG{gCtZgh#7wRp{_snSKUGAr3JE`kM@YGd*K{f! zz9)996k~EcLf_?Zv9;UJJNEvyh<@jai4P-_a&6V@Q7j!!#i#D|j&z#qbAOt32WQI0 znlxCpDs{8`Z0Br8w3!Z;46ZV}jFuRDWT|~+l#0HH$Rg^O7W-PJKPjH5us0=Z`SJ}; zhtY3kOO)PKFX?tqf)}J{rG9$}qN`=>6nGkAzOg}i%2W8o)7VPm=gmjx@kPvhm`o}T zczwiHYR9?EIDSy0CQt6k4S%-UtA{h=t--nFPZ?UHf%1DMq|7xaOZCF|CjD&3;09&% zJbO>{KO+2h4*paVY8r4Pw- zjbnatY7K95Xjj~Kd%dXcu$abIAe3cqe&Fft*`W%+n;x!a0^O%4_uIr6VS}5IpHvq9It)g#m02 zm4ZsTduC=`nZQ|Tx&LjZ!^m^}ejb>njV9XYTf#P+|3ogoJ7PD_1-fYsIpb?-^QZ@M z__nDja5j~X34!&bw}0XW7O;_*qv;0YX%vthv=0G1J_{<{v4I4aB6rhdrTkzaQ5fe^ zjm@sVP$Mp&GU=kYVxFBVQcr#p8$eeegoR>E>TVXY94|apKzkGt+6sb2t*cv&0&xj} zqYL&6+I#LX7Il;77TRbX)EgQUu7(^Rnbq!@=?4M@*f+4dpc$EXhj% zySgOitFyHS>Smobbc7gC#k!h~CD>T+h3Of#Z~bE* zt2+*$I?58GpGslLIa0>ipP?uQ`8#ns(kM z>KiB60KMY$$HvM|kEwlGaACW22BT3p{3Z56Ib6g%+o{Hb`QjUizW1R7r+MLLi!W-Y ztzq9i!_Xp@i2`p^Y6+9_?K;&}1{t`Ib$$m#Bo5QV7THKkM_xvKQFs;OfYZiP4faK% zCl~b%rGItE^}!jg=R4|07A*k2O4h2-#ioK#{+IN@K5!7-s_P~Vqnn{wy+k`dI*7mo z;h&2vGujU6FnHk8lU1kO6aV5^*-+`9@f>sA2*fZ8^SAxWZ|O_4mu>!bIlQ^j7@;Cu z$A-a6+c1HtncFGHDn!N#iD#P7ns${H?&~vQG=DbG3gBgs^j}6VpAQy>N#{5}KPN#N%3wdEL%Xi?2cgsu* z_$&5l93Q#?umS zVSncJtr^e6Jga{ubS9b=9=X`k%TlG@xfh^J$EX*&Qk38rR%wqvJ^a&9)8W{WhRDT1 zIq&u!5Y%4YE{911o>-@Ndznq_+MK_5!4ZasBW(3kHGPPOMJ4j@sw>YwTZn+(kqlgT zeN`TJ`TKFk6%0F45<2jh5#NM<28#@2d=V7kzK=+0UV_KXneySVFO;a7}FJ}Prn&0c1I$_>di7Z{MpqJIRp zJ=^|%3sMAQut?(59!dU^nJc5Y*`F!W8TQ@id&ax%{WDAIUy_F? zIrx3HPH;5|i*%Qkn8S0XHO%IG3^pbORq;}{EtN6emgS^BJJRzmwX60}7&}6UAs16- z;ku_76n^0kz-egy8fV zHAwzsZNFpVa(4CAc{g`M-dNVJgF6~>$552BDx?cm9S5dHD43$`khl8GQb-{KW@sg4nQ+65)4p3%*=;v;-GzClggbX zCX&?T!O0c0S(yJP#{29SCR4NVUzB4LxvNTZY2`pRQMVB4;>y96-_0IpC#%e`ViTs(jDnx&8Sj!WzPV ztqITOXFHDG>sN#HntLi6YQZmI+ zo~z5=aeNbAVa7~!PJbA0VpMUR+}8@!T{8`I*O3~sJ9R}E%xd6Seis(__E=TQ=V2W; zh^sMEybN0{y)_>dnaNp2pV1y57qKlG7O*pt9z=pZ-_la*;9@UA01HC`y=@?G$ks%* zv8s6xP?(^F=>2c3d9`CNRR*^0*-e78(h9zYD(BT(IGsQ)B!9eE)g0sjWG(!Bb=}PW z;*_^`J=<5Y!~GWXHJnMFK9NCGDWCCYddNot(rCKIJ4Lz3mIp`z&fIe0e@Bk~^yv&7 zj5V7-yI@AWD6ps>}x>Vp+A)p!)!4HA|xEQ}9pa)7CUpBEUmvLF!r zt$m3BND&Af=YL=GLi#+zaRpI-Gs;1G8U8zNNJ$?7nSMq|mVSB`lf;jx+eS7Y_h-|6+2@O;co%)-x#r&f}lZkj(_*Hx+t)YFrJtHeILq5kG@Rd zmOU9m-9g^}X@HO+vRTp-)>e?@CiMkALDtf!mJFo}I-O$~y4;)NawWR%KXU--n{buJ z<_`GHlKwNbk1g%A!P?L=(JRiDO4AoqUirBJjK`*mNT)SW?BNmwa~i#UgZ;{F zHD^OHSWbRhBep?_BP<#PxuQmn(0WT&+z8Whu3Jd5@- zD3C;AOKsh!{FGSS;G1l<113huwITDTY18BC`YxHV({zlhw)8vIqr-)?B1d@&(4|x1 zI#v#fsMU~&mY+q9Uj?{GMtj(FFqYRmhRz~h{MQ0^6E6uWx1n7X8&Jj%PHeMzw7a)7lE4T}`9f_JoyD69r|)K;#4~nwdh3^rSC*{12>YrRaV+*HV+r=M2zR zctJLY^|||1@h24EYRyZ9(v0hF#~n)8*$FTT;YI2v3>Y21aw?}EPIBB zmlMs_gFY`3hU7>9Y3AY4#HY3mqTI#)sDHwKLO*|FAoU8I1o3)dOr~cCgcpafn9DMS z;}!VVttBy)DP%F_$o@%`k=$7$T15-yg$K#^pN6~VRNF&Bdx62tbVuF(EKY&g>Q%0h z2MKK4zER0S!-BX)^I=aW)5NWmkm#54aSJY_c6mvF;EhBaLTqj5KA`;qsj8s*Dj`ljbrpv76zRdBzAq?Im=gC0s zdhX+d-0pbjhr1ip%gp6qT{~Y@D`0(|7a)NtL$CY%{a=&bh$dA0ozZ|3-Lmbg2^Z%> zo`DV9JBE@wTPB~F2=qK}bSeTMz<#qZ;vN?4#msE^bt(Se!;TsZBu~ zQvbpa#7iaWg6gU_#4H;f45-B_9JCIKdLjFCvcQc!Na7&F!jObyGJG7xEPvQd*>0{x z0EYgnSl-1OYX$M-nn}G+^6SOJ&5UiaG`$q2ocA#rJ9B65HjTIA>xcxfKxRaH__3^X zapJNn=9c$;2HR_CJ#ZgX_-@E-5-$9&Uul+x>bontW4Rom{Lx~S*qq#Ce3FUpm9j@l zP=8v9Ks!@nT&$ND0PL!X!+)9uJtEvVkNspU`-cG&8$F4c(p;zVpqkC{vVMXyzKp!fpWtypn2m2Nr{H^XFzs1 z3KGFy#A`+!j|T%!`w1$E;aD~$Om&m~SNnny7yPN4Ns+0dtu5~&wSO8&0$sQZTFo{h zmH=<>yfFc%nCB8FRCKMH)_F!Sz{3^q(S39WHE5$0m{qx`y+GZ}3>OqI;=Ak4aeMA3 z5D{cBu@ap_5D|ke+&PBYJP*lSn}=mYbkjw)aQU?`B>{s!bUW!|=S}wuf0z&a=Uhk# z1M|XFb+An!LNZmr+<$v2+u5w3$FK!0NY}`)ZSgBufmV`lNmkEc`vnQ|7dXYPqRkUCyFnO*X63y*%8CCqoXo~0kDAZ)eFxT!QXDtn+S(3X#U-+;hiyT*0x zl4X|FXvlL{yC;5Fz{rwlGjxKfK)@iK??wkUxR*XB;z(%`+<)CynYVRiE3q<3Ast{c z?26wY@E;#9{u#%HV`*`*F8|PYhLZEC2zD zjmqFDVbB9ZosDp^iZnQh{ao4d+WVXLr28E)|56H3--{{W+K|4m0 zd1sh#RNi@VBY!`>@Idv-BytB@Nfe83-Zn%w0e<`lSru6RjKiF+Va!^M1az7VfLEnhSZgixi!#4nbzSl*z&+*eF`X2}ZhkOVjRlS2hGnGmUa885| z%nu4c;D3Qaw{hn>+Oqf_V&8|lftBj{EFe=3tdBCw9Ldua*8BmTZ1!XBhlchxcp%;V zabj1yG(s_gg8n;?*Em+V#N0N9duyu6LtZ9Y@4OYUfnkpJ7;PXOVYxbwA^6A_^6@z{ z*yp22)vBGoh~`&EN0O2Y99MU_kg%nP`Mf^I>VIX+5AsNr0ULw3#Tjb+`s+72LW1fL zAGUA+gz+NG1^#m;F;?)w`%6-Q0F&-a>sWSJx8hyXcX7|c7p&o|us=fim62}UyM1Wj z5ft}pTa(S?&kS~_Y93DC62vTy?#~v$_#;eF3W~#LPoCb5g7fY@9xiCRH+t&FjRX=O zbboKU?`@>;x1>LQLkm|iGd*C(g}_8_`AeO|DQh5LeYbjPQqFZaf+lGD?hxW#tp=z4 zm3lp)6!x;6f)ut?G;qG)I|yUwE1FA;=qm#2B5xCzKVM7AE=DO~rXLc^mX69@B8X3d zWY&NLPdL#}D^;s&G%NI3-c`du_hR3Mb$_#k!O(6h#X-}IKo@7%#F}@qB!QN`%akE&_KI*uY``2Td0>8p zEDKCyjRBO`+dTE*{vkHY{G@~!$P+MSJrLGw@3Da6w?@mRf6d2LSOBkxmfbq<(SKGg zp0Re2aP|*7)5$UiwLZR)WoT<|#;R~hf-nG(l1~i>Oz0ob@>@OXZfwiJ?Z^I>P{e{- zJL^v4PMIi(a-}3_r41`86fb|k!oiTutk3Svh=YyGwZwnQFUYwT^i6ZM5Gp!?(Vt77Z1~JrLAH~6#S%1MwDaHRq zVtl#t3b}gJ72zHrxZ{UG71Rgr9Gk3vV5)SEngA-2>-%k#~px z^@~Vi(a(m8z&_y8J>Qa{Td=ar(|VYFC%2Nw=BL$t1G_&c7L{6HqhecfR3q{&0c6qO z5-_1u)P9YO{Gk%f{q|8I58j`cG}T4VBAFrvv6dZ9OAKC)KZC4A(|T@95L1O%>d$%;1{(ZkZqrh$XPQct473Aa2}I|PR~2V(2E zYp22sAOZVdXu!WDMkjTrKz-YQG>OIS^!GACsbQo2(9N(4aFV@(K>N-n(i|9=kbjlQsLGy=843Sb3@ z7?{FMG<0i!O=T01LTL8Y9)cztUjC{{+U&kxpa|)JC=ZVF*QYyox^CWn-qTs}C_*7lh^6szq{*fMRk`o* zzYZ2@hE;)on3FTZC8&R+?L#&Bmlr$o^REC2Kz;2^N?qr(2^Fw3slDud|fGpd)2@{Y|Z=pAWTib91s*?2)*-M*f zI0jDFFN5}|{L~)UOzS~geNo4BJu%YZad{z`ZVUx>ZmN3e%}jq2Aa8|@H`QjX%qz3} zQB1WXr*EwmXNFHcJ~uhtBbdCYTo4WGhsaJQEs|C-NKxjp*9xQkA?r~r0?QIHWS-$2 zg-(b*S*(ZFY5x^pcUpj{e_N%amSvdvq0Em6el(BRGh8f*EYkn_htzUM(T=*CXh1kAof0L^bhGFAR&;S&0Od!e;=5gGb1BU^||3JQgqnXJy zaXvIHU1Z@60N{O0Yw*Q=x>LVtI)=~Jmovo;WFv1Ya_N6~#@POOrrvKD!bpBNG*hH9 zKrgxl+QZM`l{X+9Zmz8oue5Z;iWHp08fE1G0()n6BKWfyj28@+Bm1v55ihbi2&6LF8ik z>mZ_^Pve263oEE46(5PtFJF{#GH*1+PU!>eAkr5RsdJo+Y=2Sq zXr$H0Z>zeI;*E%K#P*_u%n0&7=GPX&P!i1#11TXEtF?wtX5dcIhgB3?`G&SmPph|p z7az@V2sIkpzP+_xFk?`D6#k)<7{CTpXDxrXQLl%v%k}r5>LTB9f~%h6Qp@cOZeVmQ z;^YB4)H7<+3s>2*=wM;mvmcZWmFfe@s*cNp5t>_^nY6U+V+}7yU3HE?dJW3+S!$9v z!eYKtoAvZIz~71|l@V0<{IS=|r}tmAsOnf>%u5dM3k_*LR)`%Uu1@|${7I6%$0~F_*nGnlCn0N%du%C#W-qwnggJjs-Ew1& z>YEx?#I1752mJR~QyIr9WU5%W!^E-Mqwok8sJNU;7>fK#%EJZc-|@XQBX#qV8iBHO zTsU~?S`UpW6e7NZFp7AmSS8YF9BogFHjE;E#bBAxL!^HIXxfo;&7X20EG5!>LN2NY zTVtd^V@s2w32vq90CxmUjmUqX)am&h-Z&xx>geq2XG|Z=rs|IeToO`UBZqO}c-wL! z6n`yUv|ckJT~6!})x>_?dw$}NhQJEQiiH~ZJI~DJ_BIojA$8A+XC~-Hdo{O9Qfp7y zN^7@A(LwS|d6fBTyA7s>jSM@(1V$5eAvGyl&9+9ATMe%-cSE?cl4pP6LpvCmxpvW7 zAzWX(o|j!mKQ|`db3ZTenxzNM<`X@Rr!4KQjj|Di@}vlSh+SXx4;de0N?i zJlwUdb6vkGSdFgsut zX|<=-Ylnr6FD{1$(zt)3H`x|3uzprsT@auoj>SjT9cr-tHFquY9F>SZ=mKbVzn(E7O%&`ViRGSv8#{3t>YFM>uaT|Yg*HAFCAN!?Nlgk>G zE7YpT59Z48sU-XY-?Gq|UB$vNFDo#%w;N9D0heAdrfT6$1d_mg07_}on>bYdMIl zHX#Y#rbN*E_~1JC;b;(hi^Q6XSE*(@QOqR_Z~D+G*ZmX?3$v9ZtWN|+%N$`+U#CcN zbSKt|NHqryYmpGyvuRpC9auz`=hJXa5@v_wqkU30LW6%6^=lh%k@-!4Gq*Y+jO!SJ zgfiGvr35KJo~5g=5&w$f9XdDhK7H~{WyXCR=`SHNnZ-Ma0NS5ffg?p`zEp_lCUw_c(f0VzTr(HgD}xaM$L$ zsHVow%t9Av?uS1M7)iSs8Plc?D8!3f2#FLK(rNA6Rxwom^mKc-P zb4{Y)?`7LAQMy5xd3_LZK&N5>in=1Hq@%5s5|>BDp=>+(g!bs_MhU7S4a5XyL;}0B zH$ONUcZ|__FtD%I@kUXa|AG4^o2Y;v*}{KD4wR&y;u-}T@uqY+&u(V2Ixb3V4@)$` zWrY)`g`qDN)pO@p&`$uaMzhUGa@`w>Lp>N?Dm*S?#*RK+vf3}Nqup=`E-D89ocoWI zxY{@0a$JSer2nvUi2&c@`qq8*PtG~&;EF2eH$%&Cmm4eF#F-dKXZv-?_UjCFUGRTG zGW>j4jXb~W6_h`JMe-n=4XUOlL7 z($NEjI_1b*k>?OkZui@(iZu^;bW30Yn}Lv_I_fq-A80dCf;K$OBqYkAO9~pcLi{UB z+<7T>ulbMBVyrC{%Kv$}^2lNXdp3X1@$$?tFZ;DSy8hBYMFg>Xzpa2W09D zdL|_5gOC;TVwh$5TEv0i#Ee&RLlVjIx6BX5aB#J1>rbb~l zakHqI14XelPVwJ&lFl`#txZx)c*{zTL*m)`-%nd{ZLcn7WJ8QPt`UD>*!psWEmvU2 zRCD#Z8NO8wx=_Ry{_51Q)4Z1J%z**7-N`7nhfO};hr85lz!U{ep6Xaotw-?vMrYpX zeeD>4Sn`%BrMZpcRSpDEdjbOnOmNvRKGeZ56fQw^&OvNO$hI{IH1h7A!r6v1`=u7K zlmt0LXs=+qARwTyXB-R&xe$gTkI&2bzOu6~AMC|IXBcm~fcDrRp$q zl1UpOpV&|$(8iT}WnzgNxAo2$$N2vbcoFi&XW?(mAr38qlJH6JJXt*~hx#(84t6m* zv762vkSJHDmMzG2wb0f0UY;|GREcVq!D#Gv#9sw&%)HD{=>>W$Ao|rh zJ5rfzkn7_DOBbXH+PMfzE@zo1AzNa888Pvb3BL3btaEHM0}(UUGKr@t3_goEb)-HN z(JY#m^d;S-^MQW{;0RdEtpiFg4C=w=<|>~HwB0ASyjYr+hYDt}X^88pK&3;0=Ic1P zVUbjii+g7{g!9;X|1q(IGqk~f5lm2*jqPZa)4;_MJNu6Uf{q&L1%JZVY7%N_y7kTo zrknO{%bs;G6yJ|_vfYga76mtc#V(d@Epr8(Uy%i(=8k_9x%Jrr1shj) zk<`%2t7dWj>w?O&!{(ksneQ+#0mh(DEo|?8);N{gIhpK^f+6ZpDiROhDw`t(8`NA# zQTVRxATW*%kA3FQRhG2iQTAAdXgwJD-`=CGD%}Z$Y4ooX_i}HuZ&H$HZUP=;U~ec_ zapa{9k!yd4&SO~kl7FlO@vySCtNq3^3Sy!(vvv2iDxjoK(Do+|i`^vq)!CI!V3ocu zjwth&v;gTQnuer-?W)0Ov%S)nL^2Yr^0w)!3!>li$m{quS#C}ae5~b80bK*-U}+HH z@>BR#p64ck$&?&w&m#M8r#!hvxYmGt0)>cT*mi$Nnkbe(R?N8Ibe`EUzGXb42u0QF z^mCy}2~NSD?FDg?+6M(nd?tLR^$o}uBiWpeXX%_rlZdVYFI4pLLA+OTCN#lwvL?eiLfhitQ<9C z>Vki<%{dBSBJO8%@rb)ECM(nFQxujjg#;6e;`{9C82PwX>-c zq_q1c;)6R)@{G$AHo)p;|L2&q2cr4=oH0H)V6Rxy>iE)2O}HX=;>drti66LLzmNZNa~5h3+UVi9`y11=14t?UQ?nfQ z1%Ytl>KyHw$LL^H3%?9F8F^~}#@@H{Kp8xpn%X{Co(^d|a8y5FVE&*o3=`B?rz@7w zK_WTszg^b@Au6uu=b4eId#Z3pDn?n&FCL&J-w^M_Oc`85OEfBsjA3apcYJ>*YrUmK z7I=)>30%FYy!&SPOd@}z>=pni%}sZPp^;xl5tm1hiHfBesxaPpW^FdWYKZHs{>Zjl z_~CBTj}Ec=rs$>2D=E(XxP`$siW9l9Rt2r!nRSMnYg)^{p$M05oMSKrpJJlNZ3nBs z{N%i}UVO)925>i#M71N3o~3_HQBVdh9iZHH<9N zOOVPG>i51DLS)tY|Mz)NZ9;^NjLyRhZ|6cT?)SVhbY=lX?7xAKM4$hcPZ-^YprH|9 zK+IKghU`(2fNn7HjJP1&1NqFrtQV={4Q>(jTB=lj&jQwB4agt1Hd1_9u`+d!sgUV)6gSg+$qO>T%Z`1J1;gu0t7kZ)o4H+2l^FH(naUxe; zDGS)y1aY#%Zf2m_PceV8YmB^hwuz_~X%=$#+A5vDh!PVg0gwvOgAXkM49w-|>8kO$ z%~v2s4Uot8>nKUVPRnTx+Lm;JbDos%rXG2OH-Qcxzi1dA?b=?=mzZpG>tIUR$`_ai zs*}9n^u0}z^4eAcEtmHll~P@wkI(onARD2?Be}?;OD0;E0^ond)Snq0bv(3frcRlN z&<>Jg3%(utO=MR7_&z&iT#B#tAg)C|n2SLkAS422M2uE3XDAQU;sk4GFCZ0pRvJyF zx&`G-Nx~H5ur+q^;GFS{>`7~J_*oDpy(#kkXrxEPE+{G}sF({%wPy7eN)I4fZgBA( zqaU?aWX!v`&v$<_h+U_9bB#AD>6(Irj@Qeh;{(dOo|?lmpBV~PsVNG7s~nulu2@os zLx~&?iyA&XX7@P_5xrw9H<-8y@oMnoo9Ea3@&mz6NYJdn;SrK`8yrFV(KLtD9xLbw z`9iJf!g;slq9e|3=et#)c~n zyDlv6ELTL{V*5BY1Kn=x9rPE-xhzn;4E;>>eFoCl<+E(4JtS_jZ`H_n!f;MweYO#j z|CAE}%NtW^h@`(*yv%)53RqvU6dK=mXR}-2tuq}f0SV(E8*X3=%yU^P)GT=Gr+g6* zk|p=5tO9?<5=QYHElL9Ap-nJM%tzNFTN>J{0v?PXn$@7V&Fjd%v2w)7h#OiLNOX7F z<)B@38T~0|_rv@H$XIvdJB*rO`W5FeY8`W=6a33V7(B%EM%9OBEn=wxdDxJ@408vg zdbEBuA#{d(t$h>g*NVYNfn{7TABXd-c;YmU2E?pBh$^WeWnZV3>Vu zKi4h!*qoRj&>tY#AvcGEnw}288R=T4e%vYeA;5KM@ zv$dkjGbvczPB+U~PMHaeFYS76oi}zq6S;7k#Cug)I(HYjh@4?+1sOED`N6GS*QKg? z`jUUAg*9CSvQErIn%f%u?c$6SHF+WEt~lFdD5{2Vjy!T5`!Uc;lEA~%?^8e{b-T23 zR|xP~W0&n54#_ZhKE`aX%ao($LxJmJ7C3*H?{%=GAN9BCUzo5x7Ul?ugVMbsYE14m zT3Pxfs4C*OeGw_hL5QCBB}GsmKu={-D~5mZ#SEsif&p|L*;S96w9%u+bY_1FZ70Qh z-DH+;pPJt)0Abj+zYk1h=H3*RTI_3q52kB1P^#B{syJC~%SG_B`7FY;YHM9F;x-Q{ zG~gR=?yJ;cuSBdvntJO+jX5X>u5olJq9mP^PME{+4Y{5wHrU_xc^(Q_6)?NFHPwG; z2lxt2k6i`1R~pjQ!;D{+-n{O9V`mnN1dY#PAPHS37*G zdbM=AGz#DT>VJAe*>^IXP%g9VL(hQW!_J^-zR)qpCM)ePP zp6>1&!=L9yXWGMmd?prwwJ{y+AZ|@OmP(cD({FMRX0IZR06r``< zPdyyVKIowM4JeeM1Tnw1Ve@~hf*~wmp2jo3#`s5TYp7_=zKnOCsDGNm(l|wTn#d-g z0Yx_)tX9JVunwst0Iwk>6_cU(ic^<5$#O^pHWBuP>mxMg?n6riaP?*mQgdEw$(!Gk z5iPd>+iulcZCO=`?&obbN6~!DS-C%S*?}5(XeNn!TDeJf^fQV=r;>j(itNv5US#L< z6A#_I*Dlc(+F7buUmI%G@2taI7(mZN)V{3)tWUw_Q!nH>M_4wj4u1>)h+xk`)TB$s z&Xqk)m3i?Ts~H+21V=?nc25pZ%shY?5^C*cUsMn)(6L)^D~cWm)=j?#EGF+i?H;pd z+lB-LLR@s{)R=Ifv-p2boRxm<{+L8trXbIPJuIDsdaud180YXUIVn}a=Y{J^sQg!0 z?SIM}X8jb;;WcD1e-BK93FZa-jibqif>~@@vI$_3o=kWkaC3gZ(Jd!bpBkt`E$dK( znUX_%#wv&RJIvx<6qRA8QAs$D%53ksdR)NcD(gB=A9nj~yrq9EPOslv^P*Ssk@swK zx|jx#>SPm}Ql^9@ZAEB`h{Ab1)+coEE~uxcF*L+N^+$Zry!}Yw@!NSz?3~wQ>Jd^U!N?Dy;lSF9g1x_k7DVI`5$gYH` z4Hgp$GTDljvd@2}#GTQLn*h}l^S$hY+{>O$-LyTagIBPyyTVic!WHK|0Jv6hl`z&S zt>b50umQrxIsyuaTxE9nUsbRt9X3K4x(V>iyF*G(cX#uN!Ltde#Ei5R+*Vhs#MP&C z;D4Tww%H^Y1v9C|QfA~Sidnih0>a115^RK{J&00oQRaUOavv|b<|PCKQcO@{C;EF* z^juMgmSWn?_ob7n4c|9&<@w#4ufbVTI2xBK~~; z&>yzU{5XGeJoYDsg8X@5XjY-y1B1AC?MR3>8-AKApAtEVBi~Z!ts{b46!9Igk*Y|0 zTg~<6`K^kB9`EP_D&0MzeV6sa;Sn7ylKuwboqGRVOT3N0a|~C-OE;sBRRH&cMYOQA z6jae6acastEiZLoG>H4iR=IrsDsb$ou}f5dGaY|OceC4B*Ov!eN(tsNJZi0cXjPg1 z2|(P3mk$E(5pA)TSX(pYXoZzoG#!bgn>eKrX7U3Axt%jA!{@A9t#UER4)(OW(Mm^X$9Nbyuc=7oVdQDL>@(U(VZ;9B_8#6-edi z_>-!Fi)&HNq0+%Mj=+J2o4I#dp*Bn9X*GyvDM(3$oP!KoyNaq_$^%xUq31jn9hv!l z5q{@oD=9dY3S96U0yDzJ-*UbBX;$@Myaj*nWf>n~3YJJb$(E&7paBjg-#gxu;^Aq9!H&r5&v z7vf%`eOR4OwtB<-iUXs4kpCr-TU}X`<<8<_@?u^SmpwwmDjcVM275B=p<_!n#6xQz zu{n}TpQN&rA_#X zVM_&o#ubSXo<1UgH%39*EH1eMh@O5ApAbHtw*Iy{F_|=AgFTEu}E)CmY4mtJs^M3=WmR+ zX1yL&a052fP?ria`BBR4NCX&e{vvLN<~7XuGx8#Z{_TaCSn>DC&Z3*^0SL><08Qbu z-S=iZl_?nH^8b!lI|~##qI6Gd7&XD_-B?q6ky7&6^A;TQ32Cp0RmTJRtshZI3JXS7 z$tX|E&7R(*v2l06$#FiFO|gH2lvYxsxO~uC_jisyFO z;oaQgDbo^nes%P@c`4w@x%8+hy96_}9s_VZkY$*#DNmx`zcQBurhHYCKN~e@o<9#Q zR>$MAlR>Abb`Kx~~zdB54u+0>wjQ(p`6oFYFfi?sGCzt{+0UH!~{+YbBPtOyPC-b})5q0~R9~O<)c#VG)7-)t{6l8_L!U}yc zMp}R3!_NbTs36cq?OOl~wQ9&PSFvvjbS;d{qg4MgPryxIMcplX(KHz=SbtsE_gVxe z$w*p3f006N{X*B==%k2XGG?gkw@rsk$nmtb2>oMZarz@} zD+$#@?8PuATLdbRz8|}}T?MbBr!9Fz-&{Ms#*6cMj3WII;V;OngzdI?BkU<=f1H;Z z2S_koOa>Q%N>tRcm0Ry%FA&k&FhRqS5fq}0al zyZu>z*B(xA7gDnnc6XX#3D@tCf1^{ljXyT$t|B{=y-uf zptbH8L}_#^Tg`2F=iJFF)>u)R5hy3ZALK^*e=TMhfF9xieASZ?;Iy&K0!?)Sg%|7E zzU;(vsABa(7P)O}t0|PR!g0S{4MW}+R!P=RvQL%^SmUGtuyx;j?##9ff3jsdP->Ek z;_dJIB!!OI2^*S<;Dy*5_yt?Yz(evNnLU^lkrX~FraQ!a#}lUjY1Cg$?WA%M{R(J> z4#ys)Zy=ZbFvhPgP{VPZ^F4OpBI}JMy4d-k(ifOf6;( zZ5{MzbX&RA&gGW^^0Free<{GU^3O~I7~Jx+iqV0j={tTX8%nCx!K@)vS&~lPcJJgpK{KP#$X;J{6wGuv%sgve`1f%jKbS?8p#9 zSJ*LxX+YH@Ot>RpGH?l$G6_n{{>|qH9<;tJ(s21ENR}d^9Xblpe+IGq$A$HNJ7jY& z4@!94@HqjghcPxZG{REWZ=IZTLTrcG?seVn*$*nld&^kdMTM28m;|(y>~3u#(CIoR z@gf|0U6dki5-T*?{v5m}1A^QQ;&m@Hx|aUoSD)NaF;rK|lbuG9=?iJJ=)%e&MB?5A z$l&{kfnQ{)_w6rZf4)3!SG3I4fVgH#LR+o_LvI1#QVU6$<5kATy4f|5Kxw*N2}}-C zmB*SMEDtVIY=hn%6;W{HG5l{EpR0TYm}zQ+dG!3mR!)ihQhnBnd7#~!-8F*U`L$9$ zGOAxmMY+cIJLs^P^lC}m>bB1$W4Qn?qvqGi6(pKW4myP7e=_6M-#T13fFlHqSaWYP zIYOYb2ID{6kaH-A$8dVHUx_E^GM*nDoV|*AhVRIQ@8ryw4N9ZA)M8n+tRg|)eHirV4$Q8iXX65lnF(+%)NJ`yM;sFIa% zR0o^6zC07ff0#i8fn2Mt2JhUeb&;=1l7b!@b;%S1;B7K|4|OTXNjL^QL$T;5fEfHj z8wCDC4!;SbA)obFeT>c(fFfFN|G4I0^HWgB3eA|Jrw+upWBOsN60;NtI0)~Ss-S0J zoRRgXQhtZ7&=LO>=+8^#FUzEL>!BX}eYTB=F4SY0f6-YVzKrlX=N${jSdWP)2_tv!N2L5?i9zap1kNx#Y6!;QCz&TV1}&r`)*R07+t>d5NQe9M+X?Cr4Kb?r%|#aujifXyXtTL z2j!cNe=0En?_p(#)WkkK_JYR3P&krfpz3#IejqAZqy<8lO2%D&r*)}1v&XeprmgqL z1$W9?-+X#v2&n_J)4jrhUJG>{TBvL7pl@Hdsn}n-=-qAWuGR|atr{k*>VKuFQnN5S zD4M*f4*=9letPQ|*F8)vAJS_4L2$Re%{1()f5ylQvH-T@pWgsn1mt4`(AX2y#SNNR zC@pDULdS~$v*s3BrANtAiQsp{<4)|F%8jH#eH<){1G~L>Enltlc9?C#|D%R~d|2{T z*F_VVWWX{5nMgcME8&r+Oi2JIoa-kpi%1q zUU+>-&4QxAj{ZKOk=ZrJKXV|6#=Q7vjsmpA2-T$6KrnZL_{-@XUg5BdE9z)b#Jb@| ztV?)Xc=6%SssDMj_MZHvVr=p}x;IBYe(ncVAwXxa3i-R3*E z;umJ<)US(!-i~g6J#1hu_)oj%D#5UPW5KWHgiVIVKFPv+tBp#zbB53BSwrMk*ba!ZAo4@QyQo3G zv59$$P1uk^8#6=yJwvSl20>eo#j`!qT02j7w36=A1nUfzB+|r;M0MYBQdQC|Q+l0U zWXNUs7Z+l{Os8%tCXb<87*(mrZPs#|d*ziNDSNVGknKzX^h^*t=TJ`Pf33Zi_S6zC zgY$=0QLkLAb_xoE7ns}9E755);4PHEq_fGqHt=p|RtUa=0;utQl;M*xk!ti2OznohkQ8G8G-;q-P7aP=j$uQCe~YUE>&!LJBh`#5;F8a$K;)5%jezYe_ICsN?~LGl2ke6d zbJv_ZkpQT-;gHU^shK}BTU)q}P01#AUadU2`!3sYN_#F3RHPRD+G)h2htq45(@`{k zhVKTELTdfwfJGsx@5OB9Xk_Mnu_KteMJ#GH?RP9ElxBBm+olp9caOvu1+cY#Nl1=q#3*%UMQwR z&HqYW0ndAJ5gM5E)(r{VGPw~ryC~<@aF=EMHC-h|WyjO0H_MA$os$v0RS_`AUd(4e z`gtu-h{08|j$6+ne`E+9H|pzszDotKY7$qCYPX(dNUHjbV8=~X5@oM=@#e_B_Fb8-E;6fDMjUR5s> zUfJVl7^CGr=(r(kuq@ozeP?dBI~(3s(~Jf`OkySsl$p9kUsdF^nH)ZY(U2#A2dK>x zl47i)I;CusIaZ*^fpMQPvEBO0Z%6ZZX3Ozn0h%ZP9bqZ*Puqp9Gk-x;dclzQg&!qty{2iRC!CM-B*}3# zPtqMZ*EdoLZIbWW0P7F+WS&JIdXLqLE)YI@ZndSs@NQpB&q2OtqeM(tw9xT=2i+%j zh_I(E^c?w6f)7qWK zTR{IaoaA~D6FcZnFDJYG^=|%#B06`ZkdbgzZ?fX^H>&c!h!ti$2EKnnT{SE@i@LId zI_buwtc?1$gb2fdv)?y4LCzgTDtYC$Vp5l09_E_=F0>y65ZlUi0XN0t)-8=sIYD`1 zMXRI_f8eWXZJ4pssp!s{_BVy!l^J!9`Q0bU%c;C!$n>Wem0I|363wBZ{Z?>)`mvMu=Az7TSjGwu@A1c$}c}fH1uyVU5d#xG#Gr0<9YrsewXc)h& zyCbp%k>_=53d9`M@*15apdN8tKYpLYf2)B=d~$b(?tVE5fFIB88U0!^|1h;qtn68% z?PL!EzfQZlK}U773v9z|?;@lTMRnwi4fPVeF3agBYznk0*2>?Jes)*NgXo02jwiM? z6%dXLPx7{Y5wqHb9WQ%mQSvR;Ku}JLMv*G5L}TOD=G%BiESsBX85LcNI%2lVf8zwU z{GvAaQ(gNFBe^~4RXR(O>$azTZ@>SGGg8E{0;y&kDKdkoM_Tz4|I+UntbXU+?{oZd zKSm@y_L7-VNxmJU@7bpqUnkBc9t|(oKtA;g%OQtCmPrJ>G{W$>h%mA{cO`&>6{xeO zrKDTwb6DeF$O9xSLoj+unC!QWf6gjp7#`&Rk1`lqxN{~qyDO?Txked?y9-T3+uK9n z)ob-JSqa7U4h=1Q=j(OjAZdbkyr|zwtl%`bOM-C&{o7cp3CFk8VpDL!k@6!M>&;)7 z!k3{{j$;V(?{RunIW|>#*K@8jGx&I4c;CakMwxI`6=pwDb=;S*LT2g8fA>RHU75s7 z`?eObpq?VgJAXi`1_Yf7e+|0v)pyj%S>DEeE&yv&5Xc&7FcjBR6zw7qZ1%Slm8Kkg zZ!`w4ISZ54+HUmzY%2kmEOQA_34#f9vM1&cVF4>##F#Z5n`#h-O3xD)zaS$^nYjdG z2kO5I0%|?ji~5hDToga3dCn9}U`*OHA@K4Su06Zv8JkF1CU%rBf0fwOO0&4wQ4wb^ zLD(HfQR~hfjM{piA z4MV`ycI+Dq^2YYVpP1Jv6XMQ$&{oHg47)#=b11>0qhyOFRk}%kS}Jdl-s2=}@r2*d zV!H{KSI~+u_^xuX?6{ML`Av5-8JRVEsi(C>UmO!FM5qrcf1na&HANNpES^KB)wIE)lIr8Iwq7Z)Jo46}>gi8?7YzC!DLQMW-w| zVd@<~e|)}y?gx@`JnvUYCAR8A#sxi3?c$>~7@ySpE?TOvh|bnzeE)*Lm_uY19nGfU z>u=M`kGm1hFmjb(DGe_Q-2`VzouPQXL9e`yLBTMR>4YQ_YhmD|xVME(0d+kK%uYt& zXJ(=w57N+Mv_c!#+fd|GdziDUdm7HBAJOhme~%L{8R5ORS)qJF@k2L;bDQkJ350eYg%p zC3HzgN7jA*$-8GRc<6*QsPDf(-3wTXrWeQf-Lk6zmjdYeuN_l}>L`0?+fS@secL1` zf5Vz`VFvo1d-iVv$a?!$73EGjAvTP?A11@As3tPRvaEhp?PI+O`n>AECEuD!ak}Cn zIH^=ChfQ@x+=_8r88q<8C-AQ`OzMt5_`rgw|2>uF+pY1JZ}Yn4yRmrkd_Zf$GARtC zp@S+ZoO=3V;zHPNHxV&Tt-Z0uoJmJ(f2}63;&yEjZ7IqDK&D|px93eID1iZihdKts zD6E)G0+2!G{Ce%ACX(r^KLmp!rH)OrQxr#|#Dk#R3eOKjk7zjMeYeO%5|X6q}wB!IrB`ZhRX||NRQKq9^%CmTZPD7|8BTq_MsDfBf(% zm%96x1YFRj6?h#}zzO?J!+#@4cp@Eu|KVozE8RB+GIbZmTdHQ<077YQ>3wiozH)7U z>mSx1lU0WCJdcFz5IU7lbTU-lPEp*yJ36!`nKhgF(Q}|&@DmnpAO@gu%Sv;sIlt zCU=8P+QnN-5QjBZabfz*3)tBJ3Vh$o@ynCPW$+oKfXdi;V40SKxMW)~M55~w$d!|W zqBP6bF|AjLUTSMWTa|u_UHr5k|BuXTby)?|2JvA$s7~PPz#XILqa~{&e^!EMjbj&7 z7X@K1$3_CPR1_2Jx2aroy-?bk^`t`FHS>8)DBZej2o=bzazAC**A$OyPKb3Blm0mx5RNfZn&+4B#bDn&)$HeK z!^~X?`V03TqD&RL>nxHOMYJz`l!3p0Hl6e^F}ZCJDmfQA)TL?_J1Qbp;rX7E zueE0ywb`Ijj_(ooH7W0YM8VqtPjfYbbzE(=7dF2|o(y=gN`$=>04YccqY@QY<$QvH+({(8$Ulud^> z0`#M}Fr3wF4emC*Hen&ZS4HITq1xWpVrycek@6x#TKKqyf2fq=M?_ZRh=_djcD%nZ zc#6;-LQl!Z3ylIH;avP_6IeEb>tSKUpHd)cPPthsqWP7)C+x^2NqD|ILcNul0w#39 z6J-4sbLD}6dA<0+xPYp^%8M@d(M1~fi0uG&FuVYC&n^f8#Ofz9LcM#HvuiFOs|OnP zG_TvfUF0y2e;bLTF&R3jOV=ta>Hg^>=0YCkI3=mk2NnYeVF?~O^NWP6w~QL36=_VXlnvik&SDGnp{Mc*ICLX(WRd7e}0vhax$0$66Mtj4G*K@`k+EC z*i;ntR65tqsri`2a}}n{5y}&is7{~;g-z-8KE#3%KoI}PwO$WG_7l58ERs=p2!}2P z8Ecv2#DGx167B4oz&20x5!6MAR?#j`lIld^t<(o!h7kDNSzae^MXy-E%L2IRCD*NK zDIa;te@t?DcHccFtrf#^Hn5-@DAa^_=^_4eCDh&+9c3k`rtB?|aR%y;O;Tp|J_)&F zS0tS@3``3^{J=eiXyjrBXII6Ngu&1qKtC!ZZ<=p4P`i?eC+y3A6c~Lq&VB=7r$m%*Mbf(^Ri6wkDH!#4sBhJH4VeoBqog z-BtroBK-HdsnlprHQKgG(AoKohfItnN$KYR<8@2BBPov~OOoe}dEh z3(7IVNv~%Iv-8=zGg$3s7jL^Jg6W5sSnM$b7NukNjh%U(zL=r0U77C;FJgWVq5l63 z>x_)~Jm14~%2G+cP*Ic%bIhYeZ>5ia;finCJzGCuBuZ5jt@wR7^yan^xZkR>EGZB@+e=#M$h-kSo*u4z$jm|jS;`9Xo?})pO4=e8$;|iZJ z&G8`did%v5R96B?$etrCx)R5*E*pR5ILheHfrTwDN;cuIsQyX3e-$%;zxJFS z)JGLrw7X{pzOn^_*K>z_XJ0@%^Vzw8^k zub5o#|9wudJ4P=7|CI^_e}Y+rV?kfvu?F!f5EFCB{ki37LakVnaBToWS#jJu(&{LQ zQS~cxKTcK_gG@G&6!Eq55ziq5*Y2AMqN=!7?;_G6x0XMbN~Qb-tM#Ug-UBchTVQZoR}15Y-UbWqF~f9&lBga8Nek;8B4 zoH0U}Q(m!Fedm#_Lm63dr=zYMNDcjZ@2jJVTH)GR!;LCdK{&6fKlq5jcH6RPS7PJW zGa4+J;dt3q>PjkUGzIWfeV-P6rDIs{By!gTh!AqfF#!q#Vc3NmM!1v_!oq`5{&O07 z31duN@$#3C^YL?Ye;cOkFdhT){_1Es?kg7_4hO%V)&Fb6pw3A`pEd_~-}>e{I|6U{ zRlYN`Bl*M#8pa^1a5;Fv7Lu@;5|dn}P*ulRFn8f01s3A2%#q^X(0Iq;%b_ z5VFE^WPkU%-m{IU3Nbk?%vJ%a^D1y<{fO~lOMwr-qk-(hu~b#F73r;m{o8m4$&Cfu zXJEqeWa!Z^1EC?lGx^7+!xV#!D~Y9iJRiHS@x?-Q7<32kenduBv@0i$Za9lDfd~HW1 zK#7tEYl19g$99bTHGh;MT@nnIQw>;BeG%S|j#pAk0{Iz`PrzRUsJ~E_DLj207-E=2 zI+TCxXc%#s^nxspqoZqLM0&nc&=(S1d(C2T&c+)af9b_KR1@asi&uIo`$YR_+&+g! zUC7R!t}hW1o3mP)72u=Sc?}KTM!douSboHa<0!m9mT$>;bExBKpX5Zt-i!UU`7SNy zWo3MBtE$$Kbpjd!yn4dLKIJ60`;>(VZ`feu)dh1@Q`&2N~e^>qRafu z7VNZrru@kQGgHOq)i(Z@I$%w(keJw)-4mQ~e_ydEsl*Ngr5Cc5_lxb80qH*Fd$ueq zMn$5@ypZL=Zp55x7!sN3KcFcGSV>XhGP#V`^}6Q5R7UOSX~Ml$ZXeHhiu{pHno_m? z(B)iIzI+f4o@RI(ATY~fI18|2{4 z30&ML_AT0y5nD5+HCx87g)Mq`ZZF2@)xl1)CZb@}=%}>*5N_``&~#v8OtwRZ2Jrmc zsx6<`CDv^NxTY~BIH=9K0{vE&SYu2Se+r2p{JusswDWa!i}op!B!FysGE|er{zL50 zppd2jB6VSmCOCN1(`W$HYcCI)T}niSE!|}H6gp8t&2F75c{kI;O$*6>Lv)kKZh`oQ zMZTQk>3{~ys)y)@9+OoEKInivialQK(YBCpBZ7fNc~Z94yuJa-vuRA5quOnaf11Gk zm954U6`#T%LOaU{ExSZUH=nCzQ0K3@fdr-S3BqRkQn^A)WKnk1X{epl0;oil9FGy0 zS`9NCWBz0*cIC=^)J1#Yz~jDtU8o4t*s$s}Vi~E_hU&~9;JL7s%C<>$tT06JzlOi| zb%7~B7pSI{ef7ojp^2<#HLpl)f6QwTnMQHd-b?>~;pA}vw05f9s8p#VlzBK{PoRG` zL;|TbCED5|+ED4UMO540U&Jiq?;Gw$4j@Nw0$clid5YxMB=U$t;(AZ7H;O5o6f2cqMwIVgm z##NL5bk{QP>Z?5=OxF}KGm#aE(<8%s5}#f0S2})o{ndtycI_M`&>t~HM`uqz_KA7D z<(uphPcuGYldA!V&Z~$4lD}xNsFH2-glY8|fB3$hHw{3Sh(aZR-PPu^V{H$9utDg& zej@znr=PwD9Y~8j1#b>Xe|$2IXvt>iVLRRodvw{!qgm&kwI9vF1xHm=;e|g+FoThn zozB{Ee+O2bJUnJ-^2koNW`vSAjKPBMfjS^21R)H*UKK>?KziGYX*RR-8Z#0AR^e*9 z;0ccLiwxYnIh>7zg=@MJ0!B@c=rCG6XOPvW)7h(H?t%rMDF%gze>@{<9gh^2E3LOQ z+V345?~{7tgn-p+^=zE$ghbiu|Mb^25=E)KC` zZittiL4~AP3fjS#VD*035si1v>cs!m20{N7FtAD^?xAJv_Ul92?F>cId`})~D^iYC zR}&S^Hj1HUL@BO_e;r2o?`53Zu;SB51BQTMBSTkesvJr$k+sUpxW@T0(obI)@N@W_ z0Pz86yb#DD5>omp=&IIRb4+f>Uda)@n+sLgoJ64;RLkj$@X4ixBiQu-lPeV(3rvyy zf$+2osLvN7bXUgn7gpwsOuqiM!i_LN+8@b-{Ci}D#hp|1fBHD$jC=bnfDu$;E`M|a zxU{m{IDRIfBXwc|WDOSA89bA!s@WZqh?YeJnlPYVH5hdmg~R1}lK3N0<1L=+5}jEz z6NQEPGtj9jLo-qQpWu9so%5@aX*}#w$|a(R26(@eTY)To_L`xyEL=f`0Q==(LbqBZs(0-z|?xe@h?M*_CJ9XSWcftB-!FGEpqb zh@~XuE4S7xh(ky|z7_I(BX!-Osr!p3Gs2d*MqC;Szd3b);}z_?h>~yKQ~-%tJUAap z_@-oZQbHr)(i0PYpI5_MwDtK+Y}s4-2BP?sC%qEHfe4(sTtgqi%v0h6z1`(G$zi&~ zNR64Be{&+f4}0h6#U~OCi}Hvgn&@ip&R7X^Ae<~q@cphP1RLkp`ISUf#iFZTKR@$UlNm;FlFwDfIb|z(JaYNHjLm#Qaf>cB`{_|G^67nwdYi)=Fl3Y z@a`w>0|pPL3Ha$Mg1SR+4KS9vCDcE1t@XAz8-5%zI$DmFyyY} zpk3v01!wBst#pqY->ZLEOM$a93ggkXA(3(0qWTs$Zl2@OG9kXs2f^ca5;f?5I&Z@+es&4CNbOi=z*Dkjm|{1O*o?~? z%07332ZCo4v@LZ}`&fobtGDW@jr59MNK#5w!#OqwD-HwEB$mz7wx0I#8qHX=LVQ?M z9dM-gfT452ukdMBC}9BH-HQ?YUU#TCf4d)#WiL&=pY95H32<%;pKI;AwkHC&MJgqA z<`K+8k~02KfdXIOsmO{K4QeSlTx2aIQV8Q$G%6;3-J&sEyd&xlb%Prg9Hss=IPFHA zG7|-iZa4WMD!9=fcbK^viB;$7lID0V(rtCA)Sj3=aaJ|FQ?-$Xe^bJwcFMQqHjMjFt~}bjuGTJ+eWeTgh!vB|Iha!t ztcyKo^1AmVaB*O#2Sayv)=lI zKSTfN5bBq8fKvZ6#M1P}qg-XR*h=WpLY<)e-YEuDwkXgo=c8q#O>0;;;*_=Ch#ELr`bcxv_nMvaQ;i|=6hhim%ZMxIbZFKLoilS5- zFpsfrJk9l5g}{c_jE2EsG|NxGS8o328~|YHuHu;jip@YTP}*_o;c9qbsPH_(|Nf1#3tm<?Tf$O66M7N=)ee@wV^X$aVc56Hhqmy4Og3i!UC2X9{dlc3Srnn0li^uoE7Mb(2pw+ zP4k>DETb#Jc%AP~YU>KWBa^iPN6eyDa7gyc+Fi46RunEjm1R+X(ylNEdsTtbREH$MpDspSJ&?E@D zEfMsoaDs7{kXihdpY`(cZa{>|5kbycbu-Q z=onUK>h6xe^==;n44dbzxtBc{v~|Oxzbq~65OdFcezh%7OJF^S2wR%oKal$q=IGGw zkT4tmx=h+*f9TSPrhfWyq{_SG-4xjZ2RpAcnFSFkrWAk|5N2Hk@ma@|6XL9K;PUU4 z{4k!#Vg3v(yc(AU%IrN2Rl8+%hAc3oaly?h#c z!F}!F6J) zp$OO86lYIFiBAW9pAt>&?g2E)3lPJ*qUMAhN|Ro|V;Y!x(n2N#;Tct;1%TzqR{0%} zkRH}Afa5s&x9kd0tl6{^yro}jiBgHW8Y4XNQonZTf~Y#AMJYQ>+y8;1BMkluI-K%qg;9gt;OEY)pJ+jfaT zWhW0Wu)zF+dpFB25n7+}EW7qKCL!=Q>7v7ycd`JuS=>De5wV{jM;tS>&s@4zPM+aW zt8@jBO=~#8@^9&6O3f|)+odS%;xvo#IBZW-e_zh5LMMHQKN6f>a;Z-M|DFA9D7xGT zeF$k@U@0(GBFtc<-(Sn9rsC1Z+&R$w>ty?K2A)Ych@NMYR5Z6^36i?lWLU)0PC&WH z5agqU@YVF;Br8rLzfYZ;_oR6&3tYm6i)m&)a}nS7gS?wY6z8JJkhUmIs1HRCRO{k;4XRyn%Qa04^At@wiFf<6?)X7MutP4K8=@ zfw^se(_~9!*){7`tD8mwL6Q(@`QkhPe_^=5Y8`H*$$xBQ&?lj;6=_4T@_|f|i`aw* zJ>XXQ%=Bi3`WSV5xBf!JbV&0xKFs96Aa;QTe!y(xKlFIm_At($Zn&QnOC=|ygN|hi zOmClTwi~FT&`%1hz^C`Xat*I0Q=Q>U$uZoA#K9%XEEyQA(n+N*?N%+Qzl2|ue~;%| z`fnfub_mU8Y9VD49R}UMd>LkbS)VIexYEYLLcrfroYOmF?_+77eHzjU z3Uwf58!TOM&I30tMazVCF!`CgSnLe7!_r3=bkbD7(~=4C9?q&-crTp2&3Wn#&GDi-CP~3%B?| zLU?{mQPw5_BZzS;i8{&xS!hybpVYaDFMzCiIHMPICKIY<{q{@V$cSUlF3>#GI1;97#QwRBp-#sEeVsoK0#)0?e<8urUGBiL z)aSKwCeE7~9F1aEc0=Idb&`aY`2UVd^-bm}S6D++Qf;;vG{&0kDKoV5f#4TOqEom6 z9VBp-wqdg0CvZ5nqw+a*_!D;?sF#DS+49@A0v^Gp_kf@rxgRdPaHJ+PGs2Mql-g7i zf8|LXm?R>Gbng%9tF0xRf3tjq>()s)AKH7KKAV45LZpy~nF-}BoPe_m+XRwS4;7N>?wI4RhoX$HYd8IATaVn>vt%n4J&R+wKLE=e>wFLm$8&;%==sQ zXP*St24~|;4rlyJ{1hr}CO$Hzm=KmO>uz_m zngS@ciWKIUP!o%4yUvlLJp6&+nSS}OF*%r%w+~%kS%&*LfB3a+ZPHu#q+3Z|I<)D8-_&i zC_}-NBIEj8d%W8nmjpa-?fNT8jM=j(huxaqu8(xu!?S1)f9{498pZjyqWuIX<;gg9 zupA?+pD1pBe=3%8f^QrBOHyE^~)i>X-^=DQ8wc(f7A*@!?dAyd9UGX2C=aeR4^>Lkv=Ru4vS=0wc0 zAgisTe(b43CYd}Kf7L-jS>Ont;%j$>`w^(ey&D=| z6wRU~2Mmp!WR5p|FMak5u@#$8ih{Sdi>vtUOd1%iCo*ESroH#+m;qg z@BraD=o~oM%y%7Y*VJ8Bj#VuYsk|+4wd|H&aP$z%T?tf8Wsex`lu<6EgT3a{#rgTF zj#?hme`lZtfD>=dF4=o`+=vozv+bF)!5{V$yiv{GmpCU?=Do1HG}fDU=F?c)Xa}>a z0FD#wPaENQ%RNkVHb_2Byh6s8S%L>iG|N>bZ;sZHzaRB`s`JLU5=jwaHG?7)e>kpWGlBDZxim+A$#9SixAs2o2TQ2HzVK zvKFpyCb>!&U(uOnpbuK6ab3bBgdJY(OfzU>>=53;&P&- ze*-h7<2LhH7WR#M(^x++pcyN&M(v;uJy!_@J&kE*x*%&GU>V|VZ!2i@uxp=|vr!c+ z(`AYG0tht()8ZmP1U{4-nbi}5MzlFWXnb!G$iRpt9|~t=4q&T{c^Dsm+021|tN)8Y zaTiy?*q6eo1N6g;7;ABvf&|ZQztPORe@kOLPbK$Sxkt3+6tAb~3?#?VGfr`);VVZB zN!;CyEER;S1>BiCsXd$jwqxoHHr~A(9J%jk7CQrexBMR>hbuvkbQvS!2ZGo+ z=0r2`ho+*}+6jkdu8{(1T$9fEQxC_Mj4|z44UEk;aUW2Z;$=-rhLLFDdqoJLf2ZPZ z$KY_y(VjTjgWQiRMG}{89=g5Q!TwA6XJJ)I?RPN}q@PV#{#FeoksTCYHp&#l7ee?d zV9F}-tmiA1b~Y*)UF(!kQyq&!&WHIM_(&3ndfx9fsxBPHZCgEHlqF;fm6iEFJ9(}B zG)NnFUs&Gzmvq9|A_M>b!zo2_f2-+rzK@YmVbsDPXr{i==g>Z6&-~0;~guR zt$q?~vKd_pt>1RCW2lAdeP)9txRA$uRBLT3?dLYI3zH8m$}wLe1-1p|$i8JwX$kiu z`V=x?GqS=5$Q*r@+69RR?aM%VMc;F83Ir@Avge(SMAYu^JVXLPaPf1O(4x(;Kf zh&dUMqB{iK9hkCwBS_9yYQi;z6W$_mPZ=m~3Lf;|i5od2$pMN1*4vX1aXJWM)lCTd z$lr za{zXqcB?VTUl%$738;UYf0#ySqpb0aBY|Mi5E>cPs#4hMS!~9e8HU>(37$C9xqrm{ z0c`$3)tbw;dJ3GfKIkV|_);u%kAS%V95&tvP`;}JO%sCm@=W*z!pPvlO5hUfs_ZK{ zfOp^bG^uG90ZrhsMk?&o1GG7k-VTW(y~RzN{qZvT-0!Fa8Cs6Of1U!eOh^;4ux;34 z{v(9P)aC z-4$^Dt{h4>Gg@bGf568AZV~lc>zp5Ezj{C8_8!(*WQV_K|| zBgFDdw&viE31*fcuK`QrYQVM<@)+)=F-drg4S*BPt`uW@e@qZHS-1Od%{G6A7@q~4 zgN+rL37Wi^SJ32VXc)(9K9fHG|YtoX(I#CtA(4S&nYLSkTais z5Xq@bnD5VK_U92Mez?|~J`dAfw2H7ZUoF#(wRMqW-tk0G)(JYH@tOy1f~cyQGg<&g z(Pc>py){%@e-7rpk}P`;GSMh;7MC%iCqtEEeKlQ0qH**x#a5dGWv5&wkn#M9(;W@F zUSxuM3m8Gy)_m_$&{l>~#<~DVv8RbQ-^HTVti>exC0ZydV;X!5=&2iu^Dgp-D6{Lo z+>4BRlJAI3`M2;hJLu=R(3%WD=vjc(%Tql(l_$}Ef3d=`S9t5pR~1L=w0y8At8oBG z04B_v-3+AMPmJAn#wEjMau}SMc>SRs2!eB>Xj?<<$trQoeL25J?W?k{;g>THhVh&1 zY;}Ms!nu?4s(>0Y@;7qvS=2JmLm!pPrL*puFnv_l2FHKd?eR#o))izils=Pc$zhwRZ@qq_h0&`E&@%hi)5ax1d1Fnib!x)GHTOYS8I1Os$U%W znijCLKWwxkJA#LDws;{!tMRR`P#K$UnAZdj;2x^}K-PN@*g9A5WO8N(ohD$6mOf<- za!OxVgQLGr@{77hp$41OA2BD)Vpd9DkDi6Qf4zs^M!o3AcZD09=h%o9^mcv=kY4Yadq+y<@0zVODnogX+vp+EO-w~|yj>9FZ7A#^6Z#&6kI_ z?%=v(dQs&9BsG(Rx}|HiUZI~45<4XNe`7OYe$=tjxUP=|h)ciQh&>IdTh=gfdZ|(F zU9lb}i3>l_+r0%W%xwI9H7=epAeUHb*!k*B1ts-6wmJlchDM(^%} z>;o4w7huMNzkjHlki1lH{0y=K|NYc-CiN-z-0gHE7&QIT?@o-Yi#al2?U{@Pq&c|crLWIpQkj`zo6uZ!O+LHa35ONEHj zf%#Sqi{KHX4g75mvcCqJgUui+e*#n;Vt0VL=z}qRTiqKA!Q1;1VV>7BhCB~T$+<~M zLSrMVPnw8~8^XydY)(%{^1ZxIwLl#_-k<*>XEeG<(KW*C^KS?foG<;9@C`^^@l{!@ zIbW8G!2)D4b>gg)>Hr*&PE84PqqvH!HH;U2VHYZO#1iO`vN;5izt}RQf9}4>%nzlu z?XzTTe8CR~j_E?GqDGH7#RK?<@jIcVa#|0^O`H^gGrht#; zd^Uk~zS+_|&SvU6sF!&tm96Mq=h(I+)WX5fk_eW^tf>V`J@s^X22d+`w6HVy z^j!F_=2YSbgY0*egw$+df4G09GSlWtfcuEwI~cO~7|&Fab`eABY=Au7+lz5yn>taH z0JLw3`wrduZB38>?4$1mXX#K;vjwnqH7$r1O{4675bV-V=ro@vougwQ1C6_MB# zt>c%^5uM6K*7v33!B9Tg69!01bB7wgh5~{*E)p1#!xX)UXDprJe=YV6XN$}e#=?Nj zUln*Uh7!!7AKk|jr9mKz(fkQx)xS;RP93oWdV}=W( zUd&Z&EK>`Z;{wJO?FH`!Hf%0#fN>7$nw#8uYyTtq4s+qn;X!LaOPSBt1#tjG49`{i zEyk5BwUV-f$4pEyf7v2JZ`SX(sJd0aXO_suAC2Zw*7e})_2>@sg+%XEAQyYjot zBHIP(JH5eu!Cd14ao&_=Ftp*B?0rW~s&RkOGH$lnII!K^Y@D>5dsz{e$`rG>e;&q0 z%e5UTGqD&P?EsJ8O2^UBn)O@zjQh{3HyfK%jkkoAW-^Mi!$imRT@s4(9?4u3$_Ni^ zX5E+zGd{3SZ~cNYk6X?hHV(mhtw1%x+9 z=jVk~CQQ=?*MC4!XGCeNCTHZ5bjV2Ae1}d7FBe`8e>ubFh{|Z4rKSvE^9t!OGzr_ES3lc3ZNI+#NjVT)9yo_N z_Stcgg7tec-2=&|IhiG>Pp?^>2}B70OgI^zN;(jRB$>d`+`?^Wt48|>Ju&Lyp-_-y z7yM{pG7SsWnMutXy{O1hrHYJU+1vF-l>GoJK-9n77=NWbYG!t6{+W;>Gi6f6f6q8p z1cIi7WjA1lT{ARzeH9(AIkcowPi0o@3`UAq(tZ@LMYeLFbHlL($Hrvl-eQ#Z*cU|U zJ&S=@-sQtomp~El{crJ1|GsN%9ASEKLl6v3&&y|ku=vC3mAVq~R>omQ5aEm5NBmXk zE71|$z<;Q=u&!P2ZghG?uiTm5N6(UF^%askledQr+uKbO{mE!MyQgFKT}P&r*cjN% zXLE^}6W-wsZ4@Ty;{h`pEO1RQ#gzf?L>b@$>7)L=@k?OQ7e@cvD0{M5_jPnd+3Sav zS%K}z2Ydi?Ea!|vG!?0~I%nlzG|z_|p`$FT^?%a45}gN8-bV+dS1t6qGEHgULF7dE z3}~>FdMK}s@>&=&r6M#BWu*c|AXHAIA{HTj)NIz7%U%0MhcPMbX?5aieci=9{rxXRo83Lh0`+HJADn3wPZ8W*fNpd^_eqMo<rYL01Qpl7FP52`>O@SxWSI64LM2lx{|wU=^|wnk%Lmn^CD= z3GcOlz65CC2yfzmXG+m5bWv6MCd(aBQzqZ_WQ(Kbiw1HlH^cE%CHc7*DeKLIxA51S>8Ec>JJGGbjO;P1UvhzD4wMbU(ZmvQJ5t=1tS24k4U?#V zTLgf8cz-*~jw(LFiTT^YI)Ah#S}oOwLIHu!W2H#dDqdhJgi~$qjkYXA8!Vo|{t2j? zRhd(|mNPd!So1%w_l#;Ck7;CwOFSon2MMsh0PQZ)(keW23T*M$X~|OOL<=N9hf=zR z`-yDbn63Ucc!os1Pb)$VwjPk+R*ulC`U@PK)% z7Ws<~qkO)w)UiY6;}hs6O~|3BNaZ_0z^qv-Gbb{$G8@*@MzJXj-DVDpb$5AaTvIOxGtH{ooZ+XE4>v+n8l_r zs|fGR)k3s&fLs6ra@v@+bb3HdjIF-@Bwj)*dok}&JE!7j7k}n1%ZI~vSFq5u76Xl$ zrK7s#aaiCTuYX$N2f;IXUkrt}X56EvF~Z?_at(;JaE#v+g5B2pYYjlgR?kRhVQI!5 zR80=eT|Ao#6W<>c6qs%7dI&P#y}>i)?p5uWXXA3;ac|Yw*=-A z_%NgXV4%H_yym1!oV)TAiOXN63Zbyw7EifCQRQFZk$(;3yu0de&IDZ*Ivi2ICjQ+^ zmDEeUjt5}4zpwGNy<|>h?I+MOU0pN0*||3;fUoiAs8Q2})YHY@&X5}NfEm_eI5R;W z7x92c^~-V#^cW~sIn`+^P&V#X87fnRYgJ+Ja6FUt#0ve>Fy3ytqc}Hhypy}=qtq;abBwr_Lp#_08rwSvf3!h27t%Wg+|Pb|2a>C$RYdq1$n zWs3#Sa_bRWCwXFG$5Y@Q?yIcGQYMFh*)eSWD>{dT5 z(xL>z`nO-C<2{M^TNJU<(f|O}h%Q!e&HZrRmVbEXAsSB3&d->lkwsTe{?Sz8nHO(5 z4=^IONX*lvMRCi8n9ydw?qV*n?u1A+UA!AqpPcq~3Bnz4A$6Z(!Vx*t!*+{2Y|5(s z#&P$H&Ppe%+Z^7yyi4yOCIT;-W`k&iKqG;JM`k6@9ibYc1YI-R_M%K{o}h@Jp<9hl z4S&r9t%04LMB#u;3XKthc&Hf;)$!%QPEM0)OteKKsuZp9mnf!J6R7y3VdU;7NdJfAR5v zXHk4P6ky?gk^`O%Kh@9XlrPDh-H5CVZ#f|R{%bDXQ!xNcc`0?8Xl59Pj<~(1H9)T~ zrZyhEk+!obrrzLVDQ!Y+9d@KXF7bwQMRYj&yu4)vS_9k9_wMkaXX#-PK}iglPk#de zwvt-+7u*X*mr;jSSkYA8;{{ZjRY@sYstymJlWQwWQxCM{Ay5^c5wmTBGr5?`Qx)}v zk(l}9&=fJ2MLy!!wC}>t%~5>ORw39hr*G*^nS|lFGnt{}ingg}i0ICeL9qw>Vr4erIqPD$-Dd8pa zO$m(664UOXcduTmTx4VAAAcmcxrEa6bXL5tMmk2+2FAn9KivpGmY_}%iGQ#s`glgM z+Tf8yoEcmp{-mJ8QVx8{W-(4Qh{!vc_;s@Am>lQy$7ohaZ3Ca3tBFrEMmg>5O{1(N zhBt%*qb*XyB|0!gExfDiNI}|6@(%qsHd$X|2cWbL9UIkA=5`6S3-Y(HmGPqI<4o4q zBiXKqwj#E*fPed1WK`VT1o8mESI0yRBTxc$*r-)$U&-SZxyh5!?Xkxn zD~-+T3KzB*(z|Dns2z6DfFrvB#Ah~>R2~+^7wB9Io2CBZG<6E#wGKqBG8Yb3h>$6B zRX=?STyAqwV-$I+;%uqlECB#iqVRrk_kG9Wx@ZY~+(q zpSof6*5jMv|NSfa&UNaxk~%T+i3*mhwIlUu%&Z1zn6UK0-}t^ss&eRH0e!G##UgJ;AyY$FM?;q)AO7Tn?& zjfp*;U!x|GqmfO`(Vsqp*>gT*fiEy@4a#4?oVXf#Ll6b}@PAS6dXq4k#o&R%$q%Ya ztK9T8#QvBck=(L3KeM0_}m7~k+k-XIBB{nu!WY^XA{B?b1V5(CLBX7-%hLm%O@7&(xoWo{B zUal%9Qu>7R#DAQR35XqOCDZnP)|22Ho8SkSY}4U6M2=u&Ou4J}BWFJKK4Sq$+`K0F z!k9>-INZo8XALNHV!i<*+e0Dqy}W@gk*FEPdek8=5wZe>QO z31lG!YUlvIkK*G`W@|ljSc=-PHl{dal<6wd56InH1BNIeiNcnc#xipMXDHg#zAjfb zmR>CJCAczARarp<&D2yaIhrQw1J=?x=y0=O^x8lUR|8OT@p17KiPpk%J+t!E0cR?4 zzR$7V+kXXrwJ3!9=9f2IzXn2t^_J<7BzbtO2tq>dqv|)d+E1YpCn3UC+iuK~SPiP1 z2U?k6r0NkzE6CAUhNA*IBkD~*>T)YhmqdQ}5S;(c!;>%OdbvWFnmuGiU`3}Fx_~2( zp9AHTR%#o;t}P4Td8wPzbh}eO&@%XhA?&;(n12RS)GrmJyRX*M2b8FK!}$C2+w$TR zfZsb=MHe#5+tUn6r?NV1S12_E8C0rYG`8n z2_A8`^mS?1QpfmQED6RihZ_Eb8_od6p}77ry7Eq`OvJ*bo+ISf=jq}5Ju`*PKpGZ< zY?2V{0fONxp~@-gb5(!|bgII*@s@W$iYqv2t87!zo$<^C*ggi?IZ)*vR%_zqaevDB zxPIpdHynoV*2?)1tJ{=I=!;8v8770k=CNKN^u7npN=;FK4ReksH_CwKoAfj}iIJaP zGn#$#1Fv*?II<2UTK&Q)8-v|QBPm89RB&kLAllVv7pq}9>1W9CZleeeFaCa~TOT=; zG?Q3o)ER!tiw@hN)H2*lS!UCTMt{N7_~b|(uERLuV=QFJoT)2sDKLkOxSrS02XcC? z3ZiI6)gMuOS@8C`;r5>D*1LD$x~rb=%N?DvcYi`iUMAsgq0;x~9SA*Cq=*F4%f7~m zk6~Ozsl=jpIPVZ&1INzJea9$6>$#jfDaUdNS1PX&=yex+sDkpCiBvp~fPc&8>?D@W zWh7#l*oCt zTkbg)*lp%OxyDUU@0c($>!|Zy;3}mOZmvBwJZr*z_i*+2Ji*oNIazeVNSzvobBp%G z%cIA=%Ll2FIhz)#3c~G|TYrUyr>hY`&VX7O%29$pan_i}E83?6r~JEO8Br#pn9t~t zL|)+Ylp$S%s%$LBcRE5PB@KFKpV16Jq!+tXj5=+VeL^Mv1t6x-z`$ zakfUjpnrB=wD;Q(l$tSMu6I2!7t8(6&Wb(_>MEw9Ay`~Py{l1|K#TE{AJ0Y~ztGb5 zX|GfLv0qf*k-=^nJAY6J(Q?X@3T6|61<68EiJVt`fH}7y^PYUbh_CJAAg!43pv{Gm zAJETyk7~TlUTplN-J58uDQ7JSokE4ofK0pzFA7D=zlML7C^Bm&fL%_wx}>g ze};S#-fCCrn=L(=V!oW0OZDxGY3GWooPc|4I*6*th664{kRc`gG9>jxZY?Xvwpe?^ zq_cB51TorqM|#}gFU;GQHB|Q|=G++gsxv9%Y-p38K>GV~;1}Tu{&8M@1#$w z)Q7Tnbbrg8r@1Nv*)|BQ1P)NHla zjpRN#1bJVKRiK?Bi@pU@C;k2{jRF|{$yAP*%hz}k@~FFO#y?SfOnPZ$(L2xR(WhMM zOtJ*LOsWt~wqgMtNcu4W+z<73HXh#*=CzK6AMR#{zJJ15K3~@y67o&ez+wKQZwene z6TV-_IZuuphC(0_0qId2SVFc8MlN9?1rO(UJ1@Rg_~ks){8uNl-{@8NZmToxgVGQ2 zi$lA0|M6>+LUx)PA6%MAgx^iIrr=_95VjDVl>rh^c0@lr zOx#>RD3*UZo1smFF&=?u5L7~bXByZh9EOrfLVq4-nxEH4+98MN<@{%al6^xyeo6;^ zrX1V!J49Kv*=)j$@w-UPitg2yJ8`z9Dt&cukO88 zl{QBW0OguCd^q~E-~LPgd?XCrTu?O?CR$XW@NMadJxPp|YkKuHskW|c5X@%n6JYOw zf`1!GKSe>QnDYiQU%fqJckrv}ya^#b$>qi{yt$%`p}zkte}<{dV)oyXr7XD$_s_?P zKk6GFFVllQTBv?ob(9=prINeA&n%CNU#yji?Z)tJj@T`WVyTJx?-bkK=fiM*KY*IS z%YfQubTy)o?m`v_It+-vgQCs|Hs%tkd4FZ7J0zl5jPViAoXq6`*%x2A=VJ_H^-Dp& zr8(eZJ8}R*@Tz*zIxo{So!%1NAQ7Y@iJyyc>?%yxgUPkp4;ORstl(H2*+J@(MhuA> z`TZDfYTJ->T~V-@HfJ(r6jIX)+{y}y-S z7O^bUONT?AeAzU9_E5EXD}A7cjS>%Y^lg))$h_by+!>(KrTO`2eecQEtE$L_+t zKOPmEbk##gcnj1a~PQK1@SWaiH+pN(Y&k4^@a06R39(n|#w1Q2SlWZqD)PDSXq)^0) zC}R=fvO$##;M~f5dy|UirR*Bzhpcq8wdv`|>ip2R+9|?}=hxY4HVPaBFg~N}orh;| zr{6V^W7rjwGb$fur%sxeI)97s!G{f}2#6yIyJ2AdEJ@PQHTP$WYanQdMu(9uBdTZ{ zyfig2N4?@J4acKhtxpJ6z{8aEx>p+~zN?I8D6rqHY~=YbqDZxm=8`-7ZD} zM{nvobx*mi_jdt4l0N#B7N}rFhzUTQ3lW%fD`|S+5`2g@&Scz}%7422^t(!=Vm8ix z9Dm+E*xY|KAAH1unj`E5tJL-N?b3M{(V6xbQoSGLOOk;(3UDYgJfV*diknQQI3=cM zU!TU%E+4)&6lySKNhAvH>K$AT3#pyz$DWrF3J>)5w)^b_xsz{K^+565=Q!A)nH8#8 z5nTPT*$WzTr%Jf^`F{f-z-+k-(F^@gRcz)~toG-vvw#t$&gw1S82h$w4aCpt1oqE2 z9#pgsM2ZwzU!L7m)oO2@Vn(y&YV5b05w>d}%GwfvNi@6v9c*mgL}VuBexE;3pq10EK>dSla8e%-^ZscJZyUFc>Tao;_5J^4T&r7yJO-135Z1;Gn<0fqT8dy*5If*<{Pp+b%-RB$;}Kb9Qj=zmeTvIAF};78csJvKoTu&GI|%W z`8#TF$ zU_B^4R)1~oQsMlxJwi|&mIrwx7JdYDVNC4DTrz&y_{aP}#HzruZ({)R7RsJH5Z|8v z0%#aMzK?FM@iKHUPmw4?Y9VO4{^mA~{&ss)@E)p8QNOM{#PFS4Z@mEs zy8dP%TBy#PDmJSUpBqg}1q?jEn2ce zo@SZ;X-wDFbxGfM`p>1-?y-~U21LpQ4u6y(%rFwWq)qmH<0%)>fE=-4wkC!9p}3p! z$TZr$OjKF)+@S^)km~31jSy%Rz<3CtY#6zZ3k@O}T`Px;^=+5a#oH?{L|~98L~F($=}o)w)D5kFy8!t(0)`1lyx`=}ZK%ih+YB2J^M60m z%CP5vb~mC1Q&4pxXEiatT@xl-hY%Y`|2y`Y%p^PlNKQ}avwTwS+YW>& z2v=xpyiCYh`Gz0R6|tsgqt(|)FYUV}xURY0|HCKVI2`+cuig%u*ON~KF3PNr@2N9* zbF}wz({TIPIPWpr+}PHdWWfYOB!68gZzUmpQMOf>o7D{F75;zCp`JTk;Daww4ku<1 zPwHl^Tg)|gS_#RnU|F*l?`G)%jOL07)i*4yyKxO|urvt~5hsPidWf0BH&S;sCL{;Y zNilt003?H0!jRtE zt0pOM@7>Wu+6jxpGzJUzGK4up6kdW?8v)IK(XIU63bf05KAp@ut^l3Cx>&=Y`asu_vT+*- znS&o`?@35Y2N2AVkMjx04!%nDm%cNH>Dt{8Ozf*`l)Xw5;(tS4SVLeN2FXA`O9s4M zN{vEHb9lG#7&|?+(88K~kIzNVa0U!C5(#iu2ui+W4j%q{nH1abgo+#~K;!__$79Ni zU-nB|ieG)V7On{XtwdG;2HulQ@6esXwec6R1vc#xO}4Z;6`R&cS%nSSr$NO2tVyXMXf&UhB}oA`SUK$ER4XuQz(7Al2!FTS z*19?&9k62mj7C$66<0OhN*~09BU8uPQS{w4wtp^apLA^9Q!$_}&jC8ZW~`mzY^d40 z20~jSV76R8g>UHMjfrvAm>xItmpD`{F98r$$5$CEtLct22$yb=jJw(K##tbX=b|xT z_ocEVfq+<2_o+Ogme+%oaBFOK8iDKyBABoy_xlC&Ge(ob- zV1M1|0=`1i-H|p`0=2ZRC>=~q-Jgg7+_Fpp^HInlPL?abecGwclG~kNzNH$~Uy!O2 zo>>R-%#d};d}C@SY8?Qg6`o4e}z6Kw^sLOANHe=n<@#FZEv|LGgO*bAf!Su#!OtDjl#vL z@s2P%M){lE;nqA-w)f|vddJ-PHP=#_L5U-rO>iJqAi5A1>2w@X>{HQBY)2k zMk7VLeqno7^y({ihbKll9q`GAfKA*xec4~y8AeXskZdZ{XPc-ff%EK<$?OR^0Cq=) ziL+Jtp@{>^qIvo7c|k>!dXtb3M|3&?KbP7a90N}`udIGq(s$LP5Aj5G4!h1L5kvf> zu@0kXvA#J-49l?rIM>wV9V1_!$bWl<00kU#W~j{Ce@WaSk7Sy1B^wD68eH1T^rchL zx$VcP{!(URq5ezf(I>^rD;?mi7pZ6Kn?FPlvEfv`?XtWvLz=T)YTM~SD{?Q zoYYcuuzeHgA?MVwXyU@p9DhJY0cGk+QPM+)l@~)0sK4KoG(CRts8iVzb=V9LWc?Dt z`f!iN8?$qwbpbOY%Z%vEs!%cK08TT7_{Wp!W_g^6=_gf2?GHhAy!1ydY6pa%+gFPg zQBZfi*`E~XX#2vHno%MXbAMYs5kuc8Fwu|fXgaM-sH)&uUnOn@FU&|B;X32K2S(_N z;{yj>Qwunvs-nMmI;!yZA~_WErkL2IJ2No8Zu z*jF7m0I03GsWFYoP8^S6Xx#%-a|aoQ{_UYL^n>m{L9ZjAf|>A-Wq*Kb+0^$#V*NAC zhFdu-mF|$DcT*ROP99%vveGn$_J~G~tl$P}_mL&G_*T3v!=BT>lw|!e<}^c&gcFJp z$wY<7)drJ@h-@D$jnGxB3Q1P1bcJ+~J%Tf7Ep12DIh?7bEPB%bOHCX~L)TVjqvA4E=Yt)Il&%oDUk z?973dbQp!oDd`TYN^iEjU=UF)8R;n15b?YS-m4O&~C&RNnst<^cM&1rqx#1o`a zi>(&eChy77rlsNIH;vcnWaC5U2lg4_gGJXDU{$#Cp6oEU`SA|=w$?B&?y?do*1_Y zyZf3i*A!Ea%d+CR8`@pIDwnqeti#&ee<%)#g-}-{NEfL6qbQtq{+$Qvj3ynpk23}~{EB&Du0+BTy$ilJ0~Cy9 zq7}+ojh0TxF=?^T_+XFiEC1k%UZ}zYT-PtC5)~u6pnFg0l5*+ zKz9Ms&^1m8%MNuMs3@JRG*ea4%fsQ>&40z_5w0$fdU|-Yw$?+{80PoOqK`CUHqT%5J>m}Eznmpi%i4S!enwsS zteX;3Hq3+--oExM8*@|ZP8%gzKJnzJ3&C-07F0x3I(;hbx{vy?Z0JR=k5Ov+7sLnz z5)#HD>Z&C1Rh!u3sfuYm)Pe3L8Gp~Bcw|lnZTr(fBgJ5{E7oovX5lQ2Vx9hX#13H| zU!1NBj`i^R0m>`r#UzFDf8xi8btOIbRz4MYYJ86TF*lQa$5+A!Qm3^ z<&;|a@-c@2#IFWIx-QE=jvNxDjLz9~o>3@(7M5t1dd)=o#+?k!t3r+`cMd#}EXZ zcEiaqEb4n{I$i#_)*Y1fU96-kgLFmB_7s1OKlj6l`Klk^Rek#W1&!f1A8!(#T_hNgFvhx7T`vHUASsqV^Zgy9b<4hiLJ8YQ<(RZl^lf<1{J01kr84}4 zQAB2V;oMQjNO|M4%A&-5@A~m|-$n9!+NdEA_rqax|GFz-D}TOsy8h6F*b)3)r#V() z_Jlyq$eT*e5z-1!hfX{TVnT3(BoGwIC?%ec;j8g zIBWoIa`Fa_x(GhX-RbxU5;+I*EketKW1-2pb;0eSf=^a$Ww&A;7D}Kmxg#2=mRW4d zCgLkqTMXppEKQr--4s{QhCxEou3BjMa#$ZKR!|PLtq9p(V^|)2u@p0h2RPJ2t+9r{lG>NJ&x%f`!G4QLNM}|ld5boY!n1C6%h+; zNFOHo1tDE9rIBJ#Lv{C!NtbB3I##uoE5qD75@9$);p~Q zVN2@r&?FJLfo~lv_Aa*#WFS{vaJgI@fY%%ZwFMdP7F87lRL>x@`DSciw`BGk;fExi z=JA#n!}X;mng;xx@7OLtpB2Q-n6g37lEu3RS5a{AaXF#2J{T97Bv+oFML;#e;q`QB zU4KT!A1On}Nwgr6!0FqyrN4V>Di4PGQ_+4xfL}mT&|4@-55iw56?0IXl2zfGuB_2+ z8Q*|=;RmYe4Fp~b07j!?vp;ptm?ytCntEZ2;v&RCkbi(EUJ37SpOF{ZkXTOrK+t#> zmLZX9U+tYAw(Wkd_2TTu;K>%3uM^qzR(}goOS@)+hdv>19uTeSSFXK3-3#g3V{NX* zJt_St>ZVN4GpY^1k^$Bm^jQ*xlK(jfsSP6~4m8p7G#jviU%9=Ds-a8}HrnIA%qcek zlqnL9j31taVnyFPqkFrJwz>T&Kjsgx-$TqCs#i{+)tW%!m70&5Fg*|rill6=%YVQB zyU}qJBeYhPmnExy;m;LPWq1b#NpuC?tISZC)?mIy2UWk|=0Y zZF&J`XrjgjbXq(VFX|AI#FidCAHSRWqrwm+&6aF4^`VcNjqbZ=cP#pX;eY>g1F&VSn6o1LOzs5&9LHhw!wag$X5)^iGMlH%vWCs@(gD3DX%t^VG@CfPoT41PaWMtrhJe4;sMIp34!m-P}krD zCz%iL==}?PCLhog*Jpe8h0t(YAqK9yL~IS*S~Dpj9IvULPPYUJ2!biq4GmE z5Vx8np5kO)6=3lb1+ML1$66ro#$5%)IPC{DMR`Ln#((sO8BQf5&}Vdg{JSHKv&kbz zjMiQco2ZXWv-8|}b6fW)AIIrG_op2{XRBhuzPdJxKpMYI!~9kC+CH!_1WLO5%&B4q zOu4;5XYv@7y@*^rd*F^T`Zt_|E}=SFC)cA^&b3KE}(OEmax0*vQz-% z6$?GgW{f_*rNkAOq2YZQ<9D_r##9hL{cWNplYc`y#_Dxt!iP2du##%w%@YZE`=0aF9>SsDPyZ+kD#!A-| zzF@JgI$3kTQP5>+*9O~Lv;QezY-+)JDT52&%QXl>Wuod0NmH~Juif40DCNjb< zz<>D))q?Ubci86OYQ~m(ch~u)v?-Qtt_o-dPGJ`IyRwz@yC@o)8Ll+*kOUt|Y&4pk z(F{Xj6-7Z>Mn2S&1QKNk(F3P)DE-uy$O7ivy>fdew4OQsWh&%#ShS*Q}0+F=&F-PL^efVMk?#- zm7_U!tI)AnCQ6qnQn|j3fU;Rw+XL36s;~ruh+G9N9SR?i^h~{Z9$lMO7~OPT&1@bw z6m_xYmS{LW9cv&*va9*`t~AcZU;B721s>%vT#DL5W;w2I_o{21f5x+~G1M)ME`L8v zqhNkAN_>E4{S3=?iZ!8Z>#fzWkXDY?2wb*=77lwf(so)WvvrPK@QCJGp zB|4qbeWIrJLExfx>ZU`|gP+}keujtjm$m9}eD!quyYH4h(jX@_oJm-lGhEunN8;8X zR`SCoPQx+)&;12hW2#2ee6RgD4V*9%-JgZdNd z5wuuM3;0$D415EsB^fReQLf@(lk{I-h5y0QiF8uO4+WIrF!jgfvV$JG%zuw&`R1fH zOR%wui}ge+YC40d0&F1U<>+0IJHz*1PW@IQ(?f4Zu-lTzbc=b|o-AYR`b_YMe8+ig zJCOK5`1>ur@NrzDox21zSZa1tWbI4JW0UG4U1hki7VxakY&&v-=i!jXD-dpi^3L&- zf5}l&#=cbO!0x43-Rp0b8-E%{r*DkRvkM7}Eb_%gfq3=~#Bp3pe%7e#>xiqK0D?iS z=sR-RT!WmscYN<$Sd&a?O}69&z1N6AI7L9o$4rPQG@Op&c{63MV~t;bE+c=2vl*jA z4s^9lhcnh$Bj74^nj{)f>{4S&cP)_c5-f)NNb zX<>-WKI0yFITA*ebjnBCc0_na`fHu{9d^7jSyY!7@R9)vjV_n3LWPaT7X!5f>P$Uv z(kO|KSTV00f`Kj=$5mxeksNwK;ti$)7tM)+<2wpksHF}A|9(h5L0!c10-2#br82-< zq_Ugw6m?eEvJIqbjzN>9!PUVgYoRX37}zQdH1L2$*=+5(cYjJHtP8++;4Wpd(&GzNwNS3!&drmYi6M z9MgSW*F2A*J~!tbk~@X8#18bES(u80x~yC1h(=SowB#cQ9j#&Kkd*~uhbkr0t_I^G z1&vF7HZd!>Gk>!^6b)=LR5&~3&s}^$VG0#PaZ-hieMEeH4a!eZ$VM%M$enH9<{OhG zM3ssot3?vMstD+y=VAFkNPsFBU%wc5qnx_&Qe#w3)fZO+e2RW*!MjHpiG%%MrIM>T zDGrY#C^k^_%LrxKfwlKJ@VP{V!+8&47%Ff{fdn#a`G3eL3PFkQ&h`r!Q$)=i(7!6; zY6zKl>QykNzR!Fb(~z^nmh&brvI1i)dQR9udgGpvEti3hUS&dPASBIC&k4oKo8(QP zRy{2z!7nvJ2ePq5wL1PQnOc8*jV++BDE^#>O-@>QYCqqyTu_G1lR8NN+-&c zW{(+{d7=lotpeiId6q9rcc)&_;bJCWU))Z54j!batoe`^9-U(MKF~HGDEVVwrz4>kLn(nC4YA zB`(b#h90}mIF|BUH$PgpcQ)rDd%S67G=EhZ0{GITf;Q3}E^CT1gBxsz0lthS?Kypq zPSI&$FJTn-W6>CCw^Q=HGr>OeGzyC-wimoHn0B@0*4QX$4UfNmvX8@c>Ye5`Mv^4@1M{)|CJ8aY$%dQACc6Tn!dTjq7ExEbz==Rtudw;7c zeTpEzwdMrli>^QlfR0g@T-7wJNVMMqiOE`#aYEd(G=tI2cq-tTpy*~5yzM+B`W2rD zK(K5Glm#0JYjG=cXM^Zr!i7ggy4SxyZc}P~s^WiOZVOiQ-zA!A4dbNiX~ch-T)L;y z>UqScrbbfM$Lpm7)eo}!8-+*zt%zI7Z&18Kp+4( zqsdYhUeWJ`y-E5UH8=+Trw?N>RA+UKy5aTFL}cnFgcltWQ%E5{MZyyRr!_X%Cy7-n za=#s2)K$~UqtzyxS8R}I2db-93(_|WSZYSN)lAL-0V!!do%0E`Ex_wI7Jr;5CXU%t zcFw6z8Zf%hZFe&u*XyZ9oHvi*&X0W42BZD&3KMN@J;@ zDwuc2h%y5tQ}f48-^&;3Mt>1bK#QW2gQ2^wD0iA*uvyM|+#x)h_H#AnxJ~@b@(6p5 z(Bmo+sh!U zEX%5~ZvE$q>2Zz<@g_=<3F)~Y@!RBQR+J3&;rC1EC9RT6t_p8S&}((A)u-5ZiN+#z z=>H&;BmG1v$O52<0s`izC@Z)E`DB-3E}Anl`r2U_sK0lg6zCNUd6u^d6Gm!^as0KX zk>0NX)AlZwE@5_6dVf5P1{+RVtm>e)4d>6^qsO&@ZQYXg%TRq1ri=lL>IbFy!Z4E4 z^|q;LXl)~9tu%lku+TLc_ytsNVF`&HyLMn)5J>^vAR*sLo)_R|yKEqE?Q4maiG9-eqkdAZ zU^Q!T-RoJXa6Q&!YY){s7lY5}0LF}AqsX=WHkVYwvq%fc43b4)(%p0YcjRngakBL3 zT1|L#THH0mSmuKAn$>@du`-foDuVUF^JBE~X_GzIy4$*ei1DG>-@IhSC^t>Q13!21 z->#)Eqp_EXg`VH5wBi8mXn%HU*On?+(FQ!S<_Vbv@m@*DWC;i(t3>VNupnS36gOLmYpMguP>N?OKRQZyl>n zDZ%ZUgnNoTO96g%gw4KwdnH#%s9($jhGxhJ%tu!fC)*gOwx?jIOGgSt1SsW3&vx{v z2_NO2Lw(xDNp{N^36!qSn>r3@@gs@6)Y-TeYQBFpu}B@cCmYfrq-joGSDmCRamg@> zIm^QaNzBvt$lHIR#wqm21umU>kHA1DkEL1^%qs#b0@$_X?5BRd%`lcWqe=&P zP7N{k$??npwg37EbO`RYd|#lPJ13E5w6CzEDPcYx*hYV;1GEL1g=CM0^7`$}I)u5w z^W1ODx8Og`TUG%9)7RcGDsC?%$qqio`c?3j?<9Mh8xpNvh&{xn9;szd4RTxnyG5TZ zZYw%y4lwV|T|n#CpA2(&KJHR2kiw&)!cXC=LvDml zxYjKj*gk)16)q(xHs6_oXT1(C!7PoC{)qM7xDpyMXXi3(!QnrwKrvg9+cYl}77f%c znsa?))GU?qRAqo&C~>VfdX9K%7QE}J{T)* zr8#@n&BBd?&MpSvb7ejl&udSFD23ZRB!2Gg%IIV+eJOu3$E$$hM;1e)R@NLO-_*nC z^e?s>onVoRTmNlZe*F7ELbCo>^u1G&5-%t6DeY4~Y|S3!@mKfA^W^1O5B;!REF+0D zJ-~k$2JZ7aozYT|^6xHT@~ET`q3_vgN4) zpX%}mLq|Vv;*H(77cmf{=2pE9$GI`=1s#28XS)vn1Laq#mR)BxEXk1! zev#URoWbd2E$yH?oTO5tEO&iB@)c)d;bMP(IHw9MI`_iwQOYXJ_?p=$vO(^8X#HqM6)EJY_L#9^UKKez_52R-5Obla(^_~I1>|-VrU|>YBnI{j|1EX zO?%g@yuk{^Oi*wL+Jy+ei#{ra(wHIJYKaX_ZT59nJmC#8>m<(SB=4iruLvple~^Fq z`9|0^HH-_T+RcSgIdY89*x~6!`1cHN;rfXzFX`79+0)BVv=yco0h?rBg=MVqOJ6v37UOuFYO%oDmxz! z@*%oM8i|QU^;Yx1BM&rpK+>X4sj!c@0VJAxj!K>!pJa`Z3%Q*eSYLImsNxeJH+YKjTssY}bDzAhasi z{WvYQ1L;FMGe_^b0$>h>Mk5DmnK?2I|&_W@?WevibqhVB+X7keNEXha-JUrTnBNXuB0uStXCrwhD81VHn*VfBmz2eg!U^BmMp{VO|f5}khni6zXjl@~1K5exo;Ijgn~Hf6B3N79r$=t&YXW~sjK7Jq^PS;g?>w(gKS*~C2$nA;gV$g+I9i`gE`|?zA4Fd zwS|eu7`WgWMg8MCOFj2Etzqf)C8}x>U|C+JsIH}9#BM1S&ZW|!MK-ENM}$mn3OI%t zBKGDq^1E||OUFUiYEYF;a98XC4fTUb;;_YN5DibAXfP7#WiNkn|A0sjvTV>Bj-4Em zJmE%?f5(*j>91N{!Z+nZIxD$C!Z-y(I43437ZP2kwfc$bX>-yNW0O4tSD4;D0?o7? ze`_ZiiV1s{#q?wVgQ>vra&X*!RWG?4*Uuhfl7bnx<;pAZ5kFyPfRHQ$53Z8 zISPv}4b`A+BsYS~6(zIZ+_OAP(+?F-2rT;HpcV`fC7&pNaM!>OT$~X}e$q;l#N<+~^+DWdG57dpaTZ$S&WYa;>#ew8OH*?fUrim|`s?md=D! zx_GGU5+mVBwk`-oNE3(JrCj1a9(G>1pp7*B`rFGERvT;uy0EgI+x3T50ajFpw7L6` z{dh=>TV)AOfwL(MT)Jpx7RI>#;cj5^q5^+OpNAX_4gBGJ-v=)vi>e!2({oM60#=&@ z8>l*N;05p%CY=E}{f%Xs&gm|}rUK~Pubht0K}pIQ+VMwN5o7-^FePx9dc`Wkpf@Ca z1GXN(QB*~r74;+(*Sd?sxYZTm!R%)@RC_+#qbyDpz??DlrLzDrRLlk*`Se(y7{hXcfW++~L)Jzw`G6a4*0rB4aaNPl~Suj`RCnT4d0^D(Qu}Ecp zM2eKzqeQ~!6^pQ=jB-{{a{?)~Mf86JTzJcAc-y`{mTP>$^i-6(w`Xq9UC48kU zxyz|ow5f9b0ibFd+aW>SVbD|T(|)1D&8=?kdL333szZ<MZuE*(H5gA~H=I`32+fvUZF)k=Y{4%ya7xiMGpHGbC z1m9T36&flPUE5+ej#lnY{B-fS@W#dnC5RQH9;a(RgLM8HYIu%T={SEI-`X%L#ojIOuMO#5@EPB zj&mOQf1Jm^Bk*W@x>wsX1=OCYl$7rZsU#nsqECsd$+}pG z3EL;UL8(p4(T;yVxu<`fMVk~T-w+JHE2#+n_Cg5sXqT9S$$fWXl>-t5cn|A4pw=fe zKNou@{d%~>l}v~1Fu#64lJI(T25h?1vacUrF8`-8`z%9)e@_YMQtSO6&NcT9T2|-L znyBs?T!qYa1O9$#VW%zoE%#YOuIf0CP+{ENpQz=O4-KJ7dzgQ3SyR061Tdeb7;~Ic z#ypiBGkilEv!dIva7$x_ko0I9uoMW@IAo`L@p|@nMRAiCn1N96mm=dT{Cf-KUMhnc z(&!TTf_%e4=h%4gOV(%-xK=zM#f`HCwW5iZ3h3jQjb`s6ys~6kj7qDQ_XAuN@CC)% zAxuDBD0p(;j%t5WG=mRVf#$-Pu9Be9g)92gUxV{BUrOEYegMW}Gq~;u1(>G1k?7^+ z`cbqN+?Nx4{$Q`lB__Y?YpJi&HnhQowpse-xLU%1>JEEdMx3L)I`&4WqA3-l+G+Dd zVvty71=%6H<0F~zD`Fx8+%{BmkX{e_%Qi+LNH8xYVLE?Nj8H{J!+k!_#p!Dj&BSw` zh#eMzL_39xheq2zzRKel}U7md4ftTRY9khNBIf4lJs;9h%y9pQYIy&f1cHj+++(zQyfSjQEZ zS%BbAYz#Ukd?b-z%A&fYX1v8s4raRT(odN&nRQOOpsrGILUm0y3Qk!VS>T4c|z_roK1obfzpuT*^7 z=AefndVzRwi`9K8TUM|wtoGg)<8Z(hh%E` zDgS@BDGpnLLnhA-0bZVfQb7^64$P`^T7xvQZ>4oh98){T3P{Pg+YQU42MabDp=+xs zoOyyJKdacTBMCQ<%g7bL-}Rn8&LSEY~{IlPZ1(IcOq^ z3R4PLO{{`0imv(`?L1}3eBYd;w9wT6=s{#*Szn!BDlllG)Pc1G@d-1tLHv%q_}iIq z=+FDP4$OiPkWy1aK`cq!XJkMdS*A$SNfR{jw(3B@5Mv9O8VF%s7W54&Q;$J?0Ly=h zXCb>`<&ZBRIdh5`EN+#qm28|RmWX+V>laivtx1`P4xXh(8;E+&GpdY|u)fLGIx@EA ze!jy0XL1IOS9=-#)b?{}{$F)Fk8{sjrz9$Hp9(Knt%66TyIm~df7JygwXI){DRa&_EeO+WiAR5k7)iJ>oZowd9)4$!h;PlFs6EW4{S;M5N^3%w zB+e8m1Fqc*dm^A8dc+GFG-Owqya8qNV4RD3u84u1j*z+4f{VbWltJsED;w~R1|ds} zV`tyZjQaER}!-XyOi;C&`inr`}8@6y=I~7i6fr+?_a%~zCOGsjEfN7Cw=Y>Eb3gE2 zOXzxcw^o^pim@}%rd#ZkB$+Xa^+mt=Q$naUSTml_Ghft8GVro6j*j&~##opB{- zIh1;8SiSvFW5O%3p7RO#iO8+oE@^IKH*2SCwEd3|*Ne^`sj3>aKEHBl8?y{$ zT*>e@EAF7MIkatg^VJ&YMUTVRriJFBE=;YXoCqJ=#sts2nYUThpL5cwWC_g~h4QzG z7O`?-A!%A80^pW8Yurg8mSD;vA?YZ+F#T^`-a;kAf}t5FS^a;Ou;ZdUO0)&^q_`Sm zFSmDJU#e6^4pGYPRyjz?M*oOI4)a}SFmHWFhDp`j7M3K8EWEyLBlW?r}M2zy= z(y1rzrkT87!ifH!EzKl{E#)g>y78#8CG&G{XOu+LEhy z{fpL+JmX=@te5!|wFmR_iv#l{>NB^X+|xQV}K9AJusd4;4?FG`ep{hKoO+n{{9o}Sl0Gx%3@y)wVPcgR=z3ZBrwu_1v6D+Z zE((nU6mfqLNfO45cS-ABW|`IrpOOha`M$~#lSUxVnl?hFI1S?}<745E#mziF)n(@* z-u6b2D$0Oi6u*0GOwL2WQe591iuOZAX%tm}5Zr^lHpSiQTalq0 zGBcyWZf6A`x}!yUa)@lC8Yj*|W(%4HqzKua?E$o}_DF2-`q}7@C6+An<#@EWZ;dJv z?4#k{l?B*g=bacv)UY&U-0Q-RafAH;se*TBdbw>r%^P`25!*;H=pzeycyQxuV;+CO zC;VwWEO%@GfGYO2EhXeGM#34Nu zSdtT&V^WPkAA2ksh+TYz4hW;H{d$e|rYqMOB)G zXQsO3SNiVOSP@u6I#mgXk?uh^KYoAMDUW7=e@IR{e1pK*38BWK)95jyLyrL?EH$mg z`_{OiE`|Un)ZGU01;w@eJ+tJpxKLQXbg~T39PaNevoo$WRmu6#>>fP5J+Xju3rP=v zsj7ZOx24mZ`<_JVCkw!Vh;_P@Gb%b#KZW;aPgMcp#;Xkg5s&<58eIOoN@0JC+yN^0 zA8ue}5n$v`B4NHnkk^}2k+u(Cc|$x0=m7RdT3{8YED`;euzq6EQr+R_MSlZ8R4_gX z=Fa0yYaB0}S)!a&0u^`y8Sn^;bx?aazp~;2rpc1l+>e2&h9S!qa(lado!avfY8GyK zqVm3$e@y@4(z|r8B#rTk0!4qps2aFy9BcB;KBxboXr}0@N0l8Hy;pz~M7lxI?k>SO zPWwQN4DgT49((Ru+Gs38iIMZWTi^ zh8T)$;AO?Sm$*V9c;tO&an!-I%=fg6W_8mybWJNoO!5}8KmiITgEL^egeNdNAYiH_ zN%1gnzNsfmsSeJjK6zola=)ilFrd<4q+tI4lHT?vYy|@$-`)XRNC|wyKRteg(JvBe z!jnXZJ?t%^d(@>^REmH2F^clK8A|V_&f-_F*wR+oGP&44v+ABd(o~uM;0|1n>&#Hn zcm=WL^5E&WJyp}5j@|;W zAyUxFQt5i-BJ)ZKhpR{x7E4QqtL(X~_NNT+(w2?b^O)?2=gNOo(cJ0Px}jHk&0TNR zCm}e1R@vnRf5aV6z~dwsV)H(K>XUepj-y)4NJoE1uO;#KHD*5m_U>O&neXrhM>D5? zwEL61)dlfG**a*p20G=9>Ozrr1fi8kUP!D2;owh-)vAU>Ht$@;Wg8hAIxB^RzQdw) zVxX(&H?OMS455Fakgb^cwYZcZuRfhl98Z{w&u4duEJnIY%kUP#r+`Zu1+g9cg=wSl z{l|jdDUPhrzVI-PEJ~5NmgBV%sHRRb@J1L<75_A(n7inpC+&)}4c^s;5jlBC)mtD# zX8bnvXBb3Z@Nk71z%t4M`5o=Og!B;bc|R2}8z7#BO3!}`EW1rq%C@j~0=(D112ou; z?PY#dgc=Q?k{r6QqQ9V%j9W%JULi$cSVql9&dQv0-yu$sUMKV`=xaq0PQ*aXXYC_N zB@f$G;L?IFE6;ee|0~i-UO2_VfNQTSG-hQrk(&iOd4~eng)aV!Jl6c5Y=awNx$wa< zhhNjVuQY$?4Vr&;ghmpeQ+`~SjUhn= zj|VNK8ww;0R!PrGU2g2GvGVVPq9SQJVmjpB(_F{d_x6`N$@7MLiN)()qrbl|=!>?j}?)zyT%&_(_ zrd$p!%Ld^GYjOLch`I28H9H>6g>&tClUsk#Ck@Z)Y7J{JHt)&5!FF6ZUq=3euVvFw zVaA+kJaWynv9>jU761X11T&=y@Cq1o)1Xnjzkq;Le`9E|Aw6@)mfC0T4+KLf#(Sro za!Z)Vdn572CTm0%Uj_wpo8yOdTJ$C*FY#TebOg|fIz9~jsk5uhV+X%PMeqfT#UOu> zK1^ox?#;Xefo|=c?w>Gn{nh&P9|T(MM^;AY6vk7t2SbJ9j;}z=o9hj8`I^<6V83h7 zqA&|wRC|x6>C7x+iX~Eg`f7^W9mWbzj{y;wzGN4%JA=K}I6;^8b++(_&T*er(k~ZB z)6T0psRcUZ=c5y!sEZc?0AzY4(r|yKRLlE1-GPK9Ih94krpX~r;-kn(u@WvTmohZx zqdKRCI&1nD-{e7q3+7Dr5X{bi1%hByqd^dmh4yqqkrGaHCvhkf!eFn(ok``gWIFw5 zb%x!fq}c6M5hv82w0cF6=EUE%;}&E zGm~iFJlRh>TN575c<`c0G#=cc8T8RIqN}jNhLL#+ua$p*j}+67G7EHTp0@Zd-T7*eIuvrF-Bkue-9xmgo?ilw#r)+$gIPP)+>{;*?lFwj^NJ65`@xnvW zr7Dch5hg2UEIF0=7^2SJo|=aZ>u)zTSb-d#%moM8r?vSDQ4W~_riTCkIyArq00GqN Y0`Z;?Ll=y6J}?c70ssa800045S}|(1PXGV_ diff --git a/data/antimicrobials.rda b/data/antimicrobials.rda index f26bff27ce1b1ae967767200bbfa71113a626f6f..2c625b215fd4fe76abb7e211f3a1974cbcc8d373 100644 GIT binary patch delta 41462 zcmV(jK=!|s>;ly70+1O5@?y4^u^ko`e{Ke=1K^a^ck~~DCap6D>%lx*u`z>Cy@@4L zk1Gts?Io!_fq7~pL8?(g9vTSKkQA78=JNFwQ|VlbtU}iZh4EGBvjKpVAJaub(6Ccc zVJ{Iu$$8|=j{+EJ^2V_G(JLYWyEitQl{)(H8khcL{6(Kr#yOWz^>?p7Q+&(Tf5PGK zP2hHYpDG0W_y)kh6MiH>TMY0X{;4A?v_DeH^UX6X4MOU;!V801T|JdEa9c{xTO)19 z<0xE$;+^9&#!vKJL$;f z1A-lHm9gjT=V()hkZ)CPR5(56fgj4t&$$w&y}MkPEf#LPu|-dkQe_@b>X|WUG zw7r>7dvwTIrK?EI`QbjFoOxHAY^tE+#D$FYEu4n6^`04wzdQ=vvwDs1umy25dL#^` z^qxWV$RlSjp5f)+5%Q$iL~%#M*G0S%>0BE}azxXFNet^sAaFep*) zG78Wh9!bvh&ZqEwiE7k7e?v456mw*ksgiA#I3lf*;S*X}EuSS@?2;t!2yPvtxi5vj zhB<`-X#M2On>#kl>B|R8ZSq`*h++-!2KWsKVWM%J(3C(F-<%9`iZo;$XsIxoD?Uyw`27#_aV5+K4p(C^?%uDdS!~@)ry8kYe_xW}t5SUTUE!@? zUH^d;wc@B0qlWmEjYP|}X+8{xPkkhRYU6PG_ndx%0_R@x1sF~=l`EaPK==)M3}53Io|$JC=3uc8sft+b2D#kdmIUsrJ?{g zjvs2YvW6W|q7ooneJBBjE4ydUB= zL5gl&kn~B`3UV_fjgq}f1e(zy%zk5_ai?hR$(ceLFoWMR_1?H8O%KY!a0PD!)7*X) z{uW0svK_c(6Sr23+}Sqm(k!2X@x&pC<9x;oN+Fr(qz`P^Sm<$Iq2sau{ufS;aPXD? zhnN*^-@*~ke`G2xNzO*oj}B!pj)95`;Uu*p1roYvMX8oLYi&5HdmQsg%@81{!o$Y9 z5+#*j%x_Al$n|n0f95BV;5F0B#$;DviAvB~Un6&m}y=WhRZr(51TPeU%jhd)B75N+4>zZXwEV zID}d^J;@e%s!Ehqug5tU(oIxIKDOMIx$Q8^t-PQ|UM8hUVK;-%%!*Pc-olw9`nS&6 z6lSj3e<~nqZA0_=dgFEy_HZ7Q@(?tMMGEWf{J`%fzUb+)mgH^5hZzy^E4a--i^aj2+7(U{U|#NnTiwPdObqoc#No8V ze`?oiU-d7!GLfl4!|fI2OzPa+3AR44YA>2}EHYBI^AUU$2H!@|;&k?ae9}0emj}`s ztV>7~{so4#C0}4;8g$EWnEYVNH0+O2S${R7>i{8hw_8O=OI6>dG1d-nj;Jh=Z76(= zN!v$U%^?nc-O{_r75;W+qlJl%AIW|Le?3<}p0*ouVza7_zt#*7A3i+Q=Tc}O$#2kP zxg>N#?McUyd0}IW?8kPD9k?fN?pxdX&f|kJ@HjpxY4b>JRBG+DaS=y9<;KkCQPvib z&?l3}-dAypSc;k=<)K`UA5XHF$2oB#o3MxdnDSz@Z{-tTFar`PO?er>#bTh;e?cS{ zUo(xV(Tj?Ze(mg8qO5h2D}Yt#Cs}Iz2g9wMkj+wgjm2|wk%9LF*`b36PqQO%)NyBg z7e@0)HM7O3e8A(nihWff&)n)+T2R&$PIRebSD6)s3^(1n)7{UqukFL7o1=l87YVs> zPXOsN799I$l>&qjc}_I+%IAiTf7)S*L?Y07ul}I^`nF=PeawxIF5`9Nxp{cIYSMw} zzx?O16fwvkL_jH{lnfzF1hoj4Ppf`vVzT0xK^d=IGefA5=9A7`Q65G{IsyKwViPkU zN1PP5QJut-)Ojjvv;Cn;q%fVP^lgMJraH&xoT}9LI+f(BF0shWg;SCE-)WGUvc8OMiIMZPn^m!c6Dh8L?iWJ|p2amksZlU^Y<;26% z4rjhc7uSm3JNTsE=+5YJ;C+=DtI+r}pDP77oAEftGffny;(ZCCog%DAwHqqr&rRZL zgudoRd6%3rYq^G1b80Kuf9d!Elip6lKi+~Sui6EbcE*$RrCL{JUs9@|+ZEK}s5N-s z4L7ZU`}H;wE*G&T=`dK#Ibj`$0gWw#v}MSr4aRoE#Aym9=hbTdvy&nWp=fWXkux4|FYK0fm zXuJ`~r8NohQucb$#;f1s&q8onDFyz@`UR22OB!LvEF0?!5y3F5KkHa<7v7xRVIiNJ4b3)fs2KLi>3zT{X5yh4xR8UN@Kte8?2TA$HU6@GKXE6I!GtC zNK#qSA0zd*f18opS&5j-S}5t?qa>DzDu#jHyfDiN^0j;rJfR!7aYCPh6)vP{i3{zd zHs!my0%4;SD-CKyL#uF-Sc^(~p_2uYd@hr$MQ!a(!JS>F_>QfA3;Y4!8GTEyGqz2q zA3`bZiQVe-%V0{vZ#43uF5M7@Q2=StvM4y6dob3Oe{_PW_%sK$;b3R!G|~gBNA?aJ zGvZA~W3|ZF!InLoy4Z4j9e*aI7G6}1bG{bk-TEfy3lr>$ddkIuga;CMFjj-50+Hb;y z*Aajn`U!VSO3Q;GKsFsaCQ(Z`RM0mX!QlbCB>}L~hpa(0?+;-suJu0DFxV%nGa|xt z%eGj_)Qj6IyHoB*LEH68lFSx{`5lb0`i zl(E0hbn_+|8RNm2Q;vV>n&OeLw6vGfM(EGxdT%zcR%kpyODh4R0r+xIOoq71rLf@V zIs-ZD)zaMC3a@)Bz^~t=Fysv=eN<@{g8J4mD4eSIY$lDauEx$nxO}g6&^h=VvI+#w ze++Qj5=As4dE`W}ynY%~2#%Wj(f;6S3#->OGULZ&-PPm&dhF`(;d^nr`A>Oc@p$Tb z)*_y5p9bY79Z->bYS=g$Z6;whQ=4Ncf8i6sAer+M|Kx`5PY%XEwA&_&x0|!9p_>zh zhtL3HK_EzA;*%dr`Opdg9-s(8FR@qn9gZu6;xL>rZzffrRW8{V-CzMy<`0D7lnm9H+=T<4f|rgt}QQto^|Im z1k5?LcsG23sQZ-34iX^2l=KIiGLk+5Rw!6Lx%Q1P-Bi128rB_Ad_z;peT?zif34+E zL}6{%9D1H2btbBL3lK}jQI<}Y`opyaH}D{m>VNP@So0>2M*UKC|Ix9O7aV<(_@5R- zhagd_TjG=>cgRD_IX1)x7mEj%O6E&S_@N#$yehn74(;O7!2&u#-#|W$!phj7#mg`( zWEYhn`t&VX_Z$870-*t8Nl@)W;yRY+!Ew^)R*D-Qik=`ZE$AvpO>6EW+eaE|0EqZEaJrCIT3B`Z zHXC(+qUDwBYnrAkiDe&yg3R5;q}TckQ1o`F;{@dfXm0z^7eo(ce}pV6e*mqS(<+Oo z$*~i-{jyT563>mCko|NU5n-GKaOB(os7zCJyYkQGEGSG%5cW|+T}%O96Hg=T{2@>{ z%4Gdxh~AJai=zF1z7x*%*54;NJAPo?q;Iz6bR@L*+8=}r%n?EnEADrQ&j)5mW9Zdq zs;zN=>wU3nKPpkP6b0tEe-8!9%UA%a_al-^oqP6a=1K_H|1bLFok`_H)d-6*q>s&3YtCv>1RZRM zEh}oRgGWa49C!cYtx4eoHttou#tK+#j%E6^zSB{85^)sWq&qno6&YlNbh zU44Bn!f2G^FnwN0f74}oV!`P%S~dr=*ksruda7+kBtk2SSO01ZR%A6Tr^dYJ9rs?@ zlj}XZ;l9wy@-X0cbEc>{cUGFn{9v@~&aulFL~t7Mc}EffPMcOfcOg0nQy*ScqHhMM zSjUTjDwxo@etDvQUV#@UsL@{v(p$9)aZMDjDGBEKiA$HOf063S!dzv4KcBNAlZ6T{ z++O9Yu8m-+bqLc63N`2Hyc|mca6n5IpWZ1V2;LjM7}NlvO?CXG#u|m@hK>a#YdA~kk|(uh!AO5MKWN(88$Y5PKl2w*<8px^w6*N@fxgE zpfySniJ~>oe<$65k2mvn{dL{3%`=>&$`0Gzabup-ay`$uSbVFb4$yHuzo= zgeD~@zX+*362Qas{s_1jCWHDaYfOKG^oi-Jj{>=pk(Qv*Y61Yzu> z)EDq{TUgYHl!PG~D4i*-;A~PRY~IAZ^E;*nsjM3e>sFyKIK!c|f9ZCcvz;6rU+byMjFc^cpFRjb{NK>`CGb?$T=>RMkfGam8S3Uux4Y6_e37;U z{GE1|P^I&K2aN!TP$%EpxM4Acosi78{7njUItXx&Bj~@6N5Mlp#C?GX%7%vw5*Uy@ zs3cDPNIN7?8j09MyBBqF%~njY(yWAu$lfO!e=D7*ai$GXhIxuj*AA}OW{;!&SvCGf z**N&ruB3bYvKMC$0LyTR(^S8|4LW<<_AO#gKPfmyR91eXL>)!!-~b~tA1!bP+F+yw zo{y^v(_4T5|t6$7K?N3LaywfbFz_`#JI5?O}+o^aLZJTCgGoaH1Vu6@JNhlTqsTD2;6;>gIKnIpr#3MRQ5BP4(lF5LIE1*ROo+08dzNw%Bdo zqu%yo7O`G-A+Ko`lUGD)uW?I@HXxMQe>X02=h(RR$H=PJhNX_Gz0$(g((4xs!iyUK zgus6KZD?tZ{|z1UoeOvo_pfB6kD zr#i`M%)rO6nOFp2`eQ$hA{4K)3CZ)hXP}t{SN{&9UHCU`G5azVf|JspmLs}$i*N1k zQfy)C+hM*ob(O~aetJxOPBG(!=j`4Wh2(o>I20TmeS#hv_{r9;K_@ALl3ggsDyxwf1r66+dv)Fd7dT8e@HdT)Zg)2#-ib`!>V!ZaQgXz zZw#V7nQIk-iJ+%ltN%?DvZsRPechJ#TiC`x1^Pk?kB4@OEyBq#evKVVS~{e`#>4K^ zybH|YJ5iD=@kEpHc?`~*lqdv5MSiIfte|%HJJ%;Wi8QAQh^f;mce|eCfA?KT=70b; zH>G?HgY5(fU^?yP!k#ck`!VfqqFBmd)CvRzRN-+##tUHu3}5k0lvm0xwDk}Sbr}5` z$_;X~&@sz%l0WNqds$;;SW}tWeQ#nFY~Z!ei3Ulqpq{k1W%xHQ4uQ;tevy^P(>cJd z@^c+ z?eVn$NBoQQTM|h8GX;2)%GTm@XCds>1r_D}@{S^9rqH3Y0=r(&dws@xGrVxdH#w6&f5+>)vl(j~RVI+@ zH)zAyR%kSn@k$dm6fZ}Fc0jx3iI_%BIwV>o_!8;GX5PDbE{-BXX(}sYMVZ)H)jaqVQZ10I_@&ge{UXGKCQ`Efz zg*78DKc3w77-pKGe?Yd3EK2oG`Z_3r{`|^eQS3C^;QsCF+$47kQkUBqe86B#EVk6QRGx|x8+{_}w!H2G zRUQ!;&UxAR>C@09vp*%&DNAE1YA~oZ^gV$d3muz;ytM44f6fAVQpB1wmm~@$w2#FR za5Ucb1AK{rrMgI3I?fa)kOgK#YZl~bQ*_sg_^hsglX|-oehr!A@r}cEy=aksp7zZ6 z+uRt>6BBT}Ero?3o^#?oxHD(?I}6~@ClC`$O&LQa3Ei!4!a*?05M1(^-J?x`ZcUZ0 z;zHQcx)>nHe;|HS)nON-d#MtfGcXk2ow$U~*6*JW`z0famy#L$ zQ+x@_1`vBucJ>>^G)p0%egtQal16M%z#--YtgJ6JooC6CZ>C>xs9=Y%N;4%Jft<7% zjg3`2_gxMem6LGKXlwGvl)JMAy27QgM-?^wvcL6ae?E*-9`-HR)P*9J-~i>JpGSj* z^F85i*meC|Km_-0e`FzK5*AoZITy!{4Fh9wFGNLCD(NZqZtyt5P`j)C+6d0) z?dYpeWi*4rqxc@*2aA^|6yOB)&gXHM${g7?&hNZs(URP_Z)vn+_09R`w6-4vx|43j zxH5)We-20%%zr(xATe>p1$f8QLYa)gk^%CqdL95XK#g5 zwG4fQ{UV(LJOdO7@d^@94|jDvROb{pIuNV!uFk}e&H;5#-5K+FkF!U^@&*fLW5d0s ze-CRD1{tJ7K*rw*DEbShbxSas?Bom#AWgw~%hx%E<}DAtuqwjBg_YI0Iqwbm zHwyLIma={X4N+P~rY0`K)JmKe$#k)uu;mQ(=QH{pM=Dy@`yC-0*YQ~4e6y2re@Kie zKNWgWFENC%5)k=9ac!vRm`msLt|L4B-br`D{A^b}>FN^!8eUuN7!FuC2TYvZK+XoF zuW3Q^#!4vmWFfz-)o9`3!{M~FXQ&TbXZ?#;bU)CKWg^mjB@DL*yDl3{1KK~(3TjoZ zWVI-2a%$^+9yvkXz}Z^FFO?6-e~r=fReGbWBTe0Sy>Uk`B!!Dbn@tR&hVmGy+yh1d??my`Zp*f15$J$@--- zJa+~Iw`(Kkl025J>phSN84T+HIqzEo^a>?a2kcH4w4t?hg^-4CqkC!}*~!sG`;}it z2w|~ZIcOX(r5+f^$T^ERwm1{jjOiMMph2H|xC51j;33C)R!cGzUz%8yf4-8AWe4CH zav`9_JbMz4J<0x?{|elE1_e&2Smd z7L~F7Lbe(stF`U|LE+vd777tZoY=4oVfDG$67KsuY^9)>ldqhAs*O)1vw-{i8BC}p zO{RSVEF7%i9ndDPQO#-e?sR{66+WT0qo>yvQAInN621y>ykvuzd3b0 zTpS%crQ|?}>XY>Wf0ipv20ibEPKl5^*)5Ab&gHo7L(>{VeDglMi9!}Fd6ivQl>cQexUo{f@7 zTV(w8wGN}e{jy$@aZMCbHP~)fTGM;{ImcDjFQbv(EJe9*e{zTD`oNnr)}Wxh3hHuB zG4|`|NPx+bNan~ve7nj7AF=83QadnhAY3Srv*7ueSd9iG`ogI4Qw_ay z?|E}!Ph=8_zbh=11==7mLp{}_iLq%2s>NuK{8_{MOZRY_+68BLQEYyOC#-j}H4t); zi9LfKT$vbaf1c=@4ueKvUFQ>}{Mh4CCghAfM*L){+(fiWYrY8(QJ%%$6bNr8UN^;~%PYq0xEuQ?B z7YNzkf8$+3SvS`>tUYW43GhwFO3s(*@lXQcn-84R=N@g$MXqXTtnWa{YP!Q0&O0L* zog@G|5&;<$o|0d$Mz5lrM#<&kZk#p#kgW4Jgdwx}M9Xuw4j5v5KO(ITgiGMZBi+ug zPhnCwU(3(}vD&SMcd{g%{q?f)d09EHl_w1Xe@(3-GcSv>qu?y`dJs@uQ#RctUK-f& zEHe3aIk}6M5u4x=ArQq@?aL(|uXQD#mVz`WD<$}oUc7lg=!WVdJ^Lg&&3y}W^OOH! zoEH(Gj5ga+s7Wa8;U_g-F{j>kuYbx#Q#Q6+XI&rE(NjV(O*)e<%5E76IjbfnH}6km zf1YEsITji}d}Jh>2#Zhtv?Z|i!nDz!dH+!<)4SC6UbbYPaobKwp#9D6E)1d-Xq>2A z6eBtMYXWdqtl`evM`LvI^TxxM2Pnj0_jYMYPnWAHhacx+3XV~*4X%FFLVJ`7FE+>V zw%C9w90jwGnZ>9Jz)D1v^;`{bZt-hle<9PNp}8gG)q=7zy<~OiMU#@|?OGPB<;I@2 zt?R1$bR=dGuN=37@odgQ^7sP&nwyyu9|iD;@amJHx#`1@I*Nfrdx1#uSo8=`?h3UA zLwx71p4oJ%3T5Ogb62Zs%x`W{Hn7lDPR(o4|Y@{K%=Ve@Gg& zeOVbgvD$nYq?BNhDv%*0$XM%vMU1rzj)k=J!F9=B^+&~~%JcX}Nhu|aOcoo4TvOQi z*$!H-a1-c-lTd@E6@ru;G0+8B#Pd*ZEM!4|a<$7&7;nL)+p!<2&603LgL-nP$~qpD z%xp8In$`s$%b5N6RiX*V4RWLQvuBVXKTW z>NPg!X2skIKRZooqNL9Rs3&HJwP0uoDhkz-dYN$4U6)VAqTjA{bb7mUDx~Z@$ETE8 z+^-gF`Ca504x5x-JLIzYJn%yd?2#ytNQa@s=v|B$H#E%LH6_vSe^f>^jz*IDg>}Bb< z9=-cXSm7l;dON2ZS8=N^+MwrUf8AE+nON1!AENw82O3&chHHzhpwDxi7r)8X5xBf+ zL4Er>$#8C{3(rGvf4;bB|CuD4S!`BO!hL`1nH$SS4Q7x?0b?lDA-Df+w8Qy=s`p$+ z_=5At+?6Of4a1f;_$#FyyH?|XlEDizEf^*x=`f#LA}IRGejH&%f^TQ&RPsPX{*%CdjLjEtB2;+_{t}%h7_N2xJ;&qXmhU*u?Wxa| z)U!g3U>ot^SUNLsEfll8QpLtW4$&+)oFy7?pv8(59JQDMa?QHjZ%9vdmJ6C#LgMQN z9e>u~47HSPe_H7Qy|F?xTcnOCX@C@gMZgg}9JgUftTj&l=dGD)ig-InTO@Mlez1-L z>s4^V-H3}aT#H94pnK9OOcls<;vCC_Mhj_?TLq%F@)s);`X{i$P_0uq8q-=JaRmXQ zy5BEt9Ai3%uQW$CM{ZvqX4cLZqlsfUc)zv5Mwvk&f4GO_D~huXYQ>JuAIi$@|MDBR;?4B7Y})8XZbh7b6`Km)s8YR@5lwAKqlJpJy1q%v6%RcN`C zjSuLjKXxXAqLZv!t2=A%L9Bd>lC}lDQG4|{vw-sdK;%B83jTJ8eB!%JF7DR<$6SSG zhu5`-e<^2)3iI^!i=h=~DHjqMyJdX<0Nho4e4pa3p<2Z;F%( zTBZw?)S{nF@m+-s$N_G>wLja?U#$>_d9ZhSe~^uy+rw;mHz+Z~2}ia1T)s10y$Gbp z{~W$AQ|i+0iwYWjVq(?x*>lq(VoaAmJ^5k19Cirvangv*VL4~QoARW+E-64(fdKCRtB0zg1HE53E2aCOp@mEt<$)Q3~EYK8c+(}BJ8e~f4j zr90$rG|P=DJU^(T0jCS8z8Gu?oJwSs5qb%xeDow)6WJ0X=Sm0lac)Dp6X2aU0Ne>a z9{COB2wQ*CW8sz(rK8$%)Nyx#{|F}(yO$w~_Alk3`dup)A2|rck&izLgY03FlaOB) zzVP%e@c_RUC9J7S6e`tjm{a-Se*nguQ|CCEItlNhEc5nNvr$t0W__yD5L9ZAsqVmsECOP3^;&b0`WHNe+sNs3b!i$pGuO+o)_uvE!ikv{UG@9wM`J|Pzi1jt-_PV}E=hxN*2l&e!rkk_&f2hzA)1q@F zgT~Vz*Tmk3gHLzW4H@l%9~YT4(C3Ck2@|_F6S`8yzDo+n@Fdsk>I_I$dz56ylPDT~ zuWZ-U3wcHCN+NK=kiX!gD(CnQ1LBWdh^2&5H5(T!lO}C9HMpuV#Q>#UtcqZVi&)zf zC?Z3E*;*GfA0&_~0bW?Oe*$*>#YnsnG_!Jt0_$uGAIcJ!582lPYZ#AetC?e1B>+ut zcma%bIQ}XcqP4TpF&J33+4KETmwL@AHYlh9@oM@BuHVAq1sLoTAJRsuo;hfUV6JF;_X7 zv6~+AU0>=ol>pnVe@lX&@l2ZKfU%=I9OqoeB2qrBV+Zq{1M8gW3rv#`rikq0xR1!2 zM6?YwHt0oqwU~asjWJUp(d7QdBvRN&l->Kp*3|V#`b7uCEFve!08D5Tp zF2F%1z?Na9zTB=6$+mG!eOIc^c1MtLvP+eIQh)`n9UNGiyVj=bnqt;1llk%8|9U8z z`@!u*Zc!0Te~21xRzId+xb6Wj3{-=Ly1Mx#Xpa8v!0oVJsqvA>|1Tz5g6oW*ina%8 z{n2^}1nzoJ9~;7qEGi}QG~`AAhFZaNH0!l^DgygJllA$sEz1-*S`%)&+E+a-x8$y%Vt91TQ1w@l=MgDGbSa3eZIw#Xe~uI?UJtdZ67Ztju<-0IYrto$ zWUS@L!vQ{2=FNGofDMzH;Iu}akTY4nVsv^k2Pq2gBjn=MIE#)=xFhW}@U zkDF0oF)ZbFfH(ZZWuxgcLPd|Q4Yf8(kMpyro#{Jce&?GYv=fjtU#$u~G%dvbf z1}q%^D0-Y^Ss=23)IezlBgbqd`pt9^{eM2rPE{a*lMw&nBIMY>=;tk zT6dQG;leUIJRIn#TPo}&;U%6ul=rCY-T}<2`J%--=;SkZaAQdWPC9d&Y+p6kROdQ7 zxQ8e=dD6npIm9#&5*Dcjx39jN&P`|7@YVyYf8nYAld)7%>;mucJ_R1n%D{dgXfyMx z0GNRp>Qu(*yUaM8xX8f4RgpVP0WaNJD9>fO9yhOUH$AcfA5S|>))Sqh!&Rmt=N`JLb zx`=;sZ{*rqgp1Yg(E@K_p2Z1D79{s2_d_IcuNoR0+A^N9?;$>3bUj%1f-twwI&U}+|p0K`# zezaPPdY-<`Wq~cVDP{0XIiScD!1@nUX^9FjYW+pozA@7rW}Bp|68szzA(h^UhK0Z{ITcrLv4kE<`;A#2gq&z zYqe<1A!0yjB9QcGK96`ac)c|Q%$DY!S;83lHKQ%2(r3&uKr{St9BD$Q{AbY+4*(dJ z5K@N^NE7!Z3c3g55>bW@JbgK|E3UjB#zTw%$Fqk~4AjUue+>of+h8jm-Zur?MPmZp zKv#eO#Ieodl><&L*Xxc}+9B)0?5M0YJVo@tX8+v_*tZ}3%sLzf51Szc&1=@M)evda zZ&Qp=8P-U4gRG85H^4;c)}M=B7LUCL_1(}7avR~^F<^>$O{aWa^w8dW;8NZdgeVfN zu-dE#ouE#Ne-XB3&0}O_BL#K=i=E4lnXNWHJiu6-i^Bm@-0SC*N-F|n2chaEK$rmQ z=}$|kHgeI^PJn(hH5el>hW(G0FUlcE;v;+Hf))K3*Iw16urtUal+2g|H?{afuh7RA z%h3k>gJ{hRs=20Q(#h{LzpTUIDJK0nsIf%i)0~)Ge}rUD>YWX*6V4l_RC+qdP8$tH zV12X^%mv3^1G|2V7d+lMjb|IhBG4Gs=4_~Od@L$HWYTwI&3%-;sO*Ik1VAqefy(>@ zNUsIT-jqq*R@B%q+0N{wS;$9l*{rB8l-h9}X%~F@w2oOz%R=&z^GQP_Fi#KCjeC{ zv_{!hXpWlNmdO(g7;onWB!pja7<_aT#3<_y&NvAohp-D|8h!jfWW$|->R6-C zf66M-_2g%LqUBQx@r!AtVD;U^Qhfhe^y4b^*|Q)3G{=DwmULR$~27O^B~UQsRjdQ zMAt@n-8>$5bgh1jt9P{^=IR9}61Fde+;Qt^4f4Ic6e{(&KtF_@(#y}3MYJ%zUD2@k<=rNRG{UOi3yf5)tF zrJ09f-bs5P;ifab7L|te?fnvvoYFzLhr9p_z9^71yCYb0SCmS}-im>@)fp<8-VOAC z>&kV(^SBeI&}q34vWA+JVgqVa>}bqvMJx&h`5SeOt$}P~uI<2it63;0wRmCuxibD! zUPZ%+B~DUbS;<_Yf$yok6vOhDe;x<3GQg3&slYysMyX@IE^wZ!h7A-bj#bFuF*vc6 za`*aKfc^^Ll78aYapZrv>PMqWVKLl8`#0}Jsnr<5czNMdZNUk+@>?I);Gn>3oX}TM zbZ{9^Qq=Ksl8>kpqOcs6KBWhNI%Yn-c;B|$H;Jpf8YHq)LG&)2#@#KIf4&BX{-NsT zsGn|Rce$YIy6b}SJ9kfiwa^?{5Y7=os=oAPk@aa%!e5?aQGx1C1uT$f3d?KvxnP^7 zYcY6eFh=<0#}Y@+y)*n{HFQV=`20gdjQ3D^*?f$*Ysn_LfeO!Nji7&L_9S)J#4CKq z;A%5DC~+zbcnu(;%?FD}e{ewzv=jERDvbimw1b!Xoy^PO?00Y)(U-M8uD|^D(^aKg zg~ed#&p0jZk|Dwh=Q91V_POGA(by^F3D#pbzi1H?)yLhqpIA`@Hc;3WI+@jWJ790? zXmO_0hR~cfKiTVcU_7|3n$^t3@+%~J(1=Yov4Afpj}~9gnnZSdIROzi+*C= zc=fG8QGWrb|HI&gf2Y0%gJ;kawiFaAPX&AU>P|E!UIb)3ev{s7%CViRpUyEf)>tw{-wF+L~ZG-huylo#q6gjo|dSnC?dia**$i#ze zKt*h&iCK!(DN-4`B^D|_F7C^$eB3&5lF#HOV$k27-y^`#dl)&`u50%gW30^)%8ucV ziIxCWIY{H=YM5ixGR=ErdvK9Kj^P10jQ8O> zdNBuTe-7S#%|udh_0W2DrH+3o26M`dJDF20>VYUygf(tY@#ntFG6=3flfau?hxk7x zPHqkN&;RlN_S2Qge?}g4g;Es1Fz7^kRBMEi^ODo+qk$oL?QCvzK8aMEKH?V`bMmfY zM3seN3qcV6kF_CR5u+}+{98_%)FhJ3AWcTWfBtMO@8l@=M;+&cu}#K?j(74JepK_V zlaWNzv+stpOSPAAQi>$earcY0CREEtXi!QTq4IifB8~e^NG@!aK)ony8TtswvS&{A zH3xNJ?u_#YGw?zDg5MgMaO@hCOM4`M3+n(a1Nef(B%QH)Q+^;5qN);Cm&m;qInUzJ<;2av>lHf%v4U zx+K|x_f+M9LY{;xR(qYNG;-2Z3=)2YlnPbj^Thj$F*Eg~@IhOqC*l((@6`mJe=K>) zO>?>X1j#T%(&DLeaoKjXiVi#1(0n4XxSiGXzRgw}-}r1p83?z@EB& z7kBRYo?C#)@j0N)b9RM)CK{73=$gy1KLT3YD2RWFar?Pq^o>1%J zYQ-CBmMhnD>J=fENz5U6H`kfVe;XR?uDS>R_qxLt&|rFT>pX}!X5g}lyCg0oC_7t| z+J8T`0;ndl%`1cNxF;naV9~Gyra=p^7%y@3$Hyn2S`CuYL^tOuBQ5??#kvU8m#J!B z+dF-W%=Z4ylg{>t{;+2P9j&2|#hkTB><(TP=pjwA1CUz^ITZswIL!Z>f5j`s^`8aZ zKWy!Z#AZ!)M#nX0w?aQfcuD7K)m=-9b{rdrlmuoKM~%YsBGzEeGl!={Na>yz*O3}J zcLxhz15t`-WsksuBC)*Zf1a=-JvX4RkNaL8lDIv6Lw2yO~MOHNo)j!1` zSxZ@K%GJ%+p)#-Kc6x$;e>d&R`gsFMPz!z*OG*+DIye`S!HdqizL|_@Zzv1)+*O6S zc(J-=mXy3J!Y0Fw=WmRkT;l{DusA6EIF2t;9;<>Z{~Q(x(CX_pJ6x$?iSJO_+kH1f z3qyL8msMn&_Nj(+=NDPBW?1wlh5|bf8bg`b_v##Kt+%X zRD-Q|s-npPbMCH8nBudK$q3G6%Fj?_;_fMx`>T0n5HjcqXM#Q!jH3>^I#hwuckDh5 zSZ4a&*v#L|8Vd;-Mo66*@I%RCLx2b)0BAm((r0Wj2_V6hc81!^uqz7n{|s6QuticG zsIz?B5kskEo+`dNe?m7+(H)f_60mJQ0ZvIt;`ZhjJxX0nGT#w>PlilhPz43-J-B*E zc)v~Ub)GwJrIdl($Kg*Sewuh>mnEy=iyOC<{yxloUsa8L@Pl=rM4}y}8qU1l`%Gwp z>a!1%JJUPIEj=V-_}^_x)QP=_McRtZklUrr(bc}O6j&B@fATRt@K(mOVJhP;5TNpN zYQ}RYq#Bu6rR718*QRdHT z2N|y1;Qp6!Z$;uE^p8F)a>`b#kQCTz3@b3UGtcz+pmf``^UXGuBsS zRbW0e&bkFYu_T(*K-XUBuNPTsbe`d~Fjg39aK2ffT1PZ`>Sd0ZXfKO;?#AD2r#7zO z!m-Pf6iylVXO=CcZW_o?kk=`U$8|!WO^sS8Ji%ShBiGz-a zZR!A%Fa%N(+*!@U_j%aX=2w?y06##$zroL{Z3;xG7=I8X#1Bi#&Qh))oseUF(qLsC zr!P3|!)iIs(E1R=XR>_7BC}q$Ut+|X08|Iz#~>PB6ZVS{F(@D5w~ue!P*0+nBsz~! zDrm~(0X*7%zmF{{q8w~~`R7qjyt;hCjqRj1G2vjFrXGvGnfTWgM5zavWw*=E5zEcG zOb)mj(tobx|In1)qGav5_7}>UX#H5NSBOZ2FVAXxr(Qp8=ngaj@kjZfBGq|&pxHOo zPb-*_Eq#+{^6+$oZ;d&l?Fn_0_2--4N2>4~{JnZrk#N#u;qqiZi;iyQ*7nEJ!5qnHWy?vuIUsl0;e&7o95r|(>n`#?W zhXlWwnL<2AKZTGHGZm-F#@(M*Rz(%r)=ckrajST0%Hm0zz@Op+EA$?PleQOp)9A}wz|t( zZ&3-hR5MMt;Iw*=QHzJ!_chNpz*sCwXk_(@4cf6!vyNaR(Q0L)KGt(nAl+=nJW~qC zGe3%SAQKwzV9N_6_iS!=>}_z zBf@b7kQ7=RgBRl8HY1oj(HEaM*+#Ws^Cz>bnZ{$qr={n?ZoJ3A+)7F!@(^h*)K#yq zk+R~M8&($$zTqM4E7n+*iAouV*0fdu9E4r6W2yp-P>kfPzNFdotVB9=$<}6~M}Lc< zTi%FP*8k?bn>u`mLeCyYnh9F|G$B@Mg#K>7Q;DOG83Q6!6O2CZS-gx zp=!jA!se}StXmiL$0Q|b{0~B!tYhSJRymu@3y=s!hc0Ev)QF1Rrd+@EzC zNfyGMO(D^u+Kj@)rGf0qkjef>TFq9Z-PuP$chiKe5dk|74Zww1o*_TZr_`qsD4IBQ z1yUxRIl(eQR)yXYqJ0lt$HL-M)`KhSNYc{;B14-ip^;_)O&BI5V=Mmv#Z1jedm>1d z!dIP7?rVJ#2fLEJD7h)-!Xgw8Qi2eI59-wFP z{cu$7N{GKCj%~&{qQTiM6y%<^OVpa(+^W+O?iNybxeb7~*SA5&+dgcPgesJ*03hc`L(_`Ew3yp{nBZf}D6wlfIZySEB3-em?AT;MuE{ zA6SBniFK;|>S2FyW?ruh8Kci){Rp+#32A(`$x>51FjUqcYGfT^uDMcxcvD+)%e0n%c_ohObdc z>4sL&Sypj2deie_OiuSEaQ{n*ZC%a9>0Ye5mLbU zS9RPrseJtu+(yhY@^Eae-jTZ8P~VdL+DVtwTDS z6v?4n2UzOV{#!;@n_CGNThXBRV^2d;=z!lM0Dtlf`e0~YEzaObvDj|sZx-$gwu3n! zM8FM&TU?qev_EeEp1>!L?SH^+F|lG!>8wY<(c9jp=u|VMIxM!x(uw%-orZ80+ zt_6FNi>uJX&8t&5z_GY9T5+&Y@n_l4<320QX|A6P`5Rpt2jg%f362uD5Lud}jEude z+kX=90HRZe4_xFRn^{Sn5N4B;_2&IPBH{nZeMngC{xPUSQAK^RV^1?Xb8)7DCCr8o6Ri_k z-Q3^WQLEq95pg^<(Cc&(bL(ylz7TT$fqzC#y6DCy)lFM{lClz+is;FXE~bFOKnY2b zr^Q9pHU`d=ZO6ZaZQ;}t_f_Sxm*no#OhcoU!D> zjAwbnzrGC>O0)4Imamku7KO~2t`DtWyo zbgm1^m6joUDir!HB>YwyW`7c6jHnV&7%Jz*maz5am+L#0s1h1JaMFx^uqc=@4-X?u z_R624Uk`y3+5B1%3>WzKIR0kk&Wa&4vl!1nnoa(@!4Fz-^FXQ2zX|JJU~ zshfhyg7Ms^O5+M_j0_5UNPOhErdUArPib(D{OOUmAd2S8dezxl_1r1yPpIRK$hiCC#6sZ5Z1wa*i7h9 zjx8FFQ@1Yn1i+A`E>a&LxPkKxx3oRKM1W=RjH3z3JVVBS)xq>FuC3JXKr?&O^};I? zPIJA!Aax<;I#fq~5Pw29sRL~biD)1C_c);gkKrk`K(%(Yhcr6q6vqGzLc+|<1GU)( z-EN=vU8}AAc_rMVm}~C)z&6i`?Vd{dNg@zP)^+IoF9F)V+{!*1x5Y&uz&ZZ<43De6 zWBZs>kryFW2#OOXYn+Fow(l;wYiS|>lZ;0!{bOXUsXedzB}ZL znSu%^&~;4eC2eV_-=$#AQe9T{kq^J6?TN+!*c8rTGd)$%t?Im*scL*rqDOqa@GQuh z^(vysSu|fj^?wl1F-pYn`86PPdBY0of@oipZsp< z8h802EIu6nbBmf*-!#y2(JdV9l2ylQh5z|UbPMa0Du1oCg~yqe2h=2=HA;43L6V%G z-gAauB)ZbPglVj}$84`PUaP&Kd&-}f55RsVLY-cg_6zhhx|k{2NmbMND+$+Ndj{NWC_V#jm7(QTTSj2Q zaiU4tJi^yp-=<2UdYrQ{-M|A^8|G6hLwh!Z@(wzOH#m$D18-O|+wd03a~8hGRCYv) z9jY24L9lMsQx@0q6oxO<*Y}dNrsj8xT_wKN>wl-lHHr1FU?#czEl)*A+`t@C^07OW z)m^m6GIy^;J+yQY@xU`*DLhLAPgXP$Rx`P$-Khk%%bQhq8N;2xSk9vr#)uNh3UAJh zA#L3>%1jp=KmGszc>9FLv+COp=5jlKq8{lEvYtjdF3v2$1G->*%@(zQR;H)H-%&N| zo`2hiq?E(nITx6Xp0-7|D8Ktud=geN@q)ajr}BHMmv&jc9!)&0ffOdEAyu+Am3v@Q zvgwO-PV%)fKiU|R@^KD1Fbgi?Zv+jXb9|d^B-tk5-9fhN%n>^_!unw<;UPCw$P}C( z`N(Ys$oqrhX_Z)7;g~6ZF{tgKuI!ffMt@PqPM=Uv+kiB#KUV^sV0g9K%^Qg|M$gX(|J^D=vOO?2r4B?Vna`IF;iyLy$aX?caID z3ED3T{A0lc8RQrP5Smb3)oH9;{$iIK*gs3r*fOSI4??qs)`E;I9*k;LB$`CmT(`k)E}k5|1gxoJIMfxPf(vuyg63{I-N9fHLjR<7M<0=f>0hq9@|6s zu&@30W2|mhWuMetXVXIEYU+rkPfGR^KOL=zd`gN+tuGwMwoTB_NP7@NLVtH2jR!!F z19da=Uv>AMar0&Bpt^h6SgBAFs;S}i|}G8O-Re0&3Lnfj;z8qH^o zv{Fplnqo?Akg9-Q5a*(D42Wn_85%i%yu6DQc2~aLhG%=6#jvtC4b^W&j3~eGCg9gF z1s&|x7ty5w4*ctrSn149?p}%GV!HWsTSkR^U{%fjEgbaG{KZAnM1PqGhaG%oiG8VJ zDMReO>10dIiiz@2qin(5{TRiMEM<@Dtc!7-Z{oRgIVhvP-9l=u2k}<~5 zLHOk3n@}zzNO*aZLVt`7CClHCP}|fBE_Bx^No@#}`cK>iWI|xiO5vht5?buIlgdO5 zgQuqEr@bCXG>A!%?9aYcA1ovr&AK8GJ0kGLR_M6KXbgT zS2m>FqFP#SFMouCXH|b?a~A*nlfKjFrv}2PS4XO6Y{d9|sFMfH<0%A*V%0O-TFKFB zAan7AGm69`E^O=GA*Ilj^q(+%dd1-xrjy24c-c}7g}brj)*xY~op4RO0)WO@<0^iN zxewqy`F7D-5Gc2L7%3u=RpPLoKJ~@~9dsY)RqnmNMt_}0I4iuLk^83k8$#Wy1Kq~7 zYkYYQ6y{FMAO)m+Hk{BeLD`dv%xo3Xn@$q8GNA%!c z5HT60Zs&$G6C>5>Anr6CYM@FsB71kh3E4D#;0HR(t@XP#K$K2aumRunr3J^2s*m0k z#7<*E_J3d>bmVUi$X6sL5z!#pp^=NO+zWr+ z@S$pf;d0&=etNB^c6}%Pm@lurn}Ip!|2DDQ(fz09hW!G0M?lnC}Z=I&uH_m}%vb z0e|L}*G|N6T~l+fRWt-rgY+Ns3CVLNbCw-Z0a~ z?53D;hOr9m^{$nzugX+sx+76i8*dkUS4|L&f1k*)3||^BNqM9fY6NlaULMp(t%7sG z6j(#%$iU1)-L08;RI~JW8=e_HTV4og<$p%x_zCXi*Fho?B;oc>_?-{z&DuJ7#~iW^ z8OVxcXOz;{S^;dLU@aaT5Gl@K?|HZAeb~FelPv0egBog4oPWj~UJETdr$AvXKn7vZ zyuLqKf=NE-E4e|1^v7A0u!y;2*qA|z}MsW$jKOuJ@Sbq)G zWX(fY2{}ssWsq^9P*o(dnY^`yZz@vLZGkG|6;J^Y#p%f#y9rl@xij`Ed zbe!8lC*gKf+M8f1x+EC*y}Ed*V1-`UEhtai(<)5Ykl_YH5y93pn)9vK4nsrY9}!W$ z<`Z5dkINRE03_mhh=PkLACJl(|m#UkmHOcO~ z8Bd47?p;|{>5__&K)Z02t=uSR8^l>Z4Vokf)T2dm1|_LNMaP;FdL16l$L~P)DoBX#xCO$dD&nOj2NB z`<0w+S}H6P&^|Vn6M9k-*P)CtRF7>VKh~NZVUnmNR1F)FI=9~n((Y<&6S;rsPy@vX znw7k;28s4~a&t3QZzmG{Cx0AdUkKL6o0{A7E}6OUQwgk0BewO7nn_6p^6qx=?{-yu zg7pm%AEY!j9nK_^{-R_R52Th5(PNn+`vX|QtF(<(f#~5-9u_&Ljdmr``!S2ZM_UN1;V{EcvUS(Gm+1+ zND};#$R>k~<^Wb<70*=*MO6;?U7VhULhb9s0GGcqDu@(CIW9Qy;sZTlAy2Y3MWBX% zPaTUxl5`9JD-l{+VSgG;VJq{CU4=Lhx`^_7C>%L21TA(gHmr8m29ru{1Zl&}gj zt;7b*)&X7LIXaAL6p(bdYYi*3-3Rbv(!bTrsr2sDu97iO%$g)5gWPT(2bIOamT-18a8n$rH~aAq6ulY0GB^W6RvxFMryJ;wN1z4(@-hRr`*+ zy?}5*@s)?jnYv(d9dvJ;e(WOlNGAo3`0hB?5+-W zN{5V(Q#<4LHh*_OZl;LGcxz>bT0K|bymSmKwl4soMZY#$DE%3oFDm>SM%K}B*c{~+ zA&Pg9J#NP@NvV_}W`ECj>I9j;u+=RbUQUmV1DaCZKi?)(m^WEF!c{cH(n8ErAWh#cC zz_@~ak$)K-yKi^9cdzdyD^UDV+2#{tzvs;3wW%pYgC+v`{anz0W!x>dfH{NsvfRNAld^`9ENWhktV61m$NTicNq68PiOS%$YIClBPHd z(QZ)Jfr4>A2UtI_R3(Zy;1KSXCm1(_H$kqgO*Ft25k@`2WYXkIT1jHNia4sAg3nu@ zhks|TZp0KFsOUs7#RPsx6JagteHki0q{JN3(&LG%FbKl2plneUC#%)1|R4q3aFRn&(PU9pKy{Siry%>dN|=6A^?|JYo2~ zlT(l*2ic(@zc^;K=~Ks6^Wi=v5&xzh_yv`oOo|6srqxjWHl)LGTmZ- zpzQp-3?w=)rX&B=alUyS%TRQKd9yF&Jb%+*zKt4eq@DH zrtGuA;Ih6iX%${@T(I1~p11gRylsL+6~|8OQ_=P{2T-X0O=&u5H4QJYrrm5n$MWAZ*_{e?nZ$A@ZBL6;XUC1QNsJ%5Ns z`{AtoXUrlgUyf=zi_R*S?%l9z{S+yPD!IsQtEsA|E)@hOw>wjUfa^5LLVY9$tsowD ze*IRF%=4y%(Oh7QWA4RWA4uUUQjl2wCImeLWXcjM3zN+DAyLN+v2}X~UP4@h^oVU` zom~%`rh*Skeb&X-$5m8_B%>|n$$#Tl0HPR=5om*=X?Cb>Q$%%r2414#$Edy~FZ#C_ zWr0+AABiw#e8Ki1HP1iIi<%OY!n;JY4kA&4mxT{)vt~G(E7Zc4XyU~BJaS?#lau1` zTBQC6IwcUcHHKpA(bCN0`NI&4$WX68?vYQr*2|rELFcmqu%ohB>~UC=8h`Tg9iL1q zrHdcOh_>9c7>vOWqq4VVT^a7Sg5SB8d@?S(?#_Q(!+tNO5W{!<#dz!lGNkfer@soo zXsv(vJ^~lkBCjO9Zma;?Auy33%{xACNa6+cy2uoy^q&<~z5}CZ8D4A=z~@&l{bbqA zU5j7089d$5C|E=~cT<`D!hdSIr=e_5(*#+L1mx(ECmcBu($LwQSJ62Vk;lj`6Z;0P zNp@v6CvqNomGSr6m9gmlSP-&T(s`g z_qG{zq_7-vxJ*G$v+pD(3OQV|@0+45=Ls_x9F$+7k_W$&V*D?>cz@N4cs5RJKKDjV z=%E&h30+dj76lRDo=Cv9Q*z!>wvTu@of_g+%{BAi!s51VBIsR@kAQOA&_PfypX1n4 zb-<46Okz>IYnLU+D!Be8mabhKj^3x^wJYp|C+JLyFXuP&{e2Es0n?S@HN-AmHJJDg zMwK8M&3{Idu16+b(|^AG_LNHIJ2fl(0or;2|JYw$vFc+#FKqNHlqociDpX3DZzL_8 zZ5pNH>y+!QI>5*2D5}LlvM|c4ta5sTs(%t7zylR<+P`0p#fh(Zqjaj4E6wA|Cl=m693Kcqa>#w-?(~dr+Kh`bJKV;Q(5X5qV#so(-rRYb!*p0U+uKd0d|g10r+7 zPbQx<4@nvn8hn_Zwp8!8%Dy>^wIqR=gDKq!tJVcg7=dL$DVQL}z|a`&4{1KA>vIB8 za14zecWNCjC4cUX$JAsh{WsNl|5T?DuPIt6C&Fr>?p`MT-As)7$+z$pWL%DwB7VlR*p>&@8TbmVwJ<&*yG+S7w}V>D-)(0C!|7Q z*zT*227lothB4avMz4K-kX_waMcl7ggf1HkFPwLkgQcW%i5fn?wj54X?_?qt)ME3KF>quUVBga}% zUXDgY+qj@4;?2K!UL<533qB-~XZE;n-GW|Nn17>dEC5Nejt}gRXW|>q1yd20sd!Xh)Y%}CaaF(D;}%j?4a^19uSp%Xe4}ul?|jZi+mjO{qQNOlUk^6kX27fx&Gg^MLS5aW&Ta28v3pC!?8>*`@Sb|UW_>!yFMDG*gafy&<3%EoN7~a8hcsQ&px=<)s%Q6U+Qk+sekgRkc?ZgoT#QSz94v0ruVSf$+EkZvb7_+OTefsT}q4~GV#|Kx#=;lc< zusaYK&Dl6qz^6%NAkT=~fvB}i?gI89SnTXKt!)#B8g^=9di+Rf8@AanK}GkY0b+N< zJR6Wc=cJnHfg<=2COq1Y%0q0xE{v1~A*)5m`UvAv0!wi)&PEJ70FY6jI)dK@9e*U_ z9KyHKZx@&jVUkHf0p=5PEcAtDR{sT~BR0M98lEIk>K#vuZt8)*7}Sm&LC(kk$^xvh zPz>YSEybX=dm*Yg_|aZ%VND#n*xxL=VH3d6N;D-~<8`ueo;jq$F8zQ@A)P?e4o!id zwd5;U6#`Db1P+-Fom9}RO!q^LA%9#?C+%?wU@uKTSccGa)l>?Ws1HMw2Pf0`V8nM% zUlyd%W*ClZ#Mmwc-1wSbUnkpDa7)u4nP63MLOOouCRs4nx-h%{Aat=tKi-!!AP(E+ zHGE850?zF2E6?xBW#y z_|EwCBhOc;w|x*RJ*BQ|J9}R%edrYt|}p<}RiQN5ajc7N{^OMeq{77KPM0;N2qh-*BMoZOo?e;_jNM_`I`m{uVE zFAr5ONet$VG(NI3D*ZW`ZQ?u|{bDUxzn-UY{2Btb2+WD_eqfZATcqHD_d}07VGQHn zNe~}xZNaLbEQunAL3aA4qHDz6v>f~owzK8>Ghniwl{s+`Y8q(w-G3UDKssbZR8|GU zvLiLG0BqpT)PKMe&yO2bm~f(UXGVbaZ4c8d1>}nFS+Y&__xJvGMjalMa|)5VqtHtr zI&o^X&W1YDn&eP!!qupGyqX$&z0y&$pj*EM=IkW?vG9m-ebQKKZ*2^m0ov9zgZ*f~ ze0O!M_KxfSB3xa;n}1$wGHS{tw(+1KQa6+9=23btj(ZCL9&x^o%*;tyi80UDDkls=zePkWWb`~Jj28MZ zS1O-GJ8xTd^ic;6W*K`2dC$l~vPAV@i}u@M-Uv$sEN?|pXMc~OtlT~vMZ(NMJGZ`# zGTzMSC2G2Cc2=>Xo4kS8hMeX+B>(}#)a|&l|BVkc@Yh^Wm z26O}6jhK9Ujx5xR!1j;}xFAABYOF*}FQx6N??7>82cn@PV&36qMEb za6&QcP^Oh1AGMUfe9VW*1DBJ>(n6 zLWlc2XVNj3U!57L*TYg!W?lcDy$?`=*f(<-P?ZjL-q?}L46AJsNWeR_54?TRO73|N z(o`rY`OHVRejJOIz32)+lI~p)Xeu}UZz_5TKYx2P{94nbctPCWz>%(R^Lf{5)nwnq1`K8M!QR8}JUk27aft9m8NAH3B4Fp>!tjSA8)` z6FO~27p`Y*K#d4#(wf0UKZg!EbAM4XN9>aU4_{l0W19Lnr)Xx#f%p!w8UXx#vuG4a z&VQWoeL`144E)U-3Y+YC?#X8DzV6+X&UjvK@&%2o&O_`!90$Y-PwsL?GD1^f^>FZY~V=5~g%$}6fNdtg!GB73e+r;SP(@u`WqOh1YlprC=ROTVc zHu*$~&q2Eoj2Hk>2Du`}xh%HAl5dZq}#5ZXS6I~^G*Iu>yI%_s_i zhlg{6mYVh}uR-|db)EB(NAbEal;DTLsOgmc4pMc-pe*@v5-IxauX~$vcl ztFr`kBExJu?-bn*&^Sd_r{*928K@4b7)K-f7T=FNihyN1x-B%qo;_xg29=&2Co;rz z>4FQnNdlDKUhLwAxrqsj-8VE6+gS_Iy@_)QDpGG$HSVE;r53%rAf#At_Di7NOM~C| zarSOMckNHYxb% z4qeyGlLNCug znqx2An!24=Sr$y{l(vg^3$htn0)Zbs@{_6!Odi*~DLvau8LRJ-cUTHRgI8E)RM;p& z)!!;rPM&5JgNsM$=7CKi34fN8j6d$Ys}9+Ozv8FqlmX0dGIWMP;+)@?3QQ-l0Ed(4 zOIi_GF^OXL{gCNB+8WVS8R%;*zzrgS%6eO3_`LQtUCqgOpFrVzpMKJ>ei-9UdY2oW z?`8KtuMj%WO~cO}AmzMD5!7wxPUG1~dq4bie$6}iKdzt@hx9`7)_<2c{Uc>ES44%Y zoC|ZYf?{<0Is1W0RFb&9e7X7uih8@#jAF&Xi>4AW7BX#F&qo&*+ZNJDp_Xj9rq1jfTPc!`n z?)n?F3}mQ=-1{gBFn=Zu4*Sf>^?Dcn;7M@@gJG~L_!X11hpY&m6-Ou}J|6Z=d3k)} zmx_?9i@@B}dboC>GR{2#g~A$y9IkauICN{4ke&@Q9F?Xvm}A)%m|P3hT&Wqyx$~o5 z3^yoQmoo>S9@|UCM9~es-(2K_$a>R2Jv1$~`faoi)DIE7d4Hg*av~e?;dAxBTaZ76 zMYER?r2iPV7$_aCvNvo<^lOI$j5P93lyu1XvDkD|m}msybR=dPQg)wP42qa`TSO;( zxxbqbg-B>*JRJ;A=gxQ<&|0Bl6&ZAhj!QUNXh27si522vM98%qJ+4dhMSro36;vDK=B~L{0}>K;uPwY5 zLn%Ul>M-p3OgTM30LwM86o-dx9Y9SktKWSn(kq_poB|Lh+AjU(I`0$dCAd}w>7oK4 zN_T}q23CaT3d`>1*575a+OL*yLdaP)Xsx6}#aPKHx5>*KuN4-T2)RjV9EPJPU6Txk z=zH!=Cx6)x8;%PgrxtN94G%fgug5`Er^m|xo<@rpfM0;r1DSfq0+?hAJ@i(_ng~=g zVU!@NMEqrI(sJ+2VqFBJWXN-T-*^SA`}jtPV{(2DSBY8D37mkN)ONVrzD*E7C^6mC zqcXWD-~o1G{nEeIk=Tefz&+yltG(>0W8b1 zoJcFkp7!xxnd~ws5jI^YI09wxxr?3q?cX{pf@c>0)T9nTNxqs!U*;*DMXL_q7I->E z_EVKSff;}<@@t2n9K6V2a+iH=Q6UFl3)Gqtd2p5}#$@N^ugqtd3PrU5ctXouMq zq2PR$9c!ts#qEFomcg7ZzM3^u4st&>#DAKGgvh;EFsNHR4UGjztdDG613QTC-D#>J15H6U!{{HYdb>O2UW_ZA5y z=%-t>E%uT?XBE6SRY*%NymW}--x=Q}4B5=G0w@5`RV!_mk5!3bj;h--Pt%sBjU?_1 zTHP?qwLed7jsu|UuQl+Ws@+*%GJm%%+0ntYZ%PKStYo>%qyo{BFx?ogpqR!ZaOnfr6oRmBBvH{EcUl%s(b2FEsPg zJ@zy){QKF2<~Ql!mWD+H984{UwmLW*Y4JWWb`w@{5Z!bJn{iI)Q~<(R>3{AK3Al#60*`rfOsZoR@s)pH(8Z_rOLm)+FNGs`=0~-?dUPm6l>Xrdlw_VyEg7 zu)bz=?_v8)fRaknPdnsE%-78La&q}ta%^B`%6w-Ia0q1qs^lu1jd4QoUl=Rvc@7l^ zo12#StL4CT5b6ZIet%})A(nCwD+pELFQ8|xz{mO{3^(qsJGM$+CaBq z6?)<%bq#T`lS~-KI2)Xm;$3hEUr%Axywqf+uR>*{OJ5S`_$O97fpSrVJ1QaadTu&@OXkejy-Tj4}0dD&1}%p z=!jPtLdjKs5|2gx-tFw_l%GM=R|Xh?6Ak*Y76W_ykIV-Uka zDTU|sqhP%5EfdEfwQw~y%N?PGa0L6`pr?x>)dlt-K@LH;eWE0nqeTu3{nL;->yYyw zk|-NX-(uD5Ti+V!j{P6ctNe+)(LR|&o)B+Obz=>xVpLl2WR_Ei$KLbQg(q7_vbLw(7NDS3S;* zX_ektdyiB)T+5v)nE}&7@Sj^wU&FrpCw=`vGCB#}1(SlY%(;;cJ^nf|{Y#sGVl9B3 z%IK*ehEbl=FzT&j^e7byJBkC=Nh6Yw?0-?j?y8i@PX6ku_@3!_3^;hLm9?=#a}(zE z2zDXSWB#0o=ZXsXXPXQ^SHTxZYa4FfDT$R`BK~V#&AeJHKvudI)CZfad)_zXzXHfW zCk~qV+g_(QCT`69A6R8-UWV|g0+9j(45UBV*$Emj3OemEJEC)t2jOT}_~qCId|cOmgNE_<383-L!LhXnCqTFI@E_LJ;xB!_+qWCI{i zAt1;bv&oA59jF)H1R_ip*b*Bm$$ueJ5BVj-GFugffm&NEU zp#!%*Z@!mSu}fBa;biU8p;h63ay_M2W0}AZyBD3pWImod5rxlcPKAgIlK8DD9V;_6SE< z6_ZFsj%nCEyv9*?Bu$w-C^vamW(b&!p$bjV9IPO3?mw*5d9LNC>>e#BBA9{@nO*mF*pwn7^z_20fjET9F=lyd_d5dU zM@16dSfv3$E}_o>{Oi*4(^Ms%13Jbz=OCv00i(d5%>)b|X3BIpt$!!9rbS5rnPp6Y$OBO_c$7~*Rz zjjSXH23I6nSvp7|qb(#6#OBgK@uvPv*G^}sO<81zbNTlQzQH;2J%R&u8F*^h1PWPn zRDfqT3ab(PM-NuJ7PMX8$pbE>dMl1+NP&a65289!xaE=xoqq!Sr6;&qlZB)A`+0oc z;Fw3oo>=}}gFuoDB&4SMWE>p-4nJ3)WRtO<+U5=V4c9`O0)Rm0L0GSy{P4LV9Cd?* zL%zI}Yvp4L0Imj8-+hxf7gL8f9B#^>eW{voaKORHXw9$T?O&ES-u30t*PRC8X%OJQ z62}vjFLV3D8Giu*I)d!hNjQ!56aG*qovULguA5FupG-kV1AjzKHwtG_sfDXIIGCQE z#({oZ5zdAext{&{i(3Hp46wZ;dB7Syoh8UW>7qtmTJiW~#;y ztbhGqY_ugnO7=X8rYE(6B310Yn_`|Q*d#WOiaBf_e1CIJL`82+Y7zLxhD-(d3)TZu zR~56%DaZF1>_jj{h8NlZkIZ0-p9}+mY|P}QC>xm*Jn?YIi$foQ`nBVQ=1(1^XkKp| zR3*ebN{@MRP^tfouv7ns{p*FHL8Bf@tiz(3pA!M>N7>O#cJ!~iWO?3WX=F!*LRUY4 zR>Br$Fn>u}=3jw2vHZ@#EA0_!v#oH#lPKL|O+BmyB(9i1o4Z7QL6`$at?m(nMASw5 z*olLGFaOIF+rR7^B|afsDFmtVsq#{nKijbuyP;L45Dp3}x{)7MfW`v}GiMBw;hrmW8-8`@{?(Tc_q zDu2#8H_zOXv>&`*+BO+AIwV#zovn{=S!W$8!J$=*eob&r4>VxugYsYNt?3N=$JC9Z z=I{tlp5rw;;koIF(zmzZ5q@G0!$Zga0_Bfu4$&XA+9}k~7I`Orum&p{I$==!BH>a} zBZ}nIUTDAWI(+^9ys>Ss1{SF>#<)CAp`fve4!$=g!{d0^kI9>t$+w628Ot)A{57v5Tf z6A5W+Z8==i?0JynCz%HH|0w)+y^M>H5;wlvzJJxU8>Hct)qd6&J)C*60e@lc7k83A zs&0VUr?Hoz=G|5<`e|#Z%PPU(lPEI9ufd59taiAE*~T_v5(?{7IHZj1Mx)pJNxr~k z`O^sb%J{$Go#r3VW%Jg2-K^(n#AwnJ_(<;rsemo}vt>+F^7SV_J-C@?#NZ?p*V9b_gxr&7t1 z9#=5L{Z9I{&s+}z(0_0xb1_rm4H3X zNH4yRzE8biTht@L=lgP6W7Wb z%{_Y4q79qkj+8XrOP&MBKa#R92mopQ+{F)UgDgQOHXWkDp0eWO-ooR$+(aKiDcK%f z?1Gq@eEDsk)rAtu-c5@(to{m7>s6bz0vYw8GY=WW*yxrP++%+#tZxjeC6K3!2HS$L z7OK-=XaXZZB^@51)s#N(tc2g5T>st}x8;321vGM(V(l#0jTh1qfF>{OFF#=Y+g88w z!)XVh(xaouKK8ad_1Wv~<$#L?>p%hS%*JXblvH5UBrLF)|ykj=cEp4^;v9ML;d(p96@RdC;Tw4Yx~oV`$C!H}uAeckn6M`l77RRe1pH)qp@$r?+AQO-0v6n(%ADr(5aPDS@ zJUK&$q6tOiJ7tFW%woyAQjmY4J?%Ts&-Kt^s);Ke{w9VDA7WGdn+e}Q z9$)JzG)I~{+1c)>b^jpgWS-VoARC;#Bmz6^%h{(NsUy&!pm!x@&xG?|vtq$t&-y^~ndsa2ZEy z^7{!kj6hYG)~@I-aDG(h0XEwp<3d^_I*nWVve%2t&5<+^UwlB-S|ERmt~Dm|>Q1?X zQbhWfRWDN(Yi+Gu1yYq7fzuA_1<722{uL(U^D{*u<;&P7KiVO=%Y0+k zKS(+|6A!}Kn9jGhAn8h>0z4Y}9)9fH%mADf9as8Gm9SRs+vB18WxNo+=Y4uwF_k6f zJqR&9-vK&>CZeGZGJlx-#mOQ1BS~jpwf78warCTZ?O=KZY@0s6+WgF`?f8GNLx^)< zYT2ihiAzXFP|rnGg;^y5Yg6%{draVa?<$BR2l^-5G0w{9( zy-$44rv(}P>^P)$TRVFki^ID)$JcA73F9pXr&)W*u=^-Gid?`(e$;=Iq_!OuF4TcZ zbmvH%Q92~Zzp2Yk5i(Mf79U5mR6b!METi{|oYm_kiZMRZOi~#a=g(yWg`u=_`xV~q z+E^s9T76cZhyrId z%NHht?sAV36iZV){rG>T3-tXCcc!IfrBfXtHEL;*u_dkvBgrJ9rCD_zseqcrI+<WXp!3rCU9IO)_Fu8 z;>enlYU=}gCp~hX!ywo*+j(4z3+PsppRz3|nFvS%H5`03FszJu+wG@dBZ4F z83@Zjh8nYF5R>nzve)U;=ClX<@7p2@fsWV_!6lZ&sgH~4+xVJ;Waa%t3?6?eXh5#( zt9=O|SKz6N5nu~YS5uydt4e5sMK}*CLt8D2c#~eSc38IyItXX$_W&NJxq<5lM)iA` zi`FOOsc)U28ZCbW04o(UYEHGOVxrL-heY?*nY&7h3^C$$PrcPv4>8;3-f+~83fJE; zsOZx!SS+8liVH|X7pILzuRPf+Ci<0 zJG73!$DoiroY}&mKI+U^@v&`~k@6bOYDEWa#6V?d;TZ`_!!8&O31?j#bIy2TOHjc_MtT(v`AJtlW`C5Y#{p&V# zK%us^u91J(F;j0+{V@e`c85OId%=fmDx=;u@X==d7|8ax1e94o9J*OhjHRBBXdO@S(~K*EOR<`#rLSKNHQPJGUGS?CuKe$OyPs0w{dSX0N4>`N{lUKK0O zaz@4?mXQ=uG4PYrFHD+lFc__@w;`O({`PzsHn1co1-Km#ZHSwCPD6%ubh*26_z0)9 zQl)=Kl_nRHaV9ESLBH(1?%fl1`rO0(b)mUUJa)!^`R7}-KP9b)_hsEAA*(L9CcHC&{-SrqdofTpqZCv3`X0c{A=W%0EEKW|rr z70Cv^PG7*%Rxol0-hz~j-QvXXBfo^4XwiRpck)`YQpa1F>h3a=v9>(&0e~m8DKI?Z zvKRU%HnoUa{;dS;Jlm4T-;+;zyj}Z=JN-5O_E!u7bvtua;VE$Ikd5Chj9tTtz?p6~ ztc_!81K7$BkPM-Fj%+AR^CMp}oKAx6j1YM!XCS|o_G;o1v$`r}8VKABy!gy#Exvyd z*eg-gi5{k)_kF>)gx~6n9RI#w9BF8}zSJlPJ1z{%xqvd)2ni5+;U0p1}F276V;-wQ85~(Eicp+Denq2561*90(x< z%32Xux1NxTAnT&7R04r6?wh*M`(zBb;x>GKxs+M5zI=k%yu6Tb+xhyr% zv{v%tnM=6gVOab2lQoQa#VXN&%2m`{aTsbHzYA>9(EE}nrYn)HTZGgp$5WHgz-rZL zU+m5PX(sSP%WwoZiBqjkZH|s#a8x$I(oraVt^GI12g`ofu!zXlVr9iD2>6ZX6tsZh z81Ls>$xo**=kk$c-e4qh4&HyR6-uIB=nPnQ-6e+)Ip~tBfkV<_-DiqRn)jKo!tfVv zE|;Dg~ z{8@qd;6{CMe>UY%O;NQ^U2h&Ez_T%?wnTT}g{6pdRkLt>wT-{IM#F!g)Qb;s1SXaH zE!lX6>^ast7m2Qjm4>X(;ZJJB%e?#YME}QCO%j%>j+NU)+WGn1V(C3&is%!>;vy?) zU$u(n)iA*46xpW)63v8^Tg0T6wce8vd6?6uM|@~aKCqDnl(tu0?x-+_o%S8qWj#1K z>>zeOKoS|@Rg@6l^R<5#;#QVb=y3M$?UYn)DU5Pgjh;ka9p#-N?9k$Y^}LyH!15cU zeaM4m{TGn(2l};zj|a=}jz)xrJLNMJ)eMJyAcGu(FtUXGVv5ixo&@u{Oq?@WW6Lcu zS6iOTaoEQ5##?Xf3Y{2Vc$}IYhJlZ+geeaLhI1Bw?|=#{Gz)(PjL}fPm_Y3392&MP zQDlMMVk(>Rj7WOnB7Hh7+P&FwBsP!+PxG+8a0%h~6xS+5&ABrOzzD#o<>kQZfQm}M z0Kl8?WPj${&LI1bJ$fNdFu*t1|4YeXDRjjDMJP4lH=Z7~-n|H)a8|`Im)o2&e0yyv zRG$Ou62{UW=#YQBA=M8D;j=jAqg~Kequ(kK(3lgCw}t;Ff3$%6P~Y>e1A`D8+zsUI z#7d#GUl=Te9xuM-Cp*dT?0M^3AveIK5W4{aiph9YRG)f6sys+spjp>ljC;*AO< zT)Fxq;mxZj4yk~EJ9}>LRAR{0SpB6&zn4QO*kR_NuHAoRe3Q5S#>L+F%@2beSWD;B zE(PMuizyqZ)Gs&}C@DdnVM=UDRXg}OrSb%FG|la@ha^%=29G=z7|Hg|f1w)fi@m#y z>d`M`xTZH*F9i{Vun0H06~gnNhYOv>yLa3FR^Axl5aHQ+9*6R&UKuqp)B(qcZjO-x zwxkJJJ3W8yFH1#w%q0O@*2rXjxF8E?#?itN@ybIBxA2ew>~bhZehhEo+?T%IxJxgl zWLXzVd=z9Kf7k8dA+rW;|B9r=M#A67g?8ddcG;t#IVZ!LdksjyZ|n9WLN_^3i2xJgpC;~FjyP}(?&ZtN#RRvW z^jv?s|IB(MF(<|PERbRtC|JONcgEdt#xQ$7hs1@yHRk>@7<*>*vK53;mY*577gZ{w zOoOiryKpjCjJWgg$h_w$={8RmuMO-#fk`=9b*YsG4*d3j%qXQ@_<^AT6(2@y^>l`l zsmkwN(}TXu!GvML4&Rt=oBxDsK$C$busMGcFT`Oyh?dfnb|Ld=5ofmm_7esK9<@k@Kyjz=LA5(xfyrtO zJ-wQS3$dm+f?qu(k@%Lov|}MR_=D>eqX@B?DE=?jODHZoT~Z|HVD}1XdFhks;WK}F zc3;H2&&{OFRRx>52gA(xn{ij}w^TbyD!^c81uB4@xFW=M(ubTl&F!hY8?m$+ptHbv z!NL{16XX=OY&0l}o2;UE6se4rJCePaPBndl99Wy1GJK`X0QMb6OjTEBh)`_HNfn||NDFDfV``{HXuK7(Ftg4tT_t8t zZis2nE3_Y(R`^3gVMJc@`d=?5*TcO^vWFe%&*`i>@Jk$f-MXZ~I}w+AL+CO#%MC9q z8W@I@xvB%ATz_nFCCOv9yHgMFWV)63s$Y{E@)8GD{#Q@}pJ=zC2@C4g)Y5-iL;mjk z8SEpTFT_)M<{8iY5{t$LZ&52WPv|S3v%Cr&=j4GIibQf5F6UQvUBhtQcEpkfUO+T8 z3mS}666neTYox1UjmLo`zM_0p4GrlIZbS(_F}%U{V!iPJ2-oJ!dV`7)nwBh(Fg zYQDTo4+vSR=!Ss0o-*|-V1b58zPPstG|#>ZNcV0UFZ40vt@5UCj68p!i30JIZ#GD& z%}EIv&d2ChSJrq*QsXnWOJ$-J9V8t+khMU6V3)id%8bDTF$;rXRl0#>g=F<2EF~ws z)9nR0WwQ{r^!2((LR1L^TEICTMqvZFA1oD1k#9G3?w7?~=hbMtQ`1!=d6l3Iyw@0R zm2lh*T8umJqBEU|YrKE4$#FtC#)oLe;!Xzn!$Nw+1=p~HXeGs_@40|auChK90$=mP zpD~k#QsMiR!}y+Erv!p7)EGiV3;TGjjW{UeZhc3|N!;YLV0Rh!3aZqI@Em0uEW&4o zunzsomX$$W5kyAOsV`-l;Eg|n%0SlxMzxBU_Up9Z293hz~4>VsDldJp$ z-5^I|6ayZ8$lM)Bfwzp}EOnL@neN*9`}SOFbZ(^Gz3lb)+=)9e2{POY)?1c}F^fL! zK`iQdKC$rmE4z(JGY60#0JPawYwxMum5*^{))gLHZqIoHkqnH%`4(;x${eQ&60N6M zlZZdKb>uG2s)m1tF;!c1@MN2G2A7yx^yr;(@QE=pvz8yLWuSWL0F-R)-zDOm2l)Do zhyZ�WAv$IwH+aHA3XKS_pz+lW%4rp$EDv)|M|?r-Z*_fAO$ zbwWkpVtU#dF0}ZKh^+I0Jon2>&~9^U>g8y{n1BhSlsLoC+NLFo-QE<>1D^mF3fr2e zda|ue$zbl9sT{z{ecrpax4RcEaF$9;q`5j#M0j1L-~2TRv#<-C<@RyAd8aM~1FZN~ zZ{0SjT48_5Vk+N&+*_lMnwwJwC?T;R`DB{=sJD|3h-yZkKHi(uEo2aX56X>9MJ#%jSK_o^9-Z4`qfWJXa#X(>K-`E+#8<**hmhxaHI#b4ykW~_7|7t<0bzSe{Qbx?0kDr* z#~WepW?^g8B5vAdaa;RQ^eH zoqRtr{|6`@QPzVxGVfbsMv(2ab8As58h}ck+1!FDQrN82_o+fg)R@<7)4B^`9tO54Kzb)*R#0 z+rdT*uK7)T5KTqvm=3Lw<%UV0Q1|Bl&RX+iw$Pq!@kB0@*(NIxfJ(F&echB-&Ev5Q zb5J;C0iL_2>BEtwj?w8&>Lb?eVEupiW)?A`)Vhp8SR|(cnIOHp>YZF|QJs;Hw2?U; z$5o{i)q}H50GEd%5?MuiPo=~+nDrPRo$E%s2AD4Y)o--9?)j~Ni(Tr)+w^suR!9`- z9r<`<8QE6~`8GL=EdYHjh$KKvwv>Ac&wA_enwOl)Bd-E>9FaH97;iD1xlw-*mvUTR zL(p=&Pwy@mfcRH`11mfYn&0SJ_gOZFOCx+wW|)V|aGhz18Sfl^y(bXH>1lZ`K^9r# z;Um)Uzm`JP^|0QklVZcEKI-A%c#0j^h^=1+aM+7PaR^Nq3HT4D5aKAc`Pxx#m;x20 zHJB_|a9TEZf;-c`1bfj30bzebp8bU=?+#YpbV9++TDiFH(eiSsbeA_faI1%;e<>#W z-d^$753dx(({_!R1+a@Yx~phBc>G0yPM@K-wKu`Aeme$Ujv2O{d+|9_+DMTF!>rWpxk$5&p8#qKlR;7T5)jq{7=2sVHG^10&HD4v&Y zVQSPM`8Ef&o<9dS;SP-aNi&w<8^?3&*BF60k(dyxtE(J^j&G70E2h~&j~zgI>(d27 zm6w&|=32mlq-#5h*`LjU0f%ZLa4&~2P z!!*oXw)yp(y^%#G2H1bKT7|dBdZ5M}E!!0rV!?VQP@5qy2AC6aBO45fW5sJXM}|^N zokM(&Q=>0Jdt=~~qBN;I#KUnT@O{YheLo`K9!f6!T9@J$JHF#5zkvq#2bu2(W2Rqw z;WIgZSIR$ke|3WI?w@5+aS2*Vu;-`s*ak}#KmyuqajAkZ%XIAV_Nobiaw4MS)j-*AV>+T!t~)g7jz9Ewn?$M7(pB3NqBOEXFURr09T^vKUb2oz`H5rz>$ zO|tkoZx{>ORIq=JJw_&$cd&Mc$N34lGa+pb+`uxNi0;W!iMOtXQ1!Qhewn*Ykp zH}@F5vZ^hVt|-!;)aWPAS}IdOYNcMWPB41a@0N6-<|9DsRoXynoyW(1w}#OxvLNs( zHwta$Ox6Z7H9l>yFaQ`WVDf($2VTP-X3&S%^7s&55pD|%y3?*-9;Y$q_r!5|4buDr#4|GlBp9YwD>@Yf z)_;(+6GZ00drRp4h|b3p=D>a&FMCN6nctrR5^|UmOa)&2c4e6Vks(w2;oX0m>`#9ecE}Gecxjq7jiG&Eb*7C6cmqoc|?*5#T1>V1q~ zr89rgz%OUPneOjwCf;gphpSAQ7TTCWA?c^O&Gf+&_?pX6UWN1*G-%!1q=?gzbIbRj z1`#ac1s5Z#G{1a(x!Dyr`P0}O+UWIn`yaRuri|bv<{yf@e!v)t@D^a%`UoC3+8sm~ zbKimjJ}iV}&ZIq_j=#*B#K2NKr|sJ|Niu)G`?feNWnB# zVhurZOrLl#1e2j+Zgzhd zp6w`=eX8+EX=*;3^)`j=XNILH&Tw-1ayhL_8h*C=@hwXZ3%Y^JY2bAV&l0o>L*8hn zkq@wvbwlBd0MibgwLE$_d_)S>)6_c4dyY_T)aua&)sUT5@!Nm}8;&tWUJ0D}l_X(+ z%+F-551o*x_imq2vBjO>k@C)r=)8aau}l}bvDw+%0xxzt1Uqyf!vR!G~BV^nM!xMxK^O(yZ98WeDm1P@v_d8 z!qA@AwWl;B@7^4wL~YojMZhnz;p)Im{+*7}{RU=q%Wa3K96UJ4&}i@MSFQXOG{|XS zyj+1NJ;q6KfxA*I1ix-&Ug>|qe-A33oQK3805rGKTrUJJJ5T-wFK~xk_1=`wJ1RQs z4a9uvL=BRQwIy3R;jiG&*xtR5A(=rsRlO!8ihkcXzX8%uzBW)cOaj4lEiPcuX&N~p zO1d5VL26B^F*;~n3Tro(TzXacAo}&i0oZbn8%jU?mnYrvh0JqO#KC`J|63@31!->} znGpCLusY{wBwr|awx2%|GsAP4$n2p%e^9GnZZ)UeQm%8;_9}}&3&+|C|DT@N_JP$K z8Z@rjf|UhnIUidk=DgVNAb>rk9Ip7a(V8fOMpf;#=w9Q4juj-9(OG%j%k?}#PHL`* zGWO+qI`$b|D1psq>_mU4C|X-Pl?U8&Kas53{&60i9;gH&Z!iR+3>;RPzCmI)Kx*rU z=mFjPw*13*RwZ}qX$}#d^;!6^4;Uw=&EF*C5lR-u9>HgXLfTJ zdVMv7Q_L)QVM`@*A;HQeQarpUktcl|%GCIg?ima0EKF?WJJ$PJxeo_va}F97&58k) m5JhOJM*sjV+G-;J0k7=>ZP?E;kS0+1O5&sDY8u^ko`e~T~EvJXrqhv2(V;e{l&0YlX2fen^recuN* zm;}Lq8FsdS$n4(Qh#3>||7t|c_!@(g<8+(HsDw}8I}M(~SB1#h->U?XZMCa%{Qt8(Z;e;a_( zy!xl&odF}Y7{GDsH(CAdOKU*br+4zJyo@tS6nIJK3Qj!Vwj{5*Aax;7JAHSF(15e_ zGF^(a!7r0BP=6fS!n4r-xkQ@(d=nb&>pLpip}YfEO&&*r@yy_PDBpUO+eg_xiYwYh zmT&0-Irnnw$ry9v2o4Z0;n52te^QC<vCysRA!_ zR1}E+IYzcj&+ONA5Wk+2;gk~MW#_Fe627JmE4R)GNH%&Z`?dl_&FcXzhAxdml}ydT zB89nTj1;T>cb_5j;iXDB%SD|k`x(WXBueIopk*q`M7c?bqM)nx+P4Bf+xU*7h^j&O zuh-W>7jO@Hj~7cKN9&D!e4lrJC#cJk2u2Xp&vfFu%!;s!mc zJIpPTl9XrVjqXiWH*x>jI*7eqkgD-g&fJQHP1HS)Se1PT3)4sfsH429!SLf_iA$8C zEM@MZi}os9OB-6h{G6s+pABKTjE9ku?|c0z;?ma}ch91t@NI9Of5C18Kw+G#K+}Eyh~5ZWWXWP)gjY{RGMok6U*bKMFk9pSB+a1t9L<8*$02 zGA9$Qt;`Ct`KV-{#Odrv^>koC)E9do^rt-uSs||GJy|dtHQ)kq@HJE&!i3)!dcOH8nR}efXw!(?> zV3^|^Vm;ia>qlNcaxdU#-w1{X4}gA`Ec)4+i|*mQzVEP0Ao}aCP_q5rXGysMe=axJMK+m<3l(D4?mRihCzA=>S}A>n26dhwyJ7}PcWqp=+`>YgE=Lah z8e}<%PhB*c$@f4|K1?1FOBX6oh@X1sKQSwX1l zuGX{;r#h6hU_ZJqjDX293cDflPz|ePg|np0w+Bh5vWURjQOPIqJj7aCEMyE2eU-*f z2E0+40a#RYWalxt)igG$78Dtk{$~H7AM)wH+QlM`TNu7WWK`awtc&JitfkH5m+;L3 z3(4$Ce{ylc+E>f_F=SoLh5nx!@eojEOZ@5ONI(^+#v{|~jv%r!BJHE-J2lWN#((;z zU$tjw$LR_$DHIJq(B~Ptt+71`6RR|5TG^^^DMNrP=e~|PGP!kos&eB@TqXdN3IC!1 zO?KElsIJ>L%k!lE1xbLhwzwNepg_=lBQ1Y(fB*HVRGqCkqg;djc8j{-`-qzzv_icdO+_mkJ77O3ZOdt?)pULZp1(&iIdp=LbF@$I$aD z^NO~1>+1Q%nOk`5zy}Y*6)#nS<#c{@jAm75(Rss(&SJiDd}_75FPAd4PFopl_E^)J ze~L<>>ZjSc;q~7ve+-r?<|4(z%UsgGiWY8nAP_lY zza+)cIa0IoVJ}tE<>K)e7c?SmVwF1Y?ngEXmzts-+eUQ8pP3vM$h=a9M;f1rNY zl8JU!Ps4OHh9_MOV85qiBz%W-S=T0Y#+RVsPa~=S$U`B>#ap!ZwMF*)JN}$fi%I4B zJUWkPxR(!pIh_7MB`+BFN~E7M)sV?dCn_c6zQ8EW3AA+3m13DD!v*zxs*?)Ob(Yu0 zG+Oxim>C?Kjy`eM7JXmf<4>tTe*;i!7VN7fC}R6puAdcZYO=7-+sZ?->F<}9z8q26 z^S3{v!_x3y{n#XFkh!dLXvv4Rv_;$sj`}SO3v>$)ZPT1L11i^n%s-@bZNc(?rm9kk zPGPjK1G?&}XmeqSPT8h>M5SRg`6I2oWn3%$JJgTBFY9cz?2 z&~#cz7x=y2A#S!hG92dPK7W$=8Kf6qe^SbEduD`8Rywl(7cn zwt2(tU)a@`dqKFJLxKi8iHz4X?(wEA7VfdXB7q+NYzHqZJCB#i&8uL2!TlTMv}ddP zt`LZF5%m*QS~W+H2cDY~;X(lmE+;`Dtx+Kd#)l#?(AyF|**mGce~*Ee>EQeNh)gUD z$*bW{NI$xSQ+6ec(P>INP?8|T6HNLQvHy>0hpAn%k{F6xpK9I9gh}nZkwBlISGMsE ze((}d)VM2kn8fPLs4`Y*Gk1{yfNLaza9U`R7z2+nTlD3P%(mIp7&Y?6BqvR~^KS== z`A@&hWsG1ZwVMx!e>ThmahHIf+n&VP2Y2N=hO6NtHhOI2V&e%y1<@~dQy?5V8%*|Q z1C3UX!Q^N3=zZ+?pHtn!Ll$&4K1aWX=4<83Bv{sZvu#|k7* zw-Q6e-EQK2*bzkqzJgP~Ani$;^x;?zODG-ECP?D|s(fGxf6T~puJ09|{5Ol^JQUT8 zOIl(jwxor36PqGD>RGN*YdH*Q#K@yI9yp9z=nNc&bjiP`4s;$W=Z>=-Y4ldHM7NW2 zxM`B4f+caz>Yssy6L2!*hRUx@v+1I*n;CHXMPcE|jt`45kTJt5%Y23U-M>J)Jjd6| zZHKiJ!$pGZIQ%urK|fPCP#33Mbn};HSWXe_tM72cZ|cWI!q!#XlaCe zZC4@QRf@WVwii{Ynl2?rMl!A{oE-5tHBc^syl^{D^4b=r#sC4`(EZ>BtDxVGP=0oI zw(`D4#E?DsTiU&6JB6C_XSY3(uF5;U<$zjDp*}wJe~az3wU`b@z^YV**E+mg={5p0 zzLDOM^JX_>nbLvq>~BV+s$sD4IkL=PoY3n3ty{Ops9WVkT2_B%k=SBZeVQ5W1o2~L zt~4>+DF_UN3p zFl>fWe;-r*0VLt2qI&ehJT}r`<8}x>OTW3H1yXy8$9T8){5+^AM7KD+2q$c?+b%|r2#mY26|NbhS@+XxZWhVIf3kFCxc>zJx?wcDW9*?XGSEjXe4jzO zs2C32Tvxu2Tp2#fIB4mK3T^Fs$Yzp1+Ha#Y7Dl#cA;i5n(JVpvEK{!!E^?W~Id^ zzXzCZ)aHhD!W3ZYKfi3RtRQMqxPFWWK~3CvDJDDuddM?Qv-|}wQ;8?gsNM6f19Y#YMNHG_QS^9vMXfi_+KVruigTjm4Rcd=T5UpR))w^zCneEPU1k@RMLfmqS_ z3FM^P2LMdF5L~wGw$IOF$x;ormkf2{M|)iE?=Af1k?)&XwuW9tQ)^;QZE+olJ$I3f zf=Y*J?h&nQL3b#kr3xhsVcIazf8mVNxm{087yiuKuJy5d2BHB|9P2yy?Q#d@?=Hl>sHa*xuh>u?qw+FTqMXmsx(4HK8?pBLJ1t+^8t z+7umZ??nI4xdWECHc&KjI%Syz-B;-v1oS|`pH#p2R28qTNvx{ht@sj_<4BpF@e?d9Zde@~2310%Wx(1$-J z3puK5YM}}s4E!e?gHR-7qQs(3meB*#5=_=<}*RheX&Frvq{!;Q=^0t*C?Tz#<}Z zgzfxhvjx)KPsoP3w*HJ#ziQxT3V-U6yxEtRBoCmI5=Ul~P6?f*i$BCkEMr%iPLj34 z)}8mtknRPVg}+=u;mhpn7u=#eqex1cd99*<9G^%uh@rA) zms*`|Y187F4|H`xK=phSRB%M$6%F1~!WH|^sm~}N-us%95@i?Lg8BXADxF@q|Mlpo z1iaD;LQ}xoWCEUg&O;R8`na%2~e_bMk;YhwL$3onSzJI7vnDc6MPY^%4{az92RwG`%1MMU?K|G&gdr0q? zLnH2_Us<0n;|M21m~oiqEYq{VwBl=8i_;U^L?2%fj+Wdn7H$8IJlFDP zt(DQL7Jxr1T7&u;HEs&S7M5{Ok5Rsg{>E0#f0N~ppETZNT^pylt9SjFrAofS{24KC zuhxcGkZGO7f=->A8lXj$whQSR-=odjSjY-HE0Q$ys#91#Tni{y(t#BxW;1Gg7G5ls=uLe`iiJ z5GyrCF81-YJNin7&&+fLE zhFSx9SMceK=-(^Xpo@@QJun|5mB9e;$hVFLaATyD;Wq^#p}e^)!YAjh5yfZu+L%P? z3zRf6i#6H(hB8qW!T9mn-s%gQf6|34Kztd~EISwm0eY&HaR+Xs|64Fd4LL%K3`G3p1v8qxMEQFfXLpc#?SJ?Q(S~if6uWS1T=kCQFY$3X=e7$Zx;E-f1S!3wW@H^ zNrG?U4NF{bzeb!+Wf-vli5sf)yi=utm90lfbV}d&={;4BkYf z3K_t3D`+v0j`3%8c`DWRQJTHF&(ZLy|81Ny1Vhc!CztdP5IbNA0wKStVQM>}S7tuh zhO12Q^z7V$G`?kLq9z6&e|EO`Hi+*);qz*hrAe$wEq`2cUgstaiOJZMr(K5eoP_z! zg4-`5CBXF%F}&j$&rI}Je()G1rLEspI+kP2)v$fGY_9y?yeh$L#pjU1Kmcs?F~7p0cFl#363b4Si!NrNLlJ@g`&FKB5LJ9 zhPycvZEDEje;n;Fq-DIC!4xXYcl#y*uNN~@Kg!X1;FElmS>1b-Cu#DXdPsP@XEkC7 zjDE^rQX}ims9;E;vSz#(@<3bOBVELp%;pBb&Tve{6{MCO;eg$@)VC-2%0mzKZ0@oL zeK`Th2Xk@&BMTlRV($nS^9m&?YdMFEJ#S*jj)A>Pe<7`RgL_ThLNZrC^jOIViSu0Y*kA zRHpAza-Tdp&L8XaOI4-DsD#ESIkm$!QMUb9=3CKV)GN%odsMk%eBFPDT6vz~uyUEC z43i}Le{Vj0z?CQ3L6q&XNHuh4a6gbk(Ev*069Q%QSVGq~17MhT2p0Xiw+PUmj059U z_%i{37Zrn?MA?V2K?+1jUJyRLCSw^`HxXfbVfX5PA{dNcNBpe%NxgQw9UwsHV9ubE z%u+5M819r;E$Bvg0#ETUMV+ssscYZS3RVj6 ze^ELX#I?nYiRuF?Pp=|SB=05%*D524c1p+vKRsCSNG_~MsZd9?tniqHquz7pbZ;?d?9NLkiBeOWOuM~;V}YXeFj2KfuhfGy50|pl^tMF zDlCt?iiPT8s#F_3XI0viCfpbe+4I)nG^d1(_ZWs!-W4x>H_=kxde8^jS{$(ve=6gT zHCDkt>!nXh$mz6*k!KQ?{cu5_@i~QvU>CdFw32x6DD8aP4(^AmMMmy@aM~%#xZxQ< z9?p>XO`n<&1%@QrvmhTdMc(Ii4Pa9k;N|P(tbLY9+#I&FauqVb#X_DU-0$y+XA%g50C0W1MwNe+Hp!K8w@|OqSd)Wp4{TttBQAO_r-y^c4;Z+BVTF z$5~6TWDy&!xT8eu58zD=t<%j6D2UUHMa?qh^x3iR9hK)aLo2mQC*Qe|)x;(pBsS zqJVG6g={>Leujjj5{p`0)5*-|5wNZmL(u!qv3{H;&hqH($2?AsDLIRUIb%bxt22P| zY^5x~<|hq(XDfY)Iog2hfg5{m2=ir&Dg6*VRHwQGKH%^;DIyZjRP^7(Q5I#23TzdW z!kI$MR<2zPW=9q^93X5ge{IFC0A`*r-cFd=y|17l3{c1`F*pwK8%I5tSH@q`)=u?6 z;->E>Q|tgyo&b*;r%#*6f-8f;!>tZ6ZmXFM8r@6WdlZQE7BV@W8;9PySMCZ6lx%fY z-76^Wh^y?40rL<`cxQgUNGz3^(cIIuCEY5>U7)Q{dIQW7(rK zV`+YRt+JDo1GJX{!c*s7!lyVzAPa*?B~!%KPeVHtKsWCRA zE$%sJUx!T@=zOv!e;9~+UfqmnX*7kB?^GK{%;B0aT{ic5ijQ}f^AE_%EGG)0A>EO% zL~}9%JiV&~XLUqWS5yf((q=Gg5k4;=`cwl$hlXN!&9zIjaG)7aC+RNqHXPR#bd6(; zDt1u+@^pwUQG11WL;zQ4MT_BU6|-MbWPj93fK`NIqt!Y5e{rNJrY4>d{*o2UP)Px& z94T!!psH(=nCv`9Pi$M=nC=Z8Uwn;frii1)62BlXE6z|*RJbsLV*%R85|5Uv)`KCT zuS}XsO92-2wWMYuav@}2t9bWlz zhHG?ygyG`Gf4QmU;R*CYpSu*K9^{R$@eSkVbndMNv`q>QGO8@AJ6v5-xzgCZK-kYn zFrx;^^9GYTsM|rAU>QXFMJVN34ynj#NSNeY_W6)YV<;dN#40ZUqA~y4ivr{}=`YT{ z0BW`Y6hzs;-x2T=tyPV7#EWGXDwU=X09Kf%-sG`vb(brdt z=qK~2#me0A|C2rsw(aPE7^VViTBXHRhXUNkYe$Y>)ua6?x-HbuPArj<7_XC4G6|o0 z((HN3e`_E$Nn6+LzS>;a@BVa*!ifde)RxYs^I=??;PFbXK^>ZknY=lZ8W&9jhu(H- zQgtM76W7Ko4Gb|Bp)IUpjid98lEM>2sCZ5&t+s8RLVz zY)S2tew)-~kxmlTGEbhnuY>5zKOwt4JTq$Se>{~4=Os6ga@yVp9~Ey}!)UvK&*J{{ z=_qm-Bx}xZWuAiMR)UtM-<-CXi#zDoArVZ$hP1T5mtiJeY8nj1$ALdt01 z7VbG;Nk*+hv9`uvq7U3v=t1G`G^Oz^MuU}Vt@Yj0h}l&^j;wh#!NXvt{N&;b316sN zf6Im|Tb}JbBt-Rjpb6$f*5;&UL|gzBBocVKCLyi%r}orTF9Sa7PalPE{g0iJ4AX_n zh&jO#b)TAtdw=~x84Y+DRni&;D?Qss=PktvcJz0LnIjfM_W?z zqWSGY67kb;4t>9y4)cSi)Rs?|e_k##C{H|3RLBHQ0oqiL-P`>}91`wPP26w3*R3Hx znKN8M*eFi03)Q>TaRS8E5=Yg?2f>z(lDRXt-`ZBD^`a7pYex)TH-jg9)8LVZU8I|F z%Ai^6oB-u#H3!7uyFaPEvW9=>SgVy2oFeQMA!P>}C#t5NJ4?y8q;+Lef2Jx`Ahb2n zX9x4uvuc@b@cK`g40P+FKLvpx0KK~%w_XQzUa@t5Y=chQQcc$rd&VqOAwF)9Q{^$w zki;%FhOEVQygZ381mB$wlDsrNO9P-S{r40d&vH8E#gvcM@)vz}7b&Qr&{=Cww|I&x z>A)aD*sQR4_{`Uy3O2mbe@h>a*?n!K6XEmRX@X8oj9WA@H*pSubxas#0}X^ zs z95_7)AbM5&NVpFVuKvFH3`8Nu&eX-zLaupW^AGz2gGLKTJZrxP2s`ksH}#S^F zvUBUP;i)K5K{%^xC%3z`ZqTWw?8)Y&87{a9k=LanM~a#diDgghXEF*A76Kz;| zIwRQ!Hv(`*Q~6wzZLNIcO$1rz2nJjzNs5;erS$&d zwoJdGfA(Czl6wfXQgL%RP%gq0>p#BEe)@?NM0UnFzB*Zt_d-vL0VK5F_iBm7HP~xu zmjnePAh*#qt5rqL?qe)*0kJb*hfAM|gnb|=i&@hQUoMVo>g;X~ZN~&Gb5v7& znuPq13UYQ{NJ}+cJ}Q@}Na=ca5Iv(0$d{c1tERE3=o$kRg5;Y0HPjNI@dIW88Ofik zh@p$(@87lBpn0r3Usf;{;&xE{T;!V_!uqDXLo)d9Lhp&xE(I=#!f)3LeGFPu8(Ac_ ze`3Ge90jm?ZsgT*S@QU2Sw-O}VbfKCL(YWvC~f(xjSRai0!cqc4ZJK$s|56k9B+;? z2n%Q4pBQj&(+xb|mHFqYleyd_rC&#g2w41*aqih| zQ@*aQMgD49r$MO<-Mmd%solYU@P{P2(~r;{t7IZ41AxZ=F&@EI_%V#ARDBXa8Q z?*pO+<2-C_es6^NHke&U1bw@8HQ%KTO_0KFzt~q+m|qDcUK*H~V_p~L*oktwk<>Cm zuu1b~VLK(*WSR^XxMS+Z@e;gge*^=HzLQwcgwPs<0fahOvn8^PYfR4hlqh^~PLeiN z5;(ov9qYkeYO>buP>v!nGDc)U3UP6f703Z>mo8*RogCV{vh`Bbi=VaOAEhH0orzg_ zMm`yF`J`@_Ou23iTxEGG<1aTh&MCsbBd-Aozp+{>R+~mWfua9`TyMq%fAX4eJywv` z*4R3?h-qd=e3&gLAq%u*5IaZk(&os7dPSWj2-^6Hp8*!4-7LiOIXILflAr5U(rFYS zUgDR3E|Z8Fdu{ZLijyEn3->klvxa}RcViIY9%bA7*B6mZH~_4|nDV>L1^DJF6fUf&{Mi1!l@-Dc>iZAq)AkoIZ|bP; zd@0N+k8U=U(}$4Ih=ccov*Whz7Iv4&LO4rDV3SErv&cl`~4GB6ub%UKohQ}2izb^&QiSV?W;Q9 z32hzW(co^{U}j$3zGZ*ew1Cn5P)X`*)eSfg{ zmHu0`el!&i?oF)TfpYo*tZyZlIr$Tlek=rUrbU!Ff4h}P1KcHpk=!7N9a(>K_?-xlJGP=fZ^$0#2;Obvlebj5-|ohu?xyd~C82-{JQ-xPmW$GV#FR>eop-yjkVB>k z(@ZvJe}vzKv4js!Ut431(VMh^QLA*u4NnH_LIp*G1*cJfA2$P76N*RP@O;26NCE9{ zIipAo(U}kVp(*`|EhNqVK89%(7Z{l zGMfR~CDn;HpQ65~ay(BAxx&~gWK40vFLW%LDaSQRk`?XSCE1g48`AKKMlhciubdMT zgraKCweMbxs^gGy|Ezl-yHb`eQU;^~k7@07RByK!z~hi2uL}`-Wn4#&kyCmh%Tbzt zf3M`@X7Mqp+IFLBGs=M-0IBMD)rp5UQ-)KeJ`X5Js)p(kZvaVof5mo55r&MJ{#$%F zBTN5zc%kcJCG&2+ICRAuc_6=HE43Ly+4s(}aFX+79AaVMHBDcb1kr3RNmf72Yn7AHjfyH22jVlN-ArtSHuuCkL{geL%C zyr9>eBX~+UNS3+$!`O0{@!XfDpL@%PxS74|o9?*9eD3nh4bV@Y$bohMqSy27M|u0z zGCM4*yNN5Zs0CKjzKouTSr9s^HBP9UZQ86)a7+-!hyw87ylO99rVfqw@(rgse`)nk z|4nmQ)DG-4n(KYc#_dW^P*SWbNl9%3unQZ^+E!ArydZpPn;{-M($D%0o%0yf?GsX2 z-ieP04=wmuc)Cmj6iM>aG;I$C6ZHnFyjv{i_3$2x6jPhD=HWJafgdUoWrqa0MJ;aI^e-d=ITqT&Io+A$o$-3!Lz`kxO%0~F04rFs1W+njD zB+ll;Ur+EG9Bd@zI$E#SePQZp%ALeEMTK1LCocApQzMkQ`P&)kHU!+sVLYVYt+Utk z%?RDVxRyUz@z}+0lrXmSt5U&kZLQN-bgD&oW+l5>T4)@58)<~7-%X$w3`KKzF81l=Y%2KTeF&U zG{xpq7Es5?r_Q&kC{jMkfAX8Z{kDO7+zq@rhE?92KyC`dqA~%XcdpMF8 zlA>@He5U%io6Z7n7~_si#hebSI{%V((TL~_!cH*E@Fykaltx=TlWkk2udLSiN9;s# zY=>!d+^!%xzlx5dGT>$bZ7YRT4&GZne{4z1L54;Dl0RhU&wwPL0dS%G%9m)d4koKiBFx`SZ`7M;<6K2@M|eTe zj7EW1gWxkp#iI2afBsq!@zsS9tw^BjtLC_48Z)di-^uGwnvGUX_uUdx!GonLtX{p9 zZ;_ewd=iXUd5@|+i3i3Ntl6TPdkwn4m)OrZOdM`(U0~gij3kJgs*HGUU{U#DtC~1Wl_4kN-YVL8t$u~#JbeLgbDu(JG($Nj z$KrV28YedDSb|_9%67Q?!$;OlOPrg$nFHx?^;s)?e^>Qj3#D9WBK9Yy^*U~=|JM{g zTIafBt`56r@#i4Z&bG*=l>4;QMB>~5Zx?N8C1n|`s{*oP;Ab0$q_c*=rfw;rFM%^> z`bA;C!)o<4rP?f~*hDy)s!V0IxDdnfxB2?Qul|fS9>O`q9AQ{EJ>z&vdLe5F>}E z@x{B5ZF^}3} zGEdNZRL~$+K98lID?ZvkC*4OGvC{;zM<#&hvT1|e?eT4k+soy&)A>dALaq4L!qj?3 zMIS$ohb!nPnF|uOZvR&26k=2VKQ?LwIs)#T6~h19j?d5^Q4A2u-aP4!YKk?2j{>nM ze@Eq;AtJpdl=?2eLDHAN_?fjQ;lg6d-+bi^4`e~?9tNkUnj~*&0LVkmv(P$S7&h(Z zZZAds@i)A{k@f_9LrCtaFlO6*yzoB(`m>$`5;AkiqQL!zzWqST}L=c=Nd@+K{w;_Ax~ zw|93coktEqs4T%vM1R`D<4gv(=^HL_+Bi}NIQnki$3+tiZ2ln_iiHmtt~0@z^-z1S z#|4~G%kp6DwUL{F+fWozIk4upAKQBJ8@%^C*UHAS<$8EK@F-@H8;PuxeIn^Df2&}g z%6(moulWzE45J-H6}+uL9N3x4e_e-$oBEn<0c2Fm30U4WMoQtnVZofMIE*so4rPY#nNpEi;6CD1`0c&>mv$N5uw1v=AwnaA8L6oJu*}Q z*0f_H{u&yd4Bw}eHw8nko(Pxt1tD`3WUMq@aq(CPvN|AIUY2|K2fRz-OPg1G{F8)( z(?5h(LCl$TWDQb+EEeUyf5ArAxw7x{&w%e45w>%LGYO>kB$mjsLsDvO^1KupCx!-T zV7kqBEIV5F0~>dSx4%o2f_qT6MziUNCHLTR?DIPQfN2Mt|9z`Ab8ggv2Wr`x4SvKA z@xWcXWtX6^30d7Ki&%3~qghtVR36*8kotw4I7{t4Kw0s%^1E;Gf8A+8FAd7(+~B$3 zcw1dipe)b~a0~=2b8%ppMuUJoe6ZT>y%#R1>^sPQwY+9`$ zb~V1IqgVN)z2YEm6+G~^aYPX|W3gVfNPr8Sc6_`4eZR)gTdwoLLeqibAe;vcxe1Xr=JKF|FE3M$d_x%{Sp@Cnp3>Nbjp$Tq)>1jz75bu%eUpOLVTyC1lkcP?v2gcp zk3%r;O&d&%Z7YkG*2hmwl7sWD1vDRRF;|>_s=Mk9(xF`ezcY<#SbPNsF3B}ojD-VW zud{$`BOQ8bf7$d>pETNPpBDUVGr3fK5JwnzEGh|TV0>=q-j-V^N>R8NRk)yyU1dmO zf5W3}ZL{OBMr~TO*3j=Cxhe94U08w_jX??xa%NkdvG0)!ZDglxTTxGAqNnArHq`)$ z%Ws;8T1NI~R$M9yOg2N#5Ug*N7+jFd@){2*>s(3Gf5o4^013#wp&$uo*7qeVe47mZ zG*0C@rxp%~gu*W!9g=AU!Hi z*3YI?yR+#d0Hot!q4JXY;;E42FOVS?y6q^t>5wg^;K>(?FkX>kpDG6M{-> z4)VH6f8geAQb0>M!A1#*r?+kkwX~75hf~HiF94uhE{&ShvhbYmO*A9XdaM~`12>d#c=heeu)3`-Ja2(F%SqwNwNJj< zqn}9P_(npL?NZ`66|?LR^;pXkLSU_!P!OWOl;oOtZC(Ojd1TD1G6%{-&P!x!f66LE z#D5?F9m!4gkqvHc7?CA0-dG4wC;XyPs`=>#{)g#>lN}=gMlk4=NEY6qS1~w_3(r^; zU>W0F(-}&>42uWq1_q^P;R#;wY3+C@?Vi9Sk~?32R{ZwmHH<-fflqS#yl#GAzue8j z=Z!5#I4jsJBLAPDG2OMuK+ccWh6`@Ms}P#Ya5 zH1eF(4tVIrI{D8+Hg;Uui zW~6?iS8^dmDkX$lrH^1oQKs_jLySepeBJeTz%yG~P6^xH^=|0(@Su5P8L&KhDkj=L z?SZucsh8FHTzHC`>H&BNf15^(kYDb8a-35ba`oertmW}}oA=jcPe!i1&hYub^s%u7 z2zZf-Te4JRs)Ui$3>;r#Ly7D{QA}X!*FkGw>58I4A(wW*>9q_jhVtS_JT1Ki}YU%PQFZIf4$#+;7p?pOU`A@{y;0HW=2$}Oy(w90i$_;9Fohi~Fi9@)3;Pxz6p z?&Ca$h6z}oM-4Kz?^0YQG>g;#CUa$HkLznbOu6wz_lb}u4WIuN`yzP1)czG~;R&Ft z#~`2k6GNR(Ael?re>lBEtuH=05zFK4CyNpDV% z9DyuLzH|-32=|=`C99|TQv<0+DGq8f2vfMO29eWaBWjHmtKJK3@S?zpD0O~zkdg-H z?Tg3gIe)28KaNSsgAW?G<*B>p24p7*Lzc21z$dWuZQR}-f7SYE+^2hdtVxvtpv->M z5{3j+&8MlYS=5FErOraa-a|l9OM9b{pix+?q8QMN1V>lRlMtvLVw<80t7~D*%pjz; z+ka$Fr+WhXK8EwQy2jFTi;l-iUfdd$PtnrSwqHU4l$;-@+0Kz)JX9N(T)>#g&%>H5 zvc}uMlqOoef9nsV{776?W!Z)d3BZx9M4XsR%Vkk9P*J6v&g!M}2$k6vMMP=MS#UW; zff60e;Yw17O)V_W^>1-7A{AsifA*nGwLJWaZ1h7)yt(b@?#ns<^z`vmYrwAZK9M$A@&EwlQAk~p~Xe>B6+X-s^#QbwNFHpEYW3Zt1m zPzC!yTP_R>>3tYNpu-f=B+0_2WGuYgnJvS;^zz4Es4_T7TJBQGSsNSzVl}rok0if{ z_DXAXtK`ZChaJk9E!k?wNZO8mp6EN|Q4q26q#hGh!L!;|i1>6u?Rhn>uNcUD4 z_9$UjzJHT&^-Xa~xo$~5sIm(Oc+Ixp-4}HZWsTIc0~k8+{n}@snvumkUs{4A> zw(SN~oerOpL~9p(E{nfP>p=taUg3SAAsqHWE3RM;q2U@$u(V7*cHKSFeNy!R0Djc% z4rKgPxv?7lOVf?y0#~4&Fl(>i-_)nP1Ce%>(SLDyLYzrJt&%=K#p#o`*~7yE8ibh! zf&lFUH=Cvw>^4l7V|gX!{;l8_1VxuCLjU0L*bZ*lzB)<16)mw~U(hNCY%^T}#s3I( zk`>4C_$k9}IoObR7qVq*ms)}5V!gaHkO1GH3Df@l;1j_SecreMqVYtt*~5729={uP zOMgb#05b2g8M-0~Kc&`@4~CTzvCyUey9ss4hvS*e_L$(xkd8?iG-q4B9}IdSUTi|g>{(_|rRD$Amw!ogGp2rdJR#Ox`@MX(QkrVQKuz$)i zSUK2WX??T?f3%Yl{t>L3orbPTD}EBNLoW^V(cfd~9&d=8ZRy8p8JizDQl>=*rq(A6 z_t9B3ffmI!?Z7KQR$R*}skGM?8;S`-yNdv8rUbl4-~U;PyDvv<=XG42nI6)ok^tof zuE+WL%3LkOHI=7tjIzM|g2H@{%YUXuE~)iiPVZzN64%8dbV?-6ak^iXikO&1=ZUMe z5osVxwBvI4swM`-PEZR*EXTBTlNRN`KZhy1Yb_ z^QbOyz=R2BBqY_r+=OfAZ~8UOQc6UAnlU%xAbfMuTW7$!tca z-d$<<#lR!-E48HbFK1sHe%OG32g4V1qfA#J-H1OH#iWkdk~#eBTj@Hj>FNxZR@U%g zre(m(W9$R?1L;Pw_({WIa4H=e_#jQ>T?BsO#xPawo!7xn(Tg9)O@^IiFy5;cm^)o-q3;ca z4XNiAN?t++pqL?Xicy+*Vdi_jOdR#Dnp7(xmpmGVkvI zXD7BEtDkoL=bnr&BHd6WZaDw48WY^P-DUpu3{Bv9>=Vr;_o%sM=fDh920S{B)hCh? zJ=0>+&4=aUyPmAl)g?Mn<{<6q??eK>BKwmd&lYmgt@H$)?|)#&TGF5`P!|a>#ESC7 zJ@Vuasu*bH9j^clW7TsMR(_5+w`rYn zB068z{*Iv3!{Z`w-LOGsZo{2=9Mz;0qWI5qxYDYWqXMpQ!dv)&^F~G)>Awj^!T6Wa zbN2`SILa9FJ3_*sSS*~bhOY-`J0eHxlGlf;_6W%v5`WCJNOxsfS25#AB0<2i*Yrvg zrPmTijVT34nZ)v9+6lp#(jJF_06(sJ>GrGg5WeRb4H_FWn@)q_4;2G3V9g)j)?4&8 zAto$^7_}K-6WfU^kqbO}`egL_=4q~>SK#Pz;NgM6kB;Py=z9f=j0(Fkf9~Khw<+JY z0UU*_DSzR~9dAh(tW3Z|ju+rWIxbykb#*>uywJaCYLThmn@us7)+cV zQGQ$n!gHZ!?~V>^PMB~$zyEx?-s5@cNV|NDAAi)r2t0WszO11;#C6WYeL1NRCGtT4 zOU?nc-DrmosJO1ZCa(B~3&SLYxo1$16D)3^w_ri^AXiO~k+SXn8JPS~A0s{0lR7ld zKF2UFtX6;H(=(7aFxp0n*;)3!&X1KE-NKHG;p-PrWC$!+2%Zyva1Sbx>QdkvgW9Uv ze}D0OavaQh(&q7c6aZGic1{LJQ5m87S!5S>TFHUWd6nB~X)fLEsZHJ>8nN|>tDko^ z`JW1JLq5Y6v@U$f9yQbsJ4MjIgJ()3jT7R>wF=V!3cVv%g=rvkn@`+?|j*0B8)HCNy z_n9|eh#O%u$ef%08ux@f10yH&BgDt|XjyEDYxel$xE!4j^bfn#;&7@zw=|vJ zQ*4=s`q;c2j=DahMc_QPdSudb*F4F3f;s!a|HlQQSj%5sH;D4?~ zTxM(y)PaCD_`0fum;3IYU^eqE3<~od)vRp|ww;W~=|h{sKXtDTZLn!%O!P|TVYu0P zMC?)JbFQdqLIa-DeWhlh%X;W@3=HVAsFN5HI3hZKdRAr@(tc?2Rf+;6CS?sS;=DD> zMJDh`F@wZU8OOU_kL-vTs$dz=Xn#vK0=q7+F)03Qv=F8@QgIc-Y)cYv?=ybs`Am5a zof=1h>k*nJle2>`COcWqR6L2zc~Ct4lJBxHLhR{4wp?eHWuM9-w9|m!KyD4T0wB@w z6`!1Ct9GX1mdSIVG4c66d2On`5pHUTQq!yI8uw}cw`jB#^UNRFQC5e`!hcI9J>Kg? zh^%oH%Agg2VuNq|Q|qtXni_e4*#B%O)BBP9|LYsABTAhOSdM+fezJR|4&ER&)oCbR z%d&E~Y>JU^**X(ItpX~)3gC=c|EpkqiJ8EiyetAz@I>&+mQ0A*ArF*d&YYiCfFpXG zTrCT8*(d~a`1>>UwkB+B`G5NOmB)*-eKVntaJvW^aCT1ae|8|eo!FJ%}j!~Z`p>r3I+mqli6{CU}(t>Ck*IR9^n3yc&XlZ64V1Hf`WJ16T$iPQh(jTG)!;RG5r>n z31kj9^nDbU`&w+2Qr?VRe{=|`P8Gr)wBxA{GY8-yRTkubi)_qC(~tVggnR}7VK;OZ z2B&dz{gD3>U&qh&2lJ3_40>n*hYM65Z~mH-i3wnX_iJe%yAR1in}-BY1zc3X(`v#I zK}nJy{7=cOKwgBRYJb4>+Sx0-7cdb1M_!>!L1Q^HWzXPYL0}Q*qXTh4YWPZ-LC1_~ zdI?}JQ}|_;wo*|zM-NzMnQMSCk>r6D9e9eUJjTu=X`$=P6l9QuB)VrOUOXrN9qEH+ zNMD_d0z~w%ThQz@%f4@Drqyl_A30ltoVn$^Q*yk~G45I4$A3Slb&02ud&2}s%8RvN ztrn%NiV}sy1d-^BA}11jahOgZUq)n=k@op>g!OxPSCf}h*fVpishQ5z%H3zEF8I~Qyu#5 znG^fyBoI&U&z{?eKKt>?zh4;%YhesNAC=LkfVnvSuFMbQbgkNuVI7t_PyGrnML#91 z=OeMXuX4C&ro?CnaKzwo(zsy!a-5*KltlO+3D!wiJ%0nL#P_0(t7aeH58TGvXz%-O zB%%H<=>=ldBNK}|i*=%HniDR9N3{OKM(O@S>L=d(eie=#w^An_XX{=Bqr;GcFPLhC zSY8uj4Kn<+7SQ0~DIfe?DkU_v;l-6VGKHKgN}A2J3C9z>KS_83-j0T<9}@t#dUP03 z#Dj1g#(%^)^z+=S!Yn^>t|6M=uM%UhHMANs@YwiW>SSR8`tt?O?S=u4c%cCyffC7; z9RVGaD%mS@0MvIp$39JIs5F?TRlZUcMf*O`v11g_lg(T2ESWZ|!U>sm|AA9IqZ6Hx zbi&NZf042+ztJrP*||QqRt z3V*eLTZrlbX9SZGT*IXlM`!pu;7m%V%qJPX_6%jy2r8GnPLW6t@J}wn!%?mbNtZjv zg-O(2C^DZ|ULpE2=(_AALxe5Ksrb_TV8$y1d57)d&cS_2OWM44qx`eUyn|bX2{QSy z--%k?9o(6K3^61#k#3#1e0CCKyUmrUeSc9lzne=EEudeE2~k?={5fc-U1nW2FoS4M zlVPJByqCStNiG&P3?SBi%Dz3=*XpSZV^P3wGo@Vt67fZbQfc|{p*(Eljd;QK&*Byn zg4F|{t#qD389I3Zd}e4ec@nLm?z9xbG0Mj~H^imE*!3xMX_vU z1UqKJ%>3wD7MHC!vji{2QP|Fx!Xa%?P$T#9>0kR)Xp9*$+_@K_VI_a#VdA{^S8E}D zi9N~Z;XK_&hEMl=SF3P!MP3dj2hRTM;lBp=(c5S{XDl51xoMZK&L#N7FMsn55R}(1 zbZ8>KBK*Qs&=}Mh48ZT4g{E)en=au*S;NxA{DlQDAa9jzDRA^$RjAniiCiCyz8V7O zgwMpZ8fV_q!&uHn)>>hFqH`EI8V!IW?#FnO=7@%G96am!l8DOX?lBm02Am*G;o=7T zWgV!EzpN*B`NW}4BVI4u(to66A;}Sfnu$3;inZ)mn%+i-=5yE?F`|K%I|2zN{q!3Y z)&}#>M{Zjkd}>E7$m2;jhuU7&09*wmN>(v3(wTub_SBT4qlHOiA`2)n@1tanWfs92 z^-P@g`QJ}QDXwQ(`=4W0W+*Ut`gV}2zN!R}dj zM%&)?9BWfzff9G*F`7Cv?3a1!CTFKMyn4`!+m}E>P$V z_|fET#a9sq))~Up%6k$xS;GkY!V^3}i_W=wPUCPO6l42MafNNB%|uD(YW z>k{aa%JtAMw|`%3<*i_I=#nbeYRyYw;<;+SK+$%W?5Ge}@{{%j5Yhr?;Bkx5b5_>z zYzTyg4yW{D{R#yz4P9T3p?MDqg3k9A?GWn6tDXDy=+nwiyHYjsKQ=LVS*$H-E5=e&hTzOA()F7HU!+D~M&< zB|M|TUAYtDHNHmR)JhEpi|>83rq{Tu?E}o2 zpNhJc?tgzDkVX5fi=4P#lEWUDI$!@~cJ4x$3PCnRsGkT({MbKjJ%!?RFe?p+6C2<+ zX${A4(ldW)n)$me(B+Do8RwDA@z9hz4{r-_cIkAF>0~w3wmCaVT)=Uys@e)9LM~G7 zS8;TBWZ|CRHr^jS_)Y&plcxk#n45-F6DGO8BzbG`E(Dzbu3a3Es>-e1#}2zOP(33ab7ahSdFba z?UHA1fYg&bdmLQ@T7l2R+IP`yA@w}`Gqt-u4hZ(U77E`G!f<%wKgAlrvCnuGP5?FB zMSrm^{Yjdd<=p6Hiqf122eXv2{||)r1ZSr_--`4z;^~I>?z^|qAo3e)8V*Ah71;uf zezUPl0cxe4AjqNgZL;sEw7V}%;l8>l+a#T7K9OhKuZR)crT)hwQ#+guanU z3t;}fCCOTzx$)147&VxfdVPapW;Kmu380iL<6UN_;>TDn*FSKU|3jpYaDQhq zIf`+`s7x`CKNRK*&@ILNF*|^icq)j0bX3{B?FxDuS`*T;QIen=&J8=ei zPf5cBT(`kEG|J15iV(4d>FR%_7Jr;_jSfPyFHtg04U~G_tMCAPylQE=oAGS-JpC!DqfB&z0TI=wIIp!+)O4C0eg; zP3&QE)PY6I^Y}hr3;j@8O&N3XhXKNnPc}75UMzH$*L>%`f8He5t`mtvlYgHdsi>sKYJiJL{AdC#F)(L1DOv5{GbK%8KVQ28Zju&G zRrsFTa!DMfO7RLEqdV>rEDIPEQa74;T*X||=xO~2we!{}8+>duYiGI17|&FU)a~fQ zQ$-J#URw@$(L#gH4l5xdGzsw}$QWY3Lo;Car-wy75BaHSjrVPFihuA!dn|W!w4EmK z8JP}EuzzSXBqnItHrNSb*I0Fr#*AVnp96W;818MK$>mQ!L*wB(2a}dQ_lM-z@^o-w z)x(e^EmH13!AqbOFT`7*>)0U5j z&EM~34&CLTbklLkCV#BV_5k_{cCj{%s+WpicaZ^45KM6HseCK$bQMfv%NJ&V93Ul=Tct>FyzG(i>imPMT*vPLY`UMD5q`m6z|BdO{XoV| znCpfKdrjtw!mFMeY_Hup98EoQMkwHi&?ng8;f3p1m~6Xk%6~!-VIeIUHfar)RQ+(7 zGlDEq_~t^IFV??5zqVk$II}Y_t9xi{O2GZtjHWO@PiH9(+r)aS?Zjug z)>Q(iNF9&1ry^Pk?)DT(AP|kLam0ggCGw$C4;%4#*aAe};7w4Q+gJTJMPmKtID-Hd z`a8vBI&{bWz<-6PQ2=Gw@eB{&*gPFGr&O9vGwo?A#GZ72+eYcI^l$F5ucDbs9!3(LRgJ^ z2T~a5?DSi|Q9$&G-bDCnqzUtyWG0eC=0NZg+_Ch-Fn>`@jJ~GdSuD^&6pDHdHSf=1 z6?aEC|Nh*oKE@-{m+XDFQ?wPANxb^rx&(6(-}>%r&m}?3xfv_dHS9c?NpFjG$NIBB zDIUy{=MeK-ji+U_6@*I@$hv!pM+@!*FXt8nKvHY3k6R&GKxIWxM0kBHRRvt6Eywh- z!_lq?D1Qv28UdbI=6}@mn0&l|xLY)wzKB1UhR&<()HXJK!6Q4BDWe&jSj@vJ7bo!o z&t;DpO425^>lVCGlPK_vdQYHRUG3pM_st91*z+}an*Q4LLC4q8^}gOg9kcx9qpklZ z#YS4b6im0Ont(^F-R0yQb9-PutIOaVjI7O(qJIE}a}+z~09l>B;}(3JcgB`%NIy8j zu5_b&JPBdKT~(Ex(?WCzkBO4ZICB%YmV=o)!c)$!U`+;~a*_zs9DlS}}$dq-^M> zhku_pQq-I?i%|C0rq@IJw4Ckoud(RqAMI@|`gI9!Sk{61>3IGxp~`VQr?prbNZJzd zK0vURMU|cFg3Iw$u`ehC5M4wmPvrEwwW7z+eQ+!yUnhc-X&GUdGjsVLtBx?@dGZh}_pEOjF5`QH> zi874QUTSGMr1?=!B>~trQXg;XT}fD^d6zWt7A@75iwfiDJM$26n6wFy~fT78tkk1uPl?sx~XDswPZVvH@Mqw{8%U)1vqtlIn8<}zka6+>VL zI`SVQ_DD%wSDV$RyU`_-#;^4DdolU0wA)f}}` z6o%b16B&YJjd^>r7d9l^$5@ye0?WY9uotbM|&e87{4cf4yWd=>L@`Q)LWl zceIyl{FLK=Vr#!Dk1($&iGMg=BC&HkO*LYbVu-@e9>7JA;e+<%36y@swAuk3m)b3^X3MrbX1l98InV0HUxn56cp7Gw!4(|DC) zh0Gs+t+Q;Zo$;T%E>dcvsp1ZvbLr|;{D`cAS{?(Exc}`%Uf$xJjDID*67aJAZ*22Q z*M4kr&H3)%5l|%^`~ylgWH}FEPeI%RE}1lquho=x@T+8x#7h?hfOvcIbnQ`P@AG%f z)q-VCZ(ozTp+;POC`&kK_@Md=Bq5aSR4S*wbO;)tVk9!bnpYPy0FZwiBxTsVx?T%Y za(3SMh40ssXI8|5IDdpap}wp6{W_!`W1&>uC%CZt29IXC<-H&Vw$W3GmV33)BT9b# zm=%(mFaI(;*_W;#DCoClFvASq`SfPTwS=F%9Fj#uj2Q?IU(U9{z)N+*x|Xh^93hwL zvyBcWSbP_^Pg!cr8sgC4aSi>vqh8nrG&!}8tw;yx?8oSKLVu0~i!J1CMK$`O&M@!< zkw>&*m|W8-1renClb!)11plaxVl2tHA)EXKru;qY)A^a;kwRiF_)cEL#p4f ztq%tz56YM&Ef(U=AwwV^y%;wK+@^L|R2{PDQo+=A7_X8>i6wo1*t$mT598(K`TU5D z4ef84Ea~vJ?tk9w+C<>``JZUx4o42es{WsTWEFGDe3Y1Q8_w)&qM!z|^S@B5RF(OE z=0l{pl;yyuE7)bkdw=FO`FUDB%|Zj`&ZPy&Eu13N^cbXu=2jMHs&EBi@G9^qD+f$@ z;MI{UWyxn%g|kUUk&1o!MreZxDFxe`91WA-DhY5xuzz7+RL1V1gmx<$wI5CTb+~SL ztB=eimx`q{L|PTYNo~My z-@HK@0*qXUt*AF}(s81qCeIW(U1y8Uq%b&Y}F+{r+MxnOwI&Ka^m*ZKU%y zuIZ9_yQHgy;zmLC4N9W<)0?p>0tSQJU^SOp=%;?VUKLXQ|2%hHq9jnLz9@7Ov;QtQ zu=x(1w{<6@H@92|&C9}Jja7IT5j{#eTkilpyML#rPj2v~6h6G1KbzVI42@|VCF(0@1p)ABr?|F4Z~U@ zf#pj>*|dKgUxrJ5n!(53uri2SAN2UPO)oA1j82JiZ@~5cYI`{?$uva@J3`Z{K_s7b z#n2e54?_HbBx_W9Xn3Ch7u~hJOCdD_;D1AoriZ{6mrO5Wba$@q_<>s|h+VQ)kO^8& zr7$z!UuEgH1#X2QkNrOYP~yCh&_;d)Ur=d^1TGVX1}Jr7g})d7AyjTrc1Z4!Nx~p% z9N^7O^KcdkB}TR40{)NgDtSCvG5QJ3Jsrv6{)-x&o~h^xEJnN`HDGMQ_d#uX(C&BBR9gDSum^VB?~rp;HJxQW z&|aB!M%s-lWHyhY?vm2B%MWetUVjl8=N7`dvOX7ApG*ur0iDb9LYH8`QVxqLZg0M7N`?0m z>>5qex~m-isDQS;P~&UuzI_?On7<^ZyOaCR<{yg2@Ta+ke3@8NY`vcH`dJ zK(PxuD-#L{q>NZWig#N_Ge}&Wm@*tWPusHGrT5Qeq;Kj^;r%yIfO0ZfDiJHgqxo}p zfgag<;Py+uTkVxfYD=Z`#KdWoyXrUjzrdP^r}J+RiD(k>rthsAySQu&)p_k}oVTqS zz-6NMAJCf$2r6Yz5r5alFEm zRA*9^8ken?f@w^t7NvHA69c44v~)y$+!Rj6j*0*b*>W?KdUOgg8oIkyh@Qgo0+OL zXgyNo`lTa`ac9hRAjv`M%~PV`De}!{AW!k|hXh+GSJ>QGIm>riKS?%@N6*Q4$(rpD zPV$%Y2z()MkNMu*RXokm15zM@E;|#(HD(;^n+fv~E`QkN_^+2CdRl65Hc&Uh*!mj- zB2sUdfcFpkn_?p zpb4vh+N2KrD1^s*ePvz4o?2Zm1&u?}>!waAekHTtDJrz@h=nZq1L=yBO3(GJ2B7_R zcRh{*d4I~>crba&riqrZM7Hp&%;(9CrpYpVc;*it^c%~b2+QsmW$B=4)eUU-mF2Tc6pCNg5+5n`%hgUd%7fZ2AEMTxRy1mJqc^d-8jD6-w4 zJhKGZgRP^<6rYTEO%X+?W%2+rVZT!ZK?|IXyTho5OAOvAEn#s}w#AI7!jknF`9EP& z34fPz3b=z{Rmb*x#7RUi8RmqEbQazj{lMmpnL>t31cZ4gqPsM@1o%^UgfMSLSYHT{ z-H;rNc2^m(g4qQjHWCVM9dM;^<&G-NVu(31qVH&hpM8(ogUYwO`zJ#$$7RKS-PGBq z;G2vw!4%v3;ihMf#)N5G6V`q2gVHT3y?;v(`65(fUbItdX;e(zXaPe-9ZeKop&HNH zZPR9;IL_C#VS=}xamLiHblrJ=$pj!Im*)HxgGDOsHF3eOEOAJk<0@S_!WvI_x?oyl zvo>p*g~-xKcWW9zly%uoroiGX-1@VciF8EOANnJb@X~L}A+S=3r)D<>uB7a0b zvyiKiAmQh*wV90=A_gpf3;#7(YC4@H`L1tdQ@^E1kkUXbld*@5Ay6Rx$ZD5YHcVMo zIIxTK_(B56dA#)9laWbZvdG+i?!Hicx;tirwU{ibZLPq|2L+MLX_)X?sbBN_3HiKcoZs!j;{AM zdlmkutZ=IN`50B(37!vNFuF5}RTE!Qj{6RP>r)>b&rN51%#SP7VpMO^Dg_8~Gb1sX z7yrsNvXtusbKBx6ok!5pX@3fbQA9Ec4RTq5)SXXXsT_~=SNBBuW>oRRy3AShzi!ue znOHz8)JAtA=+LM%3ODpt^8eKf_Af~_9!wUURQ%VTiw_@H(;7h$`%C1~Sd}IAFDg&! zGEf?~3Svo4FokLS_3$`6Bl=ks{7`K#^jGQq;O;i2SW*VVT$5Y_bU(G2 z*2}4DU=+KW+dEf2UbtQGC9s|>@c_VF`iOk`a-k=Z8-i64PXx~qt>=SeR=HHXV@j&k z6jU4Ji213w)r6GyY=0+>KH4w9m}jq#xMo8<{>9_MMZrp>D&WC!X1F$2(RwKuIy5LN z3rk>BunE$-JsT=4)4W#WY36+QDS8FF!qG$g8fU)i>#{#tV&Sto&|UwaU`u$wZL_2r zmOJ=+M`V&O%(g+}EsX%{@LjCbnt&Z7OLgH}E4J{RwHNL31}|7ho0YIx#uO4woW%R?Rn2tdd5!lkIMBV%d5PvRV-wK=v9PbHTEv7bFq8Z;=w+xx2f9zj-#8w7~(yM)bSqMVEs*7#i zUTT-UPvkI@9L{dxSpKM{U!F_Ap{}>awhv!7d+!k6t+dv6=n+Bzj^H}vfgindP5#p> zBBfHj17E&OK_$+LN&^b&aW)=Oi|qe6wlQM4%D*xi8h>>@e#shBXy4;Z{@`hxzc&YW zud36;?U$D|Qcl~kM?Db|M&Q-23gd6O2BnSKeVVTPe(>6THJl<{nwGLY0O%udreZgx zmeGd1^q=>{hDo>V;7<(6>mPG^Y~eR{#E%5#r|j=au{M^Ap8sk&w61Z`IBz;Zbg!Vg zA+q{VB!9eCV=b(?B<5SDK=4}$&$<$G!4Q0^)aW-)dzt`$fItV7-XzU-Hq{$g))Z7u zqE5d$tf$GGoxXIVmZ8fRsYop>L3}Xn*r>+_MJ0_$4Gg0_v8VKE`r`w}PZ{6Sn_mq+ ziw;Qn>qzHR9mSx-L{tg06?y<$#EX^E&8;9T7JsuE#16~0-lgq&*Cg(Rtq-y|OprGF z<_YVUJ>t9KDsblPH`}2mp9@5lV|(`2VkjvZnnkOs$%Mf>ifESOG^V)7V>O%-mjn{^ zB&=9GAmEW-fEiV^{JBV!4GRcF&2)RL;d=?UIZ}dm|C@?4mHCyLL8bzH-p$?D(!F*L zv42Xu0Vb!s?dC7Zc91CnJezouh>O@c7%EXr*bCom@2VSRCwik`Wi5I;w37Mn1~O3^ zEIyC$YnI~oWgML)IpA|CkjCyOk~niZ(&PuF&uf207Dw0_Ks#w@9ms>u@X8BX-I!|k zH3&J7CodVgB;#I3rDj<3mR9`h26v?XhrRzg14`x4xY zo@moQu5)8-i7ZE2S%? zwp~Tc=X`TxL{_33Z4lJsgG(86o2i~NqLL@LWG+f&!W9sADm0)q98adYvoUWMaeu0M z?z2m_?!%w|)Pt>_Q=TvJwbfHInD~pFVx+$7nVoBRP$y8_T*p4p2J~eAL-Y+o&a;Ay z9FbEk5kwAIVs$#eQiGLz>&Cv(l0rNT&`(1q3X*V`1bw>MX!{qtJ{MBNjAePkmt}Ff zD!fO^Gy?Ie_syRwQgG{=>VaUt;eP;5GL1J4oQBu~3qQ}9DCwcX^W#iq8Jl{$HjrtR znAzv0lrE8Kp1!1znY%5Xf_8f&TG~PQ&4y+-o&5pU8abzkv*wqT6taGDM;H|FUZtS& zD^qk<>N_FFSQ7YW=-;I+bM}x#_Q!FLKdPp#wJ}kz*jW8<1_~+Y{$cjZn|}vjDTq6K zb4hUqA2UzLTjD?WzLIB8%6T=MWL{Xx5>L-A0gdD;<_VQwVRK^>%B-vuXFiO@dNcdc zKU?}=;ACOh+ZrHayUmWr`#IdxjyB=GEl19`SRB~gUyLn6M27Y29p|J5&LeM@DK#Qs zBx9Ms(D{a3w&pf0OM)r)T7Te7te2?96y9GEvlaowW!OM9JM01axuRU7N?$p1&l#>! z^?cP;l;JS1p8%t%OK&h+un-+z%#1z4_tTbF3n=;|ewEJ*749zH?_v=|zfeQ4{Dz;o z-;a+kImNbMgkPJ(E6K`_AjS`qFFEmT?)Bu1a(mLF5Sfh|6VLnXob-1GA`MKyq=H`{Q&kDw!A(HWjLLIos&+5_dmnF$4fAKCa!}`y=5>ytA@*&Z zs~MD>AbRU~H-Fxa0fbiRlYH|(nWg^jQ&WQ_laJOk$BQ?72SW(fKiO8 zj3Q;mesn=;`DO!Xo_}+=v>ZYIVV#K~V-CpFKrKQ1v=l)6ODj-71{yNUoT1+AdN3F5 zdT@1;w^WCf?c*xssAR8cXUOps85k4b)vY<;a@_(wDLU))SY#x-F$wj+34GP`) zp4p;9`eRT;wcxxUeB@Sc%j z0>!)Ec(1e;e^k)4KHzKQXHmIi!o)G+mwK#6MQD$WD|kfORM_V`djZN#l`(4 zaLuK42D%y@SzI1_)XjVcWpdG zdJ1V2xH_7L;~#OHTFrNfNz`diWA<1B+X`akf(^`>IS7x32!z1ZbQtjMZrjG?%3il+ zyX0aC6lYvGx_AfxuCC}#@j@>(cb^)@&@)g@T=!mNQ$U`XG>gKTPKPsWe!)yKEYGHR9(iHGEW>$cP7oPQO_#%>r(LAr z2@ZL1O>kJprc1@Y`R`~g^kRbeQ6(T7KofWiB_zM{mIEV=C=44KoRk9ypb3{nFYPU> z$?mBthZ6}AN-NTn#F3incr%(K!%)d-(SIfAf-Sza!80h7GnP!92%<>?Mku&l0zL@! z$6=()A;}c~>cLxZ`gLC57%lX&zYUb@QTs<`U@Oyk_>Z)RB<+Zf&DmJ(G;qP|W(OcpG12;D7}&ZU*8kD9%0{z|GSN7wLTSB@t@u=gUR{X9PnS)+6#*HSmWG$ z>1zaJ5|uUqnDl6_mi>h4K9B_>2TVS&=Ebl7R6g)Mjfk1S)op2{$}=-TS%hXo?#tg; za+*TIMj`!!Iz*kKs}z`mFu>!KaeutNoReI!Fa1ltW?MiWZjZdZew){UtGNZlaI%bu zjP?@96IidqkH&5sD#Vklf(E!*8(5n@R`U=QpuPPQ{5GX_th|0@{A@>{?Gx4beEz5yd&Yd4C=}e}wB# zt33wI%@JB7tZL#vKu{Fza9(2;)E{37ri|x|8(09ojYxZKbX%foA2}C7-U{qDkQ}nK z(xj=4RTRwle6D+N`6rK5$v%ecPXnXK0RC9Gzotss?0()-_B?qaoflh)x95rZ!&#%HCyKiTeQW1EG~Wa! zC{mi3l=qZ{>T2o}M`AZ6|NK(<%fYVzf93nDoS>{PQskMM1#(P~41X(h`Y(FO`@1Tx|bO^sLcK<`@aVUePlAcFmAPiq&s}x z?$CtE4!dTTl6WA;lYb=iZih{yrvS1nx3l{@7{3T0)bL5Gn`-1J_nKs+_?~}e@6qb_ zRu}TEi5x1HfjQM=pz_zO%9A7BqVB^GkfINM{(&eS)jSNt-5Q%jGHAOtqANh%YS=d6 zidfW&{x)Ll*iI=u;g+2S9FIIDM&kH&cSg^RCbn0BQNxvU*4J6o<{_h>mfigg@J z^zWskVs%Z9VYX;PO_oye@WWZX9Z=c%1|ihkZ;b9cs{|0zN4y64 zX@uy91x|sNtAA0~wnQl`8AgY8`3}$v_tlzTnXrP%s37GV$+cAoY8pgZi6Os42B7^k zFdQ<2L}Vht>!iC6cOSlu8~~byAdT_NCA~9=%U3Cm>9tW@Tze>anjMbq0&I#3Ai!p4 zQLmeIIr~ufDW=&rOT{E7he4>t?FXRwr&D64Cxsfgl7C$>zcW-5gG(=U+}woJ`L)n6 z{vliDJT-6l#)0u2i?FIU(}y^)2Nodg`#m zKO4i{w~1+&fu&rh=-hyd%FjF^Um!6C4v}0Om4AEDV(Pq5TVWgR#6lrWl3>={2}k6q zs4?(6heI|pzE)V6Xg)qXs@x4&yn;g&e>~e_It@Od*Ed?WdW*QYU4i8YYPs~z(6FO} z#lU>o|H6x+yguM@?Duq%)V4DOjwMN)Ooj9y36d-QSMmr42C}rVC|`@n!%~<(CjZGm z$$#DT+GQ5}?u~q-&5F5vL#szl$s2;>B%fAndYWW#K@xit;hL>;9Apb*M`Is)M zpf3hNEY}O~xua-4aRdUX|3XM0yd_5?+)jj!oJu|HgeSg^t6kTp228?$VD0`&W zo7UhV+VH>;>=?+uWbkpM=A=&mp*7=VP0~}{g)zZCiR1__9+P!TB-1H66cM4!lJN$y zDddd&6B6Ls4mtxu&9^T@igPZzqFGurrEQekf}*WgX_mKftMtua_h=;LR$<^X-+who zWfG%&rNEaJ#|U}E;K?EhWdha6tH{;kkg+XdfPNMB4yE}9d}st^AzSdOj!4e0f<@yw zq*Jovoz2OZLN!)I%CF#q;Y{=%Tnft6~=(`gi0w)=qX^zgp3s08u3jc(xFX>kYn0;(?$7o|H;EBVw+PS${6UD9{$X zQfQ7W*&=zN&3on;#KM9TP(M48?{XM?6geS(rtuL%3a;puSdasqy0_}MxXIPQo|g0r zfM_$WIkN9P74ejEm9z)z`6nm!TAia^DULgXx}K|75~zTygvzBXD!maUz#7&}{5)Yz zh|)r@c~?09H{pboq?V06(tqHqmyfGxcBQ>-3MAnZVCQ(O+B%V9%G^^ru&b8ibLh-D zw_d*&v#6jCKJ|CF$G%`q5W$KEWK>b@o(&Uc(mo+t!$9AT+?IfpX{Z zcm+vB8VgkZpo=sgHHokLAw;}M`FW|<=<8JNNGIq zOjeb9wgck*Q_5gfsY5c9Mw4FHVY8~|0#SO(DcU`*v1=jBOo5SVZY7h#&=`C~pa#k0 za7nGDf{cTbPrHB?*MHb5n-9ZB?rtI*^_Q`h7unbl6hXE$~DL?=Lb{IgO{uA0zKZ!zAnC|zkdQi?zg-=q3u2KclRJN zB|zTra&AK1(xuUS z&ClSZx!98UtU}N7?5@2sm1`QiZg1T4;|W2?y*HhGZ35Va;*Ne+U~plX`=HMAt-J44 zH=mUk@sS>dA?Mip7jv1-rg0ou?qaSIutsIRZL?cwKWFM}^Pe+&N8xOmms}Q?5kuX=#Y@f zF{gpCkcprVS`oF-Up=2Oe7e8Ww)QOE*6qED0YVE|^(|0)X=!`nn4|AzgDG+8GqR() z@la7x;KQ_ZXgYuOOV>$i)FSeV$Ql|AYO2HZer@1ew?{Gpxz?S~WeY|HmNEM}Q~#7D zJuUZkZ`ok5H^vPpKEi7#!zwG1x0ctQ?r;1>i2bftf)&8*pQAfwcz#S=;i>iH1k z6n);N*qw1YP*hu~+c8}(5@q%_9cy@b3KpYgX6?etL4iN4VQ*F8ZbgS7h$rsP*RzKZbSDM8D3lkI3v( z=zUE%#67zp%2OSZXo)`^af~bH74Ow-Cdi$1Tk^hS`hi{1`If*ha_^L9XaqPC%8Q=U zNd;J;jBUg6r|s8_tg|L0z}#nw#EdKM&8wFR*$993|Lb=ENlefMmd*u;lP$CZ;WAMm zdEFNLG~Rlej2dFN)l!G%6KK7D=e7bi_d2zy*cRLLmZlS#Z%e-B>8`k(tqEQ`S+y{X zugLjG5b8fzo)qXlRh`2?LzFebexVnBO`YcADN1U3uS5*|U?!a6e|LG4trzATr&l_l zLFs=;yYnLow_sLp=QCMGXhD~?z}XNcct0^Lq(?oISuX3{W8P{#kzZ)?qx?-pQwhlY zXF}z7RvHjoRG4M-N7DS-*@O*&M7HQUNc+O194>u(jxn^F4NN8Z(xW2y^*VcSL>KZc zy_JxO3h9g+G;9LoL;*X2q?b!n9VVWTVx2QVl_<((D|&JEO4>KnbB_@FjJm3nAo$MAc=#lgfwx5-`x9LHI*uHM{KMG=^o*Q!;5SNT&z1uCnsS<+)4^UrCUob!&j)pE_bJ1>$ zaV;sO@#3|kp3a@*0u<0GQ$OvRQ58&2~w`C#DxC}v_$08fP*eIFN_NO$M6z1Ng-(O@wDN9gA{fi5%8mTpVIxut}4JGJ=+I}e@ zY7J*I6!qH+jbs9RWZ&N6{OsPOfRKm1+I{5uW2|~=`^Xa#VQ+trUss5@j2rMTKVpt{ zL0QBr7j_0p`U9;4ca%6;ku?rfUVrEV;TMUS=NHQD8n(fE<1$*Z^&ceZbF%lDa~z_b z-K(#l%>_4VG#N_KYv(6wp}t=N1}K9|-oVhU*MzPl5NPnG*4XePPkihJQBz*_ZY#-;g#rZOOC|0jkF4PfTjOeeP-f^ck79Yiw1^4pd?&$wR-&y_S56 zGZ|r2)uVqBqI?$`5^SptRpVCLhxzYZZ;9v=$e0*Geq`h)hMfDthJ?8T11su;Ho6Im z%$ajb8>2|p<+K!a?gA?73J!OIZ9iU~zq%nkG;i1+jU(DBV>{(W3o>hbMtbo~O`YEg zm!&7@6)F4>Pj!oSFDR!UQ9p)7le_UPPd*A&7MXvFD1lp_yc?FqjD}ag7b;_^Bp##w zHlt0v(`P9POU|`DP8A|sq|gRG@Rz8FLOw5wig4i}t4N@pY$<+Go8Q(Xz0KCvsom(<(jx5a@QDLAG8W zwU$$wXKEL*5r(*cv(lql3-#7+s{Ik)ya+m$qH@i`*URfx_7K0BzXu;+4Ewg7{f#~i@ILEyus^$I&0xdUJc|H;H#ph z1`=^pEu0Bjq2Gl5#^AGLgXHVPGvcv*c~mauk-n&X4pKkvLMMA?P!1WQ;ymN#TcYhF zmLpf;Kg~Ol%lcAE?Isk-p@_=s!wr8hJm|jh4BL}q>bj!C{PJc4p?6(6s1JpKuL=>8 zavw!7Tv3660d#qY{;Mzo9J#0yfTdxwTah8XjYB&x~mostQ-A;&P#5lQSuv61?CXbB;|*Brln zL;)R#Dxv~jU?C_61)^XU-4s5DkKH2fn1FctajMN3xUyaA1#m!D>wWy^)V(*`U&w-m zq(KJu2Bdb_m4Rf$xiNj_y=r%d_cHkdl`V!zb^+}xLOKPRQSKL$49J|R72mOE7Jz(#cBbhdOEDAUwjyD*+OTf|~Vd0HGh+^Zw9`?oRt)qe& z2mTG*ohK(VHe~VwWOC81c(u8K_7{4R`EsQ()6J%*=v)vSGDUrudZZ=Fq7^v9RrV<% zM07xi2~}C#MVV#63CZ_+ZIy7J4?Z6y%S>)blO1_ol1_Uj1c`rh(Qu&;<&~2BS$>z{ zu)84~G8gB9vY&YnjHn!wBV)K`#!Udg2MRhM@#D8#LML_aykG%G{1pYe2StcKaiJ`s z85e&QHYhwuGGC=?o8Wfu-E@Hm8%B(^YU0`0Tg`PLQ#qA1JUKQPi{C;O(u{6pSR;4y==&v@gOCBSC+bj#9lW7L!`6mT0;87!V0@ z@XxYGa^G%s^mc@R4k6;je0Q1eH*Oe6o2)(} zcA={&w6+vK>beVU?`mYa#8;5(%Y7XPZrRVLeffXek6h%J!QpKkHq5`=9-w80YcT^B z+bNk?;|iORF<=9}xqz)i2R)hcrLv#{7HAGA;SIXvJFpV>k@iPvFSV6>t7ovDzXD^K zeM03TA2rrW3>?xL`Lhs_qKVrLKBboxPZ%P1Z0+k1tM+!aDH+K9hAp}xpZm_dVRszK zAYgx&^k@{~T9%qIT|pE*wak5@n1mNs0p%1(P1+le_AY5;pcjf(PPr}!%BF{3vAx|W9Y!k8-KrWi` zfeHv}!FdF;9JE=yFXaFD;?|Hh+)E><24~Gmohs{(YHxkwTF4C&#kL|`uO#S8sW$gP z2y8d)cfa0J9Sgu7#3d(~Fl!%gtOYU)Ls8TokYw-(MO2quq=Nn zQCjspBoSwf*NZJ-Q#c4~%K9>Q${_ZnzbbxA(1sAA|C3s!6c;2ZqfmK%YI@Syl%a3K z87+?N5M*Z{VEilpNoTf9YcF!2%w`iARP8B{XF#%{A?8?%!22(nTMGm>`GR({NrIci zI7Wl+aGSbwhCFCY9*Sv&=$ICh2`_)-c{jXKWCiSuR)X)i8%30UuEo9HD-$~ydGZ#b zF+RxJb|>EoO8%QYt|G^I>gt_lrwrkh5NAXWxJFhT!$gG?RX61CBYC{I#)@_Ce=NCg zbkRNw;b7l+N4w+!+^tD)n|j@IQZS72WWo4bF-vZ)7C10oMA<&jsPPs9`2~N3spk@t zus2g2P!{+|%0zDrh&jOHxLx8*@DTG*BI#&%wCFOiz*&6H+kCyczrk6dJ#XcZ+fgdfu~+1WLK6olWh294_ylMgF_#~%D-x3J%~BP>4AP1_CieI zL0uD0&0Ai%wJo*g@G@S8&Jrb$aT6j9gr%r*`Ge%>Y z3)$kLi72U=mi&V_Z3uq_(*iU_BP&GRI*I|C@t`vMc!Kl7b_((6utW$E!GoO^MA&>p z;xp3O6tCs6#PiTdvh;wevMo>*k82We%@}*Cs)Z+e`uRy+wxl*-r`I3sZN(OhD_F~b zCS22gv`WNL>_umM37Y8+f^`693TeTspFr=O^2AFAcqV2WXP|jnWfPid)-wC7uRKoMmjAG{{%|QDth1s(&aV zG1>+-xj&>yTsX5?HS!|w3!*T{!TBG6`#X?O_hMPBlxAxU5h7GEtORGf!{K?$mFde^@w^$BCd$sSCSs`v>d6|?q^Ep{X@l;IHe%Cya;_|=etwUC znP)|yr;U3sOlRl%A{8Cv7w~0~d~e}8U^UsL&Q-%u|0)J`qT%B-KfATb$v`y6!sW`- zGdiViwxU`I@kR(uJ#rp!j3ru31z&?9ntbeLz1nC&wU2)Y!XWrUu0Lx^T|y|L*%mQs zu7D)U#ro|#~5o89gG;T*%E&QTA?Fe48kGO~8jw$|N-PEr|fD7dFya}hI^E{sB1 zifSIJk`&}BmZH4bqApCn`p}D*Bder3Kmq+;B+B>aFrWo)jOoF3Qb&0Bqn~ZIzy+RR z3HG*_<-DYakH63k+#}uVCHz*pU0V`W@*Xk<@Vc9GDUW4AK!dt^Ral)$EJE{B z(gIV;LfX~v$%1kV0o!?()E=(!h@&*=jZ6J_VRwy4V&30Ojh~-ku-*gzSa4G?fH&TONBAcFW2 z_}I%wM9o4MYjo3Hn(ii|-A2-9iXj@vF5HeB-HnZ>^tyx_`E*M1l&$0=?l{&}S9dP1 zH|Og)ww*p)&gC$Vocg>28R6hfvTtCu>Lq{qSbBcM3pb>?>hu3Bl7-VsC96CoeE!*h zaMb%8v(L=6`L_C;`&Vk-h`I*RikHhD=sN|lo=1|a66W+1f^npyz?NN}nxKqJxUgin zdWeikZ+e4o-+s_GTaD}Hclv|Z%>9nB%RbzXDx358r;FaLo7L9cvUQ_FigzrjtMY#{ zWDKM;m1t{5HOm}C7MG9U_FUotnW&7>+~xNuc8b2sGfu9d^auyhCL)ssy3U1Q##!)l zhl~Q}Xcecfb`}PY@>+H0OGaP2Q_gG=Ah-9Gn{oaO*ukIiH6(Rj5973$e5Q`!ogeof znX92Kd1Zq_LI7No9D!1hAiH_rAw~5F|h_`)s?cD6UN*i7S~vRZ}?!WMAJn#FH`vD z!^mbRF7RPX7px6R7_e@einQ7t?Fs{3eF@M(L0~2PKik{2Y<3i=0S%eQHa366I!;E4 z&9lJr?fTFV4zcX(-maOLH@m=CV^08#H!vv+&|#7-E0UkqqX;OKPY^=N3Dc!Q1-h|7 z<|rLRT7;~N?(=#XDedeZ@BkNr-2`PaXb5BIvtlO)U^%F`Z!uHMkbVy*%3~|@o1&cE z!TRJvAK~WaybR?3Oi_O~8g7%R=!~iH&E34F%ZU~aGb)1aU^W{D4-B3vmdU~z zKgHJ_>AUOYk+8t04(l~06^m^#42SxzWCQ@_Ui(dT>s;K+g3#y6MB_@f`yAU%Jf(gr z+XUfRidc>;mPpz#lo07y^{K*zx)Mc&=&Z<7SofY^kr*a_Tzj(#x%ZFR zLdWeA#QcSQay$jWd2K2{+3Bk5=^#Rf=k^z4^B*RrUP);RW?opcO zxoE6_{;(5TWxHKK~wCCQ$cee85xAQeG-1LX)+)tWSC{@O4TNmQWL?o`|ZBE5oqbvP} zVF$grq)fwu)+(P6|4_jS9VDCK|9WejMO#+cfm?MgFQ<# z;Nxs?At<5(WgUzoJoqrP5i?u=(5{$ZR-++8IFr?xZSa5aUd%DMaz-e8FC`7>POE<5 zOSid%YR*RN{7lm26s0ckPbC4V-<2X)oX}f8*R6a<=`>80)c?NdkHIY(hna3sY$XdI zc_DX$U99|rQe{(N?Vh!Q#;vccFw;3@$ynYxs<7_xWRAc5&rs7xDt_KN*C#+{A{5?o zW=*s%@%ewX;reahBY$$rj6;Um~H@ux|$&hSg#w=Yv*k{Uj9n?)fb_$&i(fEG|>>!`~00e0BBGqu-NXSXYwO8oY zus{2F2f}gQfMF)#F|~4eW4ODf3AS=DNB^mj3(tPlJ1HnjncRit|4jbd?O;tJy!HZw znJSFJCz=Pmyhyo~yG!t$X;GNs0)Gwm(`~ZD_MCnQWA}AkPwFnna=AMQf!)8m$+s^! z4$uf!U?;=vp^rX25(1u7*jl81JM5Dh%;HRLZMWVmYg%zkZ0mLVtCZ< zZev^J`(=QBtso6?%dx;#_K|C)u%k1zBm{rvc(1VRn;|+x#fsL~@Y*gcyw1*zlmJ{~ zAhwYy;p{XhE@8zIO|Reesy4Vcj{v3p%G!dQbj`EL=>nX{Re*- z-DlI2JM5h!<_r`qxJn10sj`w=wpiuju$FM*E3iaDB>pd_2^i8hobCobb@`y8Ra&x} z@N0oSTWH~BYb!lqwH02TrL`13z1Sg&s@qua-Uo`$zuq z2+Gh6OBgutdK3R)eh)NpQUl0PFkF8qBj)*L3ANtPp9ZTr;2HD_Wp7Qu+&(EedDJ-sd|LHs;YuMAARe$=_VGL0;5uHSOOF^Nkw*dG#(cId56u}0i+R! zBnvAH>29ZSB@TfIry#`zsEkP*e?ztARksWj3xHx(Ni*BU#R0g726!*b-nD-@EKR)@ zf;9ianxGx(pC@mxFxxC@6t|XKBVNUTKhi?SbrRoobv^SOgtMSeW&VMfUxl=Q_eL2q zb@p?rPJ_$jbbGfea?Vh|9d>u&kCQVpUBAW}Ep`MMfU>6o8fMc`(j0SpPDUEriNkSp zWu;+L>c{ExKBfVGX8u2~s(ODlk+&nrxI@8$fy|U5s>VGe5A$Hs1Kss=4T+ z=Zy2TZ`i2?7RN3Y3;)C-zz6*hjHD{H)y?p}2vO($;{fSA2-988S8#t1*E5Fo$X69Z z+dIH>wNO`RitWgGHt6-Xfbo!ET?E65p0dCi71%U4^y-r*)-)EAyMaE;Pn->AHI_nd zaOB`Q$F^*dC?$%&3`Ik=Y*yUGS7mcS-ND^b<1sUefGZ=P#Mm?1=Ely>nmc&-_iY+7 z=07@3L0Hz&afSAEV-h0{%d-iW000rv;xzyP@9P5Ao)1W{GbcVU4T}N*00001Sz6XY B94i0- diff --git a/index.md b/index.md index 523723c56..07bd5026f 100644 --- a/index.md +++ b/index.md @@ -259,10 +259,10 @@ antibiogram(example_isolates, language = "uk") # Ukrainian ``` -| Збудник | Гентаміцин | Тобраміцин | Ципрофлоксацин | -|:--------------|:--------------------|:-------------------|:-------------------| -| Грамнегативні | 96% (95-98%,N=684) | 96% (94-97%,N=686) | 91% (88-93%,N=684) | -| Грампозитивні | 63% (60-66%,N=1170) | 34% (31-38%,N=665) | 77% (74-80%,N=724) | +| Збудник | Ciprofloxacin | Гентаміцин | Тобраміцин | +|:--------------|:-------------------|:--------------------|:-------------------| +| Gram-negative | 91% (88-93%,N=684) | 96% (95-98%,N=684) | 96% (94-97%,N=686) | +| Gram-positive | 77% (74-80%,N=724) | 63% (60-66%,N=1170) | 34% (31-38%,N=665) | ### Interpreting and plotting MIC and SIR values diff --git a/man/ab_property.Rd b/man/ab_property.Rd index 61ede52d7..7673b7d41 100644 --- a/man/ab_property.Rd +++ b/man/ab_property.Rd @@ -27,7 +27,7 @@ ab_synonyms(x, ...) ab_tradenames(x, ...) -ab_group(x, language = get_AMR_locale(), ...) +ab_group(x, language = get_AMR_locale(), all_groups = FALSE, ...) ab_atc(x, only_first = FALSE, ...) diff --git a/man/antimicrobial_selectors.Rd b/man/antimicrobial_selectors.Rd index dea1d2e86..06368f43a 100644 --- a/man/antimicrobial_selectors.Rd +++ b/man/antimicrobial_selectors.Rd @@ -26,9 +26,11 @@ \alias{oxazolidinones} \alias{penicillins} \alias{phenicols} +\alias{phosphonics} \alias{polymyxins} \alias{quinolones} \alias{rifamycins} +\alias{spiropyrimidinetriones} \alias{streptogramins} \alias{sulfonamides} \alias{tetracyclines} @@ -98,6 +100,8 @@ penicillins(only_sir_columns = FALSE, return_all = TRUE, ...) phenicols(only_sir_columns = FALSE, return_all = TRUE, ...) +phosphonics(only_sir_columns = FALSE, return_all = TRUE, ...) + polymyxins(only_sir_columns = FALSE, only_treatable = TRUE, return_all = TRUE, ...) @@ -106,6 +110,8 @@ quinolones(only_sir_columns = FALSE, only_treatable = TRUE, rifamycins(only_sir_columns = FALSE, return_all = TRUE, ...) +spiropyrimidinetriones(only_sir_columns = FALSE, return_all = TRUE, ...) + streptogramins(only_sir_columns = FALSE, return_all = TRUE, ...) sulfonamides(only_sir_columns = FALSE, return_all = TRUE, ...) @@ -179,7 +185,7 @@ The \code{\link[=not_intrinsic_resistant]{not_intrinsic_resistant()}} function c \itemize{ \item \code{\link[=aminoglycosides]{aminoglycosides()}} can select: \cr amikacin (AMK), amikacin/fosfomycin (AKF), apramycin (APR), arbekacin (ARB), astromicin (AST), bekanamycin (BEK), dibekacin (DKB), framycetin (FRM), gentamicin (GEN), gentamicin-high (GEH), habekacin (HAB), hygromycin (HYG), isepamicin (ISE), kanamycin (KAN), kanamycin-high (KAH), kanamycin/cephalexin (KAC), micronomicin (MCR), neomycin (NEO), netilmicin (NET), pentisomicin (PIM), plazomicin (PLZ), propikacin (PKA), ribostamycin (RST), sisomicin (SIS), streptoduocin (STR), streptomycin (STR1), streptomycin-high (STH), tobramycin (TOB), and tobramycin-high (TOH) -\item \code{\link[=aminopenicillins]{aminopenicillins()}} can select: \cr amoxicillin (AMX) and ampicillin (AMP) +\item \code{\link[=aminopenicillins]{aminopenicillins()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), and ampicillin (AMP) \item \code{\link[=antifungals]{antifungals()}} can select: \cr amorolfine (AMO), amphotericin B (AMB), amphotericin B-high (AMH), anidulafungin (ANI), butoconazole (BUT), caspofungin (CAS), ciclopirox (CIX), clotrimazole (CTR), econazole (ECO), fluconazole (FLU), flucytosine (FCT), fosfluconazole (FFL), griseofulvin (GRI), hachimycin (HCH), ibrexafungerp (IBX), isavuconazole (ISV), isoconazole (ISO), itraconazole (ITR), ketoconazole (KET), manogepix (MGX), micafungin (MIF), miconazole (MCZ), nystatin (NYS), oteseconazole (OTE), pimaricin (PMR), posaconazole (POS), rezafungin (RZF), ribociclib (RBC), sulconazole (SUC), terbinafine (TRB), terconazole (TRC), and voriconazole (VOR) \item \code{\link[=antimycobacterials]{antimycobacterials()}} can select: \cr 4-aminosalicylic acid (AMA), calcium aminosalicylate (CLA), capreomycin (CAP), clofazimine (CLF), delamanid (DLM), enviomycin (ENV), ethambutol (ETH), ethambutol/isoniazid (ETI), ethionamide (ETI1), isoniazid (INH), isoniazid/sulfamethoxazole/trimethoprim/pyridoxine (IST), morinamide (MRN), p-aminosalicylic acid (PAS), pretomanid (PMD), protionamide (PTH), pyrazinamide (PZA), rifabutin (RIB), rifampicin (RIF), rifampicin/ethambutol/isoniazid (REI), rifampicin/isoniazid (RFI), rifampicin/pyrazinamide/ethambutol/isoniazid (RPEI), rifampicin/pyrazinamide/isoniazid (RPI), rifamycin (RFM), rifapentine (RFP), sodium aminosalicylate (SDA), streptomycin/isoniazid (STI), terizidone (TRZ), thioacetazone (TAT), thioacetazone/isoniazid (THI1), tiocarlide (TCR), and viomycin (VIO) \item \code{\link[=betalactams]{betalactams()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), benzylpenicillin screening test (PEN-S), biapenem (BIA), carbenicillin (CRB), carindacillin (CRN), carumonam (CAR), cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/enmetazobactam (FPE), cefepime/nacubactam (FNC), cefepime/taniborbactam (FTA), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime screening test (CTX-S), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening test (FOX-S), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), doripenem (DOR), epicillin (EPC), ertapenem (ETP), flucloxacillin (FLC), hetacillin (HET), imipenem (IPM), imipenem/EDTA (IPE), imipenem/relebactam (IMR), latamoxef (LTM), lenampicillin (LEN), loracarbef (LOR), mecillinam (MEC), meropenem (MEM), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), oxacillin screening test (OXA-S), panipenem (PAN), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), razupenem (RZM), ritipenem (RIT), ritipenem acoxil (RIA), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), taniborbactam (TAN), tebipenem (TBP), temocillin (TEM), ticarcillin (TIC), ticarcillin/clavulanic acid (TCC), and tigemonam (TMN) @@ -194,17 +200,19 @@ The \code{\link[=not_intrinsic_resistant]{not_intrinsic_resistant()}} function c \item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin (BES), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) \item \code{\link[=glycopeptides]{glycopeptides()}} can select: \cr avoparcin (AVO), bleomycin (BLM), dalbavancin (DAL), norvancomycin (NVA), oritavancin (ORI), ramoplanin (RAM), teicoplanin (TEC), teicoplanin-macromethod (TCM), telavancin (TLV), vancomycin (VAN), and vancomycin-macromethod (VAM) \item \code{\link[=isoxazolylpenicillins]{isoxazolylpenicillins()}} can select: \cr cloxacillin (CLO), dicloxacillin (DIC), flucloxacillin (FLC), meticillin (MET), oxacillin (OXA), and oxacillin screening test (OXA-S) -\item \code{\link[=lincosamides]{lincosamides()}} can select: \cr clindamycin (CLI), lincomycin (LIN), and pirlimycin (PRL) +\item \code{\link[=lincosamides]{lincosamides()}} can select: \cr clindamycin (CLI), clindamycin inducible screening test (CLI-S), lincomycin (LIN), and pirlimycin (PRL) \item \code{\link[=lipoglycopeptides]{lipoglycopeptides()}} can select: \cr dalbavancin (DAL), oritavancin (ORI), and telavancin (TLV) -\item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin (ACM), acetylspiramycin (ASP), azithromycin (AZM), clarithromycin (CLR), dirithromycin (DIR), erythromycin (ERY), flurithromycin (FLR1), gamithromycin (GAM), josamycin (JOS), kitasamycin (KIT), meleumycin (MEL), midecamycin (MID), miocamycin (MCM), nafithromycin (ZWK), oleandomycin (OLE), rokitamycin (ROK), roxithromycin (RXT), solithromycin (SOL), spiramycin (SPI), telithromycin (TLT), tildipirosin (TIP), tilmicosin (TIL), troleandomycin (TRL), tulathromycin (TUL), tylosin (TYL), and tylvalosin (TYL1) +\item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin (ACM), acetylspiramycin (ASP), azithromycin (AZM), clarithromycin (CLR), clindamycin inducible screening test (CLI-S), dirithromycin (DIR), erythromycin (ERY), flurithromycin (FLR1), gamithromycin (GAM), josamycin (JOS), kitasamycin (KIT), meleumycin (MEL), midecamycin (MID), miocamycin (MCM), nafithromycin (ZWK), oleandomycin (OLE), pirlimycin (PRL), primycin (PRM), rokitamycin (ROK), roxithromycin (RXT), solithromycin (SOL), spiramycin (SPI), telithromycin (TLT), tildipirosin (TIP), tilmicosin (TIL), troleandomycin (TRL), tulathromycin (TUL), tylosin (TYL), and tylvalosin (TYL1) \item \code{\link[=monobactams]{monobactams()}} can select: \cr aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), carumonam (CAR), and tigemonam (TMN) \item \code{\link[=nitrofurans]{nitrofurans()}} can select: \cr furazidin (FUR), furazolidone (FRZ), nifurtoinol (NFR), nitrofurantoin (NIT), and nitrofurazone (NIZ) \item \code{\link[=oxazolidinones]{oxazolidinones()}} can select: \cr cadazolid (CDZ), cycloserine (CYC), linezolid (LNZ), tedizolid (TZD), and thiacetazone (THA) \item \code{\link[=penicillins]{penicillins()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), benzylpenicillin screening test (PEN-S), carbenicillin (CRB), carindacillin (CRN), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), epicillin (EPC), flucloxacillin (FLC), hetacillin (HET), lenampicillin (LEN), mecillinam (MEC), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), oxacillin screening test (OXA-S), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), temocillin (TEM), ticarcillin (TIC), and ticarcillin/clavulanic acid (TCC) \item \code{\link[=phenicols]{phenicols()}} can select: \cr chloramphenicol (CHL), florfenicol (FLR), and thiamphenicol (THI) +\item \code{\link[=phosphonics]{phosphonics()}} can select: \cr amikacin/fosfomycin (AKF) and fosfomycin (FOS) \item \code{\link[=polymyxins]{polymyxins()}} can select: \cr colistin (COL), polymyxin B (PLB), and polymyxin B/polysorbate 80 (POP) -\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin (BES), cinoxacin (CIN), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), flumequine (FLM), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nalidixic acid (NAL), nalidixic acid screening test (NAL-S), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), oxolinic acid (OXO), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pipemidic acid (PPA), piromidic acid (PIR), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rosoxacin (ROS), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) +\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin (BES), cinoxacin (CIN), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), flumequine (FLM), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nalidixic acid (NAL), nalidixic acid screening test (NAL-S), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), oxolinic acid (OXO), ozenoxacin (OZN), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pipemidic acid (PPA), piromidic acid (PIR), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rosoxacin (ROS), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) \item \code{\link[=rifamycins]{rifamycins()}} can select: \cr rifabutin (RIB), rifampicin (RIF), rifampicin/ethambutol/isoniazid (REI), rifampicin/isoniazid (RFI), rifampicin/pyrazinamide/ethambutol/isoniazid (RPEI), rifampicin/pyrazinamide/isoniazid (RPI), rifamycin (RFM), and rifapentine (RFP) +\item \code{\link[=spiropyrimidinetriones]{spiropyrimidinetriones()}} can select: \cr zoliflodacin (ZFD) \item \code{\link[=streptogramins]{streptogramins()}} can select: \cr pristinamycin (PRI) and quinupristin/dalfopristin (QDA) \item \code{\link[=sulfonamides]{sulfonamides()}} can select: \cr brodimoprim (BDP), sulfadiazine (SDI), sulfadiazine/tetroxoprim (SLT), sulfadimethoxine (SUD), sulfadimidine (SDM), sulfafurazole (SLF), sulfaisodimidine (SLF1), sulfalene (SLF2), sulfamazone (SZO), sulfamerazine (SLF3), sulfamethizole (SLF4), sulfamethoxazole (SMX), sulfamethoxypyridazine (SLF5), sulfametomidine (SLF6), sulfametoxydiazine (SLF7), sulfamoxole (SLF8), sulfanilamide (SLF9), sulfaperin (SLF10), sulfaphenazole (SLF11), sulfapyridine (SLF12), sulfathiazole (SUT), and sulfathiourea (SLF13) \item \code{\link[=tetracyclines]{tetracyclines()}} can select: \cr cetocycline (CTO), chlortetracycline (CTE), clomocycline (CLM1), demeclocycline (DEM), doxycycline (DOX), eravacycline (ERV), lymecycline (LYM), metacycline (MTC), minocycline (MNO), omadacycline (OMC), oxytetracycline (OXY), penimepicycline (PNM1), rolitetracycline (RLT), sarecycline (SRC), tetracycline (TCY), tetracycline screening test (TCY-S), and tigecycline (TGC) diff --git a/man/antimicrobials.Rd b/man/antimicrobials.Rd index 8b0bbb2d2..f8f5bf59e 100644 --- a/man/antimicrobials.Rd +++ b/man/antimicrobials.Rd @@ -12,7 +12,7 @@ \item \code{ab}\cr antimicrobial ID as used in this package (such as \code{AMC}), using the official EARS-Net (European Antimicrobial Resistance Surveillance Network) codes where available. \emph{\strong{This is a unique identifier.}} \item \code{cid}\cr Compound ID as found in PubChem. \emph{\strong{This is a unique identifier.}} \item \code{name}\cr Official name as used by WHONET/EARS-Net or the WHO. \emph{\strong{This is a unique identifier.}} -\item \code{group}\cr A short and concise group name, based on WHONET and WHOCC definitions +\item \code{group}\cr One or more short and concise group names, based on WHONET and WHOCC definitions \item \code{atc}\cr ATC codes (Anatomical Therapeutic Chemical) as defined by the WHOCC, like \code{J01CR02} (last updated May 4th, 2025): \item \code{atc_group1}\cr Official pharmacological subgroup (3rd level ATC code) as defined by the WHOCC, like \code{"Macrolides, lincosamides and streptogramins"} \item \code{atc_group2}\cr Official chemical subgroup (4th level ATC code) as defined by the WHOCC, like \code{"Macrolides"} diff --git a/man/custom_eucast_rules.Rd b/man/custom_eucast_rules.Rd index 057698dce..2195bcfd4 100644 --- a/man/custom_eucast_rules.Rd +++ b/man/custom_eucast_rules.Rd @@ -98,12 +98,13 @@ x #> amoxicillin (AMX), ampicillin (AMP), azlocillin (AZL), mezlocillin (MEZ), piperacillin (PIP), piperacillin/tazobactam (TZP) }\if{html}{\out{}} -These 35 antimicrobial groups are allowed in the rules (case-insensitive) and can be used in any combination: +These 38 antimicrobial groups are allowed in the rules (case-insensitive) and can be used in any combination: \itemize{ \item aminoglycosides\cr(amikacin, amikacin/fosfomycin, apramycin, arbekacin, astromicin, bekanamycin, dibekacin, framycetin, gentamicin, gentamicin-high, habekacin, hygromycin, isepamicin, kanamycin, kanamycin-high, kanamycin/cephalexin, micronomicin, neomycin, netilmicin, pentisomicin, plazomicin, propikacin, ribostamycin, sisomicin, streptoduocin, streptomycin, streptomycin-high, tobramycin, and tobramycin-high) -\item aminopenicillins\cr(amoxicillin and ampicillin) +\item aminopenicillins\cr(amoxicillin, amoxicillin/clavulanic acid, and ampicillin) \item antifungals\cr(amorolfine, amphotericin B, amphotericin B-high, anidulafungin, butoconazole, caspofungin, ciclopirox, clotrimazole, econazole, fluconazole, flucytosine, fosfluconazole, griseofulvin, hachimycin, ibrexafungerp, isavuconazole, isoconazole, itraconazole, ketoconazole, manogepix, micafungin, miconazole, nystatin, oteseconazole, pimaricin, posaconazole, rezafungin, ribociclib, sulconazole, terbinafine, terconazole, and voriconazole) \item antimycobacterials\cr(4-aminosalicylic acid, calcium aminosalicylate, capreomycin, clofazimine, delamanid, enviomycin, ethambutol, ethambutol/isoniazid, ethionamide, isoniazid, isoniazid/sulfamethoxazole/trimethoprim/pyridoxine, morinamide, p-aminosalicylic acid, pretomanid, protionamide, pyrazinamide, rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, rifapentine, sodium aminosalicylate, streptomycin/isoniazid, terizidone, thioacetazone, thioacetazone/isoniazid, tiocarlide, and viomycin) +\item betalactamase_inhibitors\cr(amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin/sulbactam, avibactam, aztreonam/avibactam, aztreonam/nacubactam, cefepime/enmetazobactam, cefepime/nacubactam, cefepime/taniborbactam, cefepime/tazobactam, cefepime/zidebactam, cefoperazone/sulbactam, cefotaxime/sulbactam, ceftaroline/avibactam, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/nacubactam, meropenem/vaborbactam, mezlocillin/sulbactam, nacubactam, penicillin/sulbactam, piperacillin/sulbactam, piperacillin/tazobactam, sulbactam, sultamicillin, taniborbactam, tazobactam, ticarcillin/clavulanic acid, and zidebactam) \item betalactams\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, biapenem, carbenicillin, carindacillin, carumonam, cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/enmetazobactam, cefepime/nacubactam, cefepime/taniborbactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime screening test, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, ciclacillin, clometocillin, cloxacillin, dicloxacillin, doripenem, epicillin, ertapenem, flucloxacillin, hetacillin, imipenem, imipenem/EDTA, imipenem/relebactam, latamoxef, lenampicillin, loracarbef, mecillinam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, panipenem, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, razupenem, ritipenem, ritipenem acoxil, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, taniborbactam, tebipenem, temocillin, ticarcillin, ticarcillin/clavulanic acid, and tigemonam) \item betalactams_with_inhibitor\cr(amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin/sulbactam, aztreonam/avibactam, aztreonam/nacubactam, cefepime/amikacin, cefepime/clavulanic acid, cefepime/enmetazobactam, cefepime/nacubactam, cefepime/taniborbactam, cefepime/tazobactam, cefepime/zidebactam, cefoperazone/sulbactam, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefpodoxime/clavulanic acid, ceftaroline/avibactam, ceftazidime/avibactam, ceftazidime/clavulanic acid, ceftolozane/tazobactam, ceftriaxone/beta-lactamase inhibitor, imipenem/relebactam, meropenem/nacubactam, meropenem/vaborbactam, mezlocillin/sulbactam, penicillin/novobiocin, penicillin/sulbactam, piperacillin/sulbactam, piperacillin/tazobactam, and ticarcillin/clavulanic acid) \item carbapenems\cr(biapenem, doripenem, ertapenem, imipenem, imipenem/EDTA, imipenem/relebactam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, panipenem, razupenem, ritipenem, ritipenem acoxil, taniborbactam, and tebipenem) @@ -118,17 +119,19 @@ These 35 antimicrobial groups are allowed in the rules (case-insensitive) and ca \item glycopeptides\cr(avoparcin, bleomycin, dalbavancin, norvancomycin, oritavancin, ramoplanin, teicoplanin, teicoplanin-macromethod, telavancin, vancomycin, and vancomycin-macromethod) \item glycopeptides_except_lipo\cr(avoparcin, bleomycin, norvancomycin, ramoplanin, teicoplanin, teicoplanin-macromethod, vancomycin, and vancomycin-macromethod) \item isoxazolylpenicillins\cr(cloxacillin, dicloxacillin, flucloxacillin, meticillin, oxacillin, and oxacillin screening test) -\item lincosamides\cr(clindamycin, lincomycin, and pirlimycin) +\item lincosamides\cr(clindamycin, clindamycin inducible screening test, lincomycin, and pirlimycin) \item lipoglycopeptides\cr(dalbavancin, oritavancin, and telavancin) -\item macrolides\cr(acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin) +\item macrolides\cr(acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, clindamycin inducible screening test, dirithromycin, erythromycin, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, pirlimycin, primycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin) \item monobactams\cr(aztreonam, aztreonam/avibactam, aztreonam/nacubactam, carumonam, and tigemonam) \item nitrofurans\cr(furazidin, furazolidone, nifurtoinol, nitrofurantoin, and nitrofurazone) \item oxazolidinones\cr(cadazolid, cycloserine, linezolid, tedizolid, and thiacetazone) \item penicillins\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, carbenicillin, carindacillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, lenampicillin, mecillinam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin, and ticarcillin/clavulanic acid) \item phenicols\cr(chloramphenicol, florfenicol, and thiamphenicol) +\item phosphonics\cr(amikacin/fosfomycin and fosfomycin) \item polymyxins\cr(colistin, polymyxin B, and polymyxin B/polysorbate 80) -\item quinolones\cr(besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) +\item quinolones\cr(besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, ozenoxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) \item rifamycins\cr(rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, and rifapentine) +\item spiropyrimidinetriones\cr(zoliflodacin) \item streptogramins\cr(pristinamycin and quinupristin/dalfopristin) \item sulfonamides\cr(brodimoprim, sulfadiazine, sulfadiazine/tetroxoprim, sulfadimethoxine, sulfadimidine, sulfafurazole, sulfaisodimidine, sulfalene, sulfamazone, sulfamerazine, sulfamethizole, sulfamethoxazole, sulfamethoxypyridazine, sulfametomidine, sulfametoxydiazine, sulfamoxole, sulfanilamide, sulfaperin, sulfaphenazole, sulfapyridine, sulfathiazole, and sulfathiourea) \item tetracyclines\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, tetracycline, tetracycline screening test, and tigecycline) diff --git a/man/custom_mdro_guideline.Rd b/man/custom_mdro_guideline.Rd index 1dae16dc6..cb93a92e6 100644 --- a/man/custom_mdro_guideline.Rd +++ b/man/custom_mdro_guideline.Rd @@ -94,10 +94,10 @@ You can define antimicrobial groups instead of single antimicrobials for the rul ) }\if{html}{\out{}} -All 35 antimicrobial selectors are supported for use in the rules: +All 38 antimicrobial selectors are supported for use in the rules: \itemize{ \item \code{\link[=aminoglycosides]{aminoglycosides()}} can select: \cr amikacin, amikacin/fosfomycin, apramycin, arbekacin, astromicin, bekanamycin, dibekacin, framycetin, gentamicin, gentamicin-high, habekacin, hygromycin, isepamicin, kanamycin, kanamycin-high, kanamycin/cephalexin, micronomicin, neomycin, netilmicin, pentisomicin, plazomicin, propikacin, ribostamycin, sisomicin, streptoduocin, streptomycin, streptomycin-high, tobramycin, and tobramycin-high -\item \code{\link[=aminopenicillins]{aminopenicillins()}} can select: \cr amoxicillin and ampicillin +\item \code{\link[=aminopenicillins]{aminopenicillins()}} can select: \cr amoxicillin, amoxicillin/clavulanic acid, and ampicillin \item \code{\link[=antifungals]{antifungals()}} can select: \cr amorolfine, amphotericin B, amphotericin B-high, anidulafungin, butoconazole, caspofungin, ciclopirox, clotrimazole, econazole, fluconazole, flucytosine, fosfluconazole, griseofulvin, hachimycin, ibrexafungerp, isavuconazole, isoconazole, itraconazole, ketoconazole, manogepix, micafungin, miconazole, nystatin, oteseconazole, pimaricin, posaconazole, rezafungin, ribociclib, sulconazole, terbinafine, terconazole, and voriconazole \item \code{\link[=antimycobacterials]{antimycobacterials()}} can select: \cr 4-aminosalicylic acid, calcium aminosalicylate, capreomycin, clofazimine, delamanid, enviomycin, ethambutol, ethambutol/isoniazid, ethionamide, isoniazid, isoniazid/sulfamethoxazole/trimethoprim/pyridoxine, morinamide, p-aminosalicylic acid, pretomanid, protionamide, pyrazinamide, rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, rifapentine, sodium aminosalicylate, streptomycin/isoniazid, terizidone, thioacetazone, thioacetazone/isoniazid, tiocarlide, and viomycin \item \code{\link[=betalactams]{betalactams()}} can select: \cr amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, biapenem, carbenicillin, carindacillin, carumonam, cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/enmetazobactam, cefepime/nacubactam, cefepime/taniborbactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime screening test, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, ciclacillin, clometocillin, cloxacillin, dicloxacillin, doripenem, epicillin, ertapenem, flucloxacillin, hetacillin, imipenem, imipenem/EDTA, imipenem/relebactam, latamoxef, lenampicillin, loracarbef, mecillinam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, panipenem, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, razupenem, ritipenem, ritipenem acoxil, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, taniborbactam, tebipenem, temocillin, ticarcillin, ticarcillin/clavulanic acid, and tigemonam @@ -112,17 +112,19 @@ All 35 antimicrobial selectors are supported for use in the rules: \item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin \item \code{\link[=glycopeptides]{glycopeptides()}} can select: \cr avoparcin, bleomycin, dalbavancin, norvancomycin, oritavancin, ramoplanin, teicoplanin, teicoplanin-macromethod, telavancin, vancomycin, and vancomycin-macromethod \item \code{\link[=isoxazolylpenicillins]{isoxazolylpenicillins()}} can select: \cr cloxacillin, dicloxacillin, flucloxacillin, meticillin, oxacillin, and oxacillin screening test -\item \code{\link[=lincosamides]{lincosamides()}} can select: \cr clindamycin, lincomycin, and pirlimycin +\item \code{\link[=lincosamides]{lincosamides()}} can select: \cr clindamycin, clindamycin inducible screening test, lincomycin, and pirlimycin \item \code{\link[=lipoglycopeptides]{lipoglycopeptides()}} can select: \cr dalbavancin, oritavancin, and telavancin -\item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin +\item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, clindamycin inducible screening test, dirithromycin, erythromycin, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, pirlimycin, primycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin \item \code{\link[=monobactams]{monobactams()}} can select: \cr aztreonam, aztreonam/avibactam, aztreonam/nacubactam, carumonam, and tigemonam \item \code{\link[=nitrofurans]{nitrofurans()}} can select: \cr furazidin, furazolidone, nifurtoinol, nitrofurantoin, and nitrofurazone \item \code{\link[=oxazolidinones]{oxazolidinones()}} can select: \cr cadazolid, cycloserine, linezolid, tedizolid, and thiacetazone \item \code{\link[=penicillins]{penicillins()}} can select: \cr amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, carbenicillin, carindacillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, lenampicillin, mecillinam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin, and ticarcillin/clavulanic acid \item \code{\link[=phenicols]{phenicols()}} can select: \cr chloramphenicol, florfenicol, and thiamphenicol +\item \code{\link[=phosphonics]{phosphonics()}} can select: \cr amikacin/fosfomycin and fosfomycin \item \code{\link[=polymyxins]{polymyxins()}} can select: \cr colistin, polymyxin B, and polymyxin B/polysorbate 80 -\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin +\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, ozenoxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin \item \code{\link[=rifamycins]{rifamycins()}} can select: \cr rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, and rifapentine +\item \code{\link[=spiropyrimidinetriones]{spiropyrimidinetriones()}} can select: \cr zoliflodacin \item \code{\link[=streptogramins]{streptogramins()}} can select: \cr pristinamycin and quinupristin/dalfopristin \item \code{\link[=sulfonamides]{sulfonamides()}} can select: \cr brodimoprim, sulfadiazine, sulfadiazine/tetroxoprim, sulfadimethoxine, sulfadimidine, sulfafurazole, sulfaisodimidine, sulfalene, sulfamazone, sulfamerazine, sulfamethizole, sulfamethoxazole, sulfamethoxypyridazine, sulfametomidine, sulfametoxydiazine, sulfamoxole, sulfanilamide, sulfaperin, sulfaphenazole, sulfapyridine, sulfathiazole, and sulfathiourea \item \code{\link[=tetracyclines]{tetracyclines()}} can select: \cr cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, tetracycline, tetracycline screening test, and tigecycline diff --git a/man/esbl_isolates.Rd b/man/esbl_isolates.Rd index a6433c08a..ffc36def3 100644 --- a/man/esbl_isolates.Rd +++ b/man/esbl_isolates.Rd @@ -9,7 +9,7 @@ A \link[tibble:tibble]{tibble} with 500 observations and 19 variables: \itemize{ \item \code{esbl}\cr Logical indicator if the isolate is ESBL-producing \item \code{genus}\cr Genus of the microorganism -\item \code{AMC:COL}\cr MIC values for 17 antimicrobial agents, transformed to class \code{\link{mic}} (see \code{\link[=as.mic]{as.mic()}}) +\item \code{AMC:COL}\cr MIC values for 17 antimicrobial drugs, transformed to class \code{\link{mic}} (see \code{\link[=as.mic]{as.mic()}}) } } \usage{ diff --git a/tests/testthat/test-amr_selectors.R b/tests/testthat/test-amr_selectors.R index 186748a58..289c58820 100644 --- a/tests/testthat/test-amr_selectors.R +++ b/tests/testthat/test-amr_selectors.R @@ -52,9 +52,11 @@ test_that("test-amr selectors.R", { expect_equal(ncol(example_isolates[, oxazolidinones(), drop = FALSE]), 1, tolerance = 0.5) expect_equal(ncol(example_isolates[, penicillins(), drop = FALSE]), 7, tolerance = 0.5) expect_equal(ncol(example_isolates[, phenicols(), drop = FALSE]), 1, tolerance = 0.5) + expect_equal(ncol(example_isolates[, phosphonics(), drop = FALSE]), 1, tolerance = 0.5) expect_equal(ncol(example_isolates[, polymyxins(), drop = FALSE]), 1, tolerance = 0.5) expect_equal(ncol(example_isolates[, quinolones(), drop = FALSE]), 2, tolerance = 0.5) expect_equal(ncol(example_isolates[, rifamycins(), drop = FALSE]), 1, tolerance = 0.5) + expect_equal(ncol(example_isolates[, spiropyrimidinetriones(), drop = FALSE]), 0, tolerance = 0.5) expect_equal(ncol(example_isolates[, streptogramins(), drop = FALSE]), 0, tolerance = 0.5) expect_equal(ncol(example_isolates[, tetracyclines(), drop = FALSE]), 3, tolerance = 0.5) expect_equal(ncol(example_isolates[, trimethoprims(), drop = FALSE]), 2, tolerance = 0.5) diff --git a/vignettes/AMR.Rmd b/vignettes/AMR.Rmd index de64a7cc2..2a5105c27 100755 --- a/vignettes/AMR.Rmd +++ b/vignettes/AMR.Rmd @@ -37,7 +37,7 @@ Conducting AMR data analysis unfortunately requires in-depth knowledge from diff Of course, we cannot instantly provide you with knowledge and experience. But with this `AMR` package, we aimed at providing (1) tools to simplify antimicrobial resistance data cleaning, transformation and analysis, (2) methods to easily incorporate international guidelines and (3) scientifically reliable reference data, including the requirements mentioned above. -The `AMR` package enables standardised and reproducible AMR data analysis, with the application of evidence-based rules, determination of first isolates, translation of various codes for microorganisms and antimicrobial agents, determination of (multi-drug) resistant microorganisms, and calculation of antimicrobial resistance, prevalence and future trends. +The `AMR` package enables standardised and reproducible AMR data analysis, with the application of evidence-based rules, determination of first isolates, translation of various codes for microorganisms and antimicrobial drugs, determination of (multi-drug) resistant microorganisms, and calculation of antimicrobial resistance, prevalence and future trends. # Preparation